<SEC-DOCUMENT>0001628280-24-015260.txt : 20240408
<SEC-HEADER>0001628280-24-015260.hdr.sgml : 20240408
<ACCEPTANCE-DATETIME>20240408162109
ACCESSION NUMBER:		0001628280-24-015260
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		131
CONFORMED PERIOD OF REPORT:	20231230
FILED AS OF DATE:		20240408
DATE AS OF CHANGE:		20240408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19621
		FILM NUMBER:		24829853

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>jan-20231230.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146,d:186f351ddce04342b829c557fbabfeb2-->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:jan="http://www.live-ventures.com/20231230" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jan-20231230</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-31">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0000862861</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-144" decimals="5" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-681">0.00001</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jan-20231230.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>jan:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>jan:patent</xbrli:measure></xbrli:unit><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:GulfCoastBankAndTrustCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:GulfCoastBankAndTrustCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>jan:state</xbrli:measure></xbrli:unit><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:GulfCoastBankAndTrustCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">jan:KlcFinancialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-28</xbrli:startDate><xbrli:endDate>2019-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ArcaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ArcaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-03</xbrli:startDate><xbrli:endDate>2022-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:PatentsAndDomainsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:PatentsAndDomainsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-18</xbrli:startDate><xbrli:endDate>2017-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-18</xbrli:startDate><xbrli:endDate>2017-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>jan:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:ArticlesOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:ArticlesOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-18</xbrli:startDate><xbrli:endDate>2023-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jan:PreFundedWarrantsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jan:PreFundedWarrantsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-03</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jan:JanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:IsaacCapitalGroupLLCICGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="officer"><xbrli:measure>jan:officer</xbrli:measure></xbrli:unit><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-25</xbrli:startDate><xbrli:endDate>2017-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AMTIMCapitalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="quarterly"><xbrli:measure>jan:Quarterly</xbrli:measure></xbrli:unit><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.SullivanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.SullivanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-19</xbrli:startDate><xbrli:endDate>2022-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="traches"><xbrli:measure>jan:traches</xbrli:measure></xbrli:unit><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:TrusteesMain270LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:TrusteesMain270LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:ApplianceSmartIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:WestervilleSquareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:WestervilleSquareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-04</xbrli:startDate><xbrli:endDate>2023-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:ApplianceSmartIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="landlord"><xbrli:measure>jan:landlord</xbrli:measure></xbrli:unit><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-12</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-12</xbrli:startDate><xbrli:endDate>2024-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-24</xbrli:startDate><xbrli:endDate>2024-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreements"><xbrli:measure>jan:agreements</xbrli:measure></xbrli:unit><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-23</xbrli:startDate><xbrli:endDate>2024-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy"><xbrli:measure>jan:insurance_policy</xbrli:measure></xbrli:unit><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jan:UniversalLifeInsurancePolicyPolicyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000862861</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jan:UniversalLifeInsurancePolicyPolicyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i186f351ddce04342b829c557fbabfeb2_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 30</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">000-19621</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">JANONE INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">41-1454591</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">325 E. Warm Springs Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Las Vegas</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Nevada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">89119</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">702</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">997-5968</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">JAN</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:26.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates, based on the closing sales price of such stock on July 1, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">2,981,872</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s common stock as of April&#160;8, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">8,593,636</ix:nonFraction>.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_13">PART I</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_19">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_22">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_22">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_25">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_25">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_28">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_28">48</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_31">PART II</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_34">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_34">Market for Our Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_34">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_37">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_37">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_40">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_40">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_103">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_103">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_106">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_106">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_106">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_226">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_226">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_226">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_229">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_229">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_229">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_232">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_232">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_232">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_235">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_235">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_235">58</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_238">PART III</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_241">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_241">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_241">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_244">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_244">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_244">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_247">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_247">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_247">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_250">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_250">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_250">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_253">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_253">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_253">66</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_256">PART IV</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_259">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_259">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_259">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_262">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_262">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_262">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_265">Index to Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_265">68</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_268">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_268">74</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i186f351ddce04342b829c557fbabfeb2_16"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JanOne Inc. (formerly known as Appliance Recycling Centers of America, Inc.) and subsidiaries (collectively, &#8220;we,&#8221; the &#8220;Company,&#8221; or &#8220;JanOne&#8221;) is focused on being a clinical-stage pharmaceutical company committed to finding treatments for conditions that cause severe pain and bringing drugs to market with non-addictive pain-relieving properties. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company&#8217;s goals is to reduce the need for prescriptions for dangerous opioid drugs by treating underlying diseases that cause severe pain. The Company&#8217;s first drug candidate is a treatment for Peripheral Artery Disease (&#8220;PAD&#8221;), a condition that can cause severe pain and affects over 8.5 million people in the United States. The Company intends to champion new initiatives&#8212;digital technologies, educational advocacy, and revolutionary painkilling drugs that address what we believe is a multibillion dollar a year market&#8212;to help combat the opioid crisis, which claims tens of thousands of lives each year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 28, 2022, we entered into a Purchase Agreement (the &#8220;Soin Purchase Agreement&#8221;) with Soin Therapeutics, LLC. Under the Soin Purchase Agreement, the Company acquired Soin Therapeutics and its LDN product, now known as JAN123. JAN123 is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for an immediate release of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially, a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the Company, JanOne Inc., was strategically chosen to express the start of a new day in the fight against the opioid epidemic. January one is the first day of a New Year&#8212;universally considered as a day of optimism, resolution, and hope. JanOne stands by its strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation&#8217;s history.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 8, 2023, the Company operated its legacy businesses through its Recycling Subsidiaries, consisting of:  (a) ARCA Recycling, Inc., a California corporation (&#8220;ARCA Recycling&#8221;), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (&#8220;ARCA Canada&#8221;), and (c) Customer Connexx, LLC, a Nevada limited liability company (&#8220;Connexx&#8221;). ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling businesses. On March 9, 2023, we entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in or accessible from our website is not incorporated into this Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;), and it should not be considered part of this Form 10-K. We have included our website address in this Form 10-K solely as an inactive textual reference. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Minnesota in 1983, although, through its predecessors, began operating its legacy recycling business in 1976. In 2018, the Company reincorporated in the State of Nevada. The Company&#8217;s principal office is located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Biotechnology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. JAN101 (formerly known as TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide. We expect to commence Phase IIb/III clinical trials for the treatment of PAD in 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">JAN101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Generally</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN101, formerly known as TV1001SR, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain. A conclusion from a round of human studies found JAN101 prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite. In a previous study of patients with PAD, a 40 mg BID treatment with immediate release sodium nitrite led to a statistically significant reduction in reported pain, while an 80 mg BID treatment had a more pronounced effect on bioactivity and Flow Mediated Dilation, a measure of vascular function. However, a number of subjects in both treatment groups reported headaches and dizziness following treatment. Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect. JAN101 was tested in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches or dizziness. Subjects in this bridging study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing, a measure of nerve function) were similar to the PAD study, where the 80 mg dosing group had the greatest improvement in Flow Mediated Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of chronic pain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Studies in Humans JAN101 Attributes</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Well-established safety profile</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Excellent bioavailability</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Lack of induced tolerance</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-narcotic</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN101 does not mask pain, but instead treats the cause of pain by improving tissue and vascular function.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefits of Sodium Nitrite on Vascular Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies involving alterations of angiogenesis &#8211; development of new blood vessels &#8211; including diabetes, wound healing, and tissue necrosis. Beneficial effects include enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis. There is also a strong association between reduced circulating nitrite levels and cardiovascular diseases in humans. We describe some of the associations and beneficial effects of sodium nitrite/nitrite below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plasma nitrite levels are negatively correlated to cardiovascular disease</span></div><div style="margin-top:12pt"><img src="jan-20231230_g1.jpg" alt="Annotation 2023-05-27 120434.jpg" style="height:194px;margin-bottom:5pt;vertical-align:text-bottom;width:416px"/></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g2.jpg" alt="img253501747_1.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plasma nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both are indicators of vascular pathology). Kleinbongard, et al. (2006) Free Radic Biol and Medicine 40:295-302. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plasma nitrite levels are reduced in diabetic and PAD patients </span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g3.jpg" alt="Annotation 2023-05-27 120832.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:368px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise is a well-known stimulator of endothelial nitric oxide synthase activity, an enzyme that enhances nitric oxide (NO) production, which leads to increased plasma nitrite. In the study by Allen, et al., these authors revealed that baseline plasma levels of nitrite were less in patients with diabetes mellitus (DM) or DM + PAD. Importantly, increases in plasma nitrite levels were not observed in either DM, PAD, or DM + PAD patients after supervised exercise. These data reveal that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">baseline nitrite availability is compromised in DM patients and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in nitrite, highlighting a physiological efficiency of this molecule. Allen, et al., Nitric Oxide 2009 20:231-2377. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Skeletal Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia (CLI) Patients</span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g4.jpg" alt="Annotation 2023-05-27 120945.jpg" style="height:301px;margin-bottom:5pt;vertical-align:text-bottom;width:436px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Skeletal muscle nitrite, nitrosothiol (RSNO), nitric oxide-heme, and cGMP are all significantly reduced in CLI (the most severe form of PAD) patients. Diabetic patients with CLI show even further nitrite reductions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease in humans:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Lower nitrite levels are associated with higher level of heart failure; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Lower nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Nitrite levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical limb ischemia. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically in animals. Below are summaries of some of the more important findings: </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Promotes angiogenesis </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Stimulates wound healing</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Prevents tissue necrosis</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From Arya, et al. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nitrite Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner</span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g5.jpg" alt="Annotation 2023-05-27 121141.jpg" style="height:598px;margin-bottom:5pt;vertical-align:text-bottom;width:432px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner. A and B show representative images of CD31 (red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7. C and D report the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 for 165 &#956;g/kg sodium nitrite and nitrate treatments, respectively. E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 &#956;g/kg sodium nitrite plus carboxy PTIO. (Scale bar, 150 &#956;m.) n = 10 mice per treatment group. Kumar D., et al., PNAS; 2008; 105:7540-7545.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nitrite Therapy Augments Arterial Perfusion of Ischemic Tissue</span></div><div style="margin-top:12pt"><img src="jan-20231230_g6.jpg" alt="Annotation 2023-05-27 121347.jpg" style="height:321px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis. A and B report 165 &#956;g/kg sodium nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively. C reports the number of arterial branches between PBS and nitrite therapies. D and E illustrate vascular casting of the arterial vasculature in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively. *, P &lt; 0.01 vs. sodium nitrite. N = 10 mice per treatment group. Kumar D., et.al., PNAS;2008; 105:7540-7545. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nitrite Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g7.jpg" alt="Annotation 2023-05-27 121529.jpg" style="height:440px;margin-bottom:5pt;vertical-align:text-bottom;width:429px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unilateral femoral artery ligation was performed on 18-20 week old male Db/Db mice. Mice were randomized to PBS or sodium nitrite (165 &#956;g/kg) therapy twice daily via I.P. injection. Laser doppler flowmetry was performed at the indicated time points. Increased wound dehiscence was noted in the PBS treated animals at day 7 but not in nitrite treated animals. (Bir, et al., Diabetes 2014, 63(1):270-81).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nitrite Therapy Increases Diabetic Ischemia Induced Angiogenesis</span></div><div style="margin-top:12pt"><img src="jan-20231230_g8.jpg" alt="Annotation 2023-05-27 121649.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:588px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nitrite therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs. Nitrite therapy significantly restored endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic conditions. These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16; Stepp et al Microcirculation 2007 14(4-5): 311-6).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delayed Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow</span></div><div style="margin-top:12pt"><img src="jan-20231230_g9.jpg" alt="Annotation 2023-05-27 122116.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Studies were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after femoral artery ligation. Femoral artery ligation was performed in C57BL/6J mice and the animals </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">randomized to either PBS or sodium nitrite therapy 5 days after artery ligation. Treatments were given b.i.d. via I.P. injection. Ischemic limb blood flow was measured using laser doppler flowmetry. (Bir, et al., Diabetes 2014, 63(1):270-81).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delayed nitrite therapy increases SPY angiogram arteriogenesis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><img src="jan-20231230_g10.jpg" alt="Annotation 2023-05-27 122308.jpg" style="height:580px;margin-bottom:5pt;vertical-align:text-bottom;width:430px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delayed nitrite therapy increases SPY angiogram arteriogenesis. Representative temporal SPY angiogram image stills (3&#8211;6s) are shown at 11 days following ligation and 6 days after beginning therapy (either PBS or sodium nitrite). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Left</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: PBS control angiogram. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: sodium nitrite angiogram following injection of ICG. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">= 5 animals per cohort. Circles identify limb anatomical regions of vascular blush, whereas arrows indicate perfused vessels that progressively occur over time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bir, et al., Am J Physiol Heart Circ Physiol 2012;303:H178-H188.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nitrite Therapy Prevents Tissue Necrosis in Aged Db/Db Mice</span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g11.jpg" alt="Annotation 2023-05-27 122514.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delayed sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post-femoral artery ligation in nine-month old Db/Db mice. Nitrite therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A). Panel D reports tissue necrosis severity as a function of degree of limb and digit involvement. Nitrite therapy, but not PBS control or sodium nitrate, significantly prevented tissue necrosis. (Bir, et al., Diabetes 2014, 63(1):270-81).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nitrite and Hind Limb Ischemia Summary</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sodium nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood pressure when given acutely. The above studies indicate that chronic administration at low doses promotes angiogenesis, unlike one-time nitrite therapy, which does not stimulate angiogenesis. In addition, these studies and a large number of other studies not reviewed above show:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Nitrite therapy is very specific, acting only in damaged, ischemic tissue;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Delayed nitrite therapy effectively restores ischemic tissue blood flow;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Nitrite therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart failure, and tissue necrosis; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Nitrite supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Beneficial effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Sustained release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">JAN101</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN 101 is designed to treat diseases associated with poor vascular function. The following table summarizes our current product candidate:</span></div><div style="margin-top:12pt;text-align:justify"><img src="jan-20231230_g12.jpg" alt="Annotation 2023-05-27 122643.jpg" style="height:81px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pain</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. The National Institutes of Health (the &#8220;NIH&#8221;) defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public health problem in the United States that costs society between $560 billion and $635 billion annually. Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University, more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and presenting patients and physicians with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad. Given the properties of JAN101, we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Peripheral artery disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peripheral artery disease (&#8220;PAD&#8221;) is a general term for conditions in which arterial blood flow to the limbs is partially blocked. When there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also known as &#8220;intermittent claudication.&#8221; In many patients, pain and fatigue are relieved through rest. Roughly half of patients with PAD are asymptomatic. The most common cause of PAD / intermittent claudication is atherosclerosis. Diabetes, chronic kidney disease, hypertension, and smoking are all risk factors that can increase the likelihood of PAD. In atherosclerosis, fat deposits (plaques) build up along arterial walls, resulting in a reduction in blood flow in the legs. This same process can cause strokes if the arteries leading up to the brain are affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the high rate of asymptomatic patients, prevalence figures vary widely. Some estimate that up to 200 million people worldwide have PAD, ranging from asymptomatic disease to severe. Prevalence increases as a function of patient age, rising sharply after the age of 60. Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase. There is also a strong ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences. Some suggest a prevalence of eight to 12 million in the United States alone, with roughly one-third experiencing pain when walking, which improves upon resting. The diagnosis of PAD usually begins with patient complaints of pain in the extremities. If the patient is already being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity. Decreased blood pressure, poor wound healing, and whooshing sounds (via stethoscope) in the legs are also tell-tale signs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of PAD / intermittent claudication. Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.</span></div><div style="margin-top:12pt;padding-left:36pt"><img src="jan-20231230_g13.jpg" alt="18902" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Figure 1: Ethnic-specific prevalence of PAD in men in the US, by age. NHW = Non-Hispanic Whites, <br/>AA = African American, HS = Hispanics, AS = Asian Americans, AI = American Indians. Source: (Criqui, 2015)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-drug treatment of PAD / intermittent claudication may be divided into four general categories:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Lifestyle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Primarily changes in diet and smoking cessation.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Exercise </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Patients who walk, cycle, stretch, or swim can experience marked improvement. Formal programs involving treadmills and track walking (usually three to five times per week) are frequently provided to patients. However, if the pain is triggered by exercise (claudication) and is significant, it can discourage the patient from exercise.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Angioplasty </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; A procedure by which the affected artery is stretched with a balloon-like device. This procedure has limited effectiveness and is reserved for severely blocked arteries.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Bypass Surgery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Arteries that are beyond angioplasty can be bypassed entirely. This procedure is typically reserved for cases where the blockage is considered very long (~10 centimeters) and nearly complete.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying condition is not addressed by surgery. Surgical approaches will not, in the long run, improve exercise capacity and walking distance. Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prescription drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity: </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Cholesterol-Lowering Agents &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Statins and bile acid sequestrants. </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Antiplatelet Medications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Aspirin and related drugs, such as clopidogrel. Cilostazol also has antiplatelet properties. </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Antihypertensives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Patients with underlying high blood pressure can and will receive any number of medications to reduce blood pressure, such as ACE inhibitors and diuretics.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Diabetes Therapies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; While a substantial portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown if aggressive treatment of diabetes has a positive effect on PAD.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Pain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; To our knowledge, no drugs are specifically indicated for PAD-associated pain. Pentoxifylline, for example, is indicated &#8220;&#8230;for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs.&#8221; (Sanofi-Aventis U.S. LLC, 2010). However, the evidence supporting the effectiveness of pentoxifylline is mixed. Short-term courses of NSAIDs, such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as ibuprofen, may be used, provided the patient is not on another anticoagulant, like aspirin. Non-drug pain relievers, such as TENS and massage therapy, may also be used in these patients. Opioids may also be used, which creates a risk for addiction and potential misuse at the medicine cabinet by family members.</span></div><div style="margin-top:12pt;text-indent:36pt"><img src="jan-20231230_g14.jpg" alt="img253501747_13.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function and reducing pain in PAD patients, has created an opportunity potentially to treat this large unmet medical need. By improving vascular function, JAN101 has the potential to reduce associated pain and improve PAD patients&#8217; quality of life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Strategy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission are the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">License, acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging our understanding of pain biology to address the large and growing problem of pain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While innovation in medical sciences has led to exciting new treatment options in many disease areas, pain has seen limited innovation in recent years. We have a deep understanding of the pathophysiology of pain and diseases that cause pain. We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted acquisitions of companies or assets in development. Our advisors and doctors have years of collective experience in leadership positions at institutions and substantial scientific experience and understand the complexity of designing and executing clinical trials for and developing therapies.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Advance the development of JAN101, designed for the treatment of patients with PAD and pain associated with the disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There are limited therapeutic options available for patients with PAD and we believe that JAN101 has the potential to transform the standard of care to a twice-a-day pill to improve moderate-to-severe PAD substantially.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Leverage clinical activity of JAN101 possibly to expand into new indications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in discussion with multiple researchers about expanding JAN101&#8217;s use into other indications. JanOne will provide the researchers previously manufactured clinical supplies of JAN101 for use in their clinical trials. </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Advance JAN101 through clinical development and pursue development of additional product candidates through acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our objective is to build a well-balanced, multi-asset portfolio targeting the large population of patients with chronic and acute pain. To achieve this, in addition to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN101, we intend to pursue partnerships, licensing agreements, and potential acquisitions of other pharma companies. We continue our search for assets with indications where we believe they could have meaningful impact and address the large unmet medical need. In addition, we may choose to selectively in-license or acquire complementary product candidates by leveraging the insights, network, and experience of our team.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Maximize the commercial potential of all our product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain all commercial rights to JAN101 in the United States and selectively partner outside of the United States. Because we believe that PAD is an attractive market for many major pharmaceutical companies, we may sub-license or partner certain indications if we believe it may enhance stockholder value. As we continue to build and develop our product portfolio, we may opportunistically pursue strategic partnerships that maximize the value of our pipeline while seeking to develop other indications. </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Leverage our management team background and expertise. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a team with extensive experience described above. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Chronic Pain</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months. We believe that chronic pain represents a significant public health crisis. It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public health problem in the United States that costs society between $560 billion and $635 billion annually. Chronic pain is the leading cause of long-term disability in the United States, and approximately 23 million adults in the United States experience severe pain over a three-month period. Globally, the prevalence of chronic pain is even larger, with over one billion people worldwide affected each year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons, ligaments, and other soft tissues. Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis, spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury, and general trauma.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing fibers. These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different locations in the body to the brain, which registers this information as a sensation of pain. In the case of tissue injury due to trauma or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing by inhibiting use of the affected body part.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain also can modify the central nervous system, such that the brain becomes sensitized and registers more pain with less provocation. This is called central sensitization. When central sensitization occurs, the nervous system goes through a process called wind-up and gets regulated in a persistent state of high reactivity. This persistent, or up-regulated, state of reactivity lowers the threshold for what triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but a disease in itself.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Therapeutic Approaches to Treating Chronic Pain and Their Limitations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NSAIDs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the most widely used therapies to treat chronic inflammatory pain are non-steroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;). NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney problems, heart problems, and rashes. On April 7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular risk for all NSAIDs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Corticosteroids</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corticosteroids, or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically or locally, depending on the condition. Steroids work by decreasing inflammation and reducing the activity of the immune system. While steroids are commonly used, they may have numerous and serious side effects. These side effects may include allergic or hypersensitivity reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density, and loss of joint cartilage volume. In addition, steroids should not be administered when there is an infection present because steroids can inhibit the body&#8217;s natural infection-fighting immune response. Also, if a joint is already damaged or is subject to chronic deterioration, intra-articular, or IA steroid injections are not likely to provide any long-term restorative benefit. For the above reasons, IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four times per year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Opioids</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opioids are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999 and 2010. According to a National Survey on Drug Use and Health report, in 2016 more than one-third of adult Americans were prescribed opioids and 230 million opioid prescriptions were written that year in the United States. Opioids act by binding to specific receptors located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord, and other nervous tissue. Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by an increase in the abuse and misuse of prescription opioids. In addition, for most patients, chronic opioid use is a poor option due to an intolerance to the many side effects, including nausea, vomiting, drowsiness, and constipation, and the propensity for opioids to become less effective with long-term use. According to the Centers for Disease Control and Prevention (the &#8220;CDC&#8221;), almost two million individuals abused or were dependent on prescription opioids in 2014. CDC figures show that the number of opioid-related overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States involve a prescription opioid. This increase in prescription opioid-related deaths in the United States prompted former President Trump to declare the opioid crisis a national Public Health Emergency in October 2017. Opioid abuse has become an epidemic in the United States, ranking as the nation&#8217;s second most prevalent illegal drug problem. These major issues create the need to find new approaches to treating chronic pain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Approach to Treating PAD and Chronic Pain</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available. Some of the reasons for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological mechanisms for pain. However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to identify new drug targets and develop new therapeutic strategies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology of pain. Pain is variable. For example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of the body or it may be generalized throughout. We believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal. We strive to maximize JAN 101&#8217;s potential based on its unique mechanism of action related to the origin of the pain signal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Background:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Objectives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained-release formulation of sodium nitrite (SR-nitrite) in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported previously by subjects receiving the same doses of an immediate release formulation. Study Design: Phase II, single-center, randomized, double-blind, placebo-controlled clinical trial. Setting: The Ohio Pain Clinic and Kettering Medical Center.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Methods:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks. The primary objective was to determine whether headaches would be reduced using SR-nitrite. The primary efficacy endpoint was the mean difference in the change of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported after 12 weeks of treatment. Secondary endpoints included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short-Form McGill Questionnaire, daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx, and quantitative sensory testing. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The number of subjects reporting adverse events and the number of adverse events did not change with dose. There were no reports of treatment-related headaches. Although no significant differences were identified in patient responses to the questionnaires, a trend was observed. In the NPSI assessment, patients in the 40 mg and 80 mg dosing groups reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group. A trend was also observed with the BPI total severity score. However, the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores, where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups. Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity. No changes were observed in HbA1c levels or PulseOx.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Small sample size.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite. In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain. Similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study. The 80 mg BID treatment had the more pronounced effect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dosing group had the greatest improvement in Flow Mediated Dilation . The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Microcirculatory injury, which is common in diabetic patients, can lead to a number of problems. Prominent among these is diabetic peripheral neuropathy (DPN). About 10% of patients will have evidence of DPN at the time they are initially evaluated, and almost 50% of diabetic patients will ultimately develop DPN. Of diabetic patients with DPN, 40% to 50% suffer from chronic pain, as well as paresthesia, sensory loss, and weakness, and have at least an eight-fold increased risk of undergoing a distal lower extremity amputation compared to similar non-diabetics. Endothelial cells play an important part in the regulation of microcirculation, as they maintain vascular tone by secreting both vasodilators and vasoconstrictors. A central feature of diabetic microvascular disease (MVD) is endothelial dysfunction, which, in turn, plays an important role in the development and progression of DPN. The pathophysiological factors leading to endothelial dysfunction in diabetes include chronic hyperglycemia and protein glycosylation, insulin resistance, inflammation, and increased oxidative stress. Studies have now shown a close relationship between endothelial dysfunction and diminished nitric oxide (NO) bioavailability. Endogenously produced NO has a half-life measured in seconds, and is rapidly oxidized to nitrite (NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;) and nitrate (NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;) end-products, the latter of which is biologically inert. In the presence of microcirculatory ischemia and endothelial cell dysfunction, however, endogenous NO production by eNOS is much more limited. In such circumstances, circulating NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> can be non-enzymatically reduced to increase NO availability. In addition to serving as a circulating NO reservoir, nitrite itself has also been shown to have direct and potent vasodilatory effects in vitro and in vivo. The findings that NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; mediates vasodilatation, both directly and through NO generation, has led to growing interest in the potential effectiveness of nitrite as a therapeutic agent in conditions associated with DPN and endothelial dysfunction. Such conditions include diabetic microvascular disease, DPN, and retinopathy, in which low levels of NO and NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;, as well as elevated levels of nitrate (NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;), suggest that the complete oxidation of NO occurs during diabetes with insufficient NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; reserves to restore NO bioavailability. Previous human studies with an oral formulation of NaNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have shown that administration twice daily improves vascular function. In the peripheral arterial disease study, subjects who received the lower dose of NaNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reported a significant reduction in pain. Although side effects were minimal, headaches and dizziness were reported by a large number of subjects, likely due to the rapid release of NaNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> leading to vasodilation. An oral, sustained-release formulation of NaNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (SR-nitrite) was developed in an attempt to overcome these problems and was tested in a porcine model of metabolic syndrome with critical limb ischemia. SR-nitrite-treated animals showed increased myocardial NO bioavailability, diminished oxidative stress, and cytoprotection in ischemic tissue. Importantly, 24-hour telemetry recordings of blood pressure showed no evidence of vasodilation. In the above study, we hypothesized that the SR-nitrite would reduce or eliminate headaches reported in patients following administration of the immediate release formulation. Given the promising results on reducing pain in diabetic patients with PAD reported in the previous study, patients with diabetic neuropathy were utilized in this study to determine whether any trends in reducing pain could be observed. The study design was a randomized, placebo controlled, double-blind phase II study was carried out to investigate the safety and potential biological activity of multiple doses of an oral, sustained-release formulation of sodium nitrite (SR-nitrite; TheraVasc Inc., Cleveland, OH, USA), BID in doses of 40 mg and 80 mg over a 12-week treatment period, in human subjects with diabetes and neuropathic pain in the lower extremities and feet. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial was approved by the Copernicus Group Institutional Review Board and listed on ClinicalTrials.gov: www.clinicaltrials.gov/ct2/show/NCT02412852. The study was funded by TheraVasc Inc. (&#8220;TheraVasc&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JAN101&#8212;Regulatory Strategy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sodium nitrite has been previously approved as one of the active components of cyanide poisoning antidote. This means the approval path for JAN101 is through a 505(b)(2) (&#8220;NDA&#8221;), which we intend to pursue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JAN101&#8212;Commercial Strategy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to use third-party providers and manufacturers to support the commercialization JAN101, if we are successful in obtaining FDA approval. We believe that we can promote JAN101 to the patients suffering from PAD in a cost effective manner. We anticipate our commercial operation will include outside sales management, outside sales support, distribution support, and an internal marketing group. Additional requisite capabilities will include focused management of key accounts, such as managed-care organizations, group purchasing organizations, and government accounts. We intend selectively to partner with third parties with vast experience in the space, as we have been partnering for every aspect of development. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Competition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We are currently focused on the development and commercialization of our asset pipeline of novel, non-opioid, and non-addictive therapies for PAD. The number of patients suffering from chronic PAD is large and growing. While we believe that JAN 101 and our Chief Scientific Officer&#8217;s development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies that market or develop therapeutics to treat chronic pain. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. The key competitive factors affecting the success of JAN 101 (as well as other subsequent product candidates), if and when approved, is likely to be its efficacy, durability, safety, price, and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant competition exists in the PAD pain field. Although we believe our approach to developing novel treatments for pain is unique from most other existing or investigational therapies, such as NSAIDs, corticosteroids, and opioids, we will need to compete with all currently available and future therapies within the indications where our development is focused. With respect to JAN101, the main classes of marketed products that are available for the treatment of PAD pain include NSAIDs and opioids. Furthermore, numerous monoclonal antibodies targeting nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase III.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with JAN 101, including many major pharmaceutical and biotechnology companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to operate without infringing or otherwise violating the proprietary rights of others. We endeavor to protect our products using a combination of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines. For example, we endeavor to protect our products by, among other methods, filing United States and foreign patent applications related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We also use other forms of protection, such as confidential information, trade secrets, and know-how, and trademarks to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proprietary nature of, and protection for, JAN 101, processes, and know-how are important to our business. Our policy is to pursue, maintain, and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trade Secrets and Other Proprietary Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed methods for more efficient manufacture of sustained released sodium nitrite tablets. We seek to protect our proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2019, we entered into a Patent and Know How License Agreement (the &#8220;License Agreement&#8221;) with UAB Research Foundation (&#8220;UABRF&#8221;), TheraPAD, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting on behalf of LSU Health Shreveport, together with UABRF and TheraPAD collectively, the &#8220;Licensors&#8221;). Under the License Agreement, the Licensors have agreed to grant to JanOne an exclusive, worldwide license, including the right to sublicense, to the Licensors&#8217; patent rights and know-how related to the Licensors&#8217; sustained release formulation of sodium nitrite. Under the License Agreement, we have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement of certain milestones of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees. The License Agreement requires us to use commercially reasonable efforts to develop and commercialize JAN101. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Soin Therapeutics</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JanOne acquired Soin Therapeutics, a company focused on the development of a novel formulation of low-dose naltrexone (&#8220;LDN&#8221;) for the treatment of chronic regional pain syndrome (&#8220;CRPS&#8221;) in 2022. CRPS is a rare pain disorder, characterized by a complex set of symptoms, affecting approximately 200,000 patients annually in the US. There are currently no approved treatments for patients with CRPS. Prior to the acquisition, Soin Therapeutics received Orphan Drug Designation for the product, which provides a variety of incentives for developing the product in this indication.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">JAN123</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Generally</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN123 is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for an immediate release of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially, a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Naltrexone</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Naltrexone was first synthesized in 1965 and approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan. Later it was approved for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to ReVia. A depot formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid dependence in 2010. Typical oral doses are 50 to 100 mg daily, with a once-monthly intramuscular formulation also available. At these doses, Naltrexone has been shown to function as a nonselective opioid antagonist with a high affinity for &#181; opioid receptors, which decreases addiction cravings (Schumacher, Basbaum et al. 2017, Opioid Agonists &amp;amp; Antagonists. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basic &amp;amp; Clinical Pharmacology, 14e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. B. G. Katzung. New York, NY, McGraw-Hill Education). However, there is a risk that patients who are non-compliant with oral naltrexone may experience opioid intoxication simply by skipping doses of naltrexone. Oral bioavailability is also variable from patient to patient, largely due to first-pass metabolism. Thus, naltrexone is pharmacologically effective, but may be ineffective in a real world setting without counseling and strong patient support (Minozzi, 2011, Oral naltrexone maintenance treatment for opioid dependence. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chchrane Database Syst Rev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4), CD001333). There are also multiple generic Naltrexone tablets available on the market for oral administration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Low-Dose Naltrexone (LDN)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to the standard dose, LDN is defined as a daily dose of Naltrexone of 1 to 5 mg, which is 10- to 100-fold lower than the dose used to manage substance use disorders (LDN Research Trust, Toljan and Vrooman 2018, Low-Dose </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Naltrexone (LDN)-Review of Therapeutic Utilization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Med Sci (Basel)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)). Off-label uses of Naltrexone at lower doses have been explored based on a different mechanism of action for the treatment of inflammatory, rheumatologic, and neurologic conditions. These include multiple sclerosis, fibromyalgia, Crohn disease, chronic fatigue syndrome (CFS), and, more recently, CRPS. At the low doses used for these conditions, Naltrexone is thought to act as an immune modulator. Some speculate that this effect is related to reduced neuroinflammation in the case of disorders like CFS (Cant, Dalgleish et al. 2017, Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Front Immunol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: 809). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evidence suggests that, at low doses, Naltrexone antagonizes TLR4 on activated glial cells without the previously mentioned function as a mu-opioid receptor antagonist (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone LDN). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">J Neuroimmune Pharmacol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3): 470-476.). TLR4 has been shown to be a key mediator of microglial activation, which has been identified as a causal mechanism of neuropathic pain in CRPS. Microglial activation is associated with the release of pro-inflammatory cytokines, reactive oxygen species, and prostaglandins, which amplify the inflammatory response (Carniglia, Ram&#237;rez et al. 2017, Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mediators of Inflammation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: 5048616). Thus, LDN presents a promising therapeutic avenue for the treatment of CRPS, a condition in which TLR4 upregulation is a primary pathway, through attenuation of glial activation and direct targeting of TLR4 activity (Del Valle, Schwartzman et al. 2009, Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Brain Behav Immun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1): 85-91. By downregulating the inflammatory cytokine release, LDN should be beneficial for CRPS patients. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRPS patients suffer from severe debilitating pain, and even light touch or benign stimulation elicits extreme amounts of pain. Microglial cells and glial cells oftentimes are involved in this pain-signaling pathway. By reducing glial cell activation, Low-dose Naltrexone can treat this pain syndrome. Another potential mechanism of action of LDN treatment on pain is a paradoxical upregulation of opioid signaling. It is noted that, when taken at bedtime, the short-acting low-dose Naltrexone binds to receptors, which leads to a brief blockade of opioid receptors between 2 and 4 a.m. This blockade is believed to upregulate vital life elements of the body and cause an increase in endorphin and enkephalin production. This increase in endorphins and enkephalins will likely cause a decrease in pain that the patient experiences overall. Therefore, LDN leads to transient opioid receptor blockade, which triggers a positive feedback mechanism that increases the production of endogenous opioids (endogenous endorphins and enkephalins) and opioid signaling (Ludwig, Zagon et al. 2017, Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exp Biol Med (Maywood)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15): 1524-1533; Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Med Sci (Basel)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)). Together, these mechanisms may work to alleviate pain associated with CRPS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interestingly, low-dose Naltrexone also has effects on the peripheral nervous system. In the peripheral nervous system, it was found that low-dose Naltrexone can modulate T and B lymphocyte production. And it was noticed that low-dose Naltrexone could reduce interleukin 6, interleukin 12, and tumor necrosis factor alpha in the periphery regarding peripheral nervous systems. CRPS patients often have an increase in inflammatory cytokines and may often note an increase in interleukin 6, 12, and tumor necrosis factor alpha. By reducing these inflammatory cytokines back to a normal state, it is predicted that low-dose Naltrexone could treat the actual disease state of CRPS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In summary, low-dose Naltrexone has a very specific mechanism of action that will distinctly treat CRPS through inhibition of inflammatory cytokines, glial cell activation, neuroinflammation, and increase of endogenous enkephalins and endorphins. In other words, low-dose Naltrexone is not just treating the symptoms with this medication but also treating the underlying disease state and process specific to CRPS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Chronic Regional Pain Syndrome (CRPS)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRPS, also termed reflex sympathetic dystrophy (RSD), is a chronic, orphan neurologic condition that typically affects the extremities after trauma or nerve injury, and can cause severe pain. As the most common and prominent symptom of CRPS, the pain is often deep inside the limbs with a burning, stinging, or tearing sensation. Sensory changes are also common and may include increased sensitivity to painful stimuli, feeling pain from stimuli that are usually non-painful, and in some instances, sensory loss (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, numbness). In addition to pain, patients commonly experience an affected extremity that is warm, red, and swollen, at least initially. As CRPS progresses, it becomes refractory to sympathetic nerve blocks, conventional analgesics, anticonvulsants, and antidepressants. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRPS is a rare neurologic disease. It is a painful progressive condition and is listed in the rare disease database of the National Organization for Rare Disorders (NORD). CRPS is subdivided into two categories: type I and type II CRPS. In CRPS type I, there are no nerve injuries or lesions identified. CRPS type I is also known as &#8220;reflex sympathetic dystrophy,&#8221; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and it comprises about 90 percent of all cases of CRPS. CRPS type II (causalgia), on the other hand, is diagnosed when there is evidence of nerve damage. As described in the NORD, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year and the incidence rate of CRPS type 2 was 0.82 persons out of every 100,000 per year, giving rise to a combined incidence rate for both CRPS types I and II of 6.28 per 100,000 person-years (Sandroni, Benrud-Larson et al. 2003, Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1-2): 199-207; Goh, Chidambaram et al. 2017, Complex regional pain syndrome: a recent update. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Burns Trauma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: 2.). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying cause of CRPS is not well understood. In most cases, it occurs after an illness or injury that did not directly damage the nerves in the affected area (Type I). In some cases, it occurs after a specific nerve injury (Type II). The exact trigger of CRPS after an injury is not known, but it may be due to abnormal interactions between the central and peripheral nervous systems and/or inappropriate inflammatory responses. There are multiple factors that may contribute to CRPS development, including immobilization, alterations to the nervous system of the body, and inflammation. Genetic factors and psychological factors, such as anxiety, depression, and anger, may also contribute to the symptoms of CRPS. However, there is no evidence that CRPS is a disease that can be caused by genetic factors alone, and the role of psychological factors in CRPS development remains unproven. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRPS is treated by approaching it from different areas: physical therapy (PT), occupational therapy (OT), medications for pain management, neuromodulation through implantable devices, and/or nerve blocks targeting the sympathetic chain. Neridronate and zoledronate D,L-lysine monohydrate (ZLM) has been designated as an orphan drugs for the treatment of CRPS in 2013 and 2015, respectively. However, neither of them has been approved. Thus, there is no current FDA-approved drug for CRPS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Studies of LDN on CRPS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LDN has been widely used for chronic pain and inflammatory condition and has been shown to alleviate symptoms of pain in patients with chronic pain. A number of case studies have also reported positive effects for LDN in the treatment of CRPS. Chopra et al. reported 2 patient case studies with CRPS who experienced significantly less pain with 4.5 mg daily LDN treatment (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone (LDN). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">J Neuroimmune Pharmacol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3): 470-476). The remission of pain and dystonic spasms in Case 1, as well as remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence that a multi-modal interventional approach, which includes low-dose Naltrexone (a known glial attenuator), should be considered as a treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders. In another CRPS case study, Sturn and Collin found alleviation of pain symptoms as early as 2 days after beginning LDN therapy, with significantly less pain at 4 weeks (Sturn and Collin 2016, Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Int J Pharm Compd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3): 197-201). Weinstock et al reported alleviation of pain symptoms within one month of LDN treatment, with complete remission of CRPS leg symptoms by 16 months (Weinstock, Myers et al. 2016, Identification and Treatment of New Inflammatory Triggers for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">A A Case Rep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9): 272-276). In a recent case study, an CRPS patient was able to discontinue gabapentin and amitriptyline via the use of LDN, while simultaneously achieving superior pain relied (Soin, 2021, Management of pediatric complex regional pain syndrome with low-dose naltrexone. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pain Medicine Case Reports, 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3), 109-113). LDN has been reported to have benefits related to other symptoms of chronic pain syndromes as well, including dystonic spasms, CRPS flares, energy, sleep disturbances, and mood.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systematic literature review of LDN use showed that the most commonly reported AEs with LDN use were dizziness, vomiting, nausea, and vivid dreams (Soin et al. 2021, Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pain Physician</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4): E393-E406.). Other reported AEs included headaches, abdominal pain, gastrointestinal issues, peripheral edema, restlessness, falls, somnolence, irritability, hematological abnormalities, urinary infection, difficulty concentrating, anxiety, sleepiness, hot flashes/sweating, tachycardia, depression, muscle and joint pain, fatigue, tinnitus, heartburn, dry mouth, and joint pain. Another systematic review also evaluated occurrence of adverse events (AEs) and serious adverse events (SAEs) with LDN use and found that only mild AEs reported among the included studies (89 studies), including nausea, vomiting, and dizziness (Bolton, Hodkinson et al. 2019, Serious adverse events reported in placebo randomized controlled trials of oral naltrexone: a systematic review and meta-analysis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">BMC Med</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1): 10). Although 119 patients reported at least one SAE in the naltrexone study arm, meta-analysis found no difference between occurrence of SAEs in naltrexone and placebo groups. Furthermore, secondary analysis found only 6 AEs that were statistically significant: decreased appetite, dizziness, nausea, sleepiness, sweating, and vomiting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Efficacy of low-dose naltrexone treatment on CRPS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Author (year)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symptoms</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symptoms alleviated</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time to alleviation of symptoms</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AEs and SAEs</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chopra et al (2013)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">swelling, allodynia, color change, temperature change, some weakness, blisters, skin ulceration, dystonic spasms, dysesthesia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dystonic spasms, CRPS flares, energy, pain tolerance, sleep disturbances, pain, mood</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&lt; 2 months</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5 mg/day</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sturn et al (2016)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 days</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 mg</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weinstock et al (2016)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe leg pain, episodic pain in arms and nose, asymmetric and shiny skin with fluctuating temperature changes, color change, edema, IBS, atypical chest pain and fatigue, edema, blue discoloration, tenderness, joint hypermobility with EDS diagnosis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leg and bowel symptoms; all CRPS pain, bowel symptoms, and fatigue</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&lt; 1 month</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5 mg/day</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Orphan Drug Designation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An orphan disease is a rare disease affecting fewer than 200,000 people in the US. It is often a serious or fatal condition for which there are no effective therapies. In 1983, the Orphan Drug Act was passed to incentivize companies to develop drugs for patients with rare diseases. Orphan drug designation provides incentives to companies, including:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Tax credits for qualifies clinical trials</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Exemption from user fees</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Potential for seven years of market exclusivity after approval</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given the small number of patients with a disease and the severity of the disease, approvals are often granted with fewer and smaller trials, saving costs and time. JAN123 was granted Orphan Status for the treatment of CRPS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LDN can be rapidly developed in the US via the 505(b)(2) regulatory pathway. This pathway is used for candidates that contain drugs that are already approved but come in a dosage form or delivery system that is different than the original, approved product. In this case, JAN123 fits these criteria perfectly. LDN has the added benefit of being developed at a much lower dose (&lt; 5 milligrams) compared to approved naltrexone products, which are 50 milligrams per tablet. Therefore, it is likely that product development will consist of the following general steps:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Manufacturing and approval of clinical batches of LDN tablets prior to clinical studies; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase I pharmacokinetic study(ies) to confirm the release profile of LDN; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A single Phase III study to demonstrate efficacy in CRPS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protocol synopsis of the development plan is presented below: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of study </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: The Pharmacokinetincs of LDN in the fed and fasted state of a Single Oral Dose of LDN, 4 mg <br/>Phase III: Double-Blind Placebo-Controlled Trial of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome (CRPS)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Phase </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: The Pharmacokinetincs of LDN in the fed and fasted state <br/>Phase III: Registration/Efficacy Study to hopefully facilitate an NDA application for the use of low-dose naltrexone to treat CRPS</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Objectives:</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: To determine pharmacokinetics of single oral low-dose naltrexone in healthy participants in fasting and fed state<br/>Phase3: The primary objective is to assess the efficacy of low-dose naltrexone in treating complex regional pain syndrome symptoms (CRPS).<br/>We plan to conduct a double-blind, randomized, placebo-controlled trial to treat CRPS using low-dose naltrexone.<br/>For Efficacy: <br/>1- Assess daily NRS (numerical pain scale 0 &#8211; 10) scores through the 3-month study<br/>2- Study the possible changes or improvement in the Brief Pain Inventory (BPI) and Oswestry Disability Index (ODI) over the three-month study<br/>For Safety:<br/>We will also monitor safety labs on enrollment and termination of the study. However, we would like to point out that this drug has been available and FDA approved at much higher doses (50 &#8211; 150mg or higher) orally with a long-standing proven safety track record. The drug has been available with multiple different embodiments, route of administration and at much higher doses for quite a long time and the safety of the drug has already been extensively established and published.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investigational product </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN123</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Study Design</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1: Single-center, dual-arm, cross-over, open-label study <br/>Phase 3: Study Description<br/>We plan to conduct a randomized, double blind placebo controlled trial to treat Complex Regional Pain Syndrome. The study duration will be three months long. Patients in the treatment group will receive a single tablet for the first month of a 2mg dose of Naltrexone. Then, after 1 month, the patient will take 2 tablets for a total of 4mg for months 2 and 3. Study conclusion will be after 3 months.<br/>Patients in the placebo group will take a single tablet for 1 month followed by 2 tablets for month 2 and 3. <br/>A total number of 200 patients with a 1:1 randomization will used. Since CRPS is an orphan disease, we will likely have to use a total of 25 clinical sites or more to be able to adequately recruit the study.<br/>Safety labs will be completed prior to first dose and upon study completion.<br/>For clinical efficacy, we will be assessing daily NRS (1-10) pain scores, a brief pain inventory (BPI) at enrollment and at months 1, 2, and 3 (study completion) and Oswestry Disability Index (ODI) at enrollment and at months 1, 2, and 3 (study completion). Statistically significant improvement in pain scores or any scales in the BPI or ODI are desired outcomes.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treatment Regimen and Route of Administration</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study Drugs are as follows:<br/>Phase I: Single Oral dose of JAN123, 4 mg given on separate days with and without food separated by a washout period of no less than 7 days<br/>Phase III: Patients will be dosed with either the low-dose naltrexone or placebo for three months. Initially for the first month patients will take 1 tablet at bedtime (typically in the evenings) for the first month and then increase to 2 tablets for month 2 and 3. Specifically the Naltrexone will be 2mg tablets, such that for the first month with the 1 tablet per day the patient will be on 2mg doses and subsequently increase to 2 tablets in the evening for a total of 4mg.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Duration of treatment: </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: One day for each dose. Two doses of 2 mg each, in total, separated by a washout period of no less than 7 days.<br/>Phase III: This will be a 3 month trial or approximately 90 days. Upon enrollment, patients will be on either low-dose naltrexone or placebo for 90 days.<br/>Participant duration is expected to be 121 days, and at the conclusion of the study (approximately day 90 post-treatment) patients will come in for a final site visit to complete remaining surveys and within 7 days of completion the patients will obtain final safety labs which are anticipated to be a complete blood count and a comprehensive metabolic panel. Since Naltrexone is non-opioid based and does not have withdrawal issues, patients can immediately discontinue the therapy without concerns. As referenced earlier, the safety of Naltrexone orally is already well established and our tested doses are low.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Centers </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1: Single Center Clinical Trial<br/>Phase 3: Multicenter Clinical Trial<br/>Likely 25 total sites. Keeping in mind this is an Orphan Disease state and recruitment may be quite difficult, we feel the need to have 25 clinical sites to enroll 200 patients.<br/>Clinical sites will be likely Pain Management Centers, both academic and private practice facilities that have access to patients who suffer from CRPS and also include local PIs who have the skill set and ability to properly diagnose CRPS. <br/>Local or regional clinical trial coordinators will be assigned to each site as well.<br/>Enrolling participants are those who meet the diagnosis criteria of CRPS. Typically CRPS is diagnosed using the Budapest Criteria. Age range of 18 - 65 for enrollment, negative pregnancy test, and stable therapy for 3 months.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subjects:</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: Adult male and female healthy subjects, 18-65 years of age, satisfying all inclusion and exclusion criteria.<br/>Phase III: Patients diagnosed with CRPS (Complex Regional Pain Syndrome), Adult male and female patients, 18-65 years of age.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of <br/>Subjects</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I: 10 patients<br/>Phase III: 200 patients</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Endpoints</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase1: Primary Outcome Measure:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PK profile for low-dose naltrexone (Time Frame: Day 1: predose and at multiple time points after low-dose naltrexone administration).</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Maximum observed plasma concentration)</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Time to reach maximum plasma concentration)</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">AUC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">0-t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable concentration)</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">AUC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">0-inf</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Area under the plasma concentration-time curve from 0 hour extrapolated to infinity)</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CL/F (Oral clearance) </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3: </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary Outcome Measure: Improvement in NRS pain scores over a 3-month time period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Secondary Outcome Measure: Improvement in Brief Pain Inventory and Oswestry Disability Index (ODI) or other verified pain scales.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">End of Study will occur upon completion of the 90-day trial of the low-dose naltrexone or placebo. It is expected that patients will complete all required surveys and testing requirements of the study. Through March 8, 2023, the Company operated its legacy businesses, ARCA Recycling, Inc. (&#8220;ARCA Recycling&#8221;), ARCA Canada Inc. (&#8220;ARCA Canada&#8221;), and Customer Connexx, LLC (&#8220;Connexx&#8221;), in its Recycling segment. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling businesses. On March 9, 2023, we entered into a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada. The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early termination is also a possible way to end the study due to issues such as side effects, adverse events or patient desire to withdraw from the study, among other reasons.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Safety<br/>Assessments </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard clinical evaluation and objective measures will be employed to monitor and assess safety during the conduct of the trial. Furthermore, the results of safety assessments will be used during the trial to monitor and protect the safety of enrolled subjects. Strict subject and study stopping criteria will be implemented to protect the subject's well-being.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of Naltrexone is off-patent and generic versions of the drug are available at 50 mg doses. LDN has been routinely compounded in compounding pharmacies and used clinically off-label. However, the 4.5 mg compounded tablets are associated with sleep disturbances, manifested in vivid and lucid unpleasant dreams. For these reasons, JAN-123 was developed as a biphasic release, orally available tablet to reduce the likelihood of unpleasant dreams. A provisional patent was filed in December 2020 and converted to a PCT application in November 2021 (Pub. No. US 2022/0202807 A1). US Patent number 11,752,143 B2 issued on September 12, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issued claims in this patent cover the use of the biphasic LDN formulation for treatment of patients with chronic pain. In addition, claims are made to the titration of the LDN for treating chronic pain. While there is no guarantee that the pending applications or future pending claims will issue, the issued US patent will provide protection of JAN123 through 2040 and the Orphan Drug Designation provides 7 years of market exclusivity after drug approval in the event that there are any challenges to this patent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trade Secrets and Other Proprietary Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed methods for more efficient manufacture of the biphasic LDN. We seek to protect our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Soin Purchase Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 28, 2022, we entered into a Purchase Agreement (the &#8220;Soin Purchase Agreement&#8221;) with Soin Therapeutics, LLC. Under the Soin Purchase Agreement, JanOne acquired Soin Therapeutics and its LDN product, now known as JAN123. This all- stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be issued to or transferred by Soin Therapeutics at any given time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Team</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tony Giordano, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Chief Scientific Officer, joined the Company in December 2019 from the Cleveland Clinic, the No.2 rated hospital in the country, where he served as Senior Director of Special Projects in the Business Development group. Dr. Giordano has extensive experience in drug development, having served as Vice President or President of seven different biotechnology companies he co-founded, including companies developing platform technologies, a cancer vaccine, and Alzheimer&#8217;s Disease and cardiovascular therapies. He has managed numerous clinical trials and the launch of a medical food product. Dr. Giordano has also served as an Associate Professor and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, Louisiana (&#8220;LSU Health Shreveport&#8221;), at which he led the licensing efforts at the campus and at Abbott Labs, where, in addition to serving as a Senior Research Scientist, he was involved in technology assessment activities. Dr. Giordano has a Ph.D. focused in Molecular Genetics from The Ohio State University and completed Fellowships at the NIH National Cancer Institute and the NIH National Institute of Aging.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we formed a Scientific Board of Advisors (the &#8220;SBA&#8221;) and the following doctors and scientists currently are members of our SBA:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chris Kevil, Ph.D., Chair of the Scientific Board of Advisors &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Kevil, an internationally known expert in vascular pathophysiology, PAD, and nitric oxide biology, discovered the role of sodium nitrite in promoting angiogenesis that led to the development of TV1001, now known as JAN101. Dr. Kevil earned his Ph.D. from LSU Health Shreveport in Molecular and Cellular Physiology, followed by a fellowship at the University of Alabama at Birmingham (UAB) with an emphasis on redox pathophysiology. Returning to LSU Health Shreveport in the Department of Pathology, he established cutting edge research programs regarding redox biology regulation of peripheral vascular diseases. This led to ground-breaking insights on how glutathione, nitrite/nitric oxide, and hydrogen sulfide regulate vascular health during ischemia. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Edgar Ross,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MD &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Ross is the current Director of the Pain Management Center at Brigham and Women&#8217;s Hospital and a professor of anesthesia at Harvard Medical School. Dr. Ross is recognized as Castle Connolly&#8217;s America&#8217;s top doctors for the fifth year in a row. In addition to serving as chairman of Pfizer&#8217;s partnership on pain, Dr. Ross also has served as a member of the Blue Cross and Blue Shield Opioid Prescribing Policy Committee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Cooke, MD, Ph.D. &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Cooke</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is the Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart &amp; Vascular Center in Houston, Texas. He trained in cardiovascular medicine and obtained a Ph.D. in physiology at the Mayo Clinic. He was recruited to Harvard Medical School as an assistant professor of medicine. In 1990, he was recruited to Stanford University to spearhead its program in vascular biology and medicine, and was appointed professor in the Division of Cardiovascular Medicine at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute until his recruitment to Houston Methodist in 2013. Dr. Cooke has published over 500 research papers, position papers, reviews, book chapters, and patents in the arena of vascular medicine and biology with over 30,000 citations. He has served on national and international committees that deal with cardiovascular diseases, including the American Heart Association, American College of Cardiology, Society for Vascular Medicine, and the National Heart, Lung and Blood Institute. He has served as president of the Society for Vascular Medicine, as a director of the American Board of Vascular Medicine, and as an associate editor of Vascular Medicine.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joshua Beckman, MD &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Beckman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is the Director of Vascular Medicine and the Gayle and Paul Stoffel Distinguished Chair in Cardiology at UT Southwestern Medical Center.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this, he founded and is director of the Section of Vascular Medicine in the Division of Cardiovascular and is Professor of Medicine at Vanderbilt University Medical Center. The overriding theme linking all of his career activities is vascular function in health and disease. Dr. Beckman&#8217;s primary research focuses on the mechanisms by which diabetes mellitus impairs vascular function. Secondary </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigations involve studying the effect on endothelial function of non-diabetes-related insulin resistance, androgen deprivation, and vascular function in venous bypass grafts. Dr. Beckman has been involved in numerous clinical studies and has published over 300 research papers with over 30,000 citations. In addition to a number of other journals, Dr. Beckman serves in editorial roles at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vascular Medicine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Circulation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two of the premier journals in the cardiovascular space. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nicolas Goeders, Ph.D. &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Goeders is a Professor and Head of the Department of Pharmacology, Toxicology and Neuroscience at LSU Health Shreveport. He has conducted addiction research for the past 30 years and is regarded as one of the world&#8217;s leaders on the role for stress in substance abuse disorder. His work has helped to determine the mechanisms responsible for how stress contributes to relapse to drug use. He has published over 100 manuscripts, has written 15 book chapters, and was issued five patents, one of which is a drug currently in clinical development. Dr. Goeders also serves as the Executive Director of the Louisiana Addiction Research Center.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have any marketing and sales organization. We have retained global rights to JAN-101 and JAN123, and, if either of them or one of our potential subsequent product candidates is approved by the FDA to market in the United States, we expect that our sales force will be supported by sales management, internal sales support, an outside marketing group, and distribution support. We intend to invest in our commercial capabilities prudently by focusing our marketing efforts on the physician subspecialties that treat patients with PAD. These physicians include, but are not limited to, pain management specialists, rheumatologist, surgeons, and sports medicine physicians. We will also evaluate licensing and partnering with third parties to help us reach other sales channels and geographic markets inside and outside of the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing. These agencies, and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">U.S. Government Regulation of Drug Products</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, the approval process, or thereafter, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;), regulations;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">approval by an institutional research board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">submission to the FDA of a new drug application (NDA);</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">payment of user fees and securing FDA and approval of the NDA; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), and the potential requirement to conduct post-approval studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pre-clinical Studies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some pre-clinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds also may be imposed by the FDA at any time before or during clinical trials, due to safety concerns about on-going or proposed clinical trials, or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Through the 505(b)2 regulatory path, the FDA allows a sponsor to rely on well documented, published studies to support the clinical development of the product. The FDA has indicated that it will accept published data in support of the Company&#8217;s development program for JAN101 but prior to filing an NDA would require the Company to complete developmental and reproductive toxicology studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website. The information contained in, or accessible through, this website does not constitute a part of this Annual Report. We have included this website address solely as an inactive, textual reference.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase I: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, and excretion and, if possible, to gain an early indication of its effectiveness.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase II: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to evaluate the efficacy of the product for specific targeted diseases preliminarily, and to determine dosage tolerance and optimal dosage.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase III: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate sufficient data statistically to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase II, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase II clinical trial to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe will support approval of the new drug. JanOne submitted briefing materials in 2021 describing the previous research and development activities and planned clinical trials. The Company is now working to implement suggestions by the FDA to be ready to submit a protocol amendment in late 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of product candidates and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">United States Review and Approval Process</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product development, pre-clinical, and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (the &#8220;PDUFA&#8221;), guidelines that are currently in effect, the FDA has a goal of 10 months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee; but, it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III trial or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA that addresses all of the deficiencies identified in the letter, or withdraw the application. Even if such additional data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase IV clinical testing, which involves clinical trials designed to assess a drug&#8217;s safety and effectiveness further after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products that already have been commercialized. The FDA may also place other conditions on approval, including the requirement for REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Food and Drug Administration Safety and Innovation Act (the &#8220;FDASIA&#8221;) made permanent the Pediatric Research Equity Act (the &#8220;PREA&#8221;), which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Special FDA Expedited Review and Approval Programs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from the &#8220;filing&#8221; date, rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials that establish that the drug product has an effect (i) on a surrogate endpoint that is reasonably likely to predict clinical benefit or (ii) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, including taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our initial (or subsequent) product candidates, as appropriate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user program fee requirements for any marketed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase IV clinical trials, and surveillance to assess further and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have promoted off-label uses improperly may be subject to significant liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Hatch-Waxman Amendments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval. First, the Hatch-Waxman amendments to the FDCA authorized the FDA to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner. The applicant may rely upon the FDA&#8217;s findings of safety and efficacy for an approved product that acts as the &#8220;listed drug.&#8221; The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug. The FDA may then approve a new product candidate for all, or some, of the label indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated new drug applications (&#8220;ANDAs&#8221;) for generic versions of branded drugs previously approved by the FDA (such previously approved drugs are referred to as &#8220;listed drugs&#8221;). An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications, and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness. However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug. The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the active pharmaceutical ingredient (the &#8220;API&#8221;) is absorbed into the bloodstream from the drug product and becomes available at the site of action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption of the generic product and the listed drug. For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially where rate and/or extent of absorption are difficult or impossible to measure. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the referenced NDA holder and patent owners assert a patent challenge directed to one of the Orange Book-listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant. The ANDA or 505(b)(2) application also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Marketing Exclusivity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">United States Coverage and Reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory approval. Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our initial or subsequent therapeutic product candidates can be subject to challenge, reduction, or denial by payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our initial or subsequent product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Healthcare Reform</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict or regulate post-approval activities, and affect the profitable sale of drug product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">major legislative initiatives. In March 2010, the Affordable Care Act, formally known as the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;), was enacted by Congress and signed into law by the President. It substantially changed the methods by which healthcare is financed by both the government and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things: (i) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid-managed care organizations; (ii) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; (iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; (v) expanded the eligibility criteria for Medicaid programs; (vi) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii) established a Center for Medicare &amp; Medicaid Innovation to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January 22, 2018, former President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of two percent per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">United States Healthcare Fraud and Abuse Laws and Compliance Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. The United States laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the federal Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act, which among other things, requires certain manufacturers of drugs, devices, and biologics that are reimbursable by a federal healthcare program to report annually to the United States Department of Health and Human Services information related to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">similar federal laws and state law equivalents of each of the above federal laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulation Outside of the United States</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that our initial or subsequent product candidates, if and when approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our future products in the European Economic Area (the &#8220;EEA&#8221;) and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (an &#8220;MA&#8221;). There are two types of Marketing Authorizations:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (the &#8220;EMA&#8221;) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, and auto-immune and viral diseases. The Centralized Procedure is optional for products that contain a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific, or technical innovation or that are in the interest of public health in the EU; and </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, a National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Data and Marketing Exclusivity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. In Japan, medicinal products approved for administration to a patient via a new route of administration qualify for six years of market exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization (the &#8220;ICH&#8221;) guidelines on GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. The sponsor must purchase a clinical trial insurance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policy and, in most EU countries, the sponsor is liable to provide &#8220;no fault&#8221; compensation to any study subject injured in the clinical trial.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an IEC. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier that contains information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new Clinical Trials Regulation (Regulation (EU) No 536/2014), which took effect on January 31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recycling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started our business in 1976 as a used appliance retailer that reconditioned old appliances to sell in our stores. Under contracts with national and regional retailers of new appliances, we collected the replaced appliance from the retailer&#8217;s customer&#8217;s residence when one of their stores delivered a new appliance. Any old appliances that we could not sell in our stores were sold to scrap metal processors. In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and we were no longer able to take appliances that contained hazardous components to scrap metal processors. At that time, we began to develop systems and equipment to remove the harmful materials so that metal processors would accept the appliance shells for processing. We then offered our services for disposing of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies, rental property managers, local governments, and the public. In 1989, we began contracting with electric utility companies to provide turnkey appliance recycling services to support their energy conservation efforts. Since that time, through March 8, 2023, we provided our services to approximately 400 utilities and other providers of energy efficiency programs throughout North America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 8, 2023, when we disposed of our recycling business, we had contracts to recycle, or to replace and recycle, major household appliances for approximately 100 utilities and other providers of energy efficiency services across North America. We operate 17 recycling centers in the United States and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules and regulations. We used United States Environmental Protection Agency (the &#8220;EPA&#8221;) Responsible Appliance Disposal (&#8220;RAD&#8221;) Program-compliant methods to remove and manage hazardous components and materials properly, including CFC refrigerants, mercury, polyurethane foam insulation, and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass. During our operations of the recycling business, all of our facilities complied with licensing and permitting requirements, and employees who process appliances receive extensive safety and hazardous materials training.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly-owned Recycling Subsidiaries in our Recycling segment included ARCA Recycling and ARCA Canada, which recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs, and Connexx, which provides call center services for the recycling segment. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Disposition of our Recycling Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement (the &#8220;Disposition Transaction&#8221;) was consummated simultaneously with the execution of the Recycling Purchase Agreement. Our Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) we reduced the liabilities on our consolidated balance sheets by approximately $17.6 million (excluding those related to the California Business Fee and Tax Division, as discussed below); (ii) we will receive not less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next five years, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1 million. We also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VM7 may prepay, at any time and in total, the estimated aggregate of the future monthly payments. That amount will be an amount equal to the then-present value of the estimated future monthly payments, discounted at the rate of 5% per annum (the &#8220;Prepayment Price&#8221;). Furthermore, VM7 will be required to pay the Prepayment Price upon the earliest of (i) Mr. Johnson holding less than 75% of the capital stock of VM7, (ii) VM7 selling substantially all of its assets, (iii) VM7 holding less than 50% of the capital stock of the Recycling Subsidiaries, or (iv) the Recycling Subsidiaries selling substantially all of their respective assets. Upon payment of the Prepayment Price, VM7 will have no further purchase price payment obligations to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional terms of the Disposition Transaction are: (i) we have the right to appoint one member of VM7&#8217;s board of directors until the sooner of VM7 having paid the Prepayment Price or having tendered all of the monthly payments; (ii) Mr. Johnson&#8217;s annual salary as Chief Executive Officer of VM7 shall be $400,000, prorated, for the remainder of the 2023 calendar year, and then adjusted annually to an amount equal to 1% of the Recycling Subsidiaries&#8217; aggregate gross revenues, until the sooner of VM7 having paid the Prepayment Price or having tendered all of the monthly payments; and (iii) we will receive additional payments from VM7 (that are not related to the on-going monthly payments) that relate to certain taxing agency issues. Upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to us 50% of the amount of the reduction between the current assessment and any such settlement. The payment will be memorialized by a three-year promissory note with interest at five percent per annum. The first payment under the note will be on the last day of VM7&#8217;s fiscal year in which the settlement occurs and the remaining payments each year thereafter. If ARCA Recycling receives a refund from the agency for payments previously made, it shall pay to us an amount equivalent to 25% of such refund after reduction for the legal fees payable to counsel for this proceeding. ARCA Recycling and Connexx are due to receive from the Internal Revenue Service two payments in the aggregate amount of approximately $931,000 in connection with the Employee Retention Credit provisions of the Coronavirus Aid, Relief, and Economic Security Act and the Taxpayer Certainty and Disaster Tax Relief Act of 2020. Those payments are to be tendered to us within 10 days of receipt by ARCA Recycling or Connexx.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To secure VM7&#8217;s obligations under the Recycling Purchase Agreement and pursuant to a Stock and Membership Interests Pledge Agreement dated March 19, 2023 (the &#8220;Pledge Agreement&#8221;), Mr. Johnson pledged to us all of the capital stock in VM7 (&#8220;VM7&#8217;s Capital Stock&#8221;) and VM7 pledged to us all of the equity interests of the Recycling Subsidiaries (the &#8220;Subject Securities&#8221;). Under the terms of the Pledge Agreement, upon an Event of Default (as defined in the Pledge Agreement), among other remedies in our favor, we may foreclose on any or all of VM7&#8217;s Capital Stock and the Subject Securities. We may also cause the ownership of VM7&#8217;s Capital Stock and of the Subject Securities to be transferred to us automatically, pursuant to an irrevocable transfer entered in our favor, as referenced in the Pledge Agreement. In the event of an automatic transfer, all of the monthly payments previously made by VM7 pursuant to the terms of the Recycling Purchase Agreement will then be characterized as contributions to the capital of the Company without dilution of the Company&#8217;s capital stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties have made customary representations, warranties, covenants, and indemnities in connection with the Disposition Transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Recycling Purchase Agreement contains certain representations and warranties that the parties made to each other as of the date of the Recycling Purchase Agreement or such other date as explicitly referenced therein. The representations and warranties were made solely for purposes of the Recycling Purchase Agreement and (i) are subject to limitations agreed by the parties in negotiating the terms and conditions thereof, (ii) may not be accurate or complete as of any specified date, (iii) will be qualified by the underlying disclosure schedules, (iv) may be subject to a contractual standard of materiality different from those generally applicable to investors, and (v) may have been used for the purpose of allocating risk among the parties thereto, rather than for establishing any matters as facts. Information concerning the subject matter of the representations and warranties may change after March 8, 2023, and subsequent information may or may not be fully </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reflected in JanOne&#8217;s public disclosures. For the foregoing reasons, the representations and warranties contained in the Recycling Purchase Agreement should not be relied upon as statements of factual information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the closing of the Disposition Transaction, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, we were advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because we did not receive all of the economic benefits of the Disposition Transaction and understand that we will not receive any future benefits of the Disposition Transaction, we determined to fully impair the approximately $5.3 million carrying value of the Disposition Transaction on our balance sheet. We also determined not to exercise any of our remedies under the Recycling Purchase Agreement so that we could maintain our focus on our clinical-stage biopharmaceutical activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 1, 2022, the Company took a full write-down of the unamortized portion of the GeoTraq intangible asset of approximately $9.8 million, and then on May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and assigned none of the liabilities of the Company&#8217;s wholly-owned subsidiary, GeoTraq Inc. The aggregate purchase price for the GeoTraq assets was $13.5 million, payable in cash and shares of SPYR&#8217;s capital stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in shares of SPYR&#8217;s restricted common stock or preferred stock. The Promissory Note matures on May 23, 2027.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Employees</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company had five employees, all of whom were full-time.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_19"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks described below with respect to an investment in our shares. If any of the following risks actually occur, our business, financial condition, operating results or cash provided by operations could be materially harmed. As a result, the trading price of our common stock could decline, and you might lose all or part of your investment. When evaluating an investment in our common stock, you should also refer to the other information in this Form 10-K, including our consolidated financial statements and related notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business Generally</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to implement our biopharmaceutical business strategy or if our biopharmaceutical business strategy is ineffective, our financial performance could be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and success are dependent in large part upon the effectiveness of our new biopharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business strategy and our ability to implement our biopharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business strategy successfully. Implementation of our strategy will require effective management of our operational, financial, and human resources and will place significant demands on those resources. There are risks involved in pursuing our strategy, including those under the caption &#8220;Risks Relating to Our Biotechnology Segment&#8221;. In addition to the risks set forth elsewhere in this Form 10-K, effectiveness of and the successful implementation of our business strategy could also be affected by a number of factors beyond our control, such as increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses, and changes in industry trends. We may decide to alter or discontinue certain aspects of our business strategy at any time. If we are not able to implement our business strategy successfully, our long-term growth and profitability may be adversely affected. Even if we are able to implement some or all of the initiatives of our business strategy successfully, our operating results may not improve and could decline substantially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified and disclosed in this Form 10-K material weaknesses in our internal control over financial reporting. If we are not able to remediate these material weaknesses and maintain an effective system of internal controls, we may not be able to accurately or timely report our financial results, which could cause our stock price to fall or result in our stock being delisted. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need to devote significant resources and time to comply with the requirements of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley&#8221;) with respect to internal control over financial reporting. In addition, Section 404 under Sarbanes-Oxley </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires that we assess the design and operating effectiveness of our controls over financial reporting, which are necessary for us to provide reliable and accurate financial reports.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reported in Part II &#8211; Item 9A, Controls and Procedures, there were material weaknesses in our internal controls over financial reporting at January 1, 2022. Specifically, management noted the following material weaknesses in internal control when conducting their evaluation of internal control as of January 1, 2022: (1) insufficient information technology general controls and segregation of duties. It was noted that people who were negotiating a contract were also involved in approving invoices without proper oversight. Additional controls and procedures are necessary and are being implemented to have checks and balances on significant transactions and governance with those charged with governance authority; (2) inadequate control design or lack of sufficient controls over significant accounting processes; the cutoff and reconciliation procedures were not effective with certain accrued and deferred expenses; (3) insufficient assessment of the impact of potentially significant transactions; and (4) insufficient processes and procedures related to proper recordkeeping of agreements and contracts. In addition, contract-to-invoice reconciliation was not effective with certain transportation service providers. As part of its remediation plan, processes and procedures have been implemented to help ensure accruals and invoices are reviewed for accuracy and properly recorded in the appropriate period. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our systems and controls to become increasingly complex to the extent that we integrate acquisitions and if and as our business grows. To effectively manage our Company today and this anticipated complexity, we need to remediate these material weaknesses and continue to improve our operational, financial, and management controls and our reporting systems and procedures. Any failure to remediate these material weaknesses and implement required new or improved controls, or difficulties encountered in the implementation or operation of these controls, could harm our operating results or cause us to fail to meet our financial reporting obligations, which could adversely affect our business and jeopardize our listing on the Nasdaq Capital Market, either of which would harm our stock price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Biotechnology Segment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our biotechnology business has a limited operating history</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our biotechnology business was started in September 2019 and has a limited operating history. We have not commenced revenue-producing operations. To date, our biotechnology-related operations have consisted of preliminary research and development, and characterization and testing of SR TV1001 (now known as JAN101) and our December 2022 acquisition of Soin Therapeutics and its LDN product (now known as JAN123). Our limited operating history makes it difficult for potential investors to evaluate our technology or the prospective operations of our biotechnology business. You should consider the prospects of our biotechnology business in light of the costs, uncertainties, delays, and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical businesses such as ours. Potential investors should carefully consider the risks and uncertainties that a biotechnology business with a limited operating history faces. In particular, potential investors should consider that we may be unable to (i) successfully implement or execute the business plan of our biotechnology business or currently validate that our biotechnology business plan is sound; (ii) successfully complete clinical trials and obtain regulatory approval for the marketing of JAN101 or JAN123; (iii) successfully demonstrate a favorable differentiation between JAN101 or JAN123 and the current products on the market; (iv) successfully manufacture our clinical drug product and establish a commercial drug supply; (v) secure market exclusivity and/or adequate intellectual property protection for JAN101 or JAN123; and (vi) raise sufficient funds in the capital markets to effectuate our biotechnology business plan, including product and clinical development, regulatory approval, and commercialization for JAN101 or JAN123.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business model is partially dependent on certain patent rights licensed to us from the Licensors (as defined below), and the loss of those license rights would, in all likelihood, cause our business, as presently contemplated, to fail.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, UABRF, TheraVasc, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting on behalf of LSU Health Shreveport, together with UABRF and TheraVasc, (collectively, the &#8220;Licensors&#8221;), granted us an exclusive worldwide, royalty-bearing license to the patent rights for SR TV1001 (now known as JAN101) in the negotiated fields of use. The patent license agreement requires us to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the event of our breach of the agreement, the Licensors may elect to terminate the agreement. As of the date of this Form 10-K, we believe we are in compliance with the patent license agreement and consider our relationship with the Licensors to be excellent. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be completely dependent on third parties to manufacture JAN101 and JAN123, and their commercialization could be halted, delayed, or made less profitable if those third parties fail to obtain manufacturing approval from the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of JAN101 or JAN123, or fail to do so at acceptable quality levels or prices. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture our drug candidate for use in our clinical trials or for commercial sales, if any. As a result, we will be obligated to rely on contract manufacturers when we conduct clinical trials and if and when our initial or subsequent product candidates are approved for commercialization. In January 2020, we entered into a Master Agreement for Development, Manufacturing and Supply with CoreRx Inc. (&#8220;CoreRx&#8221;), pursuant to which CoreRx has agreed to provide to us certain product testing, development, and clinical manufacturing services for JAN101. We have not yet entered into any manufacturing agreements for the manufacture of JAN123 and must identify and contract with a company capable of producing sufficient quantities of this product for our clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into agreements with any contract manufacturers for commercial supply for either JAN101 or JAN123 and may not be able to engage contract manufacturers for commercial supply of our initial or subsequent product candidates on favorable terms to us, or at all, should the need arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture our drug candidate for use in our clinical trials or for commercial sales, if any. As a result, we will be obligated to rely on contract manufacturers when we conduct clinical trials and if and when our initial or subsequent product candidates are approved for commercialization. In January 2020, we entered into a Master Agreement for Development, Manufacturing and Supply with CoreRx Inc. (&#8220;CoreRx&#8221;), pursuant to which CoreRx has agreed to provide to us certain product testing, development, and clinical manufacturing services for JAN 101. We have not entered into agreements with any contract manufacturers for commercial supply and may not be able to engage contract manufacturers for commercial supply of our initial or subsequent product candidates on favorable terms to us, or at all, should the need arise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a previous clinical trial, the manufacture of JAN101 by a different manufacturing company resulted in a product that demonstrated initial instability that led to the product being out-of-specification. While the FDA allowed the trial to continue, there is no guarantee that, if the product manufactured by CoreRx is similarly unstable, the FDA will allow us to continue to develop that product. Even if the product manufactured by CoreRx is stable, the FDA may require additional studies to confirm the stability of the product, increasing development cost and times.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by CoreRx to manufacture JAN101 must be approved by the FDA or comparable foreign regulatory authorities. Such approvals are subject to inspections that will be conducted after we submit an NDA to the FDA or their equivalents to other relevant regulatory authorities. We will not control the manufacturing process of JAN101, JAN123 or subsequent product candidates and will be completely dependent on our contract manufacturing partners for compliance with cGMPs, for manufacture of both active drug substances and finished drug products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control, storage, distribution, and record keeping relating to our initial or subsequent product candidates. If our contract manufacturers do not successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure or maintain regulatory approval for products made at their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our initial or subsequent product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, manufacture, obtain regulatory approval for, or market our initial or subsequent product candidates, if approved. Likewise, we could be negatively impacted if any of our contract manufacturers elect to discontinue their business relationship with us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract manufacturer will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturer&#8217;s compliance with these regulations and standards. Failure by our contract manufacturer to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market JAN101 or JAN123, delays, suspensions or withdrawals of approvals, inability to supply product, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect our biotechnology business. In addition, we will not have control over the ability of our contract manufacturer to maintain adequate quality control, quality assurance, and qualified personnel. Failure by our contract manufacturer to comply with or maintain any of these standards could adversely affect our ability to develop, manufacture, obtain regulatory approval for or market JAN101 or JAN123, if approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturer must obtain the API from a third party. A number of groups manufacture our API; however, some of these are manufactured as a food product, and others, while manufactured under GMP, do not have the required Drug Master File on file with the FDA. CoreRx identified an API from Merck KGaA for use in the current production of clinical grade JAN101. At the time of the manufacture of the API, the product met the specifications outlined in both the drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substance monographs for Europe and the US. However, subsequent to the manufacture of the API, the US monograph was changed in the US Pharmacopeia (&#8220;USP&#8221;) and, while most of the tests conform, Merck KGaA was unable to complete two of the new testing requirements. Although the two tests are not considered safety issues and do not impact the quality of the product, there is no guarantee the FDA will approve the product for clinical trials if the two tests are not completed, which could delay our ability to start the Phase IIb clinical trial, as planned. Identifying an analytical laboratory to perform the two tasks may be difficult and could require development and validation of the tests, adding both time and costs to us. In addition, there is no guarantee that, once developed, the product will meet the specifications as outlined in the USP. Even if the FDA allows the current product to be used in the Phase IIb clinical trial, there is no guarantee that the FDA will allow further clinical work with the product or commercialization of the product until it is shown to conform to USP standards. We may be required to work with the API manufacturer to file the appropriate documents and there is no guarantee that the FDA will approve the filing. This could necessitate additional funding to hire an API manufacturer and produce the product under GMP with all necessary filings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, for any reason, these third parties are unable or unwilling to perform, we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes for APIs or finished products or should cease doing business with us for any reason, we could experience significant interruptions in the supply of our initial or subsequent product candidates or may not be able to create a supply of any of our ls at all. Were we to encounter manufacturing difficulties, our ability to produce a sufficient supply of any of our product candidates might be negatively affected. Our inability to coordinate the efforts of our third-party manufacturing partners, or the lack of capacity available at our third-party manufacturing partners, could impair our ability to supply any of our product candidates at required levels. Because of the significant regulatory requirements that we would need to satisfy in order to qualify a new bulk drug substance or finished product manufacturer, if we face these or other difficulties with our then-current manufacturing partners, we could experience significant interruptions in the supply of any of our product candidates if we decided to transfer the manufacture of any of our product candidates to one or more alternative manufacturers in an effort to deal with such difficulties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CoreRx currently serves as our sole manufacturer of JAN101. As CoreRx also manufactures other products, there can be no guarantee that CoreRx will have the capacity to manufacture additional clinical product for us in a timely manner, when required, which could lead to significant delays in initiating other clinical studies. CoreRx will unlikely have the capacity to manufacture the amount of product needed, if and when JAN101 is approved for marketing. This would necessitate identifying additional manufacturer(s) who may or may not be able to replicate the manufacturing process developed at CoreRx. In addition, the increase in quantities required for commercialization of the product, if commercialization occurs, could require modifying the manufacturing process to produce larger quantities of tablets more efficiently. Such modifications of the manufacturing process, if even possible, could result in significant delays in the delivery of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be validating the manufacturing process, with appropriate process parameters and critical process, at CoreRx in 2024. Based on current batch sizes, these validated processes will support the manufacture of approximately 6.5 million tablets a month. This would allow us to enter the marketplace, but would support sales of only 1-2% of the addressable market. There is no guarantee that CoreRx will increase its manufacturing capacity when needed by us; thus, we will likely need to identify another approved manufacturer with increased capacity. In addition, we will need to revalidate the manufacturing process to demonstrate to the FDA the ability to reproducibly manufacture larger batch sizes, which will increase time and costs. If these activities are not carried out in a timely manner, a shortage of product could result following commercial launch, which could significantly affect sales and overall valuation of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any manufacturing problem or the loss of our contract manufacturer could be disruptive to our operations and result in development delays and lost sales. Additionally, we will rely on third parties to supply the raw materials needed to manufacture our initial or subsequent product candidates. Any such reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability, and quality. Any unanticipated disruption to the operation of one of our contract manufacturers caused by problems with suppliers could delay shipment of any of our product candidates, increase our cost of goods sold and result in lost sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacies may be able to compound LDN in competition with us, but the economic impact may not be material.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN123 is a biphaisc formulation of LDN being developed for CRPS. However, compounding pharmacies have already sold a non-biphasic LDN for this purpose and for other purposes. The patent JanOne was issued for JAN123, in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjunction with Orphan Drug approval, will provide additional marketing protection for CRPS. Compounding pharmacies are not subject to FDA approval and could compound LDN for their patients. We believe that production and sales by a single compounding pharmacy of a material amount of a compounded product would transform such compounding pharmacy into a pharmaceutical manufacturer, which would then subject it to all of the FDA approval protocols, including cGMP requirements. Thus, compounding pharmacies would not be able to scale their compounding activities for LDN to facilitate their material sales growth of LDN or to become impactful in the marketplace</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed below, we cannot provide assurances with respect to third-party coverage and reimbursement. We believe that persons who purchase LDN from a compounding pharmacy may need to pay out-of-pocket for the product with limited or no insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our initial or subsequent product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face a potential risk of product liability as a result of the clinical testing of our initial or subsequent product candidates. For example, we may be sued if any product we develop, including JAN101, JAN123 or any materials that we use in it, allegedly causes injury or is found to be otherwise unsuitable during product testing and manufacturing. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. In the United States, claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our initial or subsequent product candidates. Even successful defense of these claims would require us to employ significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in, among other things (i) decreased demand for JAN101, JAN123 or any future products that we may develop; (ii) failure to obtain regulatory approval for our product candidates; (iii) withdrawal of participants in our clinical trials; (iv) substantial monetary awards to trial participants or patients; (v) product recalls or withdrawals or labeling, marketing, or promotional restrictions; and (vi) the inability to commercialize our initial or subsequent product candidates. As of the date of this Form 10-K, we do not carry product liability insurance. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our biotechnology business is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory authorities in foreign jurisdictions in which we intend to market them, of which there can be no assurance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to market JAN101 or JAN123 as prescription pharmaceutical products in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United States, the FDA generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA is approved. Of the large number of drugs in development, only a small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for commercialization. As of the date of this Form 10-K, we have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for any subsequent product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the clinical trial history of JAN101, we believe that JAN101 will qualify for FDA approval through the FDA&#8217;s 505(b)(2) regulatory pathway and in corresponding regulatory paths in other foreign jurisdictions. Notwithstanding the use of the FDA&#8217;s 505(b)(2) regulatory pathway, we will be required to conduct Phase IIb and Phase III studies prior to filing for marketing approval of JAN101. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The active ingredient in JAN123 is naltrexone, which has been approved for use at much higher doses by the FDA for other indications, thus we believe that JAN123 will also qualify for the 505(b)(2) regulatory pathway.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA has approved the Orphan Designation for JAN123, which could lead to approval after just two clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, based on the strength of the results of the registration trial, the FDA could request additional clinical studies prior to approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain and subject to a number of risks, including the following: (i) the results of toxicology studies may not support the filing of an NDA for JAN101; (ii) the FDA may require additional pharmacokinetic studies with JAN101, including studies with food, prior to allowing the Company to conduct Phase IIb and Phase III clinical trials; (iii) the FDA or comparable foreign regulatory authorities or Institutional Review Boards (&#8220;IRBs&#8221;) may disagree with the design or implementation of our clinical trials; (iv) we may not be able to provide acceptable evidence of JAN101&#8217;s safety and efficacy; (v) the results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required by the FDA, the EMA, or other regulatory agencies for us to receive marketing approval for JAN101; (vi) the dosing of JAN101 in a particular clinical trial may not be at an optimal level; (vii) patients in our clinical trials may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suffer adverse effects for reasons that may or may not be related to JAN101; (viii) the data collected from clinical trials may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; (ix) the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and (x) the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval of JAN101.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things, the type, complexity, and novelty of the product candidates involved, the jurisdiction in which regulatory approval is sought, and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily mean that a product candidate will receive regulatory approval in any or all other jurisdictions in which we may seek approval; but, the failure to obtain approval in one jurisdiction may negatively impact our ability to seek approval in a different jurisdiction. Failure to obtain regulatory approval for JAN101 or JAN123 for the foregoing, or any other reasons, will prevent us from commercializing JAN101 or JAN123, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing is expensive, is difficult to design and implement, can take many years to complete, and is uncertain as to outcome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model depends in part on the successful development, regulatory approval, and commercialization of JAN101 or JAN123, which may never occur. Both JAN101 and JAN123 are in the early stages of development and, as of the date of this Form 10-K, we have not progressed JAN101 beyond early clinical studies designed only to show safety, nor has JAN123 been tested in any FDA approved clinical trials. Three INDs have previously been submitted by previous licensees/assignees of JAN101 and were accepted by the FDA. These INDs were transferred to JanOne in 2020. Even though the INDs were transferred to us, the FDA may still require additional work prior to re-initiation of clinical trials. If we do not obtain such approvals to re-initiate trials as presently planned, the time in which we expect to commence clinical programs for any product candidate will be extended and such extension will increase our expenses, delay our potential receipt of any revenues, and increase our need for additional capital. Moreover, there is no guarantee that we will receive approval to commence human clinical trials or, if we do receive approval, that our clinical trials will be successful or that we will continue clinical development in support of an approval from the FDA or comparable foreign regulatory authorities for any indication. We note that most product candidates never reach the clinical development stage and even those that do commence clinical development have only a small chance of successfully completing clinical development and gaining regulatory approval. Success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent our ability to receive regulatory approval or commercialize our initial or any subsequent product candidates. Therefore, our business currently depends entirely on the successful development, regulatory approval, and commercialization of our product candidates, which may never occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN123 has received Orphan Drug designation from the FDA, allowing for fewer and smaller clinical trials prior to approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In part, this is due to fewer patients being available for treatment and may lead to delays in recruiting subjects for the trial and therefore delays in reaching the market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for JAN101 or JAN123, we may not be able to commercialize it successfully and the revenue that we generate from its sales, if any, may be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved for marketing, the commercial success of JAN101 will depend upon the product&#8217;s acceptance by the medical community, including physicians, patients, and health care payors. The degree of market acceptance for JAN101 will depend on a number of factors, including (i) demonstration of clinical safety and efficacy; (ii) relative convenience, dosing burden, and ease of administration; (iii) the prevalence and severity of any adverse effects; (iv) the willingness of physicians to prescribe JAN101 and the target patient population to try new therapies; (v) efficacy of JAN 101 compared to competing products; (vi) the introduction of any new products that may in the future become available, targeting indications for which JAN101 may be approved; (vii) new procedures or therapies that may reduce the incidences of any of the indications in which JAN101 may show utility; (viii) pricing and cost-effectiveness; (ix) the inclusion or omission of JAN101 in applicable guidelines; (x) the effectiveness of our own or any future collaborators&#8217; sales and marketing strategies; (xi) limitations or warnings contained in approved labeling from regulatory authorities; (xii) our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Medicaid, private health insurers, and other third-party payors or to receive the necessary pricing approvals from government bodies regulating the pricing and usage of therapeutics; and (xiii) the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAN123 will face al the commercialization factors described above with an additional risk of compounding pharmacies prescribing the product to patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The active ingredient, naltrexone, is available and has been compounded into LDN formulations similar to JAN123.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These compounded LDN formulations have been provided to numerous patients with different forms of pain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While not approved for the treatment of pain and therefore unlikely to be reimbursed, the low cost of the compounded LDN could cause reduce pricing of JAN123.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that JAN123 will have advantages over the compounded LDN in terms of reduced side effects, but many patients currently have not had the side effects or accepted these as part of reducing their pain with compounded LDN.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JanOne may have to enforce its patents, which could result in lengthy and costly litigation, to prevent compounding pharmacies from selling LDN for indications for which JanOne has received patent protection. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If JAN101 or JAN123 is approved but does not achieve an adequate level of acceptance by physicians, health care payors, and patients, our biotechnology business may not generate sufficient revenue to cover costs. Our efforts to educate the medical community and third-party payors on the benefits of JAN101 or JAN123 may require significant resources and may never be successful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize JAN101 or JAN123 successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that renders our product candidate not commercially viable. For example, regulatory authorities may approve our product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidate, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals or require risk management plans or a REMS to assure the safe use of the drug. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for our product candidate, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidate could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidate for an indication, the FDA or foreign equivalent may still impose significant restrictions on its indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase IV clinical trials, and post-market surveillance to monitor safety and efficacy. Our product candidate will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events, and other post-market information. These requirements include registration with the FDA, as well as continued compliance with current good clinical practices regulations for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current cGMPs, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has the authority to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment in a registry.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to sales and marketing activities related to our product candidate, advertising and promotional materials must comply with FDA rules in addition to other applicable federal, state, and local laws in the United States and similar legal requirements in other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of the United States Prescription Drug Marketing Act. Application holders must obtain FDA approval for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product and manufacturing changes, depending on the nature of the change. We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the United States Anti-Kickback Statute, United States False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate in the United States Medicaid Drug Rebate Program, the Federal Supply Schedule of the United States Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also potentially subject to United States federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if JAN101 or JAN123 is approved for a particular indication, our product labeling, advertising, and promotion would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for JAN101 or JAN123, physicians may nevertheless legally prescribe our product to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a regulatory agency discover previously unknown problems with one of our product candidates, such as adverse events of unanticipated severity or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements, we may be subject to the following administrative or judicial sanctions: (i) restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; (ii) issuance of warning letters or untitled letters; (iii) clinical holds; (iv) injunctions or the imposition of civil or criminal penalties or monetary fines; (v) suspension or withdrawal of regulatory approval; (vi) suspension of any ongoing clinical trials; (vii) refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; (viii) suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or (ix) product seizure or detention or refusal to permit the import or export of product. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of JAN101 or JAN123 in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of JAN101 or JAN123 in other jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our initial or subsequent product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction; but, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of that product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our initial or subsequent product candidates and affect the prices we may obtain.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for JAN101 or JAN123, restrict, or regulate post-approval activities and affect our ability to profitably sell JAN101 or JAN123. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of JAN101 or JAN123, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidate for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to: (i) the FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing the clinical study on hold; (ii) subjects for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect; (iii) a facility manufacturing our initial or subsequent product candidates being ordered by the FDA or other government or regulatory authorities to shut down, temporarily or permanently, due to violations of cGMP requirements or other applicable requirements, or cross-contaminations of the product candidates in the manufacturing process; (iv) any changes to our manufacturing process that may be necessary or desired; (v) subjects choosing an alternative treatment for the indications for which we are developing our initial or subsequent product candidates, or participating in competing clinical studies; (vi) subjects experiencing severe or unexpected drug-related adverse effects; (vii) reports from clinical testing on similar technologies and products raising safety and/or efficacy concerns; (viii) third-party clinical investigators losing their licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule, or employing methods consistent with the clinical trial protocol, cGMP requirements, or other third parties not performing data collection and analysis in a timely or accurate manner; (ix) inspections of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding regulatory violations that require us to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study, or that prohibit us from using some or all of the data in support of our marketing applications; (x) third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or any of the data produced by such contractors in support of our marketing applications; (xi) one or more IRBs refusing to approve, suspending, or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; (xii) reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; (xiii) deviations of the clinical sites from trial protocols or dropping out of a trial; (xiv) adding new clinical trial sites; (xv) the inability of the CRO to execute any clinical trials for any reason; and (xvi) government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of a trial.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs for our initial and any subsequent product candidates will increase if we have delays in testing or approval or if we need to perform more or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory authorities, and IRBs for reexamination, which may impact the costs, timing, or successful completion of that study. If we experience delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical study sites suspend or terminate any of our clinical studies of any of our product candidates, their commercial prospects may be materially harmed and our ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow our development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and prospects significantly. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial of regulatory approval of one of more of our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able to bring competing products to market before we do, and the commercial viability of our affected product candidates could be significantly reduced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to market JAN101 or JAN123 successfully will depend in part on the level of reimbursement that government health administration authorities, private health coverage insurers, and other organizations provide for the cost of JAN101 or JAN123 and related treatments. Countries in which JAN101 or JAN123 is sold through reimbursement schemes under national health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price increases. In certain countries, including the United States, government-funded and private medical care plans can exert significant indirect pressure on prices. We may not be able to sell JAN101 or JAN123 profitably if adequate prices are not approved or coverage and reimbursement is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unavailable or limited in scope. Increasingly, third-party payors attempt to contain health care costs in ways that are likely to impact the development of our product including: (i) failing to approve or challenging the prices charged for health care products; (ii) introducing reimportation schemes from lower priced jurisdictions; (iii) limiting both coverage and the amount of reimbursement for new therapeutic products; (iv) denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or investigational by third-party payors; and (v) refusing to provide coverage when an approved product is used in a way that has not received regulatory marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on successfully blocking others from developing and commercializing similar products. As repurposed drugs, our APIs have previously been approved for other indications, none of which currently represent a threat to our products, and therefore cannot be protected. We will rely on our method of use and oral formulation patents to protect our products, which may also put our products at risk from companies developing oral formulations using the same API for other indications. Even though our patents provide protection for specific uses, we will not be able to prevent other companies from developing the same APIs for other uses. If a similar dose, formulation, and route of administration is developed for another indication by a different company, we cannot guarantee that the product they market for the other indication will not be prescribed off-label by doctors or filled by pharmacists for use in indications our patents cover and that if less expensive, would not negatively affect our sales, if our products are ultimately approved by the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by the patent rights licensed to us is uncertain, because legal means afford only limited protection and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive advantage at all. We cannot be certain that any patent application owned by a third party will not have priority over patent applications in which we hold license rights or that we will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent offices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the Licensors were to initiate legal proceedings against a third party to enforce a patent covering JAN101, the defendant could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark Office (the &#8220;PTO&#8221;) or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include regarding-examination, post-grant review, and equivalent proceedings in foreign jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, opposition proceedings. Such proceedings could result in revocation or amendment of the Licensors&#8217; patents in such a way that they no longer cover JAN101 or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which the Licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on any of our product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may rely on know-how and trade secrets to protect technology, especially in cases in which we believe patent protection is not appropriate or obtainable. However, know-how and trade secrets are difficult to protect. While we intend to require employees, academic collaborators, consultants, and other contractors to enter into confidentiality agreements, we may not be able adequately to protect our trade secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and information in which we may have rights. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover, our competitors may independently develop equivalent or better knowledge, methods, and know-how.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to block others from developing similar products for other indications, and we cannot ensure that these products will not be less expensive and thus be prescribed off-label by physicians for use in our indications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on successfully blocking others from developing and commercializing similar products. As a repurposed drugs, our APIs have previously been approved for other indications and therefore cannot be protected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although none of the approved indications for the API used in JAN101 represent a threat to JAN101, the API used in naltrexone has been formulated by compounding pharmacies to treat the indication JanOne is pursuing and thus represents a real threat in commercialization of JAN123.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will rely on our method of use and oral formulation patents to protect JAN101 and JAN123, which may also put JAN101 and JAN123 at risk from companies developing oral formulations using the same API for other indications. Even though our patents provide protection for specific uses, we will not be able to prevent other companies from developing the same API for other uses. If a similar dose, formulation, and route of administration is developed for another indication by a different company, we cannot guarantee that the product they market for the other indication will not be prescribed off-label by doctors or filled by pharmacists for use in indications our patents cover and that if less expensive, would not negatively affect our sales, if JAN101 or JAN123 is ultimately approved by the FDA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JAN101 or JAN123 may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of JAN101, JAN123 or any subsequent product candidate. There may be certain issued patents and patent applications claiming subject matter that we may be required to license in order to research, develop, or commercialize any of our product candidates, and we do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims of patent infringement asserted by third parties would be time-consuming and may: (i) result in costly litigation; (ii) divert the time and attention of our technical personnel and management; (iii) prevent us from commercializing a product candidate until the asserted patent expires or is held finally invalid or not infringed in a court of law; (iv) require us to cease or modify our use of the technology and/or develop non-infringing technology; or (v) require us to enter into royalty or licensing agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may hold proprietary rights that could prevent JAN101 or JAN123 from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market JAN101, JAN123 or any subsequent product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign JAN101, JAN123 or any subsequent product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing JAN101, JAN123 or a subsequent product candidate, which could harm our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that there are other companies, including major pharmaceutical companies, working in the areas competitive to JAN101 or JAN123 that either have resulted, or may result, in the filing of patent applications that may be deemed related to our activities. If we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. If we were to challenge the validity of these or any issued United States patent in an administrative trial before the Patent Trial and Appeal Board in the PTO, we would have to prove that the claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on questions of infringement, validity, or enforceability. Even if we are successful, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation, announcements of technological innovations or new products by us, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions. Some of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading in our stock, regardless of our financial condition, results of operations, business or prospects. Among the factors that may cause the market price of our common stock to fluctuate are the risks described in this &#8220;Risk Factors&#8221; section. In addition, the stock markets, in general, The Nasdaq Capital Market and the market for biopharmaceutical companies in particular, may experience a loss of investor confidence. Such loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, financial condition or results of operations. These broad market and industry factors may materially harm the market price of our common stock and expose us to securities class action litigation. Such litigation, even if unsuccessful, could be costly to defend and divert management&#8217;s attention and resources, which could further materially harm our financial condition and results of operations.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i186f351ddce04342b829c557fbabfeb2_22"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices were located in Las Vegas, Nevada in a leased facility consisting of 11,000 square feet of office space. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, we reduced the leased office space in the Las Vegas, Nevada facility to approximately 800 square feet.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_25"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in response to this item is included in Note 19, Commitments and Contingencies, to the Consolidated Financial Statements included in Part II, Item 8, of this Form 10-K.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_28"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i186f351ddce04342b829c557fbabfeb2_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET FOR OUR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;JAN&#8221; on The Nasdaq Capital Market. As of April&#160;8, 2024, there were approximately 50 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers. We have no record of the number of holders of our common stock who hold their shares in &#8220;street name&#8221; with various brokers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid dividends on our common stock and do not presently plan to pay dividends on our common stock for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information concerning securities authorized for issuance under equity compensation plans is included in Part III, Item 12 of this report.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies and an understanding of the significant factors that influenced our performance during the fiscal year ended December&#160;30, 2023, this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; (hereafter referred to as &#8220;MD&amp;A&#8221;) should be read in conjunction with the consolidated financial statements, including the related notes, appearing in Part II, Item 8 of this 10-K for the fiscal year ended December&#160;30, 2023.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note about Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K includes statements that constitute &#8220;forward-looking statements.&#8221; These forward-looking statements are often characterized by the terms &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; or &#8220;anticipates,&#8221; and do not reflect historical facts. Specific forward-looking statements contained in this portion of the Form 10-K include, but are not limited to: (i) statements relating to JAN 101, including statements relating to the commencement of Phase IIb clinical trials for the treatment of PAD and the results of those trials, (ii) statements that are based on current projections and expectations about the markets in which we operate, (iii) statements relating to the sale of our Recycling business, (iv) statements about current projections and expectations of general economic conditions, (v) statements about specific industry projections and expectations of economic activity, (vi) statements relating to our future operations and prospects, (vii) statements about future results and future performance, (viii) statements that the cash on hand, together with potential sources of cash through issuance of debt or equity, will provide the Company with sufficient liquidity for the next 12 months, and (ix) statements that the outcome of pending legal proceedings will not have a material adverse effect on business, financial position and results of operations, cash flow, or liquidity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve risks, uncertainties, and other factors, which may cause our actual results, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results, future performance, and capital requirements and cause them to differ materially from those contained in the forward-looking statements include those identified in this Form 10-K under Item 1A &#8220;Risk Factors&#8221;, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the foregoing factors may generally affect our business, results of operations and financial position. Forward-looking statements speak only as of the date the statements were made. We do not undertake and specifically decline any obligation to update any forward-looking statements. Any information contained on our website www.janone.com or any other websites referenced in this Form 10-K are not part of this Form 10-K.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Company</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. In addition, through our now-sold Recycling Subsidiaries (ARCA Recycling, ARCA Canada, and Connexx), we were engaged in the business of recycling major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Also, through our now-sold GeoTraq Inc. subsidiary, we were engaged in the development and design of wireless transceiver modules with technology that provides LBS directly from global Mobile IoT networks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate three reportable segments:</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Biotechnology: Our biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Recycling: On March 19, 2023, the Company entered into a Stock Purchase Agreement with VM7 Corporation under which the it agreed to acquire our recycling segment. The results for this segment for the years ended December&#160;30, 2023 and December&#160;31, 2022 are reported as discontinued operations below.</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Technology: We have suspended all operations for GeoTraq, and, on May 24, 2022, sold substantially all of the GeoTraq assets to an otherwise unrelated third party. The results for this segment for the years ended December&#160;30, 2023 and December&#160;31, 2022 are reported as discontinued operations below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reporting Period. We report on a 52-or 53-week fiscal year. Our 2023 fiscal year ended on December&#160;30, 2023 (&#8220;fiscal 2023&#8221;). Our 2022 fiscal year ended on December&#160;31, 2022 (&#8220;fiscal 2022&#8221;). </span></div><div id="i186f351ddce04342b829c557fbabfeb2_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Application of Critical Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion of the financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of any contingent assets and liabilities at the date of the financial statements. Management regularly reviews its estimates and assumptions, which are based on historical factors and other factors believed to be relevant under the circumstances. Actual results may differ from these estimates under different assumptions, estimates or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties and potentially result in materially different results under different assumptions and conditions. Critical accounting policies include intangible impairment under ASC 350, revenue recognition under ASC 606, and going concern under ASC 205.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain statement of operations items from continuing and discontinued operations and as a percentage of revenue, for the periods indicated (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:69.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.138%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 30, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,746&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,149&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19,846)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,149)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on litigation settlement</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,950&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on reversal of contingency loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">637&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (loss) income before provision for income taxes</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17,524)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,399&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17,095)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision for discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,812)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,992&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent <br/>of Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent <br/>of Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from discontinued operations</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biotechnology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Profit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross <br/>Profit % </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Profit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross <br/>Profit %</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Profit</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biotechnology</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total gross profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div id="i186f351ddce04342b829c557fbabfeb2_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue decreased by approximately $35.8 million for the fiscal year ended December&#160;30, 2023, as compared to the year ended December&#160;31, 2022. The decrease is due to the disposition of our recycling segment as of March 1, 2023.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue decreased by approximately $28.0 million for the fiscal year ended December&#160;30, 2023, as compared to the year ended December&#160;31, 2022. The decrease is due to the disposition of our recycling segment as of March 1, 2023.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses from continuing operations increased by approximately $1.6 million for the fiscal year ended December&#160;30, 2023, as compared to the year ended December&#160;31, 2022, primarily due to increased amortization costs relating to the Soin intangibles. Selling, general and administrative expenses from discontinued operations decreased by approximately $7.2 million. The decrease is due to the disposition of our recycling segment as of March 1, 2023.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_850"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment Charges</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges recorded during the fiscal year ended December&#160;30, 2023 were approximately $15.1 million. These charges relate to the full impairment of the VM7 and SPYR notes receivable of approximately $5.3 million and $9.8 million, respectively (See Note 8 of the Consolidated Financial Statements). No impairment charges were recorded during the fiscal year ended December&#160;31, 2022.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net, increased by approximately $1.8 million for the fiscal year ended December&#160;30, 2023, as compared to the year ended December&#160;31, 2022, primarily due to the accretion of discount in connection with the promissory notes with SPYR and VM7, as well as interest recorded on the note with SPYR.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Sale of the Recycling Subsidiaries</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;30, 2023, we recorded a gain on the sale of the Recycling Subsidiaries of approximately $12.1 million from discontinued operations. See Note 4 of the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Sale of GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;31, 2022, we recorded a gain on the sale of GeoTraq of approximately $9.4 million from discontinued operations. See Note 5 of the Consolidated Financial Statements.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Loss on Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities for the fiscal year ended December&#160;30, 2023 was approximately $926,000, as compared to a loss of approximately $631,000 for the fiscal year ended December&#160;31, 2022. An unrealized gain or loss on marketable securities is recorded to mark to fair value securities received in connection to the sale of GeoTraq.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Litigation Settlement, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we recorded a gain on litigation settlement from continuing operations of approximately $1.95 million due to the receipt of a payment from Sompo International Companies (&#8220;Sompo&#8221;) in exchange for a full release in favor of Sompo from liability for both the GeoTraq and SEC-related matters. We recorded a loss on litigation from discontinued operations of approximately $1.0 million due to an accrual of approximately $894,000 for the Skybridge settlement (see Note 19 of the Consolidated Financial Statements for further discussion of this matter), and an accrual of approximately $115,000 for adjudication of the Blackhawk matter.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Reversal of Contingency Loss</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we recorded a gain on reversal of contingency liabilities of approximately $637,000 relating to guarantees of ApplianceSmart leases that no longer exist as a result of ApplianceSmart's emergence from bankruptcy. See Note 19 of the Consolidated Financial Statements.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, from continuing operations was approximately $998,000 for the fiscal year ended December&#160;30, 2023 as compared to income of approximately $2.1 million for the fiscal year ended December&#160;31, 2022. Other expense, net, from discontinued operations was approximately $180,000 for the fiscal year ended December&#160;30, 2023, as compared to expense of approximately $1.3 million for the fiscal year ended December&#160;31, 2022.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our business in the following segments: Biotechnology and discontinued operations. We expect revenues and profits for our biotechnology segment to be driven by the development of pharmaceuticals that treat the root cause of pain but are non-opioid painkillers. We include Corporate expenses within the Biotechnology segment. As discussed above, we sold our Technology segment, GeoTraq, during the fiscal year ended December&#160;31, 2022, and our Recycling segment in March 2023, and detail those results as discontinued operations below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income (loss) by operating segment, is defined as income (loss) before net interest expense, other income and expense, provision for income taxes.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year Ended December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Biotechnology</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discontinued Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Biotechnology</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discontinued Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,100&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,100&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19,846)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,149)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i186f351ddce04342b829c557fbabfeb2_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biotechnology Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022, respectively, our Biotechnology segment incurred operating expenses of approximately $10.1 million and $3.1 million. The increase is primarily related to the $5.3 million </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">full impairment of the VM7 note receivable from the Recycling Subsidiaries transaction, as well as increased amortization costs relating to the Soin intangibles. </span></div><div id="i186f351ddce04342b829c557fbabfeb2_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations consists of our Recycling segment, which was disposed of effective March 1, 2023, and our Technology segment, which was disposed of during May 2022. Operating income for the fiscal year ended December&#160;30, 2023 increased by approximately $2.0 million, as compared to the fiscal year ended December&#160;31, 2022. The increase in operating income is primarily due to the gain on sale of the Recycling Subsidiaries of approximately $12.1 million during fiscal 2023, partially offset by the gain on the sale of the GeoTraq intangible, in the amount of approximately $9.4 million during the year ended December&#160;31, 2022, as well as reduced operating expenses for the year ended December&#160;30, 2023 due to the sale of the Recycling Subsidiaries.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared under the assumption that we will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, our cash on hand was approximately $5,000. We intend to raise funds to support future development of JAN 123 either through capital raises or structured arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123, as well as to fund our day-to-day operations. The accompanying financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. While we will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;30, 2023, cash used in operations was approximately $855,000, compared to cash used in operations of approximately $557,000 during the fiscal year ended December&#160;31, 2022. Cash provided by operating activities from discontinued operations during the fiscal year ended December&#160;30, 2023 was approximately $2.3 million, as compared to cash used in operating activities of approximately $2.5 million for the fiscal year ended December&#160;31, 2022. The changes in cash was primarily due to results of operations as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was approximately $156,000 and $1.5 million, respectively, for the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022. Cash used in investing activities was all associated with discontinued operations and was related to purchases of property and equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was approximately $777,000 for the fiscal year ended December&#160;30, 2023. Cash used in financing activities from discontinued operations for the fiscal year ended December&#160;30, 2023 was approximately $2.2 million and was primarily due to the repayment of debt obligations in the amount of approximately $7.3 million, partially offset by proceeds from the issuance of debt obligations of approximately $5.1 million. Cash used by financing activities was approximately $14,000 for the fiscal year ended December&#160;31, 2022. Cash provided by financing activities from discontinued operations for fiscal year ended December&#160;31, 2022 was approximately $4.0 million, and was primarily due to proceeds from the issuance of notes payable of approximately $17.5 million, partially offset by payments on notes payable of approximately $13.4 million, and payment on related party debt of approximately $162,000. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acknowledge that we continue to face a challenging competitive environment as we continue to focus on our overall profitability, including managing expenses. We reported a net loss of approximately $7.7 million from continuing operations for the fiscal year ended December&#160;30, 2023, and net income from continuing operations of approximately $8.0 million for the fiscal year ended December&#160;31, 2022, for the reasons discussed above. Additionally, the Company has total current assets of approximately $350,000 and total current liabilities approximately of $5.6 million, resulting in a net negative working capital of approximately $5.2 million. Cash used in operations was approximately $855,000.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Item 1A. Risk Factors, management has addressed and evaluated the risk factors that could materially and adversely affect the entity&#8217;s business, financial condition and results of operations, cash flows, and liquidity. The Company has determined that the risk factors do not materially affect the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the above, management has concluded that the Company is not aware and did not identify any other conditions or events that would cause the Company to not be able to continue business as a going concern for the next 12 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Sources of Cash; New Acquisitions, Products and Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials, or consummate other strategic investments in our business. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off Balance Sheet Arrangements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, we had no off-balance sheet arrangements, commitments or guarantees that require additional disclosure or measurement.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, we did not participate in any market risk-sensitive commodity instruments for which fair value disclosure would be required. We believe we are not subject in any material way to other forms of market risk, such as foreign currency exchange risk or foreign customer purchases or commodity price risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div id="i186f351ddce04342b829c557fbabfeb2_109"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reports of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112">Report of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112">Hudgens CPA</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112"> P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112">LLC (PCAOB ID</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-35">6849</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_112">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_112">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_115">Report of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_115">Frazier &amp; Deeter</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_115">, LLC (PCAOB ID </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_115">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_115">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">Consolidated Balance Sheets as of December </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">December 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_118">, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_118">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">Consolidated Statements of Operations and Comprehensive Income (Loss) for the fiscal years ended December </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">December 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_121">, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_121">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the fiscal years ended December </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">December 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_124">, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_124">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">Consolidated Statements of Cash Flows for the fiscal years ended December </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">December 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_127">, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_127">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i186f351ddce04342b829c557fbabfeb2_130">9</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Stockholders of JanOne, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of JanOne, Inc. (the Company) as of December 30, 2023, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for the year ended December 30, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 30, 2023, and the results of its operations and its cash flows for the year ended December 30, 2023, in conformity with accounting principles generally accepted in the United States of America. The year ended December 31, 2022 was audited by another auditor that issued an unqualified opinion on April 17, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has negative working capital, an accumulated deficit, a history of significant operating losses from continuing operations, and a history of negative operating cash flow. These factors raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. We have determined that there were no critical audit matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">Hudgens CPA, PLLC</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.hudgenscpas.com</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Houston, Texas</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 8, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JanOne Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Las Vegas, Nevada </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of JanOne Inc. (the "Company") as of  December 31, 2022, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders' equity (deficit) and cash flows for the year then ended, and the related notes (collectively referred to as the consolidated financial statements).  In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of their operations and cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America ("US GAAP").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Substantial Doubt About the Company's Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1 to the consolidated financial statements, the Company has negative working capital, an accumulated deficit, a history of significant operating losses from continuing operations, and a history of negative operating cash flow.  These factors raise substantial doubt about its ability to continue as a going concern.  Management's plans in regard to these matters are also described in Note 1.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audit.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.  Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.  Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.  We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that:  (1) relate to accounts or disclosures that are material to the consolidated financial statements and  (2) involved our especially challenging, subjective, or complex judgments.  The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Note Receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 27 to the consolidated financial statements, on May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc. (SPYR), pursuant to which the Company sold SPYR substantially all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the assets of its wholly-owned subsidiary GeoTraq Inc.  SPYR issued shares of its common stock and delivered a five-year promissory note for the acquisition consideration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the Company's valuation of the promissory note at the transaction date as a critical audit matter because of the significant estimates and assumptions management used in the estimate of the fair value, mainly as it relates to the selection of the discount rate.  Auditing management's selection of the discount rate involved a high degree of auditor judgment and increased audit effort, including the use of our valuation specialists, as changes in this assumption could have a significant impact on the preliminary fair value of the promissory note received.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the Company's fair value estimate of the promissory note received included the following, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We read the asset purchase agreement to understand and evaluate the terms of the transaction.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We obtained the Company's third-party expert valuation report to gain an understanding of the processes and key assumptions for estimating the fair value of the promissory note received.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We utilized our valuation specialists to evaluate the adequacy and appropriateness of the methodologies and assumptions, including the discount rate used by the Company in developing the estimated fair value of the promissory note.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We performed independent calculations to test the reasonableness and mathematical accuracy of the fair values concluded on by the Company.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the qualifications of the Company's third-party valuation expert based on credentials, reputation, and experience.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We assessed the appropriateness of the disclosures in the consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Valuation of purchase price consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3 to the consolidated financial statements, on December 28, 2022, the Company acquired Soin Therapeutics LLC (Soin) through an all-stock transaction.  As part of the consideration of the transaction, the Company issued Soin shares of its Series S preferred convertible stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the Company's valuation of the preferred shares issued as a critical audit matter because of the significant estimates and assumptions management used in its fair value estimate, including forecasted product revenues, the expected FDA approval date and the selection of discount rates.  Auditing management's estimates of the forecasted product revenues, the expected FDA approval date and the selection of discount rates involves a high degree of auditor judgment and increased audit effort, including the use of our valuation specialists, as changes in these assumptions could have a significant impact on the acquisition date fair value of the purchase price consideration.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the Company's estimate of the fair value of the preferred Series S shares included the following, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We read the asset purchase agreement to understand and evaluate the terms of the transaction to determine that the acquisition met the requirements of an asset acquisition, including an understanding of the assets being acquired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We obtained the Company's third-party expert valuation report to gain an understanding of the processes and key assumptions for estimating the fair value of the Series S preferred shares issued.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We utilized our valuation specialists to evaluate the adequacy and appropriateness of the methodologies and assumptions, including the reasonableness of discount rates and volatility estimates used by the Company in developing the estimated fair value of the preferred Series S shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We assessed management's estimates of the projection risk associated with the probability and timing of achieving FDA approval and revenue forecasts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the mathematical accuracy of the model used to determine the fair value concluded on by the Company.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the qualifications of the Company's third-party valuation expert based on credentials, reputation, and experience.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We assessed the appropriateness of the disclosures in the consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We served as the Company's auditor in 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/s/ Frazier &amp; Deeter, LLC</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tampa, Florida</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 17, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="f-38">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="f-39">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="f-40">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="f-41">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-42">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-43">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets from discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">8,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-46">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">9,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible assets-Soin, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-48">17,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-49">19,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="f-50">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="f-51">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note receivable - SPYR, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-53">8,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="f-54">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="f-55">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-56">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-57">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:OtherAssetsFromDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:OtherAssetsFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-59">8,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-60">18,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-61">46,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities, Mezzanine Equity, and Stockholders' Equity (Deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued liabilities - other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">3,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="f-67">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">20,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">5,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">23,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-72">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-73">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLongTermNotesPayable" scale="3" id="f-74">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-76">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-77">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">7,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-81">29,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commitments and Contingencies (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-82"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-83"/></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mezzanine equity</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Convertible preferred stock, series S - par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-84"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-85">0.001</ix:nonFraction></ix:nonFraction> per share <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-87">200,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-89">100,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-91">100,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-92">14,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-93">14,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Convertible preferred stock, series A-1 - par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-95">0.001</ix:nonFraction></ix:nonFraction> per share <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97">2,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99">193,730</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-101">222,588</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-104"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-105">0.001</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-109">4,957,647</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111">2,827,410</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;30, 2023 and at December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-112">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-113">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-114">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-115">45,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-116">50,634</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-117">42,822</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-119">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-120">3,308</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities, mezzanine equity, and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">18,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">46,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">4,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-132">15,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">19,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">19,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">3,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-138">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-139">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-141">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on reversal of contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="jan:GainsOnReversalOfContingencyLoss" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="jan:GainsOnReversalOfContingencyLoss" scale="3" id="f-143">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-144">926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-145">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-146">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">4,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income before benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">17,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-152">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-153">6,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-154">17,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-155">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-156">10,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-157">5,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" scale="3" id="f-158">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-159">2,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-160">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-161">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">7,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share from continuing operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-165">4.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-166"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-167">2.55</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share from discontinued operations, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-168">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-169">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share from discontinued operations, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-170">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-171">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173">1.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-175">3.49</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-176">4,005,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-177">3,150,230</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-178">4,444,361</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">3,150,230</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">7,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-181">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-183">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-185">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-186">7,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-187">10,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.450%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A Preferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive <br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188">238,729</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-190">2,827,410</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-191">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">45,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">53,804</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-194">617</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">8,676</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-196">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-197">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-198">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-199">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-200">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A-1 preferred converted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-201">16,141</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-202">322,820</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-205">222,588</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-207">3,150,230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-208">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">45,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">42,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-211">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-214">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-215">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock issued for equity financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-216">779,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-217">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-218">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-219">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-220">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-221">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A-1 preferred converted for legal settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-222">27,353</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-223">547,069</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-224">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-225">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A-1 preferred forfeited</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" format="ixt:num-dot-decimal" scale="0" id="f-226">1,505</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="jan:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-227">481,348</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="jan:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="f-228">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="jan:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="f-229">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-230">7,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">7,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">193,730</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-234">4,957,647</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-235">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-237">50,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">3,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-240">17,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-241">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-242">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-243">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accretion of note receivable discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" format="ixt:num-dot-decimal" scale="3" id="f-244">1,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" scale="3" id="f-245">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-246">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-247">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-248">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on reversal of contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="3" id="f-251">637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Write off of VM7 note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-252">5,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Write off of SPYR note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="jan:GainLossOnWriteOffOfNotesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-254">9,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="jan:GainLossOnWriteOffOfNotesReceivable" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-256">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-257">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="f-258">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-259">4,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-260">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-261">5,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-262">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-263">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-264">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-265">1,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-266">1,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-267">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Operating cash flows provided by (used in) discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-268">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-269">2,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-270">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-271">3,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investing cash flows used in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-272">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-273">1,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-274">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-275">1,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from equity financings, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-276">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-278">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments on short term notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-280">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-281">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing cash flows (used in) provided by discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-282">2,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-283">3,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-284">1,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-285">3,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-286">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-287">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-288">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-289">591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-290">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-291">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">LESS CASH OF DISCONTINUED OPERATIONS, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" id="f-293">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-294">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-295">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncash recognition of new leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="jan:NoncashRecognitionOfNewLeases" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="jan:NoncashRecognitionOfNewLeases" format="ixt:num-dot-decimal" scale="3" id="f-297">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-298">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-299">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-301">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_130"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="i186f351ddce04342b829c557fbabfeb2_133"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-302" continuedAt="f-302-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: Background and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of JanOne Inc., a Nevada corporation, and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;JanOne&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-303">three</ix:nonFraction> operating segments &#8211; Biotechnology, Recycling, and Technology. In connection with the sale of GeoTraq, Inc. (&#8220;GeoTraq&#8221;) (see Note 5) and the sale of the Recycling segment consisting of the following Recycling Subsidiaries: (a) ARCA Recycling, Inc., a California corporation, (b) ARCA Canada, a corporation organized under the laws of Ontario, Canada, and (c) Customer Connexx LLC, a Nevada limited liability company (see Note 4), the accounts for the Recycling and Technology segments have been consolidated and presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Biotechnology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2019, JanOne, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone, (&#8220;JAN123&#8221;). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of <ix:nonNumeric contextRef="c-1" name="jan:PotentialMarketExclusivityPeriod" format="ixt-sec:durwordsen" id="f-304">seven years</ix:nonNumeric> of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recycling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Recycling Subsidiaries constituted the Company&#8217;s Recycling segment and provided turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx provided call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221; with VM7 Corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. In connection with the disposition of the Recycling Subsidiaries, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeoTraq Inc. (&#8220;GeoTraq&#8221;) was the Company&#8217;s Technology segment. On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-305">13.5</ix:nonFraction>&#160;million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-306">30,000,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-307">0.03</ix:nonFraction> per share, and delivered a <ix:nonNumeric contextRef="c-40" name="jan:NotesReceivableTerm" format="ixt-sec:durwordsen" id="f-308">five-year</ix:nonNumeric> Promissory Note in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:ReceivableWithImputedInterestFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-309">12.6</ix:nonFraction>&#160;million. The Promissory Note bears simple interest at the rate of <ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="f-310">8</ix:nonFraction>% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in SPYR&#8217;s restricted common stock. The Promissory Note matures on May 23, 2027. The accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports on a 52- or 53-week fiscal year. The Company's 2023 fiscal year (&#8220;2023&#8221;) ended on December&#160;30, 2023, and our fiscal year (&#8220;2022&#8221;) ended on December&#160;31, 2022.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-302-1" continuedAt="f-302-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company&#8217;s ability to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-311">17.1</ix:nonFraction> million for the year ended December&#160;30, 2023, and net income from continuing operations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-312">8.0</ix:nonFraction> million for the fiscal year ended December&#160;31, 2022. Additionally, as of December&#160;30, 2023, the Company has total current assets of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-313">346,000</ix:nonFraction> and total current liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-314">5.9</ix:nonFraction> million resulting in a net negative working capital of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="jan:CurrentAssetsCurrentLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-315">5.2</ix:nonFraction> million. Cash used in continuing operations was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="f-316">855,000</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise funds to support future development of JAN 123 either through capital raises or structured arrangements. However, the success of such funding cannot be assured.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-302-2">The ability of the Company to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123, as well as to fund its day-to-day operations. Such approval is contingent on several factors and no assurance can be provided that approval will be obtained. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. While the Company will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured or FDA approvals will be obtained.</ix:continuation> </span></div><div id="i186f351ddce04342b829c557fbabfeb2_136"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-317" continuedAt="f-317-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-318" continuedAt="f-318-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-318-1">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-319" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The prior year amounts have also been modified in these financial statements to properly present amounts under continuing and discontinued operations. See Note 6.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-320" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made in connection with the accompanying consolidated financial statements include the fair values in connection with the GeoTraq promissory note, analysis of other intangibles and long-lived assets for impairment, valuation allowance against deferred tax assets, lease terminations, and estimated useful lives for intangible assets and property and equipment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-321" continuedAt="f-321-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-321-1">Financial instruments consist primarily of cash equivalents, trade and other receivables, notes receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company&#8217;s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at December&#160;30, 2023 and December&#160;31, 2022 approximate fair value.</ix:continuation> </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-317-1" continuedAt="f-317-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-322" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with a maturity of three months or less at the time of purchase. Fair value of cash equivalents approximates carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-323" continuedAt="f-323-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and Other Receivables and Allowance for Doubtful Accounts</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-323-1">The Company carries unsecured trade receivables at the original invoice amount less an estimate made for doubtful accounts based on a monthly review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions. The Company writes off trade receivables when it deems them to be uncollectible. The Company records recoveries of trade receivables previously written off when we receive them. The Company considers a trade receivable to be past due if any portion of the receivable balance is outstanding for more than ninety days. The Company does not charge interest on past due receivables.</ix:continuation> The Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-324"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-325">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts for the years ended December&#160;30, 2023 and December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-326" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the Company's trade and other receivables as of December&#160;30, 2023 and December&#160;31, 2022 (in $000&#8217;s):</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"/><td style="width:70.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-327">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-328">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="f-329">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="f-330">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-331" continuedAt="f-331-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for intangible assets in accordance with ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 350, intangible assets subject to amortization, shall be reviewed for impairment in accordance with the Impairment or Disposal of Long-Lived Assets in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 360, long-lived assets are tested for recoverability whenever events or changes in circumstances (&#8216;triggering event&#8217;) indicate that the carrying amount may not be recoverable. In making this determination, triggering events that were considered included:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant decrease in the market price of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); and,</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a triggering event has occurred, for purposes of recognition and measurement of an impairment loss, a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If after identifying a triggering event it is determined that the asset group&#8217;s carrying value may not be recoverable, a recoverability test is performed by forecasting the expected cash flows to be derived from the asset group for the remaining useful life of the asset group&#8217;s primary asset compared to its carrying value. The recoverability test relies upon the undiscounted cash flows (excluding interest and taxes) which are derived from the Company&#8217;s specific use of those assets (not how a market participant would use those assets); and, are </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-317-2" continuedAt="f-317-3"><ix:continuation id="f-331-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon the existing service potential of the current assets (excluding any improvements that would materially enhance the assets). If the expected undiscounted cash flows exceed the carrying value, the assets are considered recoverable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of trade names, licenses for the use of internet domain names, Universal Resource Locators, or URL&#8217;s, computer software, patent USPTO reference No. 10,182,402, and designs and related manufacturing procedures. In connection with the Soin merger (see Note 3), intangible assets consist of <ix:nonFraction unitRef="patent" contextRef="c-45" decimals="INF" name="jan:NumberOfAcquiredIntangibleAssets" format="ixt-sec:numwordsen" scale="0" id="f-332">three</ix:nonFraction> patents pending, orphan drug status for Naltrexone, as granted by the FDA, and the formula for Naltrexone. Upon acquisition, critical estimates are made in valuing acquired intangible assets, which include but are not limited to: future expected cash flows from customer contracts, customer lists, and estimating cash flows from projects when completed; tradename and market position, as well as assumptions about the period of time that customer relationships will continue; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from the assumptions used in determining the fair values. All intangible assets are capitalized at their original cost and amortized over their estimated useful lives as follows: domain name and marketing &#8211; <ix:nonNumeric contextRef="c-46" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-333">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-47" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-334">20</ix:nonNumeric> years; software &#8211; <ix:nonNumeric contextRef="c-48" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-335">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-49" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-336">5</ix:nonNumeric> years, technology intangibles &#8211; <ix:nonNumeric contextRef="c-50" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-337">7</ix:nonNumeric> years, customer relationships &#8211; <ix:nonNumeric contextRef="c-51" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-338">7</ix:nonNumeric> to <ix:nonNumeric contextRef="c-52" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-339">15</ix:nonNumeric> years.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-340" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biotechnology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates no revenue from its Biotechnology segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recycling Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, retroactive to March 1, 2023, the Company entered into the Recycling Purchase Agreement with VM7, under which VM7 agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. As discussed previously, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements..</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Technology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates no revenue from its Technology segment. GeoTraq was the Company&#8217;s Technology segment. The Company suspended all operations for GeoTraq during the year ended December&#160;31, 2022. On May 24, 2022, the Company sold substantially all of the GeoTraq assets . GeoTraq is being presented as a discontinued operation. See Note 5. As discussed previously, the accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-341" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: Level 1 - inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Level 2 &#8211; to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 &#8211; inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-342" continuedAt="f-342-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided on deferred taxes if it is determined that it is more likely than not that the asset will not be realized. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision for income taxes in its Consolidated Statements of Income.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-317-3"><ix:continuation id="f-342-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the amount of benefit to be recognized in relation to an uncertain tax position. The Company uses a two-step process to evaluate tax positions. The first step requires an entity to determine whether it is more likely than not (greater than 50% chance) that the tax position will be sustained. The second step requires an entity to recognize in the financial statements the benefit of a tax position that meets the more-likely-than-not recognition criterion. The amounts ultimately paid upon resolution of issues raised by taxing authorities may differ materially from the amounts accrued and may materially impact the financial statements of the Company in future periods.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-343" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-344" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is calculated in accordance with ASC 260, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. Under ASC 260 basic earnings per share is computed using the weighted average number of common shares outstanding during the period except that it does not include unvested restricted stock subject to cancellation. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of warrants, options, restricted shares and convertible preferred stock. The dilutive effect of outstanding restricted shares, options and warrants is reflected in diluted earnings per share by application of the treasury stock method. Convertible preferred stock is reflected on an if-converted basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-345" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 280, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; requires use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a Company&#8217;s management organizes segments within the Company for making operating decisions and assessing performance. The Company determined it had <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-346">three</ix:nonFraction> reportable segments, however the Recycling and Technology segments have been consolidated and presented as discontinued operations. See Note 21.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-347" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash balances at a bank in Nevada. The account is insured by the Federal Deposit Insurance Corporation up to $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="INF" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" format="ixt:num-dot-decimal" scale="0" id="f-348">250,000</ix:nonFraction>. At times, balances may exceed federally insured limits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-349" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_139"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3: Mergers and Acquisitions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Soin Pharmaceuticals</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-350-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In anticipation of the closing of the merger, the Company formed a merger subsidiary known as STI Merger Sub, Inc., a Delaware corporation (our &#8220;Merger Sub&#8221;), and designated a series of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-351">200,000</ix:nonFraction> shares of its preferred stock, stated value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-352">300.00</ix:nonFraction> per share (the &#8220;Series S Convertible Preferred Stock&#8221; or the &#8220;Series S Stock&#8221;). See Note 15. The acquisition was memorialized by an Agreement and Plan of Merger, dated as of December&#160;28, 2022 (the &#8220;Merger Agreement&#8221;), by and among STLLC, Amol Soin, M.D., the sole stockholder of STLLC (&#8220;Dr. Soin&#8221;), the Company's Merger Sub, and us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For not less than six months after the closing and potentially up to approximately one year from the closing, Dr. Soin will remain the Company's Chief Medical Officer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the merger, (i) our Merger Sub merged with and into STLLC with STLLC as the surviving entity and (ii) the Company issued <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-353">100,000</ix:nonFraction> shares of its Series S Stock to Dr. Soin. This all-stock transaction has an initial value of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-354">13,000,000</ix:nonFraction>, potentially increasing by an additional $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="jan:StockIssuedDuringPeriodAdditionalValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-355">17,000,000</ix:nonFraction> to up to a total value of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="0" id="f-356">30,000,000</ix:nonFraction>, depending on revenues generated by the STLLC product. Dr. Soin agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of <ix:nonFraction unitRef="number" contextRef="c-56" decimals="4" name="jan:CommonStockSharesOutstandingPercentage" scale="-2" id="f-357">4.99</ix:nonFraction>% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin may convert up to <ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt-sec:numwordsen" scale="6" id="f-358">three</ix:nonFraction> million dollars of value of the Series S Stock into shares of the Company's common stock commencing <ix:nonNumeric contextRef="c-58" name="jan:ConversionOfStockCommencementPeriod" format="ixt-sec:durwordsen" id="f-359">one year</ix:nonNumeric> from the closing and may convert up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="6" id="f-360">10</ix:nonFraction> million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) <ix:nonNumeric contextRef="c-60" name="jan:ConversionOfStockPeriodFollowingClosing" format="ixt-sec:duryear" id="f-361">10</ix:nonNumeric> years from the closing. Further, during the <ix:nonNumeric contextRef="c-60" name="jan:ConversionOfStockPeriodFollowingClosing" format="ixt-sec:duryear" id="f-362">10</ix:nonNumeric>-year period following the closing, Dr. Soin may convert up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="6" id="f-363">17</ix:nonFraction> million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the completion of the merger, the Company performed a screen test, as defined in ASC 805 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine whether the Soin Pharmaceutical merger was considered a business combination or an asset acquisition. The results of the screen test revealed that substantially all of the fair value was concentrated in a group of similar assets, and that the assets did not possess the inputs, outputs, nor processes required to be considered a business, as defined in ASC 805. Consequently, <ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-364">no</ix:nonFraction> goodwill was recognized as part of this transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series S Stock issued in connection with the merger, as valued by a third-party, independent, valuation firm was approximately $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="jan:FairValueOfStockIssued" format="ixt:num-dot-decimal" scale="6" id="f-365">14.5</ix:nonFraction> million. The assets acquired by the Company consist of 1) <ix:nonFraction unitRef="patent" contextRef="c-45" decimals="INF" name="jan:NumberOfAcquiredIntangibleAssets" format="ixt-sec:numwordsen" scale="0" id="f-366">three</ix:nonFraction> pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. Consequently, the Company has recorded the assets as intangible assets on its consolidated balance sheets. In addition, the Company recognized a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-367">4.8</ix:nonFraction> million. The total value of the intangible assets purchased is $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-368">19.3</ix:nonFraction> million. The Company will amortize the intangible assets ratably over a <ix:nonNumeric contextRef="c-65" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-369">10</ix:nonNumeric>-year period. See Note 9. Because of certain conversion features of the Series S Stock that place redemption of these shares outside the control of the Company, the Series S Stock will be presented as mezzanine equity on the Company's consolidated balance sheets. As of December&#160;30, 2023, the Soin intangible had a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-370">17.8</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_142"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-371" continuedAt="f-371-1" escape="true">Sale of Recycling Subsidiaries</ix:nonNumeric></span></div><ix:continuation id="f-371-1" continuedAt="f-371-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-372">17.6</ix:nonFraction>&#160;million, and includes those liabilities related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" format="ixt:num-dot-decimal" scale="6" id="f-373">24.0</ix:nonFraction>&#160;million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next <ix:nonNumeric contextRef="c-67" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" format="ixt-sec:durwordsen" id="f-374">five years</ix:nonNumeric>, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" format="ixt:num-dot-decimal" scale="6" id="f-375">1</ix:nonFraction>&#160;million. The Company also received <ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" format="ixt-sec:numwordsen" scale="0" id="f-376">one thousand</ix:nonFraction> dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" format="ixt:num-dot-decimal" scale="0" id="f-377">140,000</ix:nonFraction> (or $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" format="ixt:num-dot-decimal" scale="0" id="f-378">100,000</ix:nonFraction> for each January and February during the <ix:nonNumeric contextRef="c-67" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" format="ixt-sec:durwordsen" id="f-379">15-year</ix:nonNumeric> payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) <ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" scale="-2" id="f-380">5</ix:nonFraction>% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" format="ixt:num-dot-decimal" scale="0" id="f-381">2,000,000</ix:nonFraction> for the relevant month, plus (ii) <ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" scale="-2" id="f-382">4</ix:nonFraction>% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" format="ixt:num-dot-decimal" scale="0" id="f-383">2,000,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" format="ixt:num-dot-decimal" scale="0" id="f-384">3,000,000</ix:nonFraction> for the relevant month, plus (iii) <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" scale="-2" id="f-385">3</ix:nonFraction>% of the Recycling Subsidiaries aggregate gross revenues over $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" format="ixt:num-dot-decimal" scale="0" id="f-386">3,000,000</ix:nonFraction> for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 9, 2023. Additionally, upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to the Company <ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="jan:DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" scale="-2" id="f-387">50</ix:nonFraction>% of the amount of the reduction between the current assessment and any such settlement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-388">1.6</ix:nonFraction>&#160;million per year for <ix:nonNumeric contextRef="c-67" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" format="ixt-sec:duryear" id="f-389">15</ix:nonNumeric> years, or $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" format="ixt:num-dot-decimal" scale="6" id="f-390">24.0</ix:nonFraction>&#160;million in the aggregate, plus cash of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" format="ixt:num-dot-decimal" scale="0" id="f-391">3,000</ix:nonFraction> paid at close. In connection with the Disposition Transaction, the Company used a discount rate of <ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="jan:DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" scale="-2" id="f-392">20</ix:nonFraction>% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="f-393">6.0</ix:nonFraction>&#160;million, which, in addition to the $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" format="ixt:num-dot-decimal" scale="0" id="f-394">3,000</ix:nonFraction> paid at close, comprises the approximately $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="jan:DisposalGroupIncludingDiscontinuedOperationNetConsideration" format="ixt:num-dot-decimal" scale="6" id="f-395">6.0</ix:nonFraction>&#160;million of net consideration. Additionally, the calculation of the gain on <ix:nonNumeric contextRef="c-1" name="jan:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" id="f-396">disposition</ix:nonNumeric> includes the book value in excess of assets disposed of, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="jan:DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-397">9.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-398">5.3</ix:nonFraction>&#160;million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities. In connection with the shutdown of the Recycling Subsidiaries, because the Company is a guarantor on the Gulf Coast Bank and Trust credit facility (see Note 6), the Company recorded a liability for approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-399">1.7</ix:nonFraction>&#160;million for estimated liability associated with this facility, which has been offset against the gain on the sale the Recycling Subsidiaries. Further, the Company has recorded additional liabilities, in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-400">2.0</ix:nonFraction>&#160;million, that were originally associated with the sale of the Recycling Subsidiaries and have reverted to the Company, which has been offset against the gain on the sale the Recycling Subsidiaries. See Note 18.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary calculation of the gain on sale was approximately $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="f-401">15.8</ix:nonFraction> million. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-402" continuedAt="f-402-1" escape="true">The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-402-1" continuedAt="f-402-2"><ix:continuation id="f-371-2" continuedAt="f-371-3"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"/><td style="width:82.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:TotalGuaranteedConsideration" format="ixt:num-dot-decimal" scale="3" id="f-403">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:PaymentFromBuyer" scale="3" id="f-404">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:NetConsideration" format="ixt:num-dot-decimal" scale="3" id="f-405">6,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-406">5,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfAccruedLiability" format="ixt:num-dot-decimal" scale="3" id="f-407">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfAccruedLiabilityCaliforniaStateSalesTax" format="ixt:num-dot-decimal" scale="3" id="f-408">6,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-409">5,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-410">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="f-411">604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:TotalDisposalOfLiability" format="ixt:num-dot-decimal" scale="3" id="f-412">20,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:TotalConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-413">26,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:CashDisposal" scale="3" id="f-414">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-415">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfInventory" scale="3" id="f-416">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-417">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfIntangibleAssets" scale="3" id="f-418">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-419">5,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:DisposalOfOtherAssets" scale="3" id="f-420">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:TotalDisposalOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-421">14,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="jan:TotalGainOnSale" format="ixt:num-dot-decimal" scale="3" id="f-422">12,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_217"></div><ix:continuation id="f-371-3" continuedAt="f-371-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: GeoTraq</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="jan:AgreedPrepaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-423">13.5</ix:nonFraction> million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May&#160;24, 2022, SPYR issued to the Company <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-424">30,000,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-425">0.03</ix:nonFraction> per share, and delivered a <ix:nonNumeric contextRef="c-79" name="jan:NotesReceivableTerm" format="ixt-sec:durwordsen" id="f-426">five-year</ix:nonNumeric> Promissory Note in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="jan:NoteReceivableFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-427">12.6</ix:nonFraction> million. The Promissory Note bears simple interest at the rate of <ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="jan:NoteReceivableStatedInterestRate" scale="-2" id="f-428">8</ix:nonFraction>% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on <ix:nonNumeric contextRef="c-80" name="jan:NoteReceivableMaturityDate" format="ixt:date-monthname-day-year-en" id="f-429">May&#160;24, 2027</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company employed an independent third-party firm to assess the fair value of the <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-430">30,000,000</ix:nonFraction> shares of SPYR stock and the Promissory Note. The assessment determined that the fair market value of the SPYR common stock was approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-431">946,000</ix:nonFraction>, or approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-432">0.032</ix:nonFraction> per share, which was approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-433">46,000</ix:nonFraction> greater than the amount of the shares received at close. The Promissory Note was valued at approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-434">11.3</ix:nonFraction> million, which was approximately $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-435">1.4</ix:nonFraction> million less than the Note issued. Consequently, the Company recorded the shares of SPYR stock at fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="jan:NoteReceivableFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-436">946,000</ix:nonFraction>, and recorded a discount offsetting the Promissory Note in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-4" name="us-gaap:ReceivableWithImputedInterestNetAmount" format="ixt:num-dot-decimal" scale="6" id="f-437">1.35</ix:nonFraction> million. The discount will be accreted ratably over the term of the Promissory Note, and recorded as interest income. Additionally, approximately $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-438">105,000</ix:nonFraction> in GeoTraq inventory was transferred as part of the sale, and was, thus, derecognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, based on declining financial trends at SPYR, the Company reviewed the original valuation of the Promissory Note to determine whether a revision of the estimate of the original <ix:nonFraction unitRef="number" contextRef="c-85" decimals="3" name="jan:NoteReceivableDiscountRate" scale="-2" id="f-439">10.5</ix:nonFraction>% used to discount the note should occur to account for the additional risk the note would not be repaid. In connection with this review, the Company determined that the discount rate should be revised to <ix:nonFraction unitRef="number" contextRef="c-85" decimals="3" name="jan:NoteReceivableRevisedDiscountRate" scale="-2" id="f-440">14.5</ix:nonFraction>%. Consequently, the Company took an additional $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-4" name="jan:ChargeAgainstIncomeForIncreaseInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-441">1.85</ix:nonFraction> million charge against income for the 13 and 26 weeks ended July 2, 2022, and restated its Quarterly Reports on Form 10-Q for the 13 and 26 weeks ended July 2, 2022, and the 13 and 39 weeks ended October 1, 2022. Additionally, due to the declining financial trends at SPYR, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="jan:ChargeAgainstIncomeForIncreaseInDiscountRate" format="ixt:num-dot-decimal" scale="0" id="f-442">813,000</ix:nonFraction> charge against income for the year ended </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-371-4" continuedAt="f-371-5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. <ix:nonFraction unitRef="usd" contextRef="c-87" decimals="INF" name="jan:ChargeAgainstIncomeForIncreaseInDiscountRate" format="ixt:fixed-zero" scale="0" id="f-443">No</ix:nonFraction> additional charges against income have been recorded by the Company for the year ended December&#160;30, 2023.</span></div><ix:continuation id="f-402-2" continuedAt="f-402-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-444">13,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-445">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PolicyholderAccountBalancePremiumReceived" scale="3" id="f-446">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" scale="3" id="f-447">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfProject" format="ixt:num-dot-decimal" scale="3" id="f-448">9,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, as of December&#160;30, 2023, the Company recorded a charge to fully impair the promissory note (see Note 8).</span></div></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_738"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:continuation id="f-371-5" continuedAt="f-371-6">Discontinued Operations</ix:continuation></span></div><ix:continuation id="f-371-6" continuedAt="f-371-7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company discontinued operations of its Recycling and Technology segments as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company executed a Recycling Purchase Agreement with VM7, under which, as of March 1, 2023, it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The assets and liabilities for the Recycling Subsidiaries were included in discontinued operations December&#160;31, 2022, but were not included at December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. No GeoTraq assets or liabilities were included in discontinued operations at December&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. <ix:continuation id="f-402-3" continuedAt="f-402-4">The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-402-4" continuedAt="f-402-5"><ix:continuation id="f-371-7" continuedAt="f-371-8"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="f-449">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-450">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="3" id="f-451">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="3" id="f-452">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">8,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-454">2,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-455">5,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="3" id="f-456">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" id="f-457">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-458">8,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-459">17,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-460">4,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-461">3,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" format="ixt:num-dot-decimal" scale="3" id="f-462">6,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="f-463">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-464">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" scale="3" id="f-465">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" scale="3" id="f-466">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-467">20,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="f-468">3,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-469">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" scale="3" id="f-470">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-472">26,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-371-8" continuedAt="f-371-9"><ix:continuation id="f-402-5" continuedAt="f-402-6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-89" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-473">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-90" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-474">30</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" scale="3" id="f-475">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-92" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-476">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-93" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-477">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" format="ixt:num-dot-decimal" scale="3" id="f-478">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" format="ixt:num-dot-decimal" scale="3" id="f-479">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" format="ixt:num-dot-decimal" scale="3" id="f-480">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-481">1,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-482">2,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-483">60,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-484">326,000</ix:nonFraction> for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><ix:continuation id="f-402-6" continuedAt="f-402-7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-485">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-486">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-487">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-488">966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="3" id="f-489">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3" id="f-490">36,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3" id="f-491">229,000</ix:nonFraction> for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><ix:continuation id="f-402-7" continuedAt="f-402-8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-492">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-493">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:AccruedIncentiveAndRebateChecksCurrent" format="ixt:num-dot-decimal" scale="3" id="f-494">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="f-495">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-496">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">3,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically the Company operated its recycling business in <ix:nonFraction unitRef="state" contextRef="c-100" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" format="ixt-sec:numwordsen" scale="0" id="f-498">fourteen</ix:nonFraction> states in the U.S. and in various provinces in Canada. From time to time, the Company is subject to sales and use tax audits that could result in additional taxes, penalties and interest owed to various taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The California Department of Tax and Fee Administration (formerly known as the California Board of Equalization) (&#8220;CDTFA&#8221;) conducted a sales and use tax examination covering ARCA Recycling&#8217;s California operations for years 2011, 2012, and 2013. The Company believed it was exempt from collecting sales taxes under service agreements with utility customers that included appliance replacement programs. During the fourth quarter of 2014, the Company received communication from the CDTFA indicating they were not in agreement with the Company&#8217;s interpretation of the law. As a result, the Company applied for and, as of February 9, 2015, received approval to participate in the CDTFA&#8217;s Managed Audit Program. The period covered under this program included the years 2011, 2012, and 2013 and extended through the nine-month period ended September 30, 2014.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-371-9" continuedAt="f-371-10"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2017 the Company received the formal CDTFA assessment for sales tax for tax years 2011, 2012, and 2013 in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-499">4.1</ix:nonFraction> million plus applicable interest of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="jan:SalesTaxAssessmentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="f-500">500,000</ix:nonFraction> related to the appliance replacement programs that the Company administered on behalf of its customers on which it did not assess, collect, or remit sales tax. The Company has appealed this assessment to the CDTFA Appeals Bureau. The appeal remains in process. Interest has continued to accrue until the matter is resolved. </span></div><ix:continuation id="f-402-8" continuedAt="f-402-9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:SalesTaxAssessmentAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-502">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" format="ixt:num-dot-decimal" scale="3" id="f-503">6,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-504">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="f-505">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-506">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-507">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="3" id="f-508">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-509">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" scale="3" id="f-510">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to Isaac Capital Group LLC (&#8220;ICG&#8221;) a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-512">2.5</ix:nonFraction> million revolving credit facility (the &#8220;ICG Note&#8221;). The ICG Note originally matured on August 28, 2020. On August 25, 2020, the ICG Note was amended to extend the maturity date to December 31, 2020. On March 30, 2021, ARCA Recycling entered into a Second Amendment and Waiver (the &#8220;Second Amendment&#8221;) to the ICG Note to further extend the maturity date to August 18, 2021 and waive certain defaults under the ICG Note. The ICG Note bears interest at <ix:nonFraction unitRef="number" contextRef="c-105" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="f-513">8.75</ix:nonFraction>% per annum and provides for the payment of interest, monthly in arrears. ARCA Recycling will pay a loan fee of <ix:nonFraction unitRef="number" contextRef="c-105" decimals="3" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-514">2.0</ix:nonFraction>% on each borrowing made under the ICG Note. In connection with entering into the ICG Note, the Borrower also entered into a security agreement in favor of the Lender, pursuant to which ARCA Recycling granted a security interest in all of its assets to the Lender.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of ARCA Recycling under the ICG Note are guaranteed by the Company. The foregoing transaction did not include the issuance of any shares of the Company&#8217;s common stock, warrants, or other derivative securities. As of January&#160;1, 2022, the balance due on ICG Note was $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-515">1.0</ix:nonFraction> million. Beginning in April 2022, the revolving credit facility was converted to a term note that amortized ratably through its maturity date of March 2026. The principal amount of the note was $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-516">1.0</ix:nonFraction> million, and was to bear interest at <ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-517">8.75</ix:nonFraction>% per annum. Monthly payments on the ICG Note were approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="0" id="f-518">24,767</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7 </span><ix:continuation id="f-402-9" continuedAt="f-402-10"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-371-10" continuedAt="f-371-11"><ix:continuation id="f-402-10" continuedAt="f-402-11"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable" scale="3" id="f-519">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable" scale="3" id="f-520">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" scale="3" id="f-521">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" scale="3" id="f-522">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). <ix:continuation id="f-402-11" continuedAt="f-402-12">The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):</ix:continuation></span></div><ix:continuation id="f-402-12" continuedAt="f-402-13"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-523">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-524">39,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="f-525">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="f-526">31,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="f-527">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-528">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-529">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-530">8,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-531">12,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-534">9,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-535">10,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" scale="3" id="f-536">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-537">10,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-538">8,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="f-539">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="f-540">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="f-542">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="3" id="f-543">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-544">1,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" scale="3" id="f-545">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" format="ixt:num-dot-decimal" scale="3" id="f-546">3,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-547">10,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-548">5,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="f-549">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-550">2,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-551">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-552">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. <ix:continuation id="f-402-13" continuedAt="f-402-14">The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-402-14"><ix:continuation id="f-371-11"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-553">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-554">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-555">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-556">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-557">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-558">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:GainLossOnLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="jan:GainLossOnLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-560">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:AmortizationOfRightOfUseAssets" scale="3" id="f-561">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="jan:AmortizationOfRightOfUseAssets" scale="3" id="f-562">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="jan:GainOnSaleNetOfCash" format="ixt:num-dot-decimal" scale="3" id="f-563">12,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="jan:GainOnSaleNetOfCash" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-566">9,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-567">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-568">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-569">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-570">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-571">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-572">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-573">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="f-574">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-575">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-576">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-577">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-578">2,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-579">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-580">808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-581">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-582">701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-583">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-584">1,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-585">5,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-586">17,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="f-587">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="f-588">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-589">7,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-590">13,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-591">2,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-592">3,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-593">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-594">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-595">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-596">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-597">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-598">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-600">53</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i186f351ddce04342b829c557fbabfeb2_151"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-601" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: Prepaids and other current assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-602" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaids and other current assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-603">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-604">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-605">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-606">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaids and other current assets</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" scale="3" id="f-607">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" scale="3" id="f-608">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="i186f351ddce04342b829c557fbabfeb2_145"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancingReceivablesTextBlock" id="f-609" continuedAt="f-609-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: Notes receivable </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SPYR Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc. (&#8220;SPYR&#8221;), pursuant to which the Company sold to SPYR substantially all of the assets and none of the specified liabilities of GeoTraq, as discussed in Note 5. In connection with the Purchase Agreement, SPYR delivered to the Company a <ix:nonNumeric contextRef="c-115" name="jan:NotesReceivableTerm" format="ixt-sec:durwordsen" id="f-610">five-year</ix:nonNumeric> </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-609-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promissory Note in the initial principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="jan:NoteReceivableFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-611">12.6</ix:nonFraction> million. The Promissory Note bears simple interest at the rate of <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="jan:NoteReceivableStatedInterestRate" scale="-2" id="f-612">8.0</ix:nonFraction>% per annum, provides quarterly interest payments due on the first day of each calendar quarter, and may be prepaid at any time without penalty. Interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May 24, 2027. The Company has received restricted shares of Series G Convertible Preferred Stock of SPYR equivalent to approximately <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-613">922,442,000</ix:nonFraction> shares of its common stock during the year ended December&#160;30, 2023, and <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-614">30,000,000</ix:nonFraction> shares of SPYR's common stock during the year ended December&#160;31, 2022. As of December&#160;30, 2023, the Company has accrued receivables of approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="0" id="f-615">254,000</ix:nonFraction> in interest income related to the Promissory Note.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the asset sale, the Company engaged a third-party valuation firm to assess the fair value of the consideration received. Based on the valuation, the Promissory Note (&#8220;Note&#8221;) was valued at approximately $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:OriginationOfNotesReceivableFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="f-616">11.3</ix:nonFraction> million. The amount of the discount, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="jan:DiscountRecordedAsOffsetToThePrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="f-617">1.3</ix:nonFraction> million, has been recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. At December&#160;31, 2022, the Company reviewed the original valuation of the Promissory Note to determine if the original <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="jan:DebtDiscountRate" scale="-2" id="f-618">10.5</ix:nonFraction>% used to discount the Note was appropriate. In connection with this review, the Company determined that the discount rate should be revised to <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="jan:DebtRevisedDiscountRate" scale="-2" id="f-619">14.5</ix:nonFraction>%. Consequently, the Company took a $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-4" name="jan:DiscountCharges" format="ixt:num-dot-decimal" scale="6" id="f-620"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-4" name="jan:DiscountCharges" format="ixt:num-dot-decimal" scale="6" id="f-621">1.85</ix:nonFraction></ix:nonFraction> million charge against income, and restated the 13 and 26 weeks ended July&#160;2, 2022, as discussed previously. Further, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="jan:AdditionalAmountChargedAgainstIncome" format="ixt:num-dot-decimal" scale="0" id="f-622">813,000</ix:nonFraction> charge against income for the year ended December&#160;31, 2022 due to SPYR's declining financial trends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, the Company recorded an impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="jan:GainLossOnWriteOffOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-623">9.8</ix:nonFraction>&#160;million for the fiscal year ended December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:InterestIncomeInterestEarningAsset" format="ixt:num-dot-decimal" scale="0" id="f-624">806,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:InterestIncomeInterestEarningAsset" format="ixt:num-dot-decimal" scale="0" id="f-625">387,000</ix:nonFraction>, respectively, of the discount was recorded as interest income. As of December&#160;30, 2023 and December&#160;31, 2022, the net principal balance on the Note was approximately $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-626">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-627">9.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">VM7 Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactive to March 1, 2023. See Note 4.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="jan:DispositionTransactionConsiderAmount" format="ixt:num-dot-decimal" scale="6" id="f-628">1.6</ix:nonFraction> million per year for <ix:nonNumeric contextRef="c-126" name="jan:DispositionTransactionTermPeriod" format="ixt-sec:duryear" id="f-629">15</ix:nonNumeric> years, or $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="jan:DispositionTransactionAggregateCost" format="ixt:num-dot-decimal" scale="6" id="f-630">24.0</ix:nonFraction> million in the aggregate, plus cash of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="f-631">3,000</ix:nonFraction> paid at close. In connection with the Disposition Transaction, the Company used a discount rate of <ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="jan:DispositionDiscountRate" scale="-2" id="f-632">20.0</ix:nonFraction>% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ReceivableWithImputedInterestNetAmount" format="ixt:num-dot-decimal" scale="6" id="f-633">6.0</ix:nonFraction> million, which, in addition to the $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="f-634">3,000</ix:nonFraction> paid at close, comprises the approximately <ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ReceivableWithImputedInterestNetAmount" scale="6" id="f-635">6.0</ix:nonFraction> million of net consideration. The amount of the revised discount amount, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="jan:RevisedDiscountAmount" format="ixt:num-dot-decimal" scale="6" id="f-636">18.0</ix:nonFraction> million, was recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. During the year ended December&#160;30, 2023, approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:InterestIncomeInterestEarningAsset" format="ixt:num-dot-decimal" scale="0" id="f-637">720,000</ix:nonFraction> of the discount was recorded as interest income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-638">5.3</ix:nonFraction> million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_157"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-639" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: Intangible assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-640" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soin intangibles</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-641">19,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-642">19,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and domains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-643">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-644">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-646">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-647">19,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-648">22,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-649">1,451</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-650">3,563</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-651">17,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-652">19,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible amortization expense for continuing operations was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-653">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-654">0</ix:nonFraction>, respectively, for the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Soin Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) <ix:nonFraction unitRef="patent" contextRef="c-45" decimals="INF" name="jan:NumberOfAcquiredIntangibleAssets" format="ixt-sec:numwordsen" scale="0" id="f-655">three</ix:nonFraction> pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a <ix:nonNumeric contextRef="c-45" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-656">10</ix:nonNumeric>-year period. See Note 3.</span></div></ix:nonNumeric><div id="i186f351ddce04342b829c557fbabfeb2_160"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-657" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: Marketable Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-658" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of the following (in $000&#8217;s, except shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series G Convertible Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common Shares Equivalent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="c-136" xsi:nil="true" name="jan:MarketableSecuritiesSharesOutstanding" id="f-659"/></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="0" name="jan:MarketableSecuritiesSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-660">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="0" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:fixed-zero" scale="0" id="f-662">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="0" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:num-dot-decimal" scale="0" id="f-663">30,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="f-664">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-665">631</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="0" name="jan:MarketableSecuritiesSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-666">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="0" name="jan:MarketableSecuritiesSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-667">30,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecurities" scale="3" id="f-668">315</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="0" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:num-dot-decimal" scale="0" id="f-669">9,224</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="0" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:num-dot-decimal" scale="0" id="f-670">922,442,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="f-671">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-672">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance, December 30, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="0" name="jan:MarketableSecuritiesSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-673">9,224</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="0" name="jan:MarketableSecuritiesSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-674">952,442,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" scale="3" id="f-675">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities reflect shares of SPYR stock received by the Company in connection with the sale of GeoTraq. See Note 5. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. Shares of Series G Convertible Preferred Stock are convertible into the SPYR&#8217;s common shares at a ratio of 1:100,000. Shares held are marked to fair market value as of each balance sheet date, with the resulting change recorded as an unrealized gain or loss. For the year ended December&#160;30, 2023, the Company received <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:num-dot-decimal" scale="0" id="f-676">9,224</ix:nonFraction> shares of Series G Convertible Preferred Stock, which are convertible into approximately <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="-5" name="jan:ConvertiblePreferredStockSharesIssuableUponConversion" format="ixt:num-dot-decimal" scale="6" id="f-677">922.4</ix:nonFraction> million shares of SPYR&#8217;s common stock. For the year ended December&#160;31, 2022, the Company received <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares" format="ixt:num-dot-decimal" scale="6" id="f-678">30</ix:nonFraction> million shares of SPYR&#8217;s common stock. Unrealized loss was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-679">926,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-680">631,000</ix:nonFraction> for the years ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_163"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-682" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: Deposits and other assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-683" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-684">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-685">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deposits and other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-686">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="jan:DepositsAndOtherAssetsNoncurrent" scale="3" id="f-687">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="i186f351ddce04342b829c557fbabfeb2_169"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-688" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: Accrued liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-689" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities of continuing consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-690">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-691">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued guarantees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:AccruedGuaranteesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-692">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:AccruedGuaranteesCurrent" scale="3" id="f-693">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="f-694">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="f-695">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued litigation/legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LitigationReserveCurrent" scale="3" id="f-696">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LitigationReserveCurrent" scale="3" id="f-697">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-698">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-699">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-700">3,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div id="i186f351ddce04342b829c557fbabfeb2_181"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShortTermDebtTextBlock" id="f-702" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13: Short-term debt</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-703" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt and other financing obligations consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AFCO Finance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="f-705">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="3" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="f-707">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AFCO Finance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a financing agreement with AFCO Credit Corporation (&#8220;AFCO&#8221;) purchased through Marsh Insurance on an annual basis to fund the annual premiums on insurance policies due July 1 of each year. These policies relate to workers&#8217; compensation and various liability policies including, but not limited to, General, Auto, Umbrella, Property, and Directors&#8217; and Officers&#8217; insurance. The total amount of the premiums financed in July 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-708">516,000</ix:nonFraction> with an interest rate ranging from approximately <ix:nonFraction unitRef="number" contextRef="c-148" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-709">6.0</ix:nonFraction>% over the period. An initial down payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-710">129,000</ix:nonFraction> was made on July 21, 2022 with additional monthly payments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="0" id="f-711">59,000</ix:nonFraction>, escalating to approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="0" id="f-712">69,000</ix:nonFraction> over the term, being made beginning August&#160;1, 2022 and ending on April&#160;1, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding principal due AFCO at December&#160;31, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-713">274,000</ix:nonFraction>. <ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-714"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="0" id="f-715">No</ix:nonFraction></ix:nonFraction> such financing agreement was entered into by the Company during fiscal 2023.</span></div></ix:nonNumeric><div id="i186f351ddce04342b829c557fbabfeb2_187"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PreferredStockTextBlock" id="f-716" continuedAt="f-716-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14: Series A-1 Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2017, the Company acquired GeoTraq by way of merger. In connection with this transaction, the Company tendered to the owners of GeoTraq $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="0" id="f-717">200,000</ix:nonFraction>, issued to them an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-718">288,588</ix:nonFraction> shares (number of shares specific &#8211; not rounded) of the Company&#8217;s Series A Convertible Preferred Stock valued at $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-719">12.3</ix:nonFraction> million, including the beneficial conversion feature of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="jan:BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" format="ixt:num-dot-decimal" scale="6" id="f-720">2.6</ix:nonFraction> million, and entered into <ix:nonNumeric contextRef="c-155" name="jan:BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" format="ixt-sec:durwordsen" id="f-721">one-year</ix:nonNumeric> unsecured promissory notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="0" id="f-722">800,000</ix:nonFraction>.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-716-1" continuedAt="f-716-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;Conversion Ratio&#8221; per share of the Series A-1 Convertible Preferred Stock in connection with any conversion shall be at a ratio of <ix:nonFraction unitRef="number" contextRef="c-158" decimals="INF" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-723">20</ix:nonFraction>:1, one share of Series A-1 Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into twenty shares Common Stock. Each holder shall have the right, exercisable at any time and from time to time (unless otherwise prohibited by law, rule, or regulation, or as restricted below), to convert any or all of such holder&#8217;s shares of Series A-1 Convertible Preferred Stock into shares of Common Stock at the Conversion Ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;30, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-724">27,353</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-725">16,141</ix:nonFraction> shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were converted into <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-726">547,069</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-727">322,820</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock. Additionally, during the year ended December&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="jan:ConversionOfStockSharesForfeited" format="ixt:num-dot-decimal" scale="0" id="f-728">1,505</ix:nonFraction> shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were forfeited. As of December&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-729">193,730</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-730">222,588</ix:nonFraction> shares, respectively, of Series A-1 Convertible Preferred Stock outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot declare, pay or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the obtaining of any consents required by our Articles of Incorporation) the holders of the Series A Convertible Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend in the aggregate amount of one dollar, regardless of the number of then-issued and outstanding shares of Series A Convertible Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount per share to the holders of outstanding common stock and Series A-1 Convertible Preferred Stock (on an as-if-converted to common stock basis pursuant to the Conversion Ratio as defined below).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of a share of Series A Convertible Preferred Stock has a number of votes as is determined by multiplying (i) the number of shares of Series A Preferred Stock held by such holder, and (ii) 17. The holders of Series A-1 Convertible Preferred Stock vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the common stockholders of the Company, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series A-1 Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Convertible Preferred Stock; or (iv) alter or change the rights, preferences or privileges of the shares of Series A-1 Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series A-1 Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series A-1 Convertible Preferred Stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_190"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-716-2" continuedAt="f-716-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15: Series S Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;28, 2022 the acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-731">30</ix:nonFraction> million, the Company tendered <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-732">100,000</ix:nonFraction> shares of the Company's Series S Convertible Preferred Stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin may convert up to <ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="jan:ConversionOfStockAmountConvertible" format="ixt-sec:numwordsen" scale="6" id="f-733">three</ix:nonFraction> million dollars of value of the Series S Stock into shares of the Company's common stock commencing <ix:nonNumeric contextRef="c-58" name="jan:ConversionOfStockCommencementPeriod" format="ixt-sec:durwordsen" id="f-734">one year</ix:nonNumeric> from the closing and may convert up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="jan:ConversionOfStockAmountConvertible" format="ixt:num-dot-decimal" scale="6" id="f-735">10</ix:nonFraction> million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) <ix:nonNumeric contextRef="c-60" name="jan:ConversionOfStockPeriodFollowingClosing" format="ixt-sec:duryear" id="f-736">10</ix:nonNumeric> years from the closing. Further, during the <ix:nonNumeric contextRef="c-60" name="jan:ConversionOfStockPeriodFollowingClosing" format="ixt-sec:duryear" id="f-737">10</ix:nonNumeric>-year period following the closing, Dr. Soin may convert up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="jan:ConversionOfStockAmountConvertible" format="ixt:num-dot-decimal" scale="6" id="f-738">17</ix:nonFraction> million of value at a rate of <ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="jan:PercentageOfGrossRevenue" format="ixt-sec:numwordsen" scale="-2" id="f-739">five</ix:nonFraction> percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin further agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="jan:CommonStockSharesOutstandingPercentage" scale="-2" id="f-740">4.99</ix:nonFraction>% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock are convertible into the Company&#8217;s common shares at a ratio of <ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-741">1</ix:nonFraction>:1. <ix:nonNumeric contextRef="c-1" name="us-gaap:TemporaryEquityTableTextBlock" id="f-742" continuedAt="f-742-1" escape="true">As of December&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-743"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-744">100,000</ix:nonFraction></ix:nonFraction> of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#8217;s).</ix:nonNumeric></span></div><ix:continuation id="f-742-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series S Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-745">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series S preferred issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="jan:TemporaryEquitySharesIssuedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-747">100,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-748">14,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="f-749">100000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-750">14,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-751">100,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-752">14,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock do not have dividend rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Holder of each share of Series S Convertible Preferred Stock shall have <ix:nonFraction unitRef="vote" contextRef="c-66" decimals="INF" name="jan:PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" format="ixt-sec:numwordsen" scale="0" id="f-753">one</ix:nonFraction> vote for such share. With respect to any stockholder vote, the Holder shall have full voting rights and powers equal to the voting rights and powers of the Common Stock stockholders, and shall be entitled to notice of any stockholders' meeting in accordance with the Bylaws of the Company, and shall be entitled to vote, together with Common Stock stockholders, with respect to any question upon which the Common Stock stockholders have the right to vote. The Holders of Series S Convertible Preferred Stock shall vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the Common Stock stockholders, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series S Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-716-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series S Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series S Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series S Convertible Preferred Stock; (iv) issue additional shares of Series S Convertible Preferred Stock other than in connection with the merger agreement, or (v) alter or change the rights, preferences or privileges of the shares of Series S Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series S Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series S Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series S Convertible Preferred Stock.</span></div></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_193"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-754" continuedAt="f-754-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16: Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's Articles of Incorporation authorize <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-755">200,000,000</ix:nonFraction> shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. As of December&#160;30, 2023, and December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-756">4,957,647</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-757">3,150,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares, respectively, of common stock issued and outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Offerings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;22, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company in a registered direct offering of <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering" format="ixt:num-dot-decimal" scale="0" id="f-758">361,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-759">0.001</ix:nonFraction> per share, at a purchase price per share of Common Stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="2" name="jan:CommonStockPurchasePricePerShare" scale="0" id="f-760">1.17</ix:nonFraction>. The offering closed on March&#160;24, 2023. The aggregate gross proceeds for the sale of the shares of Common Stock were approximately $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:ProceedsFromSaleOfInterestInPartnershipUnit" format="ixt:num-dot-decimal" scale="0" id="f-761">422,000</ix:nonFraction>, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2023, the Company entered into a Securities Purchase Agreement with a certain institutional investor for the sale by the Company in a registered direct offering of: (i) <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-762">418,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-763">0.001</ix:nonFraction> per share, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-764">0.8811</ix:nonFraction> per share and (ii) pre-funded warrants exercisable for up to <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-765">481,348</ix:nonFraction> shares of Common Stock to the Investor at an offering price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-766">0.8801</ix:nonFraction> per pre-funded Warrant. The aggregate gross proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="0" id="f-767">790,000</ix:nonFraction>, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes. On August&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="jan:ClassOfWarrantOrRightWarrantsOrRightsExercised" format="ixt:num-dot-decimal" scale="0" id="f-768">481,348</ix:nonFraction> of the pre-funded warrants were exercised. In a concurrent private placement, the Company also granted warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-769">899,348</ix:nonFraction> shares of Common Stock. Each warrant is exercisable immediately following issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-770">0.7561</ix:nonFraction> per share and expires August&#160;31, 2023. As of December&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-771">899,348</ix:nonFraction> of the private placement warrants outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 annual meeting of stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (<ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-772">2,000,000</ix:nonFraction>) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the year ended December&#160;30, 2023, the Company granted $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-773">345,000</ix:nonFraction> in restricted stock units, or <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-774">908,852</ix:nonFraction> underlying shares of the Company's common stock, which were all immediately vested. As of December&#160;30, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-775">345,000</ix:nonFraction> in restricted stock units, or <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-776">908,852</ix:nonFraction> underlying shares of the Company's common stock, were outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October&#160;28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-754-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-777">400,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-778">800,000</ix:nonFraction>. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of December&#160;30, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-779">100,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-780">90,000</ix:nonFraction> options were outstanding under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May&#160;12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of December&#160;30, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-781">14,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-782">20,000</ix:nonFraction> options, respectively, were outstanding under the 2011 Plan. <ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="jan:AdditionalAwardsToBeGranted" format="ixt:fixed-zero" scale="0" id="f-783">No</ix:nonFraction> additional awards will be granted under the 2011 Plan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-784" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022 (Aggregate Intrinsic Value in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options <br/>Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-785">117,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-786">7.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-787">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-191" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-788">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-789">7,500</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-790">110,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-791">6.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-793">6.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-794">10,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-795">1.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-796">6,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-798">114,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-799">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-801">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-802">114,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-803">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="f-804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-805">6.1</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-806" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price for stock options outstanding and exercisable outstanding at December&#160;30, 2023 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.447%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-807">6,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-808">17.35</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-809">23.45</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-810">6,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-811">17.35</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-812">23.45</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:fixed-zero" scale="0" id="f-813">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-814">11.10</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-815">15.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="0" id="f-816">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-817">11.10</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-818">15.00</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-819">42,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-820">5.70</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-821">9.90</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-822">42,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-823">5.70</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-824">9.90</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-825">66,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-826">3.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-827">5.25</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-828">66,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-829">3.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-830">5.25</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-831">114,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-832">114,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-833" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s non-vested shares outstanding as of December&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-vested Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-834">7,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-835">7,500</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-836">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-837">10,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-838">10,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-839">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense related to equity incentive awards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-840">14,000</ix:nonFraction> and approximately $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">5,000</ix:nonFraction> for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively. As of December&#160;30, 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:fixed-zero" scale="3" id="f-842">no</ix:nonFraction> unrecognized share-based compensation expense associated with stock option awards.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_175"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-843" continuedAt="f-843-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17: Income taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-844" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, the Company recorded an income tax benefit from continuing operations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-845">429,000</ix:nonFraction> and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-846">6.6</ix:nonFraction>&#160;million, respectively, and an income tax provision from discontinued operations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-847">971,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-848">2.1</ix:nonFraction> million, respectively, which consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-850">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-851">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-852">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-853">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-854">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax provision (benefit) - domestic</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-855">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-856">4,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision (benefit) of income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="jan:ProvisionBenefitOfIncomeTaxes" scale="3" id="f-857">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="jan:ProvisionBenefitOfIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-858">4,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-859" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's income tax benefit (provision) with the federal statutory tax rate for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively, is shown below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-860">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-861">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal income tax for installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" format="ixt:fixed-zero" scale="-2" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" scale="-2" id="f-863">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State tax rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-864">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-865">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-866">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-867">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-868">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-869">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-871">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of sale of ARCA Recycling and Canada</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="f-872">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-874">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-875">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-876">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-877">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-878">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-879">65.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-880" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision of income taxes was derived from the following sources for fiscal years December&#160;30, 2023 and December&#160;31, 2022, respectively, as shown below (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-881">6,613</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-882">6,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-883">657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-884">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-885">7,270</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-886">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-843-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-887" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets (liabilities) as of December&#160;30, 2023 and December&#160;31, 2022, respectively, are as follows (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="f-888">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-889">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="f-890">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="f-891">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:Section174Expenses" scale="3" id="f-892">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:Section174Expenses" scale="3" id="f-893">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-894">16</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-895">184</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-896">5,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-897">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:DeferredTaxAssetsLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:DeferredTaxAssetsLeaseLiability" scale="3" id="f-899">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="f-900">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="f-901">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-902">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-903">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-904">3,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-905">4,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-907">483</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:DeferredTaxLiabilitiesInstallmentSale" format="ixt:fixed-zero" scale="3" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:DeferredTaxLiabilitiesInstallmentSale" format="ixt:num-dot-decimal" scale="3" id="f-909">2,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="3" id="f-910">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="3" id="f-911">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 163(j) interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:DeferredTaxAssetsInterest" format="ixt:fixed-zero" scale="3" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:DeferredTaxAssetsInterest" scale="3" id="f-913">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-914">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" scale="3" id="f-915">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-916">2,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-917">904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-918">639</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-919">195</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company has net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-920">20.9</ix:nonFraction> million for federal income tax purposes, and approximately $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-921">14.8</ix:nonFraction> million for state income tax purposes, which will be available to offset future taxable income. Due to recent tax legislation, the federal net operating losses are eligible for indefinite carryforward, limited by certain taxable income limitations. State net operating losses begin to expire in 2029. The Company evaluates all available evidence to determine if a valuation allowance is needed to reduce its deferred tax assets. During the fourth quarter of fiscal year 2023, management concluded that a valuation allowance is necessary for the state net operating loss carryforward and a portion of the federal net operating loss carryforward. Due to the 2023 sale of ARCA Canada (as part of the Recycling Subsidiaries transaction), the valuation allowance was released. The Company has recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-922">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-923">904,000</ix:nonFraction> as of December&#160;30, 2023, and December&#160;31, 2022, respectfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company annually conducts an analysis of its uncertain tax positions and has concluded that it has no uncertain tax positions as of December&#160;30, 2023. The Company&#8217;s policy is to record uncertain tax positions as a component of income tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. and state income tax returns in jurisdictions with differing statutes of limitations. The 2020 through 2023 tax years remain subject to selection for examination as of December&#160;30, 2023. None of the Company&#8217;s income tax returns are currently under audit.</span></div></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_208"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-924" continuedAt="f-924-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18: Related parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac, the Company&#8217;s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures Incorporated (&#8220;Live Ventures&#8221;) and managing member of ICG. Tony Isaac, Chief Executive Officer and Richard Butler, Board of Directors member of the Company, are both Board of Directors members of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="f-925">203,000</ix:nonFraction> and approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="f-926">314,000</ix:nonFraction> for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively. Connexx rents approximately <ix:nonFraction unitRef="sqft" contextRef="c-210" decimals="0" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-927">9,900</ix:nonFraction> square feet of office space from Live Ventures at its Las Vegas, Nevada office. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, we ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expenses for Connexx at the Las Vegas, Nevada office were approximately $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-928">103,000</ix:nonFraction> and approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-929">215,000</ix:nonFraction> for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-924-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During Q4 2023, operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. See Note 4. Consequently, outstanding liabilities for shared rent and services for the Recycling Subsidiaries reverted to the Company. As such, the Company has recorded a liability in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedRentCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-930">258,000</ix:nonFraction>, which was offset against the gain on sale of the Recycling Subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Recycling Subsidiaries</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries consisting of: (a) ARCA Recycling, Inc., (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Agreement. The Company's Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023. During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understands that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-931">5.3</ix:nonFraction>&#160;million carrying value of the Disposition Transaction on its balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to ICG a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-932">2.5</ix:nonFraction> million revolving credit facility (the &#8220;ICG Note&#8221;). See Note 6. Jon Isaac is the manager and sole member of ICG, and the son of Tony Isaac, the Chief Executive Officer of JanOne and, previously, ARCA Recycling. ICG is a record and beneficial owner of <ix:nonFraction unitRef="number" contextRef="c-211" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-933">13.6</ix:nonFraction>% of the outstanding common stock of the Company. The ICG Note was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the ICG Note was guaranteed by the Company, it recorded a liability in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-934">690,000</ix:nonFraction> for the principal balance due on the note, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. Additionally, effective February 2024, the ICG Note was amended to reflect the Company as co-maker on the ICG Note. See Note 22. The ICG Note matures in March 2026, and bears interest at <ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-935">8.75</ix:nonFraction>% per annum. Monthly payments on the note are approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="0" id="f-936">24,767</ix:nonFraction>. As of December&#160;30, 2023, the balance outstanding was approximately $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-937">706,000</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARCA Recycling Purchasing Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, ARCA Recycling entered into a Purchasing Agreement with Live Ventures. Pursuant to the Purchasing Agreement, Live Ventures agrees to purchase inventory from time to time for ARCA, as set forth in submitted purchase orders. The inventory is owned by Live Ventures until payment from ARCA Recycling is received. All purchases made by ARCA Recycling shall be paid back to Live Ventures in full plus an additional <ix:nonFraction unitRef="number" contextRef="c-213" decimals="2" name="jan:RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" format="ixt-sec:numwordsen" scale="-2" id="f-938">five</ix:nonFraction> percent surcharge or broker-type fee. The term of the Purchasing Agreement is <ix:nonNumeric contextRef="c-213" name="jan:RelatedPartyTransactionPurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-939">one year</ix:nonNumeric>, and automatically renews if not terminated by either party, as provided for in the Purchasing Agreement. The liability for the Purchasing Agreement was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the Purchasing Agreement was guaranteed by the Company, it recorded a liability in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-940">692,000</ix:nonFraction> for the principal balance due under the Purchasing Agreement, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. As of the years ended December&#160;30, 2023 and December&#160;31, 2022, the amount due to Live Ventures was approximately $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-941">692,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-942">624,000</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_184"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-943" continuedAt="f-943-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19: Commitments and Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Complaint</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) filed a civil complaint (the &#8220;SEC Complaint&#8221;) in the United States District Court for the District of Nevada naming the Company and <ix:nonFraction unitRef="officer" contextRef="c-217" decimals="INF" name="jan:LossContingencyNumberOfExecutiveOfficersNamedInComplaint" format="ixt-sec:numwordsen" scale="0" id="f-944">one</ix:nonFraction> of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the &#8220;Defendants&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC Complaint alleges financial, disclosure and reporting violations against the Company and the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC seeks permanent injunctions and civil penalties against the Defendants, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC&#8217;s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assert that the SEC&#8217;s pursuit of this matter will not result in any benefit to investors and instead will only serve as a distraction from its core business. On October 1, 2021, the Company, filed a motion with the court to dismiss the complaint. The SEC filed its response opposing the motions on November 1, 2021. On September 7, 2022, the motions to dismiss were denied by the court. Pursuant to the automatic stay of proceedings under the Private Securities Litigation Reform Act, all discovery was stayed pending the motions to dismiss and the June 23, 2023 mediation to which all of the parties agreed. As of the date of these financial statements, the Company and the SEC have reached a settlement agreement in principal, the written agreement for which is pending at the SEC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Skybridge</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2016, the Company served a Minnesota state court complaint for breach of contract on Skybridge Americas, Inc. (&#8220;SA&#8221;), the Company&#8217;s primary call center vendor throughout 2015 and most of 2016. The Company seeks damages in the millions of dollars as a result of alleged overcharging by SA and lost client contracts. On January&#160;25, 2017, SA served a counterclaim for unpaid invoices in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="0" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-945">460,000</ix:nonFraction> plus interest and attorneys&#8217; fees. On March 29, 2017, the Hennepin County district court (the &#8220;District Court&#8221;) dismissed the Company&#8217;s breach of contract claim based on SA&#8217;s overuse of its Canadian call center but permitted the Company&#8217;s remaining claims to proceed. Following motion practice, on January 8, 2018 the District Court entered judgment in SA&#8217;s favor, which was amended as of February&#160;28, 2018, for a total amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="0" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="0" id="f-946">614,000</ix:nonFraction> including interest and attorneys&#8217; fees. On March 4, 2019, the Minnesota Court of Appeals (the &#8220;Court of Appeals&#8221;) ruled and (i) reversed the District Court&#8217;s judgment in favor of Skybridge on the call center location claim and remanded the issue back to the District Court for further proceedings, (ii) reversed the District Court&#8217;s judgment in favor of Skybridge on the net payment issue and remanded the issue to the District Court for further proceedings, and (iii) affirmed the District Court&#8217;s judgment in Skybridge&#8217;s favor against the Company&#8217;s claim that Skybridge breached the contract when it failed to meet the service level agreements. As a result of the decision by the Court of Appeals, the District Court&#8217;s award of interest and attorneys&#8217; fees, etc. was reversed. The Company and SA held a mediation session in July 2020. Trial was held in August 2020 and on February&#160;1, 2021, the District Court assessed damages against the Company in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="0" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="0" id="f-947">715,000</ix:nonFraction>, plus interest, fees, and costs and attorneys&#8217; fees of $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="0" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="0" id="f-948">475,000</ix:nonFraction>. In subsequent proceedings, the Appeals Court affirmed the District Court judgment. Of the total amount awarded to SA, less the funds that the Company had previously deposited with the District Court, SA remains entitled to approximately $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="0" name="jan:StatutoryInterestReceivable" format="ixt:num-dot-decimal" scale="0" id="f-949">422,000</ix:nonFraction> of statutory interest, which obligation has been assumed by VM7 in connection with the Recycling Subsidiaries Disposition transaction. See Note 4.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">AMTIM Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMTIM Capital, Inc. (&#8220;AMTIM&#8221;) acts as the Company&#8217;s representative to market our recycling services in Canada under an arrangement that pays AMTIM for revenues generated by recycling services in Canada as set forth in the agreement between the parties. A dispute has arisen between AMTIM and the Company with respect to the calculation of amounts due to AMTIM pursuant to the agreement. In a lawsuit filed by AMTIM in the province of Ontario, AMTIM claims a discrepancy in the calculation of fees due to AMTIM by the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-950">2.0</ix:nonFraction> million. Trial commenced in February 2022, and, on December 12, 2022, a decree was issued by the court dismissing the case.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-943-1" continuedAt="f-943-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about April&#160;9, 2021, GeoTraq, Gregg Sullivan, Tony Isaac, and the Company, among others, resolved all of the claims that related to, among other items, the Company's acquisition of GeoTraq in August 2017, all post-acquisition activities, and Mr. Sullivan&#8217;s post-acquisition employment relationship with GeoTraq (all of such claims, the &#8220;GeoTraq Matters&#8221;). The resolution was effectuated through the parties&#8217; execution and delivery of a Settlement Agreement and Mutual Agreement of Claims (the &#8220;GeoTraq Settlement Agreement&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Settlement Agreement, the Company, on its own behalf and on behalf of GeoTraq and Mr. Isaac, agreed to tender to Mr. Sullivan an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-4" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-951">1.95</ix:nonFraction> million (the &#8220;GeoTraq Settlement Consideration&#8221;) in the following manner: (i) $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="f-952">250,000</ix:nonFraction>, which was tendered in cash on or about the date of the Settlement Agreement and (ii) up to <ix:nonFraction unitRef="quarterly" contextRef="c-1" decimals="INF" name="jan:NumberOfInstallment" scale="0" id="f-953">10</ix:nonFraction> quarterly installments of not less than $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="0" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="f-954">170,000</ix:nonFraction> that commenced on June&#160;1, 2021, and continued not less frequently than every three months thereafter (the &#8220;GeoTraq Installments&#8221;). The Company may tender the GeoTraq Installments in cash or in the equivalent value of shares of its common stock (the value of the shares to be determined by a formula set forth in the Settlement Agreement), in either case at the Company's discretion. The Company may also prepay one or more GeoTraq Installments in full or in part at any time or from time to time either in cash or in shares of its common stock (a &#8220;GeoTraq Prepayment&#8221;). If the Company elected to prepay one or more GeoTraq Installments with shares of its common stock, Mr. Sullivan reserved the right not to consent to a tender thereof in excess of <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="jan:PercentOfPrepaymentTenderRestrictions" scale="-2" id="f-955">50</ix:nonFraction>% of the value of that specific GeoTraq Prepayment; however, Mr. Sullivan was restricted in the reasons for which he can refuse to provide his written consent. The number of shares of the Company's common stock to be issued upon any GeoTraq Prepayment is determined by a different formula than the one to be utilized for a GeoTraq Installment. On March 17, 2023, the Company converted <ix:nonFraction unitRef="shares" contextRef="c-225" decimals="0" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-956">5,185</ix:nonFraction> of Mr. Sullivan&#8217;s Series A-1 Preferred shares and issued <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="0" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-957">103,707</ix:nonFraction> shares of the Company's common stock as payment for its quarterly installment. On June 1, 2023, the Company converted <ix:nonFraction unitRef="shares" contextRef="c-227" decimals="0" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-958">7,697</ix:nonFraction> of Mr. Sullivan&#8217;s Series A-1 Preferred shares into <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="0" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-959">153,941</ix:nonFraction> shares of the Company&#8217;s common stock in payment of its June 30, 2023 quarterly installment. On September 1, 2023, the Company converted <ix:nonFraction unitRef="shares" contextRef="c-229" decimals="0" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-960">14,471</ix:nonFraction> of Mr. Sullivan&#8217;s Series A-1 Preferred shares into <ix:nonFraction unitRef="shares" contextRef="c-230" decimals="0" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-961">289,421</ix:nonFraction> shares of the Company&#8217;s common stock in payment of its September 30, 2023 quarterly installment. See Note 14. As of September 30, 2023, the full balance due under the Settlement Agreement had been repaid and the remaining <ix:nonFraction unitRef="shares" contextRef="c-231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-962">1,505</ix:nonFraction> shares of Mr. Sullivan&#8217;s Series A-1 Preferred shares were returned to the Company for cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties to the Settlement Agreement released and forever discharged one another from any and all known and unknown claims that were asserted or could have been asserted arising out of the GeoTraq Litigation Matters. The accrued liability for payments due to Mr. Sullivan is $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="0" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" id="f-963">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-964">510,000</ix:nonFraction> as of December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Alixpartners, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;19, 2022, Alixpartners, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alixpartners, LLC, plaintiff/petitioner, against JanOne Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Index No. 653877/2022. Plaintiff alleged the breach of an agreement and sought damages in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="0" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-965">345,000</ix:nonFraction>. The Company denied that obligation. After extensive negotiations, the parties reached a settlement, pursuant to which the Company agreed to pay to Alixpartners the sum of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="0" name="jan:AgreedSettlementValue" format="ixt:num-dot-decimal" scale="0" id="f-966">125,000</ix:nonFraction> in <ix:nonFraction unitRef="traches" contextRef="c-236" decimals="INF" name="jan:NumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-967">two</ix:nonFraction> tranches and to provide a confession of judgment in its favor in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="0" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="0" id="f-968">450,000</ix:nonFraction>, which represented the amount sought in the complaint plus interest thereon. The confession of judgment will be null and void and the complaint will be dismissed with prejudice upon the Company tendering both tranches timely. The Company tendered both settlement payments in May 2023, and the complaint was subsequently dismissed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sieggreen</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-943-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Main/270</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="0" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-969">90,000</ix:nonFraction> therefor. Plaintiff also seeks approximately $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="0" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-970">1,420,000</ix:nonFraction> against ApplianceSmart and the Company on a joint and several basis. The Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Westerville Square</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an attempt to recover payments due under a lease, in 2021, Westerville Square, Inc., as the landlord, initiated a civil action against the Company, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Westerville Square, Inc. v. Appliance Recycling Centers Of America, Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Court of Common Pleas of Franklin County, Ohio, Case No. 19 CV 8627. The case was stayed during the bankruptcy proceedings of ApplianceSmart, Inc., and was reinstated on June 7, 2021. The landlord is currently seeking $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="0" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-971">120,000</ix:nonFraction>, which amount is disputed by the Company. Effective June 4, 2023, the parties settled the matter, pursuant to which settlement the Company tendered the sum of $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="0" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="f-972">110,000</ix:nonFraction> to the landlord, the parties entered into a Settlement Agreement and Release, and the case was dismissed with prejudice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January&#160;2, 2021, the Company accrued an aggregate amount of future real property lease payments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-973">767,000</ix:nonFraction> which represented amounts guaranteed or which may have been owed under certain lease agreements to <ix:nonFraction unitRef="landlord" contextRef="c-242" decimals="INF" name="jan:OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" format="ixt-sec:numwordsen" scale="0" id="f-974">three</ix:nonFraction> third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (&#8220;ApplianceSmart Leases&#8221;). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December&#160;30, 2023, the Company reversed approximately $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="0" name="jan:OperatingLeasesFutureMinimumPaymentsDue1" format="ixt:num-dot-decimal" scale="0" id="f-975">637,000</ix:nonFraction> of the accrual, as the Company is no longer liable for <ix:nonFraction unitRef="landlord" contextRef="c-4" decimals="INF" name="jan:OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" format="ixt-sec:numwordsen" scale="0" id="f-976">two</ix:nonFraction> of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December&#160;30, 2023, a balance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="0" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-977">130,000</ix:nonFraction> remains as an accrued liability due to an ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys&#8217; fees expended in relation thereto.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of December&#160;30, 2023.</span></div></ix:continuation><div id="i186f351ddce04342b829c557fbabfeb2_196"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-978" continuedAt="f-978-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20: Earnings (Loss) per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company&#8217;s Consolidated Balance Sheet. Diluted net earnings per share is computed using the weighted average number of common shares outstanding, and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable with respect to restricted share awards, stock options and convertible preferred stock.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-979" escape="true"><ix:continuation id="f-978-1" continuedAt="f-978-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share (in $000&#8217;s, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-980"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-981">17,095</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-982"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-983">8,020</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-984">4,005,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-985"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-986">3,150,230</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-987"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-988">4.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-989"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-990">2.55</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-991">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-992">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-993">4,005,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-994">3,150,230</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-995">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-996">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-997">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-998">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-999">4,444,361</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1000">3,150,230</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-1001">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-1002">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1003"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1004">7,812</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1005"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1006">10,992</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1007">4,005,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1008"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1009">3,150,230</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1010"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1011">1.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1012"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1013">3.49</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-978-2">Potentially dilutive securities totaling approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1014">3.9</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1015">4.6</ix:nonFraction>&#160;million shares, respectively, were excluded from the calculation of diluted net earnings (loss) per share for the years ended December&#160;30, 2023 and December&#160;31, 2022 because the effects were anti-dilutive based on the application of the treasury stock method.</ix:continuation> </span></div><div id="i186f351ddce04342b829c557fbabfeb2_205"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1016" continuedAt="f-1016-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21: Segment information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates within targeted markets through <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1017">three</ix:nonFraction> reportable segments for continuing operations: biotechnology, recycling, and technology. The biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The technology segment designed wireless modules to connect devices to the Mobile Internet of Things (&#8220;IoT&#8221;) which contain location-based service (&#8220;LBS&#8221;) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1018" escape="true"><ix:continuation id="f-1016-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in $000&#8217;s): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1021">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1022">39,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1023">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1024">39,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="f-1027">197</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1028">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="f-1029">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1030">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating income</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1031">19,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1032">3,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1033">10,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1034">8,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1035">9,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1036">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1037">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-1038">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-1039">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-1040">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1041">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-1042">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-1043">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-1044">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-1045">181</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-1046">957</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Interest income (expense), net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-1047">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-1048">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income after provision for income taxes</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1049">17,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1050">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1051">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1052">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Net income after provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1053">7,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1054">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1055">18,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1056">29,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinue operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:Assets" format="ixt:fixed-zero" scale="3" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1058">17,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1059">18,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1060">46,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1061">17,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1062">19,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-1064">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1065">17,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1066">20,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i186f351ddce04342b829c557fbabfeb2_223"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1067" continuedAt="f-1067-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22: Subsequent events</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the filing of this Form 10-K, and determined that there have been no events that have occurred that would require adjustments to disclosures in its consolidated financial statements other than as discussed below:</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-1067-1" continuedAt="f-1067-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Warrant Purchase Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2024, the Company entered into a Warrant Purchase Agreement with a certain institutional investor that had purchased a Common Stock Purchase Warrant on August 22, 2023, in connection with such Investor&#8217;s purchase of shares of the Company&#8217;s common stock. The Warrant is exercisable from time to time for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1068">899,348</ix:nonFraction> shares of the Company&#8217;s common stock with a per-share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1069">0.7561</ix:nonFraction>. Pursuant to the terms of the Warrant Purchase Agreement, the Company or assigns agreed to purchase the Warrant for an aggregate price of $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1070">250,000</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1071">200,000</ix:nonFraction> was paid at the closing of the transaction and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1072">50,000</ix:nonFraction> was paid on March 5, 2024. In connection with the January transaction, the Company assigned the Common Stock Purchase Warrant to an otherwise unaffiliated third party. See Note 16.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Soin Amendment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 24, 2024, the Company, Amol Soin (&#8220;Dr. Soin&#8221;), and Soin Therapeutics LLC, a wholly-owned subsidiary of ours that we had purchased from Dr. Soin entered into an amendment (the &#8220;Soin Amendment&#8221;) to the parties&#8217; Agreement and Plan of Merger that was dated as of December 28, 2022 (the &#8220;Soin Agreement&#8221;). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-1073">3.0</ix:nonFraction>&#160;million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the &#8220;Soin Preferred&#8221;) that constituted the consideration under the Soin Agreement. We tendered the first $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="f-1074">100,000</ix:nonFraction> amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="f-1075">100,000</ix:nonFraction>, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-1076">2.8</ix:nonFraction>&#160;million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ICG Promissory Obligation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2024, the Company amended its outstanding related party promissory obligations in favor of ICG and in favor of Live Ventures to add convertibility provisions to each. The per-share conversion price for each obligation, as amended, was set at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-259" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1077">0.61</ix:nonFraction>, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#8217;s board of directors provided its final approvals of the amendments on February 7, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amended Promissory Note</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2024, the Company entered into a promissory note with each of the holders of the amended promissory notes (see above). The initial principal amount of each note is $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-1078">300,000</ix:nonFraction>, with an interest rate of <ix:nonFraction unitRef="number" contextRef="c-259" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1079">10</ix:nonFraction>% per annum. Pursuant to an amendment to each note, one hundred thousand dollars of principal, and accrued interest thereon, is due on September 7, 2024 for each note, and the balance of each note is due on December 31, 2024. At the Company&#8217;s option, the obligation under each note is convertible after the <ix:nonNumeric contextRef="c-259" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:durwordsen" id="f-1080">six-month</ix:nonNumeric> anniversary thereof at a per-share conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-259" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1081">0.61</ix:nonFraction>, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#8217;s board of directors approved the issuance of the notes on February 7, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unit Purchase Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, the Company entered into Unit Purchase Agreements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with <ix:nonFraction unitRef="agreements" contextRef="c-260" decimals="INF" name="jan:NumberOfAgreementsToBePurchased" format="ixt-sec:numwordsen" scale="0" id="f-1082">two</ix:nonFraction> otherwise unaffiliated third-party investors, pursuant to which each Investor agreed to purchase <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1083">408,163</ix:nonFraction> units of securities from the Company, at a price per Unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-260" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1084">0.735</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1085">300,000</ix:nonFraction> per investor for an aggregate price of $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1086">600,000</ix:nonFraction>. Each Unit consists of <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="jan:SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" format="ixt-sec:numwordsen" scale="0" id="f-1087">one</ix:nonFraction> share of the Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pany&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock and <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="jan:SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" format="ixt-sec:numwordsen" scale="0" id="f-1088">one</ix:nonFraction> warrant to purchase an additional share of common stock. The per-Unit price is allocated as follows: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-262" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1089">0.61</ix:nonFraction> per share of common stock and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-261" decimals="INF" name="jan:ClassOfWarrantPricePerShare" scale="0" id="f-1090">0.125</ix:nonFraction> per Warrant. The Warrant has a <ix:nonNumeric contextRef="c-260" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-1091">three-year</ix:nonNumeric> term and will be immediately exercisable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant is exercisable at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-260" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1092">0.61</ix:nonFraction> per share. The Company intends to use the proceeds from the Unit Purchases for its working capital needs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Isaac Consulting Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, we entered into a <ix:nonNumeric contextRef="c-263" name="jan:RelatedPartyTransactionConsultingAgreementTerm" format="ixt-sec:durwordsen" id="f-1093">two-year</ix:nonNumeric> Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Jon Isaac, pursuant to which he will </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide to us (the &#8220;Services&#8221;):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) strategic financial advice, including growth strategies, capital </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-1067-2"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation, and financial restructuring; (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which we and he may be agree that will be memorialized in writing if, when, and as needed during the <ix:nonNumeric contextRef="c-263" name="jan:RelatedPartyTransactionConsultingAgreementTerm" format="ixt-sec:durwordsen" id="f-1094">two-year</ix:nonNumeric> term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Isaac is the son of our Chief Executive Officer, but otherwise does not have a current relationship with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As compensation for the Services, we agreed to (i) assign to him <ix:nonFraction unitRef="insurance_policy" contextRef="c-264" decimals="INF" name="jan:RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" format="ixt-sec:numwordsen" scale="0" id="f-1095">two</ix:nonFraction> universal life insurance policies that relate to the life of one of the founders of our now-disposed legacy recycling business (the first policy has an accumulated value/surrender value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="0" name="us-gaap:CashSurrenderValueOfLifeInsurance" format="ixt:num-dot-decimal" scale="0" id="f-1096">3,854</ix:nonFraction> and the second has an accumulated value/surrender value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="0" name="us-gaap:CashSurrenderValueOfLifeInsurance" scale="0" id="f-1097">468</ix:nonFraction>); (ii) contingently tender to him funds in our Canadian counsel&#8217;s trust account in the event that the prospective Order of the Court of Appeal for Ontario Canada in the matter styled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amtim Capital Inc. and Appliance Recycling Centers of America</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. COA-23-CV-0156, becomes the final Order of the Court, which amount we estimated not to exceed approximately US$<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="jan:RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" format="ixt:num-dot-decimal" scale="0" id="f-1098">220,000</ix:nonFraction>; (iii) issue to him <ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="jan:RelatedPartyTransactionConsultingAgreementSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1099">200,000</ix:nonFraction> restricted shares of our common stock with the per-share value being the average of the Nasdaq historical NOCP closing price during the <ix:nonFraction unitRef="d" contextRef="c-264" decimals="INF" name="jan:NumberOfTradingDaysBeforeBoardApproval" format="ixt-sec:numwordsen" scale="0" id="f-1100">five</ix:nonFraction> trading days prior to our board approving the Consulting Agreement, which shares were awarded from our 2023 Equity Incentive Plan; and (iv) a <ix:nonNumeric contextRef="c-263" name="jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" format="ixt-sec:durwordsen" id="f-1101">two-year</ix:nonNumeric>, straight <ix:nonFraction unitRef="number" contextRef="c-264" decimals="2" name="jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" scale="-2" id="f-1102">10</ix:nonFraction>% convertible promissory note in the initial principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-1103">500,000</ix:nonFraction>, with a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="2" name="jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" scale="0" id="f-1104">1.16</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_226"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_229"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Evaluation of Disclosure control and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We carried out an evaluation, under the supervision, and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of December&#160;30, 2023, the period covered in this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure due to material weaknesses in internal control over financial reporting further described below. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the identified material weaknesses, management concluded that the consolidated financial statements included in this Annual Report on Form 10-K present fairly, in all material respects, the financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP. Hudgens CPA, PLLC, the Company&#8217;s independent registered public accounting firm, has issued an unqualified opinion on our consolidated financial statements as of and for the year ended December&#160;30, 2023. They were not engaged to perform, and did not perform, an audit of internal control over financial reporting. This material weakness has no impact on our consolidated financial statements in prior years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Report on Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, including the Company&#8217;s CEO and CFO, do not expect that the Company&#8217;s disclosure controls and procedures or the Company&#8217;s internal control over financial reporting will prevent or detect all errors and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgements in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the design and effectiveness of our internal control over financial reporting as of December&#160;30, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) of 2013 regarding Internal Control &#8211; Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal controls over financial reporting were ineffective as of September 30, 2021. Management noted the following deficiencies that management believes to be material weaknesses: </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company does not have sufficient written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management does not have sufficient resources to maintain adequate segregation of duties and maintain its internal control environment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the above identified weaknesses in our internal control over financial reporting, we plan to improve the documentation of our internal control policies and procedures and develop an internal testing plan to document our evaluation of effectiveness of the internal controls. We expect to conclude these remediation initiatives during the fiscal year ended December 28, 2024. We continue to evaluate testing of our internal control policies and procedures, including assessing internal and external resources that may be available to complete these tasks, but do not know when these tasks </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be completed. Management notes that the following material weaknesses, as reported in our 10-K for the fiscal year ended December&#160;31, 2022, have been remediated due to the sale of the Recycling Subsidiaries, as detailed in Note 4 of the Notes to the Consolidated Financial Statements above:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insufficient information technology general controls;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insufficient assessment of the impact of potentially significant transactions; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insufficient processes and procedures related to proper recordkeeping of agreements and contracts</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company&#8217;s financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management&#8217;s report in this annual report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for the remediation of the material weaknesses previously described, there were no changes in the Company&#8217;s internal control over financial reporting during the fiscal year ended December&#160;30, 2023 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_232"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_235"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_238"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i186f351ddce04342b829c557fbabfeb2_241"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and executive officers of the Company and their ages as of December 30, 2023, [are as follows]:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:42.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard D. Butler, Jr.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nael Hajjar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Bitar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virland A. Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Richard D. Butler, Jr.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been one of our directors since May 2015. Mr. Butler is the owner of an advisory firm that provides real estate, corporate, and financial advisory services since 1999, and is the co-Founder, Managing Director, and, since 2005, a major stockholder of Ref-Razzer Company, a whistle manufacturing and vending company. Prior to this, Mr. Butler was the Co-Founder and Executive Vice President of Aspen Healthcare, Inc. from 1996 to 1999. From 1993 to 1996, Mr. Butler was a Managing Director at Landmark Financial and from 1989 to 1993 he was a Partner at Cal Ventures Real Estate Investment Group. Prior to this, Mr. Butler also served as the President and Chief Executive Officer of Mt. Whitney Savings Bank, Chief Executive Officer of First Federal Mortgage Bank, Chief Executive Officer of Trafalgar Mortgage, and Executive Officer and Member of the President&#8217;s Advisory Committee at State Savings &amp; Loan Association (peak assets $14 billion) and American Savings &amp; Loan Association (NYSE: FCA; peak assets $34 billion). Mr. Butler has served on the Board of Directors of Live Ventures Incorporated (&#8220;Live Ventures&#8221;) (Nasdaq: LIVE) since August 2006. Mr. Butler attended Bowling Green University in Ohio, San Joaquin Delta College in California, and Southern Oregon State College. We believe that Mr. Butler brings to our Board extensive experience in financial management and executive roles, which enable him to provide important expertise in financial, operating, and strategic matters that impact our Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nael Hajjar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been one of our directors since August 2018. Mr. Hajjar is currently the Unit Head for the Annual Wholesale Trade Survey in Statistics Canada&#8217;s Manufacturing and Wholesale Trade Division. From March 2011 through May 2016, Mr. Hajjar was a Senior Analyst&#8201;&#8212;&#8201;Economist of Statistics Canada&#8217;s Producer Prices Division, where he developed Canada&#8217;s first ever Investment Banking Services Price Index while leading the development of a variety of Financial Services Price Index development projects. We believe that Mr. Hajjar brings to our Board extensive experience in research and analysis of financial statistics, economics, and business practices in a variety of industries, including manufacturing, logging, Wholesale Trade, and financial services. We believe that Mr. Hajjar also has extensive experience in project management, and he holds a Bachelor of Social Science, Honors in Economics (which he earned in 2006), and Bachelor of Commerce, Option in Finance (which he earned in 2008), both from the University of Ottawa.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Bitar </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been one of our directors since January 2020. Since 2012, Mr. Bitar has been providing consulting services to companies and clients on business and legal strategies, management, operations, and cost controls. From 2007 to 2012, Mr. Bitar co-founded and was Managing Partner of a worker&#8217;s compensation law firm. Mr. Bitar has been an attorney admitted to the California State Bar since 1999. Mr. Bitar graduated from the University of Southern California in 1996 and earned his Juris Doctorate Degree in 1999 from University of the Pacific, McGeorge School of Law. We believe that Mr. Bitar brings to our Board significant business experience and brings operational expertise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tony Isaac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been one of our directors since May 2015 and our Chief Executive Officer since May 2016; he also became our Corporate Secretary in 2021. He served as our Interim Chief Executive Officer from February 2016 until May 2016. Mr. Isaac has served as Financial Planning and Strategist/Economist of Live Ventures (Nasdaq: LIVE), a holding company for diversified businesses, since July 2012. He is the Chairman and Co-Founder of Isaac Organization, a privately held investment company. Mr. Isaac has invested in various companies, both private and public from 1980 to present. Mr. Isaac&#8217;s specialty is negotiation and problem-solving of complex real estate and business transactions. Mr. Isaac has served as a director of Live Ventures since December 2011. Mr. Isaac graduated from Ottawa University in 1981, where he majored in Commerce and Business Administration and Economics. We believe that Mr. Isaac brings to our Board significant investment and financial expertise and public board experience.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Virland A. Johnson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was appointed our Chief Financial Officer on August 21, 2017. He had previously served us as a consultant beginning in February 2017. Mr. Johnson served as Chief Financial Officer for Live Ventures between January 3, 2017 and September 21, 2021. Prior to joining Live Ventures, Mr. Johnson was Sr. Director of Revenue for JDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software from February 2010 to April 2016, where he was responsible for revenue recognition determination, sales and contract support while acting as a subject matter expert. Prior to joining JDA, Mr. Johnson provided leadership and strategic direction while serving in C-Level executive roles in public and privately held companies such as Cultural Experiences Abroad, Inc., Fender Musical Instruments Corp., Triumph Group, Inc., Unitech Industries, Inc. and Younger Brothers Group, Inc. Mr. Johnson&#8217;s more than 30 years of experience is primarily in the areas of process improvement, complex debt financings, SEC and financial reporting, turn-arounds, corporate restructuring, global finance, merger and acquisitions and returning companies to profitability and enhancing stockholder value. In January 2024, Mr. Johnson filed for protection under Chapter 7 of the U.S. Bankruptcy Code. Mr. Johnson holds a Bachelor&#8217;s degree in Accountancy from Arizona State University which he earned in 1982, and holds an active CPA license in the State of Arizona.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delinquent Section 16(a) Reports </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company&#8217;s officers and directors, and persons who own more than 10% of a registered class of the Company&#8217;s equity securities, to file reports of ownership on Form 3 and changes in ownership on Form 4 or Form 5 with the SEC. Such officers, directors and 10% stockholders are also required by SEC rules to furnish the Company with copies of all Section 16(a) forms they file.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based solely on its review of copies of such forms received by it, or written representations from certain reporting persons, the Company believes that, during the fiscal year ended December&#160;30, 2023, all of its officers, directors and 10% stockholders complied with all Section 16(a) timely filing requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee has adopted a code of ethics applicable to our directors and officers (including our Chief Executive Officer, President, and Chief Financial Officer) and other of our senior executives and employees in accordance with applicable rules and regulations of the SEC and Nasdaq. A copy of the code of ethics may be obtained upon request, without charge, by addressing a request to Corporate Secretary, JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119. The code of ethics is also posted on our website at www.janone.com under &#8220;Investors&#8201;&#8212;&#8201;Governance&#8201;&#8212;&#8201;Governance Documents.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding the amendment to, or waiver from, a provision of the code of ethics by posting such information on our website at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Capital Market, by filing a Current Report on Form 8-K with the SEC disclosing such information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee (the &#8220;Audit Committee&#8221;) of our Board is comprised entirely of non-employee directors. In fiscal 2023, the members of our Audit Committee were Mr. Bitar, Mr. Butler (Chair), and Mr. Hajjar. Each of Messrs. Bitar, Butler, and Hajjar was an &#8220;independent&#8221; director as defined under Nasdaq rules. Our Audit Committee is responsible for selecting and approving our independent auditors, for relations with the independent auditors, for review of internal auditing functions (whether formal or informal) and internal controls, and for review of financial reporting policies to assure full disclosure of financial condition. Our Audit Committee operates under a written charter adopted by our Board, which is posted on our website at www.janone.com under the caption &#8220;Investors&#8201;&#8212;&#8201;Governance&#8201;&#8212;&#8201;Governance Documents.&#8221; The Board has determined that Mr. Butler is an &#8220;audit committee financial expert&#8221; as defined in SEC rules. Our Audit Committee operates under a written charter adopted by our Board, which is posted on our website at www.janone.com under the caption &#8220;Investors&#8201;&#8212;&#8201;Governance&#8201;&#8212;&#8201;Governance Documents.&#8221; </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits Committee</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee (the &#8220;Compensation Committee&#8221;) of our Board is comprised entirely of non-employee directors. In fiscal 2023, the members of our Compensation Committee were Mr. Hajjar and Mr. Butler (Chair), each of whom was also an &#8220;independent&#8221; director as defined under Nasdaq rules. Our Compensation Committee is responsible for review and approval of officer salaries and other compensation and benefits programs and determination of officer bonuses. Annual compensation for our executive officers, other than our Chief Executive Officer, is recommended by our Chief Executive Officer and approved by our Compensation Committee. The annual compensation for our Chief Executive Officer is recommended by our Compensation Committee and formally approved by our full Board. Our Compensation Committee may approve grants of equity awards under our stock compensation plans. Our Compensation Committee operates under a written charter adopted by our Board in March 2011, which is posted on our website at www.janone.com under the caption &#8220;Investors&#8201;&#8212;&#8201;Governance&#8201;&#8212;&#8201;Governance Documents.&#8221; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the performance of its duties, our Compensation Committee may select independent compensation consultants to advise the committee when appropriate. No compensation consultant played a role in the executive officer and director compensation for fiscal 2023. In addition, our Compensation Committee may delegate authority to subcommittees where appropriate. Our Compensation Committee may separately meet with management if deemed necessary and appropriate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance Committee</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee (our &#8220;Governance Committee&#8221;) is comprised entirely of non-employee directors. In fiscal 2023, the members of our Governance Committee were Mr. Butler and Mr. Bitar, each of whom was also an &#8220;independent&#8221; director as defined under Nasdaq rules. The primary purpose of our Governance Committee is to ensure an appropriate and effective role for our Board in our governance. The principal recurring duties and responsibilities of our Governance Committee include (i) making recommendations to our Board regarding the size and composition of our Board, (ii) identifying and recommending to our Board candidates for election as directors, (iii) reviewing our Board&#8217;s committee structure, composition and membership and recommending to our Board candidates for appointment as members of our Board&#8217;s standing committees, (iv) reviewing and recommending to our Board corporate governance policies and procedures, (v) reviewing our Code of Business Ethics and Conduct and compliance therewith, and (vi) ensuring that emergency succession planning occurs for the positions of Chief Executive Officer, other key management positions, our Board chairperson and Board members. Our Governance Committee operates under a written charter adopted by our Board, which is posted on our website at www.janone.com under the caption &#8220;Investors&#8201;&#8212;&#8201;Governance&#8201;&#8212;&#8201;Governance Documents.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Governance Committee will consider director candidates recommended by stockholders. The criteria applied by our Governance Committee in the selection of director candidates is the same whether the candidate was recommended by a Board member, an executive officer, a stockholder, or a third party, and accordingly, our Governance Committee has not deemed it necessary to adopt a formal policy regarding consideration of candidates recommended by stockholders. Stockholders wishing to recommend candidates for Board membership should submit the recommendations in writing to our Secretary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Governance Committee identifies director candidates primarily by considering recommendations made by directors, management, and stockholders. Our Governance Committee also has the authority to retain third parties to identify and evaluate director candidates and to approve any associated fees or expenses. Board candidates are evaluated on the basis of a number of factors, including the candidate&#8217;s background, skills, judgment, diversity, experience with companies of comparable complexity and size, the interplay of the candidate&#8217;s experience with the experience of other Board members, the candidate&#8217;s independence or lack of independence, and the candidate&#8217;s qualifications for committee membership. Our Governance Committee does not assign any particular weighting or priority to any of these factors and considers each director candidate in the context of the current needs of our Board as a whole. Director candidates recommended by stockholders are evaluated in the same manner as candidates recommended by other persons.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_244"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the cash and non-cash compensation for fiscal years ended December&#160;30, 2023 and December&#160;31, 2022, earned by each person who served as Chief Executive Officer during fiscal 2023, and our other most highly compensated executive officer who held office as of December&#160;30, 2023 (&#8220;named executive officers&#8221;):</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Compensation Table </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Principal Position </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Salary ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bonus ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Award ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Award ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">All Other Compensation ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tony Isaac</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">617,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">817,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">President, Chief Executive Officer, and Secretary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">625,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Virland A. Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">224,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">349,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company only had two executive officers as of December&#160;30, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Equity Awards at December&#160;30, 2023</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of stock options outstanding for our Named Executive Officers at December&#160;30, 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities Underlying Unexercised Options (in shares) exercisable </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities Underlying Unexercised Options (in shares) unexercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Exercise Price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tony Isaac</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/18/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Virland A. Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the year ended December&#160;30, 2023, the Company granted $200,000 in restricted stock units, or 526,870 in underlying shares of the Company's common stock, to Mr. Isaac, and $125,000 in restricted stock units, or 329,294 in underlying shares of the Company's common stock to Mr. Johnson, both tranches of which were immediately vested. As of December&#160;30, 2023, both Mr. Isaac's and Mr. Johnson's restricted stock units were outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use stock options, restricted stock awards, and restricted stock units to attract and retain executives, directors, consultants, and key employees. As of December&#160;30, 2023, stock options are outstanding under the 2011 Plan and the 2016 Plan, and restricted stock units are outstanding under the 2023 Plan. Our 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) was adopted by our Board in August 2023 and approved by the stockholders at the 2023 annual meeting of stockholders. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. Our 2016 Stock Compensation Plan (the &#8220;2016 Plan&#8221;) was adopted by our Board in October 2016 and approved by the stockholders at the 2016 annual meeting of stockholders. Under the Plan, we reserved an aggregate of 400,000 shares of our Common Stock for option grants. Our 2011 Stock Compensation Plan (the &#8220;2011 Plan&#8221;) was adopted by our Board in March 2011 and approved by our stockholders at the 2011 Annual Meeting of stockholders. The 2011 Plan expired on December 29, 2016, but options granted under the 2011 Plan before it expired will continue to be exercisable in accordance with their terms. As of December&#160;30, 2023, options to purchase an aggregate of up to 114,000 shares of our Common Stock were outstanding, including options to purchase an aggregate of up to 100,000 shares of our Common Stock under the 2016 Plan and options to purchase an aggregate of up to 14,000 shares of our Common Stock under the 2011 Plan. As of December&#160;30, 2023, $345,000 in restricted stock units, or 908,852 underlying shares of our Common Stock, were outstanding. The Plans are administered by our Compensation Committee or our full Board, acting as the Committee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Non-Employee Directors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a combination of cash and share-based incentive compensation to attract and retain qualified candidates to serve on our Board. In setting director compensation, we consider the significant amount of time that directors expend fulfilling their duties to the Company, as well as the skill level that we require of members of our Board.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents cash and non-cash compensation paid to non-employee directors during the 2023 fiscal year.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Management Director Compensation for Fiscal Year Ended December&#160;30, 2023</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fees Earned or Paid in Cash ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Awards ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">All Other Compensation ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">John Bitar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Richard D. Butler, Jr.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nael Hajjar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_247"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth as of April&#160;8, 2024 the beneficial ownership of common stock by each of the Company&#8217;s directors, each of the named executive officers, and all directors and executive officers of the Company as a group, as well as information about beneficial owners of 5.0% or more of the Company&#8217;s voting securities. Beneficial ownership includes shares that may be acquired in the next 60 days through the exercise of options or warrants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Position with Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of Shares Beneficially Owned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent of Outstanding Common </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Officers &amp; Directors:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tony Isaac </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">President, Chief Executive Officer, and Secretary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Virland A. Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Richard D. Butler, Jr. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">John Bitar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nael Hajjar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All Executive Officers and Directors as a group (5 persons):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other 5% Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Michael Bigger </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">361,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">Indicates ownership of less than 1% of the outstanding shares</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Unless otherwise noted, each person or group identified possesses sole voting and investment power with respect to such shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Applicable percentage of ownership is based on 8,593,636 shares of common stock outstanding as of March 22, 2024, plus, for each stockholder, all shares that such stockholder could purchase within 60 days upon the exercise of existing stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Includes shares that could be purchased within 60 days upon the exercise of existing stock options, as follows: Mr. Isaac, 2,000 shares and Mr. Butler, 4,000 shares. All directors and executive officers as a group could purchase 6,000 shares. The address for each individual is 325 E. Warm Springs Road Suite 102, Las Vegas, Nevada, 89119.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. Bigger beneficially owned 361,000 shares of common stock. The business address for Mr. Bigger with respect to the shares of common stock is 2250 Red Springs Drive, Las Vegas, Nevada 89135.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">For two persons, who own shares of our Series A-1 Convertible Preferred Stock and Series S Convertible Preferred Stock, each of whom has a conversion limitation of 4.99%, see respective tables, below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Ownership of Series A-1 Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, as of April&#160;8, 2024, the beneficial ownership of Series A-1 Convertible Preferred Stock by each owner of 5% or more of the Company&#8217;s Series A-1 Convertible Preferred Stock. No officers or directors of the Company have beneficial ownership of Series A-1 Convertible Preferred Stock. There are no options or warrants to purchase shares of Series A-1 Convertible Preferred Stock.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares Beneficially Owned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percentage Outstanding Series A Preferred </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greenfield Investments, LTD. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,730</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Unless otherwise noted, each person or group identified possesses sole voting and investment power with respect to such shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Applicable percentage of ownership is based on 137,730 shares of Series A-1 Convertible Preferred Stock outstanding as of April&#160;8, 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The business address for Greenfield with respect to the shares of Series A-1 Preferred Stock is P.O. Box 926, Regent Village Grace Bay Provenciales, Turks &amp; Caicos Islands, British West Indies. Under its Series A-1 Preferred Stock agreement, Greenfield is restricted to a beneficial ownership limit of 4.99% of our outstanding Common Stock. As a result of this restriction, as of the Record Date, Greenfield could only convert 22,567 shares of Series A-1 Preferred Stock into 451,345 shares of our Common Stock. If converted in full, Greenfield would own 2,754,600 shares of our Common Stock, which would result in its reporting beneficial ownership of 24.3% in the &#8220;Percent of Outstanding Common&#8221; in the Common Stock chart, above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Ownership of Series S Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name of Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount and Nature of Beneficial Ownership </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Outstanding Series S Preferred </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amol Soin, MD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Unless otherwise noted, each person or group identified possesses sole voting and investment power with respect to such shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Applicable percentage of ownership is based on 100,000 shares of Series S Preferred Stock outstanding as of April 8, 2024. As of this date, Dr. Soin has not converted any of his shares of Series S Preferred Stock into shares of our Common Stock and is precluded from any such conversions due to certain contractual restrictions and other temporal and FDA restrictions set forth in the Certificate of Designation for the Series S Preferred Stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The business address for Dr. Soin with respect to the shares of Series S Preferred Stock is c/o JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119. Under the Amended and Restated Certificate of Designation of our Series S Preferred Stock, Dr. Soin is restricted to a beneficial ownership limit of 4.99% of our then outstanding Common Stock. Separate from this limitation, as of the Record Date, Dr. Soin could not convert any shares of his Series S Preferred Stock due to certain contractual restrictions and other temporal and FDA restrictions set forth in the Certificate of Designation for the Series S Preferred Stock. Separate from such restrictions, as of April&#160;8, 2024, Dr. Soin could convert certain of his shares of Series S Preferred Stock into 451,345 shares of our Common Stock. If fully converted, Dr. Soin would own 18,072,289 shares of Common Stock, which would result in his reporting beneficial ownership of 67.8% in the &#8220;Percent of Outstanding Common&#8221; in the Common Stock chart, above.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i186f351ddce04342b829c557fbabfeb2_250"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review, Approval or Ratification of Transactions with Related Persons</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of the directors or executive officers of the Company. Of the current directors, each of Messrs. Butler, Bitar, and Hajjar is an &#8220;independent&#8221; director, as defined under the rules of The Nasdaq Stock Market and each has been an independent director since each joined the Board.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its charter, the Audit Committee reviews and recommends for approval all related party transactions (as such term is defined for purposes of Item 404 of Regulation S-K). The Audit Committee participated in the approval of the transactions described above. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac, the Company&#8217;s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing member of Isaac Capital Group LLC (&#8220;ICG&#8221;). Tony Isaac, Chief Executive Officer and Richard Butler, Board of Directors member of the Company, are both Board of Directors members of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $203,000 and approximately $314,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively. Connexx rents approximately 9,900 square feet of office space from Live Ventures at its Las Vegas, Nevada </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">office. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, we ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expenses for Connexx at the Las Vegas, Nevada office were approximately $103,000 and approximately $215,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During Q4 2023, operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. See Note 4 of the Consolidated Financial Statements. Consequently, outstanding liabilities for shared rent and services for the Recycling Subsidiaries reverted to the Company. As such, the Company has recorded a liability in the amount of approximately $258,000, which was offset against the gain on sale of the Recycling Subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to ICG a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#8220;ICG Note&#8221;). See Note 6 of the Consolidated Financial Statements. Jon Isaac is the manager and sole member of ICG, and the son of Tony Isaac, the Chief Executive Officer of JanOne and, previously, ARCA Recycling. ICG is a record and beneficial owner of 13.6% of the outstanding common stock of the Company. The ICG Note was originally a component of the sale of the Recycling Subsidiaries in March 2023, however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the ICG Note is guaranteed by the Company, it recorded a liability in the amount of approximately $690,000 for the principal balance due on the note, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4 of the Consolidated Financial Statements. Additionally, effective February 2024, the ICG Note was amended to reflect the Company as co-maker on the ICG Note. See Note 22 of the Consolidated Financial Statements. The ICG Note matures in March 2026, and bears interest at 8.75% per annum. Monthly payments on the ICG Note are approximately $24,767. As of December&#160;30, 2023, the balance outstanding was approximately $706,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARCA Recycling Purchasing Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, ARCA Recycling entered into a Purchasing Agreement with Live Ventures. Pursuant to the Purchasing Agreement, Live Ventures agrees to purchase inventory from time to time for ARCA Recycling, as set forth in submitted purchase orders. The inventory is owned by Live Ventures until which time payment by ARCA Recycling is received. All purchases made by ARCA Recycling shall be paid back to Live Ventures in full, plus an additional five percent surcharge or broker-type fee. The term of the Purchasing Agreement is one year, and automatically renews if not terminated by either party, as provided for in the Purchasing Agreement. The liability for the Purchasing Agreement was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the Purchasing Agreement is guaranteed by the Company, it recorded a liability in the amount of approximately $692,000 for the principal balance due on the Purchasing Agreement, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4 of the Consolidated Financial Statements. As of the years ended December&#160;30, 2023 and December&#160;31, 2022, the amount due to Live Ventures was approximately $692,000 and $624,000, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recycling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries Disposition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $17.6 million, excluding those related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next five years, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1 million. The Company also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understands that it will not receive any future benefits of the Disposition Transaction, the Company determined to impair the $5.3&#160;million carrying value of the Disposition Transaction fully on its balance sheet. The Company also determined not to exercise any of its remedies under the Stock Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.</span></div><div id="i186f351ddce04342b829c557fbabfeb2_253"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Audit Committee approves the annual audit engagement in advance. The Audit Committee also has established procedures to pre-approve all non-audit services provided by the Company&#8217;s independent registered public accounting firm. All non-audit services for the fiscal years ended December 31, 2022, and January 1, 2022 that are listed below were pre-approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Audit fees include fees for the audit of the Corporation&#8217;s consolidated financial statements and interim reviews of the Corporation&#8217;s quarterly financial statements, comfort letters, consents and other services related to Securities and Exchange Commission matters.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit-Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Audit-related fees primarily include fees for certain audits of subsidiaries not required for purposes of WSRP's audit of the Corporation&#8217;s consolidated financial statements or for any other statutory or regulatory requirements, and consultations on various other accounting and reporting matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: This category consists of professional services rendered by our independent auditors for tax compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consist of fees for services other than the services described above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fees were billed to us by our independent registered public accounting firms, Frazier &amp; Deeter, LLC (&#8220;Frazier &amp; Deeter&#8221;) and Hudgens CPA, PLLC (&#8220;Hudgens&#8221;) and for 2023, and WSRP, LLC (&#8220;WSRP&#8221;) and Frazier &amp; Deeter for 2022. Frazier &amp; Deeter was appointed as our auditor on February 7, 2023 and served in such capacity until June 26, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit-related Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_256"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i186f351ddce04342b829c557fbabfeb2_259"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Financial Statements, Financial Statement Schedules and Exhibits</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements under Item 8 of this report.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Exhibits</span></div><div id="i186f351ddce04342b829c557fbabfeb2_262"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_265"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;padding-left:6pt;padding-right:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316817002753/arca_ex1009.htm">Agreement and Plan of Merger dated August 18, 2017, between the Company, Appliance Recycling Acquisition Corp., GeoTraq Inc., and the stockholders of GeoTraq Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.9 to the Company&#8217;s Form 10-Q/A for the quarterly period ended July 1, 2017 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818001663/arca_10k-ex1028.htm">Stock Purchase Agreement dated December 30, 2017</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.28 to the Company&#8217;s Form 10-K for the fiscal year ended December 30, 2017 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021008815/jan-ex101_6.htm">Asset Purchase Agreement among JanOne Inc., ARCA Recycling, Inc., and Customer Connexx LLC, on the one hand, and ARCA Affiliated Holdings Corporation, ARCA Services Inc., and Connexx Services Inc., on the other hand, dated February 19, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as 10.1 to the Company&#8217;s Form 8-K filed on February 25, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0303.htm">Articles of Incorporation of Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.3 to the Company&#8217;s Form 8-K filed on March 13, 2018 (File No. 0-19621) and incorporated herein by reference]. </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0301.htm">Articles of Conversion</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.1 to the Company&#8217;s Form 8-K filed on March 13, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0302.htm">Articles of Conversion</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.2 to the Company&#8217;s Form 8-K filed on March 13, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0301.htm">Certificate of Correction to Articles of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.1 to the Company&#8217;s Form 10-Q for the quarterly period ended June 30, 2018 (File No 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819001137/arca_ex0301.htm">Certificate of Change</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819001983/arca_8k-ex0307.htm">Certificate of Correction to Articles of Incorporation of Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.7 to the Company&#8217;s Current Report on Form 8-K filed on June 24, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819001983/arca_8k-ex0308.htm">Certificate of Designation of Powers, Preferences, and Rights of Series A-1 Convertible Preferred Stock of Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.8 to the Company&#8217;s Current Report on Form 8-K filed on June 24, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316820003334/janone_8k-ex0308a.htm">Amended and Restated Certificate of Designation of the Preferences, Rights, and Limitations of the Series A-1 Convertible Preferred Stock of JanOne Inc., dated October 1, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.8(a) to the Company&#8217;s Current Report on Form 8-K filed on October 2, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021019200/jan-ex38b_22.htm">Second Amendment and Restated Certificate of Designation of the Preferences, Rights, and Limitations of the Series A-1 Convertible Preferred Stock of JanOne Inc., dated April 13, 2021 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[filed as Exhibit 3.8(b) to the Company&#8217;s Current Report on Form 8-K filed on April 16, 2021 (File No. 0-19621) and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819002925/janone_ex0309.htm">Articles of Incorporation of JanOne Inc. (the Name Change Subsidiary), filed with the Secretary of State of the State of Nevada on September 6, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.9 to the Company&#8217;s Current Report on Form 8-K filed on September 13, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020052676/jan-ex39_224.htm">Certificate of Amendment to Articles of Incorporation, filed with the Secretary of State for the State of Nevada on November 5, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as 3.9 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 26, 2020 filed on November 10, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819002925/janone_ex0310.htm">Articles of Merger for JanOne Inc. into Appliance Recycling Centers of America, Inc., filed with the Secretary of State of the State of Nevada on September 9, 2019, and effective on September 10, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.10 to the Company&#8217;s Current Report on Form 8-K filed on September 13, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0304.htm">Bylaws of Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.4 to the Company&#8217;s Form 8-K filed on March 13, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex0301.htm">First Amendment to Bylaws of Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 3.1 to the Company&#8217;s Form 8-K filed on December 31, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex3_14.htm">Certificate of Designation of the Rights, Preferences, and Limitations of Series S Convertible Preferred Stock, filed with the Secretary of State of the State of Nevada on December 28, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex4_1.htm">Description of Our Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020052676/jan-ex42_14.htm">Specimen Stock Certificate</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 4.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 26, 2020 filed on November 10, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828023030392/ex43janprefundedwarrantfin.htm">Form of Pre-Funded Warrant, dated August 22, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828023030392/ex44jancommonwarrantfinal.htm">Form of Warrant, dated August 22, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828023030392/ex45janplacementagentwarra.htm">Form of Placement Agent Warrant, dated August 22, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819003807/janone_8k-ex1001.htm">Patent and Know How License Agreement dated November 19, 2019, by and among JanOne Inc., and UAB Research Foundation, TheraVasc, Inc., and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting on behalf of LSU Health Sciences Center at Shreveport</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 25, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020003764/jan-ex101_6.htm">Master Agreement for Development, Manufacturing and Supply Services dated February 5, 2020 by and between JanOne Inc. and CoreRx Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 7, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-ex101_14.htm">Promissory Note between JanOne Inc., as the borrower, and Texas Capital Bank, N.A., as lender</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 4, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex1001.htm">Amended and Restated Promissory Note, effective April 1, 2018, issued by ApplianceSmart Holdings LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Form 8-K filed on December 31, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex1002.htm">Security Agreement dated December 26, 2018 by and between ApplianceSmart Holdings LLC and Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Form 8-K filed on December 31, 2018 (File No. 0-19621) and incorporated herein by reference]. </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex1003.htm">Security Agreement dated December 26, 2018 by and between ApplianceSmart, Inc. and Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.3 to the Company&#8217;s Form 8-K filed on December 31, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex1004.htm">Security Agreement dated December 26, 2018 by and between ApplianceSmart Contracting Inc. and Appliance Recycling Centers of America, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.4 to the Company&#8217;s Form 8-K filed on December 31, 2018 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819000749/arca_8k-ex1001.htm">Subordination Agreement, dated March 15, 2019, from Appliance Recycling Centers of America, Inc. to Crossroads Financing, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Form 8-K filed on March 21, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819000749/arca_8k-ex1002.htm">Intercreditor and Subordination Agreement, dated March 18, 2019, by and between Appliance Recycling Centers of America, Inc. and Crossroads Financing, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Form 8-K filed on March 21, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316819002793/arca_ex1001.htm">Secured Revolving Line of Credit Promissory Note</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 30, 2019 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020052676/jan-ex102_13.htm">Amendment to Secured Line of Credit Promissory Note dated August 25, 2020 between ARCA Recycling, Inc. and Isaac Capital Group, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2020 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021016696/jan-ex1012_320.htm">Second Amendment and Waiver to Secured Line of Credit Promissory Note dated March 30, 2021 between ARCA Recycling, Inc. and Isaac Capital Group, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.12 to the Company&#8217;s Annual Report on Form 10-K filed on March 30, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316816000662/appliance_10q-ex1001.htm">Securities Purchase Agreement dated November 8, 2016, between Energy Efficiency Investments, LLC and the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2016 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex1018_406.htm">Termination Agreement by and between Energy Efficiency Investments, LLC and JanOne Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as 10.18 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 28, 2019 filed on April 6, 2020 (File No. 0-19621) and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316816000662/appliance_10q-ex1002.htm">Form of 3% Original Issue Discount Senior Convertible Promissory Note issuable under Securities Purchase Agreement dated November 8, 2016, between Energy Efficiency Investments, LLC and the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2016 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316816000662/appliance_10q-ex1003.htm">Form of Common Stock Purchase Warrant issuable under Securities Purchase Agreement dated November 8, 2016, between Energy Efficiency Investments, LLC and the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2016 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000110465911017989/a11-2661_1def14a.htm">2011 Stock Compensation Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed with the Company&#8217;s Schedule DEF 14A on March 31, 2011 and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000168316817000707/arca_10k-ex1003.htm">2016 Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.3 to the Company&#8217;s Form 10-K for the fiscal year ended December 31, 2016 (File No. 0-19621) and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459020045736/jan-def14a_20201104.htm">First Amendment to the JanOne Inc. 2016 Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed with the Company&#8217;s Schedule DEF 14A on October 2, 2020 and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20*&#215;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021016696/jan-ex1020_399.htm">Master Equipment Finance Agreement dated as of March 25, 2021 between KLC Financial, Inc. and ARCA Recycling, Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. [filed as Exhibit 10.20 to the Company&#8217;s Form 10-K for the fiscal year ended January 2, 2021 (File No. 0-19621) and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021008815/jan-ex101_6.htm">Asset Purchase Agreement among JanOne Inc., ARCA Recycling, Inc., and Customer Connexx LLC, on the one hand, and ARCA Affiliated Holdings Corporation, ARCA Services Inc., and Connexx Services Inc., on the other hand, dated February 19, 2021 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 25, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021016696/jan-ex1012_320.htm">Second Amendment and Waiver to Secured Line of Credit Promissory Note dated March 30, 2021 between ARCA Recycling, Inc. and Isaac Capital Group, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. [filed as Exhibit 10.12 to the Company&#8217;s Form 10-K for the fiscal year ended January 2, 2021 (File No. 0-19621) and incorporated herein by reference]</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000149315221002066/ex10-1.htm">Securities Purchase Agreement dated January 29, 2021 by and between JanOne Inc. and the purchasers listed therein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. [filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 29, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000156459021028450/jan-ex102_13.htm">Addendum to Master Equipment Finance Agreement dated as of April 14, 2021 between KLC Financial, LLC and ARCA Recycling, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 17, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017021001461/jan-20210703ex10_2.htm">Settlement Agreement and Mutual Release of Claims dated April 9, 2021 by and among JanOne Inc. (f/k/a Appliance Recycling Centers of America, Inc.); GeoTraq, Inc.; Antonio Isaac; and Gregg Sullivan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 16, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017021001461/jan-20210703ex10_3.htm">Amendment No. One to Asset Purchase Agreement among JanOne Inc., ARCA Recycling, Inc. and Customer Connexx LLC, on the one hand, and ARCA Affiliated Holdings Corporation, ARCA Services Inc., and Connexx Services Inc., on the other hand</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 16, 2021 (File No. 0-19621) and incorporated herein by reference].</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex10_27.htm">Third Amendment to Secured Revolving Line of Credit Promissory Note dated March 17, 2022 with Isaac Capital Group, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017022010897/jan-ex10_28.htm">Asset Purchase Agreement between JanOne Inc. and SPYR Technologies Inc., dated May 24, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017022010897/jan-ex10_29.htm">Promissory Note of SPYR Technologies Inc. in favor of JanOne Inc., dated May 24, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.92</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017022019120/jan-ex10_92.htm">General Credit and Security Agreement, dated as of September 26, 2022, between Gulf Coast Bank and Trust Company and ARCA.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.93</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017022019120/jan-ex10_93.htm">Guaranty to Gulf Coast Bank and Trust by JanOne Inc., dated as of September 21, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.94</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017022019120/jan-ex10_94.htm">Debt Subordination Agreement by Isaac Capital Group, dated as of September 21, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.95</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023008681/jan-ex10_95.htm">Agreement and Plan of Merger made and entered into as of December 28, 2022, among the registrant, STI Merger Sub Inc., Soin Therapeutics, LLC, and Amol Soin, M.D. </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.96</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023008681/jan-ex10_95.htm">Stock Purchase Agreement between JanOne Inc. and VM7 Corporation, dated as of March 19, 2023 (Filed as Exhibit 10.95)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023008681/jan-ex10_96.htm">Stock and Membership Interests Pledge Agreement made by VM7 Corporation and Virland Johnson in favor of JanOne Inc., dated March 19, 2023 (Filed as Exhibit 10.96)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.98</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023009752/jan-ex10_98.htm">Form of Securities Purchase Agreement dated March 22, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.99</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828023030392/ex1099janspafinal2.htm">Form of Securities Purchase Agreement, dated August 18, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.100</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828024001259/exh10100_janwarrantrepurch.htm">Warrant Purchase Agreement by and between JanOne, Inc. or its assigns and the Investor made effective as of January 12, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10101_icgjanonefourthame.htm">Form of Fourth Amendment to Secured Revolving Line of Credit with Isaac Capital Group LLC, dated February 7, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.102</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10102_livejanonefirstame.htm">Form of First Amendment to Promissory Note with Live Ventures Incorporated, dated February 7, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.103</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10103_janonepromissoryno.htm">Form of Promissory Note in favor of Isaac Capital Group LLC, dated February 7, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10104_janonepromissoryno.htm">Form of Promissory Note in favor of Live Ventures Incorporated, dated February 7, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.105</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10105_amendmenttomergera.htm">Form of First Amendment to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10105_amendmenttomergera.htm">Agreement and Plan of Merger </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10105_amendmenttomergera.htm">among the registrant, STI Merger Sub Inc., Soin Therapeutics, LLC, and Amol Soin, M.D.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10105_amendmenttomergera.htm">, dated January 24, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.106</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10106_janonepromissoryno.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10106_janonepromissoryno.htm">orm of Promissory Note in favor of Jon Isaac, dated March 4, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.107</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10107_consultingagreemen.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10107_consultingagreemen.htm">onsulting Agreement with Jon Isaac, dated March 4, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex21_1.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex231_consentofhudgenscpap.htm">Consent of Hudgens, LLC, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex232_consentoffd.htm">Consent of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex232_consentoffd.htm">Frazier &amp; Deeter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex232_consentoffd.htm">, LLC, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="jan-20231230xex311.htm">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="jan-20231230xex312.htm">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="jan-20231230xex321.htm">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="jan-20231230xex322.htm">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following materials from our Annual Report on Form 10-K for the fiscal year ended January 1, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive Income, (iii) the Consolidated Statements of Cash Flows, (iv) the Consolidated Statements of Shareholders&#8217; Equity, (v) the Notes to Consolidated Financial Statements, and (vi) document and entity information.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 12.25pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items that are management contracts or compensatory plans or arrangements required to be filed as an exhibit pursuant to Item 14(a)3 of this Form 10-K.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[For the exhibits that are being incorporated by reference, we need to say what filings they came from and I don&#8217;t know that I see that here.]</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#215;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i186f351ddce04342b829c557fbabfeb2_268"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i186f351ddce04342b829c557fbabfeb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANONE INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tony Isaac</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tony Isaac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, Treasurer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Financial and Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Virland A. Johnson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virland A. Johnson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tony Isaac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard Butler</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Butler</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John Bitar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Bitar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Nael Hajjar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;8, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nael Hajjar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.105
<SEQUENCE>2
<FILENAME>ex10105_amendmenttomergera.htm
<DESCRIPTION>EX-10.105
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i37c2868e598046c8ad08bc62313cb029_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.105</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Agreement and Amendment to Merger Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement and Amendment to Merger Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) is made as of January &#91;&#9679;&#93;, 2024 among JanOne Inc., a Nevada</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Acquirer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), Soin Therapeutics, LLC, a Delaware limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), and Amol Soin, M.D. a resident of the State of Ohio (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Sole Owner </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Acquirer, the Company and Sole Owner are parties to that certain Agreement and Plan of Merger dated as of December 28, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Merger Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Acquirer, the Company and Sole Owner desire to provide for certain payments to Sole Owner and to amend the Merger Agreement on the terms set forth herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Acquirer, the Company and Sole Owner agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Merger Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt">Upon full execution of this Amendment, Acquirer shall pay Sole Owner the amount of $100,000 by wire transfer of immediately available funds.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt">On or before July 1, 2024, Acquirer shall pay Sole Owner the amount of $100,000 by wire transfer of immediately available funds.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:9.06pt">On or before December 31, 2024, Acquirer shall pay Sole Owner the amount of $2,800,000 by wire transfer of immediately available funds.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> of the Merger Agreement is hereby amended to add new </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.16,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">4.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Right to Asset Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Upon the occurrence of any of the Transfer Events&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Acquirer automatically shall be deemed to have transferred to Sole Owner all of Acquirer&#8217;s right, title and interest in and to the membership interests of the Company and Acquirer&#8217;s capital account balance in the Company (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Transferred Interest</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), free and clear of any Encumbrances of any kind.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Sole Owner automatically shall be deemed to have transferred to Acquirer all of Sole Owner&#8217;s right, title and interest in and to the shares of Series S Convertible Preferred Stock of Acquirer then held by Sole Owner (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Transferred Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), free and clear of any Encumbrances of any kind. </font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Sole Owner may complete and insert the date of the Transfer Event into the Instrument of Assignment signed by Acquirer (and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">) and take title to and possession of the Transferred Interests.  For the avoidance of doubt, such Instrument of Assignment is not effective until the occurrence of a Transfer Event.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Acquirer may complete and insert the date of the Transfer Event into the Stock Power signed by Sole Owner (and attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">) and take title to and possession of the Transferred Shares.  For the avoidance of doubt, such Stock Power is not effective unless and until the occurrence of a Transfer Event.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Each of Acquirer and Sole Owner shall deliver such instruments of transfer and other documents as reasonably required by the other party in order to effectuate the foregoing potential transfers.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Unless and until Acquirer pays all of the amounts described in clauses (i) and (ii) of the definition of Transfer Events, (a) Acquirer shall not sell, transfer, convey, lease or grant any interest in any equity of the Company, and (b) the Company shall not, and Acquirer shall not permit the Company to, sell, transfer, convey, lease or grant any interest in any of the Company&#8217;s assets.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Conversions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  So long as Acquirer pays each of the amounts described in clauses (i) and (ii) of the definition of Transfer Events, Sole Owner shall refrain from exercising his rights to convert any of his Series S Convertible Stock of Acquirer, which rights are set forth in the Series S CoD.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Section 8.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> of the Merger Agreement is hereby amended to insert immediately after the phrase &#8220;including the Company Disclosure Letter,&#8221; the phrase &#8220;and the Agreement and Amendment to Merger Agreement among the parties dated of January &#91;&#9679;&#93;, 2024&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:9.06pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> to the Merger Agreement is hereby amended to add the following definition in its appropriate alphabetical order&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Transfer Events</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;Acquirer shall have failed to pay Sole Owner the amount of $100,000 by wire transfer of immediately available funds on or before July 1, 2024.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;Acquirer shall have failed to pay Sole Owner the amount of $2,800,000 by wire transfer of immediately available funds on or before December 31, 2024.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;Pursuant to or within the meaning of the United States Bankruptcy Code or any other federal or state law relating to insolvency or relief of debtors (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Bankruptcy Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), Acquirer&#58;  (A) commences a voluntary case or proceeding&#59; (B) consents to the appointment of a custodian, trustee, receiver, assignee, examiner, liquidator, or similar official&#59; (C) makes an assignment for the benefit of its creditors&#59; or (D) admits in writing its inability to pay its debts as they become due.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(iv)&#160;&#160;&#160;&#160;If an action is filed against Acquirer&#58; (A) under any Bankruptcy Law in an involuntary case&#59; or (B) seeking to appoint a custodian, trustee, receiver, assignee, examiner, liquidator, or similar official for Acquirer or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">substantially all of Acquirer&#8217;s properties and any such action is not dismissed within 60 calendar days of its filing.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(v)&#160;&#160;&#160;&#160;Acquirer&#8217;s common stock is delisted by the Nasdaq Stock Market.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt">The Merger Agreement is hereby amended to add the Instrument of Assignment and the Stock Power attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, respectively, as new </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> and new </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> to the Merger Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Representations and Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Acquirer and Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Each of Acquirer and the Company hereby represents and warrants to, and covenants with, Sole Owner that (i) the assets of the Company are the same assets as were owned by the Company as of the date of the Merger except that U.S. patent application no. 11&#47;527,336 has issued as U.S. patent no. 11,752,143, (ii) Acquirer owns, and is the sole and exclusive owner of, all of the membership interests in the Company, free and clear of any Encumbrances of any kind, and, until Acquirer makes all payments described in Section 2 of this Amendment, Acquirer shall continue to own such membership interests free and clear of any Encumbrances of any kind, and (iii) the Company owns, and is the sole and exclusive owner of, all of its assets free and clear of any Encumbrances of any kind, and, until Acquirer makes all payments described in Section 2 of this Amendment, the Company shall continue to own assets free and clear of any Encumbrances of any kind.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Sole Owner</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Sole Owner hereby represents and warrants to, and covenants with, each of Acquirer and the Company that Sole Owner owns, and is the sole and exclusive owner of, all of the shares of Series S Convertible Preferred Stock of Acquirer held by Sole Owner free and clear of any Encumbrances of any kind, and until Acquirer makes all payments described in Section 2 of this Amendment, Sole Owner shall continue to own such shares free and clear of any Encumbrances of any kind.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Except as otherwise expressly modified by this Amendment, all terms and provisions of the Agreement shall remain in full force and effect.  All references to the Agreement shall hereinafter be deemed to be references to the Agreement as amended by this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:8.42pt;text-decoration:underline">Incorporation By Reference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> of the Merger Agreement, as amended hereby, is hereby incorporated by reference and shall apply hereto, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Acquirer, the Company, and the Sole Owner have each caused this Amendment to be executed and delivered by their respective managers or officers thereunto duly authorized or by an individual, as relevant, all as of the date first written above.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">JanOne Inc.</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Tony Isaac, Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Soin Therapeutics, LLC</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:238.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Amol Soin, M.D.</font></div><div style="margin-bottom:12pt;padding-left:238.5pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Instrument of Assignment</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">See attached.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">INSTRUMENT OF ASSIGNMENT</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:232%">&#160;&#160;&#160;&#160;For Value Received</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:232%">, the undersigned entity does hereby sell, assign, transfer and convey unto Amol Soin, M.D., all of its right, title, and interest in and to all of the membership interests of Soin Therapeutics, LLC, a Delaware limited liability company (the &#8220;Company&#8221;), and its capital account balance in the Company, standing in its name on the books of the Company, and does hereby irrevocably constitute and appoint ____________________________________________ as its attorney-in-fact to transfer said membership interests and capital account on the books of the Company with full power of substitution in the premises.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dated&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JanOne Inc.</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      Tony Isaac, Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Power</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:125%">See attached.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">STOCK POWER</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:232%">Amol Soin, M.D. does hereby sell, assign, transfer and convey unto JanOne, Inc., a Nevada corporation, all of his right, title, and interest in and to ______________ shares of Series S Convertible Preferred Stock of JanOne, Inc. standing in his name on the books of said Corporation and does hereby irrevocably constitute and appoint _______________________________________, or any officer of said Corporation, as his attorney-in-fact to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Dated&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amol Soin, M.D.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">130666102v5</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.106
<SEQUENCE>3
<FILENAME>ex10106_janonepromissoryno.htm
<DESCRIPTION>EX-10.106
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic8a5fa9b71f24998ad927ad75c4a81f8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.106</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECURITIES ACT</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANIES.  THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">PROMISSORY NOTE</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Principal Amount&#58; $500,000.00</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Issue Date&#58;  March 4, 2024</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JANONE INC.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">a Nevada corporation with its principal place of business at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby unconditionally promises to pay to the order of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JON ISAAC</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, an individual residing in the State of Nevada (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Noteholder</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at 505 E. Windmill Ln, Ste 1C #295, Las Vegas, Nevada 89123 or at such other place as the Noteholder hereof may from time to time designate in writing to the Borrower, the principal amount of FIVE HUNDRED THOUSAND AND NO&#47;100 DOLLARS ($500,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loan</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), together with all accrued interest thereon, as provided in this Promissory Note (this &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">The</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Borrower Covenants and Agrees with the Noteholder as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Payment of Indebtedness</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower will pay the indebtedness evidenced by this Note as provided herein.  All amounts due hereunder shall be payable in lawful money of the United States, and all or any portion thereof may be prepaid at any time or from time to time without premium, penalty, or advance notice.  Notwithstanding the foregoing, if, after the date of this Note, the Borrower is sold, merged, or consolidated with another business entity or is reorganized or recapitalizes, the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note immediately shall become due and payable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Maturity </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Date.  Absent the occurrence and continuation of an Event of Default (as hereinafter defined), the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note shall be due and payable not later than 12&#58;00 noon Pacific Standard Time on March 4, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The principal amount outstanding under this Note from time to time shall bear interest at ten percent (10%) per annum (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Computation of Interest</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All computations of interest hereunder shall be made on the basis of a year of 365&#47;366 days, as the case may be, and the actual number of days elapsed.  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Interest shall begin to accrue on the Loan on the date of this Note.  For any portion of the Loan that is repaid, interest shall not accrue on the date on which such payment is made.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If, at any time, the Interest Rate payable on the Loan shall exceed the maximum rate of interest permitted under applicable law, such Interest Rate shall be reduced automatically to the maximum rate permitted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Payment </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mechanics</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Manner of Payment</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments hereunder shall be made in US dollars.  Such payments shall be made by wire transfer of immediately available funds to the Noteholder&#8217;s account at a bank specified by the Noteholder in writing to the Borrower from time to time.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Application of Payments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments shall be applied, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">first</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to fees or charges outstanding under this Note, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">second</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to accrued interest, and, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">third</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to principal outstanding under this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower represents and warrants to the Noteholder as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Existence</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Nevada.  The Borrower has the requisite power and authority to own, lease, and operate its property, and to carry on its business.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower is in compliance with all laws, statutes, ordinances, rules, and regulations applicable to or binding on the Borrower, its property, and business.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Power and Authority</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower has the requisite power and authority to execute, deliver, and perform its obligations under this Note.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.02pt;text-decoration:underline">Authorization&#59; Execution and Delivery</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The execution and delivery of this Note by the Borrower and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with applicable law.  The Borrower has duly executed and delivered this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The occurrence and continuance of any of the following shall constitute an &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; hereunder&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Failure to Pay</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower fails to pay the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note by the Maturity Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Breach of Representations and Warranties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Any representation or warranty made by the Borrower to the Noteholder herein contains an untrue or misleading statement of a material fact as of the date made.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Bankruptcy&#59; Insolvency</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.28pt">The Borrower institutes a voluntary case seeking relief under any law relating to bankruptcy, insolvency, reorganization, or other relief for debtors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.54pt">An involuntary case is commenced seeking the liquidation or reorganization of the Borrower under any law relating to bankruptcy or insolvency, and such case is not dismissed or vacated within sixty (60) days of its filing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.8pt">The Borrower makes a general assignment for the benefit of its creditors.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.66pt">The Borrower is unable, or admits in writing its inability, to pay its debts as they become due.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.4pt">A case is commenced against the Borrower or its assets seeking attachment, execution, or similar process against all or a substantial part of its assets, and such case is not dismissed or vacated within sixty (60) days of its filing.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.02pt;text-decoration:underline">Failure to Give Notice.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The Borrower fails to give the notice of Event of Default specified in Section 7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Notice of Event of Default</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">As soon as possible after it becomes aware that an Event of Default has occurred, and in any event within two (2) Business Days</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrower shall notify the Noteholder in writing of the nature and extent of such Event of Default and the action, if any, it has taken or proposes to take with respect to such Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the occurrence and during the continuance of an Event of Default, the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note immediately shall become due and payable.  Further, from and after an Event of Default, the Noteholder has the right, but not the obligation, to convert at any time or from time to time any or all of the unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Convertible Obligations</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into shares of common stock, $0.001 par value per share, of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The conversion rights are set forth in the Conversion Rights Addendum, attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Mandatory Conversion Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The Noteholder hereby grants to the Borrower the option (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to convert all, but not less than all, of the Borrower&#8217;s obligations hereunder into shares of the Borrower&#8217;s Common Stock.  The Borrower shall provide to the Noteholder ten (10) days&#8217; written notice of the Borrower&#8217;s exercise of the Option.  The Borrower may not exercise the Option until after the six (6)-month anniversary of Issue Date.  The provisions of sections (c) and (d) of the Conversion Rights Addendum shall apply to the Borrower&#8217;s exercise of the Option.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The per-share conversion price of the Option shall be $1.16, subject to adjustment as set forth in section (c) of the Conversion Rights Addendum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower shall reimburse the Noteholder on demand for all reasonable out-of-pocket costs, expenses, and fees, including the reasonable fees and expenses of counsel, incurred by the Noteholder in connection with the enforcement of the Noteholder&#8217;s rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (x) deposit with the United States Postal Service or overnight courier service, properly addressed and postage prepaid&#59; (y) transmittal by electronic communication (including email, internet or intranet websites, or facsimile properly addressed (with written acknowledgment from the intended recipient such as &#8220;return receipt requested&#8221; function, return e-mail, or other written acknowledgment)&#59; or (z) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party shall specify in writing&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt">If to the Borrower&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">JanOne Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">325 E. Warm Springs Road, Suite 102</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day that is not a Saturday, Sunday, or other holiday or day that commercial banks in Las Vegas, Nevada are authorized or required to be closed.</font></div><div style="margin-bottom:6pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If the Beneficial Ownership Limitation (as set forth in section (d) of the Conversion Rights Addendum) shall preclude the issuance of shares of Common Stock upon the Borrower&#8217;s exercise of the Option, then the exercise shall be limited to comply with such Beneficial Ownership Limitation and the balance of the Borrower&#8217;s obligations under the Note shall remain outstanding (principal and accrued, but unpaid and unconverted interest thereon) and shall be subject to the Borrower&#8217;s future exercise of the Option.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Las Vegas, Nevada 89119</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">E-mail&#58;  t.isaac&#64;isaac.com</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt">If to the Noteholder&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jon Isaac</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">505 E. Windmill Ln, Ste 1C #295</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Las Vegas, Nevada 89123</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">E-mail&#58;  j.isaac&#64;isaac.com</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based on, arising out of, or relating to this Note and the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of Nevada without regard for any principals of conflicts of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Submission to Jurisdiction</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.28pt">The Borrower irrevocably and unconditionally (A) agrees that any action, suit, or proceeding arising from or relating to this Note may be brought in the courts of the State of Nevada sitting in Clark County, and in the United States District Court for the Nevada and (B) submits to the exclusive jurisdiction of such courts in any such action, suit, or proceeding.  Final judgment against the Borrower in any such action, suit, or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.54pt">Nothing in this </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ic8a5fa9b71f24998ad927ad75c4a81f8_1" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section&#160;13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> shall affect the right of the Noteholder to bring any action, suit, or proceeding relating to this Note against the Borrower or its properties in the courts of any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.8pt">Nothing in this </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ic8a5fa9b71f24998ad927ad75c4a81f8_1" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section 13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> shall affect the right of the Noteholder to serve process upon the Borrower in any manner authorized by the laws of any such jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Venue</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by law, (i) any objection that it may now or hereafter have to the laying of venue in any action, suit, or proceeding relating to this Note in any court referred to in </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ic8a5fa9b71f24998ad927ad75c4a81f8_1" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section&#160;13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, and (ii)&#160;the defense of inconvenient forum to the maintenance of such action, suit, or proceeding in any such court.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  THE BORROWER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note may be assigned or transferred by the Noteholder to any individual, corporation, company, limited liability company, trust, joint venture, association, partnership, unincorporated organization, governmental authority, or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note constitutes the entire contract between the Borrower and the Noteholder with respect to the subject matter hereof and supersedes all previous agreements and understandings, oral or written, with respect thereto.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Amendments and Waivers</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Noteholder.  Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#59; Cumulative Remedies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No failure by the Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof&#59; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power.  The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page to this Note by facsimile or in electronic (&#8220;pdf&#8221; or &#8220;tiff&#8221; or any other electronic means that reproduces an image of the actual executed signature page) format shall be as effective as delivery of a manually executed counterpart of this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Electronic Execution</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of similar import in this Note shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15&#160;U.S.C.&#160;&#167;&#167;&#160;7001-7031), the Electronic Signatures and Records Act of 1999 (N.Y. State Tech. Law &#167;&#167;&#160;301-309), and any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;signature page follows&#93;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrower has executed this Note as of the Issue Date.</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JANONE INC.</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Tony Isaac</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">ACKNOWLEDGED AND ACCEPTED<br>AS OF THE ISSUE DATE BY&#58;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JON ISAAC</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><div id="ic8a5fa9b71f24998ad927ad75c4a81f8_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">CONVERSION RIGHTS ADDENDUM</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.64pt;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Noteholder shall effect conversions by delivering to the Borrower a Notice of Conversion, the form of which is attached hereto as Annex A (each, a &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), specifying therein the amount of the remaining obligations hereunder with interest accrued thereon to be converted and the date on which such conversion shall be effected (such date, the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion is deemed delivered hereunder.  No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">To effect conversions hereunder, the Noteholder shall not be required to physically surrender the Promissory Note or this First Amendment to the Borrower unless all of the remaining obligations thereunder and hereunder have been so converted and the shares of Conversion Stock have been delivered.  Conversions hereunder shall have the effect of lowering the amount of any remaining Convertible Obligations hereunder.  The Noteholder and the Borrower shall maintain a Conversion Schedule showing the amount(s) converted and the date(s) of such conversion(s).  The Borrower may deliver an objection to any Notice of Conversion within one (1) Business Day of delivery of such Notice of Conversion.  In the event of any dispute or discrepancy, the records of the Noteholder shall be controlling and determinative in the absence of manifest error.  Each of the Noteholder and any assignee by acceptance hereof acknowledges and agrees that, by reason of the provisions of this paragraph, following conversion of a portion hereof, the unpaid and unconverted then-outstanding obligations set forth in this Note may be less than the amount stated on the face hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.39pt;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of the Convertible Obligations is $1.16 per share, subject to adjustment as set forth below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.52pt;text-decoration:underline">Mechanics of Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.64pt;text-decoration:underline">Conversion Stock Issuable Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The number of shares of Conversion Stock issuable upon a conversion hereunder shall be determined by the quotient obtained by dividing (x) the amount of the Convertible Obligations by (y) the Conversion Price.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.9pt;text-decoration:underline">Delivery of Certificate Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Not later than two (2) Business Days</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> after each Conversion Date (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Borrower shall deliver, or cause to be delivered, to the Noteholder a certificate or certificates representing the shares of Conversion Stock that, on or after the date on which such shares of Conversion Stock are (A) eligible to be sold under Rule 144 without the need for current public information and the Borrower has received an opinion of counsel to such effect reasonably acceptable to the Borrower (which opinion the Borrower will be responsible for obtaining at the cost of the Borrower) or (B) subject to a registration statement that has been declared effective by the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and which registration statement is then neither stale nor subject to any stop order, shall be free of restrictive legends and trading restrictions, representing the number of shares of Conversion Stock being acquired upon the relevant conversion hereof.  All certificate or certificates required to be delivered by the Borrower under this Section (c) shall be delivered electronically through the Depositary Trust Company or another established clearing corporation performing similar functions.  If the Conversion Date is prior to the date on which such shares of Conversion Stock are eligible to be sold unde</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day that is not a Saturday, Sunday, or other holiday or day that commercial banks in Las Vegas, Nevada are authorized or required to be closed.</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">r Rule 144 without the need for current public information the shares of Conversion Stock shall bear a restrictive legend in the following form, as appropriate&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&#160;IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE NOTEHOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, commencing on such date that the shares of Conversion Stock are eligible for sale under Rule 144 subject to current public information requirements, the Borrower, upon request and at the expense of the Borrower, shall obtain a legal opinion to allow for such sales under Rule 144.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.16pt;text-decoration:underline">Failure to Deliver Certificates</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the case of any Notice of Conversion, such certificate or certificates are not delivered to or as directed by the Noteholder by the Share Delivery Date, the Noteholder shall be entitled to elect by written notice to the Borrower at any time on or before its receipt of such certificate or certificates, to rescind such Conversion, in which event the Borrower shall promptly return to the Noteholder any of the Note, delivered to the Borrower and the Noteholder shall promptly return to the Borrower the Common Stock certificates issued to such Noteholder pursuant to the rescinded Conversion Notice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Obligation Absolute&#59; Partial Liquidated Damages</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower&#8217;s obligations to issue and deliver the shares of Conversion Stock upon conversion hereof in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Noteholder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation, or termination, or any breach or alleged breach by the Noteholder or any other Person of any obligation to the Borrower or any violation or alleged violation of law by the Noteholder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Noteholder in connection with the issuance of such shares of Conversion Stock&#59; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, that such delivery shall not operate as a waiver by the Borrower of any such action the Borrower may have against the Noteholder.  In the event the Noteholder shall elect to convert any or all of the outstanding principal or interest amount hereof, the Borrower may not refuse conversion based on any claim that the Noteholder or anyone associated or affiliated with the Noteholder has been engaged in any violation of law, agreement, or for any other reason, unless an injunction from a court, on notice to Noteholder, restraining and or enjoining conversion of all or part hereof shall have been sought.  If the injunction is not granted, the Borrower shall promptly comply with all conversion obligations herein.  If the injunction is obtained, the Borrower must post a surety bond for the benefit of </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">the Noteholder in the amount of 150% of the outstanding amount that is subject to the injunction, which bond shall remain in effect until the completion of arbitration&#47;litigation of the underlying dispute and the proceeds of which shall be payable to the Noteholder to the extent it obtains judgment.  In the absence of seeking such injunction, the Borrower shall issue The shares of Conversion Stock or, if applicable, cash, upon a properly noticed conversion.  If the Borrower fails for any reason to deliver to the Noteholder such certificate or certificates pursuant to Section (c)(ii) by the Share Delivery Date, the Borrower shall pay to the Noteholder, in cash, as liquidated damages and not as a penalty, $1,000 per Business Day for each Business Day after such Share Delivery Date until such certificates are delivered or Noteholder rescinds such conversion.  Nothing herein shall limit Noteholder&#8217;s right to pursue actual damages or declare an event of default for the Borrower&#8217;s failure to deliver The shares of Conversion Stock within the period specified herein and the Noteholder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief.  The exercise of any such rights shall not prohibit the Noteholder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.76pt;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any other rights available to the Noteholder, if the Borrower fails for any reason to deliver to the Noteholder such certificate or certificates by the Share Delivery Date pursuant to Section (c)(ii), and, if after such Share Delivery Date the Noteholder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Noteholder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Noteholder of the shares of Conversion Stock that the Noteholder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Borrower shall (A) pay in cash to the Noteholder (in addition to any other remedies available to or elected by the Noteholder) the amount, if any, by which (x) the Noteholder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the Noteholder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of the Noteholder, either reissue (if surrendered) this Note in an amount equal to the amount of the attempted conversion (in which case such conversion shall be deemed rescinded) or deliver to the Noteholder the number of shares of Common Stock that would have been issued if the Borrower had timely complied with its delivery requirements under Section (c)(ii).  For example, if the Noteholder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion hereof with respect to which the actual sale price of the shares of Conversion Stock (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Borrower shall be required to pay to the Noteholder the sum of $1,000.  The Noteholder shall provide the Borrower written notice indicating the amounts payable to the Noteholder in respect of the Buy-In and, upon request of the Borrower, evidence of the amount of such loss.  Nothing herein shall limit Noteholder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Borrower&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of this Note as required pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">vi.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Reservation of Shares Issuable Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower covenants that it will at all times reserve and keep available out of its authorized and </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">unissued shares of Common Stock a number of shares of Common Stock at least equal to 200% of the Required Minimum (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserve Amount</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the sole purpose of issuance of shares of Common Stock hereunder, as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Noteholder.  The Borrower covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, and nonassessable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">vii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.28pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No fractional shares or scrip representing fractional shares shall be issued upon the conversion hereof.  As to any fraction of a share to which the Noteholder would otherwise be entitled to purchase upon such conversion, the Borrower shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">viii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.54pt;text-decoration:underline">Transfer Taxes and Expenses</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The issuance of certificates for shares of the Common Stock on partial or complete conversion hereof shall be made without charge to the Noteholder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that, the Borrower shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Noteholder so converted and the Borrower shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Borrower the amount of such tax or shall have established to the satisfaction of the Borrower that such tax has been paid.  The Borrower shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Noteholder&#8217;s Conversion Limitations</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Noteholder shall not effect any conversion of any amount due hereunder and shall not have the right to convert any amounts due hereunder, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Noteholder (together with the Noteholder&#8217;s Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Noteholder and its Affiliates shall include the number of shares of Common Stock issuable upon the relevant conversion hereof with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted amounts due hereunder beneficially owned by the Noteholder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Borrower subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, any obligations in favor of any Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) beneficially owned by the Noteholder or any Persons acting as a group together with the Noteholder.  Except as set forth in the preceding sentence, for purposes of this Section (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)and the rules and regulations promulgated thereunder.  To the extent that the limitation contained in this Section (d) applies, the determination of whether the Joint Obligor&#8217;s obligations hereunder are convertible (in relation to other securities owned by the Noteholder together with any Affiliates and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) and of which obligations hereunder are convertible shall be in the sole discretion of the Noteholder, and the submission of a Notice of Conversion shall be deemed to be the Noteholder&#8217;s determination of whether any of the Joint Obligor&#8217;s obligations hereunder may be converted (in relation to other securities owned by the </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Noteholder together with any Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates, and which amount owing hereunder is convertible, in each case subject to the Beneficial Ownership Limitation.  To ensure compliance with this restriction, the Noteholder will be deemed to represent to the Borrower each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Borrower shall have no obligation to verify or confirm the accuracy of such determination.  In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of this Section (d), in determining the number of outstanding shares of Common Stock, the Noteholder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following&#58; (i) the Borrower&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Borrower, or (iii) a more recent written notice by the Borrower or the Borrower&#8217;s transfer agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request of the Noteholder, the Borrower shall, within two Business Days confirm orally and in writing to the Noteholder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Borrower, including the obligations set forth in the Note, by the Noteholder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported.  The &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon the relevant conversion hereunder.  The Noteholder, upon not less than sixty-one (61) days&#8217; prior notice to the Borrower, may increase or decrease the Beneficial Ownership Limitation provisions of this Section (d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon the relevant conversion hereunder held by the Noteholder and the Beneficial Ownership Limitation provisions of this Section (d) shall continue to apply.  Any such increase or decrease will not be effective until the sixty-first (61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">) calendar day after such notice is delivered to the Borrower.  The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section (d) to correct this paragraph (or any portion hereof) that may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.  The limitations contained in this paragraph shall apply to a successor holder hereof.</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum 5</font></div></div></div><div id="ic8a5fa9b71f24998ad927ad75c4a81f8_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">NOTICE OF CONVERSION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned hereby elects to convert obligations of the Joint Obligors under the Promissory Note, as amended, of ARCA Recycling, Inc. and JanOne Inc. (&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JanOne</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into shares of common stock (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of JanOne according to the conditions hereof, as of the date written below.  If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by JanOne in accordance therewith.  No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">By the delivery of this Notice of Conversion the undersigned represents and warrants to the Companies that its ownership of the Common Stock does not exceed the amounts specified under Section 2(d) of this First Amendment, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion calculations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Date to Effect Conversion&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amount of obligations to be Converted&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of Common Stock to be issued&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Signature&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;     Name&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Delivery Instructions&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">JanOne Promissory Note to Jon Isaac March 2024 consulting agreement.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ANNEX A</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.107
<SEQUENCE>4
<FILENAME>ex10107_consultingagreemen.htm
<DESCRIPTION>EX-10.107
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3f26240cbf2940cf8e6793d7da8e2247_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.107</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), executed as of March 4, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between JanOne Inc., a Nevada corporation with its principal offices located at </font><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, on the one hand (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Jon Isaac, an individual residing in the State of Nevada (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at 505 E. Windmill Ln, Ste 1C #295, Las Vegas, Nevada 89123</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, serves to memorialize and ratify the understanding between the Parties in respect of the Services (as defined in Paragraph 2 of this Agreement) to be provided by the Consultant to the Company during the Term (as defined in Paragraph 1 of this Agreement).  Each of the Company and the Consultant is individually a &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively, are the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Company desires to engage the Consultant to furnish certain Services and the Consultant is willing and able to perform such Services for the benefit of the Company for the consideration and on the terms and conditions as memorialized and ratified herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the presents and for such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Term of this Agreement</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  In connection with this Agreement, the Company hereby engages the Consultant as an independent contractor, and the Consultant agrees to be so engaged, to provide the Services to the Company.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall commence on the &#91;Execution Date&#93; and shall continue until the third anniversary thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Services</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Services to be provided herewith by an executive officer of the Consultant (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are set forth on Exhibit A hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Work Product</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Consultant acknowledges and agrees that all right, title, and interest in and to the product of all work and Services to be performed by the Consultant hereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Work Product</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall belong to, and shall upon their creation become the exclusive property of the Company.  All Work Product shall be deemed a &#8220;work made for hire&#8221; to the full extent of that doctrine under the laws of the United States of America and of all foreign nations having the same or a similar law or doctrine.  The Consultant covenants and agrees promptly to execute, upon the Company&#8217;s written demand, any and all documents necessary or appropriate to confirm, perfect, and protect the Company&#8217;s rights as owner in and to all Work Product.  In the event that the Consultant wrongfully refuses or is unable to execute any such documents, the Consultant hereby irrevocably appoints the Company as the Consultant&#8217;s attorney-in-fact with power and authority to execute any such documents on behalf of and in the name and place of the Consultant, which power is coupled with an interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Compensation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall tender to the Consultant compensation in the manner, specie, and amount as set forth on Exhibit B hereof (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Parties mutually agree and acknowledge that the Compensation is deemed fully earned as of the Execution Date.  In respect of the performance of the Services, the Consultant shall bear all of its expenses, including travel and meals, including any time spent by the Consultant in traveling to a location for the performance of the Services, subject to reimbursement in part or in full on a case-by-case basis.  Such expenses shall be included in the Consultant&#8217;s compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Independent Contractor Relationship</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that, during the Term, the Consultant will be an independent contractor and, for all purposes, will not be an employee, agent, broker, or dealer (each as defined in Sections 3(a)(4) or 3(a)(5), respectively, of the Securities Exchange Act of 1934, as amended), or a joint venturer with, or partner of, the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Company, including for state or federal tax purposes.  The Consultant has sought such accounting, legal, and tax advice as the Consultant has considered necessary to make an informed decision with respect to the Compensation Stock.  The Consultant understands that the Consultant (and not the Company) shall be responsible for its own tax liabilities and any tax reporting obligations that may arise as a result of receiving the Compensation Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">At no time, will the Consultant have any authority to represent itself as an agent or employee of the Company or to obligate, bind, or commit the Company to any agreement, arrangement, proposal, partnership, transaction, or opportunity (each, an &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Opportunity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) without the prior written approval of the Chief Executive Officer of the Company, which approval may be withheld, delayed, denied, or conditioned for any reason or for no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Consultant agrees that it is solely responsible for and will indemnify, defend, and hold the Company harmless from, any actions, proceedings, claims or demands for the payment of any taxes, interest, penalties, levies, or assessments applicable to the expenses reimbursed under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Special Skill and Time Devoted to Services</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is a personal services agreement and calls for all Services to be performed exclusively by the Consultant.  The Consultant represents and warrants that, at all times relevant to this Agreement, it will have the special skill and professional competence, expertise, and experience to perform the Services.  The Consultant further represents and warrants that none of the Services requires the Consultant to have and maintain licensure of any kind.  The Consultant retains the right to perform services for other parties during the Term, except that the Consultant shall not perform services that would in any way interfere with the performance of the Services described herein.  The Consultant agrees to devote such time to the business of the Company as is reasonably necessary to provide the Services and to perform the Services in a diligent, efficient, competent, and skillful manner commensurate with the highest standards of his profession.  The Consultant agrees to comply with all applicable federal, state, and local laws and regulations.  If, by any act of negligence or gross or willful misconduct, the Consultant violates any such laws or regulations, the Consultant agrees to indemnify the Company and to hold it harmless from and against any claim, demand, right, damage, debt, liability, action, cause of action, cost, or expense, including attorneys&#8217; fees actually paid or incurred, arising out of such violation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Termination of this Agreement</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Consultant&#8217;s engagement hereunder shall terminate at the expiration of the Term or immediately upon the dissolution of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Reserved.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;  (i) any information disclosed by the Company to the Consultant, either directly or indirectly, in writing, orally, or by inspection of tangible objects that has been designated by the Company as &#8220;confidential,&#8221; either in writing or orally, prior to, at, or promptly after the time of disclosure, or that the Consultant clearly understands (by the nature of the information) to be confidential, proprietary information of the Company and (ii) any information obtained or derived by the Consultant, directly or indirectly, through inspection, examination, review, or analysis of the such information.  Confidential Information may also include information of a third party that is in the possession of the Company and is disclosed to the Consultant.  Confidential Information does not include information&#58;  (x) that is or becomes publicly known without any breach of this Agreement or (y) that is independently developed by the Consultant without use of any Confidential Information (the Consultant shall bear the burden of establishing the applicability of this exception by competent evidence).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">The Consultant shall not, without the prior written consent of the Company&#58;  (a) use Confidential Information for any purpose other than to perform the Services&#59; (b) disclose Confidential Information to any third party&#59; (c) reverse engineer the function or mechanism of any Confidential Information&#59; (d) make any copies of Confidential Information&#59; (e) enter into a transaction with any third party, the existence of or opportunity for which was first disclosed by the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Company to the Consultant as Confidential Information&#59; or (f) remove any Confidential Information from the Company&#8217;s premises.  Immediately upon termination of this Agreement, the Consultant shall return to the Company and delete from any personal computer or other device all originals and all copies of any Company property, Confidential Information, and all materials, documents, notes, manuals, computer disks, computers or lists containing or embodying Confidential Information, or relating directly or indirectly to the business of Company that are in the Consultant&#8217;s possession or control.  The Consultant specifically acknowledges that the Company&#8217;s possession of its Confidential Information gives the Company a competitive advantage over other companies or persons who do not possess such Confidential Information, and, therefore, that any disclosure to or use of Confidential Information by persons not engaged by the Company or who are not authorized by the Company to receive or use the information will cause harm to the Company and provides such persons an unfair competitive advantage that they would not have had without having obtained access to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Injunctive Relief</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Consultant agrees that his violation or threatened violation of any of the provisions of Paragraph 10 of this Agreement shall cause immediate and irreparable harm to the Company.  In the event of any breach or threatened breach of any of said provisions, the Consultant consents to the entry of preliminary and permanent injunctions by a court of competent jurisdiction prohibiting the Consultant from any violation or threatened violation of such provisions and compelling the Consultant to comply with such provisions.  This Paragraph 11 shall not affect or limit, and the injunctive relief provided in this Paragraph 11 shall be in addition to, any other remedies available to the Company at law or in equity or in arbitration for any such violation by the Consultant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Representations and Warranties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Consultant represents, warrants, covenants, and agrees that the Consultant has full power and authority to execute and deliver this Agreement and perform the Services.  The Consultant represents, warrants, covenants, and agrees that&#58;  (1) it and none of its employees or affiliates who will providing the Services is, or during the term will be, a member of the Financial Industry Regulatory Authority, Inc. (&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FINRA</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and none is or, during the term will be, engaged in the securities brokerage business&#59; (2) the Consultant provides consulting advisory services in the ordinary course of the Consultant&#8217;s business&#59; (3) the Services will not be of the nature of services that require the Consultant to be registered with FINRA or otherwise registered or licensed as a broker or a dealer&#59; (4) the Consultant will promptly notify the Company if it requests or requires the Consultant to perform any services in connection herewith that would require the Consultant to be so registered or licensed&#59; (5) the Consultant is not a party to any agreement or understanding, oral or written, that would prohibit, or interfere with, performance of the Services&#59; (6) the Consultant will not use in the performance of the Services any proprietary information of any other party that the Consultant is legally prohibited from using&#59; (7) the Consultant has disclosed to the Company any other agreements and&#47;or circumstances that the Consultant recognizes, or with the exercise of reasonable care should recognize, create any actual or potential conflicts of interest between such other agreement or circumstance, on the one hand, and the Consultant&#8217;s performance of the Services, on the other hand&#59; (8) the Consultant will act in the best interests of the Company and will not do or perform any act that could potentially injure the Company&#8217;s (or its affiliate&#8217;s) business, prospects, interests, or reputation&#59; (9) the Consultant will provide to the President of the Company reasonably detailed written reports of the Services and advice when requested by the President&#59; (10) if the Consultant comes into possession of material non-public information in respect of any entity whose securities are publicly traded, which information in any manner relates to the Services, the Consultant shall immediately inform the Company thereof and adhere to the standard Ethical Wall policies and procedures of the Company in respect of such information, such that, among other items, the Consultant will not divulge any such material non-public information to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">The Consultant further acknowledges that the shares of Compensation Stock have not been registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1933 Act</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or qualified under the securities laws of any state, and instead will be issued under an exemption from the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">registration requirements of the 1933 Act and the qualification requirements of such laws.  The shares of Compensation will be subject to restrictions on transferability and resale and may not be transferred or resold, except as permitted under the 1933 Act and such laws pursuant to registration or qualification, as applicable, or exemption therefrom.  No shares of Compensation Stock were approved or disapproved by the Securities and Exchange Commission, any state securities commission, or any other regulatory authority&#59; nor did any of the foregoing authorities pass upon or endorse the merits of that issuance.  Any representation to the contrary will be a criminal offense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Company represents, warrants, covenants, and agrees that it has full power and authority to execute and deliver this Agreement and perform its obligations hereunder.  The Company further represents, warrants, covenants, and agrees that Services if, when, and as performed will not be of the nature of services that require the Consultant to be registered with FINRA or otherwise registered or licensed as a broker or dealer and the Company will not request or require the Consultant to perform any such services in connection herewith that would require it to be so registered or licensed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Company Information</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company recognizes and confirms that the Consultant, in advising the Company and in fulfilling its engagement hereunder, may use and rely on data, material, and other information that may be furnished to the Consultant by the Company, without the Consultant independently verifying the accuracy, completeness, or veracity thereof.  In addition, in the performance of the Services, the Consultant may obtain such factual information, economic advice, and&#47;or research from various third parties as the Consultant shall in good faith deem appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Notices</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice, consent, or any other communication required under the provisions of this Agreement shall be given in writing and sent or delivered by hand, overnight courier, or messenger service, against a signed receipt or acknowledgment of receipt, or by registered or certified mail, return receipt requested, postage prepaid, via email or by facsimile transmission or similar means of communication if receipt is acknowledged or if transmission is confirmed by mail as provided in this Paragraph 14 to the other Party at its respective address set forth at the beginning of this Agreement, with notice to the Company being sent to the attention of the individual who executed this Agreement on behalf of the Company.  Either Party may, by like notice, change the person, physical or email address, or facsimile number to which notice is to be sent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Governing Law</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of Nevada without regard to the conflicts of laws principles thereof.  The Parties hereby agree that any suit or proceeding arising directly and&#47;or indirectly pursuant to or under this Agreement shall be brought solely in a federal or state court located in Clark County, State of Nevada.  By its execution hereof, each Party hereby covenants and irrevocably submits to the </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in personam</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> jurisdiction of the federal and state courts located in Clark County, State of Nevada, and agrees that any process in any such action may be served upon it personally, or by certified mail or registered mail upon such Party or its respective agent, return receipt requested, postage prepaid, with the same full force and effect as if personally served upon such Party.  Each Party waives any claim that any such jurisdiction is not a convenient forum for any such suit or proceeding and any defense or lack of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in personam</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> jurisdiction with respect thereto.  In the event of any such action or proceeding, the Party prevailing therein shall be entitled to payment from the other Party of its reasonable counsel fees and disbursements in an amount judicially determined.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Severability</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If any term, covenant, or condition of this Agreement or the application thereof to any Party or circumstance shall, to any extent, be determined to be invalid or unenforceable, the remainder of this Agreement, as applicable, or the application of such term, covenant, or condition to parties or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant, or condition thereof or hereof shall be valid and be enforced to the fullest extent permitted by law, and any court or arbitrator having jurisdiction may reduce the scope of any provision thereof or hereof so that it complies with applicable law.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Entire Agreement</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement and understanding of the Company and the Consultant as to the subject matter hereof, superseding all prior written or prior or contemporaneous oral understandings or agreements including any previous agreements, or understandings with respect to the subject matter covered in this Agreement.  This Agreement may not be modified or amended, nor may any right be waived, except by a writing which expressly refers to this Agreement, states that it is intended to be a modification, amendment, or waiver hereof, and is signed by both Parties in the case of a modification or amendment or by the Party granting the waiver.  No course of conduct or dealing between the Parties and no custom or trade usage shall be relied upon to vary the terms of this Agreement.  The failure of a Party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that Party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Assignment, Successors, and Assigns</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Consultant has no right to assign, delegate, or otherwise transfer this Agreement, or any of the Consultant&#8217;s rights, duties, or any other interests herein to any party, and any purported assignment will be null and void.  The Company may, without notice to the Consultant and without the Consultant&#8217;s prior consent or approval, assign, delegate, and transfer any or all of its rights and obligations hereunder to any third party or to any affiliate or any successor corporation or entity that continues the business of the Company or a substantial portion thereof.  This Agreement will inure to and be binding upon each of the Parties and their respective legal representatives, heirs, successors, and permissible assigns, but this provision is not intended to modify the restrictions on assignment by the Consultant set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Headings</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings in this Agreement are for convenience of reference only and shall not affect in any way the construction or interpretation hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Waivers</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No delay or omission to exercise any right, power or remedy accruing to either party hereto shall impair any such right, power, or remedy or shall be construed to be a waiver of or an acquiescence to any breach hereof.  No waiver of any breach of this Agreement shall be deemed to be a waiver of any other breach hereof.  Any waiver of any provision hereof shall be effective only to the extent specifically set forth in an applicable writing.  All remedies afforded to either Party under this Agreement, by law or otherwise, shall be cumulative and not alternative and shall not preclude assertion by such Party of any other rights or the seeking of any other rights or remedies against any other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Representation by Counsel</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party has had the opportunity to be represented by and have its legal counsel review and this Agreement, therefore, shall not be interpreted against any Party as the drafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Execution</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which shall constitute one and the same instrument.  Facsimile, PDF, or other electronic signatures shall be accepted by the Parties as originals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement as of the Execution Date.</font></div><div style="margin-bottom:36pt;padding-left:216pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JANONE INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:238.3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tony Isaac, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(as of the Execution Date)</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;JON ISAAC</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div></div></div><div id="i3f26240cbf2940cf8e6793d7da8e2247_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">THE SERVICES</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.26pt">Providing strategic financial advice, including growth strategies, capital allocation, and financial restructuring&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Sales and Business Development&#58; Acquire new clients through networking, referrals, and marketing efforts&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.76pt">Conducting in-depth research and market intelligence on specific industries, sectors, and market trends&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">D.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.13pt">Developing financial models and conducting financial analysis to support strategic decision-making&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">E.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.51pt">Site visits to assist in the preparation of new client offers and bids for proposed projects&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">F.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.63pt">Conduct weekly update calls with management to align on progress of objectives and goals&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">G.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.13pt">Enhance non-confidential materials&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">H.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.26pt">Business risk management support&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.14pt">Other services that may be agreed to between the Parties, which other services will be memorialized in writing if, when, and as needed during the Term.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT A</font></div></div></div><div id="i3f26240cbf2940cf8e6793d7da8e2247_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">THE COMPENSATION</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt">Assignment to Consultant of two universal life insurance policies underwritten by ReliaStar Life Insurance Company and, upon the assignment, Consultant shall become responsible for the payment of all on-going policy premiums and all other expenses attendant thereto.  Policy RL3000730R annual premium of $7,525.00 (each October 9)&#59; Policy RL3001576E annual premium of $7,525.00 (each March 12)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.51pt">RL3000730R (Accumulated Value&#58;  $3,853.55&#59; Surrender Value&#58;  $3,853.55)&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.26pt">RL3001576E (Accumulated Value&#58;  $467.74&#59; Surrender Value&#58;  $467.74).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt">The funds in the Cambridge LLP Trust Account, which funds (in an amount estimated not to exceed approximately CDN$300,000) are to be released to the Company in accordance with a prospective Order of the Court of Appeal for Ontario Canada in the matter styled, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Amtim Capital Inc. and Appliance Recycling Centers of America</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, Case No. COA-23-CV-0156.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt">200,000 restricted shares of common stock of the Company with a per-share value of $1.16 (such per-share value being the five-trading day average of the historical NOCP closing price for March 1 &#8211; February 26, 2024), as awarded from the Company&#8217;s 2023 Stock Equity Incentive Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt">A $500,000 principal amount promissory note of the Company in favor of the Consultant, the form of which note is attached hereto as Exhibit B-4.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B</font></div></div></div><div id="i3f26240cbf2940cf8e6793d7da8e2247_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECURITIES ACT</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANIES.  THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">PROMISSORY NOTE</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Principal Amount&#58; $500,000.00</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Issue Date&#58;  March 4, 2024</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JANONE INC.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">a Nevada corporation with its principal place of business at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby unconditionally promises to pay to the order of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JON ISAAC</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, an individual residing in the State of Nevada (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Noteholder</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at 505 E. Windmill Ln, Ste 1C #295, Las Vegas, Nevada 89123 or at such other place as the Noteholder hereof may from time to time designate in writing to the Borrower, the principal amount of FIVE HUNDRED THOUSAND AND NO&#47;100 DOLLARS ($500,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loan</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), together with all accrued interest thereon, as provided in this Promissory Note (this &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">The</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">Borrower Covenants and Agrees with the Noteholder as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Payment of Indebtedness</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower will pay the indebtedness evidenced by this Note as provided herein.  All amounts due hereunder shall be payable in lawful money of the United States, and all or any portion thereof may be prepaid at any time or from time to time without premium, penalty, or advance notice.  Notwithstanding the foregoing, if, after the date of this Note, the Borrower is sold, merged, or consolidated with another business entity or is reorganized or recapitalizes, the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note immediately shall become due and payable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Maturity </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Date.  Absent the occurrence and continuation of an Event of Default (as hereinafter defined), the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note shall be due and payable not later than 12&#58;00 noon Pacific Standard Time on March 4, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The principal amount outstanding under this Note from time to time shall bear interest at ten percent (10%) per annum (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Computation of Interest</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All computations of interest hereunder shall be made on the basis of a year of 365&#47;366 days, as the case may be, and the actual number of days elapsed.  Interest shall begin to accrue on the Loan on the date of this Note.  For any portion of the Loan that is repaid, interest shall not accrue on the date on which such payment is made.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If, at any time, the Interest Rate payable on the Loan shall exceed the maximum rate of interest permitted under applicable law, such Interest Rate shall be reduced automatically to the maximum rate permitted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Payment </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mechanics</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Manner of Payment</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments hereunder shall be made in US dollars.  Such payments shall be made by wire transfer of immediately available funds to the Noteholder&#8217;s account at a bank specified by the Noteholder in writing to the Borrower from time to time.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Application of Payments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments shall be applied, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">first</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to fees or charges outstanding under this Note, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">second</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to accrued interest, and, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">third</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, to principal outstanding under this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower represents and warrants to the Noteholder as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Existence</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Nevada.  The Borrower has the requisite power and authority to own, lease, and operate its property, and to carry on its business.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower is in compliance with all laws, statutes, ordinances, rules, and regulations applicable to or binding on the Borrower, its property, and business.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Power and Authority</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower has the requisite power and authority to execute, deliver, and perform its obligations under this Note.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.02pt;text-decoration:underline">Authorization&#59; Execution and Delivery</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The execution and delivery of this Note by the Borrower and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with applicable law.  The Borrower has duly executed and delivered this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The occurrence and continuance of any of the following shall constitute an &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; hereunder&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Failure to Pay</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower fails to pay the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note by the Maturity Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Breach of Representations and Warranties</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Any representation or warranty made by the Borrower to the Noteholder herein contains an untrue or misleading statement of a material fact as of the date made.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Bankruptcy&#59; Insolvency</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.28pt">The Borrower institutes a voluntary case seeking relief under any law relating to bankruptcy, insolvency, reorganization, or other relief for debtors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.54pt">An involuntary case is commenced seeking the liquidation or reorganization of the Borrower under any law relating to bankruptcy or insolvency, and such case is not dismissed or vacated within sixty (60) days of its filing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.8pt">The Borrower makes a general assignment for the benefit of its creditors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.66pt">The Borrower is unable, or admits in writing its inability, to pay its debts as they become due.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.4pt">A case is commenced against the Borrower or its assets seeking attachment, execution, or similar process against all or a substantial part of its assets, and such case is not dismissed or vacated within sixty (60) days of its filing.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.02pt;text-decoration:underline">Failure to Give Notice.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The Borrower fails to give the notice of Event of Default specified in Section 7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Notice of Event of Default.  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">As soon as possible after it becomes aware that an Event of Default has occurred, and in any event within two (2) Business Days</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrower shall notify the Noteholder in writing of the nature and extent of such Event of Default and the action, if any, it has taken or proposes to take with respect to such Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the occurrence and during the continuance of an Event of Default, the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note immediately shall become due and payable.  Further, from and after an Event of Default, the Noteholder has the right, but not the obligation, to convert at any time or from time to time any or all of the unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Convertible Obligations</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into shares of common stock, $0.001 par value per share, of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The conversion rights are set forth in the Conversion Rights Addendum, attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Mandatory Conversion Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The Noteholder hereby grants to the Borrower the option (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to convert all, but not less than all, of the Borrower&#8217;s obligations hereunder into shares of the Borrower&#8217;s Common Stock.  The Borrower shall provide to the Noteholder ten (10) days&#8217; written notice of the Borrower&#8217;s exercise of the Option.  The Borrower may not exercise the Option until after the six (6)-month anniversary of Issue Date.  The provisions of sections (c) and (d) of the Conversion Rights Addendum shall apply to the Borrower&#8217;s exercise of the Option.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">  The per-share conversion price of the Option shall be $1.16, subject to adjustment as set forth in section (c) of the Conversion Rights Addendum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower shall reimburse the Noteholder on demand for all reasonable out-of-pocket costs, expenses, and fees, including the reasonable fees and expenses of counsel, incurred by the Noteholder in connection with the enforcement of the Noteholder&#8217;s rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (x) deposit with the United States Postal Service or overnight courier service, properly addressed and postage prepaid&#59; (y) transmittal by electronic communication (including email, internet or intranet websites, or facsimile properly addressed (with written acknowledgment from the intended recipient such as &#8220;return receipt requested&#8221; function, return e-mail, or other written acknowledgment)&#59; or (z) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party shall specify in writing&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt">If to the Borrower&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">JanOne Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">325 E. Warm Springs Road, Suite 102</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Las Vegas, Nevada 89119</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">E-mail&#58;  t.isaac&#64;isaac.com</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day that is not a Saturday, Sunday, or other holiday or day that commercial banks in Las Vegas, Nevada are authorized or required to be closed.</font></div><div style="margin-bottom:6pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If the Beneficial Ownership Limitation (as set forth in section (d) of the Conversion Rights Addendum) shall preclude the issuance of shares of Common Stock upon the Borrower&#8217;s exercise of the Option, then the exercise shall be limited to comply with such Beneficial Ownership Limitation and the balance of the Borrower&#8217;s obligations under the Note shall remain outstanding (principal and accrued, but unpaid and unconverted interest thereon) and shall be subject to the Borrower&#8217;s future exercise of the Option.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt">If to the Noteholder&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jon Isaac</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">505 E. Windmill Ln, Ste 1C #295</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Las Vegas, Nevada 89123</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">E-mail&#58;  j.isaac&#64;isaac.com</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.76pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based on, arising out of, or relating to this Note and the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of Nevada without regard for any principals of conflicts of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.15pt;text-decoration:underline">Submission to Jurisdiction</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.28pt">The Borrower irrevocably and unconditionally (A) agrees that any action, suit, or proceeding arising from or relating to this Note may be brought in the courts of the State of Nevada sitting in Clark County, and in the United States District Court for the Nevada and (B) submits to the exclusive jurisdiction of such courts in any such action, suit, or proceeding.  Final judgment against the Borrower in any such action, suit, or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.54pt">Nothing in this </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i3f26240cbf2940cf8e6793d7da8e2247_10" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section&#160;13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> shall affect the right of the Noteholder to bring any action, suit, or proceeding relating to this Note against the Borrower or its properties in the courts of any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.8pt">Nothing in this </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i3f26240cbf2940cf8e6793d7da8e2247_10" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section 13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> shall affect the right of the Noteholder to serve process upon the Borrower in any manner authorized by the laws of any such jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.9pt;text-decoration:underline">Venue</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by law, (i) any objection that it may now or hereafter have to the laying of venue in any action, suit, or proceeding relating to this Note in any court referred to in </font><font style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i3f26240cbf2940cf8e6793d7da8e2247_10" style="background-color:#c0c0c0;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Section&#160;13(a)</a></font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, and (ii)&#160;the defense of inconvenient forum to the maintenance of such action, suit, or proceeding in any such court.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  THE BORROWER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note may be assigned or transferred by the Noteholder to any individual, corporation, company, limited liability company, trust, joint venture, association, partnership, unincorporated organization, governmental authority, or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note constitutes the entire contract between the Borrower and the Noteholder with respect to the subject matter hereof and supersedes all previous agreements and understandings, oral or written, with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Amendments and Waivers</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Noteholder.  Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#59; Cumulative Remedies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No failure by the Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof&#59; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power.  The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page to this Note by facsimile or in electronic (&#8220;pdf&#8221; or &#8220;tiff&#8221; or any other electronic means that reproduces an image of the actual executed signature page) format shall be as effective as delivery of a manually executed counterpart of this Note.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.14pt;text-decoration:underline">Electronic Execution</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of similar import in this Note shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15&#160;U.S.C.&#160;&#167;&#167;&#160;7001-7031), the Electronic Signatures and Records Act of 1999 (N.Y. State Tech. Law &#167;&#167;&#160;301-309), and any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;signature page follows&#93;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrower has executed this Note as of the Issue Date.</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JANONE INC.</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Tony Isaac</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">ACKNOWLEDGED AND ACCEPTED<br>AS OF THE ISSUE DATE BY&#58;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">JON ISAAC</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 5</font></div></div></div><div id="i3f26240cbf2940cf8e6793d7da8e2247_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">CONVERSION RIGHTS ADDENDUM</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.64pt;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Noteholder shall effect conversions by delivering to the Borrower a Notice of Conversion, the form of which is attached hereto as Annex A (each, a &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), specifying therein the amount of the remaining obligations hereunder with interest accrued thereon to be converted and the date on which such conversion shall be effected (such date, the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion is deemed delivered hereunder.  No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">To effect conversions hereunder, the Noteholder shall not be required to physically surrender the Promissory Note or this First Amendment to the Borrower unless all of the remaining obligations thereunder and hereunder have been so converted and the shares of Conversion Stock have been delivered.  Conversions hereunder shall have the effect of lowering the amount of any remaining Convertible Obligations hereunder.  The Noteholder and the Borrower shall maintain a Conversion Schedule showing the amount(s) converted and the date(s) of such conversion(s).  The Borrower may deliver an objection to any Notice of Conversion within one (1) Business Day of delivery of such Notice of Conversion.  In the event of any dispute or discrepancy, the records of the Noteholder shall be controlling and determinative in the absence of manifest error.  Each of the Noteholder and any assignee by acceptance hereof acknowledges and agrees that, by reason of the provisions of this paragraph, following conversion of a portion hereof, the unpaid and unconverted then-outstanding obligations set forth in this Note may be less than the amount stated on the face hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.39pt;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of the Convertible Obligations is $1.16 per share, subject to adjustment as set forth below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.52pt;text-decoration:underline">Mechanics of Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.64pt;text-decoration:underline">Conversion Stock Issuable Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The number of shares of Conversion Stock issuable upon a conversion hereunder shall be determined by the quotient obtained by dividing (x) the amount of the Convertible Obligations by (y) the Conversion Price.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.9pt;text-decoration:underline">Delivery of Certificate Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Not later than two (2) Business Days</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> after each Conversion Date (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Borrower shall deliver, or cause to be delivered, to the Noteholder a certificate or certificates representing the shares of Conversion Stock that, on or after the date on which such shares of Conversion Stock are (A) eligible to be sold under Rule 144 without the need for current public information and the Borrower has received an opinion of counsel to such effect reasonably acceptable to the Borrower (which opinion the Borrower will be responsible for obtaining at the cost of the Borrower) or (B) subject to a registration statement that has been declared effective by the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and which registration statement is then neither stale nor subject to any stop order, shall be free of restrictive legends and trading restrictions, representing the number of shares of Conversion Stock being acquired upon the relevant conversion hereof.  All certificate or certificates required to be delivered by the Borrower under this Section (c) shall be delivered electronically through the Depositary Trust Company or another established clearing corporation performing similar functions.  If the Conversion Date is prior to the date on which such shares of Conversion Stock are eligible to be sold unde</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day that is not a Saturday, Sunday, or other holiday or day that commercial banks in Las Vegas, Nevada are authorized or required to be closed.</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">r Rule 144 without the need for current public information the shares of Conversion Stock shall bear a restrictive legend in the following form, as appropriate&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">&#8220;NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&#160;IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE NOTEHOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Notwithstanding the foregoing, commencing on such date that the shares of Conversion Stock are eligible for sale under Rule 144 subject to current public information requirements, the Borrower, upon request and at the expense of the Borrower, shall obtain a legal opinion to allow for such sales under Rule 144.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.16pt;text-decoration:underline">Failure to Deliver Certificates</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the case of any Notice of Conversion, such certificate or certificates are not delivered to or as directed by the Noteholder by the Share Delivery Date, the Noteholder shall be entitled to elect by written notice to the Borrower at any time on or before its receipt of such certificate or certificates, to rescind such Conversion, in which event the Borrower shall promptly return to the Noteholder any of the Note, delivered to the Borrower and the Noteholder shall promptly return to the Borrower the Common Stock certificates issued to such Noteholder pursuant to the rescinded Conversion Notice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Obligation Absolute&#59; Partial Liquidated Damages</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower&#8217;s obligations to issue and deliver the shares of Conversion Stock upon conversion hereof in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Noteholder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation, or termination, or any breach or alleged breach by the Noteholder or any other Person of any obligation to the Borrower or any violation or alleged violation of law by the Noteholder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Noteholder in connection with the issuance of such shares of Conversion Stock&#59; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">, that such delivery shall not operate as a waiver by the Borrower of any such action the Borrower may have against the Noteholder.  In the event the Noteholder shall elect to convert any or all of the outstanding principal or </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">interest amount hereof, the Borrower may not refuse conversion based on any claim that the Noteholder or anyone associated or affiliated with the Noteholder has been engaged in any violation of law, agreement, or for any other reason, unless an injunction from a court, on notice to Noteholder, restraining and or enjoining conversion of all or part hereof shall have been sought.  If the injunction is not granted, the Borrower shall promptly comply with all conversion obligations herein.  If the injunction is obtained, the Borrower must post a surety bond for the benefit of the Noteholder in the amount of 150% of the outstanding amount that is subject to the injunction, which bond shall remain in effect until the completion of arbitration&#47;litigation of the underlying dispute and the proceeds of which shall be payable to the Noteholder to the extent it obtains judgment.  In the absence of seeking such injunction, the Borrower shall issue The shares of Conversion Stock or, if applicable, cash, upon a properly noticed conversion.  If the Borrower fails for any reason to deliver to the Noteholder such certificate or certificates pursuant to Section (c)(ii) by the Share Delivery Date, the Borrower shall pay to the Noteholder, in cash, as liquidated damages and not as a penalty, $1,000 per Business Day for each Business Day after such Share Delivery Date until such certificates are delivered or Noteholder rescinds such conversion.  Nothing herein shall limit Noteholder&#8217;s right to pursue actual damages or declare an event of default for the Borrower&#8217;s failure to deliver The shares of Conversion Stock within the period specified herein and the Noteholder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief.  The exercise of any such rights shall not prohibit the Noteholder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.76pt;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any other rights available to the Noteholder, if the Borrower fails for any reason to deliver to the Noteholder such certificate or certificates by the Share Delivery Date pursuant to Section (c)(ii), and, if after such Share Delivery Date the Noteholder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Noteholder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Noteholder of the shares of Conversion Stock that the Noteholder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Borrower shall (A) pay in cash to the Noteholder (in addition to any other remedies available to or elected by the Noteholder) the amount, if any, by which (x) the Noteholder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the Noteholder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of the Noteholder, either reissue (if surrendered) this Note in an amount equal to the amount of the attempted conversion (in which case such conversion shall be deemed rescinded) or deliver to the Noteholder the number of shares of Common Stock that would have been issued if the Borrower had timely complied with its delivery requirements under Section (c)(ii).  For example, if the Noteholder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion hereof with respect to which the actual sale price of the shares of Conversion Stock (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Borrower shall be required to pay to the Noteholder the sum of $1,000.  The Noteholder shall provide the Borrower written notice indicating the amounts payable to the Noteholder in respect of the Buy-In and, upon request of the Borrower, evidence of the amount of such loss.  Nothing herein shall limit Noteholder&#8217;s right to pursue any </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Borrower&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of this Note as required pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">vi.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Reservation of Shares Issuable Upon Conversion</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrower covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock a number of shares of Common Stock at least equal to 200% of the Required Minimum (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserve Amount</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the sole purpose of issuance of shares of Common Stock hereunder, as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Noteholder.  The Borrower covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, and nonassessable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">vii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.28pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  No fractional shares or scrip representing fractional shares shall be issued upon the conversion hereof.  As to any fraction of a share to which the Noteholder would otherwise be entitled to purchase upon such conversion, the Borrower shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">viii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.54pt;text-decoration:underline">Transfer Taxes and Expenses</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  The issuance of certificates for shares of the Common Stock on partial or complete conversion hereof shall be made without charge to the Noteholder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that, the Borrower shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Noteholder so converted and the Borrower shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Borrower the amount of such tax or shall have established to the satisfaction of the Borrower that such tax has been paid.  The Borrower shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.9pt;text-decoration:underline">Noteholder&#8217;s Conversion Limitations</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.  Noteholder shall not effect any conversion of any amount due hereunder and shall not have the right to convert any amounts due hereunder, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Noteholder (together with the Noteholder&#8217;s Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Noteholder and its Affiliates shall include the number of shares of Common Stock issuable upon the relevant conversion hereof with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted amounts due hereunder beneficially owned by the Noteholder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Borrower subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, any obligations in favor of any Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) beneficially owned by the Noteholder or any Persons acting as a group together with the Noteholder.  Except as set forth in the preceding sentence, for purposes of this Section (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)and the rules and regulations promulgated thereunder.  To the extent that the limitation contained in this </font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Section (d) applies, the determination of whether the Joint Obligor&#8217;s obligations hereunder are convertible (in relation to other securities owned by the Noteholder together with any Affiliates and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates) and of which obligations hereunder are convertible shall be in the sole discretion of the Noteholder, and the submission of a Notice of Conversion shall be deemed to be the Noteholder&#8217;s determination of whether any of the Joint Obligor&#8217;s obligations hereunder may be converted (in relation to other securities owned by the Noteholder together with any Affiliates, and any Persons acting as a group together with the Noteholder or any of the Noteholder&#8217;s Affiliates, and which amount owing hereunder is convertible, in each case subject to the Beneficial Ownership Limitation.  To ensure compliance with this restriction, the Noteholder will be deemed to represent to the Borrower each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Borrower shall have no obligation to verify or confirm the accuracy of such determination.  In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of this Section (d), in determining the number of outstanding shares of Common Stock, the Noteholder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following&#58; (i) the Borrower&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Borrower, or (iii) a more recent written notice by the Borrower or the Borrower&#8217;s transfer agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request of the Noteholder, the Borrower shall, within two Business Days confirm orally and in writing to the Noteholder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Borrower, including the obligations set forth in the Note, by the Noteholder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported.  The &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon the relevant conversion hereunder.  The Noteholder, upon not less than sixty-one (61) days&#8217; prior notice to the Borrower, may increase or decrease the Beneficial Ownership Limitation provisions of this Section (d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon the relevant conversion hereunder held by the Noteholder and the Beneficial Ownership Limitation provisions of this Section (d) shall continue to apply.  Any such increase or decrease will not be effective until the sixty-first (61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">) calendar day after such notice is delivered to the Borrower.  The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section (d) to correct this paragraph (or any portion hereof) that may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.  The limitations contained in this paragraph shall apply to a successor holder hereof.</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 5</font></div></div></div><div id="i3f26240cbf2940cf8e6793d7da8e2247_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">ANNEX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:133%">NOTICE OF CONVERSION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">The undersigned hereby elects to convert obligations of the Joint Obligors under the Promissory Note, as amended, of ARCA Recycling, Inc. and JanOne Inc. (&#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">JanOne</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;) into shares of common stock (the &#8220;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;) of JanOne according to the conditions hereof, as of the date written below.  If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by JanOne in accordance therewith.  No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">By the delivery of this Notice of Conversion the undersigned represents and warrants to the Companies that its ownership of the Common Stock does not exceed the amounts specified under Section 2(d) of this First Amendment, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Conversion calculations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Date to Effect Conversion&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Amount of obligations to be Converted&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Number of shares of Common Stock to be issued&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Signature&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;     Name&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%">Delivery Instructions&#58;  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">consulting agreement JanOne Jon Isaac.4  </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Conversion Rights Addendum &#91;Annex A&#93;&#160;&#160;&#160;&#160;EXHIBIT B-4&#160;&#160;&#160;&#160;Page 6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex231_consentofhudgenscpap.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if157e6d584504ef8b336d165714e7c94_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 23.1</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-251645) and Form S-8 (Nos. 333-226775 and 333-254873) of our report dated April 8, 2024 relating to the consolidated financial statements of JanOne Inc. which appear in this Annual Report on Form 10-K.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;Hudgens CPA, PLLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Houston, Texas</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 8, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ex232_consentoffd.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i95310aee05d44ef98f4b567dd6dbc5b7_1"></div><div style="min-height:180pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 23.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We hereby consent to the use in this Annual Report on Form 10-K of our report dated April&#160;17, 2023, with respect to the consolidated financial statements of JanOne Inc. as of and for the year ended December&#160;31, 2022.  Our report contained an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Frazier &#38; Deeter, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tampa, Florida</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 8, 2024</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>jan-20231230xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1f8c65967cb24ef6b861534f1d9fa447_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tony Isaac, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 of JanOne Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tony Isaac</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tony Isaac</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President, Chief Executive Officer, and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; April 17, 2023</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:6pt;padding-right:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>jan-20231230xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i455f226a92f44688b6c2d57259a3563b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Virland A. Johnson, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended January December 31, 2022 of JanOne Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Virland A. Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Virland A. Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; April 17, 2023</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:6pt;padding-right:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>jan-20231230xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i282e51a7949b4d87a538ab8cff482e65_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of JanOne Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Tony Isaac, the President and Chief Executive Officer of the Company, to the best of my knowledge and belief, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tony Isaac</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tony Isaac</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President, Chief Executive Officer, and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; April 17, 2023</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report as a separate disclosure document of the Company or the certifying officers.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>jan-20231230xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3c8677110ab74e60aca6c46a6f14013c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of JanOne Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Virland A. Johnson, the Chief Financial Officer (Principal Financial Officer) of the Company, to the best of my knowledge and belief, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Virland A. Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Virland A. Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; April&#160;17, 2023</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report as a separate disclosure document of the Company or the certifying officers.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>jan-20231230.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jan="http://www.live-ventures.com/20231230" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.live-ventures.com/20231230">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jan-20231230_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jan-20231230_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jan-20231230_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jan-20231230_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.live-ventures.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.live-ventures.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentation" roleURI="http://www.live-ventures.com/role/BackgroundandBasisofPresentation">
        <link:definition>0000008 - Disclosure - Background and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersandAcquisitions" roleURI="http://www.live-ventures.com/role/MergersandAcquisitions">
        <link:definition>0000010 - Disclosure - Mergers and Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofRecyclingSubsidiaries" roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries">
        <link:definition>0000011 - Disclosure - Sale of Recycling Subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeoTraq" roleURI="http://www.live-ventures.com/role/GeoTraq">
        <link:definition>0000012 - Disclosure - GeoTraq</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.live-ventures.com/role/DiscontinuedOperations">
        <link:definition>0000013 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherCurrentAssets" roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets">
        <link:definition>0000014 - Disclosure - Prepaids and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesReceivable" roleURI="http://www.live-ventures.com/role/NotesReceivable">
        <link:definition>0000015 - Disclosure - Notes Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.live-ventures.com/role/IntangibleAssets">
        <link:definition>0000016 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.live-ventures.com/role/MarketableSecurities">
        <link:definition>0000017 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepositsandOtherAssets" roleURI="http://www.live-ventures.com/role/DepositsandOtherAssets">
        <link:definition>0000018 - Disclosure - Deposits and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.live-ventures.com/role/AccruedLiabilities">
        <link:definition>0000019 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shorttermdebt" roleURI="http://www.live-ventures.com/role/Shorttermdebt">
        <link:definition>0000020 - Disclosure - Short-term debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesA1ConvertiblePreferredStock" roleURI="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock">
        <link:definition>0000021 - Disclosure - Series A-1 Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesSConvertiblePreferredStock" roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock">
        <link:definition>0000022 - Disclosure - Series S Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.live-ventures.com/role/StockholdersEquity">
        <link:definition>0000023 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.live-ventures.com/role/IncomeTaxes">
        <link:definition>0000024 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.live-ventures.com/role/RelatedParties">
        <link:definition>0000025 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.live-ventures.com/role/CommitmentsandContingencies">
        <link:definition>0000026 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLosspershare" roleURI="http://www.live-ventures.com/role/EarningsLosspershare">
        <link:definition>0000027 - Disclosure - Earnings (Loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.live-ventures.com/role/SegmentInformation">
        <link:definition>0000028 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.live-ventures.com/role/SubsequentEvents">
        <link:definition>0000029 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofRecyclingSubsidiariesTables" roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables">
        <link:definition>9954473 - Disclosure - Sale of Recycling Subsidiaries (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeoTraqTables" roleURI="http://www.live-ventures.com/role/GeoTraqTables">
        <link:definition>9954474 - Disclosure - GeoTraq (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsTables">
        <link:definition>9954475 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherCurrentAssetsTables" roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables">
        <link:definition>9954476 - Disclosure - Prepaids and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.live-ventures.com/role/IntangibleAssetsTables">
        <link:definition>9954477 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.live-ventures.com/role/MarketableSecuritiesTables">
        <link:definition>9954478 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepositsandOtherAssetsTables" roleURI="http://www.live-ventures.com/role/DepositsandOtherAssetsTables">
        <link:definition>9954479 - Disclosure - Deposits and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.live-ventures.com/role/AccruedLiabilitiesTables">
        <link:definition>9954480 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermdebtTables" roleURI="http://www.live-ventures.com/role/ShorttermdebtTables">
        <link:definition>9954481 - Disclosure - Short-term debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesSConvertiblePreferredStockTables" roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables">
        <link:definition>9954482 - Disclosure - Series S Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.live-ventures.com/role/StockholdersEquityTables">
        <link:definition>9954483 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.live-ventures.com/role/IncomeTaxesTables">
        <link:definition>9954484 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLosspershareTables" roleURI="http://www.live-ventures.com/role/EarningsLosspershareTables">
        <link:definition>9954485 - Disclosure - Earnings (Loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.live-ventures.com/role/SegmentInformationTables">
        <link:definition>9954486 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentationDetails" roleURI="http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails">
        <link:definition>9954487 - Disclosure - Background and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails" roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails">
        <link:definition>9954489 - Disclosure - Summary of Significant Accounting Policies - Trade and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersandAcquisitionsDetails" roleURI="http://www.live-ventures.com/role/MergersandAcquisitionsDetails">
        <link:definition>9954490 - Disclosure - Mergers and Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofRecyclingSubsidiariesAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails">
        <link:definition>9954491 - Disclosure - Sale of Recycling Subsidiaries - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails">
        <link:definition>9954492 - Disclosure - Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeoTraqAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - GeoTraq - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeoTraqScheduleofGainonSaleofGeoTraqDetails" roleURI="http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails">
        <link:definition>9954494 - Disclosure - GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails">
        <link:definition>9954495 - Disclosure - Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails">
        <link:definition>9954496 - Disclosure - Discontinued Operations - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>9954497 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofIntangibleAssetsDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails">
        <link:definition>9954498 - Disclosure - Discontinued Operations - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails">
        <link:definition>9954499 - Disclosure - Discontinued Operations - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails">
        <link:definition>9954500 - Disclosure - Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofShorttermDebtDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails">
        <link:definition>9954501 - Disclosure - Discontinued Operations - Schedule of Short-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofLongtermDebtDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails">
        <link:definition>9954502 - Disclosure - Discontinued Operations - Schedule of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofLongtermDebtDetails_1" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1">
        <link:definition>9954502 - Disclosure - Discontinued Operations - Schedule of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofRelatedPartyDebtDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails">
        <link:definition>9954503 - Disclosure - Discontinued Operations - Schedule of Related Party Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails">
        <link:definition>9954504 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails">
        <link:definition>9954505 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherCurrentAssetsDetails" roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails">
        <link:definition>9954506 - Disclosure - Prepaids and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesReceivableDetails" roleURI="http://www.live-ventures.com/role/NotesReceivableDetails">
        <link:definition>9954507 - Disclosure - Notes Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9954508 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>9954509 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofMarketableSecuritiesDetails" roleURI="http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails">
        <link:definition>9954510 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>9954511 - Disclosure - Marketable Securities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails" roleURI="http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails">
        <link:definition>9954512 - Disclosure - Deposits and Other Assets - Schedule of Deposits and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>9954513 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails" roleURI="http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails">
        <link:definition>9954514 - Disclosure - Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermdebtAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails">
        <link:definition>9954515 - Disclosure - Short-term debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesA1ConvertiblePreferredStockDetails" roleURI="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails">
        <link:definition>9954516 - Disclosure - Series A-1 Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesSConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>9954517 - Disclosure - Series S Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails" roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails">
        <link:definition>9954518 - Disclosure - Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>9954519 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionsActivityDetails" roleURI="http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails">
        <link:definition>9954520 - Disclosure - Stockholders' Equity - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails" roleURI="http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails">
        <link:definition>9954521 - Disclosure - Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails" roleURI="http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails">
        <link:definition>9954522 - Disclosure - Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954523 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofBenefitofIncomeTaxesDetails" roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails">
        <link:definition>9954524 - Disclosure - Income Taxes - Schedule of Benefit of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails" roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails">
        <link:definition>9954525 - Disclosure - Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails" roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails">
        <link:definition>9954526 - Disclosure - Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>9954527 - Disclosure - Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesDetails" roleURI="http://www.live-ventures.com/role/RelatedPartiesDetails">
        <link:definition>9954528 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.live-ventures.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954529 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9954530 - Disclosure - Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLosspershareAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails">
        <link:definition>9954531 - Disclosure - Earnings (Loss) per share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9954532 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentInformationDetails" roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails">
        <link:definition>9954533 - Disclosure - Segment Information - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofBalanceSheetInformationDetails" roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails">
        <link:definition>9954534 - Disclosure - Segment Information - Schedule of Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.live-ventures.com/role/SubsequentEventsDetails">
        <link:definition>9954535 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jan_StockConversion1Member" abstract="true" name="StockConversion1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NumberOfTranches" abstract="false" name="NumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_GeoTraqIncMember" abstract="true" name="GeoTraqIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_ConversionOfStockAmountConvertible" abstract="false" name="ConversionOfStockAmountConvertible" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NetConsideration" abstract="false" name="NetConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DispositionTransactionAggregateCost" abstract="false" name="DispositionTransactionAggregateCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DebtRevisedDiscountRate" abstract="false" name="DebtRevisedDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_ConversionOfStockSharesForfeited" abstract="false" name="ConversionOfStockSharesForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" abstract="false" name="SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" abstract="false" name="LossContingencyNumberOfExecutiveOfficersNamedInComplaint" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_FinancingArrangementMember" abstract="true" name="FinancingArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_CommonShareEquivalentsMember" abstract="true" name="CommonShareEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_AuditorAbstract" abstract="true" name="AuditorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_PercentOfPrepaymentTenderRestrictions" abstract="false" name="PercentOfPrepaymentTenderRestrictions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_DisposalOfInventory" abstract="false" name="DisposalOfInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_SkyBridgeAmericasMember" abstract="true" name="SkyBridgeAmericasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_UniversalLifeInsurancePolicyPolicyOneMember" abstract="true" name="UniversalLifeInsurancePolicyPolicyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_VM7CorporationMember" abstract="true" name="VM7CorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_CurrentAssetsCurrentLiabilitiesNet" abstract="false" name="CurrentAssetsCurrentLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_WestervilleSquareMember" abstract="true" name="WestervilleSquareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DispositionTransactionConsiderAmount" abstract="false" name="DispositionTransactionConsiderAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jan_IcgNoteMember" abstract="true" name="IcgNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_TemporaryEquitySharesIssuedDuringPeriodShares" abstract="false" name="TemporaryEquitySharesIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_DisposalGroupConsiderationPaymentPeriodAxis" abstract="true" name="DisposalGroupConsiderationPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jan_AccruedGuaranteesCurrent" abstract="false" name="AccruedGuaranteesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_AmortizationOfRightOfUseAssets" abstract="false" name="AmortizationOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DiscontinuedFinancingActivities" abstract="true" name="DiscontinuedFinancingActivities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_TotalGuaranteedConsideration" abstract="false" name="TotalGuaranteedConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DiscountCharges" abstract="false" name="DiscountCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NotesReceivableTerm" abstract="false" name="NotesReceivableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_NoteReceivableDiscountRate" abstract="false" name="NoteReceivableDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_IsaacConsultingAgreementMember" abstract="true" name="IsaacConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_DisposalOfIntangibleAssets" abstract="false" name="DisposalOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupConsiderationPaymentPeriodDomain" abstract="true" name="DisposalGroupConsiderationPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_SeriesGConvertiblePreferredStockMember" abstract="true" name="SeriesGConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_DiscountRecordedAsOffsetToThePrincipalAmount" abstract="false" name="DiscountRecordedAsOffsetToThePrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" abstract="false" name="OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_ConvertiblePreferredStockSharesIssuableUponConversion" abstract="false" name="ConvertiblePreferredStockSharesIssuableUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationShortTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ProvisionBenefitOfIncomeTaxes" abstract="false" name="ProvisionBenefitOfIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NoteReceivableMaturityDate" abstract="false" name="NoteReceivableMaturityDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_LiveVenturesIncorporatedMember" abstract="true" name="LiveVenturesIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_UniversalLifeInsurancePolicyPolicyTwoMember" abstract="true" name="UniversalLifeInsurancePolicyPolicyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_A2023PlanMember" abstract="true" name="A2023PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_AMTIMCapitalIncMember" abstract="true" name="AMTIMCapitalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_OperatingExpensesFromDiscontinuedOperationsAbstract" abstract="false" name="OperatingExpensesFromDiscontinuedOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_PercentageOfGrossRevenue" abstract="false" name="PercentageOfGrossRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ChargeAgainstIncomeForIncreaseInDiscountRate" abstract="false" name="ChargeAgainstIncomeForIncreaseInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfLeaseLiability" abstract="false" name="DisposalOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelevantMonth2Member" abstract="true" name="RelevantMonth2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" abstract="false" name="NoncashOrPartNoncashDivestitureConsiderationReceivedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_BuildingsAndImprovementsMember" abstract="true" name="BuildingsAndImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SoinIntangiblesMember" abstract="true" name="SoinIntangiblesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_RecyclingSegmentAndTechnologySegmentMember" abstract="true" name="RecyclingSegmentAndTechnologySegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_TotalDisposalOfAssets" abstract="false" name="TotalDisposalOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" abstract="false" name="BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_TechnologySegmentMember" abstract="true" name="TechnologySegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_PreFundedWarrantsMemberMember" abstract="true" name="PreFundedWarrantsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_NoteReceivableStatedInterestRate" abstract="false" name="NoteReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_DisposalOfAccountsPayable" abstract="false" name="DisposalOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_NumberOfAcquiredIntangibleAssets" abstract="false" name="NumberOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" abstract="false" name="SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SalesTaxAssessmentAccruedInterest" abstract="false" name="SalesTaxAssessmentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" abstract="false" name="DisposalOfAccruedLiabilityCaliforniaStateSalesTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_TotalGainOnSale" abstract="false" name="TotalGainOnSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" abstract="false" name="StockIssuedDuringPeriodAdditionalValueAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_TotalConsiderations" abstract="false" name="TotalConsiderations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ClassOfWarrantPricePerShare" abstract="false" name="ClassOfWarrantPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="jan_RelevantMonth3Member" abstract="true" name="RelevantMonth3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_GulfCoastBankAndTrustCreditFacilityMember" abstract="true" name="GulfCoastBankAndTrustCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_PaymentFromBuyer" abstract="false" name="PaymentFromBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementTerm" abstract="false" name="RelatedPartyTransactionConsultingAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_NumberOfInstallment" abstract="false" name="NumberOfInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_AFCOCreditCorporationFinancingAgreementMember" abstract="true" name="AFCOCreditCorporationFinancingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" abstract="false" name="RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jan_StiMergerSubIncMember" abstract="true" name="StiMergerSubIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_FairValueOfStockIssued" abstract="false" name="FairValueOfStockIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_Mr.SullivanMember" abstract="true" name="Mr.SullivanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_OtherAssetsFromDiscontinuedOperations" abstract="false" name="OtherAssetsFromDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" abstract="false" name="RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jan_ARCAAndSubsidiariesMember" abstract="true" name="ARCAAndSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_JanOneMember" abstract="true" name="JanOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" abstract="false" name="FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NoteReceivableFaceAmount" abstract="false" name="NoteReceivableFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ConversionOfStockCommencementPeriod" abstract="false" name="ConversionOfStockCommencementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_DrSoinMember" abstract="true" name="DrSoinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_ARCARecyclingPurchasingAgreementMember" abstract="true" name="ARCARecyclingPurchasingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DiscontinuedOperatingActivities" abstract="true" name="DiscontinuedOperatingActivities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" abstract="false" name="PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_TotalDisposalOfLiability" abstract="false" name="TotalDisposalOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" abstract="false" name="RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementSharesIssued" abstract="false" name="RelatedPartyTransactionConsultingAgreementSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_DisposalOfAccruedLiability" abstract="false" name="DisposalOfAccruedLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" abstract="false" name="IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_AgreedPrepaymentAmount" abstract="false" name="AgreedPrepaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DiscontinuedInvestingActivities" abstract="true" name="DiscontinuedInvestingActivities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_CommonStockPurchasePricePerShare" abstract="false" name="CommonStockPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="jan_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_Plan2011Member" abstract="true" name="Plan2011Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" abstract="false" name="BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_CommonStockSharesOutstandingPercentage" abstract="false" name="CommonStockSharesOutstandingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DeferredTaxAssetsInterest" abstract="false" name="DeferredTaxAssetsInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_Mr.JonIsaacMember" abstract="true" name="Mr.JonIsaacMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" abstract="false" name="RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfDebt" abstract="false" name="DisposalOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_SpyrTechnologiesIncMember" abstract="true" name="SpyrTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_AlixpartnersLlcMember" abstract="true" name="AlixpartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SeriesA1Member" abstract="true" name="SeriesA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_OtherIncomeExpenseFromDiscontinuedOperations" abstract="true" name="OtherIncomeExpenseFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_KlcFinancialMember" abstract="true" name="KlcFinancialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_RelatedPartyTransactionPurchaseAgreementTerm" abstract="false" name="RelatedPartyTransactionPurchaseAgreementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_Plan2016Member" abstract="true" name="Plan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DispositionDiscountRate" abstract="false" name="DispositionDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" abstract="false" name="RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DispositionTransactionTermPeriod" abstract="false" name="DispositionTransactionTermPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_AdditionalAmountChargedAgainstIncome" abstract="false" name="AdditionalAmountChargedAgainstIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DeferredTaxLiabilitiesInstallmentSale" abstract="false" name="DeferredTaxLiabilitiesInstallmentSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_ArcaMember" abstract="true" name="ArcaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_AgreedSettlementValue" abstract="false" name="AgreedSettlementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DepositsAndOtherAssetsNoncurrent" abstract="false" name="DepositsAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NumberOfTradingDaysBeforeBoardApproval" abstract="false" name="NumberOfTradingDaysBeforeBoardApproval" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightWarrantsOrRightsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_DisposalOfAccountsReceivable" abstract="false" name="DisposalOfAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_IsaacCapitalGroupLLCICGMember" abstract="true" name="IsaacCapitalGroupLLCICGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" abstract="false" name="PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" abstract="false" name="DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NumberOfAgreementsToBePurchased" abstract="false" name="NumberOfAgreementsToBePurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelevantMonth1Member" abstract="true" name="RelevantMonth1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_RevisedDiscountAmount" abstract="false" name="RevisedDiscountAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfPropertyPlantAndEquipment" abstract="false" name="DisposalOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" abstract="false" name="RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_AFCOCreditCorpMember" abstract="true" name="AFCOCreditCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_ArticlesOfIncorporationMember" abstract="true" name="ArticlesOfIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_RecyclingMember" abstract="true" name="RecyclingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_AdditionalAwardsToBeGranted" abstract="false" name="AdditionalAwardsToBeGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_MarketableSecuritiesSharesOutstanding" abstract="false" name="MarketableSecuritiesSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_GainLossOnWriteOffOfNotesReceivable" abstract="false" name="GainLossOnWriteOffOfNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_StockConversion3Member" abstract="true" name="StockConversion3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_GainsOnReversalOfContingencyLoss" abstract="false" name="GainsOnReversalOfContingencyLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_NoncashRecognitionOfNewLeases" abstract="false" name="NoncashRecognitionOfNewLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_PotentialMarketExclusivityPeriod" abstract="false" name="PotentialMarketExclusivityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_GulfCoastBankAndTrustCompanyMember" abstract="true" name="GulfCoastBankAndTrustCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_OperatingLeasesFutureMinimumPaymentsDue1" abstract="false" name="OperatingLeasesFutureMinimumPaymentsDue1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_AccruedIncentiveAndRebateChecksCurrent" abstract="false" name="AccruedIncentiveAndRebateChecksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_GainOnSaleNetOfCash" abstract="false" name="GainOnSaleNetOfCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_BiotechnologyMember" abstract="true" name="BiotechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_ContinuingOperationsAndDiscontinuedOperationsMember" abstract="true" name="ContinuingOperationsAndDiscontinuedOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" abstract="false" name="OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" abstract="false" name="RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="jan_PatentsAndDomainsMember" abstract="true" name="PatentsAndDomainsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_NoteReceivableRevisedDiscountRate" abstract="false" name="NoteReceivableRevisedDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:tokenItemType"/>
  <xs:element id="jan_ConversionOfStockPeriodFollowingClosing" abstract="false" name="ConversionOfStockPeriodFollowingClosing" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jan_StockConversion2Member" abstract="true" name="StockConversion2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_TrusteesMain270LlcMember" abstract="true" name="TrusteesMain270LlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_ApplianceSmartIncMember" abstract="true" name="ApplianceSmartIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SeriesSMember" abstract="true" name="SeriesSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_Section174Expenses" abstract="false" name="Section174Expenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfOtherAssets" abstract="false" name="DisposalOfOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_SoinTherapeuticsLLCMember" abstract="true" name="SoinTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SeriesSConvertiblePreferredStockMember" abstract="true" name="SeriesSConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_SeriesA1ConvertiblePreferredStockMember" abstract="true" name="SeriesA1ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jan_StatutoryInterestReceivable" abstract="false" name="StatutoryInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DebtDiscountRate" abstract="false" name="DebtDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jan_GainLossOnLitigationSettlement" abstract="false" name="GainLossOnLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_DisposalOfRightOfUseAssets" abstract="false" name="DisposalOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jan_CashDisposal" abstract="false" name="CashDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>jan-20231230_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_54a984fb-5892-48e2-91c3-c9299d03a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:to="loc_us-gaap_PreferredStockValue_54a984fb-5892-48e2-91c3-c9299d03a8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9cdfda68-6f8e-45f8-9ff7-b459156db260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:to="loc_us-gaap_CommonStockValue_9cdfda68-6f8e-45f8-9ff7-b459156db260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4b05f58-3310-4882-96fa-34475e12d655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4b05f58-3310-4882-96fa-34475e12d655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11dbad6c-766b-49cb-b795-9fd38f9f5702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11dbad6c-766b-49cb-b795-9fd38f9f5702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_550a696c-f83d-4811-8e25-62a2eb28a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a77f71d-d6e5-4ccf-b174-5b94801f7ea3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_550a696c-f83d-4811-8e25-62a2eb28a93a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6f5bdcb-66b3-4b9f-9742-8e96514ed60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e53b6303-c896-4e83-9f48-6aee6d712707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6f5bdcb-66b3-4b9f-9742-8e96514ed60c" xlink:to="loc_us-gaap_Liabilities_e53b6303-c896-4e83-9f48-6aee6d712707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_622fedbd-26e8-4ef3-b70d-d31bf26b9039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6f5bdcb-66b3-4b9f-9742-8e96514ed60c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_622fedbd-26e8-4ef3-b70d-d31bf26b9039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a5ec93b-872e-4a6f-aad9-2b99a05e4ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6f5bdcb-66b3-4b9f-9742-8e96514ed60c" xlink:to="loc_us-gaap_StockholdersEquity_4a5ec93b-872e-4a6f-aad9-2b99a05e4ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28938659-3455-440c-b63e-b2ef5f8b9de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6f5bdcb-66b3-4b9f-9742-8e96514ed60c" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28938659-3455-440c-b63e-b2ef5f8b9de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f618f48f-fa36-4084-99ff-924c00d4711a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_70bfeb73-1eec-47ff-94dc-d48705ff594f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f618f48f-fa36-4084-99ff-924c00d4711a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_70bfeb73-1eec-47ff-94dc-d48705ff594f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_dfc483c8-a9e8-4d0d-967d-4d27726a4a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f618f48f-fa36-4084-99ff-924c00d4711a" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_dfc483c8-a9e8-4d0d-967d-4d27726a4a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6f29f5e7-1489-490f-ae0e-b0083efaa216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f618f48f-fa36-4084-99ff-924c00d4711a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6f29f5e7-1489-490f-ae0e-b0083efaa216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4e2813bc-6013-4ed5-9a4b-a9e28d090940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f618f48f-fa36-4084-99ff-924c00d4711a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4e2813bc-6013-4ed5-9a4b-a9e28d090940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_96a3edc6-0fb0-4a7a-b152-3094a03a6fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_96a3edc6-0fb0-4a7a-b152-3094a03a6fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_918fa5b4-73c8-4683-b5d3-acc59384d9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_918fa5b4-73c8-4683-b5d3-acc59384d9f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent_b60e83dd-d41d-4288-b1e7-dce328cd672e" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_jan_DepositsAndOtherAssetsNoncurrent_b60e83dd-d41d-4288-b1e7-dce328cd672e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherAssetsFromDiscontinuedOperations_0d990b2a-8e83-4c82-aa98-73334af1ab0d" xlink:href="jan-20231230.xsd#jan_OtherAssetsFromDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_jan_OtherAssetsFromDiscontinuedOperations_0d990b2a-8e83-4c82-aa98-73334af1ab0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_27c54572-182c-43b6-b3b4-a11694c79946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_us-gaap_AssetsCurrent_27c54572-182c-43b6-b3b4-a11694c79946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_68b79aa3-0b79-4d24-8320-5f22f2ad4652" xlink:href="jan-20231230.xsd#jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_68b79aa3-0b79-4d24-8320-5f22f2ad4652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_19ab4909-85dc-425d-bc31-cae4c38680db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_de967a7e-01e6-4a71-8a6e-5e2ac2b78a45" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_19ab4909-85dc-425d-bc31-cae4c38680db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e6101e70-3930-48ef-95da-1231013a0bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e6101e70-3930-48ef-95da-1231013a0bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f9515418-a551-4af4-b74f-975b90bed3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f9515418-a551-4af4-b74f-975b90bed3f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_68f57b5a-2c73-40ad-9f44-c9aa5ac7f1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:to="loc_us-gaap_LiabilitiesCurrent_68f57b5a-2c73-40ad-9f44-c9aa5ac7f1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_290dead6-1955-4df7-b93a-64797295fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_290dead6-1955-4df7-b93a-64797295fdcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8b71103b-a6bc-4385-8d0c-36de12eee1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c62554cc-44b2-4dea-b011-b01c54ff3abd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8b71103b-a6bc-4385-8d0c-36de12eee1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a8b181db-6064-4b7a-bd9c-cb8390ef5a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fb8e0b34-ed0b-44ad-90a7-c2a57fdec524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8b181db-6064-4b7a-bd9c-cb8390ef5a28" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fb8e0b34-ed0b-44ad-90a7-c2a57fdec524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7537faf4-c8aa-4350-b2e5-3c880545b948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8b181db-6064-4b7a-bd9c-cb8390ef5a28" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7537faf4-c8aa-4350-b2e5-3c880545b948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4ae89458-8840-4e6c-96a5-9f596daf36a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8b181db-6064-4b7a-bd9c-cb8390ef5a28" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4ae89458-8840-4e6c-96a5-9f596daf36a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f1803d74-7cc1-4c90-a050-c027dc598d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8b181db-6064-4b7a-bd9c-cb8390ef5a28" xlink:to="loc_us-gaap_AccountsPayableCurrent_f1803d74-7cc1-4c90-a050-c027dc598d6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5bf78f20-56c9-4ff0-8e91-3b34925e7026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_02bc4ee1-c47c-476e-8f7f-5c3ed8974b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5bf78f20-56c9-4ff0-8e91-3b34925e7026" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_02bc4ee1-c47c-476e-8f7f-5c3ed8974b06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_a718fd8d-e648-41a1-9853-b49cdbf20bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5bf78f20-56c9-4ff0-8e91-3b34925e7026" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_a718fd8d-e648-41a1-9853-b49cdbf20bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_46d5bccf-2344-4dce-bbfe-0d24cd748219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4454e138-d06d-47ed-961f-705d03a147b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_46d5bccf-2344-4dce-bbfe-0d24cd748219" xlink:to="loc_us-gaap_NetIncomeLoss_4454e138-d06d-47ed-961f-705d03a147b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d14d636b-af33-4870-86ab-a511ee3e8d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_46d5bccf-2344-4dce-bbfe-0d24cd748219" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d14d636b-af33-4870-86ab-a511ee3e8d6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5a7e2b83-bc70-421b-98eb-6e3fcdccc530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_5a7e2b83-bc70-421b-98eb-6e3fcdccc530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_49ff9e9a-40cc-4e6c-9bab-0580ff3c12b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_49ff9e9a-40cc-4e6c-9bab-0580ff3c12b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainsOnReversalOfContingencyLoss_e8c31239-accf-4e72-a671-6c07ae30690d" xlink:href="jan-20231230.xsd#jan_GainsOnReversalOfContingencyLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:to="loc_jan_GainsOnReversalOfContingencyLoss_e8c31239-accf-4e72-a671-6c07ae30690d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_580c89f3-456e-4336-847f-40c27dfe51b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_580c89f3-456e-4336-847f-40c27dfe51b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67819df5-e4fa-456b-aadb-6bbd6d2ab4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f4417f9-4658-416a-b31b-c7e16834f927" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67819df5-e4fa-456b-aadb-6bbd6d2ab4cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_d1baaf55-bb96-46b8-9aa0-a52bd5b1a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd3e03bf-ee77-417a-b3f0-b39f7a95adba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_d1baaf55-bb96-46b8-9aa0-a52bd5b1a71a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd3e03bf-ee77-417a-b3f0-b39f7a95adba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2291269d-9872-4beb-9551-b2ccd27cb3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_d1baaf55-bb96-46b8-9aa0-a52bd5b1a71a" xlink:to="loc_us-gaap_CostOfRevenue_2291269d-9872-4beb-9551-b2ccd27cb3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3d4c6a65-96e3-4c33-8de9-2f97d5e7d117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_badc99b0-5910-485b-825d-6528a2d781a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3d4c6a65-96e3-4c33-8de9-2f97d5e7d117" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_badc99b0-5910-485b-825d-6528a2d781a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_dd6b498e-a851-4f6c-9850-73310ba1e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3d4c6a65-96e3-4c33-8de9-2f97d5e7d117" xlink:to="loc_us-gaap_AssetImpairmentCharges_dd6b498e-a851-4f6c-9850-73310ba1e76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ea59d496-ef09-47d4-909f-3d913af1e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9efc32e0-70b2-40a0-b562-5a8ecf654162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ea59d496-ef09-47d4-909f-3d913af1e9db" xlink:to="loc_us-gaap_GrossProfit_9efc32e0-70b2-40a0-b562-5a8ecf654162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aaa18f9a-b125-4458-a9c3-ef0254b187f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ea59d496-ef09-47d4-909f-3d913af1e9db" xlink:to="loc_us-gaap_OperatingExpenses_aaa18f9a-b125-4458-a9c3-ef0254b187f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_6aeec799-b8ec-4dcb-9124-5b1853711807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8bbd50c7-b21b-4aff-aa55-8974874665a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_6aeec799-b8ec-4dcb-9124-5b1853711807" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8bbd50c7-b21b-4aff-aa55-8974874665a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_db573839-3757-4e19-8eb1-fb92e9f8d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_6aeec799-b8ec-4dcb-9124-5b1853711807" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_db573839-3757-4e19-8eb1-fb92e9f8d46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e78980ca-fe3a-476e-8fbc-b7692bc2696b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4fc668bc-f86a-44ef-9027-b2356ed19174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e78980ca-fe3a-476e-8fbc-b7692bc2696b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4fc668bc-f86a-44ef-9027-b2356ed19174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c9ec59da-7f84-4a6c-9d12-96d70a2f9d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e78980ca-fe3a-476e-8fbc-b7692bc2696b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c9ec59da-7f84-4a6c-9d12-96d70a2f9d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3318f31f-2aed-4d72-8216-2a18e7109458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f6c3041-aaaf-4983-b67a-b0e50966b726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3318f31f-2aed-4d72-8216-2a18e7109458" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f6c3041-aaaf-4983-b67a-b0e50966b726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc2dbb0-0b5d-40f3-8bd2-642d8fcb1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3366449-346f-4f2f-a011-17af0d8657b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc2dbb0-0b5d-40f3-8bd2-642d8fcb1dbd" xlink:to="loc_us-gaap_OperatingIncomeLoss_f3366449-346f-4f2f-a011-17af0d8657b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_48c8de6a-4f2a-4d52-a2dc-6f853f21b686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc2dbb0-0b5d-40f3-8bd2-642d8fcb1dbd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_48c8de6a-4f2a-4d52-a2dc-6f853f21b686" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a2d93d8f-e92c-4018-9a42-d73d1b843c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a2d93d8f-e92c-4018-9a42-d73d1b843c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d3490995-586a-4615-b42b-37c28bf3c531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d3490995-586a-4615-b42b-37c28bf3c531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_97177881-5f77-4803-87cb-1c7fa4956e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_97177881-5f77-4803-87cb-1c7fa4956e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_01ce5308-1450-4506-ae25-97957c8508c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_01ce5308-1450-4506-ae25-97957c8508c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ece4f84-8b40-4b06-adf7-a17514e6da42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ece4f84-8b40-4b06-adf7-a17514e6da42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_17fb4aa4-8fe9-4e6f-bb79-c8ebefbd6d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_ShareBasedCompensation_17fb4aa4-8fe9-4e6f-bb79-c8ebefbd6d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_94627e3c-dab1-4b77-a4c8-e4657b629c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_94627e3c-dab1-4b77-a4c8-e4657b629c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_747fc7fb-8de5-4845-91d0-89f5d803a327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_747fc7fb-8de5-4845-91d0-89f5d803a327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_e78d6f6f-057f-4684-8f69-15870160f886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_e78d6f6f-057f-4684-8f69-15870160f886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8762c0a1-d498-4b5d-8ef8-0ffc47eabf73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8762c0a1-d498-4b5d-8ef8-0ffc47eabf73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7a438e35-21c3-48d7-b374-4a9d29f2c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7a438e35-21c3-48d7-b374-4a9d29f2c43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_a20eabee-f640-47e8-b918-0c311b016b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_a20eabee-f640-47e8-b918-0c311b016b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_9b5c3741-bb69-4d32-8fbd-f17688f5a9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_9b5c3741-bb69-4d32-8fbd-f17688f5a9af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_80241302-1855-41f3-a9ba-ce76d70c4313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_80241302-1855-41f3-a9ba-ce76d70c4313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnWriteOffOfNotesReceivable_1970aae3-ecb1-4f7f-930d-d2cba98587da" xlink:href="jan-20231230.xsd#jan_GainLossOnWriteOffOfNotesReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5b3eea6-353f-436a-8080-5495c4e3fed9" xlink:to="loc_jan_GainLossOnWriteOffOfNotesReceivable_1970aae3-ecb1-4f7f-930d-d2cba98587da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04643a73-11cc-4be3-ad23-87402b841305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9b96890e-c6e0-4fad-ae50-8181b95885d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04643a73-11cc-4be3-ad23-87402b841305" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9b96890e-c6e0-4fad-ae50-8181b95885d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f57a621-f2b7-4d1f-9a1d-71bce0180c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04643a73-11cc-4be3-ad23-87402b841305" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f57a621-f2b7-4d1f-9a1d-71bce0180c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c825406c-3a0c-4818-9690-54a49679cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04643a73-11cc-4be3-ad23-87402b841305" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c825406c-3a0c-4818-9690-54a49679cfbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_973ec2a0-7c88-4d08-a110-00f40dabbd55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04643a73-11cc-4be3-ad23-87402b841305" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_973ec2a0-7c88-4d08-a110-00f40dabbd55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f42359a3-882d-4601-adde-5f9c14e0e702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_df68286f-d928-4672-86fd-15d3badd30b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f42359a3-882d-4601-adde-5f9c14e0e702" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_df68286f-d928-4672-86fd-15d3badd30b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0cb83977-10d8-4046-9b11-ab70782e2545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f42359a3-882d-4601-adde-5f9c14e0e702" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0cb83977-10d8-4046-9b11-ab70782e2545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a863a23-551b-479e-b1ff-e53cbdae9389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_1313ea5c-da93-4730-aee3-fcf8b4191376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a863a23-551b-479e-b1ff-e53cbdae9389" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_1313ea5c-da93-4730-aee3-fcf8b4191376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62d8d8d1-3129-4eb1-8b9a-e1301b07060e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_573d636f-36b2-4c89-abd1-a3249226aff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62d8d8d1-3129-4eb1-8b9a-e1301b07060e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_573d636f-36b2-4c89-abd1-a3249226aff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38e11b9c-39e6-403c-a7ec-964a55120309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62d8d8d1-3129-4eb1-8b9a-e1301b07060e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38e11b9c-39e6-403c-a7ec-964a55120309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_875700cb-97f8-4309-9501-e65df440da7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62d8d8d1-3129-4eb1-8b9a-e1301b07060e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_875700cb-97f8-4309-9501-e65df440da7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a0eae5b-132e-4837-a36f-11c0c7e51fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62d8d8d1-3129-4eb1-8b9a-e1301b07060e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a0eae5b-132e-4837-a36f-11c0c7e51fb5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalConsiderations_b7b6d087-cf86-42fb-b14d-a6ff6f13c578" xlink:href="jan-20231230.xsd#jan_TotalConsiderations"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NetConsideration_3ea47087-7414-4b42-9bde-7c54c9dc9bdf" xlink:href="jan-20231230.xsd#jan_NetConsideration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalConsiderations_b7b6d087-cf86-42fb-b14d-a6ff6f13c578" xlink:to="loc_jan_NetConsideration_3ea47087-7414-4b42-9bde-7c54c9dc9bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfLiability_236ef494-669f-4244-a7cd-30b8951cfe1c" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalConsiderations_b7b6d087-cf86-42fb-b14d-a6ff6f13c578" xlink:to="loc_jan_TotalDisposalOfLiability_236ef494-669f-4244-a7cd-30b8951cfe1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CashDisposal_00d12bf4-86bc-4e9c-a44f-991070c3bd29" xlink:href="jan-20231230.xsd#jan_CashDisposal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_CashDisposal_00d12bf4-86bc-4e9c-a44f-991070c3bd29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsReceivable_dd31c0c9-1b4a-4665-91b4-73d19cac2703" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfAccountsReceivable_dd31c0c9-1b4a-4665-91b4-73d19cac2703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfInventory_9c6d4315-e9ca-4cd7-bc1e-433ba3c75da5" xlink:href="jan-20231230.xsd#jan_DisposalOfInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfInventory_9c6d4315-e9ca-4cd7-bc1e-433ba3c75da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfRightOfUseAssets_c74edf8d-4e2b-4568-9230-9f1fcc76b853" xlink:href="jan-20231230.xsd#jan_DisposalOfRightOfUseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfRightOfUseAssets_c74edf8d-4e2b-4568-9230-9f1fcc76b853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfOtherAssets_d32f8f82-03ea-490f-b27b-29f6052880c3" xlink:href="jan-20231230.xsd#jan_DisposalOfOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfOtherAssets_d32f8f82-03ea-490f-b27b-29f6052880c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfPropertyPlantAndEquipment_d9b29cab-b423-4207-8a08-19764cf951bd" xlink:href="jan-20231230.xsd#jan_DisposalOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfPropertyPlantAndEquipment_d9b29cab-b423-4207-8a08-19764cf951bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfIntangibleAssets_557e0853-9dfb-4d50-8167-b59931a4db30" xlink:href="jan-20231230.xsd#jan_DisposalOfIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfAssets_d4267aca-1b65-4ab8-ae7d-dda5f303a185" xlink:to="loc_jan_DisposalOfIntangibleAssets_557e0853-9dfb-4d50-8167-b59931a4db30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NetConsideration_b1998c03-eb23-484f-9403-a662d1b9e00f" xlink:href="jan-20231230.xsd#jan_NetConsideration"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGuaranteedConsideration_55c26fb1-1d59-4c75-9156-9ef89e07a416" xlink:href="jan-20231230.xsd#jan_TotalGuaranteedConsideration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_NetConsideration_b1998c03-eb23-484f-9403-a662d1b9e00f" xlink:to="loc_jan_TotalGuaranteedConsideration_55c26fb1-1d59-4c75-9156-9ef89e07a416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PaymentFromBuyer_bcde4e7d-766c-4041-98c3-abe6cedbc1ac" xlink:href="jan-20231230.xsd#jan_PaymentFromBuyer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_NetConsideration_b1998c03-eb23-484f-9403-a662d1b9e00f" xlink:to="loc_jan_PaymentFromBuyer_bcde4e7d-766c-4041-98c3-abe6cedbc1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93f99bc2-91f8-4286-a5d4-f5e7661effce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93f99bc2-91f8-4286-a5d4-f5e7661effce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfDebt_171cb248-f7f2-49b4-91f5-dce69a06258a" xlink:href="jan-20231230.xsd#jan_DisposalOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_jan_DisposalOfDebt_171cb248-f7f2-49b4-91f5-dce69a06258a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfLeaseLiability_7915fd6b-53c1-4d71-b9cf-6a751b71eb4a" xlink:href="jan-20231230.xsd#jan_DisposalOfLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_jan_DisposalOfLeaseLiability_7915fd6b-53c1-4d71-b9cf-6a751b71eb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_f64e0e8a-6133-4af5-aa6b-567a923b1b4d" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_f64e0e8a-6133-4af5-aa6b-567a923b1b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiability_f77421d2-0bbc-459f-b301-b515a845de21" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_jan_DisposalOfAccruedLiability_f77421d2-0bbc-459f-b301-b515a845de21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsPayable_5e3ed3c7-a3db-492f-b2d8-1a4b90983430" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalDisposalOfLiability_19c02651-2073-4b96-bd01-4cc52c84d762" xlink:to="loc_jan_DisposalOfAccountsPayable_5e3ed3c7-a3db-492f-b2d8-1a4b90983430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGainOnSale_c056186c-e49f-4a31-a1c7-7204fe3a8ed3" xlink:href="jan-20231230.xsd#jan_TotalGainOnSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalConsiderations_be4b6a98-7d0d-414e-bf9a-97ed13e50f2d" xlink:href="jan-20231230.xsd#jan_TotalConsiderations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalGainOnSale_c056186c-e49f-4a31-a1c7-7204fe3a8ed3" xlink:to="loc_jan_TotalConsiderations_be4b6a98-7d0d-414e-bf9a-97ed13e50f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfAssets_6f753b05-4bcf-47a3-b7df-0bcb1de122d5" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_TotalGainOnSale_c056186c-e49f-4a31-a1c7-7204fe3a8ed3" xlink:to="loc_jan_TotalDisposalOfAssets_6f753b05-4bcf-47a3-b7df-0bcb1de122d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_525d9ad2-3703-4c93-9af3-06a5d88ded90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_d142b665-7452-4c2b-9138-e363d271be02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_525d9ad2-3703-4c93-9af3-06a5d88ded90" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_d142b665-7452-4c2b-9138-e363d271be02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_e59fbd12-3225-4535-b74c-6837fb693e48" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_525d9ad2-3703-4c93-9af3-06a5d88ded90" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_e59fbd12-3225-4535-b74c-6837fb693e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_94bcf7b4-a959-4509-ab98-51d502705b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_525d9ad2-3703-4c93-9af3-06a5d88ded90" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_94bcf7b4-a959-4509-ab98-51d502705b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_c4a059cb-5743-4d03-a356-62cfe58e221a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_525d9ad2-3703-4c93-9af3-06a5d88ded90" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_c4a059cb-5743-4d03-a356-62cfe58e221a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_f0b0da88-d398-492c-8a30-fbcda52060bc" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_f0b0da88-d398-492c-8a30-fbcda52060bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_c54aad46-4830-42b7-82b0-694658e1e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_c54aad46-4830-42b7-82b0-694658e1e8b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_5178cd2e-2a13-415a-8827-a1fdf138ee6f" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_5178cd2e-2a13-415a-8827-a1fdf138ee6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_c7124aa2-72d1-41b5-867a-0fe90c08adf9" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_c7124aa2-72d1-41b5-867a-0fe90c08adf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_b1a9dfb8-9af7-4609-875d-f7358b77125e" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_b1a9dfb8-9af7-4609-875d-f7358b77125e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_d0c56921-1b39-4cea-8d58-278667ef8632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_d0c56921-1b39-4cea-8d58-278667ef8632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_434dbd99-f85d-4e42-bc9c-8e9e951c0399" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_fd847bfa-8af9-4e29-b909-8955e097f737" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_434dbd99-f85d-4e42-bc9c-8e9e951c0399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_95ea5309-4805-4754-a9a3-c1756ba73b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_47d9ea4f-9588-4345-b143-ce729f296fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_95ea5309-4805-4754-a9a3-c1756ba73b5a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_47d9ea4f-9588-4345-b143-ce729f296fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_aeea34f1-85b0-43ff-a497-897ee7c51e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_95ea5309-4805-4754-a9a3-c1756ba73b5a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_aeea34f1-85b0-43ff-a497-897ee7c51e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_374b5cdb-7461-448a-88a4-6707cc308399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_95ea5309-4805-4754-a9a3-c1756ba73b5a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_374b5cdb-7461-448a-88a4-6707cc308399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_512c7ecc-54d9-4ecd-970d-b488833daa00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_95ea5309-4805-4754-a9a3-c1756ba73b5a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_512c7ecc-54d9-4ecd-970d-b488833daa00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd675bdc-9945-4dcd-a3ba-b234f64e83b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9e16a75e-fc1a-41a8-adf5-90909e206666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd675bdc-9945-4dcd-a3ba-b234f64e83b1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9e16a75e-fc1a-41a8-adf5-90909e206666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4fba4006-bfbb-49ba-89ac-7e8d1d673e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd675bdc-9945-4dcd-a3ba-b234f64e83b1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4fba4006-bfbb-49ba-89ac-7e8d1d673e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_7f026de4-d896-4a76-a6a3-0512098ae864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_4c704de4-65c4-45e6-8b4a-6a4ae44a7151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_7f026de4-d896-4a76-a6a3-0512098ae864" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_4c704de4-65c4-45e6-8b4a-6a4ae44a7151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3ccdb2b4-630b-42c9-97cb-eb917132a42a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_7f026de4-d896-4a76-a6a3-0512098ae864" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3ccdb2b4-630b-42c9-97cb-eb917132a42a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_42919b22-18e4-443e-91a2-ca58d4191562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_0d962c03-5d8f-4278-9ba9-371cdb00b93b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_42919b22-18e4-443e-91a2-ca58d4191562" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_0d962c03-5d8f-4278-9ba9-371cdb00b93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_4dce6870-f9d7-401c-8273-730e7b0cf3de" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_42919b22-18e4-443e-91a2-ca58d4191562" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_4dce6870-f9d7-401c-8273-730e7b0cf3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_e9cc8e89-ea02-4704-9de4-8b086abe58a1" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_42919b22-18e4-443e-91a2-ca58d4191562" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_e9cc8e89-ea02-4704-9de4-8b086abe58a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3d555f3c-3448-49d3-89d6-56e64bdf37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_47dc947e-ebfe-4a8b-bda2-10e94b863289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3d555f3c-3448-49d3-89d6-56e64bdf37e2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_47dc947e-ebfe-4a8b-bda2-10e94b863289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_29658a06-36f2-4cc4-ae88-e9e9d66abfce" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3d555f3c-3448-49d3-89d6-56e64bdf37e2" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_29658a06-36f2-4cc4-ae88-e9e9d66abfce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_b1132576-b3de-423c-a8f7-9e73080b8613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c5b81055-7a92-491a-8302-4a6e3f73400a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_b1132576-b3de-423c-a8f7-9e73080b8613" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c5b81055-7a92-491a-8302-4a6e3f73400a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_03a3bd71-28ff-47e1-be7e-74a1380aa801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_b1132576-b3de-423c-a8f7-9e73080b8613" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_03a3bd71-28ff-47e1-be7e-74a1380aa801" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_93e23a76-1342-4c31-b4c2-52f54cda505c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_93e23a76-1342-4c31-b4c2-52f54cda505c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f3eaa781-3bd9-453b-ad89-68ca7b2f2d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f3eaa781-3bd9-453b-ad89-68ca7b2f2d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedIncentiveAndRebateChecksCurrent_0be10e2e-46c5-44fa-9f45-f525ccd2d431" xlink:href="jan-20231230.xsd#jan_AccruedIncentiveAndRebateChecksCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:to="loc_jan_AccruedIncentiveAndRebateChecksCurrent_0be10e2e-46c5-44fa-9f45-f525ccd2d431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ac64cb24-ac05-4f30-880d-f164855c2a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ac64cb24-ac05-4f30-880d-f164855c2a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a35ffe49-58c3-4a08-9e9f-197a8748cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4cd53bb3-2a4f-4268-a081-b870e856e7bf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a35ffe49-58c3-4a08-9e9f-197a8748cf26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_16390f23-f203-4c47-a469-a99d7959a967" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_5568d3c1-5edc-4d0b-a1f9-b091e59e926a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_16390f23-f203-4c47-a469-a99d7959a967" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_5568d3c1-5edc-4d0b-a1f9-b091e59e926a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest_56a114fa-5523-4d44-b6ef-79abd37e99a7" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_16390f23-f203-4c47-a469-a99d7959a967" xlink:to="loc_jan_SalesTaxAssessmentAccruedInterest_56a114fa-5523-4d44-b6ef-79abd37e99a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofShorttermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_7fb097cf-8f98-4959-a71f-f7063028acc7" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_dc8e15bd-e6de-471a-b15a-ac81bace0a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_7fb097cf-8f98-4959-a71f-f7063028acc7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_dc8e15bd-e6de-471a-b15a-ac81bace0a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_50abfbbb-74d7-4f73-a07b-2b79641ae832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_7fb097cf-8f98-4959-a71f-f7063028acc7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_50abfbbb-74d7-4f73-a07b-2b79641ae832" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_84cbf79f-1e65-4609-b4f2-a4afe2a7c90d" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0651654a-9c31-42c5-bf98-9a3aab62cac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_84cbf79f-1e65-4609-b4f2-a4afe2a7c90d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0651654a-9c31-42c5-bf98-9a3aab62cac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_411449ab-d78f-4a85-969a-79a71b01354b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_84cbf79f-1e65-4609-b4f2-a4afe2a7c90d" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_411449ab-d78f-4a85-969a-79a71b01354b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofLongtermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_a0712468-e33f-4e67-9b10-486a281d0d63" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_a8770213-8f4a-42d4-8cf2-bb522dd0a0c5" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_a0712468-e33f-4e67-9b10-486a281d0d63" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_a8770213-8f4a-42d4-8cf2-bb522dd0a0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_db955361-c673-4636-aa45-691b2ee0c35f" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_a0712468-e33f-4e67-9b10-486a281d0d63" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_db955361-c673-4636-aa45-691b2ee0c35f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4bd194f1-88a4-45e4-95a9-f1a42179268c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_70268692-ae0c-4b6e-9919-011fe6a818f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4bd194f1-88a4-45e4-95a9-f1a42179268c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_70268692-ae0c-4b6e-9919-011fe6a818f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53b91759-00f4-415a-864a-69470c3a166f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4bd194f1-88a4-45e4-95a9-f1a42179268c" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53b91759-00f4-415a-864a-69470c3a166f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_92551941-b223-4405-9bbf-deff801724c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_ad82ee59-8906-4591-96b1-845e4f023511" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_92551941-b223-4405-9bbf-deff801724c7" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_ad82ee59-8906-4591-96b1-845e4f023511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1d47f165-5da9-4710-922a-d7524497c12d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_92551941-b223-4405-9bbf-deff801724c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1d47f165-5da9-4710-922a-d7524497c12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_7bc9e18e-e244-49e9-991e-83c576f84bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_118b0911-655b-42ee-ac9f-2c708813225a" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_7bc9e18e-e244-49e9-991e-83c576f84bd9" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_118b0911-655b-42ee-ac9f-2c708813225a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_ee474222-7b26-4474-8697-16faab0dd31a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_7bc9e18e-e244-49e9-991e-83c576f84bd9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_ee474222-7b26-4474-8697-16faab0dd31a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_c11f458f-3518-4f7c-bbcc-267c29f0d808" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_6f5a4167-6409-47a8-a27b-0d8c31277c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_c11f458f-3518-4f7c-bbcc-267c29f0d808" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_6f5a4167-6409-47a8-a27b-0d8c31277c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_ddcb0e0c-3882-4e62-99d3-2fc76f60bc6b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_c11f458f-3518-4f7c-bbcc-267c29f0d808" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_ddcb0e0c-3882-4e62-99d3-2fc76f60bc6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_ecec6bf9-87f2-4b4b-afd0-f832cc290aab" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_c11f458f-3518-4f7c-bbcc-267c29f0d808" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_ecec6bf9-87f2-4b4b-afd0-f832cc290aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_51bd893e-a3e2-4f10-8821-015bcd605c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8f3c44a-f1e4-4e57-9977-fb80fa3b41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_51bd893e-a3e2-4f10-8821-015bcd605c1f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8f3c44a-f1e4-4e57-9977-fb80fa3b41f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_bb76712f-fc9f-4b50-bb45-f7ea8fe3cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_51bd893e-a3e2-4f10-8821-015bcd605c1f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_bb76712f-fc9f-4b50-bb45-f7ea8fe3cf2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_cc27110f-33e0-4caa-a25b-bb17e8c0547f" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_ebbd90bb-b42a-4e54-948a-270414f23d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_cc27110f-33e0-4caa-a25b-bb17e8c0547f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_ebbd90bb-b42a-4e54-948a-270414f23d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_5aba85bc-be6b-4cfc-bda9-b8d1691d6ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_cc27110f-33e0-4caa-a25b-bb17e8c0547f" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_5aba85bc-be6b-4cfc-bda9-b8d1691d6ae8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e4ba137e-5ff6-4f72-9cd4-a36224b448e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f6fe1350-ac30-4a0c-8715-579162ea7d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e4ba137e-5ff6-4f72-9cd4-a36224b448e2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f6fe1350-ac30-4a0c-8715-579162ea7d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea5bae2d-69c5-4050-b4eb-74c68f4b5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e4ba137e-5ff6-4f72-9cd4-a36224b448e2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea5bae2d-69c5-4050-b4eb-74c68f4b5e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_d8cb6a3a-841a-4b25-a701-e6fc9b24a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_62332060-3d8d-4d43-9f42-4a002140c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_d8cb6a3a-841a-4b25-a701-e6fc9b24a50a" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_62332060-3d8d-4d43-9f42-4a002140c7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_734a457f-064d-422c-a81b-b2649c56436d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_d8cb6a3a-841a-4b25-a701-e6fc9b24a50a" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_734a457f-064d-422c-a81b-b2649c56436d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_e2c53e87-88df-4317-a646-47f1ed0e4935" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_d8cb6a3a-841a-4b25-a701-e6fc9b24a50a" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_e2c53e87-88df-4317-a646-47f1ed0e4935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bb6be25c-5320-46d0-b6b4-1289ff730a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bb6be25c-5320-46d0-b6b4-1289ff730a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnLitigationSettlement_5ce17738-6ea8-45dc-9bf3-46edc4993dfd" xlink:href="jan-20231230.xsd#jan_GainLossOnLitigationSettlement"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_jan_GainLossOnLitigationSettlement_5ce17738-6ea8-45dc-9bf3-46edc4993dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_f5faa54a-d63d-493d-8f6a-bb18da369a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_f5faa54a-d63d-493d-8f6a-bb18da369a51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8a46f228-4d42-4fe4-912c-ecfe61b07881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8a46f228-4d42-4fe4-912c-ecfe61b07881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ca244e74-4b87-4414-878e-f9c8c8612ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ca244e74-4b87-4414-878e-f9c8c8612ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3a3634a9-cea6-4bfd-892c-237b001ad875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3a3634a9-cea6-4bfd-892c-237b001ad875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AmortizationOfRightOfUseAssets_3f4512f3-d4a0-451e-8488-ab219ec38dbb" xlink:href="jan-20231230.xsd#jan_AmortizationOfRightOfUseAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_jan_AmortizationOfRightOfUseAssets_3f4512f3-d4a0-451e-8488-ab219ec38dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1aebe112-0f22-4d11-874a-eaf55a807610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1aebe112-0f22-4d11-874a-eaf55a807610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ae3985ce-a729-4e17-ad9c-3717b4b774e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ae3985ce-a729-4e17-ad9c-3717b4b774e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f3d61a7-b49c-405a-bd4a-096de1f48cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f3d61a7-b49c-405a-bd4a-096de1f48cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainOnSaleNetOfCash_215a7c4e-01dd-4cc0-8dcd-368b7d1020d5" xlink:href="jan-20231230.xsd#jan_GainOnSaleNetOfCash"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_jan_GainOnSaleNetOfCash_215a7c4e-01dd-4cc0-8dcd-368b7d1020d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_712dc7ff-beb7-4269-9c80-d01368b96f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bdf32c7a-562c-40f2-a203-0d657b11b048" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_712dc7ff-beb7-4269-9c80-d01368b96f6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#PrepaidsandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_64497dee-96a4-43a5-9794-d71f00457f33" xlink:href="jan-20231230.xsd#jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_8f6c94b2-3f34-4c3d-8102-cf7e9df72b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_64497dee-96a4-43a5-9794-d71f00457f33" xlink:to="loc_us-gaap_PrepaidInsurance_8f6c94b2-3f34-4c3d-8102-cf7e9df72b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_b4ebc194-a70d-4524-ac65-194d88d5dced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_64497dee-96a4-43a5-9794-d71f00457f33" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_b4ebc194-a70d-4524-ac65-194d88d5dced" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5238c9c7-0e98-4cae-a753-63d89fd7ea40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e35bca2c-a7aa-42a9-b93a-e8e201329c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5238c9c7-0e98-4cae-a753-63d89fd7ea40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e35bca2c-a7aa-42a9-b93a-e8e201329c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da44831-3261-4d1a-a52c-559ed771ac89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5238c9c7-0e98-4cae-a753-63d89fd7ea40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da44831-3261-4d1a-a52c-559ed771ac89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6cdc3f50-2047-47af-8045-e53acacc3135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6cdc3f50-2047-47af-8045-e53acacc3135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedGuaranteesCurrent_4edce73f-d18f-42d9-9f8d-d146ce85e543" xlink:href="jan-20231230.xsd#jan_AccruedGuaranteesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:to="loc_jan_AccruedGuaranteesCurrent_4edce73f-d18f-42d9-9f8d-d146ce85e543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_7bc46c71-d31c-4baa-8366-c178911597f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:to="loc_us-gaap_LitigationReserveCurrent_7bc46c71-d31c-4baa-8366-c178911597f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7b526d84-6cca-4d11-94ef-299f178b52fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7b526d84-6cca-4d11-94ef-299f178b52fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_b604058f-baef-44eb-b8ae-38ff0310929b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad523faf-4211-4eca-bb8a-9ffd11158af7" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_b604058f-baef-44eb-b8ae-38ff0310929b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_ProvisionBenefitOfIncomeTaxes_67284848-27ee-4000-8a41-6ec875bbe2fa" xlink:href="jan-20231230.xsd#jan_ProvisionBenefitOfIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0b8df05b-4e2d-4dcf-905f-8ef7279b54dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_ProvisionBenefitOfIncomeTaxes_67284848-27ee-4000-8a41-6ec875bbe2fa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0b8df05b-4e2d-4dcf-905f-8ef7279b54dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ee8ab295-1347-4645-b994-6f9813d7c3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_ProvisionBenefitOfIncomeTaxes_67284848-27ee-4000-8a41-6ec875bbe2fa" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ee8ab295-1347-4645-b994-6f9813d7c3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1747e3a-d51b-433f-9e2d-b2f0fda7c834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_23591c0f-341c-426d-b6d9-f622f103b7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1747e3a-d51b-433f-9e2d-b2f0fda7c834" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_23591c0f-341c-426d-b6d9-f622f103b7fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c4554d4e-e6aa-4620-afad-16fb452883e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1747e3a-d51b-433f-9e2d-b2f0fda7c834" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c4554d4e-e6aa-4620-afad-16fb452883e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cde32a5b-8f44-4c0a-87de-ee66fb4a3413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cde32a5b-8f44-4c0a-87de-ee66fb4a3413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_42879466-ed41-489f-80e8-5a9e7c76e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_42879466-ed41-489f-80e8-5a9e7c76e9b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e3f8d407-d488-4dae-95b8-306f5e2e8c0d" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e3f8d407-d488-4dae-95b8-306f5e2e8c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70aefb42-44e7-4d98-90df-62fb28fa629d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70aefb42-44e7-4d98-90df-62fb28fa629d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_5f5d2320-80f5-4a98-94c3-8aa2791cc807" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_5f5d2320-80f5-4a98-94c3-8aa2791cc807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5f767267-db0f-4578-b5b2-57efdc9b9f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5f767267-db0f-4578-b5b2-57efdc9b9f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3042fdb8-590c-4f5c-95cf-f034ae878328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3042fdb8-590c-4f5c-95cf-f034ae878328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_352084f6-1ce1-4cc2-a216-0cb9b8f7006a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_352084f6-1ce1-4cc2-a216-0cb9b8f7006a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0118abeb-c059-4153-b9c3-f4e5543575d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7bc0fee-f68e-40e5-a21e-d7e3e3292865" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0118abeb-c059-4153-b9c3-f4e5543575d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_1eff2cf8-6819-41f6-92c8-3c7de4fbd46c" xlink:href="jan-20231230.xsd#jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4895621d-5db2-441e-9554-78979a40d269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_1eff2cf8-6819-41f6-92c8-3c7de4fbd46c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4895621d-5db2-441e-9554-78979a40d269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c4d00f5f-f31e-4791-b023-4935bdb32e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_1eff2cf8-6819-41f6-92c8-3c7de4fbd46c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c4d00f5f-f31e-4791-b023-4935bdb32e37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_efc72d42-f570-4e2b-afc3-9a25d972f533" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_07b5d16d-60ca-45e5-ab2e-0e80ae1f1c63" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_efc72d42-f570-4e2b-afc3-9a25d972f533" xlink:to="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_07b5d16d-60ca-45e5-ab2e-0e80ae1f1c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8fc9d1fa-ef49-42bd-8fe9-8bc2163b3d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_efc72d42-f570-4e2b-afc3-9a25d972f533" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8fc9d1fa-ef49-42bd-8fe9-8bc2163b3d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_fa6f75cb-fe90-4580-bf62-ef1365c473d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_fa6f75cb-fe90-4580-bf62-ef1365c473d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8095ce53-2cf9-48c5-a448-ab15b36eb446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8095ce53-2cf9-48c5-a448-ab15b36eb446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_3cf2fa56-818a-4ccf-a218-c83c64ff0057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_3cf2fa56-818a-4ccf-a218-c83c64ff0057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b4b44621-7ad4-4ed3-ac7e-475651c8310e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b4b44621-7ad4-4ed3-ac7e-475651c8310e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLeaseLiability_20ec2219-f8ed-4eee-8398-c6d5672ad8d0" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_jan_DeferredTaxAssetsLeaseLiability_20ec2219-f8ed-4eee-8398-c6d5672ad8d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9b816f9a-4f6a-41c7-8e5d-c61c77ecc234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9b816f9a-4f6a-41c7-8e5d-c61c77ecc234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_813c18b6-a180-4a70-8b9e-0a273155e66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_813c18b6-a180-4a70-8b9e-0a273155e66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4eaf8be3-ff34-4ebf-a056-b82a4e5feaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4eaf8be3-ff34-4ebf-a056-b82a4e5feaa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_414473f5-2745-4068-93fa-3797a808894d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_414473f5-2745-4068-93fa-3797a808894d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_a4dc3e29-4105-43b9-aed9-c8a478defef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_a4dc3e29-4105-43b9-aed9-c8a478defef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsInterest_528457f9-1cbe-481d-b7da-84a11f6220c1" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsInterest"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_jan_DeferredTaxAssetsInterest_528457f9-1cbe-481d-b7da-84a11f6220c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxLiabilitiesInstallmentSale_054aa210-8779-416f-adfa-fe5214bd5ed5" xlink:href="jan-20231230.xsd#jan_DeferredTaxLiabilitiesInstallmentSale"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_jan_DeferredTaxLiabilitiesInstallmentSale_054aa210-8779-416f-adfa-fe5214bd5ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Section174Expenses_a4074106-ead7-40ee-a0b4-471ca19eaae4" xlink:href="jan-20231230.xsd#jan_Section174Expenses"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_2a3fe444-4134-45ea-8050-0420c1b09ea4" xlink:to="loc_jan_Section174Expenses_a4074106-ead7-40ee-a0b4-471ca19eaae4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>jan-20231230_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:to="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c8618523-90aa-43bc-8969-300e452345c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:to="loc_us-gaap_ClassOfStockDomain_c8618523-90aa-43bc-8969-300e452345c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:to="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSMember_202c2a9d-a305-479c-ac5b-f032a6edea18" xlink:href="jan-20231230.xsd#jan_SeriesSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:to="loc_jan_SeriesSMember_202c2a9d-a305-479c-ac5b-f032a6edea18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1Member_8edaa471-d97c-4372-9de7-5fcf5354e0c3" xlink:href="jan-20231230.xsd#jan_SeriesA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:to="loc_jan_SeriesA1Member_8edaa471-d97c-4372-9de7-5fcf5354e0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_606d1fce-9136-43ed-b021-eff65e807552_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:to="loc_us-gaap_RelatedPartyDomain_606d1fce-9136-43ed-b021-eff65e807552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:to="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3d78734f-15d9-4e15-9563-fdf91bf33476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:to="loc_us-gaap_RelatedPartyMember_3d78734f-15d9-4e15-9563-fdf91bf33476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:to="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e11d1bd5-d946-4940-8c23-d6ecdd90b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e11d1bd5-d946-4940-8c23-d6ecdd90b3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7534ecd9-24c4-4445-bbd3-ab5382d2340d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7534ecd9-24c4-4445-bbd3-ab5382d2340d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9b49f9a-d417-49f3-9951-93fb2b2e1e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9b49f9a-d417-49f3-9951-93fb2b2e1e37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_969a306c-e839-4206-b274-5c06064d2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_969a306c-e839-4206-b274-5c06064d2ec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_104aaf86-030e-440d-ba4e-b5106ff04fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AssetsCurrent_104aaf86-030e-440d-ba4e-b5106ff04fef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_dee1ddf0-4bf1-44ce-a38b-ada360df73f5" xlink:href="jan-20231230.xsd#jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_dee1ddf0-4bf1-44ce-a38b-ada360df73f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_04286d55-06bf-4c9d-89fb-aed4bb85536c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_04286d55-06bf-4c9d-89fb-aed4bb85536c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_191612ad-fbf0-476d-ac73-a9c7858b18cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_191612ad-fbf0-476d-ac73-a9c7858b18cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ed74188a-cc52-4fe3-99c7-74232f3c39df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ed74188a-cc52-4fe3-99c7-74232f3c39df" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent_f9be761b-3f37-40f0-be8c-9201cb899682" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_DepositsAndOtherAssetsNoncurrent_f9be761b-3f37-40f0-be8c-9201cb899682" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherAssetsFromDiscontinuedOperations_ef947ecd-73f4-4edd-8d89-9b5ebda4bbf3" xlink:href="jan-20231230.xsd#jan_OtherAssetsFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_OtherAssetsFromDiscontinuedOperations_ef947ecd-73f4-4edd-8d89-9b5ebda4bbf3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ec1b57ab-023b-4b82-8a14-4c5480ce92fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_Assets_ec1b57ab-023b-4b82-8a14-4c5480ce92fd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a608df5d-81fc-48f4-afcd-9ab5a0fcdc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_AccountsPayableCurrent_a608df5d-81fc-48f4-afcd-9ab5a0fcdc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_42737087-7d33-4f83-a49a-b212859f9549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_42737087-7d33-4f83-a49a-b212859f9549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ec07fcf0-3e92-4d17-aa02-f4e182c7b363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ec07fcf0-3e92-4d17-aa02-f4e182c7b363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ebaebe0-513f-4c1d-98d2-1ec9ce6279d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ebaebe0-513f-4c1d-98d2-1ec9ce6279d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b69bd8a-ae18-4082-a104-40b67fe24d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b69bd8a-ae18-4082-a104-40b67fe24d9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad7e24f3-ee92-4a72-82b0-843612dff2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad7e24f3-ee92-4a72-82b0-843612dff2d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_affa3f2f-44b3-443d-91f0-c574d0f93b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_affa3f2f-44b3-443d-91f0-c574d0f93b6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f3961761-d761-4714-af68-5d21b816b566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f3961761-d761-4714-af68-5d21b816b566" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ba259fb0-53df-4cb8-b033-115a0c97441f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ba259fb0-53df-4cb8-b033-115a0c97441f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2457895-b70f-4cdd-8d11-9991ae620eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_Liabilities_d2457895-b70f-4cdd-8d11-9991ae620eff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_651227d1-86d0-4b44-9aa9-94ac54751d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_651227d1-86d0-4b44-9aa9-94ac54751d24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:href="jan-20231230.xsd#jan_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8293b3ed-3d2a-477d-a210-0e85bc4b18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8293b3ed-3d2a-477d-a210-0e85bc4b18bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_59d97489-8fbe-4f60-bc81-f92f81187f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_PreferredStockValue_59d97489-8fbe-4f60-bc81-f92f81187f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e1bf7a5-cceb-471a-b2aa-679fb8756b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_CommonStockValue_9e1bf7a5-cceb-471a-b2aa-679fb8756b5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_856c7f0c-72eb-41b7-98a3-af4a05805209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_856c7f0c-72eb-41b7-98a3-af4a05805209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df180856-e49a-4e87-8d4d-cbbe1c21cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df180856-e49a-4e87-8d4d-cbbe1c21cf26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1cf7241-92c7-431c-944b-3e8e97827be8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1cf7241-92c7-431c-944b-3e8e97827be8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b756cc7f-bbc8-41de-ba1d-9bedc38760e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_StockholdersEquity_b756cc7f-bbc8-41de-ba1d-9bedc38760e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e7298dde-6d1a-44ae-b15a-5895ff9332fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e7298dde-6d1a-44ae-b15a-5895ff9332fd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7bdf56e9-4435-456f-8c41-87c2b7713377_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:to="loc_us-gaap_ClassOfStockDomain_7bdf56e9-4435-456f-8c41-87c2b7713377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:to="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSMember_e1ba7a07-823f-4562-b2ac-c61195612510" xlink:href="jan-20231230.xsd#jan_SeriesSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:to="loc_jan_SeriesSMember_e1ba7a07-823f-4562-b2ac-c61195612510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1Member_1f35c600-cc07-4125-bf03-beae837aabe7" xlink:href="jan-20231230.xsd#jan_SeriesA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:to="loc_jan_SeriesA1Member_1f35c600-cc07-4125-bf03-beae837aabe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_52bf93c6-46d2-40aa-a159-8216000ed417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_52bf93c6-46d2-40aa-a159-8216000ed417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_0181b745-b9b5-44be-9410-76b5b444ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_0181b745-b9b5-44be-9410-76b5b444ea5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_3d833662-f60b-45fe-b450-e27c5ff74397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_3d833662-f60b-45fe-b450-e27c5ff74397" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ddc8a45c-d78c-48cb-90c0-5cdfb7bc8c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ddc8a45c-d78c-48cb-90c0-5cdfb7bc8c87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5093e92d-50fb-43e8-aba5-675ce81bdbac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5093e92d-50fb-43e8-aba5-675ce81bdbac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_761cc067-ca3e-427d-b052-abe7df8a0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_761cc067-ca3e-427d-b052-abe7df8a0f39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_94e386fb-db4f-4fda-9e20-92eb8d4a01ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesIssued_94e386fb-db4f-4fda-9e20-92eb8d4a01ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0c0a4524-dd1d-441c-b99c-f1377ac4d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0c0a4524-dd1d-441c-b99c-f1377ac4d9f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eee40e7f-397f-4454-bd12-0e4c97971c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eee40e7f-397f-4454-bd12-0e4c97971c70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dab3a4fb-041b-4e80-a4c6-214618d40a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dab3a4fb-041b-4e80-a4c6-214618d40a94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f324a70d-ab9a-48c8-ba35-824d5981917b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesIssued_f324a70d-ab9a-48c8-ba35-824d5981917b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54c1dce6-54f5-43d5-a7cf-2bb633878333" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54c1dce6-54f5-43d5-a7cf-2bb633878333" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:to="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc14f456-cc8e-448b-8ce4-94cb18e94feb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:to="loc_us-gaap_EquityComponentDomain_bc14f456-cc8e-448b-8ce4-94cb18e94feb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:to="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_65584030-88ec-4db9-acab-f370c45e167b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_PreferredStockMember_65584030-88ec-4db9-acab-f370c45e167b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ab791d6-0784-43f2-9dec-e0034ab7c676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_CommonStockMember_2ab791d6-0784-43f2-9dec-e0034ab7c676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fb6ddd5d-5b4f-4842-9617-47862bd12360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fb6ddd5d-5b4f-4842-9617-47862bd12360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e89bce94-2ad1-4e74-b90d-710b6553d597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_RetainedEarningsMember_e89bce94-2ad1-4e74-b90d-710b6553d597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c455d565-f19d-4183-a582-68c7e76f5837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c455d565-f19d-4183-a582-68c7e76f5837" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_def91418-3bd0-4935-a1e2-432fc18449e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_def91418-3bd0-4935-a1e2-432fc18449e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5186f4b5-1fe8-42ba-9520-bfce639a4b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockholdersEquity_5186f4b5-1fe8-42ba-9520-bfce639a4b38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_94391702-a85a-45fe-a133-e69f9763562f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_94391702-a85a-45fe-a133-e69f9763562f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_1a331500-2fa8-41db-a9c4-87396c79fdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_1a331500-2fa8-41db-a9c4-87396c79fdd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa720aa1-7b73-41c8-bc2f-a64e19ba2224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa720aa1-7b73-41c8-bc2f-a64e19ba2224" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_df2d116b-98e4-4d7c-b033-04912af15e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_df2d116b-98e4-4d7c-b033-04912af15e19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f3c8eb8-4408-45e1-89eb-5e69712aa7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f3c8eb8-4408-45e1-89eb-5e69712aa7f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_02d5dc97-e963-4f8f-b9e3-2ed109accca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_02d5dc97-e963-4f8f-b9e3-2ed109accca9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_86cd80c4-108d-4e09-acf5-faf84844218a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_86cd80c4-108d-4e09-acf5-faf84844218a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_42e8746e-5d6b-4cbe-8105-14f9e4e5b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_42e8746e-5d6b-4cbe-8105-14f9e4e5b42c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised_f046431d-3eb7-43e9-947a-e48aaf193887" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised_f046431d-3eb7-43e9-947a-e48aaf193887" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised_b6853bcb-4641-466a-a3f7-2d15d2ce415a" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised_b6853bcb-4641-466a-a3f7-2d15d2ce415a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f65bdbf8-62bd-4760-91c7-79df693f49cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_ProfitLoss_f65bdbf8-62bd-4760-91c7-79df693f49cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ae5071eb-8b4f-4cc0-94c2-25f57778bf38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ba5d93c1-8adb-4df7-b4cf-b11adb105103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c98681ff-2868-4b5b-b0df-a1bfcb09fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#BackgroundandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a48e95fe-7628-4ad1-b0e0-2011c857aa86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a48e95fe-7628-4ad1-b0e0-2011c857aa86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AssetPurchaseAgreementMember_604397d6-e80d-499d-a4ec-16e9d540938b" xlink:href="jan-20231230.xsd#jan_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:to="loc_jan_AssetPurchaseAgreementMember_604397d6-e80d-499d-a4ec-16e9d540938b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f5c2497-de17-4301-a28f-1a0ce86595cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f5c2497-de17-4301-a28f-1a0ce86595cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_a0bd83b7-0c30-4858-ad55-b70f084113a1" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:to="loc_jan_SpyrTechnologiesIncMember_a0bd83b7-0c30-4858-ad55-b70f084113a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_8a02d26b-9b0d-4f40-98a0-29ad99a8c742" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:to="loc_jan_GeoTraqIncMember_8a02d26b-9b0d-4f40-98a0-29ad99a8c742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_85683f41-5749-4668-8dcf-d6af1d4bb77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_NumberOfOperatingSegments_85683f41-5749-4668-8dcf-d6af1d4bb77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PotentialMarketExclusivityPeriod_a039ea07-7a4c-49dc-ade7-016cabc6def2" xlink:href="jan-20231230.xsd#jan_PotentialMarketExclusivityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_PotentialMarketExclusivityPeriod_a039ea07-7a4c-49dc-ade7-016cabc6def2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f7f97481-b32a-497e-88dd-5f6020ab06b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f7f97481-b32a-497e-88dd-5f6020ab06b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68ee9ce4-85ca-4175-93c8-e3d7eb90bb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68ee9ce4-85ca-4175-93c8-e3d7eb90bb24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cfd1564-62e1-4f55-af23-5d9449f8bf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cfd1564-62e1-4f55-af23-5d9449f8bf2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_bee84875-8c5f-4a9a-b01d-33b7ecdbe509" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_NotesReceivableTerm_bee84875-8c5f-4a9a-b01d-33b7ecdbe509" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_d2170683-ce1c-42bb-9ec5-b02d6a55dbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_d2170683-ce1c-42bb-9ec5-b02d6a55dbe8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_2d97fd02-fa0e-4546-a743-38d7f2994d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_2d97fd02-fa0e-4546-a743-38d7f2994d83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_11570962-3ab2-4828-81f8-8a946864c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_11570962-3ab2-4828-81f8-8a946864c47d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5f434d5-cd23-4c0e-875d-0d55a37f7e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_AssetsCurrent_c5f434d5-cd23-4c0e-875d-0d55a37f7e3b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d76d8266-42e8-4bdf-83a7-7a86b8baae7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_LiabilitiesCurrent_d76d8266-42e8-4bdf-83a7-7a86b8baae7b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CurrentAssetsCurrentLiabilitiesNet_c25ca654-67df-48e1-8a7a-af5f3219ab83" xlink:href="jan-20231230.xsd#jan_CurrentAssetsCurrentLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_CurrentAssetsCurrentLiabilitiesNet_c25ca654-67df-48e1-8a7a-af5f3219ab83" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_fdbdf555-4e68-41a6-afff-c20df9fb3fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_fdbdf555-4e68-41a6-afff-c20df9fb3fd3" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:to="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_862e50be-d426-4ffc-9369-5f9eb38e9dfc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:to="loc_srt_RangeMember_862e50be-d426-4ffc-9369-5f9eb38e9dfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:to="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc52a088-d507-4095-a801-6437c8dd9a18" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:to="loc_srt_MinimumMember_bc52a088-d507-4095-a801-6437c8dd9a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b6a3d5f-311b-4e1a-8f91-29163573bb88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:to="loc_srt_MaximumMember_2b6a3d5f-311b-4e1a-8f91-29163573bb88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3e05fd7-dfd6-4645-ba07-3895d0257160_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3e05fd7-dfd6-4645-ba07-3895d0257160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_9ab62778-08fb-4165-b22b-7d5ac1b89c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_9ab62778-08fb-4165-b22b-7d5ac1b89c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_4ba973fe-ba9b-4688-bb9c-f2bf418cfdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_4ba973fe-ba9b-4688-bb9c-f2bf418cfdf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a2b98b60-980f-45e3-9881-478a8e3af573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a2b98b60-980f-45e3-9881-478a8e3af573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8b29ba8b-307d-4c46-9882-4c7ad0f6f67c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8b29ba8b-307d-4c46-9882-4c7ad0f6f67c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_4be8a1c5-4fd7-4cc1-b1c0-37f1c00261c5" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_jan_SoinIntangiblesMember_4be8a1c5-4fd7-4cc1-b1c0-37f1c00261c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d85195ea-49d8-4640-8c1e-0a64cf15b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d85195ea-49d8-4640-8c1e-0a64cf15b32e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_004713cd-674d-42fe-ad4c-96e1f3b3c24d" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_004713cd-674d-42fe-ad4c-96e1f3b3c24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3394a253-2c10-4b01-8d80-476bb45a0c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3394a253-2c10-4b01-8d80-476bb45a0c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e32d148f-8dd8-4143-af77-c6f2b5f6bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_NumberOfReportableSegments_e32d148f-8dd8-4143-af77-c6f2b5f6bfc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_0804c9f6-388a-48ba-a065-ca9f8bf3980b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_0804c9f6-388a-48ba-a065-ca9f8bf3980b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_412cf0f8-840f-4f17-8774-8fd1902c27c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_412cf0f8-840f-4f17-8774-8fd1902c27c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_825d9122-0418-4966-bdda-963d3bba0fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_825d9122-0418-4966-bdda-963d3bba0fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_cfc4ae6b-db35-4050-ad39-0cb820dfc751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_cfc4ae6b-db35-4050-ad39-0cb820dfc751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_85555b0f-f372-43d8-b895-cf2581f44880" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_85555b0f-f372-43d8-b895-cf2581f44880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_768de2b9-2c85-4caf-890e-2340728b9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_768de2b9-2c85-4caf-890e-2340728b9aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_532b75cb-61aa-474e-bf5d-d05c5bc2dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_532b75cb-61aa-474e-bf5d-d05c5bc2dd22" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MergersandAcquisitionsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MergersandAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/MergersandAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a87d92b-95e1-4737-8995-d0ed6fd3d948_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a87d92b-95e1-4737-8995-d0ed6fd3d948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_26b0bab4-295a-48ee-91d6-798208a47290" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:to="loc_jan_SoinTherapeuticsLLCMember_26b0bab4-295a-48ee-91d6-798208a47290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6753fdbd-34be-4bce-b6ca-5d9a688272c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6753fdbd-34be-4bce-b6ca-5d9a688272c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StiMergerSubIncMember_7ba95c65-75b5-4938-94ad-769983d84ad0" xlink:href="jan-20231230.xsd#jan_StiMergerSubIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:to="loc_jan_StiMergerSubIncMember_7ba95c65-75b5-4938-94ad-769983d84ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b183f000-ebe7-466e-8db0-23de9903ff78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:to="loc_us-gaap_ClassOfStockDomain_b183f000-ebe7-466e-8db0-23de9903ff78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:to="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_0b081c2d-54cc-4851-8247-0b429490ab0f" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_0b081c2d-54cc-4851-8247-0b429490ab0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_f2adcaa2-3f57-4174-b036-eaffee032e37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_f2adcaa2-3f57-4174-b036-eaffee032e37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion1Member_4d81d75c-9298-4269-90c8-814bfb7eaed7" xlink:href="jan-20231230.xsd#jan_StockConversion1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion1Member_4d81d75c-9298-4269-90c8-814bfb7eaed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion2Member_b8970bc2-4ea8-4bf3-a94f-6463603eb3fa" xlink:href="jan-20231230.xsd#jan_StockConversion2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion2Member_b8970bc2-4ea8-4bf3-a94f-6463603eb3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion3Member_fc7735dd-b7bb-4255-a9d4-5acc2cf7106b" xlink:href="jan-20231230.xsd#jan_StockConversion3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion3Member_fc7735dd-b7bb-4255-a9d4-5acc2cf7106b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c00b3a5-a495-4643-bfd8-b7d148fe335d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c00b3a5-a495-4643-bfd8-b7d148fe335d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DrSoinMember_41738f73-8adf-4cd8-977f-b1dab3df2c15" xlink:href="jan-20231230.xsd#jan_DrSoinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:to="loc_jan_DrSoinMember_41738f73-8adf-4cd8-977f-b1dab3df2c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9ad4d4d9-9ca3-4e9d-adcf-849810005a54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:to="loc_us-gaap_RelatedPartyDomain_9ad4d4d9-9ca3-4e9d-adcf-849810005a54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:to="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_29b60827-2566-41fc-8b5c-9f2aa7881d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:to="loc_us-gaap_RelatedPartyMember_29b60827-2566-41fc-8b5c-9f2aa7881d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3e49f35-e807-4394-b47f-7d09ae37f3d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3e49f35-e807-4394-b47f-7d09ae37f3d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_16c02478-9468-43f3-b87a-9eca8415f01e" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:to="loc_jan_SoinIntangiblesMember_16c02478-9468-43f3-b87a-9eca8415f01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2fc8d4f0-2922-4038-b3fd-ee51af9d18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2fc8d4f0-2922-4038-b3fd-ee51af9d18bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_83b0eaa0-e81c-488d-a6b5-a5999b32f193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_83b0eaa0-e81c-488d-a6b5-a5999b32f193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_52fd68b1-2421-4488-82e3-f5dc78c1978b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_52fd68b1-2421-4488-82e3-f5dc78c1978b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb224408-95ae-4008-9a85-4bf4f4f2f842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb224408-95ae-4008-9a85-4bf4f4f2f842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_b82bd6a9-eafd-425b-8d51-0cf64e9c10fd" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodAdditionalValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_b82bd6a9-eafd-425b-8d51-0cf64e9c10fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4f514e6e-7e8d-4498-9e77-1257d67bacca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4f514e6e-7e8d-4498-9e77-1257d67bacca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockSharesOutstandingPercentage_72616db1-fb1f-4120-9922-648a6889da7e" xlink:href="jan-20231230.xsd#jan_CommonStockSharesOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_CommonStockSharesOutstandingPercentage_72616db1-fb1f-4120-9922-648a6889da7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_3f03e856-f00b-4e86-82e8-1577d3dab196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_3f03e856-f00b-4e86-82e8-1577d3dab196" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockCommencementPeriod_0a465dbd-1217-4cee-9ac4-96364205a046" xlink:href="jan-20231230.xsd#jan_ConversionOfStockCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_ConversionOfStockCommencementPeriod_0a465dbd-1217-4cee-9ac4-96364205a046" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockPeriodFollowingClosing_1904fce8-230a-46b0-96e2-ca351cdc6df6" xlink:href="jan-20231230.xsd#jan_ConversionOfStockPeriodFollowingClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_ConversionOfStockPeriodFollowingClosing_1904fce8-230a-46b0-96e2-ca351cdc6df6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7cbf70de-e407-47d3-8f9a-314c6464f947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_Goodwill_7cbf70de-e407-47d3-8f9a-314c6464f947" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FairValueOfStockIssued_c3f7fada-c705-4dd5-a645-8234c16ddbe0" xlink:href="jan-20231230.xsd#jan_FairValueOfStockIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_FairValueOfStockIssued_c3f7fada-c705-4dd5-a645-8234c16ddbe0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_a5e9be26-d52e-4bfb-b4ac-f0b5a91acdc2" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_a5e9be26-d52e-4bfb-b4ac-f0b5a91acdc2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cccbe3a9-439e-4856-aa65-83b490843cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cccbe3a9-439e-4856-aa65-83b490843cc6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3ccdce5e-d476-4433-ad80-f8c4311c4d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3ccdce5e-d476-4433-ad80-f8c4311c4d37" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03dbe1a0-dbd9-4854-8671-165e0045421c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03dbe1a0-dbd9-4854-8671-165e0045421c" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bf01142e-604f-4725-af41-4e8b2862b9b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bf01142e-604f-4725-af41-4e8b2862b9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2ccf3fab-dce6-42db-b6c5-1a1692b45106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2ccf3fab-dce6-42db-b6c5-1a1692b45106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_527c0507-2eb5-4976-88c9-eb35f88a204a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_527c0507-2eb5-4976-88c9-eb35f88a204a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCreditFacilityMember_84a2d64a-0fca-46e4-95ef-af9774897eed" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:to="loc_jan_GulfCoastBankAndTrustCreditFacilityMember_84a2d64a-0fca-46e4-95ef-af9774897eed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_20280df7-9f96-4c59-9cc3-833c943ae049" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_20280df7-9f96-4c59-9cc3-833c943ae049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ac3d305-9e5d-46cc-927c-10ec4d7dc460_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:to="loc_srt_RangeMember_7ac3d305-9e5d-46cc-927c-10ec4d7dc460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:to="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a603eb07-a252-46fe-b73f-3664b9cf71bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:to="loc_srt_MinimumMember_a603eb07-a252-46fe-b73f-3664b9cf71bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6347f0cd-0585-4dad-a997-5e970cd3cc37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:to="loc_srt_MaximumMember_6347f0cd-0585-4dad-a997-5e970cd3cc37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_b7fbd9be-52be-4ebe-81e7-131e026fd74e_default" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:to="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_b7fbd9be-52be-4ebe-81e7-131e026fd74e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:to="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth1Member_8b653b33-2de6-4b98-bb40-1193d0095306" xlink:href="jan-20231230.xsd#jan_RelevantMonth1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth1Member_8b653b33-2de6-4b98-bb40-1193d0095306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth2Member_9e47b584-8062-4420-90fc-5f7ec1fe27db" xlink:href="jan-20231230.xsd#jan_RelevantMonth2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth2Member_9e47b584-8062-4420-90fc-5f7ec1fe27db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth3Member_061d6a9f-4313-4de0-a699-e1d8d19d156b" xlink:href="jan-20231230.xsd#jan_RelevantMonth3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth3Member_061d6a9f-4313-4de0-a699-e1d8d19d156b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_8542e0fb-d53b-4c2e-b343-460f78460367_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_8542e0fb-d53b-4c2e-b343-460f78460367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_e80d34e6-5b1f-4165-8d48-4286a8057e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:to="loc_us-gaap_FinancialGuaranteeMember_e80d34e6-5b1f-4165-8d48-4286a8057e79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_9c83980d-efe3-48bd-886f-aef6880196e3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_9c83980d-efe3-48bd-886f-aef6880196e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_0413a89c-0f8f-4b1e-99f9-1bffff306e12" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_0413a89c-0f8f-4b1e-99f9-1bffff306e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_fff2d693-6c2c-4f0f-b329-9889399dab7d" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_fff2d693-6c2c-4f0f-b329-9889399dab7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_7e300eb4-9211-4654-ad29-62a672a95466" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_7e300eb4-9211-4654-ad29-62a672a95466" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_98b2a162-faff-41ed-a3b4-09529a252838" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_98b2a162-faff-41ed-a3b4-09529a252838" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_b4023933-a15a-4729-90ce-03ab9377f29b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_b4023933-a15a-4729-90ce-03ab9377f29b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_fb723932-7c8a-4223-8a7e-405907341e75" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_fb723932-7c8a-4223-8a7e-405907341e75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_9a3d1d91-5e2a-42c3-b490-d1b3b901e0b6" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_9a3d1d91-5e2a-42c3-b490-d1b3b901e0b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_456bd625-61c8-4e59-849c-376e32860720" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_456bd625-61c8-4e59-849c-376e32860720" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_1c20a101-d3da-4d47-b062-5253ad0763d0" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_1c20a101-d3da-4d47-b062-5253ad0763d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_d7270fe3-8d7d-4714-bb94-f45e762f82c2" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_d7270fe3-8d7d-4714-bb94-f45e762f82c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_279e3256-e617-4a33-8f61-1f5ec0ddc3e3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_279e3256-e617-4a33-8f61-1f5ec0ddc3e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_071e7666-c9fe-4019-bad9-102a4b57de53" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_071e7666-c9fe-4019-bad9-102a4b57de53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_43bf9a7b-2d9a-40be-b5b3-539ea274a7c3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_43bf9a7b-2d9a-40be-b5b3-539ea274a7c3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_f6518da2-56ab-4526-a3bc-0886f23b64be" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_f6518da2-56ab-4526-a3bc-0886f23b64be" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_a6f50445-41f4-4dc8-a46b-9f66e73483b5" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_a6f50445-41f4-4dc8-a46b-9f66e73483b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_bc4e00e2-5adb-4133-bc9b-de9a04aabc33" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_bc4e00e2-5adb-4133-bc9b-de9a04aabc33" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_09318033-8452-49e2-bfb4-8605d1bd02aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_09318033-8452-49e2-bfb4-8605d1bd02aa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_647687d7-fa09-481a-809d-26acf74d6365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_647687d7-fa09-481a-809d-26acf74d6365" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_dc413729-ebc7-444f-86ea-b9c671515e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_dc413729-ebc7-444f-86ea-b9c671515e7d" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cfd1f953-0b5a-4d3e-a948-23611ae0b56b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cfd1f953-0b5a-4d3e-a948-23611ae0b56b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_967dca97-805c-4698-9acc-9b74ac248546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_967dca97-805c-4698-9acc-9b74ac248546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7b499259-0b3e-405f-ac9f-d644e2f3e6ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7b499259-0b3e-405f-ac9f-d644e2f3e6ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_27135516-bb33-47a9-ad2a-a7e867e5738c" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:to="loc_jan_ARCAAndSubsidiariesMember_27135516-bb33-47a9-ad2a-a7e867e5738c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGuaranteedConsideration_e6ff51e2-9bda-4c17-978c-90df072044b5" xlink:href="jan-20231230.xsd#jan_TotalGuaranteedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalGuaranteedConsideration_e6ff51e2-9bda-4c17-978c-90df072044b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PaymentFromBuyer_a5c134ba-d65d-4d62-9604-56e81738f816" xlink:href="jan-20231230.xsd#jan_PaymentFromBuyer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_PaymentFromBuyer_a5c134ba-d65d-4d62-9604-56e81738f816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NetConsideration_14be9cf2-5af1-4ab2-ad73-c08c2d6d79fb" xlink:href="jan-20231230.xsd#jan_NetConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_NetConsideration_14be9cf2-5af1-4ab2-ad73-c08c2d6d79fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsPayable_cf34cab7-88e3-4497-9154-1d918d853801" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccountsPayable_cf34cab7-88e3-4497-9154-1d918d853801" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiability_dada150c-b194-43de-84a2-7bb0cbb4992b" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccruedLiability_dada150c-b194-43de-84a2-7bb0cbb4992b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_55c8be48-c33f-4df0-8b91-58833388f99b" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_55c8be48-c33f-4df0-8b91-58833388f99b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfLeaseLiability_5e33baca-ab46-4e7e-8834-c3b16ffd1924" xlink:href="jan-20231230.xsd#jan_DisposalOfLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfLeaseLiability_5e33baca-ab46-4e7e-8834-c3b16ffd1924" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfDebt_9f9d36ff-ddb0-4eac-ba8c-1a1fb1694c4f" xlink:href="jan-20231230.xsd#jan_DisposalOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfDebt_9f9d36ff-ddb0-4eac-ba8c-1a1fb1694c4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c8c21826-f959-4018-a26c-daa6fb672573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c8c21826-f959-4018-a26c-daa6fb672573" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfLiability_af534f44-4018-4e2f-ac28-c756862f52d5" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalDisposalOfLiability_af534f44-4018-4e2f-ac28-c756862f52d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalConsiderations_2a3f1e5d-7928-4d0c-9cdc-6f96533d0ea9" xlink:href="jan-20231230.xsd#jan_TotalConsiderations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalConsiderations_2a3f1e5d-7928-4d0c-9cdc-6f96533d0ea9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CashDisposal_0b8d8565-65e9-4a59-8c77-9c8f297ee322" xlink:href="jan-20231230.xsd#jan_CashDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_CashDisposal_0b8d8565-65e9-4a59-8c77-9c8f297ee322" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsReceivable_99c15df1-4014-4141-b79d-17dda8a6ceee" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccountsReceivable_99c15df1-4014-4141-b79d-17dda8a6ceee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfInventory_dd2b4478-5760-466a-8f91-61ab50fe8ef0" xlink:href="jan-20231230.xsd#jan_DisposalOfInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfInventory_dd2b4478-5760-466a-8f91-61ab50fe8ef0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfPropertyPlantAndEquipment_dea50143-8656-4d86-b802-fbaf8f9c9597" xlink:href="jan-20231230.xsd#jan_DisposalOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfPropertyPlantAndEquipment_dea50143-8656-4d86-b802-fbaf8f9c9597" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfIntangibleAssets_e12ca90a-8008-4aac-a6fe-e76481f05953" xlink:href="jan-20231230.xsd#jan_DisposalOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfIntangibleAssets_e12ca90a-8008-4aac-a6fe-e76481f05953" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfRightOfUseAssets_4e0e54eb-6709-453d-bff3-85b93bf395cf" xlink:href="jan-20231230.xsd#jan_DisposalOfRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfRightOfUseAssets_4e0e54eb-6709-453d-bff3-85b93bf395cf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfOtherAssets_0df497fc-5b16-4515-8a3a-427d402834ae" xlink:href="jan-20231230.xsd#jan_DisposalOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfOtherAssets_0df497fc-5b16-4515-8a3a-427d402834ae" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfAssets_dbf4dd69-f3fd-4c9c-9b29-20711dee79e6" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalDisposalOfAssets_dbf4dd69-f3fd-4c9c-9b29-20711dee79e6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGainOnSale_5917ac3d-448f-4033-b656-61826f4da46c" xlink:href="jan-20231230.xsd#jan_TotalGainOnSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalGainOnSale_5917ac3d-448f-4033-b656-61826f4da46c" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#GeoTraqAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b0593fdc-9191-4e8b-9173-f5709fd4d1af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b0593fdc-9191-4e8b-9173-f5709fd4d1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_b5f26f02-142b-48bb-84d4-88dbca234b83" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:to="loc_jan_SpyrTechnologiesIncMember_b5f26f02-142b-48bb-84d4-88dbca234b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_675c0cda-4ea0-4d15-a375-704b6cbca9d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_675c0cda-4ea0-4d15-a375-704b6cbca9d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AssetPurchaseAgreementMember_c8b46a72-d0c7-458a-80dc-97e8c3dab7b1" xlink:href="jan-20231230.xsd#jan_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:to="loc_jan_AssetPurchaseAgreementMember_c8b46a72-d0c7-458a-80dc-97e8c3dab7b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:to="loc_srt_RangeMember_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:to="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d72431e0-d28e-4f40-82b5-dfe89f3dd6ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:to="loc_srt_MaximumMember_d72431e0-d28e-4f40-82b5-dfe89f3dd6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b192e9d6-623e-4eb2-a8d8-86ec5f323008" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:to="loc_srt_MinimumMember_b192e9d6-623e-4eb2-a8d8-86ec5f323008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedPrepaymentAmount_be3dcc16-89b1-462b-8122-04991d014d37" xlink:href="jan-20231230.xsd#jan_AgreedPrepaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_AgreedPrepaymentAmount_be3dcc16-89b1-462b-8122-04991d014d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ce9e5054-0ec9-465e-af5e-62f51384a172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockSharesIssued_ce9e5054-0ec9-465e-af5e-62f51384a172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_792f38d1-95f4-4e23-9d1d-d941986b5b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_792f38d1-95f4-4e23-9d1d-d941986b5b62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_06124d71-c83f-493c-80a7-5bed14b106fb" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NotesReceivableTerm_06124d71-c83f-493c-80a7-5bed14b106fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableFaceAmount_f74362fa-06f5-406e-b127-7067108f88b1" xlink:href="jan-20231230.xsd#jan_NoteReceivableFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableFaceAmount_f74362fa-06f5-406e-b127-7067108f88b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableStatedInterestRate_d70154ca-7b54-4d05-be34-d315e0206893" xlink:href="jan-20231230.xsd#jan_NoteReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableStatedInterestRate_d70154ca-7b54-4d05-be34-d315e0206893" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableMaturityDate_bc1e41db-d05c-4c50-9a37-d47d44e5ba1e" xlink:href="jan-20231230.xsd#jan_NoteReceivableMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableMaturityDate_bc1e41db-d05c-4c50-9a37-d47d44e5ba1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0a433ab4-2e69-49f1-b84f-4ac102f03c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockValue_0a433ab4-2e69-49f1-b84f-4ac102f03c3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_3a1ba033-3bfe-4193-b64f-5aa5bfb9b467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_3a1ba033-3bfe-4193-b64f-5aa5bfb9b467" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_9622f22d-23b1-41e2-bfad-ee61c88df569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_9622f22d-23b1-41e2-bfad-ee61c88df569" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_ecfa6099-de2e-42f6-98ac-c33cf02520be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_ecfa6099-de2e-42f6-98ac-c33cf02520be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableDiscountRate_c243d09e-a445-44e8-880b-375bdc67178c" xlink:href="jan-20231230.xsd#jan_NoteReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableDiscountRate_c243d09e-a445-44e8-880b-375bdc67178c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableRevisedDiscountRate_e1e2008a-b3de-4aed-9fc4-3d23d4f76a97" xlink:href="jan-20231230.xsd#jan_NoteReceivableRevisedDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableRevisedDiscountRate_e1e2008a-b3de-4aed-9fc4-3d23d4f76a97" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_6b4a53ba-17bc-47f5-9577-1f36ce460a0c" xlink:href="jan-20231230.xsd#jan_ChargeAgainstIncomeForIncreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_6b4a53ba-17bc-47f5-9577-1f36ce460a0c" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3c26debd-675a-42dc-a02b-d06050bf2485_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3c26debd-675a-42dc-a02b-d06050bf2485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_909deba5-d862-458f-bdaa-2d8c40ad336f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_909deba5-d862-458f-bdaa-2d8c40ad336f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_745f0aa6-e503-41bc-9880-52c4e194f3d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_745f0aa6-e503-41bc-9880-52c4e194f3d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_0290b2dd-4744-4e5f-a3e7-19b43f0f9066" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_0290b2dd-4744-4e5f-a3e7-19b43f0f9066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52027d84-df25-426f-aa62-71b9f73d544f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:to="loc_us-gaap_SegmentDomain_52027d84-df25-426f-aa62-71b9f73d544f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:to="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_c5783c68-cd57-451e-bcba-befe78c82a2c" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_c5783c68-cd57-451e-bcba-befe78c82a2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_31dc6b2b-8e69-4e88-963d-f4d9781e177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_31dc6b2b-8e69-4e88-963d-f4d9781e177b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2ad28098-1537-46c2-916b-c39e1560c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2ad28098-1537-46c2-916b-c39e1560c2bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_59f37d15-b159-4a79-8209-e0b8915fac78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_59f37d15-b159-4a79-8209-e0b8915fac78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b9c7549e-a3a8-4ec4-b010-7fe1e76324e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b9c7549e-a3a8-4ec4-b010-7fe1e76324e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_401efb99-6da5-4eb9-aefa-4ee5d433cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_401efb99-6da5-4eb9-aefa-4ee5d433cfcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_bbd01a2a-71f9-4e60-bf7e-754020f25b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_bbd01a2a-71f9-4e60-bf7e-754020f25b36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_6ad5002b-7192-4938-ada8-99d9f04f05d4" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_6ad5002b-7192-4938-ada8-99d9f04f05d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_c8cd50dd-545b-4b79-815d-14cf3d77f247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_c8cd50dd-545b-4b79-815d-14cf3d77f247" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_cc7e6c91-7d48-4b20-992f-9f2dafb37111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_cc7e6c91-7d48-4b20-992f-9f2dafb37111" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9d9af62f-b3cf-40c3-9de3-580f55ea5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9d9af62f-b3cf-40c3-9de3-580f55ea5e62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c51b1bc1-c439-4170-b688-d129a9a77a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c51b1bc1-c439-4170-b688-d129a9a77a5f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_dbd5edea-7e0b-48b5-a049-c22e18bc7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_dbd5edea-7e0b-48b5-a049-c22e18bc7a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a91161b3-39cc-4ec7-b014-55a5edbcce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a91161b3-39cc-4ec7-b014-55a5edbcce6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_8a05a85d-577b-4edc-ab82-7aa736bb8f2b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_8a05a85d-577b-4edc-ab82-7aa736bb8f2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_fd9d4a2e-2d63-4c82-a69a-5da4d142c160" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_fd9d4a2e-2d63-4c82-a69a-5da4d142c160" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_413a48cf-1d35-42e1-a5c8-906a1f6a712c" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_413a48cf-1d35-42e1-a5c8-906a1f6a712c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_b79b7a15-0247-42ff-9ad6-01d85d78d850" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_b79b7a15-0247-42ff-9ad6-01d85d78d850" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_1336f4be-7009-42cf-932b-ea8eb0daa35b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_1336f4be-7009-42cf-932b-ea8eb0daa35b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1956cd0c-313e-4ce4-b026-6bc41ce8c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1956cd0c-313e-4ce4-b026-6bc41ce8c1c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_e1e74880-fd60-4f0b-af74-e81011948170" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_e1e74880-fd60-4f0b-af74-e81011948170" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_8573cad1-6644-440a-a05f-f9ebabcbef8b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_8573cad1-6644-440a-a05f-f9ebabcbef8b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_c4c2f0ca-6120-4bcd-a1e1-cd3f292ac44a" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_c4c2f0ca-6120-4bcd-a1e1-cd3f292ac44a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_53f4886c-c16e-4ce2-81ae-221e1404aaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_53f4886c-c16e-4ce2-81ae-221e1404aaf4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4ad6b75c-da70-4f58-9f0e-c6fb48e883e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4ad6b75c-da70-4f58-9f0e-c6fb48e883e9" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b777cdcc-137a-494f-9330-605848dde92e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b777cdcc-137a-494f-9330-605848dde92e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BuildingsAndImprovementsMember_4f062251-088c-4dec-96df-910c510c833c" xlink:href="jan-20231230.xsd#jan_BuildingsAndImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_jan_BuildingsAndImprovementsMember_4f062251-088c-4dec-96df-910c510c833c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f91cf0da-1aba-43fc-8c6d-5cf7d8341c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_us-gaap_EquipmentMember_f91cf0da-1aba-43fc-8c6d-5cf7d8341c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionMember_2ce299f8-73e5-4a8c-81d7-125f8bf7c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_us-gaap_ConstructionMember_2ce299f8-73e5-4a8c-81d7-125f8bf7c60b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b092dcc-1540-4416-8ff9-a20ca31e9f64_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:to="loc_srt_RangeMember_0b092dcc-1540-4416-8ff9-a20ca31e9f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:to="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf06831-eaf4-4ab1-9030-93f0682df286" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:to="loc_srt_MinimumMember_7cf06831-eaf4-4ab1-9030-93f0682df286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_75019a7d-ca3e-4556-a29a-aa3beaf318ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:to="loc_srt_MaximumMember_75019a7d-ca3e-4556-a29a-aa3beaf318ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26f74738-fe5c-41d1-9d2a-2573c6aab0b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26f74738-fe5c-41d1-9d2a-2573c6aab0b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_0dac9dc7-e271-4894-bddc-dfe70b2a08df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_0dac9dc7-e271-4894-bddc-dfe70b2a08df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_29152816-8b7f-412a-9899-7a6516c26149" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_29152816-8b7f-412a-9899-7a6516c26149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:to="loc_us-gaap_SegmentDomain_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:to="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_7f0b20a5-b32b-40a8-ba18-c5adbd18eb2e" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_7f0b20a5-b32b-40a8-ba18-c5adbd18eb2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_41c73d71-23cc-4e3e-97ea-cf890ba78e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_41c73d71-23cc-4e3e-97ea-cf890ba78e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_8d5c8530-59be-4f7a-b184-04ba02f48d7a" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_8d5c8530-59be-4f7a-b184-04ba02f48d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aad23461-837f-4da5-80f9-52d5a6a14988" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aad23461-837f-4da5-80f9-52d5a6a14988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3c2d40a3-d898-48d2-bf65-f25425111063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3c2d40a3-d898-48d2-bf65-f25425111063" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e2753105-be7a-46ce-b5d5-57cd204fe33e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e2753105-be7a-46ce-b5d5-57cd204fe33e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_045ba90c-c005-44a2-8994-ed9c7fa180af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_045ba90c-c005-44a2-8994-ed9c7fa180af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10f5e0dc-7fe1-4309-8cf6-31265b902207_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10f5e0dc-7fe1-4309-8cf6-31265b902207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_f1be87d4-e267-42aa-b786-884ed592afa1" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:to="loc_jan_ARCAAndSubsidiariesMember_f1be87d4-e267-42aa-b786-884ed592afa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ce1a66a-a5af-4443-9e40-1dfd017b4723_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:to="loc_us-gaap_SegmentDomain_2ce1a66a-a5af-4443-9e40-1dfd017b4723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:to="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e5b7d562-486d-44b8-96a0-00bf40189ee4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e5b7d562-486d-44b8-96a0-00bf40189ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f4e1fea5-8dae-4910-be38-673a43fae4a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:to="loc_us-gaap_CreditFacilityDomain_f4e1fea5-8dae-4910-be38-673a43fae4a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:to="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6f1de413-e4df-4709-9be4-e30a4e513fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6f1de413-e4df-4709-9be4-e30a4e513fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_69513df5-5f45-4059-8ef0-a7e713430caf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_69513df5-5f45-4059-8ef0-a7e713430caf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_b79b98c5-164c-459c-881c-fe01221f63ca" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:to="loc_jan_IcgNoteMember_b79b98c5-164c-459c-881c-fe01221f63ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:to="loc_us-gaap_RelatedPartyDomain_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:to="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_224343fd-03f7-4f9c-8d67-a5c3556e5170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:to="loc_us-gaap_BeneficialOwnerMember_224343fd-03f7-4f9c-8d67-a5c3556e5170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ab227d6-a69d-42dd-af23-151e76ce61f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ab227d6-a69d-42dd-af23-151e76ce61f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_15943178-20b6-4330-a6ba-3f25c6c7aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_15943178-20b6-4330-a6ba-3f25c6c7aaf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_463eed45-8902-4cc1-8118-512f5099dfcd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_463eed45-8902-4cc1-8118-512f5099dfcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_JanOneMember_386ffd42-bda3-46fb-9787-f6c304bf7093" xlink:href="jan-20231230.xsd#jan_JanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:to="loc_jan_JanOneMember_386ffd42-bda3-46fb-9787-f6c304bf7093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3aebb313-5cb6-4136-be58-1c033679f315_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:to="loc_dei_EntityDomain_3aebb313-5cb6-4136-be58-1c033679f315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:to="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacCapitalGroupLLCICGMember_89f12434-baf5-491c-b035-d3ba3e60faa3" xlink:href="jan-20231230.xsd#jan_IsaacCapitalGroupLLCICGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:to="loc_jan_IsaacCapitalGroupLLCICGMember_89f12434-baf5-491c-b035-d3ba3e60faa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a492cbba-ad32-42d4-9802-cec37ffdfc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_Depreciation_a492cbba-ad32-42d4-9802-cec37ffdfc22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6d13b00f-71dd-4ebb-8249-c2944f4bbcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_AdjustmentForAmortization_6d13b00f-71dd-4ebb-8249-c2944f4bbcbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ff685e16-8d94-4605-b591-ffb6ecbbe86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ff685e16-8d94-4605-b591-ffb6ecbbe86e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_d4b29a44-1809-40da-a4be-1c81ea636a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_d4b29a44-1809-40da-a4be-1c81ea636a80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest_d6de6dac-1302-456e-b656-a23a4392f913" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_jan_SalesTaxAssessmentAccruedInterest_d6de6dac-1302-456e-b656-a23a4392f913" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c13a521-5d6f-4fc5-a4c9-45b2b078b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c13a521-5d6f-4fc5-a4c9-45b2b078b8ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_c64dcccf-6feb-46a7-9ef6-56a0c9df7967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_c64dcccf-6feb-46a7-9ef6-56a0c9df7967" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dadb5674-6139-4370-99f7-3e5b370bd41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dadb5674-6139-4370-99f7-3e5b370bd41f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_466673f5-118b-4536-b49b-24072cb0b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCredit_466673f5-118b-4536-b49b-24072cb0b8b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b6a6fb10-0a59-47ef-a703-72dd14247aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b6a6fb10-0a59-47ef-a703-72dd14247aa4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_79b8ee48-5365-407c-aa1d-772e24dcf559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_79b8ee48-5365-407c-aa1d-772e24dcf559" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_20b6ee35-e725-40f3-a3f4-37406254590a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_20b6ee35-e725-40f3-a3f4-37406254590a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_935893ca-b12e-42cc-850f-286fb464913a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_935893ca-b12e-42cc-850f-286fb464913a" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_e772a61c-f647-4d19-a3f8-42ea010cd8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:to="loc_us-gaap_PatentsMember_e772a61c-f647-4d19-a3f8-42ea010cd8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e921f891-8694-4a16-a5c0-b464cc560c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e921f891-8694-4a16-a5c0-b464cc560c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a92e2f44-3749-483d-825f-cdc3f616796e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a92e2f44-3749-483d-825f-cdc3f616796e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_302223da-9588-4bf1-967d-850e2d066001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_302223da-9588-4bf1-967d-850e2d066001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_d1edefc4-4f71-4af8-a896-2cfb3b0785f9" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:to="loc_jan_ARCAAndSubsidiariesMember_d1edefc4-4f71-4af8-a896-2cfb3b0785f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:to="loc_us-gaap_SegmentDomain_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:to="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_37b911bd-6375-4dd6-a9b8-fa8a4762be73" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_37b911bd-6375-4dd6-a9b8-fa8a4762be73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d64ea4e4-715a-484c-b13b-52477b82c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d64ea4e4-715a-484c-b13b-52477b82c4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a737024d-243d-4688-b4aa-a060eef484b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a737024d-243d-4688-b4aa-a060eef484b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_805477c7-0ad6-49b4-9f2c-35cb8027ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_805477c7-0ad6-49b4-9f2c-35cb8027ddbf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2805f911-eaa2-4cbf-8a7b-720b9d8731c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_2805f911-eaa2-4cbf-8a7b-720b9d8731c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_90871680-3279-4536-b028-b2adff4fe965" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:to="loc_jan_ARCAAndSubsidiariesMember_90871680-3279-4536-b028-b2adff4fe965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b55140c2-45ea-43e5-9e25-4e370f0de0e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:to="loc_us-gaap_SegmentDomain_b55140c2-45ea-43e5-9e25-4e370f0de0e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:to="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_2b203b55-f079-4892-9c82-50df829e99bf" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_2b203b55-f079-4892-9c82-50df829e99bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_705501dc-f8c8-4790-8800-54ccf0c953e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_705501dc-f8c8-4790-8800-54ccf0c953e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_584a3d30-3e06-4f93-93ca-13e48ef5d238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_584a3d30-3e06-4f93-93ca-13e48ef5d238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedIncentiveAndRebateChecksCurrent_e2abf238-4191-4473-9034-8a455dc7d0e9" xlink:href="jan-20231230.xsd#jan_AccruedIncentiveAndRebateChecksCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_jan_AccruedIncentiveAndRebateChecksCurrent_e2abf238-4191-4473-9034-8a455dc7d0e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_37b9c565-c617-45f0-b1b9-46352602af97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_37b9c565-c617-45f0-b1b9-46352602af97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e83842ba-938d-4d68-bc5e-7afc7e774efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e83842ba-938d-4d68-bc5e-7afc7e774efe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4698b09d-922a-4041-a148-042b91399c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4698b09d-922a-4041-a148-042b91399c0a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_4087f918-1f0e-45ff-bc88-a2855f687a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_4087f918-1f0e-45ff-bc88-a2855f687a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00dd2f23-b164-4d26-9e70-5bda2339106e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00dd2f23-b164-4d26-9e70-5bda2339106e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_b00d2309-0c2b-4040-98b2-f842888c8290" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:to="loc_jan_ARCAAndSubsidiariesMember_b00d2309-0c2b-4040-98b2-f842888c8290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0a050090-829d-49da-bbc4-85b0d211ab36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:to="loc_us-gaap_SegmentDomain_0a050090-829d-49da-bbc4-85b0d211ab36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:to="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_32097207-8124-46f7-9904-35c17f89ff1e" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_32097207-8124-46f7-9904-35c17f89ff1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6edc5190-3e5c-4afe-b44e-4df767402d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6edc5190-3e5c-4afe-b44e-4df767402d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest_61f55b24-4730-4851-b819-9d2df51fb1a8" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_jan_SalesTaxAssessmentAccruedInterest_61f55b24-4730-4851-b819-9d2df51fb1a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_9770dacb-0846-4208-a5ac-c7eab3497713" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_9770dacb-0846-4208-a5ac-c7eab3497713" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofShorttermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCompanyMember_ebabfc67-c5f3-40eb-9dce-cd496f4f3a73" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:to="loc_jan_GulfCoastBankAndTrustCompanyMember_ebabfc67-c5f3-40eb-9dce-cd496f4f3a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f8ce3325-a859-4fb3-8e84-85aa5644e09f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f8ce3325-a859-4fb3-8e84-85aa5644e09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c10aa810-4755-4a4e-b669-7d5dae27fd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c10aa810-4755-4a4e-b669-7d5dae27fd0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38f29a94-d4f1-4d01-9c58-23fee0ba6969_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38f29a94-d4f1-4d01-9c58-23fee0ba6969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_b6a68c96-46e8-46c3-8b61-19ed3cfcdff8" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:to="loc_jan_ARCAAndSubsidiariesMember_b6a68c96-46e8-46c3-8b61-19ed3cfcdff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3d84c30d-edd7-4503-84d2-35bbdf3f6695_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:to="loc_us-gaap_SegmentDomain_3d84c30d-edd7-4503-84d2-35bbdf3f6695_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:to="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_64a49d17-bfd6-4bf7-9c11-28577860881d" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_64a49d17-bfd6-4bf7-9c11-28577860881d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_70bc2b47-f638-4d14-a29f-89e9eeea954c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_70bc2b47-f638-4d14-a29f-89e9eeea954c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_5d498040-a03c-490f-bc86-f800cbfa5236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_5d498040-a03c-490f-bc86-f800cbfa5236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_54818161-73a7-4bb5-9892-56e890bf9258" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_54818161-73a7-4bb5-9892-56e890bf9258" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc930ea9-4488-4059-8ccd-594ebf3d064c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc930ea9-4488-4059-8ccd-594ebf3d064c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_KlcFinancialMember_cf3cd46a-2e3e-4c60-a679-0893eb723438" xlink:href="jan-20231230.xsd#jan_KlcFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:to="loc_jan_KlcFinancialMember_cf3cd46a-2e3e-4c60-a679-0893eb723438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3ea7fc19-dfa9-446d-8f44-35d452ad94f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3ea7fc19-dfa9-446d-8f44-35d452ad94f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_28897a38-7626-444d-b1b9-8a58823ab43d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_28897a38-7626-444d-b1b9-8a58823ab43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ddbe768f-1ebf-4084-a8a1-07be829aa075_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ddbe768f-1ebf-4084-a8a1-07be829aa075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_ab59984c-73d1-4c2e-960c-567eb0664862" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:to="loc_jan_ARCAAndSubsidiariesMember_ab59984c-73d1-4c2e-960c-567eb0664862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d908ef32-e5f0-45db-9c6c-4161ff27cb97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:to="loc_us-gaap_SegmentDomain_d908ef32-e5f0-45db-9c6c-4161ff27cb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:to="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_5bc94188-e0d0-4233-ac4a-b9f91b220a48" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_5bc94188-e0d0-4233-ac4a-b9f91b220a48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8fe6be6c-81aa-472e-862c-fcc1938f9442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8fe6be6c-81aa-472e-862c-fcc1938f9442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_776bdb89-1a2a-44d0-8653-f23d012e9342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_776bdb89-1a2a-44d0-8653-f23d012e9342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_45b63674-23a5-40ce-842f-a252115f776e" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_45b63674-23a5-40ce-842f-a252115f776e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_264745a5-3ea2-4c73-8e31-352ea080a257" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_264745a5-3ea2-4c73-8e31-352ea080a257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_d83be9e8-3690-4903-b82b-85a3f1e46d30" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_d83be9e8-3690-4903-b82b-85a3f1e46d30" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofRelatedPartyDebtDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ef5909f-1a0a-42e7-a26c-2405555af507_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ef5909f-1a0a-42e7-a26c-2405555af507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_dd104b57-3a27-4d74-a177-5539cb4ea3b3" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:to="loc_jan_IcgNoteMember_dd104b57-3a27-4d74-a177-5539cb4ea3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2091513a-4ef2-40ef-8abe-63aa64b01cde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:to="loc_us-gaap_RelatedPartyDomain_2091513a-4ef2-40ef-8abe-63aa64b01cde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:to="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_fecf029c-403a-4b55-a696-9410042921c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:to="loc_us-gaap_RelatedPartyMember_fecf029c-403a-4b55-a696-9410042921c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6970b443-9184-4458-9b2f-6e45244c1538_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6970b443-9184-4458-9b2f-6e45244c1538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_a7fb4130-f7e7-4767-853f-48eb51bd086f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_a7fb4130-f7e7-4767-853f-48eb51bd086f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6184b1c7-5c13-4fc6-984f-f9b231df417f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6184b1c7-5c13-4fc6-984f-f9b231df417f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_90aebf25-b26e-4ac0-9bc5-c7b846c7cce4" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:to="loc_jan_ARCAAndSubsidiariesMember_90aebf25-b26e-4ac0-9bc5-c7b846c7cce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:to="loc_us-gaap_SegmentDomain_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:to="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_864f125d-ce45-46dd-a385-1170964f52b4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_864f125d-ce45-46dd-a385-1170964f52b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_f966b730-c8c0-4331-8fa0-5deeb74d6f18" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_f966b730-c8c0-4331-8fa0-5deeb74d6f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_9f0867b0-6a1b-4647-a745-10c411b836b6" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_9f0867b0-6a1b-4647-a745-10c411b836b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_10498a36-10c1-4eb6-a6dc-d3a342815955" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_10498a36-10c1-4eb6-a6dc-d3a342815955" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b6640fa3-76a7-4229-b6aa-d19cd675b552_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b6640fa3-76a7-4229-b6aa-d19cd675b552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c6201426-267e-404e-a578-113ba79de6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c6201426-267e-404e-a578-113ba79de6f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_183f0716-87d3-4a98-b26c-9f41a7419c82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_183f0716-87d3-4a98-b26c-9f41a7419c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_13ef4e0d-954c-44c7-aa31-e1b404398154" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_13ef4e0d-954c-44c7-aa31-e1b404398154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArcaMember_73615710-d94d-48f9-bd1c-c42e0dc606cb" xlink:href="jan-20231230.xsd#jan_ArcaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_ArcaMember_73615710-d94d-48f9-bd1c-c42e0dc606cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_9a890dde-4603-4970-afdf-1e16de666ccd" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_GeoTraqIncMember_9a890dde-4603-4970-afdf-1e16de666ccd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1d2ad46c-8aa1-4250-9055-7e2e44a79445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:to="loc_us-gaap_SegmentDomain_1d2ad46c-8aa1-4250-9055-7e2e44a79445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:to="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_98ddce47-1c4f-40b5-af40-a8e8f3d9f3f4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_98ddce47-1c4f-40b5-af40-a8e8f3d9f3f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_266cf3e9-95bb-46c1-af20-4edaa3396ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_266cf3e9-95bb-46c1-af20-4edaa3396ab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c6570578-8da6-4821-97ce-6e96c382911e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c6570578-8da6-4821-97ce-6e96c382911e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_559cd9d9-0e7b-4dcc-af7a-445abfed629b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_559cd9d9-0e7b-4dcc-af7a-445abfed629b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:href="jan-20231230.xsd#jan_OperatingExpensesFromDiscontinuedOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c6887dd1-c4be-4df5-9ddc-2d2e92e4c12b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c6887dd1-c4be-4df5-9ddc-2d2e92e4c12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_bfe97453-f534-48bb-8593-2d945b340bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_bfe97453-f534-48bb-8593-2d945b340bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_1f41c707-60a1-44ca-bcaa-30f0f48efa18" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_1f41c707-60a1-44ca-bcaa-30f0f48efa18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_19997c05-0915-489a-9b13-d1d52cb502e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_19997c05-0915-489a-9b13-d1d52cb502e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:href="jan-20231230.xsd#jan_OtherIncomeExpenseFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_ad3be0b0-c52c-4695-95fe-361d184caf45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_ad3be0b0-c52c-4695-95fe-361d184caf45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_2065c5c8-e706-4223-b096-1c52171774bb" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_2065c5c8-e706-4223-b096-1c52171774bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_3d1e5564-4359-4a9b-b0b8-133ec555d3ac" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_3d1e5564-4359-4a9b-b0b8-133ec555d3ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_fc829d7d-a019-4c6e-b09f-fb6f47242e30" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_fc829d7d-a019-4c6e-b09f-fb6f47242e30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5fb4ad70-db2e-4094-b056-83d0666a7317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5fb4ad70-db2e-4094-b056-83d0666a7317" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9c00ac63-0cbc-4ae3-bab2-dbf4efb8f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9c00ac63-0cbc-4ae3-bab2-dbf4efb8f3f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_679c3cee-2449-4bb5-b3f2-415dd8ada4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_679c3cee-2449-4bb5-b3f2-415dd8ada4fc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_19cb755e-b678-4aea-bac1-39f3e8d86e5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_19cb755e-b678-4aea-bac1-39f3e8d86e5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_09aa3cfe-7530-476d-b572-bef2a6acc469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_09aa3cfe-7530-476d-b572-bef2a6acc469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ee66d36b-a879-489c-8917-c61f72546df5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ee66d36b-a879-489c-8917-c61f72546df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_47f5e3cb-f6e9-488e-a4a9-bbdada4858e1" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:to="loc_jan_ARCAAndSubsidiariesMember_47f5e3cb-f6e9-488e-a4a9-bbdada4858e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f775c04b-bd10-4d80-b988-dbaf511b0b4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:to="loc_us-gaap_SegmentDomain_f775c04b-bd10-4d80-b988-dbaf511b0b4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:to="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_51f3beab-13dc-43f0-a8af-53e7df7fe671" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_51f3beab-13dc-43f0-a8af-53e7df7fe671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:href="jan-20231230.xsd#jan_DiscontinuedOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_601038fe-7342-4db8-a617-d3da25cbca22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_601038fe-7342-4db8-a617-d3da25cbca22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4e536d82-9784-4206-9960-26aba72e7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4e536d82-9784-4206-9960-26aba72e7bb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32a29914-2000-4bb7-90d3-6b228a19add9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32a29914-2000-4bb7-90d3-6b228a19add9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnLitigationSettlement_6cd35a63-fefe-4285-bfa4-1e609aaa2bc8" xlink:href="jan-20231230.xsd#jan_GainLossOnLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_GainLossOnLitigationSettlement_6cd35a63-fefe-4285-bfa4-1e609aaa2bc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AmortizationOfRightOfUseAssets_d3072e72-0639-413c-850e-36addeba9b34" xlink:href="jan-20231230.xsd#jan_AmortizationOfRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_AmortizationOfRightOfUseAssets_d3072e72-0639-413c-850e-36addeba9b34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainOnSaleNetOfCash_2a95ea12-1e32-4601-9d6e-8ce503f26cd5" xlink:href="jan-20231230.xsd#jan_GainOnSaleNetOfCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_GainOnSaleNetOfCash_2a95ea12-1e32-4601-9d6e-8ce503f26cd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a986309b-c542-4b88-b670-2f19c8f37cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a986309b-c542-4b88-b670-2f19c8f37cc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7eafd483-d74e-4168-a3f8-cf6de5a107c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7eafd483-d74e-4168-a3f8-cf6de5a107c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0e188394-0d72-4e2d-9507-48a41ba8b252" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0e188394-0d72-4e2d-9507-48a41ba8b252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1511f35c-cd47-4482-84cd-7a036f9452d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1511f35c-cd47-4482-84cd-7a036f9452d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_88ddca4c-6151-41b0-b712-bda164547ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_88ddca4c-6151-41b0-b712-bda164547ced" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48d0b50b-6ea4-42cb-ac08-5935436df400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48d0b50b-6ea4-42cb-ac08-5935436df400" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_df62f33e-d86b-4c2f-90e9-bf14a0050dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_df62f33e-d86b-4c2f-90e9-bf14a0050dd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:href="jan-20231230.xsd#jan_DiscontinuedInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16ef8e0c-48fd-4a26-8cd5-cb8c94441846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16ef8e0c-48fd-4a26-8cd5-cb8c94441846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6516b0ca-773a-42b8-93d1-c12afd4beea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6516b0ca-773a-42b8-93d1-c12afd4beea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fe48430f-2238-47ba-8e27-54603a2cb2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fe48430f-2238-47ba-8e27-54603a2cb2f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:href="jan-20231230.xsd#jan_DiscontinuedFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_5b9cc7c3-3f8f-43c8-a5d7-cb7fd5675457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_5b9cc7c3-3f8f-43c8-a5d7-cb7fd5675457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_682ef88a-c46d-4e34-a082-26153426532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_682ef88a-c46d-4e34-a082-26153426532c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_004ac492-c285-462b-a64d-19c5238e96f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_004ac492-c285-462b-a64d-19c5238e96f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b00a688d-2001-4773-b115-7993a775cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b00a688d-2001-4773-b115-7993a775cbb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f35a48da-de7d-4355-8ce7-8e1d7484b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f35a48da-de7d-4355-8ce7-8e1d7484b34a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_452f5a3d-bb91-4287-99bd-377087263fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_452f5a3d-bb91-4287-99bd-377087263fb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2a193d03-58e9-4853-93b1-f8a9393ce697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2a193d03-58e9-4853-93b1-f8a9393ce697" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8a9f8f1a-eb93-49b8-a125-41a0ffd8cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/NotesReceivableDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#NotesReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/NotesReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_ab01d163-b483-4aa3-bedb-bb1cd9021d2e" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:to="loc_jan_GeoTraqIncMember_ab01d163-b483-4aa3-bedb-bb1cd9021d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13f697ba-a592-479f-8f68-967755e8a486_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13f697ba-a592-479f-8f68-967755e8a486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_f9806ceb-153d-4dc6-8bdf-51c8435b8121" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:to="loc_jan_SpyrTechnologiesIncMember_f9806ceb-153d-4dc6-8bdf-51c8435b8121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_VM7CorporationMember_ae222ceb-f124-4229-953f-5691ef831e15" xlink:href="jan-20231230.xsd#jan_VM7CorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:to="loc_jan_VM7CorporationMember_ae222ceb-f124-4229-953f-5691ef831e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49a07351-2d51-41d9-a586-ff08452848e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49a07351-2d51-41d9-a586-ff08452848e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockPurchaseAgreementMember_d5a3d44d-2402-43f5-8567-a24fbc094608" xlink:href="jan-20231230.xsd#jan_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:to="loc_jan_StockPurchaseAgreementMember_d5a3d44d-2402-43f5-8567-a24fbc094608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_7a3ae7c8-7bca-4cc9-8004-f473b1e96647" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NotesReceivableTerm_7a3ae7c8-7bca-4cc9-8004-f473b1e96647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableFaceAmount_dd89d7fe-525c-47f8-818c-0ce3ee5ba189" xlink:href="jan-20231230.xsd#jan_NoteReceivableFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NoteReceivableFaceAmount_dd89d7fe-525c-47f8-818c-0ce3ee5ba189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableStatedInterestRate_05f93560-a5b8-4aec-be30-c974b3a00744" xlink:href="jan-20231230.xsd#jan_NoteReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NoteReceivableStatedInterestRate_05f93560-a5b8-4aec-be30-c974b3a00744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_66f67f9e-87b8-4a3e-80de-fe9c6d76a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_66f67f9e-87b8-4a3e-80de-fe9c6d76a9f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_6e203ff7-7c2b-46a0-8f81-ae93fbdb97db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_InterestReceivable_6e203ff7-7c2b-46a0-8f81-ae93fbdb97db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_01d47155-8fe8-4535-b3ff-42fa3a8804bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_01d47155-8fe8-4535-b3ff-42fa3a8804bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount_f5fed73e-4fe3-4d81-9470-da2274b24fd8" xlink:href="jan-20231230.xsd#jan_DiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount_f5fed73e-4fe3-4d81-9470-da2274b24fd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtDiscountRate_00c300aa-3e35-4417-922c-1c35406b63c8" xlink:href="jan-20231230.xsd#jan_DebtDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DebtDiscountRate_00c300aa-3e35-4417-922c-1c35406b63c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtRevisedDiscountRate_c2b36d0e-3434-488f-ac44-93fe8aa0709f" xlink:href="jan-20231230.xsd#jan_DebtRevisedDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DebtRevisedDiscountRate_c2b36d0e-3434-488f-ac44-93fe8aa0709f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountCharges_5cf19180-1f88-45a9-ac22-d736f752b314" xlink:href="jan-20231230.xsd#jan_DiscountCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DiscountCharges_5cf19180-1f88-45a9-ac22-d736f752b314" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAmountChargedAgainstIncome_6eb8c7e8-741e-4eef-8e68-1bb681974cb1" xlink:href="jan-20231230.xsd#jan_AdditionalAmountChargedAgainstIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_AdditionalAmountChargedAgainstIncome_6eb8c7e8-741e-4eef-8e68-1bb681974cb1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnWriteOffOfNotesReceivable_089da150-d29c-4901-a101-ab4a79f86643" xlink:href="jan-20231230.xsd#jan_GainLossOnWriteOffOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_GainLossOnWriteOffOfNotesReceivable_089da150-d29c-4901-a101-ab4a79f86643" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAsset_7dfcbc7f-d6d9-46d9-9f93-461204718513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_InterestIncomeInterestEarningAsset_7dfcbc7f-d6d9-46d9-9f93-461204718513" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_d0e86b14-f54a-4a6d-b960-35c5216346fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_d0e86b14-f54a-4a6d-b960-35c5216346fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionConsiderAmount_7144b82f-3f0b-47eb-9be2-655f634a16fe" xlink:href="jan-20231230.xsd#jan_DispositionTransactionConsiderAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionConsiderAmount_7144b82f-3f0b-47eb-9be2-655f634a16fe" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionTermPeriod_2fde1773-1a17-492d-a88f-5c5b08a7bd58" xlink:href="jan-20231230.xsd#jan_DispositionTransactionTermPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionTermPeriod_2fde1773-1a17-492d-a88f-5c5b08a7bd58" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionAggregateCost_39832897-8057-4e69-8b56-4a443ccf8133" xlink:href="jan-20231230.xsd#jan_DispositionTransactionAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionAggregateCost_39832897-8057-4e69-8b56-4a443ccf8133" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_83d461c0-74c3-4699-b29c-fb9d2abbc74f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_PaymentsForCommissions_83d461c0-74c3-4699-b29c-fb9d2abbc74f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionDiscountRate_4c69dbab-b9c1-4c26-9a0c-1a21e59ada3b" xlink:href="jan-20231230.xsd#jan_DispositionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionDiscountRate_4c69dbab-b9c1-4c26-9a0c-1a21e59ada3b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_4109efaa-6bef-499b-83e8-6d2d38c3ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_4109efaa-6bef-499b-83e8-6d2d38c3ea6d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RevisedDiscountAmount_ce84f280-941a-473d-ad08-8ddaf0a2317b" xlink:href="jan-20231230.xsd#jan_RevisedDiscountAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_RevisedDiscountAmount_ce84f280-941a-473d-ad08-8ddaf0a2317b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5617688b-7a3f-4d7f-b5db-cb3bdb685fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5617688b-7a3f-4d7f-b5db-cb3bdb685fe5" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_b5bafdd0-597c-4a03-9567-745b35ce91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_b5bafdd0-597c-4a03-9567-745b35ce91c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9ba89a0-55cd-4287-9f79-435e761838bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9ba89a0-55cd-4287-9f79-435e761838bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_a2012b9f-fe36-4272-9ec2-77c0012ce379" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_jan_SoinIntangiblesMember_a2012b9f-fe36-4272-9ec2-77c0012ce379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PatentsAndDomainsMember_f13fd50a-a081-4281-b99a-9d415813750f" xlink:href="jan-20231230.xsd#jan_PatentsAndDomainsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_jan_PatentsAndDomainsMember_f13fd50a-a081-4281-b99a-9d415813750f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_437d4b95-5e5c-41a3-8c44-6c827bd3e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_437d4b95-5e5c-41a3-8c44-6c827bd3e53b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1bafd7ff-9c34-44c5-b5b8-abf76eded489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1bafd7ff-9c34-44c5-b5b8-abf76eded489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_51621fb3-284b-43f3-8783-30c3209985cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_51621fb3-284b-43f3-8783-30c3209985cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2c34d032-5a8f-469f-89a6-fbb49fc6c485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2c34d032-5a8f-469f-89a6-fbb49fc6c485" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a922e22-269f-45ac-a8b4-f31e168042b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a922e22-269f-45ac-a8b4-f31e168042b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_7bc573d4-4646-4e6d-af9d-9d9c356462cd" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:to="loc_jan_SoinIntangiblesMember_7bc573d4-4646-4e6d-af9d-9d9c356462cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_59ebe005-f319-4c55-84b2-d06f33bc4141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_59ebe005-f319-4c55-84b2-d06f33bc4141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_3a9a6fd2-4397-4cf4-868f-dd107ef1d270" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_3a9a6fd2-4397-4cf4-868f-dd107ef1d270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_36d5c3c4-6159-4dd4-b50c-c885f3c885cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_36d5c3c4-6159-4dd4-b50c-c885f3c885cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecuritiesScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61872f46-2825-4177-bc50-7feb6ff09fa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_61872f46-2825-4177-bc50-7feb6ff09fa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesGConvertiblePreferredStockMember_3607942a-ca89-4974-bfc1-316d9c4de568" xlink:href="jan-20231230.xsd#jan_SeriesGConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:to="loc_jan_SeriesGConvertiblePreferredStockMember_3607942a-ca89-4974-bfc1-316d9c4de568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonShareEquivalentsMember_238c0be5-6d4c-4028-a97c-9b9d25c18b46" xlink:href="jan-20231230.xsd#jan_CommonShareEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:to="loc_jan_CommonShareEquivalentsMember_238c0be5-6d4c-4028-a97c-9b9d25c18b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:to="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MarketableSecuritiesSharesOutstanding_b56cf500-1516-483b-927b-466fde437fdb" xlink:href="jan-20231230.xsd#jan_MarketableSecuritiesSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:to="loc_jan_MarketableSecuritiesSharesOutstanding_b56cf500-1516-483b-927b-466fde437fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_079a3bfe-8371-4d40-a212-a269b14f58e0" xlink:href="jan-20231230.xsd#jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:to="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_079a3bfe-8371-4d40-a212-a269b14f58e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MarketableSecuritiesSharesOutstanding_97a2f1c4-e585-4ea8-91ad-6dfe7103afe7" xlink:href="jan-20231230.xsd#jan_MarketableSecuritiesSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:to="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8ff6fd3c-abb3-45de-8b6f-b7b5e0d1aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_MarketableSecurities_8ff6fd3c-abb3-45de-8b6f-b7b5e0d1aec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_db3b9c8d-c3fd-4844-a212-1632cbc703d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_db3b9c8d-c3fd-4844-a212-1632cbc703d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_16c71270-ad88-499f-8603-73d9f56fff93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_16c71270-ad88-499f-8603-73d9f56fff93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_69f6efa0-3b81-415f-b369-9c1edfd43ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:to="loc_us-gaap_ClassOfStockDomain_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:to="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesGConvertiblePreferredStockMember_a4ec9f37-5340-4b17-9a35-1ef787214010" xlink:href="jan-20231230.xsd#jan_SeriesGConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:to="loc_jan_SeriesGConvertiblePreferredStockMember_a4ec9f37-5340-4b17-9a35-1ef787214010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonShareEquivalentsMember_39e89da6-5ffd-46a8-a1b6-7a9be74f235a" xlink:href="jan-20231230.xsd#jan_CommonShareEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:to="loc_jan_CommonShareEquivalentsMember_39e89da6-5ffd-46a8-a1b6-7a9be74f235a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:to="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_90925684-ae70-4d11-82d1-c5ff53915f43" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:to="loc_jan_SpyrTechnologiesIncMember_90925684-ae70-4d11-82d1-c5ff53915f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_d80bddc9-0169-4edd-be3d-baa2ac11d0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_d80bddc9-0169-4edd-be3d-baa2ac11d0be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_4d607b18-ea8e-48b9-86f2-a2ea26ae129f" xlink:href="jan-20231230.xsd#jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_4d607b18-ea8e-48b9-86f2-a2ea26ae129f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion_f24c8d09-fc72-4b97-a08e-8ffba382cf26" xlink:href="jan-20231230.xsd#jan_ConvertiblePreferredStockSharesIssuableUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion_f24c8d09-fc72-4b97-a08e-8ffba382cf26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5d30cb96-0d40-4f19-8768-e09566b728ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5d30cb96-0d40-4f19-8768-e09566b728ad" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_cce312d5-60e7-4451-b3d3-5fce9874023d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_cce312d5-60e7-4451-b3d3-5fce9874023d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_61a26940-b0b4-4147-9038-ae298ad4c1bf" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_61a26940-b0b4-4147-9038-ae298ad4c1bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent_9dfe0e6c-a502-417f-9e26-3b7a26c11b68" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:to="loc_jan_DepositsAndOtherAssetsNoncurrent_9dfe0e6c-a502-417f-9e26-3b7a26c11b68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:to="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_e23a83d3-d675-445e-9fe5-60f6ff2123cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_e23a83d3-d675-445e-9fe5-60f6ff2123cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FinancingArrangementMember_3cf39455-0fa0-49b7-94eb-9b805a637c12" xlink:href="jan-20231230.xsd#jan_FinancingArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:to="loc_jan_FinancingArrangementMember_3cf39455-0fa0-49b7-94eb-9b805a637c12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorporationFinancingAgreementMember_108ca669-6e24-49c7-8a2a-ddfc4ddacf10" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorporationFinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:to="loc_jan_AFCOCreditCorporationFinancingAgreementMember_108ca669-6e24-49c7-8a2a-ddfc4ddacf10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorpMember_0711dadf-9c7b-4c73-bafa-dc259fdd55fc" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:to="loc_jan_AFCOCreditCorpMember_0711dadf-9c7b-4c73-bafa-dc259fdd55fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1fa34c09-c005-4d98-b57e-bc9c350c64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:to="loc_us-gaap_ShortTermBorrowings_1fa34c09-c005-4d98-b57e-bc9c350c64b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#ShorttermdebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48bdbbf-32f6-4ddf-aef9-82c3681913c8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48bdbbf-32f6-4ddf-aef9-82c3681913c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorpMember_12be6161-b420-44ea-bdd4-ef15501b6638" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:to="loc_jan_AFCOCreditCorpMember_12be6161-b420-44ea-bdd4-ef15501b6638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac51bc2b-6d94-4132-bd18-bfd607c208a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac51bc2b-6d94-4132-bd18-bfd607c208a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorporationFinancingAgreementMember_bbdc1fbb-397d-4403-8f55-939208b2dece" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorporationFinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:to="loc_jan_AFCOCreditCorporationFinancingAgreementMember_bbdc1fbb-397d-4403-8f55-939208b2dece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da99e91c-f940-44a8-83be-027ac0d9dca8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:to="loc_srt_RangeMember_da99e91c-f940-44a8-83be-027ac0d9dca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:to="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c99b8b6-c751-4524-bf94-5a69fc4e079e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:to="loc_srt_MinimumMember_3c99b8b6-c751-4524-bf94-5a69fc4e079e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_340953cd-e637-4a49-b09a-31936262361f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:to="loc_srt_MaximumMember_340953cd-e637-4a49-b09a-31936262361f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FinancingArrangementMember_f0a55c5f-6082-479e-8030-195d21b3d959" xlink:href="jan-20231230.xsd#jan_FinancingArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:to="loc_jan_FinancingArrangementMember_f0a55c5f-6082-479e-8030-195d21b3d959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_68883c01-0e58-4161-81ed-8163acc658e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_68883c01-0e58-4161-81ed-8163acc658e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5c868170-8222-418a-8977-9e9a97aa3c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5c868170-8222-418a-8977-9e9a97aa3c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_901477fe-8f72-4f81-85a9-681a6b251def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_901477fe-8f72-4f81-85a9-681a6b251def" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e5b25622-347f-4afe-931b-108ab4a32e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e5b25622-347f-4afe-931b-108ab4a32e11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_cb6d98c9-bf9f-4faf-ab23-d746ee5019e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a797c05-32b6-4aae-9d39-6a8f41297d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_LongTermDebt_6a797c05-32b6-4aae-9d39-6a8f41297d76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9a0db09a-30ef-4f6e-8c79-9d87a3093c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9a0db09a-30ef-4f6e-8c79-9d87a3093c09" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesA1ConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e92f8569-a08b-40e6-8e45-9705c8a7c730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e92f8569-a08b-40e6-8e45-9705c8a7c730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_4addaabc-8b89-4934-8340-f80b1ef84b11" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:to="loc_jan_GeoTraqIncMember_4addaabc-8b89-4934-8340-f80b1ef84b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesAConvertiblePreferredStockMember_baa640ad-e6cd-480f-ad50-3bae595ec622" xlink:href="jan-20231230.xsd#jan_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:to="loc_jan_SeriesAConvertiblePreferredStockMember_baa640ad-e6cd-480f-ad50-3bae595ec622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1ConvertiblePreferredStockMember_338e9306-4339-4be2-ac51-c21023cac623" xlink:href="jan-20231230.xsd#jan_SeriesA1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:to="loc_jan_SeriesA1ConvertiblePreferredStockMember_338e9306-4339-4be2-ac51-c21023cac623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4fcf364f-d4c1-47be-a530-63273b561007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4fcf364f-d4c1-47be-a530-63273b561007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ab7c620b-2da1-44b2-855f-e24c50f7aec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ab7c620b-2da1-44b2-855f-e24c50f7aec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_3a72a534-fc1c-4744-b70d-89a4e5eccd64" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_3a72a534-fc1c-4744-b70d-89a4e5eccd64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_e26b6718-a444-411b-b9b3-abcaaa873423" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_e26b6718-a444-411b-b9b3-abcaaa873423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1df5e530-437f-48e5-b757-3b4d53e0fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1df5e530-437f-48e5-b757-3b4d53e0fe09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_ba03d247-c877-4327-8fcd-7f9c70f67c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_ba03d247-c877-4327-8fcd-7f9c70f67c92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27db7aba-67a3-4e8d-8240-b824ae129f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27db7aba-67a3-4e8d-8240-b824ae129f79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_3a75c4a8-a226-4869-9c1f-f4bb455a15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_3a75c4a8-a226-4869-9c1f-f4bb455a15aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockSharesForfeited_fbe4bd34-4a42-4631-a7b4-46bd9e276969" xlink:href="jan-20231230.xsd#jan_ConversionOfStockSharesForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_ConversionOfStockSharesForfeited_fbe4bd34-4a42-4631-a7b4-46bd9e276969" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2042b9df-3702-4afe-aa46-eb9043add2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2042b9df-3702-4afe-aa46-eb9043add2fe" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:to="loc_us-gaap_ClassOfStockDomain_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:to="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_9d29d2d8-9e14-49c3-bbde-d09f95b52b81" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_9d29d2d8-9e14-49c3-bbde-d09f95b52b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:to="loc_srt_RangeMember_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:to="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_393da64b-acfe-448e-bd30-82069033a9cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:to="loc_srt_MaximumMember_393da64b-acfe-448e-bd30-82069033a9cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_dbcdbbaa-84e5-47d3-a430-8b969149e7af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_dbcdbbaa-84e5-47d3-a430-8b969149e7af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion1Member_5c390cba-9421-4282-a435-c3c4b28f26bb" xlink:href="jan-20231230.xsd#jan_StockConversion1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion1Member_5c390cba-9421-4282-a435-c3c4b28f26bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion2Member_fdc3b59f-665e-4b96-aa89-548c9d20398b" xlink:href="jan-20231230.xsd#jan_StockConversion2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion2Member_fdc3b59f-665e-4b96-aa89-548c9d20398b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion3Member_d557b15f-0c50-486e-88e3-8adf062e3e29" xlink:href="jan-20231230.xsd#jan_StockConversion3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion3Member_d557b15f-0c50-486e-88e3-8adf062e3e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5539c971-bae4-4efe-ac1b-bbf760e7529f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5539c971-bae4-4efe-ac1b-bbf760e7529f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_eb04eb1a-e450-42e6-9dac-d24c72dc4e72" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:to="loc_jan_SoinTherapeuticsLLCMember_eb04eb1a-e450-42e6-9dac-d24c72dc4e72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13b02bff-e248-499d-8e0e-d045ba449df7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13b02bff-e248-499d-8e0e-d045ba449df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DrSoinMember_ced046c8-42c3-4184-b199-86593721ec2b" xlink:href="jan-20231230.xsd#jan_DrSoinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:to="loc_jan_DrSoinMember_ced046c8-42c3-4184-b199-86593721ec2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6f822abf-842d-4e34-8eb5-f1bcd2c76319_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:to="loc_us-gaap_RelatedPartyDomain_6f822abf-842d-4e34-8eb5-f1bcd2c76319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:to="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c993ea86-6f91-4e74-8f75-d79aeb93d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:to="loc_us-gaap_RelatedPartyMember_c993ea86-6f91-4e74-8f75-d79aeb93d5f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a515c0f4-4416-4c96-83db-a31fbae196c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a515c0f4-4416-4c96-83db-a31fbae196c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_026ba92d-08b8-47e7-8546-52bcc392f540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_026ba92d-08b8-47e7-8546-52bcc392f540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockAmountConvertible_ce2c6951-83b7-485b-86b7-8da5c75387d8" xlink:href="jan-20231230.xsd#jan_ConversionOfStockAmountConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockAmountConvertible_ce2c6951-83b7-485b-86b7-8da5c75387d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockCommencementPeriod_91082641-bea3-4412-a739-48320e738b4e" xlink:href="jan-20231230.xsd#jan_ConversionOfStockCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockCommencementPeriod_91082641-bea3-4412-a739-48320e738b4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockPeriodFollowingClosing_9c8aa946-4b7c-4b88-a8f3-4f3b194ccda8" xlink:href="jan-20231230.xsd#jan_ConversionOfStockPeriodFollowingClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockPeriodFollowingClosing_9c8aa946-4b7c-4b88-a8f3-4f3b194ccda8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentageOfGrossRevenue_4edcf497-0612-4d03-871d-75fa8d54dde2" xlink:href="jan-20231230.xsd#jan_PercentageOfGrossRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_PercentageOfGrossRevenue_4edcf497-0612-4d03-871d-75fa8d54dde2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockSharesOutstandingPercentage_fee8d172-ba3d-4599-af46-4183cfe52819" xlink:href="jan-20231230.xsd#jan_CommonStockSharesOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_CommonStockSharesOutstandingPercentage_fee8d172-ba3d-4599-af46-4183cfe52819" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_875adc88-50f4-4735-9271-567fe88589b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_875adc88-50f4-4735-9271-567fe88589b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_20782fbb-612e-440c-a391-8a24ea4a0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_20782fbb-612e-440c-a391-8a24ea4a0b06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_9ef3ed64-e79b-4cfe-a68e-bc4906e4cbeb" xlink:href="jan-20231230.xsd#jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_9ef3ed64-e79b-4cfe-a68e-bc4906e4cbeb" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:to="loc_us-gaap_ClassOfStockDomain_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:to="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_56ff5d1c-a9e8-42e9-9f90-6c9fcb226e81" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_56ff5d1c-a9e8-42e9-9f90-6c9fcb226e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_21806ed8-3039-433d-ad91-1f6623495131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_21806ed8-3039-433d-ad91-1f6623495131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a6f14fe1-c08c-4cd4-b097-658603d4b12d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a6f14fe1-c08c-4cd4-b097-658603d4b12d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares_76b100bd-7878-4845-b91a-63ad67a827c4" xlink:href="jan-20231230.xsd#jan_TemporaryEquitySharesIssuedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares_76b100bd-7878-4845-b91a-63ad67a827c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_7d1edabd-40f1-4338-8b7a-d63cf8c3f520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_7d1edabd-40f1-4338-8b7a-d63cf8c3f520" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_feb1783d-8bc5-4d09-968e-29248105e155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0e188270-5e4a-4417-9b1e-d3e8b98b14d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_48a268c0-d83e-45b9-95be-691488573f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b95c7247-42c7-4624-af0a-4838aa55a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7137b5bd-eafa-453f-a3be-2049af0eb143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7137b5bd-eafa-453f-a3be-2049af0eb143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArticlesOfIncorporationMember_69b176d1-7d41-4041-9530-c35d367cf9bc" xlink:href="jan-20231230.xsd#jan_ArticlesOfIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:to="loc_jan_ArticlesOfIncorporationMember_69b176d1-7d41-4041-9530-c35d367cf9bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SecuritiesPurchaseAgreementMember_6434c78d-f5b2-4ec1-aa0d-562a53784397" xlink:href="jan-20231230.xsd#jan_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:to="loc_jan_SecuritiesPurchaseAgreementMember_6434c78d-f5b2-4ec1-aa0d-562a53784397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba3e183a-b785-4357-9841-28175cddc81e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba3e183a-b785-4357-9841-28175cddc81e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_31315f91-5bf1-4ed4-a7b3-18d3ec5f9bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:to="loc_us-gaap_PrivatePlacementMember_31315f91-5bf1-4ed4-a7b3-18d3ec5f9bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d86516f0-4079-41b8-9506-fec9a2a2838b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d86516f0-4079-41b8-9506-fec9a2a2838b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreFundedWarrantsMemberMember_8e0d0c5d-dd4b-403d-a805-3306c7589bfa" xlink:href="jan-20231230.xsd#jan_PreFundedWarrantsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:to="loc_jan_PreFundedWarrantsMemberMember_8e0d0c5d-dd4b-403d-a805-3306c7589bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a379582d-7ad3-4872-a077-20ec148a24a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:to="loc_us-gaap_PlanNameDomain_a379582d-7ad3-4872-a077-20ec148a24a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:to="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2016Member_10db48d7-4fd0-438b-bbe4-4b8439cdf13a" xlink:href="jan-20231230.xsd#jan_Plan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_Plan2016Member_10db48d7-4fd0-438b-bbe4-4b8439cdf13a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2011Member_2b8e2884-0604-4b94-9547-6593d745ebbe" xlink:href="jan-20231230.xsd#jan_Plan2011Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_Plan2011Member_2b8e2884-0604-4b94-9547-6593d745ebbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_A2023PlanMember_e05f980f-c6d1-4ce1-9d1a-1a7f3f0dd3c9" xlink:href="jan-20231230.xsd#jan_A2023PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_A2023PlanMember_e05f980f-c6d1-4ce1-9d1a-1a7f3f0dd3c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_426a866b-98e4-4c44-a610-a674c226638e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_426a866b-98e4-4c44-a610-a674c226638e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747a5934-14c2-4754-b734-75c965bb7f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747a5934-14c2-4754-b734-75c965bb7f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_06742ed7-53b6-4966-b4f6-307f81ad294d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_06742ed7-53b6-4966-b4f6-307f81ad294d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_22f5fa9d-78c7-4a0a-9e29-1e28f6736ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_22f5fa9d-78c7-4a0a-9e29-1e28f6736ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_31fdcf80-77be-48b6-9f90-0e34ed204ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesIssued_31fdcf80-77be-48b6-9f90-0e34ed204ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e870d845-f122-4e08-9b9d-71e086033565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e870d845-f122-4e08-9b9d-71e086033565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_7638aef0-f8c1-4d89-ad06-8df1606cf5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_7638aef0-f8c1-4d89-ad06-8df1606cf5db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e647e1ee-fa4b-4bad-9566-02a210576130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e647e1ee-fa4b-4bad-9566-02a210576130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockPurchasePricePerShare_4bb18cb2-caef-489d-9ba6-c121e842f99b" xlink:href="jan-20231230.xsd#jan_CommonStockPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_CommonStockPurchasePricePerShare_4bb18cb2-caef-489d-9ba6-c121e842f99b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_793ac632-9d97-4176-96d5-5e7dbc460235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_793ac632-9d97-4176-96d5-5e7dbc460235" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1d4014c-6b02-43f4-9f26-e98d8aa59a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1d4014c-6b02-43f4-9f26-e98d8aa59a39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_78bdb79a-d344-425a-b90f-569b9f8061ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_78bdb79a-d344-425a-b90f-569b9f8061ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6f7bedff-f26a-4e06-9da1-2e616d0ed33a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6f7bedff-f26a-4e06-9da1-2e616d0ed33a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e2d2d7db-97c7-4f61-850d-99de073fffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e2d2d7db-97c7-4f61-850d-99de073fffee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1cf96932-e48c-4482-92cf-8fd8ef659b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1cf96932-e48c-4482-92cf-8fd8ef659b37" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_d209fd99-3a7b-43f2-8784-2bef5a82acc4" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantOrRightWarrantsOrRightsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_d209fd99-3a7b-43f2-8784-2bef5a82acc4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4387960c-3092-45d9-b276-e12b50353022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4387960c-3092-45d9-b276-e12b50353022" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59999ec0-36ae-4d45-8df7-44aa25ce9e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59999ec0-36ae-4d45-8df7-44aa25ce9e0c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2b0cd0c5-0616-4c08-8bed-3639841263e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2b0cd0c5-0616-4c08-8bed-3639841263e8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7beb5b0c-9eb3-4521-b2ff-d21ca7400071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7beb5b0c-9eb3-4521-b2ff-d21ca7400071" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_4e46dcde-9aee-4d3d-b343-2a35b7b588d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_4e46dcde-9aee-4d3d-b343-2a35b7b588d2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_372b1ba5-76cd-4fc4-bc05-7d9b7caacb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_651f3ae5-104c-40c1-b64b-dd8a484b94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_651f3ae5-104c-40c1-b64b-dd8a484b94c2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAwardsToBeGranted_3e45ae10-799b-488e-b3d5-bede16abb12f" xlink:href="jan-20231230.xsd#jan_AdditionalAwardsToBeGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_AdditionalAwardsToBeGranted_3e45ae10-799b-488e-b3d5-bede16abb12f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c23060c0-d5c3-4b73-a85a-494823ac86be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c23060c0-d5c3-4b73-a85a-494823ac86be" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2141d6a3-64d9-4f3f-94a8-265c7e57d122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2141d6a3-64d9-4f3f-94a8-265c7e57d122" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9c6788a3-7542-42df-9c1d-e5b09041aad1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9c6788a3-7542-42df-9c1d-e5b09041aad1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeOneMember_644a3c10-3e47-486f-8d74-947132a85057" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeOneMember_644a3c10-3e47-486f-8d74-947132a85057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeTwoMember_3d67c0db-3633-4d77-a3fd-db882b329bcf" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeTwoMember_3d67c0db-3633-4d77-a3fd-db882b329bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeThreeMember_aa3a1975-892a-4f1d-bcb6-c5bfb9ec3cb0" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeThreeMember_aa3a1975-892a-4f1d-bcb6-c5bfb9ec3cb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeFourMember_5398df46-74f4-455c-ba7c-1cb827cc6301" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeFourMember_5398df46-74f4-455c-ba7c-1cb827cc6301" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d7c2061b-7aab-44e9-8b2a-73a944a52430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d7c2061b-7aab-44e9-8b2a-73a944a52430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_25d885f9-fe27-4032-97b2-ac3511849d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_25d885f9-fe27-4032-97b2-ac3511849d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e22ad69b-b00a-417a-9281-89e179b20963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e22ad69b-b00a-417a-9281-89e179b20963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0ab5755d-8776-4f4d-a0a5-6175534d95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0ab5755d-8776-4f4d-a0a5-6175534d95f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_dc9bb9fc-8893-4948-8343-4222f6771462_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_dc9bb9fc-8893-4948-8343-4222f6771462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_7d1ad891-9dd7-4766-b487-657b0d2a9a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_7d1ad891-9dd7-4766-b487-657b0d2a9a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_08a98eba-a21a-420d-93cb-e0dfbed3fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_08a98eba-a21a-420d-93cb-e0dfbed3fa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_525832db-9fd8-4e4e-a946-dab32c53ac2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_525832db-9fd8-4e4e-a946-dab32c53ac2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_eb6837bb-477c-4578-b3d4-75a6482f7116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:to="loc_us-gaap_DomesticCountryMember_eb6837bb-477c-4578-b3d4-75a6482f7116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ceb50912-05b3-47e7-bce0-52426eef9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ceb50912-05b3-47e7-bce0-52426eef9c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_99b3a27b-c3a8-4a48-a7d2-cc1f167440cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_99b3a27b-c3a8-4a48-a7d2-cc1f167440cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_cb6258fe-47ce-4969-8fb9-ce6878fbac21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_OperatingLossCarryforwards_cb6258fe-47ce-4969-8fb9-ce6878fbac21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_3d88025e-2bbf-4988-9889-eba9cf1246c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_3d88025e-2bbf-4988-9889-eba9cf1246c9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#RelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_90f1d148-f1e6-4e12-8871-e0a1ba30477a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:to="loc_us-gaap_RelatedPartyDomain_90f1d148-f1e6-4e12-8871-e0a1ba30477a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:to="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0f178e1a-1672-4adb-b97f-d03a949b63a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:to="loc_us-gaap_RelatedPartyMember_0f178e1a-1672-4adb-b97f-d03a949b63a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_c9b62656-0aaa-450f-b0ff-cd385a48a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:to="loc_us-gaap_BeneficialOwnerMember_c9b62656-0aaa-450f-b0ff-cd385a48a1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78fae241-3856-41ba-9cb5-30ec4b3306bc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78fae241-3856-41ba-9cb5-30ec4b3306bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LiveVenturesIncorporatedMember_6c9e127f-e15b-402b-a298-947309085463" xlink:href="jan-20231230.xsd#jan_LiveVenturesIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:to="loc_jan_LiveVenturesIncorporatedMember_6c9e127f-e15b-402b-a298-947309085463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_62fe1e96-fe1c-43f5-8bac-38d31936c10f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:to="loc_us-gaap_CreditFacilityDomain_62fe1e96-fe1c-43f5-8bac-38d31936c10f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:to="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4a819575-8cf9-44ab-a441-3fe645723bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4a819575-8cf9-44ab-a441-3fe645723bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_33f4bb00-56a0-42ab-96de-e759721e54ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_33f4bb00-56a0-42ab-96de-e759721e54ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_403139fc-6bef-4735-86ca-d689ba4b0250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_403139fc-6bef-4735-86ca-d689ba4b0250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_07d8f159-c5c5-4987-a426-10f19069c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_07d8f159-c5c5-4987-a426-10f19069c3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9fd7326b-45b5-4d24-aafa-928248840456_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9fd7326b-45b5-4d24-aafa-928248840456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_316db926-2943-4c9e-ad6d-f40e77b972c4" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:to="loc_jan_ARCAAndSubsidiariesMember_316db926-2943-4c9e-ad6d-f40e77b972c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_f00ae3e0-04f8-4723-a3a2-9abefcafdc5c" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:to="loc_jan_IcgNoteMember_f00ae3e0-04f8-4723-a3a2-9abefcafdc5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCARecyclingPurchasingAgreementMember_89a74c7a-441e-4b16-b94c-38c1d3d8b072" xlink:href="jan-20231230.xsd#jan_ARCARecyclingPurchasingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:to="loc_jan_ARCARecyclingPurchasingAgreementMember_89a74c7a-441e-4b16-b94c-38c1d3d8b072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fec69e26-d0ba-4c50-90a4-a7f1f60157f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:to="loc_us-gaap_SegmentDomain_fec69e26-d0ba-4c50-90a4-a7f1f60157f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:to="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e8ce7463-9399-4a3d-aa2c-cf1407dec399" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e8ce7463-9399-4a3d-aa2c-cf1407dec399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_780b0e62-d8bb-487e-958f-014adb759942_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_780b0e62-d8bb-487e-958f-014adb759942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_JanOneMember_954e1f36-4c5a-4ad3-a03b-fb5a7a7fbc74" xlink:href="jan-20231230.xsd#jan_JanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:to="loc_jan_JanOneMember_954e1f36-4c5a-4ad3-a03b-fb5a7a7fbc74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_59328fc1-52ec-43ce-9b60-aecb93e0aa40_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:to="loc_dei_EntityDomain_59328fc1-52ec-43ce-9b60-aecb93e0aa40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:to="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacCapitalGroupLLCICGMember_9b0cbdbf-a67d-43d0-82fa-93b4e1d170d3" xlink:href="jan-20231230.xsd#jan_IsaacCapitalGroupLLCICGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:to="loc_jan_IsaacCapitalGroupLLCICGMember_9b0cbdbf-a67d-43d0-82fa-93b4e1d170d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86749513-fc11-428c-a3e5-4f49e5676c79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86749513-fc11-428c-a3e5-4f49e5676c79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_043eb55e-cda1-423d-8b92-fc13b3546a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_043eb55e-cda1-423d-8b92-fc13b3546a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_1e5bbb00-0f0d-49a0-bbf4-5adcb16d103d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_1e5bbb00-0f0d-49a0-bbf4-5adcb16d103d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_9acf84e8-d204-4beb-9f73-ea6e1d9e3763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_NetRentableArea_9acf84e8-d204-4beb-9f73-ea6e1d9e3763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bebbdc3b-31d0-44ac-97e8-e1f00c7f3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_OperatingLeaseExpense_bebbdc3b-31d0-44ac-97e8-e1f00c7f3d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_d70adad7-8aa0-4e1d-ae0a-09da63b13bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_d70adad7-8aa0-4e1d-ae0a-09da63b13bc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_a0333074-ee23-4f0d-a616-26ab96134032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_a0333074-ee23-4f0d-a616-26ab96134032" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c1d5ebcf-7c49-4e59-8534-9d0e7da3b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c1d5ebcf-7c49-4e59-8534-9d0e7da3b6d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7216c044-d1fa-4984-ac9a-052dff4b8288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7216c044-d1fa-4984-ac9a-052dff4b8288" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_cd052ad4-dabd-4ddd-a2dd-5086127993c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_cd052ad4-dabd-4ddd-a2dd-5086127993c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4b3069cb-3c62-45cb-92e1-dfb4ea19bb83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4b3069cb-3c62-45cb-92e1-dfb4ea19bb83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_b3fd2ef4-9754-4f36-9992-f019f96b1717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_b3fd2ef4-9754-4f36-9992-f019f96b1717" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_5d4f49af-6175-425f-98d2-d66b682f7e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_OtherLiabilities_5d4f49af-6175-425f-98d2-d66b682f7e39" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_ee856089-ac31-48f4-85e8-c1baad3ccd96" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_ee856089-ac31-48f4-85e8-c1baad3ccd96" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm_190f4586-24e3-427d-abf8-ae7cefc86801" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm_190f4586-24e3-427d-abf8-ae7cefc86801" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f61231a4-e0af-40ce-b340-884355930c88_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f61231a4-e0af-40ce-b340-884355930c88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SkyBridgeAmericasMember_17380134-7db6-457e-8808-d915ee38e193" xlink:href="jan-20231230.xsd#jan_SkyBridgeAmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_SkyBridgeAmericasMember_17380134-7db6-457e-8808-d915ee38e193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AMTIMCapitalIncMember_b29d7cb1-9464-4b3c-a654-9c713ade4d57" xlink:href="jan-20231230.xsd#jan_AMTIMCapitalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_AMTIMCapitalIncMember_b29d7cb1-9464-4b3c-a654-9c713ade4d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.SullivanMember_8ba6a445-8a05-4218-9a90-3f3ecc9e2d40" xlink:href="jan-20231230.xsd#jan_Mr.SullivanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_Mr.SullivanMember_8ba6a445-8a05-4218-9a90-3f3ecc9e2d40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AlixpartnersLlcMember_81861211-1541-498c-a708-59336b7c0000" xlink:href="jan-20231230.xsd#jan_AlixpartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_AlixpartnersLlcMember_81861211-1541-498c-a708-59336b7c0000" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_WestervilleSquareMember_23f3d6e1-b3d4-413c-9fd3-6ef52f3a1709" xlink:href="jan-20231230.xsd#jan_WestervilleSquareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_WestervilleSquareMember_23f3d6e1-b3d4-413c-9fd3-6ef52f3a1709" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TrusteesMain270LlcMember_fdec8add-7e06-42b1-9689-0e81ce130cd5" xlink:href="jan-20231230.xsd#jan_TrusteesMain270LlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_TrusteesMain270LlcMember_fdec8add-7e06-42b1-9689-0e81ce130cd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1689ae5f-7516-45f5-b287-7eb552a3aabe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:to="loc_srt_RangeMember_1689ae5f-7516-45f5-b287-7eb552a3aabe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:to="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da66ef63-50ff-4703-9383-1003ccef6869" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:to="loc_srt_MinimumMember_da66ef63-50ff-4703-9383-1003ccef6869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a978638e-14a7-4f67-95c1-e73b0128798b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:to="loc_srt_MaximumMember_a978638e-14a7-4f67-95c1-e73b0128798b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:to="loc_dei_EntityDomain_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:to="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ApplianceSmartIncMember_44274d6c-22c9-4992-aab8-a7245d9f10a9" xlink:href="jan-20231230.xsd#jan_ApplianceSmartIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:to="loc_jan_ApplianceSmartIncMember_44274d6c-22c9-4992-aab8-a7245d9f10a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_071b07cf-158e-42ad-b9f9-f9d5a59a3433_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_071b07cf-158e-42ad-b9f9-f9d5a59a3433_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_96a8b562-883f-47db-9a49-48d935daa253" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:to="loc_jan_GeoTraqIncMember_96a8b562-883f-47db-9a49-48d935daa253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_563d80d8-195e-43d7-af1a-3ca0eea34416_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:to="loc_us-gaap_RelatedPartyDomain_563d80d8-195e-43d7-af1a-3ca0eea34416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:to="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d85b8fe6-8f7b-465e-a32a-7862c00a8d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:to="loc_us-gaap_RelatedPartyMember_d85b8fe6-8f7b-465e-a32a-7862c00a8d70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_d5ba2d75-6f76-48fc-8be1-45528eee1186_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:to="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_d5ba2d75-6f76-48fc-8be1-45528eee1186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_bc44fa7c-a591-4c01-907f-75da84e05319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:to="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_bc44fa7c-a591-4c01-907f-75da84e05319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_12eef560-5fd5-4a30-a5f6-124f690daf56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:to="loc_us-gaap_ClassOfStockDomain_12eef560-5fd5-4a30-a5f6-124f690daf56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:to="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1ConvertiblePreferredStockMember_24091ed0-b680-44f2-a188-a5c9796042f6" xlink:href="jan-20231230.xsd#jan_SeriesA1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:to="loc_jan_SeriesA1ConvertiblePreferredStockMember_24091ed0-b680-44f2-a188-a5c9796042f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a877d94-75a6-4e6d-8581-224aeaa0e8fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:to="loc_us-gaap_EquityComponentDomain_0a877d94-75a6-4e6d-8581-224aeaa0e8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:to="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02a2d067-2ed9-4943-87e1-9971432bad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:to="loc_us-gaap_CommonStockMember_02a2d067-2ed9-4943-87e1-9971432bad9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_2e421c18-a74e-440d-9575-acb600f93ebd" xlink:href="jan-20231230.xsd#jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_2e421c18-a74e-440d-9575-acb600f93ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e0f14c92-d4ff-4f0f-9186-dfb51855377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e0f14c92-d4ff-4f0f-9186-dfb51855377e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_42a605a4-338e-4d71-9b61-bb8ecdebf671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_42a605a4-338e-4d71-9b61-bb8ecdebf671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_5ef72d42-6cba-4271-9431-f20782e7acad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LegalFees_5ef72d42-6cba-4271-9431-f20782e7acad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StatutoryInterestReceivable_bd1b28ad-b49f-420c-83a1-4aa78da9ff43" xlink:href="jan-20231230.xsd#jan_StatutoryInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_StatutoryInterestReceivable_bd1b28ad-b49f-420c-83a1-4aa78da9ff43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_489e4662-63e0-4eb8-9eb4-d0c4be208461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_489e4662-63e0-4eb8-9eb4-d0c4be208461" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfInstallment_382ee860-18f1-4787-a229-8c807bece3ad" xlink:href="jan-20231230.xsd#jan_NumberOfInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_NumberOfInstallment_382ee860-18f1-4787-a229-8c807bece3ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentOfPrepaymentTenderRestrictions_6bf4aaf3-3a2b-41dd-b740-d6f7d3586c58" xlink:href="jan-20231230.xsd#jan_PercentOfPrepaymentTenderRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_PercentOfPrepaymentTenderRestrictions_6bf4aaf3-3a2b-41dd-b740-d6f7d3586c58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d6cc42f9-70e1-4696-b58a-965ef968e8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d6cc42f9-70e1-4696-b58a-965ef968e8b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_addbde41-2619-4cc0-a074-dbbc3a788d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_addbde41-2619-4cc0-a074-dbbc3a788d27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f8827d9d-bd55-4b14-9c82-5aeeb47a1584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f8827d9d-bd55-4b14-9c82-5aeeb47a1584" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e6ff759d-6184-4449-9936-c59ace6572ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e6ff759d-6184-4449-9936-c59ace6572ba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedSettlementValue_a38da160-60ad-48e6-8cb7-6ada4134e0f4" xlink:href="jan-20231230.xsd#jan_AgreedSettlementValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_AgreedSettlementValue_a38da160-60ad-48e6-8cb7-6ada4134e0f4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTranches_b446cd3c-59af-44d6-b866-23f7c581761f" xlink:href="jan-20231230.xsd#jan_NumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_NumberOfTranches_b446cd3c-59af-44d6-b866-23f7c581761f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_357c4735-266e-4834-b525-b534ab45c0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_357c4735-266e-4834-b525-b534ab45c0bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1_de3a0302-dba0-4c91-9c20-7a5ab785fef2" xlink:href="jan-20231230.xsd#jan_OperatingLeasesFutureMinimumPaymentsDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1_de3a0302-dba0-4c91-9c20-7a5ab785fef2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_9dbc523f-a60e-4159-a56e-32dbb5587c6f" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_9dbc523f-a60e-4159-a56e-32dbb5587c6f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_926cf7ae-8fed-4648-9f73-d0b1050daa63" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_926cf7ae-8fed-4648-9f73-d0b1050daa63" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_f8bfe036-4523-4e33-a19f-89e2f925333e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_f8bfe036-4523-4e33-a19f-89e2f925333e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_0430608f-21b8-4bb2-82cf-9ca159f462f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_0430608f-21b8-4bb2-82cf-9ca159f462f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_fc57f1e8-363c-4842-89ca-7b49255a08a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_fc57f1e8-363c-4842-89ca-7b49255a08a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_4b31b693-e6f9-41a4-8c1e-413dbc10914a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_4b31b693-e6f9-41a4-8c1e-413dbc10914a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_5a20193c-dd45-4c7d-891a-9b44b7830843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_5a20193c-dd45-4c7d-891a-9b44b7830843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9156b38-aba7-43ab-bab9-be2fafb0e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9156b38-aba7-43ab-bab9-be2fafb0e4e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21d1d7e6-d253-4b02-af76-5cdb10a92835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21d1d7e6-d253-4b02-af76-5cdb10a92835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_747db8a9-8f70-4d86-8532-6ebed81f919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_747db8a9-8f70-4d86-8532-6ebed81f919b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ec04f09-72c3-4370-bad9-68aec150f67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ec04f09-72c3-4370-bad9-68aec150f67d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:to="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_b6a17f52-2a7a-4b1e-8331-436daf83f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_b6a17f52-2a7a-4b1e-8331-436daf83f8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b038f22-cf4f-4a44-a967-08578de7ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b136c7f7-ee01-45bd-8db2-5fc583b20d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b136c7f7-ee01-45bd-8db2-5fc583b20d7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_e834d119-db93-4632-ac45-e288f5c8beee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_e834d119-db93-4632-ac45-e288f5c8beee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73884146-28f3-4d35-bf21-4d173dd56e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1cb69e99-846b-4ecc-9aa9-fa905cb6e722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1cb69e99-846b-4ecc-9aa9-fa905cb6e722" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d041fa00-a004-426e-82e7-7b32dfaa12bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d041fa00-a004-426e-82e7-7b32dfaa12bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f99922a5-5203-4f4e-a1b1-92a7edf50945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d30ba4b5-e813-4d31-882f-1e9d84ee2763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:to="loc_us-gaap_EarningsPerShareBasic_d30ba4b5-e813-4d31-882f-1e9d84ee2763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_257d2993-9e55-43c7-9736-992b2eebddd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_257d2993-9e55-43c7-9736-992b2eebddd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e91c1d2-0273-4e51-aaab-cdbbc4157e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d81b362d-2016-4d87-8e01-8b663eebc2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d81b362d-2016-4d87-8e01-8b663eebc2a4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationScheduleofSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4548130c-25d1-4259-b1b1-742008ba3352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:to="loc_us-gaap_SegmentDomain_4548130c-25d1-4259-b1b1-742008ba3352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:to="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BiotechnologyMember_54902182-77f8-4976-9111-7ee49ebdcec7" xlink:href="jan-20231230.xsd#jan_BiotechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_BiotechnologyMember_54902182-77f8-4976-9111-7ee49ebdcec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingMember_826764ed-dba0-4bb2-9003-e0f5b960a4d6" xlink:href="jan-20231230.xsd#jan_RecyclingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_RecyclingMember_826764ed-dba0-4bb2-9003-e0f5b960a4d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TechnologySegmentMember_8b98353f-026d-4d6c-a6da-d91683fc11b3" xlink:href="jan-20231230.xsd#jan_TechnologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_TechnologySegmentMember_8b98353f-026d-4d6c-a6da-d91683fc11b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_da69a7d6-9aed-4d63-b147-9701a7cf8a94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_da69a7d6-9aed-4d63-b147-9701a7cf8a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_eb758b29-0305-4a61-8911-df00d142b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_eb758b29-0305-4a61-8911-df00d142b9bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_e0f632a9-d463-444d-ae50-645227df1635" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_e0f632a9-d463-444d-ae50-645227df1635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63c70e1b-a8d3-42cb-bd2a-35c802197c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63c70e1b-a8d3-42cb-bd2a-35c802197c4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_feec06b6-5e1f-41e8-8c03-804b2b9d8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_GrossProfit_feec06b6-5e1f-41e8-8c03-804b2b9d8d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e0c175d-4284-41bb-a2ff-4a10f29cce04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e0c175d-4284-41bb-a2ff-4a10f29cce04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7c6c788d-2391-48ac-a405-573e3c5f9aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7c6c788d-2391-48ac-a405-573e3c5f9aa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_2c2454e5-6b42-469a-942c-a3c76840f165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_2c2454e5-6b42-469a-942c-a3c76840f165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9aa5b51d-83c7-413b-b450-35c63a9db721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_NetIncomeLoss_9aa5b51d-83c7-413b-b450-35c63a9db721" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationScheduleofBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30b5e6f2-e7b1-4d93-842d-8d89140a0de9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:to="loc_us-gaap_SegmentDomain_30b5e6f2-e7b1-4d93-842d-8d89140a0de9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:to="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BiotechnologyMember_acab2dc2-54ad-4d7a-93e4-3c07f8cbb4e4" xlink:href="jan-20231230.xsd#jan_BiotechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:to="loc_jan_BiotechnologyMember_acab2dc2-54ad-4d7a-93e4-3c07f8cbb4e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_b0596764-b3fd-41ab-9f05-83fb7d359ee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_b0596764-b3fd-41ab-9f05-83fb7d359ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b6509710-7a6f-45bb-ab7b-847de075a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b6509710-7a6f-45bb-ab7b-847de075a71b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3062ee66-a9ef-4ae2-bc2a-8cc84d3bb891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:to="loc_us-gaap_Assets_3062ee66-a9ef-4ae2-bc2a-8cc84d3bb891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_348fa2f6-a630-4989-aa08-4f6b34e27ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_348fa2f6-a630-4989-aa08-4f6b34e27ac8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.live-ventures.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_149a653e-6db7-4448-a45d-079e9cc1cf21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_149a653e-6db7-4448-a45d-079e9cc1cf21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c0730c5a-d7d6-4b9c-b1cc-3e328fcf26f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:to="loc_us-gaap_SubsequentEventMember_c0730c5a-d7d6-4b9c-b1cc-3e328fcf26f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6748c4b9-318d-410e-ab3e-d51e1502feb4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6748c4b9-318d-410e-ab3e-d51e1502feb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2b4cc330-9bfd-40ff-b9f9-82c1082c21d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:to="loc_srt_ScenarioForecastMember_2b4cc330-9bfd-40ff-b9f9-82c1082c21d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_da8bb7ff-239c-4098-a48b-575405f83e92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_da8bb7ff-239c-4098-a48b-575405f83e92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_3f22cfcb-c831-460c-b52c-4318e84be2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_3f22cfcb-c831-460c-b52c-4318e84be2b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:to="loc_srt_ProductsAndServicesDomain_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:to="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember_713de295-7f31-4cb1-9f61-f4f585f563b8" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:to="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember_713de295-7f31-4cb1-9f61-f4f585f563b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember_4a4fbaff-8ed9-4bc1-8040-ad3db5ca0d89" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:to="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember_4a4fbaff-8ed9-4bc1-8040-ad3db5ca0d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fa2f946d-0408-4b00-9c5a-4946d94dd1f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fa2f946d-0408-4b00-9c5a-4946d94dd1f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_31648a17-2048-4e90-aedb-215483ffd835" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:to="loc_jan_IcgNoteMember_31648a17-2048-4e90-aedb-215483ffd835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacConsultingAgreementMember_b8616558-542f-4796-b589-e7ca8bddd033" xlink:href="jan-20231230.xsd#jan_IsaacConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:to="loc_jan_IsaacConsultingAgreementMember_b8616558-542f-4796-b589-e7ca8bddd033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7bff6d1d-e516-4d6a-b61d-35b90715d0f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:to="loc_us-gaap_RelatedPartyDomain_7bff6d1d-e516-4d6a-b61d-35b90715d0f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:to="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_37afbb3b-9721-428b-a0a9-046568cee5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:to="loc_us-gaap_RelatedPartyMember_37afbb3b-9721-428b-a0a9-046568cee5a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d732637d-fc99-44e4-85c9-fd5a7607673a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d732637d-fc99-44e4-85c9-fd5a7607673a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.JonIsaacMember_d074ba4b-86e5-4dd0-aafd-a60151404d95" xlink:href="jan-20231230.xsd#jan_Mr.JonIsaacMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:to="loc_jan_Mr.JonIsaacMember_d074ba4b-86e5-4dd0-aafd-a60151404d95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc172e69-c6c2-41e4-acc1-314f2fa6507e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc172e69-c6c2-41e4-acc1-314f2fa6507e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_ea53c095-d0f4-4128-98c2-9fc573785a54" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:to="loc_jan_SoinTherapeuticsLLCMember_ea53c095-d0f4-4128-98c2-9fc573785a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:to="loc_us-gaap_ClassOfStockDomain_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:to="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_b3e68c3b-de51-4b4e-a365-2345fe5deb89" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_b3e68c3b-de51-4b4e-a365-2345fe5deb89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_342c948a-b907-4544-bc6e-4323285a4ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_342c948a-b907-4544-bc6e-4323285a4ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ca802806-22fe-4510-82f3-6c8206762c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ca802806-22fe-4510-82f3-6c8206762c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6398a786-28de-4443-b28c-620ee94818bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6398a786-28de-4443-b28c-620ee94818bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9aa59909-5195-424a-ade1-d62c0c55f279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9aa59909-5195-424a-ade1-d62c0c55f279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d8fccb4-a19a-4ee2-b86b-26b61383991c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d8fccb4-a19a-4ee2-b86b-26b61383991c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_974a39cb-47af-4d24-96cb-c0a37bbaabfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_974a39cb-47af-4d24-96cb-c0a37bbaabfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea7077e0-8e8f-4fcc-85ec-2e4a72a1aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea7077e0-8e8f-4fcc-85ec-2e4a72a1aa05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cda85b8-14d7-4381-9ad3-00fa7bb25ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cda85b8-14d7-4381-9ad3-00fa7bb25ee0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_92f6f79a-b920-47c4-9ef0-12fbeac9a83b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_92f6f79a-b920-47c4-9ef0-12fbeac9a83b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_43995231-1a8f-4f32-b85b-3a7d5c48a58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_43995231-1a8f-4f32-b85b-3a7d5c48a58c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAgreementsToBePurchased_c8bab0d2-e877-4d09-a52f-bcafd1f2f3f1" xlink:href="jan-20231230.xsd#jan_NumberOfAgreementsToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_NumberOfAgreementsToBePurchased_c8bab0d2-e877-4d09-a52f-bcafd1f2f3f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_56388cb3-9ee7-4f80-8423-ad4f06f8fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_56388cb3-9ee7-4f80-8423-ad4f06f8fb73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b4a3db86-1743-43a2-8eb8-0183c780e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b4a3db86-1743-43a2-8eb8-0183c780e80f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_c387ef55-7d5a-4541-b45d-ce2139cd5bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_c387ef55-7d5a-4541-b45d-ce2139cd5bbc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9beb533a-af21-44f0-8b77-072005f1cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9beb533a-af21-44f0-8b77-072005f1cee5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_28e8ed38-e386-47c5-bd91-9a48a488688f" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_28e8ed38-e386-47c5-bd91-9a48a488688f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_113f3e06-d2b7-4655-9dd8-bbc4cf5ffa8f" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_113f3e06-d2b7-4655-9dd8-bbc4cf5ffa8f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantPricePerShare_f2763d41-6325-4cc9-859c-cdbbc52a822c" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_ClassOfWarrantPricePerShare_f2763d41-6325-4cc9-859c-cdbbc52a822c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c36cefb-3fad-4314-8848-cfac04dcfed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c36cefb-3fad-4314-8848-cfac04dcfed9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementTerm_517cee87-78e0-45c4-a73d-12cc052e02ca" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementTerm_517cee87-78e0-45c4-a73d-12cc052e02ca" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_9d72ef61-47bb-4141-9692-8fb5a3779451" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_9d72ef61-47bb-4141-9692-8fb5a3779451" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance_f8a46daf-9b08-4615-9f24-1f91a8fbcb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_CashSurrenderValueOfLifeInsurance_f8a46daf-9b08-4615-9f24-1f91a8fbcb0e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_2609e25d-2375-45ff-a47d-a02619b96ecf" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_2609e25d-2375-45ff-a47d-a02619b96ecf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_806f800f-d3e1-4309-a41c-968248efe788" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_806f800f-d3e1-4309-a41c-968248efe788" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTradingDaysBeforeBoardApproval_d6ac1012-f990-4cea-a452-e848f312f8ea" xlink:href="jan-20231230.xsd#jan_NumberOfTradingDaysBeforeBoardApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_NumberOfTradingDaysBeforeBoardApproval_d6ac1012-f990-4cea-a452-e848f312f8ea" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_b834c7fa-bc83-43ed-9358-54ecbfb57f13" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_b834c7fa-bc83-43ed-9358-54ecbfb57f13" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_bb215058-16dc-45ed-98af-95bd7d8b5fcb" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_bb215058-16dc-45ed-98af-95bd7d8b5fcb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_afea056c-7a5a-4483-ae4e-3227568de7ef" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_afea056c-7a5a-4483-ae4e-3227568de7ef" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_3e97ea2e-da9f-4ebc-9cf5-3f3ee1cbf963" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_3e97ea2e-da9f-4ebc-9cf5-3f3ee1cbf963" xlink:type="arc" order="28"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>jan-20231230_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_jan_PaymentFromBuyer_b771c6a0-b3f7-424d-a419-de383f75272e_terseLabel_en-US" xlink:label="lab_jan_PaymentFromBuyer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment from buyer</link:label>
    <link:label id="lab_jan_PaymentFromBuyer_label_en-US" xlink:label="lab_jan_PaymentFromBuyer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment from Buyer</link:label>
    <link:label id="lab_jan_PaymentFromBuyer_documentation_en-US" xlink:label="lab_jan_PaymentFromBuyer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment from Buyer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PaymentFromBuyer" xlink:href="jan-20231230.xsd#jan_PaymentFromBuyer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PaymentFromBuyer" xlink:to="lab_jan_PaymentFromBuyer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_6e587817-54e1-489c-83dc-ff309975c9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_aeb21a64-a321-4e7f-9030-12e70665ddf4_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_2653dc8a-dabc-4268-989a-4d0d97061b26_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages awarded plus interest and attorney fees</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_91e05858-7245-47ca-885e-c10517d4b196_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce9298c9-09c1-4265-94d4-faa696211177_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_350693eb-7bb3-481d-8559-5712c9855b2e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_08d7e757-fc26-4c13-9580-6a82b23412b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of preferred converted to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a725fc12-3a4b-4bba-bea0-bf0038219cd4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cc9a26e0-ceff-4f4d-af3c-d1cf799fa576_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_71db66bf-7796-4b87-a499-8f9be1100ccd_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial down payment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_70158f04-bb69-4231-b246-60fd664c1735_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payment tendered</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_366e4887-7bd0-4c3a-b049-151cc8cd49ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6ddb1c13-050c-4f59-81ac-db5ee7a4d0a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PotentialMarketExclusivityPeriod_28bbd15e-298b-4c4a-ade8-9015e4d72d26_terseLabel_en-US" xlink:label="lab_jan_PotentialMarketExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential market exclusivity period</link:label>
    <link:label id="lab_jan_PotentialMarketExclusivityPeriod_label_en-US" xlink:label="lab_jan_PotentialMarketExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Market Exclusivity Period</link:label>
    <link:label id="lab_jan_PotentialMarketExclusivityPeriod_documentation_en-US" xlink:label="lab_jan_PotentialMarketExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Market Exclusivity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PotentialMarketExclusivityPeriod" xlink:href="jan-20231230.xsd#jan_PotentialMarketExclusivityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PotentialMarketExclusivityPeriod" xlink:to="lab_jan_PotentialMarketExclusivityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_a6e6c72c-d5eb-4c70-ac87-0436aa9f26da_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write off of VM7 note receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_413206da-f734-474b-8afb-95a9aed6bb1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write off of VM7 note receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c13c274b-c152-4dca-a656-6149adf1b228_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AssetPurchaseAgreementMember_2102ccd4-f781-4cfa-aba4-33bcbd7de0ab_terseLabel_en-US" xlink:label="lab_jan_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_jan_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_jan_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_jan_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_jan_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AssetPurchaseAgreementMember" xlink:href="jan-20231230.xsd#jan_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AssetPurchaseAgreementMember" xlink:to="lab_jan_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_92ea5525-7e93-4d88-8ae3-770f61923194_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate monthly pre-payments</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Prepayment</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PreFundedWarrantsMemberMember_fade0573-beea-433f-a792-63673891e3e2_terseLabel_en-US" xlink:label="lab_jan_PreFundedWarrantsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants Member</link:label>
    <link:label id="lab_jan_PreFundedWarrantsMemberMember_label_en-US" xlink:label="lab_jan_PreFundedWarrantsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants Member [Member]</link:label>
    <link:label id="lab_jan_PreFundedWarrantsMemberMember_documentation_en-US" xlink:label="lab_jan_PreFundedWarrantsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreFundedWarrantsMemberMember" xlink:href="jan-20231230.xsd#jan_PreFundedWarrantsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PreFundedWarrantsMemberMember" xlink:to="lab_jan_PreFundedWarrantsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_8cafc3e3-d78b-4203-bdd6-f7464980d225_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate monthly payments from the buyer</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments from Buyer</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments from Buyer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_31afd55c-928c-42cd-8e45-f9c81bcd2f31_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax provision (benefit) - domestic</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_dd613655-7446-4391-9008-99b4326e4568_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, series A-1 - par value $0.001 per share 2,000,000 authorized, 193,730 and 222,588 shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_520076a1-ee03-4034-a12b-e9d2fa0a3f76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">KLC Financial loan origination fees</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d7234205-989c-432b-82bf-c21bb642d3d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_67c86678-23e0-4491-b5c5-7e55a0288deb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fb889069-5278-4e9b-b81c-8274ddfd4c42_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ecbda47a-40c5-4f4f-8882-264dbcf36426_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_A2023PlanMember_34ec4f97-bf96-4570-a4c7-e39f65186a23_terseLabel_en-US" xlink:label="lab_jan_A2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Plan</link:label>
    <link:label id="lab_jan_A2023PlanMember_label_en-US" xlink:label="lab_jan_A2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Plan [Member]</link:label>
    <link:label id="lab_jan_A2023PlanMember_documentation_en-US" xlink:label="lab_jan_A2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_A2023PlanMember" xlink:href="jan-20231230.xsd#jan_A2023PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_A2023PlanMember" xlink:to="lab_jan_A2023PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SecuritiesPurchaseAgreementMember_d9ca6a9e-0525-446d-b37c-639fe8192709_terseLabel_en-US" xlink:label="lab_jan_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_jan_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_jan_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_jan_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_jan_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SecuritiesPurchaseAgreementMember" xlink:href="jan-20231230.xsd#jan_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SecuritiesPurchaseAgreementMember" xlink:to="lab_jan_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ArcaMember_40d7207d-7652-41ea-94c8-cda377a2f4d3_terseLabel_en-US" xlink:label="lab_jan_ArcaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARCA</link:label>
    <link:label id="lab_jan_ArcaMember_label_en-US" xlink:label="lab_jan_ArcaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARCA Member</link:label>
    <link:label id="lab_jan_ArcaMember_documentation_en-US" xlink:label="lab_jan_ArcaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARCA Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArcaMember" xlink:href="jan-20231230.xsd#jan_ArcaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ArcaMember" xlink:to="lab_jan_ArcaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_e0a09cbf-457b-4911-a823-5aea38ad0454_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on reversal of contingent liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_1cfec6e9-692b-4041-896d-84068c0b186c_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities, Value [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchased under Agreements to Resell, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward" xlink:to="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c459b06a-7dba-4a11-802c-90406508b490_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DispositionTransactionTermPeriod_168c7b91-9db5-438b-aa18-4f6ccf1b4a01_terseLabel_en-US" xlink:label="lab_jan_DispositionTransactionTermPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposition transaction term period</link:label>
    <link:label id="lab_jan_DispositionTransactionTermPeriod_label_en-US" xlink:label="lab_jan_DispositionTransactionTermPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposition Transaction Term Period</link:label>
    <link:label id="lab_jan_DispositionTransactionTermPeriod_documentation_en-US" xlink:label="lab_jan_DispositionTransactionTermPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposition Transaction Term Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionTermPeriod" xlink:href="jan-20231230.xsd#jan_DispositionTransactionTermPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DispositionTransactionTermPeriod" xlink:to="lab_jan_DispositionTransactionTermPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f525d775-6828-4c2b-8125-70f1a0898b3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_4cf350de-5696-429e-94f9-8f5d59bb7b3a_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d34ca0be-1da3-407c-9dab-7cc351e4d6ae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of provision for income taxes with federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_191d3299-bb5f-4710-a8fa-29719d71efdf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6db54dbd-a50f-4e0f-ae7e-a6b919312e70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PatentsAndDomainsMember_955e4ffe-9561-4079-84d9-8ab5fa614ded_terseLabel_en-US" xlink:label="lab_jan_PatentsAndDomainsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and domains</link:label>
    <link:label id="lab_jan_PatentsAndDomainsMember_label_en-US" xlink:label="lab_jan_PatentsAndDomainsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Domains [Member]</link:label>
    <link:label id="lab_jan_PatentsAndDomainsMember_documentation_en-US" xlink:label="lab_jan_PatentsAndDomainsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents and domains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PatentsAndDomainsMember" xlink:href="jan-20231230.xsd#jan_PatentsAndDomainsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PatentsAndDomainsMember" xlink:to="lab_jan_PatentsAndDomainsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_4d3fc16d-9b0e-44b9-ac37-d71372ed6947_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares issued (in shares)</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Shares Issued</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e39955b9-21ae-4014-aa65-5e3fb4850db0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3f9a8c49-8d38-4539-969c-ad2eb69b9a9d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_464d3382-b35a-4bf2-9e67-f801270d2d42_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable face amount</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable with Imputed Interest, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0737cf5a-a2e8-46e0-b32e-3576bab10e85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_d1ccdb73-a363-4bc8-b212-b87115e41cb4_terseLabel_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal deposit insurance corporation insured per institution</link:label>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_label_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_efb814cf-f15d-48b3-a1ba-b934122d7061_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in exchange rate on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e947073d-ccd8-4485-a07d-bdf91d4e5437_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_052fb0f8-459c-44bc-9930-c10a4b71f1c5_terseLabel_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax for installment sale</link:label>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_label_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Federal Income Tax, Percent</link:label>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_documentation_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Federal Income Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:to="lab_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5a1eb2dd-1be2-41e9-aea6-6ee046557f7d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_da784f8a-6666-4d3b-b001-fd1ae887b21a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant offering and exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_BuildingsAndImprovementsMember_9eb12c82-6eb8-4583-8888-53a8687e5e7a_terseLabel_en-US" xlink:label="lab_jan_BuildingsAndImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_jan_BuildingsAndImprovementsMember_label_en-US" xlink:label="lab_jan_BuildingsAndImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements [Member]</link:label>
    <link:label id="lab_jan_BuildingsAndImprovementsMember_documentation_en-US" xlink:label="lab_jan_BuildingsAndImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Buildings and Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BuildingsAndImprovementsMember" xlink:href="jan-20231230.xsd#jan_BuildingsAndImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_BuildingsAndImprovementsMember" xlink:to="lab_jan_BuildingsAndImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AccruedGuaranteesCurrent_43dad1e3-c878-4a42-a9a0-1454ed126e92_terseLabel_en-US" xlink:label="lab_jan_AccruedGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued guarantees</link:label>
    <link:label id="lab_jan_AccruedGuaranteesCurrent_label_en-US" xlink:label="lab_jan_AccruedGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Guarantees Current</link:label>
    <link:label id="lab_jan_AccruedGuaranteesCurrent_documentation_en-US" xlink:label="lab_jan_AccruedGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued guarantees current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedGuaranteesCurrent" xlink:href="jan-20231230.xsd#jan_AccruedGuaranteesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AccruedGuaranteesCurrent" xlink:to="lab_jan_AccruedGuaranteesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfRightOfUseAssets_c177395b-fa1a-4034-b72f-fff8fe477926_terseLabel_en-US" xlink:label="lab_jan_DisposalOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_jan_DisposalOfRightOfUseAssets_label_en-US" xlink:label="lab_jan_DisposalOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Right-of-use Assets</link:label>
    <link:label id="lab_jan_DisposalOfRightOfUseAssets_documentation_en-US" xlink:label="lab_jan_DisposalOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Right-of-use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfRightOfUseAssets" xlink:href="jan-20231230.xsd#jan_DisposalOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfRightOfUseAssets" xlink:to="lab_jan_DisposalOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9eb6b7f6-9546-4223-8374-ddbc0fea29d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ab24b4c9-8ba3-4fa2-bc89-8d16cff21237_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TechnologySegmentMember_6b9f2712-8b9b-4690-8474-1d92bc030948_terseLabel_en-US" xlink:label="lab_jan_TechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_jan_TechnologySegmentMember_label_en-US" xlink:label="lab_jan_TechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Segment [Member]</link:label>
    <link:label id="lab_jan_TechnologySegmentMember_documentation_en-US" xlink:label="lab_jan_TechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TechnologySegmentMember" xlink:href="jan-20231230.xsd#jan_TechnologySegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TechnologySegmentMember" xlink:to="lab_jan_TechnologySegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5bef791a-37b0-492f-8d88-df66474d46cc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_11474b73-5406-44ac-9adb-2501db542809_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_8bf82c81-bcf0-414a-aeda-e84776ef066a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3cc76864-d22f-46aa-bc06-46ad607a0335_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_60a0e58c-2e5d-4c37-a612-73a088079329_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3d18cd9f-0e01-44dd-ae13-e38ad903156d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_b164ec00-4645-4033-a8dd-8c028ed2a6fc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_CashDisposal_c57441d5-0f4b-4904-a6dd-2f9d18b3e00e_terseLabel_en-US" xlink:label="lab_jan_CashDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_jan_CashDisposal_label_en-US" xlink:label="lab_jan_CashDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Disposal</link:label>
    <link:label id="lab_jan_CashDisposal_documentation_en-US" xlink:label="lab_jan_CashDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CashDisposal" xlink:href="jan-20231230.xsd#jan_CashDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_CashDisposal" xlink:to="lab_jan_CashDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e455caf-efb1-4ac0-8786-c6b7d498dc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_f616e91a-0035-4716-8db5-709add573019_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_70c18fae-bded-4e7f-b865-fa3f9c708123_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_336d562d-ccc4-4646-8544-4132a389eeeb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_c8c53325-92bc-478b-b2b6-4e247844a1f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_0912fb15-1883-4a11-b252-a97c70d9e8ce_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_f10d57da-dc1e-41d7-9835-b21794268fc8_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liability - California sales taxes</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_0f453c64-588c-46b1-95f4-87001902ce7b_totalLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f1353d50-6ce6-4252-b83b-237a8627e3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_99c2ff22-73a8-4dc8-920e-8f53bd557aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DiscontinuedInvestingActivities_d169f955-df94-4fef-8969-3f5c3be0a501_terseLabel_en-US" xlink:label="lab_jan_DiscontinuedInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DISCONTINUED INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedInvestingActivities_label_en-US" xlink:label="lab_jan_DiscontinuedInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DISCONTINUED INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedInvestingActivities_documentation_en-US" xlink:label="lab_jan_DiscontinuedInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DISCONTINUED INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedInvestingActivities" xlink:href="jan-20231230.xsd#jan_DiscontinuedInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DiscontinuedInvestingActivities" xlink:to="lab_jan_DiscontinuedInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_0064acbe-92e7-4143-90bf-9178a4be374a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_5d33bccd-9ec5-409b-9ae6-465110df24dd_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligation short-term - operating leases</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Lease Obligation Short Term, Operating Leases</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Lease Obligation Short Term, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_6a451361-0193-4925-aa95-b229de38c99e_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of the reduction percentage (percent)</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Payment Receivable, Percentage Of Difference Between Assessment And Settlement Value</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Payment Receivable, Percentage Of Difference Between Assessment And Settlement Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_87c8c471-7ce5-4e8f-bde7-d19dd226d995_negatedLabel_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of note receivable discount</link:label>
    <link:label id="lab_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_label_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Guarantee Insurance Contracts, Premiums Receivable, Adjustment, Accretion of Discount on Premium Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" xlink:to="lab_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a89a24f2-2ff7-4c2d-ae97-05bb72e47b77_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive shares excluded from earnings per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0e66f032-892c-4802-aa37-527a8f83e5e0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesGConvertiblePreferredStockMember_259de109-3132-4ce4-a8d6-ac238b2398cf_terseLabel_en-US" xlink:label="lab_jan_SeriesGConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series G Convertible Preferred Stock</link:label>
    <link:label id="lab_jan_SeriesGConvertiblePreferredStockMember_label_en-US" xlink:label="lab_jan_SeriesGConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_jan_SeriesGConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_jan_SeriesGConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series G Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesGConvertiblePreferredStockMember" xlink:href="jan-20231230.xsd#jan_SeriesGConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesGConvertiblePreferredStockMember" xlink:to="lab_jan_SeriesGConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ExercisePriceRangeTwoMember_009f399b-60fe-46e0-a971-b041e084cceb_terseLabel_en-US" xlink:label="lab_jan_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$11.10 to $15.00</link:label>
    <link:label id="lab_jan_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_jan_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_jan_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_jan_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price range two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeTwoMember" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ExercisePriceRangeTwoMember" xlink:to="lab_jan_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8b923cc4-b17f-4efd-a564-fa40328993ed_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_9ec461d1-931b-4d65-b7e4-4e50d5d38c2c_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share value of the restricted shares issued (in usd per share)</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Conversion Price</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_44d31c28-652c-4a1f-9a26-8708a18a5cd5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d6390074-c004-4ac8-af23-b4482638cebe_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d808feae-85a4-4749-9ff6-fd6eb75b536d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Benefit of Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockConversion2Member_a92686b1-be6d-47d7-835d-0f256e860a23_terseLabel_en-US" xlink:label="lab_jan_StockConversion2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion 2</link:label>
    <link:label id="lab_jan_StockConversion2Member_label_en-US" xlink:label="lab_jan_StockConversion2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion 2 [Member]</link:label>
    <link:label id="lab_jan_StockConversion2Member_documentation_en-US" xlink:label="lab_jan_StockConversion2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Conversion 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion2Member" xlink:href="jan-20231230.xsd#jan_StockConversion2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockConversion2Member" xlink:to="lab_jan_StockConversion2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_VM7CorporationMember_ee9bcf14-7d4f-45c7-a173-918c09b4f03e_terseLabel_en-US" xlink:label="lab_jan_VM7CorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VM7 Corporation</link:label>
    <link:label id="lab_jan_VM7CorporationMember_label_en-US" xlink:label="lab_jan_VM7CorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">V M 7 Corporation [Member]</link:label>
    <link:label id="lab_jan_VM7CorporationMember_documentation_en-US" xlink:label="lab_jan_VM7CorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VM7 Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_VM7CorporationMember" xlink:href="jan-20231230.xsd#jan_VM7CorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_VM7CorporationMember" xlink:to="lab_jan_VM7CorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_472425ea-e14d-4a4f-9874-d8b1b07efcd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deposits and Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_2f111fe0-3778-46ba-a37f-79749293056c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_3ef3dec6-ab80-4d26-b9a9-97dc3252cc8f_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_9eb7506b-775b-43a8-b58b-c5b2d217368d_totalLabel_en-US" xlink:label="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision of income taxes, Total</link:label>
    <link:label id="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_label_en-US" xlink:label="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations Before Provision (Benefit) Of Income Taxes</link:label>
    <link:label id="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_documentation_en-US" xlink:label="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations Before Provision (Benefit) Of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:href="jan-20231230.xsd#jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:to="lab_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4afec214-42cc-4aee-8f6c-c05d87305f51_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_61d4ead8-0d0f-46b6-b284-190631df32f7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a77646fe-d3b2-42cc-94de-eb06dac26926_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_2796f46b-a1ff-4b5c-bb9b-c0685a544f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable interest rate</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable with Imputed Interest, Effective Yield (Interest Rate)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:to="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7df2018f-ad76-42ed-bc25-0a3a5bda1309_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfAccountsReceivable_e22d854e-34c8-4479-8909-69023be7a35e_terseLabel_en-US" xlink:label="lab_jan_DisposalOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_jan_DisposalOfAccountsReceivable_label_en-US" xlink:label="lab_jan_DisposalOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Accounts receivable</link:label>
    <link:label id="lab_jan_DisposalOfAccountsReceivable_documentation_en-US" xlink:label="lab_jan_DisposalOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsReceivable" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfAccountsReceivable" xlink:to="lab_jan_DisposalOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_IcgNoteMember_67c12793-24be-4e57-9235-8b35ee5fc378_terseLabel_en-US" xlink:label="lab_jan_IcgNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICG Note</link:label>
    <link:label id="lab_jan_IcgNoteMember_label_en-US" xlink:label="lab_jan_IcgNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICG Note [Member]</link:label>
    <link:label id="lab_jan_IcgNoteMember_documentation_en-US" xlink:label="lab_jan_IcgNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ICG Note Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_IcgNoteMember" xlink:to="lab_jan_IcgNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3ed67da3-b007-48dd-b840-e6dd4e4917a2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75587c7c-f09b-4876-a98c-a1760035f61b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c68405e8-aec0-4893-bb63-b8d3642ef656_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AMTIMCapitalIncMember_92ba2dca-aefc-4868-89ae-373649ba1fc8_terseLabel_en-US" xlink:label="lab_jan_AMTIMCapitalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AMTIM Capital Inc</link:label>
    <link:label id="lab_jan_AMTIMCapitalIncMember_label_en-US" xlink:label="lab_jan_AMTIMCapitalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A M T I M Capital Inc [Member]</link:label>
    <link:label id="lab_jan_AMTIMCapitalIncMember_documentation_en-US" xlink:label="lab_jan_AMTIMCapitalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AMTIM Capital, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AMTIMCapitalIncMember" xlink:href="jan-20231230.xsd#jan_AMTIMCapitalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AMTIMCapitalIncMember" xlink:to="lab_jan_AMTIMCapitalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a4e8001f-4514-4a38-ad42-bff5f3ddfb7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Before Benefit of Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_d863c7df-e8f0-4d1f-858b-a11da8405f91_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_396e24ac-ce20-4c91-b354-9526523f732f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_07d16939-c3a6-4b1c-9b6e-5ef21c9768f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ArticlesOfIncorporationMember_c7ead8ef-db7e-4873-b71c-8fbb5321c81a_terseLabel_en-US" xlink:label="lab_jan_ArticlesOfIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Articles of Incorporation</link:label>
    <link:label id="lab_jan_ArticlesOfIncorporationMember_label_en-US" xlink:label="lab_jan_ArticlesOfIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Articles Of Incorporation [Member]</link:label>
    <link:label id="lab_jan_ArticlesOfIncorporationMember_documentation_en-US" xlink:label="lab_jan_ArticlesOfIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Articles of incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArticlesOfIncorporationMember" xlink:href="jan-20231230.xsd#jan_ArticlesOfIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ArticlesOfIncorporationMember" xlink:to="lab_jan_ArticlesOfIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_15d605e9-a9e1-4c41-a8fa-61cfe9c89cc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_a0e0f103-d68f-4b4f-b567-a797aae6130d_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_27299cec-ce4c-41b1-a98c-c2bae9b3ebb2_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9172b8e4-fdb8-4cb8-9092-0f17a3758f69_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9de7a0ee-7b82-4dd3-9ad1-ae599c34264d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of loan fee on each borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_51adb456-4088-4f9f-92c4-d7e55a7420cd_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ff63be54-f7e7-47b3-a153-b5fd69e3cbb1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_11a467db-a5ae-4a17-8990-ba53f7db47a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f37cb3bc-59f4-4d62-a3c9-937c7967ba6f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NumberOfAgreementsToBePurchased_02c6d579-08e6-4129-a029-51354e6fc7b5_terseLabel_en-US" xlink:label="lab_jan_NumberOfAgreementsToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaffiliated third-part investors</link:label>
    <link:label id="lab_jan_NumberOfAgreementsToBePurchased_label_en-US" xlink:label="lab_jan_NumberOfAgreementsToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Agreements To Be Purchased</link:label>
    <link:label id="lab_jan_NumberOfAgreementsToBePurchased_documentation_en-US" xlink:label="lab_jan_NumberOfAgreementsToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Agreements To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAgreementsToBePurchased" xlink:href="jan-20231230.xsd#jan_NumberOfAgreementsToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NumberOfAgreementsToBePurchased" xlink:to="lab_jan_NumberOfAgreementsToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalancePremiumReceived_21535708-a00b-404b-98d4-acaa28a72b6c_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalancePremiumReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on shares received</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalancePremiumReceived_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalancePremiumReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Premium Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalancePremiumReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalancePremiumReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalancePremiumReceived" xlink:to="lab_us-gaap_PolicyholderAccountBalancePremiumReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_05aae11e-bef0-4efb-9dfe-8b745568d580_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_1c411e21-eb8d-4ad7-9f16-5732e50bd448_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid at close of transactions</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Asset Acquisition, Consideration Transferred, At Closure</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Asset Acquisition, Consideration Transferred, At Closure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_65617017-ce0f-47d0-9cea-da10b5aa1e18_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36626ec0-cb1b-4964-8c32-25468f3c1669_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_35e8f9ab-6e44-4c9c-93e5-5c688ad0e3d3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b5d2305e-ca68-4387-95a8-d39a0d0bb06f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_3af3dcb7-340e-48f5-aa2b-07fae9aa4bb5_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_ed60fc93-4ba1-4afb-9dd8-b12a57fd3b50_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfAccruedLiability_9bffc960-aab8-45ab-887f-8600fef21dbc_terseLabel_en-US" xlink:label="lab_jan_DisposalOfAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_jan_DisposalOfAccruedLiability_label_en-US" xlink:label="lab_jan_DisposalOfAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Accrued liability</link:label>
    <link:label id="lab_jan_DisposalOfAccruedLiability_documentation_en-US" xlink:label="lab_jan_DisposalOfAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Accrued liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiability" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfAccruedLiability" xlink:to="lab_jan_DisposalOfAccruedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_83e1ab08-cdb2-4c1c-a17a-9d43a9bc8009_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_KlcFinancialMember_77e27d74-ae27-4a4f-9977-047c759a11e7_terseLabel_en-US" xlink:label="lab_jan_KlcFinancialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KLC Financial</link:label>
    <link:label id="lab_jan_KlcFinancialMember_label_en-US" xlink:label="lab_jan_KlcFinancialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KLC Financial [Member]</link:label>
    <link:label id="lab_jan_KlcFinancialMember_documentation_en-US" xlink:label="lab_jan_KlcFinancialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KLC Financial.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_KlcFinancialMember" xlink:href="jan-20231230.xsd#jan_KlcFinancialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_KlcFinancialMember" xlink:to="lab_jan_KlcFinancialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_e8797d56-93e3-4405-a824-7269dcccf825_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_608c8f7b-71d4-4437-8016-ad68a6373603_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable - long term portion</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_7c143e38-f6b6-4d43-824f-5996674a8d1d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember_6a38311c-fb8e-4e2d-8ee9-02c383302dad_terseLabel_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1st policy</link:label>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember_label_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Universal Life Insurance Policy, Policy One [Member]</link:label>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember_documentation_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Universal Life Insurance Policy, Policy One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:to="lab_jan_UniversalLifeInsurancePolicyPolicyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_1827a0b2-d83f-48af-acc7-14b8bb9868e4_terseLabel_en-US" xlink:label="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of executive officers named in complaint</link:label>
    <link:label id="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_label_en-US" xlink:label="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Executive Officers Named In Complaint</link:label>
    <link:label id="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_documentation_en-US" xlink:label="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Executive Officers Named In Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:href="jan-20231230.xsd#jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:to="lab_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_91542a2b-2c79-4c53-99a7-8454f64b3e81_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DrSoinMember_ff5cdc4f-809f-4aea-b90f-1dee0ca490ef_terseLabel_en-US" xlink:label="lab_jan_DrSoinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dr. Soin</link:label>
    <link:label id="lab_jan_DrSoinMember_label_en-US" xlink:label="lab_jan_DrSoinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Soin [Member]</link:label>
    <link:label id="lab_jan_DrSoinMember_documentation_en-US" xlink:label="lab_jan_DrSoinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr. Soin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DrSoinMember" xlink:href="jan-20231230.xsd#jan_DrSoinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DrSoinMember" xlink:to="lab_jan_DrSoinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a0bcc542-6245-4d77-b809-8497924ac11e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashSurrenderValueOfLifeInsurance_e7e65e76-030e-4e3e-a2ed-d39b9c132cef_terseLabel_en-US" xlink:label="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated value / surrender value of life insurance policy</link:label>
    <link:label id="lab_us-gaap_CashSurrenderValueOfLifeInsurance_label_en-US" xlink:label="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Surrender Value of Life Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:to="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DebtDiscountRate_6657e3fb-42c3-4241-8db2-7c81344200e5_terseLabel_en-US" xlink:label="lab_jan_DebtDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original issuance discount rate percentage</link:label>
    <link:label id="lab_jan_DebtDiscountRate_label_en-US" xlink:label="lab_jan_DebtDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Discount Rate</link:label>
    <link:label id="lab_jan_DebtDiscountRate_documentation_en-US" xlink:label="lab_jan_DebtDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtDiscountRate" xlink:href="jan-20231230.xsd#jan_DebtDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DebtDiscountRate" xlink:to="lab_jan_DebtDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_624bb2d8-536f-4625-a765-864a854e7c8b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_c20d3c81-8ddc-421f-8a0c-9d1a089ac1fe_terseLabel_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants in each unit (in shares)</link:label>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_label_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unit Composition, Number Of Warrants Issued In Each unit</link:label>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_documentation_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unit Composition, Number Of Warrants Issued In Each unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:to="lab_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_63e022c1-f540-498c-a7b1-9c1307a0fd73_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional proceeds received for the equity of each subsidiary</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Proceeds Received For Equity Of Each Subsidiary</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Proceeds Received For Equity Of Each Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_c194096e-0d16-4e4a-8dfa-cc96abbacf09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, conversion ratio</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ee3a88c7-f55a-489a-bb61-895a283f3cc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0d2a085f-440d-47e4-a681-b14a7be56b3a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b8a46a75-a0b3-43b6-beb1-943692a07869_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DeferredTaxAssetsInterest_ce32db8c-0be8-401f-ad60-1c562ae3df6f_terseLabel_en-US" xlink:label="lab_jan_DeferredTaxAssetsInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 163(j) interest</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsInterest_label_en-US" xlink:label="lab_jan_DeferredTaxAssetsInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Interest</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsInterest_documentation_en-US" xlink:label="lab_jan_DeferredTaxAssetsInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsInterest" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DeferredTaxAssetsInterest" xlink:to="lab_jan_DeferredTaxAssetsInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ecdb7a6f-48b1-454a-a7b3-af604c772f7e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoncashRecognitionOfNewLeases_33e95f70-c813-4fc1-94d3-d1f0dd149de7_terseLabel_en-US" xlink:label="lab_jan_NoncashRecognitionOfNewLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash recognition of new leases</link:label>
    <link:label id="lab_jan_NoncashRecognitionOfNewLeases_label_en-US" xlink:label="lab_jan_NoncashRecognitionOfNewLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash recognition of new leases</link:label>
    <link:label id="lab_jan_NoncashRecognitionOfNewLeases_documentation_en-US" xlink:label="lab_jan_NoncashRecognitionOfNewLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash recognition of new leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashRecognitionOfNewLeases" xlink:href="jan-20231230.xsd#jan_NoncashRecognitionOfNewLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoncashRecognitionOfNewLeases" xlink:to="lab_jan_NoncashRecognitionOfNewLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2389bd6a-b131-414f-82ee-d92468795199_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1ab28b5d-7172-4ce5-bda6-33c2f9cad160_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Trade and Other Receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7a335efb-8050-4a5f-bf70-7c84de0730b0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f1001bb7-bba3-4614-b987-4bd4ec61a542_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_edc21e5e-1db1-40ea-922e-2ffc8b754dc0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_65a2c3e0-290d-4f59-8991-6a4e6a5e0a5e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RecyclingMember_ca775449-a832-47d7-8ec0-7b6a52e54cab_terseLabel_en-US" xlink:label="lab_jan_RecyclingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recycling</link:label>
    <link:label id="lab_jan_RecyclingMember_label_en-US" xlink:label="lab_jan_RecyclingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling [Member]</link:label>
    <link:label id="lab_jan_RecyclingMember_documentation_en-US" xlink:label="lab_jan_RecyclingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recycling.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingMember" xlink:href="jan-20231230.xsd#jan_RecyclingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RecyclingMember" xlink:to="lab_jan_RecyclingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfLeaseLiability_3916d009-b404-4ff2-9178-ee33e9bf62e3_terseLabel_en-US" xlink:label="lab_jan_DisposalOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_jan_DisposalOfLeaseLiability_label_en-US" xlink:label="lab_jan_DisposalOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Lease Liability</link:label>
    <link:label id="lab_jan_DisposalOfLeaseLiability_documentation_en-US" xlink:label="lab_jan_DisposalOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfLeaseLiability" xlink:href="jan-20231230.xsd#jan_DisposalOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfLeaseLiability" xlink:to="lab_jan_DisposalOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_bd70a34c-cc6e-463c-b689-f7da8240f377_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9deaa510-005b-44ee-9197-7ea3cb234f74_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_BiotechnologyMember_755d7aeb-430d-42c2-896b-ba5dcf6a741a_terseLabel_en-US" xlink:label="lab_jan_BiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biotechnology</link:label>
    <link:label id="lab_jan_BiotechnologyMember_label_en-US" xlink:label="lab_jan_BiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biotechnology [Member]</link:label>
    <link:label id="lab_jan_BiotechnologyMember_documentation_en-US" xlink:label="lab_jan_BiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biotechnology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BiotechnologyMember" xlink:href="jan-20231230.xsd#jan_BiotechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_BiotechnologyMember" xlink:to="lab_jan_BiotechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedAndNonrelatedPartyStatusAxis_7ec21557-5475-4f0e-b9eb-3331e18ba111_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Party Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedAndNonrelatedPartyStatusAxis_label_en-US" xlink:label="lab_us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Party Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="lab_us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_833512f3-3722-4f32-aa2c-5958d936b372_negatedTotalLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses from discontinued operations</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Total Operating Income (Expenses) From Discontinued Operations</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Total Operating Income (Expenses) From Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_458c3067-a025-4a12-9eb4-c84f62c7e711_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_848e08ed-c057-41d1-9099-38c625b7c501_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityUnitPurchaseAgreementsMember_316b9084-69d2-4f97-a8ca-ae57dd6b4a7e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Unit Purchase Agreements</link:label>
    <link:label id="lab_us-gaap_EquityUnitPurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Unit Purchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:to="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7064f418-5f7c-49a3-86aa-18b2cc1ef0d9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_58cef8cc-952c-49a2-be2c-75c8db5fd4d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities - other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ba015982-8b3f-4a35-b98b-63ac57c084f8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets from discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_baaaaa43-925c-47b2-a2f4-23af74a57701_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5584d09a-917a-4159-99f7-8c8a2264f206_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5226f4f-fa36-4769-8e5b-0e42da276dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_65da50fd-c643-4c52-8e20-d931ec63df7c_terseLabel_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares in each unit (in shares)</link:label>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_label_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unit Composition, Number Of Common Shares In Each Unit</link:label>
    <link:label id="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_documentation_en-US" xlink:label="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unit Composition, Number Of Common Shares In Each Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:to="lab_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_Section174Expenses_82b0351e-33c7-4de2-80a1-c475ac68e7b6_terseLabel_en-US" xlink:label="lab_jan_Section174Expenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 expenses</link:label>
    <link:label id="lab_jan_Section174Expenses_label_en-US" xlink:label="lab_jan_Section174Expenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 174 Expenses</link:label>
    <link:label id="lab_jan_Section174Expenses_documentation_en-US" xlink:label="lab_jan_Section174Expenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Section 174 Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Section174Expenses" xlink:href="jan-20231230.xsd#jan_Section174Expenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_Section174Expenses" xlink:to="lab_jan_Section174Expenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_60194a76-0f5c-4951-a6e5-8cb037e027bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0a539001-d379-4191-b539-8cb23a82adac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b578afe9-3144-42dc-9fac-2eec43f7920e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e1ca253e-fb91-4efc-a5f5-9506aa584277_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis_8f15e78c-cafd-4d56-a2eb-5f0d4a7985c0_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Consideration, Payment [Axis]</link:label>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis_label_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Consideration, Payment Period [Axis]</link:label>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis_documentation_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:to="lab_jan_DisposalGroupConsiderationPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_e35e7d78-1e81-4912-91ef-12d79dcd9f57_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_22517dc5-8f3a-467a-bb34-a686f5e6ea5e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_a0f4f98a-a0ea-48ca-9f53-ea518639e3c6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TotalDisposalOfAssets_be513caf-7ab2-4488-9fe8-11c9b4f8c659_totalLabel_en-US" xlink:label="lab_jan_TotalDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total disposal of assets</link:label>
    <link:label id="lab_jan_TotalDisposalOfAssets_label_en-US" xlink:label="lab_jan_TotalDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Disposal of Assets</link:label>
    <link:label id="lab_jan_TotalDisposalOfAssets_documentation_en-US" xlink:label="lab_jan_TotalDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Disposal of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfAssets" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TotalDisposalOfAssets" xlink:to="lab_jan_TotalDisposalOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_5e1237bd-a177-45db-8b4f-03db68dcce3b_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0e972eff-df99-4e9d-98f9-4bd20f6a90bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2af64bc4-a26d-462f-9580-10154073b7f1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_bd871e25-5fc2-48b8-9cd9-481843ec46a6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigation/legal</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0db0d25-0aea-42fb-be3e-7779644f4a24_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NotesReceivableTerm_c43bb7a9-10f5-4ea8-9dbd-489ea2beb1ba_terseLabel_en-US" xlink:label="lab_jan_NotesReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of notes receivable</link:label>
    <link:label id="lab_jan_NotesReceivableTerm_label_en-US" xlink:label="lab_jan_NotesReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Term</link:label>
    <link:label id="lab_jan_NotesReceivableTerm_documentation_en-US" xlink:label="lab_jan_NotesReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Receivable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NotesReceivableTerm" xlink:to="lab_jan_NotesReceivableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2980ae83-9c1c-4ecb-b7e8-5ae20b7c9a08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_bb5a0f06-2257-429f-828b-ab1d7b1a305f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_2cd4ed69-d0aa-4a7d-abaf-034908db3f07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_84963ab2-c380-406e-b10b-a209e9f0f326_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_42b06836-992a-415d-81fb-a096cb214bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_be406e17-428e-4157-979e-890a686f9bb0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_26fb92c4-b46f-4ce2-83a3-103a91571d06_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesA1ConvertiblePreferredStockMember_e3454865-bd22-48e3-a2db-2c125eacb316_terseLabel_en-US" xlink:label="lab_jan_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A1 Convertible Preferred Stock</link:label>
    <link:label id="lab_jan_SeriesA1ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_jan_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A1 Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_jan_SeriesA1ConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_jan_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1ConvertiblePreferredStockMember" xlink:href="jan-20231230.xsd#jan_SeriesA1ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesA1ConvertiblePreferredStockMember" xlink:to="lab_jan_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7ea2a2da-8c19-4fb1-907d-7a79f5438069_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_6d3aacca-0700-47e1-af74-7d6b556ea26e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7edbc9e9-2fb6-490b-a46e-2dbfe46ad9e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_34e313fc-1ded-4423-8ec9-6468f2f3e3c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory transferred part of the sale, derecognized</link:label>
    <link:label id="lab_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Involvement with Derecognized Transferred Financial Assets, Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" xlink:to="lab_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoteReceivableStatedInterestRate_fa41dc5b-3ae1-4573-a97f-e625cce5e061_terseLabel_en-US" xlink:label="lab_jan_NoteReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable interest rate</link:label>
    <link:label id="lab_jan_NoteReceivableStatedInterestRate_label_en-US" xlink:label="lab_jan_NoteReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Receivable Stated Interest Rate</link:label>
    <link:label id="lab_jan_NoteReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_jan_NoteReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note receivable interest rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableStatedInterestRate" xlink:href="jan-20231230.xsd#jan_NoteReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoteReceivableStatedInterestRate" xlink:to="lab_jan_NoteReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_d6a5053a-a0e1-45cf-afb7-e3e3f189c9cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_8e1f89f9-fa83-49c9-b6b8-54a1734528d3_terseLabel_en-US" xlink:label="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities - California state sales tax</link:label>
    <link:label id="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_label_en-US" xlink:label="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Accrued liability - California state sales tax</link:label>
    <link:label id="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_documentation_en-US" xlink:label="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Accrued liability - California state sales tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:to="lab_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4dc30401-0b3d-4473-a9d3-a09da2264ba6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd507054-ea39-45b8-a53a-e9b641c653fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ba759dc6-1096-4a13-a4a9-c33ab33741ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Recycling Subsidiaries</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8614d4de-8f31-4b93-9c7f-2fbde253b056_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_34786151-9bee-4868-a646-275543253d96_terseLabel_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, additional value, acquisitions</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_label_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Additional, Value, Acquisitions</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_documentation_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Additional, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodAdditionalValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:to="lab_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_949cfdd4-261c-4fff-a014-8383f6686098_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ConversionOfStockCommencementPeriod_fa283026-489a-42d2-a539-685c05da44bc_terseLabel_en-US" xlink:label="lab_jan_ConversionOfStockCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, commencement period</link:label>
    <link:label id="lab_jan_ConversionOfStockCommencementPeriod_label_en-US" xlink:label="lab_jan_ConversionOfStockCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Commencement Period</link:label>
    <link:label id="lab_jan_ConversionOfStockCommencementPeriod_documentation_en-US" xlink:label="lab_jan_ConversionOfStockCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Commencement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockCommencementPeriod" xlink:href="jan-20231230.xsd#jan_ConversionOfStockCommencementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ConversionOfStockCommencementPeriod" xlink:to="lab_jan_ConversionOfStockCommencementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_6a0c0c8d-bddf-4356-9335-a506a853cd20_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_055171bc-4e84-46a3-b0ab-379c7d7eee96_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b369c616-fb01-43d2-8bbc-335df24f3cb7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8420e1af-f7de-4440-88a7-6e70b8003e94_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_92b39105-19c2-4be4-a194-3b0fa408711d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_3e50c089-84a3-4fb4-b0cb-e86505f50ad7_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Consideration Received on Transaction</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_1d88a672-2e71-4df7-a242-81460d0f7c35_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_d65931a0-ad94-43e2-829e-bc3935ea81af_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5533f857-4e85-4765-b39a-2bf39e3136f5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount owed by company</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6d294e3c-df8b-40b9-b691-fc9186ae47f7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SalesTaxAssessmentAccruedInterest_0772c86c-f3cd-49c8-b142-a610830bd54c_terseLabel_en-US" xlink:label="lab_jan_SalesTaxAssessmentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liability - interest on CA sales tax assessment</link:label>
    <link:label id="lab_jan_SalesTaxAssessmentAccruedInterest_label_en-US" xlink:label="lab_jan_SalesTaxAssessmentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Tax Assessment, Accrued Interest</link:label>
    <link:label id="lab_jan_SalesTaxAssessmentAccruedInterest_documentation_en-US" xlink:label="lab_jan_SalesTaxAssessmentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Tax Assessment, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SalesTaxAssessmentAccruedInterest" xlink:to="lab_jan_SalesTaxAssessmentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_40348572-2fad-4876-aff3-2ae01ae1e4e3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets from discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_c02274fe-3e23-42ca-8779-d15f5f468cdd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_84e608d8-2211-41f5-88c8-64c1a27bb536_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_d52c18c7-0920-413f-998f-c2271e1de7b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c467bcbb-428b-4090-85cc-bd7934b62f25_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_30fdc237-056c-45de-8daf-74f0e33d1ecf_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ConversionOfStockSharesForfeited_68b1f236-4a5b-4ac3-853b-8302519f6c1f_terseLabel_en-US" xlink:label="lab_jan_ConversionOfStockSharesForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, forfeited (in shares)</link:label>
    <link:label id="lab_jan_ConversionOfStockSharesForfeited_label_en-US" xlink:label="lab_jan_ConversionOfStockSharesForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Forfeited</link:label>
    <link:label id="lab_jan_ConversionOfStockSharesForfeited_documentation_en-US" xlink:label="lab_jan_ConversionOfStockSharesForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockSharesForfeited" xlink:href="jan-20231230.xsd#jan_ConversionOfStockSharesForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ConversionOfStockSharesForfeited" xlink:to="lab_jan_ConversionOfStockSharesForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementTerm_4a1a40ab-d57c-495b-8b79-7361ffb6d7af_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of consulting agreement</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementTerm_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Term</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementTerm_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9759fbe1-4dea-4784-87f2-e9cc0f648fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5812a062-cdba-4846-b774-394dfd4dced3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_8ae07ffd-d5ac-48d8-b1d3-662bc76c0240_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_42d0fbff-3b76-4149-89be-b0d32a99eca7_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9b9d7103-2fe3-4123-b0fc-16e8431cbe8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8bd94520-5415-4e9f-9bd5-8ebd887475d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5c298619-7cf6-43b7-82c0-d7d18162fb33_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion_f35d5ef4-dcdf-4458-af53-48973a2a869d_terseLabel_en-US" xlink:label="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon conversion (in shares)</link:label>
    <link:label id="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion_label_en-US" xlink:label="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issuable Upon Conversion</link:label>
    <link:label id="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion_documentation_en-US" xlink:label="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issuable Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:href="jan-20231230.xsd#jan_ConvertiblePreferredStockSharesIssuableUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:to="lab_jan_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_bd4f4dff-e646-4a71-8069-9462f53f7cf4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_a5ee41bc-18cd-4c4a-8e9e-87b24578815b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f138fc0c-6474-4495-824b-0945fe39139c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8963b7fe-50c9-4847-a538-8e163848b274_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties_0a2cd736-a4b2-4a94-9856-2e359be565db_terseLabel_en-US" xlink:label="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note</link:label>
    <link:label id="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Origination of Notes Receivable from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:to="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermNotesPayable_20e6921a-e7b3-4e5f-add1-592927bc4e73_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party note</link:label>
    <link:label id="lab_us-gaap_OtherLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermNotesPayable" xlink:to="lab_us-gaap_OtherLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PercentageOfGrossRevenue_d10fcbbc-18fc-421d-909a-36e4507c0d47_terseLabel_en-US" xlink:label="lab_jan_PercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of gross revenue</link:label>
    <link:label id="lab_jan_PercentageOfGrossRevenue_label_en-US" xlink:label="lab_jan_PercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Gross Revenue</link:label>
    <link:label id="lab_jan_PercentageOfGrossRevenue_documentation_en-US" xlink:label="lab_jan_PercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Gross Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentageOfGrossRevenue" xlink:href="jan-20231230.xsd#jan_PercentageOfGrossRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PercentageOfGrossRevenue" xlink:to="lab_jan_PercentageOfGrossRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_4595c289-d3d5-481e-9614-c5731e64e8e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_643e818a-e190-441d-a0aa-2d7eee3e1fc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelevantMonth3Member_86be1b9f-6a6c-4d61-aaa6-d12379fb0bd0_terseLabel_en-US" xlink:label="lab_jan_RelevantMonth3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relevant Month 3</link:label>
    <link:label id="lab_jan_RelevantMonth3Member_label_en-US" xlink:label="lab_jan_RelevantMonth3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relevant Month 3 [Member]</link:label>
    <link:label id="lab_jan_RelevantMonth3Member_documentation_en-US" xlink:label="lab_jan_RelevantMonth3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relevant Month 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth3Member" xlink:href="jan-20231230.xsd#jan_RelevantMonth3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelevantMonth3Member" xlink:to="lab_jan_RelevantMonth3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a5a3877c-fdb9-468b-a1fc-ae459b760b6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ClassOfWarrantPricePerShare_aaf49f5b-5080-4037-bec3-f82778dbce31_terseLabel_en-US" xlink:label="lab_jan_ClassOfWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant price per share (in usd per share)</link:label>
    <link:label id="lab_jan_ClassOfWarrantPricePerShare_label_en-US" xlink:label="lab_jan_ClassOfWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Price Per Share</link:label>
    <link:label id="lab_jan_ClassOfWarrantPricePerShare_documentation_en-US" xlink:label="lab_jan_ClassOfWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantPricePerShare" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ClassOfWarrantPricePerShare" xlink:to="lab_jan_ClassOfWarrantPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a74111d8-5aaf-4acd-92e2-dc1ec6624eb7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AFCOCreditCorporationFinancingAgreementMember_2bd466d0-3bd8-4264-85a8-d25879f787c9_terseLabel_en-US" xlink:label="lab_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AFCO Credit Corporation Financing Agreement</link:label>
    <link:label id="lab_jan_AFCOCreditCorporationFinancingAgreementMember_label_en-US" xlink:label="lab_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AFCO Credit Corporation Financing Agreement [Member]</link:label>
    <link:label id="lab_jan_AFCOCreditCorporationFinancingAgreementMember_documentation_en-US" xlink:label="lab_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AFCO credit corporation financing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorporationFinancingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:to="lab_jan_AFCOCreditCorporationFinancingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_9b0b6fd7-4919-4523-8340-d656973f9aed_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate monthly payments from buyer, period (years)</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Period</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5428fdd1-c7c3-461e-ad9c-c7ec844f6e0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain_ff18aa5d-2a58-4996-a875-9155a12831d4_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Consideration, Payment Period [Domain]</link:label>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain_label_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Consideration, Payment Period [Domain]</link:label>
    <link:label id="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain_documentation_en-US" xlink:label="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:to="lab_jan_DisposalGroupConsiderationPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9b508d73-40c2-44e1-ac7f-c2bf1e07ff80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_67d32ed6-7947-434d-b116-7bbd43718a7c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_eac8c4bc-832e-4047-8784-1aec765a4ef0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DiscontinuedOperatingActivities_32135b9f-af0a-407a-a01a-106a5d9c95aa_terseLabel_en-US" xlink:label="lab_jan_DiscontinuedOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DISCONTINUED OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedOperatingActivities_label_en-US" xlink:label="lab_jan_DiscontinuedOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DISCONTINUED OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedOperatingActivities_documentation_en-US" xlink:label="lab_jan_DiscontinuedOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DISCONTINUED OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedOperatingActivities" xlink:href="jan-20231230.xsd#jan_DiscontinuedOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DiscontinuedOperatingActivities" xlink:to="lab_jan_DiscontinuedOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5dcdc8ee-f615-464e-8c67-873750893f5d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_46e89e6b-fcbf-454e-b47f-444353b57598_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_957d3eaa-61b9-464b-89bf-366e0eddf37d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax_5f67964b-18c5-46d3-a141-6d75ec287691_terseLabel_en-US" xlink:label="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of GeoTraq inventory</link:label>
    <link:label id="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax_label_en-US" xlink:label="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Adjustment from AOCI for Derecognition, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" xlink:to="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_928db214-db1b-4c3e-956d-58a18bd2a914_verboseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent, Gross</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_b7526d78-7ecb-4bde-8739-ef5160970a37_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestNetAmount_3e19bd02-c880-4b8c-8a7a-1ee4324458fd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable with imputed interest, net amount</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestNetAmount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockConversion3Member_672e9aad-fdde-4fe4-9603-1280d53a53d1_terseLabel_en-US" xlink:label="lab_jan_StockConversion3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion 3</link:label>
    <link:label id="lab_jan_StockConversion3Member_label_en-US" xlink:label="lab_jan_StockConversion3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion 3 [Member]</link:label>
    <link:label id="lab_jan_StockConversion3Member_documentation_en-US" xlink:label="lab_jan_StockConversion3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Conversion 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion3Member" xlink:href="jan-20231230.xsd#jan_StockConversion3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockConversion3Member" xlink:to="lab_jan_StockConversion3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3361bdcc-6db4-47ba-885f-ccc097086a9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations_bd6863dd-6be5-4e4a-bf68-539884afea42_terseLabel_en-US" xlink:label="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense from discontinued operations</link:label>
    <link:label id="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations_label_en-US" xlink:label="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income (Expense) From Discontinued Operations</link:label>
    <link:label id="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income (Expense) From Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:href="jan-20231230.xsd#jan_OtherIncomeExpenseFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:to="lab_jan_OtherIncomeExpenseFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_76882158-a756-476a-9018-d00eea91947b_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share from discontinued operations, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c17d42dc-c6eb-4b73-93db-1bfde1667e60_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic income per share from discontinued operations, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_113f2f3b-d9e2-4767-94fe-172132fbe354_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_Plan2016Member_c2facc91-a56f-4274-81b2-24dc270c746c_terseLabel_en-US" xlink:label="lab_jan_Plan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_jan_Plan2016Member_label_en-US" xlink:label="lab_jan_Plan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan2016 [Member]</link:label>
    <link:label id="lab_jan_Plan2016Member_documentation_en-US" xlink:label="lab_jan_Plan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plan 2016.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2016Member" xlink:href="jan-20231230.xsd#jan_Plan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_Plan2016Member" xlink:to="lab_jan_Plan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OtherAssetsFromDiscontinuedOperations_844a6d0c-971c-4e6b-9434-faad48352146_terseLabel_en-US" xlink:label="lab_jan_OtherAssetsFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets from discontinued operations</link:label>
    <link:label id="lab_jan_OtherAssetsFromDiscontinuedOperations_label_en-US" xlink:label="lab_jan_OtherAssetsFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets from discontinued operations</link:label>
    <link:label id="lab_jan_OtherAssetsFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_jan_OtherAssetsFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other assets from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherAssetsFromDiscontinuedOperations" xlink:href="jan-20231230.xsd#jan_OtherAssetsFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OtherAssetsFromDiscontinuedOperations" xlink:to="lab_jan_OtherAssetsFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_c75db982-bf3e-409f-a29f-867c20ab900a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NumberOfTradingDaysBeforeBoardApproval_8c829ee8-90e1-4565-894a-1bc8510f290c_terseLabel_en-US" xlink:label="lab_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of trading days prior to court approval</link:label>
    <link:label id="lab_jan_NumberOfTradingDaysBeforeBoardApproval_label_en-US" xlink:label="lab_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Trading Days Before Board Approval</link:label>
    <link:label id="lab_jan_NumberOfTradingDaysBeforeBoardApproval_documentation_en-US" xlink:label="lab_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Trading Days Before Board Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:href="jan-20231230.xsd#jan_NumberOfTradingDaysBeforeBoardApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:to="lab_jan_NumberOfTradingDaysBeforeBoardApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NumberOfInstallment_b7834ef3-2dd3-4e03-b734-d66c5abba00d_terseLabel_en-US" xlink:label="lab_jan_NumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_jan_NumberOfInstallment_label_en-US" xlink:label="lab_jan_NumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Installment</link:label>
    <link:label id="lab_jan_NumberOfInstallment_documentation_en-US" xlink:label="lab_jan_NumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfInstallment" xlink:href="jan-20231230.xsd#jan_NumberOfInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NumberOfInstallment" xlink:to="lab_jan_NumberOfInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_69ff614b-99dd-4a23-9250-318c4a0dbd3c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_cbfa8750-00ac-42bb-9b45-c3634d9d9a89_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dba91f20-e74e-4c51-b9fd-c93d49ec0c99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_b871765e-e266-4fec-a65d-fd63086a3754_totalLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Notes Payable</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fcf32fc9-97e2-4f11-a030-7158092b5d05_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_f343f8f0-feea-48b9-b079-3e9b85034469_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a2ec3d42-c3fc-4888-bf39-d0f2d35b4a87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ebf6349c-b12e-41de-b7e9-294a19ce36f9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_504406e0-0b11-45b5-be9a-0fa8cef8db8d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing agreements entered into</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_2545a989-f51d-4600-924a-88b6496dc485_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4217e88-04b4-4683-9448-2bbacc5cfa79_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_99f7b3c3-be76-4da1-9a61-f864baf788cd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3bc590d6-b572-42bb-8092-23e455df9ba4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share from continuing operations, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_96ed02c9-53cc-45d9-a03d-2e710101d08e_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Diluted (loss) per share from continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ARCARecyclingPurchasingAgreementMember_35c64bda-2d68-4ff8-8062-457934b2b211_terseLabel_en-US" xlink:label="lab_jan_ARCARecyclingPurchasingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARCA Purchasing Agreement</link:label>
    <link:label id="lab_jan_ARCARecyclingPurchasingAgreementMember_label_en-US" xlink:label="lab_jan_ARCARecyclingPurchasingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARCA Recycling Purchasing Agreement [Member]</link:label>
    <link:label id="lab_jan_ARCARecyclingPurchasingAgreementMember_documentation_en-US" xlink:label="lab_jan_ARCARecyclingPurchasingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARCA Purchasing Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCARecyclingPurchasingAgreementMember" xlink:href="jan-20231230.xsd#jan_ARCARecyclingPurchasingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ARCARecyclingPurchasingAgreementMember" xlink:to="lab_jan_ARCARecyclingPurchasingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dfc79e88-6ed5-492b-b780-73569a003b99_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5dab6bd4-38ac-454a-a96d-72da98b05b32_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4396d455-969f-4813-ba58-5c2dd0211a69_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e03dc6e9-95d0-4f97-a084-d3b1c9f402c6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f6f38c22-4623-4609-b423-85acc79a2d5a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d5e48bf3-5cfc-4df0-9d53-28b5da91fe0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3b72394e-53a7-4209-a981-c40dd914038c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_a35c1be7-527e-4cf1-b717-3388d2a671f1_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of disposition transaction</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_c3028601-9dc9-4b4d-8e67-84585aabfc8b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2eefde95-c163-4a41-80df-9896bedb9379_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant excise and granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_e325febc-9b23-4887-9254-f1082b9e75b0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of sale of ARCA Recycling and Canada</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockConversion1Member_a3af4ac9-62f3-4204-ba63-c0380d14a597_terseLabel_en-US" xlink:label="lab_jan_StockConversion1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion 1</link:label>
    <link:label id="lab_jan_StockConversion1Member_label_en-US" xlink:label="lab_jan_StockConversion1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion 1 [Member]</link:label>
    <link:label id="lab_jan_StockConversion1Member_documentation_en-US" xlink:label="lab_jan_StockConversion1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Conversion 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion1Member" xlink:href="jan-20231230.xsd#jan_StockConversion1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockConversion1Member" xlink:to="lab_jan_StockConversion1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_9e74b424-7ebf-4cce-94f4-9c7aa4d95683_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of gross revenue (percent)</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Percentage of Gross Revenue</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Percentage of Gross Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a106ffe2-8ae2-4719-970f-b41cd2ae52d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfIntangibleAssets_e2a215ad-5a54-4008-bf41-0a1c47d334b7_terseLabel_en-US" xlink:label="lab_jan_DisposalOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_jan_DisposalOfIntangibleAssets_label_en-US" xlink:label="lab_jan_DisposalOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Intangible assets</link:label>
    <link:label id="lab_jan_DisposalOfIntangibleAssets_documentation_en-US" xlink:label="lab_jan_DisposalOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfIntangibleAssets" xlink:href="jan-20231230.xsd#jan_DisposalOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfIntangibleAssets" xlink:to="lab_jan_DisposalOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_76ef62a7-3727-4ac0-acd8-9268bb7c04ac_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_79154709-3428-42bc-9de3-f23b05c30dd6_terseLabel_en-US" xlink:label="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charge against income for increase in discount rate</link:label>
    <link:label id="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_label_en-US" xlink:label="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charge Against Income For Increase In Discount Rate</link:label>
    <link:label id="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_documentation_en-US" xlink:label="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charge Against Income For Increase In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:href="jan-20231230.xsd#jan_ChargeAgainstIncomeForIncreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:to="lab_jan_ChargeAgainstIncomeForIncreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69c4f075-7c21-42cb-aaf8-ff7b2a4fb4a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_3ee712b8-c899-4afc-a480-e7f79c54f79d_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Intangibles</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_652b8b5c-4621-4782-9473-3ac95ca7e060_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_525db2db-aac6-418f-85bb-02f165ce5387_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelevantMonth1Member_9fc5fa75-e4f6-4e43-b85f-824f1d01a92d_terseLabel_en-US" xlink:label="lab_jan_RelevantMonth1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relevant Month 1</link:label>
    <link:label id="lab_jan_RelevantMonth1Member_label_en-US" xlink:label="lab_jan_RelevantMonth1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relevant Month 1 [Member]</link:label>
    <link:label id="lab_jan_RelevantMonth1Member_documentation_en-US" xlink:label="lab_jan_RelevantMonth1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relevant Month 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth1Member" xlink:href="jan-20231230.xsd#jan_RelevantMonth1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelevantMonth1Member" xlink:to="lab_jan_RelevantMonth1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RecyclingSegmentAndTechnologySegmentMember_251842c1-1056-4e1e-bed5-eddf9d124a5d_terseLabel_en-US" xlink:label="lab_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recycling Segment and Technology Segment</link:label>
    <link:label id="lab_jan_RecyclingSegmentAndTechnologySegmentMember_label_en-US" xlink:label="lab_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling Segment And Technology Segment [Member]</link:label>
    <link:label id="lab_jan_RecyclingSegmentAndTechnologySegmentMember_documentation_en-US" xlink:label="lab_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recycling Segment And Technology Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:to="lab_jan_RecyclingSegmentAndTechnologySegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_594b6afd-f7fe-4453-b37d-a01d17707837_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Company</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_761e52a1-7e01-440e-a681-5f64c1e8e6f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KLC Financial</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_59ca4ff1-8b22-4153-a8f3-6d11f77b2f1c_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset - operating leases</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Right of Use Asset</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Right of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ecc9448b-26de-4245-ab87-0a8f74e47274_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preliminary calculation of gain on sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockPurchaseAgreementMember_37d12885-3d2c-486c-9d8a-d79eb962cb75_terseLabel_en-US" xlink:label="lab_jan_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_jan_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_jan_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_jan_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_jan_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockPurchaseAgreementMember" xlink:href="jan-20231230.xsd#jan_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockPurchaseAgreementMember" xlink:to="lab_jan_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StatutoryInterestReceivable_0234bdba-dfaf-4eab-a7cf-7ac2760862db_terseLabel_en-US" xlink:label="lab_jan_StatutoryInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory interest, receivable</link:label>
    <link:label id="lab_jan_StatutoryInterestReceivable_label_en-US" xlink:label="lab_jan_StatutoryInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statutory Interest, Receivable</link:label>
    <link:label id="lab_jan_StatutoryInterestReceivable_documentation_en-US" xlink:label="lab_jan_StatutoryInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statutory Interest, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StatutoryInterestReceivable" xlink:href="jan-20231230.xsd#jan_StatutoryInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StatutoryInterestReceivable" xlink:to="lab_jan_StatutoryInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_04bdd344-7e24-4038-b998-0665010f0b4d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities, Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Auction Market Preferred Securities, Shares Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward" xlink:to="lab_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1b848ea2-3c58-41fc-8416-a0d3aa19760a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_22830eb5-6e25-4830-93d2-75490be2791e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_us-gaap_ShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_218e39f5-5c11-467e-a2a6-dfe2f07b3843_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate payment period (years)</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Payment Period</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0d1a2648-9915-46a4-825b-365ee419f103_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_67df141d-c5b8-4b3b-84ed-c0a92c08bbcc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_9035282d-4418-4d16-9a8e-1c356c5bc997_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision for discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_65c01bc5-dac0-4413-95f9-63b8deba02d7_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_eef1f425-44d9-419d-bc99-98a7a4ea6608_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_429fc784-185a-4bf2-8613-274115b7014f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company tendered, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_5dc64ace-2ef4-464b-8fd9-b362752649ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaids and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_f930e78f-8c31-4bb2-a968-1a52d1c2f5a4_terseLabel_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of unsecured notes entered into</link:label>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_label_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Term</link:label>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_documentation_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:to="lab_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_67e6af61-15e3-4d1b-9491-49495154d722_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_ff8a5449-6fd1-42eb-834b-1697c561b4ba_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attorneys fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_41afea03-00bc-4f2a-8efe-6e5bd77edfac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares, acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_03e624b9-26fc-4324-b9c1-664848c4f67c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, upper range limit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9d89eb18-f35e-4d36-8731-9869db72216e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AuditorAbstract_label_en-US" xlink:label="lab_jan_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_jan_AuditorAbstract_documentation_en-US" xlink:label="lab_jan_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AuditorAbstract" xlink:href="jan-20231230.xsd#jan_AuditorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AuditorAbstract" xlink:to="lab_jan_AuditorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember_83a5b3b6-cd73-429f-9222-f82808bb3e14_terseLabel_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2nd policy</link:label>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember_label_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Universal Life Insurance Policy, Policy Two [Member]</link:label>
    <link:label id="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember_documentation_en-US" xlink:label="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Universal Life Insurance Policy, Policy Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:to="lab_jan_UniversalLifeInsurancePolicyPolicyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b71c267b-67e7-4420-83f9-97fb377e95a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_a110066b-9358-4faf-93a1-190020076430_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ca3d0a6e-ae06-485e-9bec-4d2bf3227015_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9ed2b3c2-fd79-4998-8cb5-c2e9bc200b68_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_28f231dd-31fa-4267-897b-39b910828224_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_041cc24f-80f2-4c00-a9cf-fe6d44204025_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelevantMonth2Member_53f63b51-79b1-4228-a825-56a1c2ebfba9_terseLabel_en-US" xlink:label="lab_jan_RelevantMonth2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relevant Month 2</link:label>
    <link:label id="lab_jan_RelevantMonth2Member_label_en-US" xlink:label="lab_jan_RelevantMonth2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relevant Month 2 [Member]</link:label>
    <link:label id="lab_jan_RelevantMonth2Member_documentation_en-US" xlink:label="lab_jan_RelevantMonth2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relevant Month 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth2Member" xlink:href="jan-20231230.xsd#jan_RelevantMonth2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelevantMonth2Member" xlink:to="lab_jan_RelevantMonth2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_6ac13bfe-0d86-4930-92e0-e3bf31d4f4fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_08708f8a-0ee4-4f7b-8e22-5aaea686a05a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BeneficialOwnerMember_0d79d39f-02ba-4275-aaaa-9ed66898ce03_terseLabel_en-US" xlink:label="lab_us-gaap_BeneficialOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Record and beneficial owner</link:label>
    <link:label id="lab_us-gaap_BeneficialOwnerMember_label_en-US" xlink:label="lab_us-gaap_BeneficialOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BeneficialOwnerMember" xlink:to="lab_us-gaap_BeneficialOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_032d410a-f9df-44c4-98d0-b0adea334ccc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm_ec4eb648-6cdf-458f-9c1c-d389d1bcdd51_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase agreement term</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchase Agreement, Term</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:to="lab_jan_RelatedPartyTransactionPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_33b30350-793d-45a3-82ac-1ed853b795ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_c3a77faa-9011-4653-a3d6-25d66cad7368_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DebtRevisedDiscountRate_b24a033c-7f11-4b37-a085-f3f17f616dfc_terseLabel_en-US" xlink:label="lab_jan_DebtRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt revised discount rate</link:label>
    <link:label id="lab_jan_DebtRevisedDiscountRate_label_en-US" xlink:label="lab_jan_DebtRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Revised Discount Rate</link:label>
    <link:label id="lab_jan_DebtRevisedDiscountRate_documentation_en-US" xlink:label="lab_jan_DebtRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Revised Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtRevisedDiscountRate" xlink:href="jan-20231230.xsd#jan_DebtRevisedDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DebtRevisedDiscountRate" xlink:to="lab_jan_DebtRevisedDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_5103a498-6996-4aa6-953a-ad826ca1404f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_df81a8b4-3f76-4201-a4d2-ee29976ea583_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_31ea607a-586f-4308-90a3-9ee9bb97b26b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on short term notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_2d2be6e3-3221-427a-966e-8a6b23ef772f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_bc578c36-6cc2-487d-8f6a-4784db283768_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares returned to the Company for cancellation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6414427c-8a3a-4087-81cf-abd16e432736_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares_61fda332-ec42-41cd-a02a-efd52af85d89_terseLabel_en-US" xlink:label="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series S preferred issued (in shares)</link:label>
    <link:label id="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares_label_en-US" xlink:label="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued During Period, Shares</link:label>
    <link:label id="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares_documentation_en-US" xlink:label="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:href="jan-20231230.xsd#jan_TemporaryEquitySharesIssuedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:to="lab_jan_TemporaryEquitySharesIssuedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7dadfacd-f835-4cf0-b892-df2224fb1398_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1f11d24f-c5c9-4fb5-91d0-7c61d674e99c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b353a152-e905-4ed0-9be6-2090e7c18748_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_aba6e033-0ab6-4768-92b1-52a313b36439_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful Life (Years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfDebt_51f170c4-9014-40b7-bd98-6bddc5830e4b_terseLabel_en-US" xlink:label="lab_jan_DisposalOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_jan_DisposalOfDebt_label_en-US" xlink:label="lab_jan_DisposalOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Debt</link:label>
    <link:label id="lab_jan_DisposalOfDebt_documentation_en-US" xlink:label="lab_jan_DisposalOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfDebt" xlink:href="jan-20231230.xsd#jan_DisposalOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfDebt" xlink:to="lab_jan_DisposalOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_e5b0628d-e89a-4bf3-81da-f150e788bbe7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages sought value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_83715e03-a20e-4d89-9fa5-502d9fe09b1d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2159486e-9d89-4f62-a59f-51c6d5c57d5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liability</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ProvisionBenefitOfIncomeTaxes_c91f42a6-ffb7-4e5d-9a34-07dd2e03c551_totalLabel_en-US" xlink:label="lab_jan_ProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision (benefit) of income taxes</link:label>
    <link:label id="lab_jan_ProvisionBenefitOfIncomeTaxes_label_en-US" xlink:label="lab_jan_ProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision (Benefit) Of Income Taxes</link:label>
    <link:label id="lab_jan_ProvisionBenefitOfIncomeTaxes_documentation_en-US" xlink:label="lab_jan_ProvisionBenefitOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision (Benefit) Of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ProvisionBenefitOfIncomeTaxes" xlink:href="jan-20231230.xsd#jan_ProvisionBenefitOfIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ProvisionBenefitOfIncomeTaxes" xlink:to="lab_jan_ProvisionBenefitOfIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_5a794d0f-766d-4095-88ea-8aa206daeba8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_94f5c457-7cf8-43bf-be0f-489497630a17_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2ba84d94-58cb-4a95-80b6-bb7da5af952c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_76311a0a-ba11-4f99-bb53-6acccd37c2f9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f283085b-698c-4d77-8f2d-6d81c9c3ebd2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bae62b19-6251-43e4-a995-9a12cc102f95_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_de5ecbd2-fc5d-48f0-9c42-3489b25723d9_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering shares</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partners' Capital Account, Units, Sold in Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b5b9300e-cd96-4294-a5e0-f7fe3bf9d513_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_d4ba421a-6b3d-48b5-bc60-fff8e31e046b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_c5816d68-860b-452c-a343-482c6956aca3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_91ee50a7-7b0d-4380-8d57-751fd4976b03_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_20a28732-bc55-4c8f-866b-ce4d3515f60a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt convertible period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ExercisePriceRangeFourMember_695b05b9-27c0-4f4a-aba1-0f686cc9d18d_terseLabel_en-US" xlink:label="lab_jan_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.54 to $5.25</link:label>
    <link:label id="lab_jan_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_jan_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_jan_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_jan_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price range four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeFourMember" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ExercisePriceRangeFourMember" xlink:to="lab_jan_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ExercisePriceRangeThreeMember_bf8fd288-328a-4de7-9c93-ef4773a6cd29_terseLabel_en-US" xlink:label="lab_jan_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$5.70 to $9.90</link:label>
    <link:label id="lab_jan_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_jan_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_jan_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_jan_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price range three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeThreeMember" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ExercisePriceRangeThreeMember" xlink:to="lab_jan_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1_88cca7c2-08b7-4e5d-acc0-00485ba655ef_terseLabel_en-US" xlink:label="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases future minimum payments due1</link:label>
    <link:label id="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1_label_en-US" xlink:label="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due1</link:label>
    <link:label id="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1_documentation_en-US" xlink:label="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:href="jan-20231230.xsd#jan_OperatingLeasesFutureMinimumPaymentsDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:to="lab_jan_OperatingLeasesFutureMinimumPaymentsDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ARCAAndSubsidiariesMember_4e920f08-b168-44c9-a421-76568d67c3b9_terseLabel_en-US" xlink:label="lab_jan_ARCAAndSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARCA And Subsidiaries</link:label>
    <link:label id="lab_jan_ARCAAndSubsidiariesMember_label_en-US" xlink:label="lab_jan_ARCAAndSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARCA And Subsidiaries [Member]</link:label>
    <link:label id="lab_jan_ARCAAndSubsidiariesMember_documentation_en-US" xlink:label="lab_jan_ARCAAndSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARCA And Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ARCAAndSubsidiariesMember" xlink:to="lab_jan_ARCAAndSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0b0849a7-2985-494b-84eb-2baa56f9b2a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_76d383e1-14df-4908-8533-49436c5512be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_682775a5-230b-4ec9-a878-1276382ff4b0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1234e222-4006-464a-947d-f45bb9e6ae37_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_648d36f8-9c9c-44b2-b9ec-f66d1d509e50_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2598a26-4a25-4b44-a8ea-4083e57e39a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_df6d7384-269c-4272-96a4-0401beb0e7db_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2bd65db8-7624-4b76-bf19-839b5dfea0f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_df068333-585f-4e55-be06-0ba8025ba2b2_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8c6d75fd-c676-4a97-9bca-80b427cdf807_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities - other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_93597ba6-d050-4f31-98be-3fa15c2da40a_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a4e347de-1a4f-401e-bc0e-4ad09ac36372_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_bdf393fa-71b0-4dc6-ae35-581ac6aa518d_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsLineItems" xlink:to="lab_us-gaap_OffsettingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_Plan2011Member_3e1389aa-b8e1-4291-9434-2bdf7ce45de9_terseLabel_en-US" xlink:label="lab_jan_Plan2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_jan_Plan2011Member_label_en-US" xlink:label="lab_jan_Plan2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan2011 [Member]</link:label>
    <link:label id="lab_jan_Plan2011Member_documentation_en-US" xlink:label="lab_jan_Plan2011Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plan 2011.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2011Member" xlink:href="jan-20231230.xsd#jan_Plan2011Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_Plan2011Member" xlink:to="lab_jan_Plan2011Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_54960ec7-0567-45b1-a1ca-bc16f417cba4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_bea59594-4482-4e6b-96ba-56c0351823cf_negatedLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6d1ed559-aff6-4211-9fe8-7c4a95a3e621_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fedb1d69-49ad-4044-b50a-fb76ae97b052_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2a1d3e5a-ff2f-424e-a695-ef9c86f7109a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_be02deb5-09a7-426b-a4a2-c9b11f484391_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_7dd78006-33ad-44d6-85ca-9591303e0391_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate percentage (percent)</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Discount Rate Percentage</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Discount Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_4cc5f8df-223f-40a4-99b3-6fd67db6ed4d_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary's revenue benchmark</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Subsidiary Revenue Benchmark</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Subsidiary Revenue Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4807f2d-0612-45c6-a9b8-20dd7288cf65_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_4b5f13b8-510f-4b78-bf6e-2874b09a6711_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_41c0c0c9-9893-4ec9-97d9-bdd0e1c75771_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoteReceivableDiscountRate_a7ad4a74-9ebb-4fd1-8c9f-8a28f875e218_terseLabel_en-US" xlink:label="lab_jan_NoteReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable discount rate</link:label>
    <link:label id="lab_jan_NoteReceivableDiscountRate_label_en-US" xlink:label="lab_jan_NoteReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Receivable Discount Rate</link:label>
    <link:label id="lab_jan_NoteReceivableDiscountRate_documentation_en-US" xlink:label="lab_jan_NoteReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note Receivable Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableDiscountRate" xlink:href="jan-20231230.xsd#jan_NoteReceivableDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoteReceivableDiscountRate" xlink:to="lab_jan_NoteReceivableDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c8422add-0514-44bc-9311-0dc48366db1a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_879330cd-4389-4da0-be9d-af478e6f5f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_37ae83de-812d-4b8f-b6c2-a89855cf6101_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan amount</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_9ea68383-9d09-419e-a35d-7ffc9d0c2ca2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AdditionalAwardsToBeGranted_f8dc83ac-d7f0-485b-a847-22d265e89384_terseLabel_en-US" xlink:label="lab_jan_AdditionalAwardsToBeGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional awards to be granted after adoption of 2016 plan (in shares)</link:label>
    <link:label id="lab_jan_AdditionalAwardsToBeGranted_label_en-US" xlink:label="lab_jan_AdditionalAwardsToBeGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Awards To Be Granted</link:label>
    <link:label id="lab_jan_AdditionalAwardsToBeGranted_documentation_en-US" xlink:label="lab_jan_AdditionalAwardsToBeGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional awards to be granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAwardsToBeGranted" xlink:href="jan-20231230.xsd#jan_AdditionalAwardsToBeGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AdditionalAwardsToBeGranted" xlink:to="lab_jan_AdditionalAwardsToBeGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e90adccc-16d7-4d21-bd39-0d1211a65ce1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share from discontinued operations, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_d36fdc46-ad10-4637-8e0e-ea9f2535cf4c_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted income per share from discontinued operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_929f6ece-20b5-4f01-806f-01c18cddac5b_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor obligations, current carrying value</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d9cfd92b-a125-416a-b70a-cbbb07d173b7_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NumberOfAcquiredIntangibleAssets_2ada3c83-72ba-43d4-89c0-9a5a5c690ef2_terseLabel_en-US" xlink:label="lab_jan_NumberOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending patents</link:label>
    <link:label id="lab_jan_NumberOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_jan_NumberOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Acquired Intangible Assets</link:label>
    <link:label id="lab_jan_NumberOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_jan_NumberOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NumberOfAcquiredIntangibleAssets" xlink:to="lab_jan_NumberOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0ab1486c-f8c6-4036-b22d-ec5d8600021e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_7be05b39-0a21-4faf-bfef-c96379580d17_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_32191410-168b-446b-bd55-c94ee77ac301_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_fb247161-e24d-4535-bd75-98cb38e6a537_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Universal life insurance policies assigned</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Number Of Life Insurance Policies Assigned</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Number Of Life Insurance Policies Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_55ba8102-87be-4685-b89d-03dbf3fba195_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income from continuing operations, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_5d9ba415-7931-470e-8c45-0e8ba7c2b493_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_361dbd3f-cb72-4842-aa86-07c8295f2f46_totalLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Short term debt</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Short Term Debt</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Short Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ebb16515-24a2-472b-acb2-9910d0c59e01_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series S preferred issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_57e8218e-ed55-4a1e-adfe-99a00a1663aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_6aae92c2-b46b-4b42-8d98-7d85e19fc335_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsTable" xlink:to="lab_us-gaap_OffsettingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_208bf8b1-6bed-4e54-a807-6673a3edcb2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9bb23890-4e1a-46d2-9ec7-46d942660948_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_74f9fc6e-14cb-4192-9965-f41a0d380586_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_428e76ea-75d6-4bf7-94d3-df1ba7851257_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DiscountCharges_9b4f9856-44b3-4637-b69e-78db606b1116_terseLabel_en-US" xlink:label="lab_jan_DiscountCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount charges</link:label>
    <link:label id="lab_jan_DiscountCharges_label_en-US" xlink:label="lab_jan_DiscountCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Charges</link:label>
    <link:label id="lab_jan_DiscountCharges_documentation_en-US" xlink:label="lab_jan_DiscountCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountCharges" xlink:href="jan-20231230.xsd#jan_DiscountCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DiscountCharges" xlink:to="lab_jan_DiscountCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c2fd3831-0881-4048-98a1-3617f7df456b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_90fb891a-8b45-4eed-8950-c85090cc2205_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_bb5bf4ff-6d2b-4e84-875c-eb0c1ac9fb8b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_299bf7b2-0065-4e52-a608-acfa1c9be92d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_19f49592-daba-480e-a581-97e554d169c2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 19)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_c4ff127d-3772-4eb9-ab29-a9927d02bddd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e5bbf185-d9a9-41f8-90a7-f8afd2293bbd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from equity financings, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionMember_211e77fe-c7b2-48ed-91cc-87f7710ec58a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projects under construction</link:label>
    <link:label id="lab_us-gaap_ConstructionMember_label_en-US" xlink:label="lab_us-gaap_ConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionMember" xlink:to="lab_us-gaap_ConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_102fea82-8d18-4743-9e1d-21910afa1f63_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b411faac-d5e3-4801-bbda-436d2c81a969_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1434ba7c-e0be-4398-95ed-1747d85e8564_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_edbebb41-ac9f-4bc3-be1e-2493cbbacb4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing cash flows used in discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c1eadbe3-da34-46f8-b9ae-b7153ff89149_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfAccountsReceivable_2087f191-7fe6-426d-baf9-c64ef1bf7975_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on note receivable</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:to="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_394a9e30-5187-4585-9b0a-e62b9d16d68c_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0c6baffd-557b-4055-8dda-cc293ad1b886_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_754375d5-c152-47fa-8ade-7cded5878d8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_468ecea4-8daf-4679-b637-8b60eb457f4d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable - SPYR, net</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25efd689-5032-4e74-bf40-73d9ac21047f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_2c6e1c3e-f3ca-408d-9e49-48404c479ebd_terseLabel_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of landlords Company is no longer liable for</link:label>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_label_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments, Number Of Landlords Company Is No Longer Liable For</link:label>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_documentation_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commitments, Number Of Landlords Company Is No Longer Liable For</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:to="lab_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoteReceivableMaturityDate_84c65ee1-c3ae-4528-b6b4-bad5334af942_terseLabel_en-US" xlink:label="lab_jan_NoteReceivableMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable maturity date</link:label>
    <link:label id="lab_jan_NoteReceivableMaturityDate_label_en-US" xlink:label="lab_jan_NoteReceivableMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Receivable Maturity Date</link:label>
    <link:label id="lab_jan_NoteReceivableMaturityDate_documentation_en-US" xlink:label="lab_jan_NoteReceivableMaturityDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note receivable maturity date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableMaturityDate" xlink:href="jan-20231230.xsd#jan_NoteReceivableMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoteReceivableMaturityDate" xlink:to="lab_jan_NoteReceivableMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_3904b227-b110-43a1-90bf-9b1d9ea5a164_totalLabel_en-US" xlink:label="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets (liabilities)</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_label_en-US" xlink:label="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Liabilities Gross Before Valuation Allowance</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_documentation_en-US" xlink:label="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets liabilities gross before valuation allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:to="lab_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a6a8a6a3-4845-471c-906e-7cec00e50987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2d2d82af-1673-4e65-91f5-5e7b30018ef6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7fb87d74-739f-4f5b-afe1-3b7fd4930c35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeInterestEarningAsset_8b97bb5c-ba8a-4cf7-b5d4-876bb0558c08_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeInterestEarningAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeInterestEarningAsset_label_en-US" xlink:label="lab_us-gaap_InterestIncomeInterestEarningAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Interest-Earning Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeInterestEarningAsset" xlink:to="lab_us-gaap_InterestIncomeInterestEarningAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_98b50589-b5a9-4708-9b23-9ca627c7830b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f9053637-0b1f-4a9f-9ddb-9204aef002ba_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7e7c080a-fcd1-4a67-980c-986b0f66042e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Net income after provision for income taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0e6be1f4-9a1a-4cca-ad51-3f6f9da87bb6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8be00fab-b0fc-47b3-bda8-edb7da2d06a8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GainLossOnWriteOffOfNotesReceivable_8207e60b-9384-4f94-be47-942401893dab_negatedTerseLabel_en-US" xlink:label="lab_jan_GainLossOnWriteOffOfNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write off of SPYR note receivable</link:label>
    <link:label id="lab_jan_GainLossOnWriteOffOfNotesReceivable_6cff4298-c1fa-479d-a072-5ad807aaf185_negatedLabel_en-US" xlink:label="lab_jan_GainLossOnWriteOffOfNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment charge related to note receivable</link:label>
    <link:label id="lab_jan_GainLossOnWriteOffOfNotesReceivable_label_en-US" xlink:label="lab_jan_GainLossOnWriteOffOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Write-Off Of Notes Receivable</link:label>
    <link:label id="lab_jan_GainLossOnWriteOffOfNotesReceivable_documentation_en-US" xlink:label="lab_jan_GainLossOnWriteOffOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Write-Off Of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnWriteOffOfNotesReceivable" xlink:href="jan-20231230.xsd#jan_GainLossOnWriteOffOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GainLossOnWriteOffOfNotesReceivable" xlink:to="lab_jan_GainLossOnWriteOffOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_d82fbb5d-da61-4d8b-acaf-527f9862b76c_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion related party note payable</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Portion Related Party Note Payable</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Portion Related Party Note Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_c1ff47fc-0596-4297-a5b7-e749f2e7d440_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum monthly payments</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Minimum Payments from Buyer</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Aggregate Monthly Minimum Payments from Buyer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SoinIntangiblesMember_b97de32d-fb9d-4bc8-8e12-ef4611588c81_terseLabel_en-US" xlink:label="lab_jan_SoinIntangiblesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soin intangibles</link:label>
    <link:label id="lab_jan_SoinIntangiblesMember_label_en-US" xlink:label="lab_jan_SoinIntangiblesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soin intangibles [Member]</link:label>
    <link:label id="lab_jan_SoinIntangiblesMember_documentation_en-US" xlink:label="lab_jan_SoinIntangiblesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Soin intangibles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SoinIntangiblesMember" xlink:to="lab_jan_SoinIntangiblesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61050564-2614-4368-a497-2920e6a1393f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Mezzanine Equity, and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_61cb66b1-b780-4184-b261-b3a0c8e5bc1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GainsOnReversalOfContingencyLoss_06fda8f6-954a-49b1-b7e1-a3d7c69db1ab_terseLabel_en-US" xlink:label="lab_jan_GainsOnReversalOfContingencyLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on reversal of contingent liabilities</link:label>
    <link:label id="lab_jan_GainsOnReversalOfContingencyLoss_label_en-US" xlink:label="lab_jan_GainsOnReversalOfContingencyLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains on Reversal of Contingency Loss</link:label>
    <link:label id="lab_jan_GainsOnReversalOfContingencyLoss_documentation_en-US" xlink:label="lab_jan_GainsOnReversalOfContingencyLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains on reversal of contingency loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainsOnReversalOfContingencyLoss" xlink:href="jan-20231230.xsd#jan_GainsOnReversalOfContingencyLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GainsOnReversalOfContingencyLoss" xlink:to="lab_jan_GainsOnReversalOfContingencyLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SkyBridgeAmericasMember_477f18d7-e8f9-4000-82d9-6971e6850972_terseLabel_en-US" xlink:label="lab_jan_SkyBridgeAmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SA</link:label>
    <link:label id="lab_jan_SkyBridgeAmericasMember_label_en-US" xlink:label="lab_jan_SkyBridgeAmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sky Bridge Americas [Member]</link:label>
    <link:label id="lab_jan_SkyBridgeAmericasMember_documentation_en-US" xlink:label="lab_jan_SkyBridgeAmericasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sky Bridge Americas.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SkyBridgeAmericasMember" xlink:href="jan-20231230.xsd#jan_SkyBridgeAmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SkyBridgeAmericasMember" xlink:to="lab_jan_SkyBridgeAmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfInventory_21c512fb-526e-4470-9094-5bfb71e85a91_terseLabel_en-US" xlink:label="lab_jan_DisposalOfInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_jan_DisposalOfInventory_label_en-US" xlink:label="lab_jan_DisposalOfInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Inventory</link:label>
    <link:label id="lab_jan_DisposalOfInventory_documentation_en-US" xlink:label="lab_jan_DisposalOfInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfInventory" xlink:href="jan-20231230.xsd#jan_DisposalOfInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfInventory" xlink:to="lab_jan_DisposalOfInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5e5e50e9-e340-4a5d-9623-375090889423_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3bf493c7-f600-4832-b9f7-74b3bb074e1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8bdc7c8e-ec37-44b6-aa44-2c6406534563_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_37ad5fb6-9323-41d7-a7f3-c4b3165d9377_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patent and domains</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f4f3fd8b-6ce6-479d-a6bb-21763e200ccd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f92db80e-7fb3-403d-92b9-11b291ef9c09_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_162b3e97-285e-43db-980d-764468344840_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3eb9e554-1f2f-4fde-9317-54938ea2ee09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_08757b0a-6d21-4691-b882-04565bc38cab_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GulfCoastBankAndTrustCreditFacilityMember_85e97fce-afee-4c8e-b686-5e825464d043_terseLabel_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Credit Facility</link:label>
    <link:label id="lab_jan_GulfCoastBankAndTrustCreditFacilityMember_label_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank And Trust Credit Facility [Member]</link:label>
    <link:label id="lab_jan_GulfCoastBankAndTrustCreditFacilityMember_documentation_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank And Trust Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:to="lab_jan_GulfCoastBankAndTrustCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_CommonStockPurchasePricePerShare_56e07307-3600-4393-9681-3d7c8819c43b_terseLabel_en-US" xlink:label="lab_jan_CommonStockPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchase price (in usd per share)</link:label>
    <link:label id="lab_jan_CommonStockPurchasePricePerShare_label_en-US" xlink:label="lab_jan_CommonStockPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Purchase Price Per Share</link:label>
    <link:label id="lab_jan_CommonStockPurchasePricePerShare_documentation_en-US" xlink:label="lab_jan_CommonStockPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock purchase price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockPurchasePricePerShare" xlink:href="jan-20231230.xsd#jan_CommonStockPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_CommonStockPurchasePricePerShare" xlink:to="lab_jan_CommonStockPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfOtherAssets_4de68443-e691-44b6-8cd7-3fc40766c64b_terseLabel_en-US" xlink:label="lab_jan_DisposalOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_jan_DisposalOfOtherAssets_label_en-US" xlink:label="lab_jan_DisposalOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Other Assets</link:label>
    <link:label id="lab_jan_DisposalOfOtherAssets_documentation_en-US" xlink:label="lab_jan_DisposalOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfOtherAssets" xlink:href="jan-20231230.xsd#jan_DisposalOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfOtherAssets" xlink:to="lab_jan_DisposalOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_64ddb637-af4f-45c7-b6c0-d4b344f557dd_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash flows (used in) provided by discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_ac63bdcd-f3d6-4942-b3c3-10d780209438_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in (provided by) financing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_cb7617fd-ca3e-43f4-9dce-3cb41e68445e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TotalGuaranteedConsideration_44e2ec1f-9998-4afb-9d4f-6a29b213c683_terseLabel_en-US" xlink:label="lab_jan_TotalGuaranteedConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total minimum consideration</link:label>
    <link:label id="lab_jan_TotalGuaranteedConsideration_label_en-US" xlink:label="lab_jan_TotalGuaranteedConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Guaranteed Consideration</link:label>
    <link:label id="lab_jan_TotalGuaranteedConsideration_documentation_en-US" xlink:label="lab_jan_TotalGuaranteedConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Guaranteed Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGuaranteedConsideration" xlink:href="jan-20231230.xsd#jan_TotalGuaranteedConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TotalGuaranteedConsideration" xlink:to="lab_jan_TotalGuaranteedConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_365965f8-334d-4f23-ae1e-7dfbd50f1399_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_17867949-500c-47f4-a492-c0230f1a1346_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_2bbaa0d3-daed-4651-a76e-11800057713a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on related party note</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cfd43046-2197-4605-801d-380fedaf85c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0713d56e-c7bf-44be-927a-bd8f4b4b942d_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_af24975a-558f-4e0e-bd3d-93f677f97b0d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9463b51a-1e5c-4618-99eb-2cc760e122e4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0790e5fa-b5cd-442f-9965-8b6094a17305_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_192b7689-a091-4eeb-be1f-5a97f549b26b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8a64f187-994a-450d-955e-ff5573a00431_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AccruedIncentiveAndRebateChecksCurrent_18154b4e-6351-4e0b-a7a8-d10908ab80c4_verboseLabel_en-US" xlink:label="lab_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued incentive and rebate checks</link:label>
    <link:label id="lab_jan_AccruedIncentiveAndRebateChecksCurrent_label_en-US" xlink:label="lab_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Incentive And Rebate Checks Current</link:label>
    <link:label id="lab_jan_AccruedIncentiveAndRebateChecksCurrent_documentation_en-US" xlink:label="lab_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued incentive and rebate checks current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:href="jan-20231230.xsd#jan_AccruedIncentiveAndRebateChecksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:to="lab_jan_AccruedIncentiveAndRebateChecksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f80d4a8c-249d-4efe-b29f-a4408d2c96e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_5f08772c-a97a-4889-a635-56e11db348e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Preferred forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_048908af-8709-44e0-869d-855a091173b2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfPropertyPlantAndEquipment_331a3fcf-5640-4825-960a-6ce21ea6ab27_terseLabel_en-US" xlink:label="lab_jan_DisposalOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_jan_DisposalOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_jan_DisposalOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Property, Plant and Equipment</link:label>
    <link:label id="lab_jan_DisposalOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_jan_DisposalOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfPropertyPlantAndEquipment" xlink:href="jan-20231230.xsd#jan_DisposalOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfPropertyPlantAndEquipment" xlink:to="lab_jan_DisposalOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bf2fe57e-8ab4-41ac-9107-a8e83b422028_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_79f6d4d7-414d-48ba-a90e-b499a785d8b4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_9c7a49ed-5a58-4d09-8187-284fb996d0b5_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca3b462e-1167-4ea5-bed8-57174dd16a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_d5178997-7ef4-4ad9-88c4-244738cfce92_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_318034cf-d232-47bc-86d0-55c659d11c96_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_43c20f7f-7810-47f8-ac4f-bd3a8bdf7757_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_61dc2f57-7b46-4911-88b3-e2ee56f7991f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6cac549c-9795-47b1-af25-ad9a21300bc2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fe4d6976-d6e3-40cd-a57f-6af460116bc4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_62a1d98a-62c9-4076-8a35-41e3c67fc343_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_c1779446-860f-4a25-84cf-6369ec65e3df_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net, from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StiMergerSubIncMember_38b95205-5399-412b-9020-66fe3986e062_terseLabel_en-US" xlink:label="lab_jan_StiMergerSubIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STI Merger Sub, Inc.</link:label>
    <link:label id="lab_jan_StiMergerSubIncMember_label_en-US" xlink:label="lab_jan_StiMergerSubIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STI Merger Sub, Inc. [Member]</link:label>
    <link:label id="lab_jan_StiMergerSubIncMember_documentation_en-US" xlink:label="lab_jan_StiMergerSubIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">STI Merger Sub, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StiMergerSubIncMember" xlink:href="jan-20231230.xsd#jan_StiMergerSubIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StiMergerSubIncMember" xlink:to="lab_jan_StiMergerSubIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_3553841d-5549-458c-a855-ad4d099df954_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e397194e-49ba-436b-aa0f-e70dde2fdb50_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9272203f-d54d-4afc-97c5-07fbfbf6074d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d98c5e39-a57a-47ed-acfc-6d8d1b961c68_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_c9874b1c-1c5b-4266-8c50-233364a044f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_f4be4140-5cd7-4c7e-8bb4-4379db0bb44a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc57f421-7219-4a20-a2c6-4717c6f1aad6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_IsaacConsultingAgreementMember_4ecd38dd-73a6-42b9-a152-de2bd8dd5496_terseLabel_en-US" xlink:label="lab_jan_IsaacConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Isaac Consulting Agreement</link:label>
    <link:label id="lab_jan_IsaacConsultingAgreementMember_label_en-US" xlink:label="lab_jan_IsaacConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Isaac Consulting Agreement [Member]</link:label>
    <link:label id="lab_jan_IsaacConsultingAgreementMember_documentation_en-US" xlink:label="lab_jan_IsaacConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Isaac Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacConsultingAgreementMember" xlink:href="jan-20231230.xsd#jan_IsaacConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_IsaacConsultingAgreementMember" xlink:to="lab_jan_IsaacConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NetConsideration_c3c1a5cd-70f6-4bd8-b72d-3d1d7c331b22_totalLabel_en-US" xlink:label="lab_jan_NetConsideration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net consideration</link:label>
    <link:label id="lab_jan_NetConsideration_label_en-US" xlink:label="lab_jan_NetConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Consideration</link:label>
    <link:label id="lab_jan_NetConsideration_documentation_en-US" xlink:label="lab_jan_NetConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NetConsideration" xlink:href="jan-20231230.xsd#jan_NetConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NetConsideration" xlink:to="lab_jan_NetConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_845a1afc-885f-4abd-89e8-09e08dc8079f_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surcharge or broker fee (percent)</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases From Related Party, Surcharge Or Broker Fee, Percent</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases From Related Party, Surcharge Or Broker Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:to="lab_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6756c17d-208a-4c91-ab13-ae79e3be4789_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_f105080e-ded0-4316-970e-7bce526ad7b9_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount recorded as offset to the principal amount</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Present Value Of Discount Recorded As Offset To The Principal Amount</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Present Value Of Discount Recorded As Offset To The Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesA1Member_03cb3667-aa54-4b25-8e83-883960e1c2d0_terseLabel_en-US" xlink:label="lab_jan_SeriesA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1</link:label>
    <link:label id="lab_jan_SeriesA1Member_label_en-US" xlink:label="lab_jan_SeriesA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 [Member]</link:label>
    <link:label id="lab_jan_SeriesA1Member_documentation_en-US" xlink:label="lab_jan_SeriesA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1Member" xlink:href="jan-20231230.xsd#jan_SeriesA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesA1Member" xlink:to="lab_jan_SeriesA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f0f2c695-4440-43fd-9bbc-892c1f524bde_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ConversionOfStockAmountConvertible_ac6aad1c-1c9d-4602-a754-9d9384635de3_terseLabel_en-US" xlink:label="lab_jan_ConversionOfStockAmountConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, amount converted</link:label>
    <link:label id="lab_jan_ConversionOfStockAmountConvertible_label_en-US" xlink:label="lab_jan_ConversionOfStockAmountConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Amount Convertible</link:label>
    <link:label id="lab_jan_ConversionOfStockAmountConvertible_documentation_en-US" xlink:label="lab_jan_ConversionOfStockAmountConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Amount Convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockAmountConvertible" xlink:href="jan-20231230.xsd#jan_ConversionOfStockAmountConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ConversionOfStockAmountConvertible" xlink:to="lab_jan_ConversionOfStockAmountConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_FinancingArrangementMember_1d184335-fd14-4434-8472-60757dd4780f_terseLabel_en-US" xlink:label="lab_jan_FinancingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Arrangement</link:label>
    <link:label id="lab_jan_FinancingArrangementMember_label_en-US" xlink:label="lab_jan_FinancingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Arrangement [Member]</link:label>
    <link:label id="lab_jan_FinancingArrangementMember_documentation_en-US" xlink:label="lab_jan_FinancingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FinancingArrangementMember" xlink:href="jan-20231230.xsd#jan_FinancingArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_FinancingArrangementMember" xlink:to="lab_jan_FinancingArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_19f692c3-034b-4129-ae25-3d910001ddff_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5c07c319-1e19-4ae1-8b67-fa00c59f215c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PercentOfPrepaymentTenderRestrictions_e9202022-01fd-416c-a802-9b6ca6bbcbe7_terseLabel_en-US" xlink:label="lab_jan_PercentOfPrepaymentTenderRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of prepayment value, tender restrictions (percent)</link:label>
    <link:label id="lab_jan_PercentOfPrepaymentTenderRestrictions_label_en-US" xlink:label="lab_jan_PercentOfPrepaymentTenderRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent Of Prepayment Tender Restrictions</link:label>
    <link:label id="lab_jan_PercentOfPrepaymentTenderRestrictions_documentation_en-US" xlink:label="lab_jan_PercentOfPrepaymentTenderRestrictions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent Of Prepayment Tender Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentOfPrepaymentTenderRestrictions" xlink:href="jan-20231230.xsd#jan_PercentOfPrepaymentTenderRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PercentOfPrepaymentTenderRestrictions" xlink:to="lab_jan_PercentOfPrepaymentTenderRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_bd03736e-aed8-44ad-a863-fb1020213a1d_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bcc129b1-0859-4c57-83c9-d6fe3bfe6e83_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e4ed9166-a6bd-47ae-94f4-9f18a13c9d01_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2a8a44a0-8671-4a7a-8e35-f925fc7ed025_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, value, acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_65c56505-3b18-419a-948b-d61aec69032c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f31173b2-7223-4093-a6f1-365bb7321f6c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5859b89d-1e20-47e9-99ea-57f1a4a025a4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets (liabilities):</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1519a0ff-835e-48fd-95f7-c6c553ccd45e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_IsaacCapitalGroupLLCICGMember_1f1b73cd-6e75-495f-8608-9afca4bd9bb6_terseLabel_en-US" xlink:label="lab_jan_IsaacCapitalGroupLLCICGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICG</link:label>
    <link:label id="lab_jan_IsaacCapitalGroupLLCICGMember_label_en-US" xlink:label="lab_jan_IsaacCapitalGroupLLCICGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Isaac Capital Group LLC (&#8220;ICG&#8221;) [Member]</link:label>
    <link:label id="lab_jan_IsaacCapitalGroupLLCICGMember_documentation_en-US" xlink:label="lab_jan_IsaacCapitalGroupLLCICGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Isaac Capital Group LLC (&#8220;ICG&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacCapitalGroupLLCICGMember" xlink:href="jan-20231230.xsd#jan_IsaacCapitalGroupLLCICGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_IsaacCapitalGroupLLCICGMember" xlink:to="lab_jan_IsaacCapitalGroupLLCICGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_14cee8e6-511b-4299-97f1-92b2780b0082_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_FairValueOfStockIssued_2990e70e-5ff0-4aa5-9360-4541eb8f955c_terseLabel_en-US" xlink:label="lab_jan_FairValueOfStockIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of stock issued connection with merger</link:label>
    <link:label id="lab_jan_FairValueOfStockIssued_label_en-US" xlink:label="lab_jan_FairValueOfStockIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Stock Issued</link:label>
    <link:label id="lab_jan_FairValueOfStockIssued_documentation_en-US" xlink:label="lab_jan_FairValueOfStockIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of stock issued connection with merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FairValueOfStockIssued" xlink:href="jan-20231230.xsd#jan_FairValueOfStockIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_FairValueOfStockIssued" xlink:to="lab_jan_FairValueOfStockIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0bf286de-71cd-4cb6-9819-7d9e90064f6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_25dd4559-547f-4e84-9255-8785b4ff9828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_00bfdd85-1116-4f8f-bb07-bc91dcce2697_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_ab6e5c52-8dff-4843-86df-a72418845a86_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, amount converted</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_dd9d9c15-368d-4813-b218-13074c1ce744_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_3122f32d-7458-407c-9940-bc60ba7b7723_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal and accrued interest due</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SpyrTechnologiesIncMember_67c9fbc4-4ea4-42f4-8668-36fb6207f88d_terseLabel_en-US" xlink:label="lab_jan_SpyrTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPYR Technologies Inc.</link:label>
    <link:label id="lab_jan_SpyrTechnologiesIncMember_label_en-US" xlink:label="lab_jan_SpyrTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPYR Technologies Inc. [Member]</link:label>
    <link:label id="lab_jan_SpyrTechnologiesIncMember_documentation_en-US" xlink:label="lab_jan_SpyrTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPYR Technologies Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SpyrTechnologiesIncMember" xlink:to="lab_jan_SpyrTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_04728f61-87e7-4b12-afe2-b5280ec7ed49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for equity financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_294975ad-b3c2-4415-ae6d-496ba7634557_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other assets from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8411851b-c202-4e53-825c-944b3156e2ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ee37b04a-9816-49a6-a59a-09309df47264_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e5e89fff-2e89-4bca-9cf8-e757f406ca91_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_e0989d28-c1ac-4e6d-8aad-4da50a173dff_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_0074ec45-97f4-4b64-8652-e0473edc8b54_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a6b5ac80-4916-4d1a-be71-5926ea4c98ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds reimbursement for accountable legal expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember_0bd8a493-ace1-41ac-8418-b151527e0969_terseLabel_en-US" xlink:label="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing and discontinued operation</link:label>
    <link:label id="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember_label_en-US" xlink:label="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations And Discontinued Operations [Member]</link:label>
    <link:label id="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember_documentation_en-US" xlink:label="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Continuing Operations And Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:to="lab_jan_ContinuingOperationsAndDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_cae4f0a1-1fe0-488b-be69-0cab40cdc61d_netLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Sale of Recycling Subsidiaries</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b9fa4c97-adda-49b2-b635-79fae8dbfe88_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GeoTraq</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_59a83a5e-b32d-4f22-a3ea-219ac9a07fef_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_ba8bb9d2-5666-48a6-84fc-fc6b3ecae75e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_81f67ab9-b37f-4ec3-9cc1-8c9ce7f138e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9345a0ee-6844-4cea-8e40-b560d96ff0dc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_d6b18cdd-1441-4219-a450-8a3d67cd4f74_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mergers and Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ded89175-a211-4c42-9df4-877d384bd479_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_6f20c101-913c-4523-b1fe-759ed5ef1308_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate on promissory note (percent)</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Stated Rate</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Stated Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ce012f9-0db5-4798-9273-5c8554da23fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2bc8f96e-4526-41e5-a73c-6ef65be00a1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fb09d1de-5a54-4df1-8348-f949698dfd14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_64cd57ad-a7a1-439e-85e0-bfe40b0da997_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a5748f2b-f00d-4558-81e5-8667f303d0ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised_afd9635b-02e9-47f9-9033-a43b4520a687_terseLabel_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_jan_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a515753-fea9-4226-bec6-e20f670557b8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_af1b83b2-69a5-48cb-8a1b-6c83c53b7fc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">LESS CASH OF DISCONTINUED OPERATIONS, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8f4aad5a-038f-4a55-9dee-9bc28ce223f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share from continuing operations, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fcaa490a-3252-4606-8374-2f3d87d647ca_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Basic (loss) income per share from continuing operations, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_96cbdd0d-64f3-4bae-87be-722452e3b2c5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_71ad3a13-0387-4aee-b33b-7613db7d7b27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Company loan origination fees</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_757b2e0d-6b4f-49d9-899a-3246521579e8_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligation long-term - operating leases</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Lease Obligation Long Term, Operating Leases</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Lease Obligation Long Term, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e80e80ce-6bdc-4af4-b44f-fcec073d711a_negatedLabel_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_4f169cec-e657-468a-acfd-f22898a167da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c405dfb2-03d9-4ed5-ab72-473b88cfe5e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a482e834-41cf-45ef-90f9-e8501b387a05_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalOfAccountsPayable_b1785f39-7dcb-4ae6-9422-772b4f38faeb_terseLabel_en-US" xlink:label="lab_jan_DisposalOfAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_jan_DisposalOfAccountsPayable_label_en-US" xlink:label="lab_jan_DisposalOfAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal of Accounts Payable</link:label>
    <link:label id="lab_jan_DisposalOfAccountsPayable_documentation_en-US" xlink:label="lab_jan_DisposalOfAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal of Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsPayable" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalOfAccountsPayable" xlink:to="lab_jan_DisposalOfAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DeferredTaxAssetsLeaseLiability_6082950c-6b50-45f3-bd87-e07a7dade025_terseLabel_en-US" xlink:label="lab_jan_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_jan_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Lease Liability</link:label>
    <link:label id="lab_jan_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_jan_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLeaseLiability" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DeferredTaxAssetsLeaseLiability" xlink:to="lab_jan_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_52ae955c-2a00-4634-a21a-cf82ce85800e_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b2f5801d-a854-4186-90dd-20deb3f7962b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TrusteesMain270LlcMember_7b0f587f-12f1-4206-9d06-83d95cab8f11_terseLabel_en-US" xlink:label="lab_jan_TrusteesMain270LlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Main/270</link:label>
    <link:label id="lab_jan_TrusteesMain270LlcMember_label_en-US" xlink:label="lab_jan_TrusteesMain270LlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trustees Main/270, LLC [Member]</link:label>
    <link:label id="lab_jan_TrusteesMain270LlcMember_documentation_en-US" xlink:label="lab_jan_TrusteesMain270LlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trustees Main/270, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TrusteesMain270LlcMember" xlink:href="jan-20231230.xsd#jan_TrusteesMain270LlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TrusteesMain270LlcMember" xlink:to="lab_jan_TrusteesMain270LlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesSConvertiblePreferredStockMember_37641430-44d8-4591-8d77-ad4a8014722e_terseLabel_en-US" xlink:label="lab_jan_SeriesSConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series S</link:label>
    <link:label id="lab_jan_SeriesSConvertiblePreferredStockMember_label_en-US" xlink:label="lab_jan_SeriesSConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series S Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_jan_SeriesSConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_jan_SeriesSConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series S Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesSConvertiblePreferredStockMember" xlink:to="lab_jan_SeriesSConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_25df3c6d-d2d5-451b-8ca8-b324b446b559_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_a9c0c173-a047-4b39-9db9-6aa9331b424f_terseLabel_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature</link:label>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_label_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Beneficial Conversion Feature, Value</link:label>
    <link:label id="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_documentation_en-US" xlink:label="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Beneficial Conversion Feature, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:to="lab_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5a5a1af7-3c23-430b-96bd-ab46f7c1365d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25bb3f44-76fa-41fc-a65f-8474008d639d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_64387ff8-4037-423f-8370-c30735268109_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of promissory note issued</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Term</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_404c22ae-0238-4ed4-bb17-ae8fa38c34af_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_d66369fa-d6b8-47d7-97f0-7bb08138bd40_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DispositionTransactionAggregateCost_056dea23-613d-4864-a999-50075bad5dd0_terseLabel_en-US" xlink:label="lab_jan_DispositionTransactionAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposition transaction aggregate cost</link:label>
    <link:label id="lab_jan_DispositionTransactionAggregateCost_label_en-US" xlink:label="lab_jan_DispositionTransactionAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposition Transaction Aggregate cost</link:label>
    <link:label id="lab_jan_DispositionTransactionAggregateCost_documentation_en-US" xlink:label="lab_jan_DispositionTransactionAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposition Transaction Aggregate cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionAggregateCost" xlink:href="jan-20231230.xsd#jan_DispositionTransactionAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DispositionTransactionAggregateCost" xlink:to="lab_jan_DispositionTransactionAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice_43dbee79-f925-493d-b662-2a2b46ff454c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Purchased with Credit Deterioration, Amount at Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_035b3467-3073-441f-a869-aded2605c0cc_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Background and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_fc79c741-c2b4-44fe-8c63-e0a283b2ecb9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreed prepayment amount</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5cd75089-eba6-4a97-b0fc-bb1483f71f56_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c0f59433-f77b-497b-b004-80365568ea98_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Deficit</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_a8f8ef61-7168-4bae-ad19-e567b2e6aebb_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess of book value over assets disposed, extensible list</link:label>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Not Discontinued Operation Gain (Loss) On Disposal, Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group Not Discontinued Operation Gain (Loss) On Disposal, Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_c827387e-c158-4839-b57d-a315dd8594be_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Guarantee</link:label>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Guarantee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialGuaranteeMember" xlink:to="lab_us-gaap_FinancialGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_924c0739-610b-41af-ad12-e02bf70e5d45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_MarketableSecuritiesSharesOutstanding_f298be8a-84a4-4d12-9460-fff5175bba4b_periodStartLabel_en-US" xlink:label="lab_jan_MarketableSecuritiesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_jan_MarketableSecuritiesSharesOutstanding_e9279061-93be-4a55-9578-a0cc1b202bbe_periodEndLabel_en-US" xlink:label="lab_jan_MarketableSecuritiesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_jan_MarketableSecuritiesSharesOutstanding_label_en-US" xlink:label="lab_jan_MarketableSecuritiesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Shares Outstanding</link:label>
    <link:label id="lab_jan_MarketableSecuritiesSharesOutstanding_documentation_en-US" xlink:label="lab_jan_MarketableSecuritiesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MarketableSecuritiesSharesOutstanding" xlink:href="jan-20231230.xsd#jan_MarketableSecuritiesSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_MarketableSecuritiesSharesOutstanding" xlink:to="lab_jan_MarketableSecuritiesSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_df504084-4aa1-4c6b-984b-fbf7bbe8ece5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b6d08429-c94e-45b2-8fb8-962572bef1d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_904f1507-8354-4002-8e73-61e83bb8e931_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1c55c2cc-14d5-43fb-b9f1-1b6b884279db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_73e078f2-6f3d-42ac-b417-ece1b1789652_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.001 per share, 200,000,000 shares authorized, 4,957,647 and 2,827,410 shares issued and outstanding at December&#160;30, 2023 and at December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_5e546d60-ca42-4204-ac63-a7057e06a81e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63a1dd29-234a-4b88-860b-eae87aa18acb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DepositsAndOtherAssetsNoncurrent_37e180a3-2717-4cea-b2f6-67c2e78c61e3_terseLabel_en-US" xlink:label="lab_jan_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_jan_DepositsAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_jan_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits And Other Assets Noncurrent</link:label>
    <link:label id="lab_jan_DepositsAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_jan_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deposits and other assets noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_jan_DepositsAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_c39f690d-d3ed-4c9a-a8f9-44e7bbd40875_totalLabel_en-US" xlink:label="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaids and other current assets</link:label>
    <link:label id="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_label_en-US" xlink:label="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense And Other Assets, including Discontinued Operations, Current</link:label>
    <link:label id="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_documentation_en-US" xlink:label="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expense And Other Assets, including Discontinued Operations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:href="jan-20231230.xsd#jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:to="lab_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_d963b8de-35d1-4a1a-8c4f-889e6796a65e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5502b015-fea1-4306-893a-140a42be2b51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_074fe538-ebef-4a83-8f62-931f909357c1_negatedTerseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other (Income) Expense, Net</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other (Income) Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a9ff7f2d-5328-4d86-91f6-0ef5d50f111c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_65f07ea8-86de-436d-8bbf-8a88bb3c1dd3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e09c5e03-7ec3-4bb1-b1cf-f17401439bb4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_47e3eb1b-2805-4cc7-bd1d-664abf97697b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_867c70e6-4ffa-4c06-93c9-ebb9816bc31c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liability - CA sales tax assessment</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5973340c-6996-4bdd-bc94-3210db55816f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_a205603b-f818-4a10-b063-f4b83159fa3b_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in liabilities</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Reduction In Liabilities</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Reduction In Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_54895035-38cb-4183-ac6b-e103305c4fde_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_715ab505-4751-4702-b45b-dc3338ff2b9d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock equivalents received (in shares)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProject_2df29752-9345-4b08-922e-c270421e0582_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProject" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProject_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProject" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Project</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProject" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfProject"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfProject" xlink:to="lab_us-gaap_GainLossOnSaleOfProject" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_340cf9cc-de3a-4e2c-ae55-4dbea3b8cacc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a07786a1-d9b3-405e-ac06-d1ef92ed2e20_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_d40b96dd-5477-4306-b6ad-d4c6a11c76c8_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingently tendered funds in counsel's trust account</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Contingently Tendered Funds</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Contingently Tendered Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_c02222df-4837-46f4-9d4e-dc9dc8f53914_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Receivables</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesTextBlock" xlink:to="lab_us-gaap_FinancingReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_71837a33-9316-4fb6-a64f-570490e0639d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c48e1580-f636-46fa-995d-84ae98a96658_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9b37f395-b4bf-4382-aa0f-c8af695e82d3_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9703073a-04a7-4763-b184-078e63faf10b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_7c035ba4-0a62-4548-9c69-30a2ff4c3484_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaids and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bede1cbb-7f06-4891-8121-879d39bde77b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount_32194403-41e9-45d9-bf61-7e94dd397508_terseLabel_en-US" xlink:label="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset to the principal amount</link:label>
    <link:label id="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount_label_en-US" xlink:label="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Recorded As Offset To The Principal Amount</link:label>
    <link:label id="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount_documentation_en-US" xlink:label="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount Recorded As Offset To The Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:href="jan-20231230.xsd#jan_DiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:to="lab_jan_DiscountRecordedAsOffsetToThePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c485d57e-3d7d-46ff-a7e3-089b06431a4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_9c424bea-74ca-4d71-b1b9-e400e14520a1_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book value in excess of assets disposed of</link:label>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_label_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Book Value In Excess Of Assets</link:label>
    <link:label id="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_documentation_en-US" xlink:label="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Book Value In Excess Of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:to="lab_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_33a6259e-6cf7-4237-8c7c-e9aaf081a3b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_f15328a2-c854-408c-8d73-7694b7f23217_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income from continuing operations, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_74f271b9-be25-4a4d-b721-3d18be72fa8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e3c144a7-fd78-47c6-9c4d-d1c0a44ecafe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_cb3f9f7e-4f34-4bc0-ba7b-f9f0c4e9ebac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of GeoTraq</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7afaaed0-f78b-4e3f-9c3e-a36954c19ad1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_937660bc-4b79-4d6a-b72b-82c008d4cf80_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e4c01586-a7f7-40a7-842c-85a1e47dee23_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_02f60b9d-a8cb-4ee3-8259-b771a9e309f4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets from discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_cd3b96aa-61b7-43f4-acb2-9364dc7458d4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets from discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dca16ec9-9688-43eb-8fe6-f3adb002d91e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c927708-bb7b-43ed-82da-66fd377a675c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e35cec97-9f5b-4911-afb2-bff654502f26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_CommonStockSharesOutstandingPercentage_87df19b9-5b49-4b84-b168-7a8d5935203a_terseLabel_en-US" xlink:label="lab_jan_CommonStockSharesOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, percentage</link:label>
    <link:label id="lab_jan_CommonStockSharesOutstandingPercentage_label_en-US" xlink:label="lab_jan_CommonStockSharesOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Outstanding, Percentage</link:label>
    <link:label id="lab_jan_CommonStockSharesOutstandingPercentage_documentation_en-US" xlink:label="lab_jan_CommonStockSharesOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Outstanding, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockSharesOutstandingPercentage" xlink:href="jan-20231230.xsd#jan_CommonStockSharesOutstandingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_CommonStockSharesOutstandingPercentage" xlink:to="lab_jan_CommonStockSharesOutstandingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_2438e725-c204-4284-9804-120fb64e8661_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0682c4ff-b137-4e4f-afc4-c29343c69279_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6fb39404-9c66-47af-bc12-6ba6d77f60e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_d702d6c0-f1d9-4b60-9799-51a432cf22b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rent</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d6bf36a9-c590-450f-9307-c33dd5812662_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NumberOfTranches_b1660f1d-f5ab-4f7f-bac0-27acd6e10f65_terseLabel_en-US" xlink:label="lab_jan_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_jan_NumberOfTranches_label_en-US" xlink:label="lab_jan_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_jan_NumberOfTranches_documentation_en-US" xlink:label="lab_jan_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTranches" xlink:href="jan-20231230.xsd#jan_NumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NumberOfTranches" xlink:to="lab_jan_NumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4b11d579-647c-4fa6-aa37-fc9dc016a7df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 preferred converted for legal settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_91bce973-2d54-46a4-a29d-cfa4d66014c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_d33f4595-183d-4438-92a6-be091efdaa9d_terseLabel_en-US" xlink:label="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, voting rights</link:label>
    <link:label id="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_label_en-US" xlink:label="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Voting Rights, Number Of Votes Entitled To Each Share</link:label>
    <link:label id="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_documentation_en-US" xlink:label="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Voting Rights, Number Of Votes Entitled To Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:href="jan-20231230.xsd#jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:to="lab_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8e1f67d-012f-4d49-83ee-178b96616f55_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ae547c6-b455-4e90-88ea-df9322865603_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GainLossOnLitigationSettlement_b19f3cb6-351f-4068-a88b-e19df40ce84d_negatedTerseLabel_en-US" xlink:label="lab_jan_GainLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on litigation settlement</link:label>
    <link:label id="lab_jan_GainLossOnLitigationSettlement_label_en-US" xlink:label="lab_jan_GainLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss on Litigation Settlement</link:label>
    <link:label id="lab_jan_GainLossOnLitigationSettlement_documentation_en-US" xlink:label="lab_jan_GainLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain loss on litigation settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnLitigationSettlement" xlink:href="jan-20231230.xsd#jan_GainLossOnLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GainLossOnLitigationSettlement" xlink:to="lab_jan_GainLossOnLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_911ce903-cef9-48c6-912c-4c672da2dfce_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f2f504bd-f339-43cc-b02c-01e94f6e7830_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_a153872b-a605-4ab8-acfc-8d5dcab9efc6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6b2d195a-a9c5-4e26-9efa-3e089f3c9556_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b013643-04d0-4cba-855f-fceac660645f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0d0a66bb-ccbb-41db-afdb-1c38e5cf03ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_45570bcd-ac1d-4def-80d6-f5076a36b501_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of note payable</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_e3ecf7eb-cd94-4ab0-ad9d-b3fbf1878734_negatedLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Note Payable, Current</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Note Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_ad1be405-77ec-4e51-9881-6c98640a15de_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domain Name and Marketing</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b9852b52-7da2-4de6-a93d-e2bc4cbe1245_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4c0e7a37-f678-4c0a-a2df-58fb3e4c697f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_48a1bc97-c557-4fbd-bb8e-beb3da3cc331_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_bc8b4992-d90b-46ee-9419-69d2557517b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Information About Non-vested Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_c6189aab-e3a4-4e1b-b049-d2bc2dd2f451_terseLabel_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial principal amount</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_label_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Face Amount</link:label>
    <link:label id="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_documentation_en-US" xlink:label="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Consulting Agreement, Convertible Debt, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:to="lab_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_d812d5c1-46b8-4777-8349-e03f846e7973_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5cd7ec6f-7490-4764-a448-56ebe69c31cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_be11034d-6a7e-45c4-b39d-2f780e43c776_negatedTerseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on litigation settlement</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Litigation Settlement Expense</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Litigation Settlement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_JanOneMember_dc39c1cd-fdfc-46dc-bd61-46c5b7222025_terseLabel_en-US" xlink:label="lab_jan_JanOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janone</link:label>
    <link:label id="lab_jan_JanOneMember_label_en-US" xlink:label="lab_jan_JanOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JanOne [Member]</link:label>
    <link:label id="lab_jan_JanOneMember_documentation_en-US" xlink:label="lab_jan_JanOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JanOne</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_JanOneMember" xlink:href="jan-20231230.xsd#jan_JanOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_JanOneMember" xlink:to="lab_jan_JanOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_7c3be650-c2dc-4406-9faf-61f75355981b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_aec1f954-3031-4441-9d65-0c8834b143d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, lower range limit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_MezzanineEquityAbstract_0baf2387-dc92-4f2c-b14a-66deef87d56b_terseLabel_en-US" xlink:label="lab_jan_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_jan_MezzanineEquityAbstract_label_en-US" xlink:label="lab_jan_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mezzanine equity [Abstract]</link:label>
    <link:label id="lab_jan_MezzanineEquityAbstract_documentation_en-US" xlink:label="lab_jan_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mezzanine equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MezzanineEquityAbstract" xlink:href="jan-20231230.xsd#jan_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_MezzanineEquityAbstract" xlink:to="lab_jan_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_22dd9ae6-6733-4594-9395-e513566e1d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d8da5dba-0ccb-4147-954b-17f7bf54c666_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_de04333b-8994-46b9-b0ac-8adced2a4da3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1738759a-8926-40a6-ae9d-11130a3d6ea7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_01f77927-30cc-49eb-84e3-3c0c2646364f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e6cf018d-ae7d-4644-be69-f12f443cee09_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_44b67340-f024-427d-b05d-d66fb92ebba0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AFCOCreditCorpMember_0af214fa-e44f-486a-8051-218084d6475c_terseLabel_en-US" xlink:label="lab_jan_AFCOCreditCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AFCO Finance</link:label>
    <link:label id="lab_jan_AFCOCreditCorpMember_label_en-US" xlink:label="lab_jan_AFCOCreditCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AFCO Credit Corp [Member]</link:label>
    <link:label id="lab_jan_AFCOCreditCorpMember_documentation_en-US" xlink:label="lab_jan_AFCOCreditCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AFCO credit corp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorpMember" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AFCOCreditCorpMember" xlink:to="lab_jan_AFCOCreditCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesAConvertiblePreferredStockMember_8f79b0a9-3d42-4314-b624-1e1896b067e3_terseLabel_en-US" xlink:label="lab_jan_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_jan_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_jan_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_jan_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_jan_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesAConvertiblePreferredStockMember" xlink:href="jan-20231230.xsd#jan_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesAConvertiblePreferredStockMember" xlink:to="lab_jan_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_707c7bb9-b351-49f6-8cb8-75cc099f0b98_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4051678c-93c9-4f59-8ff9-30c5bbeec3a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GulfCoastBankAndTrustCompanyMember_92f528d4-e700-4a98-a34f-7dc33fe59728_terseLabel_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Company</link:label>
    <link:label id="lab_jan_GulfCoastBankAndTrustCompanyMember_label_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Company [Member]</link:label>
    <link:label id="lab_jan_GulfCoastBankAndTrustCompanyMember_documentation_en-US" xlink:label="lab_jan_GulfCoastBankAndTrustCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gulf Coast Bank and Trust Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCompanyMember" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GulfCoastBankAndTrustCompanyMember" xlink:to="lab_jan_GulfCoastBankAndTrustCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f989368b-a774-4055-bf13-445fc497b40a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ea02a1fc-f644-4861-90df-e8d0232979e1_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before provision for income taxes from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_015b8610-1032-4816-8b0a-88dad167384b_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_fad05783-b78d-4de2-af46-56e6da895911_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of ARCA &amp; GeoTraq</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_67f0fe92-efdc-438d-ba64-c680d3c0ef4f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_df973782-a565-490d-a36d-dfd6d3820d09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_77129470-3ee8-4069-9f62-97b542944b03_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_b69bdcf6-a2d6-4cec-96fa-b9187ce7e3ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GainOnSaleNetOfCash_f96757a7-1d2a-4ae5-aaff-7c0f9ce921f8_negatedTerseLabel_en-US" xlink:label="lab_jan_GainOnSaleNetOfCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of ARCA, net of cash</link:label>
    <link:label id="lab_jan_GainOnSaleNetOfCash_label_en-US" xlink:label="lab_jan_GainOnSaleNetOfCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Sale, Net of Cash</link:label>
    <link:label id="lab_jan_GainOnSaleNetOfCash_documentation_en-US" xlink:label="lab_jan_GainOnSaleNetOfCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on Sale, Net of Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainOnSaleNetOfCash" xlink:href="jan-20231230.xsd#jan_GainOnSaleNetOfCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GainOnSaleNetOfCash" xlink:to="lab_jan_GainOnSaleNetOfCash" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_47e8689b-3034-467d-aa85-631d941e753c_totalLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Total Other Income (Loss), Net</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total other loss, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_72fd36db-32ad-43d2-882e-c959e7ebf495_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_054b5054-913b-4d23-a5cf-aff258f76bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d88e2fe2-a69e-4a3c-b35c-4c6576e2990f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AdditionalAmountChargedAgainstIncome_c9ad620d-6250-4655-ab89-9cf0be5e6854_terseLabel_en-US" xlink:label="lab_jan_AdditionalAmountChargedAgainstIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional amount charge aganist income</link:label>
    <link:label id="lab_jan_AdditionalAmountChargedAgainstIncome_label_en-US" xlink:label="lab_jan_AdditionalAmountChargedAgainstIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Amount Charged Against Income</link:label>
    <link:label id="lab_jan_AdditionalAmountChargedAgainstIncome_documentation_en-US" xlink:label="lab_jan_AdditionalAmountChargedAgainstIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Amount Charged Against Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAmountChargedAgainstIncome" xlink:href="jan-20231230.xsd#jan_AdditionalAmountChargedAgainstIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AdditionalAmountChargedAgainstIncome" xlink:to="lab_jan_AdditionalAmountChargedAgainstIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_a7216643-0392-4a22-b653-b8967b35180b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised_0f764185-a326-4ab6-b2ca-f3780da50a51_terseLabel_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_jan_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SoinTherapeuticsLLCMember_37d0f147-4d0f-4cab-a4bb-cd7f5215e8c7_terseLabel_en-US" xlink:label="lab_jan_SoinTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soin Therapeutics LLC</link:label>
    <link:label id="lab_jan_SoinTherapeuticsLLCMember_label_en-US" xlink:label="lab_jan_SoinTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soin Therapeutics LLC [Member]</link:label>
    <link:label id="lab_jan_SoinTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_jan_SoinTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Soin Therapeutics L L C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SoinTherapeuticsLLCMember" xlink:to="lab_jan_SoinTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_bd3cc28f-5470-4448-9f4d-44d7e875d2ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_4fb65875-c9cd-415b-9662-2894c3b8695c_terseLabel_en-US" xlink:label="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses from discontinued operations:</link:label>
    <link:label id="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses From Discontinued Operations [Abstract]</link:label>
    <link:label id="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_documentation_en-US" xlink:label="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Expenses From Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:href="jan-20231230.xsd#jan_OperatingExpensesFromDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:to="lab_jan_OperatingExpensesFromDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_8c901b6e-4936-42d3-ad3d-95976a3a44e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Interest in Partnership Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7b0cdf0-f568-44c5-94e3-d85f6987567d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_15410a29-4c77-47f9-9e42-f51b94c07c30_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_b44672b6-f43a-47a1-8bd3-1ae1b1cad8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued upon exchange of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_c31b1b08-e4a9-4411-84a6-275af8e8bba0_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_050688e0-27b1-4fa1-bd6a-7111d26334c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoteReceivableRevisedDiscountRate_cbdec1bb-e0a1-41b6-9d14-1492f3ee1549_terseLabel_en-US" xlink:label="lab_jan_NoteReceivableRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable revised discount rate</link:label>
    <link:label id="lab_jan_NoteReceivableRevisedDiscountRate_label_en-US" xlink:label="lab_jan_NoteReceivableRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Receivable Revised Discount Rate</link:label>
    <link:label id="lab_jan_NoteReceivableRevisedDiscountRate_documentation_en-US" xlink:label="lab_jan_NoteReceivableRevisedDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note Receivable Revised Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableRevisedDiscountRate" xlink:href="jan-20231230.xsd#jan_NoteReceivableRevisedDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoteReceivableRevisedDiscountRate" xlink:to="lab_jan_NoteReceivableRevisedDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DeferredTaxLiabilitiesInstallmentSale_74c4e363-9d6b-4985-b8b1-7fb8bedf6066_negatedTerseLabel_en-US" xlink:label="lab_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Installment sale</link:label>
    <link:label id="lab_jan_DeferredTaxLiabilitiesInstallmentSale_label_en-US" xlink:label="lab_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Installment Sale</link:label>
    <link:label id="lab_jan_DeferredTaxLiabilitiesInstallmentSale_documentation_en-US" xlink:label="lab_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Installment Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:href="jan-20231230.xsd#jan_DeferredTaxLiabilitiesInstallmentSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:to="lab_jan_DeferredTaxLiabilitiesInstallmentSale" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_CommonShareEquivalentsMember_375e3041-dcd6-4998-8a4d-1ff573ee7738_terseLabel_en-US" xlink:label="lab_jan_CommonShareEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Share Equivalent</link:label>
    <link:label id="lab_jan_CommonShareEquivalentsMember_label_en-US" xlink:label="lab_jan_CommonShareEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Share Equivalents [Member]</link:label>
    <link:label id="lab_jan_CommonShareEquivalentsMember_documentation_en-US" xlink:label="lab_jan_CommonShareEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Share Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonShareEquivalentsMember" xlink:href="jan-20231230.xsd#jan_CommonShareEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_CommonShareEquivalentsMember" xlink:to="lab_jan_CommonShareEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e1217097-60ee-4fd9-a9a2-1ef6ab476c97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AlixpartnersLlcMember_65bf6ad6-ecdb-47e9-b2a9-fb5920bae673_terseLabel_en-US" xlink:label="lab_jan_AlixpartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alixpartners, LLC</link:label>
    <link:label id="lab_jan_AlixpartnersLlcMember_label_en-US" xlink:label="lab_jan_AlixpartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alixpartners, LLC [Member]</link:label>
    <link:label id="lab_jan_AlixpartnersLlcMember_documentation_en-US" xlink:label="lab_jan_AlixpartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alixpartners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AlixpartnersLlcMember" xlink:href="jan-20231230.xsd#jan_AlixpartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AlixpartnersLlcMember" xlink:to="lab_jan_AlixpartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_1a6d1774-e22b-455b-9bdf-85708ecba93b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AmortizationOfRightOfUseAssets_0c07a84b-9766-4bce-b6d6-efeabab85e76_terseLabel_en-US" xlink:label="lab_jan_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_jan_AmortizationOfRightOfUseAssets_label_en-US" xlink:label="lab_jan_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_jan_AmortizationOfRightOfUseAssets_documentation_en-US" xlink:label="lab_jan_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AmortizationOfRightOfUseAssets" xlink:href="jan-20231230.xsd#jan_AmortizationOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AmortizationOfRightOfUseAssets" xlink:to="lab_jan_AmortizationOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1efedda8-e6c2-4ba6-a662-1e16d783b860_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6f45392b-7617-4f2c-a523-3aceb2705774_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TotalDisposalOfLiability_67a93bce-5c31-4e16-ab53-4ea8bca290b2_totalLabel_en-US" xlink:label="lab_jan_TotalDisposalOfLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total disposal of liabilities</link:label>
    <link:label id="lab_jan_TotalDisposalOfLiability_label_en-US" xlink:label="lab_jan_TotalDisposalOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Disposal of Liability</link:label>
    <link:label id="lab_jan_TotalDisposalOfLiability_documentation_en-US" xlink:label="lab_jan_TotalDisposalOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Disposal of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfLiability" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TotalDisposalOfLiability" xlink:to="lab_jan_TotalDisposalOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_4640cba8-cf2d-4e87-a293-ef81ca0cb447_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party note</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Related Party Note</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Related Party Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_03dd3c04-7c48-4aad-b986-4d2756dcfc62_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4cbe1565-a576-444f-a682-4d10a2ccce5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_f8e10963-8aa7-465f-b42e-37553a499e33_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series S Convertible Preferred Stock outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_28155895-57c9-45df-96ef-b71406e77273_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8334ae02-8edf-4edd-acc4-d3ffc65e0777_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02a10eda-353d-4bc4-a34a-67a7e89aa724_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fc47ca65-ab47-4d69-872e-9f793adae69a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TotalGainOnSale_007d5e67-817e-48e8-a878-f7dc9a1979b2_totalLabel_en-US" xlink:label="lab_jan_TotalGainOnSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gain on sale</link:label>
    <link:label id="lab_jan_TotalGainOnSale_label_en-US" xlink:label="lab_jan_TotalGainOnSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Gain on Sale</link:label>
    <link:label id="lab_jan_TotalGainOnSale_documentation_en-US" xlink:label="lab_jan_TotalGainOnSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Gain on Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGainOnSale" xlink:href="jan-20231230.xsd#jan_TotalGainOnSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TotalGainOnSale" xlink:to="lab_jan_TotalGainOnSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_757a759e-c038-4008-a1b6-1874fe663ea9_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_76198d56-fb12-4f65-bf1a-c762ddefa03c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_624d3078-1728-4a1e-b37e-6ae9e17c882a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e86d18df-1046-43be-af98-314bf991c477_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f1d7c89f-8fc8-40b4-ab7e-1ecd7ae6ccfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f6c992b2-9993-4f05-9013-76c6e136a174_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_Mr.JonIsaacMember_6745ceb4-6999-4f97-8e60-dd341469750a_terseLabel_en-US" xlink:label="lab_jan_Mr.JonIsaacMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mr. Jon Isaac</link:label>
    <link:label id="lab_jan_Mr.JonIsaacMember_label_en-US" xlink:label="lab_jan_Mr.JonIsaacMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mr. Jon Isaac [Member]</link:label>
    <link:label id="lab_jan_Mr.JonIsaacMember_documentation_en-US" xlink:label="lab_jan_Mr.JonIsaacMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mr. Jon Isaac</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.JonIsaacMember" xlink:href="jan-20231230.xsd#jan_Mr.JonIsaacMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_Mr.JonIsaacMember" xlink:to="lab_jan_Mr.JonIsaacMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5c75ccfd-d849-4e0c-bce5-fc59419bc2ae_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_WestervilleSquareMember_9d030296-cde2-4ee4-aa94-4f2e8466af7b_terseLabel_en-US" xlink:label="lab_jan_WestervilleSquareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Westerville Square</link:label>
    <link:label id="lab_jan_WestervilleSquareMember_label_en-US" xlink:label="lab_jan_WestervilleSquareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Westerville Square [Member]</link:label>
    <link:label id="lab_jan_WestervilleSquareMember_documentation_en-US" xlink:label="lab_jan_WestervilleSquareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Westerville Square [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_WestervilleSquareMember" xlink:href="jan-20231230.xsd#jan_WestervilleSquareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_WestervilleSquareMember" xlink:to="lab_jan_WestervilleSquareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cc251d6b-0d1a-49df-ad30-c1de3e781acb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b6736ea8-d62f-48e3-9f78-6fe35aef09a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7b13bb2c-8784-4ab7-9617-2b5f940781f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_054e895d-7437-4a78-96a5-cfd92c3da160_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_184eef9b-c699-4e8a-a75f-bd6ad290f024_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_fcb1179c-6c35-4794-9b09-a67f8d804dfa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity note, subscriptions receivable</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_0282e384-50fa-4503-97a2-62fb4d92f3f8_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows provided by (used in) discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_678e05c1-879b-4d7f-a24f-db6ad2f696c8_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ConversionOfStockPeriodFollowingClosing_276e6336-8900-4b3c-9c30-54190731d715_terseLabel_en-US" xlink:label="lab_jan_ConversionOfStockPeriodFollowingClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, period after closing</link:label>
    <link:label id="lab_jan_ConversionOfStockPeriodFollowingClosing_label_en-US" xlink:label="lab_jan_ConversionOfStockPeriodFollowingClosing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Period Following Closing</link:label>
    <link:label id="lab_jan_ConversionOfStockPeriodFollowingClosing_documentation_en-US" xlink:label="lab_jan_ConversionOfStockPeriodFollowingClosing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Period Following Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockPeriodFollowingClosing" xlink:href="jan-20231230.xsd#jan_ConversionOfStockPeriodFollowingClosing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ConversionOfStockPeriodFollowingClosing" xlink:to="lab_jan_ConversionOfStockPeriodFollowingClosing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd49ce1c-c162-4630-a13b-7a1097502d69_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for equity financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11ec3917-1600-44f6-a96b-d776602299b1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a9027047-8c0b-443d-87e1-3f5ebd01c249_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_4425f1cf-4956-4632-9597-4fa74570d7ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rented office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d63c62d4-2f7a-40ca-800a-452ba65d3098_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_17bd4c49-ed19-4a80-9808-9d58f1a2ac80_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39c0d1a8-4faa-4bcc-9268-a61b53a69879_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2b366857-f4cb-40f4-9870-14ab8d9508ec_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_04519dc0-f77d-494b-bb81-db9af6c8d2b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_001b2e6e-c445-4345-a5c4-253f9eaccd90_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4162f02a-3b99-4422-9a02-f5e3b2de4117_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_885004d0-37ee-40e4-bf6b-71b11eeafa82_terseLabel_en-US" xlink:label="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, warrants or rights exercised (in shares)</link:label>
    <link:label id="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_label_en-US" xlink:label="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Warrants Or Rights Exercised</link:label>
    <link:label id="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Warrants Or Rights Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantOrRightWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:to="lab_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_9af406a3-4649-4b6d-bb4d-433353dda210_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_bb5633ad-9c59-4a8c-9abf-8a4679e980dc_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_c2dc2ec2-1d04-4bc8-bd64-aa92e0e153ad_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DispositionTransactionConsiderAmount_a4a3e2f7-c4b2-42fd-8c81-3ba880efd645_terseLabel_en-US" xlink:label="lab_jan_DispositionTransactionConsiderAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposition transaction consider amount</link:label>
    <link:label id="lab_jan_DispositionTransactionConsiderAmount_label_en-US" xlink:label="lab_jan_DispositionTransactionConsiderAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposition Transaction Consider Amount</link:label>
    <link:label id="lab_jan_DispositionTransactionConsiderAmount_documentation_en-US" xlink:label="lab_jan_DispositionTransactionConsiderAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposition Transaction Consider Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionConsiderAmount" xlink:href="jan-20231230.xsd#jan_DispositionTransactionConsiderAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DispositionTransactionConsiderAmount" xlink:to="lab_jan_DispositionTransactionConsiderAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DiscontinuedFinancingActivities_d01d0bd2-a987-450c-b026-f5da239f956c_terseLabel_en-US" xlink:label="lab_jan_DiscontinuedFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DISCONTINUED FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedFinancingActivities_label_en-US" xlink:label="lab_jan_DiscontinuedFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DISCONTINUED FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_jan_DiscontinuedFinancingActivities_documentation_en-US" xlink:label="lab_jan_DiscontinuedFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DISCONTINUED FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedFinancingActivities" xlink:href="jan-20231230.xsd#jan_DiscontinuedFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DiscontinuedFinancingActivities" xlink:to="lab_jan_DiscontinuedFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_d04e9ee2-540d-4821-b120-0051c8eb89e1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_9231dff4-3896-40bf-b13d-51622e4eb988_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_28117ab1-5dcf-46e9-8ee6-df40a49f80aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_44d9e566-c88d-4279-8b96-5965bf1b41db_terseLabel_en-US" xlink:label="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_label_en-US" xlink:label="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets, Net, Excluding Other Intangible Assets, Net</link:label>
    <link:label id="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_documentation_en-US" xlink:label="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets, Net, Excluding Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:href="jan-20231230.xsd#jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:to="lab_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_65818dbf-b61f-46ec-bf12-e14e4b490a36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_fb20a5d7-b47c-4414-8497-c146e524b9e9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedAndNonrelatedPartyStatusDomain_bd9ab591-8d4b-4dc9-aa88-aa64bd83c2dd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Party Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedAndNonrelatedPartyStatusDomain_label_en-US" xlink:label="lab_us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Party Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:to="lab_us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_28e9b992-b36c-4033-b986-e5f97f496ef0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9b53859-3d27-4375-8100-826fc764643b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3022c15d-576d-4908-aff4-6663caa6129d_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_CurrentAssetsCurrentLiabilitiesNet_d74e7863-6b83-4aea-9238-65ce736a9b33_negatedTerseLabel_en-US" xlink:label="lab_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_jan_CurrentAssetsCurrentLiabilitiesNet_label_en-US" xlink:label="lab_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets (Current Liabilities), Net</link:label>
    <link:label id="lab_jan_CurrentAssetsCurrentLiabilitiesNet_documentation_en-US" xlink:label="lab_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net working capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:href="jan-20231230.xsd#jan_CurrentAssetsCurrentLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:to="lab_jan_CurrentAssetsCurrentLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_43eec447-3f05-4d52-a50c-6b41cf4fc3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_55760da1-d993-42a1-9b6f-6be45928a2f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_49f43401-01c5-4692-8050-d9274894417c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_63607f1d-cf19-4a2b-8a48-ae1758fbb3a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_RevisedDiscountAmount_d8b2cb9e-6d4d-4237-afc8-c2f411530ab1_terseLabel_en-US" xlink:label="lab_jan_RevisedDiscountAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revised discount amount</link:label>
    <link:label id="lab_jan_RevisedDiscountAmount_label_en-US" xlink:label="lab_jan_RevisedDiscountAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revised Discount Amount</link:label>
    <link:label id="lab_jan_RevisedDiscountAmount_documentation_en-US" xlink:label="lab_jan_RevisedDiscountAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revised Discount Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RevisedDiscountAmount" xlink:href="jan-20231230.xsd#jan_RevisedDiscountAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_RevisedDiscountAmount" xlink:to="lab_jan_RevisedDiscountAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2fa96530-acc6-4c1a-8070-5063f08682d9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_964e32ac-53de-40ec-950e-ca28c84116b2_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_01c7b657-0b9b-4866-8484-ec0cb8268d07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_30ebd6b9-7fe5-4a9c-8db6-afe2b21c65f7_terseLabel_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of landlords originally purported to be covered under Company's guarantee or commitment</link:label>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_label_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments, Number Of Landlords Originally Purported To Be Liable For</link:label>
    <link:label id="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_documentation_en-US" xlink:label="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commitments, Number Of Landlords Originally Purported To Be Liable For</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:to="lab_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_1463ea2a-caac-4a4f-bd3b-ae34ce6dda80_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for close</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_60ca279c-44f8-4d68-9b8a-9c09db9214a0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of states in which Company operated its recycling business</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8e8e198c-1c11-486d-b7ec-467cff2510b9_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DispositionDiscountRate_67fea030-76f7-48cb-be06-4c8cbe39f9ae_terseLabel_en-US" xlink:label="lab_jan_DispositionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposition discount rate (percent)</link:label>
    <link:label id="lab_jan_DispositionDiscountRate_label_en-US" xlink:label="lab_jan_DispositionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposition Discount Rate</link:label>
    <link:label id="lab_jan_DispositionDiscountRate_documentation_en-US" xlink:label="lab_jan_DispositionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposition Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionDiscountRate" xlink:href="jan-20231230.xsd#jan_DispositionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DispositionDiscountRate" xlink:to="lab_jan_DispositionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_239af583-1edf-42d3-b9bc-70612165c707_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ApplianceSmartIncMember_ff936766-d401-4233-8e98-889f5e2c3780_terseLabel_en-US" xlink:label="lab_jan_ApplianceSmartIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Appliance Smart, Inc.</link:label>
    <link:label id="lab_jan_ApplianceSmartIncMember_label_en-US" xlink:label="lab_jan_ApplianceSmartIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Appliance Smart Inc [Member]</link:label>
    <link:label id="lab_jan_ApplianceSmartIncMember_documentation_en-US" xlink:label="lab_jan_ApplianceSmartIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApplianceSmart, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ApplianceSmartIncMember" xlink:href="jan-20231230.xsd#jan_ApplianceSmartIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ApplianceSmartIncMember" xlink:to="lab_jan_ApplianceSmartIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AgreedSettlementValue_bac38ae8-08e0-4c31-b5af-5e5b8ca3c573_terseLabel_en-US" xlink:label="lab_jan_AgreedSettlementValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreed settlement value</link:label>
    <link:label id="lab_jan_AgreedSettlementValue_label_en-US" xlink:label="lab_jan_AgreedSettlementValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreed Settlement Value</link:label>
    <link:label id="lab_jan_AgreedSettlementValue_documentation_en-US" xlink:label="lab_jan_AgreedSettlementValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreed Settlement Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedSettlementValue" xlink:href="jan-20231230.xsd#jan_AgreedSettlementValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AgreedSettlementValue" xlink:to="lab_jan_AgreedSettlementValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_ExercisePriceRangeOneMember_7c0fedb7-f832-48af-a0eb-19149dab6056_terseLabel_en-US" xlink:label="lab_jan_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$17.35 to $23.45</link:label>
    <link:label id="lab_jan_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_jan_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_jan_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_jan_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price range one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeOneMember" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_ExercisePriceRangeOneMember" xlink:to="lab_jan_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_SeriesSMember_80ba84c2-cd4a-4405-a1ad-18d124b4540c_terseLabel_en-US" xlink:label="lab_jan_SeriesSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series S</link:label>
    <link:label id="lab_jan_SeriesSMember_label_en-US" xlink:label="lab_jan_SeriesSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series S [Member]</link:label>
    <link:label id="lab_jan_SeriesSMember_documentation_en-US" xlink:label="lab_jan_SeriesSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series S [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSMember" xlink:href="jan-20231230.xsd#jan_SeriesSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_SeriesSMember" xlink:to="lab_jan_SeriesSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_3b5b5468-0cb7-471a-8eb4-e4e20e5938e1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shared expenses with another company</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_d77145b2-cd10-485a-8271-c80daa504aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_49dbf186-9d32-41c0-b16c-b3543484d06a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3f7fc1e-6602-453c-bb60-a6fe4a9089f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_860ff05a-f82b-4199-a61a-2fb5c63b7b77_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_473c1e42-4c05-455f-9e17-84525e77d793_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_e9d82110-f7df-42ff-bda2-25a70674dfa5_terseLabel_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net consideration</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_label_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Consideration</link:label>
    <link:label id="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_documentation_en-US" xlink:label="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:to="lab_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_aa90a52e-1314-4db4-adc8-3764c73f3f4a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, shares issued, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_77bf6750-ff39-4bfe-a7d6-5b118c0072ef_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6f027d95-e75c-4b57-8423-2aff8ef0915d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_31100d91-1eb8-4a0b-8bfc-9cd6974128c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a2d166d-79df-4716-bf35-26f5e30bcb99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c0bf15e-249c-4d8f-a954-d9e4ffc36831_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_9b9332e8-8e96-4a8c-88f6-5e4d84c86d3c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_1b5e7b04-f64c-4dea-8822-bd05eda6517d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Short Term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_GeoTraqIncMember_7bc0e23f-9011-4c80-af61-e2b815e3e678_terseLabel_en-US" xlink:label="lab_jan_GeoTraqIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GeoTraq Inc.</link:label>
    <link:label id="lab_jan_GeoTraqIncMember_label_en-US" xlink:label="lab_jan_GeoTraqIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geo Traq Inc [Member]</link:label>
    <link:label id="lab_jan_GeoTraqIncMember_documentation_en-US" xlink:label="lab_jan_GeoTraqIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GeoTraq Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_GeoTraqIncMember" xlink:to="lab_jan_GeoTraqIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1e3b7df0-676d-44f4-9048-8485e59facb3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b4db7a55-9bd0-4b84-a6e0-577a191d8558_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_00ec15f6-8110-43e1-bb47-3e43ea149253_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_Mr.SullivanMember_6962d8cf-53f0-4625-acf6-dda0445f6ce6_terseLabel_en-US" xlink:label="lab_jan_Mr.SullivanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mr. Sullivan</link:label>
    <link:label id="lab_jan_Mr.SullivanMember_label_en-US" xlink:label="lab_jan_Mr.SullivanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mr. Sullivan [Member]</link:label>
    <link:label id="lab_jan_Mr.SullivanMember_documentation_en-US" xlink:label="lab_jan_Mr.SullivanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mr. Sullivan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.SullivanMember" xlink:href="jan-20231230.xsd#jan_Mr.SullivanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_Mr.SullivanMember" xlink:to="lab_jan_Mr.SullivanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_TotalConsiderations_187c8074-c11d-4540-9c82-2d5ff24a79d9_totalLabel_en-US" xlink:label="lab_jan_TotalConsiderations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_jan_TotalConsiderations_label_en-US" xlink:label="lab_jan_TotalConsiderations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Considerations</link:label>
    <link:label id="lab_jan_TotalConsiderations_documentation_en-US" xlink:label="lab_jan_TotalConsiderations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Considerations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalConsiderations" xlink:href="jan-20231230.xsd#jan_TotalConsiderations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_TotalConsiderations" xlink:to="lab_jan_TotalConsiderations" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_b9833a2d-7e47-4e6d-bfc5-0843d8edf654_terseLabel_en-US" xlink:label="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities received (in shares)</link:label>
    <link:label id="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_label_en-US" xlink:label="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Divestiture, Consideration Received, Shares</link:label>
    <link:label id="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_documentation_en-US" xlink:label="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Divestiture, Consideration Received, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:href="jan-20231230.xsd#jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:to="lab_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_6f1b941a-f586-4154-b187-813bd0413067_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b780bd9f-eaa1-41a8-ab6a-0cfe71fb5ee6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b99b3354-0b92-47bb-a235-9e3cd6379ea3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 preferred converted for legal settlement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a28a7301-f28f-4d13-b0f6-a902d40acfd4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_AgreedPrepaymentAmount_364bfb90-d394-44af-83cc-9864f8429bfb_terseLabel_en-US" xlink:label="lab_jan_AgreedPrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreed prepayment amount</link:label>
    <link:label id="lab_jan_AgreedPrepaymentAmount_label_en-US" xlink:label="lab_jan_AgreedPrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreed Prepayment Amount</link:label>
    <link:label id="lab_jan_AgreedPrepaymentAmount_documentation_en-US" xlink:label="lab_jan_AgreedPrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreed prepayment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedPrepaymentAmount" xlink:href="jan-20231230.xsd#jan_AgreedPrepaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_AgreedPrepaymentAmount" xlink:to="lab_jan_AgreedPrepaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_17094b94-a96b-431d-b61b-d4549fb38624_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long Term Debt and Other Financing Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_NoteReceivableFaceAmount_c48e8633-5bb4-4350-93cc-a4d4dcee5687_terseLabel_en-US" xlink:label="lab_jan_NoteReceivableFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable face amount</link:label>
    <link:label id="lab_jan_NoteReceivableFaceAmount_label_en-US" xlink:label="lab_jan_NoteReceivableFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Receivable Face Amount</link:label>
    <link:label id="lab_jan_NoteReceivableFaceAmount_documentation_en-US" xlink:label="lab_jan_NoteReceivableFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note receivable face amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableFaceAmount" xlink:href="jan-20231230.xsd#jan_NoteReceivableFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_NoteReceivableFaceAmount" xlink:to="lab_jan_NoteReceivableFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jan_LiveVenturesIncorporatedMember_3a6912c0-fe6a-4ce6-a0f5-b06af97da529_terseLabel_en-US" xlink:label="lab_jan_LiveVenturesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Live Ventures Incorporated</link:label>
    <link:label id="lab_jan_LiveVenturesIncorporatedMember_label_en-US" xlink:label="lab_jan_LiveVenturesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Live Ventures Incorporated [Member]</link:label>
    <link:label id="lab_jan_LiveVenturesIncorporatedMember_documentation_en-US" xlink:label="lab_jan_LiveVenturesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Live Ventures Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LiveVenturesIncorporatedMember" xlink:href="jan-20231230.xsd#jan_LiveVenturesIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jan_LiveVenturesIncorporatedMember" xlink:to="lab_jan_LiveVenturesIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_66c9dce1-28d1-4921-ad81-89977e6a4bb1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cf08959c-d7c9-4140-8887-c702d2e3ec1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>jan-20231230_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:aab867d1-3c3a-4ae8-a7bb-b062e81499b6,g:fd931dab-a437-4656-92e6-d2e3ed927146-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.live-ventures.com/role/Cover" xlink:type="simple" xlink:href="jan-20231230.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1eb39338-7f0b-40ae-939a-a4f52f75eca3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentType_1eb39338-7f0b-40ae-939a-a4f52f75eca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_26770cf3-5dc6-421c-9e1c-59b6ee85774f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentAnnualReport_26770cf3-5dc6-421c-9e1c-59b6ee85774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_725f0b68-2f89-4b03-a726-4c1f7cfd7bb6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_CurrentFiscalYearEndDate_725f0b68-2f89-4b03-a726-4c1f7cfd7bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1d77f84e-c6e8-49a6-8cc6-a976ac0e8987" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentPeriodEndDate_1d77f84e-c6e8-49a6-8cc6-a976ac0e8987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3a3a99b8-ed4c-4c95-a0a8-d4b37870004d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentTransitionReport_3a3a99b8-ed4c-4c95-a0a8-d4b37870004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2376167a-1bb4-45d5-a7ac-627922a116df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityFileNumber_2376167a-1bb4-45d5-a7ac-627922a116df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f7ea902f-2766-429d-9db4-1971931650de" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityRegistrantName_f7ea902f-2766-429d-9db4-1971931650de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e7bb3e0e-ce0d-4eb4-9c8a-f998bffbaa56" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e7bb3e0e-ce0d-4eb4-9c8a-f998bffbaa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_df85f8cb-36c9-4feb-ad0e-9409309817fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityTaxIdentificationNumber_df85f8cb-36c9-4feb-ad0e-9409309817fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0fec09e8-1d6d-474f-bf68-f928bae9082b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityAddressAddressLine1_0fec09e8-1d6d-474f-bf68-f928bae9082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1153fe62-c8ab-41c3-bca5-f74698bf9bd6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityAddressCityOrTown_1153fe62-c8ab-41c3-bca5-f74698bf9bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ff30ae59-7b51-42c1-bb27-426df96bb71d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityAddressStateOrProvince_ff30ae59-7b51-42c1-bb27-426df96bb71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_10c720fd-00a1-426f-8706-13feca267899" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityAddressPostalZipCode_10c720fd-00a1-426f-8706-13feca267899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_48cabcc5-9a70-4abe-a3ff-076a2de522ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_CityAreaCode_48cabcc5-9a70-4abe-a3ff-076a2de522ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_69fb9834-87f9-47d8-849a-8b3a2be98f23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_LocalPhoneNumber_69fb9834-87f9-47d8-849a-8b3a2be98f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6bfafc60-46a3-4afe-a196-6e246daab20a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_Security12bTitle_6bfafc60-46a3-4afe-a196-6e246daab20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d6547216-dfbd-41ef-8e84-3b896843b2d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_TradingSymbol_d6547216-dfbd-41ef-8e84-3b896843b2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc59dd0b-0846-4d81-92f9-5b3d179378ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_SecurityExchangeName_dc59dd0b-0846-4d81-92f9-5b3d179378ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8be31c7b-e13e-4699-a957-acee8a1e4ed5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8be31c7b-e13e-4699-a957-acee8a1e4ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_354fdb09-db19-4449-bb60-dcde7a321630" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityVoluntaryFilers_354fdb09-db19-4449-bb60-dcde7a321630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a0fad0d5-1cec-4115-9d04-259ca128379d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityCurrentReportingStatus_a0fad0d5-1cec-4115-9d04-259ca128379d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9093133b-659f-412c-bcd7-c783005debd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityInteractiveDataCurrent_9093133b-659f-412c-bcd7-c783005debd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e7fc036f-d1e2-4e6b-b980-370087846773" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityFilerCategory_e7fc036f-d1e2-4e6b-b980-370087846773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_33d5b85d-d80b-46d0-9de0-7f75597f4440" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntitySmallBusiness_33d5b85d-d80b-46d0-9de0-7f75597f4440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_544ddd65-9b08-4805-9ddc-c57ac576caf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityEmergingGrowthCompany_544ddd65-9b08-4805-9ddc-c57ac576caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c6918999-ba4c-4245-9067-ed659a4b92c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c6918999-ba4c-4245-9067-ed659a4b92c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_46b047ba-d62e-468a-b734-aa4f7d13ef68" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_46b047ba-d62e-468a-b734-aa4f7d13ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1c1c0300-1ff9-4158-a732-e98365e9e654" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityShellCompany_1c1c0300-1ff9-4158-a732-e98365e9e654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4c14aab7-5002-446c-a5ba-1da3e3375c31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityPublicFloat_4c14aab7-5002-446c-a5ba-1da3e3375c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c3276973-94a6-489b-bcda-eea48e07476c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c3276973-94a6-489b-bcda-eea48e07476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_faf22090-0b2b-406b-9b9f-c652e6772dd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_AmendmentFlag_faf22090-0b2b-406b-9b9f-c652e6772dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_40a23132-a452-45be-88eb-b8ddb068026f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_EntityCentralIndexKey_40a23132-a452-45be-88eb-b8ddb068026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_502a0136-b065-4d16-a923-b8bc05f89e50" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentFiscalYearFocus_502a0136-b065-4d16-a923-b8bc05f89e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9a719ddd-e5e7-4804-89cf-e4fdd11e053f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5e2e8eb5-b887-4cc3-b94a-604e029fb26f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9a719ddd-e5e7-4804-89cf-e4fdd11e053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/AuditInformation" xlink:type="simple" xlink:href="jan-20231230.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jan_AuditorAbstract_252f33a4-e8c2-4d40-a5a5-a87aa7e9ad07" xlink:href="jan-20231230.xsd#jan_AuditorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c2b1b7c1-cad6-4ba4-95e8-88a3a099aa54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_AuditorAbstract_252f33a4-e8c2-4d40-a5a5-a87aa7e9ad07" xlink:to="loc_dei_AuditorFirmId_c2b1b7c1-cad6-4ba4-95e8-88a3a099aa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_b8a0f75d-db08-4439-aac8-049fdc2e6bc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_AuditorAbstract_252f33a4-e8c2-4d40-a5a5-a87aa7e9ad07" xlink:to="loc_dei_AuditorName_b8a0f75d-db08-4439-aac8-049fdc2e6bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b28c3cac-dcad-44ef-8ea2-45e57304fd44" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_AuditorAbstract_252f33a4-e8c2-4d40-a5a5-a87aa7e9ad07" xlink:to="loc_dei_AuditorLocation_b28c3cac-dcad-44ef-8ea2-45e57304fd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cd131486-7d9e-430e-95ff-9b0462ec3174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cd131486-7d9e-430e-95ff-9b0462ec3174" xlink:to="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8618523-90aa-43bc-8969-300e452345c8" xlink:to="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSMember_202c2a9d-a305-479c-ac5b-f032a6edea18" xlink:href="jan-20231230.xsd#jan_SeriesSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:to="loc_jan_SeriesSMember_202c2a9d-a305-479c-ac5b-f032a6edea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1Member_8edaa471-d97c-4372-9de7-5fcf5354e0c3" xlink:href="jan-20231230.xsd#jan_SeriesA1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c808be17-29e9-4edb-b60d-39a52fa5fced" xlink:to="loc_jan_SeriesA1Member_8edaa471-d97c-4372-9de7-5fcf5354e0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_606d1fce-9136-43ed-b021-eff65e807552" xlink:to="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3d78734f-15d9-4e15-9563-fdf91bf33476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_aee3e684-1f3a-4d4c-ae72-bde215415fac" xlink:to="loc_us-gaap_RelatedPartyMember_3d78734f-15d9-4e15-9563-fdf91bf33476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17893830-173f-49f6-808a-d378bac4dbd5" xlink:to="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:to="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e11d1bd5-d946-4940-8c23-d6ecdd90b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e11d1bd5-d946-4940-8c23-d6ecdd90b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7534ecd9-24c4-4445-bbd3-ab5382d2340d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7534ecd9-24c4-4445-bbd3-ab5382d2340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9b49f9a-d417-49f3-9951-93fb2b2e1e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9b49f9a-d417-49f3-9951-93fb2b2e1e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_969a306c-e839-4206-b274-5c06064d2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_969a306c-e839-4206-b274-5c06064d2ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_104aaf86-030e-440d-ba4e-b5106ff04fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_AssetsCurrent_104aaf86-030e-440d-ba4e-b5106ff04fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_dee1ddf0-4bf1-44ce-a38b-ada360df73f5" xlink:href="jan-20231230.xsd#jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet_dee1ddf0-4bf1-44ce-a38b-ada360df73f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_04286d55-06bf-4c9d-89fb-aed4bb85536c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_04286d55-06bf-4c9d-89fb-aed4bb85536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_191612ad-fbf0-476d-ac73-a9c7858b18cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_191612ad-fbf0-476d-ac73-a9c7858b18cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ed74188a-cc52-4fe3-99c7-74232f3c39df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ed74188a-cc52-4fe3-99c7-74232f3c39df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent_f9be761b-3f37-40f0-be8c-9201cb899682" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_DepositsAndOtherAssetsNoncurrent_f9be761b-3f37-40f0-be8c-9201cb899682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherAssetsFromDiscontinuedOperations_ef947ecd-73f4-4edd-8d89-9b5ebda4bbf3" xlink:href="jan-20231230.xsd#jan_OtherAssetsFromDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_jan_OtherAssetsFromDiscontinuedOperations_ef947ecd-73f4-4edd-8d89-9b5ebda4bbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ec1b57ab-023b-4b82-8a14-4c5480ce92fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e438922-95da-4dcf-82b7-64aaeff2ccdc" xlink:to="loc_us-gaap_Assets_ec1b57ab-023b-4b82-8a14-4c5480ce92fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d69f42e2-d70c-4ba3-8dd6-cafd1437f87a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a608df5d-81fc-48f4-afcd-9ab5a0fcdc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_AccountsPayableCurrent_a608df5d-81fc-48f4-afcd-9ab5a0fcdc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_42737087-7d33-4f83-a49a-b212859f9549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_42737087-7d33-4f83-a49a-b212859f9549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ec07fcf0-3e92-4d17-aa02-f4e182c7b363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ec07fcf0-3e92-4d17-aa02-f4e182c7b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ebaebe0-513f-4c1d-98d2-1ec9ce6279d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ebaebe0-513f-4c1d-98d2-1ec9ce6279d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b69bd8a-ae18-4082-a104-40b67fe24d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b69bd8a-ae18-4082-a104-40b67fe24d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad7e24f3-ee92-4a72-82b0-843612dff2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad7e24f3-ee92-4a72-82b0-843612dff2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_affa3f2f-44b3-443d-91f0-c574d0f93b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_affa3f2f-44b3-443d-91f0-c574d0f93b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f3961761-d761-4714-af68-5d21b816b566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f3961761-d761-4714-af68-5d21b816b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ba259fb0-53df-4cb8-b033-115a0c97441f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ba259fb0-53df-4cb8-b033-115a0c97441f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2457895-b70f-4cdd-8d11-9991ae620eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd48b451-7abc-49a8-be13-1a3fd5827d5d" xlink:to="loc_us-gaap_Liabilities_d2457895-b70f-4cdd-8d11-9991ae620eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_651227d1-86d0-4b44-9aa9-94ac54751d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_651227d1-86d0-4b44-9aa9-94ac54751d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:href="jan-20231230.xsd#jan_MezzanineEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8293b3ed-3d2a-477d-a210-0e85bc4b18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_MezzanineEquityAbstract_4edfe617-117e-4073-b6fe-733d36d04483" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8293b3ed-3d2a-477d-a210-0e85bc4b18bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_59d97489-8fbe-4f60-bc81-f92f81187f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_PreferredStockValue_59d97489-8fbe-4f60-bc81-f92f81187f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e1bf7a5-cceb-471a-b2aa-679fb8756b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_CommonStockValue_9e1bf7a5-cceb-471a-b2aa-679fb8756b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_856c7f0c-72eb-41b7-98a3-af4a05805209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_856c7f0c-72eb-41b7-98a3-af4a05805209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df180856-e49a-4e87-8d4d-cbbe1c21cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df180856-e49a-4e87-8d4d-cbbe1c21cf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1cf7241-92c7-431c-944b-3e8e97827be8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1cf7241-92c7-431c-944b-3e8e97827be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b756cc7f-bbc8-41de-ba1d-9bedc38760e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fabbe8bd-0039-4e97-a21c-262fe9812292" xlink:to="loc_us-gaap_StockholdersEquity_b756cc7f-bbc8-41de-ba1d-9bedc38760e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e7298dde-6d1a-44ae-b15a-5895ff9332fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99930c33-fade-4bb8-835d-28d2062629a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e7298dde-6d1a-44ae-b15a-5895ff9332fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_94eddb06-9746-40ed-8f51-cce617953db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_94eddb06-9746-40ed-8f51-cce617953db0" xlink:to="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bdf56e9-4435-456f-8c41-87c2b7713377" xlink:to="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSMember_e1ba7a07-823f-4562-b2ac-c61195612510" xlink:href="jan-20231230.xsd#jan_SeriesSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:to="loc_jan_SeriesSMember_e1ba7a07-823f-4562-b2ac-c61195612510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1Member_1f35c600-cc07-4125-bf03-beae837aabe7" xlink:href="jan-20231230.xsd#jan_SeriesA1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af6b47a7-a256-4671-a10a-b648298ca04e" xlink:to="loc_jan_SeriesA1Member_1f35c600-cc07-4125-bf03-beae837aabe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4b779971-e7f8-4424-8958-996fcada2b57" xlink:to="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_52bf93c6-46d2-40aa-a159-8216000ed417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_52bf93c6-46d2-40aa-a159-8216000ed417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_0181b745-b9b5-44be-9410-76b5b444ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_0181b745-b9b5-44be-9410-76b5b444ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_3d833662-f60b-45fe-b450-e27c5ff74397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_3d833662-f60b-45fe-b450-e27c5ff74397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ddc8a45c-d78c-48cb-90c0-5cdfb7bc8c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ddc8a45c-d78c-48cb-90c0-5cdfb7bc8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5093e92d-50fb-43e8-aba5-675ce81bdbac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5093e92d-50fb-43e8-aba5-675ce81bdbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_761cc067-ca3e-427d-b052-abe7df8a0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_761cc067-ca3e-427d-b052-abe7df8a0f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_94e386fb-db4f-4fda-9e20-92eb8d4a01ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesIssued_94e386fb-db4f-4fda-9e20-92eb8d4a01ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0c0a4524-dd1d-441c-b99c-f1377ac4d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0c0a4524-dd1d-441c-b99c-f1377ac4d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eee40e7f-397f-4454-bd12-0e4c97971c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eee40e7f-397f-4454-bd12-0e4c97971c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dab3a4fb-041b-4e80-a4c6-214618d40a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dab3a4fb-041b-4e80-a4c6-214618d40a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f324a70d-ab9a-48c8-ba35-824d5981917b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesIssued_f324a70d-ab9a-48c8-ba35-824d5981917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54c1dce6-54f5-43d5-a7cf-2bb633878333" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc3d02b5-5e46-474c-9f4d-1c617b43f226" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54c1dce6-54f5-43d5-a7cf-2bb633878333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d9147be-368c-4bdc-8799-58dd2f20a8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d9147be-368c-4bdc-8799-58dd2f20a8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_3590129a-3f75-45be-a669-38b8708c41ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_CostOfRevenue_3590129a-3f75-45be-a669-38b8708c41ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4d4a1b02-5cb4-4c4c-84f4-23f2d123ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_GrossProfit_4d4a1b02-5cb4-4c4c-84f4-23f2d123ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5a24418c-757c-48a7-a90b-48f3aef0b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5a24418c-757c-48a7-a90b-48f3aef0b6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50264471-871f-4200-8e46-b71a4c603b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a24418c-757c-48a7-a90b-48f3aef0b6e7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50264471-871f-4200-8e46-b71a4c603b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0ecb18e3-fcc4-42c0-a3c3-e81604ab7897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a24418c-757c-48a7-a90b-48f3aef0b6e7" xlink:to="loc_us-gaap_AssetImpairmentCharges_0ecb18e3-fcc4-42c0-a3c3-e81604ab7897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e26f82e7-d39f-480a-88c0-f8e726da00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a24418c-757c-48a7-a90b-48f3aef0b6e7" xlink:to="loc_us-gaap_OperatingExpenses_e26f82e7-d39f-480a-88c0-f8e726da00c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5335ebd2-c358-46f0-82ef-c87da264c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_OperatingIncomeLoss_5335ebd2-c358-46f0-82ef-c87da264c45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d80d7d3-4606-4c8d-a353-a95fb52abd2c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6772c710-859c-455a-9495-03cb54d0374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6772c710-859c-455a-9495-03cb54d0374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_92146486-2deb-4e5d-b2bc-8ccf25810808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_92146486-2deb-4e5d-b2bc-8ccf25810808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainsOnReversalOfContingencyLoss_bb6c0b60-4846-4b1a-823d-8d4a705bb218" xlink:href="jan-20231230.xsd#jan_GainsOnReversalOfContingencyLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_jan_GainsOnReversalOfContingencyLoss_bb6c0b60-4846-4b1a-823d-8d4a705bb218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ef43d0f1-45e4-4ae2-8612-bb5271d4d757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ef43d0f1-45e4-4ae2-8612-bb5271d4d757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ff233b98-5fb6-4aeb-931c-db0461857bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ff233b98-5fb6-4aeb-931c-db0461857bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c986fd9f-7aff-49a0-a5ad-35d36b1f7453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c986fd9f-7aff-49a0-a5ad-35d36b1f7453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1dfe9b6f-3671-4462-b5e0-e7defa628112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1dfe9b6f-3671-4462-b5e0-e7defa628112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72c04148-4eb0-4d67-bb3e-631093f9df0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72c04148-4eb0-4d67-bb3e-631093f9df0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_16b757c2-a8a2-4994-b5e3-8b64dd2410a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_16b757c2-a8a2-4994-b5e3-8b64dd2410a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_91044962-fbc1-44e3-8b2d-03b772c3a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_91044962-fbc1-44e3-8b2d-03b772c3a9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_39317910-581c-4b15-b82b-3b2cf6d940a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_39317910-581c-4b15-b82b-3b2cf6d940a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c81c0866-fe8e-4e19-b9f9-9c685c880241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c81c0866-fe8e-4e19-b9f9-9c685c880241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dcb6c2e2-30c2-48d5-8c99-32f9d0362fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_NetIncomeLoss_dcb6c2e2-30c2-48d5-8c99-32f9d0362fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1fa5a48f-01dd-4c51-8cde-e6a65dd56de1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9cb87abb-752f-421c-a058-859449f2d633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9cb87abb-752f-421c-a058-859449f2d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8fd478a3-60fb-42f3-a24f-841df4e73eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8fd478a3-60fb-42f3-a24f-841df4e73eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_65a17129-bbe0-4bed-805d-5e3351006ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_65a17129-bbe0-4bed-805d-5e3351006ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_30e22d3c-9ed3-4d0b-9ff4-139e5d9fd5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_30e22d3c-9ed3-4d0b-9ff4-139e5d9fd5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0b7e0575-3954-42ed-a2af-3dc13d2d69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_EarningsPerShareBasic_0b7e0575-3954-42ed-a2af-3dc13d2d69ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e2d6f41a-6620-4b01-a5c9-7244d2f2efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e2d6f41a-6620-4b01-a5c9-7244d2f2efaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_573e4344-fe15-4644-bc66-79b99b406cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_573e4344-fe15-4644-bc66-79b99b406cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28d80c0a-8e4b-48b9-90f9-27fbea317be2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_573e4344-fe15-4644-bc66-79b99b406cf1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28d80c0a-8e4b-48b9-90f9-27fbea317be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e53c0de-1fe9-4c03-a363-dd02fb310ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_573e4344-fe15-4644-bc66-79b99b406cf1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e53c0de-1fe9-4c03-a363-dd02fb310ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44e727bb-6e44-4cf0-a47b-23c0ebd10941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_NetIncomeLoss_44e727bb-6e44-4cf0-a47b-23c0ebd10941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_752c3b5f-1b0d-4c3d-99bf-6d1007e489b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_752c3b5f-1b0d-4c3d-99bf-6d1007e489b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0267e78-3bfc-49e6-8dc2-13a5acd95807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_752c3b5f-1b0d-4c3d-99bf-6d1007e489b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0267e78-3bfc-49e6-8dc2-13a5acd95807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0e2b8bc-6c27-43e4-9a02-4409c289b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_752c3b5f-1b0d-4c3d-99bf-6d1007e489b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0e2b8bc-6c27-43e4-9a02-4409c289b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2381e915-631a-457f-a946-b173cc86cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfc49cf9-49b4-4b29-b427-355a32ba077c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2381e915-631a-457f-a946-b173cc86cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3e7bcb6-55fc-4bfb-a12e-cd1c8e291cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3e7bcb6-55fc-4bfb-a12e-cd1c8e291cd2" xlink:to="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc14f456-cc8e-448b-8ce4-94cb18e94feb" xlink:to="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_65584030-88ec-4db9-acab-f370c45e167b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_PreferredStockMember_65584030-88ec-4db9-acab-f370c45e167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ab791d6-0784-43f2-9dec-e0034ab7c676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_CommonStockMember_2ab791d6-0784-43f2-9dec-e0034ab7c676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fb6ddd5d-5b4f-4842-9617-47862bd12360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fb6ddd5d-5b4f-4842-9617-47862bd12360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e89bce94-2ad1-4e74-b90d-710b6553d597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_RetainedEarningsMember_e89bce94-2ad1-4e74-b90d-710b6553d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c455d565-f19d-4183-a582-68c7e76f5837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc15c9c8-6956-4915-9bd0-d325c7b9d4d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c455d565-f19d-4183-a582-68c7e76f5837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257dfc64-0f28-478e-9ddf-9d04b1f03d37" xlink:to="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98723475-1c8b-47c9-82dc-e019484913ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_def91418-3bd0-4935-a1e2-432fc18449e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_def91418-3bd0-4935-a1e2-432fc18449e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5186f4b5-1fe8-42ba-9520-bfce639a4b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockholdersEquity_5186f4b5-1fe8-42ba-9520-bfce639a4b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_94391702-a85a-45fe-a133-e69f9763562f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_94391702-a85a-45fe-a133-e69f9763562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_1a331500-2fa8-41db-a9c4-87396c79fdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_1a331500-2fa8-41db-a9c4-87396c79fdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa720aa1-7b73-41c8-bc2f-a64e19ba2224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa720aa1-7b73-41c8-bc2f-a64e19ba2224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_df2d116b-98e4-4d7c-b033-04912af15e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_df2d116b-98e4-4d7c-b033-04912af15e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f3c8eb8-4408-45e1-89eb-5e69712aa7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f3c8eb8-4408-45e1-89eb-5e69712aa7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_02d5dc97-e963-4f8f-b9e3-2ed109accca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_02d5dc97-e963-4f8f-b9e3-2ed109accca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_86cd80c4-108d-4e09-acf5-faf84844218a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_86cd80c4-108d-4e09-acf5-faf84844218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_42e8746e-5d6b-4cbe-8105-14f9e4e5b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_42e8746e-5d6b-4cbe-8105-14f9e4e5b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised_f046431d-3eb7-43e9-947a-e48aaf193887" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_jan_StockIssuedDuringPeriodSharesWarrantsExercised_f046431d-3eb7-43e9-947a-e48aaf193887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised_b6853bcb-4641-466a-a3f7-2d15d2ce415a" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_jan_StockIssuedDuringPeriodValueWarrantsExercised_b6853bcb-4641-466a-a3f7-2d15d2ce415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f65bdbf8-62bd-4760-91c7-79df693f49cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_ProfitLoss_f65bdbf8-62bd-4760-91c7-79df693f49cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ae5071eb-8b4f-4cc0-94c2-25f57778bf38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ae5071eb-8b4f-4cc0-94c2-25f57778bf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ba5d93c1-8adb-4df7-b4cf-b11adb105103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_StockholdersEquity_ba5d93c1-8adb-4df7-b4cf-b11adb105103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c98681ff-2868-4b5b-b0df-a1bfcb09fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2c05f75-23a1-4019-95db-49b93c342bb8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c98681ff-2868-4b5b-b0df-a1bfcb09fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="jan-20231230.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_92e114b3-a360-4f72-a20d-cb448e623db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_92e114b3-a360-4f72-a20d-cb448e623db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_8c470d5a-2d55-4e53-afe5-c913642a88f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_8c470d5a-2d55-4e53-afe5-c913642a88f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_66081694-fa35-40ce-be21-e3a2577118f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_66081694-fa35-40ce-be21-e3a2577118f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_1c41c335-6493-47a8-b298-785885c37223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable_1c41c335-6493-47a8-b298-785885c37223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cfdd7a5f-2641-4668-b9eb-f8833e40dfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_ShareBasedCompensation_cfdd7a5f-2641-4668-b9eb-f8833e40dfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f102f64a-b6cf-419a-a770-5d00cbad69d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f102f64a-b6cf-419a-a770-5d00cbad69d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_85ca4e69-2198-499f-ab71-41824f432fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_85ca4e69-2198-499f-ab71-41824f432fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9458e4c9-417e-471f-8906-6c25ed1252e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9458e4c9-417e-471f-8906-6c25ed1252e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnWriteOffOfNotesReceivable_2d7a24ef-1707-4b42-babd-f62b6c3272a2" xlink:href="jan-20231230.xsd#jan_GainLossOnWriteOffOfNotesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_jan_GainLossOnWriteOffOfNotesReceivable_2d7a24ef-1707-4b42-babd-f62b6c3272a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_460e876d-e566-477e-be90-aed95dd2f781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_460e876d-e566-477e-be90-aed95dd2f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4cc24bd2-5513-4fda-9438-e766484f10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4cc24bd2-5513-4fda-9438-e766484f10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13185931-b118-4dc9-9a7b-8f4ed55f24c7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_341b6d7f-4766-4d08-84aa-78ad43ac9657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_341b6d7f-4766-4d08-84aa-78ad43ac9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89d08ec8-0abb-4725-abc2-3d342199b409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89d08ec8-0abb-4725-abc2-3d342199b409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c731118f-81c5-45ec-af05-e0bac995605d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c731118f-81c5-45ec-af05-e0bac995605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23e9450e-ea85-41d9-9db1-e3da7b4fc068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23e9450e-ea85-41d9-9db1-e3da7b4fc068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_170ce66c-3e5e-4331-a73e-78895495842d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d057c25-c36c-439a-91d0-52c12d7b2a8d" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_170ce66c-3e5e-4331-a73e-78895495842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da1288d2-2a77-42bf-b010-d7a9021e46a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da1288d2-2a77-42bf-b010-d7a9021e46a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d18b181c-2175-451e-ac6d-84fa5b4e0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d18b181c-2175-451e-ac6d-84fa5b4e0ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_a8f16717-846d-4ba7-9f6c-40376f11e775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d18b181c-2175-451e-ac6d-84fa5b4e0ffa" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_a8f16717-846d-4ba7-9f6c-40376f11e775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba0ee9fa-0cbb-4bcd-96dd-9b5053c8e3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d18b181c-2175-451e-ac6d-84fa5b4e0ffa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba0ee9fa-0cbb-4bcd-96dd-9b5053c8e3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9c0cd94-2849-468e-a1cb-f43b061cad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9c0cd94-2849-468e-a1cb-f43b061cad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0aab7a68-90dd-4dc8-9751-233593041ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0aab7a68-90dd-4dc8-9751-233593041ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_56642741-5968-4b54-9fda-7acc3ed3f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_56642741-5968-4b54-9fda-7acc3ed3f1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_de9f6278-4bd7-4e58-9aaa-3fed3b1fcf68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_de9f6278-4bd7-4e58-9aaa-3fed3b1fcf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d1ddc5-6047-4fc2-9bb5-2957140c589d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6fc691e9-58c0-49f6-91df-fbaa8e5e4150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d1ddc5-6047-4fc2-9bb5-2957140c589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f3851fac-1adc-406c-97d7-14e5fda88048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f3851fac-1adc-406c-97d7-14e5fda88048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2d448be-b138-44c7-a5cc-2d8a0f9d3386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2d448be-b138-44c7-a5cc-2d8a0f9d3386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65d62148-0b39-445c-9940-2383f6da8d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65d62148-0b39-445c-9940-2383f6da8d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_3f26ba42-235c-4301-b91e-c4671a3c952d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_3f26ba42-235c-4301-b91e-c4671a3c952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d788e08-1aaa-4ea2-a496-187e0877ad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d788e08-1aaa-4ea2-a496-187e0877ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1fbb57b8-f6b0-4bb5-87fb-ec563e7991bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76bb74aa-5e96-4c2b-879e-131339c34336" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1fbb57b8-f6b0-4bb5-87fb-ec563e7991bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashRecognitionOfNewLeases_42cae048-57d7-4744-b088-ba0b92860921" xlink:href="jan-20231230.xsd#jan_NoncashRecognitionOfNewLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1fbb57b8-f6b0-4bb5-87fb-ec563e7991bb" xlink:to="loc_jan_NoncashRecognitionOfNewLeases_42cae048-57d7-4744-b088-ba0b92860921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3f88df2f-4aff-47cf-b057-c66414c86a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1fbb57b8-f6b0-4bb5-87fb-ec563e7991bb" xlink:to="loc_us-gaap_InterestPaidNet_3f88df2f-4aff-47cf-b057-c66414c86a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_302d7395-5b1b-4706-81cf-ee53d33f3dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1fbb57b8-f6b0-4bb5-87fb-ec563e7991bb" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_302d7395-5b1b-4706-81cf-ee53d33f3dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/BackgroundandBasisofPresentation" xlink:type="simple" xlink:href="jan-20231230.xsd#BackgroundandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/BackgroundandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00cd097c-2f68-4a40-a7e2-d3f6ca98ce27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3f73aa13-69ba-4670-aa6c-4424d6ac228b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00cd097c-2f68-4a40-a7e2-d3f6ca98ce27" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3f73aa13-69ba-4670-aa6c-4424d6ac228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c0c6fce0-06e9-4277-a792-c95efe000b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_724e1cad-1a60-499f-b909-7056a81867d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c6fce0-06e9-4277-a792-c95efe000b8b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_724e1cad-1a60-499f-b909-7056a81867d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MergersandAcquisitions" xlink:type="simple" xlink:href="jan-20231230.xsd#MergersandAcquisitions"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MergersandAcquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd6b9374-991c-4cf7-af47-1a626f41c0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_0d7b4b63-f492-4042-9e41-1f024799371a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd6b9374-991c-4cf7-af47-1a626f41c0e9" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_0d7b4b63-f492-4042-9e41-1f024799371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiaries"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d40990a9-bbd6-4fcb-916e-b3bea15207e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3bfd3d06-8639-435c-8f28-50d6234e401e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d40990a9-bbd6-4fcb-916e-b3bea15207e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3bfd3d06-8639-435c-8f28-50d6234e401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/GeoTraq" xlink:type="simple" xlink:href="jan-20231230.xsd#GeoTraq"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/GeoTraq" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9560514c-5bd4-47b8-82ad-b9c14d3598a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_aad086b8-f1e1-4dee-a8a3-85bb59ffe766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9560514c-5bd4-47b8-82ad-b9c14d3598a4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_aad086b8-f1e1-4dee-a8a3-85bb59ffe766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ef8edff1-6604-4ab8-b0c7-6799b25f2eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45b2153b-a708-4d7b-874d-9c34a93aa8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ef8edff1-6604-4ab8-b0c7-6799b25f2eb5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45b2153b-a708-4d7b-874d-9c34a93aa8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets" xlink:type="simple" xlink:href="jan-20231230.xsd#PrepaidsandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bbe65523-aaba-44b4-ba39-a432c9f89ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_08709832-6668-4ed5-acc9-55f506675eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bbe65523-aaba-44b4-ba39-a432c9f89ca0" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_08709832-6668-4ed5-acc9-55f506675eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/NotesReceivable" xlink:type="simple" xlink:href="jan-20231230.xsd#NotesReceivable"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/NotesReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_d57cfa45-3123-4681-99fe-3dfa14603ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock_c8711c8e-20bb-4917-b28f-67e42d07bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_d57cfa45-3123-4681-99fe-3dfa14603ec8" xlink:to="loc_us-gaap_FinancingReceivablesTextBlock_c8711c8e-20bb-4917-b28f-67e42d07bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssets" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a37d6e19-ab62-4158-b9e2-929863874e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_0c276404-9956-415e-94bd-2b60e5f3011b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a37d6e19-ab62-4158-b9e2-929863874e32" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_0c276404-9956-415e-94bd-2b60e5f3011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecurities" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_3a3bfddc-e942-4e8b-b546-3b56f65f8d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2f63440c-a6dd-4da0-a728-c923c20e6d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_3a3bfddc-e942-4e8b-b546-3b56f65f8d08" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2f63440c-a6dd-4da0-a728-c923c20e6d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DepositsandOtherAssets" xlink:type="simple" xlink:href="jan-20231230.xsd#DepositsandOtherAssets"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DepositsandOtherAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ad8353dd-9ef6-4c8f-8f2f-64c40548b847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_827fbe94-98a4-4df5-b323-754980c16370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ad8353dd-9ef6-4c8f-8f2f-64c40548b847" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_827fbe94-98a4-4df5-b323-754980c16370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="jan-20231230.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b28d4fce-ff2d-4d70-975e-2fee185ac8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_e359ee45-f07f-4049-a3f3-48657fd17099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b28d4fce-ff2d-4d70-975e-2fee185ac8f5" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_e359ee45-f07f-4049-a3f3-48657fd17099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/Shorttermdebt" xlink:type="simple" xlink:href="jan-20231230.xsd#Shorttermdebt"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/Shorttermdebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_99fd2798-9941-4533-b41e-ea74dd1b7f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_4bde8ef2-ddb6-494d-bdcd-4a177699d564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_99fd2798-9941-4533-b41e-ea74dd1b7f86" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_4bde8ef2-ddb6-494d-bdcd-4a177699d564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesA1ConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7609b41d-8319-459f-bc29-689eeca36225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_bc96287b-b2bb-42f2-b59d-9b97208cedcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7609b41d-8319-459f-bc29-689eeca36225" xlink:to="loc_us-gaap_PreferredStockTextBlock_bc96287b-b2bb-42f2-b59d-9b97208cedcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c0ccabd4-8c32-432a-9be6-e7f846e79604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_9238d761-0293-4ba6-b363-20b23db7a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c0ccabd4-8c32-432a-9be6-e7f846e79604" xlink:to="loc_us-gaap_PreferredStockTextBlock_9238d761-0293-4ba6-b363-20b23db7a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquity" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_735911b7-16e5-4020-8e39-9a00c0897ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_34993b6a-9f3b-4e24-beb8-dcd5cc1ae64a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_735911b7-16e5-4020-8e39-9a00c0897ad2" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_34993b6a-9f3b-4e24-beb8-dcd5cc1ae64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e3d280-1258-438c-ad65-0cd41ca3e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c227f16-2909-46ca-83d4-9f4cba71c800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e3d280-1258-438c-ad65-0cd41ca3e7b3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c227f16-2909-46ca-83d4-9f4cba71c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/RelatedParties" xlink:type="simple" xlink:href="jan-20231230.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d3eb8c00-2c26-41f0-a3d5-4c62c35f265d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e67cde7c-08e0-455c-93ae-706b740adda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d3eb8c00-2c26-41f0-a3d5-4c62c35f265d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e67cde7c-08e0-455c-93ae-706b740adda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="jan-20231230.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8d8303e-9ecc-49a5-8126-777e3f87bc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c1e22cd0-12ac-4bb2-9ae5-d6a4529d2c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8d8303e-9ecc-49a5-8126-777e3f87bc4e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c1e22cd0-12ac-4bb2-9ae5-d6a4529d2c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/EarningsLosspershare" xlink:type="simple" xlink:href="jan-20231230.xsd#EarningsLosspershare"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/EarningsLosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36d14ef8-f735-46f0-996b-780a2e9db3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_44487f1e-4cb0-4dd5-9a84-edf0dbcec6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36d14ef8-f735-46f0-996b-780a2e9db3c1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_44487f1e-4cb0-4dd5-9a84-edf0dbcec6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformation" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1da52bc4-0695-4106-bdb6-1349eae7a441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7e957d59-ea69-4d0d-a46a-541b19f74888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1da52bc4-0695-4106-bdb6-1349eae7a441" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7e957d59-ea69-4d0d-a46a-541b19f74888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SubsequentEvents" xlink:type="simple" xlink:href="jan-20231230.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_243873fd-3450-4abc-9114-d6b75a740f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_71d02a36-4996-4d64-944e-9a1992b53ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_243873fd-3450-4abc-9114-d6b75a740f80" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_71d02a36-4996-4d64-944e-9a1992b53ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3f78ed9a-c22a-4fc6-be49-d7713d0a23c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3f78ed9a-c22a-4fc6-be49-d7713d0a23c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_fe587b63-1506-4800-95f6-206c413f2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_fe587b63-1506-4800-95f6-206c413f2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_845f0da5-a04e-4415-8028-65125d6359fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_UseOfEstimates_845f0da5-a04e-4415-8028-65125d6359fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ae0c4254-f63c-48b8-8c4e-0f91c6f69a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ae0c4254-f63c-48b8-8c4e-0f91c6f69a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_de9fc7be-dfee-4755-a2ab-c5bd3e9cfd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_de9fc7be-dfee-4755-a2ab-c5bd3e9cfd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_23412b11-75e5-4c85-8670-a120e5a3db1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_23412b11-75e5-4c85-8670-a120e5a3db1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6849a46e-26b6-49d2-8a99-754b542889e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6849a46e-26b6-49d2-8a99-754b542889e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9a04571d-42e9-4201-8c4d-b42162af60cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9a04571d-42e9-4201-8c4d-b42162af60cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6fb51bee-2f55-4121-a3af-424ec65f595b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6fb51bee-2f55-4121-a3af-424ec65f595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_bb7f60d7-6dc2-4b1d-9b15-5d5ed7e9d735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_bb7f60d7-6dc2-4b1d-9b15-5d5ed7e9d735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_85eb3188-3bc3-47d0-b923-65d954f51a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_85eb3188-3bc3-47d0-b923-65d954f51a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b7008835-e0b8-4c16-bb32-90bfcba25742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b7008835-e0b8-4c16-bb32-90bfcba25742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4e6a2965-0f3a-4d84-9fee-2d6b56c04509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4e6a2965-0f3a-4d84-9fee-2d6b56c04509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ec005899-ae44-4d4b-888c-bf5da27b25df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ec005899-ae44-4d4b-888c-bf5da27b25df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_de874790-c9e4-4481-97ce-b44dc9cdd202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9669e0a4-47d8-479b-96b6-3be499444b5a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_de874790-c9e4-4481-97ce-b44dc9cdd202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd13150a-4228-423e-a3f7-fc6c9f8d27e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4f59304d-9ec1-4768-adb7-9ef83dbd3eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd13150a-4228-423e-a3f7-fc6c9f8d27e6" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4f59304d-9ec1-4768-adb7-9ef83dbd3eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c58b5acc-1641-4e45-a176-757aff0084d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9d888230-857a-4352-ba91-dab95f491911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c58b5acc-1641-4e45-a176-757aff0084d8" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9d888230-857a-4352-ba91-dab95f491911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/GeoTraqTables" xlink:type="simple" xlink:href="jan-20231230.xsd#GeoTraqTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/GeoTraqTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_84cd2cc9-de22-4236-a43c-3821e106dad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_afffda84-fdb8-4d60-81fb-10763683f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_84cd2cc9-de22-4236-a43c-3821e106dad0" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_afffda84-fdb8-4d60-81fb-10763683f3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b1fec19b-a83f-49a3-a88c-d146ac3ae4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_16980106-77b1-4759-bcee-2f33f551003a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b1fec19b-a83f-49a3-a88c-d146ac3ae4d3" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_16980106-77b1-4759-bcee-2f33f551003a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="jan-20231230.xsd#PrepaidsandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28471d32-5977-4f2c-a9a9-8c0f36117efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_e09d27cb-021c-48e5-ac22-318ebbf3c623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28471d32-5977-4f2c-a9a9-8c0f36117efd" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_e09d27cb-021c-48e5-ac22-318ebbf3c623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4165b386-aca0-4fa3-99e9-ae6c9b02ac10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f882b7f2-6f40-4771-bdde-0078256ac485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4165b386-aca0-4fa3-99e9-ae6c9b02ac10" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f882b7f2-6f40-4771-bdde-0078256ac485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_87ee15ad-3b05-4687-9d1e-40a34a5948b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_0d73e239-7b6d-4045-80be-7758a0287c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_87ee15ad-3b05-4687-9d1e-40a34a5948b4" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_0d73e239-7b6d-4045-80be-7758a0287c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DepositsandOtherAssetsTables" xlink:type="simple" xlink:href="jan-20231230.xsd#DepositsandOtherAssetsTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DepositsandOtherAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5400226d-db6f-4d47-bc2b-e85f166f1a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_0f6a2c13-f2a8-44da-8212-897f4ed63826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5400226d-db6f-4d47-bc2b-e85f166f1a5a" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_0f6a2c13-f2a8-44da-8212-897f4ed63826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="jan-20231230.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_764e8a69-552d-49ae-a496-672321409136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cebad882-7410-4257-8d4d-7e979421e758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_764e8a69-552d-49ae-a496-672321409136" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cebad882-7410-4257-8d4d-7e979421e758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/ShorttermdebtTables" xlink:type="simple" xlink:href="jan-20231230.xsd#ShorttermdebtTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/ShorttermdebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b25a47da-89de-4725-b41d-c6cc602960ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ac37bd30-0669-405a-b5c9-46febaa09ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b25a47da-89de-4725-b41d-c6cc602960ab" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ac37bd30-0669-405a-b5c9-46febaa09ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8834bbcf-35ab-43cb-a66a-eddfaba10125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_b6d5af2f-9da2-4192-9224-17f2027a15e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8834bbcf-35ab-43cb-a66a-eddfaba10125" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_b6d5af2f-9da2-4192-9224-17f2027a15e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3a2b6135-268b-4aa6-8356-441aa3796c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50234e1f-db2d-48e3-8e45-1f641e7606f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a2b6135-268b-4aa6-8356-441aa3796c96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50234e1f-db2d-48e3-8e45-1f641e7606f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2c8eb56e-6f20-4a26-bcab-16a273d0c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a2b6135-268b-4aa6-8356-441aa3796c96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2c8eb56e-6f20-4a26-bcab-16a273d0c7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_58ec0045-5fe4-4e9a-b7ed-8307ec505330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a2b6135-268b-4aa6-8356-441aa3796c96" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_58ec0045-5fe4-4e9a-b7ed-8307ec505330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4448cc00-abb6-48d6-a9a1-ee6887b4875d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1fc8098f-3ef7-4764-bac2-db56a001456c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4448cc00-abb6-48d6-a9a1-ee6887b4875d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1fc8098f-3ef7-4764-bac2-db56a001456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ab411803-9fc1-4446-883e-12ad76747699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4448cc00-abb6-48d6-a9a1-ee6887b4875d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ab411803-9fc1-4446-883e-12ad76747699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9e441ca3-a440-4405-9e62-df438a60c064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4448cc00-abb6-48d6-a9a1-ee6887b4875d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9e441ca3-a440-4405-9e62-df438a60c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f82e427f-9b0f-4dd8-bdc3-258e12ff13b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4448cc00-abb6-48d6-a9a1-ee6887b4875d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f82e427f-9b0f-4dd8-bdc3-258e12ff13b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/EarningsLosspershareTables" xlink:type="simple" xlink:href="jan-20231230.xsd#EarningsLosspershareTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/EarningsLosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9417ba17-82de-4c0e-beb5-73ee1c691215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f797cbd2-c78d-469b-93f5-1c13818630d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9417ba17-82de-4c0e-beb5-73ee1c691215" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f797cbd2-c78d-469b-93f5-1c13818630d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28f79074-f1bd-4732-be6b-1f69b684e3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ec73876a-7a20-4a06-bf1b-0d36ca0e86ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28f79074-f1bd-4732-be6b-1f69b684e3f3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ec73876a-7a20-4a06-bf1b-0d36ca0e86ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#BackgroundandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16137508-c5f3-495f-a808-37491dde76f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16137508-c5f3-495f-a808-37491dde76f6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a48e95fe-7628-4ad1-b0e0-2011c857aa86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AssetPurchaseAgreementMember_604397d6-e80d-499d-a4ec-16e9d540938b" xlink:href="jan-20231230.xsd#jan_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1160bee1-d1ba-4692-9447-f9685d18cc07" xlink:to="loc_jan_AssetPurchaseAgreementMember_604397d6-e80d-499d-a4ec-16e9d540938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8f5c2497-de17-4301-a28f-1a0ce86595cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_a0bd83b7-0c30-4858-ad55-b70f084113a1" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c70d582-f844-4dd1-9f6e-31d5bfa52f7b" xlink:to="loc_jan_SpyrTechnologiesIncMember_a0bd83b7-0c30-4858-ad55-b70f084113a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b5fbe0c3-8619-4cce-b4ae-a8eeba594b58" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_8a02d26b-9b0d-4f40-98a0-29ad99a8c742" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31d25b06-6344-4024-b4c8-e109ae475872" xlink:to="loc_jan_GeoTraqIncMember_8a02d26b-9b0d-4f40-98a0-29ad99a8c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_271d5481-68bc-4c43-9c0e-305d6b54f0cf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_85683f41-5749-4668-8dcf-d6af1d4bb77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_NumberOfOperatingSegments_85683f41-5749-4668-8dcf-d6af1d4bb77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PotentialMarketExclusivityPeriod_a039ea07-7a4c-49dc-ade7-016cabc6def2" xlink:href="jan-20231230.xsd#jan_PotentialMarketExclusivityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_PotentialMarketExclusivityPeriod_a039ea07-7a4c-49dc-ade7-016cabc6def2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f7f97481-b32a-497e-88dd-5f6020ab06b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f7f97481-b32a-497e-88dd-5f6020ab06b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68ee9ce4-85ca-4175-93c8-e3d7eb90bb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68ee9ce4-85ca-4175-93c8-e3d7eb90bb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cfd1564-62e1-4f55-af23-5d9449f8bf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cfd1564-62e1-4f55-af23-5d9449f8bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_bee84875-8c5f-4a9a-b01d-33b7ecdbe509" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_NotesReceivableTerm_bee84875-8c5f-4a9a-b01d-33b7ecdbe509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_d2170683-ce1c-42bb-9ec5-b02d6a55dbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_d2170683-ce1c-42bb-9ec5-b02d6a55dbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_2d97fd02-fa0e-4546-a743-38d7f2994d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_2d97fd02-fa0e-4546-a743-38d7f2994d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_11570962-3ab2-4828-81f8-8a946864c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_11570962-3ab2-4828-81f8-8a946864c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5f434d5-cd23-4c0e-875d-0d55a37f7e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_AssetsCurrent_c5f434d5-cd23-4c0e-875d-0d55a37f7e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d76d8266-42e8-4bdf-83a7-7a86b8baae7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_LiabilitiesCurrent_d76d8266-42e8-4bdf-83a7-7a86b8baae7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CurrentAssetsCurrentLiabilitiesNet_c25ca654-67df-48e1-8a7a-af5f3219ab83" xlink:href="jan-20231230.xsd#jan_CurrentAssetsCurrentLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_jan_CurrentAssetsCurrentLiabilitiesNet_c25ca654-67df-48e1-8a7a-af5f3219ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_fdbdf555-4e68-41a6-afff-c20df9fb3fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2633eb6b-6bca-4f93-80b5-1e56a16d9f95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_fdbdf555-4e68-41a6-afff-c20df9fb3fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_388cb535-2cc4-452f-9c81-3b9830e56fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_388cb535-2cc4-452f-9c81-3b9830e56fda" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:to="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_862e50be-d426-4ffc-9369-5f9eb38e9dfc" xlink:to="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc52a088-d507-4095-a801-6437c8dd9a18" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:to="loc_srt_MinimumMember_bc52a088-d507-4095-a801-6437c8dd9a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b6a3d5f-311b-4e1a-8f91-29163573bb88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac32e5e4-ec52-4fa2-a917-b8fea0a4efa0" xlink:to="loc_srt_MaximumMember_2b6a3d5f-311b-4e1a-8f91-29163573bb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d3e05fd7-dfd6-4645-ba07-3895d0257160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_9ab62778-08fb-4165-b22b-7d5ac1b89c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_9ab62778-08fb-4165-b22b-7d5ac1b89c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_4ba973fe-ba9b-4688-bb9c-f2bf418cfdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_4ba973fe-ba9b-4688-bb9c-f2bf418cfdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a2b98b60-980f-45e3-9881-478a8e3af573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a2b98b60-980f-45e3-9881-478a8e3af573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8b29ba8b-307d-4c46-9882-4c7ad0f6f67c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8b29ba8b-307d-4c46-9882-4c7ad0f6f67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_4be8a1c5-4fd7-4cc1-b1c0-37f1c00261c5" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_281e5ba4-5d23-4f99-a41a-61b875db260b" xlink:to="loc_jan_SoinIntangiblesMember_4be8a1c5-4fd7-4cc1-b1c0-37f1c00261c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2607d0a9-2195-41c9-b493-cf5ed7a06a69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d85195ea-49d8-4640-8c1e-0a64cf15b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d85195ea-49d8-4640-8c1e-0a64cf15b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_004713cd-674d-42fe-ad4c-96e1f3b3c24d" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_004713cd-674d-42fe-ad4c-96e1f3b3c24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3394a253-2c10-4b01-8d80-476bb45a0c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3394a253-2c10-4b01-8d80-476bb45a0c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e32d148f-8dd8-4143-af77-c6f2b5f6bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_NumberOfReportableSegments_e32d148f-8dd8-4143-af77-c6f2b5f6bfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_0804c9f6-388a-48ba-a065-ca9f8bf3980b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d003225-4fc1-4750-966b-92723937444d" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_0804c9f6-388a-48ba-a065-ca9f8bf3980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ab56ed4-3e65-44a1-a9a4-689ecf6a6585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ab56ed4-3e65-44a1-a9a4-689ecf6a6585" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_412cf0f8-840f-4f17-8774-8fd1902c27c2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_825d9122-0418-4966-bdda-963d3bba0fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_825d9122-0418-4966-bdda-963d3bba0fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_cfc4ae6b-db35-4050-ad39-0cb820dfc751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_cfc4ae6b-db35-4050-ad39-0cb820dfc751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_85555b0f-f372-43d8-b895-cf2581f44880" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_75a4267a-d88f-476a-b5ee-6aeba0680db4" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_85555b0f-f372-43d8-b895-cf2581f44880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4bf182ab-ac8f-465a-9cdf-cfffd22ec99f" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_768de2b9-2c85-4caf-890e-2340728b9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_768de2b9-2c85-4caf-890e-2340728b9aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_532b75cb-61aa-474e-bf5d-d05c5bc2dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_6b4a42f8-5350-4116-9cd0-c44a5a78703e" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_532b75cb-61aa-474e-bf5d-d05c5bc2dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MergersandAcquisitionsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MergersandAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MergersandAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_288b9ebb-067c-4012-a6f4-317e24a146ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_288b9ebb-067c-4012-a6f4-317e24a146ae" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a87d92b-95e1-4737-8995-d0ed6fd3d948" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_26b0bab4-295a-48ee-91d6-798208a47290" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89e279cd-a4ce-428a-a5a5-c2879e93c9ae" xlink:to="loc_jan_SoinTherapeuticsLLCMember_26b0bab4-295a-48ee-91d6-798208a47290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6753fdbd-34be-4bce-b6ca-5d9a688272c6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StiMergerSubIncMember_7ba95c65-75b5-4938-94ad-769983d84ad0" xlink:href="jan-20231230.xsd#jan_StiMergerSubIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b1221258-1db7-42a4-8dfd-7766150bee50" xlink:to="loc_jan_StiMergerSubIncMember_7ba95c65-75b5-4938-94ad-769983d84ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b183f000-ebe7-466e-8db0-23de9903ff78" xlink:to="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_0b081c2d-54cc-4851-8247-0b429490ab0f" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1efa1473-716a-46cd-8ece-d399be6e6672" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_0b081c2d-54cc-4851-8247-0b429490ab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f2adcaa2-3f57-4174-b036-eaffee032e37" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion1Member_4d81d75c-9298-4269-90c8-814bfb7eaed7" xlink:href="jan-20231230.xsd#jan_StockConversion1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion1Member_4d81d75c-9298-4269-90c8-814bfb7eaed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion2Member_b8970bc2-4ea8-4bf3-a94f-6463603eb3fa" xlink:href="jan-20231230.xsd#jan_StockConversion2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion2Member_b8970bc2-4ea8-4bf3-a94f-6463603eb3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion3Member_fc7735dd-b7bb-4255-a9d4-5acc2cf7106b" xlink:href="jan-20231230.xsd#jan_StockConversion3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fdac412-e317-4c05-8220-01126e0487fa" xlink:to="loc_jan_StockConversion3Member_fc7735dd-b7bb-4255-a9d4-5acc2cf7106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6c00b3a5-a495-4643-bfd8-b7d148fe335d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DrSoinMember_41738f73-8adf-4cd8-977f-b1dab3df2c15" xlink:href="jan-20231230.xsd#jan_DrSoinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ca8a3cd-3549-4741-b431-4019e4f18886" xlink:to="loc_jan_DrSoinMember_41738f73-8adf-4cd8-977f-b1dab3df2c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad4d4d9-9ca3-4e9d-adcf-849810005a54" xlink:to="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_29b60827-2566-41fc-8b5c-9f2aa7881d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d172ed8d-acb3-43bf-8716-740c0327b05c" xlink:to="loc_us-gaap_RelatedPartyMember_29b60827-2566-41fc-8b5c-9f2aa7881d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b3e49f35-e807-4394-b47f-7d09ae37f3d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_16c02478-9468-43f3-b87a-9eca8415f01e" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_376a7f7c-9302-4217-b0a1-273674baf557" xlink:to="loc_jan_SoinIntangiblesMember_16c02478-9468-43f3-b87a-9eca8415f01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95511f38-b7c2-43db-afcf-d08126271667" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2fc8d4f0-2922-4038-b3fd-ee51af9d18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2fc8d4f0-2922-4038-b3fd-ee51af9d18bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_83b0eaa0-e81c-488d-a6b5-a5999b32f193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_83b0eaa0-e81c-488d-a6b5-a5999b32f193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_52fd68b1-2421-4488-82e3-f5dc78c1978b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_52fd68b1-2421-4488-82e3-f5dc78c1978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb224408-95ae-4008-9a85-4bf4f4f2f842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb224408-95ae-4008-9a85-4bf4f4f2f842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_b82bd6a9-eafd-425b-8d51-0cf64e9c10fd" xlink:href="jan-20231230.xsd#jan_StockIssuedDuringPeriodAdditionalValueAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions_b82bd6a9-eafd-425b-8d51-0cf64e9c10fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4f514e6e-7e8d-4498-9e77-1257d67bacca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4f514e6e-7e8d-4498-9e77-1257d67bacca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockSharesOutstandingPercentage_72616db1-fb1f-4120-9922-648a6889da7e" xlink:href="jan-20231230.xsd#jan_CommonStockSharesOutstandingPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_CommonStockSharesOutstandingPercentage_72616db1-fb1f-4120-9922-648a6889da7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_3f03e856-f00b-4e86-82e8-1577d3dab196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_3f03e856-f00b-4e86-82e8-1577d3dab196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockCommencementPeriod_0a465dbd-1217-4cee-9ac4-96364205a046" xlink:href="jan-20231230.xsd#jan_ConversionOfStockCommencementPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_ConversionOfStockCommencementPeriod_0a465dbd-1217-4cee-9ac4-96364205a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockPeriodFollowingClosing_1904fce8-230a-46b0-96e2-ca351cdc6df6" xlink:href="jan-20231230.xsd#jan_ConversionOfStockPeriodFollowingClosing"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_ConversionOfStockPeriodFollowingClosing_1904fce8-230a-46b0-96e2-ca351cdc6df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7cbf70de-e407-47d3-8f9a-314c6464f947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_Goodwill_7cbf70de-e407-47d3-8f9a-314c6464f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FairValueOfStockIssued_c3f7fada-c705-4dd5-a645-8234c16ddbe0" xlink:href="jan-20231230.xsd#jan_FairValueOfStockIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_FairValueOfStockIssued_c3f7fada-c705-4dd5-a645-8234c16ddbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_a5e9be26-d52e-4bfb-b4ac-f0b5a91acdc2" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_a5e9be26-d52e-4bfb-b4ac-f0b5a91acdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cccbe3a9-439e-4856-aa65-83b490843cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cccbe3a9-439e-4856-aa65-83b490843cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3ccdce5e-d476-4433-ad80-f8c4311c4d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3ccdce5e-d476-4433-ad80-f8c4311c4d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03dbe1a0-dbd9-4854-8671-165e0045421c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d2fee342-a8a8-424f-8ece-4b67e01d7777" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03dbe1a0-dbd9-4854-8671-165e0045421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f9d16892-d2f7-4111-ab7e-fb139a9f41b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f9d16892-d2f7-4111-ab7e-fb139a9f41b9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf01142e-604f-4725-af41-4e8b2862b9b3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2ccf3fab-dce6-42db-b6c5-1a1692b45106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8d658799-a62f-4b62-9749-39f97a170f77" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2ccf3fab-dce6-42db-b6c5-1a1692b45106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_527c0507-2eb5-4976-88c9-eb35f88a204a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCreditFacilityMember_84a2d64a-0fca-46e4-95ef-af9774897eed" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0435601e-c488-4ea0-9528-5bb05470b0d5" xlink:to="loc_jan_GulfCoastBankAndTrustCreditFacilityMember_84a2d64a-0fca-46e4-95ef-af9774897eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_563f32ac-31aa-42f6-b9cc-432dbbbf0e7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_20280df7-9f96-4c59-9cc3-833c943ae049" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72319632-3d44-40a5-b0cf-50931653039a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_20280df7-9f96-4c59-9cc3-833c943ae049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ac3d305-9e5d-46cc-927c-10ec4d7dc460" xlink:to="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a603eb07-a252-46fe-b73f-3664b9cf71bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:to="loc_srt_MinimumMember_a603eb07-a252-46fe-b73f-3664b9cf71bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6347f0cd-0585-4dad-a997-5e970cd3cc37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_678a0107-3d5d-40c1-a9c9-9151883b4515" xlink:to="loc_srt_MaximumMember_6347f0cd-0585-4dad-a997-5e970cd3cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:href="jan-20231230.xsd#jan_DisposalGroupConsiderationPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodAxis_b7fbd9be-52be-4ebe-81e7-131e026fd74e" xlink:to="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth1Member_8b653b33-2de6-4b98-bb40-1193d0095306" xlink:href="jan-20231230.xsd#jan_RelevantMonth1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth1Member_8b653b33-2de6-4b98-bb40-1193d0095306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth2Member_9e47b584-8062-4420-90fc-5f7ec1fe27db" xlink:href="jan-20231230.xsd#jan_RelevantMonth2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth2Member_9e47b584-8062-4420-90fc-5f7ec1fe27db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelevantMonth3Member_061d6a9f-4313-4de0-a699-e1d8d19d156b" xlink:href="jan-20231230.xsd#jan_RelevantMonth3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DisposalGroupConsiderationPaymentPeriodDomain_7afb6b4b-8a94-4588-99ea-094257ee895c" xlink:to="loc_jan_RelevantMonth3Member_061d6a9f-4313-4de0-a699-e1d8d19d156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_8542e0fb-d53b-4c2e-b343-460f78460367" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_e80d34e6-5b1f-4165-8d48-4286a8057e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_41af13ae-f966-4884-a8fa-94b9d68d756d" xlink:to="loc_us-gaap_FinancialGuaranteeMember_e80d34e6-5b1f-4165-8d48-4286a8057e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_94070ffd-bfc9-448c-91d1-64467f96b06c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_9c83980d-efe3-48bd-886f-aef6880196e3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities_9c83980d-efe3-48bd-886f-aef6880196e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_0413a89c-0f8f-4b1e-99f9-1bffff306e12" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer_0413a89c-0f8f-4b1e-99f9-1bffff306e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_fff2d693-6c2c-4f0f-b329-9889399dab7d" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod_fff2d693-6c2c-4f0f-b329-9889399dab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_7e300eb4-9211-4654-ad29-62a672a95466" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment_7e300eb4-9211-4654-ad29-62a672a95466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_98b2a162-faff-41ed-a3b4-09529a252838" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary_98b2a162-faff-41ed-a3b4-09529a252838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_b4023933-a15a-4729-90ce-03ab9377f29b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer_b4023933-a15a-4729-90ce-03ab9377f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_fb723932-7c8a-4223-8a7e-405907341e75" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod_fb723932-7c8a-4223-8a7e-405907341e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_9a3d1d91-5e2a-42c3-b490-d1b3b901e0b6" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue_9a3d1d91-5e2a-42c3-b490-d1b3b901e0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_456bd625-61c8-4e59-849c-376e32860720" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark_456bd625-61c8-4e59-849c-376e32860720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_1c20a101-d3da-4d47-b062-5253ad0763d0" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue_1c20a101-d3da-4d47-b062-5253ad0763d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_d7270fe3-8d7d-4714-bb94-f45e762f82c2" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction_d7270fe3-8d7d-4714-bb94-f45e762f82c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_279e3256-e617-4a33-8f61-1f5ec0ddc3e3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure_279e3256-e617-4a33-8f61-1f5ec0ddc3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_071e7666-c9fe-4019-bad9-102a4b57de53" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage_071e7666-c9fe-4019-bad9-102a4b57de53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_43bf9a7b-2d9a-40be-b5b3-539ea274a7c3" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount_43bf9a7b-2d9a-40be-b5b3-539ea274a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_f6518da2-56ab-4526-a3bc-0886f23b64be" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration_f6518da2-56ab-4526-a3bc-0886f23b64be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_a6f50445-41f4-4dc8-a46b-9f66e73483b5" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets_a6f50445-41f4-4dc8-a46b-9f66e73483b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_bc4e00e2-5adb-4133-bc9b-de9a04aabc33" xlink:href="jan-20231230.xsd#jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag_bc4e00e2-5adb-4133-bc9b-de9a04aabc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_09318033-8452-49e2-bfb4-8605d1bd02aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_09318033-8452-49e2-bfb4-8605d1bd02aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_647687d7-fa09-481a-809d-26acf74d6365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_647687d7-fa09-481a-809d-26acf74d6365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_dc413729-ebc7-444f-86ea-b9c671515e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea233ff7-c3fd-4af0-85ed-a8544643a380" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_dc413729-ebc7-444f-86ea-b9c671515e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eb8ae0b8-6dc3-4216-8ac2-5cf9aec1f76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eb8ae0b8-6dc3-4216-8ac2-5cf9aec1f76d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cfd1f953-0b5a-4d3e-a948-23611ae0b56b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_967dca97-805c-4698-9acc-9b74ac248546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_14db686a-18e2-4ff1-844e-cfbf39566ee7" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_967dca97-805c-4698-9acc-9b74ac248546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7b499259-0b3e-405f-ac9f-d644e2f3e6ce" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_27135516-bb33-47a9-ad2a-a7e867e5738c" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4ced1e0-0969-4e70-8045-9fe8f66e2e8e" xlink:to="loc_jan_ARCAAndSubsidiariesMember_27135516-bb33-47a9-ad2a-a7e867e5738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87d5187-5376-4cb6-af86-5ca9e6604371" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGuaranteedConsideration_e6ff51e2-9bda-4c17-978c-90df072044b5" xlink:href="jan-20231230.xsd#jan_TotalGuaranteedConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalGuaranteedConsideration_e6ff51e2-9bda-4c17-978c-90df072044b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PaymentFromBuyer_a5c134ba-d65d-4d62-9604-56e81738f816" xlink:href="jan-20231230.xsd#jan_PaymentFromBuyer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_PaymentFromBuyer_a5c134ba-d65d-4d62-9604-56e81738f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NetConsideration_14be9cf2-5af1-4ab2-ad73-c08c2d6d79fb" xlink:href="jan-20231230.xsd#jan_NetConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_NetConsideration_14be9cf2-5af1-4ab2-ad73-c08c2d6d79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsPayable_cf34cab7-88e3-4497-9154-1d918d853801" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccountsPayable_cf34cab7-88e3-4497-9154-1d918d853801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiability_dada150c-b194-43de-84a2-7bb0cbb4992b" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccruedLiability_dada150c-b194-43de-84a2-7bb0cbb4992b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_55c8be48-c33f-4df0-8b91-58833388f99b" xlink:href="jan-20231230.xsd#jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax_55c8be48-c33f-4df0-8b91-58833388f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfLeaseLiability_5e33baca-ab46-4e7e-8834-c3b16ffd1924" xlink:href="jan-20231230.xsd#jan_DisposalOfLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfLeaseLiability_5e33baca-ab46-4e7e-8834-c3b16ffd1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfDebt_9f9d36ff-ddb0-4eac-ba8c-1a1fb1694c4f" xlink:href="jan-20231230.xsd#jan_DisposalOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfDebt_9f9d36ff-ddb0-4eac-ba8c-1a1fb1694c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c8c21826-f959-4018-a26c-daa6fb672573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c8c21826-f959-4018-a26c-daa6fb672573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfLiability_af534f44-4018-4e2f-ac28-c756862f52d5" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalDisposalOfLiability_af534f44-4018-4e2f-ac28-c756862f52d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalConsiderations_2a3f1e5d-7928-4d0c-9cdc-6f96533d0ea9" xlink:href="jan-20231230.xsd#jan_TotalConsiderations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalConsiderations_2a3f1e5d-7928-4d0c-9cdc-6f96533d0ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CashDisposal_0b8d8565-65e9-4a59-8c77-9c8f297ee322" xlink:href="jan-20231230.xsd#jan_CashDisposal"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_CashDisposal_0b8d8565-65e9-4a59-8c77-9c8f297ee322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfAccountsReceivable_99c15df1-4014-4141-b79d-17dda8a6ceee" xlink:href="jan-20231230.xsd#jan_DisposalOfAccountsReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfAccountsReceivable_99c15df1-4014-4141-b79d-17dda8a6ceee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfInventory_dd2b4478-5760-466a-8f91-61ab50fe8ef0" xlink:href="jan-20231230.xsd#jan_DisposalOfInventory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfInventory_dd2b4478-5760-466a-8f91-61ab50fe8ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfPropertyPlantAndEquipment_dea50143-8656-4d86-b802-fbaf8f9c9597" xlink:href="jan-20231230.xsd#jan_DisposalOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfPropertyPlantAndEquipment_dea50143-8656-4d86-b802-fbaf8f9c9597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfIntangibleAssets_e12ca90a-8008-4aac-a6fe-e76481f05953" xlink:href="jan-20231230.xsd#jan_DisposalOfIntangibleAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfIntangibleAssets_e12ca90a-8008-4aac-a6fe-e76481f05953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfRightOfUseAssets_4e0e54eb-6709-453d-bff3-85b93bf395cf" xlink:href="jan-20231230.xsd#jan_DisposalOfRightOfUseAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfRightOfUseAssets_4e0e54eb-6709-453d-bff3-85b93bf395cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalOfOtherAssets_0df497fc-5b16-4515-8a3a-427d402834ae" xlink:href="jan-20231230.xsd#jan_DisposalOfOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_DisposalOfOtherAssets_0df497fc-5b16-4515-8a3a-427d402834ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalDisposalOfAssets_dbf4dd69-f3fd-4c9c-9b29-20711dee79e6" xlink:href="jan-20231230.xsd#jan_TotalDisposalOfAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalDisposalOfAssets_dbf4dd69-f3fd-4c9c-9b29-20711dee79e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TotalGainOnSale_5917ac3d-448f-4033-b656-61826f4da46c" xlink:href="jan-20231230.xsd#jan_TotalGainOnSale"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d23e2d56-9e6f-48d4-866b-ae45ee37d6dd" xlink:to="loc_jan_TotalGainOnSale_5917ac3d-448f-4033-b656-61826f4da46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#GeoTraqAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3e6a27e8-64d6-4c1e-8173-be6a7de18316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3e6a27e8-64d6-4c1e-8173-be6a7de18316" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b0593fdc-9191-4e8b-9173-f5709fd4d1af" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_b5f26f02-142b-48bb-84d4-88dbca234b83" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_801604f3-9eb9-4db6-a9b1-aec7d8be348d" xlink:to="loc_jan_SpyrTechnologiesIncMember_b5f26f02-142b-48bb-84d4-88dbca234b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_675c0cda-4ea0-4d15-a375-704b6cbca9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AssetPurchaseAgreementMember_c8b46a72-d0c7-458a-80dc-97e8c3dab7b1" xlink:href="jan-20231230.xsd#jan_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c1845a7-9069-41c0-b5b7-f937fdc7c355" xlink:to="loc_jan_AssetPurchaseAgreementMember_c8b46a72-d0c7-458a-80dc-97e8c3dab7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cd1988be-e6ec-4647-88d0-4e0e0dcc24ac" xlink:to="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d72431e0-d28e-4f40-82b5-dfe89f3dd6ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:to="loc_srt_MaximumMember_d72431e0-d28e-4f40-82b5-dfe89f3dd6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b192e9d6-623e-4eb2-a8d8-86ec5f323008" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb9c5fc4-8a71-4756-8ee7-7d941255d8e4" xlink:to="loc_srt_MinimumMember_b192e9d6-623e-4eb2-a8d8-86ec5f323008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_691deb22-8eb0-42f3-a07d-07965925ece3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedPrepaymentAmount_be3dcc16-89b1-462b-8122-04991d014d37" xlink:href="jan-20231230.xsd#jan_AgreedPrepaymentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_AgreedPrepaymentAmount_be3dcc16-89b1-462b-8122-04991d014d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ce9e5054-0ec9-465e-af5e-62f51384a172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockSharesIssued_ce9e5054-0ec9-465e-af5e-62f51384a172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_792f38d1-95f4-4e23-9d1d-d941986b5b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_792f38d1-95f4-4e23-9d1d-d941986b5b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_06124d71-c83f-493c-80a7-5bed14b106fb" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NotesReceivableTerm_06124d71-c83f-493c-80a7-5bed14b106fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableFaceAmount_f74362fa-06f5-406e-b127-7067108f88b1" xlink:href="jan-20231230.xsd#jan_NoteReceivableFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableFaceAmount_f74362fa-06f5-406e-b127-7067108f88b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableStatedInterestRate_d70154ca-7b54-4d05-be34-d315e0206893" xlink:href="jan-20231230.xsd#jan_NoteReceivableStatedInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableStatedInterestRate_d70154ca-7b54-4d05-be34-d315e0206893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableMaturityDate_bc1e41db-d05c-4c50-9a37-d47d44e5ba1e" xlink:href="jan-20231230.xsd#jan_NoteReceivableMaturityDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableMaturityDate_bc1e41db-d05c-4c50-9a37-d47d44e5ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0a433ab4-2e69-49f1-b84f-4ac102f03c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_CommonStockValue_0a433ab4-2e69-49f1-b84f-4ac102f03c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_3a1ba033-3bfe-4193-b64f-5aa5bfb9b467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_3a1ba033-3bfe-4193-b64f-5aa5bfb9b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_9622f22d-23b1-41e2-bfad-ee61c88df569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_9622f22d-23b1-41e2-bfad-ee61c88df569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_ecfa6099-de2e-42f6-98ac-c33cf02520be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding_ecfa6099-de2e-42f6-98ac-c33cf02520be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableDiscountRate_c243d09e-a445-44e8-880b-375bdc67178c" xlink:href="jan-20231230.xsd#jan_NoteReceivableDiscountRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableDiscountRate_c243d09e-a445-44e8-880b-375bdc67178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableRevisedDiscountRate_e1e2008a-b3de-4aed-9fc4-3d23d4f76a97" xlink:href="jan-20231230.xsd#jan_NoteReceivableRevisedDiscountRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_NoteReceivableRevisedDiscountRate_e1e2008a-b3de-4aed-9fc4-3d23d4f76a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_6b4a53ba-17bc-47f5-9577-1f36ce460a0c" xlink:href="jan-20231230.xsd#jan_ChargeAgainstIncomeForIncreaseInDiscountRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_83b6889e-6d87-41f2-8e3c-2c8c42987dd1" xlink:to="loc_jan_ChargeAgainstIncomeForIncreaseInDiscountRate_6b4a53ba-17bc-47f5-9577-1f36ce460a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#GeoTraqScheduleofGainonSaleofGeoTraqDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice_417ed7f4-9e67-48f3-a34c-4336c9afc13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice_417ed7f4-9e67-48f3-a34c-4336c9afc13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_b4313259-db22-459e-9f16-bfec4f52ae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_b4313259-db22-459e-9f16-bfec4f52ae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalancePremiumReceived_f2f6ea0d-cb69-424b-afd0-a35f9ac964f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalancePremiumReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:to="loc_us-gaap_PolicyholderAccountBalancePremiumReceived_f2f6ea0d-cb69-424b-afd0-a35f9ac964f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax_90176754-b407-46d7-b3bd-7d4e1921d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:to="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax_90176754-b407-46d7-b3bd-7d4e1921d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProject_43cbf175-dc0e-43dd-90e2-ace9d4f52539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfProject"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6df114af-ac0d-4542-8cac-e11638f8baf9" xlink:to="loc_us-gaap_GainLossOnSaleOfProject_43cbf175-dc0e-43dd-90e2-ace9d4f52539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ee7ea50-63fa-443b-82f0-a3df04f1b32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ee7ea50-63fa-443b-82f0-a3df04f1b32b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3c26debd-675a-42dc-a02b-d06050bf2485" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_909deba5-d862-458f-bdaa-2d8c40ad336f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_521c417e-7d1e-4f90-a7a3-d58ab7bf6c03" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_909deba5-d862-458f-bdaa-2d8c40ad336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_745f0aa6-e503-41bc-9880-52c4e194f3d8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_0290b2dd-4744-4e5f-a3e7-19b43f0f9066" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17aa3cb-c4ac-485a-be49-616cd2c3767a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_0290b2dd-4744-4e5f-a3e7-19b43f0f9066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52027d84-df25-426f-aa62-71b9f73d544f" xlink:to="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_c5783c68-cd57-451e-bcba-befe78c82a2c" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fb342195-bebd-430e-a7db-b84c292a109c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_c5783c68-cd57-451e-bcba-befe78c82a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_182a8f68-9054-49fb-ad78-bdbd7308ed1c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_31dc6b2b-8e69-4e88-963d-f4d9781e177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_31dc6b2b-8e69-4e88-963d-f4d9781e177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2ad28098-1537-46c2-916b-c39e1560c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2ad28098-1537-46c2-916b-c39e1560c2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_59f37d15-b159-4a79-8209-e0b8915fac78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_59f37d15-b159-4a79-8209-e0b8915fac78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b9c7549e-a3a8-4ec4-b010-7fe1e76324e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b9c7549e-a3a8-4ec4-b010-7fe1e76324e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_401efb99-6da5-4eb9-aefa-4ee5d433cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_401efb99-6da5-4eb9-aefa-4ee5d433cfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_bbd01a2a-71f9-4e60-bf7e-754020f25b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_bbd01a2a-71f9-4e60-bf7e-754020f25b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_6ad5002b-7192-4938-ada8-99d9f04f05d4" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset_6ad5002b-7192-4938-ada8-99d9f04f05d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_c8cd50dd-545b-4b79-815d-14cf3d77f247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_c8cd50dd-545b-4b79-815d-14cf3d77f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_cc7e6c91-7d48-4b20-992f-9f2dafb37111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_cc7e6c91-7d48-4b20-992f-9f2dafb37111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9d9af62f-b3cf-40c3-9de3-580f55ea5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9d9af62f-b3cf-40c3-9de3-580f55ea5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c51b1bc1-c439-4170-b688-d129a9a77a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_17ef29f6-f6ea-41b6-bc8b-52c850da9b1c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c51b1bc1-c439-4170-b688-d129a9a77a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fa4cdc-5717-460e-899f-ec8c0e949873" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_dbd5edea-7e0b-48b5-a049-c22e18bc7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_dbd5edea-7e0b-48b5-a049-c22e18bc7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a91161b3-39cc-4ec7-b014-55a5edbcce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a91161b3-39cc-4ec7-b014-55a5edbcce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_8a05a85d-577b-4edc-ab82-7aa736bb8f2b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_8a05a85d-577b-4edc-ab82-7aa736bb8f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_fd9d4a2e-2d63-4c82-a69a-5da4d142c160" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases_fd9d4a2e-2d63-4c82-a69a-5da4d142c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_413a48cf-1d35-42e1-a5c8-906a1f6a712c" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_413a48cf-1d35-42e1-a5c8-906a1f6a712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_b79b7a15-0247-42ff-9ad6-01d85d78d850" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_b79b7a15-0247-42ff-9ad6-01d85d78d850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_1336f4be-7009-42cf-932b-ea8eb0daa35b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote_1336f4be-7009-42cf-932b-ea8eb0daa35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1956cd0c-313e-4ce4-b026-6bc41ce8c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1956cd0c-313e-4ce4-b026-6bc41ce8c1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_e1e74880-fd60-4f0b-af74-e81011948170" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases_e1e74880-fd60-4f0b-af74-e81011948170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_8573cad1-6644-440a-a05f-f9ebabcbef8b" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_8573cad1-6644-440a-a05f-f9ebabcbef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_c4c2f0ca-6120-4bcd-a1e1-cd3f292ac44a" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable_c4c2f0ca-6120-4bcd-a1e1-cd3f292ac44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_53f4886c-c16e-4ce2-81ae-221e1404aaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_53f4886c-c16e-4ce2-81ae-221e1404aaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4ad6b75c-da70-4f58-9f0e-c6fb48e883e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e61072b6-9e1a-4d68-ba27-77e4621467ff" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4ad6b75c-da70-4f58-9f0e-c6fb48e883e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6e663ff-c4f3-4dc6-9907-b472b2e38bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6e663ff-c4f3-4dc6-9907-b472b2e38bae" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b777cdcc-137a-494f-9330-605848dde92e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BuildingsAndImprovementsMember_4f062251-088c-4dec-96df-910c510c833c" xlink:href="jan-20231230.xsd#jan_BuildingsAndImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_jan_BuildingsAndImprovementsMember_4f062251-088c-4dec-96df-910c510c833c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f91cf0da-1aba-43fc-8c6d-5cf7d8341c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_us-gaap_EquipmentMember_f91cf0da-1aba-43fc-8c6d-5cf7d8341c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionMember_2ce299f8-73e5-4a8c-81d7-125f8bf7c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d046b4b6-9487-4f4e-84ba-8f7872652341" xlink:to="loc_us-gaap_ConstructionMember_2ce299f8-73e5-4a8c-81d7-125f8bf7c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b092dcc-1540-4416-8ff9-a20ca31e9f64" xlink:to="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf06831-eaf4-4ab1-9030-93f0682df286" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:to="loc_srt_MinimumMember_7cf06831-eaf4-4ab1-9030-93f0682df286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_75019a7d-ca3e-4556-a29a-aa3beaf318ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5496b302-2552-46a8-913d-23ecc17b441e" xlink:to="loc_srt_MaximumMember_75019a7d-ca3e-4556-a29a-aa3beaf318ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26f74738-fe5c-41d1-9d2a-2573c6aab0b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_0dac9dc7-e271-4894-bddc-dfe70b2a08df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_518cf7da-dbcc-4c86-8115-6bbb3ed14721" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_0dac9dc7-e271-4894-bddc-dfe70b2a08df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23ab6ab0-0c52-43bd-bc01-6c2bddfa9cec" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_29152816-8b7f-412a-9899-7a6516c26149" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4c521fc7-aa3b-4385-87ab-8658438b094a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_29152816-8b7f-412a-9899-7a6516c26149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d770d7a8-e3c5-404e-ac4e-1d68bc5c3aa2" xlink:to="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_7f0b20a5-b32b-40a8-ba18-c5adbd18eb2e" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5ad07a3-3e35-4bfc-8a82-dd32ccbd14b5" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_7f0b20a5-b32b-40a8-ba18-c5adbd18eb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b97ac98b-14d3-4c4c-8f88-5732cd836951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_41c73d71-23cc-4e3e-97ea-cf890ba78e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_41c73d71-23cc-4e3e-97ea-cf890ba78e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_8d5c8530-59be-4f7a-b184-04ba02f48d7a" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross_8d5c8530-59be-4f7a-b184-04ba02f48d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aad23461-837f-4da5-80f9-52d5a6a14988" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aad23461-837f-4da5-80f9-52d5a6a14988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3c2d40a3-d898-48d2-bf65-f25425111063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380f797c-fb93-4e7e-b067-58ad8f1cc417" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3c2d40a3-d898-48d2-bf65-f25425111063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fe4e0f3b-dcd4-4ef3-9ae7-a636abc139d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fe4e0f3b-dcd4-4ef3-9ae7-a636abc139d5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e2753105-be7a-46ce-b5d5-57cd204fe33e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_045ba90c-c005-44a2-8994-ed9c7fa180af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eafd69bc-0870-482a-a193-fe3e7f8009ad" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_045ba90c-c005-44a2-8994-ed9c7fa180af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f5e0dc-7fe1-4309-8cf6-31265b902207" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_f1be87d4-e267-42aa-b786-884ed592afa1" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1074cef7-17d3-4f74-a956-0a361118a382" xlink:to="loc_jan_ARCAAndSubsidiariesMember_f1be87d4-e267-42aa-b786-884ed592afa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ce1a66a-a5af-4443-9e40-1dfd017b4723" xlink:to="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e5b7d562-486d-44b8-96a0-00bf40189ee4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2ef3e8b7-68c1-4286-9b41-c789fd3bbfa7" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e5b7d562-486d-44b8-96a0-00bf40189ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f4e1fea5-8dae-4910-be38-673a43fae4a6" xlink:to="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6f1de413-e4df-4709-9be4-e30a4e513fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4887a0dd-1992-4abe-ad49-00a6d2f2abd0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6f1de413-e4df-4709-9be4-e30a4e513fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_69513df5-5f45-4059-8ef0-a7e713430caf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_b79b98c5-164c-459c-881c-fe01221f63ca" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_993b49e7-1983-4841-8168-d2a97e5c7452" xlink:to="loc_jan_IcgNoteMember_b79b98c5-164c-459c-881c-fe01221f63ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5c63f6-ae2c-4b27-a1a8-bebe309399b2" xlink:to="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_224343fd-03f7-4f9c-8d67-a5c3556e5170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d8f8b2e2-d1fb-4a1e-a655-b3d21797c2e6" xlink:to="loc_us-gaap_BeneficialOwnerMember_224343fd-03f7-4f9c-8d67-a5c3556e5170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ab227d6-a69d-42dd-af23-151e76ce61f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_15943178-20b6-4330-a6ba-3f25c6c7aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66a8d09c-fa6a-4a64-935f-be5f30bda5fb" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_15943178-20b6-4330-a6ba-3f25c6c7aaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_463eed45-8902-4cc1-8118-512f5099dfcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_JanOneMember_386ffd42-bda3-46fb-9787-f6c304bf7093" xlink:href="jan-20231230.xsd#jan_JanOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7cc179a6-b23f-4eca-8a35-470d014bdeaa" xlink:to="loc_jan_JanOneMember_386ffd42-bda3-46fb-9787-f6c304bf7093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3aebb313-5cb6-4136-be58-1c033679f315" xlink:to="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacCapitalGroupLLCICGMember_89f12434-baf5-491c-b035-d3ba3e60faa3" xlink:href="jan-20231230.xsd#jan_IsaacCapitalGroupLLCICGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_eeeebeff-66d5-4024-a125-4645ed16ba0f" xlink:to="loc_jan_IsaacCapitalGroupLLCICGMember_89f12434-baf5-491c-b035-d3ba3e60faa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c7759757-5c0a-41b6-974f-a0ff34959be0" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a492cbba-ad32-42d4-9802-cec37ffdfc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_Depreciation_a492cbba-ad32-42d4-9802-cec37ffdfc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6d13b00f-71dd-4ebb-8249-c2944f4bbcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_AdjustmentForAmortization_6d13b00f-71dd-4ebb-8249-c2944f4bbcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ff685e16-8d94-4605-b591-ffb6ecbbe86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ff685e16-8d94-4605-b591-ffb6ecbbe86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_d4b29a44-1809-40da-a4be-1c81ea636a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_d4b29a44-1809-40da-a4be-1c81ea636a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest_d6de6dac-1302-456e-b656-a23a4392f913" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_jan_SalesTaxAssessmentAccruedInterest_d6de6dac-1302-456e-b656-a23a4392f913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c13a521-5d6f-4fc5-a4c9-45b2b078b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c13a521-5d6f-4fc5-a4c9-45b2b078b8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_c64dcccf-6feb-46a7-9ef6-56a0c9df7967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_c64dcccf-6feb-46a7-9ef6-56a0c9df7967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dadb5674-6139-4370-99f7-3e5b370bd41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dadb5674-6139-4370-99f7-3e5b370bd41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_466673f5-118b-4536-b49b-24072cb0b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_LineOfCredit_466673f5-118b-4536-b49b-24072cb0b8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b6a6fb10-0a59-47ef-a703-72dd14247aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b6a6fb10-0a59-47ef-a703-72dd14247aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_79b8ee48-5365-407c-aa1d-772e24dcf559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_79b8ee48-5365-407c-aa1d-772e24dcf559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_20b6ee35-e725-40f3-a3f4-37406254590a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_20b6ee35-e725-40f3-a3f4-37406254590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_935893ca-b12e-42cc-850f-286fb464913a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2f5fce98-a6d4-482a-b78e-4e5bace16e51" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_935893ca-b12e-42cc-850f-286fb464913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_88e07715-b513-4969-a190-fe017e50a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_88e07715-b513-4969-a190-fe017e50a13b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb64cd02-44d3-40ab-bf0f-2a9fc473ac98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_e772a61c-f647-4d19-a3f8-42ea010cd8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:to="loc_us-gaap_PatentsMember_e772a61c-f647-4d19-a3f8-42ea010cd8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e921f891-8694-4a16-a5c0-b464cc560c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5c370c-3a0b-4a05-81ab-65184b95a117" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e921f891-8694-4a16-a5c0-b464cc560c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a92e2f44-3749-483d-825f-cdc3f616796e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_302223da-9588-4bf1-967d-850e2d066001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5e6212be-d65f-4b29-9f93-cd07b41eaf4b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_302223da-9588-4bf1-967d-850e2d066001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab0deebe-b1e7-49b5-9b84-864af4fe5b2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_d1edefc4-4f71-4af8-a896-2cfb3b0785f9" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7f4f01-9482-4a96-821c-2b2c3349fe2b" xlink:to="loc_jan_ARCAAndSubsidiariesMember_d1edefc4-4f71-4af8-a896-2cfb3b0785f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ddd2db79-96e0-4540-b2d4-8d69b3cbd7ff" xlink:to="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_37b911bd-6375-4dd6-a9b8-fa8a4762be73" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_045d9a3d-19d0-4d86-9f27-7841c17857ad" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_37b911bd-6375-4dd6-a9b8-fa8a4762be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_887ebbdb-9129-4cc4-a7ce-ba9513447d73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d64ea4e4-715a-484c-b13b-52477b82c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d64ea4e4-715a-484c-b13b-52477b82c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a737024d-243d-4688-b4aa-a060eef484b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a737024d-243d-4688-b4aa-a060eef484b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_805477c7-0ad6-49b4-9f2c-35cb8027ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13dcee5d-e648-48bd-ae46-9667818eeb1d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_805477c7-0ad6-49b4-9f2c-35cb8027ddbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_108a119e-12db-4ebd-94c1-c837902d4bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_108a119e-12db-4ebd-94c1-c837902d4bdc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d2a85900-8ac8-4cfc-96cc-fbcd6c166b98" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2805f911-eaa2-4cbf-8a7b-720b9d8731c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5a1b657e-00d7-4d91-827d-345ac38d9e17" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_2805f911-eaa2-4cbf-8a7b-720b9d8731c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_208bf3f0-2f59-48bc-ba22-0b4ad76cdb4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_90871680-3279-4536-b028-b2adff4fe965" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b7438a15-c635-414a-816f-5f8cb3faa36d" xlink:to="loc_jan_ARCAAndSubsidiariesMember_90871680-3279-4536-b028-b2adff4fe965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b55140c2-45ea-43e5-9e25-4e370f0de0e1" xlink:to="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_2b203b55-f079-4892-9c82-50df829e99bf" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_32b41297-a709-4600-87b6-b9c297c3c1a9" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_2b203b55-f079-4892-9c82-50df829e99bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_babcdb71-0ed5-4972-89da-b638d56d2189" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_705501dc-f8c8-4790-8800-54ccf0c953e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_705501dc-f8c8-4790-8800-54ccf0c953e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_584a3d30-3e06-4f93-93ca-13e48ef5d238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_584a3d30-3e06-4f93-93ca-13e48ef5d238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedIncentiveAndRebateChecksCurrent_e2abf238-4191-4473-9034-8a455dc7d0e9" xlink:href="jan-20231230.xsd#jan_AccruedIncentiveAndRebateChecksCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_jan_AccruedIncentiveAndRebateChecksCurrent_e2abf238-4191-4473-9034-8a455dc7d0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_37b9c565-c617-45f0-b1b9-46352602af97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_37b9c565-c617-45f0-b1b9-46352602af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e83842ba-938d-4d68-bc5e-7afc7e774efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e83842ba-938d-4d68-bc5e-7afc7e774efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4698b09d-922a-4041-a148-042b91399c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b718038c-984e-4b48-88a9-1a5e2084f739" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4698b09d-922a-4041-a148-042b91399c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6a770aa-4270-408d-b88c-b1a11d872265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6a770aa-4270-408d-b88c-b1a11d872265" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3eab1d52-e593-4f34-b9c4-4ae7c867a4f7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_4087f918-1f0e-45ff-bc88-a2855f687a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57cf08ad-6b1d-4010-a3f9-91fb47e0a047" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_4087f918-1f0e-45ff-bc88-a2855f687a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_00dd2f23-b164-4d26-9e70-5bda2339106e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_b00d2309-0c2b-4040-98b2-f842888c8290" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe790d6-e814-4b98-b5b9-a15716ce4cea" xlink:to="loc_jan_ARCAAndSubsidiariesMember_b00d2309-0c2b-4040-98b2-f842888c8290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a050090-829d-49da-bbc4-85b0d211ab36" xlink:to="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_32097207-8124-46f7-9904-35c17f89ff1e" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_13fef0c4-efde-417e-a5d4-86c1b3fb8b8c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_32097207-8124-46f7-9904-35c17f89ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1fcad772-80e5-43e1-99d5-db686021fb77" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8b6911db-716d-4b83-9b4c-119a49414ba8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6edc5190-3e5c-4afe-b44e-4df767402d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6edc5190-3e5c-4afe-b44e-4df767402d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SalesTaxAssessmentAccruedInterest_61f55b24-4730-4851-b819-9d2df51fb1a8" xlink:href="jan-20231230.xsd#jan_SalesTaxAssessmentAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_jan_SalesTaxAssessmentAccruedInterest_61f55b24-4730-4851-b819-9d2df51fb1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_9770dacb-0846-4208-a5ac-c7eab3497713" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_072d45fa-fd97-47db-bbe6-9eac7f7d39f2" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes_9770dacb-0846-4208-a5ac-c7eab3497713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofShorttermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d6a739e5-f679-4e2f-8639-d0c79efc0129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d6a739e5-f679-4e2f-8639-d0c79efc0129" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_409bfee4-e7b0-4de4-a0ac-24e7d91c3d67" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GulfCoastBankAndTrustCompanyMember_ebabfc67-c5f3-40eb-9dce-cd496f4f3a73" xlink:href="jan-20231230.xsd#jan_GulfCoastBankAndTrustCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_f8791659-776f-4ce3-b4e1-2542e9a047af" xlink:to="loc_jan_GulfCoastBankAndTrustCompanyMember_ebabfc67-c5f3-40eb-9dce-cd496f4f3a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f8ce3325-a859-4fb3-8e84-85aa5644e09f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c10aa810-4755-4a4e-b669-7d5dae27fd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_89541e51-ee37-4528-8c72-57dbb78779ef" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c10aa810-4755-4a4e-b669-7d5dae27fd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_38f29a94-d4f1-4d01-9c58-23fee0ba6969" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_b6a68c96-46e8-46c3-8b61-19ed3cfcdff8" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cf4ee087-36b0-486e-be24-58286de1c48b" xlink:to="loc_jan_ARCAAndSubsidiariesMember_b6a68c96-46e8-46c3-8b61-19ed3cfcdff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d84c30d-edd7-4503-84d2-35bbdf3f6695" xlink:to="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_64a49d17-bfd6-4bf7-9c11-28577860881d" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dd941bb0-babf-4c0b-9136-5839fa8a4397" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_64a49d17-bfd6-4bf7-9c11-28577860881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_d103ecb5-202c-4159-8259-1b4efdda6e5e" xlink:to="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_70bc2b47-f638-4d14-a29f-89e9eeea954c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_70bc2b47-f638-4d14-a29f-89e9eeea954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_5d498040-a03c-490f-bc86-f800cbfa5236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_5d498040-a03c-490f-bc86-f800cbfa5236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_54818161-73a7-4bb5-9892-56e890bf9258" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2668ef18-149e-412a-93a7-b8a57624e78f" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt_54818161-73a7-4bb5-9892-56e890bf9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2df44a46-170b-4e68-8cc0-2eee64e00b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2df44a46-170b-4e68-8cc0-2eee64e00b2b" xlink:to="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc930ea9-4488-4059-8ccd-594ebf3d064c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_KlcFinancialMember_cf3cd46a-2e3e-4c60-a679-0893eb723438" xlink:href="jan-20231230.xsd#jan_KlcFinancialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1c4ec-bc05-47ae-9db9-1511eb1b4be9" xlink:to="loc_jan_KlcFinancialMember_cf3cd46a-2e3e-4c60-a679-0893eb723438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3ea7fc19-dfa9-446d-8f44-35d452ad94f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_28897a38-7626-444d-b1b9-8a58823ab43d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fb089eb4-d3d1-4fed-aec3-0725e7592681" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_28897a38-7626-444d-b1b9-8a58823ab43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ddbe768f-1ebf-4084-a8a1-07be829aa075" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_ab59984c-73d1-4c2e-960c-567eb0664862" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_110a8587-a041-45cd-b11b-1459007f8c1f" xlink:to="loc_jan_ARCAAndSubsidiariesMember_ab59984c-73d1-4c2e-960c-567eb0664862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d908ef32-e5f0-45db-9c6c-4161ff27cb97" xlink:to="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_5bc94188-e0d0-4233-ac4a-b9f91b220a48" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a4b8b55-0090-4533-a531-a79119413d25" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_5bc94188-e0d0-4233-ac4a-b9f91b220a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11a689ad-d288-42a2-b244-2ab10efd5938" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8fe6be6c-81aa-472e-862c-fcc1938f9442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8fe6be6c-81aa-472e-862c-fcc1938f9442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_776bdb89-1a2a-44d0-8653-f23d012e9342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_776bdb89-1a2a-44d0-8653-f23d012e9342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_45b63674-23a5-40ce-842f-a252115f776e" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_45b63674-23a5-40ce-842f-a252115f776e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_264745a5-3ea2-4c73-8e31-352ea080a257" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_264745a5-3ea2-4c73-8e31-352ea080a257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_d83be9e8-3690-4903-b82b-85a3f1e46d30" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c490158-b06d-4b1f-ba3a-c51c90722f8a" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_d83be9e8-3690-4903-b82b-85a3f1e46d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofRelatedPartyDebtDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dfc2949c-f753-4f24-ac7f-8407d8d4eca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dfc2949c-f753-4f24-ac7f-8407d8d4eca1" xlink:to="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ef5909f-1a0a-42e7-a26c-2405555af507" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_dd104b57-3a27-4d74-a177-5539cb4ea3b3" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c78c05c-eb5b-4cba-9b7e-aa1c445d9795" xlink:to="loc_jan_IcgNoteMember_dd104b57-3a27-4d74-a177-5539cb4ea3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2091513a-4ef2-40ef-8abe-63aa64b01cde" xlink:to="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_fecf029c-403a-4b55-a696-9410042921c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_46d9f1dc-e9a0-45b2-9c1b-c9695e8175f0" xlink:to="loc_us-gaap_RelatedPartyMember_fecf029c-403a-4b55-a696-9410042921c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6970b443-9184-4458-9b2f-6e45244c1538" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_a7fb4130-f7e7-4767-853f-48eb51bd086f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8df08d20-5ed4-4433-a0d2-b06e97e56794" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_a7fb4130-f7e7-4767-853f-48eb51bd086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6184b1c7-5c13-4fc6-984f-f9b231df417f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_90aebf25-b26e-4ac0-9bc5-c7b846c7cce4" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09174a71-e230-4392-8db5-b4cdcc4a377c" xlink:to="loc_jan_ARCAAndSubsidiariesMember_90aebf25-b26e-4ac0-9bc5-c7b846c7cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_af8bd43b-9066-4db5-bfb1-01d00cbbeb7c" xlink:to="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_864f125d-ce45-46dd-a385-1170964f52b4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5d119370-7384-4d90-b608-e0301f43d924" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_864f125d-ce45-46dd-a385-1170964f52b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39826d27-6eb0-455c-9b08-7642caeb141c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_f966b730-c8c0-4331-8fa0-5deeb74d6f18" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable_f966b730-c8c0-4331-8fa0-5deeb74d6f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_9f0867b0-6a1b-4647-a745-10c411b836b6" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent_9f0867b0-6a1b-4647-a745-10c411b836b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_10498a36-10c1-4eb6-a6dc-d3a342815955" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bee7b67f-6dc2-41cc-af31-988d46bd3033" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent_10498a36-10c1-4eb6-a6dc-d3a342815955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a27b06e0-231f-4fe7-bbf8-9be8501516cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a27b06e0-231f-4fe7-bbf8-9be8501516cd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6640fa3-76a7-4229-b6aa-d19cd675b552" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c6201426-267e-404e-a578-113ba79de6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b8db9178-e012-4acc-b071-5aea83999312" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c6201426-267e-404e-a578-113ba79de6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_183f0716-87d3-4a98-b26c-9f41a7419c82" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_13ef4e0d-954c-44c7-aa31-e1b404398154" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_ARCAAndSubsidiariesMember_13ef4e0d-954c-44c7-aa31-e1b404398154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArcaMember_73615710-d94d-48f9-bd1c-c42e0dc606cb" xlink:href="jan-20231230.xsd#jan_ArcaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_ArcaMember_73615710-d94d-48f9-bd1c-c42e0dc606cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_9a890dde-4603-4970-afdf-1e16de666ccd" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b3c4d626-8ab3-4121-a8c0-4a73945bdd2a" xlink:to="loc_jan_GeoTraqIncMember_9a890dde-4603-4970-afdf-1e16de666ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1d2ad46c-8aa1-4250-9055-7e2e44a79445" xlink:to="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_98ddce47-1c4f-40b5-af40-a8e8f3d9f3f4" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6440e3a4-a089-4f9e-82c3-f52cd1f3e53d" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_98ddce47-1c4f-40b5-af40-a8e8f3d9f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4bc81ec-83bc-4ea1-9a48-b6162babe7e6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_266cf3e9-95bb-46c1-af20-4edaa3396ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_266cf3e9-95bb-46c1-af20-4edaa3396ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c6570578-8da6-4821-97ce-6e96c382911e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c6570578-8da6-4821-97ce-6e96c382911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_559cd9d9-0e7b-4dcc-af7a-445abfed629b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_559cd9d9-0e7b-4dcc-af7a-445abfed629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:href="jan-20231230.xsd#jan_OperatingExpensesFromDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c6887dd1-c4be-4df5-9ddc-2d2e92e4c12b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c6887dd1-c4be-4df5-9ddc-2d2e92e4c12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_bfe97453-f534-48bb-8593-2d945b340bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_bfe97453-f534-48bb-8593-2d945b340bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_1f41c707-60a1-44ca-bcaa-30f0f48efa18" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations_1f41c707-60a1-44ca-bcaa-30f0f48efa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_19997c05-0915-489a-9b13-d1d52cb502e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OperatingExpensesFromDiscontinuedOperationsAbstract_af57dbf4-19e1-4e80-9442-2c374b7b972f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_19997c05-0915-489a-9b13-d1d52cb502e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:href="jan-20231230.xsd#jan_OtherIncomeExpenseFromDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9696e0b4-3ca3-4855-a771-db19584921e8" xlink:to="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_ad3be0b0-c52c-4695-95fe-361d184caf45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_ad3be0b0-c52c-4695-95fe-361d184caf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_2065c5c8-e706-4223-b096-1c52171774bb" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense_2065c5c8-e706-4223-b096-1c52171774bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_3d1e5564-4359-4a9b-b0b8-133ec555d3ac" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_3d1e5564-4359-4a9b-b0b8-133ec555d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_fc829d7d-a019-4c6e-b09f-fb6f47242e30" xlink:href="jan-20231230.xsd#jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet_fc829d7d-a019-4c6e-b09f-fb6f47242e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5fb4ad70-db2e-4094-b056-83d0666a7317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5fb4ad70-db2e-4094-b056-83d0666a7317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9c00ac63-0cbc-4ae3-bab2-dbf4efb8f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9c00ac63-0cbc-4ae3-bab2-dbf4efb8f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_679c3cee-2449-4bb5-b3f2-415dd8ada4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_OtherIncomeExpenseFromDiscontinuedOperations_195be8ac-db14-4307-aecb-7fdfba45d6af" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_679c3cee-2449-4bb5-b3f2-415dd8ada4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f5098f84-96ad-465a-84c7-f789fecbedfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f5098f84-96ad-465a-84c7-f789fecbedfd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_19cb755e-b678-4aea-bac1-39f3e8d86e5f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_09aa3cfe-7530-476d-b572-bef2a6acc469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff2fcc03-ad8e-4d06-ae72-29c28e52325a" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_09aa3cfe-7530-476d-b572-bef2a6acc469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee66d36b-a879-489c-8917-c61f72546df5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_47f5e3cb-f6e9-488e-a4a9-bbdada4858e1" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63b187c9-3b2b-41cd-bc2b-b29ead097641" xlink:to="loc_jan_ARCAAndSubsidiariesMember_47f5e3cb-f6e9-488e-a4a9-bbdada4858e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f775c04b-bd10-4d80-b988-dbaf511b0b4f" xlink:to="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_51f3beab-13dc-43f0-a8af-53e7df7fe671" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_998711e5-54f0-4741-b2a0-0e0ea44a6103" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_51f3beab-13dc-43f0-a8af-53e7df7fe671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a587ef15-8bb6-43e9-9c8a-4de49600f46d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:href="jan-20231230.xsd#jan_DiscontinuedOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_601038fe-7342-4db8-a617-d3da25cbca22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_601038fe-7342-4db8-a617-d3da25cbca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4e536d82-9784-4206-9960-26aba72e7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4e536d82-9784-4206-9960-26aba72e7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32a29914-2000-4bb7-90d3-6b228a19add9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32a29914-2000-4bb7-90d3-6b228a19add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnLitigationSettlement_6cd35a63-fefe-4285-bfa4-1e609aaa2bc8" xlink:href="jan-20231230.xsd#jan_GainLossOnLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_GainLossOnLitigationSettlement_6cd35a63-fefe-4285-bfa4-1e609aaa2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AmortizationOfRightOfUseAssets_d3072e72-0639-413c-850e-36addeba9b34" xlink:href="jan-20231230.xsd#jan_AmortizationOfRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_AmortizationOfRightOfUseAssets_d3072e72-0639-413c-850e-36addeba9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainOnSaleNetOfCash_2a95ea12-1e32-4601-9d6e-8ce503f26cd5" xlink:href="jan-20231230.xsd#jan_GainOnSaleNetOfCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_jan_GainOnSaleNetOfCash_2a95ea12-1e32-4601-9d6e-8ce503f26cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a986309b-c542-4b88-b670-2f19c8f37cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a986309b-c542-4b88-b670-2f19c8f37cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedOperatingActivities_c01b7337-55a3-4d95-b553-4c6b1e7d8ee2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7eafd483-d74e-4168-a3f8-cf6de5a107c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7eafd483-d74e-4168-a3f8-cf6de5a107c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0e188394-0d72-4e2d-9507-48a41ba8b252" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0e188394-0d72-4e2d-9507-48a41ba8b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1511f35c-cd47-4482-84cd-7a036f9452d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1511f35c-cd47-4482-84cd-7a036f9452d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_88ddca4c-6151-41b0-b712-bda164547ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_88ddca4c-6151-41b0-b712-bda164547ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48d0b50b-6ea4-42cb-ac08-5935436df400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48d0b50b-6ea4-42cb-ac08-5935436df400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_df62f33e-d86b-4c2f-90e9-bf14a0050dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3da4deae-7d22-45f0-a203-04d982e35c66" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_df62f33e-d86b-4c2f-90e9-bf14a0050dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:href="jan-20231230.xsd#jan_DiscontinuedInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16ef8e0c-48fd-4a26-8cd5-cb8c94441846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16ef8e0c-48fd-4a26-8cd5-cb8c94441846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6516b0ca-773a-42b8-93d1-c12afd4beea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6516b0ca-773a-42b8-93d1-c12afd4beea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fe48430f-2238-47ba-8e27-54603a2cb2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedInvestingActivities_af9aeef2-4841-4ff1-a294-f530a887de19" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fe48430f-2238-47ba-8e27-54603a2cb2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:href="jan-20231230.xsd#jan_DiscontinuedFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_5b9cc7c3-3f8f-43c8-a5d7-cb7fd5675457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_5b9cc7c3-3f8f-43c8-a5d7-cb7fd5675457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_682ef88a-c46d-4e34-a082-26153426532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_682ef88a-c46d-4e34-a082-26153426532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_004ac492-c285-462b-a64d-19c5238e96f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_004ac492-c285-462b-a64d-19c5238e96f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b00a688d-2001-4773-b115-7993a775cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jan_DiscontinuedFinancingActivities_abeb0593-b8ec-4272-9a53-5afecd0552b1" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b00a688d-2001-4773-b115-7993a775cbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f35a48da-de7d-4355-8ce7-8e1d7484b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f35a48da-de7d-4355-8ce7-8e1d7484b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_452f5a3d-bb91-4287-99bd-377087263fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_452f5a3d-bb91-4287-99bd-377087263fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2a193d03-58e9-4853-93b1-f8a9393ce697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2a193d03-58e9-4853-93b1-f8a9393ce697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8a9f8f1a-eb93-49b8-a125-41a0ffd8cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff9458c0-d871-4b6d-a73b-3ea4bd96ad18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8a9f8f1a-eb93-49b8-a125-41a0ffd8cf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#PrepaidsandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0e8bd99e-0e07-4743-9b32-e26f7c48f560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_0a7152c1-2f0d-4dfc-8297-320b63538763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0e8bd99e-0e07-4743-9b32-e26f7c48f560" xlink:to="loc_us-gaap_PrepaidInsurance_0a7152c1-2f0d-4dfc-8297-320b63538763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_7b6b0502-0fc8-419e-8400-305038a70671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0e8bd99e-0e07-4743-9b32-e26f7c48f560" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_7b6b0502-0fc8-419e-8400-305038a70671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_67feb901-c2e2-4d09-9e1b-769468425662" xlink:href="jan-20231230.xsd#jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0e8bd99e-0e07-4743-9b32-e26f7c48f560" xlink:to="loc_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent_67feb901-c2e2-4d09-9e1b-769468425662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/NotesReceivableDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#NotesReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/NotesReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_da0fef06-11e8-4e9a-a435-141385b1e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_da0fef06-11e8-4e9a-a435-141385b1e2fe" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb44c4a3-ae77-41e1-8c0c-8f667fd125b8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_ab01d163-b483-4aa3-bedb-bb1cd9021d2e" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74ce41bd-8863-4607-9833-c9e74eb3f1a0" xlink:to="loc_jan_GeoTraqIncMember_ab01d163-b483-4aa3-bedb-bb1cd9021d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13f697ba-a592-479f-8f68-967755e8a486" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_f9806ceb-153d-4dc6-8bdf-51c8435b8121" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:to="loc_jan_SpyrTechnologiesIncMember_f9806ceb-153d-4dc6-8bdf-51c8435b8121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_VM7CorporationMember_ae222ceb-f124-4229-953f-5691ef831e15" xlink:href="jan-20231230.xsd#jan_VM7CorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7809dd9d-932c-4c8b-85c3-5b49ccd9ab96" xlink:to="loc_jan_VM7CorporationMember_ae222ceb-f124-4229-953f-5691ef831e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_49a07351-2d51-41d9-a586-ff08452848e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockPurchaseAgreementMember_d5a3d44d-2402-43f5-8567-a24fbc094608" xlink:href="jan-20231230.xsd#jan_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c0420a8-31f9-4711-9322-c147dc2134a0" xlink:to="loc_jan_StockPurchaseAgreementMember_d5a3d44d-2402-43f5-8567-a24fbc094608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b1c17f66-687d-4237-8a10-dcefebc74150" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NotesReceivableTerm_7a3ae7c8-7bca-4cc9-8004-f473b1e96647" xlink:href="jan-20231230.xsd#jan_NotesReceivableTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NotesReceivableTerm_7a3ae7c8-7bca-4cc9-8004-f473b1e96647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableFaceAmount_dd89d7fe-525c-47f8-818c-0ce3ee5ba189" xlink:href="jan-20231230.xsd#jan_NoteReceivableFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NoteReceivableFaceAmount_dd89d7fe-525c-47f8-818c-0ce3ee5ba189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoteReceivableStatedInterestRate_05f93560-a5b8-4aec-be30-c974b3a00744" xlink:href="jan-20231230.xsd#jan_NoteReceivableStatedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_NoteReceivableStatedInterestRate_05f93560-a5b8-4aec-be30-c974b3a00744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_66f67f9e-87b8-4a3e-80de-fe9c6d76a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_66f67f9e-87b8-4a3e-80de-fe9c6d76a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_6e203ff7-7c2b-46a0-8f81-ae93fbdb97db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_InterestReceivable_6e203ff7-7c2b-46a0-8f81-ae93fbdb97db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_01d47155-8fe8-4535-b3ff-42fa3a8804bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_01d47155-8fe8-4535-b3ff-42fa3a8804bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount_f5fed73e-4fe3-4d81-9470-da2274b24fd8" xlink:href="jan-20231230.xsd#jan_DiscountRecordedAsOffsetToThePrincipalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DiscountRecordedAsOffsetToThePrincipalAmount_f5fed73e-4fe3-4d81-9470-da2274b24fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtDiscountRate_00c300aa-3e35-4417-922c-1c35406b63c8" xlink:href="jan-20231230.xsd#jan_DebtDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DebtDiscountRate_00c300aa-3e35-4417-922c-1c35406b63c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DebtRevisedDiscountRate_c2b36d0e-3434-488f-ac44-93fe8aa0709f" xlink:href="jan-20231230.xsd#jan_DebtRevisedDiscountRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DebtRevisedDiscountRate_c2b36d0e-3434-488f-ac44-93fe8aa0709f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DiscountCharges_5cf19180-1f88-45a9-ac22-d736f752b314" xlink:href="jan-20231230.xsd#jan_DiscountCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DiscountCharges_5cf19180-1f88-45a9-ac22-d736f752b314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAmountChargedAgainstIncome_6eb8c7e8-741e-4eef-8e68-1bb681974cb1" xlink:href="jan-20231230.xsd#jan_AdditionalAmountChargedAgainstIncome"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_AdditionalAmountChargedAgainstIncome_6eb8c7e8-741e-4eef-8e68-1bb681974cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GainLossOnWriteOffOfNotesReceivable_089da150-d29c-4901-a101-ab4a79f86643" xlink:href="jan-20231230.xsd#jan_GainLossOnWriteOffOfNotesReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_GainLossOnWriteOffOfNotesReceivable_089da150-d29c-4901-a101-ab4a79f86643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAsset_7dfcbc7f-d6d9-46d9-9f93-461204718513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_InterestIncomeInterestEarningAsset_7dfcbc7f-d6d9-46d9-9f93-461204718513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_d0e86b14-f54a-4a6d-b960-35c5216346fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_d0e86b14-f54a-4a6d-b960-35c5216346fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionConsiderAmount_7144b82f-3f0b-47eb-9be2-655f634a16fe" xlink:href="jan-20231230.xsd#jan_DispositionTransactionConsiderAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionConsiderAmount_7144b82f-3f0b-47eb-9be2-655f634a16fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionTermPeriod_2fde1773-1a17-492d-a88f-5c5b08a7bd58" xlink:href="jan-20231230.xsd#jan_DispositionTransactionTermPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionTermPeriod_2fde1773-1a17-492d-a88f-5c5b08a7bd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionTransactionAggregateCost_39832897-8057-4e69-8b56-4a443ccf8133" xlink:href="jan-20231230.xsd#jan_DispositionTransactionAggregateCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionTransactionAggregateCost_39832897-8057-4e69-8b56-4a443ccf8133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_83d461c0-74c3-4699-b29c-fb9d2abbc74f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_PaymentsForCommissions_83d461c0-74c3-4699-b29c-fb9d2abbc74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DispositionDiscountRate_4c69dbab-b9c1-4c26-9a0c-1a21e59ada3b" xlink:href="jan-20231230.xsd#jan_DispositionDiscountRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_DispositionDiscountRate_4c69dbab-b9c1-4c26-9a0c-1a21e59ada3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_4109efaa-6bef-499b-83e8-6d2d38c3ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_4109efaa-6bef-499b-83e8-6d2d38c3ea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RevisedDiscountAmount_ce84f280-941a-473d-ad08-8ddaf0a2317b" xlink:href="jan-20231230.xsd#jan_RevisedDiscountAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_jan_RevisedDiscountAmount_ce84f280-941a-473d-ad08-8ddaf0a2317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5617688b-7a3f-4d7f-b5db-cb3bdb685fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fb35b647-490a-42a7-acf4-3173de7ddc12" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5617688b-7a3f-4d7f-b5db-cb3bdb685fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_98595d39-3860-4158-8c66-6380c2b22b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_98595d39-3860-4158-8c66-6380c2b22b58" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_785a8aaf-c88a-4c3b-9c0b-7132d5c235c0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_b5bafdd0-597c-4a03-9567-745b35ce91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_19ff720d-ac67-42c5-b48e-68b442ef7b55" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_b5bafdd0-597c-4a03-9567-745b35ce91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9ba89a0-55cd-4287-9f79-435e761838bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_a2012b9f-fe36-4272-9ec2-77c0012ce379" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_jan_SoinIntangiblesMember_a2012b9f-fe36-4272-9ec2-77c0012ce379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PatentsAndDomainsMember_f13fd50a-a081-4281-b99a-9d415813750f" xlink:href="jan-20231230.xsd#jan_PatentsAndDomainsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_jan_PatentsAndDomainsMember_f13fd50a-a081-4281-b99a-9d415813750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_437d4b95-5e5c-41a3-8c44-6c827bd3e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f5593dd-e968-4af8-a543-befb305836c2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_437d4b95-5e5c-41a3-8c44-6c827bd3e53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0c9c804-47be-4141-b9c4-2b5070fa1fa8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1bafd7ff-9c34-44c5-b5b8-abf76eded489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1bafd7ff-9c34-44c5-b5b8-abf76eded489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_51621fb3-284b-43f3-8783-30c3209985cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_51621fb3-284b-43f3-8783-30c3209985cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2c34d032-5a8f-469f-89a6-fbb49fc6c485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0215eff-a73c-4e25-ba46-a3b01ac0aabf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2c34d032-5a8f-469f-89a6-fbb49fc6c485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_963363f8-77e4-45dd-b0b6-d18eb7f319ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_963363f8-77e4-45dd-b0b6-d18eb7f319ca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a922e22-269f-45ac-a8b4-f31e168042b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinIntangiblesMember_7bc573d4-4646-4e6d-af9d-9d9c356462cd" xlink:href="jan-20231230.xsd#jan_SoinIntangiblesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9fd04196-9122-437a-b0ba-f26476d366d4" xlink:to="loc_jan_SoinIntangiblesMember_7bc573d4-4646-4e6d-af9d-9d9c356462cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7d1cad75-4d56-46cb-ba07-d598bef81179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_59ebe005-f319-4c55-84b2-d06f33bc4141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_59ebe005-f319-4c55-84b2-d06f33bc4141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAcquiredIntangibleAssets_3a9a6fd2-4397-4cf4-868f-dd107ef1d270" xlink:href="jan-20231230.xsd#jan_NumberOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_jan_NumberOfAcquiredIntangibleAssets_3a9a6fd2-4397-4cf4-868f-dd107ef1d270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_36d5c3c4-6159-4dd4-b50c-c885f3c885cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62460e58-0bb3-41d8-9155-743c12466aec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_36d5c3c4-6159-4dd4-b50c-c885f3c885cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecuritiesScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_b999d4b2-91cf-4d1f-99af-c627a7d31b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_b999d4b2-91cf-4d1f-99af-c627a7d31b09" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_61872f46-2825-4177-bc50-7feb6ff09fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesGConvertiblePreferredStockMember_3607942a-ca89-4974-bfc1-316d9c4de568" xlink:href="jan-20231230.xsd#jan_SeriesGConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:to="loc_jan_SeriesGConvertiblePreferredStockMember_3607942a-ca89-4974-bfc1-316d9c4de568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonShareEquivalentsMember_238c0be5-6d4c-4028-a97c-9b9d25c18b46" xlink:href="jan-20231230.xsd#jan_CommonShareEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_03e4fd79-2431-4fc5-a9bd-c88b82d65c90" xlink:to="loc_jan_CommonShareEquivalentsMember_238c0be5-6d4c-4028-a97c-9b9d25c18b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_865caafb-93f6-4e08-a6d1-f782707f65bc" xlink:to="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:to="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MarketableSecuritiesSharesOutstanding_b56cf500-1516-483b-927b-466fde437fdb" xlink:href="jan-20231230.xsd#jan_MarketableSecuritiesSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:to="loc_jan_MarketableSecuritiesSharesOutstanding_b56cf500-1516-483b-927b-466fde437fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_079a3bfe-8371-4d40-a212-a269b14f58e0" xlink:href="jan-20231230.xsd#jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:to="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_079a3bfe-8371-4d40-a212-a269b14f58e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_MarketableSecuritiesSharesOutstanding_97a2f1c4-e585-4ea8-91ad-6dfe7103afe7" xlink:href="jan-20231230.xsd#jan_MarketableSecuritiesSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward_efc35679-b250-4d58-8e85-cf002dcd0b84" xlink:to="loc_jan_MarketableSecuritiesSharesOutstanding_97a2f1c4-e585-4ea8-91ad-6dfe7103afe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ccedf86e-6e10-44e3-b1ac-df1862e84111" xlink:to="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8ff6fd3c-abb3-45de-8b6f-b7b5e0d1aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_MarketableSecurities_8ff6fd3c-abb3-45de-8b6f-b7b5e0d1aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_db3b9c8d-c3fd-4844-a212-1632cbc703d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_db3b9c8d-c3fd-4844-a212-1632cbc703d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_16c71270-ad88-499f-8603-73d9f56fff93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_16c71270-ad88-499f-8603-73d9f56fff93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_69f6efa0-3b81-415f-b369-9c1edfd43ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward_4c90e72f-506f-4e1b-9d7b-651b34e47f72" xlink:to="loc_us-gaap_MarketableSecurities_69f6efa0-3b81-415f-b369-9c1edfd43ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_b75e7aed-e7ef-4eed-aaaf-c2a4e68a22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_b75e7aed-e7ef-4eed-aaaf-c2a4e68a22e2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb4d6bf-08da-4e18-a7be-f8b48d8bf985" xlink:to="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesGConvertiblePreferredStockMember_a4ec9f37-5340-4b17-9a35-1ef787214010" xlink:href="jan-20231230.xsd#jan_SeriesGConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:to="loc_jan_SeriesGConvertiblePreferredStockMember_a4ec9f37-5340-4b17-9a35-1ef787214010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonShareEquivalentsMember_39e89da6-5ffd-46a8-a1b6-7a9be74f235a" xlink:href="jan-20231230.xsd#jan_CommonShareEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd8525aa-5eb0-4e10-b95b-3dbd8bc2f95e" xlink:to="loc_jan_CommonShareEquivalentsMember_39e89da6-5ffd-46a8-a1b6-7a9be74f235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:to="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b1e54fe4-b612-4aee-95c0-47ccf00b7bcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SpyrTechnologiesIncMember_90925684-ae70-4d11-82d1-c5ff53915f43" xlink:href="jan-20231230.xsd#jan_SpyrTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c18443f3-bc88-42f7-84ed-28321bfd006c" xlink:to="loc_jan_SpyrTechnologiesIncMember_90925684-ae70-4d11-82d1-c5ff53915f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dcba0674-febb-4540-be76-50166f2d98f5" xlink:to="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_d80bddc9-0169-4edd-be3d-baa2ac11d0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_d80bddc9-0169-4edd-be3d-baa2ac11d0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_4d607b18-ea8e-48b9-86f2-a2ea26ae129f" xlink:href="jan-20231230.xsd#jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares_4d607b18-ea8e-48b9-86f2-a2ea26ae129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion_f24c8d09-fc72-4b97-a08e-8ffba382cf26" xlink:href="jan-20231230.xsd#jan_ConvertiblePreferredStockSharesIssuableUponConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_jan_ConvertiblePreferredStockSharesIssuableUponConversion_f24c8d09-fc72-4b97-a08e-8ffba382cf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5d30cb96-0d40-4f19-8768-e09566b728ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a1845666-4cdd-424b-84bc-4abfece4314d" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5d30cb96-0d40-4f19-8768-e09566b728ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2bf2954a-30e1-4379-a45b-d6e6dcd6428d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2bf2954a-30e1-4379-a45b-d6e6dcd6428d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cce312d5-60e7-4451-b3d3-5fce9874023d" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_61a26940-b0b4-4147-9038-ae298ad4c1bf" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_5792de7a-3b27-4362-81c9-8261fc6cbdb3" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_61a26940-b0b4-4147-9038-ae298ad4c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_10f58363-80d0-4d60-a592-7193eaf96c24" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DepositsAndOtherAssetsNoncurrent_9dfe0e6c-a502-417f-9e26-3b7a26c11b68" xlink:href="jan-20231230.xsd#jan_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_07bb6b7e-e666-4904-b176-1d8b2484870e" xlink:to="loc_jan_DepositsAndOtherAssetsNoncurrent_9dfe0e6c-a502-417f-9e26-3b7a26c11b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d8133510-9d5f-4d62-ac3d-6d7c31d3a887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d8133510-9d5f-4d62-ac3d-6d7c31d3a887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AccruedGuaranteesCurrent_6ea2426b-992d-40d4-a205-3dd297616745" xlink:href="jan-20231230.xsd#jan_AccruedGuaranteesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_jan_AccruedGuaranteesCurrent_6ea2426b-992d-40d4-a205-3dd297616745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a50d282b-e4c0-4737-8eaf-276c1565068f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a50d282b-e4c0-4737-8eaf-276c1565068f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_74eb2565-edf8-4f16-a17a-36a5840b92ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_us-gaap_LitigationReserveCurrent_74eb2565-edf8-4f16-a17a-36a5840b92ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_0a0d55b7-26d9-4ecc-9937-f2950cad549d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_0a0d55b7-26d9-4ecc-9937-f2950cad549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_802deb0d-3785-47a5-bce5-a18803827b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aac7525b-5151-4d87-9189-67983410b62e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_802deb0d-3785-47a5-bce5-a18803827b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c45a7c6b-9540-49f3-8f2d-a378fcc603a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c45a7c6b-9540-49f3-8f2d-a378fcc603a2" xlink:to="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e23a83d3-d675-445e-9fe5-60f6ff2123cd" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FinancingArrangementMember_3cf39455-0fa0-49b7-94eb-9b805a637c12" xlink:href="jan-20231230.xsd#jan_FinancingArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5a6bfd9a-8f8c-4668-b823-251af2a3ab7e" xlink:to="loc_jan_FinancingArrangementMember_3cf39455-0fa0-49b7-94eb-9b805a637c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa24ff8b-1c3f-4ee4-8b4f-f70d580e6aaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorporationFinancingAgreementMember_108ca669-6e24-49c7-8a2a-ddfc4ddacf10" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorporationFinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:to="loc_jan_AFCOCreditCorporationFinancingAgreementMember_108ca669-6e24-49c7-8a2a-ddfc4ddacf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorpMember_0711dadf-9c7b-4c73-bafa-dc259fdd55fc" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorpMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b9b9b1e7-6c64-485c-9414-356cbab4fb58" xlink:to="loc_jan_AFCOCreditCorpMember_0711dadf-9c7b-4c73-bafa-dc259fdd55fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca711745-c794-4f4c-b449-57069278d6c6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1fa34c09-c005-4d98-b57e-bc9c350c64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_136ab359-998e-4594-8b8d-569f88a8335b" xlink:to="loc_us-gaap_ShortTermBorrowings_1fa34c09-c005-4d98-b57e-bc9c350c64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#ShorttermdebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26ae2652-90e4-47c5-b3af-8c892ab8de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26ae2652-90e4-47c5-b3af-8c892ab8de4d" xlink:to="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b48bdbbf-32f6-4ddf-aef9-82c3681913c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorpMember_12be6161-b420-44ea-bdd4-ef15501b6638" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee40f683-0669-4d92-ade7-c4ee15539c87" xlink:to="loc_jan_AFCOCreditCorpMember_12be6161-b420-44ea-bdd4-ef15501b6638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac51bc2b-6d94-4132-bd18-bfd607c208a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AFCOCreditCorporationFinancingAgreementMember_bbdc1fbb-397d-4403-8f55-939208b2dece" xlink:href="jan-20231230.xsd#jan_AFCOCreditCorporationFinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9fb28c40-60d6-4a1f-81f6-d9bde9c79ac9" xlink:to="loc_jan_AFCOCreditCorporationFinancingAgreementMember_bbdc1fbb-397d-4403-8f55-939208b2dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da99e91c-f940-44a8-83be-027ac0d9dca8" xlink:to="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c99b8b6-c751-4524-bf94-5a69fc4e079e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:to="loc_srt_MinimumMember_3c99b8b6-c751-4524-bf94-5a69fc4e079e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_340953cd-e637-4a49-b09a-31936262361f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14ba4452-e327-4b23-9b19-026ae2aed12a" xlink:to="loc_srt_MaximumMember_340953cd-e637-4a49-b09a-31936262361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3cc9ab0c-fdbf-4514-aa46-17f1f9935d6a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_FinancingArrangementMember_f0a55c5f-6082-479e-8030-195d21b3d959" xlink:href="jan-20231230.xsd#jan_FinancingArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7450771c-2954-4b71-b2ce-c06e3c24690f" xlink:to="loc_jan_FinancingArrangementMember_f0a55c5f-6082-479e-8030-195d21b3d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cde5197a-f37f-446d-9e0b-b5a347c142fb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_68883c01-0e58-4161-81ed-8163acc658e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_68883c01-0e58-4161-81ed-8163acc658e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5c868170-8222-418a-8977-9e9a97aa3c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5c868170-8222-418a-8977-9e9a97aa3c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_901477fe-8f72-4f81-85a9-681a6b251def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_901477fe-8f72-4f81-85a9-681a6b251def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e5b25622-347f-4afe-931b-108ab4a32e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e5b25622-347f-4afe-931b-108ab4a32e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_cb6d98c9-bf9f-4faf-ab23-d746ee5019e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a797c05-32b6-4aae-9d39-6a8f41297d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_LongTermDebt_6a797c05-32b6-4aae-9d39-6a8f41297d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9a0db09a-30ef-4f6e-8c79-9d87a3093c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b051b1d7-ba73-4009-93e6-23d6b52f2745" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9a0db09a-30ef-4f6e-8c79-9d87a3093c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesA1ConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d4cdb19e-07e3-4c58-b7f3-f28d7bd1d45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d4cdb19e-07e3-4c58-b7f3-f28d7bd1d45d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e92f8569-a08b-40e6-8e45-9705c8a7c730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_4addaabc-8b89-4934-8340-f80b1ef84b11" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e8fc6dd0-9162-43c7-80b8-5be51ced0e60" xlink:to="loc_jan_GeoTraqIncMember_4addaabc-8b89-4934-8340-f80b1ef84b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5b174376-aab8-4bb0-9dc3-7aef0e66ffd9" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesAConvertiblePreferredStockMember_baa640ad-e6cd-480f-ad50-3bae595ec622" xlink:href="jan-20231230.xsd#jan_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:to="loc_jan_SeriesAConvertiblePreferredStockMember_baa640ad-e6cd-480f-ad50-3bae595ec622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1ConvertiblePreferredStockMember_338e9306-4339-4be2-ac51-c21023cac623" xlink:href="jan-20231230.xsd#jan_SeriesA1ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_88d6b766-6cee-4170-9c19-f8eebd02bed3" xlink:to="loc_jan_SeriesA1ConvertiblePreferredStockMember_338e9306-4339-4be2-ac51-c21023cac623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48a171a5-cfd0-4343-965e-9239b59e5a61" xlink:to="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4fcf364f-d4c1-47be-a530-63273b561007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4fcf364f-d4c1-47be-a530-63273b561007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ab7c620b-2da1-44b2-855f-e24c50f7aec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ab7c620b-2da1-44b2-855f-e24c50f7aec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_3a72a534-fc1c-4744-b70d-89a4e5eccd64" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue_3a72a534-fc1c-4744-b70d-89a4e5eccd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_e26b6718-a444-411b-b9b3-abcaaa873423" xlink:href="jan-20231230.xsd#jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm_e26b6718-a444-411b-b9b3-abcaaa873423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1df5e530-437f-48e5-b757-3b4d53e0fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1df5e530-437f-48e5-b757-3b4d53e0fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_ba03d247-c877-4327-8fcd-7f9c70f67c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_ba03d247-c877-4327-8fcd-7f9c70f67c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27db7aba-67a3-4e8d-8240-b824ae129f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27db7aba-67a3-4e8d-8240-b824ae129f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_3a75c4a8-a226-4869-9c1f-f4bb455a15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_3a75c4a8-a226-4869-9c1f-f4bb455a15aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockSharesForfeited_fbe4bd34-4a42-4631-a7b4-46bd9e276969" xlink:href="jan-20231230.xsd#jan_ConversionOfStockSharesForfeited"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_jan_ConversionOfStockSharesForfeited_fbe4bd34-4a42-4631-a7b4-46bd9e276969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2042b9df-3702-4afe-aa46-eb9043add2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f28a45-c176-4887-b4dd-1a5e6e8d174d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2042b9df-3702-4afe-aa46-eb9043add2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fa2158d2-34e2-4ca7-8400-0c7ae7ee586a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fa2158d2-34e2-4ca7-8400-0c7ae7ee586a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aec1eaef-b2a4-4838-b4aa-2adcc1bcf983" xlink:to="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_9d29d2d8-9e14-49c3-bbde-d09f95b52b81" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8c5053af-4f45-412e-a435-a6ebd166e3f7" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_9d29d2d8-9e14-49c3-bbde-d09f95b52b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6f4f101-1a0f-4e2d-9c5a-2c440166e5db" xlink:to="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_393da64b-acfe-448e-bd30-82069033a9cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30e9aebe-4b2e-45ba-9ded-9012fc204c61" xlink:to="loc_srt_MaximumMember_393da64b-acfe-448e-bd30-82069033a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_dbcdbbaa-84e5-47d3-a430-8b969149e7af" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion1Member_5c390cba-9421-4282-a435-c3c4b28f26bb" xlink:href="jan-20231230.xsd#jan_StockConversion1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion1Member_5c390cba-9421-4282-a435-c3c4b28f26bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion2Member_fdc3b59f-665e-4b96-aa89-548c9d20398b" xlink:href="jan-20231230.xsd#jan_StockConversion2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion2Member_fdc3b59f-665e-4b96-aa89-548c9d20398b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StockConversion3Member_d557b15f-0c50-486e-88e3-8adf062e3e29" xlink:href="jan-20231230.xsd#jan_StockConversion3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_001332e1-6be6-40e0-b680-86ac9cf5d043" xlink:to="loc_jan_StockConversion3Member_d557b15f-0c50-486e-88e3-8adf062e3e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5539c971-bae4-4efe-ac1b-bbf760e7529f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_eb04eb1a-e450-42e6-9dac-d24c72dc4e72" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9205fd6b-b483-45ac-b0d6-883a10039914" xlink:to="loc_jan_SoinTherapeuticsLLCMember_eb04eb1a-e450-42e6-9dac-d24c72dc4e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13b02bff-e248-499d-8e0e-d045ba449df7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DrSoinMember_ced046c8-42c3-4184-b199-86593721ec2b" xlink:href="jan-20231230.xsd#jan_DrSoinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ef3fce0-376f-4ba0-b3d9-830e790b7d8a" xlink:to="loc_jan_DrSoinMember_ced046c8-42c3-4184-b199-86593721ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f822abf-842d-4e34-8eb5-f1bcd2c76319" xlink:to="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c993ea86-6f91-4e74-8f75-d79aeb93d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a3b2b6b7-3ab8-4012-b8e7-e15a0945d1d0" xlink:to="loc_us-gaap_RelatedPartyMember_c993ea86-6f91-4e74-8f75-d79aeb93d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_179e8f00-0417-4332-9968-15e437ffff5a" xlink:to="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a515c0f4-4416-4c96-83db-a31fbae196c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a515c0f4-4416-4c96-83db-a31fbae196c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_026ba92d-08b8-47e7-8546-52bcc392f540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_026ba92d-08b8-47e7-8546-52bcc392f540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockAmountConvertible_ce2c6951-83b7-485b-86b7-8da5c75387d8" xlink:href="jan-20231230.xsd#jan_ConversionOfStockAmountConvertible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockAmountConvertible_ce2c6951-83b7-485b-86b7-8da5c75387d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockCommencementPeriod_91082641-bea3-4412-a739-48320e738b4e" xlink:href="jan-20231230.xsd#jan_ConversionOfStockCommencementPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockCommencementPeriod_91082641-bea3-4412-a739-48320e738b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ConversionOfStockPeriodFollowingClosing_9c8aa946-4b7c-4b88-a8f3-4f3b194ccda8" xlink:href="jan-20231230.xsd#jan_ConversionOfStockPeriodFollowingClosing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_ConversionOfStockPeriodFollowingClosing_9c8aa946-4b7c-4b88-a8f3-4f3b194ccda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentageOfGrossRevenue_4edcf497-0612-4d03-871d-75fa8d54dde2" xlink:href="jan-20231230.xsd#jan_PercentageOfGrossRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_PercentageOfGrossRevenue_4edcf497-0612-4d03-871d-75fa8d54dde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockSharesOutstandingPercentage_fee8d172-ba3d-4599-af46-4183cfe52819" xlink:href="jan-20231230.xsd#jan_CommonStockSharesOutstandingPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_CommonStockSharesOutstandingPercentage_fee8d172-ba3d-4599-af46-4183cfe52819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_875adc88-50f4-4735-9271-567fe88589b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_875adc88-50f4-4735-9271-567fe88589b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_20782fbb-612e-440c-a391-8a24ea4a0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_20782fbb-612e-440c-a391-8a24ea4a0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_9ef3ed64-e79b-4cfe-a68e-bc4906e4cbeb" xlink:href="jan-20231230.xsd#jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_23bc18da-ff84-4561-b0d6-4045b6fb7dc6" xlink:to="loc_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare_9ef3ed64-e79b-4cfe-a68e-bc4906e4cbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6657ee21-5794-4ca6-aab7-7017506363dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6657ee21-5794-4ca6-aab7-7017506363dd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58cc1f49-dd5e-43ef-8ff6-0aeefd5b79b5" xlink:to="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_56ff5d1c-a9e8-42e9-9f90-6c9fcb226e81" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6332be7a-6adb-4b63-85c5-b1bc034a63e1" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_56ff5d1c-a9e8-42e9-9f90-6c9fcb226e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac03e86a-c38a-4906-853f-5255c5e569f1" xlink:to="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bfe5f498-72b7-4524-8c79-c8d9b06d2a82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_21806ed8-3039-433d-ad91-1f6623495131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_21806ed8-3039-433d-ad91-1f6623495131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a6f14fe1-c08c-4cd4-b097-658603d4b12d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a6f14fe1-c08c-4cd4-b097-658603d4b12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares_76b100bd-7878-4845-b91a-63ad67a827c4" xlink:href="jan-20231230.xsd#jan_TemporaryEquitySharesIssuedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_jan_TemporaryEquitySharesIssuedDuringPeriodShares_76b100bd-7878-4845-b91a-63ad67a827c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_7d1edabd-40f1-4338-8b7a-d63cf8c3f520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_7d1edabd-40f1-4338-8b7a-d63cf8c3f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_feb1783d-8bc5-4d09-968e-29248105e155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_feb1783d-8bc5-4d09-968e-29248105e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0e188270-5e4a-4417-9b1e-d3e8b98b14d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0e188270-5e4a-4417-9b1e-d3e8b98b14d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_48a268c0-d83e-45b9-95be-691488573f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_48a268c0-d83e-45b9-95be-691488573f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b95c7247-42c7-4624-af0a-4838aa55a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59780142-9dbc-4072-af05-0aa57c70baa5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b95c7247-42c7-4624-af0a-4838aa55a62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9e9ee123-11dc-4d95-aeee-efbaaf4c935b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9e9ee123-11dc-4d95-aeee-efbaaf4c935b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7137b5bd-eafa-453f-a3be-2049af0eb143" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ArticlesOfIncorporationMember_69b176d1-7d41-4041-9530-c35d367cf9bc" xlink:href="jan-20231230.xsd#jan_ArticlesOfIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:to="loc_jan_ArticlesOfIncorporationMember_69b176d1-7d41-4041-9530-c35d367cf9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SecuritiesPurchaseAgreementMember_6434c78d-f5b2-4ec1-aa0d-562a53784397" xlink:href="jan-20231230.xsd#jan_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8801e62-7417-419c-86f6-cf6b40fd69bc" xlink:to="loc_jan_SecuritiesPurchaseAgreementMember_6434c78d-f5b2-4ec1-aa0d-562a53784397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba3e183a-b785-4357-9841-28175cddc81e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_31315f91-5bf1-4ed4-a7b3-18d3ec5f9bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f96b59-2631-491b-880e-68e71395ea9c" xlink:to="loc_us-gaap_PrivatePlacementMember_31315f91-5bf1-4ed4-a7b3-18d3ec5f9bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d86516f0-4079-41b8-9506-fec9a2a2838b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PreFundedWarrantsMemberMember_8e0d0c5d-dd4b-403d-a805-3306c7589bfa" xlink:href="jan-20231230.xsd#jan_PreFundedWarrantsMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0531eb3b-53fc-4564-a1b6-60fc28d8d4df" xlink:to="loc_jan_PreFundedWarrantsMemberMember_8e0d0c5d-dd4b-403d-a805-3306c7589bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a379582d-7ad3-4872-a077-20ec148a24a1" xlink:to="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2016Member_10db48d7-4fd0-438b-bbe4-4b8439cdf13a" xlink:href="jan-20231230.xsd#jan_Plan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_Plan2016Member_10db48d7-4fd0-438b-bbe4-4b8439cdf13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Plan2011Member_2b8e2884-0604-4b94-9547-6593d745ebbe" xlink:href="jan-20231230.xsd#jan_Plan2011Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_Plan2011Member_2b8e2884-0604-4b94-9547-6593d745ebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_A2023PlanMember_e05f980f-c6d1-4ce1-9d1a-1a7f3f0dd3c9" xlink:href="jan-20231230.xsd#jan_A2023PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f14039c-96f0-4432-882b-6fb1ddb6b16c" xlink:to="loc_jan_A2023PlanMember_e05f980f-c6d1-4ce1-9d1a-1a7f3f0dd3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_426a866b-98e4-4c44-a610-a674c226638e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747a5934-14c2-4754-b734-75c965bb7f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747a5934-14c2-4754-b734-75c965bb7f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_06742ed7-53b6-4966-b4f6-307f81ad294d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ac3c378-31c3-416d-a20f-ab0429288fb0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_06742ed7-53b6-4966-b4f6-307f81ad294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c1f45b17-79fc-4df3-b49f-0d339a0ea62c" xlink:to="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_22f5fa9d-78c7-4a0a-9e29-1e28f6736ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_22f5fa9d-78c7-4a0a-9e29-1e28f6736ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_31fdcf80-77be-48b6-9f90-0e34ed204ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesIssued_31fdcf80-77be-48b6-9f90-0e34ed204ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e870d845-f122-4e08-9b9d-71e086033565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e870d845-f122-4e08-9b9d-71e086033565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_7638aef0-f8c1-4d89-ad06-8df1606cf5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_7638aef0-f8c1-4d89-ad06-8df1606cf5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e647e1ee-fa4b-4bad-9566-02a210576130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e647e1ee-fa4b-4bad-9566-02a210576130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_CommonStockPurchasePricePerShare_4bb18cb2-caef-489d-9ba6-c121e842f99b" xlink:href="jan-20231230.xsd#jan_CommonStockPurchasePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_CommonStockPurchasePricePerShare_4bb18cb2-caef-489d-9ba6-c121e842f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_793ac632-9d97-4176-96d5-5e7dbc460235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit_793ac632-9d97-4176-96d5-5e7dbc460235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1d4014c-6b02-43f4-9f26-e98d8aa59a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1d4014c-6b02-43f4-9f26-e98d8aa59a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_78bdb79a-d344-425a-b90f-569b9f8061ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_78bdb79a-d344-425a-b90f-569b9f8061ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6f7bedff-f26a-4e06-9da1-2e616d0ed33a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6f7bedff-f26a-4e06-9da1-2e616d0ed33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e2d2d7db-97c7-4f61-850d-99de073fffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e2d2d7db-97c7-4f61-850d-99de073fffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1cf96932-e48c-4482-92cf-8fd8ef659b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1cf96932-e48c-4482-92cf-8fd8ef659b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_d209fd99-3a7b-43f2-8784-2bef5a82acc4" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantOrRightWarrantsOrRightsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised_d209fd99-3a7b-43f2-8784-2bef5a82acc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4387960c-3092-45d9-b276-e12b50353022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4387960c-3092-45d9-b276-e12b50353022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59999ec0-36ae-4d45-8df7-44aa25ce9e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59999ec0-36ae-4d45-8df7-44aa25ce9e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2b0cd0c5-0616-4c08-8bed-3639841263e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2b0cd0c5-0616-4c08-8bed-3639841263e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7beb5b0c-9eb3-4521-b2ff-d21ca7400071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7beb5b0c-9eb3-4521-b2ff-d21ca7400071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_4e46dcde-9aee-4d3d-b343-2a35b7b588d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_4e46dcde-9aee-4d3d-b343-2a35b7b588d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_372b1ba5-76cd-4fc4-bc05-7d9b7caacb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_651f3ae5-104c-40c1-b64b-dd8a484b94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_651f3ae5-104c-40c1-b64b-dd8a484b94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AdditionalAwardsToBeGranted_3e45ae10-799b-488e-b3d5-bede16abb12f" xlink:href="jan-20231230.xsd#jan_AdditionalAwardsToBeGranted"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_jan_AdditionalAwardsToBeGranted_3e45ae10-799b-488e-b3d5-bede16abb12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c23060c0-d5c3-4b73-a85a-494823ac86be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c23060c0-d5c3-4b73-a85a-494823ac86be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2141d6a3-64d9-4f3f-94a8-265c7e57d122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ae7961-dec3-49df-863d-479d371ab3b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2141d6a3-64d9-4f3f-94a8-265c7e57d122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquitySummaryofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_58260f47-4bed-4aef-8303-2a1dfd104f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_58260f47-4bed-4aef-8303-2a1dfd104f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9bbe8aa-0f37-408b-847f-d4d0d44ef408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9bbe8aa-0f37-408b-847f-d4d0d44ef408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e1fbff46-e41a-488f-a93f-ea873e4d15ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e1fbff46-e41a-488f-a93f-ea873e4d15ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bfe12e87-dce8-427e-9b0f-168df4f0df73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e71b2985-8820-48a3-9afb-4df5c8fa3687" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bfe12e87-dce8-427e-9b0f-168df4f0df73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e302e1bf-3c2f-4738-93d3-9c5c5681f283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e302e1bf-3c2f-4738-93d3-9c5c5681f283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f044a09c-d53a-4efb-89dc-d6b790f9583d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f044a09c-d53a-4efb-89dc-d6b790f9583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23ea811e-a77e-46a4-a715-c16a97e9c652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23ea811e-a77e-46a4-a715-c16a97e9c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a347f625-42e3-4105-9203-5eb1c92aa92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a347f625-42e3-4105-9203-5eb1c92aa92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_154d4487-0e02-497c-8ef3-011f246948a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_97e70137-d4a8-4fd0-aa7f-1085479f66ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_154d4487-0e02-497c-8ef3-011f246948a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6987161d-a371-4797-a4ef-e0b48409da28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6987161d-a371-4797-a4ef-e0b48409da28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35c0aa2f-9231-4812-bccb-9aec03dce021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35c0aa2f-9231-4812-bccb-9aec03dce021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_59728cb0-4c81-409a-8ab8-f5c393bbbe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35c0aa2f-9231-4812-bccb-9aec03dce021" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_59728cb0-4c81-409a-8ab8-f5c393bbbe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c00ecfca-8d9c-4917-bf70-46552cb4abb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c00ecfca-8d9c-4917-bf70-46552cb4abb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08d267ef-64be-426d-bd01-67d5827b8809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08d267ef-64be-426d-bd01-67d5827b8809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ae93bda3-f8bb-4788-be93-e074c74dbebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d386e86-0138-43a4-ba36-26d646dd9e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ae93bda3-f8bb-4788-be93-e074c74dbebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ef0df49-6cad-4b11-9cbf-0d6d460df781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ef0df49-6cad-4b11-9cbf-0d6d460df781" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9c6788a3-7542-42df-9c1d-e5b09041aad1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeOneMember_644a3c10-3e47-486f-8d74-947132a85057" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeOneMember_644a3c10-3e47-486f-8d74-947132a85057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeTwoMember_3d67c0db-3633-4d77-a3fd-db882b329bcf" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeTwoMember_3d67c0db-3633-4d77-a3fd-db882b329bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeThreeMember_aa3a1975-892a-4f1d-bcb6-c5bfb9ec3cb0" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeThreeMember_aa3a1975-892a-4f1d-bcb6-c5bfb9ec3cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ExercisePriceRangeFourMember_5398df46-74f4-455c-ba7c-1cb827cc6301" xlink:href="jan-20231230.xsd#jan_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eb66c224-0a38-49b8-9611-94497d60923c" xlink:to="loc_jan_ExercisePriceRangeFourMember_5398df46-74f4-455c-ba7c-1cb827cc6301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_594782f2-b6d5-4da4-a235-e16a473d93c4" xlink:to="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d7c2061b-7aab-44e9-8b2a-73a944a52430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d7c2061b-7aab-44e9-8b2a-73a944a52430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_25d885f9-fe27-4032-97b2-ac3511849d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_25d885f9-fe27-4032-97b2-ac3511849d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e22ad69b-b00a-417a-9281-89e179b20963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e22ad69b-b00a-417a-9281-89e179b20963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0ab5755d-8776-4f4d-a0a5-6175534d95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8db3ce68-a5c5-45dd-b4ed-6f6ac2d0e7de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0ab5755d-8776-4f4d-a0a5-6175534d95f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ba924404-e16f-4282-9068-89b6cb6383d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ba924404-e16f-4282-9068-89b6cb6383d5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0235eb6f-e43a-4357-964a-09a699a0a676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0235eb6f-e43a-4357-964a-09a699a0a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7a03265-03bb-4ea0-93ef-91329866f367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7a03265-03bb-4ea0-93ef-91329866f367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_585168ac-56c8-4048-9046-9ac0dac61e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_585168ac-56c8-4048-9046-9ac0dac61e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_adca1f12-8c7d-4dc8-a636-d5acf440ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_86dd762c-b276-4474-b3c5-04424684ca84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_adca1f12-8c7d-4dc8-a636-d5acf440ab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7e4447e2-ec4e-44dd-be24-98cee6c4660f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e4447e2-ec4e-44dd-be24-98cee6c4660f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dc9bb9fc-8893-4948-8343-4222f6771462" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_7d1ad891-9dd7-4766-b487-657b0d2a9a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_7d1ad891-9dd7-4766-b487-657b0d2a9a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_08a98eba-a21a-420d-93cb-e0dfbed3fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_c4e770a2-d207-41c2-aed2-0976daf7ee5a" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_08a98eba-a21a-420d-93cb-e0dfbed3fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_525832db-9fd8-4e4e-a946-dab32c53ac2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_eb6837bb-477c-4578-b3d4-75a6482f7116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:to="loc_us-gaap_DomesticCountryMember_eb6837bb-477c-4578-b3d4-75a6482f7116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ceb50912-05b3-47e7-bce0-52426eef9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_11073c09-bfef-410d-83c0-8c0c64271547" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ceb50912-05b3-47e7-bce0-52426eef9c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d7aac229-04bb-42cd-9601-a3c05b850f66" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_99b3a27b-c3a8-4a48-a7d2-cc1f167440cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_99b3a27b-c3a8-4a48-a7d2-cc1f167440cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_cb6258fe-47ce-4969-8fb9-ce6878fbac21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_OperatingLossCarryforwards_cb6258fe-47ce-4969-8fb9-ce6878fbac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_3d88025e-2bbf-4988-9889-eba9cf1246c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_be79c572-3f1f-478a-9229-f67abc7ee940" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_3d88025e-2bbf-4988-9889-eba9cf1246c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8ddfc446-1e4c-4dbc-b865-dce1165c3555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_c639fce0-3db9-4c0f-ab10-8cb61801358d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ddfc446-1e4c-4dbc-b865-dce1165c3555" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_c639fce0-3db9-4c0f-ab10-8cb61801358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a38a536e-e0b0-402e-8154-76c6777ad4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_c639fce0-3db9-4c0f-ab10-8cb61801358d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a38a536e-e0b0-402e-8154-76c6777ad4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ecd7890b-43de-4449-9175-a51d53de2567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_c639fce0-3db9-4c0f-ab10-8cb61801358d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ecd7890b-43de-4449-9175-a51d53de2567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c8a423db-7d4b-448b-a7a0-5949a14a505f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_c639fce0-3db9-4c0f-ab10-8cb61801358d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c8a423db-7d4b-448b-a7a0-5949a14a505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1aab4c50-39d9-4210-a0c6-2976b931339f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ddfc446-1e4c-4dbc-b865-dce1165c3555" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1aab4c50-39d9-4210-a0c6-2976b931339f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ProvisionBenefitOfIncomeTaxes_498459c2-f98f-4506-b690-ee14daa3d923" xlink:href="jan-20231230.xsd#jan_ProvisionBenefitOfIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ddfc446-1e4c-4dbc-b865-dce1165c3555" xlink:to="loc_jan_ProvisionBenefitOfIncomeTaxes_498459c2-f98f-4506-b690-ee14daa3d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aca198e0-6cad-4817-b58e-c6860374a075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aca198e0-6cad-4817-b58e-c6860374a075" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d2c0de2f-c726-4635-bf14-f68dddcf4aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d2c0de2f-c726-4635-bf14-f68dddcf4aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_f736bfc8-6e99-4a21-91ef-7aa41f01bdd9" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent_f736bfc8-6e99-4a21-91ef-7aa41f01bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_38b8a6bf-90e9-4896-a5f7-138a11fbc419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_38b8a6bf-90e9-4896-a5f7-138a11fbc419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c8cacc29-adca-4beb-85cf-2cbee48b93e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c8cacc29-adca-4beb-85cf-2cbee48b93e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_7ca2a2ac-f66f-4a8d-bf4c-caf733217575" xlink:href="jan-20231230.xsd#jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences_7ca2a2ac-f66f-4a8d-bf4c-caf733217575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_fa26ce9e-b366-4cd2-9175-221ac6799df0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_fa26ce9e-b366-4cd2-9175-221ac6799df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_68e07155-753b-47ff-a168-6d4d99963038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_68e07155-753b-47ff-a168-6d4d99963038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_872c3b8f-ae77-4007-ace1-6a3e7c6d3314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_872c3b8f-ae77-4007-ace1-6a3e7c6d3314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_efc7e337-7687-4c68-89d7-979691371ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_efc7e337-7687-4c68-89d7-979691371ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fbf9d4d5-5096-4168-a81e-b95a364f74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ce9124af-f7fb-4fa4-9135-ee6b9f680888" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fbf9d4d5-5096-4168-a81e-b95a364f74c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e8490dd0-0a74-4200-b414-d372ad0c33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_db6a4c2e-f8b2-47d1-9e6c-088761eb1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8490dd0-0a74-4200-b414-d372ad0c33b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_db6a4c2e-f8b2-47d1-9e6c-088761eb1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f9c07441-72cb-4209-b82a-f79f8219a216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8490dd0-0a74-4200-b414-d372ad0c33b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f9c07441-72cb-4209-b82a-f79f8219a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_f0211809-85da-481d-980d-4397c407e2b7" xlink:href="jan-20231230.xsd#jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8490dd0-0a74-4200-b414-d372ad0c33b9" xlink:to="loc_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes_f0211809-85da-481d-980d-4397c407e2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_233d4a63-dee5-48df-aa87-5634486002b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_233d4a63-dee5-48df-aa87-5634486002b3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ef02d507-0f6d-4288-bc51-bad8426a6340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ef02d507-0f6d-4288-bc51-bad8426a6340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_85a580e1-8447-43c6-851c-43c40bb55bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_85a580e1-8447-43c6-851c-43c40bb55bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Section174Expenses_18a1cd6e-13d6-446f-aeac-a91143d2266c" xlink:href="jan-20231230.xsd#jan_Section174Expenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_jan_Section174Expenses_18a1cd6e-13d6-446f-aeac-a91143d2266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_42b83be0-1a28-4cfc-9da5-7ed4d0303364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_42b83be0-1a28-4cfc-9da5-7ed4d0303364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_028597d5-1680-4665-8fcc-57f9b0e46b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_028597d5-1680-4665-8fcc-57f9b0e46b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLeaseLiability_1affa038-4dee-47be-8c36-fe98d6dfcfe3" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_jan_DeferredTaxAssetsLeaseLiability_1affa038-4dee-47be-8c36-fe98d6dfcfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_634e0272-eceb-4b1a-8c91-15a2fca0a168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_634e0272-eceb-4b1a-8c91-15a2fca0a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0196b0d9-2a77-40c0-85f2-e9b932a66b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0196b0d9-2a77-40c0-85f2-e9b932a66b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9477dc5b-9825-44b2-a350-5cfbd5bdf33b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9477dc5b-9825-44b2-a350-5cfbd5bdf33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7e1c7906-efd8-47ea-94b8-8f7debad7303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7e1c7906-efd8-47ea-94b8-8f7debad7303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxLiabilitiesInstallmentSale_ad2e3177-8a59-4a84-8222-826a7d60514e" xlink:href="jan-20231230.xsd#jan_DeferredTaxLiabilitiesInstallmentSale"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_jan_DeferredTaxLiabilitiesInstallmentSale_ad2e3177-8a59-4a84-8222-826a7d60514e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_23c8c043-53b8-4cc2-aca1-6f57d483a237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_23c8c043-53b8-4cc2-aca1-6f57d483a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsInterest_2129fc57-7eb5-4061-9186-303e5ca22ef6" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_jan_DeferredTaxAssetsInterest_2129fc57-7eb5-4061-9186-303e5ca22ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_89816884-950f-4673-9c3d-d7755a5b3b01" xlink:href="jan-20231230.xsd#jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0bbffede-69f2-4315-a196-6899546bbc7b" xlink:to="loc_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance_89816884-950f-4673-9c3d-d7755a5b3b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8c7261c5-6630-402e-bd90-23e8b1331714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_233d4a63-dee5-48df-aa87-5634486002b3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8c7261c5-6630-402e-bd90-23e8b1331714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_26ec4eb7-0344-4818-b54a-7236e6073a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_233d4a63-dee5-48df-aa87-5634486002b3" xlink:to="loc_us-gaap_DeferredTaxLiabilities_26ec4eb7-0344-4818-b54a-7236e6073a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#RelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0af49600-a775-4a50-bb04-41378bdc2db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0af49600-a775-4a50-bb04-41378bdc2db6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90f1d148-f1e6-4e12-8871-e0a1ba30477a" xlink:to="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0f178e1a-1672-4adb-b97f-d03a949b63a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:to="loc_us-gaap_RelatedPartyMember_0f178e1a-1672-4adb-b97f-d03a949b63a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_c9b62656-0aaa-450f-b0ff-cd385a48a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7e25cb4b-fb16-4f17-811f-0529ca2fa9d7" xlink:to="loc_us-gaap_BeneficialOwnerMember_c9b62656-0aaa-450f-b0ff-cd385a48a1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_78fae241-3856-41ba-9cb5-30ec4b3306bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LiveVenturesIncorporatedMember_6c9e127f-e15b-402b-a298-947309085463" xlink:href="jan-20231230.xsd#jan_LiveVenturesIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc4f78e-fb53-4647-83b9-f0cb922e29ae" xlink:to="loc_jan_LiveVenturesIncorporatedMember_6c9e127f-e15b-402b-a298-947309085463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_62fe1e96-fe1c-43f5-8bac-38d31936c10f" xlink:to="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4a819575-8cf9-44ab-a441-3fe645723bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_823ec7d7-4ae3-4743-a6cb-c28ac301f40b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4a819575-8cf9-44ab-a441-3fe645723bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_33f4bb00-56a0-42ab-96de-e759721e54ec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_403139fc-6bef-4735-86ca-d689ba4b0250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_403139fc-6bef-4735-86ca-d689ba4b0250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_07d8f159-c5c5-4987-a426-10f19069c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a49f732-4142-47c9-b686-8ff0a0f973b9" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_07d8f159-c5c5-4987-a426-10f19069c3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9fd7326b-45b5-4d24-aafa-928248840456" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCAAndSubsidiariesMember_316db926-2943-4c9e-ad6d-f40e77b972c4" xlink:href="jan-20231230.xsd#jan_ARCAAndSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7528a586-54b1-43f7-b1a6-88234217b575" xlink:to="loc_jan_ARCAAndSubsidiariesMember_316db926-2943-4c9e-ad6d-f40e77b972c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3fab3ee9-0fd5-44e0-adbc-f83ee8528c51" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_f00ae3e0-04f8-4723-a3a2-9abefcafdc5c" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:to="loc_jan_IcgNoteMember_f00ae3e0-04f8-4723-a3a2-9abefcafdc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ARCARecyclingPurchasingAgreementMember_89a74c7a-441e-4b16-b94c-38c1d3d8b072" xlink:href="jan-20231230.xsd#jan_ARCARecyclingPurchasingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1df97122-0e31-473c-9079-d2c55b4c6b13" xlink:to="loc_jan_ARCARecyclingPurchasingAgreementMember_89a74c7a-441e-4b16-b94c-38c1d3d8b072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fec69e26-d0ba-4c50-90a4-a7f1f60157f8" xlink:to="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e8ce7463-9399-4a3d-aa2c-cf1407dec399" xlink:href="jan-20231230.xsd#jan_RecyclingSegmentAndTechnologySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52776710-7e69-4dff-928f-f99f8cb97d1c" xlink:to="loc_jan_RecyclingSegmentAndTechnologySegmentMember_e8ce7463-9399-4a3d-aa2c-cf1407dec399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_780b0e62-d8bb-487e-958f-014adb759942" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_JanOneMember_954e1f36-4c5a-4ad3-a03b-fb5a7a7fbc74" xlink:href="jan-20231230.xsd#jan_JanOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9268d5d5-d8e1-43f7-b33e-fe8839bfa4ec" xlink:to="loc_jan_JanOneMember_954e1f36-4c5a-4ad3-a03b-fb5a7a7fbc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_59328fc1-52ec-43ce-9b60-aecb93e0aa40" xlink:to="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacCapitalGroupLLCICGMember_9b0cbdbf-a67d-43d0-82fa-93b4e1d170d3" xlink:href="jan-20231230.xsd#jan_IsaacCapitalGroupLLCICGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_961d7b3d-1b59-4063-b05d-54a02b75700c" xlink:to="loc_jan_IsaacCapitalGroupLLCICGMember_9b0cbdbf-a67d-43d0-82fa-93b4e1d170d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86749513-fc11-428c-a3e5-4f49e5676c79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_043eb55e-cda1-423d-8b92-fc13b3546a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4beb24e0-6d54-45b8-b7fb-c3de566c3338" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_043eb55e-cda1-423d-8b92-fc13b3546a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5777a149-cd54-48ab-9d0e-f91efa0b6b0f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_1e5bbb00-0f0d-49a0-bbf4-5adcb16d103d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_1e5bbb00-0f0d-49a0-bbf4-5adcb16d103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_9acf84e8-d204-4beb-9f73-ea6e1d9e3763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_NetRentableArea_9acf84e8-d204-4beb-9f73-ea6e1d9e3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bebbdc3b-31d0-44ac-97e8-e1f00c7f3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_OperatingLeaseExpense_bebbdc3b-31d0-44ac-97e8-e1f00c7f3d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_d70adad7-8aa0-4e1d-ae0a-09da63b13bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_d70adad7-8aa0-4e1d-ae0a-09da63b13bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_a0333074-ee23-4f0d-a616-26ab96134032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_a0333074-ee23-4f0d-a616-26ab96134032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c1d5ebcf-7c49-4e59-8534-9d0e7da3b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c1d5ebcf-7c49-4e59-8534-9d0e7da3b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7216c044-d1fa-4984-ac9a-052dff4b8288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7216c044-d1fa-4984-ac9a-052dff4b8288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_cd052ad4-dabd-4ddd-a2dd-5086127993c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_cd052ad4-dabd-4ddd-a2dd-5086127993c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4b3069cb-3c62-45cb-92e1-dfb4ea19bb83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4b3069cb-3c62-45cb-92e1-dfb4ea19bb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_b3fd2ef4-9754-4f36-9992-f019f96b1717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_b3fd2ef4-9754-4f36-9992-f019f96b1717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_5d4f49af-6175-425f-98d2-d66b682f7e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_us-gaap_OtherLiabilities_5d4f49af-6175-425f-98d2-d66b682f7e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_ee856089-ac31-48f4-85e8-c1baad3ccd96" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent_ee856089-ac31-48f4-85e8-c1baad3ccd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm_190f4586-24e3-427d-abf8-ae7cefc86801" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionPurchaseAgreementTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cf019c52-7f19-45c1-b34f-868f408dd53d" xlink:to="loc_jan_RelatedPartyTransactionPurchaseAgreementTerm_190f4586-24e3-427d-abf8-ae7cefc86801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48971ddf-f21f-4fb8-b299-72f79a05dd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48971ddf-f21f-4fb8-b299-72f79a05dd3e" xlink:to="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f61231a4-e0af-40ce-b340-884355930c88" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SkyBridgeAmericasMember_17380134-7db6-457e-8808-d915ee38e193" xlink:href="jan-20231230.xsd#jan_SkyBridgeAmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_SkyBridgeAmericasMember_17380134-7db6-457e-8808-d915ee38e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AMTIMCapitalIncMember_b29d7cb1-9464-4b3c-a654-9c713ade4d57" xlink:href="jan-20231230.xsd#jan_AMTIMCapitalIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_AMTIMCapitalIncMember_b29d7cb1-9464-4b3c-a654-9c713ade4d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.SullivanMember_8ba6a445-8a05-4218-9a90-3f3ecc9e2d40" xlink:href="jan-20231230.xsd#jan_Mr.SullivanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_Mr.SullivanMember_8ba6a445-8a05-4218-9a90-3f3ecc9e2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AlixpartnersLlcMember_81861211-1541-498c-a708-59336b7c0000" xlink:href="jan-20231230.xsd#jan_AlixpartnersLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_AlixpartnersLlcMember_81861211-1541-498c-a708-59336b7c0000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_WestervilleSquareMember_23f3d6e1-b3d4-413c-9fd3-6ef52f3a1709" xlink:href="jan-20231230.xsd#jan_WestervilleSquareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_WestervilleSquareMember_23f3d6e1-b3d4-413c-9fd3-6ef52f3a1709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TrusteesMain270LlcMember_fdec8add-7e06-42b1-9689-0e81ce130cd5" xlink:href="jan-20231230.xsd#jan_TrusteesMain270LlcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78c7545b-1fad-4f0f-96b6-aa8372edda75" xlink:to="loc_jan_TrusteesMain270LlcMember_fdec8add-7e06-42b1-9689-0e81ce130cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1689ae5f-7516-45f5-b287-7eb552a3aabe" xlink:to="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da66ef63-50ff-4703-9383-1003ccef6869" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:to="loc_srt_MinimumMember_da66ef63-50ff-4703-9383-1003ccef6869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a978638e-14a7-4f67-95c1-e73b0128798b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b454a778-08cf-4ef0-affd-47885a356a7e" xlink:to="loc_srt_MaximumMember_a978638e-14a7-4f67-95c1-e73b0128798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5f684aeb-bfbf-4a77-b4a9-18f07ac76ca5" xlink:to="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ApplianceSmartIncMember_44274d6c-22c9-4992-aab8-a7245d9f10a9" xlink:href="jan-20231230.xsd#jan_ApplianceSmartIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c9d9317b-c9e5-43c1-8ec6-7b1797752451" xlink:to="loc_jan_ApplianceSmartIncMember_44274d6c-22c9-4992-aab8-a7245d9f10a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_071b07cf-158e-42ad-b9f9-f9d5a59a3433" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_GeoTraqIncMember_96a8b562-883f-47db-9a49-48d935daa253" xlink:href="jan-20231230.xsd#jan_GeoTraqIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c056b0-f2ef-413f-a789-c1fe4f80c3d0" xlink:to="loc_jan_GeoTraqIncMember_96a8b562-883f-47db-9a49-48d935daa253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_563d80d8-195e-43d7-af1a-3ca0eea34416" xlink:to="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d85b8fe6-8f7b-465e-a32a-7862c00a8d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7bf44bc7-fe5c-4d22-9775-a589a190396c" xlink:to="loc_us-gaap_RelatedPartyMember_d85b8fe6-8f7b-465e-a32a-7862c00a8d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_bc44fa7c-a591-4c01-907f-75da84e05319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedAndNonrelatedPartyStatusAxis_d5ba2d75-6f76-48fc-8be1-45528eee1186" xlink:to="loc_us-gaap_RelatedAndNonrelatedPartyStatusDomain_bc44fa7c-a591-4c01-907f-75da84e05319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12eef560-5fd5-4a30-a5f6-124f690daf56" xlink:to="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesA1ConvertiblePreferredStockMember_24091ed0-b680-44f2-a188-a5c9796042f6" xlink:href="jan-20231230.xsd#jan_SeriesA1ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8d66fe63-fc1a-48a7-a04d-3843827b18b0" xlink:to="loc_jan_SeriesA1ConvertiblePreferredStockMember_24091ed0-b680-44f2-a188-a5c9796042f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a877d94-75a6-4e6d-8581-224aeaa0e8fa" xlink:to="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02a2d067-2ed9-4943-87e1-9971432bad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57768a24-c86d-4d63-b8b5-e6b8dce97a44" xlink:to="loc_us-gaap_CommonStockMember_02a2d067-2ed9-4943-87e1-9971432bad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_d4d8f22a-07d9-4cde-ab8f-37550a31310d" xlink:to="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_2e421c18-a74e-440d-9575-acb600f93ebd" xlink:href="jan-20231230.xsd#jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint_2e421c18-a74e-440d-9575-acb600f93ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e0f14c92-d4ff-4f0f-9186-dfb51855377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e0f14c92-d4ff-4f0f-9186-dfb51855377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_42a605a4-338e-4d71-9b61-bb8ecdebf671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_42a605a4-338e-4d71-9b61-bb8ecdebf671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_5ef72d42-6cba-4271-9431-f20782e7acad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_LegalFees_5ef72d42-6cba-4271-9431-f20782e7acad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_StatutoryInterestReceivable_bd1b28ad-b49f-420c-83a1-4aa78da9ff43" xlink:href="jan-20231230.xsd#jan_StatutoryInterestReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_StatutoryInterestReceivable_bd1b28ad-b49f-420c-83a1-4aa78da9ff43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_489e4662-63e0-4eb8-9eb4-d0c4be208461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_489e4662-63e0-4eb8-9eb4-d0c4be208461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfInstallment_382ee860-18f1-4787-a229-8c807bece3ad" xlink:href="jan-20231230.xsd#jan_NumberOfInstallment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_NumberOfInstallment_382ee860-18f1-4787-a229-8c807bece3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_PercentOfPrepaymentTenderRestrictions_6bf4aaf3-3a2b-41dd-b740-d6f7d3586c58" xlink:href="jan-20231230.xsd#jan_PercentOfPrepaymentTenderRestrictions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_PercentOfPrepaymentTenderRestrictions_6bf4aaf3-3a2b-41dd-b740-d6f7d3586c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d6cc42f9-70e1-4696-b58a-965ef968e8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d6cc42f9-70e1-4696-b58a-965ef968e8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_addbde41-2619-4cc0-a074-dbbc3a788d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_addbde41-2619-4cc0-a074-dbbc3a788d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f8827d9d-bd55-4b14-9c82-5aeeb47a1584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f8827d9d-bd55-4b14-9c82-5aeeb47a1584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e6ff759d-6184-4449-9936-c59ace6572ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e6ff759d-6184-4449-9936-c59ace6572ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_AgreedSettlementValue_a38da160-60ad-48e6-8cb7-6ada4134e0f4" xlink:href="jan-20231230.xsd#jan_AgreedSettlementValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_AgreedSettlementValue_a38da160-60ad-48e6-8cb7-6ada4134e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTranches_b446cd3c-59af-44d6-b866-23f7c581761f" xlink:href="jan-20231230.xsd#jan_NumberOfTranches"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_NumberOfTranches_b446cd3c-59af-44d6-b866-23f7c581761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_357c4735-266e-4834-b525-b534ab45c0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_357c4735-266e-4834-b525-b534ab45c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1_de3a0302-dba0-4c91-9c20-7a5ab785fef2" xlink:href="jan-20231230.xsd#jan_OperatingLeasesFutureMinimumPaymentsDue1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OperatingLeasesFutureMinimumPaymentsDue1_de3a0302-dba0-4c91-9c20-7a5ab785fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_9dbc523f-a60e-4159-a56e-32dbb5587c6f" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor_9dbc523f-a60e-4159-a56e-32dbb5587c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_926cf7ae-8fed-4648-9f73-d0b1050daa63" xlink:href="jan-20231230.xsd#jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_60949969-91a4-4060-9cc0-fa0455623ae3" xlink:to="loc_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor_926cf7ae-8fed-4648-9f73-d0b1050daa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35d685c9-4018-4ec9-b24a-c33fcca18eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35d685c9-4018-4ec9-b24a-c33fcca18eed" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_f8bfe036-4523-4e33-a19f-89e2f925333e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_0430608f-21b8-4bb2-82cf-9ca159f462f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_0430608f-21b8-4bb2-82cf-9ca159f462f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_fc57f1e8-363c-4842-89ca-7b49255a08a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_60af1db7-b23f-4838-b5d1-3ab3c88a387b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_fc57f1e8-363c-4842-89ca-7b49255a08a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8c9da1d4-2dae-4a02-bdb5-061980f35c0e" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_4b31b693-e6f9-41a4-8c1e-413dbc10914a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_4b31b693-e6f9-41a4-8c1e-413dbc10914a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_5a20193c-dd45-4c7d-891a-9b44b7830843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_5a20193c-dd45-4c7d-891a-9b44b7830843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9156b38-aba7-43ab-bab9-be2fafb0e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9156b38-aba7-43ab-bab9-be2fafb0e4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21d1d7e6-d253-4b02-af76-5cdb10a92835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21d1d7e6-d253-4b02-af76-5cdb10a92835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_747db8a9-8f70-4d86-8532-6ebed81f919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_747db8a9-8f70-4d86-8532-6ebed81f919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ec04f09-72c3-4370-bad9-68aec150f67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_a8a1e2ea-4c15-4663-a904-b61c8afbb057" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ec04f09-72c3-4370-bad9-68aec150f67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_74e5dc1d-f5a4-4c0d-b7af-bb7c4107759a" xlink:to="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_b6a17f52-2a7a-4b1e-8331-436daf83f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_b6a17f52-2a7a-4b1e-8331-436daf83f8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b038f22-cf4f-4a44-a967-08578de7ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b038f22-cf4f-4a44-a967-08578de7ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b136c7f7-ee01-45bd-8db2-5fc583b20d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b136c7f7-ee01-45bd-8db2-5fc583b20d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_e834d119-db93-4632-ac45-e288f5c8beee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_e834d119-db93-4632-ac45-e288f5c8beee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73884146-28f3-4d35-bf21-4d173dd56e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73884146-28f3-4d35-bf21-4d173dd56e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1cb69e99-846b-4ecc-9aa9-fa905cb6e722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1cb69e99-846b-4ecc-9aa9-fa905cb6e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d041fa00-a004-426e-82e7-7b32dfaa12bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d041fa00-a004-426e-82e7-7b32dfaa12bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f99922a5-5203-4f4e-a1b1-92a7edf50945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f99922a5-5203-4f4e-a1b1-92a7edf50945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d30ba4b5-e813-4d31-882f-1e9d84ee2763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c6b5bb0a-accb-42b0-a3ee-ed87f9ad4008" xlink:to="loc_us-gaap_EarningsPerShareBasic_d30ba4b5-e813-4d31-882f-1e9d84ee2763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d2311c81-630d-460e-ac81-7b04d4c37eb7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_257d2993-9e55-43c7-9736-992b2eebddd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_257d2993-9e55-43c7-9736-992b2eebddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e91c1d2-0273-4e51-aaab-cdbbc4157e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e91c1d2-0273-4e51-aaab-cdbbc4157e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d81b362d-2016-4d87-8e01-8b663eebc2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_88fae996-44e3-408c-8e33-f658e4aeaf04" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d81b362d-2016-4d87-8e01-8b663eebc2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#EarningsLosspershareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_297d3993-cccb-4b78-99c2-102ba11d894a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ad992933-1c2e-4d96-86de-ebbd41bb1188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_297d3993-cccb-4b78-99c2-102ba11d894a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ad992933-1c2e-4d96-86de-ebbd41bb1188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_facbdb34-6961-4931-8d31-862087dad9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7dc7ff6d-179a-4e05-bec0-3b75158b60b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_facbdb34-6961-4931-8d31-862087dad9a6" xlink:to="loc_us-gaap_NumberOfReportableSegments_7dc7ff6d-179a-4e05-bec0-3b75158b60b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationScheduleofSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2fe82347-7810-44e6-ba5f-7de101cf9989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2fe82347-7810-44e6-ba5f-7de101cf9989" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4548130c-25d1-4259-b1b1-742008ba3352" xlink:to="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BiotechnologyMember_54902182-77f8-4976-9111-7ee49ebdcec7" xlink:href="jan-20231230.xsd#jan_BiotechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_BiotechnologyMember_54902182-77f8-4976-9111-7ee49ebdcec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RecyclingMember_826764ed-dba0-4bb2-9003-e0f5b960a4d6" xlink:href="jan-20231230.xsd#jan_RecyclingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_RecyclingMember_826764ed-dba0-4bb2-9003-e0f5b960a4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_TechnologySegmentMember_8b98353f-026d-4d6c-a6da-d91683fc11b3" xlink:href="jan-20231230.xsd#jan_TechnologySegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c403ac1a-5d94-4518-ab8b-8c5df778722b" xlink:to="loc_jan_TechnologySegmentMember_8b98353f-026d-4d6c-a6da-d91683fc11b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_da69a7d6-9aed-4d63-b147-9701a7cf8a94" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_eb758b29-0305-4a61-8911-df00d142b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_eb758b29-0305-4a61-8911-df00d142b9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_e0f632a9-d463-444d-ae50-645227df1635" xlink:href="jan-20231230.xsd#jan_ContinuingOperationsAndDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_39611bb8-f352-4212-b1f1-64813983d775" xlink:to="loc_jan_ContinuingOperationsAndDiscontinuedOperationsMember_e0f632a9-d463-444d-ae50-645227df1635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1370c68e-5b68-424c-bf5e-b6ec7728b02e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63c70e1b-a8d3-42cb-bd2a-35c802197c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63c70e1b-a8d3-42cb-bd2a-35c802197c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_feec06b6-5e1f-41e8-8c03-804b2b9d8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_GrossProfit_feec06b6-5e1f-41e8-8c03-804b2b9d8d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e0c175d-4284-41bb-a2ff-4a10f29cce04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e0c175d-4284-41bb-a2ff-4a10f29cce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7c6c788d-2391-48ac-a405-573e3c5f9aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7c6c788d-2391-48ac-a405-573e3c5f9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_2c2454e5-6b42-469a-942c-a3c76840f165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_2c2454e5-6b42-469a-942c-a3c76840f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9aa5b51d-83c7-413b-b450-35c63a9db721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b2540c0-f21c-428e-b4ed-ba1833a0e33e" xlink:to="loc_us-gaap_NetIncomeLoss_9aa5b51d-83c7-413b-b450-35c63a9db721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SegmentInformationScheduleofBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aef8cdf8-c17e-4af5-afb5-a13621ecde78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aef8cdf8-c17e-4af5-afb5-a13621ecde78" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30b5e6f2-e7b1-4d93-842d-8d89140a0de9" xlink:to="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_BiotechnologyMember_acab2dc2-54ad-4d7a-93e4-3c07f8cbb4e4" xlink:href="jan-20231230.xsd#jan_BiotechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7763b4c9-72c1-4443-8afe-6d3316978107" xlink:to="loc_jan_BiotechnologyMember_acab2dc2-54ad-4d7a-93e4-3c07f8cbb4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_b0596764-b3fd-41ab-9f05-83fb7d359ee5" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b6509710-7a6f-45bb-ab7b-847de075a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_6c587de3-28ee-4b6c-b60b-206452a047a3" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b6509710-7a6f-45bb-ab7b-847de075a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_86bd4ac3-83d3-4e84-b76b-d57940583125" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3062ee66-a9ef-4ae2-bc2a-8cc84d3bb891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:to="loc_us-gaap_Assets_3062ee66-a9ef-4ae2-bc2a-8cc84d3bb891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_348fa2f6-a630-4989-aa08-4f6b34e27ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df0b3a6f-655e-473e-b07b-d1ebac78a79c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_348fa2f6-a630-4989-aa08-4f6b34e27ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.live-ventures.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="jan-20231230.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.live-ventures.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8f63cb56-af46-4f65-8c4e-959b28161f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8f63cb56-af46-4f65-8c4e-959b28161f04" xlink:to="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_149a653e-6db7-4448-a45d-079e9cc1cf21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c0730c5a-d7d6-4b9c-b1cc-3e328fcf26f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e77b7f26-5b8e-42ee-a333-dbb2e9460ce5" xlink:to="loc_us-gaap_SubsequentEventMember_c0730c5a-d7d6-4b9c-b1cc-3e328fcf26f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6748c4b9-318d-410e-ab3e-d51e1502feb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2b4cc330-9bfd-40ff-b9f9-82c1082c21d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_911b2801-0c7e-4674-96b9-c7cc92efa6b5" xlink:to="loc_srt_ScenarioForecastMember_2b4cc330-9bfd-40ff-b9f9-82c1082c21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da8bb7ff-239c-4098-a48b-575405f83e92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_3f22cfcb-c831-460c-b52c-4318e84be2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db5a4e69-fd15-4cac-a64e-bff59b00111f" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_3f22cfcb-c831-460c-b52c-4318e84be2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b1e8406-6ebb-4b14-9a07-0ef022cf8e3e" xlink:to="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember_713de295-7f31-4cb1-9f61-f4f585f563b8" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:to="loc_jan_UniversalLifeInsurancePolicyPolicyOneMember_713de295-7f31-4cb1-9f61-f4f585f563b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember_4a4fbaff-8ed9-4bc1-8040-ad3db5ca0d89" xlink:href="jan-20231230.xsd#jan_UniversalLifeInsurancePolicyPolicyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e10f68f9-c521-4ec6-afce-a598ba48f8b1" xlink:to="loc_jan_UniversalLifeInsurancePolicyPolicyTwoMember_4a4fbaff-8ed9-4bc1-8040-ad3db5ca0d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fa2f946d-0408-4b00-9c5a-4946d94dd1f0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IcgNoteMember_31648a17-2048-4e90-aedb-215483ffd835" xlink:href="jan-20231230.xsd#jan_IcgNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:to="loc_jan_IcgNoteMember_31648a17-2048-4e90-aedb-215483ffd835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_IsaacConsultingAgreementMember_b8616558-542f-4796-b589-e7ca8bddd033" xlink:href="jan-20231230.xsd#jan_IsaacConsultingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a18c44fb-1906-45de-a2c9-413452423146" xlink:to="loc_jan_IsaacConsultingAgreementMember_b8616558-542f-4796-b589-e7ca8bddd033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bff6d1d-e516-4d6a-b61d-35b90715d0f6" xlink:to="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_37afbb3b-9721-428b-a0a9-046568cee5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9ec8d578-d221-46ab-bd0d-d39c43290ad9" xlink:to="loc_us-gaap_RelatedPartyMember_37afbb3b-9721-428b-a0a9-046568cee5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d732637d-fc99-44e4-85c9-fd5a7607673a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_Mr.JonIsaacMember_d074ba4b-86e5-4dd0-aafd-a60151404d95" xlink:href="jan-20231230.xsd#jan_Mr.JonIsaacMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_04a972e3-b4d6-4cd1-9a28-5efa758aa77a" xlink:to="loc_jan_Mr.JonIsaacMember_d074ba4b-86e5-4dd0-aafd-a60151404d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc172e69-c6c2-41e4-acc1-314f2fa6507e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SoinTherapeuticsLLCMember_ea53c095-d0f4-4128-98c2-9fc573785a54" xlink:href="jan-20231230.xsd#jan_SoinTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80c98fcc-6aaa-491a-8703-fde8c4a5eaa9" xlink:to="loc_jan_SoinTherapeuticsLLCMember_ea53c095-d0f4-4128-98c2-9fc573785a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8e05ecd4-bfda-4b05-ae58-cc9106ad51a8" xlink:to="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SeriesSConvertiblePreferredStockMember_b3e68c3b-de51-4b4e-a365-2345fe5deb89" xlink:href="jan-20231230.xsd#jan_SeriesSConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ff75fcf-a706-4905-8558-b3339695e88b" xlink:to="loc_jan_SeriesSConvertiblePreferredStockMember_b3e68c3b-de51-4b4e-a365-2345fe5deb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8994f04b-5d27-4857-b485-40b90cb5d367" xlink:to="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_342c948a-b907-4544-bc6e-4323285a4ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_342c948a-b907-4544-bc6e-4323285a4ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ca802806-22fe-4510-82f3-6c8206762c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ca802806-22fe-4510-82f3-6c8206762c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6398a786-28de-4443-b28c-620ee94818bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6398a786-28de-4443-b28c-620ee94818bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9aa59909-5195-424a-ade1-d62c0c55f279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9aa59909-5195-424a-ade1-d62c0c55f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d8fccb4-a19a-4ee2-b86b-26b61383991c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d8fccb4-a19a-4ee2-b86b-26b61383991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_974a39cb-47af-4d24-96cb-c0a37bbaabfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_974a39cb-47af-4d24-96cb-c0a37bbaabfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea7077e0-8e8f-4fcc-85ec-2e4a72a1aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea7077e0-8e8f-4fcc-85ec-2e4a72a1aa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cda85b8-14d7-4381-9ad3-00fa7bb25ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cda85b8-14d7-4381-9ad3-00fa7bb25ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_92f6f79a-b920-47c4-9ef0-12fbeac9a83b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_92f6f79a-b920-47c4-9ef0-12fbeac9a83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_43995231-1a8f-4f32-b85b-3a7d5c48a58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_43995231-1a8f-4f32-b85b-3a7d5c48a58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfAgreementsToBePurchased_c8bab0d2-e877-4d09-a52f-bcafd1f2f3f1" xlink:href="jan-20231230.xsd#jan_NumberOfAgreementsToBePurchased"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_NumberOfAgreementsToBePurchased_c8bab0d2-e877-4d09-a52f-bcafd1f2f3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_56388cb3-9ee7-4f80-8423-ad4f06f8fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_56388cb3-9ee7-4f80-8423-ad4f06f8fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b4a3db86-1743-43a2-8eb8-0183c780e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b4a3db86-1743-43a2-8eb8-0183c780e80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_c387ef55-7d5a-4541-b45d-ce2139cd5bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_c387ef55-7d5a-4541-b45d-ce2139cd5bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9beb533a-af21-44f0-8b77-072005f1cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9beb533a-af21-44f0-8b77-072005f1cee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_28e8ed38-e386-47c5-bd91-9a48a488688f" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit_28e8ed38-e386-47c5-bd91-9a48a488688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_113f3e06-d2b7-4655-9dd8-bbc4cf5ffa8f" xlink:href="jan-20231230.xsd#jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit_113f3e06-d2b7-4655-9dd8-bbc4cf5ffa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_ClassOfWarrantPricePerShare_f2763d41-6325-4cc9-859c-cdbbc52a822c" xlink:href="jan-20231230.xsd#jan_ClassOfWarrantPricePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_ClassOfWarrantPricePerShare_f2763d41-6325-4cc9-859c-cdbbc52a822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c36cefb-3fad-4314-8848-cfac04dcfed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c36cefb-3fad-4314-8848-cfac04dcfed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementTerm_517cee87-78e0-45c4-a73d-12cc052e02ca" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementTerm_517cee87-78e0-45c4-a73d-12cc052e02ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_9d72ef61-47bb-4141-9692-8fb5a3779451" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned_9d72ef61-47bb-4141-9692-8fb5a3779451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance_f8a46daf-9b08-4615-9f24-1f91a8fbcb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_us-gaap_CashSurrenderValueOfLifeInsurance_f8a46daf-9b08-4615-9f24-1f91a8fbcb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_2609e25d-2375-45ff-a47d-a02619b96ecf" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds_2609e25d-2375-45ff-a47d-a02619b96ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_806f800f-d3e1-4309-a41c-968248efe788" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementSharesIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementSharesIssued_806f800f-d3e1-4309-a41c-968248efe788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_NumberOfTradingDaysBeforeBoardApproval_d6ac1012-f990-4cea-a452-e848f312f8ea" xlink:href="jan-20231230.xsd#jan_NumberOfTradingDaysBeforeBoardApproval"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_NumberOfTradingDaysBeforeBoardApproval_d6ac1012-f990-4cea-a452-e848f312f8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_b834c7fa-bc83-43ed-9358-54ecbfb57f13" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm_b834c7fa-bc83-43ed-9358-54ecbfb57f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_bb215058-16dc-45ed-98af-95bd7d8b5fcb" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate_bb215058-16dc-45ed-98af-95bd7d8b5fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_afea056c-7a5a-4483-ae4e-3227568de7ef" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount_afea056c-7a5a-4483-ae4e-3227568de7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_3e97ea2e-da9f-4ebc-9cf5-3f3ee1cbf963" xlink:href="jan-20231230.xsd#jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6b8b079d-4765-4944-a0c9-f21a22849c32" xlink:to="loc_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice_3e97ea2e-da9f-4ebc-9cf5-3f3ee1cbf963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jan-20231230_g1.jpg
<TEXT>
begin 644 jan-20231230_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "K 6\# 2(  A$! Q$!_\0
M'0   00# 0$               $%!@<"! @#"?_$ %L0  $"!0(" P8/"0H.
M P    $" P $!081!R$2,1-!LR(W46%ULA05%B,G,C4V<7)S=(&QM @7)"4F
M,T)VTC1%56-E@Y&AP<)&4E-45F2"DI.4HJ/1X4-$8O_$ !8! 0$!
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M0 &\.-MS+4Y0I%;*N-LLH&X(W W&\!K6I=C%T,SJF9:9E'9.8,L^S-(X5H6
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MB?GZ9+34XQ@-O.(RH8.1_0=_%&=-M*E4MYEZ6DFT/L-J9;>4,K2A2N)203N
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MM.OEI_[,8"PH2 <H# 0/33W4O;RTOLT1/8@6F?NK>WEI?9HB>P!!!! $$$$
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M,Q#I?4^R&TK#-R4A S@]',(&_C\<.='ONWJ_.&4IE:D9Z9X2OH9=Y*E\(YG
M@'^"$'*%@$(R(;*E;5)K#S+T]39:<=9W;6^T%E.^>OJSOB'2$@*FUH&+OTL
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M5(ITS9M:#\M+(:<X4H(R!@_I0]??"J(_P,KG^XC]J \-0??G8'E![L%1.TD
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;;@8QB%Y0"<(\$)P)WVYQE! 8\"?!&4$$!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jan-20231230_g10.jpg
<TEXT>
begin 644 jan-20231230_g10.jpg
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M8K*8EE*+0,?ORU:J[E74S,24G:64IIIH-((F+E"4LIL57))-XD$>&IV,&_\
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M'6<@:6=>D2;PU-JW)TJF J$QBZA561QUL[FUAJ6Q51,Q90X=S,TTH<Y*O?\
M5N 7^]*HB0BQ(CB""%G!?VW47\>8^43'U&M^2>\_&8Y(T,4*Y2V,S3.7)LZI
M[6T*KTU7.4E+E%EI1]33"')M=U!2'T-E+Y"&W"M"RD%(&8$@6QY0E:<PYL4Q
MG5&7.9=DZ>X^E0ZTV-O@MZ8J$SR@)/$<O]F).>7XM+,-OJ(43Y9">CVD9;$\
M1'5-;<F*QB>D414WF<4X9QT(=O=(NE(/6+  ?P85*]M!*)3(N< 7EOS>8G+U
MGN[8A+&.T)^;\82V^;9C=6<@'T_QN[(A3%&/%2*%..S^4)5:P"E*OU]Q!N._
MULA>V0-3?.+J01E7JVV#9=P+7.G'LN+0J4K:TNI-.7J(0ZE:"3KT4@D*MIK?
M=>^EKQ).%MH%/JDNI*9YTO*%\N8I*=-";Z<.$+AQ)D0D"I(:44A(;*S<D=EM
M/\^R-"6QHLS:LDTTI9)RG,5$=E]/VWA1E:X7U*2EU2<J<RWQ<&XTUL.X>CMA
M/J-<>L4)F'4E)2$J;.50-[VZ5KWTOQAEXQKBVI9:3,J L;#4@JUZNK?%;\<3
M"IHD)?R!0^_<5G4"+DD=9(XZQ'A=6%*Z9&4W&O'T1B^]S@MG)TUU)N?3&O!!
M!!'L;X$G[B&/?RC3^JM1>?'6(?L6KQ=!"5*0%%7'>;?%$(XPQ('TEOG03FUN
M?XZ^$1!B.=:2\I;BT+-\R4JXC4@B(;Q[/T^8YPK=N@@IRIT5E)_C6*RXIJ<H
ME^8:;=2A*5"P205;]VHUOQ[8[<*R7CE4EF4*7,.N.);;9;3G4\M1LE"1Q))M
M;CZ8L]7<9TWD^,.X;P\IE>T!;7-5FMM+"C3E*%C)2ROO5)&CKJ=;W2DZ&(?<
MQJIR6)?#"E$DJRJOK;>3P/Q\8;51Q8VO,WSB5,"]PFUBF_?K&FG%"7DK2MX+
MO;+91UZHY$^IW*ZIX.EW<@FP%@2G2_Q1@7PD.3 )URBS1'1U&]/#=OC?9FF)
M\E#[P+83J4+ 4K7<;\.SNA*KV&Z*\%NK]V:!*UC*0W>U@+\1NX;XK_CV@-TN
MI.@("%J(.5  3QW6]&D,P[S#^V.[:<0[&J^_/4=R7F9"=9,I5*-46N?D*I+'
MRF)EHZ+01N/E).J2"+P]-NNR_#BL.4O:CLU2^-GU:=,K,4N8<YV8P[4@DK7(
M.KMTT%-ULN'5:!8]))B#8((6<%_;=1?QYCY1,?4:WY)[S\9@4;).E^R*EXEV
MFXZJ&VD..[!J/.42GXKE</)Q%4$..U-<N7$%$RPGQ<@-H*E3 <S\VE*2+AS2
M)@Y4LK+3O)XQ_+3;8>EGZ4ZRM!W$*LG]N^/G]HNVFOX.PY6L/RTRM+KQ3+"8
M0K5#:%*-@?\ M6/=%C.29B1PX>G,1UEZ72ZZZ)%AY5RX2G4G7B2?V=<.[:[M
MHI6$6W5U'H\ZE00VDYEKL-!;MOU6T-XJ[BGE&SE4==$C*%MHJ!0IU>HW\ >V
M(UJ.+YRI%P/ 95JS9038=VO=ZH25SRUJ*K $ZW[8S9JTW+Y.;?6CFR"FQW$&
M_P <+M*VD5RE.\XU-<XJUO=4W-N^'-2]L4R7!XTV4KO?G><)[-^\;]\2;@''
M35<R./MYF&D\XIY N,XL/))LDW(M?K]<I/XCHDW(S19F6V5>XY&E'I@@G-?A
M8[]">X0PZUCI%-0WXNXA)6 $J6K-QOZ1PUZH9=0VCL34S,2[LLII)<#10ZX
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M">S77CIOC:I&%ESCQ'-H<0?ZJ1NMO.F[M[8:>-L'S#[#[#*&\NHL$J( UUS
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M[Y2_UL'L?>1G^!MF?OE+_6Q-&PG!.RG!-#J,MLHE</RM*=F@Y-HP\^AYLOY
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MI#]$J<Q)3  =964*RJS#0D;_ $1H0001[&^!)^XACW\HT_JK4>B[KB6T$J(
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M)&73+,M*1[E=1)4$CJW$]9,2AM%VQ2DC+NI=G&F1J$E.ENN^H[!ZXK57MN[
MFUI:YJ81J"I*"H#@=^_=\,1U6]I,S4,X0AL%2<N=&9)W[^_MA 5B>=*@4N%
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M$$$$>QO@2?N(8]_*-/ZJU&/+)VNL;/N5J_(/.B5,UA65=:4DBZU)=F+W!W@
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M&ZNX6UM'0_0F$3H3S:0I1"M59E9QJ"=>K6PT^&.Q%!8K:T.NK<#)LM#CW0!
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MA/-$>ZEPJL H[P.))_;&W,R04A332$+*-5*43SBCJ#J8ZES$O($LK;#W$AL
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M7\I1XW)A+F0TA#B4I96LJS-I%\MQ8:GCK;2&I5*&'&RU:[3=@2E&^^_X_5"
MK"@6%V!6I)L5N6-U>KA#<KF$4AAUQ*4VOHHIW [K"VZ(]K>!F9YT (#RD\"K
M(#KN(MIU Q&V/=B:9E;I6PMUE0*D*<LE0WWLH#A^R(+Q9LYGL,/9E-IF),:!
M\=)02=;$<+7ALA3)*@4 J L@J6$D$[[7C6F7&;94E2;< ;7%R2=1&F\CG@5H
M4E(U!N22G?:^D:H&4*038@9;6U$=1LE*M02(ZK]1CD'?K'&8Y2+QC<PLX+^V
MZB_CS'RB8^HUOR3WGXS KR3'FWR@I-52Y>F&YG$.&&)>IR]2H+-+4UB#,Y4)
M7Q]>688EE2))6V HO)2Z VA1(-U%47WVL *V<U\:D>+'R-YU&Z*IRF(GY-"V
MVJ:E.F;,D](CC8?'<QNIK$D]+JYR1*590A:G&O)M8BY$='V1I*&4K;6%K!)!
M*KY0=_=I"'.3P+X2R5.M DI4>B5=O=\YC56^R\^E(N%K.YHZ;CUPJTNF!QUM
MM+.5@*T!407#>^IX"T2[@'!*9^10A;16GRRXE>J'+DZ'T_!$I2&#I5B70VY=
M:4BUE:D]\=->P_SS+266QS*$Y>C:XA,DL."9NE2LZTBR<R01;L[8[IW LH^P
MH.RZ756WJ3U=7JB&-I.QZGSTI,,*E0M+B;%MT H4+$%)'$'B#'G-RC>0FNF,
MSM:P1+.IF$DK<I U;6./-'@?]4W!X6BE$[(3%.FG9::97+S#2BAQIU)2I!&\
M$'4&.B""""""/8WP)/W$,>_E&G]5:BY^T5U#-<0HHS*YA-K[MYAML5.460HV
M*LW2';&VXIJ=;(1E*MZ2JQUA,G))2F@3E"U'>I5[VO8 7[-\1UB690W,%1;M
MD;T"C9(2C>>V^D(*V@L)0;-(*QT4Y;"QUN>.EKQI&00DJ;R.+0'%)S7-[\-(
MW96A"81=M >2+<XJ_24-;'LUA#J-#6W+J#J3G3F(!3P/ :]N@ZH9=4H:$L %
ME3S@"K(!O?3=J?A[8:&(&5<TRER6<%D94MFQN#K8W/>(C?%.$9>8E2O*"S:R
MD6OI?73JB(\;;&)&I4]<]2F1+3-LZRD$M$[[$7^'3TQ!55H=4H,RZW499;+P
M22,YLE0MK90WBWQPCN/ !+J0 3<'.K>/7&@ZZEQ2R4I)!/$VM'0XL;A:_'32
M.BT<VN.JT -@1 ;<(6,%_;=1?QYCY1,?4:WY)[S\9@4;),4?V]U6=D^6EAEU
M%;G'Z3+_ &!:FY<MU,RM(6_./-LE2I>:::2J:6,@SM.@E S@)N#;[:&TE[!%
M90I.9*F",OIBL<U3Y?*ZI0<'1R!2>%AZMT:;,NW=7,E0N=4&]\I[/1'3.2%,
MD$ OLA7.:E.6W'2^D)4U-RCS);0P&W%6;"TJN;"_9&E)TB76ZKF;MNBR4DC0
M:[^TQ(6&L.YGTETW</1#9UN+]?=II$PX*8%$95SB0E)438'<3_E#N%0840.<
MT(N.N-M*T*! TMJ1 F7:!S)2 KK$#R!S2M=!U;X;=9HS<^@@M GR0H'=OB*L
M<8 5,2\QD:"U(!(0HY;]5S%)^4_R.*3M%+E4E7DTG$B4$)F$(NA_30.) UZ@
M1J.T:1YMXOP96,#UF8I=;D'I&;:41E=00%BY&9)X@]<(D$$$$$>QO@2?N(8]
M_*-/ZJU%DN45BB8HF)Y1MHD),J#Y647NJVO;$84?&TX\AO.M2@4BR@;BQ)U'
MSPXY'%DR5I0V"FZK7ZR/60(WI_%[CDH$N$MJ S+6FQ*=2+'O'"&-5*XW,)*F
MW.<4$\V!?351\KJW".*=,^.OM(=2VTHO*N$C11(TUZN$/*DX:?JB6W@"+(-E
M!/&UO38@PZJ7A!$LA86+C10[#;6T=E3P_*O)"2$(Z)3J(C6NX01++7F3=LJL
ME2#N&L,NMX*EG7U+:==(6;I;*+V(&NG"&#/;/&W4E2^<S*64*2H:IU%R#;3N
MA'J.!F3(.+ET<XI-PM@I\OA<]_9ZQ$+[1,"RM5EYAA^52XP4ZI(%T;SI>_5I
MNBKF-=FL[AW-,2:%SDBG5)*>FA)/$#>-^[U1'O.V6<W2!UT-HP*].L]9XQP%
M:=L<9B+]L<0$WA9P7]MU%_'F/E$Q]1K?DGO/QF.3H(HQRD*E+RO+3P%+S*L*
M/U)Q=$<I<U/%CQJF-B>=1-)<065+<\8#B$,$+&1Q.89=2;H8J0',-U%)3F',
MG2UX@6H4YZ[QYH!(/DH1O/ >J&L@J2ZY,3*5,(;"NCEZ1MP/^4-MR?15E <Q
ME#RLH45:%7&VNX<3"?4.9I[YR*2I.6U@-3U_#&FBNML3-R]8*4 HZ;^Z_8(?
MF&L:4YM+9$QSJDCI$GLW6O$B47'8F6TI2$*1895%0N?AAR-S#528<2AT(=(%
MED V-[@_!"W1J@XVI*)AWG";=+=?T7A>"T.CHJT(TM&+A<2+Y0<O7"%/3SB5
MK-R$#K'\7A#JSH?96XM6X'0&V_CJ8AG'*&N9<5E2O4@"PL.%]#U143E.[(I#
M:CAUP**&*E*DJEIE*<Q2>(MOL>(XQYPUVBS6'JK-4Z=:+4S+K*%I(]1[B+&$
M^T$$$$>QO@2?N(8]_*-/ZJU$V\JUQQ.+F0%N)M)-Y A 5F45+Z]-(@-BJ3C,
MTD/LN)/DFPN5=^G[;0Z*?C=4LT;M72L  HLI:NO=:P^>-X8VDG+(4 T5WOF2
M+6'#40WG:M+K6XVPX7,ZBY8M^5<VOZ-PAZ4!MQ#Z'#JEQ1)&73=I$F4&>99=
M0A S7%]-+'JA\L+06"H$:CJO>,U41^K);6RT3;0N*&5([R=(U)_"-/#1\>G6
MT"Q.2607#Z]!#*F<.X7E2ZIUJJ3SJ$G*I*FF>/ 65\,-2IMX4$TMQN@3Z["R
MRY4!F4KCH&[=6HAOSXP2VA*%T&MM$I*E&4JJ I)ON(4T3KU[H8U7P#L_K3<S
M-C$57H[JE)3EJ%+;?;U)T*F5A2N\)B/\1<EBK566=_DM/T;& "2HM4N8"9D$
M<#+N!*]!Q .^*.[;]D,YANN3B13GJ=/M7+]/>8+*Q;><B@"".[6(7((WBT<0
M000LX+^VZB_CS'RB8^HUOR3WGXS'*C9)BEG*!V08VQ/RPL$8II&S*F5B@4Y=
M*6_B1;S@<RHFU<ZA;:9EM*BV%)<25-KRA&F8G*FW&,JDFD87J4ZI02EAK.5'
MO$5ZE-H+=)Q(])3BD+9,PYXN\XDY74FQ( OO!*1Z89>/<>-3[=YY2 EF82PV
MA)-E'+FN+$=8)MU6TO#.:Q4^GQ=T2J)9EMM2 D(!*@>)&Y/'0>F\,NMXP?\
M&7D_S#:3<J*+E1MIQA@3NTY+3JTN3" X3E3<:'>+_!"IA?:5+Y0/&6M+)N4[
MB2=3_'&)BPMM-E9=;:!--/*L.@D6S'JU^*)BPOCMJ8*5J4E+E@E0$2'2JRS,
M %#B%"_]7^.N''3JH$= A-[9AT876Y]"T#.-%=D)58ERW<I0E:%"_;I#(Q$
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M&^/:-06Y83:I92ZC-+;)RI4<V1 MO)!&AW)M?C$@UW&#--IA3,A >+73*+I
MMO%['=_'&(6Q1M"%3=*6@I(N=2JUM>CT1O'48BRLXQ8E)L.HR%W7I*!R\<IT
MN-]Q<:PB26UB6E)A?22LK< NL^4.M/=O^>)/P5MPE9F8:0Q,*<F+E24K.O\
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,@@@@@@@@@@@@C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jan-20231230_g11.jpg
<TEXT>
begin 644 jan-20231230_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I ;D# 2(  A$! Q$!_\0
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MI7[T4]6:(N7*2EME#16>2$= *VPA'L4>2:7<)MDXO\1I3S;?UXWAU:\8!?\
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M.*W--.G4M>+1K1>;C#EN-?5!^&=V Q.1N'SFM]VU'*^IZO.8,:YH\8[FU7M
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M-%2B4I^45VZ:;BRW5J4GIWBH]+205TZ:6!:2X=V#6>5R=B\?DUM--<,V4M?
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MTI7];]W6LGTY*5#/LHS5CX((-QH5LX97X_\ 8_IJI<%X+4.9]E6OXXKQPNU
M1S^TC^.J<PIO9GKBMVFX9DK*[)O&1M3D'I73),-,1QV4PT^D#X+B <_/3);+
MD%<E*%/J'67&%Y0'$*&"DUO3N9TT<,I&FOJ<V\_:HBE.?<=DG(^:F.7"TNM"
MLZ>:6T.JFB/]-:;[I>/+*BTZY&'@D[OR&HZGAU+>96(]\E-$]$J;3MJMY=C9
M3G2^:0XM0],P'5/6FU/1WU=5=HH)^;-<,;S%JX^<H!9?4=JF@YZ/MQ2A<+;X
M4E#FI-C9Z[&>8_+7IC@]%AK6[)O=RDO$_"0L-@?(*K=_TFI:FG2X=S5,T_;9
M;JWS<NS63S!!Q3+O=@3%;;T$QD'/9H .\4^S>'C79*$*]3X[XZ%U0=2?:DBH
M3J72VIK6RX[V<*[,)'-31[-P_(>56<E'E#H:N,N6=EYU\A)((+VWD".M-[FK
M6+O%*%HW<L%)J'-7-AE.R?;ID1YSIO;5@?XW2O#UWB0)*D-O(0>Y*R*4YI\&
ME.G+@=+HU97O]\,E*AT5M!%,;5J@Q97;0U E0P=I]'YJQ)OS<D+*GDJ'>1@F
MN2S.,JD.EI[M,=4_>UERO+<76A'RFUR2ZVMY '2N.S7]5@U<[:B4+:<3V@;S
MGT3U!]M136O%")HR*J.P!(N[B<-1^N,]YIFX5)EW&_KN\TJ>F.X4XXLX ]0S
M5W)-V1FT49QDY/@LH>'L=JX,S%M8'HJ;<2GJ#W4]W2>[ F1B'"VR$E(220*8
M7=:NO6UEDNA(9'5/,FF5.L(SRS(><5);9^"@]QIV48G5C4=KS"O;;8!;UR]^
M"1N*QDFF"T0I%UN*I&  5;4NNKZ > J -<8IMW1(ML1)!6-J$M=:<]/6*\AH
MKN=P4A*CN0PA6"!ZS4YI\&*K6CU853;[;'3MD7%.?NO2S7J,XL+'U%;#Y^^6
M< U$68L=E&.:_'>HDDU.=&N!IK(& .X"FK?H<NI4B^@WWAZ6&%>?,LMOG_HR
M2*@-TE+4A6/''*B!J)"YTM:4 G/0"FEOAY.N1]%I>3TSRJDEL9DP62TGKSYF
MI!I^*$Q2M2,'QHDV_@%=;CL"FB$$CF1RHMZ9\FIB+$0B:1SYG%97)(:KOH2G
MR8$A/"YD#IYY(_ET6JC^A]*1=&V--MAD%E+BW.7BHY-2"L3Y9J7 ,6D[O*'N
M@SC_ &*P^8Z_[\DTV'R7-%..N.$W,*6HJ($OES.>7HTZ1_W1%T_%:'^>R:)0
M'(TJFVLBD4MP/N>2MHA]!0OZIE)[O.__ +:%G%7A-P:X/W#3S>HCJ&.S>Y1B
MMRV)!6S'4!G>\0GT$>*N@[ZMHGOJ-:JT!9=77:U7"ZQ?.WK;VO8-K42T0X@H
M6%HZ*!2<8--R9;%%;G.&/ B&P^NY7BX6T)?=8 E3OAAO&YP;4G[6-R?3Z<QF
MN^!PDX$/ZC:L,343SMU6X641T7'F7 @.% 5LQNV$*QGISJ>1/)-T-:K1]3;,
MN]V-DMR6%+M]T<0M<=]04Y'*CG[7E*<)^YQR(I^_H?M%)3:VA;%JC6^<N>Q'
M6\HM=JN.(Y"DGX2>S &T^VK*<EPPQ0(-0\.N".BM1R[9?IURMZXT=F07Y,TE
MISM5%*$)P,J42.F*D%XLW  VJ+$4U:DK?82\RJ(E0?6DA6W*@/1*MJL;L9(Y
M5F5H[A?Q#T===4,09UFMJ'/J6ZF&M,;88TA2!M;.48W[NH](=U,ECM7 >P+%
MMM.OI5O[)H1)L:->GD>>I;6ML=O@>GL4M2<@@#D#R %&<NY88K?PW\G+4EB-
MW:N\B T&VWEI<G+9<&_DCT2GTB2"/1SDC%:YW"[R=+:S'?D:WG-MR&P^A8NR
M^2-^S<K"/1&[T?2QSY5*K?8."'%VZ_6^W,>5=[7MM45AZ6I#R3$5N2MK.4J(
MW9SS)'440[;Y-&B+7895H9AS%QI4417UKE*WNH#P>YD8P=Z0>0'A0IR74E-K
M@ ,[@9Y.-U]*7J&Y/P@VXXY*>NN$M*0L(*%)4C=NW$#&.^I!IGR$^!NL;4)]
ME?O4F(I11VC5P*"% \P06P01X$47+MY,.A[W=[G=)46?]4)[RY#CR)RP6W%+
M"RM'WI"D@C%3_1^DFM(VOS-N=<+D2M3CDJZ2E2'W%$\R5'^(  >%5O<NJDUP
MP$0?V/[AA!3AE[4*1C'.Y _YE8D?L?O#&5%=C.2-1%IT@J NF,\\_>5984J@
MAU)/EE=+9Y!W#&U(2AKZMJ"1@=I<=W^;7F1Y!7"Z2IPK;O.'!A21<.7S;:L;
M2H(SEW*Q3OV.WA-<6@V\+]M P FYD?YE0W6OD)<#.'R($ZXIU,A$N4W#2MJZ
M$A*E9P5>CTY<S5SZCFLM$6S7,2-&NS;JVHLE$IKL75-D+3G!R.>*BP92[E5]
M/\&O)MM\!Z?!U')<9C.):6Y]45KW+)( 3Z'IDD'X.>E.)L? :^ZB>L:K]<8S
MK1:;0X91;9=+@.T!6SD>6/2Q4SU+Y/\ PYX8VJYZID+OS;R'FG42XDT^<1U[
ML)+6 !N]+!)R2.IKWJ[1G"K1L)R'JJX3VXM\[&X29MUNBUEPL'*"M2CNYE7,
M 8/JJZDUP6\R:5KD)/#;R=K?%E2%ZJ<2W'6$+)N).5%6T!/H95E7+EGG3K9F
M.!-B@2G[1?ES5MC*VQ*^V#"@DCTT@ @D9&<CPIHA:5\G2QQ95RMU[5.$0B:S
M$BSE;V>Q7VA2TG:D\B<E*B3CU5.M/\-^$7&BRA5HF/72.R\J4XTQ.6A;3CQ"
MR%I/,9(&.[KSJ<Y=RKE)[-G?I33W"_55X<A66\NW&>SE:F6Y!4GEUPK;M.#R
M.":)U[T%;=0VQJ#)5);C-@!*&7=OZ*9M%\&[+H*>9%IE75$- 4&+6[/6J&QN
M.5%#73)/CG'=BI\GX(S49-E++@'+' 33$=)"#/Y^,G^:M+_D]:4D+"G#<"1_
M=/\ -1-I49/N%DA@TEHNW:,A.1;=VH:6K<>U7N.?FI^%9I54D9]4Z8AZNL<J
MTS^T\TDIVN=DO8K&>XT.$>2YHI'0W/\ RS_[:+]*K*37!#2?(*6O)KT@P<H5
M<A_\W_-4"N\CA;ICB._H:X/7>/=D0O/4+=</8.CGAM*\8[0X.$GK5DL4.M8\
M!M(:\EWV3?;<Y/<O,1N%*W/J2$H;45(+>/@+!YA0YU;S)KJ5PCV(!!1PAGF(
MVY>E19,EI+HCR)6U2 02 HXP%8'0G)IQT?9>%&MW'F=/WSZI+:0'%AJ21Z!)
M 4,I&X9&,C-.;7DNZ+92RRW]54VY'9+<MOU07YM(<;3M0ZZGJI8'?GF>9S73
M=.%>A="VE5]N-H5<(UGMHCA$D^<;66R5#"5<BH$GGUH\R?<,(]B'/S>$=MG^
M8W&]2;9-5(<CM1Y$@[W"@X4I("3Z//K3?JV\\&=-1)CLJ^RI1B/)9=1%?*\$
MJ Y*VX.,C(!)%='$'A[PIO$33\J^/7"V0[LIR7'6B<&4A.SM%E0.2D83]QS&
M.M-C;/ QV-)$364N;;F'#-;LD6[N]@AU/VPE#6!Z2L9PHG/=1YD^Y.,>QW.0
M^!YAM2W-6*;:==4RD+FE*@M(RH%.W<G (R2.6:X[I&X#-RGK7)U<X) 4$%")
MBU;E;-X2DA!"CMYX&3CG6_3'"[@IQ[+M^LTJ3)N$M9N$@MRRB0V'D)"D*2H'
M:DA !QT(.%42XOD^:.BN02S#E-)A2W)K"4REX0XMCL"?9L'(=QYT.I-\L,5V
M NYH7@,GMT/:BFM,)4@-*^J&_P XW)*@4)2DJ. "3R[JF]M\D/A==HT>>RQ,
MGL.H2XTXN2%!:2,@CT*?H/DMZ+L[K4BTJN]HN#)RU<(5Q6A]&4E! 5@\BDD'
MEWT4K3:F[/;HT-I3SC4="6TJ?<+BR ,94I7-1]9JN3+ )G^0EPKGNJ<5"N3!
M/_03-@_(FDSY"?"R*TE$:)=(Y'5;<\Y5[<C'Y*L-6:B[#I8J<]^QF\'Y5S>N
M#[FI7Y+IR2Y=L@>H#9R%2JT>0MPTLK"6HHO(0/OI^3_(JP]8QZA0FT64FE9,
M"$GR/N'\EKLUHN:0$[<HF8./^[0KUKY.' _1U]BV*_3[];$OP9%Q,IRY;&4M
M-*2%[E;>OIC [ZN&>AJ ZXX/:?U_<D7"Z-RA+;@OV]+D>0IHI:=*2O '+.4)
MYG]-3DRSJ2:M<!&GN''D]Z;A0WX-]>:1*"RR52EJ6L)("E$=GD $C*CRYUU:
M97P.U=$EO?5^9;C%5*#K<^462$,.%MQ8)3@C(SR.<$<J?IO!?AYPSN&E[-'D
M:EM=PU#+>MK4JVW):%OA2%.K;=6,;6R&R0$ 8/3&<UPZNTAP+L;)T7JB6J%&
M@+D+99G3UJ+CDPJ=<*<$J)!02"1RQRH4I(4TGR<\BV\!H<5N0]JQ:6G"M*<3
M%J7E"0I>Y(1E.$D$Y Y'/2G2WN\'8K41<"_KE1)#O8F2)H#;?VE;P62H#*2A
M!((SFF*TP. .D8J+C$U Y<RZI41Z>W-+BMLIL(!7M"0I)2@ $ ]/'-$&!P1X
M9\2;#;)T(+O5I;9;8CNMS5K;4AMER. KO)"7%@@\\X\*G.2ZD8Q.O0FC>'FK
M4.3[!+?N33:AO67%  GFG(4D'!','OHCP=(6JWC#45.!]]SIOT+H-G0\5UAB
MYW:Z=H4GM+O.5)4A*1A*4YP$@#P'/O)J549R?4%%(T-1&F1A"0D#H!W5E^,'
MT;"M:/6@X-;J54+'- @H@,EI"W%C<59<5N/.NFE2H &4?]T1=/Q6A_GLFB4.
MAH:Q_P!T1=/Q6A_GLFB4.AI</F%QZF4]]>J\I[Z]4Q#$8KRM!/0@>VO=*@ 2
M6KR=+3:(%PMC&H=0*L<V2[+7:793:F$N..EU13]KW ;R3C=72GR=])HM/U.2
MB8&1#EPMP?&_LY#Y>=Y[>N\\CW#E3QQFXJPN#FA9FI9T5^>EIQJ.S$CX"WWG
M5A#:,GDD%1 *CR%-&F]5\3Q?+<UJ'1MF1:YH)=D6>[*><MZL9 =2XV@+!Z;D
M'EX4 <NC_)LTSHN\QY\.7=IB(TMV?'A3IG:1V9#B A;B4A(.2E(ZG [J+* 0
MG!I-G(-9H 6*S2I5%P%2I4J+@*E2I47 58K-*BX$<UYHB#Q"TQ.L-Q<D,Q)8
M2%N1'-CB<'(*200#D>%02\^358]4(A)U!?M07Q<(;6')DIO*$Y!V^BVG/P11
M>I4 "#4'DP:.U(U);EFXA+\YVXK4U*VJ[5QL-JP=O3:!RJ4</^$UIX=O39$&
M1.N$Z8AIIZ;<GPZ\I#8VMHR$@!*1TY5-Z52!A(P *S2I4 *E2K% &:5*E0 J
M5*E0 JQ2-!&X<5N(%XXHZFTMI*P:=E1[$TRXX[=K@^PX^7 <)3L:4D?*: #?
M31JC3D;5E@N-GFEQ$2<RIAU3*MJPD_>G'(U%>#G%=/%33\V8NVJL]QMTUVVW
M""IT.AI]LX4$N  *2>H.!1 !Y=U  B<\FNRS8]KCW34.H;TS; I,-,Z4T>Q2
MI!00-C2?N3WUNO?DU:1OK4]N1Y^E,U]E]WLI 2=S;>Q&#MY#%%>LT #WAQP4
MLG#1Y+T&3<+C)1$;@-2+G(#KC4=!REI)"4C:#ZLT0A2I4 *E2I4 *E2I4 *E
M2I4 *L$<C6:5 $'XB<*+?Q&?L4F5<;E:9UDEF;"EVMY+;B'"VILYW)4""E9&
M,4P->3EI[Z[XFJ)MRO%TOD906)4R2D[R&7&1N"4 'T'%?DHKTJ  ]_0OZ3;M
MUIB1I=X@FU,1F(<B-,"76@PM2FU9*#DY4<Y'.IYH70MOX?V!JSVOME1DNN2%
MNR7"X\\ZXLK<6M7>HJ42:DM*@!4J5*@!4J5*@!4J5*@ 91_W1%T_%:'^>R:)
M0Z&AK'_=$73\5H?Y[)HE#H:7#YA<>IE/?7JO*>^O5,0Q"I4J\+7M!Y$T 1[B
M!H.T<2=+S]/7V*9EKFH"76PLH4"#E*DJ'-*@<$$=XJ V/R=FHFH+-=+YK?5N
MK465P.6V!=9K:8["@G:%J#+:"ZH#H7">M3&!Q4TW<M5KTXS.4+N-^UAR.X@.
M;,;]BU)"5;<C.#WU(!>H0.%S(R5 \P7DY'Y:A>K@BX+I_E1:/M=QEP7V;J7H
MSJF5E$5)3E)P<'?6&_*ET:[T8NWRQD_Z]5VU1I2Z2-4WEUJWR%H7+=4E249!
M!4<$&N)G2-X0K)MLG_\ ;K<J"ZBG4L6<3Y3>D>@9NG^3)_UZVH\I+2BTE08N
M>/[W3_KU6YC3%U/PK?(2G&<[::9%Q5#%Q0N)+@,Q(RI#MPGQEM14X(&-^.9.
M>6 >AJLX4Z2]5[]NOZ&O3:>OJF_+6W?C\WL6G_HD]*CHQ=/\F3_K5Y'E*Z4(
M)[*YD>J,G_6JD-\UC<K=93<';M!$)0PAZ"I+ZED] ,9P3ZZBL=NZW^.N;<G;
MX]#^$&W)O9 I_@M\Q7)JZBM35UI9V[M6_7?\CT^C\#TU:5M1KJ<7V5Y/[[+\
MSZ!/>5#HV/\ MB+B@_OF4#^-=<9\KC0*"07I@/AV;?TE4>TY:=!W>,'WK4Z4
M;MJWY#SCX"O62>7RU.8?##2#L=#C%FM[C2O@E+>X?/FJZ>O+42<()9+E-M-?
M@TANK\,\-T,5*M.JXOB2C&S^GJ?ZEJ4>5OH%SDEZ83X;&\_RZWH\J?1COP&[
MFO\ @QT'_/JJ+W"K2SZ<*L$( =-J,'YQ7$[P9TUS4U;UPU]RHK[C9_(:W*CJ
M><4_Q:_9G.C'P.>RK5(OWBG^C1;Q7E2:/0"2Q=O\E3_KURK\K?13><QKQR\(
MB?\ 7JFEUT1'L&40]776VN'FEIQT20?\50SCY::&W=5X4&%6_4C*>NU!BO8]
M0R036"7B&GIU'2J;2[)I_ES^1TX_PT]12\[25TX],HRA?\7>/YEW4^6%H8Y^
MT7G_ "1/^O7,YY:.@6U$*CWO(_N-'TE4@^NR/!D>;W6)(LTA7()F(P@^Q8Y&
MMCZ4OJW(4E:%<PH$8K;2J4:R]$O\_8\]KO#=9X=;_4T[7Z\I_1K;[%VD^6KP
M_()["]>'^\T_25WVSRN-$W8$L1KQRY>E$2/\^J)J:*&3D$ &IEPZCM%+SBE^
MBD\N=:XTHLX[GL6WO/E?:'L2094>\#/0)BI/^?3YPG\HC2_&:Y3X.GVKBAZ&
MV''?/6$MC!.!C"C5%>+Y >9*%[A@J'KHJ_L?!W:SU4<\S#;R/\>HE244VB5)
MMV+T)Y#F<^NLTJ59AHJ5*E0!@BA/?/)^:N6M[OJBVZTU/IJ9=6VVY;-I>CI0
MX$?!(WLJ4D^PT6:5 $1X=\-;-PPT_P#4BQLNAA3JY#S\ETNO27EG*W7%GX2B
M>9-.>J579K3]P796VW+LEA1BMN\T%S'HYYCO]8KMG76);&>VF2F(C6<;WW A
M.?:3BM*]0VY%J=N1F1_J>V@K7*[5);"1U)5G'*J/>+!.S IH/7_%6T2M&VOB
M+9[(B1?93T1;T&0M#[90A3B5%L)+8!"<8"R>='Q/P0>^@%>>*&E^)VL^$MST
MQ>HEVB+O$H(4RX-QVL.)4=N<XR.N,&C^GX(]E,?<A*QFE6 <TLU!)FE6 <UF
M@!4J5*@!4J5*@!4J5*@!4J5*@!4J5*@!4J5*@!4J5*@!4J5*@ 91_P!T1=/Q
M6A_GLFB4.AH:Q_W1%T_%:'^>R:)0Z&EP^87'J93WUZKRGOKU3$,0JTNG"ASP
M._-;JTO#)_\ ]XT #[3O"9JQZYN>JW+_ '*[SIQ(V3^S6AAL]&F?1RVV,=!C
M)YG-.<OA/HVYR79,K2]KD/O+W..N1DE2R>I)\:@.G>&&IX''27JHI:MUE7&>
M8>::N2GTRU*4"ASLRA)0L8P0I2DI'P>M3V7I;4K\IQR/J]Z,TI1*6_J>TK8,
M\AD]:HYRI_ B\*:FW>5OO_@J7>(F-1W>-"M,)4>,^YA+=O0K8@*(Y\CR'C4/
MU#K2-:WE0H=OM<VY]"SYHT WX;B!R]E$74^I;; N=]M*;ZFR7F476FWU,-MF
M2H+Y_ &X$XSRH=2]$>8AR>PL7:YE>]YTLAHNCVYRH^L\ZY7B'BWB#A*CI*;L
MK92YMOOMW/:^#>$^&P2U7B-9._P0LTI/HVW\M_H<VE8NIBXN9<(UNNP6<HBL
MQX[338]2=I)^4U)I%PL$^W3;9JK3"H<24P6BZU'0WM.1@I=0DXYC\M09=T,:
M1VL-;S!0?MC1)2M/^FI;9KNY<VO0G9W=6G#N"O40:W:+_4NFZFEU<F_^VZ_*
MS0OQ'40JU[:[1QC;;T>FR]N8O]^Y$I_"MNSSX%QL%OAS+/'7VAC1>:G>7W9)
M)41W?Q4VW?4EZNA=M$"UM6!AP[5SYCH*D)/7:@=]2;4;EZT=)3)M79P0\0%L
ME.]I9SSPGN^2I-&UE8+RTA,]*&GL +3*9P-W?@G_ $U?1>(>(.M4@ZBSI[VF
MLH[_ -+NGO[WL5U^FT-*G3K2I-TY+:4%9[?U1W6W=6(-;M!6ZSVA#-MN8=2D
M;UO*4 5+[^7?SKFM>H).EYZNSS+C?V1I'3VBB%<-$V:XH+T%#"'"-P[$A23\
ME1J- ;@27(TB.EONW 8Q4:G2:S7ZF-2MC%IWRC?+Z=-BFDUGA^EH5*-'*2G%
MJTDK?6UW=]B5Z=U1;]0-E49T*4CX;1^$D^RG><^(T"0Z "IM"E8^2A/=M).Q
M9@N%HD.0YPY@M'"5CU^/LJ0V+B#'=Q;-0!-OF+&SME##3GL/05V:\93IRBUZ
MK;?8\I"DH5H3YBGN<>GXJEK\^6$NN.@J6M1SMY]*]WZ''=C.2&$ICS6/3&WE
MN'Z:\,.?6M<5LNK"XBU;V'T#<A0)Z$CI6K6DR"X";?(0^XZC)#*BK'M[A7B8
M/1Q\-="I95(JS7S97O?\6?1Y4-=4\5CJ:-Y49N\7\JCU3Z;+HQKD):NL4)DM
MI>;<&%(<&4U"9VEI-E?6_87^R2!E4)Y1+:QX#[TU,;3*9FP@6U@E'HK3GFD^
MNN:X-DO^BHY]1KM4=.JU&%2HK3LMUR>:7B];P[4U:>FE>BY/T2]46K]4^_=<
M=Q@LNHF;H'([@5%GM_MD9SD?:#WBC'PPL"IEDF.H'0Y*@!^6@QJ'33T]I,QE
M0:G1_3:>'PN7=4\X::\O%RTQ*8@E,<MDHEMI"2H*'4\^ZM>FKSA5\BOO?A]R
M?$M!I]5I/YIX:FHWM.']#^O6+Z#1Q?;*)K#?HG"2".ZB]^Q[)QK'5)Q_R-OI
M_#-!;5[;$]O+TC+G7F11H_8]TI1K/524G($1&".GPZW5'Z6>07Q;%Z:5*E6$
MT"I4J5 "K'<:S6/&@"L'E\WBZ6W@N\B#8X=T9=?1VSUR[,Q& #R+H61RSW@'
MV40/)N:9OG +3#-Q@1"S(A!+L1+22P0>H">8*?"HUY91LPX:MF^W1V'"\Y2!
M'B--.2'EYY=F'%I!(\,BI)P4N[=YX+1FM._50/1HZF&%W>*F(Z5CH3\-/R@J
M%5IO&%3ZK]");SB_;]QHU7P[TGH?B1PK&G=.6FR%=VD[E0(;;2CF.X3DI /,
M^NCJ%I"0-PSBJQV^R\2[5K7A2-?:BMEU<-WE[&8T'#R!YNYMWOA82L@<N38]
MM5%_9J[S<+1>N&(A3Y,1+D:7N3'?6V#A2<9"2,U8D^E>HN'=MU1/\[ES;TR[
ML"-L"]RHC>!^\:<2,^O&:%O"OA_#U%/UPU<+[JF0BW7]V'%"M33DEMD--J">
M3HSS4KF<GGUK\^/UZ7\?V[N/^6._ZU8:UA>6M^V[W!.\[E;9;@R?$^E0!^GR
MS6IJR6YF$P[(<::&T*E25ON'VK62HGVDTY)4%=#7Y=&=9WXN)'U;N/PA_P L
M=\?X5?I7X,!3G"712UK*U*LL-2E*.22649R: )K2I4J %2I4J %7G>".1'JK
M)^":'W&O5MUT/H==TLIB)N*YL.&VJ:RIUI/;2$-%10E22<!>0-PH D>J&=1/
M04C3DRVPY>\%3ETBNR&]F#D!+;C9SG'//R4+[AJ;BI!XCV32AN^CUFY6^7/$
MH668.S[%32=NWSOGN[7KGEMZ'/*7C3O$G_KKI['XKN_KM,,OA3KR;K:V:H<U
MS9!/M\*1!:;3IEP-J0\IM2BH>>9)!:&,$=30!.M+,:KCA_ZY+A:)V2GL3:H+
ML8('/=N[1YS=W8QCOJ1!0.>8J G3G$K!QK73O_A=W]=KCX/:OOVI9VMK;J%Z
M!+E:>OAMC<FWQ%1D/-^;LNA10IQPA672.2L<A0 3*5*E0 J5*E0 J5*E0 ,H
M_P"Z(NGXK0_SV31*'0T-8_[HBZ?BM#_/9-$H=#2X?,+CU,I[Z]5Y3WUZIB&(
M5>=HR37JO"UA /CZAF@#&Q// ^2L9"._ H.\-^-USUUQ1U7IV9IFX6*WVUAM
MV$N=!D-/2 5*2I:BI(0D$C*0"21SKMG\7]1L3GXZ.$&M)+:'"A,AIRW!#@!Y
M*2#*!P?7BC?H197W*,\1-6V6Q\=M57K4=QC6VVVK>VTY)7@;U+.0!U)(\ :X
M8GE26R[8&DM%:NU<UT;?@6PMLJ]86X0,>N@5Q"U7,XK<;INH[MPVNT-BV760
MV_%6GM(L@)6H'D2,.C']C*P2.7*C+H[B]IN_-*1I34S<>2TG"K1.W19+)'W)
M0KDKY*SZ2,J3E>6[;OWL>F\8U$-:J,H4[14(P5T\;KFW"Y'*Y<2=4WIO?)X!
MZK6H?V9,R*VL>ODO)J-R>*LV ^6IW#77UM)'HIV1'3U];B?XZ)5OXBNNA*)<
MYQ$CH5$[1\G*G>3<IM_MBD(N\:5'2<*:D(3D#QI>I\+ISBZM*RFMVW=77U37
MYC/#_$-12:I59-P>UDD[=FE)-6^@&[MQCL]K[*3<;7K.VAL_!OFGWDH3ZPIL
MK2?;G%2/2W'C0&J%]BF]6]]>,!IYP-.D_P !>#4LT_J"_P ;M8$.<%1VU82I
M20X!ZDY/2N+4_#VW:\B.IO\ INRW(\]SCL)L+]H4D!6?EIG@ZHU-.JM&&.3L
M^MVO=\HOXPM=1U+H5ZBGC:W2R>_"M9F^Y,6:?'28CRH[N,A;:B,?**CC2+]&
MN80J6J;#QG,CFH>RH<WY/U[T;*7-T!J:38G4^FFVSUF7 =\$$*])&?$9J6<(
M.)YU[!O-JO%I1:-4V9P,3XJ%=HTHGX*T'KM)[J[=I3EZMF<6,E%V2);9KW+=
M?2R\P"T1A+QR=I]8QRKHGQ8US:6U(C(E#G@@9Q7-&GMPW5"2VM!VY.T]]>F;
MZJ"C<E#Q(.\.=#CPQ6E02Y8]T\MQBM=BDVF:\^"YYBH83&4>:CZL]!4G!$^R
MYC]DV1R/8C<?EP*W2XS%_;3*9>+(SA6XD$G]%/>F;:U&!C89;"^BT'/Y*S*G
M'.[2+RJ2C#%-I=NGV -<HUST9>%RXR^VA.K!D)(P0#X#QJ0MWV!<GD%B2VHJ
M&0G.#\U3C5FB>U[1(7VB_A8QD?.:$>I-#V^(L.ORUP).0$K:!Y'U^JE2I.)R
MY1C/X27.).T]#40M<YW3NM9[4<[6I; *AW9KU/CW_3]O#S,YBZL  ;03O \2
M".GKJ.V6^(O&IW9,A0CN(92VEM9ZJ'6N3K9)RII?%=?;J>M_AZG.&GUTJG_'
MY3OVO?TK[CY?E$QP<\P>M6/_ &/(?[,=5?WFW_+JN-_Y1TG/(]"*LC^QZIVZ
MPU4?[C;_ )9KIS^%G@HWR+T4JP*S60T"I4J5 "K%9I4 5N\N/3XNO"4R6HT9
MV5'DH#;LQIQQIC)YJ*4'/R@'V5/^"*TV+@O87I3[4AJ/##BW(C+H20.9VH5Z
M?Y/DH?>7A.L43@;/-^4GS0OHQEKM2,'F=FY)5CU$>VISP&AV74/ G3D9F.W)
MLTN"$AI40QT.H(Y_:]ZL C]\<U6DGA4MW7Z$2:RBF0^\<8='\2>)?"QO3U\9
MG2FKK*[6(H%M]O;'<!*FU $527]F]/\ 5OA;_>TS^4FKYZJT?9-#:QX16JP6
MUBTVUF[2 W&C)VH3F,X>0JA?[-YSO?"W^]IG\I-7VX!7L?+RE2I5!)[8_;4?
MPA_'7Z<N"W]:+0_^ X7_ )"*_,:Q^VH_A#^.OTY<%_ZT6A_\!PO_ "$4 3.E
M2I4 *E7@.CUU[H 5"CRE?ZV;7^&;5^?,T5Q0H\I7^MFU_AFU?GS- !63T-9K
M">AK- &.XT(N!W_'3C%^-O\ Z"+1=[C0BX'?\=.,/XV_^@BT %ZE2I4 *E2I
M4 *E2I4 #*/^Z(NGXK0_SV31*'0T-8_[HBZ?BM#_ #V31*'0TN'S"X]3*>^O
M5>4]]>J8AB%7A384<FO=:E\E9SR'=0!Y[!M/,#G@#..=(-)QU/7.?"A0>.,A
M/%U6CG[ N+;E/JB,7B1).V2\EH.%MM"4$9 /W2D]*?[UQAL=AN#T*3$O;CK*
MPE2HUEEOMD^I:&RDCU@U7)18VG2J5=H1N5"XT:57K6==FD/EFYQ9KCD*0?N%
MA9PGV&A="T7H?C IVUZRTQ#9U5$]%Y03V+R\?V1"Q@G/6C?>0F;>[A+1Y\&G
MI"W$I79Y@(!42,_:J8;]H*R:J>BO3C<XDQA8+4Z':9B7FQGG@]ESY9ZTFO"F
MY>?3:RZI]5]>A[/PRM7EIOY;XC"2IW;C)*[@_IUB^JY!9(\D!B,"=-<0=361
M*?@L27$364CN&U>#CY:Y5^3]Q=@H4B#K;35X2/@_5*VO1UX]K9(HB0.-=E:U
M%<+*IB\.HA.% DR8BBH)'W2]HR/\8"I8_P 1[<]IN1<K#,BW13?(EEP*V'Q4
M!S%5J5_#J]"4Y\+E?_MC//P;^(O"Z\*<(M9;*72SZW7P_0 J>$''N%C$31LM
M(Y!;=V>: ]9RU6?K1XYQ-S:DZ$BJ/(K?U"L@?)V>:,5C:8U \W+O\]^>VI.5
M-*=*&TY/<!R/RULGG3<>2M#5OB,,I5A*^RW''CSSFK::KJ*\%+2TU&/2\OV2
MV,E:CIJ-5PU-><YI[M1Z_5N[^P'%\'N-.J&U-/\ $+2-D;5Z*DV5*WGL?O5K
MZ>T"G3AYY-NI>%;K[MI4W<IDI7:2YTB7N>E*^^42,>P5/7[+9YZ5N-/Q D=R
MF-F?FIN5.N-@:6_;KHXTTCJV7=Z#Z@#3:E;5Z5>;7IIP7+C+=>]GT_&Y:EH-
M+JY>7IJ[4^BE'9_BGM]A_NMJE>9HVQFHTH)&Y)(4"?;3594R9@>;G6U+?9#T
MG"/A'U>JD;P_,A-39$I3:U#<%$Y]HQ7J+?VY<Q*D;PI W%)4-JQ77T]2->G&
MM![-7,%15--5E1JO>+L_P&28Y(M;[C++;K<9XYWE.X)/@#7AJ^F&A"I"WDMI
M5Z249*CZZF#=_CJC/!5N0Z@GD"KO]M,-^NUME,I'F/9+0<CGO2?5XUJE%+=%
M8UL[JPY6#7\&Z,+:9*G6VSE0>;P17->$Q94MQY" \VYU94 0?DJ)7K7=JLL8
M@*:C$CX*>2B?4.^H'/U7>=1]HF"V8D9P;0^YR<5_!'=6&MK:5/TKU3[+_)W=
M%X!J-7'SZB\JE_7+9?AU;^A+M::BC/-(L%FCM2KFZ-N$C C)/4J-1A_AC&:A
M(;R'7$\U. X45=_.L:9?%C0XVA@]JYS6\KTE+/B33^;C(2R7&\KY=1G K'2H
M2E-UZZ]7;L:?$-91HZ?^6>'_ /&G>3ZS??V79$%DZ/GQ XTF8\,]$/+/+V&K
M2_L><6?%UMJI$I +7F+>U8.<G?5?W]43&4*#[:76R>BTYJS'D%W!F;JK4Q:;
M#?\ 2C>0GD!Z=7E:UD>/G144VD763TK-8'2LT@QBI4J5 "I4J5  _P"*' S2
M'&), :IMZYWF"RXP4/K:VD]<[3S^6GNPZ%MVD](LZ=L:7+;!CLEJ/V:]RFLY
MY@GO[ZD>.7*F?56IX>D=/S[S<"L0X3)>=[-.Y6!X"JVM==PM?< SNAM2Z/U[
MPH:ONM9^IBFZRP&Y3+6T L.%)WA(<4<>)(JEW[-[_P .<+O[VF?RDU<>\<>M
M-\0M2\.KY:8E_<A6VYR%SBW89CR6$EA:02MII:%9) ]%1ZU4+]E;L.H./EVT
M [P^TCJK4Z+<Q)1+,33<]/9%2DE.=[*>N#TJ[OU*Q5CY8TJ*)\E?C/\ %-K;
M_P /2_HZY8/DU\6KF9(A\,=7RE1G2P\&;')7V3@ )0K".2L$<CSYU!8';'[:
MC^$/XZ_3EP7_ *T6A_\  <+_ ,A%?G>:\E?C.EQ)/";6^ 1_[/2_'_X=?>CA
M?QFTY8>&VE+9.9O\>;#M,6.^RK3-SRVXEI*5).(_<010 :R0*B6K>)VG]%2&
MH]XGKBNO(*VPB(^]D9QG[6A0'LS03\H;CS=CHN$CALYJ5N]+ND9+[D72DYQQ
M$0J^VJ =BE/(>HF@T>+W&#'/4.O!_P#HY?ZE1R 2+3QXUDYK78_K_1LBR1[H
M528D>SSS+;A*22A!^T\G._GC(YYJSFG=66_55K:N-L?,B(Z2E+BF7&R2#S]%
M:0?R5\^[+Q+XA1-2:@EV[4VMW+M+4Q]4PC2[CBTJ2@AH*3YF=GHYQTS3\OC!
MQB#:MNH->%0!(SHU?,_Y%1;:P=;GT !R*%/E*_ULVO\ #-J_/F:CG!SC\AWA
MCII6MAJ%&JS$3]4DN:6N"5=MDYR$1MO3'3E7#QTXK6356@T0;5%U!,EBZ6Y_
MLD:9N8.QN6VM:N<<=$I)^2@"PZ>AK-#H<?-(C/\ P]_X8N?ZO7*ORD="M7!B
M J9=DSGVUNM1CIZY=JXA! 6I*?-\D#<G)'3(\: "=W&A%P._XZ<8?QM_]!%I
MY^SYI+']O?\ PS<_U>AQPHXI673^J.)LNX1=01F+KJ/SV$M6F;EAYGS..WO&
M(_3<A8Y_>GU4 6,I4V6'4,/4=JCW*$IWS5\909$=R.OJ1S;<2E2>8/4"G.@!
M4J5*@!4J5*@ 91_W1%T_%:'^>R:)0Z&AK'_=$73\5H?Y[)HE#H:7#YA<>IE/
M?7JO*>^O5,0Q"KRI&[J3BO5*@!B1H^R-7U=Z3:H7U76,&:&$]L1C!]+&>G*G
M4-E(&%8'+E6\I!KR<)[ZCJ1;<HCJF:[]=EZ2IU9'GCO51^_-9MMQ5'=0M"SN
M0H*!)[P<BN'5W:?7?>_07CSU[GM/WYKEC=IW(5CQVFNG!Q4;6,34D[7)VB\+
MN+[SSP:"Y"M[H;;" M7B0.ORU&;_ ,(=*ZC=5),(VZ:KK*MRRPL^W'(_**]P
M7G$X]%7+]Z:?X+ZU) *%^W::BI0T]:&%2*:-^E\4U^BJ^=IJTHR]F#"7PGOU
MF"_J/J!N6T.C4YLH7C^$GD?E%1RYVS6EN!2]852A_P!)"D-KQ\BB#^2CX8CC
MB>05S]1KG787WLX;)2>_::XC\ TT7?3U)4_[9-+[7/6T_P",M5)WUNGIUO[H
MV?W5OT*[)N%P;0?/H.HHAZ;1;E*3\I2:9W;Z\MQ0/G+* <GM+?()/M&PU:>-
M9EQ<G:H'U @UM2VXWR < ]6:5_)%E>=5S_NN_P!S8_XNTLEC'1X?V22_]6_S
M*NJ?:N:&VG[W=$)/5$6S2%GV#*0*<HEGM3:$B)9]<W5Q/+M%,>;C]  JR;S[
MO9[?MA'ASIIE%:R<H63ZP:ZJT]9+%U4E[+_+.%/Q;P]MM:63?_:I_B*_4!*]
M'ZGN&3:;-/LI[GKG>0K_ /C .:Y;]P]XBLPO^$F)[>/38@K#+BA[5#G1M=<4
MD\D+)'@DUI0^LDY;6/\ %-76C@]YU)/\;+[(M'^(ZM#_ ,/3PI^]LG]Y7_)(
MJXZ_ TNZ$7>Q2+=*)VEV<%+/_?YBI'#G6:;%"4/L 'GO:<!5BB;K6$W,<2%Q
M0Z#W+:R/XJ@%ST+9GBETVOS>4"#VT9LH)^:K0C"CM!+_ ._^[F+4^+:K6O/4
MS<G[N_Y/]ANDHC(6!%>"\GFDYR!6EZ[/,A3:5%IL=2<#-=]ST6]>,%$V8AU*
M0E"E)R0/FKQ*X/WQ%N+S5Z+RP,E#D<^E\M,<VS/'4Q>PTRI?G#9[1P)3CN5S
MJS/['M%+6L=5*"U*0J&W@*/[\U4V5IZ]-*+2P@O$[<@*PG\E7#\@+AYJ#2M\
MOUSNZ&Q&F0T!E:5Y).[O'=6:38R6HC*FXIEV$]!6:PGI6:2814J5*@!4J5*@
M# &,UJ=C-OM*;<2E;:A@H6,@CU@]:W5C% '+ M<:UQ41H3#4.,CX+4=L-I'/
M/(#D*WNNH:;6M:PA*1DJ4< #VU[Q7E;2'$%*DA22,$'F#4.X%4.._EFHLRW]
M/<-F'-17Q1[$W.*WVT:,X<X2.Y:SCESP<<J+OD_1=9LZ/<DZWMEMMMZFO^=.
M" WL<=W)3Z;X!(#O+!P>X5*=*\,].:*N%VEV.U,VQRYNA^2F.-K:W!]T$]$G
MV5*.Q1X5,=D0]W['L#E2Q6:P>AH)-87[?GH+\9/*<LW#A9M-D9;UAJ_M V-/
M090$A'(G<L8) QX<SW U+.,>C]3:ZT3-M6E=2G2UU='HRE1DO(6.]"L\P#]\
MGF*A7!?R8;7PZ@Q7;])&K;XTH/(EW!A"Q%<ZDM$C(YYY\O' -0ED]P?I/?D[
MKXAW6;J'4>M8=JMD>[N-N18T>"6)H2D82'E9.\!)P">?LHY8KSV2>I&3XFO=
M6;*I&,5A1"03SI9.*@/&.V:ZNVBID?A_<H%MOQ&$+N+2U(4G!RE*DJ!0KP5S
M /451NR+I7V-?%OC+9^$FF95QG]I-N"([C\:T0@794K8,G8@<\#D2KH!0LX"
M:RXB\9=70]?W2QPM.:0<AJ9B6^Y0%)N317M*^S>SZ3:E)222 #@<N6:SP+\D
M^1HVZHU/K6_2=1:F<6E]0*U%IM8! R5$DX!QR('R59)+*0  .0Z5=+'?J5O=
M61[ I%.>\TARK-02:PUZ6<FME*E0 J5*E0 J5*E0 *=1QM36+B\_J&UZ5?U#
M;9-B8@%<:='84VZB2\X04NJ3D;7$\QGO%.(U]K+!_P!K&Y^]X'TM$%/PA\O\
M=;*A*Q"5@=C7^LA_S8W/WM ^EI?9 UE\6-S][0/I:(E*I)!W]D#67Q8W/WM
M^EI?9 UE\6-S][0/I:(E*@ =_9 UE\6-S][0/I:P=?ZR/_-C<S_^;P/I:(M*
M@ <#76L.?^UA<N?_ +VM_P!+2^OK6'Q7W+WK;_I:(]*@+ Y^OO6'Q7W+WM ^
MEI?7WK#XL+E[V@?2T1J5&Y%D#@ZZU>>O#"Y>]H'TM+Z_-8CIPPN?O:W_ $M$
M>E4W860./K[UAW\+[G[VM_TM+Z^]8?%A<_>T#Z6B/2J-PL@<_7WK#XL+E[V@
M?2TOK[UA\6%R][0/I:(U*INPL@<_7YK ?\U]R][6_P"EK'U]ZP^*^Y>]K?\
M2T1Z502#CZ^M8?%A<O>MO^EI#76L/BON7O:W_2T1Z5!%@<?7UK#XL+E[VM_T
MM+Z^M8?%A<O>UO\ I:(]*@D&_P!?&K_BNN/O6W_2UE.O-9(SCAA<_>T#Z6B/
M2H(L@=C7^L@,?8QN?O:!]+2^R!K+XL;G[V@?2T1*5!(._L@:R^+&Y^]H'TM+
M[(&LOBQN?O:!]+1$I4 #O[(&LOBQN?O:!]+2^R!K+XL;G[V@?2T1*5  [^R!
MK+XL;G[V@?2TOL@:R^+&Y^]H'TM$2E0 ._L@:R^+&Y^]H'TM+[(&LOBQN?O:
M!]+1$I4 #O[(&LOBQN?O:!]+2^R!K+XL;G[V@?2T1*5  [^R!K+XL;G[V@?2
MTOL@:R^+&Y^]H'TM$2E0 ._L@:R^+&Y^]H'TM+[(&LOBQN?O:!]+1$I4 #O[
M(&LOBQN?O:!]+2^R!K+XL;G[V@?2T1*5  [^R!K+XL;G[V@?2TOL@:R^+&Y^
M]H'TM$2E0 .QK_60_P";&Y^]H'TM+Z_]99_K97/WM ^EHB4J !W]D#67Q8W/
MWM ^EI?9 UE\6-S][0/I:(E*@ =_9 UE\6-S][0/I:7V0-9?%C<_>T#Z6B)2
MH '?V0-9?%C<_>T#Z6E]D#67Q8W/WM ^EHB4J &C2]TN%WM@D7.S/6*5O4DP
8WWVGE  \E;FU*3SZXSFG>O#??7N@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jan-20231230_g12.jpg
<TEXT>
begin 644 jan-20231230_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( ;D# 2(  A$! Q$!_\0
M'0 !  (" P$!              8' P@! @4$"?_$ %@0  $# P$$ @T&"04-
M"0    $" P0 !1$&!Q(A,0@3%!<B05%487&1E:/1TA465I/3U!@C)C)&@862
MH20T0D2R)3,U-D524V)S=)3!\$-59')V@Z2T\?_$ !P! 0 " P$! 0
M       !! (#!08'"/_$ #T1  $"! (&!0H%! ,       $  @,$!1&1T086
M(3%24P<2%1=!%$-$46%Q@9*AHA,B5+'P(S,TP7+A\?_:  P# 0 "$0,1 #\
MW^VEZZN^F[XS&@.-H94R%G>;"CDDC_E45&US4PY2(_ZV!7V;:N&J6!_X9/\
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M6.:O0J;*/8'.@M!]RF/;>U*!DR8P_P#8%16[=*6?8;\NV7%:HB$.,LJN#L-
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M<%I25) 2 "..,FISI?3T72>G+9982EJBV^,W&;4X<J4$C&2?">=4*EI-.,A
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M.2G6>5X'+7_>\_HIGS^BM@>U1IOQ#VBO?7':GTUXA[17OIW3U?FLQ.2:SRO
MY:_Y\_HIGAW_ $5L!VI]->(>T5[Z=J?37B'M%>^@Z)ZP/.LQ.2:SRO 50!63
MX:XWO/Z*V [4^FO$/:*]].U/IKQ#VBO?4]U%8YK,3DFLTKP%:_9X=_T5SGR&
MM@>U1IOQ#VBO?7F:@T;H;2EGDW:\]CVNVQDA3\N5(+;;0) !4HG XD#]=.ZB
ML'SK,3DFM$KP.5(Y\E-[GP-3H:YV$<<ZPT]ZU3\5/GUL'^F.G?6J?BK6.BNK
M#ST/$Y)K/+<#E!0K'>KG>YY%3GY\[!_ICIWULGXJ?/K8/],=.^M4_%4]U=6\
M(T/$Y)K/*\!_GQ4%WO(:!7#D:G7SZV#G],M.^MD_%7'SZV#_ $RTYZV3\5.Z
MNK<V'B<E&L\KP'^?%08''>IO<^!J<_/O8-],M.^MD_%0:[V#?3+3OK5/Q5 Z
M*ZMSH>)R4ZSRO ?Y\5!@KR&@4<\B:G/S[V#?3+3OK5/Q4&O-@WTRTYZU3\53
MW5U;G0\3DHUGE> _SXJ#9\AKC/DJ='7FP8?IGISULGXJ#7NP7OZRTYZV3\53
MW4U<^=AXG)-:)7@/TS4&SPKG>YU./GYL%^F6G/6R?BI\_-@OTRTYZV3\53W5
M5@#^ZS$Y*=9Y3@/TS4&SY,TWO(:G/S]V"_3/3GK9/Q5Q\_=@OTTTWZW3\51W
M4U?FP\3DHUGE. _3-0<JSWJ9\E3CY^[!?IIISULGXJ]C2<S9%KFZ*MNG;Y:;
MU/2V7C&@W .N! (!5@*Y9(X^6LAT45@[HC,3DHUGE. _SXJK][GP--[R$?JK
M8 ;*--'^H>T5[Z=J?37B'M%>^I'136!YUF)R66L\KP%:_P"]WN/HIGR'T5L!
MVI]->(>T5[Z=J?37B'M%>^H[J*QS68G)-9Y7@*U_WO)_"F]Y_16P':GTUXA[
M17OIVI]->(>T5[Z=U%8YK,3DFL\KP%:_Y\_HIO>?T5L!VI]->(>T5[Z=J?37
MB'M%>^H[IZN/.LQ.2:SRO Y:_P"]Y/X4WO\ K%; =J?37B'M%>^G:GTUXA[1
M7OJ>ZBL<UF)R36>5X"M?][S^B@/G]%; =J?37B'M%>^G:GTT/ZA[17OIW45C
MFLQ.2:SRO 5 MB9_*"=_NP_M5<N]7D631-JT[(<?M\;J'7$[BE;Q.1G/?KV.
MQSY*^Z:)T:9T?I3)&.0YP).R]MI^"\-59IL_,F,P6!LOHI2E>Z7-7%4=KK:O
MJO26TN9$CP_E'3<%J-,G;EL<Q&AJ0\J0\J4%[H6VEG>2V4Y7G='AJ\JCJM#6
M5-XN]V5#ZV9=HZ(LTO.K<;>:2"$H+2E% &%*'!(SDYSFHLBJ=SI-!^S2I2]$
MZJM8:M<F[*5+899<$5HI'6-I<4-\GK$$)('?YXX]-1=(J6ZM$*T66?"F?*Q@
MLN3$,K3-ZB8RQ*;2 O\ %DAY*DJ5PQGEC%3=6P70RH!@JLSBHRK8Y9RV9\D_
MR-:@5,@]9D)[E./   ,#A7DZ;Z-^F;6F\*N@>O3T^[.71#KCKS)C[SJ'$MHW
M7. 2IM!*N!64I*LD"F\;% 7BR^E5;V8LN4QI#4T^+"@]ES9,2,A3,5PHWPPM
MPJ"=[=P<@D<4\\TVC;>I]DFRM/Q("K1J*.W;;AB0MJ4AR*[<&(SHPA64DATA
M)//!('#C+4]'O0*;;,MZ;"41)D40I#29LD!YH**DA9#F5$;R@%'N@"4@XX5E
MN^P+0M]G2YLZPI>EREH<>>[*?2I:DK;6#E+@_ILM*..90">_G)I"*.;;>D):
MMD.K=$V:7<;='>OEQ;8=CS%+#SC"W SO, #!6EQ:"=[ANA5?'J/I,(T]<'TK
MTM<5VR)=9EIE35OM!85&8+JUMM DK"NY"1D$[W>/"K%U%LOT[JEB^M7:"Y-;
MO<=N+/0J4\E+S39)0D!*P$8)/%&"<\<UY@V%:(<@OPGK$B7'=FNW!Q,N2^^5
MON-=4XLJ6LD[R.!!.#SQGC1MO%2%#W^DJ\RR\5Z U'$DQ;8;O-C7#J8JV(R7
MU,J6 M658*2KD,I((X\*]?7.T:]_,FRW?3_8UM7<+_#MB')K0EH<CO20QUR0
MA:>85O)R?(1QX>XO8W88@>?M;"H=Q<MGR/V8^\]*/8F^5ELH<<(5G)[HY/'F
M<8K[KKLMTW>M*6G3<R"M5IM:HZXC+$EV.6EL8ZI04TI)RG (X\P#S%-B!50_
MTDW=%S]2V[5D9Q^1IQZ4E^?:F4HB2&6V&'PMP+45-*2A\%0&\D!*CG&!4D:Z
M1<:=*NR+7IF\7*%;88DO75H-IMX<+3;W5=D*4$9ZMU"MX$CF.?.3-[$M&,*A
M+:LY8<AF0IEYF6^AS??QURUK"PI:U;J<K42KN1QX5B;V#:$:C/1VM/,1XSR&
M$.,,/.MMJZG'5**4K WQN@;^-X@8)(J+A-BA(Z7&FWVDB%:[I<)S]M@7*';H
MZ$JE2TR_[SU;8.5)SO K&0"A7DS<^G;L;[9(-Q5"EVU4IE#QASF^K?9R,[CB
M<G"AR(J'N[!="R(D6,YI]I3,-E+$0!]X&*D+2L%HA>6U;R$'?00KN0,X%3N'
M%;A1FX[*=QIM(2D$D\!Y3Q/G-+A%FI2E$2E*41*4I1%QG@:J/I2<=ANI3_K0
MQ_\ ,9JW.\:KS;GI"YZ[V6WRQ69+"[G)#"F$R7.K;*D/MN$%6#C(0>.*UQ 7
M-(&^RC8-ZIU]EOKG#U:.*C_1'AKY5M(X_BV_W17HKV>;4W%*5\V+$ 23CY>5
M]A6-6S7:F0?R8L?KU7V-?CS4+2N_]O[QFOIPK5.&R_VG)>466^/XMO\ =%8%
MM(_T;?[HKV.UCM5/Z,V+UXK[&L9V6;4R/\6[%Z\5]C6T:!Z5#S?WC-9=M4WB
M^TY+PEM(P?Q:.'^J*P.-(X_BT?NBO?5LEVJ']'+#Z\5]C716R+:JK/Y.6(?M
MQ7V-;FZ"Z4CS?WC-.VJ;Q?:<E&5-H)/XM'[HK"MIOC^+1^Z*D_::VJ$G\GK%
MZ[5]C6,[%MJJL_D_8?7:OL:WMT'TGY?WC-3VU3>+[3DH=-D1H,=;\A33#*,;
MSC@  R<#^./36"2VD$C<1^Z*F+^PO:C(;4AW3NGW$*YI7>2I)\X+.*QKV#[5
M5_Y"L/Z[TK[&K;="=(PT?D-_^8S4=M4[B^TY* NH3@C<1^Z*\]U">/<I_=%6
M,KH^;55@_P!Q;"/VRK[&OG<Z.6U51_P/81^V5?8U:9H;I&-[/O&:UFLTX^/T
M.2K-X)PH;B?0*^!Y"<GN4\?(*M-71HVJ*S_<FPC]L*^RK OHN[55CA;+#Y_E
M=7V57&:(Z0C>S[QFM1K%/.X_0Y*HWT)X]R/0*^!Y*>/<CT5<:^BEM67_ )-L
M/K97V5?.KHD;5E?U"PC]JJ^RJZS12O#>W[AFM)JTCZ_HJ>BP4SW^K4\U'21D
MK<'#]>*M+H[N_,':6Y?&%,WEQ%JDL")#WM\;RVU;YRG\T;G'SUG7T/-JJ^<&
MP#]JJ^RJR>C=T<-;[-]J*[]J1FU-V_Y+?A[L287EJ6M;9&04)X80?37HZ-H[
M6I:=;%>_\-H!VW:[P(W7\5S9RHR42"6M'6-QZPMD] :F<U?I2!>'(BH2I3>_
MU2CD?^9)[Z3S!/'!J15AB,I8:"$)"$) "4I& D> "LU?7H+7,AM:\W-MI]9]
M:\FX@N) L$I2E;EBE*4HB4I2B)2E*(E*4HB4I2B)2E*(E<8KFE$7&!7-*41<
M8KFE='#A!(HB[9KJA842._6O-ZUKJZ!M<U4];+VIS3NGE,R;HU<94?L)B,J(
MM:VPA#9D)<ZP(4%\0!O YY5XUNZ6<B5)AARS6QBXO$Q5!^].,LA7RGV'OAM3
M>=TC<=!(WBDD<!Q)HZPN$6T(IBHILJUP-H^@++J0,MQS/9*U-,N]8A*@HI4$
MJP,C*3WJEE$7&*YI2B)2E*(E*4HB5QFN"< \:IC6VT@Z;VK2G_E]Y5GLVGGG
MI]H;6UU79JWFDQ4KRG>#C@6L)&^ >!QPJ$5T9X>6@.36K=IVI:ROEDCVIO5#
M5MVCV2_KA.6R[-L1T79M3:WV6GFAO% <; 0%MD%*AO'/$'V]+;2;W)FZ#DJO
M5UBM7S4-SBOV>^-,(D%+;+I1'/< IZMQL %)[K.25 BIMMLH.Q;$9YU%]?;0
M+3LWL)O%Z5(3#,AJ,E,6.I]Q3CB]U"0A(R<GA5#-;7-4MZ*G7-S4Y:=:<L3\
MA]V.R$QY4F4IN7;QO)[E*4!/ Y6G>XJXU.^E"?R!M'_J:T__ &TU6F8OD\!\
M:U^J"<!=9L'6<&^M9$]*/1PX=AZD]02OAH>E-HU/.)J3U#)^&J]4I1SW1]-?
M.X2<\3Z:_-PZ7IK](WYBO=C1F'S3A_VK(_"IT7WXNH_4,GX:ZCI4Z*\6U'^N
MPR?AJL3G!X_QK HX'/CYZS'2Y,GT1OS')-6(?-. S5J_A5Z)''L?47J*3\-#
MTK]$ <6-1>HI/PU43A.#@GTU\RR>/$^FMHZ6)H[I5OS%-6(?-. S5QCI9Z&_
MT.HO44GX:?A::%XY:U"/V')^&J3.<GB?36%8XGC_ !K:.E6:/HK?F*G5B'S3
M@,U>/X6N@Q_V>H/4<GX:Z_A=:!'--_\ 4DGX:H=TD C)KX7L\>/\:VMZ49D^
MC-Q*C5F'S3@,UL*>E_L_3S^71^Q)/PUT/3#V>#^E?1^Q9'PUK:\#QKSW^&>/
M\:M-Z3)AWHS<2M6K<,>=. 6S_P"&-LY[[M['GLLCX:X/3*V;)YOWH>>S2/AK
M5)_D>/\ &O/>QQJVWI&CN]';B5AJZP>=/T6W9Z:&S09_E-Y]32/AKH>FGLQ'
M.7>!^QY'PUIP^<?_ +7P/'GQ_C5IO2!&=Z.,2M9T?9S?VS6ZAZ;&R]/.;=Q^
MQY'PU)MF_23T/M4U(JQ6"7-=N(CKE;DF ZP"VDI"B"H 'BI/"OSU?[_'T5<7
M0N3G;X,_]Q2R/K6*]+1-*GU:<;*NA!MP=M_4"5S9VE"4@F*'WM9;^M\C7:NC
M1RDUWKZ&-RX"4I2I1*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2NJD[R
M2/#2E0BP)M["%.*2V@*<_/(0,J\_A_76)5HB+P3'9.. RTDX'HI2C47TQV&X
M[00TA*$#DE*0 ./@%9:4J42E*41*4I1$I2E$7&Z""/#7S.06'2LK:0LKQO;R
M <XY9X<:4HH6/Y(B*<ZQ4=E3F=[?+2=[/ASC.:R*@LK4E2VTK4@Y25)!(/A'
M@I2H4KHNVL.(4E3:%)4K>(4@$%7A(\/EJ%[9=G<S:/I%FU6ZY,6J:Q<8L]J1
M)CJ>;RRZ'-U2$J22#C',4I6+V-B-+'BX.PCV* 2-H5;'8'M!<XG66G/4+_WF
MNAZ/VT$\]9Z<_58'OO-*5Y'5"@#T-F"Z;:E.V_NG%=/P>=?G/Y::=]0O?>:Z
M'HYZ_/Z::>]0O?>:4K(:(T&_^(S!.TYWG.Q70]&_7Q_373WJ%[[S7571KUZK
MGK73_J%[[S2E9:IT+](S!1VG.\YV*Q_@S:[X_EK8/43WWFNBNC!KE7/6M@]0
MO?>:4J=5*'^D9@I[3G><[%=#T6];J&#K:P^HGOO-8E=%+6ROTWL0\UB>^\TI
M60T6H@W2K,%':<[SG8K">B1K-><ZXLGJ)[[Q6%?0]U@OGKFRCS6-W[Q2E9C1
MFC#T5N"GM&</G78K"KH9ZN5SUU9OU6-W[Q6%70JU8K].[/ZC=^\4I60T=I W
M2S<%CY?-\TXK$KH0ZJ5SUY:/4COWBL2^@QJ98XZ\M7ZK(Y]O2E;!0*4!_C-P
M3RZ:YIQ6%70/U*OGKVU^I'/MZGNP7HK739!M#5J6?JF)>$& [!3&CV];!!6I
M"M[>+BN6YRQWZ4JY+4R1E'_BP(+6N'B J\69CQ6]6(\D+9!'(UVI2NJJZ4I2
5B)2E*(E*4HB4I2B)2E*(E*4HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jan-20231230_g13.jpg
<TEXT>
begin 644 jan-20231230_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHK\E/\ @K7_ ,$YOV)OV4/@NNO?"G1?BIX@^,GQ9\80>%?A
M-X9;XX^(T@O/$&H2-MFD1+P!+6W7?/)@! L:H2F\$ 'ZUT5^6/[0'[.?C/\
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M/^&[/VC_ /I&S\2__ RVH ^G**^8_P#ANS]H_P#Z1L_$O_P,MJ/^&[/VC_\
MI&S\2_\ P,MJ /IRBOF/_ANS]H__ *1L_$O_ ,#+:C_ANS]H_P#Z1L_$O_P,
MMJ /IRBOF/\ X;L_:/\ ^D;/Q+_\#+:C_ANS]H__ *1L_$O_ ,#+:@#Z<HKY
MC_X;L_:/_P"D;/Q+_P# RVH_X;L_:/\ ^D;/Q+_\#+:@#Z<HKYC_ .&[/VC_
M /I&S\2__ RVH_X;L_:/_P"D;/Q+_P# RVH ^G**^8_^&[/VC_\ I&S\2_\
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M .&[/VC_ /I&S\2__ RVH_X;L_:/_P"D;/Q+_P# RVH ^G**^8_^&[/VC_\
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MQ+_\#+:@#Z<HKYC_ .&[/VC_ /I&S\2__ RVH_X;L_:/_P"D;/Q+_P# RVH
M^G**^8_^&[/VC_\ I&S\2_\ P,MJ/^&[/VC_ /I&S\2__ RVH ^G**^8_P#A
MNS]H_P#Z1L_$O_P,MJ/^&[/VC_\ I&S\2_\ P,MJ /IRBOF/_ANS]H__ *1L
M_$O_ ,#+:C_ANS]H_P#Z1L_$O_P,MJ /IRBOF/\ X;L_:/\ ^D;/Q+_\#+:C
M_ANS]H__ *1L_$O_ ,#+:@#Z<HKYC_X;L_:/_P"D;/Q+_P# RVKJOV:?VS-4
M^/7Q5\0?!SQ?\ O$/@37/#^D0:C<6FO7,3L\4SE4P$Z9QF@#W*BBB@ HHHH
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M,O\ P2F_Y-WUO_L>[_\ ]%6]?35 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-/P
MO_Y2G_%+_LFFB?\ HUZ^EJ^:?A?_ ,I3_BE_V331/_1KT ?2U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\R_\ !*;_ )-W
MUO\ ['N__P#15O7TU7S+_P $IO\ DW?6_P#L>[__ -%6]?35 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?-/PO\ ^4I_Q2_[)IHG_HUZ^EJ^:?A?_P I3_BE_P!D
MTT3_ -&O0!]+4444 %%%% !1110 4444 %%%% !1110 5^#WA3]I_P#X)F_M
MI:)\0_VM/^"FOQM^*/B'Q-XD\5ZVO@^Q^'__  DD]G\'/"UK?3V.GW#KI -O
M97#M:M=/+.&>7*-Y>QF,G[PU^2?_  3V_:+^ O\ P11^$?Q3_8%_:_\ A)XP
MTKQ)8?$K7]7\&KHGPYU#58?B?I5[(&LI+*:U@DAFN&B\NV>&5U\LHJL0%?8
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M,?#'_0:@_P"^J^<O^"5-E92?L\:T7M(FQXZOP,Q@X'E6_%?3/]G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I
M_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]
MG:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X
M3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7S3\+_ /E*?\4O^R::)_Z->OI:OFGX7_\ *4_XI?\
M9--$_P#1KT ?2U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\R_\$IO^3=];_P"Q[O\ _P!%6]?35?,O_!*;_DW?6_\ L>[_
M /\ 15O7TU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+?\ "#Z1_P _-[_X%M7S[_P2F_Y-WUO_ +'N_P#_ $5;U]-4 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "OFGX7_\ *4_XI?\ 9--$_P#1KU]+5\T_"_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4
M ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1
M_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16
M/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#
MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L4
M5C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P
M@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_
M ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1
M_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'
M_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[
M_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/
MS>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X
M%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@
M6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;
M%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?
M\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C
M_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L5\T_"_P#Y2G_%+_LFFB?^C7KW
M[_A!](_Y^;W_ ,"VKYZ^#^GPZ9_P5$^*%G;O(RK\-=%(,CECS*YZF@#Z=HHH
MH **** "BBB@ HHHH *_+'_@KI_P5<_X*'^"/VAOB-^R=_P3(\ ^#X9_@C\(
M9OB'\8O'OC5/-^PV:V[7*6EG 3L>5H%5@65][2;<1B-G;]*_BW\7OA?\!?AW
MJ?Q<^-'C[2O"_AC18DEU;7M;O%M[6T1I%C5I)'("@NZJ,]V K\9/^"MGA;_@
MFK^VW\8-6_:A_8X_X+K_  O^#_CWQ9X"F\%_$:S?Q?!-I?B_19(VC,%R(Y0R
M'RV\LDK(K+''A49-Y /J;]BC_@J?^U?XH_;D^%?[)7[4GPXT9_#7QJ_9UT+Q
MQ\-_&VE;8[F[U-=&M;G5XKB)&VI&9FN2@V(4V(!O60>7^C%?CK_P0C_9<_95
M\&_M6:7\6OB9_P %A/!?[2OQET#X<CPI\.?#'AC78Y+7PMH-O&BNMM&9"[[8
MUV9"1JJR2EE=I-Z_L50 5ROQL^"/PG_:.^%NK_!/XY>!;'Q+X4U^%(M8T/4D
M+07:)(LJJX!!(#HC=>JBNJHH Y'XR? 3X+_M#?"K4?@=\<?ACHWBKPCJMNL%
M_P"'];LEGMI40@H=K=&5E5E<8964,I! -<9^R=^P!^QO^PU::M;?LI_ #1/!
MTFO/&VM7UGYL]W?",$1I+<W#R3.B9.U"^U<G &37L-% '%^+_P!GSX3^/?C/
MX/\ C_XO\-O?>)_ -KJ,/A&[EOIO*TXWT:17,JP!Q$TS1((Q*REU1Y%4J)'#
M>>_M'?\ !-']B/\ :T^)-M\6OC]\#XM<UV'3X=/NYX]<O[.'5;*&8SQ6FH6]
MK/'#J4"2DNL-TDJ DX&"0?=J* &PPPV\*6]O$L<:*%1$7 4#@  =!3J** "B
MBB@#YE_X)3?\F[ZW_P!CW?\ _HJWKZ:KYE_X)3?\F[ZW_P!CW?\ _HJWKZ:H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5O7TU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[OP5XK^S?!?X40KX+2UBL8''B7Q@&2?4K@3M&9DBL(S#9A$94>>2ZW;C$FT
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M?_$T?\-M_LH?]%ST/_OZW_Q-'UG#?SK[T'^K^??] E7_ ,%S_P CU.BO+/\
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M/^BYZ'_W];_XFC_AMO\ 90_Z+GH?_?UO_B:Z/K.&_G7WH\'_ %?S[_H$J_\
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M]7\^_P"@2K_X+G_D>IT5Y9_PVW^RA_T7/0_^_K?_ !-'_#;?[*'_ $7/0_\
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MZ:_BCPQ8:N^G2MEK4W-O',8B2!DKOV]!TKIZ;###;PI;V\2QQHH5$1<!0.
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M)_\ B:^C:*/J&"_Y]K[@_P!=.+?^@ZK_ .!L^<O^'6?[*?\ SX:__P"#D_\
MQ-'_  ZS_93_ .?#7_\ P<G_ .)KZ-HH^H8+_GVON#_73BW_ *#JO_@;/G+_
M (=9_LI_\^&O_P#@Y/\ \31_PZS_ &4_^?#7_P#P<G_XFOHVBCZA@O\ GVON
M#_73BW_H.J_^!L^<O^'6?[*?_/AK_P#X.3_\31_PZS_93_Y\-?\ _!R?_B:^
MC:*/J&"_Y]K[@_UTXM_Z#JO_ (&SX9^,/[ GPV^"_P 0;?Q2_P -_%7BGX?W
MEF([Z+0+HRZCI%R#_K=@&9H6'7NISR, -1\#?L2?"GX[?$O3A\-OACXQ\/\
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MU]&T4?4,%_S[7W!_KIQ;_P!!U7_P-GSE_P .L_V4_P#GPU__ ,')_P#B:/\
MAUG^RG_SX:__ .#D_P#Q-?1M%'U#!?\ /M?<'^NG%O\ T'5?_ V?.7_#K/\
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M8RE9)*RU;NWU;>K=V?.7_#K/]E/_ )\-?_\ !R?_ (FC_AUG^RG_ ,^&O_\
M@Y/_ ,37T;15_4,%_P ^U]QR_P"NG%O_ $'5?_ V?.7_  ZS_93_ .?#7_\
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MPU__ ,')_P#B:/\ AUG^RG_SX:__ .#D_P#Q-?1M%'U#!?\ /M?<'^NG%O\
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M &GK/]HCQ=_P4_\ B;\5;.UT>\L6\(^*89Q:2-.@43$O?3#<F,CY._45^B5
M!1110 4444 %%%% !1110 4444 ?,O\ P2F_Y-WUO_L>[_\ ]%6]?35?,O\
MP2F_Y-WUO_L>[_\ ]%6]?35 !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-/PO_Y2
MG_%+_LFFB?\ HUZ^EJ^:?A?_ ,I3_BE_V331/_1KT ?2U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\R_\ !*;_ )-WUO\
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M #ZZS_X,_P#[&C_AWY^SW_SZZS_X,_\ [&CFQ_:/XA[;C/\ Y]4?_ IG7?\
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M #ZZS_X,_P#[&C_AWY^SW_SZZS_X,_\ [&CFQ_:/XA[;C/\ Y]4?_ IG7?\
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M?X5R/_#OS]GO_GUUG_P9_P#V-'_#OS]GO_GUUG_P9_\ V-'-C^T?Q#VW&?\
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MXW^%'_#57[.__16=)_[^-_A7(_\ #OS]GO\ Y]=9_P#!G_\ 8T?\._/V>_\
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MB@ HHHH ^9?^"4W_ ";OK?\ V/=__P"BK>OIJOF7_@E-_P F[ZW_ -CW?_\
MHJWKZ:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KYI^%_P#RE/\ BE_V331/_1KU
M]+5\T_"__E*?\4O^R::)_P"C7H ^EJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#YE_X)3?\F[ZW_P!CW?\ _HJWKZ:KYE_X
M)3?\F[ZW_P!CW?\ _HJWKZ:H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYI^%_\
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MY1\Z:2V26ZD;S%$49@^5S,-H![#1110 4444 ?,O_!*;_DW?6_\ L>[_ /\
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MPG_/R/WH/9U.S+=%5/[?T+_H-6G_ ($K_C1_;^A?]!JT_P# E?\ &CZWA/\
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M?T+_ *#5I_X$K_C1_;^A?]!JT_\  E?\:/K>$_Y^1^]![.IV9;HJI_;^A?\
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MVYFO_/U_<O\ (\F_X9ED_P"AH7_OS1_PS+)_T-"_]^:]9HH_XAGP-_T!1_\
M I__ "0?VYFO_/U_<O\ (\F_X9ED_P"AH7_OS1_PS+)_T-"_]^:]9HH_XAGP
M-_T!1_\  I__ "0?VYFO_/U_<O\ (\F_X9ED_P"AH7_OS1_PS+)_T-"_]^:]
M9HH_XAGP-_T!1_\  I__ "0?VYFO_/U_<O\ (\F_X9ED_P"AH7_OS1_PS+)_
MT-"_]^:]9HH_XAGP-_T!1_\  I__ "0?VYFO_/U_<O\ (\F_X9ED_P"AH7_O
MS1_PS+)_T-"_]^:]9HH_XAGP-_T!1_\  I__ "0?VYFO_/U_<O\ (\F_X9ED
M_P"AH7_OS1_PS+)_T-"_]^:]9HH_XAGP-_T!1_\  I__ "0?VYFO_/U_<O\
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M(9\#?] 4?_ I_P#R0?VYFO\ S]?W+_(\F_X9ED_Z&A?^_-'_  S+)_T-"_\
M?FO6:*/^(9\#?] 4?_ I_P#R0?VYFO\ S]?W+_(\F_X9ED_Z&A?^_-'_  S+
M)_T-"_\ ?FO6:*/^(9\#?] 4?_ I_P#R0?VYFO\ S]?W+_(\F_X9ED_Z&A?^
M_-'_  S+)_T-"_\ ?FO6:*/^(9\#?] 4?_ I_P#R0?VYFO\ S]?W+_(\F_X9
MED_Z&A?^_-'_  S+)_T-"_\ ?FO6:*/^(9\#?] 4?_ I_P#R0?VYFO\ S]?W
M+_(\F_X9ED_Z&A?^_-'_  S+)_T-"_\ ?FO6:*/^(9\#?] 4?_ I_P#R0?VY
MFO\ S]?W+_(\F_X9ED_Z&A?^_-'_  S+)_T-"_\ ?FO6:*/^(9\#?] 4?_ I
M_P#R0?VYFO\ S]?W+_(\F_X9ED_Z&A?^_-(?V9G R?%"@#J3#7K5<Q\;/%\O
MP]^#7B[Q]#IT=X^A^&+_ %!+29RJ3F&WDD",1R VW!(YYI2\,^!^5\N"C?\
MQ3_^2!9YFM]:K^Y?Y'E_@WX6:=KLDVJCQ9:PV]O>E+4SE<W 0\O@GA2>GXUV
M7P\N/$6F:C>?#JS\0V;+8#SK%RGF"2!CG@@_PDX.?6OSI_9B_:^_X+3_ +77
MP!\+?M*_!S_@F-\ )O"_C'2UU#19=0^*%U!,T)9E!>,H2ARIXKT7]E;]MO\
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M?VX_^C__ /R;U/\ ^.5^KE% 'Y1_\.&?VX_^C_\ _P F]3_^.4?\.&?VX_\
MH_\ _P#)O4__ (Y7ZN44 ?E'_P .&?VX_P#H_P#_ /)O4_\ XY1_PX9_;C_Z
M/_\ _)O4_P#XY7ZN44 ?E'_PX9_;C_Z/_P#_ ";U/_XY1_PX9_;C_P"C_P#_
M ,F]3_\ CE?JY10!^4?_  X9_;C_ .C_ /\ \F]3_P#CE'_#AG]N/_H__P#\
MF]3_ /CE?JY10!^4?_#AG]N/_H__ /\ )O4__CE'_#AG]N/_ */_ /\ R;U/
M_P".5^KE% 'Y1_\ #AG]N/\ Z/\ _P#R;U/_ ..4?\.&?VX_^C__ /R;U/\
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M_P#Y-ZG_ /'*_5RB@#\H_P#APS^W'_T?_P#^3>I__'*/^'#/[<?_ $?_ /\
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M ";U/_XY7ZN44 ?E'_PX9_;C_P"C_P#_ ,F]3_\ CE'_  X9_;C_ .C_ /\
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M (Y1_P .&?VX_P#H_P#_ /)O4_\ XY7ZN44 ?E'_ ,.&?VX_^C__ /R;U/\
M^.4?\.&?VX_^C_\ _P F]3_^.5^KE% 'Y1_\.&?VX_\ H_\ _P#)O4__ (Y1
M_P .&?VX_P#H_P#_ /)O4_\ XY7ZN44 ?E'_ ,.&?VX_^C__ /R;U/\ ^.4?
M\.&?VX_^C_\ _P F]3_^.5^KE% 'Y1_\.&?VX_\ H_\ _P#)O4__ (Y1_P .
M&?VX_P#H_P#_ /)O4_\ XY7ZN44 ?E'_ ,.&?VX_^C__ /R;U/\ ^.4?\.&?
MVX_^C_\ _P F]3_^.5^KE% 'Y1_\.&?VX_\ H_\ _P#)O4__ (Y1_P .&?VX
M_P#H_P#_ /)O4_\ XY7ZN44 ?E'_ ,.&?VX_^C__ /R;U/\ ^.4?\.&?VX_^
MC_\ _P F]3_^.5^KE% 'Y1_\.&?VX_\ H_\ _P#)O4__ (Y7*_'3_@AO^VKX
M5^"7C'Q1JG[=_P!KMM-\*ZA=7%I]KU+]]'';2.R<R8Y (YXYK]AJI^(= T;Q
M9H%]X6\1Z='=Z?J=G+:W]I,/DFAD0HZ-[%20?K0!^"?_  27_8B\2>(_V2/@
MM\99?^"G/@OPQ8-IUGJ,G@W4/&+P36D27!9K=X_/"J2%/&T#YNE?;WQ0^)OP
MV^)O_!Q=^SY??#?X@Z'XA@M?@'XMCN9M#U:&[2%S/$0K&)F"DCG!KUO_ (<$
M?\$;?^D>WP__ / .;_XY7>?LY?\ !*7_ ()U_LB_$N+XQ_LU?LD^$_!WBB"S
MFM(M:T>WD69890!(@+.1A@!GB@#Z#HHHH **** "BBB@ HHHH *^:?A?_P I
M3_BE_P!DTT3_ -&O7TM7S3\+_P#E*?\ %+_LFFB?^C7H ^EJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YE_P""4W_)N^M_
M]CW?_P#HJWKZ:KYE_P""4W_)N^M_]CW?_P#HJWKZ:H **** "BBB@ HHHH *
M1F55+,0 !DD]J6N'_:.^&/BCXP_!W6?A]X/\9S:%?W\&V*ZBX64#K#(0-PC?
M[K%<'![C*M=.,9U%&3LF]^WF15E*%-RBKM+;OY'FGBC]OCPUH?C_ ':9X2N;
M_P"']C??V;K?CBW;,45\W(\E1S-$@&'=<_?4C^'S/9+7XJ_#"^MH[RS^(^@R
MQ2H'BDCU>$JRD9!!W<BOCGXR:E\(/B'\!=)^"WC7P]J/@_QGX(U 65M\/]"M
M!)+J-W*FV-H"V[?#(?G,N6(W<ERRE[?PX_X))P:EX0M-2^)WQ(O-.U>X3S+C
M3M.MHY$M<](RY/SL!U( &<@9 R??JX'+(T5*I)TW=K:_-V?G?>ZTU2/G:6/S
M25=QI051-)[\O+W7E9Z6?O:-GU__ ,++^''_ $4#1/\ P:P__%4?\++^''_1
M0-$_\&L/_P 57R[_ ,.AOAQ_T5_6_P#P!AH_X=#?#C_HK^M_^ ,-<OU7)_\
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MH;X<?]%?UO\ \ 8:/^'0WPX_Z*_K?_@##1]5R?\ Z"'_ . ,/K6=_P#0.O\
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M_P ++^''_10-$_\ !K#_ /%5\N_\.AOAQ_T5_6__  !AH_X=#?#C_HK^M_\
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M_P"#6'_XJOEW_AT-\./^BOZW_P" ,-'_  Z&^''_ $5_6_\ P!AKS_JN3_\
M00__  !GH_6L[_Z!U_X&CZB_X67\./\ HH&B?^#6'_XJC_A9?PX_Z*!HG_@U
MA_\ BJ^7?^'0WPX_Z*_K?_@##1_PZ&^''_17];_\ 8:/JN3_ /00_P#P!A]:
MSO\ Z!U_X&CZB_X67\./^B@:)_X-8?\ XJC_ (67\./^B@:)_P"#6'_XJOEW
M_AT-\./^BOZW_P" ,-'_  Z&^''_ $5_6_\ P!AH^JY/_P!!#_\  &'UK._^
M@=?^!H^HO^%E_#C_ **!HG_@UA_^*H_X67\./^B@:)_X-8?_ (JOEW_AT-\.
M/^BOZW_X PT?\.AOAQ_T5_6__ &&CZKD_P#T$/\ \ 8?6L[_ .@=?^!H^HO^
M%E_#C_HH&B?^#6'_ .*H_P"%E_#C_HH&B?\ @UA_^*KY=_X=#?#C_HK^M_\
M@##1_P .AOAQ_P!%?UO_ , 8:/JN3_\ 00__  !A]:SO_H'7_@:/J+_A9?PX
M_P"B@:)_X-8?_BJ/^%E_#C_HH&B?^#6'_P"*KY=_X=#?#C_HK^M_^ ,-'_#H
M;X<?]%?UO_P!AH^JY/\ ]!#_ / &'UK._P#H'7_@:/J+_A9?PX_Z*!HG_@UA
M_P#BJ/\ A9?PX_Z*!HG_ (-8?_BJ^7?^'0WPX_Z*_K?_ ( PT?\ #H;X<?\
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M%E_#C_HH&B?^#6'_ .*H_P"%E_#C_HH&B?\ @UA_^*KY=_X=#?#C_HK^M_\
M@##1_P .AOAQ_P!%?UO_ , 8:/JN3_\ 00__  !A]:SO_H'7_@:/J+_A9?PX
M_P"B@:)_X-8?_BJ/^%E_#C_HH&B?^#6'_P"*KY=_X=#?#C_HK^M_^ ,-'_#H
M;X<?]%?UO_P!AH^JY/\ ]!#_ / &'UK._P#H'7_@:/J+_A9?PX_Z*!HG_@UA
M_P#BJ/\ A9?PX_Z*!HG_ (-8?_BJ^7?^'0WPX_Z*_K?_ ( PT?\ #H;X<?\
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M@84/8JI//<B@#[JHKXLT#X7?\%HO$6A67B"S_:]^&Z0WUI'<1++X>C#!74,
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M/&OP_P#!/Q'TN+1/'GA>RU:TANX[F*WOH ZI*ARK 'OV/J"0<@D'75550J@
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M 4444 %%%% !7D'@WP+XNL/VT_&GQ O-!GCT74/!^G6MEJ+ >7+-&[%T'/4
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MS%\%_$O[0'QJ\40Z-X6\):3+J.M:C-SLB0?=5>KR.Q5$0?,[NJJ"6 K\S/\
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M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XE?M7_%G]D'X]?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[&>EZM<>,M;7XSWO[3-AJ\WB^T)2023V'V,D[4G-P8A&CS?:E. Q,0K]P/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYQ_8X_P"2N>-/^!?^E#5]'5\X_L<?\E<\:?\
M O\ TH:@#Z.HHHH **** "BBB@ HHKS7XD_MA?LT?![X[^"OV9?B=\7M,T3Q
MS\1EN&\$Z!?+(KZKY(S(L<FSRPW8*S*S$A5#$@4 >E45Q/[0/[1GP5_98^'+
M_%OX_>/+?PWX=CU&TL'U.YMY94%Q=3I!!'MB1VR\KHH.,#/) YIL_P"TE\$;
M;]HZ#]D:?Q_;K\1KGP:WBN'PP;>;S6T=;K[(;O?L\O;Y_P FW?OSSMQS0!W%
M%</\<?VDO@C^S;!X5N?C=X^M] 3QMXTL/"7A9KBWFD^WZU>[_LMFOE(VUI/+
M?#-M0;>6%)\'OVD_@A\?=?\ &?A;X1^/[?6=1^'OBB7P[XSLX[::*32]2C56
M:!Q*B[OE8$.FY&!^5C0!W-%>6_"/]M7]EKX[_&_QS^S=\(_C)IFN>-_AK,D7
MC?P]:QS++I;NS* S.@1\,I4^6S;3PV"16UX=_:1^"7BWX\^(_P!F+PWX]M[S
MQUX1T>SU3Q)X?AMIB^GVEUG[/)))L\L&3:2$#%L#.,<T =Q1110 4444 %%%
M% !1110 4444 %%%>7_$S]M+]EOX.?M >"_V6/B=\9M*T?X@?$2.5_!OAFZ$
MOG:DL>[<594*)DHRKO9=[*57<>* /4***\O^'7[:/[+?Q:_:)\9?LF_#CXS:
M5JWQ$^']O%/XP\+6PE\_3HY!&59F9 CX\V,-L9MC.%;:>* /4**** "BBB@
MHHHH **** "BBB@ HHKA_P!H?]I+X(_LH?#27XP_M">/K?PUX;AU"UL9=5NK
M>:5%N+F988$VPH[9>1U4'&!GD@<T =Q15;6M8TWP]H]WK^LW0@L[&VDN+N=@
M2(XD4LS$#). ">*\RTK]N3]DG5_V5H?VW8OCSH-M\*+C3VOH?&^IS-9V;0"8
MP[OWZHX)E4QJI7<S$*H)(! /5J*^4_@!_P %O_\ @E?^T]\4M-^"WP<_:]TB
M[\3:W*(M"TW6-$U+2/[4D)PJ6LFH6T,=RS'A5B9BQX4$U]64 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX5>"]1^(GQ$\16^DZ)I-N9]2U*[)$=O&" 68@'C)%>*_\/6/^"=O_1VOA/\
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MO2OIOX?_ /!1?]B#XJ^--.^'?P[_ &D_#FK:WJUP(--TVTG<R7$A!(505'.
M:^!?^"2?_!#S]C_XI_\ !-SX/_$/XV^!O%]CXLU;PC'/KMI+J\UHT4YDD!!A
M9 8^ .#7UG\%/^"+O[$'P ^*VA_&7X=Z%XCBUOP]?"[TV2[\0O+&L@! W(5^
M88)XH ^L:_!3]I;X@?!;]O)/VOO^"A5E^U%X"T'XC?#SQII-E^RW8ZOXQL8+
M^"'P;*UX]S;0R2K(RZC<S78C&!DOZ=?V6_;CTW]HO7/V0OB)X<_9'L;2;XE:
MKX6NM/\ !SWVHK:16UY<+Y*W)E;A3"':8>IB [UX]^R#_P $9OV!OV?/V7/
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MEXF^"WPY^%9T/X8^%_$$-OJ<5_KE_.DVH:E-:3(R(4BC2W7<.=B.,8S7,?\
M!0G_ ()*:%&GPK_:1_X)?_LX?#3P1\7?A%\4-/\ $%G%H6B66@1:_I1#0ZAI
MMQ-;PKE)87ZMG 5U&"YKH/<.4^+/PZ_;S_X)W_\ !2GXR_MX?!']B2/]HGP-
M\;-/T$:D?#OB.VLO%/@\Z;9BU:VABN5/VRUE*B010D'=MW8V OUG_!-?]H#]
M@+]J;]O'XH?'/X4_#3XD?";]H&_\&6-E\5/A-\1]!;1+R:S@G'D:H]G\R7$@
M9UA^TK(6".@95\Q2T7B[X,_\%8/V'?VL/B3\:/V+O OAGX\?"[XM:W'X@O\
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ML%_M+_%WPEH/PN^$_@'5O&_Q(M?%?B2UL+;5M7U*UDTO3-/!N'7,T5O<W%V
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MBT?^1+C_ .*H_P"&./BY_P!%H_\ (EQ_\50!]'45\X_\,<?%S_HM'_D2X_\
MBJ/^&./BY_T6C_R)<?\ Q5 'T=17SC_PQQ\7/^BT?^1+C_XJC_ACCXN?]%H_
M\B7'_P 50!]'45\X_P##''Q<_P"BT?\ D2X_^*H_X8X^+G_1:/\ R)<?_%4
M?1U%?./_  QQ\7/^BT?^1+C_ .*H_P"&./BY_P!%H_\ (EQ_\50!]'45\X_\
M,<?%S_HM'_D2X_\ BJ/^&./BY_T6C_R)<?\ Q5 'T=17SC_PQQ\7/^BT?^1+
MC_XJC_ACCXN?]%H_\B7'_P 50!]'45\X_P##''Q<_P"BT?\ D2X_^*H_X8X^
M+G_1:/\ R)<?_%4 ?1U%?./_  QQ\7/^BT?^1+C_ .*H_P"&./BY_P!%H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jan-20231230_g14.jpg
<TEXT>
begin 644 jan-20231230_g14.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  8X# 2(  A$! Q$!_\0
M&P !  ,! 0$!              0%!@," 0?_Q !6$  ! P,! P<&" <,"00#
M   !  (#! 41!A(A,1,4%19!4=$B559ADY0R5'&!D9+2TR,S-4)24Z$'%R0E
M<G1U@I6BL;,T-C=E@Z.RP?!#1$5&8J3A_\0 %0$! 0
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MOI'U?XX$-8P9()#?A8#B!V[)[E[K:*:X5CZJIT?5/D>S9=BX1!IW%H. _&T
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MI$])5U$E.^32M>3!"8!_&;/+C.,M?Y?E@XWYR@\,?9'QAXUI<<'<,UK0>!/
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MU<],R1RZ6M3XGM>PTD0VFG(W, 5'<X+U>+95VRMGT])3U,3HY6%TGP2"._\
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M3M;]_:<8'[/F3F,C9Y)FV6$.:[:R"<N .[&_CC_OWJ-<]":8@M-9+':8&/9
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MJIZE:6]';5[HSP3J5I;T=M7NC/!!;\ZI_P!?%]<+$1N;U5MSMH;/6#.<[O\
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M<6M)P?(X;E<-U!IIN]MWM(^2IC\56:IU%8YM(WB**\VY\CZ*5K6-JF$N)8<
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M3]9US'N' T-/N/=D,QE :TM:\:UK2QSBUKA0P$$C&?S/6KOI_3.R&]+VG &
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M=;U@X8/,8,.SW>0K\ZBTZ]H#[S:W;NVJC/\ W42X7ZRR4^*2\V<2D_"?41$
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7[+0W/<,+TB("(B B(@(B("(B B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jan-20231230_g2.jpg
<TEXT>
begin 644 jan-20231230_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "I 'X# 2(  A$! Q$!_\0
M'0   @(# 0$!              8%!P$#! (("?_$ $D0  $# P,"! ,#" 8%
M#0    $" P0 !1$&$B$3,0<4(D$R46$5<9$((S9T@9*TT187,U)5<T)#H;'P
M)"8T-6)D<G6"I++!\?_$ !4! 0$                    !_\0 %1$! 0
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)_*O>:H*B@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jan-20231230_g3.jpg
<TEXT>
begin 644 jan-20231230_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #] 44# 2(  A$! Q$!_\0
M'@   @(" P$!              @!!P8) @0% PK_Q !K$  ! @4" P,$"0P*
M# H(!P ! @, ! 4&$0<2""$Q$R)!"111=146(S(W.&&SM!<8)#,T0EAQ<G:!
ML38Y0W-T=Y2RP]$9)2A$4F*1EJ'2T]0F*35&4U56A)7!14AD96>%AK6BHZ3$
MU>'C_\0 %@$! 0$                   $"_\0 )1$! 0$  @$$ @(# 0
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M3_T=R%D/[5-*?Q<,?1DP#*:%? M87J&1^81&<Q@VA7P+6%ZAD?F$1G, 1!Y
MQ,<2<I@%HXBN,6V+!LO460M.Z*,YJ-:[()H]0ZE?=) 22-_=5]Z>1C,M).)F
MRM0)R@VJBZ:74K[F*2U/SU.IRBM+2]B2Z,C(&"KWN<Q3O%QPQU'7[5"T;>DK
M/I=+M2:*YROWHRRT)Y.S.UA)QN&[(.3G/Z(R'@DT/K.CU+KU!N>RJ-3YNCSJ
MI2F71)LMI?JTK]ZM>!N! QSY9APRRZG+Q^*_]3?@UNWU1.?,KBH_)]_$[TM]
M5?TSD6[J=\&UV#_W3-_,KBHO)]_$[TM]5'YYR"F%@@@@"""" (((( C@Z@.-
MJ2H I(P01F.<03A)YX@*,N/ADL'V0[25KMPV69IPDRE#N)Z28>622<-;L _D
M@1G>G&D=KZ;-33M#EWG)R<2D3-2GYMR;FI@)SMW.N*)(!)( Y<^D+KQ.6%<M
MT:LR56MJATB^'I1B54:?-UE,H[2TI6YO6$J."AT'!4.\-O*+YX<J0[0]&+3I
M[]8EZ\Y+20;5/RCQ=97A:NZA9YJ2GW@)YG;#CWQV)>N6,*F; ?L_B!K-T4>T
MNUHJK2>2XF080D3LZ9GM"V?\)Q8\3F*=MBUKKU.MJ^:K?NF=V-714Q*DR;#K
M,@TS(L/[VY.37N)*DXWG=@J/0B'>+8,1V0QC:/T")QGXS#%#Z5VCJ%6-)+NI
M51K]<M:<J4V^+=G:PXF=JM+E5)3V9>)40M86%D D\B 3%4\.=D7'8/&[?E*N
M>]9R_JE[2Y-X56?ED,.!!F>3>U)(P,'GXYASPG:, <H6>T!CRA-]?F'(?2C%
M),,TH920#CY82;C5H^K>F=-G+]M_6JK4ZGS];D*=+V[+TUE+,HV^\EG(<R5*
M(SNYCF8<FMU^FVW2WZE5IZ6IM/8 +LU-NAMM )P-RCR',B%"X^M7+'N70R0E
M*3=]$J4TFYZ,\6)2H-.+V)G$%2L!6<  DGP@IC-$[!N?3ZV'Y&Z[\G=09]U\
MO(J,_*HEUMH*1[F$H)! ()S\L)[Y8)*56/I6E9<"#<+@466@XL#L#[U!("C\
MAY'I#GT'66PZ_/2M-IEXT.H3[Y"&I:6J#2W'%8Z!(.282WRPS3<Q86EK;KC3
M+:Z^ZA3C[A;;0#+J!*E#FD#Q(Z#/C!&OA+DL_,3SCDR-Z99U:3)NKFF2I*$!
M.YY;Q4EO'OW02IE7<1A/*&X\E/L'$7>Z&U*6A%LH"2LE+@'G*/?(W$(/R#EC
M!ZJ,+!5:=6)FNS;M3F6)>H(+;J&YY]MEY4PB70)="4-]Q3BFSEML]UQ/-?>A
MIO)7,O2W$)=S*W&WF$6JD,.,N!QM2#.#FA?50W;ASYY!'0""1M.'(1,0(F#0
M@@@@".O/_<,Q^]J_48[$=>?^X9C][5^HP"R>38^*S1?652^E+AHX5SR;'Q6:
M+ZRJ7TI<-' $0>AB8@C*2(#"J%I9;5N:E7+?<E+NMW'<$O+2E0?4^I2'&V$[
M6@$$X20.N.L9HA86,@Y$:U>(;AUH=K\6VC]I25Q7>:1>LS..U<.7!,%:U!6X
M=FK=W!DGD/#$;!=-; IVF%ETRV:5,3LS3Z>WV;3M1F53#Z@25'>XKFHY/C =
M36?X(;Y]13_T=R%D/[5-*?Q<,?1DPS>L_P $-\^HI_Z.Y"R']JFE/XN&/HR8
M!E-"O@6L+U#(_,(C.8P;0KX%K"]0R/S"(SF (J3B>UM?X?\ 2J;N^6I+=:=9
MG)64$JX\6@>V=#>=P!Z9SCQBVX5KRDH_N8JCZXI?TM,!R3.<7[@"FY+24H/-
M.XS^<>&>_P!<8B1,\80!/F6D?^6?Y_\ XX9N3&)5C\A/ZH^Q$ J%M:S:C5"L
MZHZ8ZI2%N-5^1M!=<E9JUR]YNMAQ#S90L.J)W!2,\N6(ROR??Q.]+?51^>=B
MOKP^.3JT/_A*W\],Q8/D^_B=:6^JC\\[ ,+!!! $$$$ 0000!'![/9+V@%6.
M0)P"8YQQ6<),0(+?_"_4K@U&J%3D-+K7J]=GY<3-5DW;YG)4LK4XO:M+:!R2
MH '/3.0!#AZ+6X_9^F%NT:8H5/MI^3E4M+I-,F%/RTL=Q[J'% %0\<GJ283W
M6J[ZG<.O]=?DJ!K%;4U3Z>U(&:LZ0043B4K60I1(.4<^2LG\0AM= /9UW1VU
MC<[53:KIDPJ:167 Y.!14K';*'(KQC,7A[/O]IRO[]L=E>)JG36I5RVN*%49
M>GT&BO5=^L32"TA_LEE*T,H4,K P>_D GD,]8P^2XS7$T>=<JMD/TZLO2\A.
M42F)J3;OLBS./%J7*G D!E6X=\$*VCQ,9U=>C4Q=.J-7K[\XTW2:C:;UN+:
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M1UY_[AF/WM7ZC'W2<YCX3P*I1](!42VH #QY& 63R;'Q6:+ZRJ7TI<-'"Y<
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M>TKGGFWE+IC=PT9^:9IJ"3M#+06EM*@/OMI/RPW5AREP25J4UBZ9Z3J=P(:
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MK)7<X\*;*_[C%26%7).N^4)E'Y*Z)NZFDV"\DS4ZPVTML^=([@"&6ACQZ'K
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MOJ+C_H&/I#<:FI-NFLT6@S99JBBIF8>6D2S3"!V;A&$SX1N<!Y9F59,J>XG
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MPD6U-W7:M2K5#EI2S*19M-EI:Y:&[.NMJO=U"^_,M(Y!T.8/,Y]]\L&#P<*
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MFPW+2[*;;D2&VT)"4I!*"3@ #)),-5)2[$G*M2TLTAB7:0&VVFD!*$) P$I
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MA162$8QRQG/..A2-+M7K5M:KV11M)[T-F7=YL_=*INCLJG@^#E[S-0.U*/\
M!W<\=8W*;1Z(,03&F::T)OVNT*2T_J^D^HHTSH#\U/4(RE)EA53,/ 9\X).P
MIR#R3SZ8AHN&'0;4FV>#VW:*[;'FMU2-X>SJ:/59A,JI;"'DG"E85L)"3@$'
M_3#[$1. (EFDZ*SJ)H[J/K9.*KE>I%*MV8IDNB5I=(9J/G1<*YAIQYUUW8D
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32E$DQDP&(F+MOJB,01,$$U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>jan-20231230_g4.jpg
<TEXT>
begin 644 jan-20231230_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* 8$# 2(  A$! Q$!_\0
M'@ !  $$ P$!              8!!P@) @0% PK_Q !?$  ! P,# @,#!@4)
M$@L)   ! @,$  41!A(A!S$($T$4(E$)%2,R87$6=8&SM"0W.$)2<Y&RT1<E
M*#,T-39%56)R=)*5H;'2TR9#4U9C=H*#A)3!&"=&5V2%D^'P_\0 ' $!  (#
M 0$!              $'! 4& @,(_\0 0!$  @$# 04#"04&!04       $"
M P01!082(3%!47&Q!Q,4%30U88&1%C)3<J$B)#-2P>%#1&*BT51SDK+P_]H
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M8ZR%H;P!N6$X_;<9/W]QF'WOK]\PIO<R58"NT6V\R+%YS,K+RGVXY>2HME(
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MD\'%""T=SZ[PM;6QV &F;8W,=9?MCTA[>9K2+A[.L;<#8O<TH@ J&"#\:O\
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MQ^J/[VLO,4Q0%GNDNMH6E=#PK9>YL@S&5+"0(TN0L-Y]T..J;^D7CNH  D\
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MEXA"6T)4-OEK3R=QSG/I6-'27QD>(7Q6:Q^:=*:+TX7HC(5*F-SKA"AQ6R2
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M%\Z_WGYU2U$6I:64F+'9V%2DI*CN84<X[$=CQ69#6]1AEQK-9)S@MUX=?"-
M\,U@NMGTCJZ[/1;E)3+>5<H\=U86$[1@A"0!BKM?@]?_ /G4[_Y!G^2I,D<5
M\WVO-:6C) 4DC([C-:FK6J5INI4>9/F^T@PEN_@EZ6:KU?>I#O4ZXKN\RY+<
MD1VG(@VR'W%N;$CR^<DJ  SVP>U57\F]H:>W<8]LU]>53H:@TZ%B,M+#A 4
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M/*CZ5#]1^&^[ZHB1HLZZVEZ+:[E(N$!AV(ZI#X>E!Y;<@!8)2 D) 01SA1[
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;2&@PLEY2DAL*RE"4DX ![8J9TI0D4I2@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>jan-20231230_g5.jpg
<TEXT>
begin 644 jan-20231230_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MP  +" (1 7X! 1$ _\0 '@   00# 0$!              $&!P@"! 4#"0K_
MQ !S$  ! P,# @($!@@,#@P*!PD! @,$  41!@<2$R$(,10B05$)%2,R87$6
M%W6!D96TTR0E,S8W0E=VE[&STA@9-#4X0U)55G)TH='4)B=$1U-B9926LK7!
M149F<W>"A9.BME1CA)*DU>$H9(.&I<+#\/'_V@ ( 0$  #\ ^J=8K!*% =CC
MM7S7U+\-'8],:DN]H<VMN+R[?,>B%U-X; 66W%(SCI]L\<_?KFCX<"P'_>HN
M1^J]-_FZ7^G@V ?[U-R_'37YND_IX5@'^]3<OQTW^:H_IX5A_<IN7XZ:_-4?
MT\*P_N4W+\=-?FJ/Z>%8?W*;E^.FOS5']/"L/[E-R_'37YJ@?#A6 _[U-R/_
M +::_-4?T\*P?N4W+\=-?FJ/Z>%8,_L4W+\=-_FJ/Z>#8?W*;E^.F_S5']/"
ML/[E-R_'3?YJC^GA6']RFY?CIK\U1_3P; /]ZFY?CIK\W2I^&]L3BL)VHN9^
M@7IO\W6Q)^&JMD)(5(V?N[23@@N7= &#Y?VNL&/AK[/*2M36T]R4E/SOT\:&
M/PMT2?ALK-$5P>VEN:21D?IVT<C_ -W7A_3O[ .WVJ;E^.FOS=+_ $\"P_N4
MW+\=-?FJM?X+_&'$\7NF]1WF'IF1II%HFM0RU(F)D%WDWSY I2G'NQWJQ:OF
MG\%?.'77PR=ET)K;4.FWML;A,=L]QDVY4A-X;2'2R\MOF!T^V>&<>S/M\ZX8
M^&_L/[E%R_'3?YNE/PW]A![[47('[M-_FZ4?#>:>X9^U7="H^SXX:Q^'A6']
M.[L1)_VJKC^.FOS=;]S^&OTI"Z'HNW-RG]1 6O%T;;Z9/[4Y0<G_ #5HCX<&
MP#M]JFY'_P!M-?FZ!\-]8%# VHN6?HO37YNNI=OAG;%:78H7M?=%MR&TN=;X
MS0E )[D)RWZ^,C)':N<OX;;3K:$%&UMT62/6!N[2>/?L >!SVP?OXKM,_#%6
M>18F+FSMM-=ZRE(]'^.6DK"T_M<\#DD8(';.:X9^&YL2"4G:>Y @XQ\=-C__
M !UT6_AJM)N6I3YV\N*9O<>AFYM]_IY\,8K1=^&XL;!]?:>Z)R 0#>6_+W_J
M=>?]/"L/[E-R_'3?YJC^GA6']RFY?CIK\U1_3PK#^Y3<OQTU^:H_IX-@/^]3
M<OQTU^;K<M'PT]DO4LQVMJ[BA?3<<&;RV<\4E6/U,>>#6G_3P+"CU?M4W+M_
MRTU^;H_IX5A_<IN7XZ:_-5-OA!^$>MWBSW4DZ,@Z(EZ<7&M3UT5+?N*'PH-N
M,HX<0@>?5SG/L^FKG#RI:3V&OS,;@Q8,K='6+4AR2)"[W+0RVPT%<R9#@ \_
M/.*F;Q7^$B!L1H#2E[L]UDW9]+QL>J6U\5(MUZ2TAY3 ('S>"\#N02A7>JM*
M)I4)!/<]J3'G[J"VH $CL:$]L]@>U)6:'"CRP*Q-"4DULPH+DUTH;4A)P5$K
M6$C ^NO$H()'G7G@TH!)KK6AE]#AE-$M)C#F7$C)!K9G:@%W6@3NHXVTDA'$
M^MD_W1KKV/+=BD(A/*?EN))+;#2E<$8)(63@8IHK?+N>IEPXP"H^5")KB&BV
M.)2>W= )_#BO#EGZ*^OWP(W[%FX_W:C?DU?297E]\?QU^:C?&,B7XB]?,K)"
M7-5W!L\?/!FN@X_#5JM0;"^&;3.^JMH4RM<_9-(NYL3-SZT66Q%D*4$H6XP
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MJV;? :D*85(E,QV5E14KEZR GS[8/<^SW_171M>M)EDBO0H_2=AN*/J26@O
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M[2 E6<_1BN '"@GB>RAW]F:\EJR3VK&LVB!FG&U!6]IUHF5;6T!QQQ(R3)!
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MCK\SOB#R=^]Q_?\ 9+<\?\[=K7VR9LJ=2Q%W%IF8&FG7#%EJ"6GEA)X()/8
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MHY[FE;<4@Y22/JK8@0W+C(0PRD%U9PD$X[UL^D/0%N14#DD92IIU(4 KV_\
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MOMG117Y@MV?V4=8_=F;^4.4U**S:&?O4X[5JUVS6-V'!2(\MUWFN6@#J%&
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MJ>(;PW[I[BW+0FC+R^;S<'FG'+CIR5*0IM$EY:"C"1CYY[Y\B*D?^F&>,S_
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M*!. :6D2H*\JRHHHHHHHHJ,O$QNJO9+8376N6&DO2[-:W7XC;B"M"I!]1D+
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M%0WN%==Z'=';.QM*,:A1=(345N^J6R,R)RHC"V?25*[JCA1DAXY2 L)![XJ
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M7U2 4]5P!/,Y[)]N#[JEP'-+2'RIN;??K;'^52_REVG)1116*QE"N^*J/O\
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M0=OMCS=J6I$MK;)%N4V>:.XD#]2.,^M7T6M Q;HW?/R2/^J*W*;&XG?3B?\
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MNCJ@AI,I3*G2K&6TAW+)F)!<;4# "2PD.5M3$IC2)(<<]'/*X!?)XP^)8&9
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M#^B-1_\ 2NW_ )ZFWX1Y7IFZGB$="Y+@.IX.%2Y3<ESM:HH[N-J4E7ECL3@
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M_-,E7J)>Z0"?C#'14W^@N/6055/WP5T1J#X?M21F4H2TSK"Z-H#<949 2%I
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M8._;^M4?^96!VDT,$'.C]/\ $?\ )4?M_P#!3#TQM3LYJ;<K4&H;+;+'<[Y
MC(TY<8[$5I<>,6G7'.!:X< Z%*4%*[G "3\T4_\ [4.B"DC[#M/\3[/BF/\
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M^422D<N@\0<XPVHY[5UHNOM-33 $>_VM_P!/:0]$Z4YI7I"%JXH4WA7KA1[
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MR9;O_AXMT#1<VV:0+D2?<M16N^W*X7.<_)?EJC38[RRX\M2EJ5TF."<G XI
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M*03^GDP=\?\ G:S&V=H QZ7>R/IOLS\[60VVM8! F7W!\_T^F_G:3[6EJ/\
MNN^?CV9^=KPT8RJW:DU%:6Y$EZ%#,=;"94A;ZDEQLE?KK)402D'!.![,4]!1
M112*[)-,/4^]FC]#:IA:?U->$Z?FSPGT.1=&EL0Y*R2 VW)4 T7.WZGR"_+
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M/G%9/;"<5UF;;6#;7X1O8^UV*$F.AK0TZ,M]:BMY]+*'6FRXL]U*"$A.3Y
M#  %7M21BM2YW>%9HJI-PEL0HR2E*GI#@0@%2@E()/;)) 'O)J.-R=1NWP6"
M/I?7-GLJ!/*[E*],:*_1@PZ $).0I75+1P<=@>_L/'8U9J)%[+CVK=/2&DMN
M#E'G--1U@MN]-(95E:5I=Z.5E9!3R]48[\*1J'6B9,4QM5VLQT\>IU[[%R0E
MAOCG#7<E\O<SVR@)P,GM+=DUK96+<VF;J6UOR,GDYZ:WZPY'!\Q["*QVMGQK
MEIE]^)(:DL*N,T!QE86DXDN9[BG?3<W&_6#J3[FROY%=58\,>D(LSPY[8/E+
M14[IJW*5G0PE')81YN\#U/\ &]OG[:DO[!8O]RU_!V/YE,'Q :.C1-C-Q74A
M 4C3EQ4..@@R<B,YCY3AZG?]M[//V59/:KOMGI$GS-GAG.<_VE%.JF!X@OV"
M-R/WM7+\E=I]1OZF:_Q!_%7K12>RH$\:6GW=3;-O0&K;(N2G+A&2KH)DK2PV
M2I+CCB8S3CRD=-2TGIH)!6D]L$T\MC;2M.R^G83Z&8Y7"4E;46*_%;;"E+]5
M#4AMMU"0%8"5H21CN/?RI/AUM[FWNF=%Q]17>)8K$Y$6U'3T7$R1'R4(?2ML
MAQ)7A921@J0GV#%0+XYO#AH^U^&_=W6<Z.N_ZC%M0N).N80I4+@ZKCT0E*0%
M?++!7@J4.()]45;3;7OM_IL^^V1?Y%%.-7<$9_!3>8M]YDLAQ-Z2@*[@>A([
M#OV^=7HFT7H>=[1]/Z!1_.KF_8(Z4LCTB" RKFV/BEGU%>MZP]Q]=7E_='WF
MO:%HZ5;DA,6;#C )0A(9M;2,)1\P=CY)[X'LSVK0M[%T@[FK1,D^F1W[/R2Z
M(X;XJ2^ 1D'OV7FGRGR]U+5*MU[#8+]XW;^W?[>W<&F]!6Q327=(+U"$GT^8
M"0VAIPMGV<L#/WJ[WVNMN?\ !R+_  *2/]4H.W.W1'ZW(O\  I(_U2FYX.K;
M;+5XN-_HMHC(B0$0K*$,MV%5E2D])6?T*I""CO[2D<O/OG-7:HIH:<_7_J[Z
MH7\DNG</*EHHK%7=)'O[51?<=^V:^\1EEW&<3<;;9-/:BCZ->]#O; E2GA<(
MR4*,9;96B/Z2&0H-N!2D<E%/<YM5N1K*ZZ2NFC&(,2(]"NUZ3;K@](<*5,,E
MAYSDA..ZB6_,D8&>Q]E>]PO&A?M.:TU5:+/8[7)M\)V-'@W"0ZZI/!U</$UT
MI[*CK3,RCAV/14>1![,:#N.YN1\(=L1<W;%<+*X[MZ]-6J4T4QW#(C*?(8<_
MMB4%S@HX&%)(J^+]RCLI<P\VIQ /R8<2%'MY=SYGMY^^H?N^\UXD,,"5M'K)
M"!+8*"F9:,EP.)*!_5WD5  T]=$;BS-4/RFKII&[Z12RE);<O,F$H/DDY2CT
M>0Z<C&3R \_;3S9?;D));6EQ/EE"LC\(K/%8K'JG!]E,C:""S LE\0RG@E>H
MKNZ1G/K*G/*4?PDT^J;FXO?0.I?N9*_D5U17P\M<MAMO%)1' ^((7^$Y_M*<
MGY'Y+/OZ?J=_5[8J0.@?[F/^#5M,O>UC.S6O,HC*_2&=VQJ@_P"YW/8[\G_]
M_P!7^Z[9J[.UG[&NDS[[1#_D44Z*8'B"_8(W(_>U<OR5VGU&_J9K_$'\5>M%
M(3@&J\>+YD[@:=MVT\$.?'NJD/3&'#(;8CM-0ULK6IXK"N0YNM<4!)RK![!)
MRZMB+I_^S_:)\1;USE)B275^G<65.2$O/%U*B@J2E/5"P""1C!J+M8^*W4EB
MV%VXU;&@6EZ_Z@2T[<8[W,LQ_P!#/2>D$I/(*=#10@J]_+!QBH:\4OB:O>L/
M#3O99+KI*?+86KT*',LD-;K5N84LD>GK4KU""W\\#OS3ZH\S>O;R4U'T!IH.
MNI:)MD7'45C/R*/?33W#WTDZ%O[5LA;=ZOUBAQI+HG:=8BNL!1)'3)<D(/(8
MR>V.X[TV=&>*)[4S]J8C[3:_B09KJ6TW*9%A)CM)*B"XLB45!(.<D GMY5.C
M,UAY82V\VM1[A*5@FO>BN%(_7I"'_)[_ /*LUW!2U1S>V[V6T^-B^JO<NVQ6
MUZ"MG35<M3R;&E1]/EY"5L'+A]O$^7G]>W]F.A/[[Z8_A:NO\ZC[,="?WWTQ
M_"U=?YU:G@HG6^X^*S?M^UNQ'X2H=FX.0;N[=&E'IJSB2Z2M??V'YOD.U7CH
MIH:<_7_J[ZH7\DNG</*EHHI",I-5=W"WDVWVO\1EHTAJ/0=N<O5_?@N6B]1;
M=!#QD//%LK=4XXEP\7.!YMI41])Q5F5LM/A/50E122H<@.Q[C/?VXS][-:PL
MMO*7$^B1REQM+2TAI.%-CYJ",=TCV ^7?%5*W+2$?"9[,A. !HZZC'N&7JI]
MN+MGI#6?B#W_ )>H;5:)[S>JU,F1/EN-)C(XMJ1UW$]XR%K]1M:0LO/*2P0A
M*N8U5^'W:]3KB5:?TW&;*I!6])N;\=#)RGJ=50ST>AY2<!7H1(".MR)&RSX?
MMM!)B8T?;'G5203'C!QYXKZ9!8#)6.4GAATQ">(8(D!SDHMBW'P3T2/!\.%X
MC1.@(K&J[DVSZ(\7FB@*2$\'" 5IQY*(!(P?HJZ58K^8KZJ9^UG]9[S]WKI^
M6.T\J;NXGZPM2?<V5_(KJA.P4W4 V-V\$;7:X,<6""E$4[H18?2 80./05;U
MEK'_  96HI\BHXS3\],U/^Z(K^%V)_\ EM,W>B;J(;.Z[#^O5RF38IP7'&Z<
M63U$^CN93TA;TES/EP"@5>61G-7EVK&-M=)]@/THA^0Q_:4>SV4Z:8'B"_8(
MW(_>U<OR5VGU&_J9K_$'\5>M%(1D$5$/B2EZ1TYHYC4>L-$P-:VRWR6VW695
ML;G.QVW3Q4XTEQ)&<A&02D$>W( +JVDONG]3[:6&YZ7MOQ/I^7%#D*"8B(P9
M;R0$=)'JH[@]AV[TY?BJ(4)1Z.UQ04J2E+0' I^:1V\Q[/=[*@+Q]Q6HW@UW
M;+*$H+EJ*UE*0GFKJ(!4?>< =ZK%\(%I^VZF;\,=KN\1F;;I,"Z)>:E*+;(2
M($0\G'NW00G *G^X: *R"$D5"K.P&W++D9QG2-I=6AZ(I*$..2E.K2V>FAI@
M*!EN.#UV8@*3/;"I"5-I04GU;\/^W"T)0-&0%!##:.3;3J@I/6)2X%]3UFE+
M);1*\I#H,,)2I!69"\*.WU@T'XOMLF[#8A:DR8&H2\^S;W$,/*2VWZHE*60X
MZ@J*7(P2#$42THK(Y5]3:*X4C]>L+[GO_P JS7<'E2U2G=EF^N^-S4 L4JXQ
MGAH*U]4V^_1[42/3YF,J>:<"_J &/OUV_0MQ/[ZZE_A#MO\ J5)Z%N'_ 'UU
M+_"';?\ 4JX/@Y^,D^+3?M-V=EOSTP;('%S;FU<'3\DK&7FFT)4,>0"1@=N]
M7:HIH:<_7_J[ZH7\DNG</*EHHI#Y&J([PVV_1_%19KM?M!6IJ(;M:X[6IK>]
M=P51E3&4QTOK1',?JAQ#0*"L#/$%6%',\[][8ZSUQKG;N[:;D(%LLD\2)T5=
MP<B\OT7#<+G%((<)89E,\5=OE_<21P=P=CKSKTZINJK-(M-PO%OMT=3-LU*X
MRZ'.LAZ7A?$H!26VV\A(ZB4J *.1-0G;]/:OT[\(=L='UA>+?<I:-!RFD1K;
M%4VW%6AA:'DA:E%3G)P*4%''GC J+YA5_1#;P_*3TJ^SBX<#&?CI<2?BY&3&
MZA"&UD I>5(PE3!4ACE(*176MJG$R[<4/WD*Q:"VN%)A(=1A)X= NJ"$A'^Y
M [^I#/IO XSS7N3EO"EEQ2/BM&&I0#D?AZ:?4*4?*>B<B5!L#TH22I93Z*4J
MJQ/P7F?M&ZLR7U*.M+ME4I;:W3\HGNM39*"KWE!XDYQVJX=8K^8KZJ9^UG]9
M[S]WKI^6.T\J;NXGZPM2?<V5_(KJI/AFMUV/AUVQ+5IU,ZT=.0"A<:'8E-J!
M91W277@Y@^SF K'F :DGXMO/]Y=6?\QT[^?IA[]VVZC8_<13UHU0TVG3UP*E
MO0K$&T@1G.ZBV\5X]_$$^X9JT.U?[&ND_/\ K/#]N?[0BG53 \07[!&Y'[VK
ME^2NT^HW]3-?X@_BKUHI/94$>+B*Y==!QH$G10UG9'9(,J.W+DH>;7@I;XLQ
MX<I3@/)63Q 3@'.<8]=$VRXWWPH(@Z,*[7>95DD,P"XXIM;,A1<'<JCLE!"\
M^;*,'MQ&*XFE=I-4R-G=,Z4OD2X-S(%^1(2]\<N)>AVTRUNAOJH>YK4B/Q9(
M*E_.R%*XYJOOBQVXW9L'ASWFD.WQJVZ6=;,^:Q>$BXS9Y4ZKFTPZEP(882.D
M4*X)5W4DH 2"K6\;J"YJ3PC-^LIQXS&4],)+G)<2$D%M*_DU.=_40[AI2L)<
M(05&F7<&6H\&Y/R'E,QXL*XRGW9"$MM);8?2VM3ZV276V>1'I#D?]$,N\40N
M;!6:\''494GY,J3,D1UA;B@H+;BAXY R ]Q(+C:?D$,%+K.92EBNKX=I:5>.
M/;:*KT4/)T_<I'J.OE_INPV%M\D$=%+6,]):?EW$ *D@.G%?3^BN'(_7I"^Y
M[_\ *LUVQY4M4LW6T.O6_C;U P@%70T#:U]K!#NQ[SY@^;)!"/K3W/M\A7<'
MA\>Q^IK_ (.;)_,H_H?'A_:U_P '-E_F4W?!WIQ6E/%OOY;59'2@V16#:V+=
MYM*/Z@P VGZQW/F>]79HIH:<_7_J[ZH7\DNG</*EHHI#\TU4C?J\/1?$5I2$
M#I91FW"RB/)F3H[;T3IR5*?0^RX%+=4ZA;:6"V!Q<Z9)&,FQ.K-T-+Z%NMDM
M5]NB(4Z]2!&@LJ;6HN**T-@JX@\$EQUIOFK">3J$YRH \#4WB,T!I&^7ZS76
M\/Q[C8V8[T]M%NDNI:,@I$=L+0V4K=65#BTDE9_N<9JO6L[S U#\)!L9<[9+
M9G0)FA[C)CR&%A2'&G ZM"Q]"DJ!'T&JZWIAU6_>^F(*I!7K9T,-BS^DB<L1
MVBIL-<AZ>6D_+%K*?1,>F>MPXG9P'8SG&VF8TK'% TZ)IDA15TCTN8]*]+'+
M!)3\;<>1Z7"AEQ@.94ZF.VDI<7)/Z&"6\A(E>E=^ Y 1_C+&5$>@\?5YFQGP
M6(6G8+4R76%1G!K&ZA3"H@B%L\TY3T,GI8\NGD\?+/:KD5BOYBOJIG[6?UHO
M/W=NGY8[3RIN;C=M ZE^YDK^175*O#I=F&]@MMVUZ?B/%.GH*>H=LM032OY!
M/K%]E!;=)\^:#Q.<CL14A_',;_!N'_!'J7\W3'WRN["]EM?)1I^(T38)XZB=
MKM0Q"G]#N=P\X@(;QY\U^J/,]JN'M6,;:Z2]_P 3P_Y!%.JH^\0BPC8?<DJ(
M"1IJY$D^P>BNT^XB@J*R1W!0/XJ]J*0@$8/E44>)21Z!MSZ6N&S/A1I\5^=&
M7<A <7%2YE[HNJ>90'.'(CFXE..1[D '#8K54*%X>]/:ANC]MMMJ9MRYCDB/
M-0_&98"EJ"B\E:TJPC!4I*E JY8)IQQ]Y]$2=.V.^IU'#3;+W)$*W.NDH7)D
MX6>@E"@%=4=-S+9 4."@0,&H(\:FY^E=>>#O>MBP7N+<G;9#5"E(:44E#H<3
MV'+','!PI.4G!P3@U"WC>&-0>$S*0I!3."T*07$N#T*'E"VAZSZ5#L6$>NZ"
M4(]90IC35="!<76V^@ZU%F+:>C)5#=96EQ(0XU(6.,)QI.4-3'<M6Y)5'?!<
M6DUBIQ7)S@XHI](="</I0 @,92V$D92VE>7413\HPX3,<^16D5VO#US3XV]L
M4=9_I"P74I8-P;4T%&*P5N"(/E&W%GUG)1/3F*^69PBOIS17"D]M9PU=^(M[
MXS[/U5FNXDY&:6JFZBD0V/'/JKTN5'B@[?6KBJ0E\@_IC+_X)2?\]25\96;^
M_%O_ /=7#\[1\96;/]>+=_[JX?G:B+PP+9=\9WB"5'=:>9] L6%LI=2D_(J\
M@X2K\)JXM%-#3GZ_]7?5"_DET[AY4M%%(>P.>PJD.Y.DYFZ?BUM][TC'TU>X
MUC?MT:[HB26#<HRF)S*W#):=>0I"4)2LA2$+*@AKYW[6SFXFR]@W,O\ IZ]7
M4RT3["[U8:XCY;']41Y Y#!S\K$8/_JD>1--75_A0T9KN^B]7E4^3=DN(?;F
M-N(:=0XDQSR*D(!<!,5H\5E0&5XQRJOT_;+3FVOPD>S$.P6],3EH>7&??4HK
M=D)C,*C,EQ1^<I+3:$Y]N*@R\O-(WY\02EOQD(;UB2^MUZ2E+*5(:2@NJ;/-
MM*UX;08V%K<(0_F-R%>DB:PPQ(><F06@SZ3U%/2)J$-E!P\%EH\T=+L'@SCI
M9Q P"JMV"K,U"4I0XH2PR&F?6<4[T@LM<'/DB]P/4+9_0O3PL?HOD:L)\%0M
M"_#UJ!3;C;K:M77,I<:6XM"QS3@I4YZY'N*_6/M[U<RL5_,5]5,_:W^M%X^[
MMT_+':>5-S<;]8.I<_WLE?R*ZI'X<]90H>P.W#"M:V6&MK3\)!CN[@R(BVB&
MD@I4RF,H-$>12%'![9/G4A#74']T"P_PFRO]4ID[Y:UA/[,Z]0G7%DE+589Z
M4LM[B2)*EDQW!Q#1BI"R?8DD9\LU<G:\\=M-)_<B'[,?VE%1ONSXT=H]D=8N
M:5UEJ65;;ZB(W-5%8L\V4 RLJ"5<F6EI'S3[>V*A*_\ PL>Q[DFXVA>G]:WR
M&5*BK6W8$*8DI*3D<'74J*5)SZJT D9R*W]*_"R;'7^<AB6QJ_3L4MA:9MRL
M*ELDG'! $=;J\J[\?5P<'OY9L#LAXD-OO$1 NTW0%\=O<>U2$QIBG(,B*6G%
M)Y!.'D))[#V#M[:D^D/D:@+QB&+>]O&-+-0[1>M17.2ARW6BZ7-4/KAO/5*>
M#B''$E*NFI*#W2\<^KFG#H#1SNN/#PQIG5,:3!7=K:_%FLA+S#C8<6Y\U+V7
M&^R@0E>2D8'LKF2_"]:KCMBG0TN]S)5J5,<FO//18Q>4ZZMQ;ZFU%L]%:E.J
M*7&PE37[0BJZ^,WP>Z&TAX5MR;VOXPO%PM<=,^U.SI1Y0BG" D%..KV6LE3G
M(J)[GM3>\<XXS_"Z>0:0B!=2M]2RVVPD6Z+EUQX#E'0@94J0@<VD@N(!4D"F
M K"V4H2XF5S<BM)C,O*DKEJ4UEN.TROU93LA(+C45PANX(2J1(*7$ ':0C*"
M$(<7AEE7,-\PI/6(2^%'YS;BOD$R3Z\EU)AN ,H"BY-@4K/C&VK=5#?2E5OU
M&GTQ5N:;:6I*&0IE,D'FXXR?4<C$=.(KY%HJ0,U]*'7 T@J4KBD#)4?8*:^I
M]Q+=IW3\VY,)5?W8Z.:;?:7V%27^X&$!QQ"<]\]U#RJ,CXJTB2E@[6:\+I;+
MH'"U_-"@DG/I_O4/PU)6DMR;=J73T:Y26'=-NN\^5MO#\=$ED)4I(*PVZM(R
M!R&%'L1G![4ZV74O-)6A0<2H A23D$>\&J5;NB<?&U?Q NIM*OL"MA4L:G%C
MYCT^9VYEAWJ?5ZN._GFNOPU%_ADK^%I'^H4G3U%_ADK^%I/^H5Q?!JJ2OQ9[
M^&7.-Q?$*R),@WGXVY?)*["3TV^0'ECB./EWJ[*EA)P?JII[C;NZ,VCMT6X:
MVU-;M+P93O08D7-\,H<<P3Q!/MP,U%$#Q@^'^WWRZW,;R:56J>&>39N3>$=-
M)2,8.>^<U/%HO4*^VB%=;=*:FVV:PB3&E,*"FW6EI"D+21YI*2"/KK>2<C-+
M16*_F'MGZ*AB7X9+-J3=./K[5=ZNFI+O;9:9-IC%2(<6 E)RAL)92E;P!P3U
MEK!(!Q[*]=Y=]7MJ];:$L#=G1<&M12DM/2''RWT6S+B1?5&#R5RFI<QY<&5C
MVY2V]Q/$/J72NJM46NS6.R:D1;(422RS#O $A"GI#2$!_J=-M*G&UN+0VE9[
M-)ROY5($'(W,8W+^$=V7N,2UW2%'.A9<A$J=$+#4H/-..Y9Y')""HH5D A22
M._F8AN<U4??_ 'L6AMY2XVN)+F4781587$;;/2=_W"K!/)U7:6@^BC*E '<1
M+5&902N0.BB-^I7],0#H<L%#A5^A@,_)9/Z5]PO',5KI:=4TN+E.'(Z(IZH,
MAO'5ZOK1@<J:R<BW@<DK_1N.*N56-^"W>Z^P^J7,K//6=U62[+$I?=Q/SGAV
M=/O6.RO/VU.F_7B4T'X;+#;KSKZYOVRWW"28<=QB([)*G0A2R"&P2.R3W/;M
M4#:B^%=V/L<Z)$9:U=>'):.;?H=A<;)_XH2\IM2C[?5!'?SKCV?X5W9)E^5&
MC:=UQ&"'E.R0FPIPRI:BI:W EXD>94>W?!P*F':#QT[0;Y:Q@:7T??9\^[SF
M7I$=$BT2H[;K;0RX4N.-A)P![_H\ZE[<7OH#4GW,E>?_ )E=5!\.#CRO#]MJ
M4L;E+3]CEO"3 U;:V8Y'02!TFW)J5(1V]5*DI(& 0,8J1>;_ /\ 1-U?^F=H
M_P!?IB[\*?\ M([A9C[F-@:?N!Y3-86MQD?H=S]40F:I2D^]*4DD=@"35K=J
MN^V6D3C&;/#[?_P$54K6RE)\<N[W%13_ +4?L./[8]3IM3B_Z('4OKK_ &2[
M</G'_!IP5&NBUJ&A-KL*4/DML1V)_N'*[?P;7?<#Q.9[_P"SQ[S_ ,9ZKRTA
M'8U$6_&Q#F^S%KM4O4";/I]GF9S,>U1Y$R024\>C(>2KT8@!7K-IY]QA0P*Z
MUV$'P_;'W!RT1IEQ@:7M3KK$>7+<>>=#:5*"5/+*E*)]YR<5&ZO$?J-W9FPZ
MIAVJQ/W^1>EV9^V.37$":XB0XSB&,$E3G3Y@K(2VCDM14$8,'>-/Q2M7+P\;
MM:+O&F;JW>)#)C1U6J.F9%:C*>6&9+\A#BD-I7T5C!PM*@0I R">/XX4EV\^
M%)E)4%O,W!ALMX#P6N#$2DLE7J)=R1P4[\DE6"YZ@53$F)<:@S7.2TM,L/27
M?3%)=8Z;!#;WI"&SU%QRL@R6V 7W7>*H?R 52(6$+4E12HH=,<AQM845-MAU
MS)3@%\MD!QQ/R"H_!MG]%!5=[P]R6E>-?;%@-P4O"RWA\]-IX20VY&94V%+/
MR18XXZ"$_+H;]61AW-?1#<_]CK5&1G]*I?L_^H77QIV4VGT+H7;FQ;B:STE;
MM;6K7UL:T]:+1%:ZDFT7!(Z2IT@$@(;4M"E<@2<*!P*=O]"YI"1I]/AK;L]D
M1NVPKXS7NH63\5N,<B_T0]\[ETU!K''&4D?339WEVNT!NMH&_P"ZFW^C;?M]
M8-$VYVU7+3]P8Z4NYRU8"93*02%)!6GUCW]4]O.OKKX>$\=A=N!G.-.6X9]_
MZ&;JL&]%LD7/QLWU+$2?**-!6Q2A;[?:9:A^CY8&1<5)2!W_ &AS[^PK=&E+
MA_>;4G_1S1OYZE^Q2X>VSZD _>YHW\]7/\%<-V%XKM^V7FI++B85ERB9%@QG
M1\FOS1")8'UI.3YGOFI?\?#SL?PJ:Y6R\ZPM0@HZC#JFE@*GQDG"DD$9!(['
MVFJ.W39#1%ZT"](N-D-P<:MB)"#,FR'0'/LJ7"*P%.$!7HP#6<?-I^W/P@[.
ML:ZD04Z#M@BH;U@M+0ZN,Q4PO1OV_P#:^JO'^-3LW'V.T7M7KRP2-*VEZS.6
M_7^CH47H7&44-,O/)#K80IPIXJP,I(QBK^4444E:-PM4*XN,+E18\E3"NHTI
MYI*RVK&.2<@X."1D>^N2G0.F@M]P:?M(=?:#"UIM[.5-CCA!]7N!P3V/;U1V
M[55S<E"6OA,MED) 2A.CKJE('8 9>P!5=IZ);GB WD++,EQT:YG&(AF&PXZ^
ML0&RZEA*_5DJ0V.;C;Y"66@IYGD^ *W(L644QT1XMR=64V]+08@QGW'!Z_HI
M;#AXN];OZ.7,&8.\O@4IK1=CI3'47E.(85 0I3KR^FRW&])P'BZCUTQ^KEKT
MD R2\#'(]'"558[X+MQQ>Q6JUO-NL.JUG=BMI]AMAQ"NHG(4VWZB%#VI3ZH\
MAV%-CX5F9H^!I;:21KZW7"[Z-;U2M5TA6E?&4\SZ&]D-GFCOG'[8?746ZHC:
MMA:_V\M^O[C"O&\MS9"MIKW:$E%KLS1 P+FGBDJ)24^3;WM^LY:<AZUFZNW*
MB:)N4&W;AVM"5;RW2Y95"OS00X0+2.*B@])+X[H9[J1W&,UCX6),:X^)'8RX
M:,Y6_9:39-2'1=BN)Y72WI24">)2@5<NI)"UM_*+P@CYOE7T:W#.= :D&<GX
MLE?R*ZJ]X8H]I5X<=KB_9'7'3IFWE2QH1Z2%?(([]4((<SY\@3RSGVU)7HUD
MQ_6%[^#I[\W3 \0,>TIV)W'+-C=0Z-.7'BLZ!=8XGT9SOU"WA&/[KV>?LJR&
MU:A]K3262/ZSP_;G^THJI.M^_CEW>Q^Y'_\ WO4Z+2<^('4O_I+MO_RVY4;Z
M*(^P3:T9_M>V/_4<KM_!M$?9_P")O]_CW\;U7DR/?2T5YO-I=;4A:0I"@0H*
M&01](K@R=#:=F0FHDFQ6N3%9*"AEV"TI"./9.$E.!CV>ZH0\>ULB6WP<;P+B
M1F8RI%L4Z\IEI*"ZLN(RI6,<B?><FJ\>-XXU'X2$\>?,S&PST^J'B8<,!HL^
M<CF2$^CCN]RZ8(*Z9K[#K$:4I+9CN(8GJ2\AOT)48MOI"GA(.1",8_)":0H6
MS)C*2HN9'@X.9=&5,XE24)2I\(X\8W,L\?V@:'R_H?<QB3.)(<XCI>'22T]X
MW=LT-3.JE-ANBO1TW,.)'*(P0]Z)YMET$.&5G$W(? 2#BOHQN=^QWJCVGXKE
MX_\ <+KY/>%7KP]'H?VM#<_<N1IJ.UK^)=O5B1K!TT])V(>W)_H]$D95W)[4
MYGXNE/Z'=BV2),O^@N]*+D>]M@_9%Z?UE>J4$?J?I/,?,^;CO[:X'BM5<;A9
MY,G>Y"+9O&QI]]O14*P^O;Y-JPKFN0KUL.@=8_.'L[5]0/#N -A-MPDY2-.6
M['U>C-U6O=B/UO&YJ ?%\&?C0%L]6=I*7?TI_3"7Y(C+26S_ ,978XQ7<^+B
M/_%O3W\#-Z_/T?%Y/_BUI_\ @:O7YZF[X-VBSXMM_DF)'A?H*RGHQ;&_9VQ\
MDKN(KZE+1GSR3W\QVJ5?']_8HZW^NW_]HQ:JR1_M<2O?\3(_^=EU,U[_ &2Y
MA]G0UY_U;?7MXB_UXP![1N3H?^735O\ (]]+112$=JA3?31>X.H]<[>7#2,M
MQFTVZ<';HPW-$?L),1960?U0&.W,9X]^\@=L94F)-?[0[Z:BU?K"[6V=+C6B
MXF(^U;$WA#2G(H7%*H" #Q;6WTYF5Y2E77 "SDXXFN_"+X@-4;I:(W$LVZ.G
MK+J+3NFH]E0[,MJI3BG5, 3%K)3Q7S=+B@2 <*'E4=3/@X=^9VH=3WJ1NYI1
M^=J6:)]V4JRK"93J>)02D# "5H2M(3@<AGZ*X6L_ -X@[+%@I9UYIW4:+E<6
MX4QF-9#\FW*7QER'<@>H>RG,=SCMBG(U\'AX@67@\WO#I9M\.^DAP656>OPZ
M?6[CY_3 ;]W$#MGO3CV@\&'B=V+TP_IW1>]>E+3:'ICL]4<Z?ZV'7,%1"EI)
M [>6<"MO6_A$\4FXMSTQ/U!O9I&X/Z;N'QG;N>FTA#;_  4WR4D(PL<5J[*R
M*8ED^#<W[T]I+56G(F\FFS;=2JY7#KVE;KN23GI.J!6SY^39339TCX!O$7N?
MMOH@7S<"UZ45IF0^W M<^UJ1*0EM\A"WW&QE]*PVE8#A5A*_I.7Y \ 7B*MN
M]"]U8V\NEF-8*85&$ANQD,(;4T&B$1^/33E*1DA(R>_GDU)-PV(\85TM\J%)
MWZTDY'DM+9=1]C#8RE22D]PC([$U'6G/ +XB-*Z?MUEMV\>F6H%OCHBQVS:7
MCQ;0,)!.>^ *X4_PM>*>'N5:M,-Z^M<JTS8+\MW4;5H<]$BN(.$LK[YYKSD5
MW[WX"_$5J.R7&TSMY=,N0IT=R*^A-I>!4VM)2H9]G8FI!M.PGC!LMJAVZ)OW
MI-J+$81'91]C*%%*$)"4C)1D]@*:$[P6>)RXZ^O>LY&]FE5Z@O-E^()L@6#"
M7(>5'IA''B#ZZO6'>N/KSPS>++0]OU!K>T[G6+56H6Y[5_%LMU@0'YDMN/Z(
MG@%)XC#*E=O(XSYUN6SP/^):':;/$8WHTNTQ;46GT5LV');^+@1$!/'OP"CG
M/SOVV:V-L/!-XFMGYVJYFE=Z]*V^3J>XJNES6NP=7JR#RRH<TGC\X]AVJ]&C
MH-VMVE[/%OTUJY7QB$PW/G,-=-N1(2@!UQ*/VJ5+Y* ]F:[=%-7=6!?[GMOJ
M>)I9XQ]1O6Y]%N>2L(*'R@A!"CV!SCN>PJN5^T7OI+V@TO:K<FZQK]%N\IR2
M#>(X=3%<$A4(+=ZF%B.KT;F,DGCZO4[TV-?>'_Q![J[=[BZ*-ZM-NMVH9?1=
M=U-)7*YQ^2U*<BACETLGI^JL#YOS1[61N/X)_%#NE+T3(O\ N)MV\K2"746Q
M+,"0V EQMMI87AK)RAM(R""/,$'&.?\ T!WB525<=Q-OD'!"5BWOJ+:LCBH
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M/;4";KWV\;ERYFWJK=>=.:J=6MIIA@K>M=VM2UCJ/+DI"0R E(!5E+S3A2E
M<#G%R5-I]H[7M98# B!+\IQYQ^1,Z*&B\XM96M0;0 AI*E'D6VPEOD5*"05&
MGX!BA2@D9-0SOUO]9]NH+EFCSI'V2R4J"$V]453T$=!Y\/.(DN(0H<([A#>>
M2PDA(SW'-T/L?IK7DV'N%?--MVJ]W1+,VXVZ(\%09LE'$LS>..044 =CQ*DJ
M2'4J+:")V0V$)(!K.N%JC6-FTBS#7>+K%M:9LMJ#&5)7QZK[BN+;2?>M:O52
M/:2 .]52U%IRT^-JYQKOIJ[7#3OQ9)AIN]NN#B7V9,-*Y(8DLAI:T-2D+])2
M KN4$AU!0MLU:W1.C+5H'3-ML-E97&MEO81'8:6ZIPA"0 ,J425' '<GZ/("
MNX3@5I76\P[+!=ESI#<6.V,J<=4 !W '?WDD #VD@>VJ<:C\25RW)ULS$L[T
M*[Z4GW5K3XT#<M/OEZ_PGN+<N09*A\@[&7UPXPM"0A+)ZARZV:L5M1L'I;:7
MFY:!+FS.EZ*U/N3W6D-Q0K+;'4P"M*.P"E\ED!(4I7$8DI(XC \J6BBBBBL2
ML)./XJCK<7=NP:/C6]=WDR(.GKFX["7J>,M)A6]\'BE+SJ59:Y*Y)"R. 4GB
MH@J2#%&RNP_V6SKCKS7+\34\B\.M/QG56]Z&M]EMTK86^TZK(XE+3S*2D*84
M7 A:D+ %FT-A P/+.?OUD3@5R=3ZEM^D]/W&]720(ENM\=R5)>7Y(;0DJ4?I
M[#\./?58W-(O^*>1>(^H+5(9MT1\R]-ZI6B"J7:4R([+BX;C(*VY+#K+S:P3
MU$K2KBZD+:!58[;W;RQ[9Z3A:=T]#$*V1.12C/)2UJ45+<4?:I2E*)/O/L%.
M0# Q6/4[D8]N*@K<3?31NJ)=KT3:]62(4S4;"7H&H+%+8/HJ^9#*PDKY.I+J
M."DI2I/<)<XA7?G>%WPKM[,HFWN_SA>-8W)YQZ:Y'=4J"ETK.7V$*2%)6Z E
M:N144*<<0A01@58=* FA2N(S[*BS<C?!.D;_ /$=ELBM47AFW2+O*B,3F6"U
M%84A+G$K/KNY6G#?8=QR4D$9B+27AJ8W)W)M6Y;FIKK>="7&#"OED:FW!X3X
MY6LR?0W0I*@N*2X' .25I*EM$K;5Q%JH4-F%$9CQVD,,M(#;;;20E*$CL  .
MP  \A6Q1111116O-FMP([K[IXMMH4M1[#L 2>Y[#L/;59=V[+JWQ!QK4K2U_
MMJ=&35A"V)]A<>E6F<VVLGTIM3R4NQW4J6RZVM)P%H4C.>:)RVJT*=N]O[)I
MQ4IZ68$=+?)Z0MX(/<E"%.>MTT9*$!62$)2"213OQVH)"02?946;O[[6C;M'
MQ0Q)8D:MDMMO1;2IM;CI94YP4]TDX*PD)<5TP0MP-J2C*L"HZ\.'AS59'KCJ
M+5ACW5ZXI+:84K]&(6E+REL/%Y9P\E"5*#"U--NMM.EM?(@8LNVVEM(2D  =
M@!65-K76N(FA;,)\MIQT./(CM-MX'4<6K"4<U82DJ/9/(@%7%.<J -7-/M:J
M\2.Y=U:U- ;:TVQ'0VPA+"G8#0:?6%A06 '52$K*5IY(>B.Q@,92%JM1HC0E
MEV_L$:SV."B'$80E(/SG'2$A/-UP^LXX0!E:B5'S))IP5BHX'OJH.N=12/$/
MOC:]#]<2=O%-OR(]WMCBT)3)91E#S,A*A^BVGQR2TIM380 L+624IL5MSMK&
MT4W+G2%1INI[FAGXYO,2+Z)\9O-I* ^ME*BE+BDXY%/F0/8  ]0 D8%+1111
M16*E8J)MV=;7>X,W?2^C513JR(RB:]:[O%?1\90",/"&\E;8+HY !84H(7Q2
MH)Y!09'AFV$U#H)-XFZFN\.;"N[0#]I9CK#,XY2IJ;)9=0.C,*"6W@C*72E"
MU?* DV/2VD#L.Q.:SKC:FU5:])661=+Q/9ML%C'4??5@)).  /,DGL .Y]E5
M&N5BU%XL-=/OE$BPZ<8" RGTIR5&S&FI=CR5H'%#<HH6EUOCUF7V'EH4I)0#
M5OK#IRU:=AJBVJWQ;='4KJ%J(R&D%6 ,X ]P 'N  \@*Z8&*Q6O@"<$_555-
M_/$Y<WF6;+M];FKTU,2%R9J2M3O02^T"6&@@A;;PZT9+Y4 T^$I7QR") V:\
M,>GML[F]>W7%WJ[.%70DS8R&UM(*^06M"?4]**>*')" DN<$E0SDF;$H"?+R
M]E*HX&<9J$/$GOA(VVA6>PVF+='+]J)Y,:/*ML)+ZXS1=;:<=90X0A]]/5"D
ML E1 4LI4AM0+.TAX64W;6C-UUQ;83\FTM)M<I]HH?8U0TVT@1Y[H.'8\I/$
MH<&5!8[96GCQLU%BM18R&&&TLM-I"$(;2$I2D=@ !V  P,5[ 8&!Y4M%%%%)
M7G(?3&96ZM02A *E*4<  >9)]@^FJAZDWQ_HA-QT;;VQ"DZ*N3LRW/72"MM_
MTU;/1>0YQ4D8904K0\RKB5H?;4DK;<!%@MG-GK1M!IQ^W6\-NNRGU29$A+"6
M0HDG@VA"<\&FTD(0C)XI &33_HIO;A6>[7_0]^MMBN/Q1>94)UF'.QGHNJ20
ME7X?;[/.H<VLV.AW6=#O-^TC/T,[:?0XL.PM7_TF/(1&69#+SZ6EE#O"2X\M
MLN$K]J@G/$6"2@(\OPTOE7+O.HX-C;494A"'./)# 4"Z[WP$H1YJ43A( '<D
M =S54&;?MKXV]2O*ND%ZV7VW1E0Y41$Q3K=RL[JPM/%UE:0EQ)+?()/486LH
M6%!0S:_36G(FF+%!M414AUB(RAE+LM]3[[O%(3S<=62IQ9 &5J)43W))KJUB
MM?!.?O5&6J-3:RFZET8_H5JT7[2#TQQG4$D2&UNM-#*06%=0)*DK&%IP< '&
M5=JW-K-D-,[1OW1>G!-0W.#+28\J8X^S#CM%PLQHZ%'#3+9>=*4#L.9 [  2
M$!BC&*6BBBBL5' -0?XD/$,]M%9);-EML6[WWXO=D!4F4VF- 62E$=<M'42M
M++JU*0'!A/)(2I2>7(<G:79MR]Z\1N?>WFYB)C'IMO9E0GXLQMYSYKLAI3A;
M;>;:4IH=-("DD<L\4FK#)2./EYUE6*P2A0'GCVU6W5F@-3:MW'EVVZ0]1R6G
M+["N,.\M3^%L@1(YZS3D=OFH-R4+"4*"T*ZV22."B!/&C=*0=%Z;MMDMR%)A
M06 PUU#R5Q'O.![23[![A7; "?*L5*Q4*;V[E:,N;DW;F^WF[V/T],-B5?+/
M(]%-K<E.NIA%4@'*%.NQG$)(!2%) 7CD,X;%>&F!M3(>NL^Z3=0WYZ2[,7(N
M,@R&V9*PIMZ2P5@N-*?0$%U/-0*D_ML<JG#B*6F!O9O!;=DM#2-3W2W7"ZQ6
M74M&+:F>J^HJ"B,(SW'J]S[!DGL":9<O9F9K3<J1?KM<8ETTC-7#N\1AP/(N
M$&2P$EA##J5\$-!7)SDG"U%UQM7)"B*F]M '+Z\YK,#%+111116#K@:;4LYP
MD9[#)JJ>L]Q-2^(+3NF[?I:<UIU^\FXS&K,S<$HG28T8):3Z4I32VVDI?=;Z
MT925\T+X\B4J09SVGVIM&VMABL1(41NZ&&Q&F36&N*G^F"$(R?6+;8/!M)SP
M;2A/DD4_****0 "CRKPG36+?$>E2GVX\5E"G'7G5!*&T 94I1/8  9)/851^
M^3H/B1\2-MLMY@2[*N&LR;:_'>4X8XAR"XV74\>)$CHK<!02VMHQU]1+K+?*
MY&G=!V+2\J1*M=KC0Y<EM#<B2VCY:0$%127%^:U94HE2B22222:[]:LN<S 9
M4[(>;8920"XZL)2"3@9)[=R0/OBJOZWW"'B4GS='[>ZHFQX#\6#/;O,"7T$*
M >?2ZEM*0AQ]M*FT-RF2ZE02XCC@YS*'ALV2.R&@Q9G[O*N\Z2L292WG$J9;
M<X@%+02VV".V2M2>:U$J6HGREK I:*****0^1J$]TO$&WI>7KZSP&X\*7I?3
MPN\F[7ETLQ6G7>0BH2G!6ZDJ2>:TCBD\4Y)) X>R.S5SGWRY:SW%MJ)6HE2U
MHA/7"'%3-Z0:#/6<+"BA"G&\-N-(PVKI(7P2HDFPR$CCY5GY445CP3G.!GWU
ME6*L^RJU>,/=NWV'3,C3*O3^:V#-F3K7*X+AMMN-=BVDA3OZHE2VT^LEHJ=
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M%05)ND=(VO15J5;;1%,6*7G9*^;BG%NNNK+CKBUJ)4M:UJ4I2E$DDDFNS05
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MF$-(]9)6WS4@+;*DR$+*E=TY%MK9;V+7 C0XK#<:-';2TTRT.*&T)&$I ]@
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$**__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>jan-20231230_g6.jpg
<TEXT>
begin 644 jan-20231230_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $< D@# 2(  A$! Q$!_\0
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M(85/2BSF&MMTA'+NY(#PSN"^7))0* W+D7N!%N<.W/3&6ITQ+BH\9:P''0@
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MEXM.-C&4JRX"M0^4I.X!/2H[9[*^M=7W;03EZ=3H^!9D7://79M1O7*:XB3
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MB7VTNAF6RS:9#J4J* L86E.#R4.E8M^FR=G/]\UU_P !ROS: W$/R35FTO\
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MRTUEEQ>-^W<K:@@K*-PR!]>CB..Q;PMS_P"KW?RI^MDDK"LXSR]U:V^CB/\
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M5+M0MVK+'K'4W#Q-HT=IE.J)4Q\-R8TB3%;C-M=>\=:D(4E_:0"EL;<J )4
M* R#LXR&97 _1BV4M(;^#FTA# 0$)P2"!L;;3R(/R4)'NKXUUPZTMIO27$2_
M6G3UMMMZNMIFJGW")%0V_+)9627%@96>0YG/05>N#MFFZ=X8::MESC/0IT2
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MC;B!H5XDMG/,W-DUZ?US][3L;1>QO\J(I2E5RR*4I0"E*4 I2E *4I0"E*4
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ME*O?Y_17R=D'#A%_!;AK6E]SAM]J(1N62<\L5E-KA-NI"B@[AT2*1(&6@HC
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MT7IQ$>.B0X@#PX2G'/YZZFM-,VHEEQ3"4J6L(44G;E7D<>?G62?"7JS*$A(
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M7YDUV@, U'_U[M. ?V!JS_$V\?Z+5?KX:<__ "&K/\3;Q_HM>3LX04%I&?\
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MF *K2@* 8ICE5:4!0#%,56E 4Q3%5I0%,56E* IBJTI0%,8IBJTH"F*8JM*
A^0D YKZI2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>jan-20231230_g7.jpg
<TEXT>
begin 644 jan-20231230_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &% 7L# 2(  A$! Q$!_\0
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MF%_Z*]D\X]>2?R'D>7V ]ZK&>$_3=VL>Y7B D7.VR8+-PU@J1%<?:*$2&_*
M*T$CWDY]14V!XZH\7.T>C-3W#3MZUK#@7BWN>5+C.,/GR5?!2@V4C\]2?8-0
M6S5%IBW6SSX]SMLI <8EQ'0XVZD^J5#@BJ9::U4WM7OYOR[J/1FH[K$O\UOV
M#V&QNRFI0#>" H#IP<CN:8=NT7K;;78K;_3=XTU>(L>[ZBN%Q>0S(EB/9HSG
M++,EJ'^5<SW"$E*03R:BP?1KK%8*@1BOG1IN9N3H;P[)U[<YE\;NNW^J'Y"K
M?<ENLB=:B1UME+I)4G!RDDDCXU:#PAP-07';V;K75$J6Y=-83W+PB)*<4H0X
MJCB.RE)X3A !..Y.:D"O<O%YL_9[Z_9YVO+;&N3,HPG([B70H/!1049Z,$]7
M'>I?CNI?92X@]2%@*2KX@]C5;[]HJ1NAXL8T6[6-2-&:.MK=R86N+TLS[F\H
M^\58]_RTCCYDYJR2<)! X%2#:BL9%9H HK&:,CXT!FBL9HH#-%8HH#-,_5F[
M&D=#:GT]IZ_WZ+:KQJ%Q;5KC22H&4M..I*3CI!]X=R,YIWYJH/C(V/<WRWTV
M?LTB'<$V8PKT)%VA(5BWO>6RJ.X5CA*@M((SWQ4 L-==Y]%V*[:BMDZ_,,S]
M/Q&Y]SC^6XI49A8RA:L).01Z#)^5*UKU_IV\S8$.'>8K\V?#%PCQ0YAYR.<8
M=\L^\$\CD@5\^].Z>WA1<=_W=5V6XC5+&E8UJB76 PYTW-;&4)>:4/K*4 %$
M#L33CM&@+A9/$7HK45WM6I#*G[?M-,SFQ(<2FYI8(*'2GA''HK ZL>M18+R:
MSUU8] 67Z5O\]-NM_G-Q_/6VM8ZW%=*!A()Y/':NFWZJL]RO$ZU1+G%DW.$E
M"Y41IT*<8"OJ]:>Z<^F:H-;-M-:VSP=V74?F:OE[BW*ZPD36Y,F0X\VPF<>
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M&S7]B"[Y[#4IEP(2OXE*7 %#CLK(IUQO$WK&%';CL-6MEEI 0VVW$Z4I X
M!X  [?*HJ"3Q6"GOFJ[DZF2T/%-K?! %N'_^8_KK'XT^M^Q-M_[L?]:HEZ,?
MVU@HXSQ4VQJ9+GXU&M@,?M=G_P"&/ZZQ^--K@>MM_P"['_6J(P/CC'RH('/-
M+8U,ED^*G7 ];;_W8_KJ9O#YNA?-R8UX<O/LV8JT);]G:Z.""3GDU3TH !]3
M5E?!]_N'4@_Y5K^C4INR\6[$CQ%>)#5>UVO?H>T"$8GLR'?R['6KJ).><CX"
MHR1XU-P%G!^BT_(Q?]JN3QJ)(W@*N2GV!K@?:JH#C-N%76 2!V!]*W54>A""
MTVRQ1\9>X>0K-K#?8GV/_:K1?C,W$*"4.6DCT_O/_:J#(ZC)2&W 0H?5Z1WK
M9XL1TA(/2L?+UK".3U.$E1;R5R3.SXU-R/.+:_HDGN"(?^U76?&7N*@C_>KG
MX0S_ *U0*>AQ8<[JR!78J3T ^Z%(P!R<$5J:K'!+=$OW/QG[H(Z1'79D'(.5
MPB>/^U7,QXX-S"^&BJT+'JL0L#[O>J&W'VG7^DJ*2?17%>B(B4*SR !BHHWA
MBQ27!-:/&QN,X>?HH$C('L?^U6BO&WN,' V#:?E_>?;_ .JH5:BALK"0,$8X
M->+\3!"D_6%4X-5@Q^Q-CGC<W*PKI-HR">/8_P#:I(>\>&Z++I3^T_3\H/\
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M:T.@*KMXZV0[LB$=_P!M(O\ ,Y5B/2J^^. $[+\=_I2-_,Y0M#D^=JK>$#D
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MYJ=/A]U0N%J.79T^2E:BIUI+X/<#D9'(X]?E45'<.4;DV_(D..NNI3YI>'O
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M+AM %&>.5?"H?AZ3A(0?. >![<Y(^^IF\6:$(W<+RB<B$UG/IRKM4'W35<>
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M@DX?2ZWTJ&>M)]T9^=3)HJ[>>$-J<0EWI[D\+SGD5?K6W@-TIK):757B9!?
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M8T98A8RHV80(X@]6<^S^4GRLYYST=/>E^DK2RDJT[;2GV4@QFCF!_N<^X/\
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M$W.L7D/:77I)2D:<RI4%:BHY4'N5G/UJN'=K<Q=[9+@R4J5'E-*8<"5%)*5
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M'W<YX^--/<#=72>UEF<NFK=0P+%"2"H+EO!*E_\ \4]U?<#0#L/ -4L\97B
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MOZUBK?CM50-(D'\)MK3!S_YCL_UK%6_':I9",T445!(4444 4444 5@BLT4
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M2%VL6D^TI:/99;^L$_/&*5_QYG_X$MT?Y <_52A9:6BJM?CSO_P);H_R O\
M51^/._\ P);H_P @+_52A9:6BJM#QS/D_P#H2W1/_4#GZJ2+'^$7M&I9=PB6
MC:O<&YRK<[Y,QF':2ZN,Y^\<"<E!^1P:4++>455K\>=[^!+='^0%_JH_'G>_
M@2W1_D!?ZJ4++2T55K\>=_\ @2W1_D!?ZJ\Y'CO,2.Z^_LMN<RPT@N...6%:
M4I2 25$D<  ')]*4++4T54?3?X0VW:PM+=TL.TVXEYMCA*43+?:"^RH@X("T
MY!P:4OQYWOX$MT?Y 7^JE$EIJ*JU^/.__ ENC_("_P!5'X\[W\"6Z/\ ("_U
M4HBRTM%5)O\ ^$*@:4M3UTO>TFXMIMK./,F3K.66D9[96K &?G77#\>7TA%:
MDQMF-S7X[J0MMUNQ+4E:3V(([BE"RU=%5:_'G>_@2W1_D!?ZJ/QYW_X$MT?Y
M 7^JE"RTM8S56_QYW_X$MT?Y 7^JDB_?A%[1I=V U>=JMP;2Y/=\B(B;:2R9
M#G[QL*QU*Y' S2A9;NLU5K\>=_D?W$=T1_U Y^JL?CS/=)/]Q'=$@#M] .?J
MJ!9::BD;1VHCJS3%MO!M\NU&:PE[V*<WY;[.1GI6GT(I9H2%%%% %%%% %%%
M% %%%% %(>L]%VC<#3DZP7Z&FX6B<CRY$92BD.)SV)!!Q2Y10$46/PM;8Z>M
M-TM<+2D9%MN481)41QUQQI;05U!/2I1"<'!&,8IP[=;.:2VJ1,&F;.W;W)A!
MDOEQ3KKV/JA2UDJ('H,X%/:B@, 48^=%:+<2E)ZE! ^)/:@&5O#M#IC>_1;N
MEM6QG9=F<?;D*::>+2NML]23U#YTZK&J$;3$%N?1(@I:2AEQMP.)4@# PH<'
MMWJMUSWQUMN7NWJ?06BU633,[3C2'7+;K"(X7+VVOJ"O+"5#I8 '^$3U9SR*
M3/!U?-3;>ZPU7LSJNU-VQ=L!O=E:BS/;&683RS^1\S ("5YZ0H ]) ["@+9
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/% %%%% %%%% %%%% ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>jan-20231230_g8.jpg
<TEXT>
begin 644 jan-20231230_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O @<# 2(  A$! Q$!_\0
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MS" QB&(S" QB,PA (0A (0A (0A (0A (0A (0A (0A (0A (0A (0A (0A
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M0<HLWTJ/SV:0_09W[8BL@Y1M6Z>C5JV_<W0JU(=AA#L,>[>^A;?HG_E5K/\
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M<HVK=/1JU;?N;H5:D.PPAV&/=O?0MOT3_P JM9_I$A]A<;$C&NWHG_E5K/\
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MD(0@$(1B PKP3%(=2JYJ)L\[45[7X=+ZKJE;%T2$E+2,Y16NOF*6&4J"F"@
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M[T+Y+\L8RRA8?>&.8C&^GRCRQX\:>+$VZ_\ &&LGK*PFK]49O*$X1N]S 8_
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M+:02&%<>8W4D ]H2(L"-.EI?E'A<5;3W-,SDSNIFN#G7E1W% CBAO>^]C\7
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MRA <H1V9\W.BOWY%UOZ(Y[(V;;#Y V3-+,G_ )D9]IC63?GR+K?T1SV1>[9
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MX\L0/L*>*/I=]3H^VJ)X\L=/AZ:<V80A%"$(0&.PQQ/(>D>V.788X'D/2/;
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MI44!2#P())SN\1YXMNG..,9RQAF$(1%(P>7YQ[8S&#R_./; :S>C:\<#7O\
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M,1(=X6[I/M^Z6B;MNO-34Y3']^FW!3LM3M)FQQ2<'"@#VI/ CB.(S%:?X,]
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M',M(<<)(0#G@, QZ/2;1*T-%9"K25G4I-'DZG.KJ#\NVXI2 XKF$ ^ GR)'
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MP77%+6<JQV)'^:D <SS),20!B+VM#&(]1(Q&8P!C,9@R(0A (0A (0A (0A
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& 0A" __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>jan-20231230_g9.jpg
<TEXT>
begin 644 jan-20231230_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $\ 8X# 2(  A$! Q$!_\0
M'@ !  (" P$! 0            <( 08"!0D$ PK_Q !:$  ! P,# @,$ PD-
M P8-!0 ! @,$  4&!Q$2""$3,4$)%")1%3)A%ADC.$)QE=+3%Q@D,U)65W5V
M@92RM"5BD34V0U-R="8G-SESA)*AHJ2SP=0H1E6"L?_$ !L! 0$  P$! 0
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M;<F4IOQ R76U(YE.XWVY;[;C>H$RWHHFY-TFX3HPG+&([V./P7E7E4!2DO\
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M^OX12AO\@*ERN*4\=_\ [5RJ[NY$K"E*4**4I0"E*4 I2E *4I0"E*4 I2E
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MD(N;)0J.X^8[;P5RVX*>!:"O(K'$=ZVI-C@)4E0A1PI*DJ20TD%)2.*2.WF
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MEJNJPE]ZV.J4HLJ_W%*"C\^WG6ZZ49G@=_L[5HP*Z6J;:[,PU%1&M3@4W%:
MXMH 'D-D[#\U5A]H1=]/$V!RWJ%M&HP=A.<C&/O9A\U?]+Q^IL%=N7S[5O\
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MIK?C&-KD/>X7?![[[K!F)2M2"ZB)(+K/%12?R-_3TKTHP=,Q&'V)-P=EO3Q
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M&2!Y]Q7IV1N/E7F-[4:W2M']=M(-;K8VL.V^6VB2IIM.Q+#H6 ?F5-E2>_H
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M-B?FI(]:B30?3S5+*NH&YZPZG8Q9,!D(Q_[G8-AM$T37WTJ?2\M^2^GX5$<
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M5'>H37_674'6K',IF1+399."W21,LEND,J\2*I11NV_OMS(\-/F!7M(6QO\
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M4E945@@#5/9]:N91>M"L#P2PL"'.AV"YK1/N>/R%0?$\0F$?'2\ M*5*7X@
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MGK3S%+_D\^->K198T.8PBRRG$MNH3LH!24$*[^H.U >AE*J']]:Z<?YW7']
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M]:N7[P7I[_HGQS_#J_6J?DUF@( _>"]/?]$^.?X=7ZU85T#=/@23^Y/CF_\
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M)(4.WF#W!%2\D ]Z @+]X+T]_P!$^.?X=7ZU/W@O3W_1/CG^'5^M4_UC>J"
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M*'%09 'X,$=CQVW'G55D1Y.Y0@#OZ^5<MJ)&PVK-1%%*4J@4I2@%*4H!2E*
M4I2@.*E<0:@+/>N?1?3C4)S#+_F+<2ZQW$L3'VXKKT2"ZK?BV_(0DH;4=O(G
MM^5M4U919EY!CMSM:+A,M2YL9R,)]N<#<F.5I*?$:400E:=]P=CL0*HA@688
MSTEXM?\ 07J!M-M1B3\>5,M65)@%47*8Y)4ZA](!)G#<#S*E'CL=^)5 =!U"
MYUJ=8M39]_5J#&LU_B,3\AMN-2KLVK'I>--*#,:,I@#^%2ISA)Y;DH  &WPU
MO3_2XM_-]$M5].],']+,Y>O;<G)[<U-:3!@P%-J$M+S*%<2MQ("4%I())',
MCMN?1UT]VN7H=@LK4'#&95QLDR9+Q=K)8R'[C9[<X^5Q&5J4"4K2C@>/Y/;R
M([6S\)/RJK!-\AKLG;T]*Y$@#O6MZAZ@X_I7A]SRC*+I'LUBMS)>DS)*MDI
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284432864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JANONE INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1454591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">325 E. Warm Springs Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Las Vegas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">997-5968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JAN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,981,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,593,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000862861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278171136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AuditorAbstract', window );"><strong>Auditor [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Hudgens CPA, PLLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, Texas<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AuditorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AuditorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284561456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">9,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">17,842<span></span>
</td>
<td class="nump">19,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Note receivable - SPYR, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_OtherAssetsFromDiscontinuedOperations', window );">Other assets from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,487<span></span>
</td>
<td class="nump">46,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued liabilities - other</a></td>
<td class="nump">3,633<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Short term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,905<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent liabilities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,285<span></span>
</td>
<td class="nump">29,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share, 200,000,000 shares authorized, 4,957,647 and 2,827,410 shares issued and outstanding at December&#160;30, 2023 and at December&#160;31, 2022, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">47,323<span></span>
</td>
<td class="nump">45,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(50,634)<span></span>
</td>
<td class="num">(42,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="num">(3,308)<span></span>
</td>
<td class="nump">2,307<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders' equity</a></td>
<td class="nump">18,487<span></span>
</td>
<td class="nump">46,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Related party note</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSMember', window );">Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">14,510<span></span>
</td>
<td class="nump">14,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, series A-1 - par value $0.001 per share 2,000,000 authorized, 193,730 and 222,588 shares issued and outstanding at December&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Net, Excluding Other Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine equity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_OtherAssetsFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets from discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_OtherAssetsFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178287491344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">4,957,647<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">4,957,647<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSMember', window );">Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">193,730<span></span>
</td>
<td class="nump">222,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, outstanding shares (in shares)</a></td>
<td class="nump">193,730<span></span>
</td>
<td class="nump">222,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284489392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">4,746<span></span>
</td>
<td class="nump">3,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">15,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,846<span></span>
</td>
<td class="nump">3,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(19,846)<span></span>
</td>
<td class="num">(3,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_GainsOnReversalOfContingencyLoss', window );">Gain on reversal of contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(926)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">4,548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before benefit from income taxes</a></td>
<td class="num">(17,524)<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(6,621)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net (loss) income from continuing operations</a></td>
<td class="num">(17,095)<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Income from discontinued operations</a></td>
<td class="nump">10,254<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Income tax provision for discontinued operations</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (7,812)<span></span>
</td>
<td class="nump">$ 10,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net (loss) income per share from continuing operations, basic (in usd per share)</a></td>
<td class="num">$ (4.27)<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net (loss) income per share from continuing operations, diluted (in usd per share)</a></td>
<td class="num">(4.27)<span></span>
</td>
<td class="nump">2.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Net income per share from discontinued operations, basic (in usd per share)</a></td>
<td class="nump">2.32<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Net income per share from discontinued operations, diluted (in usd per share)</a></td>
<td class="nump">2.09<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in usd per share)</a></td>
<td class="num">(1.95)<span></span>
</td>
<td class="nump">3.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in usd per share)</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">4,005,334<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">4,444,361<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (7,812)<span></span>
</td>
<td class="nump">$ 10,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Effect of foreign currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (7,812)<span></span>
</td>
<td class="nump">$ 10,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_GainsOnReversalOfContingencyLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on reversal of contingency loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_GainsOnReversalOfContingencyLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284837216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Preferred</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2022</a></td>
<td class="num">$ (8,676)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 45,743<span></span>
</td>
<td class="num">$ (53,804)<span></span>
</td>
<td class="num">$ (617)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series A-1 preferred converted for legal settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,141)<span></span>
</td>
<td class="nump">322,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">10,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">45,748<span></span>
</td>
<td class="num">(42,822)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">2,827,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for equity financing</a></td>
<td class="nump">793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series A-1 preferred converted for legal settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,353)<span></span>
</td>
<td class="nump">547,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series A-1 preferred converted for legal settlement</a></td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Series A-1 Preferred forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(7,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 30, 2023</a></td>
<td class="num">$ (3,308)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 47,323<span></span>
</td>
<td class="num">$ (50,634)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 30, 2023</a></td>
<td class="nump">4,957,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,957,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284639408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net (loss) income from continuing operations</a></td>
<td class="num">$ (17,095)<span></span>
</td>
<td class="nump">$ 8,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable', window );">Accretion of note receivable discount</a></td>
<td class="num">(1,223)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Gain on reversal of contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Write off of VM7 note receivable</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_GainLossOnWriteOffOfNotesReceivable', window );">Write off of SPYR note receivable</a></td>
<td class="nump">9,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="nump">444<span></span>
</td>
<td class="num">(4,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(5,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,052)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Operating cash flows provided by (used in) discontinued operations</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Investing cash flows used in discontinued operations</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from equity financings, net</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants exercised</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on short term notes payable</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Financing cash flows (used in) provided by discontinued operations</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,435)<span></span>
</td>
<td class="nump">3,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of changes in exchange rate on cash and cash equivalents</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">LESS CASH OF DISCONTINUED OPERATIONS, end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashRecognitionOfNewLeases', window );">Noncash recognition of new leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_GainLossOnWriteOffOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Write-Off Of Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_GainLossOnWriteOffOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoncashRecognitionOfNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash recognition of new leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoncashRecognitionOfNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of the discount for premiums receivable on financial guarantee insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(4)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278167616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background and Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: Background and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of JanOne Inc., a Nevada corporation, and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;JanOne&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had three operating segments &#8211; Biotechnology, Recycling, and Technology. In connection with the sale of GeoTraq, Inc. (&#8220;GeoTraq&#8221;) (see Note 5) and the sale of the Recycling segment consisting of the following Recycling Subsidiaries: (a) ARCA Recycling, Inc., a California corporation, (b) ARCA Canada, a corporation organized under the laws of Ontario, Canada, and (c) Customer Connexx LLC, a Nevada limited liability company (see Note 4), the accounts for the Recycling and Technology segments have been consolidated and presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Biotechnology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2019, JanOne, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone, (&#8220;JAN123&#8221;). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recycling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Recycling Subsidiaries constituted the Company&#8217;s Recycling segment and provided turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx provided call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221; with VM7 Corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. In connection with the disposition of the Recycling Subsidiaries, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeoTraq Inc. (&#8220;GeoTraq&#8221;) was the Company&#8217;s Technology segment. On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5&#160;million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6&#160;million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in SPYR&#8217;s restricted common stock. The Promissory Note matures on May 23, 2027. The accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports on a 52- or 53-week fiscal year. The Company's 2023 fiscal year (&#8220;2023&#8221;) ended on December&#160;30, 2023, and our fiscal year (&#8220;2022&#8221;) ended on December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company&#8217;s ability to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $17.1 million for the year ended December&#160;30, 2023, and net income from continuing operations of approximately $8.0 million for the fiscal year ended December&#160;31, 2022. Additionally, as of December&#160;30, 2023, the Company has total current assets of approximately $346,000 and total current liabilities of approximately $5.9 million resulting in a net negative working capital of approximately $5.2 million. Cash used in continuing operations was approximately $855,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise funds to support future development of JAN 123 either through capital raises or structured arrangements. However, the success of such funding cannot be assured.</span></div>The ability of the Company to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123, as well as to fund its day-to-day operations. Such approval is contingent on several factors and no assurance can be provided that approval will be obtained. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. While the Company will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured or FDA approvals will be obtained.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178379912960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The prior year amounts have also been modified in these financial statements to properly present amounts under continuing and discontinued operations. See Note 6.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made in connection with the accompanying consolidated financial statements include the fair values in connection with the GeoTraq promissory note, analysis of other intangibles and long-lived assets for impairment, valuation allowance against deferred tax assets, lease terminations, and estimated useful lives for intangible assets and property and equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist primarily of cash equivalents, trade and other receivables, notes receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company&#8217;s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at December&#160;30, 2023 and December&#160;31, 2022 approximate fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with a maturity of three months or less at the time of purchase. Fair value of cash equivalents approximates carrying value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and Other Receivables and Allowance for Doubtful Accounts</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries unsecured trade receivables at the original invoice amount less an estimate made for doubtful accounts based on a monthly review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions. The Company writes off trade receivables when it deems them to be uncollectible. The Company records recoveries of trade receivables previously written off when we receive them. The Company considers a trade receivable to be past due if any portion of the receivable balance is outstanding for more than ninety days. The Company does not charge interest on past due receivables. The Company had no allowance for doubtful accounts for the years ended December&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the Company's trade and other receivables as of December&#160;30, 2023 and December&#160;31, 2022 (in $000&#8217;s):</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:70.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for intangible assets in accordance with ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 350, intangible assets subject to amortization, shall be reviewed for impairment in accordance with the Impairment or Disposal of Long-Lived Assets in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 360, long-lived assets are tested for recoverability whenever events or changes in circumstances (&#8216;triggering event&#8217;) indicate that the carrying amount may not be recoverable. In making this determination, triggering events that were considered included:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant decrease in the market price of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); and,</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a triggering event has occurred, for purposes of recognition and measurement of an impairment loss, a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If after identifying a triggering event it is determined that the asset group&#8217;s carrying value may not be recoverable, a recoverability test is performed by forecasting the expected cash flows to be derived from the asset group for the remaining useful life of the asset group&#8217;s primary asset compared to its carrying value. The recoverability test relies upon the undiscounted cash flows (excluding interest and taxes) which are derived from the Company&#8217;s specific use of those assets (not how a market participant would use those assets); and, are </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon the existing service potential of the current assets (excluding any improvements that would materially enhance the assets). If the expected undiscounted cash flows exceed the carrying value, the assets are considered recoverable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of trade names, licenses for the use of internet domain names, Universal Resource Locators, or URL&#8217;s, computer software, patent USPTO reference No. 10,182,402, and designs and related manufacturing procedures. In connection with the Soin merger (see Note 3), intangible assets consist of three patents pending, orphan drug status for Naltrexone, as granted by the FDA, and the formula for Naltrexone. Upon acquisition, critical estimates are made in valuing acquired intangible assets, which include but are not limited to: future expected cash flows from customer contracts, customer lists, and estimating cash flows from projects when completed; tradename and market position, as well as assumptions about the period of time that customer relationships will continue; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from the assumptions used in determining the fair values. All intangible assets are capitalized at their original cost and amortized over their estimated useful lives as follows: domain name and marketing &#8211; 3 to 20 years; software &#8211; 3 to 5 years, technology intangibles &#8211; 7 years, customer relationships &#8211; 7 to 15 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biotechnology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates no revenue from its Biotechnology segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recycling Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, retroactive to March 1, 2023, the Company entered into the Recycling Purchase Agreement with VM7, under which VM7 agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. As discussed previously, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements..</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Technology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates no revenue from its Technology segment. GeoTraq was the Company&#8217;s Technology segment. The Company suspended all operations for GeoTraq during the year ended December&#160;31, 2022. On May 24, 2022, the Company sold substantially all of the GeoTraq assets . GeoTraq is being presented as a discontinued operation. See Note 5. As discussed previously, the accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: Level 1 - inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Level 2 &#8211; to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 &#8211; inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided on deferred taxes if it is determined that it is more likely than not that the asset will not be realized. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision for income taxes in its Consolidated Statements of Income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the amount of benefit to be recognized in relation to an uncertain tax position. The Company uses a two-step process to evaluate tax positions. The first step requires an entity to determine whether it is more likely than not (greater than 50% chance) that the tax position will be sustained. The second step requires an entity to recognize in the financial statements the benefit of a tax position that meets the more-likely-than-not recognition criterion. The amounts ultimately paid upon resolution of issues raised by taxing authorities may differ materially from the amounts accrued and may materially impact the financial statements of the Company in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is calculated in accordance with ASC 260, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. Under ASC 260 basic earnings per share is computed using the weighted average number of common shares outstanding during the period except that it does not include unvested restricted stock subject to cancellation. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of warrants, options, restricted shares and convertible preferred stock. The dilutive effect of outstanding restricted shares, options and warrants is reflected in diluted earnings per share by application of the treasury stock method. Convertible preferred stock is reflected on an if-converted basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 280, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; requires use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a Company&#8217;s management organizes segments within the Company for making operating decisions and assessing performance. The Company determined it had three reportable segments, however the Recycling and Technology segments have been consolidated and presented as discontinued operations. See Note 21.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash balances at a bank in Nevada. The account is insured by the Federal Deposit Insurance Corporation up to $250,000. At times, balances may exceed federally insured limits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278203696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Mergers and Acquisitions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3: Mergers and Acquisitions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Soin Pharmaceuticals</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In anticipation of the closing of the merger, the Company formed a merger subsidiary known as STI Merger Sub, Inc., a Delaware corporation (our &#8220;Merger Sub&#8221;), and designated a series of 200,000 shares of its preferred stock, stated value of $300.00 per share (the &#8220;Series S Convertible Preferred Stock&#8221; or the &#8220;Series S Stock&#8221;). See Note 15. The acquisition was memorialized by an Agreement and Plan of Merger, dated as of December&#160;28, 2022 (the &#8220;Merger Agreement&#8221;), by and among STLLC, Amol Soin, M.D., the sole stockholder of STLLC (&#8220;Dr. Soin&#8221;), the Company's Merger Sub, and us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For not less than six months after the closing and potentially up to approximately one year from the closing, Dr. Soin will remain the Company's Chief Medical Officer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the merger, (i) our Merger Sub merged with and into STLLC with STLLC as the surviving entity and (ii) the Company issued 100,000 shares of its Series S Stock to Dr. Soin. This all-stock transaction has an initial value of $13,000,000, potentially increasing by an additional $17,000,000 to up to a total value of $30,000,000, depending on revenues generated by the STLLC product. Dr. Soin agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of 4.99% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the completion of the merger, the Company performed a screen test, as defined in ASC 805 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine whether the Soin Pharmaceutical merger was considered a business combination or an asset acquisition. The results of the screen test revealed that substantially all of the fair value was concentrated in a group of similar assets, and that the assets did not possess the inputs, outputs, nor processes required to be considered a business, as defined in ASC 805. Consequently, no goodwill was recognized as part of this transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series S Stock issued in connection with the merger, as valued by a third-party, independent, valuation firm was approximately $14.5 million. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. Consequently, the Company has recorded the assets as intangible assets on its consolidated balance sheets. In addition, the Company recognized a deferred tax liability of $4.8 million. The total value of the intangible assets purchased is $19.3 million. The Company will amortize the intangible assets ratably over a 10-year period. See Note 9. Because of certain conversion features of the Series S Stock that place redemption of these shares outside the control of the Company, the Series S Stock will be presented as mezzanine equity on the Company's consolidated balance sheets. As of December&#160;30, 2023, the Soin intangible had a carrying value of approximately $17.8 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284137472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Recycling Subsidiaries<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Recycling Subsidiaries</a></td>
<td class="text">Sale of Recycling Subsidiaries<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $17.6&#160;million, and includes those liabilities related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $24.0&#160;million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next five years, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1&#160;million. The Company also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 9, 2023. Additionally, upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to the Company 50% of the amount of the reduction between the current assessment and any such settlement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6&#160;million per year for 15 years, or $24.0&#160;million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0&#160;million, which, in addition to the $3,000 paid at close, comprises the approximately $6.0&#160;million of net consideration. Additionally, the calculation of the gain on disposition includes the book value in excess of assets disposed of, or approximately $9.8&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities. In connection with the shutdown of the Recycling Subsidiaries, because the Company is a guarantor on the Gulf Coast Bank and Trust credit facility (see Note 6), the Company recorded a liability for approximately $1.7&#160;million for estimated liability associated with this facility, which has been offset against the gain on the sale the Recycling Subsidiaries. Further, the Company has recorded additional liabilities, in the amount of approximately $2.0&#160;million, that were originally associated with the sale of the Recycling Subsidiaries and have reverted to the Company, which has been offset against the gain on the sale the Recycling Subsidiaries. See Note 18.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary calculation of the gain on sale was approximately $15.8 million. The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: GeoTraq</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5 million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May&#160;24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May&#160;24, 2027.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company employed an independent third-party firm to assess the fair value of the 30,000,000 shares of SPYR stock and the Promissory Note. The assessment determined that the fair market value of the SPYR common stock was approximately $946,000, or approximately $0.032 per share, which was approximately $46,000 greater than the amount of the shares received at close. The Promissory Note was valued at approximately $11.3 million, which was approximately $1.4 million less than the Note issued. Consequently, the Company recorded the shares of SPYR stock at fair market value of $946,000, and recorded a discount offsetting the Promissory Note in the amount of $1.35 million. The discount will be accreted ratably over the term of the Promissory Note, and recorded as interest income. Additionally, approximately $105,000 in GeoTraq inventory was transferred as part of the sale, and was, thus, derecognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, based on declining financial trends at SPYR, the Company reviewed the original valuation of the Promissory Note to determine whether a revision of the estimate of the original 10.5% used to discount the note should occur to account for the additional risk the note would not be repaid. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took an additional $1.85 million charge against income for the 13 and 26 weeks ended July 2, 2022, and restated its Quarterly Reports on Form 10-Q for the 13 and 26 weeks ended July 2, 2022, and the 13 and 39 weeks ended October 1, 2022. Additionally, due to the declining financial trends at SPYR, the Company recorded an additional $813,000 charge against income for the year ended </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. No additional charges against income have been recorded by the Company for the year ended December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, as of December&#160;30, 2023, the Company recorded a charge to fully impair the promissory note (see Note 8).</span></div>Discontinued Operations<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company discontinued operations of its Recycling and Technology segments as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company executed a Recycling Purchase Agreement with VM7, under which, as of March 1, 2023, it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The assets and liabilities for the Recycling Subsidiaries were included in discontinued operations December&#160;31, 2022, but were not included at December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. No GeoTraq assets or liabilities were included in discontinued operations at December&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately $60,000 and $326,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was approximately $36,000 and $229,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically the Company operated its recycling business in fourteen states in the U.S. and in various provinces in Canada. From time to time, the Company is subject to sales and use tax audits that could result in additional taxes, penalties and interest owed to various taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The California Department of Tax and Fee Administration (formerly known as the California Board of Equalization) (&#8220;CDTFA&#8221;) conducted a sales and use tax examination covering ARCA Recycling&#8217;s California operations for years 2011, 2012, and 2013. The Company believed it was exempt from collecting sales taxes under service agreements with utility customers that included appliance replacement programs. During the fourth quarter of 2014, the Company received communication from the CDTFA indicating they were not in agreement with the Company&#8217;s interpretation of the law. As a result, the Company applied for and, as of February 9, 2015, received approval to participate in the CDTFA&#8217;s Managed Audit Program. The period covered under this program included the years 2011, 2012, and 2013 and extended through the nine-month period ended September 30, 2014.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2017 the Company received the formal CDTFA assessment for sales tax for tax years 2011, 2012, and 2013 in the amount of approximately $4.1 million plus applicable interest of $500,000 related to the appliance replacement programs that the Company administered on behalf of its customers on which it did not assess, collect, or remit sales tax. The Company has appealed this assessment to the CDTFA Appeals Bureau. The appeal remains in process. Interest has continued to accrue until the matter is resolved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to Isaac Capital Group LLC (&#8220;ICG&#8221;) a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#8220;ICG Note&#8221;). The ICG Note originally matured on August 28, 2020. On August 25, 2020, the ICG Note was amended to extend the maturity date to December 31, 2020. On March 30, 2021, ARCA Recycling entered into a Second Amendment and Waiver (the &#8220;Second Amendment&#8221;) to the ICG Note to further extend the maturity date to August 18, 2021 and waive certain defaults under the ICG Note. The ICG Note bears interest at 8.75% per annum and provides for the payment of interest, monthly in arrears. ARCA Recycling will pay a loan fee of 2.0% on each borrowing made under the ICG Note. In connection with entering into the ICG Note, the Borrower also entered into a security agreement in favor of the Lender, pursuant to which ARCA Recycling granted a security interest in all of its assets to the Lender.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of ARCA Recycling under the ICG Note are guaranteed by the Company. The foregoing transaction did not include the issuance of any shares of the Company&#8217;s common stock, warrants, or other derivative securities. As of January&#160;1, 2022, the balance due on ICG Note was $1.0 million. Beginning in April 2022, the revolving credit facility was converted to a term note that amortized ratably through its maturity date of March 2026. The principal amount of the note was $1.0 million, and was to bear interest at 8.75% per annum. Monthly payments on the ICG Note were approximately $24,767.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281911808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GeoTraq<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">GeoTraq</a></td>
<td class="text">Sale of Recycling Subsidiaries<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $17.6&#160;million, and includes those liabilities related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $24.0&#160;million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next five years, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1&#160;million. The Company also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 9, 2023. Additionally, upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to the Company 50% of the amount of the reduction between the current assessment and any such settlement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6&#160;million per year for 15 years, or $24.0&#160;million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0&#160;million, which, in addition to the $3,000 paid at close, comprises the approximately $6.0&#160;million of net consideration. Additionally, the calculation of the gain on disposition includes the book value in excess of assets disposed of, or approximately $9.8&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities. In connection with the shutdown of the Recycling Subsidiaries, because the Company is a guarantor on the Gulf Coast Bank and Trust credit facility (see Note 6), the Company recorded a liability for approximately $1.7&#160;million for estimated liability associated with this facility, which has been offset against the gain on the sale the Recycling Subsidiaries. Further, the Company has recorded additional liabilities, in the amount of approximately $2.0&#160;million, that were originally associated with the sale of the Recycling Subsidiaries and have reverted to the Company, which has been offset against the gain on the sale the Recycling Subsidiaries. See Note 18.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary calculation of the gain on sale was approximately $15.8 million. The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: GeoTraq</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5 million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May&#160;24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May&#160;24, 2027.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company employed an independent third-party firm to assess the fair value of the 30,000,000 shares of SPYR stock and the Promissory Note. The assessment determined that the fair market value of the SPYR common stock was approximately $946,000, or approximately $0.032 per share, which was approximately $46,000 greater than the amount of the shares received at close. The Promissory Note was valued at approximately $11.3 million, which was approximately $1.4 million less than the Note issued. Consequently, the Company recorded the shares of SPYR stock at fair market value of $946,000, and recorded a discount offsetting the Promissory Note in the amount of $1.35 million. The discount will be accreted ratably over the term of the Promissory Note, and recorded as interest income. Additionally, approximately $105,000 in GeoTraq inventory was transferred as part of the sale, and was, thus, derecognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, based on declining financial trends at SPYR, the Company reviewed the original valuation of the Promissory Note to determine whether a revision of the estimate of the original 10.5% used to discount the note should occur to account for the additional risk the note would not be repaid. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took an additional $1.85 million charge against income for the 13 and 26 weeks ended July 2, 2022, and restated its Quarterly Reports on Form 10-Q for the 13 and 26 weeks ended July 2, 2022, and the 13 and 39 weeks ended October 1, 2022. Additionally, due to the declining financial trends at SPYR, the Company recorded an additional $813,000 charge against income for the year ended </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. No additional charges against income have been recorded by the Company for the year ended December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, as of December&#160;30, 2023, the Company recorded a charge to fully impair the promissory note (see Note 8).</span></div>Discontinued Operations<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company discontinued operations of its Recycling and Technology segments as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company executed a Recycling Purchase Agreement with VM7, under which, as of March 1, 2023, it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The assets and liabilities for the Recycling Subsidiaries were included in discontinued operations December&#160;31, 2022, but were not included at December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. No GeoTraq assets or liabilities were included in discontinued operations at December&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately $60,000 and $326,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was approximately $36,000 and $229,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically the Company operated its recycling business in fourteen states in the U.S. and in various provinces in Canada. From time to time, the Company is subject to sales and use tax audits that could result in additional taxes, penalties and interest owed to various taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The California Department of Tax and Fee Administration (formerly known as the California Board of Equalization) (&#8220;CDTFA&#8221;) conducted a sales and use tax examination covering ARCA Recycling&#8217;s California operations for years 2011, 2012, and 2013. The Company believed it was exempt from collecting sales taxes under service agreements with utility customers that included appliance replacement programs. During the fourth quarter of 2014, the Company received communication from the CDTFA indicating they were not in agreement with the Company&#8217;s interpretation of the law. As a result, the Company applied for and, as of February 9, 2015, received approval to participate in the CDTFA&#8217;s Managed Audit Program. The period covered under this program included the years 2011, 2012, and 2013 and extended through the nine-month period ended September 30, 2014.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2017 the Company received the formal CDTFA assessment for sales tax for tax years 2011, 2012, and 2013 in the amount of approximately $4.1 million plus applicable interest of $500,000 related to the appliance replacement programs that the Company administered on behalf of its customers on which it did not assess, collect, or remit sales tax. The Company has appealed this assessment to the CDTFA Appeals Bureau. The appeal remains in process. Interest has continued to accrue until the matter is resolved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to Isaac Capital Group LLC (&#8220;ICG&#8221;) a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#8220;ICG Note&#8221;). The ICG Note originally matured on August 28, 2020. On August 25, 2020, the ICG Note was amended to extend the maturity date to December 31, 2020. On March 30, 2021, ARCA Recycling entered into a Second Amendment and Waiver (the &#8220;Second Amendment&#8221;) to the ICG Note to further extend the maturity date to August 18, 2021 and waive certain defaults under the ICG Note. The ICG Note bears interest at 8.75% per annum and provides for the payment of interest, monthly in arrears. ARCA Recycling will pay a loan fee of 2.0% on each borrowing made under the ICG Note. In connection with entering into the ICG Note, the Borrower also entered into a security agreement in favor of the Lender, pursuant to which ARCA Recycling granted a security interest in all of its assets to the Lender.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of ARCA Recycling under the ICG Note are guaranteed by the Company. The foregoing transaction did not include the issuance of any shares of the Company&#8217;s common stock, warrants, or other derivative securities. As of January&#160;1, 2022, the balance due on ICG Note was $1.0 million. Beginning in April 2022, the revolving credit facility was converted to a term note that amortized ratably through its maturity date of March 2026. The principal amount of the note was $1.0 million, and was to bear interest at 8.75% per annum. Monthly payments on the ICG Note were approximately $24,767.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278269584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Sale of Recycling Subsidiaries<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $17.6&#160;million, and includes those liabilities related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $24.0&#160;million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#8217; future performance; and (iii) during the next five years, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1&#160;million. The Company also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#8217; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#8217; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 9, 2023. Additionally, upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to the Company 50% of the amount of the reduction between the current assessment and any such settlement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6&#160;million per year for 15 years, or $24.0&#160;million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0&#160;million, which, in addition to the $3,000 paid at close, comprises the approximately $6.0&#160;million of net consideration. Additionally, the calculation of the gain on disposition includes the book value in excess of assets disposed of, or approximately $9.8&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities. In connection with the shutdown of the Recycling Subsidiaries, because the Company is a guarantor on the Gulf Coast Bank and Trust credit facility (see Note 6), the Company recorded a liability for approximately $1.7&#160;million for estimated liability associated with this facility, which has been offset against the gain on the sale the Recycling Subsidiaries. Further, the Company has recorded additional liabilities, in the amount of approximately $2.0&#160;million, that were originally associated with the sale of the Recycling Subsidiaries and have reverted to the Company, which has been offset against the gain on the sale the Recycling Subsidiaries. See Note 18.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary calculation of the gain on sale was approximately $15.8 million. The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: GeoTraq</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5 million, payable in cash and shares of SPYR&#8217;s common stock. As of the closing of the transaction on May&#160;24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May&#160;24, 2027.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company employed an independent third-party firm to assess the fair value of the 30,000,000 shares of SPYR stock and the Promissory Note. The assessment determined that the fair market value of the SPYR common stock was approximately $946,000, or approximately $0.032 per share, which was approximately $46,000 greater than the amount of the shares received at close. The Promissory Note was valued at approximately $11.3 million, which was approximately $1.4 million less than the Note issued. Consequently, the Company recorded the shares of SPYR stock at fair market value of $946,000, and recorded a discount offsetting the Promissory Note in the amount of $1.35 million. The discount will be accreted ratably over the term of the Promissory Note, and recorded as interest income. Additionally, approximately $105,000 in GeoTraq inventory was transferred as part of the sale, and was, thus, derecognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, based on declining financial trends at SPYR, the Company reviewed the original valuation of the Promissory Note to determine whether a revision of the estimate of the original 10.5% used to discount the note should occur to account for the additional risk the note would not be repaid. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took an additional $1.85 million charge against income for the 13 and 26 weeks ended July 2, 2022, and restated its Quarterly Reports on Form 10-Q for the 13 and 26 weeks ended July 2, 2022, and the 13 and 39 weeks ended October 1, 2022. Additionally, due to the declining financial trends at SPYR, the Company recorded an additional $813,000 charge against income for the year ended </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. No additional charges against income have been recorded by the Company for the year ended December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, as of December&#160;30, 2023, the Company recorded a charge to fully impair the promissory note (see Note 8).</span></div>Discontinued Operations<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company discontinued operations of its Recycling and Technology segments as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company executed a Recycling Purchase Agreement with VM7, under which, as of March 1, 2023, it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The assets and liabilities for the Recycling Subsidiaries were included in discontinued operations December&#160;31, 2022, but were not included at December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. No GeoTraq assets or liabilities were included in discontinued operations at December&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately $60,000 and $326,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was approximately $36,000 and $229,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically the Company operated its recycling business in fourteen states in the U.S. and in various provinces in Canada. From time to time, the Company is subject to sales and use tax audits that could result in additional taxes, penalties and interest owed to various taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The California Department of Tax and Fee Administration (formerly known as the California Board of Equalization) (&#8220;CDTFA&#8221;) conducted a sales and use tax examination covering ARCA Recycling&#8217;s California operations for years 2011, 2012, and 2013. The Company believed it was exempt from collecting sales taxes under service agreements with utility customers that included appliance replacement programs. During the fourth quarter of 2014, the Company received communication from the CDTFA indicating they were not in agreement with the Company&#8217;s interpretation of the law. As a result, the Company applied for and, as of February 9, 2015, received approval to participate in the CDTFA&#8217;s Managed Audit Program. The period covered under this program included the years 2011, 2012, and 2013 and extended through the nine-month period ended September 30, 2014.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2017 the Company received the formal CDTFA assessment for sales tax for tax years 2011, 2012, and 2013 in the amount of approximately $4.1 million plus applicable interest of $500,000 related to the appliance replacement programs that the Company administered on behalf of its customers on which it did not assess, collect, or remit sales tax. The Company has appealed this assessment to the CDTFA Appeals Bureau. The appeal remains in process. Interest has continued to accrue until the matter is resolved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to Isaac Capital Group LLC (&#8220;ICG&#8221;) a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#8220;ICG Note&#8221;). The ICG Note originally matured on August 28, 2020. On August 25, 2020, the ICG Note was amended to extend the maturity date to December 31, 2020. On March 30, 2021, ARCA Recycling entered into a Second Amendment and Waiver (the &#8220;Second Amendment&#8221;) to the ICG Note to further extend the maturity date to August 18, 2021 and waive certain defaults under the ICG Note. The ICG Note bears interest at 8.75% per annum and provides for the payment of interest, monthly in arrears. ARCA Recycling will pay a loan fee of 2.0% on each borrowing made under the ICG Note. In connection with entering into the ICG Note, the Borrower also entered into a security agreement in favor of the Lender, pursuant to which ARCA Recycling granted a security interest in all of its assets to the Lender.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of ARCA Recycling under the ICG Note are guaranteed by the Company. The foregoing transaction did not include the issuance of any shares of the Company&#8217;s common stock, warrants, or other derivative securities. As of January&#160;1, 2022, the balance due on ICG Note was $1.0 million. Beginning in April 2022, the revolving credit facility was converted to a term note that amortized ratably through its maturity date of March 2026. The principal amount of the note was $1.0 million, and was to bear interest at 8.75% per annum. Monthly payments on the ICG Note were approximately $24,767.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178282022640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaids and Other Current Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: Prepaids and other current assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaids and other current assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaids and other current assets</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178280929392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Notes Receivables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: Notes receivable </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SPYR Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc. (&#8220;SPYR&#8221;), pursuant to which the Company sold to SPYR substantially all of the assets and none of the specified liabilities of GeoTraq, as discussed in Note 5. In connection with the Purchase Agreement, SPYR delivered to the Company a five-year </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8.0% per annum, provides quarterly interest payments due on the first day of each calendar quarter, and may be prepaid at any time without penalty. Interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May 24, 2027. The Company has received restricted shares of Series G Convertible Preferred Stock of SPYR equivalent to approximately 922,442,000 shares of its common stock during the year ended December&#160;30, 2023, and 30,000,000 shares of SPYR's common stock during the year ended December&#160;31, 2022. As of December&#160;30, 2023, the Company has accrued receivables of approximately $254,000 in interest income related to the Promissory Note.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the asset sale, the Company engaged a third-party valuation firm to assess the fair value of the consideration received. Based on the valuation, the Promissory Note (&#8220;Note&#8221;) was valued at approximately $11.3 million. The amount of the discount, or approximately $1.3 million, has been recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. At December&#160;31, 2022, the Company reviewed the original valuation of the Promissory Note to determine if the original 10.5% used to discount the Note was appropriate. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took a $1.85 million charge against income, and restated the 13 and 26 weeks ended July&#160;2, 2022, as discussed previously. Further, the Company recorded an additional $813,000 charge against income for the year ended December&#160;31, 2022 due to SPYR's declining financial trends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, the Company recorded an impairment charge of approximately $9.8&#160;million for the fiscal year ended December&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022, approximately $806,000 and $387,000, respectively, of the discount was recorded as interest income. As of December&#160;30, 2023 and December&#160;31, 2022, the net principal balance on the Note was approximately $0 and $9.0 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">VM7 Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#8217;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactive to March 1, 2023. See Note 4.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6 million per year for 15 years, or $24.0 million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20.0% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0 million, which, in addition to the $3,000 paid at close, comprises the approximately 6.0 million of net consideration. The amount of the revised discount amount, or approximately $18.0 million, was recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. During the year ended December&#160;30, 2023, approximately $720,000 of the discount was recorded as interest income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3 million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-42<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481933/310-10-55-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 44<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-44<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178377010496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: Intangible assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soin intangibles</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and domains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,563&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,451)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,563)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible amortization expense for continuing operations was approximately $1.5&#160;million and $0, respectively, for the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Soin Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#8220;STLLC&#8221;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a 10-year period. See Note 3.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281036480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of the following (in $000&#8217;s, except shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series G Convertible Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common Shares Equivalent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,224</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">922,442,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance, December 30, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,224</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">952,442,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities reflect shares of SPYR stock received by the Company in connection with the sale of GeoTraq. See Note 5. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. Shares of Series G Convertible Preferred Stock are convertible into the SPYR&#8217;s common shares at a ratio of 1:100,000. Shares held are marked to fair market value as of each balance sheet date, with the resulting change recorded as an unrealized gain or loss. For the year ended December&#160;30, 2023, the Company received 9,224 shares of Series G Convertible Preferred Stock, which are convertible into approximately 922.4 million shares of SPYR&#8217;s common stock. For the year ended December&#160;31, 2022, the Company received 30 million shares of SPYR&#8217;s common stock. Unrealized loss was approximately $926,000 and $631,000 for the years ended December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178380053584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits and Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Deposits and Other Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: Deposits and other assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deposits and other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281046576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: Accrued liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities of continuing consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued guarantees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued litigation/legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368592992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-term debt</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13: Short-term debt</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt and other financing obligations consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AFCO Finance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AFCO Finance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a financing agreement with AFCO Credit Corporation (&#8220;AFCO&#8221;) purchased through Marsh Insurance on an annual basis to fund the annual premiums on insurance policies due July 1 of each year. These policies relate to workers&#8217; compensation and various liability policies including, but not limited to, General, Auto, Umbrella, Property, and Directors&#8217; and Officers&#8217; insurance. The total amount of the premiums financed in July 2022 was approximately $516,000 with an interest rate ranging from approximately 6.0% over the period. An initial down payment of approximately $129,000 was made on July 21, 2022 with additional monthly payments of approximately $59,000, escalating to approximately $69,000 over the term, being made beginning August&#160;1, 2022 and ending on April&#160;1, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding principal due AFCO at December&#160;31, 2022 was approximately $274,000. No such financing agreement was entered into by the Company during fiscal 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281101088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A-1 Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14: Series A-1 Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2017, the Company acquired GeoTraq by way of merger. In connection with this transaction, the Company tendered to the owners of GeoTraq $200,000, issued to them an aggregate of 288,588 shares (number of shares specific &#8211; not rounded) of the Company&#8217;s Series A Convertible Preferred Stock valued at $12.3 million, including the beneficial conversion feature of $2.6 million, and entered into one-year unsecured promissory notes in the aggregate principal amount of $800,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;Conversion Ratio&#8221; per share of the Series A-1 Convertible Preferred Stock in connection with any conversion shall be at a ratio of 20:1, one share of Series A-1 Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into twenty shares Common Stock. Each holder shall have the right, exercisable at any time and from time to time (unless otherwise prohibited by law, rule, or regulation, or as restricted below), to convert any or all of such holder&#8217;s shares of Series A-1 Convertible Preferred Stock into shares of Common Stock at the Conversion Ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;30, 2023 and December&#160;31, 2022, 27,353 and 16,141 shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were converted into 547,069 and 322,820 shares, respectively, of the Company&#8217;s common stock. Additionally, during the year ended December&#160;30, 2023, 1,505 shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were forfeited. As of December&#160;30, 2023 and December&#160;31, 2022, there were 193,730 and 222,588 shares, respectively, of Series A-1 Convertible Preferred Stock outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot declare, pay or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the obtaining of any consents required by our Articles of Incorporation) the holders of the Series A Convertible Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend in the aggregate amount of one dollar, regardless of the number of then-issued and outstanding shares of Series A Convertible Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount per share to the holders of outstanding common stock and Series A-1 Convertible Preferred Stock (on an as-if-converted to common stock basis pursuant to the Conversion Ratio as defined below).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of a share of Series A Convertible Preferred Stock has a number of votes as is determined by multiplying (i) the number of shares of Series A Preferred Stock held by such holder, and (ii) 17. The holders of Series A-1 Convertible Preferred Stock vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the common stockholders of the Company, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series A-1 Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Convertible Preferred Stock; or (iv) alter or change the rights, preferences or privileges of the shares of Series A-1 Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series A-1 Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series A-1 Convertible Preferred Stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15: Series S Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;28, 2022 the acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin further agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of 4.99% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock are convertible into the Company&#8217;s common shares at a ratio of 1:1. As of December&#160;30, 2023 and December&#160;31, 2022, there were 100,000 of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#8217;s).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series S Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series S preferred issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock do not have dividend rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Holder of each share of Series S Convertible Preferred Stock shall have one vote for such share. With respect to any stockholder vote, the Holder shall have full voting rights and powers equal to the voting rights and powers of the Common Stock stockholders, and shall be entitled to notice of any stockholders' meeting in accordance with the Bylaws of the Company, and shall be entitled to vote, together with Common Stock stockholders, with respect to any question upon which the Common Stock stockholders have the right to vote. The Holders of Series S Convertible Preferred Stock shall vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the Common Stock stockholders, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series S Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series S Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series S Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series S Convertible Preferred Stock; (iv) issue additional shares of Series S Convertible Preferred Stock other than in connection with the merger agreement, or (v) alter or change the rights, preferences or privileges of the shares of Series S Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series S Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series S Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series S Convertible Preferred Stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178280833904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series S Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14: Series A-1 Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2017, the Company acquired GeoTraq by way of merger. In connection with this transaction, the Company tendered to the owners of GeoTraq $200,000, issued to them an aggregate of 288,588 shares (number of shares specific &#8211; not rounded) of the Company&#8217;s Series A Convertible Preferred Stock valued at $12.3 million, including the beneficial conversion feature of $2.6 million, and entered into one-year unsecured promissory notes in the aggregate principal amount of $800,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;Conversion Ratio&#8221; per share of the Series A-1 Convertible Preferred Stock in connection with any conversion shall be at a ratio of 20:1, one share of Series A-1 Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into twenty shares Common Stock. Each holder shall have the right, exercisable at any time and from time to time (unless otherwise prohibited by law, rule, or regulation, or as restricted below), to convert any or all of such holder&#8217;s shares of Series A-1 Convertible Preferred Stock into shares of Common Stock at the Conversion Ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;30, 2023 and December&#160;31, 2022, 27,353 and 16,141 shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were converted into 547,069 and 322,820 shares, respectively, of the Company&#8217;s common stock. Additionally, during the year ended December&#160;30, 2023, 1,505 shares of the Company&#8217;s Series A-1 Convertible Preferred Stock were forfeited. As of December&#160;30, 2023 and December&#160;31, 2022, there were 193,730 and 222,588 shares, respectively, of Series A-1 Convertible Preferred Stock outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot declare, pay or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the obtaining of any consents required by our Articles of Incorporation) the holders of the Series A Convertible Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend in the aggregate amount of one dollar, regardless of the number of then-issued and outstanding shares of Series A Convertible Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount per share to the holders of outstanding common stock and Series A-1 Convertible Preferred Stock (on an as-if-converted to common stock basis pursuant to the Conversion Ratio as defined below).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of a share of Series A Convertible Preferred Stock has a number of votes as is determined by multiplying (i) the number of shares of Series A Preferred Stock held by such holder, and (ii) 17. The holders of Series A-1 Convertible Preferred Stock vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the common stockholders of the Company, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series A-1 Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Convertible Preferred Stock; or (iv) alter or change the rights, preferences or privileges of the shares of Series A-1 Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series A-1 Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series A-1 Convertible Preferred Stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15: Series S Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">History</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;28, 2022 the acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Soin further agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of 4.99% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock are convertible into the Company&#8217;s common shares at a ratio of 1:1. As of December&#160;30, 2023 and December&#160;31, 2022, there were 100,000 of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#8217;s).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series S Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series S preferred issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Series S Convertible Preferred Stock do not have dividend rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Holder of each share of Series S Convertible Preferred Stock shall have one vote for such share. With respect to any stockholder vote, the Holder shall have full voting rights and powers equal to the voting rights and powers of the Common Stock stockholders, and shall be entitled to notice of any stockholders' meeting in accordance with the Bylaws of the Company, and shall be entitled to vote, together with Common Stock stockholders, with respect to any question upon which the Common Stock stockholders have the right to vote. The Holders of Series S Convertible Preferred Stock shall vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the Common Stock stockholders, except to the extent that voting as a separate class or series is required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series S Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series S Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without first obtaining the affirmative approval of a majority of the holders of the shares of Series S Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series S Convertible Preferred Stock; (iv) issue additional shares of Series S Convertible Preferred Stock other than in connection with the merger agreement, or (v) alter or change the rights, preferences or privileges of the shares of Series S Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series S Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series S Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series S Convertible Preferred Stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178377853520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16: Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. As of December&#160;30, 2023, and December&#160;31, 2022, there were 4,957,647 and 3,150,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares, respectively, of common stock issued and outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Offerings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;22, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company in a registered direct offering of 361,000 shares of the Company&#8217;s common stock, par value $0.001 per share, at a purchase price per share of Common Stock of $1.17. The offering closed on March&#160;24, 2023. The aggregate gross proceeds for the sale of the shares of Common Stock were approximately $422,000, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2023, the Company entered into a Securities Purchase Agreement with a certain institutional investor for the sale by the Company in a registered direct offering of: (i) 418,000 shares of the Company&#8217;s common stock, par value $0.001 per share, at an offering price of $0.8811 per share and (ii) pre-funded warrants exercisable for up to 481,348 shares of Common Stock to the Investor at an offering price equal to $0.8801 per pre-funded Warrant. The aggregate gross proceeds from the offering were approximately $790,000, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes. On August&#160;31, 2023, 481,348 of the pre-funded warrants were exercised. In a concurrent private placement, the Company also granted warrants to purchase up to 899,348 shares of Common Stock. Each warrant is exercisable immediately following issuance at an exercise price of $0.7561 per share and expires August&#160;31, 2023. As of December&#160;30, 2023, there were 899,348 of the private placement warrants outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 annual meeting of stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the year ended December&#160;30, 2023, the Company granted $345,000 in restricted stock units, or 908,852 underlying shares of the Company's common stock, which were all immediately vested. As of December&#160;30, 2023, $345,000 in restricted stock units, or 908,852 underlying shares of the Company's common stock, were outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October&#160;28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of December&#160;30, 2023 and December&#160;31, 2022, 100,000 and 90,000 options were outstanding under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May&#160;12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of December&#160;30, 2023 and December&#160;31, 2022, 14,000 and 20,000 options, respectively, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022 (Aggregate Intrinsic Value in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options <br/>Outstanding </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price for stock options outstanding and exercisable outstanding at December&#160;30, 2023 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.35 to $23.45</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.35 to $23.45</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.10 to $15.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.10 to $15.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.70 to $9.90</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.70 to $9.90</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.54 to $5.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.54 to $5.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s non-vested shares outstanding as of December&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-vested Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,500)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,000)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense related to equity incentive awards of approximately $14,000 and approximately $5,000 for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively. As of December&#160;30, 2023, the Company had no unrecognized share-based compensation expense associated with stock option awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178287643632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17: Income taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, the Company recorded an income tax benefit from continuing operations of approximately $429,000 and an income tax benefit of $6.6&#160;million, respectively, and an income tax provision from discontinued operations of approximately $971,000 and $2.1 million, respectively, which consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax provision (benefit) - domestic</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,589)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision (benefit) of income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,512)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's income tax benefit (provision) with the federal statutory tax rate for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively, is shown below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal income tax for installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State tax rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of sale of ARCA Recycling and Canada</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision of income taxes was derived from the following sources for fiscal years December&#160;30, 2023 and December&#160;31, 2022, respectively, as shown below (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,613)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,717&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,270)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,480&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets (liabilities) as of December&#160;30, 2023 and December&#160;31, 2022, respectively, are as follows (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(483)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 163(j) interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">709&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(639)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(195)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;30, 2023, the Company has net operating loss carryforwards of approximately $20.9 million for federal income tax purposes, and approximately $14.8 million for state income tax purposes, which will be available to offset future taxable income. Due to recent tax legislation, the federal net operating losses are eligible for indefinite carryforward, limited by certain taxable income limitations. State net operating losses begin to expire in 2029. The Company evaluates all available evidence to determine if a valuation allowance is needed to reduce its deferred tax assets. During the fourth quarter of fiscal year 2023, management concluded that a valuation allowance is necessary for the state net operating loss carryforward and a portion of the federal net operating loss carryforward. Due to the 2023 sale of ARCA Canada (as part of the Recycling Subsidiaries transaction), the valuation allowance was released. The Company has recorded a valuation allowance of approximately $2.8 million and $904,000 as of December&#160;30, 2023, and December&#160;31, 2022, respectfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company annually conducts an analysis of its uncertain tax positions and has concluded that it has no uncertain tax positions as of December&#160;30, 2023. The Company&#8217;s policy is to record uncertain tax positions as a component of income tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. and state income tax returns in jurisdictions with differing statutes of limitations. The 2020 through 2023 tax years remain subject to selection for examination as of December&#160;30, 2023. None of the Company&#8217;s income tax returns are currently under audit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368641904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18: Related parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Isaac, the Company&#8217;s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures Incorporated (&#8220;Live Ventures&#8221;) and managing member of ICG. Tony Isaac, Chief Executive Officer and Richard Butler, Board of Directors member of the Company, are both Board of Directors members of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $203,000 and approximately $314,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively. Connexx rents approximately 9,900 square feet of office space from Live Ventures at its Las Vegas, Nevada office. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, we ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expenses for Connexx at the Las Vegas, Nevada office were approximately $103,000 and approximately $215,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During Q4 2023, operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. See Note 4. Consequently, outstanding liabilities for shared rent and services for the Recycling Subsidiaries reverted to the Company. As such, the Company has recorded a liability in the amount of approximately $258,000, which was offset against the gain on sale of the Recycling Subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Recycling Subsidiaries</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#8220;Recycling Purchase Agreement&#8221;) with VM7 Corporation, a Delaware corporation (&#8220;VM7&#8221;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries consisting of: (a) ARCA Recycling, Inc., (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Agreement. The Company's Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023. During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understands that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on its balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ICG Note</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2019, ARCA Recycling entered into and delivered to ICG a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#8220;ICG Note&#8221;). See Note 6. Jon Isaac is the manager and sole member of ICG, and the son of Tony Isaac, the Chief Executive Officer of JanOne and, previously, ARCA Recycling. ICG is a record and beneficial owner of 13.6% of the outstanding common stock of the Company. The ICG Note was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the ICG Note was guaranteed by the Company, it recorded a liability in the amount of approximately $690,000 for the principal balance due on the note, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. Additionally, effective February 2024, the ICG Note was amended to reflect the Company as co-maker on the ICG Note. See Note 22. The ICG Note matures in March 2026, and bears interest at 8.75% per annum. Monthly payments on the note are approximately $24,767. As of December&#160;30, 2023, the balance outstanding was approximately $706,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARCA Recycling Purchasing Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, ARCA Recycling entered into a Purchasing Agreement with Live Ventures. Pursuant to the Purchasing Agreement, Live Ventures agrees to purchase inventory from time to time for ARCA, as set forth in submitted purchase orders. The inventory is owned by Live Ventures until payment from ARCA Recycling is received. All purchases made by ARCA Recycling shall be paid back to Live Ventures in full plus an additional five percent surcharge or broker-type fee. The term of the Purchasing Agreement is one year, and automatically renews if not terminated by either party, as provided for in the Purchasing Agreement. The liability for the Purchasing Agreement was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the Purchasing Agreement was guaranteed by the Company, it recorded a liability in the amount of approximately $692,000 for the principal balance due under the Purchasing Agreement, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. As of the years ended December&#160;30, 2023 and December&#160;31, 2022, the amount due to Live Ventures was approximately $692,000 and $624,000, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178282014640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19: Commitments and Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Complaint</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) filed a civil complaint (the &#8220;SEC Complaint&#8221;) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the &#8220;Defendants&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC Complaint alleges financial, disclosure and reporting violations against the Company and the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC seeks permanent injunctions and civil penalties against the Defendants, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC&#8217;s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assert that the SEC&#8217;s pursuit of this matter will not result in any benefit to investors and instead will only serve as a distraction from its core business. On October 1, 2021, the Company, filed a motion with the court to dismiss the complaint. The SEC filed its response opposing the motions on November 1, 2021. On September 7, 2022, the motions to dismiss were denied by the court. Pursuant to the automatic stay of proceedings under the Private Securities Litigation Reform Act, all discovery was stayed pending the motions to dismiss and the June 23, 2023 mediation to which all of the parties agreed. As of the date of these financial statements, the Company and the SEC have reached a settlement agreement in principal, the written agreement for which is pending at the SEC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Skybridge</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2016, the Company served a Minnesota state court complaint for breach of contract on Skybridge Americas, Inc. (&#8220;SA&#8221;), the Company&#8217;s primary call center vendor throughout 2015 and most of 2016. The Company seeks damages in the millions of dollars as a result of alleged overcharging by SA and lost client contracts. On January&#160;25, 2017, SA served a counterclaim for unpaid invoices in the amount of approximately $460,000 plus interest and attorneys&#8217; fees. On March 29, 2017, the Hennepin County district court (the &#8220;District Court&#8221;) dismissed the Company&#8217;s breach of contract claim based on SA&#8217;s overuse of its Canadian call center but permitted the Company&#8217;s remaining claims to proceed. Following motion practice, on January 8, 2018 the District Court entered judgment in SA&#8217;s favor, which was amended as of February&#160;28, 2018, for a total amount of approximately $614,000 including interest and attorneys&#8217; fees. On March 4, 2019, the Minnesota Court of Appeals (the &#8220;Court of Appeals&#8221;) ruled and (i) reversed the District Court&#8217;s judgment in favor of Skybridge on the call center location claim and remanded the issue back to the District Court for further proceedings, (ii) reversed the District Court&#8217;s judgment in favor of Skybridge on the net payment issue and remanded the issue to the District Court for further proceedings, and (iii) affirmed the District Court&#8217;s judgment in Skybridge&#8217;s favor against the Company&#8217;s claim that Skybridge breached the contract when it failed to meet the service level agreements. As a result of the decision by the Court of Appeals, the District Court&#8217;s award of interest and attorneys&#8217; fees, etc. was reversed. The Company and SA held a mediation session in July 2020. Trial was held in August 2020 and on February&#160;1, 2021, the District Court assessed damages against the Company in the amount of approximately $715,000, plus interest, fees, and costs and attorneys&#8217; fees of $475,000. In subsequent proceedings, the Appeals Court affirmed the District Court judgment. Of the total amount awarded to SA, less the funds that the Company had previously deposited with the District Court, SA remains entitled to approximately $422,000 of statutory interest, which obligation has been assumed by VM7 in connection with the Recycling Subsidiaries Disposition transaction. See Note 4.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">AMTIM Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMTIM Capital, Inc. (&#8220;AMTIM&#8221;) acts as the Company&#8217;s representative to market our recycling services in Canada under an arrangement that pays AMTIM for revenues generated by recycling services in Canada as set forth in the agreement between the parties. A dispute has arisen between AMTIM and the Company with respect to the calculation of amounts due to AMTIM pursuant to the agreement. In a lawsuit filed by AMTIM in the province of Ontario, AMTIM claims a discrepancy in the calculation of fees due to AMTIM by the Company of approximately $2.0 million. Trial commenced in February 2022, and, on December 12, 2022, a decree was issued by the court dismissing the case.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">GeoTraq</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about April&#160;9, 2021, GeoTraq, Gregg Sullivan, Tony Isaac, and the Company, among others, resolved all of the claims that related to, among other items, the Company's acquisition of GeoTraq in August 2017, all post-acquisition activities, and Mr. Sullivan&#8217;s post-acquisition employment relationship with GeoTraq (all of such claims, the &#8220;GeoTraq Matters&#8221;). The resolution was effectuated through the parties&#8217; execution and delivery of a Settlement Agreement and Mutual Agreement of Claims (the &#8220;GeoTraq Settlement Agreement&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Settlement Agreement, the Company, on its own behalf and on behalf of GeoTraq and Mr. Isaac, agreed to tender to Mr. Sullivan an aggregate of $1.95 million (the &#8220;GeoTraq Settlement Consideration&#8221;) in the following manner: (i) $250,000, which was tendered in cash on or about the date of the Settlement Agreement and (ii) up to 10 quarterly installments of not less than $170,000 that commenced on June&#160;1, 2021, and continued not less frequently than every three months thereafter (the &#8220;GeoTraq Installments&#8221;). The Company may tender the GeoTraq Installments in cash or in the equivalent value of shares of its common stock (the value of the shares to be determined by a formula set forth in the Settlement Agreement), in either case at the Company's discretion. The Company may also prepay one or more GeoTraq Installments in full or in part at any time or from time to time either in cash or in shares of its common stock (a &#8220;GeoTraq Prepayment&#8221;). If the Company elected to prepay one or more GeoTraq Installments with shares of its common stock, Mr. Sullivan reserved the right not to consent to a tender thereof in excess of 50% of the value of that specific GeoTraq Prepayment; however, Mr. Sullivan was restricted in the reasons for which he can refuse to provide his written consent. The number of shares of the Company's common stock to be issued upon any GeoTraq Prepayment is determined by a different formula than the one to be utilized for a GeoTraq Installment. On March 17, 2023, the Company converted 5,185 of Mr. Sullivan&#8217;s Series A-1 Preferred shares and issued 103,707 shares of the Company's common stock as payment for its quarterly installment. On June 1, 2023, the Company converted 7,697 of Mr. Sullivan&#8217;s Series A-1 Preferred shares into 153,941 shares of the Company&#8217;s common stock in payment of its June 30, 2023 quarterly installment. On September 1, 2023, the Company converted 14,471 of Mr. Sullivan&#8217;s Series A-1 Preferred shares into 289,421 shares of the Company&#8217;s common stock in payment of its September 30, 2023 quarterly installment. See Note 14. As of September 30, 2023, the full balance due under the Settlement Agreement had been repaid and the remaining 1,505 shares of Mr. Sullivan&#8217;s Series A-1 Preferred shares were returned to the Company for cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties to the Settlement Agreement released and forever discharged one another from any and all known and unknown claims that were asserted or could have been asserted arising out of the GeoTraq Litigation Matters. The accrued liability for payments due to Mr. Sullivan is $0 and $510,000 as of December&#160;30, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Alixpartners, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;19, 2022, Alixpartners, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alixpartners, LLC, plaintiff/petitioner, against JanOne Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Index No. 653877/2022. Plaintiff alleged the breach of an agreement and sought damages in the amount of approximately $345,000. The Company denied that obligation. After extensive negotiations, the parties reached a settlement, pursuant to which the Company agreed to pay to Alixpartners the sum of $125,000 in two tranches and to provide a confession of judgment in its favor in the amount of approximately $450,000, which represented the amount sought in the complaint plus interest thereon. The confession of judgment will be null and void and the complaint will be dismissed with prejudice upon the Company tendering both tranches timely. The Company tendered both settlement payments in May 2023, and the complaint was subsequently dismissed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sieggreen</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Main/270</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $90,000 therefor. Plaintiff also seeks approximately $1,420,000 against ApplianceSmart and the Company on a joint and several basis. The Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Westerville Square</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an attempt to recover payments due under a lease, in 2021, Westerville Square, Inc., as the landlord, initiated a civil action against the Company, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Westerville Square, Inc. v. Appliance Recycling Centers Of America, Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Court of Common Pleas of Franklin County, Ohio, Case No. 19 CV 8627. The case was stayed during the bankruptcy proceedings of ApplianceSmart, Inc., and was reinstated on June 7, 2021. The landlord is currently seeking $120,000, which amount is disputed by the Company. Effective June 4, 2023, the parties settled the matter, pursuant to which settlement the Company tendered the sum of $110,000 to the landlord, the parties entered into a Settlement Agreement and Release, and the case was dismissed with prejudice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January&#160;2, 2021, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000 which represented amounts guaranteed or which may have been owed under certain lease agreements to three third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (&#8220;ApplianceSmart Leases&#8221;). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December&#160;30, 2023, the Company reversed approximately $637,000 of the accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December&#160;30, 2023, a balance of approximately $130,000 remains as an accrued liability due to an ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys&#8217; fees expended in relation thereto.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of December&#160;30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278281296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20: Earnings (Loss) per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company&#8217;s Consolidated Balance Sheet. Diluted net earnings per share is computed using the weighted average number of common shares outstanding, and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable with respect to restricted share awards, stock options and convertible preferred stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share (in $000&#8217;s, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444,361</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Potentially dilutive securities totaling approximately 3.9&#160;million and 4.6&#160;million shares, respectively, were excluded from the calculation of diluted net earnings (loss) per share for the years ended December&#160;30, 2023 and December&#160;31, 2022 because the effects were anti-dilutive based on the application of the treasury stock method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281103584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21: Segment information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates within targeted markets through three reportable segments for continuing operations: biotechnology, recycling, and technology. The biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The technology segment designed wireless modules to connect devices to the Mobile Internet of Things (&#8220;IoT&#8221;) which contain location-based service (&#8220;LBS&#8221;) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in $000&#8217;s): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating income</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,408)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Interest income (expense), net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income after provision for income taxes</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Net income after provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinue operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178380332112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22: Subsequent events</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the filing of this Form 10-K, and determined that there have been no events that have occurred that would require adjustments to disclosures in its consolidated financial statements other than as discussed below:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Warrant Purchase Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2024, the Company entered into a Warrant Purchase Agreement with a certain institutional investor that had purchased a Common Stock Purchase Warrant on August 22, 2023, in connection with such Investor&#8217;s purchase of shares of the Company&#8217;s common stock. The Warrant is exercisable from time to time for an aggregate of 899,348 shares of the Company&#8217;s common stock with a per-share exercise price of $0.7561. Pursuant to the terms of the Warrant Purchase Agreement, the Company or assigns agreed to purchase the Warrant for an aggregate price of $250,000, of which $200,000 was paid at the closing of the transaction and the remaining $50,000 was paid on March 5, 2024. In connection with the January transaction, the Company assigned the Common Stock Purchase Warrant to an otherwise unaffiliated third party. See Note 16.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Soin Amendment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 24, 2024, the Company, Amol Soin (&#8220;Dr. Soin&#8221;), and Soin Therapeutics LLC, a wholly-owned subsidiary of ours that we had purchased from Dr. Soin entered into an amendment (the &#8220;Soin Amendment&#8221;) to the parties&#8217; Agreement and Plan of Merger that was dated as of December 28, 2022 (the &#8220;Soin Agreement&#8221;). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0&#160;million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the &#8220;Soin Preferred&#8221;) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8&#160;million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ICG Promissory Obligation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2024, the Company amended its outstanding related party promissory obligations in favor of ICG and in favor of Live Ventures to add convertibility provisions to each. The per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#8217;s board of directors provided its final approvals of the amendments on February 7, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amended Promissory Note</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2024, the Company entered into a promissory note with each of the holders of the amended promissory notes (see above). The initial principal amount of each note is $300,000, with an interest rate of 10% per annum. Pursuant to an amendment to each note, one hundred thousand dollars of principal, and accrued interest thereon, is due on September 7, 2024 for each note, and the balance of each note is due on December 31, 2024. At the Company&#8217;s option, the obligation under each note is convertible after the six-month anniversary thereof at a per-share conversion price of $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#8217;s board of directors approved the issuance of the notes on February 7, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unit Purchase Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, the Company entered into Unit Purchase Agreements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with two otherwise unaffiliated third-party investors, pursuant to which each Investor agreed to purchase 408,163 units of securities from the Company, at a price per Unit of $0.735, for an aggregate purchase price of $300,000 per investor for an aggregate price of $600,000. Each Unit consists of one share of the Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pany&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock and one warrant to purchase an additional share of common stock. The per-Unit price is allocated as follows: $0.61 per share of common stock and $0.125 per Warrant. The Warrant has a three-year term and will be immediately exercisable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant is exercisable at $0.61 per share. The Company intends to use the proceeds from the Unit Purchases for its working capital needs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Isaac Consulting Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, we entered into a two-year Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Jon Isaac, pursuant to which he will </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide to us (the &#8220;Services&#8221;):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) strategic financial advice, including growth strategies, capital </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation, and financial restructuring; (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which we and he may be agree that will be memorialized in writing if, when, and as needed during the two-year term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Isaac is the son of our Chief Executive Officer, but otherwise does not have a current relationship with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As compensation for the Services, we agreed to (i) assign to him two universal life insurance policies that relate to the life of one of the founders of our now-disposed legacy recycling business (the first policy has an accumulated value/surrender value of approximately $3,854 and the second has an accumulated value/surrender value of approximately $468); (ii) contingently tender to him funds in our Canadian counsel&#8217;s trust account in the event that the prospective Order of the Court of Appeal for Ontario Canada in the matter styled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amtim Capital Inc. and Appliance Recycling Centers of America</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. COA-23-CV-0156, becomes the final Order of the Court, which amount we estimated not to exceed approximately US$220,000; (iii) issue to him 200,000 restricted shares of our common stock with the per-share value being the average of the Nasdaq historical NOCP closing price during the five trading days prior to our board approving the Consulting Agreement, which shares were awarded from our 2023 Equity Incentive Plan; and (iv) a two-year, straight 10% convertible promissory note in the initial principal amount of $500,000, with a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($1.16).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178287659488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Financial Statement Reclassification</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The prior year amounts have also been modified in these financial statements to properly present amounts under continuing and discontinued operations. See Note 6.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made in connection with the accompanying consolidated financial statements include the fair values in connection with the GeoTraq promissory note, analysis of other intangibles and long-lived assets for impairment, valuation allowance against deferred tax assets, lease terminations, and estimated useful lives for intangible assets and property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div>Financial instruments consist primarily of cash equivalents, trade and other receivables, notes receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company&#8217;s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at December&#160;30, 2023 and December&#160;31, 2022 approximate fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with a maturity of three months or less at the time of purchase. Fair value of cash equivalents approximates carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Receivables and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and Other Receivables and Allowance for Doubtful Accounts</span></div>The Company carries unsecured trade receivables at the original invoice amount less an estimate made for doubtful accounts based on a monthly review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions. The Company writes off trade receivables when it deems them to be uncollectible. The Company records recoveries of trade receivables previously written off when we receive them. The Company considers a trade receivable to be past due if any portion of the receivable balance is outstanding for more than ninety days. The Company does not charge interest on past due receivables.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for intangible assets in accordance with ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 350, intangible assets subject to amortization, shall be reviewed for impairment in accordance with the Impairment or Disposal of Long-Lived Assets in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 360, long-lived assets are tested for recoverability whenever events or changes in circumstances (&#8216;triggering event&#8217;) indicate that the carrying amount may not be recoverable. In making this determination, triggering events that were considered included:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant decrease in the market price of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); and,</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a triggering event has occurred, for purposes of recognition and measurement of an impairment loss, a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If after identifying a triggering event it is determined that the asset group&#8217;s carrying value may not be recoverable, a recoverability test is performed by forecasting the expected cash flows to be derived from the asset group for the remaining useful life of the asset group&#8217;s primary asset compared to its carrying value. The recoverability test relies upon the undiscounted cash flows (excluding interest and taxes) which are derived from the Company&#8217;s specific use of those assets (not how a market participant would use those assets); and, are </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon the existing service potential of the current assets (excluding any improvements that would materially enhance the assets). If the expected undiscounted cash flows exceed the carrying value, the assets are considered recoverable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of trade names, licenses for the use of internet domain names, Universal Resource Locators, or URL&#8217;s, computer software, patent USPTO reference No. 10,182,402, and designs and related manufacturing procedures. In connection with the Soin merger (see Note 3), intangible assets consist of three patents pending, orphan drug status for Naltrexone, as granted by the FDA, and the formula for Naltrexone. Upon acquisition, critical estimates are made in valuing acquired intangible assets, which include but are not limited to: future expected cash flows from customer contracts, customer lists, and estimating cash flows from projects when completed; tradename and market position, as well as assumptions about the period of time that customer relationships will continue; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from the assumptions used in determining the fair values. All intangible assets are capitalized at their original cost and amortized over their estimated useful lives as follows: domain name and marketing &#8211; 3 to 20 years; software &#8211; 3 to 5 years, technology intangibles &#8211; 7 years, customer relationships &#8211; 7 to 15 years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biotechnology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently generates no revenue from its Biotechnology segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recycling Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, retroactive to March 1, 2023, the Company entered into the Recycling Purchase Agreement with VM7, under which VM7 agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. As discussed previously, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements..</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Technology Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates no revenue from its Technology segment. GeoTraq was the Company&#8217;s Technology segment. The Company suspended all operations for GeoTraq during the year ended December&#160;31, 2022. On May 24, 2022, the Company sold substantially all of the GeoTraq assets . GeoTraq is being presented as a discontinued operation. See Note 5. As discussed previously, the accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: Level 1 - inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Level 2 &#8211; to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 &#8211; inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided on deferred taxes if it is determined that it is more likely than not that the asset will not be realized. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision for income taxes in its Consolidated Statements of Income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the amount of benefit to be recognized in relation to an uncertain tax position. The Company uses a two-step process to evaluate tax positions. The first step requires an entity to determine whether it is more likely than not (greater than 50% chance) that the tax position will be sustained. The second step requires an entity to recognize in the financial statements the benefit of a tax position that meets the more-likely-than-not recognition criterion. The amounts ultimately paid upon resolution of issues raised by taxing authorities may differ materially from the amounts accrued and may materially impact the financial statements of the Company in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is calculated in accordance with ASC 260, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. Under ASC 260 basic earnings per share is computed using the weighted average number of common shares outstanding during the period except that it does not include unvested restricted stock subject to cancellation. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of warrants, options, restricted shares and convertible preferred stock. The dilutive effect of outstanding restricted shares, options and warrants is reflected in diluted earnings per share by application of the treasury stock method. Convertible preferred stock is reflected on an if-converted basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 280, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; requires use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a Company&#8217;s management organizes segments within the Company for making operating decisions and assessing performance. The Company determined it had three reportable segments, however the Recycling and Technology segments have been consolidated and presented as discontinued operations. See Note 21.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash balances at a bank in Nevada. The account is insured by the Federal Deposit Insurance Corporation up to $250,000. At times, balances may exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178376954736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Trade and Other Receivables</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the Company's trade and other receivables as of December&#160;30, 2023 and December&#160;31, 2022 (in $000&#8217;s):</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:70.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178406123248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Recycling Subsidiaries (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text">The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278227552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GeoTraq (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text">The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281649552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text">The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"><tr><td style="width:1.0%"></td><td style="width:82.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment from buyer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - California state sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount on note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on shares received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition of GeoTraq inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,428&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities - other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - California sales taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation short-term - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligation long-term - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable - long-term portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion related party note payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s property and equipment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 30</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net, from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and domains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued liabilities consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued incentive and rebate checks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrual relating to the California sales tax assessment consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - CA sales tax assessment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liability - interest on CA sales tax assessment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gulf Coast Bank and Trust Company loan origination fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KLC Financial loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s related party debt consisted of the following (in $000&#8217;s):</span><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Isaac Capital Group LLC</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses from discontinued operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense from discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#8217;s):<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of ARCA, net of cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of GeoTraq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCONTINUED FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on related party note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in (provided by) financing activities from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of changes in exchange rate on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178377491712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaids and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaids and other current assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaids and other current assets</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281983328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soin intangibles</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and domains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,563&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,451)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,563)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278445712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of the following (in $000&#8217;s, except shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series G Convertible Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common Shares Equivalent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities received</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,224</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">922,442,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark-to-market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance, December 30, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,224</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">952,442,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278241216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Deposits and Other Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deposits and other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178281155984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities of continuing consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued guarantees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued litigation/legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278333056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long Term Debt and Other Financing Obligations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt and other financing obligations consist of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AFCO Finance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178282009728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series S Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Series S Convertible Preferred Stock outstanding</a></td>
<td class="text">As of December&#160;30, 2023 and December&#160;31, 2022, there were 100,000 of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#8217;s).<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series S Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series S preferred issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278055408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022 (Aggregate Intrinsic Value in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options <br/>Outstanding </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price for stock options outstanding and exercisable outstanding at December&#160;30, 2023 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price ($)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.35 to $23.45</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.35 to $23.45</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.10 to $15.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.10 to $15.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.70 to $9.90</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.70 to $9.90</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.54 to $5.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.54 to $5.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Information About Non-vested Shares Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s non-vested shares outstanding as of December&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-vested Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,500)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,000)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested at December 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278014176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Benefit of Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, the Company recorded an income tax benefit from continuing operations of approximately $429,000 and an income tax benefit of $6.6&#160;million, respectively, and an income tax provision from discontinued operations of approximately $971,000 and $2.1 million, respectively, which consisted of the following (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax provision (benefit) - domestic</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,589)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision (benefit) of income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,512)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's income tax benefit (provision) with the federal statutory tax rate for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively, is shown below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal income tax for installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State tax rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of sale of ARCA Recycling and Canada</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Benefit of Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision of income taxes was derived from the following sources for fiscal years December&#160;30, 2023 and December&#160;31, 2022, respectively, as shown below (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,613)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,717&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,270)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,480&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets (liabilities) as of December&#160;30, 2023 and December&#160;31, 2022, respectively, are as follows (in $000&#8217;s):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(483)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Installment sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 163(j) interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">709&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(639)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(195)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278263632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share (in $000&#8217;s, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income from discontinued operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444,361</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted income per share from discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,005,334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,150,230</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted (loss) income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278181712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in $000&#8217;s): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Years Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(197)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating income</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,408)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Interest income (expense), net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income after provision for income taxes</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,972&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Net income after provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinue operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178369022144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PotentialMarketExclusivityPeriod', window );">Potential market exclusivity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net (loss) income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,095)<span></span>
</td>
<td class="nump">$ 8,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">9,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
<td class="nump">$ 23,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CurrentAssetsCurrentLiabilitiesNet', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember', window );">SPYR Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NotesReceivableTerm', window );">Term of notes receivable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | SPYR Technologies Inc. | GeoTraq Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Agreed prepayment amount</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NotesReceivableTerm', window );">Term of notes receivable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Note receivable face amount</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate', window );">Note receivable interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_CurrentAssetsCurrentLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_CurrentAssetsCurrentLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NotesReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NotesReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PotentialMarketExclusivityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Market Exclusivity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PotentialMarketExclusivityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal amount of the receivable or note before consideration of the discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_GeoTraqIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_GeoTraqIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284868592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember', window );">Soin intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfAcquiredIntangibleAssets', window );">Number of pending patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Domain Name and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation insured per institution</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Domain Name and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284291776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Trade and Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember', window );">Continuing and discontinued operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368490848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Mergers and Acquisitions (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>USD ($) </div>
<div>patent </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 639,000<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember', window );">Soin intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfAcquiredIntangibleAssets', window );">Number of pending patents | patent</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_DrSoinMember', window );">Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CommonStockSharesOutstandingPercentage', window );">Common stock, shares outstanding, percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_FairValueOfStockIssued', window );">Fair value of stock issued connection with merger</a></td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 19,300,000<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Stock Conversion 1 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockCommencementPeriod', window );">Conversion of stock, commencement period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Stock Conversion 3 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockPeriodFollowingClosing', window );">Conversion of stock, period after closing</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC | Series S | Stock Conversion 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount converted</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC | Series S | Stock Conversion 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount converted</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC | Series S | Stock Conversion 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount converted</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC | STI Merger Sub, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CommonStockSharesOutstandingPercentage', window );">Common stock, shares outstanding, percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember', window );">Soin Therapeutics LLC | STI Merger Sub, Inc. | Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="nump">$ 300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, shares, acquisition (in shares) | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, value, acquisition</a></td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions', window );">Stock issued during period, additional value, acquisitions</a></td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business acquisition, shares issued, fair value</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_CommonStockSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Outstanding, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_CommonStockSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Commencement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockPeriodFollowingClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Period Following Closing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockPeriodFollowingClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_FairValueOfStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock issued connection with merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_FairValueOfStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_StockIssuedDuringPeriodAdditionalValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Additional, Value, Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_StockIssuedDuringPeriodAdditionalValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_DrSoinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_DrSoinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=jan_StiMergerSubIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=jan_StiMergerSubIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178377784544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Recycling Subsidiaries - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Excess of book value over assets disposed, extensible list</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">disposition<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Write off of VM7 note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,320)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jan_GulfCoastBankAndTrustCreditFacilityMember', window );">Gulf Coast Bank and Trust Credit Facility | Financial Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantor obligations, current carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities', window );">Reduction in liabilities</a></td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer', window );">Aggregate monthly payments from the buyer</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod', window );">Aggregate monthly payments from buyer, period (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment', window );">Aggregate monthly pre-payments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary', window );">Additional proceeds received for the equity of each subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer', window );">Minimum monthly payments</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod', window );">Aggregate payment period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue', window );">Amount of the reduction percentage (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure', window );">Consideration paid at close of transactions</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage', window );">Discount rate percentage (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount', window );">Discount recorded as offset to the principal amount</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration', window );">Net consideration</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets', window );">Book value in excess of assets disposed of</a></td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Write off of VM7 note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary calculation of gain on sale</a></td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Relevant Month 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue', window );">Percentage of gross revenue (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark', window );">Subsidiary's revenue benchmark</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Relevant Month 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue', window );">Percentage of gross revenue (percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Relevant Month 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue', window );">Percentage of gross revenue (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark', window );">Subsidiary's revenue benchmark</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer', window );">Minimum monthly payments</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Minimum | Relevant Month 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark', window );">Subsidiary's revenue benchmark</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries | Maximum | Relevant Month 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark', window );">Subsidiary's revenue benchmark</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | Gulf Coast Bank and Trust Credit Facility | Financial Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantor obligations, current carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Minimum Payments from Buyer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Percentage of Gross Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Subsidiary Revenue Benchmark</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments from Buyer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Prepayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Asset Acquisition, Consideration Transferred, At Closure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Discount Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Payment Receivable, Percentage Of Difference Between Assessment And Settlement Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Present Value Of Discount Recorded As Offset To The Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Proceeds Received For Equity Of Each Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Reduction In Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Book Value In Excess Of Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Not Discontinued Operation Gain (Loss) On Disposal, Statement Of Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:tokenItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jan_GulfCoastBankAndTrustCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jan_GulfCoastBankAndTrustCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupConsiderationPaymentPeriodAxis=jan_RelevantMonth3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368332048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details) - Sale of Recycling Subsidiaries - ARCA And Subsidiaries<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TotalGuaranteedConsideration', window );">Total minimum consideration</a></td>
<td class="nump">$ 6,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PaymentFromBuyer', window );">Payment from buyer</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NetConsideration', window );">Net consideration</a></td>
<td class="nump">6,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfAccruedLiability', window );">Accrued liabilities</a></td>
<td class="nump">1,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax', window );">Accrued liabilities - California state sales tax</a></td>
<td class="nump">6,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">5,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfDebt', window );">Debt</a></td>
<td class="nump">2,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TotalDisposalOfLiability', window );">Total disposal of liabilities</a></td>
<td class="nump">20,320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TotalConsiderations', window );">Total consideration</a></td>
<td class="nump">26,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CashDisposal', window );">Cash</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">4,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfInventory', window );">Inventory</a></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">5,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalOfOtherAssets', window );">Other assets</a></td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TotalDisposalOfAssets', window );">Total disposal of assets</a></td>
<td class="nump">14,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TotalGainOnSale', window );">Total gain on sale</a></td>
<td class="nump">$ 12,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_CashDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Disposal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_CashDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Accounts receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Accrued liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Accrued liability - California state sales tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Intangible assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Property, Plant and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of Right-of-use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NetConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NetConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PaymentFromBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment from Buyer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PaymentFromBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TotalConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Considerations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TotalConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TotalDisposalOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Disposal of Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TotalDisposalOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TotalDisposalOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Disposal of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TotalDisposalOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TotalGainOnSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Gain on Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TotalGainOnSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TotalGuaranteedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Guaranteed Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TotalGuaranteedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178407087392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GeoTraq - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
<td class="nump">4,957,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stockholders' equity note, subscriptions receivable</a></td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stockholders' equity note, subscriptions receivable</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_SpyrTechnologiesIncMember', window );">SPYR Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableFaceAmount', window );">Note receivable face amount</a></td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Receivable with imputed interest, net amount</a></td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ChargeAgainstIncomeForIncreaseInDiscountRate', window );">Charge against income for increase in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_SpyrTechnologiesIncMember', window );">SPYR Technologies Inc. | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AgreedPrepaymentAmount', window );">Agreed prepayment amount</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NotesReceivableTerm', window );">Term of notes receivable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableFaceAmount', window );">Note receivable face amount</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableStatedInterestRate', window );">Note receivable interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableMaturityDate', window );">Note receivable maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 24,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding', window );">Inventory transferred part of the sale, derecognized</a></td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableDiscountRate', window );">Note receivable discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableRevisedDiscountRate', window );">Note receivable revised discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ChargeAgainstIncomeForIncreaseInDiscountRate', window );">Charge against income for increase in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AgreedPrepaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed prepayment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AgreedPrepaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ChargeAgainstIncomeForIncreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charge Against Income For Increase In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ChargeAgainstIncomeForIncreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Receivable Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable face amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableRevisedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Receivable Revised Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableRevisedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NotesReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NotesReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transferred financial assets in which the transferor has continuing involvement with the assets underlying the transaction that have been derecognized. Continuing involvement includes, but is not limited to, servicing, recourse, and restrictions on transferor's interests in transferred financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jan_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_SpyrTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_SpyrTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284250016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfAccountsReceivable', window );">Discount on note receivable</a></td>
<td class="num">(4,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalancePremiumReceived', window );">Premium on shares received</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax', window );">Derecognition of GeoTraq inventory</a></td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProject', window );">Gain on sale</a></td>
<td class="nump">$ 9,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount at purchase price of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), purchased with credit deterioration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains and losses included in earning resulting from the sale of a project.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustment from accumulated other comprehensive income for gain (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk, not recognized in income and used in calculating liability for future policy benefit for payout annuity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (n)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalancePremiumReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow to policyholder account balance from premium received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13J<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13J<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalancePremiumReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368194336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total noncurrent liabilities from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | ARCA And Subsidiaries | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade and other receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset', window );">Right of use asset - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Total other assets from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued liabilities - other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes', window );">Accrued liability - California sales taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases', window );">Lease obligation short-term - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent', window );">Current portion of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote', window );">Related party note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases', window );">Lease obligation long-term - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent', window );">Notes payable - long term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable', window );">Long-term portion related party note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total noncurrent liabilities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Lease Obligation Long Term, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Lease Obligation Short Term, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Long-term Portion Related Party Note Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Note Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Related Party Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Right of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Short Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178405628624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Property and Equipment (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross', window );">Property and equipment</a></td>
<td class="nump">$ 4,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Total property and equipment, net, from discontinued operations</a></td>
<td class="nump">2,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jan_BuildingsAndImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross', window );">Property and equipment</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jan_BuildingsAndImprovementsMember', window );">Buildings and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jan_BuildingsAndImprovementsMember', window );">Buildings and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionMember', window );">Projects under construction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jan_BuildingsAndImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jan_BuildingsAndImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178369048976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 13, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="nump">229,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which Company operated its recycling business | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Accrued liability - CA sales tax assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_SalesTaxAssessmentAccruedInterest', window );">Accrued liability - interest on CA sales tax assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">ICG Note | Record and beneficial owner | Janone | ICG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Common stock, shares outstanding, ownership percentage</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">ICG Note | Record and beneficial owner | Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Installment</a></td>
<td class="nump">$ 24,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Revolving Credit Facility | ICG Note | Record and beneficial owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Percentage of loan fee on each borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_SalesTaxAssessmentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Tax Assessment, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_SalesTaxAssessmentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jan_JanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jan_JanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jan_IsaacCapitalGroupLLCICGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jan_IsaacCapitalGroupLLCICGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284775904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Intangible Assets (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">$ 1,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Total intangible assets</a></td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patent and domains</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">$ 1,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178378019344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | ARCA And Subsidiaries | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AccruedIncentiveAndRebateChecksCurrent', window );">Accrued incentive and rebate checks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AccruedIncentiveAndRebateChecksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued incentive and rebate checks current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AccruedIncentiveAndRebateChecksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284816208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 13, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Accrued liability - CA sales tax assessment</a></td>
<td class="nump">$ 4,132<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_SalesTaxAssessmentAccruedInterest', window );">Accrued liability - interest on CA sales tax assessment</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes', window );">Total</a></td>
<td class="nump">$ 6,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_SalesTaxAssessmentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Tax Assessment, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_SalesTaxAssessmentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284843904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Short-term Debt (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt', window );">Short term debt</a></td>
<td class="nump">$ 4,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=jan_GulfCoastBankAndTrustCompanyMember', window );">Gulf Coast Bank and Trust Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gulf Coast Bank and Trust Company</a></td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Gulf Coast Bank and Trust Company loan origination fees</a></td>
<td class="num">$ (34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Short Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=jan_GulfCoastBankAndTrustCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=jan_GulfCoastBankAndTrustCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284889328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Long-term Debt (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable', window );">Total</a></td>
<td class="nump">$ 1,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent', window );">Less current portion</a></td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent', window );">Notes payable - long term portion</a></td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=jan_KlcFinancialMember', window );">KLC Financial</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">KLC Financial</a></td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">KLC Financial loan origination fees</a></td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent', window );">Less current portion</a></td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent', window );">Notes payable - long term portion</a></td>
<td class="nump">$ 1,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Note Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=jan_KlcFinancialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=jan_KlcFinancialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368736752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Related Party Debt (Details) - Discontinued operations - ARCA And Subsidiaries - Recycling Segment and Technology Segment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable', window );">Total</a></td>
<td class="nump">$ 1,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent', window );">Less current portion</a></td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent', window );">Notes payable - long term portion</a></td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=jan_IcgNoteMember', window );">ICG Note | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable', window );">Total</a></td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent', window );">Less current portion</a></td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent', window );">Notes payable - long term portion</a></td>
<td class="nump">$ 605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Note Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=jan_IcgNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=jan_IcgNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368988816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of ARCA &amp; GeoTraq</a></td>
<td class="num">$ (10,254)<span></span>
</td>
<td class="num">$ (5,081)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | ARCA And Subsidiaries | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">39,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="nump">3,992<span></span>
</td>
<td class="nump">31,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">8,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations', window );">Total operating expenses from discontinued operations</a></td>
<td class="num">(10,635)<span></span>
</td>
<td class="num">(776)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income from discontinued operations</a></td>
<td class="nump">10,438<span></span>
</td>
<td class="nump">8,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_OtherIncomeExpenseFromDiscontinuedOperations', window );"><strong>Other expense from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense, net</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense', window );">Loss on litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet', window );">Total other expense, net</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(3,314)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income before provision for income taxes from discontinued operations</a></td>
<td class="nump">10,254<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax provision</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | ARCA | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of ARCA &amp; GeoTraq</a></td>
<td class="num">(12,102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | GeoTraq Inc. | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of ARCA &amp; GeoTraq</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9,428)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Litigation Settlement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other (Income) Expense, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Total Operating Income (Expenses) From Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total other loss, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_OtherIncomeExpenseFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense) From Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_OtherIncomeExpenseFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ArcaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ArcaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_GeoTraqIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_GeoTraqIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368589104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedOperatingActivities', window );"><strong>DISCONTINUED OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 2,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(5,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) operating activities from discontinued operations</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedInvestingActivities', window );"><strong>DISCONTINUED INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities from discontinued operations</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedFinancingActivities', window );"><strong>DISCONTINUED FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in (provided by) financing activities from discontinued operations</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of changes in exchange rate on cash and cash equivalents</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | ARCA And Subsidiaries | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedOperatingActivities', window );"><strong>DISCONTINUED OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_GainLossOnLitigationSettlement', window );">Loss on litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_GainOnSaleNetOfCash', window );">Gain on sale of ARCA, net of cash</a></td>
<td class="num">(12,248)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of GeoTraq</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) operating activities from discontinued operations</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedInvestingActivities', window );"><strong>DISCONTINUED INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities from discontinued operations</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscontinuedFinancingActivities', window );"><strong>DISCONTINUED FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">17,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party note</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="nump">7,336<span></span>
</td>
<td class="nump">13,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in (provided by) financing activities from discontinued operations</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of changes in exchange rate on cash and cash equivalents</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DiscontinuedFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DISCONTINUED FINANCING ACTIVITIES:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DiscontinuedFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DiscontinuedInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DISCONTINUED INVESTING ACTIVITIES:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DiscontinuedInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DiscontinuedOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DISCONTINUED OPERATING ACTIVITIES:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DiscontinuedOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_GainLossOnLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_GainLossOnLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_GainOnSaleNetOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on Sale, Net of Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_GainOnSaleNetOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278197936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaids and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent', window );">Total prepaids and other current assets</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense And Other Assets, including Discontinued Operations, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178287503040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Jul. 02, 2022</div></th>
<th class="th"><div>Jul. 02, 2022</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscountCharges', window );">Discount charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AdditionalAmountChargedAgainstIncome', window );">Additional amount charge aganist income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_GainLossOnWriteOffOfNotesReceivable', window );">Impairment charge related to note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,780,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Note receivable - SPYR, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,974,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Carrying value of disposition transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember', window );">SPYR Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NotesReceivableTerm', window );">Term of notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Common stock equivalents received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,442<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_VM7CorporationMember', window );">VM7 Corporation | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeInterestEarningAsset', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DispositionTransactionConsiderAmount', window );">Disposition transaction consider amount</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DispositionTransactionTermPeriod', window );">Disposition transaction term period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DispositionTransactionAggregateCost', window );">Disposition transaction aggregate cost</a></td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash paid for close</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DispositionDiscountRate', window );">Disposition discount rate (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Receivable with imputed interest, net amount</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RevisedDiscountAmount', window );">Revised discount amount</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember', window );">GeoTraq Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableFaceAmount', window );">Note receivable face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoteReceivableStatedInterestRate', window );">Note receivable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DiscountRecordedAsOffsetToThePrincipalAmount', window );">Offset to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DebtDiscountRate', window );">Original issuance discount rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DebtRevisedDiscountRate', window );">Debt revised discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeInterestEarningAsset', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 806,000<span></span>
</td>
<td class="nump">$ 387,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Note receivable - SPYR, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AdditionalAmountChargedAgainstIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Amount Charged Against Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AdditionalAmountChargedAgainstIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DebtDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DebtDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DebtRevisedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Revised Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DebtRevisedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DiscountCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DiscountCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DiscountRecordedAsOffsetToThePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Recorded As Offset To The Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DiscountRecordedAsOffsetToThePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DispositionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DispositionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DispositionTransactionAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition Transaction Aggregate cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DispositionTransactionAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DispositionTransactionConsiderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition Transaction Consider Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DispositionTransactionConsiderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DispositionTransactionTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition Transaction Term Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DispositionTransactionTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_GainLossOnWriteOffOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Write-Off Of Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_GainLossOnWriteOffOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable face amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoteReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoteReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NotesReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NotesReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RevisedDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revised Discount Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RevisedDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeInterestEarningAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income from interest-earning asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeInterestEarningAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OriginationOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_VM7CorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_VM7CorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jan_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jan_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368273808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 17,846<span></span>
</td>
<td class="nump">$ 20,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">19,297<span></span>
</td>
<td class="nump">22,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(1,451)<span></span>
</td>
<td class="num">(3,563)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">17,846<span></span>
</td>
<td class="nump">19,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations | Soin intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">19,293<span></span>
</td>
<td class="nump">19,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations | Patents and domains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations | Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_PatentsAndDomainsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_PatentsAndDomainsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178283583584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember', window );">Soin intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfAcquiredIntangibleAssets', window );">Number of pending patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jan_SoinIntangiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178380070512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward', window );"><strong>Marketable Securities, Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Beginning balance</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Securities received</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(926)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Ending balance</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember', window );">Series G Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward', window );"><strong>Marketable Securities, Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_MarketableSecuritiesSharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares', window );">Securities received (in shares)</a></td>
<td class="nump">9,224<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_MarketableSecuritiesSharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">9,224<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember', window );">Common Share Equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward', window );"><strong>Marketable Securities, Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_MarketableSecuritiesSharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares', window );">Securities received (in shares)</a></td>
<td class="nump">922,442,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_MarketableSecuritiesSharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">952,442,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_MarketableSecuritiesSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_MarketableSecuritiesSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Divestiture, Consideration Received, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178380226416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities | $</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember', window );">SPYR Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares', window );">Securities received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember', window );">Series G Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, conversion ratio</a></td>
<td class="nump">0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares', window );">Securities received (in shares)</a></td>
<td class="nump">9,224<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember', window );">Common Share Equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares', window );">Securities received (in shares)</a></td>
<td class="nump">922,442,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConvertiblePreferredStockSharesIssuableUponConversion', window );">Shares issuable upon conversion (in shares)</a></td>
<td class="nump">922,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConvertiblePreferredStockSharesIssuableUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issuable Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConvertiblePreferredStockSharesIssuableUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Divestiture, Consideration Received, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_SpyrTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesGConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_CommonShareEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178287786416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits and Other Assets - Schedule of Deposits and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember', window );">Continuing and discontinued operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284470400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AccruedGuaranteesCurrent', window );">Accrued guarantees</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation/legal</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AccruedGuaranteesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued guarantees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AccruedGuaranteesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284260816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=jan_FinancingArrangementMember', window );">Financing Arrangement | AFCO Credit Corporation Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=jan_FinancingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=jan_FinancingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jan_AFCOCreditCorporationFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jan_AFCOCreditCorporationFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178283856160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term debt - Additional Information (Details) - AFCO Finance - AFCO Credit Corporation Financing Agreement - Financing Arrangement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 21, 2022</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Initial down payment</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Financing agreements entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_AFCOCreditCorpMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Monthly principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_AFCOCreditCorpMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Monthly principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_AFCOCreditCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_AFCOCreditCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jan_AFCOCreditCorporationFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jan_AFCOCreditCorporationFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=jan_FinancingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=jan_FinancingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368454752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A-1 Convertible Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_SeriesA1ConvertiblePreferredStockMember', window );">Series A1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of preferred converted to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,353<span></span>
</td>
<td class="nump">16,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued upon exchange of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,069<span></span>
</td>
<td class="nump">322,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockSharesForfeited', window );">Convertible preferred stock, forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,730<span></span>
</td>
<td class="nump">222,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember', window );">GeoTraq Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business acquisition, shares issued, fair value | $</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Company tendered, shares (in shares)</a></td>
<td class="nump">288,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm', window );">Term of unsecured notes entered into</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Aggregate principal amount | $</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember', window );">GeoTraq Inc. | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business acquisition, shares issued, fair value | $</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue', window );">Beneficial conversion feature | $</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Beneficial Conversion Feature, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Liabilities Incurred, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockSharesForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Shares Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockSharesForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284499088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Series S Convertible Preferred Stock - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_DrSoinMember', window );">Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CommonStockSharesOutstandingPercentage', window );">Common stock, shares outstanding, percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion3Member', window );">Stock Conversion 3 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PercentageOfGrossRevenue', window );">Percentage of gross revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare', window );">Convertible preferred stock, voting rights | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Soin Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Potential value</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Company tendered, shares (in shares) | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Stock Conversion 1 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockAmountConvertible', window );">Conversion of stock, amount converted</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockCommencementPeriod', window );">Conversion of stock, commencement period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Stock Conversion 2 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockAmountConvertible', window );">Conversion of stock, amount converted</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember', window );">Series S | Stock Conversion 3 | Dr. Soin | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockAmountConvertible', window );">Conversion of stock, amount converted</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ConversionOfStockPeriodFollowingClosing', window );">Conversion of stock, period after closing</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_CommonStockSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Outstanding, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_CommonStockSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockAmountConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Amount Convertible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockAmountConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Commencement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ConversionOfStockPeriodFollowingClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Period Following Closing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ConversionOfStockPeriodFollowingClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PercentageOfGrossRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Gross Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PercentageOfGrossRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Voting Rights, Number Of Votes Entitled To Each Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_DrSoinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_DrSoinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=jan_StockConversion2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284710880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details) - Series S - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Preferred Stock Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_TemporaryEquitySharesIssuedDuringPeriodShares', window );">Series S preferred issued (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Series S preferred issued</a></td>
<td class="nump">$ 14,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="nump">$ 14,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">$ 14,510<span></span>
</td>
<td class="nump">$ 14,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_TemporaryEquitySharesIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Issued During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_TemporaryEquitySharesIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178283321168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Nov. 04, 2020</div></th>
<th class="th"><div>Nov. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,957,647<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,957,647<span></span>
</td>
<td class="nump">2,827,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, net of estimated forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jan_Plan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jan_Plan2011Member', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AdditionalAwardsToBeGranted', window );">Additional awards to be granted after adoption of 2016 plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jan_A2023PlanMember', window );">2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Underlying shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jan_A2023PlanMember', window );">2023 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 0.8811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant excise and granted (in shares)</a></td>
<td class="nump">899,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant offering and exercise price (in usd per share)</a></td>
<td class="nump">$ 0.7561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds reimbursement for accountable legal expenses</a></td>
<td class="nump">$ 790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-Funded Warrants Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant excise and granted (in shares)</a></td>
<td class="nump">481,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant offering and exercise price (in usd per share)</a></td>
<td class="nump">$ 0.8801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised', window );">Class of warrant or right, warrants or rights exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_ArticlesOfIncorporationMember', window );">Articles of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,957,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jan_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Common stock offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_CommonStockPurchasePricePerShare', window );">Common stock purchase price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AdditionalAwardsToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional awards to be granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AdditionalAwardsToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ClassOfWarrantOrRightWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Warrants Or Rights Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ClassOfWarrantOrRightWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_CommonStockPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_CommonStockPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds from the sale of an interest in a unit of partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jan_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jan_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jan_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jan_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jan_A2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jan_A2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jan_PreFundedWarrantsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jan_PreFundedWarrantsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jan_ArticlesOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jan_ArticlesOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jan_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jan_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178369127408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled/expired (in shares)</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">114,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options outstanding, exercisable (in shares)</a></td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in usd per share)</a></td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/expired (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in usd per share)</a></td>
<td class="nump">5.68<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 7.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share)</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178369038048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options, outstanding (in shares)</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeOneMember', window );">$17.35 to $23.45</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options, outstanding (in shares)</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 23.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeTwoMember', window );">$11.10 to $15.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 11.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeThreeMember', window );">$5.70 to $9.90</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options, outstanding (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 9.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeFourMember', window );">$3.54 to $5.25</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options, outstanding (in shares)</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jan_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278072848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Non-vested Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178279835904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="num">$ (429)<span></span>
</td>
<td class="num">$ (6,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating loss carryforwards, valuation allowance</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="num">(429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284568448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Benefit of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit) - domestic</a></td>
<td class="nump">445<span></span>
</td>
<td class="num">(4,589)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ProvisionBenefitOfIncomeTaxes', window );">Total provision (benefit) of income taxes</a></td>
<td class="nump">$ 542<span></span>
</td>
<td class="num">$ (4,512)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ProvisionBenefitOfIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision (Benefit) Of Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ProvisionBenefitOfIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178284650752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of provision for income taxes with federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent', window );">Federal income tax for installment sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Impact of sale of ARCA Recycling and Canada</a></td>
<td class="num">(4.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.70%)<span></span>
</td>
<td class="num">(96.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(7.30%)<span></span>
</td>
<td class="num">(65.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Federal Income Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178278197936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (6,613)<span></span>
</td>
<td class="nump">$ 6,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Canada</a></td>
<td class="num">(657)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes', window );">Loss before provision of income taxes, Total</a></td>
<td class="num">$ (7,270)<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Continuing Operations Before Provision (Benefit) Of Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368497104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_Section174Expenses', window );">Section 174 expenses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">5,360<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(3,747)<span></span>
</td>
<td class="num">(4,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DeferredTaxLiabilitiesInstallmentSale', window );">Installment sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized losses</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DeferredTaxAssetsInterest', window );">Section 163(j) interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance', window );">Total deferred tax assets (liabilities)</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(2,773)<span></span>
</td>
<td class="num">(904)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (639)<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DeferredTaxAssetsInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DeferredTaxAssetsInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities gross before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_DeferredTaxLiabilitiesInstallmentSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Installment Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_DeferredTaxLiabilitiesInstallmentSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_Section174Expenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 174 Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_Section174Expenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178407076512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th">
<div>Aug. 28, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Write off of VM7 note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,320,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=jan_ARCARecyclingPurchasingAgreementMember', window );">ARCA Purchasing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,000<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent', window );">Surcharge or broker fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionPurchaseAgreementTerm', window );">Purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Sale of Recycling Subsidiaries | ARCA And Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Write off of VM7 note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Accrued rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | ICG Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantor obligations, current carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 706,000<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Live Ventures Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Shared expenses with another company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="nump">314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rented office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Live Ventures Incorporated | ARCA Purchasing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,000<span></span>
</td>
<td class="nump">$ 692,000<span></span>
</td>
<td class="nump">$ 624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember', window );">Record and beneficial owner | Discontinued operations | ARCA And Subsidiaries | ICG Note | Recycling Segment and Technology Segment | Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Installment</a></td>
<td class="nump">$ 24,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember', window );">Record and beneficial owner | Discontinued operations | ARCA And Subsidiaries | ICG Note | Recycling Segment and Technology Segment | Janone | ICG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Common stock, shares outstanding, ownership percentage</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember', window );">Record and beneficial owner | Revolving Credit Facility | Discontinued operations | ARCA And Subsidiaries | ICG Note | Recycling Segment and Technology Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Purchases From Related Party, Surcharge Or Broker Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=jan_ARCARecyclingPurchasingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=jan_ARCARecyclingPurchasingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jan_ARCAAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_LiveVenturesIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_LiveVenturesIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_RecyclingSegmentAndTechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jan_JanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jan_JanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jan_IsaacCapitalGroupLLCICGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jan_IsaacCapitalGroupLLCICGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178286190848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 19, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2023 </div>
<div>USD ($) </div>
<div>traches </div>
<div>Quarterly </div>
<div>landlord</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>officer</div>
</th>
<th class="th">
<div>Dec. 30, 2017 </div>
<div>landlord</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint', window );">Number of executive officers named in complaint | officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfInstallment', window );">Number of installments | Quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor', window );">Number of landlords originally purported to be covered under Company's guarantee or commitment | landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor', window );">Number of landlords Company is no longer liable for | landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,941<span></span>
</td>
<td class="nump">103,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1ConvertiblePreferredStockMember', window );">Series A1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares returned to the Company for cancellation (in shares) | shares</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember', window );">GeoTraq Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_PercentOfPrepaymentTenderRestrictions', window );">Percent of prepayment value, tender restrictions (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jan_ApplianceSmartIncMember', window );">Appliance Smart, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Amount owed by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_OperatingLeasesFutureMinimumPaymentsDue1', window );">Operating leases future minimum payments due1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_SkyBridgeAmericasMember', window );">SA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded plus interest and attorney fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715,000<span></span>
</td>
<td class="nump">$ 614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Attorneys fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_StatutoryInterestReceivable', window );">Statutory interest, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_AMTIMCapitalIncMember', window );">AMTIM Capital Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_Mr.SullivanMember', window );">Mr. Sullivan | GeoTraq Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_AlixpartnersLlcMember', window );">Alixpartners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded plus interest and attorney fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_AgreedSettlementValue', window );">Agreed settlement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfTranches', window );">Number of tranches | traches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_WestervilleSquareMember', window );">Westerville Square</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_TrusteesMain270LlcMember', window );">Main/270</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jan_TrusteesMain270LlcMember', window );">Main/270 | Appliance Smart, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_AgreedSettlementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed Settlement Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_AgreedSettlementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Executive Officers Named In Complaint</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Installment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_OperatingLeasesFutureMinimumPaymentsDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Payments Due1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_OperatingLeasesFutureMinimumPaymentsDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitments, Number Of Landlords Company Is No Longer Liable For</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitments, Number Of Landlords Originally Purported To Be Liable For</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_PercentOfPrepaymentTenderRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent Of Prepayment Tender Restrictions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_PercentOfPrepaymentTenderRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_StatutoryInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory Interest, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_StatutoryInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_GeoTraqIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jan_ApplianceSmartIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jan_ApplianceSmartIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_SkyBridgeAmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_SkyBridgeAmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_AMTIMCapitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_AMTIMCapitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_Mr.SullivanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_Mr.SullivanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_AlixpartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_AlixpartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_WestervilleSquareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_WestervilleSquareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_TrusteesMain270LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_TrusteesMain270LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368803120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract', window );"><strong>Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net (loss) income from continuing operations, basic</a></td>
<td class="num">$ (17,095)<span></span>
</td>
<td class="nump">$ 8,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted', window );">Net (loss) income from continuing operations, diluted</a></td>
<td class="num">$ (17,095)<span></span>
</td>
<td class="nump">$ 8,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">4,005,334<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">4,444,361<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (loss) income per share from continuing operations, basic (in usd per share)</a></td>
<td class="num">$ (4.27)<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (loss) per share from continuing operations (in usd per share)</a></td>
<td class="num">$ (4.27)<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic', window );">Net income from discontinued operations, basic</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 2,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">4,005,334<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic income per share from discontinued operations, basic (in usd per share)</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted', window );">Net income from discontinued operations, diluted</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 2,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">4,444,361<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted income per share from discontinued operations (in usd per share)</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income, basic</a></td>
<td class="num">$ (7,812)<span></span>
</td>
<td class="nump">$ 10,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">4,005,334<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income per share (in usd per share)</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income, diluted</a></td>
<td class="num">$ (7,812)<span></span>
</td>
<td class="nump">$ 10,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">4,444,361<span></span>
</td>
<td class="nump">3,150,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income per share (in usd per share)</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178280910192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from earnings per share calculation (in shares)</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178282020864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178368623648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Operating income</a></td>
<td class="num">(19,846)<span></span>
</td>
<td class="num">(3,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Net income after provision for income taxes</a></td>
<td class="num">(7,812)<span></span>
</td>
<td class="nump">10,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">39,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Operating income</a></td>
<td class="nump">10,438<span></span>
</td>
<td class="nump">8,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Net income after provision for income taxes</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember', window );">Continuing and discontinued operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">39,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Operating income</a></td>
<td class="num">(9,408)<span></span>
</td>
<td class="nump">5,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="num">(489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Net income after provision for income taxes</a></td>
<td class="num">(7,812)<span></span>
</td>
<td class="nump">10,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember', window );">Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Operating income</a></td>
<td class="num">(19,846)<span></span>
</td>
<td class="num">(3,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Net income after provision for income taxes</a></td>
<td class="num">$ (17,095)<span></span>
</td>
<td class="nump">$ 8,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=jan_ContinuingOperationsAndDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178369144816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Schedule of Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 18,487<span></span>
</td>
<td class="nump">$ 46,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total Intangible Assets</a></td>
<td class="nump">17,846<span></span>
</td>
<td class="nump">20,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total Intangible Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember', window );">Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,487<span></span>
</td>
<td class="nump">29,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total Intangible Assets</a></td>
<td class="nump">$ 17,846<span></span>
</td>
<td class="nump">$ 19,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jan_BiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178283745744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>USD ($) </div>
<div>d </div>
<div>insurance_policy </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>USD ($) </div>
<div>agreements </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Due | Soin Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payment tendered</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant excise and granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant offering and exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Soin Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payment tendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Soin Therapeutics LLC | Series S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business acquisition, shares issued, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | ICG Note | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt convertible period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Isaac Consulting Agreement | Related Party | Mr. Jon Isaac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementTerm', window );">Term of consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned', window );">Universal life insurance policies assigned | insurance_policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds', window );">Contingently tendered funds in counsel's trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementSharesIssued', window );">Restricted shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfTradingDaysBeforeBoardApproval', window );">Number of trading days prior to court approval | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm', window );">Term of promissory note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate', window );">Stated interest rate on promissory note (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice', window );">Per share value of the restricted shares issued (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 1st policy | Isaac Consulting Agreement | Related Party | Mr. Jon Isaac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueOfLifeInsurance', window );">Accumulated value / surrender value of life insurance policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2nd policy | Isaac Consulting Agreement | Related Party | Mr. Jon Isaac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueOfLifeInsurance', window );">Accumulated value / surrender value of life insurance policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Equity Unit Purchase Agreements | ICG Note | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant offering and exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_NumberOfAgreementsToBePurchased', window );">Unaffiliated third-part investors | agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregated consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit', window );">Number of common shares in each unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit', window );">Number of warrants in each unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jan_ClassOfWarrantPricePerShare', window );">Warrant price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_ClassOfWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_ClassOfWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfAgreementsToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Agreements To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfAgreementsToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_NumberOfTradingDaysBeforeBoardApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Trading Days Before Board Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_NumberOfTradingDaysBeforeBoardApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Contingently Tendered Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Convertible Debt, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Convertible Debt, Face Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Convertible Debt, Stated Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Convertible Debt, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Number Of Life Insurance Policies Assigned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_RelatedPartyTransactionConsultingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_RelatedPartyTransactionConsultingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Unit Composition, Number Of Common Shares In Each Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Unit Composition, Number Of Warrants Issued In Each unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jan_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueOfLifeInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueOfLifeInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jan_SoinTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jan_SeriesSConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=jan_IcgNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=jan_IsaacConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=jan_IsaacConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jan_Mr.JonIsaacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jan_Mr.JonIsaacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jan_UniversalLifeInsurancePolicyPolicyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jan_UniversalLifeInsurancePolicyPolicyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jan_UniversalLifeInsurancePolicyPolicyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jan_UniversalLifeInsurancePolicyPolicyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>125
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLYD7)G_1+CVV8S60'86"^?MB>0:^&Z2OY&4/XJC ,DL*\+X ORDPVR4%UK[
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M&TH<RN,#Y.<KQL1A(_Z"K'5\^!]02P,$%     @ G8*(6'LQUD(V @  J@4
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M!B'-A0#\/L\ROKD1+ZC_&6'X'U!+ P04    " "=@HA8K=IG@B8'   ,-0
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M)LG4,$8YE[\FLET^&,UGT?SK=#R\G8Q!="O_?)O,;B,POP*C8?0%7'V=?X]
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M0]:K/VBN<X&@\9:[IP0V5:-.7;1IU,'0(;MB*O1#=;0B<M8JR,B:E'*N@5.
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MQ+]SZ;47=B&NG/+*!$FN>WT4((G6'V7IU/-XZO214R=3\=Z:L/+B1Y.KO'_
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M(=@U?UPIE%%'"_!^85%;TA<2T/Q:>_8O4$L#!!0    ( )V"B%@X*!WF>Q4
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M^EMV3#@A<.02*9LF[]9TULAQ'[-(GUZV /JEX![/\M9SPJB9$\)S"M3NNW%
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M>RH5<U=;QGS#9!#146X]J5J7P=&#K6G&IG6*E/%J29!'>4,<!)BS"O$+ZW4
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MRD9P\L$]%=9ZZB<&T%EW_P7=P=ER9XJ8[E,NCBZINS.,T*OHVS==<_=@/N2
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M^'(M[HI%%@:A3$.5_?@BQQFT\L72[/=&[^<=V<_UQ#^2.-]DXB8.5-#<X 6
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M?@W3B!9?#L3?DDV<$=9)D8JK3:A6XFT82[R"-SZN5N%2I7JCS+#P#\&(2$3
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M?B-;?\3P<1N3D#]>";!FI5D<-+#Q_J; DB > T*GU">G(I>,ZY!#BF?CJJP
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M5AP>C*_NB0,X>9^DUOZ\)[%*NSH++137-/JO@W:[:VT*QW:=N)RITV,#KCY
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MN"]6:U]WP0374#2@RI6AS3-%%1;?*!_H:2(R!NX/&T#N2^)J**D3['OE8K9
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M3\<1,\U%HGEPN@J']T([7 7"LL#=BXS?@.]+#9[M@W?0W>;F_P)02P,$%
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M$#2Z'%P%H)M5T2A6U7X\5\K2L'NQI.V*VCG0>:&H\ZWB G3[.OT-4$L#!!0
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M3>"XK.F3!QT+T'UEZ:7=;-A _Q$U_P]02P,$%     @ G8*(6,;G?UD_#
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M5)7)^>-<22A$#^#^U" FPA=BT/[F^/(_4$L#!!0    ( )V"B%AN<$V,-@D
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M$1DKK8P!$Y4)D>^9(FBRTZO#V&&";W#TJT2I@-/9R00NHS@ R$%) 'AY#41
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M]%/\_4:$RLI_=G !>@LW'!SQT6@\]ZU7TR:U'?8CR>L,V:8A]L$3VSFD]>Q
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M4W</IR/TFO80/)Y?%HBS\KEO,J'U!GF^%CIO&P^B /6E&0E\/7A>MU>U7E4
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M<Y+_8ZN5^X0SJZRMENYQ(07TXPU8GU<X^#=_6,#NF][E_P%02P,$%     @
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M2  ,]24T$AYH03L"D%X0 JEK8SB0=0,3HF*1%@EYZ(DPX<S.^PT[-+09]>P
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M-0KS#FK90B5'H.*$?)+"E)I\$ 44^P A\MJ12WIRR^0DX@WD 4DCGR11DI[
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M&N#_:XE#M%O8 +N;^.(?4$L#!!0    ( )V"B%B!'Z<6908  $T/   9
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MK<^B5;9@LRQ:)@G[I*G+#JA'W>Q1/_^=H6"A'K;2_0^;QTFV.F$K0&:=R4?
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MSPF'+L3OTCD)7>]:E\$02EPOG.*MXM:('Z5I 5%B.N,8/!FQ$9+AL$B1Y-I
M./D:J;5NEEB1*==(DMSX1C<MP1&$U6:ED-\N&247=:208P^854"M^\9F#SWI
MQ M/KML%C 0_AS09D6E@%A/ACEG[-EN*3Y'/M]^<SZ;?7?J.#;G3+R69E1W;
M:=BMS((0GH08<_ D 1 $ZE&Y3'LY+Q$?SE:B 5J3O_@7]4*0[1<PQ@)>(1;G
MWW\_.CXY_Q^8)@O6RAWRKL15B=KIC*GN3\;?G9Y-QV0EWY)P) ,(4U!V7%[V
MTJ9S26SO]<)XR(X5.5'K+#:D]$S#7J+9Z60TF0# <+%>:CAA'U62;HDUHK&6
M&B[F/!$4V5UJ@0%(>QDKELGYGE-476G1_ND6$:SZ+"&;. V!.H:WGT4!T4@1
M/:"_J7=06N7IYBO!1U%O0H*MR1.MD04!!"<C\,$ADJ5KGL;B7BG!:#0]PX5%
MA%[#XCGGQL>B4%R2.]DHSYYEVPA;4!5Y\QN*D=GD\H,+U/AR>GD04(B7($:=
MK!5R+//BIY]N\ @>L&7Y=&C7)N*<SC7Q@\DM0B8BD-I*00[IQ&DKY^&;3H\W
M)&P4;%/%)%Z*1S**5CX&^@ F2/J[DFQ:B,_*+53$!')S@#C)<8RZJ*HYGL[.
MV5*S'<P3T<1\+'ZG&$"O _E-II(PFZM'0P$WEW2*IG2(""_VC\<3M"1E28&&
MF%L!Y32! <48FL<@7*$=4"I%]Q(DD&)ZH0D!PR;N[^(>CV#*6?UM"0]BC9B3
MF$\,.A"S\P^!G_304_:XGPH85:P!JV>H=Z\<:7V/D.N5N&.+D<M#%CRS=+>@
M=S-9ABH3@WQ,);K64$ER/KZD';Q$>$5/X[Y@M_UIA V.-WH4;<O*PA#LF2U#
M!$2@3+ID4EY!B/RK22!E2F^)$&V6E6T-.S#),B+PSUM%X/-C6Z)*CB*S!%@!
M [Z>WW-6L_%Y"JTANRX!CJ<)[SZTCI"1PY?XF>PI^34)P(R3%*@DVN:CWF##
ML,;S$&7&-BFD!5>%@J.HCYO-$!B+ZP+X$$!DM>7)9'Z3?X5A_*9EMD+7T8SA
MN?+LI/QJ9JUASUA+-M*UC\EN>^WL2M/N/D<VPG50FDK&IQLB5N@L%OH/BHI)
M"/DD[+;%/A5DKMRRK8/!_K2Y0'#H3ERRTEST"J)O8=&*V50<2'ZI:\)T.,LW
MO6-W5!&(L]Q!KO5!Z!<"@[7/(#?&3C8']+[Y*Y[;2GMO481NYZ5>!$NA\?Q!
MS1W7PN]V-9[)$M0!8\!&MVMR"O[D!:ZZY+Q$W';$N7,NY KB0$B2@30:WON)
M2O%OL"GWV53E\KR/$Y3W0#K%!18HF2U#5]BW9X/ "^T0&8 6#F0943F+NHRX
MR'G54#^$3NX,B8T2_6^T!L2"5904!(.1@$B^T0>Q0\SU"OAJ<L\:^1J"^A&>
MTX)^IHF98]%T$%[XX%&LPC)H175#TI30.#WG!MV/A\-2UYS.+4D#<^485#)T
MU3X8);FEX/R1-=T$C&Y 41Q,GGMY'*HL2 P"@_NF/PR)K5EDX'M#^[G_"^8/
M@J 50J+Y;8C<VN?%&X]"+>=VI0Z"(=" -IJA06/6JDG)#JZ9 ?,#7.T?IS(1
M>G?3Y1<9F>%A.OD+A0R>F;;:[-LW6JL88TP:O;2!^ "K@*NV]3QZHK6309].
MLN!;F66N#98)W'DJW:PG]ZIN0D&)QNW#-?!,.#>7)27Q,V5?KDO7S<[AQM9]
MZ]UG1,3@#=)#B)9<71AH].-A1:<M9#Q-J<9=/:M64 [)UY(Q3$O_ASD6$BH6
M5 1JF[Q!UR%B=^;5KXC:'2.?WT@L&I[_(+->I!,&K+5]=1PZ#,"<!GX8IAZ$
M?!@0V?=I5-\U>IY,SD?3LV.0UZ%2H5"B]^&&/8S?PZ$I1 ([G3*-Y8^S\C%F
MQ>>S:V+3!TK,8][?G56\,O2>A?5C\9%488[<_,;"2ND;PK*?^\7+@S^%#FU9
M]T-G)R,)D.<ZGJ-T1)^?5E JL"!!2F25+$N;I9&J 'C8M;\(2<&*[B3&PF#-
M=';*B^(@O'DB0L=I,DPXAT]*.CY^X)W<-&!NT56E<@H+],R#PY-HL!=.5E)9
M[*7;2!J&-TI,[D7" 052)4/T#,)B(WQ#<E,0T8$Y]0^9K'4#2QK:A0[%2YG1
M,.3;LJ'G&V=C8;KH1G7T6%LU"-D0#+"3PG".VK6@FZ8XLWZ$"UB<72F3^K%8
M@&,[MC&H*;>"XWTB>A$QC0K10F>#DT.9TT(:1;*RY:9JX>R:CM#B8H6L37:*
M011:&3,\@*1"X]JLX:'D,B*D+%4 SGGKM5$>94.M5&GKT$H_XYPZ9IE]:=%M
M-7%H-6HMLE(S[! UNH;J.=CUA[5&-=&KHS#S.W0A0<I*N@?%QE8%6$20MZTC
M*KZ.AS&)XF4$;FT.<U1).D'PBEW?T^+@PY"VX(,%RA90H3$ #_*6<)ZLY@.&
M#X5 "TU!2SQ6!P/S5397I=^RJ422/P%&N%:U=0W1!R[,P9$JW&$E'X+-09$.
MLZBLD5V396!():A[I=(5)\[:*4"S?&[A4,2BUW0>3 73U-:';HF*)\F_@HG6
M2CT@I=N:SFH0)&49ZT(%T1<JM3(2AC*":[%%M/N BER&8?C :V'A+B8+NLHL
M206:1LTAH+2@&LQ-6 5&3G=+L;8++:?]PY!QM-AEK,6/!_%DW,?4Z-.)AJ<P
MY53RB?"*BU"<I"*$86JRQ%C_A_-=K*D (:)T 218JI@/0$*"$BS)^^F\@P7"
MQ;'X[!+0Z#A"!1]0/-XLM2K$QT<4.([)6]333+D1M&P&A3:W$)^F1YZYI> 7
M"M2'J#!K\7#'CFB!:M=<8&IE_-9<&@VQ,3U:!HIP)MI-C:CR;>RY2E'J@IIB
MWSIN16I;ZHS/SLA<82!+YVB\-%; 6/L*RQV?3QH;NSY$9Q3"JT1ES9Y )'O*
M^+5+Y]S!B1HS#"]QJ!QF65NU80JD5SKJR+,QJ*OD:V+$3=2CKD(%VC\>G9^>
M=!UN'+O_!+V3L_.#"'D@16$!9^!!FNV#%8N6JA5"AQV-.$5%I/.(UGA5=JT
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M6]M;39AQ8YNC]%%N"D4XX$:772O $.-QU!Q91_??.H+*KI6K)-]S/U(%X"U
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M6PK[J-;?<9//I>/+E##^"^O6]S()(%L:J^H-F!347+9_]K*YAQW =?0)(-D
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M)J(EP]P+%*ME'9I1'-!_C(+2@:K:U(JJ6>%9<>P2)?U!.&U2(  %N2!&)HA
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MLP62IB<I[K7Z[>Y>>@^.779XT*H%ZI4?2(8.MI2VZMIZMYYYDZK5W]RK@?G
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MRE(G\\.</AVHG0'M+Y6R^XD+T'R,IK\!4$L#!!0    ( )V"B%AF$=JH=P(
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MP4T NAD.S<*JR@MRI2S)VYL%S5/4+H#V<Z7L;N$*M!,Z^0-02P,$%     @
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MBS1'KE+!0>)RXLR"T65L[ML+]REN5.<;3"1S(7Z8S<UBXOC&(<PPT0:!T?*
M5YAE!HC<^%EC.JU)H]C];M!_L[%3+'.F\$IDW].%7D^<<P<6N&1EIK^*S1]8
MQQ,9O$1DRO["IK[K.Y"42HN\5B8/\I17*WNLW^$M"F&M$%J_*T/6RX],L^E8
MB@U(<YO0S(<-U6J3<RDW2;G3DDY3TM/3.RV2'VN1+5"J]^_.PV!X =<_RU0_
MP<DW-L]0G8X]38;,=2^I02\KT/  :!#")\'U6L$U7^!B%\ C#ULWP\;-R_ H
MXD=,7.C[9Q#Z8?\(7K\-NV_Q^F\(^Y<FX,]"(_P]FRLMB2S_[(N[0AWL1S4%
M-%(%2W#B4(4HE _H3-^_"V+_XHC/@];GP3'TZ5U5-R"68-V'+X4AMH*9838%
ML,_AXY#?U@A+D5%EIGP%VN2[+L_T7U2@K!E1;.O'/!-U M!&,54)R^ )F52
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MI7A6;"8$QT3H"^#\EL.-J7;T /7RW>(_4$L#!!0    ( )V"B%@7W0>3H 4
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M'8?2*(IFBV;L>!3N8,44ZM.AM!1*HRB:K4YO.=OK--TI;IW5"%LH+L@LK[2
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M[7[1H>H;!2@IM9%9-1@49#P__=/G*A%G R!0_P!2#7")"$]$3N4#-70^5?*
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M&QZ289>&LQ/FSQC<^4G;RTY:YRE,</3?JH=G=P5[[X)S\9;#P5*P#8R+KL<
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M#'X -[Y/5"A0 &ZC;$*IP+QQL4 DX&]EDX^/+GCS[=OY4,B>E?W0RWM99;W
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MI:1* I+%X)J1'4N88E2"EY=4$9;(5SK6Q^TE>/GB%7AARG\X\I/4I>724YK
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M&869GBX WR\%Q,?EB:Z@VC$W_1]02P,$%     @ G8*(6*0\.![P @  60D
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M#PAM@,\WG*N'C1[']==4\!M02P,$%     @ G8*(6#NYL<*1 P  9 T  !D
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M>J3O!=_1*F.&!S&#=E:#FM6@DU6C<.1KX7PC\X?%O*C'9;[2+&94V2WZC3Q
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MC+T?I G ]QN!7JN):4?UOXG@#U!+ P04    " "=@HA8^H6N>&8%  !9&0
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M+:!^7S$F#S?Z >6_*?/_ %!+ P04    " "=@HA8LNSD#.D'  "_)P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R]6FUOVS@2_BN$;W%H@:867^27
M7&+ M=VN@5TG%Z>]S[1$V\+*HDO*27/8'W^DI)BV1#).ZQQ0-+(\'#WDD/,\
M,];5(Q=_R35C.?BQ23-YW5KG^?:RW9;1FFVH_,BW+%/?++G8T%Q]%*NVW I&
MXV+0)FVC(.BT-S3)6H.KXMZM&%SQ79XF&;L50.XV&RJ>/K&4/UZW8.OYQEVR
M6N?Z1GMPM:4K-F?YU^VM4)_:>R]QLF&93'@&!%M>MX;P<D2Z>D!A\2UAC_+@
M&NBI+#C_2W^8QM>M0"-B*8MR[8*J/P]LQ-)4>U(XOE=.6_MGZH&'U\_>/Q>3
M5Y-94,E&//U/$N?KZU:O!6*VI+LTO^./O[-J0J'V%_%4%O^#Q\HV:(%H)W.^
MJ08K!)LD*__2']5"' R '<< 5 U ]0'$,0!7 W QT1)9,:TQS>G@2O!'(+2U
M\J8OBK4I1JO9))D.XSP7ZMM$C<L'XT1&/,N3;,=B<+-E@NK5E> "S-6.B7<I
M WP)7%9)!O(U R-US=,DIKGZ>IZK/RK0N=0C1U2NP6>U621X-V8Y35+Y7CG_
M.A^#=[^]![]I%_=KOI,TB^55.U=3TL#:407_4PD?.>!#!/Y4P-823+*8Q<<.
MVFHM]@N"GA?D$_)Z'+/H(\#!!X "A"V 1J<,A\5PY(&#]_'!A3_L\C>=CVYF
M]]/9U\D8W-Q.[H;J^@L8CNZGWZ;WT\G\TK9HI4]B]ZDSPZ7<THA=M]31ETP\
ML-;@G_^ G>!?M@F?R=G1],E^^L3G?3!3B2S)(KYA8"GX!L2'&Y'O-Z)M#4K'
M8>%8)[.'01_U5$0?#N?6-$+]+MH;'6$.]YA#+^8Q4PL1);1,4UD,Z(:+//EO
M<<.&M'37.0 !28AJ2)M&#IB=/<R.=V>-UC1;L>(,4RF9.JX::YK019(F><*D
M=6=USKFSSN3L:/K=_?2[WB@-HXCO=))2L6+) UVDS#;?;F/9+W"G6XN-Q2B$
M/6*/3V\/L.<%>*,RJZA"8T/6:SRT5X/5M( 8]>RH^GM4_1</9*1S^E;PAT2E
M7+!X N]V4ETDV?OG(YFM2GXN]M&K3VZ_N=4Q[-<FUS2Z0&$ [;.#@:'#X/1\
M.YU]F\Q/R;>5TS,=BW-Y.UZ" T4 3PMQ%57U[X')7PUJ]="C@,$PK$75;A7T
M'6%%9D[H]+!^GLZ&L]$I845G#>N9O!TO@1$2T$O4@UOZ5*FR#&0\5R'<TB=7
MVJM\'9W!+JD'JVD$'4D/&L*'+S/^T>Y[=Y!IWH-EDM$L^M6]2"S) \$ZY5K,
M<+^/'3,T\@#Z]<%DN50UC!;'D:%@]J/\ !1LID-4K(%FY.*"?=\ICDIU_*P3
MLDB(.DE9;"Y<T3(: GHY>C">C.XFP_E$I4HP&LY_!\/9N+R8_/OK]-OPC\GL
M?FY%W+$<=!C4,5NLPKXKR1OJAW[N=R+] !9LE629WE\J/FH3)3RVPF]2/H2-
M9-8TZ@:A [R1!="O"YS@P<UG4"4YG=NJ8N%FIF;%U#[RS\?[S%=G.HOR@*Z)
M&^4!_=)C;#_@X&\PO!L-P5#-<;Y;R"1.J-!9X6]PQZ*G*-7!G+.53G[%@;IG
MT3KC*5\]/=^VKH@7S*M7Y$S>CDM:HVK0*U3-R54D.JNJ.9>WXR4PJ@:]K&I^
MLI)$35%B*24M5NY:$AGE@KRRX/759.7O"&VGCK5I$X:. XJ,PD!^A3$\0*;3
M3<P6:LVEW"G&9B#BTDY>R"(C8!UPTP8[:  9J8'\4N,/+@LUI,O=58E:%5MY
MREPY 34%09VQ+"8P<.E79#0#\FN&^M(*W9V\X,L+I9(\-2)J<GZCL6"S<6T%
MHPN07Q=\H4K3Z/6D90-19^@/(&.E[%&*QHK6I@D0(O6ZUF(7.  ;28#\DJ .
M^ OC]X)^M\)LTGIC%U@Z GWBJKV1X7[4>X.>#3HKN9_+V_$2&!6 _"K@Q+X-
MLC01^KBQ]YM6D/0<.1L;NL5>+AM,5<&<Y5RK$&MW-K!@J_<W+$9=[-A V+ @
M]K/@K6!;FL2JW-BR3+)R__"BTQ3MA"@DDC.;X";#A75FL=GT'"43-B2(_22X
M#WI5LI9$&$5"D_?S7*R0FT0'>[A>&EFL+DCH*([P0>O>SX<O=?"PA?CJR)HF
M%\0%S! ?/K'&?L,F'FX2H:6+9['RM/&PX4L<OD$;#WM)^-6_FYS)V_$2& K&
M?@J^W8EH3?49UY6?T-'*GXJ#HYL)6Y?&P582KHM=FU4O<*4GP\+8S\+/F#7D
M),L5V27%:7<?(5M_OI[E;49=YQXS9(S]A?C;]$EQLW:V]$GM5BZ=B0V[XOX;
M]$GQ66OE<WD[_L'1D#?QD_>MX!%C<14YW2GU-4I)DZ9#V*GO0(L5[(;$(;.)
MH7/R IT?]'0%2XO?W[=4GW.-VXK7TF#'=8%M,SJ<U#%:P^+$S^*OZD"3)B=W
M,:[+#8L5Q+CO* >(H6[BI^[_1Q>:6+C=TH6VF+F[T.3@AW6_!GB#+C2QD'D]
M<=EL''J&&+8G+_SB_K-=:&+IB8>-=P0L1LC!'L30,_'3\Z_WH$F3@YO8FS9=
MUW(;EB8_V3[_E0YT]<S#5S'J5;7%)*R?@_;!JU ;)E;%&V(2%.5#^1+0_N[^
M+;1A\>Y5[?XG>#DJWR4S;LI7V_ZD0L5'@I0ME<O@8U<!$N7;8N6'G&^+%ZX6
M/,_YIKA<,QHSH0W4]TNNDE_U03]@_\[>X']02P,$%     @ G8*(6"!)U".$
M @  >P8  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULK55=;YLP%/TK
M5ZR:6BDK!/*Q=0E2FVC:'J9%_=@>ICTX<!.L&LQLDW3[];LV!-&45GW8"]CF
MGG///;8OL[U4]SI#-/"0BT+/O<R8\L+W=9)ASO2Y++&@+QNI<F9HJK:^+A6R
MU(%RX8=!,/%SQ@LOGKFUE8IGLC*"%[A2H*L\9^K/%0JYGWM#[[!PS;>9L0M^
M/"O9%F_0W)4K13._94EYCH7FL@"%F[EW.;Q8C&V\"_C.<:\[8["5K*6\MY,O
MZ=P+K" 4F!C+P.BUPP4*88E(QN^&TVM36F!W?&#_Y&JG6M9,XT**'SPUV=Q[
M[T&*&U8)<RWWG[&IQPE,I-#N"?LZ=CKU(*FTD7D#)@4Y+^HW>VA\Z "&HV<
M80,(7PN(&D#D"JV5N;*6S+!XIN0>E(TF-CMPWC@T5<,+NXLW1M%73C@3KQ26
MC*<:6)'"-Y.A@D6E%!8&+K5&H^%TB89QH<_@'=S=+.'TY Q.@!=PF\E*$TS/
M?$-*+)^?-%FOZJSA,UF7F)Q#% P@#,*H![YX#7SHX.%CN$_UMR:$K0FAXXN>
MY=L@U9S"0FJC![!@)3=,\+^8#J!Q:-!QJ'%FR74BI*X4PL_+M3:*SN2O/C/J
M[*/^[/:>7NB2)3CWZ")J5#OTXK=OAI/@8Y\U_XGLD5%1:U3T$OOAM-#N4]6L
M2+"OVIIB["AL$]G%M,6[;@D]$9-1&_-(V:A5-GJ5,FDWJ$]5#9]T<D[#(UE/
M0Z*@7]6X535^4=6MI&,$9?>..8%TL^L[QMQ)ZM,[?N+1='RD]VE(].'81K_3
M&FQ;_LK4EG8/!&X(%9Q/":[J5E=/C"Q=MUA+0[W'#3/Z.Z"R ?1](Z4Y3&P#
M:O\W\3]02P,$%     @ G8*(6 ^5]6E^"   'E   !D   !X;"]W;W)K<VAE
M971S+W-H965T-C8N>&ULO9QK;Z-(%H;_2LF[6G5+O;$!WY)-+"7AUJOIF2CI
MF=5JM1\JN&RC!LI=A9.)M#]^"TR,,44E:-[I_M Q-N<Y97A=E_< E\]<?),;
MQG+R>YID\FJPR?/MQ7 HHPU+J3SC6Y:I3U9<I#17FV(]E%O!Z+(,2I.A/1I-
MARF-L\'BLGSO3BPN^2Y/XHS="2)W:4K%RPU+^//5P!J\OG$?KS=Y\<9P<;FE
M:_; \E^W=T)M#0^499RR3,8\(X*MK@;7UD7H.$5 N<=O,7N61Z])\54>.?]6
M;'Q>7@U&18M8PJ*\0%#UYXG=LB0I2*H=WROHX)"S"#Q^_4KWRR^OOLPCE>R6
M)_^*E_GF:C ?D"5;T5V2W_/GD%5?:%+P(I[(\G_RO-]WJC)&.YGSM I6VVF<
M[?_2WZL#<11@C3L"["K /@UP.@*<*L Y#9AT!(RK@/%[FS2I B;OS3"M J:G
M =..@%D5,'MOD^95P+P\N_O349Y+E^9T<2GX,Q'%WHI6O"@%44:K4QAGA78?
M<J$^C55<OOB9YTR2>Q:Q^(D^)HQ\<%E.XT1^)'\GOSZXY,-?/Q*YH4+M%6?D
MZX;O),V6\G*8J^P%8QA5F=Q])KLCDT.^\"S?2.)E2[;4Q/OF^.E;\8$YWK(-
M@*$Z;(=C9[\>NQO;2/Q"Q1D9G7\B]LAV- VZ?2O\A=CC,MK6'4YSM,NB,^*,
M.I-[YO!_[A+5=KLSN__'PH,_UOCP/>&6+GOC1#J''X%3\IP.WG44\5V6RT^D
M_#E\(C]QFDFB=$[\.*-9%&?KX]_(?WY2 /(Y9ZG\KZ;U-_ML8WVV8C2ZD%L:
ML:N!&FXD$T]LL/C;7ZSIZ!\Z$2%A+A+F(6$^$A8@82$(UE#F^*#,L8F^<&-9
M2I-$J@M>,UVW>V,D]%4;$N8B8=X>-BEAQ8SL:6'-)R/U[W+X="RD=^X7(!L7
M@F -C4P.&ID8-7*]7,;%/) FA*9'8B%T3;-8YFK<CGC*=-(Q@OM*!PESD3 /
M"?.1L  )"R<MY<\MYUCX#7E-#_*:&N7U.=W26*CERD%7@B4T9TN2<Y*I\5)M
MOXZ,.HT9Z7TUAH2Y2)B'A/E(6#!MR>)\-F]WB.%^O^G1?AW*F1V4,S,JY^>F
M.-2"XN'NW_>?2,9RG5",L+Y"0<+<6>L(GAP[#YG.1\*"-]L>MO>8G\_&G?W&
M_'#VY\:S?TN%>"DFSD\TV3'"5V09RRV7Y5A%<J%FV+3T+W1:,*+[:@$)<^>M
M7\FDZ&-/?TT>,JF/A 5(6 B"-11V?E#8N5%A16]"OK)HD_&$KV,FR><L.M/)
MR<CI*R<DS$7"/"3,1\(")"P$P1J:LT:U83;ZH69!E0XD3BC-A=(\*,V'T@(H
M+431FA(]\G0M8\?XE8FT&'"STMPU3\_-J-[R,S=L0EX8%7KS&-D.#TKSH;0
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M7 -+0=D ?+^4TCS=V$-V_:=*\C]02P,$%     @ G8*(6.;(DS ; P  S@L
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M"&.@OZ><J]W$;%"V\.%O4$L#!!0    ( )V"B%A#(PG TP,   L0   9
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M;"]W;W)K<VAE971S+W-H965T-S N>&ULK5=M;]LV$/XKA!8,"=!%;[829[:
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M#KCZ,>-AJDE'-3F+2F_BW*RM32''= APTJ_<S>&J]F/&[I'"33O$Z4G$'[(
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M)44.=]8VM38F,KBF A5<<,%$RHWU>E[RG-D3T7 X16*\U$>&Y7XVA<.#(S@
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ML<LCLNJAOG=1'K]'?KGSR3MB[Y:W<MEOQFN_Y/4O=D</TB632NS*<?//%]T
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MB2A_T:%^UW=06 C)TCI8$:1Q5AWI4]T1K8 QZ0D@=0 IN:M")>4-E72]Y.R
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MTSW0"+A^03W?,B:?+W2!9D=S_0]02P,$%     @ G8*(6$_\H9BR @  [P<
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MZVG3K=X;N(,6P^O(EJ0OLSD[A8,W^KVG;%<= ;A?\ /%!6/E[];KA4-WW);
MC=#IR)+[95[A*:^P4^P+5@3"RM\=U['@Z\BWKOC@=  'G4=7] $_4%-4GF_>
M;3OB#:W>V.VW\=^(' W=:8O]WEF=5X#8F/)7DICO2E45/DUO4V+?F\+RJG^A
M2V]3/YYDJKK],Q4;/*P(@Q0E?7>,1XZH2N&JH?C65)//7&%M:FXS_/L 0@_
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MUW_M6,8E(I_:0A++IV<'FL2B(($Z2$ $/K-$[#CXD(0D/ >PY8J4RX).R[)
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MNTO'^V6)QCYKAN"@\1>CQ<P=>!V)@:JN ,$KW5"GVB)C/_'6U+@5VCG/JGU
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M)*N4J20UWIY&DLZB)\GK)'E:29\)BS+P^Q:745TF:1&3'*O$>=*M+V$8.-Y
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M\]9W(GV4TT<YEN5"QN:+Y7%S$OUQCS1)HBB.L1D=CYT.QMB\Q3'\N=4P;\#
M\D"FE\TUOMIXA>RO VQ-]U4(-E*\$K&1XG,-B'O>@)$D[M7&\@ #6P6L=B"_
M.P_4E)L31;"JF#?L"L:1),$0J$5WC<8Q,CLQ?-WK@UTE490D;@0PMX,HPA"X
M&G$$<P >,"2*S'-PYWD4K)]3P>;_U*._4$L#!!0    ( )V"B%B7BKL<P
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M/GA+A]-6M>;#C6+, MIM"K;2)(J)!.0S"Z@+\U::^NY\L5&EF$A /G<9U-G
M_!M1BHD$Y'/O%^ONLVZR>+H]$ DHX!;0WD9K$U&*B004<.])[FBTDD%$,9&
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M4$L! A0#%     @ G8*(6 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "=@HA8X/YR&NX    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" "=@HA8F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( )V"B%@(%:$8' <  $8N   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" "=@HA8>S'60C8"  "J!0  &               @(%?#P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ G8*(6.P.T%XB!P  S2(  !@
M             ("!RQ$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( )V"B%C8J)M55P,  (P.   8              " @2,9  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "=@HA8)W6!] D'  "8
M(   &               @(&P'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ G8*(6*W:9X(F!P  ##4  !@              ("![R,
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )V"B%C8I\1
M?P<  #L@   8              " @4LK  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " "=@HA8\^DD<78+  "Y'0  &
M@($ ,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ G8*(
M6#@H'>9[%0  =C\  !@              ("!K#X  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( )V"B%B8N:KRH0H  %8;   9
M      " @5U4  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ G8*(6"]2W'S,&@  #E8  !D              ("!-5\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "=@HA88VVB'\L:  #@50
M&0              @($X>@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( )V"B%C[J1:(RQH   !6   9              " @3J5  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ G8*(6- A;5",
M @  \04  !D              ("!/+   'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " "=@HA8H73^9>T)  !&&P  &0
M@('_L@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )V"
MB%BY&>.H@@0  -D)   9              " @2.]  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ G8*(6*.:&-\L!   >0H  !D
M         ("!W,$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " "=@HA8EL(%FF\"  "[!0  &0              @($_Q@  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )V"B%B^E'*#H@(  .8%
M   9              " @>7(  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ G8*(6!'-!Z5"!   4 D  !D              ("!OLL
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "=@HA8QN=_
M63\,  !N+   &0              @($WT   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( )V"B%@4X0R!2@P  '\L   9
M  " @:W<  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MG8*(6&YP38PV"0  YAL  !D              ("!+ND  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " "=@HA8E6.?J*$'  #?$P  &0
M            @(&;\@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( )V"B%BI+".&?0D  (8;   9              " @7/Z  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ G8*(6.XTM3IC%
M.3D  !D              ("!)P0! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " "=@HA8D1($1C4$  "5"P  &0              @('!
M& $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )V"B%B!
M'Z<6908  $T/   9              " @2T= 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ G8*(6!N46#X"#0  G"(  !D
M     ("!R2,! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )V"B%@"+Z/U^0D  & <   9              "
M@71< 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ G8*(
M6%;F%8F2 @  W 4  !D              ("!I&8! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " "=@HA8MF[!U\$"   5!@  &0
M        @(%M:0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( )V"B%C5UOR!W@(  )@&   9              " @65L 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ G8*(6&81VJAW @  K04
M !D              ("!>F\! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " "=@HA8)H\>TZH"  #>!0  &0              @($H<@$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )V"B%C'@S4S
M@ (  )(%   9              " @0EU 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ G8*(6-E&"+"U @  908  !D
M ("!P'<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "=
M@HA8%^W,J_X#   >"P  &0              @(&L>@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )V"B%@C(##BY04  +L/   9
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M970T-RYX;6Q02P$"% ,4    " "=@HA8DNECZ=X"  #)"@  &0
M    @('REP$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M )V"B%C_\R ;TP<  #=)   9              " @0>; 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ G8*(6%/Y?N,:"0  [U$  !D
M             ("!$:,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " "=@HA8!^SAR5$$  !<#@  &0              @(%BK $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )V"B%BI*^^<N 8
M )\O   9              " @>JP 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ G8*(6+,A1$#' @  UP8  !D              ("!
MV;<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "=@HA8
M:#]2$[0%  "['P  &0              @('7N@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( )V"B%A/9BKR^0,  ' 3   9
M      " @<+  0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ G8*(6/KZ'>_#!@  /3<  !D              ("!\L0! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "=@HA8I#PX'O "  !9"0
M&0              @('LRP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( )V"B%@[N;'"D0,  &0-   9              " @1// 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ G8*(6 SW[MK
M @  .P<  !D              ("!V](! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " "=@HA8@2(5-*,"   7!P  &0
M@('2U0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( )V"
MB%CA=%$%[P(  .$(   9              " @:S8 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ G8*(6,CV0,S> @  60@  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( )V"B%@TP@2*G@,  & 1   9
M  " @13X 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
MG8*(6.;(DS ; P  S@L  !D              ("!Z?L! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " "=@HA80R,)P-,#   +$   &0
M            @($[_P$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( )V"B%@/U\-#NP,  ,(/   9              " @44# @!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ G8*(6!0QCG1_ @
MXP<  !D              ("!-P<" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " "=@HA8#*!=T<D"   P"   &0              @('M
M"0( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( )V"B%C9
M%*'FF0(  .D'   9              " @>T, @!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ G8*(6-K2/H4\!   [1H  !D
M     ("!O0\" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )V"B%A?K_2]O00  .D7   9              "
M@9<N @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ G8*(
M6.Y[QJH8!   W10  !D              ("!BS," 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " "=@HA83_RAF+("  #O!P  &0
M        @(':-P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( )V"B%@Z\ZFQO0,  )<1   9              " @<,Z @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ G8*(6$A/<3?? @  /P@
M !D              ("!MSX" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " "=@HA8#A8-N;(#  "<#   &0              @('-00(
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( )V"B%@..B72
MN@(  !@'   9              " @;9% @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ G8*(6#PNFUP(!   N X  !D
M ("!IT@" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " "=
M@HA8Y)LX=>0(  "87   &0              @('F3 ( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( )V"B%AF_["#61   (T, 0 9
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M970Y,BYX;6Q02P$"% ,4    " "=@HA8!M_HW1$#  !$#   &0
M    @('\=0( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M )V"B%CEMW\G<0T  &6Q   9              " @41Y @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ G8*(6!\'CQEE P  M!8   T
M             ( ![(8" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "=@HA8
MEXJ[',     3 @  "P              @ %\B@( 7W)E;',O+G)E;'-02P$"
M% ,4    " "=@HA8XQB?1YP&  "M/0  #P              @ %EBP( >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ G8*(6+;U/P:V @  43<  !H
M         ( !+I(" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ G8*(6+CD,TQ& @  C#4  !,              ( !')4" %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     &8 9@ !'   DY<"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>266</ContextCount>
  <ElementCount>526</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Background and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/BackgroundandBasisofPresentation</Role>
      <ShortName>Background and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Mergers and Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MergersandAcquisitions</Role>
      <ShortName>Mergers and Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Sale of Recycling Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries</Role>
      <ShortName>Sale of Recycling Subsidiaries</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - GeoTraq</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/GeoTraq</Role>
      <ShortName>GeoTraq</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Prepaids and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets</Role>
      <ShortName>Prepaids and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Notes Receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.live-ventures.com/role/NotesReceivable</Role>
      <ShortName>Notes Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Deposits and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DepositsandOtherAssets</Role>
      <ShortName>Deposits and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Short-term debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/Shorttermdebt</Role>
      <ShortName>Short-term debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Series A-1 Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock</Role>
      <ShortName>Series A-1 Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Series S Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock</Role>
      <ShortName>Series S Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings (Loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/EarningsLosspershare</Role>
      <ShortName>Earnings (Loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Sale of Recycling Subsidiaries (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables</Role>
      <ShortName>Sale of Recycling Subsidiaries (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - GeoTraq (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/GeoTraqTables</Role>
      <ShortName>GeoTraq (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/GeoTraq</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Prepaids and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaids and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/IntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/MarketableSecurities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Deposits and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DepositsandOtherAssetsTables</Role>
      <ShortName>Deposits and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/DepositsandOtherAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/AccruedLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Short-term debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/ShorttermdebtTables</Role>
      <ShortName>Short-term debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/Shorttermdebt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Series S Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables</Role>
      <ShortName>Series S Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Earnings (Loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/EarningsLosspershareTables</Role>
      <ShortName>Earnings (Loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/EarningsLosspershare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SegmentInformation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Background and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails</Role>
      <ShortName>Background and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/BackgroundandBasisofPresentation</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Summary of Significant Accounting Policies - Trade and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Trade and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Mergers and Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MergersandAcquisitionsDetails</Role>
      <ShortName>Mergers and Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/MergersandAcquisitions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Sale of Recycling Subsidiaries - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails</Role>
      <ShortName>Sale of Recycling Subsidiaries - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails</Role>
      <ShortName>Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - GeoTraq - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails</Role>
      <ShortName>GeoTraq - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails</Role>
      <ShortName>GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Discontinued Operations - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Discontinued Operations - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Discontinued Operations - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Discontinued Operations - Schedule of Short-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Short-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Discontinued Operations - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Discontinued Operations - Schedule of Related Party Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Related Party Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Prepaids and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaids and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Notes Receivable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.live-ventures.com/role/NotesReceivableDetails</Role>
      <ShortName>Notes Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/NotesReceivable</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Marketable Securities (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Deposits and Other Assets - Schedule of Deposits and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails</Role>
      <ShortName>Deposits and Other Assets - Schedule of Deposits and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails</Role>
      <ShortName>Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Short-term debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails</Role>
      <ShortName>Short-term debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Series A-1 Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails</Role>
      <ShortName>Series A-1 Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Series S Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Series S Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails</Role>
      <ShortName>Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Stockholders' Equity - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Income Taxes - Schedule of Benefit of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Benefit of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/RelatedParties</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/CommitmentsandContingencies</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/EarningsLosspershareTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Earnings (Loss) per share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails</Role>
      <ShortName>Earnings (Loss) per share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/EarningsLosspershareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Segment Information - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Segment Information - Schedule of Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="jan-20231230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.live-ventures.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.live-ventures.com/role/SubsequentEvents</ParentRole>
      <Position>94</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-K, CurrentFiscalYearEndDate value, --12-30, should match the Entity Registrant Fiscal Year End Date "12/31" on record within EDGAR. jan-20231230.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PreferredStockConvertibleConversionRatio -  jan-20231230.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="jan-20231230.htm">jan-20231230.htm</File>
    <File>jan-20231230.xsd</File>
    <File>jan-20231230_cal.xml</File>
    <File>jan-20231230_def.xml</File>
    <File>jan-20231230_lab.xml</File>
    <File>jan-20231230_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jan-20231230_g1.jpg</File>
    <File>jan-20231230_g10.jpg</File>
    <File>jan-20231230_g11.jpg</File>
    <File>jan-20231230_g12.jpg</File>
    <File>jan-20231230_g13.jpg</File>
    <File>jan-20231230_g14.jpg</File>
    <File>jan-20231230_g2.jpg</File>
    <File>jan-20231230_g3.jpg</File>
    <File>jan-20231230_g4.jpg</File>
    <File>jan-20231230_g5.jpg</File>
    <File>jan-20231230_g6.jpg</File>
    <File>jan-20231230_g7.jpg</File>
    <File>jan-20231230_g8.jpg</File>
    <File>jan-20231230_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="850">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>132
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "jan-20231230.htm": {
   "nsprefix": "jan",
   "nsuri": "http://www.live-ventures.com/20231230",
   "dts": {
    "inline": {
     "local": [
      "jan-20231230.htm"
     ]
    },
    "schema": {
     "local": [
      "jan-20231230.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "jan-20231230_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jan-20231230_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "jan-20231230_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jan-20231230_pre.xml"
     ]
    }
   },
   "keyStandard": 388,
   "keyCustom": 138,
   "axisStandard": 32,
   "axisCustom": 1,
   "memberStandard": 30,
   "memberCustom": 61,
   "hidden": {
    "total": 5,
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 266,
   "entityCount": 1,
   "segmentCount": 96,
   "elementCount": 780,
   "unitCount": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 850,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "report": {
    "R1": {
     "role": "http://www.live-ventures.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.live-ventures.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.live-ventures.com/role/BackgroundandBasisofPresentation",
     "longName": "0000008 - Disclosure - Background and Basis of Presentation",
     "shortName": "Background and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.live-ventures.com/role/MergersandAcquisitions",
     "longName": "0000010 - Disclosure - Mergers and Acquisitions",
     "shortName": "Mergers and Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries",
     "longName": "0000011 - Disclosure - Sale of Recycling Subsidiaries",
     "shortName": "Sale of Recycling Subsidiaries",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://www.live-ventures.com/role/GeoTraq",
     "longName": "0000012 - Disclosure - GeoTraq",
     "shortName": "GeoTraq",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperations",
     "longName": "0000013 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets",
     "longName": "0000014 - Disclosure - Prepaids and Other Current Assets",
     "shortName": "Prepaids and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.live-ventures.com/role/NotesReceivable",
     "longName": "0000015 - Disclosure - Notes Receivable",
     "shortName": "Notes Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.live-ventures.com/role/IntangibleAssets",
     "longName": "0000016 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.live-ventures.com/role/MarketableSecurities",
     "longName": "0000017 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.live-ventures.com/role/DepositsandOtherAssets",
     "longName": "0000018 - Disclosure - Deposits and Other Assets",
     "shortName": "Deposits and Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.live-ventures.com/role/AccruedLiabilities",
     "longName": "0000019 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.live-ventures.com/role/Shorttermdebt",
     "longName": "0000020 - Disclosure - Short-term debt",
     "shortName": "Short-term debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock",
     "longName": "0000021 - Disclosure - Series A-1 Convertible Preferred Stock",
     "shortName": "Series A-1 Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock",
     "longName": "0000022 - Disclosure - Series S Convertible Preferred Stock",
     "shortName": "Series S Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.live-ventures.com/role/StockholdersEquity",
     "longName": "0000023 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.live-ventures.com/role/IncomeTaxes",
     "longName": "0000024 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.live-ventures.com/role/RelatedParties",
     "longName": "0000025 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.live-ventures.com/role/CommitmentsandContingencies",
     "longName": "0000026 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.live-ventures.com/role/EarningsLosspershare",
     "longName": "0000027 - Disclosure - Earnings (Loss) per share",
     "shortName": "Earnings (Loss) per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.live-ventures.com/role/SegmentInformation",
     "longName": "0000028 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.live-ventures.com/role/SubsequentEvents",
     "longName": "0000029 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables",
     "longName": "9954473 - Disclosure - Sale of Recycling Subsidiaries (Tables)",
     "shortName": "Sale of Recycling Subsidiaries (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.live-ventures.com/role/GeoTraqTables",
     "longName": "9954474 - Disclosure - GeoTraq (Tables)",
     "shortName": "GeoTraq (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsTables",
     "longName": "9954475 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables",
     "longName": "9954476 - Disclosure - Prepaids and Other Current Assets (Tables)",
     "shortName": "Prepaids and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.live-ventures.com/role/IntangibleAssetsTables",
     "longName": "9954477 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.live-ventures.com/role/MarketableSecuritiesTables",
     "longName": "9954478 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.live-ventures.com/role/DepositsandOtherAssetsTables",
     "longName": "9954479 - Disclosure - Deposits and Other Assets (Tables)",
     "shortName": "Deposits and Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.live-ventures.com/role/AccruedLiabilitiesTables",
     "longName": "9954480 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.live-ventures.com/role/ShorttermdebtTables",
     "longName": "9954481 - Disclosure - Short-term debt (Tables)",
     "shortName": "Short-term debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables",
     "longName": "9954482 - Disclosure - Series S Convertible Preferred Stock (Tables)",
     "shortName": "Series S Convertible Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.live-ventures.com/role/StockholdersEquityTables",
     "longName": "9954483 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesTables",
     "longName": "9954484 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.live-ventures.com/role/EarningsLosspershareTables",
     "longName": "9954485 - Disclosure - Earnings (Loss) per share (Tables)",
     "shortName": "Earnings (Loss) per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.live-ventures.com/role/SegmentInformationTables",
     "longName": "9954486 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
     "longName": "9954487 - Disclosure - Background and Basis of Presentation (Details)",
     "shortName": "Background and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails",
     "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies - Trade and Other Receivables (Details)",
     "shortName": "Summary of Significant Accounting Policies - Trade and Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
     "longName": "9954490 - Disclosure - Mergers and Acquisitions (Details)",
     "shortName": "Mergers and Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "jan:FairValueOfStockIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
     "longName": "9954491 - Disclosure - Sale of Recycling Subsidiaries - Additional Information (Details)",
     "shortName": "Sale of Recycling Subsidiaries - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jan:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jan:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails",
     "longName": "9954492 - Disclosure - Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details)",
     "shortName": "Sale of Recycling Subsidiaries - Schedule of calculation of the gain on sale of ARCA and subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "jan:TotalGuaranteedConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "jan:TotalGuaranteedConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - GeoTraq - Additional Information (Details)",
     "shortName": "GeoTraq - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails",
     "longName": "9954494 - Disclosure - GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)",
     "shortName": "GeoTraq - Schedule of Gain on Sale of GeoTraq (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
     "longName": "9954495 - Disclosure - Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details)",
     "shortName": "Discontinued Operations - Schedule Discontinued Amount Included in Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
     "longName": "9954496 - Disclosure - Discontinued Operations - Schedule of Property and Equipment (Details)",
     "shortName": "Discontinued Operations - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "longName": "9954497 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
     "longName": "9954498 - Disclosure - Discontinued Operations - Schedule of Intangible Assets (Details)",
     "shortName": "Discontinued Operations - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
     "longName": "9954499 - Disclosure - Discontinued Operations - Schedule of Accrued Liabilities (Details)",
     "shortName": "Discontinued Operations - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
     "longName": "9954500 - Disclosure - Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details)",
     "shortName": "Discontinued Operations - Schedule of Accrual Relating to California Sales Tax Assessment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:SalesAndExciseTaxPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
     "longName": "9954501 - Disclosure - Discontinued Operations - Schedule of Short-term Debt (Details)",
     "shortName": "Discontinued Operations - Schedule of Short-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
     "longName": "9954502 - Disclosure - Discontinued Operations - Schedule of Long-term Debt (Details)",
     "shortName": "Discontinued Operations - Schedule of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
     "longName": "9954503 - Disclosure - Discontinued Operations - Schedule of Related Party Debt (Details)",
     "shortName": "Discontinued Operations - Schedule of Related Party Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
     "longName": "9954504 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details)",
     "shortName": "Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
     "longName": "9954505 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details)",
     "shortName": "Discontinued Operations - Schedule of Discontinued Operations in the Consolidated Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails",
     "longName": "9954506 - Disclosure - Prepaids and Other Current Assets (Details)",
     "shortName": "Prepaids and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.live-ventures.com/role/NotesReceivableDetails",
     "longName": "9954507 - Disclosure - Notes Receivable (Details)",
     "shortName": "Notes Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "jan:DiscountCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "jan:DiscountCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "jan:DiscountCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "jan:DiscountCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9954508 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
     "longName": "9954509 - Disclosure - Intangible Assets - Narrative (Details)",
     "shortName": "Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
     "longName": "9954510 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "longName": "9954511 - Disclosure - Marketable Securities (Additional Information) (Details)",
     "shortName": "Marketable Securities (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
     "longName": "9954512 - Disclosure - Deposits and Other Assets - Schedule of Deposits and Other Assets (Details)",
     "shortName": "Deposits and Other Assets - Schedule of Deposits and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "jan:DepositsAndOtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "jan:DepositsAndOtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails",
     "longName": "9954513 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "jan:AccruedGuaranteesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails",
     "longName": "9954514 - Disclosure - Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details)",
     "shortName": "Short-term debt - Summary of Long Term Debt and Other Financing Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
     "longName": "9954515 - Disclosure - Short-term debt - Additional Information (Details)",
     "shortName": "Short-term debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
     "longName": "9954516 - Disclosure - Series A-1 Convertible Preferred Stock (Details)",
     "shortName": "Series A-1 Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:PreferredStockConvertibleConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:PreferredStockConvertibleConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "9954517 - Disclosure - Series S Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Series S Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-167",
      "name": "jan:CommonStockSharesOutstandingPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "jan:PercentageOfGrossRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
     "longName": "9954518 - Disclosure - Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details)",
     "shortName": "Series S Convertible Preferred Stock - Summary of Series S Convertible Preferred Stock outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
     "longName": "9954519 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails",
     "longName": "9954520 - Disclosure - Stockholders' Equity - Summary of Stock Options Activity (Details)",
     "shortName": "Stockholders' Equity - Summary of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails",
     "longName": "9954521 - Disclosure - Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)",
     "shortName": "Stockholders' Equity - Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails",
     "longName": "9954522 - Disclosure - Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details)",
     "shortName": "Stockholders' Equity - Summary of Information About Non-vested Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954523 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails",
     "longName": "9954524 - Disclosure - Income Taxes - Schedule of Benefit of Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Benefit of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails",
     "longName": "9954525 - Disclosure - Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails",
     "longName": "9954526 - Disclosure - Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Loss Before Benefit of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails",
     "longName": "9954527 - Disclosure - Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Income Taxes - Summary of Components of Net Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.live-ventures.com/role/RelatedPartiesDetails",
     "longName": "9954528 - Disclosure - Related Parties (Details)",
     "shortName": "Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-213",
      "name": "jan:RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954529 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "jan:LossContingencyNumberOfExecutiveOfficersNamedInComplaint",
      "unitRef": "officer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "jan:LossContingencyNumberOfExecutiveOfficersNamedInComplaint",
      "unitRef": "officer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9954530 - Disclosure - Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Earnings (Loss) per share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails",
     "longName": "9954531 - Disclosure - Earnings (Loss) per share - Additional Information (Details)",
     "shortName": "Earnings (Loss) per share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9954532 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R92": {
     "role": "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails",
     "longName": "9954533 - Disclosure - Segment Information - Schedule of Segment Information (Details)",
     "shortName": "Segment Information - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-204",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
     "longName": "9954534 - Disclosure - Segment Information - Schedule of Balance Sheet Information (Details)",
     "shortName": "Segment Information - Schedule of Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-249",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.live-ventures.com/role/SubsequentEventsDetails",
     "longName": "9954535 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-258",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-258",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jan-20231230.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "jan_A2023PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "A2023PlanMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan",
        "label": "2023 Plan [Member]",
        "documentation": "2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "jan_AFCOCreditCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AFCOCreditCorpMember",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AFCO Finance",
        "label": "AFCO Credit Corp [Member]",
        "documentation": "AFCO credit corp."
       }
      }
     },
     "auth_ref": []
    },
    "jan_AFCOCreditCorporationFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AFCOCreditCorporationFinancingAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AFCO Credit Corporation Financing Agreement",
        "label": "AFCO Credit Corporation Financing Agreement [Member]",
        "documentation": "AFCO credit corporation financing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "jan_AMTIMCapitalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AMTIMCapitalIncMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AMTIM Capital Inc",
        "label": "A M T I M Capital Inc [Member]",
        "documentation": "AMTIM Capital, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ARCAAndSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ARCAAndSubsidiariesMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA And Subsidiaries",
        "label": "ARCA And Subsidiaries [Member]",
        "documentation": "ARCA And Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "jan_ARCARecyclingPurchasingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ARCARecyclingPurchasingAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA Purchasing Agreement",
        "label": "ARCA Recycling Purchasing Agreement [Member]",
        "documentation": "ARCA Purchasing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables, net",
        "verboseLabel": "Trade and other receivables, net",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities - other",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r777"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "jan_AccruedGuaranteesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AccruedGuaranteesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued guarantees",
        "label": "Accrued Guarantees Current",
        "documentation": "Accrued guarantees current."
       }
      }
     },
     "auth_ref": []
    },
    "jan_AccruedIncentiveAndRebateChecksCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AccruedIncentiveAndRebateChecksCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued incentive and rebate checks",
        "label": "Accrued Incentive And Rebate Checks Current",
        "documentation": "Accrued incentive and rebate checks current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued taxes",
        "terseLabel": "Accrued taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r222"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liability",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_AccruedRentCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRentCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued rent",
        "label": "Accrued Rent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r223"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r251",
      "r612"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r171",
      "r258",
      "r609",
      "r644",
      "r645"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Deficit",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r54",
      "r543",
      "r546",
      "r562",
      "r640",
      "r641",
      "r815",
      "r816",
      "r817",
      "r825",
      "r826",
      "r827"
     ]
    },
    "jan_AdditionalAmountChargedAgainstIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AdditionalAmountChargedAgainstIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional amount charge aganist income",
        "label": "Additional Amount Charged Against Income",
        "documentation": "Additional Amount Charged Against Income"
       }
      }
     },
     "auth_ref": []
    },
    "jan_AdditionalAwardsToBeGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AdditionalAwardsToBeGranted",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional awards to be granted after adoption of 2016 plan (in shares)",
        "label": "Additional Awards To Be Granted",
        "documentation": "Additional awards to be granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r660",
      "r825",
      "r826",
      "r827",
      "r890",
      "r912"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r82"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_AgreedPrepaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AgreedPrepaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreed prepayment amount",
        "label": "Agreed Prepayment Amount",
        "documentation": "Agreed prepayment amount."
       }
      }
     },
     "auth_ref": []
    },
    "jan_AgreedSettlementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AgreedSettlementValue",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreed settlement value",
        "label": "Agreed Settlement Value",
        "documentation": "Agreed Settlement Value"
       }
      }
     },
     "auth_ref": []
    },
    "jan_AlixpartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AlixpartnersLlcMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alixpartners, LLC",
        "label": "Alixpartners, LLC [Member]",
        "documentation": "Alixpartners, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r501"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r370",
      "r382"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r438",
      "r560",
      "r820"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r78",
      "r82"
     ]
    },
    "jan_AmortizationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AmortizationOfRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Amortization of right-of-use assets",
        "documentation": "Amortization of right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive shares excluded from earnings per share calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "jan_ApplianceSmartIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ApplianceSmartIncMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appliance Smart, Inc.",
        "label": "Appliance Smart Inc [Member]",
        "documentation": "ApplianceSmart, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ArcaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ArcaMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA",
        "label": "ARCA Member",
        "documentation": "ARCA Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "jan_ArticlesOfIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ArticlesOfIncorporationMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Articles of Incorporation",
        "label": "Articles Of Incorporation [Member]",
        "documentation": "Articles of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r83"
     ]
    },
    "jan_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Purchase Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "documentation": "Asset purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r284",
      "r332",
      "r353",
      "r359",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r535",
      "r540",
      "r551",
      "r603",
      "r694",
      "r777",
      "r791",
      "r849",
      "r850",
      "r896"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r260",
      "r284",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r535",
      "r540",
      "r551",
      "r777",
      "r849",
      "r850",
      "r896"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196",
      "r246",
      "r247"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets from discontinued operations",
        "totalLabel": "Total current assets from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r193",
      "r196",
      "r246",
      "r247"
     ]
    },
    "jan_AuditorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "AuditorAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Abstract]",
        "documentation": "Auditor"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.live-ventures.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.live-ventures.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.live-ventures.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ]
    },
    "us-gaap_BeneficialOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BeneficialOwnerMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Record and beneficial owner",
        "label": "Beneficial Owner [Member]",
        "documentation": "Any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has shares of the entity with 1) voting power which includes the power to vote, or to direct the voting of, such security, and/or 2) investment power which includes the power to dispose, or to direct the disposition of, such security."
       }
      }
     },
     "auth_ref": []
    },
    "jan_BiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "BiotechnologyMember",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biotechnology",
        "label": "Biotechnology [Member]",
        "documentation": "Biotechnology."
       }
      }
     },
     "auth_ref": []
    },
    "jan_BuildingsAndImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "BuildingsAndImprovementsMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and improvements",
        "label": "Buildings and Improvements [Member]",
        "documentation": "Buildings and Improvements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r771",
      "r772"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r529",
      "r771",
      "r772"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company tendered, shares (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination and Asset Acquisition [Abstract]",
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential value",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r21"
     ]
    },
    "jan_BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial conversion feature",
        "label": "Business Combination, Consideration Transferred, Beneficial Conversion Feature, Value",
        "documentation": "Business Combination, Consideration Transferred, Beneficial Conversion Feature, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, shares issued, fair value",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r116",
      "r531"
     ]
    },
    "jan_BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of unsecured notes entered into",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred, Term",
        "documentation": "Business Combination, Consideration Transferred, Liabilities Incurred, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount owed by company",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r117",
      "r532"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r250",
      "r749"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r186",
      "r282"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "LESS CASH OF DISCONTINUED OPERATIONS, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r186",
      "r282"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r186",
      "r282"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "DECREASE IN CASH AND CASH EQUIVALENTS",
        "terseLabel": "DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r186"
     ]
    },
    "jan_CashDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "CashDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash Disposal",
        "documentation": "Cash Disposal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash flows (used in) provided by discontinued operations",
        "totalLabel": "Net cash used in (provided by) financing activities from discontinued operations",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing cash flows used in discontinued operations",
        "totalLabel": "Net cash used in investing activities from discontinued operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r186"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows provided by (used in) discontinued operations",
        "totalLabel": "Net cash provided by (used in) operating activities from discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r186"
     ]
    },
    "us-gaap_CashSurrenderValueOfLifeInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashSurrenderValueOfLifeInsurance",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated value / surrender value of life insurance policy",
        "label": "Cash Surrender Value of Life Insurance",
        "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "jan_ChargeAgainstIncomeForIncreaseInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ChargeAgainstIncomeForIncreaseInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge against income for increase in discount rate",
        "label": "Charge Against Income For Increase In Discount Rate",
        "documentation": "Charge Against Income For Increase In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r255",
      "r256",
      "r257",
      "r284",
      "r310",
      "r311",
      "r318",
      "r320",
      "r326",
      "r327",
      "r379",
      "r414",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r442",
      "r443",
      "r446",
      "r447",
      "r450",
      "r551",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r682",
      "r703",
      "r725",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r802",
      "r821",
      "r829"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r326",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r650",
      "r651",
      "r652",
      "r653",
      "r769",
      "r802",
      "r821"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant offering and exercise price (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant excise and granted (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ClassOfWarrantOrRightWarrantsOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ClassOfWarrantOrRightWarrantsOrRightsExercised",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, warrants or rights exercised (in shares)",
        "label": "Class of Warrant Or Right, Warrants Or Rights Exercised",
        "documentation": "Class of Warrant Or Right, Warrants Or Rights Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "jan_ClassOfWarrantPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ClassOfWarrantPricePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant price per share (in usd per share)",
        "label": "Class Of Warrant Price Per Share",
        "documentation": "Class Of Warrant Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies (Note 19)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r128",
      "r605",
      "r681"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r404",
      "r405",
      "r742",
      "r842"
     ]
    },
    "jan_CommonShareEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "CommonShareEquivalentsMember",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Share Equivalent",
        "label": "Common Share Equivalents [Member]",
        "documentation": "Common Share Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r825",
      "r826",
      "r890",
      "r910",
      "r912"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "jan_CommonStockPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "CommonStockPurchasePricePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase price (in usd per share)",
        "label": "Common Stock Purchase Price Per Share",
        "documentation": "Common stock purchase price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r682"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued shares (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding shares (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r163",
      "r682",
      "r700",
      "r912",
      "r913"
     ]
    },
    "jan_CommonStockSharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "CommonStockSharesOutstandingPercentage",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding, percentage",
        "label": "Common Stock, Shares Outstanding, Percentage",
        "documentation": "Common Stock, Shares Outstanding, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $0.001 per share, 200,000,000 shares authorized, 4,957,647 and 2,827,410 shares issued and outstanding at December\u00a030, 2023 and at December\u00a031, 2022, respectively",
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r607",
      "r777"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets (liabilities):",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r265",
      "r267",
      "r273",
      "r599",
      "r618"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "verboseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r838",
      "r839"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r239"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r535",
      "r536",
      "r540",
      "r541",
      "r571",
      "r743",
      "r848",
      "r851",
      "r852"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r535",
      "r536",
      "r540",
      "r541",
      "r571",
      "r743",
      "r848",
      "r851",
      "r852"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r754"
     ]
    },
    "us-gaap_ConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projects under construction",
        "label": "Construction [Member]",
        "documentation": "Building or developing real estate. Includes, but is not limited to, improvement to land for drainage, utilities, grading and subdividing."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "jan_ContinuingOperationsAndDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ContinuingOperationsAndDiscontinuedOperationsMember",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing and discontinued operation",
        "label": "Continuing Operations And Discontinued Operations [Member]",
        "documentation": "Continuing Operations And Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liability",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r457"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, amount converted",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_ConversionOfStockAmountConvertible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ConversionOfStockAmountConvertible",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, amount converted",
        "label": "Conversion Of Stock, Amount Convertible",
        "documentation": "Conversion Of Stock, Amount Convertible"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_ConversionOfStockCommencementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ConversionOfStockCommencementPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, commencement period",
        "label": "Conversion Of Stock, Commencement Period",
        "documentation": "Conversion Of Stock, Commencement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_ConversionOfStockPeriodFollowingClosing": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ConversionOfStockPeriodFollowingClosing",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, period after closing",
        "label": "Conversion Of Stock, Period Following Closing",
        "documentation": "Conversion Of Stock, Period Following Closing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_ConversionOfStockSharesForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ConversionOfStockSharesForfeited",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, forfeited (in shares)",
        "label": "Conversion of Stock, Shares Forfeited",
        "documentation": "Conversion of Stock, Shares Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued upon exchange of convertible preferred stock (in shares)",
        "verboseLabel": "Conversion of stock, shares issued (in shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_ConvertiblePreferredStockSharesIssuableUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ConvertiblePreferredStockSharesIssuableUponConversion",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion (in shares)",
        "label": "Convertible Preferred Stock, Shares Issuable Upon Conversion",
        "documentation": "Convertible Preferred Stock, Shares Issuable Upon Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of preferred converted to common stock (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r91",
      "r162",
      "r203",
      "r448"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r284",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r551",
      "r849"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r426",
      "r445",
      "r569",
      "r751",
      "r753"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "jan_CurrentAssetsCurrentLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "CurrentAssetsCurrentLiabilitiesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Working capital",
        "label": "Current Assets (Current Liabilities), Net",
        "documentation": "Net working capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r824",
      "r887"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails": {
       "parentTag": "jan_ProvisionBenefitOfIncomeTaxes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r516",
      "r521",
      "r824"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r824",
      "r887"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DebtDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DebtDiscountRate",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issuance discount rate percentage",
        "label": "Debt Discount Rate",
        "documentation": "Debt Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r158",
      "r159",
      "r221",
      "r224",
      "r291",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r561",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r822"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gulf Coast Bank and Trust Company",
        "terseLabel": "KLC Financial",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r224",
      "r440"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in usd per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r425"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt convertible period",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r423",
      "r561",
      "r765",
      "r766"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r424"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r561",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r822"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r291",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r561",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r822"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment",
        "verboseLabel": "Principal and accrued interest due",
        "label": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly principal payments",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r91",
      "r94",
      "r120",
      "r121",
      "r123",
      "r130",
      "r202",
      "r204",
      "r291",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r561",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r822"
     ]
    },
    "jan_DebtRevisedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DebtRevisedDiscountRate",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt revised discount rate",
        "label": "Debt Revised Discount Rate",
        "documentation": "Debt Revised Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Debt Securities, Available-for-Sale, Purchased with Credit Deterioration, Amount at Purchase Price",
        "documentation": "Amount at purchase price of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), purchased with credit deterioration."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaids and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails": {
       "parentTag": "jan_ProvisionBenefitOfIncomeTaxes",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax provision (benefit) - domestic",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r886",
      "r887"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gulf Coast Bank and Trust Company loan origination fees",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "KLC Financial loan origination fees",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r604"
     ]
    },
    "jan_DeferredTaxAssetsInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DeferredTaxAssetsInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 163(j) interest",
        "label": "Deferred Tax Assets Interest",
        "documentation": "Deferred tax assets interest."
       }
      }
     },
     "auth_ref": []
    },
    "jan_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets Liabilities Gross Before Valuation Allowance",
        "documentation": "Deferred tax assets liabilities gross before valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r884"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "jan_DeferredTaxLiabilitiesInstallmentSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DeferredTaxLiabilitiesInstallmentSale",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Installment sale",
        "label": "Deferred Tax Liabilities Installment Sale",
        "documentation": "Deferred Tax Liabilities Installment Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r885"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "jan_DepositsAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other assets",
        "label": "Deposits And Other Assets Noncurrent",
        "documentation": "Deposits and other assets noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r84"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r337"
     ]
    },
    "us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory transferred part of the sale, derecognized",
        "label": "Continuing Involvement with Derecognized Transferred Financial Assets, Amount Outstanding",
        "documentation": "Amount of transferred financial assets in which the transferor has continuing involvement with the assets underlying the transaction that have been derecognized. Continuing involvement includes, but is not limited to, servicing, recourse, and restrictions on transferor's interests in transferred financial assets."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "jan_DiscontinuedFinancingActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DiscontinuedFinancingActivities",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISCONTINUED FINANCING ACTIVITIES:",
        "label": "DISCONTINUED FINANCING ACTIVITIES:",
        "documentation": "DISCONTINUED FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DiscontinuedInvestingActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DiscontinuedInvestingActivities",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISCONTINUED INVESTING ACTIVITIES:",
        "label": "DISCONTINUED INVESTING ACTIVITIES:",
        "documentation": "DISCONTINUED INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DiscontinuedOperatingActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DiscontinuedOperatingActivities",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISCONTINUED OPERATING ACTIVITIES:",
        "label": "DISCONTINUED OPERATING ACTIVITIES:",
        "documentation": "DISCONTINUED OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income from discontinued operations",
        "negatedTerseLabel": "Gain on sale of ARCA &amp; GeoTraq",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r141",
      "r143"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before provision for income taxes from discontinued operations",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r149",
      "r174",
      "r906"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share from discontinued operations, basic (in usd per share)",
        "terseLabel": "Basic income per share from discontinued operations, basic (in usd per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share from discontinued operations, diluted (in usd per share)",
        "verboseLabel": "Diluted income per share from discontinued operations (in usd per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax provision",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r149",
      "r154",
      "r507",
      "r520",
      "r525"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax provision for discontinued operations",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r154",
      "r889"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DiscountCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DiscountCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount charges",
        "label": "Discount Charges",
        "documentation": "Discount Charges"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DiscountRecordedAsOffsetToThePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DiscountRecordedAsOffsetToThePrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset to the principal amount",
        "label": "Discount Recorded As Offset To The Principal Amount",
        "documentation": "Discount Recorded As Offset To The Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupConsiderationPaymentPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupConsiderationPaymentPeriodAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Consideration, Payment [Axis]",
        "label": "Disposal Group, Consideration, Payment Period [Axis]",
        "documentation": "Disposal Group, Consideration, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupConsiderationPaymentPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupConsiderationPaymentPeriodDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Consideration, Payment Period [Domain]",
        "label": "Disposal Group, Consideration, Payment Period [Domain]",
        "documentation": "Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Recycling Subsidiaries",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r28"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables, net",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r193",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities - other",
        "totalLabel": "Total accrued expenses",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r193",
      "r196"
     ]
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liability - California sales taxes",
        "totalLabel": "Total",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes",
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Sales Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreed prepayment amount",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of revenues",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r247"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r247"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8",
      "r135",
      "r152",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r39",
      "r150"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196"
     ]
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligation long-term - operating leases",
        "label": "Disposal Group, Including Discontinued Operation, Lease Obligation Long Term, Operating Leases",
        "documentation": "Disposal Group, Including Discontinued Operation, Lease Obligation Long Term, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligation short-term - operating leases",
        "label": "Disposal Group, Including Discontinued Operation, Lease Obligation Short Term, Operating Leases",
        "documentation": "Disposal Group, Including Discontinued Operation, Lease Obligation Short Term, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on litigation settlement",
        "label": "Disposal Group, Including Discontinued Operation, Litigation Settlement Expense",
        "documentation": "Disposal Group, Including Discontinued Operation, Litigation Settlement Expense"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term portion related party note payable",
        "label": "Disposal Group, Including Discontinued Operation, Long-term Portion Related Party Note Payable",
        "documentation": "Disposal Group, Including Discontinued Operation, Long-term Portion Related Party Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationNetConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net consideration",
        "label": "Disposal Group, Including Discontinued Operation, Net Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Net Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of note payable",
        "negatedLabel": "Less current portion",
        "label": "Disposal Group, Including Discontinued Operation, Note Payable, Current",
        "documentation": "Disposal Group, Including Discontinued Operation, Note Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Disposal Group, Including Discontinued Operation, Notes Payable",
        "documentation": "Disposal Group, Including Discontinued Operation, Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails_1": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationNotesPayable",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable - long term portion",
        "label": "Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent",
        "documentation": "Disposal Group, Including Discontinued Operation, Notes Payable, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196"
     ]
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Other (Income) Expense, Net",
        "documentation": "Disposal Group, Including Discontinued Operation, Other (Income) Expense, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8",
      "r135",
      "r152",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r193",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net, from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8",
      "r135",
      "r152",
      "r196"
     ]
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent, Gross",
        "documentation": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party note",
        "label": "Disposal Group, Including Discontinued Operation, Related Party Note",
        "documentation": "Disposal Group, Including Discontinued Operation, Related Party Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r247"
     ]
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset - operating leases",
        "label": "Disposal Group, Including Discontinued Operation, Right of Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Right of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "totalLabel": "Short term debt",
        "label": "Disposal Group, Including Discontinued Operation, Short Term Debt",
        "documentation": "Disposal Group, Including Discontinued Operation, Short Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Total Operating Income (Expenses) From Discontinued Operations",
        "documentation": "Disposal Group, Including Discontinued Operation, Total Operating Income (Expenses) From Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum monthly payments",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Minimum Payments from Buyer",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Minimum Payments from Buyer"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate payment period (years)",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Payment Period",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross revenue (percent)",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Percentage of Gross Revenue",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Percentage of Gross Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary's revenue benchmark",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Subsidiary Revenue Benchmark",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payment, Subsidiary Revenue Benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate monthly payments from the buyer",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments from Buyer",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments from Buyer"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate monthly payments from buyer, period (years)",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Period",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Period"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate monthly pre-payments",
        "label": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Prepayment",
        "documentation": "Disposal Group, Including Discontinued Operations, Aggregate Monthly Payments From Buyer, Prepayment"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid at close of transactions",
        "label": "Disposal Group, Including Discontinued Operations, Asset Acquisition, Consideration Transferred, At Closure",
        "documentation": "Disposal Group, Including Discontinued Operations, Asset Acquisition, Consideration Transferred, At Closure"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Disposal Group, Including Discontinued Operations, Consideration Received on Transaction",
        "documentation": "Disposal Group, Including Discontinued Operations, Consideration Received on Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate percentage (percent)",
        "label": "Disposal Group, Including Discontinued Operations, Discount Rate Percentage",
        "documentation": "Disposal Group, Including Discontinued Operations, Discount Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of the reduction percentage (percent)",
        "label": "Disposal Group, Including Discontinued Operations, Payment Receivable, Percentage Of Difference Between Assessment And Settlement Value",
        "documentation": "Disposal Group, Including Discontinued Operations, Payment Receivable, Percentage Of Difference Between Assessment And Settlement Value"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount recorded as offset to the principal amount",
        "label": "Disposal Group, Including Discontinued Operations, Present Value Of Discount Recorded As Offset To The Principal Amount",
        "documentation": "Disposal Group, Including Discontinued Operations, Present Value Of Discount Recorded As Offset To The Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional proceeds received for the equity of each subsidiary",
        "label": "Disposal Group, Including Discontinued Operations, Proceeds Received For Equity Of Each Subsidiary",
        "documentation": "Disposal Group, Including Discontinued Operations, Proceeds Received For Equity Of Each Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in liabilities",
        "label": "Disposal Group, Including Discontinued Operations, Reduction In Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operations, Reduction In Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "label": "Disposal Group, Including Discontinued Operations, Total Other Income (Loss), Net",
        "documentation": "Total other loss, net"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book value in excess of assets disposed of",
        "label": "Disposal Group, Not Discontinued Operation, Book Value In Excess Of Assets",
        "documentation": "Disposal Group, Not Discontinued Operation, Book Value In Excess Of Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preliminary calculation of gain on sale",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r820",
      "r840"
     ]
    },
    "jan_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "xbrltype": "tokenItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess of book value over assets disposed, extensible list",
        "label": "Disposal Group Not Discontinued Operation Gain (Loss) On Disposal, Statement Of Income Extensible List Not Disclosed Flag",
        "documentation": "Disposal Group Not Discontinued Operation Gain (Loss) On Disposal, Statement Of Income Extensible List Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write off of VM7 note receivable",
        "negatedTerseLabel": "Write off of VM7 note receivable",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r195"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperations",
      "http://www.live-ventures.com/role/GeoTraq",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiaries"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Sale of Recycling Subsidiaries",
        "terseLabel": "GeoTraq",
        "verboseLabel": "Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r192"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r772"
     ]
    },
    "jan_DisposalOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Disposal of Accounts Payable",
        "documentation": "Disposal of Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Disposal of Accounts receivable",
        "documentation": "Disposal of Accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfAccruedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfAccruedLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Disposal of Accrued liability",
        "documentation": "Disposal of Accrued liability"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfAccruedLiabilityCaliforniaStateSalesTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfAccruedLiabilityCaliforniaStateSalesTax",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities - California state sales tax",
        "label": "Disposal of Accrued liability - California state sales tax",
        "documentation": "Disposal of Accrued liability - California state sales tax"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Disposal of Debt",
        "documentation": "Disposal of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disposal of Intangible assets",
        "documentation": "Disposal of Intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfInventory",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Disposal of Inventory",
        "documentation": "Disposal of Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Disposal of Lease Liability",
        "documentation": "Disposal of Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Disposal of Other Assets",
        "documentation": "Disposal of Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disposal of Property, Plant and Equipment",
        "documentation": "Disposal of Property, Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DisposalOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DisposalOfRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Disposal of Right-of-use Assets",
        "documentation": "Disposal of Right-of-use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DispositionDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DispositionDiscountRate",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposition discount rate (percent)",
        "label": "Disposition Discount Rate",
        "documentation": "Disposition Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DispositionTransactionAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DispositionTransactionAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposition transaction aggregate cost",
        "label": "Disposition Transaction Aggregate cost",
        "documentation": "Disposition Transaction Aggregate cost"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DispositionTransactionConsiderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DispositionTransactionConsiderAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposition transaction consider amount",
        "label": "Disposition Transaction Consider Amount",
        "documentation": "Disposition Transaction Consider Amount"
       }
      }
     },
     "auth_ref": []
    },
    "jan_DispositionTransactionTermPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DispositionTransactionTermPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposition transaction term period",
        "label": "Disposition Transaction Term Period",
        "documentation": "Disposition Transaction Term Period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797",
      "r799"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "jan_DrSoinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "DrSoinMember",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Soin",
        "label": "Dr. Soin [Member]",
        "documentation": "Dr. Soin [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share, basic (in usd per share)",
        "verboseLabel": "Basic income per share (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r307",
      "r310",
      "r318",
      "r319",
      "r320",
      "r324",
      "r549",
      "r550",
      "r600",
      "r619",
      "r757"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r318"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share, diluted (in usd per share)",
        "verboseLabel": "Diluted income per share (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r310",
      "r318",
      "r319",
      "r320",
      "r324",
      "r549",
      "r550",
      "r600",
      "r619",
      "r757"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (Loss) per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r321",
      "r322",
      "r323"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of changes in exchange rate on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of provision for income taxes with federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r508",
      "r523"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r888"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r883"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of sale of ARCA Recycling and Canada",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r888"
     ]
    },
    "jan_EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax for installment sale",
        "label": "Effective Income Tax Rate Reconciliation, Federal Income Tax, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Federal Income Tax, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r888"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r888"
     ]
    },
    "jan_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "documentation": "Effective income tax rate reconciliation permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofReconciliationofOurBenefitofIncomeTaxeswiththeFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax rate",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r888"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation and benefits",
        "terseLabel": "Compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, net of estimated forfeitures",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r244",
      "r269",
      "r270",
      "r271",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r304",
      "r325",
      "r380",
      "r381",
      "r452",
      "r493",
      "r494",
      "r495",
      "r517",
      "r518",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r552",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r562",
      "r640",
      "r641",
      "r642",
      "r660",
      "r725"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding, ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_EquityUnitPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityUnitPurchaseAgreementsMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Unit Purchase Agreements",
        "label": "Equity Unit Purchase Agreements [Member]",
        "documentation": "Contracts and securities that allow the holder to buy equity units from the entity."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "jan_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.54 to $5.25",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise price range four."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$17.35 to $23.45",
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise price range one."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$5.70 to $9.90",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise price range three."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$11.10 to $15.00",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise price range two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r32"
     ]
    },
    "jan_FairValueOfStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "FairValueOfStockIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of stock issued connection with merger",
        "label": "Fair Value of Stock Issued",
        "documentation": "Fair value of stock issued connection with merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation insured per institution",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of note receivable discount",
        "label": "Financial Guarantee Insurance Contracts, Premiums Receivable, Adjustment, Accretion of Discount on Premium Receivable",
        "documentation": "Amount of accretion of the discount for premiums receivable on financial guarantee insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_FinancialGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialGuaranteeMember",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Guarantee",
        "label": "Financial Guarantee [Member]",
        "documentation": "An agreement (contract) that requires the guarantor to make payments to the guaranteed party based on another entity's failure to pay specified obligations, such as debt, to a lender."
       }
      }
     },
     "auth_ref": []
    },
    "jan_FinancingArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "FinancingArrangementMember",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Arrangement",
        "label": "Financing Arrangement [Member]",
        "documentation": "Financing Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable - SPYR, net",
        "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablesTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Receivables",
        "label": "Financing Receivables [Text Block]",
        "documentation": "The entire disclosure for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r371",
      "r372",
      "r373",
      "r761"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated amortization",
        "negatedLabel": "Less accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r398"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r583",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "terseLabel": "Intangible assets, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets, net",
        "verboseLabel": "Total Intangible Assets",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r583"
     ]
    },
    "jan_FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Finite Lived Intangible Assets, Net, Excluding Other Intangible Assets, Net",
        "documentation": "Finite Lived Intangible Assets, Net, Excluding Other Intangible Assets, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value of disposition transaction",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "jan_GainLossOnLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GainLossOnLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on litigation settlement",
        "label": "Gain Loss on Litigation Settlement",
        "documentation": "Gain loss on litigation settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Discount on note receivable",
        "label": "Gain (Loss) on Sale of Accounts Receivable",
        "documentation": "Amount of gain (loss) on sale of accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of GeoTraq",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r820"
     ]
    },
    "us-gaap_GainLossOnSaleOfProject": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfProject",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale",
        "label": "Gain (Loss) on Sale of Project",
        "documentation": "The gains and losses included in earning resulting from the sale of a project."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "jan_GainLossOnWriteOffOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GainLossOnWriteOffOfNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write off of SPYR note receivable",
        "negatedLabel": "Impairment charge related to note receivable",
        "label": "Gain (Loss) on Write-Off Of Notes Receivable",
        "documentation": "Gain (Loss) on Write-Off Of Notes Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on litigation settlement",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "jan_GainOnSaleNetOfCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GainOnSaleNetOfCash",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of ARCA, net of cash",
        "label": "Gain on Sale, Net of Cash",
        "documentation": "Gain on Sale, Net of Cash"
       }
      }
     },
     "auth_ref": []
    },
    "jan_GainsOnReversalOfContingencyLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GainsOnReversalOfContingencyLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on reversal of contingent liabilities",
        "label": "Gains on Reversal of Contingency Loss",
        "documentation": "Gains on reversal of contingency loss."
       }
      }
     },
     "auth_ref": []
    },
    "jan_GeoTraqIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GeoTraqIncMember",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GeoTraq Inc.",
        "label": "Geo Traq Inc [Member]",
        "documentation": "GeoTraq Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r385",
      "r597",
      "r763",
      "r777",
      "r836",
      "r837"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r284",
      "r332",
      "r352",
      "r358",
      "r361",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r551",
      "r759",
      "r849"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Axis]",
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413"
     ]
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor obligations, current carrying value",
        "label": "Guarantor Obligations, Current Carrying Value",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Domain]",
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413"
     ]
    },
    "jan_GulfCoastBankAndTrustCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GulfCoastBankAndTrustCompanyMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gulf Coast Bank and Trust Company",
        "label": "Gulf Coast Bank and Trust Company [Member]",
        "documentation": "Gulf Coast Bank and Trust Company."
       }
      }
     },
     "auth_ref": []
    },
    "jan_GulfCoastBankAndTrustCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "GulfCoastBankAndTrustCreditFacilityMember",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gulf Coast Bank and Trust Credit Facility",
        "label": "Gulf Coast Bank And Trust Credit Facility [Member]",
        "documentation": "Gulf Coast Bank And Trust Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ]
    },
    "jan_IcgNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "IcgNoteMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICG Note",
        "label": "ICG Note [Member]",
        "documentation": "ICG Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income from continuing operations",
        "terseLabel": "Net (loss) income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r179",
      "r188",
      "r297",
      "r298",
      "r299",
      "r300",
      "r316",
      "r320"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsAttributableToParentAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing Operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails": {
       "parentTag": "jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r522"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before benefit from income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r173",
      "r227",
      "r332",
      "r352",
      "r358",
      "r361",
      "r601",
      "r613",
      "r759"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails": {
       "parentTag": "jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r522"
     ]
    },
    "jan_IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofLossBeforeBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision of income taxes, Total",
        "label": "Income (Loss) from Continuing Operations Before Provision (Benefit) Of Income Taxes",
        "documentation": "Income (Loss) from Continuing Operations Before Provision (Benefit) Of Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share from continuing operations, basic (in usd per share)",
        "netLabel": "Basic (loss) income per share from continuing operations, basic (in usd per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r226",
      "r228",
      "r274",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r310",
      "r318",
      "r319",
      "r550",
      "r600",
      "r907"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share from continuing operations, diluted (in usd per share)",
        "netLabel": "Diluted (loss) per share from continuing operations (in usd per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r274",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r310",
      "r318",
      "r319",
      "r320",
      "r550",
      "r600",
      "r907"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r154",
      "r247",
      "r526",
      "r614"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from discontinued operations",
        "terseLabel": "Net income from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r149",
      "r154",
      "r219"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r772"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r28",
      "r38",
      "r135",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r155",
      "r156",
      "r197"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r112",
      "r212",
      "r213"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r502",
      "r509",
      "r510",
      "r514",
      "r519",
      "r524",
      "r527",
      "r528",
      "r655"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "verboseLabel": "Income tax (benefit) provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r242",
      "r303",
      "r304",
      "r340",
      "r507",
      "r520",
      "r620"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense:",
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r503",
      "r504",
      "r510",
      "r511",
      "r513",
      "r515",
      "r649"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid, net",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 10.0
      },
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in deferred income taxes",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Preferred Stock Outstanding [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r579",
      "r580",
      "r581",
      "r583",
      "r755"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income, net",
        "terseLabel": "Interest income (expense), net",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_InterestIncomeInterestEarningAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeInterestEarningAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Interest-Earning Asset",
        "documentation": "Amount of interest income from interest-earning asset."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280",
      "r281"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued receivables",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r914"
     ]
    },
    "jan_IsaacCapitalGroupLLCICGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "IsaacCapitalGroupLLCICGMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICG",
        "label": "Isaac Capital Group LLC (\u201cICG\u201d) [Member]",
        "documentation": "Isaac Capital Group LLC (\u201cICG\u201d)"
       }
      }
     },
     "auth_ref": []
    },
    "jan_IsaacConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "IsaacConsultingAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Isaac Consulting Agreement",
        "label": "Isaac Consulting Agreement [Member]",
        "documentation": "Isaac Consulting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "jan_JanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "JanOneMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janone",
        "label": "JanOne [Member]",
        "documentation": "JanOne"
       }
      }
     },
     "auth_ref": []
    },
    "jan_KlcFinancialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "KlcFinancialMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KLC Financial",
        "label": "KLC Financial [Member]",
        "documentation": "KLC Financial."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attorneys fees",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r284",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r536",
      "r540",
      "r541",
      "r551",
      "r680",
      "r758",
      "r791",
      "r849",
      "r896",
      "r897"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r225",
      "r611",
      "r777",
      "r823",
      "r833",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Mezzanine Equity, and Stockholders' Equity (Deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r249",
      "r284",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r536",
      "r540",
      "r541",
      "r551",
      "r777",
      "r849",
      "r896",
      "r897"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r196",
      "r246",
      "r247"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities from discontinued operations",
        "totalLabel": "Total current liabilities from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r152",
      "r193",
      "r196",
      "r246",
      "r247"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liabilities from discontinued operations",
        "totalLabel": "Total noncurrent liabilities from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8",
      "r135",
      "r152",
      "r196",
      "r246",
      "r247"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r224",
      "r905"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of loan fee on each borrowings",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Availability under revolving credit facility",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation/legal",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r843"
     ]
    },
    "jan_LiveVenturesIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "LiveVenturesIncorporatedMember",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Live Ventures Incorporated",
        "label": "Live Ventures Incorporated [Member]",
        "documentation": "Live Ventures Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r224",
      "r430",
      "r441",
      "r765",
      "r766",
      "r905"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short term debt",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r86"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages awarded plus interest and attorney fees",
        "label": "Loss Contingency, Damages Awarded, Value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages sought value",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ]
    },
    "jan_LossContingencyNumberOfExecutiveOfficersNamedInComplaint": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "LossContingencyNumberOfExecutiveOfficersNamedInComplaint",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of executive officers named in complaint",
        "label": "Loss Contingency, Number Of Executive Officers Named In Complaint",
        "documentation": "Loss Contingency, Number Of Executive Officers Named In Complaint"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r811"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Abstract]",
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "jan_MarketableSecuritiesSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "MarketableSecuritiesSharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Marketable Securities, Shares Outstanding",
        "documentation": "Marketable Securities, Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of marketable securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "negatedLabel": "Unrealized loss on marketable securities",
        "negatedTerseLabel": "Unrealized loss on marketable securities",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domain Name and Marketing",
        "label": "Marketing-Related Intangible Assets [Member]",
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r460",
      "r578",
      "r639",
      "r672",
      "r673",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r744",
      "r745",
      "r761",
      "r769",
      "r773",
      "r780",
      "r853",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mergers and Acquisitions",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r215"
     ]
    },
    "jan_MezzanineEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "MezzanineEquityAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mezzanine equity",
        "label": "Mezzanine equity [Abstract]",
        "documentation": "Mezzanine equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r460",
      "r578",
      "r639",
      "r672",
      "r673",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r744",
      "r745",
      "r761",
      "r769",
      "r773",
      "r780",
      "r853",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInAuctionMarketPreferredSecuritiesSharesOutstandingRollForward",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities, Shares [Roll Forward]",
        "label": "Movement in Auction Market Preferred Securities, Shares Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "jan_Mr.JonIsaacMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "Mr.JonIsaacMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Jon Isaac",
        "label": "Mr. Jon Isaac [Member]",
        "documentation": "Mr. Jon Isaac"
       }
      }
     },
     "auth_ref": []
    },
    "jan_Mr.SullivanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "Mr.SullivanMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Sullivan",
        "label": "Mr. Sullivan [Member]",
        "documentation": "Mr. Sullivan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInContinuingOperations",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NetConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NetConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalConsiderations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net consideration",
        "label": "Net Consideration",
        "documentation": "Net Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net income",
        "verboseLabel": "Total Net income after provision for income taxes",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r188",
      "r229",
      "r247",
      "r263",
      "r266",
      "r271",
      "r284",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r316",
      "r332",
      "r352",
      "r358",
      "r361",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r550",
      "r551",
      "r616",
      "r702",
      "r723",
      "r724",
      "r759",
      "r789",
      "r849"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r297",
      "r298",
      "r299",
      "r300",
      "r307",
      "r308",
      "r317",
      "r320",
      "r332",
      "r352",
      "r358",
      "r361",
      "r759"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income, diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r309",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r320"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income from continuing operations, basic",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r320"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income from continuing operations, diluted",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r313",
      "r314",
      "r315",
      "r320"
     ]
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations, basic",
        "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations, diluted",
        "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from discontinued operations available to common shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rented office space (in sqft)",
        "label": "Net Rentable Area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock equivalents received (in shares)",
        "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued",
        "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "jan_NoncashOrPartNoncashDivestitureConsiderationReceivedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoncashOrPartNoncashDivestitureConsiderationReceivedShares",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities received (in shares)",
        "label": "Noncash Or Part Noncash Divestiture, Consideration Received, Shares",
        "documentation": "Noncash Or Part Noncash Divestiture, Consideration Received, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoncashRecognitionOfNewLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoncashRecognitionOfNewLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash recognition of new leases",
        "label": "Noncash recognition of new leases",
        "documentation": "Noncash recognition of new leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoteReceivableDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoteReceivableDiscountRate",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable discount rate",
        "label": "Note Receivable Discount Rate",
        "documentation": "Note Receivable Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoteReceivableFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoteReceivableFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable face amount",
        "label": "Note Receivable Face Amount",
        "documentation": "Note receivable face amount."
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoteReceivableMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoteReceivableMaturityDate",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable maturity date",
        "label": "Note Receivable Maturity Date",
        "documentation": "Note receivable maturity date."
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoteReceivableRevisedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoteReceivableRevisedDiscountRate",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable revised discount rate",
        "label": "Note Receivable Revised Discount Rate",
        "documentation": "Note Receivable Revised Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NoteReceivableStatedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NoteReceivableStatedInterestRate",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable interest rate",
        "label": "Note Receivable Stated Interest Rate",
        "documentation": "Note receivable interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "jan_NotesReceivableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NotesReceivableTerm",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of notes receivable",
        "label": "Notes Receivable, Term",
        "documentation": "Notes Receivable, Term"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NumberOfAcquiredIntangibleAssets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NumberOfAcquiredIntangibleAssets",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pending patents",
        "label": "Number Of Acquired Intangible Assets",
        "documentation": "Number Of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NumberOfAgreementsToBePurchased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NumberOfAgreementsToBePurchased",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaffiliated third-part investors",
        "label": "Number Of Agreements To Be Purchased",
        "documentation": "Number Of Agreements To Be Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NumberOfInstallment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NumberOfInstallment",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of installments",
        "label": "Number of Installment",
        "documentation": "Number of Installment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformationAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfStatesInWhichEntityOperates",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of states in which Company operated its recycling business",
        "label": "Number of States in which Entity Operates",
        "documentation": "The number of states the entity operates in as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "jan_NumberOfTradingDaysBeforeBoardApproval": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NumberOfTradingDaysBeforeBoardApproval",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days prior to court approval",
        "label": "Number Of Trading Days Before Board Approval",
        "documentation": "Number Of Trading Days Before Board Approval"
       }
      }
     },
     "auth_ref": []
    },
    "jan_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Number Of Tranches",
        "documentation": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition of GeoTraq inventory",
        "label": "OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Adjustment from AOCI for Derecognition, before Tax",
        "documentation": "Amount, before tax, of adjustment from accumulated other comprehensive income for gain (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk, not recognized in income and used in calculating liability for future policy benefit for payout annuity."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r261"
     ]
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets [Line Items]",
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets [Table]",
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_OperatingExpensesFromDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OperatingExpensesFromDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses from discontinued operations:",
        "label": "Operating Expenses From Discontinued Operations [Abstract]",
        "documentation": "Operating Expenses From Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "terseLabel": "Total Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r352",
      "r358",
      "r361",
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "jan_OperatingLeasesFutureMinimumPaymentsDue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue1",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases future minimum payments due1",
        "label": "Operating Leases Future Minimum Payments Due1",
        "documentation": "Operating Leases Future Minimum Payments Due1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, valuation allowance",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r218",
      "r646",
      "r647"
     ]
    },
    "us-gaap_OriginationOfNotesReceivableFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OriginationOfNotesReceivableFromRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note",
        "label": "Origination of Notes Receivable from Related Parties",
        "documentation": "The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and Other Assets",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "jan_OtherAssetsFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OtherAssetsFromDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets from discontinued operations",
        "label": "Other assets from discontinued operations",
        "documentation": "Other assets from discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "jan_OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of landlords Company is no longer liable for",
        "label": "Other Commitments, Number Of Landlords Company Is No Longer Liable For",
        "documentation": "Other Commitments, Number Of Landlords Company Is No Longer Liable For"
       }
      }
     },
     "auth_ref": []
    },
    "jan_OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of landlords originally purported to be covered under Company's guarantee or commitment",
        "label": "Other Commitments, Number Of Landlords Originally Purported To Be Liable For",
        "documentation": "Other Commitments, Number Of Landlords Originally Purported To Be Liable For"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r552",
      "r553",
      "r558",
      "r598",
      "r617",
      "r815",
      "r816"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive loss, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r31",
      "r264",
      "r267",
      "r272",
      "r552",
      "r553",
      "r558",
      "r598",
      "r617",
      "r815",
      "r816"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalDisposalOfLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r171",
      "r262",
      "r375"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaids and Other Current Assets",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "jan_OtherIncomeExpenseFromDiscontinuedOperations": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "OtherIncomeExpenseFromDiscontinuedOperations",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense from discontinued operations",
        "label": "Other Income (Expense) From Discontinued Operations",
        "documentation": "Other Income (Expense) From Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, net",
        "label": "Other Intangible Assets, Net",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r602",
      "r676",
      "r677",
      "r791",
      "r911"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party note",
        "label": "Other Notes Payable, Noncurrent",
        "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails": {
       "parentTag": "jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r835"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PartnersCapitalAccountUnitsSoldInPublicOffering",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering shares",
        "label": "Partners' Capital Account, Units, Sold in Public Offering",
        "documentation": "The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206"
     ]
    },
    "jan_PatentsAndDomainsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PatentsAndDomainsMember",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents and domains",
        "label": "Patents And Domains [Member]",
        "documentation": "Patents and domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patent and domains",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on reversal of contingent liabilities",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "jan_PaymentFromBuyer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PaymentFromBuyer",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_NetConsideration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment from buyer",
        "label": "Payment from Buyer",
        "documentation": "Payment from Buyer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for close",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for legal settlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment tendered",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r530"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "jan_PercentOfPrepaymentTenderRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PercentOfPrepaymentTenderRestrictions",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of prepayment value, tender restrictions (percent)",
        "label": "Percent Of Prepayment Tender Restrictions",
        "documentation": "Percent Of Prepayment Tender Restrictions"
       }
      }
     },
     "auth_ref": []
    },
    "jan_PercentageOfGrossRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PercentageOfGrossRevenue",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross revenue",
        "label": "Percentage of Gross Revenue",
        "documentation": "Percentage of Gross Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "jan_Plan2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "Plan2011Member",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Plan",
        "label": "Plan2011 [Member]",
        "documentation": "Plan 2011."
       }
      }
     },
     "auth_ref": []
    },
    "jan_Plan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "Plan2016Member",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Plan2016 [Member]",
        "documentation": "Plan 2016."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_PolicyholderAccountBalancePremiumReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalancePremiumReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqScheduleofGainonSaleofGeoTraqDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premium on shares received",
        "label": "Policyholder Account Balance, Premium Received",
        "documentation": "Amount of cash inflow to policyholder account balance from premium received."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r909"
     ]
    },
    "jan_PotentialMarketExclusivityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PotentialMarketExclusivityPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential market exclusivity period",
        "label": "Potential Market Exclusivity Period",
        "documentation": "Potential Market Exclusivity Period"
       }
      }
     },
     "auth_ref": []
    },
    "jan_PreFundedWarrantsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PreFundedWarrantsMemberMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants Member",
        "label": "Pre-Funded Warrants Member [Member]",
        "documentation": "Pre-Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, conversion ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r785",
      "r786",
      "r787",
      "r788",
      "r910",
      "r912"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r442"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r682"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r442"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, outstanding shares (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r682",
      "r700",
      "r912",
      "r913"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStock",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Convertible Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible preferred stock, series A-1 - par value $0.001 per share 2,000,000 authorized, 193,730 and 222,588 shares issued and outstanding at December\u00a030, 2023 and December\u00a031, 2022, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r606",
      "r777"
     ]
    },
    "jan_PreferredStockVotingRightsNumberOfVotesEntitledToEachShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PreferredStockVotingRightsNumberOfVotesEntitledToEachShare",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, voting rights",
        "label": "Preferred Stock, Voting Rights, Number Of Votes Entitled To Each Share",
        "documentation": "Preferred Stock, Voting Rights, Number Of Votes Entitled To Each Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaids and other current assets",
        "label": "Prepaid Expense And Other Assets, including Discontinued Operations, Current",
        "documentation": "Prepaid Expense And Other Assets, including Discontinued Operations, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails": {
       "parentTag": "jan_PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/PrepaidsandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r762",
      "r835"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Reclassification",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from equity financings, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing agreements entered into",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r650"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds reimbursement for accountable legal expenses",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of Warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from note payable",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities received",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfInterestInPartnershipUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfInterestInPartnershipUnit",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock",
        "label": "Proceeds from Sale of Interest in Partnership Unit",
        "documentation": "The proceeds from the sale of an interest in a unit of partnership."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r363",
      "r582",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r747",
      "r770",
      "r778",
      "r805",
      "r846",
      "r847",
      "r854",
      "r908"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r363",
      "r582",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r747",
      "r770",
      "r778",
      "r805",
      "r846",
      "r847",
      "r854",
      "r908"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r263",
      "r266",
      "r278",
      "r284",
      "r295",
      "r303",
      "r304",
      "r332",
      "r352",
      "r358",
      "r361",
      "r379",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r534",
      "r537",
      "r538",
      "r550",
      "r551",
      "r601",
      "r615",
      "r659",
      "r702",
      "r723",
      "r724",
      "r759",
      "r775",
      "r776",
      "r790",
      "r817",
      "r849"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful Life (Years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "jan_ProvisionBenefitOfIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "ProvisionBenefitOfIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesScheduleofBenefitofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision (benefit) of income taxes",
        "label": "Provision (Benefit) Of Income Taxes",
        "documentation": "Provision (Benefit) Of Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r383"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r458",
      "r460",
      "r488",
      "r489",
      "r490",
      "r575",
      "r578",
      "r639",
      "r672",
      "r673",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r744",
      "r745",
      "r761",
      "r769",
      "r773",
      "r780",
      "r783",
      "r841",
      "r853",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r458",
      "r460",
      "r488",
      "r489",
      "r490",
      "r575",
      "r578",
      "r639",
      "r672",
      "r673",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r744",
      "r745",
      "r761",
      "r769",
      "r773",
      "r780",
      "r783",
      "r841",
      "r853",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable interest rate",
        "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)",
        "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r561"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableWithImputedInterestFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable face amount",
        "label": "Receivable with Imputed Interest, Face Amount",
        "documentation": "The principal amount of the receivable or note before consideration of the discount or premium."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r561"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestNetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableWithImputedInterestNetAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable with imputed interest, net amount",
        "label": "Receivable with Imputed Interest, Net Amount",
        "documentation": "The receivable or note face amount less the unamortized discount or premium."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RecyclingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RecyclingMember",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recycling",
        "label": "Recycling [Member]",
        "documentation": "Recycling."
       }
      }
     },
     "auth_ref": []
    },
    "jan_RecyclingSegmentAndTechnologySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RecyclingSegmentAndTechnologySegmentMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recycling Segment and Technology Segment",
        "label": "Recycling Segment And Technology Segment [Member]",
        "documentation": "Recycling Segment And Technology Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedAndNonrelatedPartyStatusAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Party Status [Axis]",
        "label": "Related and Nonrelated Party Status [Axis]",
        "documentation": "Information by related and nonrelated party status."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r566",
      "r567",
      "r568",
      "r569",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r699",
      "r701",
      "r784"
     ]
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedAndNonrelatedPartyStatusDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Party Status [Domain]",
        "label": "Related and Nonrelated Party Status [Domain]",
        "documentation": "Related and nonrelated party status."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r566",
      "r567",
      "r568",
      "r569",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r699",
      "r701",
      "r784"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r566",
      "r567",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r699",
      "r701",
      "r731"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r566",
      "r567",
      "r568",
      "r569",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r699",
      "r701",
      "r731"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r895"
     ]
    },
    "jan_RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingently tendered funds in counsel's trust account",
        "label": "Related Party Transaction, Consulting Agreement, Contingently Tendered Funds",
        "documentation": "Related Party Transaction, Consulting Agreement, Contingently Tendered Funds"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share value of the restricted shares issued (in usd per share)",
        "label": "Related Party Transaction, Consulting Agreement, Convertible Debt, Conversion Price",
        "documentation": "Related Party Transaction, Consulting Agreement, Convertible Debt, Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial principal amount",
        "label": "Related Party Transaction, Consulting Agreement, Convertible Debt, Face Amount",
        "documentation": "Related Party Transaction, Consulting Agreement, Convertible Debt, Face Amount"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate on promissory note (percent)",
        "label": "Related Party Transaction, Consulting Agreement, Convertible Debt, Stated Rate",
        "documentation": "Related Party Transaction, Consulting Agreement, Convertible Debt, Stated Rate"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of promissory note issued",
        "label": "Related Party Transaction, Consulting Agreement, Convertible Debt, Term",
        "documentation": "Related Party Transaction, Consulting Agreement, Convertible Debt, Term"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universal life insurance policies assigned",
        "label": "Related Party Transaction, Consulting Agreement, Number Of Life Insurance Policies Assigned",
        "documentation": "Related Party Transaction, Consulting Agreement, Number Of Life Insurance Policies Assigned"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementSharesIssued",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares issued (in shares)",
        "label": "Related Party Transaction, Consulting Agreement, Shares Issued",
        "documentation": "Related Party Transaction, Consulting Agreement, Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionConsultingAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionConsultingAgreementTerm",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of consulting agreement",
        "label": "Related Party Transaction, Consulting Agreement, Term",
        "documentation": "Related Party Transaction, Consulting Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r710"
     ]
    },
    "jan_RelatedPartyTransactionPurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionPurchaseAgreementTerm",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase agreement term",
        "label": "Related Party Transaction, Purchase Agreement, Term",
        "documentation": "Related Party Transaction, Purchase Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shared expenses with another company",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surcharge or broker fee (percent)",
        "label": "Related Party Transaction, Purchases From Related Party, Surcharge Or Broker Fee, Percent",
        "documentation": "Related Party Transaction, Purchases From Related Party, Surcharge Or Broker Fee, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r566",
      "r567",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r699",
      "r701",
      "r731",
      "r895"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r567",
      "r570",
      "r656",
      "r657",
      "r658",
      "r708",
      "r709",
      "r710",
      "r728",
      "r729"
     ]
    },
    "jan_RelevantMonth1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelevantMonth1Member",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relevant Month 1",
        "label": "Relevant Month 1 [Member]",
        "documentation": "Relevant Month 1"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelevantMonth2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelevantMonth2Member",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relevant Month 2",
        "label": "Relevant Month 2 [Member]",
        "documentation": "Relevant Month 2"
       }
      }
     },
     "auth_ref": []
    },
    "jan_RelevantMonth3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RelevantMonth3Member",
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relevant Month 3",
        "label": "Relevant Month 3 [Member]",
        "documentation": "Relevant Month 3"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on short term notes payable",
        "terseLabel": "Payments on notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments on related party note",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial down payment",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r426",
      "r445",
      "r569",
      "r752",
      "r753"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r205",
      "r610",
      "r643",
      "r645",
      "r654",
      "r683",
      "r777"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r304",
      "r380",
      "r381",
      "r493",
      "r494",
      "r495",
      "r517",
      "r518",
      "r542",
      "r544",
      "r545",
      "r547",
      "r548",
      "r640",
      "r642",
      "r660",
      "r912"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r351",
      "r356",
      "r357",
      "r363",
      "r365",
      "r366",
      "r455",
      "r456",
      "r582"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r746",
      "r756"
     ]
    },
    "jan_RevisedDiscountAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "RevisedDiscountAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revised discount amount",
        "label": "Revised Discount Amount",
        "documentation": "Revised Discount Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "jan_SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares in each unit (in shares)",
        "label": "Sale of Stock, Unit Composition, Number Of Common Shares In Each Unit",
        "documentation": "Sale of Stock, Unit Composition, Number Of Common Shares In Each Unit"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants in each unit (in shares)",
        "label": "Sale of Stock, Unit Composition, Number Of Warrants Issued In Each unit",
        "documentation": "Sale of Stock, Unit Composition, Number Of Warrants Issued In Each unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liability - CA sales tax assessment",
        "label": "Sales and Excise Tax Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "jan_SalesTaxAssessmentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SalesTaxAssessmentAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails": {
       "parentTag": "jan_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liability - interest on CA sales tax assessment",
        "label": "Sales Tax Assessment, Accrued Interest",
        "documentation": "Sales Tax Assessment, Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r461",
      "r828"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r461",
      "r803",
      "r828"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Receivables",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r529"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefit of Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long Term Debt and Other Financing Obligations",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r95",
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsTables",
      "http://www.live-ventures.com/role/GeoTraqTables",
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r28",
      "r38",
      "r135",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r155",
      "r156",
      "r197"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r310",
      "r311",
      "r318"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Our Benefit of Income Taxes with the Federal Statutory Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Benefit of Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information About Non-vested Shares Outstanding",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deposits and Other Assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.live-ventures.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r706",
      "r707",
      "r710"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exercise Price for Stock Options Outstanding and Exercisable Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Short Term Debt [Table]",
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r202",
      "r204",
      "r205",
      "r255",
      "r256",
      "r257",
      "r326",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r650",
      "r651",
      "r652",
      "r653",
      "r769",
      "r802",
      "r821"
     ]
    },
    "jan_Section174Expenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "Section174Expenses",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "jan_DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesSummaryofComponentsofNetDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 expenses",
        "label": "Section 174 Expenses",
        "documentation": "Section 174 Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities, Value [Roll Forward]",
        "label": "Securities Purchased under Agreements to Resell, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentContinuingOperationsMember",
     "presentation": [
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations",
        "label": "Continuing Operations [Member]",
        "documentation": "Component of an entity expected to operate in the foreseeable future."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations",
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r136",
      "r137",
      "r138"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r366",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r402",
      "r403",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r763",
      "r805",
      "r908"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities [Domain]",
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r344",
      "r355",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r365",
      "r760"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "jan_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A1 Convertible Preferred Stock",
        "label": "Series A1 Convertible Preferred Stock [Member]",
        "documentation": "Series A-1 Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "jan_SeriesA1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesA1Member",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1",
        "label": "Series A-1 [Member]",
        "documentation": "Series A-1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesA1ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "jan_SeriesGConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesGConvertiblePreferredStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series G Convertible Preferred Stock",
        "label": "Series G Convertible Preferred Stock [Member]",
        "documentation": "Series G Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SeriesSConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesSConvertiblePreferredStockMember",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series S",
        "label": "Series S Convertible Preferred Stock [Member]",
        "documentation": "Series S Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SeriesSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SeriesSMember",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series S",
        "label": "Series S [Member]",
        "documentation": "Series S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled/expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/expired (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails",
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance (in usd per share)",
        "periodEndLabel": "Weighted average exercise price, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r466",
      "r485",
      "r486",
      "r487",
      "r488",
      "r491",
      "r496",
      "r497",
      "r498",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, lower range limit (in usd per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityScheduleofExercisePriceforStockOptionsOutstandingandExercisableOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, upper range limit (in usd per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Non-vested, beginning balance (in shares)",
        "periodEndLabel": "Non-vested, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquitySummaryofInformationAboutNonvestedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r207"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total short-term debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r221",
      "r777",
      "r904"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Debt [Line Items]",
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/Shorttermdebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/ShorttermdebtAdditionalInformationDetails",
      "http://www.live-ventures.com/role/ShorttermdebtSummaryofLongTermDebtandOtherFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r283"
     ]
    },
    "jan_SkyBridgeAmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SkyBridgeAmericasMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SA",
        "label": "Sky Bridge Americas [Member]",
        "documentation": "Sky Bridge Americas."
       }
      }
     },
     "auth_ref": []
    },
    "jan_SoinIntangiblesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SoinIntangiblesMember",
     "presentation": [
      "http://www.live-ventures.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soin intangibles",
        "label": "Soin intangibles [Member]",
        "documentation": "Soin intangibles [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SoinTherapeuticsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SoinTherapeuticsLLCMember",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soin Therapeutics LLC",
        "label": "Soin Therapeutics LLC [Member]",
        "documentation": "Soin Therapeutics L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_SpyrTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "SpyrTechnologiesIncMember",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPYR Technologies Inc.",
        "label": "SPYR Technologies Inc. [Member]",
        "documentation": "SPYR Technologies Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleDiscontinuedAmountIncludedinAssetsandLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccrualRelatingtoCaliforniaSalesTaxAssessmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofAccruedLiabilitiesDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsinConsolidatedStatementsofOperationsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofDiscontinuedOperationsintheConsolidatedStatementsofCashFlowsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofLongtermDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofPropertyandEquipmentDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofRelatedPartyDebtDetails",
      "http://www.live-ventures.com/role/DiscontinuedOperationsScheduleofShorttermDebtDetails",
      "http://www.live-ventures.com/role/RelatedPartiesDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r366",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r401",
      "r402",
      "r403",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r763",
      "r805",
      "r908"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r255",
      "r256",
      "r257",
      "r284",
      "r310",
      "r311",
      "r318",
      "r320",
      "r326",
      "r327",
      "r379",
      "r414",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r442",
      "r443",
      "r446",
      "r447",
      "r450",
      "r551",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r682",
      "r703",
      "r725",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r802",
      "r821",
      "r829"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51",
      "r244",
      "r269",
      "r270",
      "r271",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r304",
      "r325",
      "r380",
      "r381",
      "r452",
      "r493",
      "r494",
      "r495",
      "r517",
      "r518",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r552",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r562",
      "r640",
      "r641",
      "r642",
      "r660",
      "r725"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r325",
      "r582",
      "r648",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r784"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.live-ventures.com/role/DepositsandOtherAssetsScheduleofDepositsandOtherAssetsDetails",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.live-ventures.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.live-ventures.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofBalanceSheetInformationDetails",
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails",
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities [Axis]",
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r461",
      "r803",
      "r804",
      "r828"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r325",
      "r582",
      "r648",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r784"
     ]
    },
    "jan_StatutoryInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StatutoryInterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory interest, receivable",
        "label": "Statutory Interest, Receivable",
        "documentation": "Statutory Interest, Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StiMergerSubIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StiMergerSubIncMember",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STI Merger Sub, Inc.",
        "label": "STI Merger Sub, Inc. [Member]",
        "documentation": "STI Merger Sub, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockConversion1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockConversion1Member",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion 1",
        "label": "Stock Conversion 1 [Member]",
        "documentation": "Stock Conversion 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockConversion2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockConversion2Member",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion 2",
        "label": "Stock Conversion 2 [Member]",
        "documentation": "Stock Conversion 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockConversion3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockConversion3Member",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion 3",
        "label": "Stock Conversion 3 [Member]",
        "documentation": "Stock Conversion 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockIssuedDuringPeriodAdditionalValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockIssuedDuringPeriodAdditionalValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period, additional value, acquisitions",
        "label": "Stock Issued During Period, Additional, Value, Acquisitions",
        "documentation": "Stock Issued During Period, Additional, Value, Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period, shares, acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 preferred converted for legal settlement (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r50",
      "r91",
      "r205",
      "r433"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for equity financing (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r162",
      "r163",
      "r205",
      "r650",
      "r725",
      "r738"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying shares granted (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Series A-1 Preferred forfeited (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/MergersandAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period, value, acquisition",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 preferred converted for legal settlement",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for equity financing",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r162",
      "r163",
      "r205",
      "r660",
      "r725",
      "r738",
      "r790"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units granted",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r162",
      "r163",
      "r205"
     ]
    },
    "jan_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "documentation": "Stock Issued During Period, Value, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "jan_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "documentation": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares returned to the Company for cancellation (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r167",
      "r190",
      "r684",
      "r700",
      "r726",
      "r727",
      "r777",
      "r791",
      "r823",
      "r833",
      "r892",
      "r912"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity note, subscriptions receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r162",
      "r163",
      "r166",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r574"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Intangibles",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "jan_TechnologySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TechnologySegmentMember",
     "presentation": [
      "http://www.live-ventures.com/role/SegmentInformationScheduleofSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology",
        "label": "Technology Segment [Member]",
        "documentation": "Technology Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at December\u00a030, 2023 and December\u00a031, 2022, respectively",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "verboseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r500",
      "r608"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in usd per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "jan_TemporaryEquitySharesIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TemporaryEquitySharesIssuedDuringPeriodShares",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series S preferred issued (in shares)",
        "label": "Temporary Equity, Shares Issued During Period, Shares",
        "documentation": "Temporary Equity, Shares Issued During Period, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockSummaryofSeriesSConvertiblePreferredStockoutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series S preferred issued",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.live-ventures.com/role/SeriesSConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series S Convertible Preferred Stock outstanding",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r87"
     ]
    },
    "jan_TotalConsiderations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TotalConsiderations",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalGainOnSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Total Considerations",
        "documentation": "Total Considerations"
       }
      }
     },
     "auth_ref": []
    },
    "jan_TotalDisposalOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TotalDisposalOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalGainOnSale",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total disposal of assets",
        "label": "Total Disposal of Assets",
        "documentation": "Total Disposal of Assets"
       }
      }
     },
     "auth_ref": []
    },
    "jan_TotalDisposalOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TotalDisposalOfLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_TotalConsiderations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total disposal of liabilities",
        "label": "Total Disposal of Liability",
        "documentation": "Total Disposal of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "jan_TotalGainOnSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TotalGainOnSale",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gain on sale",
        "label": "Total Gain on Sale",
        "documentation": "Total Gain on Sale"
       }
      }
     },
     "auth_ref": []
    },
    "jan_TotalGuaranteedConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TotalGuaranteedConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails": {
       "parentTag": "jan_NetConsideration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.live-ventures.com/role/SaleofRecyclingSubsidiariesScheduleofcalculationofthegainonsaleofARCAandsubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total minimum consideration",
        "label": "Total Guaranteed Consideration",
        "documentation": "Total Guaranteed Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Receivables and Allowance for Doubtful Accounts",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r368",
      "r369",
      "r374"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.live-ventures.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "jan_TrusteesMain270LlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "TrusteesMain270LlcMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Main/270",
        "label": "Trustees Main/270, LLC [Member]",
        "documentation": "Trustees Main/270, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.live-ventures.com/role/BackgroundandBasisofPresentationDetails",
      "http://www.live-ventures.com/role/GeoTraqAdditionalInformationDetails",
      "http://www.live-ventures.com/role/NotesReceivableDetails",
      "http://www.live-ventures.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "jan_UniversalLifeInsurancePolicyPolicyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "UniversalLifeInsurancePolicyPolicyOneMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1st policy",
        "label": "Universal Life Insurance Policy, Policy One [Member]",
        "documentation": "Universal Life Insurance Policy, Policy One"
       }
      }
     },
     "auth_ref": []
    },
    "jan_UniversalLifeInsurancePolicyPolicyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "UniversalLifeInsurancePolicyPolicyTwoMember",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2nd policy",
        "label": "Universal Life Insurance Policy, Policy Two [Member]",
        "documentation": "Universal Life Insurance Policy, Policy Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.live-ventures.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r237",
      "r238",
      "r240",
      "r241"
     ]
    },
    "jan_VM7CorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "VM7CorporationMember",
     "presentation": [
      "http://www.live-ventures.com/role/NotesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VM7 Corporation",
        "label": "V M 7 Corporation [Member]",
        "documentation": "VM7 Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.live-ventures.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r320"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.live-ventures.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.live-ventures.com/role/EarningsLosspershareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r320"
     ]
    },
    "jan_WestervilleSquareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.live-ventures.com/20231230",
     "localname": "WestervilleSquareMember",
     "presentation": [
      "http://www.live-ventures.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Westerville Square",
        "label": "Westerville Square [Member]",
        "documentation": "Westerville Square [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(ee)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(n)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-20/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-10"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(4)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13J",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13J"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>133
<FILENAME>0001628280-24-015260-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-015260-xbrl.zip
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M0W(7TU3=I=EA7X5*G[ZJTL\9'CGH\)X,AZ=_NY,]8=B-&+ OJL>COWF&1^;
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MS.#E2J3G9OL['Q2;1!_7Y8 "9FS__ WBV3U!Z7/.^BH$H4 GT'=  )AN7XC
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M-X80$JB*#=TR2)A;=Z!1*#JP<N(M(+B+"V G.18]%=_0H0#W@?@.<2[((7&
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M15TF"Y"!Y.G0RS7?&:%&C1,(--5!]]+=-@F!1?]>C</&L P6O:%&=QO\PMC
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MM1J,\') IYR:K555<_E()P0E!MK20*<5,A[N$^(HN>^S6ZRVFD0YO M]J%5
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M!QH!>IDI/T<*(7*!!Q.3W(*I!FH"[P[P,KC#NTF]V:VSSY>"B#<2=1L',E;
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MU=I(8N1E86PEXJXXZ[)Z=(U_GM,?2=R6V1DZ,,8S4(XP8B"\L)I:S#FE0%C
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MAI1\F+":4M[T<1APBW3$J"!<6_B#&EB^O,U\LYZ;^6KW^,#BN\Z]4I^H[U1
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MRKE.8:4<V%[,:M7& E^_50$ 4K"@4]I_S)&F$A&?4IVPI/ S_13-G;/SP4]
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MJ:#,T@7:&BD.DYQL<#2CO4G!!D0S!@LW:==9.@I&%U%>,(Z7.:"%<!<WAK(
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M4-ALV^BVWW>CK71]Z#9V!H_T6=[8>2UH#_UB[=<_GV6_KGWHY'130R=O.1
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M;D/_"7N\_(ZWUTD;$S<[V6C36(9QK95#'C"[G6>((8I=(JG?I8:5O$H3A/S
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MQ"#)D?>:@+JD/:J;!#ZYK!K%/H7:8\?DP['>] @3KI@OR,\S-')KWAK+WGV
MW8NF)97QMHGHLDF*%U J(&8IY%+).=.PNM4;!.9E++DI!!)1>F42S.])[GG
M9*#!J+/:L%^8FW_%?OZCW<XC3>W>"  0[(ZX66U__RJP&_H3US28\$H,GO;\
M1LY;>L A@D<%39?2GP$S1?=$Y@1 ]W[>BCZJ/75-]_.")+DQ@SWF$;^ ?";X
M% %7Q"'@Z!LIT@R-DH=3)6[<L4(>00TWR%,ZR\OTK,73)#<S< M@)P%?;"]2
MJ-TBG$#5XL<&S6PZRR/,.P+[+FYS6L=S.]O)K2[H8X"6#[[%W,A^'JO9=F4G
M,4[);].I8OKILR+%OMTFK5 6 BZV."?3S\MB+W>KYBY[CV1%E+%=IRN&-2-]
M70FBUT4(XB>@5+%S#^%!5H,6\TC?= 1KH,)HSA2,-'+90S*:A&?#A;NHLV4%
MSI+\(;)<S5X,+K5J()16"RE,.GP2FHO\W8[IQA /!@G"I;LUMF:J(7$:$+3<
M2U.C,-D)A9AL64+2S)M-RO#+*U@%B5.5@VT=CER2J3R93%P-XR*=3O%=Q0R?
M+L#/ LZ<,+ 4I6_*9WP(>@LP+I2BY@'V::"_:2Y-!<Q&CU9 V$HBKG,LN>LN
M3")/K[]^E?4E]1I]VDNE$5W+#O-5?ICZQ51@3)FK3Y&:R^:MO##,)*VAUY2U
M%A;/36%CB088TJ3\$+LYPF*BY[.]^M1Z#2ZR?+2%U<_]%G9WZ8B7##2ABTA,
M6G=90- &_5@/2=G-B#2'J&>@4^Z]W:6L A-<R1-O54%8,<M-C8"CHU5EY8&=
M!&VZ!^,UW]W/+]3]O/_=_?R5%5-3/\A9?[:Z4#G.R!I2-<'$&4M5,H!'IL=Y
MZ15I2$^L+=$M'3AXY$TF8<2?C!"S;C,9&BJ^\6ZD?*XJQ"<,0&7HGQ2*245:
M<V**:RJ7$)GR3PE;<]M:C[L#47Y.:?Z5 W'9?:Z34&(:NXJQ6T5++4<4:2#<
M*NBY7?B$77#+B+DU'@G?W5#E7-":R61L,^R>@>V^<.4$D-",HU:T%,:+WJ93
M0>M;CCD",\RS\;!P3.6@HB46%/M8Q6H2MC6\:]2R=H[V_J>-8\L5.FII.<&J
MHW1%>:+W\Q)PI18AJG'R$3PHC"0W"!9%:>+PTG$HF2=_^_'P! Y 7M.RV 2B
M4EQ=IZ2M8NDDE;4 M,V\N9W>5%7<\Q)"+=2YMIE1MDOA9]4L94I]HK0*QF\M
MI]ZR_VS?7#]LTR1 M.'$ FIST45SZ^K486X1&LV%W@.+>$I*,2]&[.G,'"NI
M>,J3TL!J+,.CWA[;$V"EM6!7L$=].O4#@3'L^@C(E\)3!BX2E<9KP,:K07(F
M/6>FP%Q#;+V?.BXP62KBJ)3 X=S)'JE\RYE\-->6P0I5UI>"/5VE4P:>;"V<
M>$2R>IT?Y]-2/U&I&.?)LPE1/L!8Q=R0$DM <:4-BJ>>/L;^.>^-T$EUO5Z@
M)A[H%.:<-XSM2>F%U+O_""E*92&=*!!226#50\M4%OJA3 %G8S;,!0ADV_'N
M8%#Z/(:Y72?KY630"70J$$$^+]$*71-RM2U4#Q=&LLO*CA.<^J1;4A SH8?R
M4;VC9+!03<1'48<EI\UD<'!+U89#>!L"@ZK/G8229@F6Z:WWSCX[I9S3IZ@$
M2&\#:WQ1;K45>]5.=D\>\=ECEIV*,Y8X>*9>%_.=/I;9.I8[_SJ<*F#%;5[]
M-4CCA^'BK.T*8AOLOGKZ&DSXVTN2Q=+B(2%#WAN6D0\S\;IZ8V5NPIO1^S].
MDT]@,R/P99A.A4GYMQ@1V2+FAC9U#%IT^DGEW$RM] $:9]"VJWL:M##SVBM*
M#Y)^4^966+#EF;<6%X4&D&(VT:\G^&D,2+8XO"9/26FOWW6/J)56=$52R,N4
M64M'M1O!+ES]K37$DN$SO-+JAKA-#\(\C!FW_4#%I^4L$3FVG^5669H(6GA;
MY,TN%N-SA(W\,)!&JK*N)FLAYCQ!T&1S1F98,X9#TQC"[ _6!.^;5/9LVZ@E
M%0K/R@,74#LKU-EU<1JCFI-N@[@&-.8;L!9OD+K:L[_MP_,,&B>I7:-Q,FU0
M7YFBHP;D,*\DED'12%@GHR/(RP W".0\'CY%MB2^]":\HVSVD M7Z+R8%;1\
MQ_<V;.S3UI2:\;[>UBD#R<PVCVQ>+GGZH+'1E+;"28DIHH)MI];-61MXP"V]
M2!-CM;@0&^2!+5LQ/XA(>0THJ+P0HDB ;DP(<9MUVD5R9'&V?WV_[Y,B"BQS
M7<*9=5%VZP44#M:6>*B]&"@3C&/5SMH0A:PFB4#$OL&#]ME#R]6(S&K4E)E\
M=; P0MK:]@,%4_NIP]8,.5$)#43K'\V84?M>B"Y9O[PDT28%/RXXGD:6SZ%X
MO00TYSV:,R\U&#CHL4+.*.,*I\CHX/!'<VHYQ)VB,9"&MGBK?5F'U&DS-WG.
MQ92'@"-8!,XF$8_JBVK)!]A+U?=,D0H?FNP!KT,8F^W1T2/>:%)R*ME!C50@
MA<.)RYTKCRBM>91DV5\W/F&?OSOE7ZA3_N"[4_[K;M5#*MEJW1NM_6X?\A&)
M@-1B>7'][ *!7,_-J+2@\BQ;K)Y99*=IO"R?Q\H3%1]+)1K"IJ9WQLL^XIU=
M,\ -(WI1,XH]%*\<B<BY#MGC%E!(OTAE."..#&#3%.M(XO'"9"%TA)2%49P*
M)(KC M+V'E='\7@K+[-TZ/V],I@RU+3_/HS#*>@>ZUF+/)3%ZY)>L;)Z9--$
M.(F4:2",.V<GS;1O@\UP&QTB72Y%)NMOA@)_QOR296PE$BG*,@+:P7GB-&]1
M:/7E$TDNRC28I@9KJV1//$3 2+4/63=&I\V2$E"&OA1%D:C6)0NKP&)^0]72
M@PB[-1-AP\P+K#-&E#I7XBFQEX&=DN%#7QC773';W=_=?_5(?GC*;CV@,&:Y
M*^I36PY#DR$H@7X:SJH"OWF=H4SAFVU.P[*\/M,.+/T@<6>2$[%BH]J^&S+M
M2_=I+1G<'$=Z=<WST&8;D@:&O)_<9'21>$G02O38#V=AOU7M-'K!A(!XS23:
M72=\I;ZFZDS*;YL03%29BWWF8"9:(XJ!=&!5DDB,\Y=V/E=[0#NGNT>/8)!1
M]Z\)!DR]SP91A.IS5I5*;<N^BFH^25)+B#0\KH@%(6GAE(A,*1<MY[0\TE,O
M4,8<@3.6WK2Y,71<*$C\ L\+PE5DN3>=$0\1R(F<5H]DF<"::K](TPO"GLK2
M+UCBUU9K,DR/.\;I:7$"M6$KXQ''FA#O\Q.&0U=J"@CCNR2Z4Z8(UVR$E;9N
MTK0;$;"Z440E7#$V"ZPH#5Y;>DXKZ/+C<ZTO9$M6@^174=Q99^.4R>1:K1$W
ME'9MF8GGS5PI0K]MJSRI>:AP_9-*QH"-9"(/J >^:@_5";'X+)-VA@.H:UME
MR@G^:XYTE]2YB;*!7;C<;ZIV$&2!DHFR3'I"+BJ36B<DT#-XT#@-@<? ''<:
MC*;S)$83K!IV]Q'TO!;?I25++XS?9#7*5 N^NRK;=-?R#JEU,AV,H% 6(*1G
MTN;P_F9&C9U?K3W-E2?4^X*RF4%1<W'2RZ#D,CM88X!N196SDE$6MT&P(Y:F
MZ7)+@JC9LJ[.(\W*)IV:X>"11V<L1@FP]^[,>>B1QF"K,\Z6=VV+.LFYD B=
M L90<L]YB9]]8H;":,P5SN5]# .[!6VX)"YGB[HD3QB2$Q&!=5!([%3S(%.5
M7(M8/.I)J(^QM9:2ZEER>XHZY5#ZWS[I55644B*UA3A9"R)+4IM@%0IAW@7#
M<*$FP2VZI4[@\S/&QH]'"Z$ZRJUPN^%EM#H;N!4 ]M9#\K05+JFKMLX4A,7<
MQS)S+&T941'KWP,6M.6H-()\I08I*P'LZC*O@I-7.HB=FK\U+4?D@:&2W"1%
MI@^Z=1?Z-!A25MPC6X^YH2OE6@0W-/'N$E-;LJHC_9QM_++Q8$>"SPB06$4"
MURF2+3')28,3V%APP;9KC9K&S RF[*#@17X14?9K2U&C?E#G8"LP85(+^="@
M'IKFR0>':^IJM(>Z*D>CUJG3(I)S#2R[B(3,,7F_B&Z\7+=J,NU$FB)VX1'3
MK1V^1U1?:$3U\&5%5!?8)DMT#UG,DE50)1 J526#"CV4V-!(72$,CRKCD_9R
M<TO+3DVW-<)ZV0IUAB.GVC7E\0+94A4=55&X5$E(=4ZZ\N5IDRX]N'$9:^&>
M/XN2RDS?IV*L(77)C_MP9S+)_6+,P05S6;BUUA(\9X?%NU-J7-]DBY>I[;@6
M2*_VJ=SK)!^>-$@9:X.IJ(;*8"0UKU*R]8B5PT).Q5A.)AES-K(")58;K-Z&
M(:C!H<N=-]&$AH^(1DA(+:&!D\D6T=0C'?70&81V,]<<*I'M%JAP2\LET_%I
MD8.-C/ XJ>$5W"%OFXOBSZGDE&$'].3YI>>R0M?5_'S.[K#)WC-A$B8=A%\&
M!=ZC;<6$/YZ4-T[NE'V\3.N(IRJ,%2WQ"W6@IL5;UW/#V(RMB>!L%Q>VVW\-
MJL(SG6*"BEBJSWD8J>^YUJKQ[BG62Z+^7F:X&G1% E(D.[,U9<:^E:ND0I^/
M<HPA(*!UH# '#JY=*ENB?%-@FGPO>"Z94[EL4'KP[%299S.N&#P6CKO/NE2M
MNI_J$.#6QKVU),4&*,""BC'C]/;(1PK')1>T29G&HU:[M1= )1^T6T&/!XW&
ME!:IDN%H2YFVR)VN2[M/JBTIS.G#AV( G+$R\6U6[]SG9Q;C2"L3Z4O9-&Q9
MW8OS!.IK.ZQ/<\K9-CW5GB[R$;AE+AE]_T"C.8TUU6HKUWU*H3C\&4;/LPML
MD<$]:QGN*0D,3X?2OOJU,TL?$8RKZFAF*.AP]_349!6U47(S &AMC)U1_0 !
M/B'/YNF>P_8FG)+ @N*Z['28A9_S^0[UM3SN;"/@=2:L26#IVP'?7.*B0*E8
MHR:1+_G[*1[=ECZ0%4%6"3@^Z8DA3DP*=761R^F:;-S3]@O^BA:YG?_ZF@HY
M<W)50?N)EMX<<T5T$+5U.TFSE)!GV0&DC&$R 4VH+RZ0T&9T+,J6[O_:1C>C
MB@./0>6MJDI=U) Y"Y$(=93U^110ZMIVPUA0SPN);X>8G(!ZCFZ_/07E1UF%
ME\PFL*:!='H2_]CE(I_70=_:J(X":&E*YZ4ZGBVQQ*JM7;<KJ0*!TO1&V=8X
M\C#+#:H;'3_T B.G>&QQ&BYX;KDQ]3XIAW5S3L4J9K(@8-@HC%)AE@4=B"Q,
M=9JYP8>XP<&5#(%+0BHV7<5+F;6X*>M;1,>2XP[P.!Q!0CT)F$4\G+#]W;.Y
MV9[-H\6>3=RL,/CG#^'!9/]X_W#/'T_V3^&?R2MU?')Z$)P$WBNUOW]X\K^=
MXQ\VR!U:P\!'4TJEW\3W>=**;MT=#'K_<KK/R2Q9Y7 'E]=]QI4_NQS\WAN.
M^I>#+QS[:O,2:3;7MP(Q1#W&F36#!D3IHIF=?6';5FW.R<ST@5+.59J@W9^D
M<[&ZT#<X)2GAXLW=X5G7&2I_[D<4?^W'_B[)0N$M]'EK^682K,A#9A*/;KGC
ML0H$8+$32\'U6<'-N&1U->'.1Q;,UL%7MFRP5$)6[">T?"0&"C<SN'*>H6ZR
M_;4+A]M@$_#4(F=;JMM_Z7)L\=A1VN.$,)PXUS"OU$U8A\^M?\&JO\[E,WXJ
M3C#569S5#!6<!SE4 TN?U2YSNK0%[@D#*0RMGW'-FNF4*"XKCA+(,E8]KKE^
ML&37*V5<X9Q&:W3I6@ZMG;BN.-_ P/E7IZK1&YZ5?+A>;/;U7*)Y9>:L+A-L
M\_A7J< $$GBK[KTTY7*:1-O/,R\.E2D0RZP<BS8;.T@4QPS83&<OON0,E=!7
M52R ?>-*AU&_(5NSBQR=,0V][$M<\H_D<&SP=M>E*FG/(DY+3$1.ITGHY!8/
M0S+DU=1$RR4:>?=9&]YR)9U;5\YC>EZ&6<OM3&QW<<;&DY9\B2ML'1>=/83L
MZ]GMH!ZA&U3"ES@K!G1*G![;L^4D.3JS3#OK$=&^N GBM_WOYNYMUQ0%U/H!
MC$T3>Q6LW3[_M.2->TJ9P)(W;O!HZ,Q2^]9N Y>\?^NW?2,8![8:52]V:_Y[
M>.BB&3GXOP%86O]U>_S4O6QO=+E274>KNWV*AOBE_O;?M'_?G Z^!R16&Y!P
M_O;C:>>7+AAGGYTN_'VP< N?&J(X7ARB^/LX">;PSVT^C7[]_P%02P,$%
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M;K?)GU_&V[7Y9SBH_U5^ 5!+ P04    " "=@HA8R)C2*MSJ @! ?1P $
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M]95%WWAB/LJ<JR  <0RNHV+ %&_' G[)58'[3*%EE.#],D;]F<:)&$[E3R)
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M9@'TZ]?K9CUR/1E+X?%>Q3"63<S*P(W05OPC8QBMBF'\T R#+'</-L<MYCC
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M>MEF;'FRKU2%993HP_0:= ZP).%8$X*0 J!AL2TLCHTH?I%E:+,X!OF /VE
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M6$[)[)%6$5ACTM51>I$S!IH#3"#V][9E\8DV8?J*@\/I_HHL/=;'V4N W0W
MIHB7%=<J7[J.R=''A_;"HY$_">RSDQS7V_NOX'%9+-+)/;G_?G/J7OFXVJT&
ME0_]P3VO#O0"*K>(QT :,1ORA,((0Y ;%2A>#Q2?[AP !K(&9*@W#'B49$P5
M$%X/"%^8\PU9,YQ0ZI#0]\"&H!Y=%1!>"PCG(#$#!IH6J$E&BL4EC#=03[B,
M;_DL_J9T<1!O%F9U4.J/-'U0:9&IA=JUB:D5I+R0OB#B..6D=LVKU4:>S<I4
M!MF<5!IP?6D2G2N3""R3?^G3^)5CR&GK3/RS0&5X8H@PYA165]9M;=8"E#8&
M)5KCS4E(\?885'T?M$>%(@53';$%#9'L.6F+H,/9BC K5UFI8Y5$"I=O0H_P
M#<Z21[G-#C>+< 2 P#0<"IS9[[5)I+585'GEQV\P3\#+;Y2!5)G=*VU_T.+)
M<@=3Q<NB"6H# 7<B4.G!8"FTI>7*]:YBLA8/QA@TI[R)?&DUS!_"[ @/GT$Q
MB@J,)X8\2QO > &F_F;/D.X?R417-(#0O@9U?(1)2:$CI-$/B[Z5B7M2'#@B
M<L@A@$&/S#Z_X6H<J(.SGL+9( (IN^2_B,G?[U*F]  -_3R;K/!5^:[!_"',
MN2#>Z34, ""WE=L_HZY6Y?8W8"VO[O;?5(6;QV*?S3&$"'G:B"G&#><3J;:P
M&.E;R"F>D#4@_)$51\[/.W^RH([)6':KW?S?D=WX<S+:03;^\TXO /5#\C&\
MH=[LUEL'%BP90"!OFVDH<=29W+U7GU+$CQ@_V[8%X2TO*V+HV/N3.VH+\2Q%
MY)ZMM I;@5M:W7:W:1]T#O[77KSXUO,6;W?:+UG\)KC;8GPC]QE(<A[%4E'(
MD"UWN<Z@721 -1TRFC2$ E Z"J57&/VL()$1+5UK4OXB*A=:8&D'>GXSZ2"^
M]K7!QT!F*2?Z[N>OIWLJ'5C?+H)$^"#EZ D//93.-W+N[IY]O=ZS=LDUS&AO
MF!J0J-3';!-:D9GN-:Q_>EP$ Y#BL$]0"A+ GH:UVVHV]_>LSQ'GUA6#=U@?
M1>C)5O>8;0#G:W6:QZVC;KW=;)F=I_54!J05%]! ,L<S#2[OG>9QBI=M^![R
M;2_#B0[;K47$W#K<?QXQM_</MXV8/]UA)DVL*JYNT1\GHWVP* H^A9',],T5
M7(*S8X5WJ-#'TR"A;!'M@T=E%V[_:^JKB)[4F=$:+3ZW>WZQIPM92$66>;*8
M(T09.CF!EHF?PEZR@@&#!V"M]M!KI:F-0A2XFA2H,L(0S@WH^LB'*)P!+\0C
MT.]4F(I6A&8MR,4\E?=7CJ1E 40?#DDD*7"(TZ][&.PX_6K]/XC2,P4Y>@OR
M7?<S3;32PP$F0$M*X8(2K4^_UF3TKO"%?$FD,@++G&!:&1X35X DPP).P&4)
M4]N7FZ_4<XWS[4H]-V M/VQ6SLZ'C ]I=E#TMR,GQNP%&=@CC@#DGQ-^H)C9
M MK'1]. 3JK 0N_A/>@-!*:=4CB_5!"I=:DU.V;O==4MUC)>J;'$8HC!N:CC
MJUEC^-W#:[(]P&0\C06YLASI+-&U,#K'WP\]#KHB;\R*JG,I$"](((*6> 3_
M<PP*3+W5/CC81D6P_XU['&O$OZ8Q5BQIAZG4=1,V"#W\\TNN(%[E"N()W$I'
M^$7X ^M,^A>9M7ORY6S/NE3HOQ9=L;.,KGC4Z2[2%=M-^YE6:_M%5NLFB" #
MKR_!FU$$_B.,04%$PV;WJ@^Z7:VD[L%[?*Z2MW_Y>BDSRCVOF$5$3"A'AB]G
MLL[&#^-$MSW ?"B5:[R7,<2&=:HMB[*^AJ^(QV +8GJ6-4PCTJHT$\QREF(S
MXQB/>>]CV6"U-LO5X>QNL*@QC6>M[5(0)_,-L\F$RWR7P3WF.RG;" "43<I=
MK//3,\_R<16@?,4H<7A;P.2"N3WK%$%)!7?2'2H1,4JL(>@::<3?+R5@*IBM
M&69%R\]=S,ETNBI3QJ*CY\O"4V  :^WO/=Y4P?05$P7FH>D1F%4QCA23\7Q2
MKJ-5'0]5':%5'0UC+:L6><^R[,L'7F2VZK@8Q+\(E-(SH<@L (HNW=Q9LR@,
M2ITB*$E;BS;,#Y],/,K!E&^C(YL);F?-463TV\6$:EWPY%%3#!:@?YCBPA3=
MQBQ1$KZJ!TPQC$JIS$([@70;L/BX8K6O2):78#F'"25K%]('*@B\'@3ZRG<,
M7RDE7%0P>$TJT&4IY?R6R@VL =>IW, &K.55W<";XQ*?L:"L%TU9%A<V64=;
M[-[3^JYLU#>U^CSKP(J]EU2PZTQG!EY+QI.E2IYB;7\B=2KK_**N)Q G./(]
MX-%:?'O=)7Q[MMU9F-31/3I\KF^OM6V^O1-5##17DRE!78AESB1^YBZE>\'K
M$WBQPA*U](_2*Q=Q[$8G=7-,$?6!T9(^?7+:MJU=L'UDIL9I[_+,"E(PI. ;
MNP,OY7L6E9FB]D]EFC-+IE;!^4^R)ZM:\XAAEJ43P!]IK-V8.LE9]J\[:%@G
M\L.ZL T5^[E=8I+^\F^-K3:]\X#JM.S]KO5??SOJ[K\?O?LV6K1^O?"\?S#U
MQ9MH<FM8GV1!)*S'#X-8W;W2A>+1/KS2B2>]C(/P;FI=7I]=-*S=/M %MP8L
MJEEVMZD>]AM[5F#];-G8BL*!![$16[G:LF']$ZPW8!*-/#YR>=[KO\? R.%[
M>+1[?-#M-.OP/U6'B9QNNY428\!:?I14TUD-H)>.9!TN];7&Y*!+'@UE"3WL
M;T85>'E^Z?XRTKS=.5@8J6L],U*WO]]\8]*<.<#:O(>D^DPY1YP;]+-E#%JH
M*V'YH,2HZ[HV6@ V' ]&,CVJ\+V\,EEZX,HKBU%0Z0@7K J$22@RQRH(5_QO
MF":6@P)I5FJ>9&T9J'M\EIC*-/H.L-J..C4HS^/EQWXFD?,CI+Z+TBG_R1(>
MR$$I@?/V$TRW/I4^3?U^=0-.9Z)&6'IS8X$=F(4_D+TJ4 _)/HD-*S[VZ[I?
M!$K0V7W]WR LK?_RDO=6L]&TK1M8W6RWB/.GR-]&+G\7B=\JERRCM/U*_AJP
MEA\BEVPYD7PE*_3B/"TBD\*_ I.I4W;-1V*WGS5[SSSF?Y"W%FL:M[@QU#VZ
MP\$RND.W=;1(=^ATFL_T!+2.MDUW^#W <@F:5C($XQ+_R^34$EB<"J2Q&&4(
M]8>B/H_V(1RT!0+SFX6=J7VT 4\'[TX')&\:UE>4.I3L#/+5#7UJR)V$)%U!
MO,VH*;ME)6(OTUN26WR/RV#3UHU@UEGCL@%B% .BU$[E"^@R8/F&&/:+2)OP
M>1)-9]:K1H2H>@Y<2*Y&-#)'EJM"%RX?@Y2FMHCX&L";O,\K+E^+914FS-P(
ME%\I&PSGRD/Y7C"7/XHHMW=/=89YJVEW:M9^>]?>.VX=-.N']EYE\F8(>E")
M7 /64HG<3.3FON]9F8LS":3%TRO$HE]N!Q\N(\OV.PME61LK#I\CR[J'6U?=
M=#YC^*I>?7G_ I97"L[5\&L/JA?*<J  V\Q[UDGWX..7=_N_Y<8;V6T-:_9C
ML\FMJG/"O=\IVH.Y*:@QB@PWK*:<685*BZ'FRU$N5?4BL+8I#.K9BZGX4?^1
MSZ,K50W%Z6C$:?@+"+-9WX%/DWBL-.;#U"-G?P($G<IL''AI5*COA 5A>2>-
M[TII]726NMY*UX+1=T2<I\*I%G2^2AEW+'<:Z[8CUN[G2,0#SJW?3JS>;Y=
M80D?1=1>W;J4N?CH,^Y:K<.CW=;>\56[>5"W]]];_81/)E+8HD(2A5D>$9%.
M$XBFL]NI=_>.K;9MU_<?D+EF>.-P%,44CNM>$^!!S?_E7.AH"2[4LNW]A5RH
M^UR-NKMUWCC==(X4X%P/!7)P0=V+?*P$NAWS4GYZQI8TW=UFX[>*;564NXXH
M".NF*94-\T!R(L>(4U?&=F31X#U:?</ZO)2ZC]GYFOD04Y(523S3@"M-50/^
ML-)4#5C+#Z&I+D; LK6M"HL7&]V:SY18Q1R+N,X'VA(W&U':[J A&FYCH4E^
M5M1HBFY^9"JJ&ZMKI=1+U5MLOJ_&3#9+9-^?7]&__+=*7(V8/Q-MV0JGW /=
M89K+* SMYN'"9)S#YRH,[:U3&%Z&)0V<6E7,K4DX9J1C]]O24Y1R@Z$]#X3V
M;ENU3=N/]V2.^YAZOB>6;4N.D/=CSA0#E/S[17XQX'"@@1KX0DO>?8CI[#76
M7=1[;XWQXH/_ IK3)HGLF,X)NX)'U")&@<JT8[K"?V_VG.:2IC16YVB:22%*
M13CYQ;13##9:T?XS2'JML6,\V G'890TK!,PBK%H2<]HDH*;!0PX*I4:14#C
MJC]C9ND/O#0>JQ[IV)PIBL+;./.PD_% (Z%TBT8]!W*$4YAD FGH.&DD!YFC
M/WX+JW)+2DK/MW[+W!&_4MTEGFS!0V&WWK>;[>-?[8/#^J_VX6'EX<].\JBR
MFPQ8RX^:U)95SJ@$]G-5.8.>C]X(YS=09!-CFFL)5-O+=%%L=>V%711;^\_L
MHMAM;JV:O"A\G,K(<1AEVE31*R['I)-_3=F[P"1AE?<XP"B$"U_WX55CBG 7
M@]L/^_WSD,-,(9:U"T?&/>OC7LEYOVBYZLX>Z,N7]*_3/(]MYJ59IP8:KIXY
MS3&2P'$ ,?Y+272<9#,2B6J_S.7TFIG-U+(P=E$Q+2OR#%N ++GIM=CRID0&
M'^+KQ58XZ(V?Z7+3E^T\MJZ/>'^^FMK#+M;DAY:-!&5K$3W[,F_("4BT"\@3
MQ%@8GR>CTO#=0C]OC(#YZ";?DUHC8!AU"91#J=PHG.3YHVCUTG@?4$0#Y9M2
MN:YZUDYXPZTX&P*C]%/Y8I4SRUS0&00E=)*-FU#UN1NBV3U95%J,LT,]\0W[
MPO,ZY9($LT0DFQMF/?FS=-K2>^1$+U=&Y'0C0[U6Z@T@9Y46\E;52'9UCQS&
MA%-F,<=$;A6L^*HWRP9Z0F0NFQCP&&0)9NLB?ZQ1HTS,# YD>P&7H1O&K<TF
M.K^OH/9Z4+O/X;9@],%#N?(5S#9+:2N>.)$/D%C<9Z56;JBT<)Q$U65I$S@Q
MV_D%]1(,CTM7R TO#/;(BDGR_KZAR[VX-C<_A(8F3L9Z:J)4H-6%4IN+B@V\
M(L@73&N1OBO,2U[=O):JN=8KP[6OAPEG@VGGM&JE=L^/L,WNR#1N;3&4Q@'0
MR,S%%D3EC,WPPVY6WE@#UO*VLUB>%#I;?JS]UOA18-D6CNW#B=$<?6FJ]RJF
MVQ2:M<[T]Z0AZ0OF7:.KHS ^F7!!]:S["YMLI)'EI%&$[A@U@@'=*JYPX=5+
M>0N>[M-N+>/3WN^T%_FT#Y]9N&VF2WMEJ'X)XG'K$!T7+6>- .8EREH#+)=N
M:G+$,8_K"NU!Z$YU#V*9TN(05Y-]ZU& 2Z\B3>Z1AI?TIUAQJ-+7N0,2G45J
M I;^7CP!@X_'Y$T<8-_&%+W5DG+.Z:3AC6<!G%2",Z'QFW+2H^Q*33I3\_WY
MV:_T+_O]'I#M$#8;EZ9JHQ.>_BOCW3P"13+!VO)IJ')F53:_,AQD)1J9H9B]
MD,*J88OEA]&]RNE'?"UZ]"DJ@=Y#2J+'6>>^RAPN>#7E<I2"# +7 MAZ,K8!
M6"/<E'FQ+FO['30M>+Z?R()_6"J%Y>U&UQJHIR8\! ,+S)[(<]',?@\/IJ!8
M4P-,=3%.<42Y;"136@:M/9_)*(UHQ>14DW"<&(.A&W] *N#N27C+ Q6AXRE:
M7">PN%%(33@OT@24MV\UZRO-L6PU[:.]AG52_"2_8S3@'CFJC]H_=J[!UN*X
M'![YJM8"$61FW'S$QW(P@V18_ Z[&@DLX(>E>_@*.(1OL%@]S$8.P<$("*-Q
MRFH6>TB>\' B0N'6!U1@Z$;I*)8;YGZHD [_ DQ"LP7[$:21B]W+PVAV @07
M<+1(H=2+H.< >I.MBF[Q($==W%<V9DIU(\@0O.<PE_MXA#*<5).'1>19".A8
MDW2 51AC20&P41 H_F)LD4@7(J:BK,)AWKJ5PG]V]YL9 N$F_G._W2W\$- H
MBH9U"M2I]'P+:!E>CZ,WU=II@6H%:*('X4T6HZ/.Y.7IH$D!8TC?)D=/UO25
M_.D>V/*#F*)??8$,!A"H2?[W"",:-US>VVIBLW0L;\'A&5/ZVN?3'L$&_YVC
MC1JE6\-_2,^_W9+ILA+\Y')@U-0I#-0X,\2L!/MEN75MQ:#E&5&5#LHY.%(>
MP<,UP(X;54RKWT,L PXM$LIV36[#^3MDL(#?"=F:@K"/)H)BNI\Z-SG2 @Z5
M>_.J04DU09;@A+X$DR=\12"R0:]2+@I',I$72XB<-;>^'8?W<HM9W"[/JZ4)
M4(!Z ;S8153$!O9$@,2)B-.T.G^?;\%,/;4C:GM%8^BP.SJ(*0VA% <I?9S*
M'>"G)?^4E<,Q*%"J[D'E6<H["O1)0T& @@/U.: !RJ<.Y(C[8OL-\D &9#[B
M@%I.+ ;94&AA( JSM]6J8KT _*H3"3I3^"[(K;Q],D!M@HJ1%%I2':;7$B;[
MS.5J?!;&;4=86\4=$2OV- R=--:3@3$I*]!RK*QXXND-"J>#;Y2:R93<I7JB
M- [%,C**NSHE##XQ&?-"UL#,,$T3-K!D]K99BN)]!VOM*NT+D"O3ODAD$<-$
M31 $.G&:O+X1Q8-DQ7FKG[P606F8LNA2H,X6*0* FYQOJ!C^,9;T)4<VTX2X
MW&.$9*SD#QP?:!@BD4+54PG86.D%)P+,6S7=DU2%HA[N&*5<#6"J6=361^C>
MXW(\NS?4$60]+5I&UEFL%5$14!U90A%VQV,I!;;1%E0GA*%E6, TXU*U^27(
M@8V@3]R0\AB%*?!#C'HU )[P;UC2&-;R "^-I_X$S"^XZ$A5FJ:W@)0 %;7$
M%*QWUKU+IDWB28=X4BIKY#33%K5L^";<@$]SM7$\1;:'I;3:@1O[X3>29VK8
M3&G<:)9+D$W)DACP#0Y@C'!5W(MB\N75U/#$ *#DRL,T'H]]3WF\!\J:\$!T
M3.!K-,E;8]HM?%TV< 00R\QDDF-J LU,_RL%=H^/J"H7<WJ83WP=+1E:LSQ*
M[.7X#8-9Q1Y3/"9?)WX%%J(0>Q 1K/$<R ( A#:2*S^<7LLS#,(]D;2FIEND
M_.285T1QI82#L!X"BF/P]@9-0;184-/LH_ZB#2:)$O+06@4#:=;4D8*4)C-B
M;#%K0UI:@^95\"XYO*A!:85J,7D=QUR6EEJ\!39L#3$67Q^/631!+95J+ C6
M,J2YWT0,22E6!60&-BPA !$E (C1XB;A1!4YPVW21"0%0UN(2J'0:U,$>@N[
MUSD*<K'W3JSGR3A0E>41(ZL%\]E LPU(B:&QE=G[-2=39>2J+-P!PDB1=;L"
MM4!.\T)I[ 675IB><5)3M$5;1'XO#SM[2,%45["SF9T1/N$'02'/#>!%1B]\
M!=>*GXD4\Z/TGK&(7#K "(>\99HA)1P!G2/#R9@USO #I0YP"CZ#C!0N2KX(
MQN\HH'P]==QI+.?P40&-@J!&!3Q-CPFEQ4L+;4[8 */2!I)\BL $@$,5F9..
MIIK/@%P$=BQD,P*4DEG@$T>]RL$C!4Y)AI!2+;52*['#&7/G&[T!!\>R;Q1/
M(4,*#$9/3H<JKI),.]U<IQQNJ4E79BF**IDXF 9A/"8JP(O ;K'*$&RA9 P<
M&53=O2+#5+P>G3\XR3;!/D1HLE1%R85XCEW%<PQ8R]N.YSR(@8_K@ W5+R=B
M/D;KL<T\J#\TST[]AKP!A$;$%%M M8@(7_8F(1>%+' D?V(8# 48!4F1]RZO
M Y4#U/L/UK@6!X_;AT?-UOS$R&<6LBX?SEBTWB4!?0)?'T3BA<,.2-FR[&/K
M$^D&=9W]N$#1 .[M\UP*]VOH6 "X-:SS7_^P?K;.PZ#^J\#5P^-_C 49 3\-
MHG<?>CVXW!M&Z*.T>CZG?]2L7_OPLWX"[NWAW[U8%&["7\_P5_4W=FE"7PUJ
M#^C:.;9V3R+Q/14U] 5V][9/6;ZFV$)01R=?V3/YF/6E%3,,"E"W#W(+I5%F
M73N9X[U*+'XM!]3BD8)BR.DU&ZTC567C8-X(C"^##EMHZYSI[]H6IV <<?@*
M=S:).Y_TQ' C4"?S)HU#,J)JEC-U/*PJ M:5..,:51S="I_$?&9]H3L[^H9,
M2EI:LH+ILPRI4G4QJ J%7%_D@ZY/[0XH2 +6ZC=MM%F[V@23057D>N2ZHPUC
M@31V-Y6M$881_YYR5>@42CX)]^<3B7\-;]'HKVG7C(ZJ@7D.=FE4'MMI[1;Y
M[Y[JT%:,OY'=[LC1AF#E1ZC5%$T]<C_HUU6$M5'"(KT5S'5XE1&TU9..0Q?U
M,4 ZZ9D@%Y+R!&KO.J*<I#8=Y&'6  @B!"V"TBQ=?D/ECN22S%]*)5\8_L/6
MACK_/D!/I4)D](]35S_T%$AG6.Y8S[R6%=IN%&T_3B<,0-9/HQ$B@Q&8J_W9
M,BD(\5?FS; "B:G\G0$MGYIK)B)2Y7XE-$7N.YVHF1(EE'3($4NM*Z2S'#$3
M6:S %)$@!O8>4>L*K A&W^/N_V<W*<=<4%UB+%EVP%F$R@\ZZ^#G+72P7\\$
M<77P# \"<Z@!;]!=)Z57+#&E02A#I3&4',%H> :Y!^&16N:;PW.+4O1 2U&=
M2S^'39A#!<OH[5/"& 1=@BE #>L"7=#9S2*).4;#0 K"*2L^Y65ZL-8\J30#
M+9]\335B5 DBQ8 J!A*S)_#=$Q0M!OXI@6-Q^LE,/!YMOD5VG8_Q* QNY#9=
MS9)SVV2)XEQ@/\,)4NI5K7DUWGBSS/MD''J<TH.\.LV91U#U1J12*VZZT<YQ
M&%/!J ;BS$  N@'!(_9@U!0KP%%EKC!HLUHK\@%@ B"Z9+J@2N8R0A&0F6TJ
M&].C()9*G8Q3S.@ .8VI:RZVD_*P@Q6F9;*_L(,:>H3'E%]7V&">(E7AW>;Q
M+D_<P%BI"0AW6<IN*8@_RCF8:35!@0=475#GB;C#T6N F39YEP:_0% @=2GQ
M@\]%0#4N]TX^@70>BX&@1!599@IW),*IK*3-HFO6K>9:3X$S E__&)-0!0P:
MH-I,U1"8SJU22B@!0Z,TJH&4P *(5R]&_H>IYV/:>5+(S)?I(FD@T\W$T&(C
MW;&OK&]F+R)>.UMFC8KDLIF@%?*N"WFI\L8$=+T.J0(-D0IL.,QS"D)ES%#C
M614K5#F0>D@3VCF 1/5"*K),#[\$# CO "4\_&2-;N1W#,UP;*I2>(5*EL3_
MM'&C"_/VBZS__BB9,HT&3.7PZ*S$T'&\E.@CR_[3J6#*+)/#0G1:YFZ?!>%0
MU'O8+@M>]7NCW["^?#FAP&-SK^!*IDP:M-W0[XW]#9# 5>IUV>^&VRB="9Z"
M+^XPC;6/33[KE""+GN189HF?]WMGIUJ=JC)ELDR95I4I8\!:7C539EGYLR&4
M!/$J!BD8,$,>U JS>-Q:(115S@)$UQTY;&1N'^H'3LA&J4>1)7+MJ]JA!B5;
MD..,(E8J&3PJ&%K7G\[E/%P?^+"*0\E6"[B64@*.=/W%O! 7NU!E++/WZHQ)
MAU(448.0&8B84)A5SU%935;MZ8L8DX%5_JJO*]P<A@6#"7HHY?G#)53#GY#L
M4U0L'LGUZ11R?>">5K?=;=H'G8/_M1?6,;=;W1]FY@TZDSV,KU(U*Y8*I5ZA
MG]9<3DHIL1=D'(4Y4;Y)MWI"HE1FT,=J7(2L;4+<AL/2Z;9X8:XB7KD.P.S*
M$G9%4-*+I7O8R>8S6B$)V#1 SW2&==XT+\HG5[+LQY<&/J"<M/(\*^ H:#].
M'UI032]>.J5YL8PY,Q!G-!T93U/N\^+:2:\Z>&]]3P'PR51V^!P:&H%86>'5
M!:B0?5G$MGUM,W'QJM8NEM5!5'VI<A5]'\,=L,Z_N"S%K%$NERP"E*F/^+=B
MC3>%H>14(2G#-#4J-/1D7*70QTYJDL7JWGGT+6JTA'JA*E@L5E2I"IHTYDH1
MOZ9" A$X8H+-F&3_+5EYFD:ZX) HB#EC%"R2AH"34_DA4_&WK'%%E5ZVGBZU
M]R23@:I-]17.]U2@/TKAI"K()\XXCXT/(B,(89Q.J!@Y(@'1+_HH9'Q)53,,
M!/;EFQ:05UI*Q%SQ Z-(=C+1E>?JP<9&HQK2ZU*N0-=$%#M"UK!0=H2:OG3G
M"++8 EC ?&6T4 5ZVEQD6"BAJO3P+3'5JZM$B_)7T>L(;YJ"J)0%W>3@80!!
M/ID_<J4>CL.)'$6 )Z\A(9V-JMO,'('_P<DB#F@["K**B,M?P9:_D2QTFZW/
MEPT@LMU/6,1<,?*S>L,$@4XR&/$P%GE-.?;(#H1T5F&P7W;O*]3[@WZ9HL)X
M(^+,<1K*:C\Z$#H?^2K/4VI((9=,R+["L(VQF%C:6J6::Z&Z*<B_,?)9\+01
MK!/*;BZ\C?+3LT.1A9R4&G"G1+2LI9>MZ:B^R4D).QQ -<(A4GED?)>VDA?H
M9Q16>=1>D4/VW!M,25C494)7V6?]$9;P+5'1;*!5NYGZ>EFG0'2X628G2_Y0
M-&O64^RHH7D7NV'"([M[<7\'BH]@_HZGQ#[0U$,*,+4%QW&3JE4!/,\BJ960
MEH#%AS0+OL[J.&Q]@K$7*OB0VC%V\$1M _"_+C/.:!D%JO6F%>V\IG:AA47&
MW9CJE).3#[+<6 RDC06<E,P=S%)!>:F<N')4\28I I7<$Q)%4^E<IJ3<5*JP
MA/!94HUN5,)1& W"-%&[RFU79;FA0<OE7J6/IK3;WUAP@5UBA&Q3>B-4!X_B
MZ[&L!IO8HK^#!2F6;M)<Q>RXJ2%NJ2<(D6J:56F*:%;R5+'Q34@7!1RM#F4P
M*4H<$AMI1-W.RH)(3P]@"[KWQ-E+BZK59L4+*FSAX$_=M)OL5]E% 4N*/:\^
M8!X>"S7. +*JD^)'P4TP$T6HU$4=!Y$60U[P/B]ULR$/F$>*DR&T[5HV2BEQ
M41\F+JH*BF1!D785%#%@+550)$?)0I.KW#Y5#!);^032IL-^?>3E(*,+AR'Y
MTO5;CBS,&IY2)$_&+/)9;H62-8SSD$0 7R$'E^Q*-LS-4Q5#SI-_9))Y21/F
MF#*.D]UE>R[.T"0<IA[JLB#%):.:<XHL\CB7AL?<<@JR.-@]074A\;))%@(K
M.LC=0[:T=/@H\Y1ZYD?31>*C[,[!Q8!=C&" (PQX@FT053/#W Q6SK^$,[]2
MN%]1G?C*[F3G..5X4![E IJCMH M7M)H :PWJV,C9<D.@H2LFJ(CGI"M['G%
M'46$@7A=J4[W-C$MDH!B"[#]! L\M%^L]%##TBV'9FU7JENGIHTLP2I"TEZH
M%C$A^B='GL_^##7?<,A>5IUQB']D) I&:9$:]<(<'B4R3I6S#S$LKD0D]+P<
M<8!6<NA\&X<>" CKAGDI;U@]'-*>,ZE<M\K=227X9VI5MK@L"A8G*B%'L=6\
M?6"1P<K3\8NX1TO1;& B)IP24F[)=QIS_DVY"[/ES-L_%=O8@)V.T((OP#_)
MM$#^;0V8\VT448N>C,LG6'&Z:68AW=T@<_T!^MJ97*Z,)-^IS.*B4'*IB&:@
MAZ096@BTLDBI;H2\E?W"J2'WV:]/::^M)LX_L<OV_7VU_YCA_J4E1%PU@'RX
M9[*#K=RJ'MU5C^XWTJ.[!#BA3!/5=S)KTX@D)7-- 7$D@*8+5Z0&+F&QYAT1
M!B@:K7:&_LREK)^%>RFP=>7IEPD+2 Q,$K(:VXOWA=@JV0NQKETE0I0;$CDS
MV\(IMM+DBE0S0'HQ=NV^C\KRPGK. -$QZ+@>']L^BNPE<L'GG%+(X^OMQH+,
M,T1Y*3,V*M)/9,/89#KA\3Q4:"H;LN)08EG 4SF23;GU1##TF._C@%ED[&*D
MXMJHSZI1QS*L] V[I<M^O("!?X:"G $# "XV/40&%)#+8,0*?@(U<34<)FK@
M1#Q/#+/1/$9MV+D,=F0>W5)S8C5I+A^WG(7;0!D'UCO& 828TS,10>G9FN+#
MV!9^ %Q\RKP13B;,67>L"[2!<2+V N+?B-BA7DY2_,F=9=V3(Y;ZS,SLL25'
MB^1#/XP<,J(7BNR;>:J>7K9]ANVZ-)$N8W>3O \VP.<&A6(\C1..O7 \?#@
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M80@T58&1ILG;;/FW_W7RX(>G3?['P"#@B9)0$'@$<'U^@J?!!-'B.NPH=>$
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MCXZ&KYEOS*TP'=CM/4^?CXM<L0AWYLON'S128JI\ O)FR75<<ZXJI6.3T5F
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M^5R+*0->:*6B*A#F0D]'0(OFPB[#)R:\JW)S.*@B-#3*;L,<'UE))U/*Y-$
MA#[LRU98;(1[ 4E#;H68W><XKJ^B#V22*C(+)6;NGMD22R,A$UQ\>5KK7:76
M*#_3-.+,JA\T:/?:2(K?!+U#.#K^%C][[@'>K]^\?;[O*_[;?C)#7:MQS* :
M=(K>.C4:0SR!^,R3<S$S^9_GFKD^K]1<X;]:Z8^4]X0BE,M_&]3T2I[)I<L/
MP]^[@AQPF##01/D*[M((J1(9[.#G'G[^> <_WX*Q?,.TAYGX[$@8-P77>DX
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M@<<%G0#5.L &'3\Y=F<CV#O +@YQ1J>Y[_\V1-2*C8.O*RZ V:GIW#!QJ%_
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M)#=^JH_#\JUC@$>8,F_J$ TJ.,N,R][^V7/-3 CW1)H;^4/]D(NL!S7G[[0
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M1,U/,]H#>E#;?B%?X*MF \?7X-7SK9"9+%&P$]S!:Y&;9HN< ?Q]G!R,KS_
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MI+(A$[_,K)G6F3/3GU_=8L]DE;V$8XE&4>O'F!J=IE':L:VEC-)FBC%;9L[
M"<>)[?QIX>%#E@*(D>JJ6[A$AI;WT+"[]=-/ D#MCO2__4BS@NUGA1#UQ[8T
M.TAM<&*&QY(,9Q]*1R;_JE%RA#AQEW79;L._J!>5K0WBUK><O]3,1)M/16Q8
M%M@YU;II9/\^Q0>[W?K"L<\P\U2M!^G74(H/"PX];BCX%@-J+%>& O^B?3_L
M"4*VM$;-$L[*Y%=KIT/>_O3J,FZ^=>>KK"5(/&H-PVYGMN&S)7LOPECUI4SY
MWF5UHTGX\#D#GL+P>'"$PL0^B%A:)M?K@*%URCX(RG,M*2(X4A4:!O #PR<
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M:E9 <S+>41X&!CEP),A^+0X,0$[@6IX[8)+/$#@:VIDV,ZR$#P,!_5P6&FQ
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M1,!%T!6GK:<IMMQTH@XTKY$9E#1KV2+6$W.V@D+<382'KD+J)U*:QJ\R8@8
MZ!SI?CE>0WRTO-:2,<PF)68F4AN(9O 2RP#P"^-=F60=S;H=9S"1$.IM2;R
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MD?)Q"+0PBR/;/13OH](.*XL'L&^>Y[.A,/+,/A%A1N8#[OCU'7ZC_1JR!W@
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MUYP5,U#3,RX<D=LGV36+<VM\*'@:OS&J_;E5[XP4  G\(BN6;(MY38W1,\^
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M6<%QS;&3*7ARA-:D8X)/(074TICN?*UVB2 R-!#"RY_/_L>K;X?&.Q-A\^0
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MU>,\D%X\!;R,WW2?>AHS$VY[O),FANH(\!6.1?*.EW8=RM D'ZW#]$9--(^
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MIM4<2@= X]F@$+3)5WGH<"(\3#<(K-UR-M67="-W4 @;09=]R$/Q[Z;M+/9
MG8H6>I=]2,YZ->[_7D]:(Q\@B^ 'B_*W$NR41=5Q\H'RH:._D_A 4.DXQ2\?
MBRU!XSD0, R+S9F'#8E@L,,MU*X.<H!AUSZ[%BHAKEG)BI@-56CXU]Y_&@1J
M2PZ326H$N4A.\QGF&.3)C" 8E/,&!HL?@')>YKX%B$O1@@Z6!FWK<'+""_&C
MV$[HM6Y62_*NZ9<KVXTL9EUGQT9+5WS0RM6YSHL6LHHG@*?++#AHH'+W]L-!
MJWJ@PY]QC\FHA0^T0WV $"%]JO,^RV;@K)[:9&D[PWU9T/4[X"A=3B^MUWES
MX)$E;#%Q^G=59AIT,>)RJ'O;\O!Y0=Y&?BEA=[)H'*(JU,(^>32@B\T_3%$&
MJ,,%)"C_0$/L!M^[CV).R$A#>]YB#OZ>NU"4 "7J%;/$%I72W>!V!59W5!EW
M=86P%0=)-4/%XLSI%;VP8;=C 3PQ_X@$@O&_T4&5J!D]CXLC_ ,LP@8HQ> U
M]FATB[.>/R:?6\;QL.G-TY7U0<>,P!P#9&+:T%4"]-%J\FCU*\;"J3\06\UM
MWDDTV36L=E:?)]9P(7\9!ZAPQ2*VR<2*HJ@0#R^&,4*VO-7IF><S_J'G% \4
M@+:L8:$TS@<P850E=SOID#]%_+Z::M,O">"I_9@:<%),?24Z6A0K6L;N1@Z.
M&)K2A2TP![5S==!&1?:464 "&]@LU#C3(WX86^"Y1S_Y?@3):>?#8A+*3]TB
ML.W/9SM*A*D"#9=*.<)-J4=L3L$R>FJ!V#G;6*W00.(R-K\.\?RFDDN2OD5,
M^-SS/X>4M*YRU,J?IU/S='W E^4I'E+6K1'91QNK9=:R!ZGS1%!'@]<'$Z6O
MUSUK06U(+K@X)%$-P$H#=:=STI?OT3F$! H6>3N%X[\)QA(D0EXT62\W]'2"
MTK>7Q@YVYCG%[W7[F!<; B=P74>YT%Q^@1:D8/=HU2"A8#V7;X\OBXT9KS6_
MPC4EUT0$4G'F%,.=6W&O+;,_G^PH$K\<12(7,.@9.273]."_B^G["3HP7G+X
M(#<5:/C76YAJ: M;U]*A10:FZ%0-::?%5.!W2M!-IH'8P,L>U"S:"83++LNU
M],FS_THU-M5/E?6@LJPN:1=->(@@RR4GQAU2JIEO^T=>!9)PC!\1I]IDNB29
ME0G>UF$SN./; /G@R-#Q=A&.W?'].L=7R#PY]&-LGG/R(AU=@Y-V\D5TZ.C@
MO GEYYH_'Y[V\<,>^JAUT*.&#S^"YFJV(&)4R37@$NZ^U2 C5[_SAS#)=7QS
MN18>C[<)I?.M##:Q>HDCZI19PX&$=NO!X; [E%_P4/YR?G%Z:B?)(IV(<[J3
M:N=30K1&&>-*#,B!G?:*LV]1!I8+CFFNULHZ%%'6=W@5!/J7TJ-7#H(C'XB[
MM 6/6&;,IK\[)%_^D(!88RE)&8V'V2$1*S4Y#QA.WN7310772A"-/QGJC0U6
M"VWK[TZ58@H$$\Y1BIO]096CBEZB,S[3<FMC/P4A7F=H.<.(+T//L=/B"DOF
M@81$\%FB] 4K6Q?W"?K![,[=U]&8%XMUBZAWE5Q8I.:R1Y2@TDRPB+ [FC^V
M01EN&%Y16!'[J HM#5-S@;**+#$DN^XPPP3GQ_RB$EPL'3]0['4\!XBX,Y(*
MO1$8P"\]B"TO%>\Z8).5_FC=CE8BP+0\V&%:MF L6]DKY"L=21=4]HSOK'WF
M*G>NLU)PG:O_G[TO?VX;2=+]5Q"]O?OL"$BMTT?WVXE0RW:/=GP]29Z.^1$D
M00EM"N  H&3N7_\JS\K"05&RVTU*?!'[IDV10!U967E\^:5H-_IJ#1Q3F#4J
MJBG$E%@G$1D01$:):-4@A GU5SE--,'KN?E$#!IG5U=8WP=V-TPWNDJA56F%
M:>+-S?;];K;*&=6(9^3[0_T]#C4G-X;4#D7%4O!AF6#PVP<>$SWU39\_S&K(
M5LI2!'?IVD4\SPNFG?#\<7<IH4#^3:PSO@RYP;$G^X0Z52C6G(+J<RU5:39T
M8(GD;W?%6V--3PE*(Z5R>N#XA?AS;*ES&JV)PX:-/H?!%3NV$3$HNSK;&FO
M.\& MPZI(Y5<E-," [.FP:;6^R7-)MRJEWV,HE,MAV;=6+)G*WK<;JM'T"HC
MZ1/H1&T\PZ[$6F+%4?/7,VC]X4:I?ML1](*U8,G7KQ4L*7DY(7/IJ6X N0/X
M%I<9:?5<=[T1Y%<A@S4LTSJ%R*H,[;5S13%?3DUP9.10UXAPB4$:])U6#@]Z
M+44J/%_1$3>3(%%ZXA["\WMWY$G2SZG) Z0R;PJ3%NY^2K7)"GQG)_'8[?<L
M!P?_W9'A!X)"?Q^L4)F&;RNO/7'QXD/< I<L,1^%W3T..7.*J9,@3R6$3ZKK
M-/4X.A3*CR*4\#'Y<9\JO;-T(/P#MSY'%YA"#<[7N_!\Z:R(@95'7LPH10U1
M"R*7+S,\2?*NUTQZT#D[>)QOEHL-O06P)3+NX0625G".<>V#.^V3J&0'77]*
M1M>$;::J/5NQB$JDXUS[&A1"8#(9B3(X"?^(X20"(O9:.4QA/J.L2BD1+=,X
M.GEU%H/6& *&(T_=IHQ2(M\GLJ*L0H6)J?-DD-9:H32KBZT,!(ZR*M<96&'R
M@EM6NY@R;\;8\WA7D6VOT#=+K$N$%@.^^XW5B$RKU'JD0%%#8GA3(^Y6! L3
MX4]400F;R\E2!8 6I0^#*%LF5QJ!E "[\] 'S&A<GPA^NM&&WT\;OD]8OMX=
MJ;E&9056%0ZQW1.B=TF::F[@0"E#\ DE/.7U"'F@<,,JF7B&?:JGC+14Y4,6
MJ*_0#003Y'B<3+"-DJ&K\VJH&A93U96=!PG0JW@AJTT,H*=DXD[]B+%7YI0$
MA=ID$MLIFAE"2PRS@$*5 %E:=W3XQ F!3? ,>X^\<R:5^_TI_0I/CQGY2=B[
M67"WG@$J&$%&M0?!NY@VH,X(5QQP6V6U#%KKU)UA/YLX%9(2]YY[XG52 A%?
M8Z/M%%XACJV][NMG]GY2R#$ZS5N>:\<W<'%W/ #&TLAY"[F"F<&20+EX=R1U
MY?<[-E#<B14FV)G$LA%#1_@MR8D-DHF0$ED!:1*!>67MJQ? 2DZIV32D4+0<
MLXL,826W\)L%"EY)NYZ'04AZ8BYXTVFLZE5OTNV5.<N\<<5(="*_0RX+I01$
MFL2 KBL?-4B^P.MI4 @&OT#6?U,;;KTA,HA:+V$R*ZXPK[27@QN?,S E&F$:
M8"#, /K1H0_/X*[>EDA(PD5O9;O*VTLCZ WC2?=;RZ7A%'H74:ITCZ]GSMX"
MBD;$+II8PC.S_K8/GVG)T#,N:/9&#*YM(_ 3+73'[C27.@$;&!">X]GDMG6G
M 5I_6K2,,N+H5(E >7>'IX;8V'223"MAA2>KD6);X7KU;D5C=KL[1(76/TN^
M_GSY8($E9%^PJ Q:5^XJCV<LFX-Y1ES7QM&HL86*S"AF0Z5[RZ63PX!Y0?/&
MWY&T*4>L"X*B<P(\*U63;0H(IG8P.J/U4XA.<7<UJ"3SA8#!^\@&PVP @'A8
M"*T/H&=%;B"DQ8$"-.?YY%18IIR7M9"L8&GN_R1.&79&80)ZG"1@S**M$*3R
MM;NWR--Q9@=WOPJ_;E46L PN4$ /_%93O,0Y4@NNW35V/ GY&X7;*12=9NCQ
M4VX[L'B>V([VRXW?P$V0BQ5M\<)2EG.2,U<N?N.XR$7MN!__/2FOBEP#@B8B
M<W+\=XW(7,PR*':$V(W[UF_''Z%:P%^8[@/[%=5^'3&HF$@MV#<Q7!=P8LID
MF#+ZF&+K"")H\F'BV6G$5=H+K+Z'D%E*;YKPSI1.8K;AG'?3PI5&AP-W" J7
M,ZP&E4+IWA^A'J F:W"/,)-SRB!##+Z0LI=Q4LVOP&:3UH"U+&N#A5 LQ,$&
M"[$"8_GN6(B54?E,;"250%=0/.1,1"WLB0--!!V],FFO(YR&K'5SJ*N=36JI
M]40G/*^\29$3K_A<LYE9_L>L])9QJ"Y6TU18N)8?Q<RC8@&JA&M,*UQ/FV9K
MZ<N&62I74SNX,>=X=T3Z[]JG/XA//(].7A\'3<?4T+WEI3@^S2!W8?; ;9MJ
M%H.>X02C+MRBBX,:4*!C5]_&E:>>7M"^.$#2)0/)H!A08&0;_O(0V@^G4HQ@
M$-O1\:PLL00T7KP"0:-@L7%:'?TZ]@2D&K$@[C0%8<',^H[T2N'R5-MI._+Q
M,#"]&X9E9' 63^Q_O_[T-'I?1(?[SW[:V]D]>"J1Y1HZWJ1<*.5+S/>QUAX*
MS:DT5CE%(QM6M#*CP3CN 0&.DMIG?NY NTUU+9,T&5%U#52.=C4:$UN/^XLT
M'Y9)]29&M*&[W%5&UN5U,;E&= &UI30T/EK2S-O3$$L%$U@!\WNJ+&M-P>@2
M!>BQA@0R4'-6>K>* _C.=G%^8%[WA"0QXN>.TI!8!#!%"2EUS3?.*M*/34M2
M7F\.0Z?!/?SMW<?MZ$-C:=U;0U-OZP84N<GO!W!M!'2C4;O22OGYG<%*PSFL
MZ\7:^6F_8P%&B<TX9J4OJG0"L/OR^3/JK(FB@S*+XE"F3JE.1,="JH3;/\!#
M)N:;7%D_F2#A[0R,T *[IY-*PN+G9,CM"4.A<@(DOAR]#%T>S)+JTQ%>,@0>
M**6\<C[%)!D&HS7M!>E)RJHLA-OZ ;-B#%,*!_I>+9D,7>ANE!M(WT.:HSE]
MZGG"U)K8!KFU&M03!;%;L%I#Y\I!E7HR$69I8.$6-D5DT]Q]^6('LMI8!YM"
M@==U5A9"-6"=WX%SM,AB\A2;H\R9#!6Q>,[RFP3KT\V8J8D%C2H',A^G_J >
MEALA8F:C,4,?;KU,_C<I1Y!I BWE%E#H%7JF=<00.,ALX7;JB)GX5@DK4;\Y
M33*5'C5.I4@O;ZCWA<"FT[\I*;6JX*K>QAN9'9D;..G]@8+B_%[@M^',)9(O
MYQ?;T>_XCIS*0_F8"",U$0C@@C+,S"P-)O+"S0$"<6<.CX3]H2[,^\,2!3H$
M+/M(30?%T<XJIL)\Z/:4$=]JSE.<IE!M1R1H\)-) 5K>,R)4GJ.$<O<H54Z8
M7IJ5ES,IJ5IJ) O1XEG-!%KR;FNX0[WKYW0>* E6B7ZQL!LMLIWQF8(X],4<
M(0ON.]S:D_@]MZ,S)@E1Z9!L)9$$OD![8Q^'KJUZ@[VAQ2V++QG(A5MZIP%Y
M%G)A<E\22Q["8TJ9O'DX]YA"@[]Y[\9X&1U=01P]6>FKK(\COWLM0=!O1$>D
MF+J -?6;*1<$KOME,C)*',\D?(_JH*D8!K0QRS+_B5@@W2I6Z65#76J_+MVR
MW?MMF<I ,BR=/]#8+CC24M2_^]Q,CN(W"YAXC]WA&B4L^$J8P5-K*O^ MP]X
MGQB]'1/B.Z9)8.\+.IET8,O9)&W!<'',> V'@WH=J'[#?=F%+OOHT66GIF7>
MD9[95W(U/.&?G!Z]TI\PO=Z6H&UKY;3TRIA!H4#ST7D3T-]%29/.(IRG0(./
MWQQ#2JC,+J #!^@LR$+- & R+29SIQNARQC@2Y(K# ,*.9G?"+RJ]"T>_06,
M6C >#!5C_!?_B5<$4 1 @W%G/M.C+MR_*FT4"&> ),82N76="NX7A3C;9"B"
M2VLF#H%3O<"RQN0V4VA.47?@I?'&(S*KE,C&5.B\D#&(A))?R-QF$ !^#_RB
M(SG,RE*J+.:;FD&3&F?OS;>@*@9Z_,@&G#F/+1ME22G=%=Q73\T-=,$E,QA^
M&$5'I\='YN](L (?T?D65U?.]0*-Y5X5Z!8LPT'=A.=^P:W( '70C]2MQYH4
M72J/ SVW7%*Q, 3FZ9<OABZ >GD!I1IKN?"%H3CS>FTO!>-;WQP;J3MM7!?*
MS*]\I-?.H_L@-,I ?$C7.N.6I\QIFY;"O)BX>Z08?HX^2J;EZ*),21[MS>%7
MI?U%O1]0M?WSW7/W)BK,P# 2/\%][FF6*8K&X.8Z2N!1E+4?4OLUTW3/&5L0
MBL'C!-H1HV%2^,;?Z58#,?4HJ;@ Y.?H2?*T<?#CZ,G@:7CRD3MU^%1.$(4Z
MIR5<TU/RF6"*617],RLGJ#>VH_\I+MW)A/Y)3H*.+[-T'+W1KE8?X(Q*UT[I
M:?!-)@@K!H/Q%)N+]BG84"OYYU &0^UR_5XF",*N9E=72=T&%&I8BYD@/)IC
MT0BV(U#@OQ;N2H*OOT+^G (IHIT_<=7H$WSK?,27Z9G+&MYO("':*JA!X-HS
M2T!\$$GW3:J\AA@HR"B'G%&V&ON+P?TQR8AS4Z"'SNE-:Z0E#PWO'W>?;S^+
MW"0G>(P1>,'DG("/,=7HJ%P ME&4>9:HWHS>I&0/ JGKJXSH6JGW858-9\B8
M-W >_LU3)N>^X:"Q6#00+<&NQ-A6]L>]@^T='0^XUDH/B:TH)W-?X841'W<R
M]/K3DMPRJ']3!F)EIHY&5 36?^@X5J1%5&F)<5^WE,R[C"3;!L;CM$B-C;T%
M4'2S25J;I/7A)FF] F-YU$TIYMH'%H--<*5.G64.?(#].H9#!/X;R17DN6%5
M?MP5/85>.Z8\%.L/,>4:7(D$NS=/)H@(90N<[_]&Z7?/[<\U <#-B7'*U_"3
MQCBQ=R'R><%7+Y#K"4% 8 O]N'NP$[O%C9ZXU__HS@G^ ]'"\"C)[,% WZ2#
M$O]A%-ON(;>HY5<1&/,IA'[ JDK\6+0G&_-O\R],U1X@)VG]G(<RG-'= BZ[
M6Z#BAMM0'/[GXA41U>SWY *#/XB!G4$&; J+\>,>S%/G&J36<,@0"G N,UY*
M!U_[3J&S-6^%!?UQ?^E!N%'LWS**_M=CU<ZM+]M&H0]N7W<?CJ";>'$#YAK&
MC'F?>20$GFW*VQ-R/9"R?6__J6^LR.<&.6GK,AO,N$ 8B>>JRPCYF-)\5+FO
M9ICSQ-KBV^Q?Z]EPSW L_ T]H#6T!6%#0#61)HHC[.(YIPH@(@)QTZ\%! )P
M!++4O23(/I&ATE1@X(_ ,^G4:;9>SR'T0)QHTOLRS;<8K,>5\OQT_^*>]W@2
M8A@<J:R2A^<.--!S U?25>">?,1)7U$['^<]^:KL-[,2@B& IHZ]T#:ZNT\3
M[<T3/(9J%G#8B;OWN(X15,N[4KTX!'6#J'G;\[G7/,,$N5D@=>?<9O(&8U(5
M,!K([F$ )>@#Q-Y>AHV;JQ06A<XU_*3]NL.=_M<M<G=!\4*;E04G9N'XZF9Q
M'PUV._H$R]8X_LVU-;N!$ N <-%>>1@G45?K@P83AM T3_(:'E># X9FPW=R
MVW"]J#8,*A$H;87(6C 6B*Z'14TSU0/QHD?&BX92#(2$%46N/X''(V]XDHVZ
M3P7$-ND[6#^!N6T?GV@>:/;6S(G107%'A<JYEF W5!P+>4U! C=)CH7(R"KH
M7 *']\<#NIXP)0+:812;FPI::XQ\[0XH=# 3@$*W1*=*\YI0P 1R@*SVGH"M
M0ZOM?N6]'G^_Y?9>9=-#-M5:+=\7]"G7;E.M:>"O%_G614%<_>'KG@JF X$&
MII],G7RAI@P8;<;28M$,T/2:N%E4;17:100RB5#K(7901^3]+@$$9[BBMB#+
MT;]98&=<"I1#UQ2&B#^-FR_5OMON0<[&,OK6&_$D>MQW0D>/DR.XGZWM)'#B
MG#)-?E </.3=EYO*'>BB%)H29!2LG?>5LC'MMB\#I *V&6;DE5;=)QQ)L,TM
M\/:D-Y%))N_S84%^$KV^$" )4/LG\Z9BL;TR GBAW>6A6P-?64$GE(2>I1 =
M".YLXX:.-AG6(C1V@B49,$;. 05@A*)U6-(,ZW"%Y6P9Q0FO$H"19C4K$;^;
MP6%G-BWXTQY=XMPJ"]]%IJ+?95$Y5)X 76G@N8)\ 2/&W9_\K:RB;%PZ0N>K
M0ZPY@HQ'D,-*<G!UDER4 I7CJ%>$^I%:F"SA:S:"=B_W=]',Q[(N]WJ:EX9K
M7W,VT;T.(U_N;\=DY[>[5!T7I=,LUUGIUO0H<PKY-'4FTYATK5($G0G+JO"Y
MPD_=@75C=TM[3,J#LY'N+@002XD'FI[F^SOM[8 ,0V@QB-:Q\RJ*DK:8RTQV
M=T" <<"XL-,:CE-C)]QF22A__:R*<VU<;H^H-9R6C/UCGMF=V5E"AT'R/L00
MCWR P#!XHHF'CY-T=&&?0%'CT*T*;?;&+WRZQQK74_R6;*2Y]T)+U^TNWF%A
M]@AG?\Q?Q D$;#D8N.E[_AU3*W9F9QPQ9EEGZX#\$8^M#LR^YF+$Y'H N=8U
MWY.O4BQQP MME(YML7+SUT]#O#P !$8FSXU-[97B#5@-(":D32REZ5BHYX-E
MU)/;GBJ&L+ W!H2Q@".>;%5/2WGK@WE-VL^6T\T\;/Z  ]T.8*F'U,DLD-P\
MRMPWKPLBG)/?FK2F71/LB\2%?KW+J^#*5/:&"GEI"/J*>)&9UKR:0!.A/)JA
MMZ1DX9'%^QIMV@'VU0*,54KEWY2<\U$4+1W@I?=,51@7 74)F+51-@ER=?QW
M#X>U1W =M24:6Z6'^>-&$,@W02"ZKS<D<KJD1/8/RA6[S4\4=P,>QU4N'3L[
M+].'E7=<*(M:1N,IV(.E),RPKB:#-LUVX$Y %R@,:Z,62_08C$RT:N$PI-,I
M/0!_!JWCODRQG8MT34RU)C;-F(GBEN$BU!F'6!43L*/0Z)R51#N_S,C(1WO:
M3#!B@8F\DU .7,PA"^/6,D\O"FR"S7%U4A'2(C83=@ WQF+,H2;0Q^#50<0.
M;'%<P))09BFM"FJQN>E*/$+((3N2[ M0N7WFAT49H3D[;M+V"WH\0)\.C%M=
M/^U@$DT4!CJCMA'@FX^H<)^ 9W#YCC*$4 O#!&62B7YM,IE;'E'LJ -%5H6T
MN7["[_6=!1$-*28[[Q9C*XHA+2>0[?B>RKKHN)C0P\XM'!6@)63\:P$TV?!S
MZ3R!J8B$ZJE-G8_AX$$/B=>#?N2=R(6R!W.B$J,@<JV(7"0(]H2PMLP(?HI$
M,"H,XQFLXR:[K-GE9YOL\@J,Y1%GE]W$N3HIPUK)#WFJ]A83*'I%Z]3+&]9G
M8,53A YP*87TK+U%F;1HCQ9>6M6E5B5A @4!RN2G5+8KC]N*,6MVHW[6T,XY
M\WI4+.:)%NXL,.DHMS%*X6;&U26N'M+7SOR@CN8!T0Y%:,AXD)0=-%1VNX <
MWD3L-,OEMA-^Y!DC>FO% CA#)QU W \!A51,P/%5]L1:N/1NGW8[.I*"A DQ
M@J/=DXRNLXKG=*?GT<]OL)QIY-Q!*OQW+BU'HYQ-#9"JT7;T:TI^(Q:6C"SW
M8>"A2TR)N8ENSZ&X%Z.207LCDEH[-&Z"=[B+G+.32SX:5\?N=\%7:^8\IHRY
M!</(V^'VOJ+3ANY$H@T5I$K[IL'HO "0YX$C9A0P)["AOP M5Y5*@ISJ<S@D
ML&0\2,KCM#11VY>C\PSD-(H:Y'+AK0H0'$ 8UFBOB:RU%"M85B6L7/VN[URU
M=G#O5QZ1@P%WHD 3\(ZMRM>  );P)RC2T0T02F[A^64Y=4KI"FCS(=* _/D^
M8O!;6CC)_3=$T9S%BL5#F"/NBD1OOY#S8-)S!6#3Y]'>0=>P0F1Z'AWAHSM#
M(\X%/_OXKU/?<0QD_R0?;H?!(I^]D'=(F2W^NIT%QX.-66_*Z53<P#CWI< A
MLK8[DA(4J52B,YU&E 6$H1*)AL;T&UER<6SD%SPJN#5^W-W?/O2+*RD*"%,
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ML A_WKRY?;K6AT2,W(UMU ([RS.&=!ZD=R50->2L&LHV:5 ?^>U5'\*^B\L
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M<]]HP2U/!<U$)O>3*WL?>OJQ*O7RN@BW_I5ZW*CQMAA95;V>&C)8=S3[>3E
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M/\,M< 6S6S*3Q-EAN-%LS,4:<MZ3#USRP)#CY@ZA8/7%#4SLL!5> (^3"A7
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MF#',RIE/C^L\@D3"=%82PA;2J\S)<?3QI*<S>X!H)\/;)),A/4G^-<?8M>6
M>P\U)8> [B78V0UNJDH]76Y!P9L\T,V%L,WOVK*;FNYBY@23F%@-6Y%N*DI"
M]DHC$6'=;PJ;?[6/XE$!VBS\ F1-D-.7TLI:)FU3Y8UW5IQOP\Q+<I7"FG8O
M6MAM'E_+PQ5-8Z0;"PFHN'KHZ_9Q31H&L**?ZY#4NRDJ=H"5&>&,;'Z(P(OD
MC H(]YA)TIXYYZ?NZ 2)1Y[>(]";O#EYT+N)R:!P&7]L3GFC\,G"+MQ_B\I4
M1Z_U!KLV2KU@R__=$$8%1;6@;CJ;<'FI=%60B/V,BF(L=L)N%I5ZDPP#!P%
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MQC,0WT( W/IC-KKP":8@"4>)8TG<3BQU36<.3;9KP78((Z@RH"V<D^2EH$5
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M+J<7W6Z7T>T<[.5=H]OY4LIO=.G&9@NI,:I)CYKU0[H&C<HPK8!;"=F3K*K
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MU'F&@^B'%X##%L28R,J/9Q/8@GHFMJM,I_6I\J50(*!Z5RO!_<<>5[ VXGS
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M,YYIMPG"TJO,*7:U6) =9&F@@\'*#!!__N;9QB!ZE94C>K>]U6<XM?D1UYG
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MH\9AW\AE)+<L'-M_"$3XA/<Q \$GNR:RC%Y^;8E*^2LIU?B<_R$AHFCUS15
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M[5K: )[,&P1,IC5WVI,6"]\^KS3N33)XR']K FZ@8-R'#X5+ER<B=R_ 1^1
MMRZ]ND@RJ$K^;"R'%'OM*%+T?AE+@H,@"0Z\.W>)3=9UK.[UTQQ2A:DZ5XFI
M+Q0P@CN::[+;^RJ0RD$A(DWG@I:0Q[_J?I@OT!6E[$2@I^/D7OKPEAI%^Q&9
M>R *@,7)$EI0B"?(),#*Q%VF\'ZC_@K6R&L'@",J>+]V_D\?DH5U"ZQ37<^(
M[-0+FA')^TN<2P(F?+Z]#S"Y9$*I?"";,FBHW<;#3 925MB*$J&+IUI=N?PF
M.!X9U)JH0ABWHP4='KB""3B+9[>DV]L+[#MW"61,5>].&PLO/U14EK@ZV?@)
MGG&4,B&VJ3^CH:X4Z@G)FWR<N3T^=$.T\?/WK)T;KV"I6-CEQ>O9\<13ZO!%
M7AF.BMG6QM+7IQ8=NK;3EO"">E_\!-WM&5X-'.H!<R[&;[IJ(@?_=/'X,*9]
M.MWPW30"1:;\"PO=%:PJ*3/0MX&5+/%Y7AV%ILYF;G;BR7BM,ADO%WLID_'R
MM=>#)..1QE$(^<3;S[M5">:"5QFQ9XM<3,*S2T+*9**%$G#U%:;_NZ+-Y?*\
MP #Y>$WZRHAK.Q$$A[W"@]8"BSN]Z"M((8VKJ=/IG(<9*=J/[ZDZ;:2H(Z[3
M7>J>]Z*ZQ%Y4E]3:BX,?5T<)Z$@F"C2\./(H((MHCT]\8HKW LJ8$U9[0##S
M)F!8*4$N6%';85-+?YUJM&S,$T/WP4_&6Q#A,@  L#(H:<?I@A5H<H<231?V
M!_Q3-(&B-G>6]H)"G5>4D55"AY'GU)\,NT+S/E%"Z#H'\[7ILGRU&K US)!_
M,>:8&T0W@)Y_VC-M#?0.Y0=^1-C%2R1HN:KTK.$FJ=NOT#FB[NY%UN;$K>!9
MRUZI;S7IGSS X&"/ ON:$ )AGR93-.83B8O.E=$-\(FF_-Z=?4BD4O#\ ?$C
M; 2%WA G2T^RY'E1;7.L;L,>MOYP.)HY%+[B_^2MYZKK02YL-BP[?>DLI_7
MF_1#-UZQ1Q>PL!MA0F!G C+M:P%54O%YRC\9*],)]WD/!;5(AV)H83PR+U:)
M#XQ1TD#(P=[>XF!_<$+]E/E'"376B.=T_L74M.[T3@.;246[T]U\#K>#N3_'
MH,I-:=7+>-L82'!2SC:?-]00*'C:!]F\-ZD(1:5B7^^EX8,U*\-6O5Z+.I>7
M</')%\8=\RL;!Q(KW/4EVH 3UQ6*_/J3_M]\]L7V&ATG8.,-J, N! NV,)!$
M*3$0DS]T7U,.Q"E,5$70?A-(+J*+ :.)]Q1P+*? D02JNN_T$)864X6KETRB
MJC1:&',RL:K2M]IEC9,4Z/*,7_C,F*N<O='O78/JTJS14][+@Y5L?B*CCG9%
MY$77<./4)I'2VU&66-I/":!GSRSA&?/S)HK_.B(->_HM7>'QTTG<!HN1MXAP
M\ZW%TU7) :G#TJDK7A"J%S.-(5ZH)&;OIU--868! 3NR-S'U3]IG"5FOAT/\
M*V<2B"XZW'",I,_X7T44 03J"V@,5/E(:?SXQ"=-^QS,2N>>WK2<.JXEJ9L3
MA53#PV*7E ;W0&$!P;)]'JO43+N%TV83,>T@:T(D='!+Z'F GF<\9\P&W<,2
M1T>UDCP.&NEDR5C\9@"%6N7%@(<8^U[0:0-T6@B<2 !5 X1)688RH1[GOXX*
M":?.XK#8GC;FH"-WI?V/W($C]V*/C-<N.!#\QS[4A7X5 [TN:%H/*4X7H@4T
M_>,)$8Q+T_^?O7=O3AQ)]H:_BH)G-TYW!&:Y7WKV)8)VMWL]3X_MT_;LQOGK
M"0&%T1F0&%WL9C[]FYE5I;N$! (+HQ-[=MTV2%59F5EY_>570HNZE6!1G#C8
MH2%*.W,3H(^W?<J9\Z$:I&%TB19DN1A";MT$5Q["ZFYX>MB#P9)-4;+ZDZJF
M##F<$)2[L_8Y IXPA@41;?8E'Z7A:^;Y@[&-:]*+/XNJ3:[HO >B6I1UL;PK
M E.C'+F5YU4WSA0<1XE&064DB)O$_1;0X9](O;I[E%,]Y/L2UQY:2/!>"BR)
M,&QE M=RJ&D<I_%PG%R"5(+?\1=:Y+>YS5,S+I]HK&=]E3<O+)&I^<E$^+KO
MY^NN7W:OZ1T^4_O>JP!^X--UU&?/_D2@>LF2@]JXVQB-(LSX]^A.X%_ZE;^V
M.+ U]\[R%5,OX!2OR'KP][7CUP1: >?(N3M7SSUFT/F\_X[![:\)UU2>.9W)
MP>=.Q^CVLXM)27P$#\WLHE.7Q=P)W!I@'0Y;0T4\%FU=3C:2ZYB#F[TE[&B"
MHS=6SIKM8!A!3%R2_-Y<W9ZA!1408'F07-WG4NZ#5.5^[0KI_8+884)'<RU+
MREN9RC+[GG@,$\LR@48K7.W<6*U$""C0<[6W.A+B@4>=CDL[#*J T,ZOA901
M5AA)7RPDK;MWN>-1;2QM_@@V;=@'<)/JP0,]Q$ 9^<_W*@*5G>^ $^]D[X3[
M3;12DX^WL&,EVI$WZ_IAEF'H_ ;^L.6V/C6-8&S-P^#'/Z,,4L!T(@-J"RH/
MBB3WO& I%4:C"0"_^/#7QW16ZC=368FSSXV,9E[SP]^-<-QO^6D;1#B.\%)#
MN7%,##;6_3?(FRR[';?LP#WF17;C/>)"9:+?.K5,H.<VR" 35/-+Q3T$0A>]
M\9Y-'(SI6K)NQ-@'%L.HXU6+CNV@@##'&Z/1)$'X3%_<^0QO0QE/X!,E?&'C
MN#BQ-Y=.A;,R"; )['HJ1I3X=4 _[)H9-GMNQ*M<_3+2[5)\?I<E@W%OVCL3
M#^5 NCY:Q2)C]1@7]4T.4GUSHKW]T91&7>*!>9ZSG-?'AV&(D_>=+'$Z<+^P
MEQ/!57TH=F(]HN5 =."*&80T^],/"B@36GYD)VS^F),EO*&ALI9H;T3,O3IV
M%/(?=)QFR?$S6!#,8\KB"9+ IM09R''+""HPET)L!Q1B)ZP0OQG&' W[H-Y;
M:#_9_.HO9AHQKGF_6QOK1E3E/8M'$8%]2"2J1:,+W;H^7UCJ#-71TS*,*!IG
MZO#X8XRF]BLN((R$)]@2**AFSJ^05-NZ?VIHW0=?!H[>FN@;C#SGNR,#'1]7
M/;]AX*+GBNN1QW%R7XH8O>HV>HG7H@_\S_**P8+XJ_[VX=;',H^7ZB<WI,D8
ME1PSY<-QXYR G;\63Z'S*=7"3O4&1]%GT4P-U(/5E?9'*H)UZ]BB8ZI <74^
M!@9:^6L )!.]!,98A0'J7C3V*H;#A8^+ITB#Z'@Z9M^O)&H05E40HCW_J)?
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M7A(B_93Z]-TV%]5.1LK2"?(JRI\]/W]VLW"G;/'X 1OB(#T/!/WB,N!5V^/
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M%,%F8'XR4F7[@'9NODR"79(!(.KP<5%!4P@^0\<F]BMXZ@PC@8A80;A%_*/
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M:.=Y^R2PQ>+%'!YXR"EU(XI*Q(^G/Q0WYM2;&3:I?BI^,PL?R^^-*A-$K,F
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MQYFCJO'I G[,H6L=U#::DW3:*WY+(P]L7)+507=.K9FI;=S8)9A5&EA%DH/
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MRJR<M@8S5P&-M]2Q<;,.#&.:7/^!)3\'5P&]7:XL?'<3)[XEC=T#+AC:Y=Q
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M^YVLVEWW3I*K]_V5^*ZM^ YTIPKOXOJ'PU;:!CR(-' AKQ8.A>!>51/8PK9
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MYO&:;JV,UY263N$=:WF(GH'0F%10[97(_'ZLFJO9'"X94\$Q00#_'/PX'QB
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MKL^O!E^-VSOXP;?+Z[O;+ ("'C-BSLU509+-MIJ@XSTY&R.5\H^=""US:-G
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M? /);F+AM1L+87J2>($WF/>"<KL \T9V2)^9FL&JO8R$[YO>@F"-'_)SX)2
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M_A*C$,=Z&3>3B07<J$(<"M4:$_Y+*M?O0 %RH>\@.%#Q"XAH<Y; =[[BO_^
M!P%C? -G;X*.[1% CW$+C=JGQ"/TL_JG#[0N:71(W#,>.P3K79W_!B2M'2GO
MV_C^#]#B45W[' 8VGNBSB_]""@8]=Q2X0/WQRAIL>+ 9V+[3_%?\U.F2FA7H
M",!)L"3:CQ1TH78)'QB-P+@G#1%W"E8":(XXB@(V+WE;QN(!CM:.'Z/EQ\:C
MP#%LNUAFO=6*30XS^!YZ %\P(7 $J_[,ULI-&XW39HYRLZO9V7_EPW6.SIKU
M',V-C.[8DO$-X:"79M?)?%6<>.F(7RAL<"Y@$GZYX//_F@0I^-5K.OQJR^"[
M%O"D0WZA@2?,K:&#,:Y*/PLV/EI[:%8)TGQ<(FP#6"C\=P*7LL1;2%WSC:\@
MH_\ :@(K_AJ,5C"E^,6J<0FJ L''&(3WP)*E>CR.K;%'BZ$_=A_)JG.C8<*K
MS; *D" 0.?4Y02L+?Y_8+BIV\'9Z;Q-S1!V^=/+V%%L%C6&&2@> -6HC31BC
M+A>.G+VL_/BS,X;8XL'#R_806Z, J"CUUZ+^_9P ZTWJ[9<E\;226,YKKJMY
MS?5R7G,A]E+.:R[67J^?85XSVWA%L^IRYG>R2_G_;DGAOZF$9U'ZB/$XU@Z
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MKDV^[SB6I9R=J&EYLLESX";>-,!6FOG+62+4J$>J]["6W%_"18#>8OP4""0
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M<?=TY76 1.G*31EVI3.W="<=F#-W=08HT'D=_;FU?N$=2J4_MR3 @_3GKJ7
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M'1(OA04((#B7'D^+D!W1;T"'<4,/H1"I ;YI2Z#HU;\:\P HZ@"J:AND0;S
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M*;YT&Y=NX[)N8N]^XVT(>+4_N=,L_<EO&I76^9/7H5(&RK2.SKK-LDOY*[3
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MZDXAA58R.0K5N!=&!I4'HICVD]&AEX,.CW%V1L3*D,S'8TMF T8(D\ZY0U.
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MO@$"'?P.0J)J?)$_:LH?=5*?-M-@P0G%7V$/..-*HSBZ 5ZOUY?K-57+9-/
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M@Z5J.,@"F$@(I$I4@"@, LP:^7*P3L2$OJ4$VO(J%Q;WH94BA@=]PR[KT:Q
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MV911;C-Z7Z^!D2=4V3BBDM@E3=]E5%/I5AOO2J;3RNGQRQB;W @YUV5*C^3
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M9L?9CL]',K50V$PP2TZ842B&430@ /' X_@_-"+P,),/#3"FC5W(J*#[S'D
M,8:2662?'>I6$,"K98.@_3QGO7SGW)O-++B.F+<X$WD4QIU(A8RS+#TF>E+
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M9B,GJA3UL+JMK+*#6?#5"OO$G5O7^$NVH(^ZH6!!G(ECC60#Q.1326%E*^G
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M$XC423>:*E)I1%9;%;6+ZLK<M ]0H>)T%%2$C3[TCMY!J(#_=G6J0]3M F#
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MM6JGM5J*W.8GI<,/M$V)Z?FFS\V 4Z>8-@X3,+#\]JO8/\NW_EO3MPYU[:<
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M7+%#3;/ H_C+F_T8K;F3!4LBQ%2,&78L>(L-6+ M3GS*5*368M-(%(7)8NR
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M2 L*,S.OD^:R98'BU^Q;SXKHJ/K^P/4)'6&N+]GV6R8H)04(DA<0 6NS=BO
M"6[H2^[0<E8OG1V\3+#MVE^3NS7^=''W-WW_. _314@KM$[SZJL+[.9_GBU6
M@XBNN,6+29(I3GY6**!\+6(R]1R$H6;>F&B;WY#I9B5#,A+-<;I-/69/8.@Q
MN-X]GE"D#W.,#%C4Q&-6)+B8!1@ELBLI\MR\H5IO06:;#&R1TABEZD @0R(O
M@B*NVMV#VU!8=D;;V+J ],D,[-##YW[P^& N;$?I]5!RK5QR&:NK6@3]D;6
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M'PP#?4>D5UMN5=V@N74I"P01.%E3KD/MKU='#)=<*(A&-)L4=^[Z_B$Y^<]
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M94FU';Z'Z#(WGF<3T+7'?,LE#,'B/0O<'PPWPZW;I9#VH=K3X[#X_'HR^_4
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M;]W7ZYVQ+V7=/48M62TS94I74DW//,%B\2 Q10)J ,Q,U:\?#Q 0-Y X .(
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M/41%$S,5C=D&9H)I7NZQ([9])9TWYLC#J>0-57'H!/%Y]'==[:^"^8U S6H
MKA)D"):2P$OC01>/43KTN70JD+<NQ6'YPL,'#[=4Y7A7D;9.;:D@EO%.'6"T
M3'6Z?O7^DYFV%/Y=]>T@N1X5&9(D/*@ DQ8$)P@(GEN(KF!@01&03@T #ZW
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M.F)K%[%ZZXWSU]%K:9NGJ3<_V/Z>!CZ_0U:Q<"="A)!H,5=&ARJ2 JF4DH7
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MP\T9_&98"DYJ+Z17./L#<53K9D^G\^(JH_P99[.KLJ/S9AP#G@0+G'&H7;!
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M6#?2@M8E6@)%ETB9[F_<OWFQ@UK&O<NT!ROB*ISB0[FUY3V^XYW$Z6P2TFS
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M+-+Q_UJ5<3 6C:S*&*/-@R37#P'X6I6QLTI'9]GOHH_#5&786)C#!(;PDH_
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MQ']^F<V7] 9]_5L.'3.%USYFJDS@[6MLE.F[>M"GFP?=65;"&)=+O8Q6OOH
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M*ZLJB@S>L C:V!R8,<J9!VU)3S7]>I1Z!J5?CY'MY.G7R3.7BZP3S JCY:8
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MU2O5?$[&,68X/P=OK9TF.S0*^#F-< B8EYHU/4I13^;0[B+E[EG31BF6)2I
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M]6*TO[N UQ!@[U&BMYW(ZY$T^_KU?+&X[@HB$QE'D9&3%:N=Y#V$:FV7X)/
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M@M(:N6X^)>9I1*=#DR8R?\P(N^=XXW7(?IO-2SY?TG%90E8AD:FO4 E01G)
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MT7K+?"D<> E.-3^%3D28+?;(:?FRBQKZ*V=]LCY.<R54+>>UL293.T4'J4W
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M9=R[3!M:A+4 XO:D^_6/JWGNX>SK.+\=_<#IK")\_%/$.\4P/'*TDI'9$NG
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MML3YC\6!7:3<@^YK)L+T(US7;>[#["M.EE_?5,UHA=$8I)T/ZHKIB/0QR"H
M%971%F3K]L-;(!W_!J"%YL;]B?UXB:/+/ :<_D8RNOMW!@)-G->7\L+)T@G
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M3EE&NVJ4B#'GW#H N#/(T^\R!ZEY[^-X'QT=[T#>Z-<;#"*)+!F7KM:3&,$
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M__N?#T1)*_SW?_V?Y8_K'Q&F^%__Y_\#4$L#!!0    ( )V"B%B? JWV2R,
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MZY$[U*.GG)=&-1,XB7=M8>0J?MBA*D0V39'B>S3<<1JVZ+?FE&%%P>F')CD
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MQ*J$Q/BN)\F8_C!P6A:;SP==/Y\:+_4 \+8G1DY".6U#=4*83]X=W'%HS,J
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M05J%Q6$HQ<N(VEM/BBV%0E#W=()];TG%B!=Q*VI&;Y7H]7G\U]'ED1HD>2$
MQ'+W=G*T/+SC)3IYLFK"3'?*EVMFJ3@7$+CB=L*8<-]*O'R'F  &@%/:@2B2
MM6.#F"ZFT4S465K;_K+6.XA*C J1J1WKGE_+:94XA7T@R.BGA6$\&DE$KVG
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ME!SGF[LT6E[J9I[I:M#))$R4@G1\R=\F/OC2Z?F%R@-W2-=43.8Z*,M%8;U
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M^_KU=X@*W->S!4!R#PF/8_)/*5.JO?'_>[$,W;EKJ[IDJ,[HJ>N>6CL5,]/
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MV^FA60HJ5"NTD.I0,HJM:"X\K&UL&7T]"T"8"<F'(90R@-$$C^>_8'[\YA4
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M91N:W#QJ374ORZ.;:'8B<>E1E\Y/M6%9#-7F3;MHC.&&(*>.^(2>^WLKRJ&
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M*7\9"EJA>MRWY$;I,"DL*09U3O\1R.=OCC#S%4N\AP'\QC&W8./XB6$!']3
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M>;X% [E[HZVHI4AJC"%$FT2-Z&^WD28'2Q SKM L+A;Y(Z+2SQ'OF?-,!W/
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M$S5,.;_NHD 9>O^;#C%EJ"-':<<I-P<:\JSYQ;"PIM2   U7W81HTAT\.,-
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M9A6X359:KB\F ='OH!GY.!5-H7/;(A2JG1(GR@)Z]NWY5/J^P")<Y5XG*CZ
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M"_P'(_Q?F,6L3[!Q:2QEF:WD]HW*E2YA;*J<-WN:JW4=SR267%W\"6I-)H-
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M$Y\C+!S+KIBA79^Q*.@<(Y4A[<1K(SGEU*MZ\&7+#>J2OH'-/[)@4 .L^S-
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MR8J5LZQATO2["08=JWQ77FW-# ^TZY[.(Q]D(N.;'EA")L;ZI$FZ9FX:IS*
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M\KEF&O*C:^K)4/%!IRZD[]=<XHW=&CS"6CG.]_6_HX4?UU8+?W,5<##99;U
MC:YL4.I%'E>2KGI'\.3%BNL83),=VAH;\AD?@-K>BY%9A7(^*3UX&BR-H4A[
ME]X40Z6%/N&PVMBQ].4R.UBPJ],;&W)[G^E&R+]J)N79<[5KM+ 'S_J47[&S
M<;'NS.O"9?M#2-Q+QRCLLV]G)5]SZ2;RB]M#0%+R(R9:_-!GDIW7U9-F8QUJ
MI\L;,*%[_%O]K1$#R#B"YG3/T;8#2VUO$0_5LGDE]BIVL0?+>4YDJ'A4+W-'
M! "D\74]K'"F^M;%%U9H8V)KID. )A</:5ZH^N BKJ-@)J"5Y+X65\2^F3!G
MLZS.AS9.CXDDF95__B=$X&-NRY?=6Q@K#V>_&^M'K[\ 83('G;1S2M5WLR9\
M:V7,XI1K*U&9\.%6\YVBW*+(]QEZJ45Z1S$!G<-<2-F6:S7.E0.;GKBAP$1"
MDMV.TM3IU;^ <=DG^R_ NO)%3*&B%[#/KWI>?!NC\&#ZM7&MA_>#);+3.N;'
MH5/XHM^]C?SU'.\BT;O#@ZC9;NL6,3&U$P-U<HD%J6>SM%=F=YIWJ[OWK_GI
M(KD]CU6!=#I@?+^?^-C9V@<&UZ\Z,_JD8S#)W:+\8U!9,*4TMO).EI&,5E5,
M4O2D-Q2AT_FY[C-WYN1.OHQV6ALR_Z-YKPR+LMO^'D*1;I!6 6$&!Q3I[I@1
MAABZE!ZZ.P5$D6[IFB$'$$D!09"6+AE*NANDX<]YGO._SGFNZWV_O)_>;WO?
M>ZW?VGOM=:_8][Z+P05X-/3QBCG*6+) AG<*O"]5[;VYUVLU^L#76BH-3/$S
MM==J)NE*SM4[LN6%)<EX =Y95ORC;@O&84.U228. F&&K'H[>4)R"6L,>G9)
M1.R&$<$<V?IB/:=$K+_")05#/:9NS)R;E6M5X.&L-<QR(<UM(6' 1VP78A>C
M >BF?2L5N=3MTNUB!=8>BS%YOPK<(A+(=$AD9) R]? /9N9]U $EK/>;N%.M
M;".PQWGBP_?$T.T=&C@)1('RE+%39-3,;O_%KQ$Y%0MN^X9PHHGM.(?=/P_<
M)>W8B5_[0#J=\EQG%3])+"\Q=[G&GC&_J0'WZZ(P[N.\L0U($*%2;[#J;$\K
M*UNT7KEH@0..('#+,-/P=RP5F=J'C]HK=G,4\60RT7->=$)K!L==A/7 KJJ=
MBW[0J_30FO30MS-5'XC#8V,+@" \&R4I/*8'0EH4B^<2UNOETL_:$T?>0%UL
M\5\A%TC T:W9EM^[/9G=1!+\*CL\L'>MC7$XZF0Q$;:OV)6(N3;?W0*$9N)S
MU!(+BGYCP[@WTZ?]8L^,/**8?9^]RFHO@D8)-3R61K ^BI')SCD'KS>*HI6J
M2_:LZWE=QMNH.ZS]Z92EL73%(I3Q4ORIT *H[3_K0QC- 7XF?'N0?]MB-PZ=
M1E*_XH1- V_KT\#8%(*UKX74!,O?)8\I!4B[TUZ=X^]7<2G+6:<H+;L;N YH
M[71W+9<2ZQ4UDB2#7.<_IW\_UQ$L)VTH-HG?Z.$VJL(K(LX(@Z"996;XJBJ3
M\SYV2UUNG$MVEY+J=A6II<LGIFF_>J!\*+%PE=S(G[<:2UG'^2DDYK*::^*;
M*B/I\.2O6J[CRY///-_CG'DS&NPLP'P%8;O:<]]26_=*W_G0!VU%DR*N UWD
MV]9G<L'U/-,CR]X$ULA""&0?[]D*_FJ@BNJK+\5/T4[DA?7.RZ>H!=D XI/5
M.,YG55I &_TV)0)UIBPIW,BBPS4C?0L_DO%A]N:3 (OZ#GC.ENL*C9(L"<V,
M+KL0*ZM8M),B*"#]>P"ST\ "<GMXV<; J%VMSP<S5FK?8VVPH*19:C\>:6_W
MK@<+\/JXT]50I%')B;NS9]@G3S]7(:B!T.+3Z$3>4@)!IE,A;E&LFA*;2Q>(
MJB",+YM#[*,C5FZ'@RSF,P+15EU(28-<P2<P7@ZU$%+&7291% >.S.WAF=:0
M._%L)5'(-G^(?QHT'8@P^&Y>1%20B_OV99II=>MODKB(CY$J4BL_OR+E?'Q=
MH1'3P,H@G6HV(#LG@(P4QCA\'P_7R^I'.G&5VZ/&<62M@:DHNE]_6H/!HOLW
M5U-L"LT#L:,8@HSEKW&1JLWX^5[>I6K+E[AUNRH"N<T6'0#\U8PP-D;RG\P7
MK-]':$J]VM4U@T]G-EIDU@7<Q'1T3=<\OGJ$<50W#L"3'@,?0C0S<(/$\"0.
M;;047/REY5EEU>G-W^#CX^0PC:<LX0U7HJU/<GY/;&K)=/$]X SJ01 ZFSEK
M&VHO#7Q%:.1@)0;.DKM=:8>?;Z>QD[Q[]_D6\*_[&?HL:U76=]6)H<0;YTT+
M\9/-IL)OS9ID/TR;T+C'CWQM9T$ "OVF3+# >UI",_IP-5"7 +1J$N&A:?.&
M6VC#75[2=N;^H:J@#L0O\S@-+*D9_R$XCL00_/V@Y4OLN?><K\^>6(S3"HS1
M<K&,F\1:+RW936<-64@?_5/IC-!_39L,P^O-1DU&$/-8A=Y1ZT#,!-QOP\1@
M*5]NS3Y%XUN5Y3)79HZGL61-B(=:9C:FPNK+OTKG&_C8U)5-8H0Q985Z^'EI
MHCSBIF(7L6D6-2A((!HB&22;SW+(,NA5,D+T<NY%](.T:+$TD)"/0<4:2/E6
MK;L'W+BNQM;OQ61&*<L$:=E>4N@J&<0Q_EIT<B%0QL6)6U"##B9HQ<"?4+C?
MNU0SH7U@_Z8G/KV7,M;C EPHB:ONDP1XP(^7<#]Z+$K90:\^M$5X.F)L#%VR
M8V@G4,;4+!#<BV247. O#'=4B;LOMQ6Z\1Y1B)K))FDJ$!"HC0P-HH@;35+9
M@ >'1@*X^(K5L)&0SU)T2$@2  2_ZY5I\)'7.QN\IXWFW+0'%Y31>\!]*5_5
M+]79AFP+G3LQLHO2:RCV6@/F5>CS517&DPFCLA#.Y!R\*"9-$*8RX;20,4K>
M2[C#[4 3UI_::%-VRN V:5_W .0F0N__)0RW'D"@O$ERCPQK958*FT,L;?N+
M&69IEI\DM_FE'<$KOH'$X6V- BHR ;[L!O&3KZ?+XP6.:)B#8C;RI8G%J2\0
MB\/5?EN!9$Z62J=L"' :SDA5Y32\W'Q?I6V)G9PA:.QC1M!6E*)TK[XROA*&
MM)1/ANJO!?Y[;7\UOC-&628!I,\^M'T,),_^K)SDW*!OI<?^J1*)F8,Z/&[#
MI O/)&$3:"N\>$7L+8S8*S]+R[/O/7#[IJ"FF\0+43VD<XZK9P>P2'<$0+A&
M<@"GQSP; CL3J7'(N4?IFN2IX4_X6E/TB< 0>SU.86'U 461+&LC0L>%Z^!2
M\8I:N/G7Y;!&]K:E09'%WAG]\;D\)(4-%!)$#8(7_<M*_FH +%A.Y8PDJ7-O
M?)]^D,W-+?O'FY-"FFKH\PGF[U,!W*N _WA!D 3:K]G!B^/#8EZ\'U+MS $=
M')W\A;(HM\$VLGN6*Q626 QB',EQDF9:S!&0Y+#,LR'D'SE'GSB@Y9-:5VKO
M3=@BHMO>>H05\6((2W!RG;)J7@1WJ BZC-N.1@ZH-49=ZKJ(OB>QZ[S^J"&C
M5<<J)'[RB+9(:L&5E5WJZ-[R<H!^V.;OCV\W;N#Z$I/.*??^."#7!XJ3$N65
M536<G#PG& Z1P^7'ICN'G;"+$Z,:A<2O2N."*?IUW?JTX'%V907I>XJX](M6
M2G-D9>EVV;< ASH085&A1D<&+'$N;IWN:V "Q[4/)@8(YJQ.NL_M=7-Z!V.0
M.DJKN8\^I,BP$D6@Y#O4.CH(/W#CO& %R=;A'R2/P7\'1YVMJGJ_9GY7*J19
MT*S3XM"26Z%26%'BV&?@N73D2Y-]P79<M-XQ>O5)<DLG;H4+^8"CJB%N,S+[
MI"1VGC^J=]9"$,]A2(Z=Z/$Z"+JI)P[H=(*5YWV>_CJ_5&[?,[TT=$-FW],<
M"[PA].MPL=GDTM31UYMNU+[VO(J!Y>^+\R,,U,L+::>,87M55X,Y,&^U]5]W
MU?"3Q9#+537)*/=.OW(^ OQ[&T%G'O;7[.H[PH@A3Z_OIVC51 =,W;+8TF^N
M">65P[%5%B*^D,]#2S2VOE%<OQ/KZOW.2S:V^M0Y'K#'KPB,FH0H.52TBPG*
M4H-&2Q;/XB/M;K(*+Y*1S-H7]P:4?=Y(,# ,'F[YB!4?F[5@-:;= D*8\*XN
M2GB<2J$2&:#O#[!&;9X'.!NJWB5?KIK:)^TF+GG?EJP.Z6>*-KT[)#LJIC+6
MNUK7JM :/'/ FRB: V-XFC@@OF/Z*DER:Q)TA3[6]/YIV\7SX,,MP+@8.2FG
M6&E!=N(^@5E83<YP4\:[TB):6D&]FQWW4GNC?:W4Z[,C'?%'7):-4I=]D=['
MG0F4#JU"W!C>**I*ML/4H0,C.JKBO)&Y@1USDI\\-5?"<J,#AKUO 6QW&_YS
M+3DZV%X.)+['>AG%H@P/V:H2HV-V=/_PI/^QX5M+U@<2'=$*M1*)W]#=&MIA
MK@2XIK4CQ0I5Q]"KZQCQ\OU9JW"#:Q51DPK@-?WTME'!N<W^U5M?PLGPRWY)
M9:,_@UQ1E!ZXG^D/^E*0Y*Q7%WDVUKD)L5+W488BT</0 6! !(S;O9PO;T T
MJZ.NZ=S$VI=".HEY_^704Q#L_/B\+9 SBJ?3-O%,Q+\T@OG=+^=Y\3?@2,K@
M2,YQZL5SK%4(;?WK(I_UTDL6/(\OXXIB/P4.);N*DMBI,.S*=:;''+&KKEME
M(TB]=Q%)(#C66TZ8WV& S0IZ]R)O&LTOD?;)W;YVY0O"1T3MM^)W5E^0!JQR
M^,Z#R7EYMAL($O'= L8^,G"_H]I<%KM*@58H>UMQ_>L_JCSO!%4?I(YE]?5W
M#^UIE^UD*M/:/3[:%^MKJ7LG$3N9[A_LK&H_ =]'63',.ST6_I,0,=(LZR!?
M/!WWB673UYK+L'R<O3)N+,F*L23&JU+U)X&U>&"'@1R:P781G-7]@78*)F<P
M9 XFK54+$TJB:8.^)LMX_2S+S0_V'>];D$X6)R* PU:"8N:X8Y,=\V2/XBU5
M7X@SIOV#^G3&$FOY<^N;[+?BB5TSH6662:\91_JEGR*TL?HM_^D&_R^-^^K_
MS!SHN_[K)&H=X70>UE6<>#I9<IAU<?)*EJP46DC N"]Z9% *;>>X!9Q& 4BK
M]_#3/F^E9Y6ZW )<&@<RE*8DO^@_M#M&9"N":U\,F7%\ZA?N6Y"(:NCQ>(7F
ML8V][)M9*E=0UNC95#XH(LE<>%<8W*7L4X0L=4]RSGJSFM8 /.[32"1@W.ZE
M4/L<288$ EGPT#"+#7O(52%C3.E<Y$@BQ. B:Z26Z)!.W";:I7#_R3X*-;OB
MV'(&,EI\RL\TQ\?UBETQ\C(5ZG',98K]?JW[D)F?=$QDA!^](A/N6-/?</SL
M/%]*<*$^N&]*S@A6;%_)[3D-<2RN,K:@U;<_>3YM"7E[?H553QEYF#O63+[Z
MN&?[F5&YA>^<6Q4]=XR#2_Z6V%;2(C-XD80BOP"UC4YLJ+W<F?GSC7A!@@&W
MQIA53_2*[ L$EF]_57?!B-'F1G%S6[3Q?]VF<7E?UA4]JA*CX1$?H*F!H"7$
MO72;MBP9)0BGT+R7MZ4^-#<:]S9%+2':['",SE.67M&6V/&Y6L"O878NV(6-
M@65C@ZOM4&;FK+[3+L$)F:W'QVLH:A/A[N)X,UW1VT]XP"0'FJQM5'PX[:B(
MZIM.;9EOH,ANJ]T^^FUH1W/F^NQ@$O-PV+MXSL1#F5W.,Y!:8/:$?7/=J%JJ
MIN;UF_8:UU41@MB$21L\?^4:AA0T$SNOO5$&V0&67>(>PDIL/VLOOF"X)NGM
MX0BE."=B&U#=:X7C&8!_"U QD5]D?K0%#RGZ4MB,JHJ^!8SL9MV<?C8*2)>%
M9(J,%,P*@Y'WK.I.%-WKW$V)'8:TM\1SB:8=WHP5.!KTJMV#[JW,#S2@?=ZJ
MIF25#_(N!9HCF,3SWNL04UK6YS3?(WK<)DCR(XSM*HD^"JN>PC#JB8C![LS]
M%^K%([;\%ZECZ$A]SU[!OHU1TS05J_ -:WB^(A#84:K,Y6_OZ?DK:6-6W7&,
M.$G!#:AT9L\2FK!=Z#WX?HA-! "R)]"6@%#.5B=\MB0,RY.-72-Y7>V4%&,2
M4U4@P/VHRY.F7XK2,?7SEUJU=E5?4FFCM(/$C5ZP#[KNUV%L0:X^Y2IPUWGC
MK$3_ZOP-=_TZ2'_,M2X;<AH0SO1K0.D-,(8_YI7]2GU VGY[MOXD==5FVR+8
MX)<_C@L5_KK2AGY-03<WMOTAV65T/AMO7IFO;YA7JCBC'_]0L84&J-]OROCT
M2N_86VT2?J"[:3T'M]RC/2PZ@:'Z\NF7V4O+U#Z!D:LS#S48Z51DK! ( 9V)
MZ[";GD<6:EGJX#(OTF;^%]6]EG:/#'39F2-&LQ 27U?K!: W$='^"HUPM\V:
MA_ BM"AXDB/-F,>@O88?L8'TX88-\\#U6^"7IX:>#Y]]_9">XR(:K&Y5=VEN
M)<QB+;X8Z?>\$F01;U;$1 ()8DD.H0]7$1<O^&DA73Q\+9#%0ICB#A-"5/#0
M@E\ W[._Z#//,T#@@PB88!*;DZ@*(:U#KKT %A<_J'3A.$(RS<O&1K!ZX9IT
M:X(G9[CC3^_3ROD\I_@'NWFGV[X<]%WPC,#NZ8VKE]+VQM.4TWTCO&O&YNKY
M?\1'$FW%X8D9P>0/60O;T>,LR"QI/P-:5!)(*W3H[W3;D[[?K#.("R^E?W'#
M_G=C=XA9N)O%Y/"TN,OV3P6 V,=<<Y=!+[PI.=*GJY^^.1&^>ND<3/;E"1GT
M,\4(%)<YAR,5N%\TF:S^A82^UK%.\4W;46(P,ZN*\..5M11+1GUIUO8G!1E4
MC77>OZLMJ_?&I8ZM-]^$S2ZB6)%FN9+$DIP@:GW'A_"+BJ$/CD(MCC/6XWZB
M(SXL'QBYZ#U5]>W"/!&B2=@,]IRKHJ'+!3@_+]8W:6)C!8D62YF^]?UHU*Y9
M4)K$1$RY.\VN;%OR,8H%K^[:SYWI0KH9&P3$:]0#+<N/G*J-ZTT?PQ+(N152
M&E[,&[Q>4.Z44>K73=@PSEN8K8/#CAI<'5\U5K+:$<X41?T.."BD>+G5:6W0
M]HVE?4SSI%V'<+<X]J/[]2]GF1J^Y>0I8H&<+-7((XV&C"Q_VZ.EDXU ENG&
MF'.SEBUM^@G:Y+J=QAG*IEWM*0>B;,H--;R-PWX;FQX'2TJ2;F?4NZ%B#>W+
M<$Q-?)Y_P6@\G'IH<F4XTRJ F\W?H/[J\2W@F6?7F=:%SN]6S0SV8:A^[UCI
M,WX@1)@M63TC#9 V\K]12"?S=[2<3RG'[S06YPKM63>)<*.17M.GBPV5"[7%
M9<43"=-*LO+R^!K*K<92,YS8BB5T8S!II=$$<.7*WCU5HR>-CYM3A;' ]5,#
MSH.2[(2[].D1L5XQYB/O]O(G'+3/77_D6J2*2G2H<#C,BZXUUFQE&?@P'J9$
MB?[(OM@J_'Q6OK=5W<X3)G+H4%MK$\[?'PNK:XN[AQI%&1(7DP)K.(N\5Y7O
MY4:2CPWA;D%?E"R%WS1PTWR8 FZKE!!^?HLG/MVHF#$[&VGVK4!::BVU"'\T
M _*]LV:TY<QH?M(V)@3S[;K8RM;6(=<'MT'?Y\P^JJ?N!]Q<;#Z]:EU=)L,I
MS&)$F(LQ#$ )U$!*W=4><,!=72N%PWD+^/IDXPQ->C3%!V$B)C:[6?]8N%@M
M.6@^S.G&5^_7MC36Z[LU[GU7MZ >O]=:L^[AWVP"OP&<7;RSQF&@',19+C-G
M;<$.:1)<<A\T<E;4VIA*LUPPK9O6M?\%S;PO"U.Z!X$DYQ6$LE'PQN*SN99/
M79F,V:D&B A)H]EJPPDH'Q>"OY, O(&/>O'P)B,$U^633CD'R?GMD[NZ[+5\
MQCP?3DS;E_K:"[-[,8Q]B<734-J_7V_JK6' _8L>*F^S8SBI,!]L!ZZJT#4(
M)?)9I_X!UGD9,>.07K0[(] H:SKE'CM]H)TU\BPHJ8A9+E+DQ75D&86P2SYW
M].*?]!:^ H3*JQEO, =!M>HL#93-OT>F@6NY[$*I-R%II='A>MO'\>&8K'Y1
M+]4.]8/O1F(.#76$<;TK/S(U?1S]LK V:XH"+5]UH\M\SGF>YKMXE0K@K!3/
M\$].C"CF9<8QB?L[<)RM)SDN<I6'YAFND;/FJHLJ]O1F+L^@YG<B9+@/D(K*
M;6FQH<ND],:%;1L#W&@N('K:4\<$/KGZLOU*5EVY1,M\AGE"6=0#H<SOF,/0
MZ!P]:+M=,&/O,X!AD+Q_7C@'H=PBL$-S3&? 8Z#.2U(V87^ S0;SQL_IO5M'
M"VX!6%[\ST8OWMX"&&J"29S@'N.AQ<HD6)NJ,,CBV)5XG6UW-.H6@-JN8QUT
MC6ZSX\%0Q5)G)W_ZO1FE(E*J\'!Y^V*VPK.79XG02%%C7:>H, H]TK/75O/I
MVW)'FI];:@Q(M+[;P(:5A;-H2:E%H2$4I(]J[W1E30NORNT_ES0^MD/V#]&G
MJ7P8NT#4#NJE8,WCDE4HTQW0%5L]$,IRWV;H+SE R.?#IS*(8!%A'E&<V6^K
MF1N5=\MGD<(^M58TO.H>2LE3%2ZS_L^:6L'DH4TN'MFZ7:#U;!K^?F3-$UYV
M$J]'5M3]]+Y.LVKQF"&/Y1WQDXWTS9Q\%[6#1WLD;D+['0@U:++X:)]SQ*1I
M B+MZ'?#*NCA*PMF&XFR8VH.7%C5JJ3Y%&.,J2!+"G8=-++CNKK78K%[@+H^
M5OF:ZA1ECU:X+T!GQY,WY'K.Q5O(N#O" XJ/?*&"G"[\A6.8;WALL>"RQ%,;
MNOD]-OZYE 1.9P%X_K5AEK0IU 9$AS] VJ\9I9?G:SS\V#_OAN9%W%$:^:8*
MJ>/[RJW#26Q5*0@&+^[DHEBC8-%EY>'@ OL VXXXL1S8-7/TZX2O^L $LI(@
MW,-V[.ST6M*1]*7PQU( 5C5E$RG%@XVMHIWDLX^=A1ZOPA[L/DZL39[P*7(O
M5ZU5[DTSH9Z<+MX*#"\>H/=W*PGL6A']TWS-M2MADOC*R?4G<XW9+<"L._ +
MD];UZOSA9OW\N:+R(.M01)7DY\W,K^U:++L"MX!DVT+)L"P"P>YFJE+L+WK$
M?Y^_=-S5+MI[W.(2W$WLO/I1=%/JRSD"VYT9SBA>[R(DGB0GWI3FS0.T #?A
M+^/$2PWZ&"*ANB>\Z\HXGS!A/H$)R[FG*:%;5*KW!P57./H)USOU=Y2^KWHX
M*&N+R_G:N+9:>QC)MF8*TZ7N]'R!OJ6@A\LRD>1$!]K.E6%+^KEJ%611@V<#
M0I7+\CZ1-CF'*QYP?/![Y@@SH<L$EI:53SP)MO_SI\N) C6&1:T<:'E\"] ^
M,[C>>7FN7+I64NV?(&O+3*Y?1C,!%IAP&,%QSN>PH4P=8)8I,MF><VW>K[O$
M6!TFZ$P'Z7P^/+R+\;A9OZYK6-I8NDP*N0D#]<&D-SAAMX#8B*O.SY<VDJ&2
MT2VJAK0WU?HL5WB$MX#'5%@O_]*0UF\1<??=(&H",60@.MUD(5UG[>>PH5I^
MK\[%5,T-74V 7S^ .F%HPA9_W98/*WI)AALOL$OU1<"=RM>?#'O6#WT,GC\8
MC92,:KEX4 TP_L?Q%U'^/_PR?\QE'G=VQ- M0#Q!+G=H9.&(,$83N%>AM2)^
MLIGZ[K%.F "5B^VLC0F[E5BX.\![FP'V7/@WT5+FHQ'GL9,!/TXUKZ7'8D;:
MT0&M];4K$D61QFS*HN9-R2%AM4.)Y+&DLT!QX,U))P/3N]_'P!<\#B*];?"B
M"3W'6EBQM5U!C"Z_8:(NQJU$"T/>H%8_C-1!6QFER:ZD9^B5"Q-(7X:%97#\
MLC8BE%\/> Z<-JX:)9L:5Q>G3:3\U=04:"[3B3^H+S@G8SFW2S&\]KVP /P#
MZ>$=% 17&L04O[O.*4LK7J]0%11*>*@+5@U'I*:DTZV%3+FN9%6G[:-6UD9M
MN8M/3(S#O^SWCJ^@;@P6G\<7>BRQE?^^R32]*)<VCV&[SXKM-DGFSA\'/'NF
M[$RII[3+H!,2D]R@LWS=\8M3X]&6/;^7TIDD'%VA:"R.CN?\@!/EH5U#W=:+
MXB')HPS#?I4: <)G<6O.9[UZ#=*]!9#O#"(::+F(NNOD!;N3#0E^^<'Q7F@5
MF[27#B6NM:T$7IJ)73&<?6S;:LMX,F$ =/NRY;Y_#0!Y27?5Z_Y080"SQAIX
M6J7A3+B,6VTI1CL+"A2L*Y6(1<R/<3WRR\RR[C!#1$D=N>P=S6=A$I+X"B$,
MJC GQI@^ XY,06;(T/@W5B*D+N02W,4L=I16FU:>UT1573UF-G)X'?^K1S\Z
M+4J'6,5[ +$[YG-MT'B)U;'O&R626\-W"R"KCHJK\0&I)'%Y;P><V&[L8&<*
M>2]/%WMI;^UBX+.]YDB/^#6EE(8-R.4*Q8MM:O& /JNLI/K1 VQ%E]2I[+3T
M))&EUPC'Z?)HOA&16J.YD$W J(WV^(9.NG&:DV%]G_N>U>A!@XT^,7>YL7%:
MH^8ZDBE[,6O^S<V63=*J]31=T<A;A>5X*OP_HUI)O)9XZ9GV4/_8XPS6!1:=
MDK@F25Y*37.(IJW:#)6J?S[U)OBZP96BP)% :D8#+E"F8P+3X-_HK&;N-_RN
M#K\#H*_P:I1L-4]=_FBPR]OG4$>WE+DB^A86Q+]0NO$N%"0S!T7H%"2:%UUL
MOIZ]$<D7HW:0+>*(!>W]&26^V+%/[%5,_0.5[EYKYAA?TD=2U<F;&8B6DF@3
M!]Y?;\.8%T],"ZMY-Y$;3H9V)(&[8H..'-PMI,@"(!^,:V9+^AX&H?(I) B\
M.;/5]HH8KW6\Q_SS7M>:*CC9DS;T= 3B>FK38S#P:ZYQB;ZKS%G:(!M^YZ--
M'E#*29_%F;OC.K0&E1=YI%2IEU\#6EV?#HU\T",.B5)@68BTS'W<%&X(XQ<B
MH=*:'_B,,J'A$\(\%"_-F#AL9G]VE@!;77K\+(6A]]R=KK7,K0BBZ;Y5H>/0
MF4TVH9Y?>*.W< LX*/26^.)_G6(N;;Y^?H 3]=2L79SL<)#G32GTDMG9JF,"
M4TP12VAL.C<>DI%Y8C(_3DDG$[*#G.A9KUXMZXHU^O[I:ZDF33KQ+0 B&)LE
MY>/NK3^A&)-)3861GX!!^E^[E8T0F?ZO)P+< B(8B48835]AE=AO9:X2<C]7
MN\!@8(8[8C?ZOI7K!AX)(\\VIND-:[]']]A(6C;WV@JOXN_M%3,+NZ#\M8H7
M-I@D)8Z<N,@6>(T]OZBNO/8B0*/=9\#^K2^_,FBL7_NVO:OX.A&  G[MPVIX
M55.-W1[&X:7DK,C,%H&<_^)["R!Q:OS;53,?=*$%?X"A[:4K*/;K;NWIC+ !
M\"]+L60*77UI+@0R5X^-5%X1#>>9,JC<))$PJL9IDA@1*=7,F_F1"'W!-W/\
M1QZBK.I9E54O#MJ]AG3HGIM!(CAZ3")O 528Z5L *?1"9"5D>;*C]%/\X_TN
MG5ZX%93TOIV+SI00@)V@39@+UT7L?(P&SRX $[- NE0QFG+O%H"F";]+N=IN
M =WR 9YIASI+(H;*8D\GSG #MX];6&Z8_-<7 NFJ5\+?832FA-.OO"MW7IA]
MZZWN'P37)\<GL2U*.N.J897%@MA+O3(+C^'O\N<XRKDJ'J$KW\<TQV58[5BK
M,?\<@O4RQ B:Y2VPOANPT=Z#?E6 [LJ/)&0XDQ-\P^0P16AV^WS(&5X\??AB
M4&WK^UU@6;E!*CZB (MY3:C:&L5L73,\Z6%>UWK*YBMV!*Z'*'-*7\(X1,^7
M6+-L!A"S>H[CVK7E ET_WT?')]:C#.WB227E$7B'.H.-/!1G890:-O@>.RKH
MF4:H)@N\C:\Q&@R"/+ &2EAZ^ AWO1H]//O>^0A3NTGL!<=B%>'W&SRGIL%\
MGU@; KAP:JYP7=MA;@%$F!8)R_P,QJ5#IH7H-.U:^C#ZLA^P<;8&9#F^CGU"
M1JC"]"B3L XIDQ#:?%R?F,Q>W1VWQW3#(;!*X5-#R.<&>[3-&J,;1/F<$[N]
M,+=L:-WY2.ENU]KGSTS7+II=*GH596J<3+%11@G"?R:VU*.S&CS*'^/>*P8>
M^<4*<K"Y=1_D8'LZY]+BM"P5/@QD"#PF1ZQMGQ=\OFZ^ Q&4'%]W;HL&ZKG=
M%"W:-88:2=-]+,\_^@75_M3P9M5O0-2WD_5X)BPZT,<?CF4&U+0(5VL?\R@Z
MY81X]IO02<<Q=6]M*@K,0.!9KT^P,];_7S\,-14S?$V(.($$/8S+WXXRT?%1
M*:$==X^DRPW]\\,,;Z33QZ50;4KIH38>MU93 ?VA4]9%=(&!R_O-3^77'L;Q
MA=J*6:+CBGO]EM/.<$^UZF>[,F^#.9H8(Q;&9PLG_?>&C,5.=GUA\VDK41C/
MQ[H'&-M"/&H&W1]C"34]&!["^F]'@_??+G/YYM:V88\O2FT=CEG> MJ8N(IF
MX0D/IE&E9:4N?802,RZ2G!5.QLY"QUI]IZCLW]]JV+##+CW2(A+Y3G+#E%!1
M%R94D^LEYQB;D<CFU.<I;;XGJ3R;$CD.!K+YFNF<QI*A68HKU(P-T_S(>JKF
M-_#<6X R@:QM5W<>Z7+^PONE#\O4@V.VF1ZT<P,,[!PMB'+6?6(^H^,3=MBE
M^<BEX4GU+2"R1L-S8F-CXF9]ZGJ\1:;QZ8*3/=Y@SB9G.&K802/A,#'-RN/B
M<$9-PJ47JV<'?(@O,5PY7AAE:6B868(W]H"_!EP__X@19SQ-YU ^:4UK\++\
M%N!J=L,]TF/&Q,PRQ=9RXG@$VLRV67V'"3AUDX'!Y;\HZ?TA*B!P^6!5(Q#Z
M/MG?U=U9K%'^Q>K2,0#4TW39G#5?2[XPD&9!79:1:W[QO;QD= )*J\6^W=(G
MI'G@2&I?@TP(_%-\\Z1%C:*9I7B73B"=[Q*XZ[/F37 +.&L5+C<X)?6*^,ES
MIOQA9VG4E*"=F],7+CQ<,TF5T$/(YL4VD2A1I6IPEY%0C4]$DWJ/)5S9?>NN
M#GR_>9<'MH^V93=7!7J;'"J51K?@0+^2>WY6JH-P(#R<- :O;TP+G-;T4!WX
MLML [SU$JU;$TRU=E9_.CYUE<T[!93&+1?<&9::R@&Z8JSFU1W^&TSDY5DME
MGN=74]P"]FYV3<?.:DOUC\;Z>RX;;V!_& KR>&EP==X>>A>L/=).*1_DI<+
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MEV:.K##R14-1LI=S3Y!>\Z1OFNX N561KY));A.HEN:!(T3VSOOW7L[K3U2
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MLA?R).F!H+ES2,&'<"$G&':$618!2IL+JBK4)]4_+/>T]6-&H]WU_F'MA&V
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M9&QL,$35YD@0YV\FEDO#\/5YGLP##TCMD\-J=R)S:G\^;K-,SE@*^419W]P
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MA\CL%+? 67=+Z4$(,Q<%3+!U@F/-;T/Y(/\$^ZB]&&@<VJ_WGHD 7T:* *2
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M)XS@-TRDBU%C.,"M!4O^H<ED_]M26SH][0_V6=R9V^JMN;B W\H!PEZ _1S
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MZ"E3E1K7H"$!#@_WU\/OY[AO.KG).?4-WT>1C[NL'KA>:'9@2%-P4V-4Z9&
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M*70\'V:84"1TBZGX>'*EN=%"Y7!E56&D1][N"9=Y-05GGLQSDO$Y<@:TE,C
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M]I"[BPG*%N.:BV.*--==]1J;6GRN7R9IF!,S>]NS_&Q-V$>AINHDJ/J!'>(
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MH"S5XM8P3Z0:!VLQK<A1@J<6OCBJN7M[C=QK,.-6")@>U[6S_--?W>!SPVY
MRV%)K[PI,](6)MSKYDY\+-;<$;_>JB]1WT]\%$&=Q89@%_:"D!<54,'1'JYW
M_>&"4%/V6B>RP=YY^M5>6<>HA]9-2Z_WGGQ!,O+F&T&:_R:V IY6)_YF;#W*
MVRC^-Z/R_PG2!R8&5PW$DF5CJ[?2;).?F9U]8!YP]ISK(<3DXZZ[?-W1_N_<
MH:SGKS V!MA:_TL7[ H_. X-'RF-W^BU:8H2,' )]M9P.99/W\=:9:[2V^F6
MS:FU0?L<;#N@F!66S&@'^A">TF[5>\=QHB,EW1E4GI+LIE1Z4LG6?-?X77(5
MCS%>^;?QI6MG(Q=F!3$#R**^" E3#G#CK=ND+*^?3E7>V(?S"8M-*DUX[%ED
M3$5RW2'?J-E-7W">A6DSGDP#L1-Q0:/5KB-+X5N<I.%'M9U2%F3XZ&M T2<7
M_ -6'L?E.7QL=]N<+(%_.K\N^F$A+/F)?%Q=U80E[.U461\2Y*MU[@GLL$N(
MT1FP3:4G.Q0G6'WR?K.WP\#+8R8 0>U!%A%8XFF*;+8V:,4!!&T8>I!#M^_$
MSHY@;UZ&1-W>/\L.]L,QI3@ ?0^VGH!P)2PO]F*IKI"L>YD?V!U,2]?!2SCF
M2A8D@%\F">1G!%?LBHJN)8N)HF:Q-^72 R"%*'K$ 8A-'(!_%$LFXHJ(S)5)
M!*@)Q8^O"2X&TXZ=GX2R5U([E'9DI<(&$+>"O*&KN.-8JG): %/+;@K2-6-7
M,PY B&&+8>MM,.^@"&[KBV. 1/+).*;>/!V2/^X4A!0OEA4#^P9M'R>&*4W(
MJPD[/Q''YM',A\3VC)7& <:??T$LT0AU<: [OI_(CGP'^4FL-%/ESO=(L666
M&0904IP/95:A"'93K"?V GOK],MV=C#$MIK'?L3_.U9VM,5-PQH,RJ!K[<\0
MH-B[RN]8A_@=:_--OT4I#@P8FUJ""H.*=O8Z#L#8M*^ E06&EXX@EA<A?5MU
MO^\;QIE^PUCQUQS@&ZR@BH3)@OS66)\]E#[A.("3Z5Y$,78#_2-T&?X$XHZU
M[NSON:?T+7?+8=\BAOA&!SXWT^,HLH/1T#@],":_ZZEON0?5)N[M_9\V%#)M
M.S]<OYV[M84^:J?X ^2^U83-7Q74Z*_Z^1:\R0AF*H?7.:257<O'N_0.#&5V
MW>B]?LX^]=/ZDVF5=GJOUA.OMH+B#$^F!K6Y7E"R#K9!RY'>J[IU;YF(J??Y
MF+I*5:_/HB%[5[? %^_3%-EK%[V>@,T6G1CQL2.=QKGPO&?N96%.5:7B<C$7
MS95XR@=R+HZ5:-3/@HJ?4Q\'SA[K@"M(+1I(3:\>@.?EG+RR6@>]YUA&B^W6
MZYOOW-1?Y$Y9CBMYE8S2F'R[/&87.WSA,5G&H+5_SL,-N5RAT.;A:Y"(^,J)
M]YIHV\[N._%Y6U_32=:$?U0SOOS*\6"A_PVZ ?N=X=G)_3>TXJ?7^A?V6AV3
MB)+9J<5';IWN:VD2G?.MH[7G PZ9OM!I?^]S6H]Q$#-8+4U#ADWM08:6E9GK
MNEN==I>4O'1E8RR?_3&MEA;5B5=ZRC*3A.^8@]=*9J\EYGD,:_1F%_1N?>^K
MD^/;(5?NY'=II\V #+WPI@DJ-=YQLY?XS8![A_6?J@7)PB^IZ^09?6AZH&9@
MT#1347;%7J%K+&-B16BZ@P'WZ.OX((B9>/NRU2+8[9,)SE9Q04KK/60TOY/Z
M:2MJ%)V/:M-\\U$I^.H1TCC/@6@NT.;TE$WYK"ZE8)F<8=NLL\_ZMLK3[_#-
MVZH:%#,01PD@[]+WLKWANL.WI+?]OM9HG\\_0S/P7_4WHNO?2S5^.JU_.Z=5
MSO*AC['2%PSV+RS1!'MZ.Q+3F[K:8IH+^!9TM+[3@')L%/:%8@B%>B^4Q$Z\
MLKWHTA4QM[T9SR@"@87FKT>\#]4T 8JJ.D\>%$QH'T9$M$4U7"K1%7G@UEG1
MVWJ_;#39!T;"3[\B#\DUL-5ZX3N&ADQ1>1.[AL>I \80$@:/-91#<'=OQ,*>
MMLR>;L["]!&*>O$YID\0#8[F",T[/%\&M\B27&%&;8$WL%1+ ]?ZX>WOO1<M
M' P"S-(_G:/QE-S:VSG(]YHH=2X@,_Y1NK3 DJ7.0ONWRO$N]*V89^<R:XS7
M2ETGVZSKP=:9,EI9P-ME?."05JZ#5YG1/\. RW[5N:"?2O>?&RG_9]SACL=%
MC-/L=@>3M.T/<<)>&OK5OTB8^MX(XHYF\6F]^Y;L[P<P"H14RGA'U86>1%V5
M,;GKK RL%UXHD%!?@0FENLS,3LM91\ZL>#Q!X^+Y[$446EHE;FL<>6-ZE8Z[
MB2UNKN< T16I;IC577ZYH2*?/U,L]CS:>:EC5!%869_S K\.1K6T"+*CY>.#
M'GL<!;'&9>5G,]1:M -$/3?:75QC8W*V\M>8/DDLLJN=]J@AK'.B(F,]TP<8
MOQ#2-?:^F5RRLTH:3E#?==MH>I1[[K**JEZ3[G1W!Z)K3G\J'FUMK7V7UIHD
M@FS->3EUUZ_J2O[0:$EI^/._\QC"+C.8_&^Q*/POFQ09O>0 (7R0M&34<X)R
M<:#BV+7S\:9J\G$>NUS.73;;?L1,:_&3&->H VI*F+')#5DX@FF4P!6%WTPE
M&\FW0O@K-*4KO$#N)>>?"MFG@&SWOZNS-?'=IRW7#F(+ Z:X&-+L>MN4DK*I
M'"KW0:IORGS30,\B+M5@B!HMO,G<Y^+<+^/W]8Y6][342&E-[3G*)_D_OU=H
M\$ D\,,9<#]W0/MO[(#V=]K/Y>%_>'GX;]9&CA) )5.FA#3=B76M*HB$O%[1
MQI15 1-'B!O==/>FD4XI6A\L?U%:51G)VXW:J,)*$1/YQ/W$#;?F <H76.F,
MI&D,%M$I5-.I7=16$]KI$E*,1Y/L=EI<I)J^)I51@Y$Z\2Z#HN8R%I#H)968
MN,WPR:S\NP,FM\Q:=N0U8EJ15"N\./HXZQ$>ZV0YD$,_UH?A1UO)0C3=2*X?
M4']*T5-SJ6_0/?QF:Y*''D/S4]6+UV\4KB>>,N*53I8'@HV-T<;4(K: ]!.T
M$1A.(FQPQQ;FS212S2D!C8Y07,:N__KJL.[LZOF)JVU591=-YK\<$ ]R-(^8
M4L^,1.F:*&RHNA3.^VJ^'E%RC4:<+J"@^J5KJE>Q.UY08:'/%Y&R@>T,N_-7
M;7."M^[5/5#[":;KIA;O^%3ZK968BU#BV_H+?"\Z_BF[PY],*J*9-!\"P[W(
M4OY1+G'.0UV;U^1<NM>='GH3L?1^0:L#BQI'+FPJAGQQ(@?8-/?B_K!=3*Y#
MVHZG%<<N)I46Q]L1@T[WS:2,^QZOZ\O>6&Y*L3M]LV)'#IT-V=G^7$OF6B0M
MBX$]P $>]N2P5^/!/E0O%3<_A[BZF^ZGMWM(W/JW%SM8A SL>_<N*!&P8UY8
M&19E8TQG]T]-^#O_O2X[%JL4F<RXX=#^[JE67QO+:98 .]06!XH01DQ_!S09
M:+F\#'O%5_2T/VG\&6YP19+%FX>@*F";XGX+\V<$A5RMB]0Z;!!E"QHK@@Y8
MTF$.$ /[+4P>&3$VBEF0?9?CXICY[/>,^CV48QVV_35KW"#MR-LRX^-LXGO"
MN)8;%/]4V'M^#P8ONP&EB'<8[X-TT^Y[1S[]'3]^!Q>,6@L%6+FEAW]BXQT*
M3!K$&G:H^T5HF5_!M L[1^[K+BISWFCPCL>:"FN0T6Y@;PJUZL9[3>?W[1HV
MG%NMLHT:J'CM*ENK7G5).=9ILT >[ +E<V)?78KCM/]P5(#+RJ;GV[=V^%U!
M[O!?3I/Y.X+RJ/PS8Z7^4:Q_"O^/"M\C'8RB&5E2,6FHO?=5M9-%3RK-G;N]
M2UBC3>YBX'+@R@-ZOFJSWINY*C':B<BG!_AG':L'%"I1!SU,!4Z_LCDB'.!J
M;WRTA(8(1ZEE588ZEBCOX#O@+7;1Q/1JPN^L\^2EE_L:#VMMZYI'?G;Y8G/D
MG<;,WV-#[I^Y*O"_F_O_/RFQC-]_<>?>;[B3CZC%2OCBQ3RNIJ=>TK>EU:I/
MP^TW*Z4+SR6M7ER^CC#A+LA/_IW0UI]*_[0O7_S<SIY,TJ!=!5+ C6UWJ@=G
M[?#AI(ELCCREJXOV][A96?UGTCN2?XKGG^=C\BTI&HV"B-H5OZJ!\R^&3UI<
MS&J)-&PX2-@34SOR:63"9Z B2'KPU.$W,B9OK.0UFPH/CF0I2_&6[^QO.A7=
MW%-K]23[6$I4_"DQ/.I4R;1?<)MB6-Z1:/<6^\/T99$.8_$O]_Z9DV?$ERLY
M $\K*PV^FJD*(L@:400AC.CX5<O(*A^&+=J@@H:-4/,40[IW;L_:[#9VY/),
MY),,:SW)>$!^;"&R"DD?944Q=S$N,;6I[?5QXF G!S@06H\0+D9([O?)&7P4
MMV?%Z_7+0QL17)NC1?9Q9P/H,6@\E9A4-O\7#K":%>S!-G1J@L,E95U7"%#2
M7*?-OID^6!8^./O@&&:X-HXIJ4WG93<@OH0T4^[T5.43SK!KR@8_.X'ZK%2?
MIIFTR7'<()XN2]6>[J#6'Z)B7HT$^]3)RE'C(J;1%B0A&?#TH3XKZDR1UTMC
M'\E[S^.5[7SC%7G.FVXA33M3$,Y84%$H$BZ&Z90DE"*GK1EV'AQ &J-<%H8@
M2[_7&D+6ESH8A(<O)-TU5]WK+^'QJ5FU<\=]5X6TD)O2=A>WP R8WJQ07PU0
ML;VN$A6#%.$ ;D-&#<A5&![T@6ZX/%H-E',CO3[;?9YF\*FQRVWE;(^M?]!+
M0K'6/MMA+N^XSR</RL<;1_,W@)J,LTPD5+KZ@YH4RQ!GUMT9C$I@:TV**O+K
MGS3%2Y\ FP8MO#2L>\\ET<V]=(=/X!AF>:IJ_O*GSZ\I[;W]Y/*,1/40*PMQ
MGH$;L!P)J$-M"FQN/I3.#YZE*#,M$"%A*8X,U*E8#8U?RI.P.[TBVQZE^T4Y
MH5);+M>_X:KRH)= 8Q\/G!WI:XR+A&N"6HR3)]&Z[^'PP-WU4'8OS41 I?%Q
MW><#C8G/-0>>]TKNMH31_>K[/YI[ONMX=_/P"\-Q02#8BX22 @,HB)!B["W,
M!H+DU2.OL@<G=$^]/U;M5TQ[7E M)*?TYF*PQ['"*@$283VD,B8QU-E:.LRY
M<X_@#N*1SFDCB3FOAQ'G(G9?T3&V2OCB4,R5,)*+V$@$3=CM9':!6\[D,4.3
MM*!@;^<PJ=T[WX7.KG.-G(.!AEC20]P"D@DY@!N/<$R;_UJTU021PS#PX&VW
M*3'41Z$WZZ_^5)6*QCWV^((J""2R0_V1X#IL4W7P#_8BO;:+W3B"71'LQY)V
M?75#O_WQ(?.?>#6#$FS9>%K\O7<)R^ADT=QTIEJQX^9*7YO-B_+7P3Y+Y->]
M=,X1/''2F'IDH5I9DT8X8NV"Y28/A_#8!930EP')6ZCLTI)XQR]O^:?ET=$B
M!N7Y)R\WF?-9G=UD<Q*IDO3&MJ-2,?/J<LHQWYX3%3C!Q5*ZP2ZV=#L%NTYU
MI2QZSSC>>\SC2_WKRNC\*KG-5*"FYDN;2Z BZ0%<LX/W*=^M&[OE\P3;RN.V
M*XO-[19Z+#2"5/I:XD!&/,<!'IUFO\.!_C-8,'(1!LHCIW&T+GI6'V8O4X.5
MA77E &N9<!JJ#K%Y,##(IHL)R[,(]K@DY[#\B=D"O-,&UH@OQ\#6[_SPO"GF
M9+W@X:/1FYW=$S<_FBIWI3;ZG-*KG'P[6'EHR3GM>(Z)5=:^[4.]=\P"'%_I
M796=Y #K6A59@@(< /-U@;5S CL,\L<$K<D]=I _V]!^G3#.CP#%H,)4+H'A
MHP6%$/P,<O2*-E-3%;>P1X.UG,662K)<V23)9O8][S!E&L%Y(;>O]/69(0<8
M#?T)\C\*$G@0MT:U.7J4&@\^YI'HK7-LO7_Q6331?U="JW![9^HSIOR+SBJC
M'#<U2NL5KT7)76IO#VHG:E!S@:O:AL$>(].6]*]_W"Z9B67E5^]#R[!B"&=0
MH6RU#HQPX%0@]F@?&CG2F@:?F+"[[FJWZ^:6T5U?:AI]L,4:T^V0&GNQHHLU
MUJ./LG(@Q%()W+[XM>[5^SJ8!GY/+L"$9_#J#^-7OIPQ/507/2(_9G 3'6S)
M/U[MMTY-T-W'F'&X8K^9@\2GD@<VJ:]F/B8X.';&8M4TCCG:?Y&9?C5+1+UD
M\?Q&/?=@ZW>W<  C*,4@IBRFJ$PA*%)4;1;7UR?@. X@?X4P>!_/9&$O<P"Y
M%@+Y_GD.D)&!G6V#4=\68M^_)RQ]?N42^0T,["?(_RR(Y=1;TGDPPU#&+*R<
M _ SMW>A+61Z9ID*]%YZQZD]MG@5);?$J]6:-8K95W%-[9*MU"527U15\/HT
MF9%QS$9"MTBGZXZ$>UZCM^6$7PN6K8Z]@G]+Z(^B5T,JW,7N0P)H-<9AYF;H
MEQ,:2*UC[^KL.]KAW U7.K5?\X#]7<GH#*7+.9$T3<MUN\W./6GG"LUND?6^
M\,9/4M.]H\?G0DFP^G2'1X\1O'''91OW-S.];L:#U73XI_?L]8X3;"4"M2@P
M9:O6,]479AO7%35@;YU9Y /BK@[]UHG.24[E,;S8P[I"3+&$6FR!QO13AB1Z
M)U6,O9NZ%T^14;2G(J+5M90/^@<=S>+ELO/9NS/(!YG94VI)Q@IVUNE\WGCX
M,FY/RJ5$TYFRP,=$]0++)'J/_'"9G"C.R?G8@ON>YV7FF%=+'^=0H(L]8OP"
MDC%O^A>?@;?/?(4$P]""',#PZ]LKR"I;-F*]70CSBZQ69MSVOVU.D&.YY5I#
M7."!,?FQS-L_8?Z9,%H1(T*APH$.C@+"%)U/Y=W>-XYFY;]_!E^(MC3>C/&;
M2:2B(&6A][">LZ79'[&"V'/M_=QT6ZI0 U($)-:DX&ZM&]:AJ:YX^G?8OQ/N
M.+WS^.C>*U+;JSZ.U+&E\I+?2&%$A)]-NRI;R.?CBY)**QST#*Z>( KBG++L
M=7NDX^*1ZLW5@7C28G*XKYE6*D+28?@*SR\O#DY6/;YX>+Y%YM*4Q^EF^N7P
M8X7A5H4T=[-UM.=W=,+#CNT61-N-8*,X /44+GQ8H(<91$& V_FFJ!68\.R/
M[I+30HU!R9?6[2J.M?&_[/^T9A9YYNM[%S<+4WH]*Y2]D=U541:JBM;S&;$4
MW)X-CWC\;FZ_2YM<R*WV>>&Y,9S#:&O5SI9JPK''VGQFQRZ9F6CFJIAI!SR+
MC;>T"7AN4^:26/31LN!PHKT/TC^S>!F)ZA[X.^%@Z'>"N-/"*D_A .U]2QIS
M^JE_B:0=OTE]/'HO9+&WXKBQ[\6P5&4.,+?_)\@_!:03UG^_IH5VX)IN@N#5
M'A^8M#Y2HYX8>EJ=MJ#K&Q"7 9[C $?-S1X\.W*V+-XPVG3+WH\B^S[?K=(D
M8>Q:0V(X0"."?4CB2@K1X=>,"!N*D7 ;F$IPSVI,>C$X.'RW1#.QK<:HE90N
MEHZ+\4<*J>L;/W;7QJU_SC1R:3VC/RFI_'GM%J?T-8BZ(^N#/>9SZ.=8> *I
MF .4]-7 !#"=!#X$Z1X1V$XE1/N6=.^Q]Q.*E#SZR_LD9YX1I<.;GU)>2=)M
M6:4< "7#Q^8W(Q$^)-.[65'5&P/YL5*!TG:T]0G/05B3Y*:[F7H&3ZQ"@=SR
MU(T&Y7C%<!W%G>0I"_Z75X^?H1"+[[I:E3?955TY^?^Q]]YA36W;WG 0E"9$
MI$F-"HJ*B$J7$E'I&[ 2!"$B(B ;LQ61("%!$) :00$%)0(B*"5*55J 4$1$
M1*2%DB:"%$D0PI*T;W'>^W[?/6>?^]U]GW/.?>_[//N/^?"LN5ACC3G''&/\
M?EFS[$W'E.]9O?9T=.#QEK%/J0?EDR=W9O<95@7Y7^>C9B+Y''TU(>3CE6XA
M1 0/]/W5U6"[XFH:[8$0<H%-XF^8([&VK/W^\^\O_M?ZM'_>;<PR"VL.D&C%
M! 7Y4Z]3SY+H'M/UN884Z )2'=%?_5_Z7O7/.OF'!,?1OM37.T&'=5K#5E8.
MM(C!8!:*VOV_T$\:JF:GOW>%0 XZ$#_NH0DA =21)!IT/I3U"1E#J"IJ[='O
ML%+.751[?MWK@G& 1T#"@3=2UN_2K_9 ,)T@?-5G#9%[1T\U3ZBP2"V]P"Y]
MLA B.C:=736$J,6Q<EI)@2F,8?D5^9B6J5S='S"!9+L0(E;)SP=?A*-(<QY^
M:E(4C-[XK>BVU2[/;Y34QJ(91#JY[-V@(X.N'>?ZZ/Q\]V;T+/(%G$7# UHH
MOM8H"+4%(CU"2*<N&,O\\,-XCBL_P5 &T4JMB&]NA#;78=^@LVY6/XN7W^[U
M2\(KK]H#7_051'XN""&R*OS7(+U>^RZUB (I /,^CAR'NP)?A0LAO)S/0@@P
MB2T_<1AV'\>B$T;Q OS:?^Y<A@O,['BF_ARF$%*P5M/5Z"J$I")F)D&I=G]*
M_>-2/W3.A8#&7P9R<-R3@GZDK!$5V$6(X\F\0)LS;A^Z41A2CLX,,ADL- 8Y
M=<#Q?EU32&SW1>X #MCC/Z?,Q,<)(94+\:$($)K>0[LR1*F8XZSOCU%/OFGJ
M9GZ_F!DQ8/-:[N=\V\4X[8VI;8BYHO8%0,N$MYG)G&IK]&?".N##!2W8;6R[
M.RB9P>JRRTH554,AFT3"MC7K0&[,NPLTUU91"B$MVQITB,- $9GP$AXUMRQS
M<%&W7OIU\ ZH6-_KZZ'\J>/-<DM/H!DD.AE>"^/#P-'H/(/C7<,#O_7.@PYA
MM]8-]VZ"J%V=./!NE^@B7J!NP+TJA/2MW?@R >+)3A#QQ&\$4<H2#HP$)L^%
M$/8[_KG\*#A8_Z?4/RB5/<4LXFVB<@98Q!;]+4#!:7Z]8"CX&8 X7O>ZBNM=
MR)UFUJ2-F-U3C[*S"$%:@*A*"#D/5\$XK\$J-(<LD+I'(VT@OT!?,BM@->4Q
M=^M][;<.TSS5H7/\MJ]I\RSR(_3.=1FU]NSU*[$-=D5V844S-ZY1J)1?K!SR
MTJ0.F;PZ:;TZU$7X?5@"&XQK0[*<A9!D[[6%O#4874"&A@)VR<8S'OLC "3Q
M\GZ@Y.A0^;Y^ET25XY;UAM<JGV.F(%%7WQ)?_J[Y32/\1R3:?1++A32BS#B'
M!!/,)>*(3BM6EGU,*<3#IBR L[BW>^,3R4U*U_8W;V0CK3^*3\)^[ZPG_HZ;
M9JR^L8%@P3M_ZZVPO_5^9,G]XW^*_8_$(M[BJNQX\CI,4LL"L&>A%1F#E,==
MF=?_A30D4)ZM2\E*KDZY,$-1VY7W4+'L??J[+2J2M TMG8Z".-UV^&4<H*,S
M9\X-GEU%).(N"R$C)63LH<^&YB;5GZXLO]68&%2.G$NJCE__Y@GT'2$%SG+N
MU0@@B%MXEH+X9GT$2_-I9JX*Z6'5=$.(;N-'IS#?S42*BY-OP)8I(Q 'BH&8
M+?H0=@BN":?E4J6L]J-AG%XAY#;.@2T>ZUOWLJ^I'VO5I9+6\=Z6'J$9HSXT
M3>69:@DD1H40>PX .F=4"([];A5%A[;"X@@0@6H 5=Q*%FW<2YY09BT_J.J[
M[F5I'_=IDX-$5/KA+DON1_&O\/_;S?E_EUB$+KM?(('B7@80M*QDS(D76)#&
M!=7T8W2+O<YY1!)/\I>NCMK//>I*/:R5:T8<OES$T!"U95^Z%4E'R7WK&_^V
M^OA132WG'C0]X.*1U)2YTW>Q52)KQW"+9?'O-#@PX"-:M-J.LSA:D94TJSTF
M</!F<J[,9XL++.? S>>4@L+PO5)/8RV"1;]^0Z(PQX$<UB@#Q5/WXEHA,29
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M:F"5(A\EA$!\"@0:,F#/):[M:!NUOV_Y'$$0#1- R']J^J>F/!G-278)IQA
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M9N+B0?IR7%W0EJ:8$ZP"SMU&?H40<IE J4<"HVSGA@,@&)^X53XCT*CHF[.
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MT4*9I4^')S098>P&UF?%\[2>> <=&A_I_!ZLEQ=>>.7FW3O#&KV*0 \8G\S
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MA5P1[?/^@TVS+!P9M1&M^C6H<</NC*G#Z>&52C3UH1X2RP,_(LXTF>_B2LW
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M7EDDK6*K]]I*W/[\43SBL?S_FP!02P,$%     @ G8*(6 CT6/[_,P  [S8
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M;N)34#C*1T839#\IQ9$!!.II<R'[4D;:$MI[/ 8B+Q;A8A(Z</B$8B<DXAZ
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MJ 1!C"1@?ZB$S5ZX<H_0=O=3KAGQTX5K52L2U3_A-NOM)P=OFU@U<G^$GSC
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M WOIR[F,1(-;O+<%TC9Z/%1&+\-<]#@6],"KGP5?+F7%(&YFH<[P_+V"4(@
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M7\<8[:O9VH\+//-BWQ;V+KP'O+;ZT;4'-M"RS'#TNUL[+]JEOQG864@+>J%
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MC<OEYE$$D'55!\BB.#;96(&5 1[2D9R\S;J))9'+&#_M<*7IH0S9V21I&9G
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M!R,&RV.?\AZ ^51$YBBX=HFEM76>H1C&AU8]VC)H#;)B8GQ%U+&_9]! "][
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M[-^M$1#[@3?ZSR_W^^G_ U!+ P04    " "=@HA8V2E.>%,4  ":%   $P
M &IA;BTR,#(S,3(S,%]G,BYJ<&>5=W<T&_S;=Q!%S*2BU*Y-0VN/%J%6K(C4
M;'70.Z6X)?9(K:K674JLU@R"V%M42XW:5:K4GK';E%;4*A[W[SGG>=[WG/>?
M]_.]SKG.N>;GC^M[G7.=3IPN '@0QF;&  8&!L#=LP<XG088 I@8&?^5,P#/
MA)F5F1D(9 :QL)QCY0!Q<+"#V-DYN2 \G%Q@+G9V'CX>\'E>*!3*P7V!GX^7
M'\(+Y?VW" /360Z0F8V9F8V7DYV3]_\;IVT ,"N@!/"8B>$2@!',P 1F./T
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M<]JRA#-]:?-0]>3Y%20EEGKIV-6P)KJJB6*H!$U)>V8B(W(@Y MO56O&G;^
M'_0NH?!2S-R92I.SQ*B-FLMAI3;7N%,-'JY1]>Y[]2;=4#=/6"36M@:6R<BL
M!A\W:,'C!EW5,D!_=Y;LE0SMQTNK_)S_L)O/^MS;*QU"*G&W^]'>P;I 7DX,
M_:NYWG^H2V.+Y_/CQH[[<G"E%""01;TLOMW(V7=D"DM +UR3DNP^L4ZH7 S_
MR1@*-V_X^&;W?A\P;1Y8)6^%2DJ:H%[;6U/S]V+* (:S:,\/VT$E55^+! 0B
ME<V,M]1_!*QEX7>WG.E% P^*2)3Q]J?4ZRD1IP V%YQ*?$O+-\R3 FW-?[<R
MI=3<#DXY\%5TNN4\S=MI6;MG:55B^*0X:9/Z,KV!L2@KZTNZG70?8<;.=[47
MU5%[ZT_;W]$[QKZ[/0V.PK%'<M96:I@WULXU'9WEY>^FT/M.=E&)V0N,>+$H
MP/44MKW*7!Y)#X?F![ONFG9O]N[61PPN.2<5T/MV"?52"*",YE*DCIWB9F:;
MM^\DFSPX"VF@(59Q+8)7I4]_[2C7J=IOHNGX5<PL]'6<C0W< (54V=XVU0O_
MVGHS$!7TJ00$6S]F;4P^SCF^#;N%C22\Q)/U#GOZS[XAL$I7:K#9:]0I'#%-
M$\F3^_87,4E;W\%Z-0[9^/M)V4I3V &Q:4NQ@X=OK/T#100._K3"^T-!DPV(
M8R-=OZJHK'AU>2BX7ASF'QUW1]BJY)Y,3, 4X "3/(@-2J4*=YK>B<^7B0T9
M0CX]Y!:,SQ@=)9>"[$O$$<$L(?IK"2I=]@%5_?(+M_UMWBG\!!G6ZN-=#W7[
M8[F]I,3Z%\4E*'MOMN#T_N!!X_YHK.^0G[<<IC3EV<%=!:+)A]##NEV:3:O(
M(Q/_V2<SLU\H+8JMM5._+NQOW+>"!+F,5KAZU"7Z[I0\*H_IL%6VASVKOMA'
M<!%*#+*"YF@1)T5425;XL7[V%R2B>ING9)ZA3L)6V)^6LFH.T&IC$>H^ VPU
M-U1RZP&SG,0U;#(M;I.X_.M7ZV>EX*05;>>P]Q:8QX]ALT?8N&_Y<<PPX7R:
M"+^C6PWD5HHS(:1497G+4$R2BZW[<X3*'OJCI?7#7"DP]?8]T\1%<9B:.,BI
MFD$3L+S 8SUPJ2Z\3HWL^<6K2GN'H]^SOEBBRO4YRZS\&LLWA)THD-Z:V]R@
M*QDXL@E!\A2W"/H0S]<SM&UJFHQA-B)HV\GQ%W-P' =G2R1@U]I%YN!VB?K!
M^:==S;S]$&*JI(_6-=DCU%KTU8LQ>?P)G?>*G#*U6/5EV!B=)X1V+,=Y3@')
MH?U\R9(D^L#D!'<CEJ9?ET\*?N3&7_)L.0(TN4,C\:4DI7K/-F6_D<0O?)'<
M-VWJ#-#Y!UNOG5UJ:SZ5MP>>*J"_N&G8X,?TO2\N)E>1JC"'T,GNJ=&A!/SN
M"IP%4H7P.0[<6U9AO5(ZOD,>H#@:P_3-3Q8F:)*<P%3AY0@2H:)4P($*8J(<
MUOTJGF6Y>[/U0K:_5>RRY(EG^8*$EA7*3.#P3[S4)KO;^H4+X.LKUS:'>?FR
M^T$L@6SRNET(_E- ?9+U1:?ID,;Z+SC2E>]&#SS8YURL]-O6(J-I\,_AF;X-
MJ0@O[$>>QJA(SU3U[%- EE/"@CKMCUR 2%$3L_K3B1>O06SZ!ORF-E+?4R(N
MS!=^ZQGWO[IY3KK??7_UAN:V)/!J.H*P5G+C,G- GQG]V%WW(^5.1F>'H87F
M506_* -0=#:': L;O^B<%DU_>[]%S2UW90QD-/^H6P8IQP$-:89_=(O<C@$/
MA=V$^6<>P"UCM"]GZQ#ON,.*?>Y3?9AGLA:!ZES&6F5?YZ2DHM?,I6B;[1B=
M@!\ZH4=4@<-1J=^KRV?GTL-4+YP#RE:<GO;$JWC))WJ=14@T+ [T8\CWYT_[
M1HFANH?2M%YLH2G^^4Y<RF?[<HT47#7#5K=I&0G"(I,1]S)828/CE0KR#M8R
MY'7[WP*[2CD0;/MAG/U/DZX6B<4/ 9<V0U]\"Y^R;!) "_J5*'0\ED@3=.E0
MUJ%NZ(^O%@OKDX\EEJ]5WT$7'/^U=/6MGI(G.BV<"KVA]*MQ>YC<<Y(X\X%)
MM'#T(FYC5>/W[-L!*N7]I]PPI9^/$$%I'\F'+E3U\$FREU*E?S/Z9DCD%.[H
MX9S5%X+*R13+.YM;Z<\A]YV*WG-&RMM:5'A=0:.$',SDK/0EW2)4HN?*CI2>
M3:4]+K)L-DY(O2@^4]F(YF:5N2O/H!.)"):4C+6-3BP'#CW)S2O8/3@%=+58
MVK/I6IW?HF<'J4?E3\O--. !>ZJY"YV?3(>39D.4\[7?)*<T\I%*+)-A,Z04
M IOH%=/#+X.,)[$/)NS4%W6_Q+_E31M%1T%JK;Z3$I6O.PQ]!%OPVL!O?<OT
M3:ZB59R7H#F AV.NX3JJ\]%$77!VUMXGN1]3M61PG[]23H9!E@&%60@'WUM-
MVOTKR:9535K;O!5/*Y-GXBP;-G$3XA#[91T&"JB;%JR;?O5T)*UQ2A!52)4A
M!+?Q"DI3!"R@"'.CM%Z?=/TI@A9HK5'7K["(ALQH'G(?DQJ]4G-1^T[[9G1L
M7>^N+-3'I$&S-V&4_$-YQ]T_'8*JO_Q GJ7I$O'R[Y5*CPO2LQY>GO$K6#2Z
M7F>[..J<GD9"Z%$ T55XD\6^^GNFZPOZZ'>HE '"E50*%_+:2/BPUHHO]7/S
M.2>O^(!"?N.NH75U[(H4K)!+DJ]Q#_9SYFB/N-D07"69I*HJVM]T-I[+M*U/
MV!?'CZH$*OFQX2M_(RQZW-274!&?'6!$4E8*=>9HAW:[CP8GOQMW+ABSMO>F
M91X['"PUTD3#YY&1]%. !6]/VJ-P E=P=G%)_/YDEJO(\28N6F1L689%;;/F
M'4:$SO9_W*]:*,P3C+::7M70R=5-7Z)L?AR7F<\,@>Z?;_Y"JEBC!$;E>@%N
M</R]IC:JH(J\^UN-Y1[XO/^[5S\JO)L.T>M.C/HZ 'I62.QX3E#)D,>S>O=G
MC>XO6WM%WIN;LC+E1^&0A.MQM97X06"7H4>H,X4=-\XI:SE(RI4_?(;(M%E8
M=-#L[:79J@U@X[Y/6-5^3.W$NK+AJT%)0]@<617OJ*Y6><>$ 4]U-KONY"?+
M6<E'EGY?(:RFP.6O#R4".X[\"O)O[(A>]W[=8QW8^982[D&HM);=FS(VR7!T
M+:P;\!(,Q.CLS.M.5#8SIBF%")3-%5+F+FB;@YX-O'CZVFYV.NJIP5O280)V
MGNUDO2A$]A)]+CNV\/+WZ;NQ%@%QH[Q'I?Y=<@@%5$H#!(U(L;(T\SX4[:B_
MY?6YLCK[.8SX!V,\UEB^:)"VLH\OO&L<8IZ6AOIBJBB[@F&0N%Y')SX"G87'
MSQONW\0255U>MK@[X,3;0FPE<!I#J'\F9W"\\/9N?$N-A6&GY=43GJ$MA8-A
M92AUX@2:_6].*-E/EQ"#JU;=??,U_1+6/8^_[/[XB \M,#<6<#*#7M_^8@$^
M!:!5COI/_#C>ML9N%X0/G_#6AJE^ 9S_;:CWKFK-?.H.XN'T(-6FAF^*6FGX
M2B"\O) OT\$ ;NZF  C!F825Y2Q%]<S2]6*8'81?+IK?&4M[=0I@Q>RE_MD(
M=UD?%+TW8J]5!ZNL$2@RPTXH((/9]F3[WT;H'1-K O'<B\9;>7_DG#1BM9W,
M6?WYTM Q)#D9^65P;K;G23F]9_\_%/0'WJX__+>#G=>&%T<5.*=.*D;^QS].
M;HI<*WZHSWX1K:< @6OX-EN]74R17H? \4JX]CG/SQE$,O&]KP,2!.1AU>TF
M:\LJ!?E0IPLT+BIP=B=,=%Q\P"!G>LC05C%9"HJ3+&J!4PV=0AW[ZF;]ED<-
M[JW0%9^Y6ZE6IPDZVK/1RT(SKUAK 3&)6K8'ALI03BMW<WK0+U1AH7?WGT5]
MX\6&&D)A%LFOA[R\X.,A7A7]6^*XO\+T9$QTU<:R^IKW<]V.W0F'OV%&AN4J
M!U\9$:.+2/K.I+B6S"J1108*&8\'JQY7,G<="^ HE9N]N9>-XK@M*CS8-H4X
MJEC[ZWH/L]#*K5+'/<=+C4?O3^Z> D(>2LW^R<MPM7!6JG0/;;[7>RMM6=T!
MY9+@:"HQ;(R^D&M&E6"9 8WK]93=6,WR_BNM^6-C265MX >N"SX%&S 1@VZ&
M"?RMWPNCH;GTPN..^H;CZE. ZBG@)[%>5;W9U>DJ%N:\ZGP[4K++_WD\S6Z!
MH;<'B._.8* >C'&M^87W5%?([9O,PO%TP6\L(>Z;D?5*?Y>)7OY3-N<1E1]]
M.OE?4$L#!!0    ( )V"B%BZ2M9RP5(  '-4   3    :F%N+3(P,C,Q,C,P
M7V<S+FIP9Z2[=52;S=<V&J18<2M6I!!<6MQ=@P?W @4:W"E0I&BA>'"7!'<(
M+D6*6W&G!0+%BQ<_?=[W>[_?\YUUSA]GG<F]UF3/O9+L[)E]77OOF?MI\>D'
M@!"DJ*((0$%! ;S]^P(\K0#D &BHJ/]<?QOZW^L9UK-GZ.C/<# Q,;!P<7!Q
MG^,\?XZ'3TR(AT^$__PY(3DA$0DI&1D9+L$+"G)2"F)2,M)_O@0%[>]GT)]A
M/WN&38KW'(_T_W-[^@H@P@(\H"B@H;P"H!*AH!&A//4#: $ U+^J_57W?S<L
M%$P,;%3T9V@X?^\[$ )04)_]U1T=^Z^N.%B8?T4T /HS#"),8BR&-R2O9+!)
MM;W(R!EYA80M&QI?4##Q\<L:NKE[?ZH3%)'S\/1)KN_[3@EDE0=;):863,_,
M,K,)*.KHZ8>E]"@HO[.Q"X] %!;!^N=^;OW],7(4E'\K\D]#0?T[#B3Z9QP5
M!?T?3?_7.!$J@\P;7NW?Q*]D+=T2"WJ>E@&X?V^B$J$1 :0 R]F$,@ 9=$+T
M_^F4R+*9MC)N7IF')0$." E8YY\ 5!V:JX^S9DTU$E*MG(3?1KF/>%O9_^AV
MW%=HVLBYZV(9.=HY*XM01F1%QGYH1R0UZ^G)J=G/F^7/%FE,VR/LB$WSAGM&
M9+8%?X1.GO9JCI@0K[9T#2JG;T*'!EG+Z4.P4+'H@_]V6!.,@[GM[QN7MV/)
MG:M8N/1S06D<KP[V5"?A$B!"#5U,\1_N\;%G<[X'H/JUVL.&%SA(4W6)I2E5
MUH\AA/ M\4^Q)O8EA,L5CJ=L5JT?IHZHPB]M^2\E]"@ID7<T:7;$6M\S##6H
MM$3$ @W'VNU(IHU76 T8]^(9LMJB'P:.NJ(K,P]B^>G,1'A@8\#NWR-\"9*F
M5FQ4C#3RW?ES AH3QG*ZM)E',/V1Y'?4:>R85I\U^9H9A4_'&+VO":FJ1+Z-
MZ\/5"XRQN_>G46><\]M"8H$ZZJ15 5DMO:M?E9=NSZF@OH%2@7_L@BQ&3RJ<
M9$44&>&X:V.&_/HG@S!;[MG:9S++SO)M.</7&6BI;WY2>O*)&GECT8?@_,=
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M1(H$7\T7(MC#7X&2W54.B2B;Z,E._G],F)GXN[6M&GSC;,R2,9/'EN[&Y>/
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MZH<O^-?A&^Y('-VJ[.EA,0O,1GT"UO<=*<=I'T+;3=6:,T>S](#)0$Q+S5P
MR)0=N/Z;T6T'B^U7(GIL,7[B/_A 12B#CO+2]PG08BOE;[#_9O%?W/P,^F\*
MQMF%6F\V*%RFJ.ZI1L3]LZ#)8FG_/!QLE)9*\5J6A%LK#0C?+71K:P6^Z]-$
MB3B0ZL$[WV=[ A2U/G_5;9^I\Z?%^M=PA(O1(Y9+GK;FP\LA(X(C'5#0"]P
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MLXV'DY!] :LY*36=38B<I7R%L\KUH%CS!RML:M67KZPP9="IU(C,#C0J)_:
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M^>%B30U!G/Y?VB"MNK\8,Y34[(Z:3[VMN+5[2V'XKT)I\N"RP5C<WG5GD'R
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M1@V>K7K[<V!RGF/9;WNVS%CA4D).O4JR[XO;^Y1W+EHHV(I"R-5LZ!2^Z>;
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M/-!9:G6,)GU*:4436NIFH2:/VBL__W[+F0?5YF,JQ&#IG-'>TG*HD!FO>XK
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M%P]7,EL*!G%LN99FY_MK<\Q& V&'^Q1L*5.![=K)MWVI;:33J&(%DMXH;$:
M%EX"OIE,/R;9WJCMT?'9+.>=(VK=BO&R/0S:#&O[+!EMDR\:%XU8RUM%'=,1
MLSYJ_%VJ/GVKRN83[&XZ]GK5(7#Q)<AL(G^<JDNA9CY+(H6$RJ?_VD]&H3C
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M"W?5OXG/P:I?_/20_P!>#ZM_$Y^#5+_YZ2'^O!30J2 DPNVO/#U4ZO4I^[;
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M1$WZ@)3Z_[K<=P H"+&(L4)QL)X L"FP<"BP[K\#F %8 "Q<G+_F_O\%'XN
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M$5:^ Z37-ZJWBE1G$X[I&!;?T:UU#RF#H]*<9U1T)2 #<1W5Y94["ZJKRWM
M/-![.$CWBG@BKOVZC?OX\&^297B0?IU_1//V1\Y/AZM*[-6Y#^^0RRUDWIO[
M?O7 H*BU)Z-$8L!\35Y=*_Z.D+,0IA(^Z5 9U(&^ZVN'R#F&!&8.+XW&(3X*
MC-\H?P$GNX#D_D\?=(B'%I$$P+?B1TV?4%-JB>"TJ&D0%I:>$3/^=( #I1D$
M'CV&<+E&8JO)M&,9V4._8D!1-/&J"X:2"]._KD2=]-8<;YPF YND'-#??^>I
MOS7IXP--Q *'"!F(SHC8DQ;)2:<F('!(%'!YG,;G)E95TR\Q!;FL%_(N\HVK
M/"YU,59B$"$KUO$&#00<LMY&9?CM9W(QI<#8Q)^/$=:%)VQAUX@\D .]B8P^
M+*R"&D4)S9'3_F#<4]I6VNF@=ZBB/^\B'L6NHA"F,8(T 6?U1L1F)N]BB3BA
M?!H-XYL7D+Y+9IXN)QZ8JN'/ QPJ(9'/!D%+UR(E_/";/!=FD$'LF_7' LRA
MC2M'&"M&I(:#2[^?IV\.5JIBB2,QJZ5<YN:;/Y"D*3W-91?>IK[JY0E,Q5-A
M%@<;+VH1P<Q#($Y6&:@!["&W"!4WQ"WV*?DO%(.E.#<=<:)KU[B$%!6_S.+\
M,)6<%=03$2/=/3>^REK@XGTNO$[[LX_!A"!Y2?W8Z+183KK'X?D#[K5[0&'U
MCRQ@D_V\MN,CN(A+H5.6UG5ZRGZF"K4QK^YI!F"-C9N=J7^[&;U"W"J--N&O
MHG+.X>)L7'DA]:("R@32/=J"4K?[076@$)D]=@Z;].95+ R<M5H:O"<27M3*
MM>_\[95),J7M .:ZX)&%NYVB'V0F*I1[4&NKH?53ER^_TE51W(>YV;(/@='7
M)@:\)SQ19KLN=0]53.MN,7L@G;"O<*RCL@2E;.TE75?Z;]<,(J['5?^@!(&[
M["+/G\]=6U/^<=E'"N0(2FQ5CR ^RT<%DI?.Q6;LNW%*=PU%_K9/,&L*R3>Y
M[IE!*/>7C^V:55 'R-:82;MDYA72@W!!,T#>3@8/(3'! 59+)0LUV2^1U"7C
M@_6Z8TB=P.?ZI?P%\ 5&Z)&^FJ7RO)I?T0-GX:^9 %$$2$=BB_=N!IC%+E\4
MI#AJD/+B%X?^->W0Q!0R:]@>E5F05'[K# X=T(>""XK?A!'AD@<P7AMZ!J;?
M V:"_/X(/OQ585![<E7P]-JU]#(@#I62K]%J,OLDX!6)J_<#(K*D77VHO$R;
M>?!-ZJGC/<#XXM^AQL*9:W(,%:THT?5N5JG:WZ?E,&.$:N-42(F1>-_L24QD
MDR:X)N1,P]4_H,A#;?3:L::R.,@1SW_IM&"A26@Z2.,K\][F8&V*NOE0"7))
M9RQ@B8"-L_8OL*9''3ZM>%8J:3BV[/C)[>L]8*GN]SZQ%[M33_@CO3V3*=4C
MP16V9[5,N;D[,'<XFPVZ8&-)IT=+60D36>Y*/W />&AHOV#JB)J0/!2%8XZ6
MQU@7ID[UD4/X4),!2D:]4B,@B!(?4/Y\2I;O8E)'7:!O;SKT=%PGOI%4LH@\
M,RO_?2"CSPB 8,VTG 5(,ZO-J\*M_90"O#]1-.23"5H$G!+';&8+Q>[0'9XL
M!F5,?\!*CG*.BXA*5\#J4R/"O1*O\"LGW9T=R'/>/]:OZXEQ+ (?QEMP%5*^
M%=B/QN&(9.IFJ\Y>JC5>Q\="2B]E#<=.2WUQ:;$)*_CIOIQ[5;(WT732G'DA
M.ERX1O1\J#O^<= #,!1>5D->5[R:+<9]2".R+#BW<R2R8UZ$V>A^NE2@_%9J
M-?>K Q0F+JT7Z987OUX5MM'WZ7M5Z<+4*^7R2@]K(1=R=CETGX<*Y20.\'WF
M3<GBFK9TGUJEHMPC 0]7_]!7#=\#"B(>(QN@T$(3.05&UE/BWX8/"R</S A_
M2GI]*P'36"WV+\)*%:AA_F&4^G(WXC>EMJZ-R@VJSY02%]'UU+]C>?@EF'I4
MD53]XHYY2P2?D6[JQ 3W -W/FU+ZV: )6![W7]]71K_V_NT,;7!NYU05BAD6
M)-K[+L-?0-*YU]R2$L&E^/D,-_0\W%[M-4XD,-Z1LQ3^>"/IIXQ3>#U^6X8#
M2D&N!)<6,GZ+0>Y14A?)$A0DL[SD"- /!+)0]=T#:E^+G88'MXW? \B_WYZG
MC]@G2/H/NMA51U&]@16TMP0,O+ .RVKM>4X6Y'E)WYD#8[BXLCXAT1Y5KW"T
M"UJ13>IW-FK:#VS1?-O; OLSK^J@MY__$V?J;GIXVS3^-,T/5?,3D)(EKW!R
M@I$3OW&4":0_KU6W:TNX!PAGG+EE-0QJG,YZ?(DH>?ZD#E' R7%G3H[@B:5*
ME,;S]^EYFOW,2TS7N+6K3DA@VLO44;B/#+U9[!S _NQY/:.Z48M&M+_\0E=R
MO[K(H,Y\M.&\@;>L??E&$=7GO.I3Y-LRR1ST#+B7;)'^5WWX683\/4!KY:3;
M!559*K,&T:F5/J1$CJP6!2!YL)_[@0-F#M)'ON^LF;R":0F7%F%<?+@$J!V[
M[P$O)+;S,$V.AOSJ=LU:*LY\SG,O;'BP/V[9<A);=.(6%&1WP'9:37(>9W,N
M_ZR=? QIS)*)4VL44W%NZ]NL?<S!3P8,7HWT.3V)]9^A6 E^S="Z%5$WJXV'
M>JSC)NCKW+&OUC--8%5N?=3KCWKJY7BGD).%+FIE2;+E3);,]RI4KM?&I!P.
M+$:]V>\5>;+-:R-J5=)K2$ZM(A1-=7?,=*._HZC^>]OY]'(0Y$*RLZ!D4.[\
M#(W!?CDF39F?2=4/8(ET2&N'E4RIN945_2@5H-I2O2QNULE;7/V&"1+' $KN
M\K=BFCMBZ9(F(Q9G&Q)O8R9TROU)Q.C8$^*!EI<61K>/+BQ.M4@1-H'V28;'
MWW8,3 ]<5;TJFCPP&0K'[KCY>,_\.G."U!?:<7RG1]RDICMU>[3</V]M$>DE
M1\S0OW])T1K +!>*O4,IN=WJ\.53E-!KH'<5=32V_!$R1A=G*H2O_T(5\;,I
MJP(RX\.O;AMO5J]2+R6CCT#Q3= E;O0G/7[X:X(10FPZ'T_FWLC]Q&8H@2*R
MY39JSIZ=S[T[HB!H,Y/X\U!,G@O4-)67/M@4GFCJM\+F8-11G'T/2&F!/C5Z
MUC5L=3A#25P^]D2"J"2:[466^W?^T6?K$?A0,1].I8>E#G;)W7XS@RBTE8;.
MVVXH@QJ>X)(".OY;1#8!S3*HDY%"@>(<H2M=6L?Q7UOGIK1NP"R=V.NQQ^T5
MDC_B\[W:S4W,4?V3EC? 2?YGJ29!OH1KL\9;55 =!&_^T:D/DH/<,T&[^P^R
M=J5%QB$FJ"; <[OI!SB*G5.+_S5L7APDSPV@^LVWYW4/^(KQ+)QU1'0-I;4Y
MW0-\;?IC@B@@9[0[T"[]X+AVP>XRNPNC)3T1!)H201V!8.<(D?*?[2FG@6AE
M[%<%.H(-2D 9^]47PGL%+I@<A7V-X+QJU4;Y9CG/X?B?(2>,F[Q\6BM^?+@%
MX8M4QH:! 5I93F$QE:#EM/>QN3=D?@GXX&NPZM_%""W8<#_,=#G>]W#Y-GWB
M4=TY!2Y/4)RLI[B.4C CZX-,_;1/F>FC(_;*+. H U@J<W\^/0I^4J<AR+EH
MK#1_^D9X%:2'9:_C.V!2*+/^/)488M3TP?/SV/P>S=/<-97:I0^XGJ+T3&:2
M9+17I,KG71\439;49B3;2Z_1AE^G=+EE)381=:+=K>>U3'4[CLX%!8E)4#\.
MJ/K+] '9Y/6KAR"(=XVK0.E,4<YG$\V>E/'71)[BBTG9ZS7*;6WVSU@%%).M
M#I?-!13,9\"8L84RW=XIA44%4+/-229]LM>Q(:KRW+E(YPE;U*=AO]#(XJ?Y
MRV#WI!64/VI\&C79#%?EE9EXZH5G[W^,,!C1KE_7O^#6I-[8*6[?8ME$<OX:
MGS2*4UQ/*+YB,$O?<0M]LFTX5#S&[%Z/__T4COLFH:F^PECU2.^/6N$8YOWJ
MP^C'%3<JTT7YBY+GZPAX/+=IM@1+QM:N- A#C;)O'@ G0?.= P&R?:5Q>"4?
M<>V;QPD2E:OO 9? \X="9K*^[1;E*0LLHQ3\ H*4NX@^0@F_UBW^W-BGG"@V
M4+^60E5FHK*75[W1AOF/5C'8='7?\/ZE/AIR)G\I]V4_@ !G>4U\@V:>OZ7Q
MPZKJ_JC)CTGN"'Y!_ZKW&7O(GBW;)KE0^M/)!% RUJ8H1L$(SJO\&.<8N<I<
ML!=+<39E_J%-MA_\/.Y;\LIDFQW$">>(^Q>>.Z:G4OIM$Q+,Q__4DMDSFXLZ
M,!=3OGP>G.2H:6H[X/[H$>S:67D]-P<8MVPA/MI3Y7SIK9F;8_=.1WVA[S(*
M(9'0[":._.;PRN6P64]I,B7&RB4U=4W*74] >E,TB@&L>X'.+-'046-J5<=N
MD9_QB4J=2HU^FB!<QK]7!JPV/!4K<32U@6^ZB::]C _.VTE?.SKO]34:\9ME
M7A^;7VJ X$%K?83W3US]-1*8,^.4Q1Q;_2IP%XX0B]S!;.V9GK$W[23KS4F3
MI>OY@Y;TD5%G67%B_$2CO0"L]$61WN)TJ_XI-7K=JQC_^$,F;5&,=7ED7@M6
MHZ7X73V=[ ?W+T''E2O/"Z]>&(14C#NW]%7[#0T,#@0U;&T6H\$ A>HJ2Z4P
MU<<CSPVC[@',JCJWI<J5WKK7'ZQH5LL@W^K.L0=9=,Q,K393-X]=UHM>KN8(
M'X[< P(>]P Y+37?!AINJK@+5*W[LMG_R#LIOHR?H5URI-CYBC[35@5#DBE-
M\(J^&"L84A84OX,A.9A[1;B< -E21AI:S"[$$B/$"OMK9J;ZE4TI9ZX/H(.;
M\?H(X*[5Y[^ (C]]0;],P^2UW\?^M!?Z:%856Q?:,3/OX4^+N40@%0\UW)..
M$B8_2()FY[1H+ZNV8F0D/QFGIF2AF;.]X2:2C#624RY$GN!)+FV^]H5*?['(
M=/KU[3T@XVINJ\>?H<)%R5>/-['@" <7"O?<IR0#4MQZ]6LA#O3]4F"R'C%G
M3PT'Q]D;]K'#)XBTP%"AOHU#9/1<W5;[*XC5 O_X]_>Z2=5U-L57_1R94/5^
MCE-UD37'.*M6@;MX7'$[N'NKUN7C8F_;0G N9A&<DDL$X"0 8*MWO[$P[KD.
MS^..&#9'6#*!,(:3*50'BV]4HV4I?042Y[;M7ZD6'/FGJO6YN[!%*+HU/ZZ\
MMO)IR(IQ-H5F/P<U'U6Z0GZE5T/JT(6UYS%%ODQ/CPJ\&CV:)%STV/A.O_&=
MICN1TU0SJ+Z!ZLMQI \&C)HA,=)IO%.BOTG:<9W2MQH^D0COD?&B)_)1(/#8
M!$QZO)X5B/OYY_K[!)3*-&AR_+QUF%A];E?>'NABG4!25W#40VQ*EHK5VQK_
MNT<$2#]5["]9?C(('2$!09R[@0;.],=$UN+&G>4'WE\#/"V3G;-A>=O]?!%7
M@*>^5T#7N N@IC/+:'$+5L_&+9Q\4OH]ZH#4Z$WMPIL^D,M)JG01(N%I!7?J
M]HMKJA'P:E\GFR)CO,-N'BQXC?U/7_&D<-]>-<R:FW]G*HY=+2J9J(O*8]EO
M_4W[0)YO#/+V)8;5?JOB0H0^'E@:YVKK*DY.'TA#C>!8I92X<31@":'/^>-L
MWC[\-UNKMB@@G]#+!.1HANHB/<M,)]R0?X:I-3/<LX>;@"[B)D[B:S*G4UA=
M<J $*RT 8WK->5 1,G^AV=]K*MEO\)U"AFG"*+&7 $*OU,E^L-^=E8;5Q**/
MH+IG8#L.IZ0K^I:^E4SU\A_/%TP;_W5(I:G=N(*6,/%(Q\EJ]T=Q[<NQ7QHC
MZ(AW;U@M<6\6X[Y;3PU)^I5J-8ZE^^KR)M@88):8_>(?M8ALH^$_ED(S77K<
M@ &7ISLL'0G3R2V#CU9C##%>*Y%:&28"M;HN#3UH)_^G!27U#$;IM9$<L>'#
MIA6%WB_&5K10DH=&,PN-A0NLW:8&P&$R/P>,;FC6?(_@@1%WORI'1/+)DWPS
MA>F/8TWV@U\MB2KI*-:K>E;G]"I?IB0UOI?2:WR3'!Z:C@1.G9UEJ7[SJ[\@
MAT; JC/?3,&RR[SC-_!TW^X/>_-&Z^#$MC0"06T_=8??NSHP^6P6'_@$%YZ-
M&6QN%75N6KYFD-CX)36S="C9M8^T9=$R<]:U[O-G; Q34@=YXSVM>*%W!.,(
MJ[1[R6C]CHZ O>M=F>$>_4/5 PF,C_6H&4<MLQ3M)0F\V^3(SW@I-#1\E$XZ
MTE,;5+P0G/1D(QK&(*ZL.DT=G#,W/5U4;&98P]^]@,*O#3/M,(XY)#WN<<]D
MSS1T^46SCUAWB9PJLM@W*6@.$PA1,;MS254TUPCD?C^R-"\;['!^(( T%3Y"
M-D/RC+\.?'*HJ@V&W:9IV':SN;Z<=R8B9'<C28:JJ/<R'4SNS>IO.!;-T@TJ
ME9E&$BS''?(2*Q4R! SH?92U^OR"D,4D-MZ1;Z+'YVS%V[1YQ-<<,QCT=G*\
MQ/Y\MZ6HE2SH^_+X^TB_B+3G-D_T/4"*<9<<OA47@0M.N+$D[A:@19K5_W'N
M6X%7I17DF,5#*&3V:,+I^0:_R;)]F.^+ :X6F)+1%Z8E)JF?G6>4\*W6(E;Z
M7V)C062+RBJTPGY ""-$XRC@0$/#CN=F,2O^&7<C7_].>@-U+NOGW?@X#^&W
MC^R!SI$-Y0**!4V,[@+\9$SS[GAV"I]IDF#AGY/WAL5<)WSLT!EZS,.NG[-B
M:QO*[/K%^SFRU8_-$3S$5AD.=<4=[&):F7,55_G>270KCCJN(Z3J[NA-/YN4
M021"7H!Z)RQ7K2(J;?=/VH3S_$)][Q=(+=1YN+]!YMK*MF:9X8$QD5:7BM0'
MO%?V8&*K$ -[W1!5%%=$G4.1M;1$T>03<;!)$JU&TA*AH5A^@(,ZCR$^6(N,
M@&:]>IR)DV4'5XQ,S_U=VV()>;);TH\!;[ROT3@FEYQR-;.L#\LN,T?VP"H/
MH?FB13B1LFI8:D;%!'2 NP:6#CX*]J_T,J8WL8VTLP4,$=&%,M]JS?68 Y"T
MF7[\-#\4!HBT-D-4M*32L\$1V;0IXSY()M*Y2[2I_3.)[::-4>2.F>%8HCX*
MFA]1@)7< 2"^ G1T&_ZWLWKJ;K_45C&7*7=<1Y@^R%8 L8GWT\2=>PFBML7'
M'.$Y[ _+98L_]U61P9CX:BEX5XV_LQI3 VN=C&AS[S%N;M[L[Z3_X$:DZXHE
M^=#RV#<2W)5A%(-_>^&&U 2IS>6LEICQ/2=L32Z$6&B-.-BB^RD9"T$M11"5
M!V^*[$'!1)VL'&Y"W>I=[NE(/GE-(X6K-_7[4OZKB^OU+_BFX"F+=%CJ.F!]
M&5P>;,)-<N 80@7KX;N"=*VG4X-60Y.4X2!+;6$4IXLH EX"E+CJ!,.T?FRF
M)\W_&/LA6NPS&&BC&$H*4TU@RHNHP\B!P 0= #Q?>TWL+Q7P]7[\>X!3DDNC
MDH,7'='<#]\)ZLB$4/SFJ1+<5Q4I]E$L;Q4-ZU"<7]>3V>H-4]7=<AL;WVR9
MM*#/,N_D?U8ZC!<=7C*8.CHW,>BR]FC-O+87U[#F^"DMP=7*IT,1L_*J;OEK
M4T;6P-CWQE)+BI2#M&N5Q)HZ=/6\.K&N#L'+9(L VO J^[2);<BADR*<7T-O
M!$VFKU^#"IHWYF.UYDY/!&<])R:;AOR?65/_+P1X1R5S'8&D$7F5BJ=!+O#_
MD0(:!7>#XG:]BGH@5VC[:.WW')D=YB>+"?0S72RP]>C\5PT*^NTANCUV1,^^
MB/^:SCEY4(AB1D3;N732:^8\&QVM*6%3>Q_AQ\<)TDYY\>B\?['PCA+92WOP
ME4DNH\)[@G^W^4"*=#Y%J9^VU4@2&-^ T4\L$*!P)F.7Z#D')+KWKS(6@%X(
MYIQ/!<K'TXN*UNYMC6SXMK ][X!8:05[U*.\H1>=71/SO(;J) T8;!C!F\PW
MAFKYU3?[=-/UR0RJY:D+UH%]SEMC03_ZY# RDW-!*"%5ZZO9PCY5/C <]_/_
MSG+YEV! U#$L?Z%J4B<0URSAV+(?X\00KD[L([F\B):GPQO._?TF7MZ0AZ@I
MM>ZRU"]\U6'IPO_8N^$<>N@U+D; G%F\FT3\"L&;6#39RKW;MTBH,\K^TJ"I
MS0P%]5;ZSGMPX$ZZ-'-D/C*X\!A-D$XB(#/%6)Z;^6.@T3S G0Y?&2$O1X$I
M,\PHH#_6T4ARG6R"LBI-+Y@UB+#M)*#X87VDN6WC:CQ@:%W.#3<K?3-V <W_
M-H3_(?R\0$6I%$VD.FIJ?#_ 34N:&O25LE1+?IRS@-8G7)1^01H GVCN-!M9
M>L+ND1-6GPCFZ-8AJ_O@!96GN^G,%<3I;$V7@F"4NYC6C(J/>F!C</\6A8SW
MYK-A1'YL7(J!N= $(;M5BDSK)_XYTRE-7G<U/!'O0.G1FY8:>L[H;YSM(@X0
M,#+7KWA+CL,3RK=T/JC6^\>.\KMYL?W"4+'64U#HFQJY: E;/CR[H.T!> @R
M3YY-@CO38&/:GW(8F6[;W*+(*M3*B]G/X'S0<SD%5M')3:1.[NPFY&<:K?B)
M0E7/814ZQPUYIQXFJ 7XI4\(,(]4U^-870E_!? ]9KUUN <4;+*T(56JQWR8
MJ"P;%OD%Y^O;)4U5#,W<'=04$ C;0J@6.36*UT25 8ZIR-7%C0\8HS$)99HB
M*'II1'XM<36YLF$FA8A?";3G-V43$:P#^H-O D)DZ4-ZQRZIIM6KX[*Y:PH'
MNKZ9&S70VKPDKEX0Q\FIB4@5),/;P64,E*CPWH&4)SYUXB\+Y+)$HUS!=$X<
M5 NRNS3+!/'JU 22!EC_HKL5:Y%B08S"1M!5_2[K!T:#_IAZ2>,OU9R/8ZO4
M>-UVEEC#G@?),\/'TZ8.I5V;-=!]#5&;RA$N#Y_U&]L_C8 G;UN[K(8VN_@Z
M=_:08CU%*)PG& G/H%L:'>I>^2M=6A5:ETM1S.A/.D 2L;LF1,L\:&#9*E+Z
M$_^UZ'$^_ZGLJ7Y7=IUJ.+*OO#PX::9PZTN%1_J1WIEV1W]IK*5F?P=QRJ@0
M6#-#C5T+9UYCW0)&$XE$_^%&0C&S"8AY/0O;!IY&A;>.G),2ZZ?0-QTFFC1U
MZPK@R@KM">Y8/(J=$BXE+W.1/]Q:SIK[=L6?_%33F9Q)A/O9APRG>4DI(Y#J
M73!*=ZB#!E 78RD X3!=JVIX%5V F"=4MR00!W?*[,I$S%HM-1IN>V#2C5*2
MJK_!60\9>6Y5K0V?W(TC=;;KFLPW>B*E<S+;/)VCW^**"3([ DF<^7-XUF"1
M_,KVNHRX.Y^V^Y0['N%O7=0LI]BP;1L46O@Q<++9LX&_=(4!^@A8+#B CUGT
MM]>YJ\K8)@[9W,8A,]U.C6H"?2I9*34#HKP?%PI?5/*B -0*GK%)\?@R- $O
MW%>.2@@FX!1-IA<91H_&76L@'-^(OVFU>YHXOOX%BXJ7C9CZH'Z0Y5DF_./!
M]R#!MY:?X@AT(I=I]1.#Q=^&-$Y50JF_)B6/R(@,XVYNAVS]AQ\NU9,-PH(8
MX!G^3Z]L1""GIX%+2=A#@/2L(/N@881[,N<_)2/7]8S D.?S_M+,'NV6BVCM
MX4&]<=RIU!6#WQEX,MN3M K.&#4AO975$F2%G,[(@&*T?F!=IG]K)PJ2]S'2
M?6?_NN>$>9I(;VPZVZ!#AG]/XR,D</L6]H-3BY=]N0L$"OKQMG+4Q$NE8.:R
MS";@:7%? JV3G^OW@"'UQ,(59_N!B;RC KSBW#OK^K7!K^QETL&EHPI>,9TE
M@@M&Z&_VEM\RMQ6DAW"Z$BQSXB#'3*F?+K7"^I.=<P06.)8LQ7:Z@IP:ZYK#
M$@O(Y61:9I-9"ILR5 .\;F(O#YT>95C9Q"$ESA9&3&<V'%X>X0IOV!$;/NH9
M[\"]_*/S<.[\'K#Q43:[''BYX6A0$5#9,;L/=JM!\K3Q/>N8'=O'+UW(Z6J5
M[V693;,X!FZ*M"$H8W.Z'(_KJ/$'OQX#_=0X(G:&1EZH]V(<OVM/ET[S[LW*
M?OQ3?GMRP-#]YVE;>2)W,7UYTCV ^(+@][;%S<!\:@00-M@>/<S+Y]5(58!\
MZ!*L-^#=;;D5V@CBR);A0D&R+^IR\/[BNT'U#R'W@)U4LY0A4P,DI,!!'17?
MNA5:76]PL&A@\':9<F?9?(IQEB_WT*",$4W84]YFNKKT%+T L?I]1=,"W:Q"
M<6*1PB_5<9-#I&8?LAMO7)=VWP-2/]QM>5]HWL""[!'YW9-<AWA;[8>/WOS4
M'E[>QN*5-7G?MUY(*+,[@O5+AS:^=_PF+B]CT%5@T.>1N@;L9\/SFT_RSYI.
MR2/@:VP/_&PY/),S;V52!9)-7<ZVAA*WD!IP4AUS>RXU9S7^%)C[=I!5>+V/
M9XBT7QD*1!$VN9<--SM'=E+E]:$E> G=L3Q:KHB NGHQW&Z<(.G^OH['.+,K
MK687AIDQS#;=\YLJ0D]ZW$F$3Q]%6R@:XY;')@B]3 !E O?349AZX_U?LPPM
MXEG29D>XQL^5C/$AE&GR+MCUV-JN/!'%.VBA/06-W.P=B0H#VK'4FZ7?&:65
M_D'^0>Y%4LR2C(%2AZ0<-Y4D/L2_]+^&(/^]+%;;>FD^+;-5Q*)FOY"[BHE:
M8J:M8QLT%X_J>6(E6 >\G@V0?US<'HOK['I/B!%LJNG^%D'U\Y<A^_M$M,)4
MD'PCG_(?VIS4,SV?'OHIR;=.6^BZIGK<,D\D#_>0CH[ZZ6E+GD3/&'!4QQ8&
MQA6M\GA9M[J9HUV?LU:LV5:[-Y=J D>A!C->4)7$%BA;#ZVP(GE(BG*0C6\\
M0U=P#PVE@S,U&TW/7Y6^VI 5%^\[(\YK)"\;XZE9A]51/E?3'7VY416]*(F%
M=3-T Y,JB DXTC*8X761 @D6\GY'ND!53'$++!_TT6U4?;\@W+%L49IF,JZS
M0&XY1@MIRE9K*2LZ#MC64,.!!T<$K'F*1"]CH:55S,]N52]P$&:&5KV(8Q*Y
MOT"*$K:0F/$^E7:C7W>QXANA-HNM!3]=/IN=5JF),WG8(M$DU-3')&D*+K-?
M^,(0(2[=I<[Q0YMW]"7%Z\A_#K3N/F0*2MP#VI(A_"ZM&@&\^HBG(N%I&*G/
MZ":O_?$4CNINWZ3J#<]RZWO IZ\?TN<K(L.[KPR%E[+Y2\GR8Q?5BD\70(>Q
M)?+2OT7>EACX5CR[!]#<@=[-8G(V!O=M5)).<J8'4ZHF$Q$./ G*J3Z1--M_
MG.RE,CPTG,MM/%[ F1UMD?$&/P^'[1,4/KS#J)X<UI[/.'KV_P@^^]-4A?;8
M1DT3#=353/)+)[<TM*)+I#XU"E_#2X/:X)"BO(JZ([7RD:*]YJ 1)X(B25LE
M-^%K^JB;;,AG7P!(1]4Z^X)P?U1OFEMIP%%U\(MKY*_.JH^5SS6"_5\NBJ-A
M5.<!OS'Y/W%7]2=5/MCX]^8<ALD^7])PES-^W33BF/B$+KUQ6ITVYVWB-T,_
M(FWT;YM'T%57#A?6U5C21A9B%))=#Z@Q=_AUY\G3CZ?+7DBJ'7Y=2I0(RM(V
MM@V<LLQ T[N?<.SX3%!3AS:@H E#"Q_[B4QMK"'IT:]*9-=(K%H.&MLH==U[
M%+\/P-8&$#= 7$WGO37GW0YK-4[7T0N5SS>TA.O8;"V)V>P)<-%5A!M+LL17
M\(56Y;P%5M5]VY%M@3B!#8%)6C;T,;,5@_W> [(-B:[8,"GKI5Q.191A,>E_
MCS"Z=X'?*+V"EM($7?1>FWKC]=;RJZ6L_A(&%R161A'>[,OK5-3N+\1'[OD4
M3M%^V4UVJ^\R&4+,3&W8L\<=@(*V.%GAB1)L',3Q$5\'WIO7R=<[DBJEEF,P
MI!>-E+[-Q5S\VR:?$0C=Q%6!,C*_][Q](V*>HQ(O"7=$$EJ?MS*X&F'"'T!,
M)$/B5!U-#PKF=-G1/XP>D^9%EKC?K?#;0Q)AY2X,XMSI34R@62HO3M@2NW&;
MKV6N_CX5C_#:2US1"1_H1AE?EUY'GP3[DZR'TJJ&6:?G_A]3?_BE44A@'J:E
MD28\R^XVJY'8+K\'#&#=,.?<NN.<3>\O^6\00#!Q[>^&NJR1TBXF%7@5ULZ+
M)-[H EA<#)]=(I81[IOMEG88P:6T[*]U@ITR AV+)H/;RHX9AT GX!_C]_08
MM2O>SZ5Z1[?BA8+ZJD)GAN)5.>5 NS\/[@'6*=![ -8]8+0"Y2'.GHX1"[L'
MS&T5M'=\.#NHV+"Y!R3H-51?LF,<?9]17DJS%9>+GXVPI9BH0Q8A86!8B#I'
M=H>^PM:T]-,&@=N5<N&QU(3\%RZO:,\N0ZK<KXQZ*]XPQSC^]&,)OR()/[A.
M&[C=?3YH/C(Z7G]!M823+;/?=LZ$=Q#L2;6TU*MY)L!3WL+PI_DB;]"L:YS1
MH9640SOQM=['=+<1!G!]#N+P:&.RH40ZIE2TH.&D^8"?&=W';%&U"$[.J?>,
M:I=JTS"]H_J0A/.;=U/D'L"Q\AN[::5*^T_^7?OB5</H1%8R&"/"("!EWZ38
M)(Q!\[MMLFT6W!*IBXOL[HA4?DCJ)M(&B>PJ4,8N8T;&\(/#?R##X_EJI_B#
M\/<1:,^FD^3.F293:XQSS0[(<R".#O%RO^^Z6(TC9Y7&\4(4U; WR.%XE)<E
M,Q$3&Z%</U>>\A?T?]GX_ "LXP;G=?FA ,O-Y&3C\(S-""W_\4[/7J,5 3R=
M?2$4BWA7HR_?*?O6W3"Y=.SU 3ZTKE.(W_ &7KKZ28Q4-CA(4_04.OF1G]\Y
ML0H[\P%H/!&9W\!5A?5\W'^KWZZZ[:([8SI<5YBI;@DZFK@.TS$E:5H6;,A]
M&DD2I(R=J/+JNXI@MW$KGIV>819%@=42I+5(\[?+HDNYV,??SBA$PV'V_$ /
MOCJAD\N6@1_%0IN#_,"_<9F;9T1R[U:Y0]VO%/_Y&9/('/#^@Y= JE2&2%2S
M;RVRY#F)5>+D2)/Z@X<W<PQR=%I$G>4PWWW@$3+X GW)[HT^[X&W'*3NW&Z3
M=LD4>#C2XC<R)-,X/10/W26'B^68_XH<\A(%1%.BPR;DM;!#"<:NIS/;?H4I
M!JFDY1^2OX:S%=1T<;:<$%XB^A7YY.48T&(ME)5@0J9/9:TD"%WZ&YULCV 6
MJN'WLT$/BXXGS))D9FDU4^E(^!22HD5='^"X=3X&@RO(/'@>N$\N^3(4,[U"
M+V;8"FX5:0]8Z;$))$93B, 2X<6X)1*X84G9?N?E&K_E[P$6=O> CU;!_J_>
MQK7-8_?.:-BB%Z/R51(*S35TZ=^O%03HB7][W^49?FR3G*#I&;GR#Z_OW^P(
MUW^Q(U(_]1T:-97^BQ[1+6C0ZX_[4]NUIF21FOGANW\%!<7_" HE_P2%2=J(
M/Z-UT1L+[_;*9W;TYNYV[KSMG(IJ]8__1 Y6R_3KG7U00"G(,4X3X<SDIU_O
M%#M#WBHA^>W?7KPGEG-@/XI*+( #OAHDS=G,.KTN,E$-:$IX34F(OQIKXWN-
MOV^RC SPSREAD66+M)NS1_/]_+*??&B_^$7&7/_/TFVE+T,PSM3T""AZZU S
M/,OKR/>]J%T,W.W+]\?%K+R_!?#'H%KX^EKXVC2813)EZ_J$[YS!CU&4AC"D
MS"P.KTZ?;.G">27<(=L!5FH-[:^>=+JS#%"9%#^#ZHZ^-7^058SJCCJ@J3/Q
MC[2KE80?Z?4%"W4KXCIW]>.,[;33..2^JI>8,1D*G\K@XT)91<?T)3P8]@8F
M<?!"RP^[%'G$<63N 3+PTO.N6)6@M/@/N\FW<#U:P<>7;]U_GOY][VE%?.O-
MN-.><.R+^;#S8?YN>')OR;?H,'%F>M "\HR2>" BLB^VG^A<:XHQV *-N!PL
M!PX):X3RIU6;CO1N-# J5+FYY75N6M7I_G!7DRUY?0\XX?X-=%S&7@"]?+ZG
ME,?&2S:\Q@X(+O6IIW=!'A -,'SI&GW1M&#!?6S#;V_:G"#1SK]HS<1P^%8!
M7"QEX)C+]Y_[4;3[?P<S>2AW%O:K0(S4D7?2I,U#G.Y[4,OOZ*J;?3U]=F'\
M)^_E)L#.]#-[WD%+[C;*/;PF_N8GKD$4K[<D?#3A-1&MW)F <!1K,>EM:8V1
MH=>?2:0M!&&JE/=D9C_GXZ:]U@N(6RQ-0('-1HBV4Z8U5T$S'E'OZ1AMD8E=
M#%ELE7:6DZWA;ZJW2O8@E1V5:0W0H+KZR/<21W"\X,"G8QUM&,ZE=/N_0D3I
M#V_P <M/D +#%YAX6M6\.S\ A5VT<$4ML=#@GVDM,0QQ9?EVS<)RXTH>$'SW
M^M&M,U_E>3N.<4GYW(S%7C!))W.\5_KQ3);CHU?SBPY\4Y@"]?1K4!(=+)%X
M0!Y/E0.0&0LG"TCO-RD*/TJ)N5I5>N4;$(>$C6EH#7R&=^O],?8=X! E-]1Y
MD TV?%1GX\.%?!=NCIR_?C5M9-;>\L6G[/LS2].M!!^I4,M7)>\:Y%D+<A3
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MFYV4E81<\J=FY%V?!0D6K]IC<WIEW,ZERPPVP1AX(S-X'(\:X,&4&(_Q.P7
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MXV(KD[E<OD3H%,\5%":5NA&R3FKNR9PC=#Z6$!LF4CQ"NE)(A'D_ <%<2'R
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M-SRO0?,X.=?N=B(\CG$(AC'X8E?;U=\$X/IO_U^Q+1$6RS7 <]URRY6HK>Z
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M'^[6S4]_F4/R'.3Q5XW\91ENJ5L#)HUOZZSJK@QJ4^4,;2FLV#EEL$#8*G4
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MZ=R]4!4).=([JN:V%RK><37(DU=JU<Q*^\,:JGZ*.:%0=4]796QW<]LN6VH
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MOJ#"M'I.03[3'W#ZJKPDIWDN7GV'\X787B'OP(7KT$?R>ZT_B-_N4W6G@05
M=L5TO'Y%8DL.O+XAVVIH98^1VZI*W6<'SDI\/1@7?<G)^ONBRJ2+BH8?>H0O
M7RM2KV:6.SNA0I3*.;$490P*T_!P_MR8B^W^^1\6-?@W*E /Q4&N(_?T'N3L
M<Y&E'T!30EZ\7^P:IX<2=Q?Z7QSJ&AT+=_=$>5P0S8=!WD2YEKD[/,3"A+^-
MP)RMTV1G83LP?R4"5C25YKE'#]L_,U_.J<5):HB$5;!B&G10"I*9QB0$X:L
M4(A\?V56(D,T69PG@)UD,JW)<Y)0W'&T9K'![-'>[/(DHD (J75JY?&!B(,#
MS&[B3_'BCT7#8#U+]U?WAFTE\X_"W5_'ZC$ZBN:9 ^[3^C$+>G%!<7O;H$5%
M"Y^2<6,LH)<[90=P3<E@03HM==\-4R\SDF;W\^>0_=\)>VQNH<LZ 27L(,F:
M&%R!4SZU<]I@J&=+\^\C<;=D>XH H7QQ]/D23D52_[@5)8>*-]\Q4@TL?V=R
M0 SB @. T,D^),I<WT0N\'F"7"0U&C(52@^4E/@%(&:?*]=R^J"UYE%D5W$X
MI?_=0:]&N7[N5B'L''@DY]XN(]-W1I%$LUM)L/ NL!RS>="/8H*,+-X4[@@Q
M/7#-=*;RGOWX.F_G!\S=5EYI.(#Y36,!FX(N63YP",V!+/!MHKN\"=K&_V"K
MBOM<$P=^Y;Q4GVJ("J^Q-+*NL(LFG89:.K;?K233K/4 2H"X4"50]=?\%]]G
M7N&8P5.-#HPK7K=\A7]0/UPIV]7 (V[8<> 40 /"AC0Z03'C@;6%5KRO]23?
MRX"_QE(&=5)9(GC'2$D"Z.F!BG(Q #C LVSF7Z6=#NBS'PZYU^.DOSZB5VD<
M+\%7'/N$Q433_7PF;-DFHV4\S1UO6]]AHJ>0<<C5 .+G5 ##PXQSF04J2IRB
MT>'_=YQ*7C<%.X+8E9,LP,*L!HI I@, M]@<0O^H'\@16<[G6B0%22MXO!$L
M@^;.=>8/))UT@B4]X\^SG,Z8OAV41I<A'@M.K"O6!1W3B% %]&<!78X]\8GO
M$)FEA7(N?JZ_SNSLWWNH]KBR?7F)=N2(N(@,)ZP4T='9]T>I()M NA,^<I@!
M@<TKA_4QV%J>J;L:\CD)L<J-:5(%#':!NYO0# Y4H!)H[.Y;9FD<J.B[2+/I
M6!S(<.U/?HR**&E,#(!&"P$B^[[Y00+@#AJ5E^ KA]:T\7T0(O0 J>L3'[_I
MQ,,L2LY\C]:;)&.?CY;^?S E8W+,#I&PL#"G6PZK$'K1)3K*_!=8<3#G_)"=
M)Q\OVD\ 557[^1>VSAGJ?!H#=D?@J-<S]^!X% 'Q+FS[P"9R];^BB1AQ(RF$
M(9 DL!H9,B""F8Z8#@ @SD7:Y(8I_T\?_]/,RI?7ALJ2-NP?:UH<)@^]"$33
M-&9=I5\A>[G<W#H,PQC>?$JFY)E*9-[,9V;^+$>.0UPN@0>R)J3,M;^E&C_Q
M3F7/D].LE'=JWEUTW3+0 "VX]L0U4.3-ETC''_ MY?[/C7'_KY9?\/__]O]I
ME0X%$_ %VB*'Y+T_" F$_FH+OT6#2T<26$%_"A;OEQ"/6E#7],7]&-R@$Y#G
M @WCH&-]OGXUG'Q9E:_UN+Y)%6()-'GW?(+C$O;;Y5IX_*7]U96DPW[RVH[P
M*5<5'V53 ?:'??)>_80$$;_=%W]K03E_!2EIOCPJ!W"B041B).BE&NGN/A5J
M3WM^44EVRK:!I/I_$"IU!FOR+W* AM_5SH#BXA+(L=.!^'3%]-(6^/MVWK_&
M6V %F[NB:F[A%K52@)_\YNGJZ9E FE,%.L![!0% ZK+PSU2\2#L.!<'B-49U
MF<@=QRXVEW74=O*#Y<DR^1C6D$@3#'.-?!*U,#+>DF,+WRAB$>5_8:=(4-GI
M(Z !),"BGZ K)BLFR<8]VE)U%4F(6,Z"8[M<:-IB;T'2,I&--M<-.ID3,53<
M"@W,!+O\?DE:JK#OWYC]G9R%0HNHF/G;/S.="# ]B[82C]!R*VJ5/=@LF1J"
MO#;*MU6Y(67J?NY->8Y#$R4?,_<&A$Y1>.R.61S['41E59TM#V/"<A(01P[Q
M7&PA.=[=XC=NX5!VG%5A5U8OIIXS*5@ZSTH:P(4,%& (MF)F155GM-7R%S/+
M:P.-MTM.B,?YG;*@[(EDE@.=$%RI.(OF1(Y"BNHY;RW_O$0VM&_SJ='K7UOG
M0J9@7URT'K^?]X"G\E%60.6^-V(*W=B*:7J[C&$Z:+KTO8*5$4^ %VEV]M N
M1E .42Z8Y)D&D6+^#Z)>4O41"WX#CNV8%32Q8C$D<"^WOB?:Z?P/H501%Z>A
M_7B,+@V8+N M%AG''W1<D!8N'<FGR@,R36-GMP_*!S2QR:5\W@OAU$$,:5)G
M^5AD=!6FN#@AK,TA-$9S45^,(PT3YJDU'<8]/(TEFA8/N<[-NB#)8T6Z_E_]
M"W_A &Y2TP0CM'3SO50/+A$3\#OJYMU;:X-UY7"'\Q2U]_-;9A7="E)<0!&M
MPD&E 6<B; FZ[VK\'U\K*8;L%[I2%VS_?7\?V#I_J16 &.BDT5/705?/)2V@
MZ6?%P6X2&O<X=UAZK?'3\ ]_99BDF5A(=/M@@:VBNE!DCOR;L#AL^2%/JW2A
M+)U9A*&_Z^F#2[@UHN.3L_)L%7-AJOQEB?3:@]@ Y.?/5+Z4.<BY:C)GFQ3E
M"Q,/<J2T?_&>/DERTFO)<&AB\Y@[!_64J%_L".I@;4PXO\5O;-HQZK7_:BI<
M2B-3"4M!/TU=JDQ"*@6D%?\K_?EB^K3=/ $9^=_&02M,7K+ OH15?2BS(IX\
MNP; (@9;S5GB<MST7R#[13.PS&QR1@**"''NBJ-'OR%$=2,=%SN8?8(CT&4K
M>&!HTWRGHO(.T_.AX@F@!B&6WE&%&,4$EH61+9+O!=+\*J++[&KCX^,.,23/
M=[6O$(5G,? 61TM%<DD$[*[)..MRRRI5%C!S7N#+X^N\2$?_Q)#I:SFEP;#?
MT?*)6%_]32/2HF& 2M'=_W@(C"56S?Z+\6>B>^_4G(\Z@L(1?B6S_ *Z,P@U
M2D573-#K;-?$P\RD_'4$_L!'W8PUMV3O WJ=Y414RH&S)?0:T"AWG2.15=G*
M=?N[WRQI0N%*'F8E,EA51SX]DIP)K4DF"^I?KX[=ZGZC96Q[XM[P\K_MC!P1
M6[DRB/#;)X"2D6*B_44=#YH"FGU^SB<9IH18?VQ93YL3ZNQ8<X>C]\?0$0/$
M!Q^I>,8*+/7,K^\'<^A(/<*!>/(7B?T"U#N]>6[O>RLJW5JT<(RM3BQ<D94Z
ML[$3W2$]W6?V)>S48X@KQ3%%-5BZ/T;E/][,]:7(IB4 =V5Q5]^URU/2>;RN
M-[Y4/%C]?F":_1Q#YB ^U7?5SLE,ZDI!+*YX ?NZ1"I(,,$D=B/^L"P:'F*M
MS]+S"4_S3T6^=?6;.(E'H6+<X\$6M\@2[3"OOQS6K7KG_E\2"V#4<+"F/OAD
M&@@B6X.L]#?V2Y*B=RJ%L=(!P"CCE7CC@\MU&\)WNT8_"C#&+6T_IAH+V]+7
M\6E"-?0U5I))=L/( I#/NQHLEK7V6CRE*AMPX B+:S?A-]0<5HURS92?B%DV
MNT*D*EKG-!/?7VD0 1(KZ.KV3C!CY'1=^$EE*X_W/%!;W-RV@X,Q1K;D>]I?
M%KSDU75QDO+Y8\C2EX% 3/R(O*_@*9V%S<GIXI=@30]']1\OF/!>,)?T9GB,
MI1B%[&N1(0HQBJ&'V?1_F%C%I*T=YB)[1UYC-3\C[W4X<7I6IK:S( Y+YJ)N
M*!SG/(;T^L'P7"> /?1BI9(M%J<L3"=\M6D-Y0?*+1PRLA/3D-BC$?/N0/K^
M/_H1_<^7K, .F<DJY[?[ZQ&8K$D2 \KA'SM5ZQO%"X\.C598'M#Z/[Z.X,IM
M(]JB=WOEV$ AB7LCOQW]BLXD@K,P<1Z=6-P,Z?L9PDWFLJ4TSIW;2WAW5V6[
M8\,6ZWY>\JGOP=6E*Q"1F?HNLT_6.>;KM-G+(.J>IEV6E7D'I))8!L+6\[ $
M,0\]:K[HZ/\@G5"=R)0#M.3$DU$$@L+"7D2X%>H=BY9O02W^BKX72_?799CY
M&6H_S9H6M'>B[\XU_X;K73[G51)R CD/A=!7N[N@?=JI,7K!AUPXDE8Q+ZG'
M))2\CKYEWZ.<['5U#QC'9OA,>&5*8%\AZ.*'23*G\T%3+//XQF$\;=!G7N>"
M*">6:X<Z*1'J<P2$@4%DI]'%18I:T4D78.#J(O$S9S[<W6B\5.3C1T5:.54\
MH3CG?-E)HT3ZCWION=9H0(SB 7X!O5**T%K\X5*_3.K^I*-'&LX17@.450R7
M=);SA$[+P<"*2_I]\D8I[\S1V\;3B8(20Q8!5E:,,(E?A82]7;];Q\%KI6Z:
M2L*F66X_W+F[D0OY(H-<GYR7:(3[02.!% M$LHIQV63X"CA#!6I$PN(?K/EO
M=,H2+JT7#E\"&\K\U] 9<[6*)LY"+-B<=YB*,4\/G13.?B7:Y)96=7XQHB&N
M%_\$!"]1ZGN8>L</KF'SQ.]3]@CQMV^L4ABU!"W^'//T=AS'WRU5;B'LE*HC
MJ<1G6T[,QD@\P6$58$5I7I'F7YYB4A7J_,1.2SC,<%-2FQ)R9LEHF#]J&-0(
MA;K>$/U-_Z%@/2;5G@/) 7:JHQ'<%#5XV"D=RY1 +^UDLZ1@S\HVL]$OQ ;P
MS67_*;9HBK57);_BDY.I&T@2LJ,DGCTCA<*;YR!4=>K0FDB^,I\?8U<OG.-M
M(,S ..0,B#[?Q#Q<E:PJ]&"7=2XVJC)^KJ_9;/ +4K'5B,_\14&I]1U;\LY&
MXAN8E%>< #(N!I1Y+;K[\_#E=V^9$BZPK]"P%^)7TVP%S\$+KMKG='TAKY)"
M"?N^_<IGWG\YHA2,^18=MX]KF/B1AON.IYS/\/#+G1!GW%HN+Y@F(6!=_I0L
M>-'KCW<117ZH$A'V,$9OF)SO6]V&UO<.]VT<.4?3@ZZIVV5OP8S*.[IY@KRQ
MK_X2O)@#C26K4:8_R,!A;-1C<77,$&[L9!6UE375'6J5=Y"6 5-]4U7GF1,N
M_FY9XRZ3;U&?9M4\FH!L %+G4BCX_L,>BCM$A?YKK%W] KWL#[,LIY8:1RG.
M[G-ASQ-#6]*FJ AGQ9>CN$P5UJ_D_RJB_B^ZWC(HSB?J'IP@01(D6()#@,!@
M 8*[!)DAV.":8($!!G>"NP0=AB!!9W"7P4-P#ZZ#!/?@)$$WO_^^M1]V]_WR
M5'754]5=U??<>TY7W].A:\=F=I^'9\DJ1 XH.Y3M*18R6M+F_;U>T8:A4E^)
MX0A3[#")<4FZJE#W"C8HARPK%A_3M#N9"':?O*KQ?*LH109A77ZZ8*&B.-J7
M)9^E\.+G'*Z5"^AL2!V1>")3POV<B/8E#*.Q3-O0,0B3HI^]YW4P2>%_^0^H
M'G1=6$_BG=E9BSD87G7:+0=-T8RYN5\U-[W4Z+MRM,Z=+M+$A)W^U$G,E8(D
M?FIW6#,$Z/BW!= X^06WXD^/,TQ6R:?1T)(Q3 NGCGR%\6>Y0'5PPP$+SLT'
MY"')\&*K.+WXI3^"D7F2XJ:"SHD]%1XN$Y/N==<1;Z,A-& 3V#B\/E(O?YC9
M$9<*0X 3MR&TXW>2]JD5BF%5:F 5U9<0CJLS9%9[9]T$-ZF8Q,"GPYF2!I/1
MR80D%2'^326T-L)3.@8-TN6S1NL>^>I%TP31E.\,C'R:7#:4P-T@>H@>*GE]
M.M]9(@BO?ECPG^A869(BQW9U9RB8%-']MEQ[YYCD "\>QG<7/+>#61,R!55R
MBK(R%L_X!O^D6H8V*@5C?Q)!X[P898XZM;2/I(4B)A/A>01$YD   '"(:Q@K
M5;4>JR/Z\EUT=MP0]46THP>#5XR\3\5[M%8?Z"I9S?&4,D%-[(?$S0%3EK\@
M! ? \5/F#BINB5D]H&C#97^'I7*HD=[[FD:4I!+.3O$L"?3=_UKT@V=!T*BU
M(H7V$S^T76\'K9^(TKYR81T4?NM#S+NR;^R5\IIYTQP,CA!CLFE$?&K;.X,7
M,?A'OZI[T?=HE,?RNYZ.EHIV#LQR\D5_ZU"MRCJ_ :)3K#RHE^=_=!=$)["%
MINL<Y7C-3+4E;X=Q_?8*=W00!,EZBF!P=@\Z)'G5IU.PP/23S.^MQ-?VC-KI
M[>J6/35KU*:!A3&L-E_,K;$$;5EI.7H1@[ST+F$+VN]"D&8UC7,"..8"Y;VK
M(_V6U8#H.7_^8MCSUKO@YV7^71N4A8:(Q#EVUT5ZHW1-9H68Z&,,>TW)+5W<
MY#\U&)&2=*S%5N9;-5E_MWUR'][*_"6938B^.IZMIV::TRB:]51? Q\(VD0]
M"M[6.CI%Q+(:VM9AG7\>X9+C_0E,Q[?B]DW_J1"\E)0-2$I:J1N_676=N:XH
M U_$S3_3.ZB@'J,$3,@E)U(D)[I6*6[]6C]7OEK>"BO.\M&6<!?J'7N+<?AE
MY !Y/<4KHL33^66//9_N"=N,Y54)_B]7_JP[/%WC-![Q%LJO!RQ7?X[=1IJ+
M8O1[NQ)2-A+=@FJ2!>+_,.AT)ZRK'S'W]<^;7-$8)V$.6B(5H/O5![=P;RNV
M1Y4Q"35;*&E=?FC94NR2&/% 2!.Q$'#W3J@LC2D<'AX:O*" MWMVI6_*SB)8
MKZ7H=GQFI5"K$?#2V 1=T'3 X9X8S@-D8W[KU2<[JG_S\61_U+@FT\^WP>X)
M6Z.1619:A*>HHN^=1R6D+41\@*<HR*AS$X3?1R XEK0!/F[4&W7SFEZTVRCG
M\:2-OBC),)(@B+6+T*LOJ&QD>/(:D#2:'U8A!@*NUV>@/>W+1(;?2<0%F"4
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MTOI$)#P<_7,S*W33V5DY5;\9(];T[D\@QA](/,&@7CBY'_$ @*C-XY<E1C"
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MB2L:Y9FB,["P_ ;U.HF7:"0XX&U8^^EPM"]]_;!QWK=2ANV&ES)4*ISO?PQ
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M=/%11:5/(TYG]J\G@H<R!@<:@P>Y[FCC.;?T1'XV^E557Z-&RL]GO723#VN
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M<3GDG03YC(L2S"/BC&N$G>_5+@=T60S*0FHP+*JJK/,<;_L-VC,?Z1E*_U9
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MJ:$N@B>NTIMCKT!($KOX!CJ?TT3W-*>V%1J<:B)5Q)9'<)-7>:,8[#(Y^R&
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M5W&N=34/IUPL0%<9]\$O .!.UC !U/81^ /4 8IL[HZ\5/@TY*F5-KJ?\/*
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M9STKW$W]M"^Q$8Y<;D<X[0^FH-GQ31VA*Z@UO4%IAYIL!@&B1(CUI'\G6^Z
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M)1H/U!H?#P*GBU/S&5$&[.OB.BB:'SP!@C2SSP)FK)X 7R4K:ZXG[(+W[9\
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MW6X^6%^O(8R-N8JSEI+__ XX"I037.KQ=G,612I[TT&[$PODJ5DYQH92,C&
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MFWV?77].5NZ\G-8FYDO272UK657"8.2C%]_%D*Q^94M%QAV>Q) ;]_9F;^:
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M0;%HW_$F]3Z<G&F%"P<GP<:#(3/3N;% 'MIH9KC*KB12E3LP&\M-.7Q.67[
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M14-]+?0E[W;NQEC-)7IR6*^>PB=EA^_*_NW9 1]-S\>M'K2@,5ZK0AVSE_+
M:&'>=SL-F[3FIFZ*:]!()!#94Z WQTN6U*X\D"GY]41ENS[G^D__0;:9.RNO
M+M8^<VKA=7)9<TN#Z4MB$.L:0HPAD]G:)Y"0S).R6>0W9ZZR2N_ M%&W)TXX
MX0:P7S5?MY%QF_O$RF!>R[7RSD5URU_KYQCMP]W3" ^&"R:D8IV*?(W),AL(
M=;TU9YW 8A?;!5H9W"*-V;L7>4<T:'%H 3.- ,%XK;11E?-)@QW\5!TI35^^
MX,[GS.$'MU8.^_/1JF\<.M'IZ^680'.8U.,AXV=9O>9L:H)\/\&]U4-K!;TS
M.[K0$V1RO D6R9\X1#(H=FOFD8%;ZH08'__]\)<O\PHZ:IFCN"B\=[.2"WQG
MF<+O(S24U?GZ\WMU]QZQ%_$)5E9@Y;82@\CQ;]J6[BFJ"]X )*6^111,OO')
M7:HP>.\7R-7M+GO13A;]EY*\%-F+KMO/NBJ,/2PMJ,=FL+;N';AXW1^0:R%7
M'%_$0*T?_8M#1#6%HM-G%UXA:%SJE%Y%&3F,1QAT!I!E?/)<[\DC"\L=!&=
M]Y).)SJ@"]O9)*@0^88+\W !["E3-!U-L><^::3*NZT0.[GM$"]V[,ZD6X*(
M!47Q":@ZV'<=TO=U3^C^OSLA/UOVT)KG%;Q9_=M0K::],,(&WYD4WSQ7SLS#
MW&#DWI('UB'D@UT]QEE@QS,%8T$ZX]^A(SD;DU[^6B^@'$0<$%/)>:6,/$IP
MXDTL89L@\W/V2OG@KYG@>)_,J:72RG&.8&O6)JD)4Q>:@!.A*>.QY"6WTP85
MBKG$Y&.GM.<WF^)R733)]WFH6JS4U7/ !$+FE*ID4:K</M"@U"/5MF0>9^:
MJLZ&EUP86B2)D-)&Q3?B* (ERTVX5_:35NN JL,"33=?:Y,QQ94^PYBD=(-^
MPJB=/W$V.6 _0:EE)FBX;&"FYNG7EYXI_,/IZAA8>4*OI7$4L>M*CAWF:FXR
MO(ST<9=H^)L0%XE^[W,Y2JCF,Q)^589U/PDARH72G@$8XJ]O03T(1\09WHP(
ME/H716O+Q[%KI^8K#T;O_RY9_Z]"G]QKU@*\?]Y@?<Q?I]6T0ZKT]3L/R6TM
M^*0-[%/^<NDZ:XU\?)]YV8(''&O2P%H4YLG>(ZIC:UJ!D(A:CR%*GQCP35F*
M,4/54R2HE\AGTYE'1S.D2H &[T6=,Y;UD(L5!W\*WAW03D)2S F)!ZR-?XI7
M;.WCDO,59,&=?AG\XF]OZ]C-F305#T 0/.%\QU+_[E"&WD-:X-+N7HE'(")7
M1P^)I*%JRP*#_(#CW77M@/PA0.EQ0?#NOHE=QE($;.61D>9$^)=#%)[JXE.X
M6 ^LZ7G+B88)X*+B+LNUK[&ZF#/CH&>GY@?5-S)4<66?4F/:IG;O VGX3@QY
MHT6;"C/BCMU>1[8,H_0\.^ETG2L,,^&9?*<LQ'=.31X]W@U*F62&V\*8RC3S
MHDTY3K(MTK4I>"#<5^<5-X R@&/U:FYKFTR<9]OJ"H54@>CB3&-2XGR>N:PV
MN-+IT_ZK-FOZ4LL[O+D#S1\>+-PWUX[8XE<.H>3VH\T84@E\\IFZ@.&:9T]>
MZ=)K$;]V#]_!FAKJ\]8[C:#D8^K^OBH+KPK5G$PL&F,0@\A^/^?UP?U*+US$
M;'/#(ZXJ?5/7E_+T%7O<1[[;:GD7D_&QWC3-,K^4^FT\$@@/.^0S?IW*[87W
MB9A]29G[R-LX&-90Q'7&0.+^$UCIW(]6T$_N@+[7<NRTRK'Z;HM&M^W6"G^F
MI6V*6!NQ3)P67!N!J3(FCC 0BZ]:N!ZG'&^SR)L/5@/188,^#H]MC$26GLEO
M=6?RM3843:3DA\B-* 85Z+MC'Y2SH=QW%F\=S<I;.^IUWTE,G30F-#8VK<U7
MV,R?-KS+3CGR;U>[?P^R8X.J[ZS*85D1BW,H"RDD8LC\;MKW#Z!V#W#0NV"&
M4&?P8Q>V)Y"&M*@(,-%L?<F0"-1!Y(<1N^ARI+3::=%M-+*[)-QZ+S*KP#=9
MN'+VUWM2,1-\%PP!I2Y8K!(&6W)7\M&4I$R3?!]O<AR9:)6C+>EA8FO@;1NF
M2Q!K78#R"UO**:G2TH1^D8KO0@=>62+EZT8XB6M*,A![C;L^9?<D]PG)A31J
M2(2-COCNZ%X IWM*:T?OK7L+V0@PY*8!PI\ *VX_]=V_\CZ?;C*F)C@<6&GH
MS*YJ(>V8NK ;KL++RP75.,0_G:4WW,VN>'C!](O%W$#7F8(W8[+,">!2-H)$
M8V&UQV)[[MKH#KS!;KX4*&B0$\:YP 'C)ND9SZ15>.H_8LT%5*$:IP7(%I$7
M1;)+:5UZ]Y#3U#?C;!T4;+!W2FA7.A=I:7&I]DX4W'0/E40N4F;^<]%2<9XT
M=OSM[\4*^&^7_V?!*4KLTJQ%4*_S[3H,/,.J/H;P-+F/VGD>CJBSNN7]&3YO
MQ91Q0';^^;Z1JG%HCI/]&6,;N'T[:,L#GVH=NQ#$+]2IW)>WWC:DB"C"J:@,
M(/3G]^K>8:\$Z8VANC6/K&W2^I-%E]2[#%M.(?&54KN^</E,?B@E\=-H"?+J
M['8[UF.9,?=WG=D-'H_97E<?UK,"W85?!AHH:?WQW?R2(T,FC.*X/D&EI)NB
M#91C;"(XO*0RVZ7GR3N3;(3,I8CICUBBI6TWF@HR]H"7-L"0371PFK_Q'NKN
MC];8<*L-*SZ).";X<:B'<3JA>4B? 5^:J@IJ*CS@Y),;!;K$4.E<ID>0E=?U
M5].2BEGY8)7@(8T[X\_!)M9X"P\*ZZU.O="<V=WO>.EWSU&.<:'J=!D+?;<%
MV\8^Y7CO=K_L"JE?#+D<:4NU>5T*'.6:CWR7*I&?&I*%,_ +3[H!/-S<E'F8
MKZ]' $^B^I]O_+\Z0'6GQ5@/W<6<ZO;(Y30,&U"K:2!S^B[,%*O^6] 9Z+/(
M8[0 @40<%8IOTOA]<)JMCT,4W)LKVZ=W%*PV#7FC^-4W#R%D!!JLY[889=,^
MPNEI!31K3;,E![ZF6_$\&4:B(]-,$X(2(AU([S.2*HV6TH:-&7+(D4F13=@2
MKKL&F,7Z%(K-4)N?;;RB$:1,6H J >_\,'Y8T)&]+0BN*H/66#J:'+X5MP1^
MS2R07C\2O&47BN,EWLK+@$P3/#F2SADL*A0A3;\!L+0B;P#BZ&MD(FH-:4K-
M?RT)\[AV0O[;G/,/79AW<1.*#_:U%D=5*\L$:4]Q:7Y_]%KO:UHIZA98W6_U
M\^:L.J,P,*5XN+]I4G4O/.(=V=96/#XP](!Y%?*Y OGAH_Q@E3>NRQ9V$.7\
MSMAP@!">M@A ^^1CKP6ZASR&PT^5V$(3F&:\N\%A(N/85IPO$^35"BI$>>5X
M>>;9S_V5&\ 3_!(.Q[9QZ!W ;AVQ^:/FM3%B-/9+2\57<FH=3L,^,/%/G5EI
MH>CYWE??A)*U4R;O.L#C,+#&23B?#X SBG(;893'/CM#'/N_L?7?(%G,W%46
M[QAIUCF,7ZT\SO0#4>]Y_O<(BXCQ Y5 9*Y6I];V^'5A^EI"AF>/3N [JJ,*
M80BK_JU8G932=/K%F9>=F.M,Y'#L9EMO^M<%L9:ZS)(JOD"^BSMY+PWST2&@
MJ3 !CA..C<.:%5M:-#/3!GLH5$B$9Y%1Z'RP)IN [,7/0@$E89G 07U,V>)R
M!+-OI(+74 SSW.Y>%3>BN]XN(ZW QKA<M4Y!J4XI"\-*K"G<UIBK"^3W$G[&
MPPM@%$H/(4H'E\(&'CV8-]OY\7H=]LCG3I95YS<W^6D) F7'=! 9D6"^$)F8
MSD!2$J=[^@_8(%9W(!&K4)XQ8W(<]]Z=_H[40&$/DHDMO8[?5H(CQ13.UY"N
M9O#D(R^1<AW'^Z4(RR+,XBVO#G]S=ZQ]!?!@CV9!PW"]:F!Q^>[7)'18@DJ[
MA13WKS_MYZ/9@C_MYYRX^5E0?9Z51^2#B><V.(X%?]='# NNV[.[(Y^TDB<O
M;'63:RJC4^5]7I[C0GZ'+ET3HW3."?ZJKDC["*VL?EWU%WEFO38ZV[\'K[VR
M /MB96W:&5O8,&Z<0D>9^>*/K+/PG(/YM9&B3Y[E6U7(4F$1O=AGM-IJ[,_%
M(4Q6B2*(2,7]OPBM2WY']<SHK(W> '[R=ZA\N75E6N1<5EP]]T],6M#O>ZVY
M)*,8KW:\^8KUUF*6]4LFL]*6]3*:E98:$M=U20B3=<>(6<%@T?ZR3L!?J>Q7
M?Y[?WP"6=?\ S!=5ZL.Z6F;U_\#4<+U1^-Z;]>,&P"WW]VL]+5.IR#O6NCF9
M(_+)-8O\]IAG(-M:*X.6LI(%YYY:^L,!8?N#S;_.Z+!<ZV0J9D*64+=JY-EA
MSV\*KS>_"&\ 9G_.NP'\YX$/CHUCL[(2:S0&)==O #]T PRN5+=PI:^Y5IA;
MW"V#R;/^$&#+J_'O?CS@@-:M2=K:9Z<84CMG9S5L6C(R\SC8"O\/,B37U2J<
MP3TO@!/7JO:XLEM (*-Y#V?P#>"_,/5RG K?0'O=U\->_O>EHM=2Y!RLC.%1
M8*,_OD4F. F_CY0RTYGZ*T8&6PL$8N\KZ+5EYSK%E-$#3Z(O1;B7HUK6V5F-
M_V%6./B/5?]5IN__+=*KILD),X$;P)EZ(5379$YW:=(+6(X>51S*J-W(2LM?
ML&H@C0R<NSV8/7G'*H/-Y9'TV5XI$&7=" 1;&3B2[PFK#UO\APGV_\L"E;]#
MO_\WZ?LMR*09ZW]@TA]\C[&;*,-&S6RYHT@GUT^?OWJ5"[W_CB;RH*$V4#2M
M=T3(TFM'^F^%G',MZ@3H_*WBVDC%L8",JT_!FE$*$8 M7"63E;LPFXX[;XW4
MY]:?L%]X;0^*\/F*1QO=H]IAY@7JPBXQ_QIY>':4F-T6J>7D/T;&Y<86^RFV
MWX$7IZ[ZSZ>J?18S4M5B4KEE[52!>*1K Q1F8<+ '>A,=3A\![+&+0P-('!U
M'Q]M\40?_.PH%%BM^;'<$X]9?*N6?NZKWW&B7&D\"WG%^5*6X:0XJI?!:4O+
M#44'SR\COIV@5$EJ_A-/\W;IBFDO:Z;Q?;:+[\FZ<'D^4!31/)TQK1R :ZR^
MT_*):6OB'J45A,47191@#.CMBR=#A2'FE YF,=F=805J;DA+J6]XV4D./TSM
M/5F;KM;NPOK[_!IE461GFL>NBHF/?P8^G\:$UTK;?<-UF@1]QA!T+5B]EL2P
MN- /JZ0=/B2GL M3CU+BH^F+:E5U28KHR7^!3AHG)1LMQH]A1@BJI?>^?Y<V
M^>%AB*ZH/U%F?-ABDVIH6EK&U:G$G?><A&WL ]Z-6B'4VZ"8J6RVL81Y;3O+
M5>I=2DK$\I"%513[,E4:)J>&M:Z_/GC.2<4UBWJZ"6?O8/R@_$_/M%OWQ.O.
MH!7&8?;JY,+'T#J KE!?GUHK^C*:8E Z[P\C[]B$ZP2\].>@[_5\45WN[_VB
MI^.+E:-C>9R53\GRZ+^,%55\!HF_01W.5AL:!#X-6I^%=&CK:6)N *U^IQ@U
MZ:>-.(,B<7^'!>:[#PKD2J4VS=F,;]^ZN^M&,H\!ECEY'76-NHOV-"T8TL/\
M+/+KHOM\7TQ@QOT-QF6WI*EVD=_]/2T6<@1]@)LGTTR*\ZQH+HAE_FR8<3QF
MU(B;YNRN$L[%P!TPB#G_T7L#^%@[ESO&$Y>U]EH75L0/L1HE5-T#*U5258%!
M<N;B.SD.^(&A;=OZ;EQN=W[B46A'NL-[7Y,W50Z#^J& *[OK3*:0E'FCSOM8
MI,E%MZ;'<U'*SV657T/U>K.8-UF^4 DQF]/EI^9#=?JR-G!7D4NE[B<_N[8Q
M_B.2+M/?M16\'C$PT'QH6>&#YU,.$F^MJ#X!"'UV:="G!CQ]?@-0XK>;@'5\
M3GM6P%-TE!1L*?ZZ2$QV 0RYT/;S85P,&@G2*V!=&LL5T3#*$:$XY'RB[J</
M&%(:VA7)W[N>Q5V1?.B(][.9X]*$MC=BU -9\5_;;79_P\F-G([@9=D,ZO#N
M_%J^I,-TDK=HVXJI3N'B>U"@*,=\EEN-%1JZ!<>]L$K,S.0TX)L:8V0,<9G)
MZ;?$:W5LU=T3D=[6[XCI:"L7*7N8F3JUD3'L#"6P%5PS1A+\?0L;0'K/\HRU
M2WV'F.:6-3M0;NW#4-BG5./,*M%MY5_61AS.2@>_"MDNWQ5)E1]!<UM?38L^
M/M./FY&@"E6ZS>TJ)+(M!^*+.*M0+FC2FLH"R52J@>(IX#K.(A9&Y*#>H>-E
MRNH3?$/&BDE@P#7BU<:.!?I80WVL1JS^^&M65;5_58*[NO_D E]A3!)?P 61
M.99,^$NA9*+XR778R-,\JO&[LH!T'V7TFU-FUX"4 ]TI9K9#?7V[@MRCV/8O
MORB-XU\051Y=.>RE*)MB[1.N&!XUK2"9Y<30WE6P(H[MIP**G]O2GY<O'OG<
M7LRCWS:S=P"R[;2PEJ^5'P6F[P1-/GR@+Q[H9%C(#^?^8J';>EQ;6BF<'GO?
M+S7<3X_@2)A[?;V@NTEG% G5 A,GT4F^M!Z_R]%>._'O2ZF0(?BBMDWHEK5S
MUJ!QGJ^:,(AC2! I@73YN?U>-M?&*:(U@C],3-I58U+]R=L+8X,L#A;0T?%8
M+RN!KN\IYS"R0V2_^L%^U6OG)KG44W@*BB'5-T90^8 O2GG)U]3[D]?F#L=B
MQS9>/'B*"@I^ [+9D<ZYE.;LKUR5C8(3XDP-$X1&-3R4Y*1JV(S=8?T'1!)Z
M6_IB-X# -]XR2CJMP<&J9JV\.%73G? \GA-3PK#HKF4&WQ012&<(31.X^U.R
M5T<=31+$^N3U\[[=[2KJ]MDL7N75 Y;:%ZDQQ\]_@) K:_T9K9UZQ4$=C8VL
M*T_A'%-&>6^=]9#2X^J3Z_!EN=DR85NB15 OHT/) K=6&RCOFRQ>+Y4NN[2H
MM&Q079N.H5"B-NS9@=VNU-L1?O*[$&,Z4O_>M2X9;TQ]R5%W"0IZV5V.M-[/
M9B3^A )EQ2B?*W48ZNM'*,L6$=76E$9$UVS^/'OU07N6MD4 K=-DB[29I[%E
M?1?:QO^6I-7NUZ(#)<LA)[\(!R^'[% I]?X!,7YOJ&H9^E"@1#_[W4R0H*UM
MZZ]%_8RK0VIW7MROPEI:WT35G_N-=Z2[)_NFT$W#GM,7K+S:7AG3DHXBP&\\
MJ\4M8%>L82#E7D.MK'C>:?4\#[ $@ZEXI10<_B<BO,]B6/$QZ]-]5"JZ[4&,
M%+T5F%G&IZO3H>$A0L%9(GVD\]CMM4R&YF=KQ$$))+_A:!LH 9<37TY-WXGE
M#A1:ZQDMN4K[N0%=&)+8$]@6-5Q:?_@J$BN<]5;WCB%8@UH*K6[XXC0#IZ<[
M(T7%SZ/4):I^H1XM'V7)0B%(?+6$' EU]VAM=VO],$4_/?F2ICNZ?'SS-MB0
M/2W/8LPZLT9O?@,7'G2-W;^P" 0'1=38:.7? -*$A3<:"<B5*+:70TGX\DZK
MB <[["0*52K3*@*P"U@!*A2O>(TWT\2]Z<N1^ZUKH@1J;CKVG9O+5-$D?&?0
M;MQ5[??<[N@9F4Y/#^UZ& 9?-$P\)<)J"QK^JNU3/MYM2E='L$R?8[)P Z >
MVQN%3[)^]V<.B/TK$^:<.UH TC 2XZE@*F?FR4\W+F9@:N&+,@UEA!9!=VP$
M%R*5ND5O-WQ)PB0_A%=1TWPAIHHY64-2%JGQ\K;7I@@1$26Z[&WT/+&5N3AF
M5EN\9W6L45OU<&/$$]$BNGLDNVL &&]8_6"__ 06?"NYS\2WJ-?![UE'2;_>
MG_1@Q/$3,&(*-%@MPF.GG2#0=M^ ]+(!GER7#M31IVDJ^9>3M)<>N)2FC-1,
MJN4M1AIL2G;CCRVM]BNCDN<@M#T,B=X:#O-\K\;O_A&2*^>E&:QC(0PBY\ M
MN#V@;"7O*)/O.ZMJ=H'X/M*"+M1HM)[19\7$VT"5Y/B<*(;Z=-P)&I<S3'#6
M4A%&+1?=2]S8EO#D.F%'0_A<HU*FU'R $_]=[F=$T;(UVO31^OXV$["'A4,9
M]Q2U[Z;QJWEW8!Q$ E6?,M)*E*3(U543$1\E0O?T-RU/!L'@:6:SCEWS/%B,
M^!U.C[$/2.+62?I\TS):4GUE:<Z0IH8]Z1N UX?W/>F%<$7FP!=WOM\+^/%R
MIYGCL-]#A3UBM8;I?5K1'BM&#=6DO\1KLS?YC=JZ<$OV\$LR S\X3#-UVR+U
MT)VWK#=BU4](M;/V5,,XI+H59RM=_LS*,AU^5*.!>W9)W2>)* C2!"=G\O0Q
M2";Y)M&)#(088&_EXSQ_LZ!F&=F,K+[[C06R4$+6&\),6RI]"HM>IH*&>">3
MW_W\6"X3"2F7E@@J:9?YWJR1&P;LV!4ZYY.8H. 0'N++WYJ>1GJV]+5HW2G4
M<F'W@;S\^[,&OG1] ,<(A7Q8A+]5MCJ!"#= 3FX5=51=OWH]5L,8UF@GEEK'
MFNVR3-AY73"UATCXJKBR!3$P^5;1#N/C/")N[@H_=ED8-GW$]_'=\W8#FFJ.
M)C2M32BU8-5,IE!,$07'M$$EQX@)/J*-]3)(ZH/M\ 3J-6FEO#+T0\OPMDS-
MR#N \_Q^$UBCTE@BW4^"G%>J$77!"]G+6ED*,$?C%! [KGM9O@+NF% O@?Z'
ME<!2K8AQ4\H&R@6^-?:9)@PP<<K:WS&7Y'[UN?PJI"[8NAG6+A"60K8! A'[
M1N4]#3.D 7;,&J&8-9Y(*VK;)K/B2=XAFG[YM/9-,D[J#,M6W-,!#89-Q+$E
M3;)!*6 M?/Q"(  ?32\!^BVF\<-%N!MBPK93]J@S:4OQ=40^H>)"QONK';U3
M%<GYL!R"$XN72:9:'Y1Y[W<ZP;+OB13;KUOS-\UL$EN^HGNJ8]E78/(\G8Z<
M[[F(Z*+*G;DN9Q;L'=:%O] C+A=4*ZSKDTK5*P2E0&^4=Z 22,*4CHY@_5D!
M).FW,BS@ZK+5UG$'+SO:.)4_,G/;V!831+TIND/\-G8O%37Y\J//06J(%$\6
MQFQW*0J+%_9U67%^Z?,RDGK8SXF</-"#XG?&MH_?G[ 94,E^G1/HIB>"8"[%
M!VEA79>2F(R_O/?WD>,95V"LI-%_*/FKW#5NI+T'ICVY<-1=U%:\)D'X7@,"
MTW+(HAR"UC416$!"<+TC$%.^WKO_0W9^4E[7@E7B0:6H:U=,SW92;M872WC1
MI4X$;''^,&*II \YW;MLHPL<P,*<Z&AJFM5</)I,^,7STQ=\0I.U;G'^@G\W
M_Y.N^8(KB>('M!,R$%*Q+^*.@7%C%#4U[AGNTV/ 2N:DTK*V/0;:LO!Y0]6+
MP2X+(&I2$L5E.-]ZPM!Z[!5[F"^?-<8%J9MP;2YT+3*R]>7INP'8D1ORI>T8
MV\<!^2L#\TNA>(]RK]-;P)9.O^B]YIW 2ZF9FB+Q>U5CH>MQ&=,HN)Q5E#Z)
MS=."-]+D5$K5"^]56L;Y&MTD7;[ &]J9V5J0NEDG='3PJIG#R51XE(*O0=-#
MV=K\P1RW/=)5S)%2CD><IN6CT@'?'^:!P[ J>G-X.EPFDQ;,Y_3"G# ) 75X
M_?R"1FN5GCE0)IZ>Q+OL@; (OQ /W_IZ-(FQ4O^DCZ-7Z[)MP%+S-&NF]Q)K
MV#&9%G1@C[DS;#J)/^:Q/75+:KJ\85A&/K3&KT?O.WYXTLGTB9<,QU"0:X;C
M=&O;CT1\[%-FXVR>-J0<#QR^HE_+';ZT'_8A5[@T4"QCLAY5LSY?[D[AMYC)
MCU?Q.I%A, U/PT*4OKZ14Q$AI)W?I_HRBX;6C!Y 3Q\$@PYG\4GNCXA0H-0F
M2A;X*OFAW%:1)2'""59&3@'J90<HB7K>CG6)&B#K:_YC?+ %0M1EVB.Z!E''
M_]GPF8"-B7!,^[JB9/R=Z=N0N!#>'+/BJ&GNVQ!THA!AXPO+XBC(7Y"%,OO5
M[W;(3T&'C)F#CLNMQO909*II3#T+A2P[$>1M[<1_#$BC4Z$BV-+=V=RN@1W*
M.3K@Z*JARV/GF+)M?B**0R92LQ<8*806050JJ9*HE)$J8Y6Z*3DWK8>[$#%"
MJ<P3K4^WL@#TP8LSX+Z;T+[5!8G=WX#TJ;((MI>IBO_A0D1V*3EY*G?BF0MP
M@4:CO<^^ /:ASR);@JB_.5E6CGV-M[&*LS&1L&F;.F&QRZ2N!=D?B*2NVX&-
M3^:E.4?.3CS.+?GJ623!EZ[4!T^7IS]^-?:U]@MH\%YSXL@?EA2HS-W^[5^7
M"(N\IU2STX8,"I_-!]SQO)$SZ*]20<C1MS-@+R#Z,2:D('"JT3_V+4B1J5>1
M> 6LF#>3U!@2.9Z]0X.U>9<@B6[YX+8Y%D0CQ^H-IWT8S]@'C[U=&^L[M%HN
M+2@-3R)2=1 >5$9FLM,LU,XJ"5$J='!*'#<%,M6^*5=.G,H(6#QYJC4Q]\-+
M(71:#/B$$T+?QV8X!LF82:*K);"]?+V2;>VAIU/KVE7:,EKE8=G4/V+C[<\T
MC9?ZX4F(@5#P@V"6QNKD?*<U!!\X.5HV]W5;;-?E!#Y7[^[S7WJ5MJ0NSI=R
M&C*H4:JQD(A\V2S]\2V+19UR>@6B#IG!/CE6D5PJXI9L7?,$=G!.P4P:'1]/
M)_<Z\NW\2(SYFE/*S8<8!.#,?7$&94H9.Y;%I?^K*?K_+Y#@9N'_ %!+ P04
M    " "=@HA8>\Z";\YK  "4<0  $P   &IA;BTR,#(S,3(S,%]G."YJ<&?<
MNG546]O;[QND15I<BKMK<8>6HL&#^\;=W4MQM^!6'((5=RGN$CQ8@5**NQ0]
M[.Y]SKOW>W]GC'O^N/>.<5>>9(RU5E8RLS+G=WZ>[S.?%I^^ 3"!4K)2 #@X
M., ?SP_ TS+@ P !'O[/>-X0G^,%\HL7B(@O4)&07B*_1GW]^A7JJU=HZ-B8
M:.A8Z*]>8>)C8N'@XN'AO<9X0X"/2X"-BX?[YX? (3Q?@_@"Y<4+%%RT5VBX
M_\?;4S< "QF.'1X) 8X* (\%AX %]]0'( /  9Z;]F=[_^>&A R' O_B)2("
MZO-Y"TP '/P+N.<=)%1D9)17+YYW$0"(+UYB(2%C4W*@X+S'I>+D5S%R<J^I
MP\/GY7-UJR6DYA+7"$RHA\Z\H0&Y)"4734NIJ1L[)^9]):"EDU0- 1?TTC-P
M\WPP,?L4%)QOFM)S<OK\1:1_-@$!@/"/AL#!OT1ZOEL(*,^G!;#@_OSFYU8A
M(2"\^/LT%@*'TW-3*+G><_.HU& ;.2/AX'*"$KY2\:H&YIW@O:&A%7^" 5XC
M//]$+ 0L@!@ ED6)C/B_@AIKBUW?LL;UAU\$<?%^D3+=ND.E5<0O<'U# ?\:
MX)SP)0),7)"9]ZZIX66\=>.XL6*+ CICSEZ"J^#:K1/X&)V0D+Q8J-L%+DV*
MBYP56,(H'9^>DY-N#5+4K]V?;/\,YOW(J9;O": 0+954]2G<MQBHP@/-><CC
M!SU,6$<4MYMZU,7UFA"<GT5TJ30,C$ [!&^NG1:TDQO"3?/SI]@INX^_C?!Q
MM>/E$(2-^?P<9 CD;K,7(9EGZI!*M5JE*Q)0*NE02[,=;ET[:-/:?Y,,E^6
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MR>V<3L,2?X2?UU<&'<OU*MLQIVHUQ :HT%9Z?54N@:I21)A[/W\46'4RG+P
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MU=ABQW/L;I.XH+=6\EY7:OB!O$V&[Y0%$/. %+?(?8HS9"6%#7.E*>"'DNF
M0IEFQ+X@U05-CP(?1J<6"]01-21S$.I@(4&FVYV2ZXXTSQ/ G"DEO(Y2H7JN
MG.7+3;ZH'M?%94I/EN<G8$]BT;9%VK!PL^&JW#0QEZ;E[(C"DH1QI6+Q.)\
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M1QQ$:C9D;]<:Y*TEKO>@#:KD&6 GVK*VQA 9&*4GL>TAQ+Q@1::(F3-%Z+/
M\K6>36>:#:IU0Y&BWR8%L$:D],94QWH6?B<HS!@O;?W\./V&-*:$B,=H70%4
M6&2>E55*2?D#L]Z(P<L"!=@VTYKCDT]CWI'3912Y-@$=J=)M951)@Z@C6.5
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MYM?=(I!W_@EWVK^7Q5Z4_WK,)IGJ!3^_NW<1X>/?82\7DN]:'AD9!1O#MF^
MS65D@DS;>SL"0NTU_6T@9AYW;?8XE6'RQS3("A1KUDZ_/"RA5:PTOGU%=N;S
M@+"^]=>*Y('?BNBU/X!W?\]$/J?[!R V=.?WVKU/7,^/O[RS>_3E^Z<O"+-O
M.Q?9X__; [^=PZ6@X(^[=8O!AOJ<T,IH8>,A@?P 4IG:Y&2%9^]?>[>4HA4X
M^I_RJTKI>=XT-H'"M9,K@;Q_Q4Z&"*IK]9=YNYW[#HA<Y13]TNCM49V;XI_W
MH4?ML*%\%K\A?]9 L8FU*F77\._' #G"#<#^:$8PA?.$7OQ^W'^5@OO! V@#
MDP)'*3JE$K4A9T[G"Q3)&E/(Y1U^W*J)104A".MMK$80:6*2-?SQ$7P1N$D!
M7!9TVYK_/3J1+*:;:]&\95]6 <'?3S.7)3PM%B@DI/4)XS2<OPN):Z* RNS/
MK="!*?P9!L-#/J%>?/68A5I7S_ZW'A)*I@<L6<?&:8%G;17FP-59U_L2Q[@M
M- V-2FW7U_6'\_7PUV_IB@Z"D@N^UH74Y58&)!&YGEH*H2>9XZZA-;7J#(<2
MU3@,/C.DYH>D[R5&!L0,I_D&P7?)N;5;RE +3\.))YU[Y=,K!Q3^*VMU&1NG
M(0-(%;F04 . 324@X X-\?>)!"=/A7;U+^Z(6^Z[,\>(-[:2#=9E$]NEKIRF
M1IX]V9!Y856LBU@\I[33M=V5>4K3\W%C297JUPOI<N>&R+=9C@-N0H)&\'U(
M%1D&PX .6U>L(PAV08JI^,D8\N/7^^HAN[RE'SZH&6AI1:5!AGM4Y!K#?CZ]
M?U[UZ9@_87=H_L/IVR%US/1VW>-COLD>OHK)"-G&8,-A;ZV;&3"A=^&D$^GU
M99NW+O+G_IDFM2P0X.#>:WSVT2I9VTR"T@6X4Y&8G8< OY.'?O#E<=2UV5CL
MD>!Z.5%?OP4GOC8S_?CJ-%"6\5BMQ"(7;%4Z"?6[U9L@X_,I$^D"./ ((DUE
M3?6_<CXSTM(#=&WUD%1'C>(+-'AL7$A':3!SQ_QW OG=S0:E#I5K5G2Q<>1P
M+O9(58!&+7/^Z7N(A_OO$YK=L?DE0?UUOK%[WZK^07!@_7.O-^:6589 :BK4
M3S:<3L97_=EK"?O,*M'G!IF/34OQMNEEDX-^M4)V4<)DQEB-\_FAXX2?'FVX
M7>+\TLO4%W?._^[+1WQCF]+>S.Z+/[0Q6/DE<W8MWL'"^J:>U=@P&RP>JG9N
M6/('D,#V(U=5Y9'F8T_31R<2XGRB^%]_D8_TUJ57=L,I]/X^49O%!OE[L%":
M2>85J+R'B#(&X5H2@H5*Y-]DFP]/QR;_5O_""7H_E"**$J6A6;\I_4!!=:*I
MCC7?J[#0/IA+AU!45#XTPY&=A:@Q,3HBP%>ZJ$4H$]2<5J-&.PJ>?Z.J.3#\
M2Y4B)QC.)8.PP$&90&7 _HOAJH\@,>-QYNJ];RC4*PHDS C5'_->RBH&_HSY
M/97W:Q-NHZL+_T_$B8].[@0"_QN%_[^F$#]R7ZF&?*RXF_</TWH.FO2?Q<U?
M*41:[69IS5=.[3')R:;PO99?,\9IBO *N@/5<Q([[L2-)/.JUHA0&PWJW4H2
M+AQ3.]U,>L1VIO=614U1:O+0:X*]=>MOA*9^#^%3>D =/)^;X#Q#AHENS10(
M*00EZJC(*89LB^O>O)KTNDQSQ^9X/KN$:W%0IM"G4O[@O]BZ&5.D"ZMI2:]_
MO>XM7B2"^XLT:0G0'9I?VBO"G\:B7!SUEQ1ZMH*97D>NWH=_&;_V\OL_D,!7
MAHIZ4QVTM55[ARJ$;0%@6<5+&?G&PIP\,6^Y]FLTH@-1BSV*$W?2)ZM& 5PH
MNNA!"5Z;7]*NX2G[S\M^<5Q=@]?B%^+.DQK&B):N15%&.%,!W'OY3.&-Q\\9
MP_2C+F4O0KKO,%C'CCX44QCXJ_NW(8S2(#J;I)Y9J;L5!!59Q: [J_\J&S]_
MB9B[RTDMU1E,Z/EO ;B!)HO'F=OGHVOW&+)_>2G\&,2P'HVP"EP:_/R=:P(_
MI9GJGY)I$;+/H2*7U>U;^WP<%G;W5FIXB9_+*M,=\5;!^S8YGA(2.FFSQ221
MFL?/2^B-]=_41XT2"_X >/_"4_HQ.+ T-#]]6LM<8PKQ^ -8_\M7JOBDO^1Q
M\=[[3OZK[.^.F_\8+LXJUY=7L[Z7:1YK5%MI'IFBL^ 4(F4#H?"T:E+\.:+"
MP&*[%&OU(FGJJ>1K+(Y,H"JVCXZKUBY",41G"A\TY5585MZ(>:^%!5JB$D*Y
M'CE!GXWPZ@#0^4GI PR-+(J9,<PDT6P\ Q2N>=F&-Q2?=:^',E(\UG']:E;Q
M4&:WZEZ@DKO_<+_-W\C [0\@G$V=':&2GNZ(?ECZ#X*$U"2K":I(746#R<,B
M,1A-0X+/;?&SGV\S<@);5R*CBO&K^1(Z=&IA.KU4_[U-TM_1Q9;4<XU+82UD
M4AR!Q/I9E^653HJ,BCHA41MQA.C1G,-I/[X$I,^*M6LE'D84:26H[X\FS?Z
MR)Y,X1#GRA 03@+/2^=+6_"A1DF&J>-YPVQ!N90I?X<$43O;2>]H?A\OO,C$
M1 BYW,8=X>Y?:<T4?E?/695)]:MB\I#@Z$Q[B)AD6>#2?%$@%%Y\UC[=VI2Z
M;N;Q^\A)P<P5I:LU7V.Q(X$QE^1]<RF;D??T5?!4QO/RE)J8MEPCCNK&P%62
M %"8!E-8H]-\!YPC<"GSNM5A7L[DPJGI. 3E69H1&3US.0*QJA8!2Y/XHV]&
MO>?)?R-%ZU.[D<%3J"5=;<<G^RR2?[UJ9JL<FKN0<1"=:ZAH+7WZ'&V>D2G\
M.YI;Z--<)=]^Q)=LC!WC#'6;!9@/+SX6,100AZX^^\H?S<XIUR,J_LY ' ]V
M<L*%FTQRUE:>74Z8UDOL62-9MNH,S>QE,6+^Q1;M;_)=7 )VV';2*KPGB%@I
ME/DCI]/R!>9*,]ULH9]+!;T6N#\ +G^"6+ D/E4Z3HQLM1 0J/:FQT*,,91<
M%%(&SO4)T$)A[DE)#]<]YS G%Z4<U!PU5P?-+T)]U(4")J>B3#!@#ZZEH1#3
MX;Z8_ I+EV4+2>DY@9V<C50Z_[9^*=>G'H,?%5&L"Z6"AF63+@MI#\2W$,D8
M <:'9>QW<\9FP4=7TJ!^9\XW8C'YR^-LI1$UCR8O,EHDDVG:F*PG$]>+0'E/
M\>9R8;H&_.J6@Y PL11#WY>T] '2JJ:=XC<\RRUP3:5I*YD1R-T;>,NL<P5-
MFEQ-9<MR'M?W &GSJJ2 =;"7P$Q1]2)\3^"I56[ PNW\BLC7 0TLLIZP*\[)
ML*S+M&:2;P^>DI,'[O0+Z)[*VA[FA90TBUPZG7DA!*=TIEO#J-)P-1U9-;(@
MP=F9KN X.OZO+5^4&5"3@?UBDD_W4 .5\$"/L<.;;I;YG8?AO^L*5&>/U59]
M8QP"_5:%\[>41:Q(WLI%NUDL#LAD#P<ZTVELR[&1LK^\^=!+]U59J&N#CQUL
M#VD*7_='6=KF"/)N"?AO#(9<2Q^-9DA?<F= *-R_?TX3:5-Z]D[?@UD%WZV/
M=L+:E2_5X%MLK9:M.#RIM=#8JI1O^:LDRMMJ0M.O'*'B>./RCQF(NL2RT0\N
MV'T8\M#-?,S$Y+SL.* .LDK?D/%55(T2(-,W$%M*5&VX6T=TN-*UP7LJXLT]
M3PZG.5IP[]Y70L\WY0^2:;]WK8UP:R8P+$MYU=RH+ ]2S6NR;=K<GTR?(R<C
M+,.M;(K6QR0XNNC#20=&N"MXU?.#2!X;W@I<LM;M_=KXNTTH31E>J20I.&^A
MI<6!*AV(B<-<&T@XU9EGCJ&/8_XWQQZ01&>1LVY&12=F:_ '$&3)%=XN$JGI
MT+!\O14&FVQKA'BR7)==/6J7@_J3"ONK-E-VCJ\, =GX:=A>FC8]*CH0?#25
MVA+T[&L%I(*9IZE4&#KS;$:M4/T$2@'%)#V)[8KQ[Q>-#-EN/HPNN=$B$K"@
MDN_"24Y3F/U-<K686/96@N.).'U@.S-+[ +(V4QM3K!\/ALI>A"J=>8+A^M>
MAWJ6!%CYNS.>S^H#X;9=8CSN=Y)'_0<37=!&@?E7?!6?OV.4],IL%/MF)ZQ<
MDH@''E"2W1F%3A;9?7/5 2YA'J;"'@,06=)711PWK;LX;QK=X.B#+X;Q0YL-
MX&]Y4_A[-7;H(/:#-VZO1%N>[<E_4/F.OL>BO+4%3.@"D7U1>(-KXAK 9<S?
MDJ<;<KK*=ROX@D>]P'1GP]15M]1'FNE@TD:PZ/P'I+$YERJU!)8O!;#'IO*%
MT]BE;'45S58LW*T)A NWU;-ZPZ&QO(ZMI!SEX^L,JJMT\9(PABA&Y6%-/T%_
M[SA=O77E[*LZL3M^D9ZJ=(NHG;96&$Y^1\:Y,63A[N("]P>85=H[LTHCL?(*
M\^TQ(=QQ"OEU,UFY(9ON!$_U]D!N$N+$#W!LQ/3Q=V,W>'+8G.MM9-E?6P%+
M^1&TT0$$OGA";L,^&GF6Y":J+=-7R9YBL:6@N%"YPBH8D:C9+"01T7Y6,9]5
M9=28V2):!Q(GOTG< N33^SFSQ+>J+CA[L'A(R"9 </"&V\0"55E7L<P$2@K/
M&\*.DCC23C4SM2< M<!HEJRY=Y6O&)<8,]TJZE5BZV'3WW(R\(*],C*:_CUF
M#VOZ-=5.QT>+-9/.KAH(#6WE,U&\+<&*&17?-4TRZ7ZBF0)8OCOWTIHP'W.^
M[%NAK,])N.,:13>'DIV^34P.FP^R369O3CTIPY47'FRZ4/\!L-"(VM  .5Y\
M[A[DDXT_2C^YWQ:R7K8<Y"G:P>>?]U36_U]?TI.Z3K6JR3 _D#O5H=YT5C=9
M!K]H4&;.XXRA$=SB@&304PM\M1#(3^\;*(W'^,/C#?F+\N08'DVH; &+(R(J
MH[]3>C&=6GI/B63T9]'C6IHR6Z<B=V(L"Y&?&<B,_0^7S<K,5A2K\%B(,P0'
M8\417KF58]Y6M(1')G4N?$NI48:T:85=?/D1I.I5@0\T%R(,6*,:@TXM7OW8
M?'6CW9H?ZC7<^^*GXT)^_@7W@S )M\F*E+KY('A*=9N/IT--:55NI"Q>ZQ6B
M.OCCBK88I%T:''#O%CO;%F-AGF>')?RSL5.@@[<GV7W6#IU<S])E2CQ"GSI7
MTY!<Y'X<0HV:O9]O@"@4Q<H%Y/MKZDCDR/]'86__EY,N.:X;EV&6WM=5Z@-F
M5L0M12 I8)/FM$PR'D8_M3(V[D NQ;=>Y/5O0G1^302-)RA3.[8^FU0JR/7[
M=D,^!0E_"2"#<CQ'JFME%C85S"ZJK#00?,U5KD+]QTP9S-.R+74UAXJ$+&,T
M.&65V7(W52M]D<F&U$WGD-]XVXC $M@37(*1NG;40GM?+1@.H3%CJ8GN8B,M
MDF'D6O/9N_NI%2YTV'IJ:9DQ<+G71*XJ 9YT&V#.YQ0F74CO2N&/'[4J6AW7
M"+*W>O_5V_;6HP_RACT;03N;K$@TM&-JI6$F;<WEQ&855#CX=I%I=SEBM@+)
M7;+$>J!H\OY497JT 2>9F@;.1@GP1XFLLE:A-;:^;XCI]+B@@Q@7.U>F$B)\
M:H<G#JQOJ)^/--R=A/P!A$C'J)3-,JO.,8/R(\+[VN/B,   MX' *F<_ZSZ'
M5A86D)&$!@,8)&OI=+[(D \=OL:<F]YW-MEKNIZ)*-B+%68RRT2<[(610&/V
M-<$:E,#4 28NE+,G2FFVR>>7:.TYG:[2Z,Q='[!%?U,/Z3(<;>SC'.PJ\'49
M2,S714YV<"ZH)+HBKNY+OL>_"5+Q0,A9VV%Z+5ENOSDQ6G+YAABF?-'L=]C'
MIWRJ*F1?>F&--UDVF.6Z'54A5#I8G#L$2!7T&G5^Y[H9)FC$"?IFITQ/J]<J
M6$J)0(56M,),,+LNF./[!NU;B.+,&9.Q"VX?N.,8E1XU !@3$.:BW_G1YZ1=
MJ"895E>1G3^+66CL.Y ]6WSC[>JC4FQ<%9S+&]E\DL_-GOAPA-J9E\KHFJ!^
MD+/ J?1(MDO',EWAQ^D"A7J/BP::^RTXYEP7HQ%YL(&6OFRDH;+ !=IYPH7N
MHSO#^S">(@&63%#<M?;B_%0*L*P9+_W8A]:O]["!6=@6[P^O6GPCZU !&7D/
M^[JRLZX1CEL/Q@*IC,*^K(?U21 :%OWOR]^>S;)C$;4J^A0,;W7S9C&"V6D4
MZ+1.8D _ND$H(^4>Y4R *FBN\ND5:L)Y)JC2 S%6YK1_6&8>@==O!Q;8]5J6
MA\7]6BTFP0@_\ '&?^ZG2O :X!<<F2_QW'_V5M42LSR-1+7!LXI"] SWHPSE
M&#.?RJ/+DG @2.^#T&$ )F#,>0K^0PH^"VZ="599RBEX0X1M&;.HB*=',S*E
MI*=)-WY=>ZGDRQT^&EY_,:+$0G+2*.5UM?YFMO0P0FN/=2FYQ4PV )VDHGH)
MZ_@D@C3\ _!46Y^*CF8WK1GBYP'2;Y%HO+Q5>;L%Y4$L/AP/'A<MTD4ZYH:Z
M:=%<U:WW,+ZAY/H -DLE<1);\*7=D+EU2%W_"T> )<B@ENJ*\?>B4LOK*(,&
M.Z_U)HOEG*;H^,DX-+Y;B,A#(;A&X-\#BLK.X3\(;>C#1I;9=T+/%L7V\^":
MRY AKB\;FR^S7?_24?[B1U/5(KK&;PF=_347AYB^&ET  H6G+RS;N?)"5>=#
MPT'Z BGN?.*ZHX4J8UA[[_N?=X]*S7$O]S/RT>]?5DQ!!:#&Z.3\RRU#$(1R
M0RR-GQ\D-._A]B19-+?:^L":;'DGRNXZ"N;U+(K06 :)?C;O27B2E6>PF;$Q
MPOC._#GK\\0'S:E:4#VCP%'2^7S_ETLZQG)46C3_YY5,3XY$X_"E""XOVV>/
M*QW6)ODB1H2 #'0=*+S/:";PFC\OH^0)8-N$=B4/Z<I8=]2^UD./;F#8!*3_
M[KY]7K!0^.5=FEP%4\20SJ2Z8MDL)SJM"9'N%H*U],RFL;>,M[+N[)@DT0.0
M<7\P.RR/-/'*%/I0=I X=::J#=Y&0D[.#F2+!P,>E0BL=QU :_/%RT2IS>C)
M'D(";E^/-)DYOZ--2$BVZ-@4-;#76LSSAR SKPOD9ABKQU4*^'7Q U/7:$OW
M'HVHUU]\O HEP!Q*=)N$@%MBLA+43PU@V$2ZUJ'-_6OJ)V&QW_M"IHFY$B\H
MVD?W\3>^+PA:15@$S!@%Q4:WJ+P8!SKH@:J<ZW.[=QBJQ_.,'ZZH+%O,<1D6
M&]LJL$P^94SV,FK-YLS,I!$5RX&'L:#-Z+IW&;P897+JAWWT+&D5 6!59V42
M3C+=A6S"1=;>C5Y^[78I(U?&&M4GH^G#D&6>?!),,=<'0S;1/MT0E:?55E;9
M=EDS='O5<OKE=KX5#GG9W53!GOT![\C5C/29B%IBOZ?;',;VME^#;:&J62MU
MR=SY1#C>KGG1<LO W^C&R/ ()N8@3@ =&,W4V>21B27H%9DLALI7N&VZ,7)G
MOO(&G%7F''-[VO4\>PQ:8Z[^-'50EUE>=Z6-4SQ766_/38=[2T +2W[R98PH
M5L69T"$&.:_=CS'SX.F+?R>Y;;>V #EX]^7UK+OO+Z9JF/PQU(.PC2C*:O5$
M^H#;P!;JB HOY>4QOX<YW8>)2O59L;"@_I"#5I^K126N[R$F2C*P@@SG\BP-
ME"J>,*S*F+80EO.#H*3I)C]98MM2;?ST8/BJ6K!QGZ7,UIC*6.(+ZAG<C&+1
MC)N4T-<%YA>O<[Z5WP788A/0TXH&C>KDS5?,=  +L-9N B*XJ02KHHA-O(F)
M5*L .I54,PN"MH*:_0'L@/IMX<?!#QT(BS0CU?8*^F;=T 0E=S?F3P]#.0PA
M,0_+GJG+P*J6&WT]*[>GLEO%16%"4ZTN,*OL7*>Z3-,ID0T!TW%!&VW4!F=@
M7SYM(0.)>=G!P@V';P'?:LP<?L@ZT)0;#(Y.52#SLU.=_".' ARO*0\-K7V+
M$V/CIYS<[1]$=J)>-2Z\#0Y(]-O=<@IF5##LL\S:LC>1Q90;\CG:'UM1 /B?
M,VI0RF3*>.Z@)2E:/_]R.U1W'92!PC_F.)J.3QS==HIQP[+Z89HG?[Y@6PWC
MILPA,X+"/3&3FYN9LC_WL0O:>FZ>B*.V5IG.AI#R#8&>!+W,ICU&Z)#0%4Y9
MB"/+L7TGF" @R'_W 5E4[Q/E>(;)E=!@T=Z&_6P6'_?F/?FA8%.33@AXG5$6
M3!9JNW9';9%V;$15\H=!U'.(^88/1N2Z(1O/WUA#K38EL8)L1KT&E>BNL=D@
M.967WB)8R40[M6?D_QN;LA=T%"U=\DV@),$A[ DMK&W'8U$)4=62+#K#D3OR
MYK6JK6.6K[%0ZKJ(O')/L>#4G(A^%6\XV6]I-;7:E8/^\4 .":B7M2L.Q7<Y
M(;KX>K'>K,C0G[']\5FNX[>V]A,U;OWH-7'/E9'DE4"K<^2CNBD5F)C\S*-/
M;UV$$TKE>U^]-F%_&[G#FA)FO>&?5-)>LEW?")L1J]BOXYXUU2RS#[K.[=N&
MDYW>8YSN^SP,,5^L!Q<"@P5.=A:W$D,8*9QO?%.KW4LQM_E?NK2HS1)1C02^
MD9SF:EMT5O0^UN4CQZE<3=&U+ NB$? LI.\YRXCWC:SE.22,>ZVQ(O$U4J)B
M[=5K,Q%;5^.Q2^@^G1XU*4V_YJE.VC7[UG^2PJ_'9&/@1.RYND2%-<+>:+0Z
MU-INPU> D5F/8K\V*;I0C4Z65F]:M45%I$JA_Z(8.]- <8:Q7,RL:\+V+3TU
MK2&CL(BY/L;IBB1+JE339Y=R:7L6:G>16SD77%&:P 6KORU_I9YG(TLT4H2H
MS&-<?IT;*V_ETW+;O#^LM"6H_#+*-<=!,#ME.)];&#<A]NL!MBX/<#1J$/_-
M)#Q]VJGU85R09 >&56$(VHS)*8;Z7%4</&;='+/%*+8?2=\; WPES0)\EG%#
M%RQ]7\WPZ7>,3&/U"^XCH+'EO#PNZ5T Y?=W%[7.\,C^])D]N$+(9/4M7/6Q
M'4%%_,I4S\G@$4-C5HS131*6)X:4S\7OE&&L*LL)1.52CJC<]++AW#L<1:_+
M7U0(*C5CJ[X8N[B':POX<=8YL4X8BW9-VY=7T5R,G=WRL HNX:M)RF;R1)B,
MX_I($B WU[@ !>N19GDR\2]:)'YS^^V?G62:+=35^ICLR1.JXVU:G<7:M_K.
MVL1P">_K+_M\T!3KJI^;Z_MB'L8(2.2?[5NC\"*Y*H-NOF2++$,5473[Z*AY
MJ;BMF+<.'#DKE*0I<K$I@VD*[B4K<].F$-,)HZKQA: 7+<NMNT&96;EX'J[-
MV%:_& .. 4[]HB3;19^/I7!Y6U'=VWH.KXS1*/$1(V-^_\;4M">,9 Y+D\HJ
MRZ I52]#O*VQSS3&>*+\I.3&R$@99R2TA&BDCOGZ$@SF 5^3Z48*DF$X7Q)S
M6!U]!9@QY>1BW62G9[HH\#RSJ;;/9H/\4N-%Y:!D!!RRC'^[88A #W=#LM*>
M/$T1MN#A?.+/@ VTV@FVM*P(LMY-K%6X&#59QQO!X)@][$QN8(S#-9#QR#(E
M]5;Z: J)5".JL:&ZS:HSB$BW]VPZZ_/"M@]'0-0YJVAB#V1=B_4Q6<<'/6D*
MO_"G.O'O1(#IT]X;[O,_8+LSG\H6TN1@7I9;E8$PT5<LP,SEL]Q,4$23:V@S
MEI \O>K"M:+6G7CS31XE7#%9TAB>TW2\\*M>A6!^4)EU($1;]YBLB6;@>2]H
M8V=HXP[%<T][Y/<VU_- 6)6*^NORR6473"(TO %OF G1,@OB/&JN.O9)'^0,
M<1./L8R.'UGFSZ'87956FRC4XDI;:[@'W2(0Y4GE="MA:=;E?-H1N1*SI5!Z
MP^"-5/J/@,V<]PYC3HY9-HB7H*Q%@^&,^B=I6\ ZA<7*N0:5B/'IVX<UNLV^
M!7QX.ZFA3^#1]N,0XR.?LNK2IS>Z>EV!\1MIL=&QG*(1.Q$CR//[8(5G)5)R
MKYO4C4+@X-T 0T,DJ@S-/")ARAM9CB+7#NXMY(E-ZS+X(8-0ZAR+2%!X<PI)
M[#RK>W,_K\1.G*S9\[5V58"#OS*/+[G[H%$T)TOT(XYE7Q=3Y$*V8I'M,>(V
MRF,815UL71&QKU8U\OHZQJ0\!F,BQJZECTRAXG\;<V/LPV%.T!^ MOG9>0U*
MP:@2+)NU7<J98S>%XQPQ\.\QT%!>E::-4!>:$-/6=1&=M H6D0]7R=_?OSG2
MN)[Q9+TECG05.)C6I=]NT#4 &EEWI@=V)_4P)/+]9T<+RN>S7/<;Y;7ZRY>;
M4+KR5]#BKK7L.W[?)!2+^N'Q77?ROS#H*WAYV+O:5QJU*<B92<SL)B^K$:47
M3B7)IQ>S(]4M*]13Z)7ZE1_XL5-(@2OW)&JK+NRU9ML\\=-[<I[=1LT2V-]B
MR95Y5NE]#+=/RSQ'+YX<\CO"6_<LJU8B/'GVW/K*6S*'9.2QOSZ;\M!F,X)H
MTV-C1^*<31S"T],WFL_>'R8&9RTVUX@J>$$) ?9EEE[DXIVMS%,8"2I+R@ZQ
MNU06V\Q4ZVB^#]Z9)4K\>='A7@6G/#,= 2NCA.F&!M'4C"E,>JO%W)W^<$TJ
MT9.0KT#6$+<B"8AS16XVTK5@M1,_39X4F^H7J;EQQT:/SAE4.(KR%UE>8P?2
M QE6@_/V6H0C'M^W?R[(#^]D3T=,[YLL=?GBS0^7Q\ 4!IRR>K)R;.-"%KN?
M#ZZP'@@ELDP:?!!$)!CWF=J3>JA_,7SI9%F3)_\/H%'AU*"VH7^\O:95_%GB
M9+7Q[#N'D""DZ6#CIW0DM)R5AJ2[?Y4=$* >]R6^IT $Y5405PG/]IV1BBH]
M@K]$V%19OQ)7]A')UD2\ZHTUP=R8?JUV$CA(5=N(U;J<_674KN@SFWOA_NA&
MV8@5]N@ZH^,02WTK)HZP)V@+#./^YL[_4EHWODEFT2/YO$K%O\&[.N.3]5)6
MJ3%,.+'2M$U$D@/&]<& &D1*#5J]*:TOW";BPL@,R4_1Y]31C6"HYTJK/\OX
MTKBU([0?3,*B#J\RR<5]KPJX'A3=]5@ P&<3P_#>B*/LU]>"(PJQSLE%+:#>
M$8V"Z%&CNV6I$FU;QM733_S26K@I.E?JZT9Z)XR:ZK_#&*G&:.^:5_\!V"C6
MO)57_((Q]S6<?P$1K;MI-CP=\519\LW"I;$RV,RFVI.K^<6![<R+DD@/"_C,
M646B(Q1GR9B5?G+4G&=J8,*<MNQYGX[P6E= ^,94"F=26$< X1 1@D/:1A08
MV!T]4Q59NK#_95(4OO?"I!<':%%< SE\[29+ I("DOJ>/]BCJ$9R)C6BD43&
M3YU!I8:BP8FK1 9E9:E6U5?EPLK&N%6C<9G>>D$&]F'3D^?-4QUHT3PSW S2
MM4G5#.>A.]Q; SV\W25%K1P[:$R'>*$6ML%VN.HTM*#HRMCWVM@"M6"'OYTN
M3H4$FQ8O>@P-=7';7.T&A<-OB$(*^#[!@,+#@O/>Y97!U 9&>F9,771"=[^$
M:?V*=P.Q)''?]1ARD.L1<YL,95$@&K[UF'Y18'MHG&5R:!2KDY'G7Q$TA7.)
M_A*M ?(% 0I=;=3H='+K>O=2%Q6)G2P!BXJ8OIX&1DT6H9QBDV$0E^2(0.H;
MC2ZM9F:T7EB*OW'0"%049BAB;Y4V?;VI[=!3$"8U,XWTU&:R!*H2<,H*ERWC
M-WXZ\G-..\\M-DYW-LY6-(WE\1)E%E*67]D1NWW&.CO?E!I0^W,D@B3$2$,Y
M*;Y2YLC<]<@:A2[KE(\AA=[NL>!]'(ZAJF\<C'(.4@1X>4$!CAS+\"4Q&G/5
M]MK-C8R [?3Q#/&GS_TD+VIW@^?SO#(&1-&TQ&HMYTZ$NA-):T.XP1C_AV*?
MI( S3:H;94$ P":9"RT3_1-:JE'>_WD1I\&?LE.HK$4Z#/:T+[OW>.@^$S,[
MT&=(Q'78>"9C[M.BI]U4X2<9-3VP<LZYAA-;4M??)8_D9(G$N@TIQ6Q;?T$Q
ME.<P]"8)E5KWB:[G5!2Z LY5<SJG6+ D7+)'#+X>4>_1'M,8-_CEEM3'Z/0B
M)4G^.-O!_MTQ1\[2U?RCI-,^-VD*"GYI-C6($_KP%_;VX&9?%G8O^-C?2$DO
M>W\'OP_M]GX6+8H@\H+H\NF^7Q^79 C9>(&F2CBU0?;CL*V?&D*R/U0CO,Q1
M*&/YN=CIJ]ZZ-[D.V+N%HB[-3TC,)#;+'WRY&]:21UV2:32*Q96KM*$@N;,J
M+J_0=##/(\8R=A"UY6OU-3^,_S93>LI#=7"1]X3'7E;5TN5RH]">Y:WKPCKG
M0K;K">0JS(9ALB#?(BEWSD 9<8Q/S+6DZIZ58@U2TC@76EH]1[8Z[:N:AD?9
M'N_G^%$.H78-C)4JXT&\3?0-9$KYY.(8K@]@_R+>%_D=*"^MH_W%TU!,9^TN
M^9;T6GYD6[JRNF;PYZ?/&>G^ ,R+_0>O)25Q;A,/$751M83#XERC1)2!'1I0
MG8XP=@0;UQ2N1W/]0*I]" M)4=M73/$>P2[4!L[)UT.#AD;D8.4!:Y?[(?,A
M#F"<6&J&*7^H!&U^:#/@ZP!GO+[L1>3U0 VDU5,MJZXRR\S*-KG[F#:!3PZ9
M'3XB&N6@*<RFHG(,:&>P:GMNEVZ<-6LL"T.DF=8Y2";>6Y:S;%!.EY&3;G<4
M].*A%>0! -CNE-Z+NO:A@F(<'B[FCO U,[&T#1^X&H[K#GXOX2XZX*3_'0<(
M5!N2$;@6WX&G=5+72=)S!CC+Y,C^-_G;+, :3K<6'F2ZN9<'J<W9+5C/-"M+
M*',RJU)MW+'CD6:*'^6G9W@V.?=KKA2NX&\78M]<^>:=0#="UG"C63I@SV#]
M;70?QE^F"CG#M]+^&<%Z67O.NM&AF-V"_-P9*R%KCG,G.3GU>N#G6CJI1PWB
M"0?IK4TKA[Q7F^9"'W')S;UX5+UKR=RBDJGG*#O'\DZ%-"!='%0[V[Y0>UDG
MTZ[EW^<2$I\V')Z>#70F< ^&DD_=QR ?9<XA:L\C+#!RRJ!!ZDP<KP8E*:Z;
M+$6 D0H$N& 0^[Q7WW%'$Y7[+"\WI"EHQNZH=>N]ZB>3:;>;C$8OZ:/1C(4:
MX:>,O<(CSF&.]LTG WNM@#[E]^M4E,(A;*-\\;T>1.F:_=GT67R;VT%^O9<<
MM='6/D1T675(^09>NY/*HDM0@.%*<ZX37>+!45@6X,G2C4/3+0<0\;FO^"U<
MR#XW@&U>]LC(K#47K*BQI((N&!7Q;;T,C =NHQ?/FJ#XB@Y;N:#%F)4"GX B
M.%;-)M];4 -7_=9_R>J>D@PCWZ28V^ /9>0AUK0UJ,E:. ,^ECHV@H/4C13(
MD3]GKKXQ4D2EE%3X@UR )'U,,C/3;5)<S"'7U]QEBM>@5#K7TS8(K8TJ2QT2
M2-^165),HG6_&[9-P3<ZBM&-[E'9/[>;$)ZA/C.Z9PXMN?ZXQ96A_0 K(KJD
M<6C1#S@=R)V5<&DXDQW.:ZW>.^4U</3PP-_(9FTH7Q,QTI=]O,Q":J.PO3(#
M7V:"!"G9>%9VE-/BL+:9X1LB$C;9P'#O8"F?%,)&-#N0E,SI.MV41W+HS%5!
MA_O]V^IF!3Y8":"L#X=0B.W-44/%#5>4NNR@U8D!E2 I*7!2,QEK]\H'YW.H
M61+<Z+,8XW-_]4?_1(XU].>/5PG0'M=Y45'M=Y%TP8:_-<S7TKA^UJ6T-7<\
MFO_^!Y"8]\[@6F+%Z"NKW?*C;]YJL4GE1Y>5:E]'A74NL9' O3/BN<%L^ %U
M"/Z'8H_;MLCUW$_9::_@D9>DGAP=[DP#]<!G3E-WKG/\-'/G+6FT*EVQ<GMK
MAF""1@Y#3"0RF['&HX*2_+&!PH;'P[+^'2,3/8+3//Q/D@0)91F!\6^UZ/_O
M+PK_KX[827J.@"TZ\W][L<G<0;OFW<S6]CPP"C7.X>@C <N-LP/C'GUXTL4F
MDZ-%_[]"D-:0%J&0HZ*]EM3O^&_JH#/[OY\'<'N,\J@8=TZ4?%(\U(IU**N%
M8L;K;'(R<O1..#5W=D]BY\<4B '>W<C/$^7H#+');B_S,[>M0I..NX0^=#[N
M@Y =R!@L4LRZX7*B9I8>WSU?R/]B7CMGQ<"*BI\?Q)^6P%FZ3O:!^((PX+ZX
M\CK8%AU,;?A]R%D8_BC81W[1%=$G"&0?(BWT3V%+.+LV#TA5IM5S^HGFZ^.E
M$OFW_O._!NF?^?\ 4$L#!!0    ( )V"B%@V+V]OHWD  ,Y\   3    :F%N
M+3(P,C,Q,C,P7V<Y+FIP9Y2[=51<P=,V.%BPX!(DN'L@6+ @P0:"#.XA6)#!
M)<@ (;@SN-O@;H-#".X$'P8)'MPMV.:WY_UV/]GWC^W;?W2?/EU=MV_54]7/
MZ?N\^/P;0 A44%8 H*"@ #[]>P#/2( <  T5]3_U7T'_5S&P,##0T3%P,#%?
M8+W$>?D2%P<7%P^?F! /GP@?%Y>0G)"(A)2,C.PEP2L*<E(*8E(RTO\(04'[
M-P<= QL# YL4#Q>/]/]W>?X!(,)"D4")14-A!* 2H: 1H3SW 6@!*(!_JOU'
MW_]1,+%07J!B8*.CX?P;-R0$H/S3&_6?YMAX:"_P,  H_]H C!>81,18#"3\
M,MBDC)ID N;DE$RBLB[)TS.O*)C?@G3U/#R_)=4WLGQ.$!*6TW)U9V43>><6
M#,TO@#7TS+(KZ 35_9--_9]5_Y>E_PE'QWB!AOEO4)0(@(KRGW6QT#$P_L<@
M&A$#.C\&L8RFN<NW%R2, @GY=:>DLJ ><N;/0;\PF5CEUI^7 "_1_KT2$1H1
MX#W@2BVI"%#$(<T!U, !):'^OYT-)>!'UVI<ZJ0GGV@BLOM*/-+^D\3#!8A&
M_]&"/D&U8"G444DNN@TJ&Y^G_AEK<38SSA)>63[;/S'N$N4)'WJ=GHZQU3'Z
M?2<9%A^P:1K@'@ 3E2J](IL+6TEALAIYJ=K*'EO12+Y%+IN5.D9?29Q]6P+I
MN*;CW!.DUMJXC$JZBOC2)+"U3(WN+[DT:8F?BQ>VMI.+P2F>!"MM3-RME9&<
M3#>H21>1Y.9"8>NV6^ 62XRR;/UX3]UDEF?,-\^XV(HL["*]%*AKD_@0N[<V
MW?$P$]MQ862J4YSH"I'K:4!:V[[+A$R2#S*D6&]6Q >@YNTR;10Q!]?D)AR*
MB'/"(>S=IOS593Z3;?ID7^1W&'E.Y$V>]-I^R/:R64GM;N5Y)R)'Q[SG5%R-
M+S'CD1-U0WX'$U4L!]0:3!YDQ?KR2"T7/+VF[?7;&Y*8)3+*"M5@D:$75@1!
MTICNQR*'^.O,L.P"3 .#V.R]$I#FVST-R]T,)XDZ!X\6F=!M(7:7YII>FN2V
M:[TEJ,C=[!^KV<Z\2%=:#[FKD@J\#],.?!].D=4RL9L981D];T_2K8Y9IWCP
MF#&XK%_\J/%P!L0TJR-;'@1[:Y#)-2_G9ZU$C&CS)F9&?;W$/15CA2UZ.P7V
M?B_IQDR&UN['A[@<+=^=+:].<Q?LVQC&1=MF)XM$5]]CTC6572H0'Q.\R.2M
MS,%:_IL=VWM8?8?XR$\SN*POIZ1LF%+] Z65M:-LO_BFAE)$F2+6K/15I?5%
MG)6>_<<^([#GE7R"S1FI22SQ+B,M$%K-B4,-.ZK3<S,ML$1[!KRH+MDF.SGG
M+/SIT D2>\#4.I/4'$R&]+E2>RK:J$1::8'KB2_,;?\.,WL38HE#"IJ&($!;
MRWN,KCMJJ=KW-BW&_1G,LVHRMG<P1Z9\TVH'F<WKA=35R</CJ^GM9JRA<^Q5
MUL3]G]M(VOBNH4:3PHY-[BH;_YX^9D=?1^QG0,7)H/1%JSZ;<IOS)ODHS\P>
MGN4-FY8/7$A0,%EX]<"F;ZW7W4=4/$Y.=\'SE-]QL+:L5?YF^^=-2N<93U@R
M71\MO0,TODO\I"]>X<GHN_&VJC6I'DQJP] <]NJUB\VGI$!EMD. 7I:DQ, <
M^],4&)+ Q%*O9+V8\KJK<'FNHZ7KN$G.46KSU(JZ>1(2%*YYTG75YNY=2757
M\]>)3K,^<X!W'G^6.DOQ*,;P&1!BG /F=?YZO1&,09H'HPL7]J)[]>6Z-=VE
M+D:CKT%5.;I@, ')F[9YP"/D$</Q0F#V]>F([ W2/P!_36JND3DF+J"^PWK6
MH4%D5BI-[%.G$>W V=!,_<UF,QAN2$3,Y44ZKF]^@@$[/0VD+J/W [(8$?OJ
M&S\#*B&R:F5K[D=4^=_V.L9H%R@KJO8?T?H_/AT60TM O99Q&(%5 \\  _$X
MR1^40A9D63F1YVAUDONOVST2\^>Y&I%6@SK\^EY8ZKP2X2?&\<F-&Z0@&+O3
M8A 6TP[7]I\+LY5]=3EN1-8B-[+ZP.-6#^LL@COB94UD$H(Y!^>UM@ASK)&C
MYVJ%7N.@PAMNWY<_^(0K>7L=VU<\7BR/W9V!JX0?&L7HM"(\;)6X<.C)4'TS
M^M<7*UAZ^OY^GW$X>-UE27'M9-EAX/#ES-%M?4PENE>=N%J-':+9SRF>*VWO
MT"\P*@7^]!U2:URX<GB122"?3?1C4YVI92N9@']QEJO:QSS<-E75\.< 0Q3B
MS--J,W$9TBY!OLDRAW6,7B8#<)1>1M,^41/Z;G2)681',DM^W-+^U[_D$R*K
MWS_6(&G+QMA0BP$4V8Q/D_05A@YS^;M&6-%>1R+Y80L#Y46I0J='8B)?:72[
M&G^G?*][RD)XGZVZB6M+SN7VDD4I[DLX5%K.%AV#W4]NLNNWGD&.QUGFZ!]?
MFKDL'R$XOL6-VES0+B7W[9F)H4K' WT]$/0;KY1F&,7(Z4 #+HFSK"M"ZSOW
M<41 ,F#F(U:7:7T'\F/5G>IH(6><6\L)SH)UT._7/5QH@QZ<6\2)W3P=L[ZZ
M,=.[N@A_BVI$2M;*A0IKL6'^YL"-T_"1L Y2V(.%OGF]HB'\MAF7^CO2BF:(
M-)O7=$)N5SH/8C^N*EY67>*ZFFRR('KC)R590Z,=,MS8;:OI<ST#PO+XV9B=
MAHW.P*'0=VNGJ>?,:>U4/I8];CU%G7-85V18876:0#F4UXV_KZ$;G!KFFDS&
M0.\-L3A?!&V<TXGA7QFVJ<U'MYNZF1AW Q/I;L3@9LD6 P:.%'*QM]2W)QQK
M0C!H3)=1Q;:NCI3V"]O_/7+][YV6=UV]3MEN12A GD?2@Q=X96VIR;:K+3U]
M^N/'HVW T X#$M*U@759[Y;=#+E(ZD"1.]V3$@B.Q=>NF'URZH0UMNV;%>F=
M8Y4D95FC1(XK1Q!\9BU(HUXW"5J]=>P[EU?TH;(2)Z&HDW6_FLFSE\'L*HCY
M4)P4P2W3L/DGC'=GB1@-//JU3$99">!)G?/8<RQEO)L7YE;6*=O*]/;-TAP_
M>GT*?8[GG )(-\<F=QU41.^8,%C'Y-,B6-'*K95)H$ 5QB4Q_;J&=W94LF=<
M#)J/\^O+(#I[5&PC^KNMG?7M,[5]9/B&%)W )[#10.U316>^:/1K_$W.([L(
MFB:;]? 3H5>WZ"$<Q3F<2EOUL'Q,E^:YQ8?.]S490ET2\FW%^K;)HM7V($(4
MPRX;I[?7&3S'1N;Q?*#.-V/SJE$X8V=^,94JDGVT'I[WP:6,#GH9[@X'!/5*
M6XE_9(Y:CY;!"QL0KJU7T02:#F(5V5S\IK8TFC2?%U (&0R7-FN)C&Z3A[BL
M' OA>S3-RYG,7$+$];7LILJ'#W,.N\H.5"Z)]DG>:?/\C *'AX.##T*B2#9+
M;."9EQFZ'SO@4&)8]V<-RP3QKJ%5'S (=ZRJ^H,CR3"S$_SQX:&BMLAD+HTS
MAV&JJ/J5@MT4=\;YRA4L0NVMCS6#91V#4\L%'T-]$:%&4<P@7[@KK4+AH2*B
MZCW%+V,^-%T(E5S+M6MTO]:,'0CT%Q3,MO)3PBSXX;V9V^ZV'CQ)WXM)CXNL
MN<BXA&*_Y.T<UPM[?"F1] ';S.U(G<:VOZ.JY)EX$J2H"NN<:^"'0?\^L.3;
MRXVG;^[;!"JY7<T^/N)N1B+"!2F@&II!<H)0[0+1"^2!UU()4!O.K9>5Y+AY
M>-#!5%PE/%.AZTLNI1BTMA 0XN.S6$ASE:K[6S;]#)O:5=U?<3]GY=[AE7^,
M!]5"Z:OH$YS9=IY"YA%P0L$V=JM%D+:!%I4BFK  ;NXWS6-9;(WE[&%:/>)D
MV9]U!5^Z<I<%!]7!HD<+S)FIQ@5YZ7IE1_G-5J*%K7JD,8$T@9ANM=10W_G$
M.2^U>K'X 7YQ"=\#7;J\<R6O\XLZE:<WGT1QI3'88A^>X+O@CG*7(EK9GN+]
M^9<[17O^1A&,AN!C,QY7\'!2\8/TL$<34[K:)J35";[I\TU@-9)U:X5U7>Q-
M5EWXB45<C[=>LC0(^@QH;VE*6/^:69(JV56'M&MJ+,#%T)IUA J<K#0SSX[S
M3/"D%0URA(X9;7?=6WP<$:_XXN(H9T8,? V4IJ;I$<\U*2N7I#!MXBI>=E)U
MI(I@W/6!KVRN;&\MZ#/TCQI9_=1<SU?>R(UF$4\F)%E.U*U/PH#L3Q8K9RM\
M;H'YFLK.2_H-\+U<S1,7)DS'VZ56?DW[*6&8;7=OV<&K2A%W3T^POPF^6X%P
MS)<>=H2Z>%6Z5DTY^&_TLM.1R$I-5$028SI7#3-G_UC$-3<&>CW,1>E;U)ZW
M%SZE-[$9_!6.BUUJDJ<8P(9.ID3UY^@D"# W)@TA/K]=AFJDHA(#M<5IAL39
M(Q,E"_9GCL3WFBFFC52'HVW@(4:6YIY_^)==S8UX0T&_#:4!21?+)]V,V6')
M/E@I/U_\0+FK.'-=HT'P#!GA<<I]"A;3P/G5G3,XIN.-BVXPG1(7\W)*0AS?
MF0#&\%.E&>,N><P]E8[Y[Q,1D/HAL,RUI4C"ZQEP9%Q^?/RA\A\&%OPWT*B-
M.[_:;?K7;LHHQ2,.^=OXF-]:/C9M@7[=2MEC*H2D1UGWM_<_03&.*^+['QY-
M?[UF$VH=B,.'7,_VW6SV;:\+-Y6X)ITS']T-"Z)' $&!@T6?N)HL[ZBFA-B,
M:[.9?- ,/.[:WR;^G*/D?7.00Z^V'/<C&0S?G-S55W,I;BT^C(F1RNBJ+B@L
M^9ZU.L(!?R >[G:]*.&L]LXU_FOVI?^X@?N=H-'*2BAI2\H5/TL^0\]6K'QG
M8O=$097X=;R(_^BGGA%N0I=1IH[.C9UTW@Y#!'-<()-;ZZ*>F)^ZLIH=?D'[
MA1G)HBT$ZS)*KZ2LK 26$2W29GOD)X_H9A[]2;9:CR>SUJTE/XP\WGGS#)C=
M]I]H!RLME"ZN!H_-=@"QQ@I/8]O]!,4L?/<\@91 V:3L:64S\& :X.[$*.F*
MU*[[>BOWNV+FW&DU0UYD2G7P7DGP]BNZ\@]-G=9Y'0WEN";=I+VNN%PN=/ M
M_]M$QA,6%R(4E\V6S7 _%EP0>3*\."6[&?CM8JE=Q4EK4>N\H<>M)8I90O9\
M!6K<6F:HL3D*QI%1[[U3 65B4T,UNZ&)70/[?[9)7CR6$H#W<4?$*@?./!/?
M#:9EVB:+3>(S;KP:BV=+/O/843&"QQ,6,7N!@M0_>6+Z)%:U:+\>%H5%AW+I
M35^X1%MAG,E-L"4ZE$U($.Z']@D78= ,]+84M'X\KB7(MC/,SF%2K]/CE8F#
MY%P<2C?W[!!:J4#Z&D>-_J(VH2IA6A8I3C=)*BY@.K]$8@Z0Q*FW=L>;,"&+
M3(B#9BED9MMDS@C.8HE_(1J/I8\+<I#?N+__VXVLBM*HI)?'!^:#A_"H<C )
MQ3=&P8,+Y^-7E+C@9F,[-!QJL>(,[R9:>VE0\@\OZGDW_+QC0B$?3]S/:HRI
M>0WH'3L?X\M7+TZ&>4D;:&#UZ\[!#)S'"ML_,"<*&,2FNRB;E>9+59+%Y-XL
M*BRO0'X$L[D"5A0_B<>_[] S@-JT/#'8MRW7B(2GW.HV,K@9>T]) !KJ40.7
MCPNDE9 >Q #T.8[:>0QYK;;POF+S=Y +FG;%3N5!QC KZ0<F7L'SZ1J45! L
M1+BH%*6..M +.>KWF6H/9]M_B'MA:[!^HMEL:9"1@8]CSIB9DX18FUI)[1E
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M<O?@6<:7HZJI,04S'*WS:X74'<L? C=H'=G%";"[;+G0SN$/Y2T&K#:?^TC
M?UU/\*=XM:B;9=_2J9B>L?B>6G5.]C6YZ [33 R4*\H:2/%G6K7B#=+L8XK-
ML<@%4_CTI^9_9 EN:2PCC@^!D5SAR(:!4V0NR!P%C 5ZTT2</EY/XISR-%"W
MR)+HJW2=L'3>2JPQG+9D3XS0#.SN*M:1'UXT4P+=SV>OXEX?G!#7&69 ;@S@
MS=;-'"U%@Z1-#+5EZ$4,0'%Z3UII LY+-RH#-SHXCQ[Z2E)I%8FS-(J /]&M
M!N8GLJMVSQ-3!PO]6)/*>9?T3R:T7^[3LH<7QC#Y[&+3HX T1E9J,)>- ECV
M#'RSY=Y^VL$\K& 3#F>6^[S&T!+#,)00$&DN R#_];2O;GZ-HI<G#OP-<WVX
MFDCBT/PU5=5G4FB0-1MF,GW;^FW<<" F'_53DHE63Z+@NU9+T8*:C3LP,L#P
MK]6E"*.N"Y??64\Q]((HNSN\?#[H_-BX0S;.=[?E4^O9Z7KWULF!;KN= WLM
M#L:1^B^'%[TSPGII1K7(UZ^K=59)XE;3 I=8VDJ8"8B [O@?*MRZ_:\L?%X_
M:/[7>9WDWE!AA?+_*VB@B,X+5TX'/BPKL>MNQB-;:OC;/KG=M/JJ-A&H&6^2
MCZ8)7M0:;=?[R3QP9(?>0]0IZ;UOR/80U'')WC%'"LW 7X^>TWB.<.':HRZC
M+]#B3+6^VC_ZF#O:")#O7P#7MH3@T[G37FIE"2C58R':[;)U;P3_]P+GK8.>
MTD+%!_%H-K2I'8&(EZ(224O3I(G/ %2NXYJRO/^O6TL=\P=<SP QQ8]K-U_,
M#HKTBJB/3.VO_DW)9BH^N6_DNYHN)0 2_PO&@#B>^X<*P?_,KB2!7V+Z_"[R
MGJ)CV3@A'[9/=<EF(#*7MU67N ^SS,=&3Z:K!=BE[V&4Z^FVG;S5.G'@_K2(
M7#TR#[J]-?5@<Z[/9:I#] =T:+QG7G":\W3QG#N\GLNG,'H&_&05#:LY7Q(O
M%F?:^%U3BY>2?W#*-E]YG/LII5.TC^?K=OHWVA4G<VYX=GME7&43G0[[<8&_
M=:O DVLWVU;8A$D.KMLESONSB5>W83%JQ<)Q#AP2[[R OGQ[[?L.'^'":YUN
M6( 3 _5DZ[;!W8W_>1\PR2!RILH>F)(O!_?97J;"6AWE$K<H-_543*YIWY3Q
M!RND4D,_Q+1ZJ:@#B''4WTOM=((U$:R-8ZEZ;P[%G@'6=2OG%,[5J1%<8?AO
MX[R,2FW5.3B9&GP9<,1KPB4#CZ7Y';4/(XMFCO/?5F8[&[^E%D9),?=D=;]<
M(N^ #E0$1)ZS"<**F(D3Z_%_.'4-B^.%F$SGD>S"KTIZYCID=W.;0CYT#:1"
MV\$F",(T V>*,F?!DG<E[G@I>:(GHUWWX-::09W+I[M<@\^*@Q?M QBN$?3*
M'P[D5,4W#J$2(IG>.+A.7??X;,[B#P=>2OV.WGHEKFU^+?JLP-D8H[EV?R?&
M3:'1^DKEM#%*]5?+4J<CU-%YA(UGNB,(HY,6LH,N6L9HW?%COO>,A,&3@9=5
M#WK4IX-D?,X$C,)LSOCW<S;C;C&V>ZO3O.FZ]D4&IE*FI[^X6+32^IJ5T8/#
MB$VL@$=7LIACV2'J/NKE<#SC7OHM<MRBZIV9*ICRQW)?-Z/H9P"A[K!+0QT'
M&_C1[]%VRD/$$)3TGV#VOU-E_X_G_;=,&1L5*.F%)&>E+U"PPTX/>,<7.JTG
M/*;I9J4XQH(>]OY66VVU':>);,:JY<&O@KK-P K&R?.3*\$8'0UAR[%F<7?S
MM'^G'95$I; :6S^SSP R8LO%RQVJEAJGT7Z<:0/V@>Z?A 9I<6M5,?R2H#TH
M54]&]<7E,PNIJR,/4+54^_G:+W/C_8W)?'NB#F)=PQXA*3D;DMHPGGKUX7S3
M7-@QYDA]<&L!S+RTX/*J1/Y)=^''-A#4(-3_OZ5A:%NMR,T5>J4(#EIN&Z26
M6J'K.P;I$+Q!_]\)2]U9U86-%VS3O 7UW+P??^Z*K5NUI,VWJ@VYJ+?2 '<I
M\C] WS%\.9>R7+CT5]@HU^UPUR/0\?DQ#='F3W>=LP;W0FR- UYN!?R4T:,;
MN9T%5=T<!L=T_,$.*SKB#%!H9,/KVQGQ!T^3DE:OLZJ4NS@"W4[C:(',A^0%
M\2*'Q)A%P*;@DO"E!FF+^;HA+[*<QP/UV7!*<"^U=[3 +NHO"&]>,^<N)8@2
MB'+;(WW22O/MLG0E^48J*?_ COT=BW^-U>8RN.^0DW5?S_CS%],LU8Z*J.8(
MZG[X!\G1FH3%HX>D1XMKO$YY>2J=] ,%+=<AZY4&55W)L%==DN"V,!XNV1QP
M$&Z%[+=;%+5[DBU%GSG!B36^BB-(8JF(=>I]SF<GBNLO<6R6(^XTTP4$U?>B
M-<^  @B>*Z<]#=!.4 N40O;D-'2S1*=H^^?J[:P+9T(R#C;0KVJ[VS,'-/8$
M/$QL$YFZ^XK/P\4W?->=985S,SS1Y>62,@N$_GHOH"X$@1$,DUD,)OL[E("?
M ?<+!R:<@A:R&24T"5NBJ415_1X>0LF/>Y)M+/4JK=R\ZT!0U^";_X4JW<AO
M4RJ77Q".L>6\J&1C;+-]^0B<E8C]W<(/)H\HIILV+QWEO$E.=L$" ]B)ZB.
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M.7\W=&Z9_S:%:W:'>#^2[Q=TQD3D>TV?0A]5%&+)J459CL&T[L&#N]^&&?>
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M34_Z]QK@KZW[.(ZD2[3&&31>-L?-085B<S,OGA@,R$PYEZ<(8M0G!(A<3RO
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M=QNX;?N^8"OC&].A%:*WP8B+0DA;T5;CFX;3$R:-[_FHV-H;>6O@D?;"")(
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M%O'QE:7A$T6MDP,EVO&A]1VDL[/W1PT]I6>O2.>#:IL'R+K*N@+BR6&XP(^
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M/F'G*_[_&27[/]W<S_TO4$L#!!0    ( )V"B%BALJL4T'(! +Y<#@ 4
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MB$<@A>T*-P#4;*G[A<ENS6O:8$#\!O28=?1O0,.!O_5O+JTG16! <%&-8 [
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ML$T88CI+,R_/ R&P/O *]+L$?%@6MATO"YOKI>14YA'+0^6*2*7]0D0@$9Q
MH:RH+!4R2%.RJK<U67^7+V7/F/E^K&\!FW^"5V,6'UH6<,<8O/$HFH$T-^#
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M1,>>]G[;*P C:[9;DVG-!?R\.[,-8O$W8K<3#-D;]J%\=?0B!BQJ/=\SV72
M;]A4&\']U?W;OAC7)VZ^"G>]\+1LD:]/&$\*@KT^W%$/ZT&GG]2]M]^*:A6(
M-)5!',$<1PRB/(@@(7$&DR@CN<QCD8C 2I\.GSYWZ$_3 IJ8I38[0L!0*[G*
M9:E=]B*!/S0EGPWISDG@:YT?/7O9]7I.K)-U=_8B^T. CZ)4Z_5794I]$65=
M:$>\[(IYFWS"KG]BE& NP@##.%0K"S&!=/_I%!(6Q3F-8IPS:1JT-R,Y=S9,
MPP3X%0S8 'L^VM8\YB%40Q3'@^'^L;',EC& Q6'"J2$^YB%A_SBYA7 G?8VL
MXJMV$E^)AQH^:+'XI9U@PWBCY9WVRO$T@_K3UVWW70T"+&.,*4P#*2!*1:#;
MD(20!B@408X8,RM]&:$SLQK\US#\,0Q O07_&B8_!H'YDKZ&S;B>\R2QG7([
M5\<!%%T'A79->G,MY@D%-]6U1Z.9? ::NA=0?]W^Z$=?&<AV14E=NWLQS60@
MPE =F5QN/]'Y-9/E[8X7"NG;NA95^Y9_69.[54YQ%.LN;S3,)$1"<DB2%$%)
MD/)_<HQC892Y>)W,S!KH]<M?/H".,AB0!IJV^<#G*S!=UT;^A+=31FYR6\V#
M'A?+:3+TE<<N-B-Z7+3AM&B#J^V-@P]BK4_ WI.R?APT=M3C]';KIBKAKA3-
M,>7 0-%YT.T_*UVFI37%"@N&TI"'$,<AA8BG":29<K"02 *>\#AGD=%L'Y],
MS1W_W0=SO^@CW$.NTWYPW'%+61WFW57\$ 2V2'SR]I[&K9KG0-].ZW0<@H;%
M87O9=L)GRR78LWESY-=H3OO?:%Y;.^H9WH2YA?4<;\3-'%ORS5@9<KXAO&+U
M>2.UF(GH&YRA/>G]V:[36\^R4>ESU?6VVI6#1BX(\3AD40[31,?>22@A)E&J
M.[KE),Q)PKC5T&@+VC/O6,/E:=T<QP9"L^#]3,!XVDPJ<. #_#%+EQL' +Q-
M@#6GO/ \6&M(3J?#VC]B]N$S??><MUMENM]N^)NM8NR0Q/%6U"N>QC@(,@19
M$" ]7"N'1$8QI CE4:HL:$&-:@IFX6YFS:3>$V\[36V;65"'E+KJ!FR$93Z=
MW_=BILR>#6T[=>?4Z[#A]@8T_#8OJ>'X*)?N[95W-.<,&W,LEY]G8\#;]SK;
MQAS6"7-N+(A,;:*H\S>V&SU&YYW<]WWO>CJ_$!LAB_I).S^>![D41, \(4H;
M9PA#+&4*)4\%S1*:Q':COR?P,O<I\J#Y7T=?_S@<4N#:1M$>=C-ENQ"8EL?.
M QP/;!U#V;=^!S]TS/UUH3:*SCAY[Z)HS\DS-5%TANQR#T7W1SHDQ>C3XX,7
M'74'>P1'::Z[E%.1<J77> ;S..$PD%&2BCP-B-EHK\LDYE973?K&($P46:1P
MG,=D/"@Z75)+77(BI$O"RGEI+1)4)DOMF)#B(+U='LI5P:[EG9R_<;D\DZN,
M'^657+_27I_\_;?LY;9\V+:V6_==$@)3)D,$,XXD1 G+( FS&.(P9P&F2 :Q
M<1W\.0(SZQ)%$@QHFB^MLV",JY&I(MHID;^#W\"1? XZY*R@YAIDJL!N^N/)
M:_6L/*[)=$5UG+UM,<5QC>FAVKAZW50OK)GSK<M@ZZ?-TU$6H2@1!(H0*:N$
M*&6"\PQ!GM.0!IF0C!OUU[2@N:!7];-0+G%1M[&3=MAYRY&K7W492%O_R0L\
M[G[2$(R%/*%1B;U[/)<I/I-G,PK!90]F_%8W)=$6V(CRXU;67TDI7BN=O[G3
MAX$-L3Z#7X9A*$4 XRS+]; E DF<29CA#.$(QT&2&F696%&=6U%TM.UT@1E>
ML9 Q%RR%A.8!1#Q*(<4$0YQQ%D=)Q%@N[>:H>D?,::9JSP6H9@3/3)5Z!\1.
MF>Z1Z.GKD'[/0:M8/9H_3D)[TJ=F-!?5J%8P/-6I=C?;^VMM?.G-MJK: L8F
M^MXT2^_;E[P0<EN*]^7V2Z%=Q"X -8A,B6J%=; [2"G,LH1"I"=DT"2GD"4T
MXI%R]=*<FXZW\\*1E3:V'VZGN0.T80,\]'QH2Z5H8[AU.[/7<@:>GW<Q[E\N
MCK"=LNKBX#]H!O_:5V3W/ Y:1(&62[!G<Q N?^=R,N'O'9B[OHN_"S=?><EW
M8N5F>\7OBE_NA\YBCKQ76(:>O]\'._>Q*FKQIOBB^^(?;8>5SL1 1 H6A0@B
M9;E"1(0>TI0RR(*$YYFR_F42FFQ&9N1FWFF:+41M*WMCC32$'=)=1E!+0XX$
MX3D,>""UTZ2<@"A',,1!&H=<QI',[)P ?[@Y6?\M<D_-7,M@R@AH9L:_/R#L
M-M*6+FP(GP+A.1O'3$A_?::N$5NZ4Y2!X&=Z/9G<Y:8@E?)5ZKA^U+.1=!O!
M5_^Y*Q[TIO]F/\&"9%F*4BD@CVG4:DJ,N(""!BDG+$IQE-K$2,9)SAP@Z1D
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M]/VX_594*^6:,:9V:IA&*(&(9QFD:IVK;1IG.$*$A:%P&<?\A,[,:WT_8WA
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MT[(L<Z)%-5O6S;_*,[D[+-7KR\J:+VM7MO=W];U]#?QGW:+<ON-WDJ$5:L,
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M$SHO:N2UWSL$?7-@Z0P9A.Z!HZ\_B($.S WTD3_&F/#M;UN\25#G!$T]$VK
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M59E$Q/7G,H(),IPK0G&19Z0$)1^')$Z2=6RZ<6,F'0>!],PVQH0G),WX L@
MLXHQ$;HDG7@)4O DHJ_50]G#P?M,FS;T->LH7^A]83#KJ=1:U0(^K+9Z\Y$_
MNBJ.F:P*)1C-D3#8$: YCJ3<_H>6E<Q3+EB:<EC.[YRHT=-W.\'-5WAI1;O)
M.DXTF.3T-%9^.9D8]@,CJ">&US*3CP.6AS"9]IH5C[[TM)BI.4M[C3U!5-K_
M>7@X\^'!Q4.WYLN:UQ7W_''3=**]6O&UNKZ_7Z]^\,6,2IHSK2EBJ<X0*<H"
M448XRH2D19::G*7>6Q@_D2,'-(T2+M>W;=1(E-7##75>K5T=M+07;A/>*N/_
M[O;$<SBLB8\2;+6W -V:I-4@<2HDC0Y)K41R/18\_K%-?)C"@ILH<('B&YCE
M/0&.YXTFBW!@AG5#'."5X=[2M?KRQ<)]36:BHIAH@U&N%+9;O10C4=FMGBI+
M67 A>)IZCQD\<?_)_.#\(!.P5SF%B+]S"[0SR)-9$SOB+K,0[I\"+;W(&7E:
M'.1U3MCCX6*Z5TWN3TZH?,IYG/H8S%-LUMO9'_/E_/O#]UU=.3.FS(A C"F%
M",\Q8GF1(IQ127BJA,)>X=/1G4?V#JTLO\5R;+84QLT,2I'=W4E$<F$!$*1
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MKXEC*3"5>V1D0-_%&6O]^RPNMSJLKR+$>E!#1;]A/0T49RZ<K&&B7_%N@\3
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M3VX=\'TMT7\505 ;=APC80%S*GLE$J=%LE<C:32X:O],K"H!Y/H0P/Q=TDC
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MV-]QZ>K$']NOF=VTL,I([=J/V.V+.PD1)2TAT30GN,0JPU[G'T%2QTY+6#U
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M65+O(Y<^02/[B*;9W=>6X5AV)?L'H;U #0?=J<P/F_V-Y0>QX/4(QOL'XJE
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MBYG!0F.$,TBDH^Z0CCY'./J<HF)*9/:OF <=]GJ)'7FW\.MJN?VR> 3?=O+
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M[\WMVT_7=^\__@U<O[Y[__?W=^_??OZO8&:[4%C]PJ)QP0ISR(ZKSBD#=MH
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MWZ[;D+(FR&J_:T558H0+&\AA12$F#$&JJ@IRA;G=#>$JS[TH//U%CNQ]&B7
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M P/]VO2#R /'?X_IX5'[@%VI O%S8J:-K0>,?18N#WT^LJ>I_*+5PT+?&,<
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M$8Y^MP]3%F]7F^WF+7N:;]G"GL0V+4^/>YT>.I(=G#(LTJ+DS*@-AG( 2T@
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MD[-6_[8AZ![#.<.A/Y@U1#J_3=T(=J>3A^&"N8>AA@@8%G#R$-0KK'1-DHX
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M_ 7RU*N/R#F)D372T71&WU;?9W"XJ99A0OIIC>/ID[VAYX!&W]=DB=;G^XS
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MT<J3^RE.7);L#,%Y.;+[K?YN2=51:3?YZT[OCC)?9@C;0P'CAI2BR  T[W'
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M_4)589JE;!>+W:_MW*/MR[UY>%OS-WL\^V05W0RCC!)9(J!YE@.HC4?!=<:
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M.S/>'DP1*P!$MA<A1]+X@=!XA$5A!\I+EF>>W2V.UA__8*VBECP9<MZ':D=
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M(2X+>BW@<.7JL'VY-TAM#M7FP_*?W^;B6SWBKT["L(U/4L%R3&U'#TT E(@
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M7+%DM521S!8'V3HT3M?=D^D=!Q':VL?E<G\=]$79*5Y?=C&,E#,"10Z$A Q
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M-,6YTB[J]2J%L5-*&E+)5TO,,69Q'8YN519%2#^%Y"J?LRKIE:%+(9B;6\K
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MZ_NJ?N.S$@NVV<SU7-3S%^5_/F^JB5:_JHU8SZM9BS,.)<>L+ $U?@: G$#
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M<X:K0G0<-)S?,]E)PU5VVT<-UR_R5P$/JRU;'.7C;V89P8*D& *191+8KJN
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MZK2I#,X7X@.SBM%I+7<6]AUCE$["5?/:\ [L4Q-A#P TE[E+T\\WT<?UPJ
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MJ-ST,&^UOR.?4B:6$7BIPPT3DQ"DD9 S$R5*SA*V=M0.)+'?@YTA(+.)\@:
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MFQ=2[Z)GD+OQ4R#M),4, &0?\.LZH7IQF>=W>5([TL8H814'[=?-5!2YM3F
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M$MO4PEHSHRRR4BXB1"[K7)UD(>B40&076/%92M>ZD]O3<MAO3=83+[<!@V<
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M+W!CY/U=H^S)N=269U!B-9F0\;KY9XA*<"-",2RU/C5]E*B]L.5^,FRU5<4
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MREQ$XD/(&6]^YHS31@YCKE4#W760\.[XN]]55=P<5?CRR\T_V>P7'[*B_U&
MG8*D.,MGH-RN@%/><<:8#KIU.^UPZ0;ARYSTX75@DW4&QMV>S-P*S([D3I%6
M(",)3]H!JUAB4MC(=&ORX>^EF#>;/I2]'X#5!.5W!I_K8B$?#7/"@M!U+#0O
M"5RLMP5%A&"=XYFU9BW[7HI^X#/%K@_ 9(*2.X#)F&$M4:+R16I 5P>+2:\H
M)*#3W&;F TI;9#X>L>*T(4SV21QZAS):WWB\ES!<6A-LL74^(B,UBCHTC04.
MPDIC50Q%Z]8O8$]V&-,HJ.PYC&F,W>:^HKR76YY3QBR4K?5/=9BX+)0P.QO
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ME)/)91)F[O^Z8=>Q[+2!TT#3'1QEOZ]6^3^+\_,SFV*Q+".@JB^QY!C!%1]
M<I6,,JIXU?KAZ/J[A\'E]*[O)^EV9H?R6UBL-TGK#N7;(/\LR6)+R &291I4
MSAJ"4;551*I$H5N..(3#Y/Y/'V;_T[E7;Z3'WB<E!XT^HC"0M:@**1&B"HFB
MK*B#YX&<G1B B2:3DOGI7($WUVT'I\B@6;PII8@R^%KF@Y41P4 (AK OH_+,
M*9F&D:XUJ9L:.229G]YU=W.;=("S7W9?^S[\\V81XN)\0SMU1E+FA!HA*VM
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M><:ML5I!5(R. Y,MI8XQ@\T*N1<\B[N)U?Z#U@ZWG'EK!H\)]EXPT<'VN'L
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M)=@@(6M7>9Z*2:PUM>"C0LWN6=M!8#B\)MBC X#]A1_J7KY_.^[H03SSI*]
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M$'2JO2(F\&*"Y8-ZRZ9^_[R5':< UNGF.AU(UMK9.YE M#[:P#4PH6R='E;
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M)NGB4>R!%;U(Z>K3U682P2V>E6"E94)E$(K."&6<@ZA"@, ,0RRTZ'A$V/U
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M=2%-#)F?,?'K>[HOW0];Q[)!L[+3H\#L#J>V,,HJ36N42(&$2K:2RU!,*K7
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MQ'AT0">IA2QS$#K%%,0XDVT:$#_=X["F<#JA'*R=;CL ]<](*Z?YU:T+?KW
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M ]0:F^?384=NX$VITUTA1HRLSK6*#LG6"RO !RU!AX(I,ZU%'/*HYX5E)L\
MOBHW\%0]]> &KI8),6^+B']?;O Z$373T:=DDP197 $EDX.@LR6WPI:LC=5*
MM^ZL_!0M?;AX)RO[X:G;0O)=5,I^Q*\[#^)]^8@7]1#_$,A7_1GC9F8HT"_.
M!4B*MIA"J2 P)T 8KJ421DO1NG'L<_3TX<&UQE(S#?3CO-UEZ=[V8$R%I+R
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MMSCM;D\V?W;UOWNR$>).W)._+.X.8!YC'M.N5GH=%GE;/_CV<E6!<75/?/Q
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M;8.H-G+O $#WA4,;8;[,\_3ABKD/JSGY@U_#Q0QU[6I#.X)< 7(. O'G)8_
MF0M1!2F0MV[A,8RRGJ+X,8Q5$XV\'IRE:+)WR=>$)G%50H%0DV79*H.H&?<X
MKH,^#&>'\W^W0<?,!.MMJLWI1*PW@8%TER79B."*XL+;;%MWC;B[_K0]<,;8
M,T=+MX.=\6&U3(AY_2M):CNT:Y'P_;V&+C,?6+Y*]#*LN\+0Z9(LR2<[&R3S
MY"2W#C]>IFH0BNQK0E%C3?3]]('L'*[?\">GR)WP\F'H1S=\^' 4-XW>/?SR
MK\OYYOM-W7M6*4<ZIX!9) 0F"EVC+1**<-G&S+/2K=\[W*>@X<"H1Y-\E0O<
M\J AE=K67BH)WM2>&T+ZJ.EP#J:U'_@,.=/F0D[0^S/SG$X2>0?'V4^7:S+&
MZ_6;1.)9;U\@735J\:(X;7P=-QG),)--=J@T>,LHY@XV6<D:(^<)4KJ9RW2:
MJI?MY=XI?.JW*[PI['8EF4SR\=Q0@"WK$W<6'>B(FB?,Q.$Y@'2/J&DAU43U
M ^!TO!XFOB+\!RX_K<*_WBW2[CI+A9Q#B*F^@_6@O%3@I&)0B ..Q:GX,)VQ
M]V+PX>?V!X,35+9L)+\.C,KM_.,;J_OG8OZO2_P9UVDU_WJS8W3D5DEK@)AS
MH&*LPP62!!NPD'!,*;EUH#64MFY&(#4]M4;13(^(NU,'[AR%HM88,!1MUE$\
MQ$KBGC8/8LQ,1,RM)P8^0\ZT-FL<_;\$LB.5,?$IM@MRGXQQKQ\ A& 4"[5(
M,&50CA4(63.0,:#V&I,10_K^#5NM,_0<J]CEJ%+N S=/)T>NJTNE0R^9(1,N
MZ5"/6.?I: Y)< )'"L22' Z<EY:;]CP;$3E-Y=S#459/^IV4;O.LRA3A0FU#
M5,?3*><L1)4SD!^ !ETF:]TZR[67D&FOED=SBTZ6>0? N8Y'WBZ_Q/EBJQ/:
M&NMYWLU1I9!BL;ZB["J5=EV8L:[)=ZP3U+=9^*TP2RK2J )UK"HH&Q&"E@R,
M%%9&;3ACK>>N-21_XE/R=# ]D1PXMV8[ O6=('LOB^]7UQS^?EFM?BT3(6WM
M?CL+T9*99Q%$#L2UB@*<U@50J*19(:\VM;[G;D/YQ,?V:% ^HSXG=@</V+P_
MX0++/,W#Q:V_]"N&>OGV7^'B$F<R6$&[54%)/-'F50JB91F<#PK)"4[9J $N
M8T.2IO4'VN%S2DV]'H#>&7CT[FK4<:Y7]3,4)AK+'02E:H\&'B'Z*"'$%$)P
M5JI!H<SIE$Q;GC89'%OHI:/#_CB.9SP7C=674=L7%0XU[3EM09*XM416L'G9
MSFD43_LH95(_]53]=8#6^\F&.UF(VR/A8V5[%@.362@+R5E+S D+KJ0,MOAD
M63$V^=83N8;2-FUI8GL$CJ*3#K#V9([KKE?\Y]?M?MOQ.1,V1QMB &.#!$62
M R<4J^-95$ N?+'C7*X=1.:T98WM$3BVIKH!XYUD[EW6>'5]=:H=5H(057K&
MUWQN@:)B5%H'KIL/OWF>HD$0<Z\-8DWD/W'H\00GORY7!><;<@E*1!4SA5$J
M* '*2 [!1OJCB=FCL,:;(2_*7UIG$$)\_PAI+M,.K,T^*_K^<K.N<U?GB\\S
MP92(/A>0EHFKASG;=@P8/5,RY"Q*ZWE]+Y T+/W,^H?3&"IX!57Z?SQYAK>>
M67#*<JVK^5MPW:C"?[OJ7\L+VBCKJ^SP[\O-;:?[$@37+M>G>$AP2X%\=\48
ML&0#6D3MVG<T>I:B,5\ <.O1E<J=XC50D0*\-PZXQAHFTW]T<V9[?0'0$!>'
MO @X1 4=')C;-_;;3MUW#H*K5KJ8. 8L$$6HLZ^DHS,@!! AI\1C*MZUKH1[
MDIA^7P4<I.Z',&HB^PY =)?^ZSJ=I)FN$T54(3="<4&GO)(:@L&8N3$H2^N:
M@,=43&V FJCWF>J3(V3=1;G;T][#K@K+9T'_RPX\\NVD1 DQ9H3,?/$Z:A'=
MD"< PU;KIP#D&'T^JG%K*MP>>A%OMTPR117..(4@K(YV%1E\TK1EDE*LRD3G
M0;.<FC:AGJ2B_Y@3YWA9]@" Z]),ACY@Q-JAM4[*BP$\A0_@&1<E45B9ACUO
M?5W-J ]2UA/-J ^17%\]B;W,P:@((14B7#F$F&7M_\2,9U(&GU(#E1_>DWCT
M9M0'J>SIGL0'R*\'/W+H@Y,<4XZ1/":GD$Y(FV4](8FOZ(WGRJ,-K?MG-7T*
M-DG-\RFARBB:Z1%Q=YX:,,9E[=0$)J*I+W091..(%1.23T5GIO[W*=A)^C_@
M*=@ARI@ZQKFM)JB\\)TMUDEZEJH=5X*#$DY<>?5))K+QK@@3'WBP^V.:O9_>
M&3J.5=RRJ13[PH&X[M:<DXS:%S#UP8FB?0$A. ]:N41Q&9/>'8$#T?O#K48X
M.$:*?>% [CC(6MO(=0%&X7Z]>4=P#B6XD LS B6*(;?5^S]]XDKK\7%PC!0[
M\#>>Z@:RG7GI:R_X4.<Q8[T43;4 -Q9K&%HMFO<</J4!SVA%T6/YKRWDWBE\
M[G<1\8+ID@UQH)RDN#$DB'6BG7,R<*+(DQ-V!B"]@@8\!ZG^X 8\A^AAZO-I
M.5]\^@M7X2M>;N9I_=MO;W?&%2-3&'D 5-6X"C+8/A,G6:AD14X*[:!N!4\M
MT!\P3E#BLK5$)\[$[9WLS65D(I;MVSD'ROL,#EF].Z@I*J5\'G:M]T)";M_:
MT[Y_&",C?[*$IT[.#Y[W[;'(DLC5D]84\M8#.7TR>W"2#*UGT6;79([D4(*F
MR_&>KO/EV J8^#CZ>57-Y\Y>UKYGRB02BDBR3GQ0$+DGNHWVT@J.20P)EN]^
MYH3Y_7'4M6P@NPY\VX]XL1WW446Q??L54E7*^J?O=W^SW2^F."%"+."4R.2Z
MU0YW&#44'E,6R1K)6S]6&4[=M*^DQ@J@1M).9[C;;;\@HX@F6I#;?F:,"X@.
M+2#7@7FE,\^MNY@^IF):YW@L?3\#JR.$WQE\K@VO]Q*#,V"*YR00J^J\&0W9
MUBM=+[,N8YJG'F*K4_7Z#$R.$'(',-G_SD+(F+C+ 4JATUEIPZ\"3%4=/U/H
MG$^M9XT<WZAKM'>5HUU:GRSS#H!SP#-Y/@N:Z\0*L:4X<92\(9<Q1PB2EQB0
M>Y/&:K\]A+Y^*BV/A,/Q+0P.TTU'N#NQ]Q(3)@9/?@%SU>I;,OA.*P-:Q)2D
M%T6K,S2$_T%Z:;7 ZAGUV=M[X:O)I7?*HRE$%LEXS6DGDF.BG(X4'=-W)&.=
MK):. NT!Z8675^JQ\]4Q:!I!KKVAA(SY%UPDO!TX-_.<.6$4R0=KRP5%KFNP
MM3VLDX*AE2ZJEUYO#ERJQY94S7!RHF1[ \H5"[\N+RZ6?\\7G]]>+-?U?;-/
M+@1/)E%%F^B+<Q!<(>:*C-RKE'(XRJ;L7Z['KE#- -- PA.#YG9X\?ORC]5R
MO?Z(WW!QB3.%.17E+3!#F%>927"69["Z!)>URAF'7*T^]?D]MFHZ%A9-9#BY
M\?CR9;G8WQ'ASH#K@MOF"@)BD)E$Y#V$4H'.G4P%M7 /$]M/V(XAJ_783.EX
MT]%<OAW$8(,;E#FK0TYD!_4VP+12@Q>6@S:VH'/:^=@ZC]2T:=R9^RF=$D>-
MHI,.L/8)OWQ=KL+J^U54N*]OBW6BQ BF/DA5BB4(TI.+'X3"H *+K#7&7J*I
MQTY,IV"KJ0ZF]GSN[9/_6FZ(_H_SSW]MUM=Y!?H9KG]9;.:;"\R?EK^$]->6
MX^WM-V:C *V/H.K3M6#JT[6D/#.H4L0AE_['4]!E3Z:CW:?S*.)5MVKZX_++
M%]IVR_+27US>;L;Q.CF=0LWY&CTUD]EY^D 9HRVBH//7>E7[_6RGE5FPC%O-
MC#0RMYZ),UT?J)"81&<").D"U,T*3LL"6FB=-&KCRW_,).B&N#BD#]0A*NC
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M2L.I&W:#PO[SX'JR*E]?A4=]Q/,3EN4*S_"89=AB(]=D','Q&8HMT"G/<F;
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M]^3%,8>]8WS:?+ ZP_>KUZOE/W'U&^). <]J);3E/I"=60L@B7'DZZ!G242
MK%+*8<@8WX8D33PV>A3432FUOL%Z53'[&5=?9R+PHFN#$:EKTUKIR!"-Q3-
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M\L__^H_=!_6/"&O\K__X?U!+ P04    " "=@HA8,9 ] -D'  !P)P  %@
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MCTFHS0+^](M*#C[Q)5G[,WW4=LP?T_T/4$L#!!0    ( )V"B%CJ;SH0HP4
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M;[_,?H?)=&E'NK[_2=O@ST(;EI35)R9B=#;L#O,OOZO[[_7W5$ DA:"185+
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M<V]R>6YO+FAT;5!+ 0(4 Q0    ( )V"B%BW=E!D<%D  +T] @ >
M      "  ;E(  !E>#$P,3 W7V-O;G-U;'1I;F=A9W)E96UE;BYH=&U02P$"
M% ,4    " "=@HA8N6%K@(,"   ["   '@              @ %EH@  97@R
M,S%?8V]N<V5N=&]F:'5D9V5N<V-P87 N:'1M4$L! A0#%     @ G8*(6';M
M@,/% @  L@@  !4              ( !)*4  &5X,C,R7V-O;G-E;G1O9F9D
M+FAT;5!+ 0(4 Q0    ( )V"B%C(F-(JW.H" $!]'  0              "
M 1RH  !J86XM,C R,S$R,S N:'1M4$L! A0#%     @ G8*(6!G26/VQ'@
M>X ! !               ( !)I,# &IA;BTR,#(S,3(S,"YX<V102P$"% ,4
M    " "=@HA8)2I.^YXV   Z/ ( %               @ $%L@, :F%N+3(P
M,C,Q,C,P7V-A;"YX;6Q02P$"% ,4    " "=@HA8-;)<-4S7  "Z] D %
M            @ '5Z , :F%N+3(P,C,Q,C,P7V1E9BYX;6Q02P$"% ,4
M" "=@HA8GP*M]DLC  !1)   $P              @ %3P 0 :F%N+3(P,C,Q
M,C,P7V<Q+FIP9U!+ 0(4 Q0    ( )V"B%A5?1NHQ)L  **E   4
M      "  <_C! !J86XM,C R,S$R,S!?9S$P+FIP9U!+ 0(4 Q0    ( )V"
MB%B:*R<;MVD   9L   4              "  <5_!0!J86XM,C R,S$R,S!?
M9S$Q+FIP9U!+ 0(4 Q0    ( )V"B%@UNE5YK2    (B   4
M  "  :[I!0!J86XM,C R,S$R,S!?9S$R+FIP9U!+ 0(4 Q0    ( )V"B%CW
M*TE&KH8  -P& 0 4              "  8T*!@!J86XM,C R,S$R,S!?9S$S
M+FIP9U!+ 0(4 Q0    ( )V"B%@(]%C^_S,  .\V   4              "
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M,C R,S$R,S!?9S4N:G!G4$L! A0#%     @ G8*(6+UQED_U?@  @8$  !,
M             ( !K$@( &IA;BTR,#(S,3(S,%]G-BYJ<&=02P$"% ,4
M" "=@HA8#/6P,@AJ  "$;   $P              @ '2QP@ :F%N+3(P,C,Q
M,C,P7V<W+FIP9U!+ 0(4 Q0    ( )V"B%A[SH)OSFL  )1Q   3
M      "  0LR"0!J86XM,C R,S$R,S!?9S@N:G!G4$L! A0#%     @ G8*(
M6#8O;V^C>0  SGP  !,              ( !"IX) &IA;BTR,#(S,3(S,%]G
M.2YJ<&=02P$"% ,4    " "=@HA8H;*K%-!R 0"^7 X %
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:+FAT;5!+!08     '0 = )H'   MOPP    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>jan-20231230_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jan="http://www.live-ventures.com/20231230"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jan-20231230.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2023-07-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">jan:StiMergerSubIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jan:DisposalGroupConsiderationPaymentPeriodAxis">jan:RelevantMonth3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:GulfCoastBankAndTrustCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:GulfCoastBankAndTrustCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jan:BuildingsAndImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-13</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:GulfCoastBankAndTrustCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">jan:KlcFinancialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-28</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-28</startDate>
            <endDate>2019-08-28</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ArcaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ArcaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SpyrTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-07-02</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2022-04-03</startDate>
            <endDate>2022-07-02</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:VM7CorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:SoinIntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:PatentsAndDomainsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jan:PatentsAndDomainsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:CommonShareEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AFCOCreditCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jan:AFCOCreditCorporationFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">jan:FinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-18</startDate>
            <endDate>2017-08-18</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-18</startDate>
            <endDate>2017-08-18</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-18</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">jan:StockConversion3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:DrSoinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:ArticlesOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:ArticlesOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jan:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jan:PreFundedWarrantsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jan:PreFundedWarrantsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-03</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-04</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jan:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <startDate>2021-01-03</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jan:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jan:JanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jan:ARCAAndSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:RecyclingSegmentAndTechnologySegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:IsaacCapitalGroupLLCICGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-05</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:LiveVenturesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:ARCARecyclingPurchasingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-25</startDate>
            <endDate>2017-01-25</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:SkyBridgeAmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AMTIMCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.SullivanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.SullivanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:GeoTraqIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-19</startDate>
            <endDate>2022-10-19</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:AlixpartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:TrusteesMain270LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:TrusteesMain270LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:ApplianceSmartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:WestervilleSquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:WestervilleSquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-04</startDate>
            <endDate>2023-06-04</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jan:ApplianceSmartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
        </entity>
        <period>
            <instant>2017-12-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">jan:ContinuingOperationsAndDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jan:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jan:SeriesSConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jan:SoinTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IcgNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jan:UniversalLifeInsurancePolicyPolicyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000862861</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jan:Mr.JonIsaacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jan:UniversalLifeInsurancePolicyPolicyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">jan:IsaacConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>jan:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="patent">
        <measure>jan:patent</measure>
    </unit>
    <unit id="state">
        <measure>jan:state</measure>
    </unit>
    <unit id="vote">
        <measure>jan:vote</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="officer">
        <measure>jan:officer</measure>
    </unit>
    <unit id="quarterly">
        <measure>jan:Quarterly</measure>
    </unit>
    <unit id="traches">
        <measure>jan:traches</measure>
    </unit>
    <unit id="landlord">
        <measure>jan:landlord</measure>
    </unit>
    <unit id="agreements">
        <measure>jan:agreements</measure>
    </unit>
    <unit id="insurance_policy">
        <measure>jan:insurance_policy</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0000862861</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockConvertibleConversionRatio contextRef="c-144" decimals="5" id="f-681" unitRef="number">0.00001</us-gaap:PreferredStockConvertibleConversionRatio>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">000-19621</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">JANONE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">41-1454591</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">325 E. Warm Springs Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Las Vegas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">89119</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">702</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">997-5968</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">JAN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">2981872</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">8593636</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c-1" id="f-35">6849</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-36">Hudgens CPA, PLLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Houston, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">5000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">61000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">266000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">106000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">75000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">394000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">8612000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">346000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">9173000</us-gaap:AssetsCurrent>
    <jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">17842000</jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet>
    <jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">19293000</jan:FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">4000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">4000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">0</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">8974000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">286000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">315000</us-gaap:MarketableSecuritiesNoncurrent>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">9000</jan:DepositsAndOtherAssetsNoncurrent>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">18000</jan:DepositsAndOtherAssetsNoncurrent>
    <jan:OtherAssetsFromDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">0</jan:OtherAssetsFromDiscontinuedOperations>
    <jan:OtherAssetsFromDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">8979000</jan:OtherAssetsFromDiscontinuedOperations>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">18487000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">46756000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">2272000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">2276000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">3633000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">1006000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">274000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">20382000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">5905000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">23938000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">639000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">195000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLongTermNotesPayable contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">707000</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLongTermNotesPayable contextRef="c-7" decimals="-3" id="f-75" unitRef="usd">0</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">34000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">46000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">5760000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">7285000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">29939000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-82" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-83" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-84"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-85"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-9" decimals="INF" id="f-86" unitRef="shares">200000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-8" decimals="INF" id="f-87" unitRef="shares">200000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-88" unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-9" decimals="INF" id="f-89" unitRef="shares">100000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-8" decimals="INF" id="f-90" unitRef="shares">100000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-91" unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-92" unitRef="usd">14510000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-93" unitRef="usd">14510000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-11" decimals="INF" id="f-96" unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-10" decimals="INF" id="f-97" unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-10" decimals="INF" id="f-98" unitRef="shares">193730</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-99" unitRef="shares">193730</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-100"
      unitRef="shares">222588</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-101"
      unitRef="shares">222588</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-10" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-11" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-104"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-105"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-108" unitRef="shares">4957647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-109" unitRef="shares">4957647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">2827410</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">2827410</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">47323000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">45748000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">-50634000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">-42822000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-621000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">-3308000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">2307000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">18487000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">46756000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-12" decimals="-3" id="f-127" unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-12" decimals="-3" id="f-129" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">4746000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">3149000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">15100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">19846000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-135" unitRef="usd">3149000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-19846000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">-3149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">2250000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-12" decimals="-3" id="f-139" unitRef="usd">468000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-12" decimals="-3" id="f-141" unitRef="usd">1950000</us-gaap:GainLossRelatedToLitigationSettlement>
    <jan:GainsOnReversalOfContingencyLoss contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">0</jan:GainsOnReversalOfContingencyLoss>
    <jan:GainsOnReversalOfContingencyLoss contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">637000</jan:GainsOnReversalOfContingencyLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-926000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">-631000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">998000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-147" unitRef="usd">2124000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">2322000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">4548000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-17524000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">1399000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-429000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-153" unitRef="usd">-6621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-17095000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-12" decimals="-3" id="f-155" unitRef="usd">8020000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">10254000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-12" decimals="-3" id="f-157" unitRef="usd">5081000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">971000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation contextRef="c-12" decimals="-3" id="f-159" unitRef="usd">2109000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">9283000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">2972000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-7812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-163" unitRef="usd">10992000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-4.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-4.27</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">2.55</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">2.55</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">2.32</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">0.94</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">2.09</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">0.94</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-176" unitRef="shares">4005334</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-177" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-178" unitRef="shares">4444361</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-179" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">-7812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-181" unitRef="usd">10992000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-183" unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-3" id="f-185" unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-7812000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-187" unitRef="usd">10988000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-188"
      unitRef="shares">238729</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-189" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-190"
      unitRef="shares">2827410</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-192" unitRef="usd">45743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-193" unitRef="usd">-53804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-194" unitRef="usd">-617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-195" unitRef="usd">-8676000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-19" decimals="-3" id="f-196" unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-20" decimals="-3" id="f-197" unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-12" decimals="-3" id="f-198" unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="-3" id="f-199" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-3" id="f-200" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-22"
      decimals="INF"
      id="f-201"
      unitRef="shares">-16141</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-23"
      decimals="INF"
      id="f-202"
      unitRef="shares">322820</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProfitLoss contextRef="c-19" decimals="-3" id="f-203" unitRef="usd">10992000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-204" unitRef="usd">10992000</us-gaap:ProfitLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-205"
      unitRef="shares">222588</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-206" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-207"
      unitRef="shares">3150230</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-208" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-209" unitRef="usd">45748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-210" unitRef="usd">-42822000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-211" unitRef="usd">-621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">2307000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-29" decimals="-3" id="f-213" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-30" decimals="-3" id="f-214" unitRef="usd">621000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">621000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-31"
      decimals="INF"
      id="f-216"
      unitRef="shares">779000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-217" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-218" unitRef="usd">792000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">793000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-32" decimals="-3" id="f-220" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-33"
      decimals="INF"
      id="f-222"
      unitRef="shares">-27353</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-31"
      decimals="INF"
      id="f-223"
      unitRef="shares">547069</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">510000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">510000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="c-33"
      decimals="INF"
      id="f-226"
      unitRef="shares">1505</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <jan:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-31"
      decimals="INF"
      id="f-227"
      unitRef="shares">481348</jan:StockIssuedDuringPeriodSharesWarrantsExercised>
    <jan:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-32" decimals="-3" id="f-228" unitRef="usd">259000</jan:StockIssuedDuringPeriodValueWarrantsExercised>
    <jan:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">259000</jan:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-230" unitRef="usd">-7812000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">-7812000</us-gaap:ProfitLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-34"
      decimals="INF"
      id="f-232"
      unitRef="shares">193730</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-233" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-35"
      decimals="INF"
      id="f-234"
      unitRef="shares">4957647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-235" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-236" unitRef="usd">47323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-237" unitRef="usd">-50634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-238" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-239" unitRef="usd">-3308000</us-gaap:StockholdersEquity>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">-17095000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-12" decimals="-3" id="f-241" unitRef="usd">8020000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">1452000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-243" unitRef="usd">2000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">1223000</us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable>
    <us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable contextRef="c-12" decimals="-3" id="f-245" unitRef="usd">387000</us-gaap:FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">14000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-247" unitRef="usd">5000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">617000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-3" id="f-249" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-12" decimals="-3" id="f-251" unitRef="usd">637000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">5320000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-12" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <jan:GainLossOnWriteOffOfNotesReceivable contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">-9780000</jan:GainLossOnWriteOffOfNotesReceivable>
    <jan:GainLossOnWriteOffOfNotesReceivable contextRef="c-12" decimals="-3" id="f-255" unitRef="usd">0</jan:GainLossOnWriteOffOfNotesReceivable>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">-926000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-257" unitRef="usd">-631000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">-444000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-12" decimals="-3" id="f-259" unitRef="usd">4588000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">367000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-261" unitRef="usd">5184000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">-320000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-263" unitRef="usd">-70000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-12" decimals="-3" id="f-265" unitRef="usd">-1328000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-1052000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-3" id="f-267" unitRef="usd">184000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">2319000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-269" unitRef="usd">-2501000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">1463000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-271" unitRef="usd">-3057000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">-155000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-273" unitRef="usd">-1509000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">-155000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-275" unitRef="usd">-1509000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">792000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">259000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-12" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">274000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-12" decimals="-3" id="f-281" unitRef="usd">14000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-2212000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-283" unitRef="usd">3993000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">-1435000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-285" unitRef="usd">3979000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">17000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-287" unitRef="usd">-4000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-110000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-289" unitRef="usd">-591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-290" unitRef="usd">115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-18" decimals="-3" id="f-291" unitRef="usd">705000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-293" unitRef="usd">53000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-294" unitRef="usd">5000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-295" unitRef="usd">61000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <jan:NoncashRecognitionOfNewLeases contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">0</jan:NoncashRecognitionOfNewLeases>
    <jan:NoncashRecognitionOfNewLeases contextRef="c-12" decimals="-3" id="f-297" unitRef="usd">4000000</jan:NoncashRecognitionOfNewLeases>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">133000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-299" unitRef="usd">407000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-12" decimals="-3" id="f-301" unitRef="usd">108000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-302">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 1: Background and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of JanOne Inc., a Nevada corporation, and its subsidiaries (collectively, the &#x201c;Company&#x201d; or &#x201c;JanOne&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had three operating segments &#x2013; Biotechnology, Recycling, and Technology. In connection with the sale of GeoTraq, Inc. (&#x201c;GeoTraq&#x201d;) (see Note 5) and the sale of the Recycling segment consisting of the following Recycling Subsidiaries: (a) ARCA Recycling, Inc., a California corporation, (b) ARCA Canada, a corporation organized under the laws of Ontario, Canada, and (c) Customer Connexx LLC, a Nevada limited liability company (see Note 4), the accounts for the Recycling and Technology segments have been consolidated and presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Biotechnology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During September 2019, JanOne, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#x201c;STLLC&#x201d;), and its product, a patent-pending, novel formulation of low-dose naltrexone, (&#x201c;JAN123&#x201d;). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recycling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Recycling Subsidiaries constituted the Company&#x2019;s Recycling segment and provided turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx provided call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement (the &#x201c;Recycling Purchase Agreement&#x201d; with VM7 Corporation (&#x201c;VM7&#x201d;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The Company&#x2019;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. In connection with the disposition of the Recycling Subsidiaries, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GeoTraq Inc. (&#x201c;GeoTraq&#x201d;) was the Company&#x2019;s Technology segment. On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5&#160;million, payable in cash and shares of SPYR&#x2019;s common stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6&#160;million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in SPYR&#x2019;s restricted common stock. The Promissory Note matures on May 23, 2027. The accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports on a 52- or 53-week fiscal year. The Company's 2023 fiscal year (&#x201c;2023&#x201d;) ended on December&#160;30, 2023, and our fiscal year (&#x201c;2022&#x201d;) ended on December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company&#x2019;s ability to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $17.1 million for the year ended December&#160;30, 2023, and net income from continuing operations of approximately $8.0 million for the fiscal year ended December&#160;31, 2022. Additionally, as of December&#160;30, 2023, the Company has total current assets of approximately $346,000 and total current liabilities of approximately $5.9 million resulting in a net negative working capital of approximately $5.2 million. Cash used in continuing operations was approximately $855,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to raise funds to support future development of JAN 123 either through capital raises or structured arrangements. However, the success of such funding cannot be assured.&lt;/span&gt;&lt;/div&gt;The ability of the Company to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123, as well as to fund its day-to-day operations. Such approval is contingent on several factors and no assurance can be provided that approval will be obtained. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. While the Company will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured or FDA approvals will be obtained.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-303"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <jan:PotentialMarketExclusivityPeriod contextRef="c-1" id="f-304">P7Y</jan:PotentialMarketExclusivityPeriod>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-39" decimals="-5" id="f-305" unitRef="usd">13500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-306"
      unitRef="shares">30000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-39"
      decimals="2"
      id="f-307"
      unitRef="usdPerShare">0.03</us-gaap:SaleOfStockPricePerShare>
    <jan:NotesReceivableTerm contextRef="c-40" id="f-308">P5Y</jan:NotesReceivableTerm>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c-39" decimals="-5" id="f-309" unitRef="usd">12600000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate contextRef="c-40" decimals="2" id="f-310" unitRef="number">0.08</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-5" id="f-311" unitRef="usd">-17100000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-12" decimals="-5" id="f-312" unitRef="usd">8000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-313" unitRef="usd">346000</us-gaap:AssetsCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-314" unitRef="usd">5900000</us-gaap:LiabilitiesCurrent>
    <jan:CurrentAssetsCurrentLiabilitiesNet contextRef="c-4" decimals="-5" id="f-315" unitRef="usd">-5200000</jan:CurrentAssetsCurrentLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-855000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-317">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 2: Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Statement Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The prior year amounts have also been modified in these financial statements to properly present amounts under continuing and discontinued operations. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates made in connection with the accompanying consolidated financial statements include the fair values in connection with the GeoTraq promissory note, analysis of other intangibles and long-lived assets for impairment, valuation allowance against deferred tax assets, lease terminations, and estimated useful lives for intangible assets and property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments consist primarily of cash equivalents, trade and other receivables, notes receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company&#x2019;s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at December&#160;30, 2023 and December&#160;31, 2022 approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with a maturity of three months or less at the time of purchase. Fair value of cash equivalents approximates carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and Other Receivables and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries unsecured trade receivables at the original invoice amount less an estimate made for doubtful accounts based on a monthly review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions. The Company writes off trade receivables when it deems them to be uncollectible. The Company records recoveries of trade receivables previously written off when we receive them. The Company considers a trade receivable to be past due if any portion of the receivable balance is outstanding for more than ninety days. The Company does not charge interest on past due receivables. The Company had no allowance for doubtful accounts for the years ended December&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the Company's trade and other receivables as of December&#160;30, 2023 and December&#160;31, 2022 (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for intangible assets in accordance with ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under ASC 350, intangible assets subject to amortization, shall be reviewed for impairment in accordance with the Impairment or Disposal of Long-Lived Assets in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 360, long-lived assets are tested for recoverability whenever events or changes in circumstances (&#x2018;triggering event&#x2019;) indicate that the carrying amount may not be recoverable. In making this determination, triggering events that were considered included:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant decrease in the market price of a long-lived asset (asset group);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); and,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a triggering event has occurred, for purposes of recognition and measurement of an impairment loss, a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If after identifying a triggering event it is determined that the asset group&#x2019;s carrying value may not be recoverable, a recoverability test is performed by forecasting the expected cash flows to be derived from the asset group for the remaining useful life of the asset group&#x2019;s primary asset compared to its carrying value. The recoverability test relies upon the undiscounted cash flows (excluding interest and taxes) which are derived from the Company&#x2019;s specific use of those assets (not how a market participant would use those assets); and, are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based upon the existing service potential of the current assets (excluding any improvements that would materially enhance the assets). If the expected undiscounted cash flows exceed the carrying value, the assets are considered recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consist of trade names, licenses for the use of internet domain names, Universal Resource Locators, or URL&#x2019;s, computer software, patent USPTO reference No. 10,182,402, and designs and related manufacturing procedures. In connection with the Soin merger (see Note 3), intangible assets consist of three patents pending, orphan drug status for Naltrexone, as granted by the FDA, and the formula for Naltrexone. Upon acquisition, critical estimates are made in valuing acquired intangible assets, which include but are not limited to: future expected cash flows from customer contracts, customer lists, and estimating cash flows from projects when completed; tradename and market position, as well as assumptions about the period of time that customer relationships will continue; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from the assumptions used in determining the fair values. All intangible assets are capitalized at their original cost and amortized over their estimated useful lives as follows: domain name and marketing &#x2013; 3 to 20 years; software &#x2013; 3 to 5 years, technology intangibles &#x2013; 7 years, customer relationships &#x2013; 7 to 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Biotechnology Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently generates no revenue from its Biotechnology segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recycling Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, retroactive to March 1, 2023, the Company entered into the Recycling Purchase Agreement with VM7, under which VM7 agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. As discussed previously, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements..&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Technology Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates no revenue from its Technology segment. GeoTraq was the Company&#x2019;s Technology segment. The Company suspended all operations for GeoTraq during the year ended December&#160;31, 2022. On May 24, 2022, the Company sold substantially all of the GeoTraq assets . GeoTraq is being presented as a discontinued operation. See Note 5. As discussed previously, the accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &#x201c;Financial Instruments,&#x201d; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: Level 1 - inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Level 2 &#x2013; to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided on deferred taxes if it is determined that it is more likely than not that the asset will not be realized. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision for income taxes in its Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the amount of benefit to be recognized in relation to an uncertain tax position. The Company uses a two-step process to evaluate tax positions. The first step requires an entity to determine whether it is more likely than not (greater than 50% chance) that the tax position will be sustained. The second step requires an entity to recognize in the financial statements the benefit of a tax position that meets the more-likely-than-not recognition criterion. The amounts ultimately paid upon resolution of issues raised by taxing authorities may differ materially from the amounts accrued and may materially impact the financial statements of the Company in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share is calculated in accordance with ASC 260, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;. Under ASC 260 basic earnings per share is computed using the weighted average number of common shares outstanding during the period except that it does not include unvested restricted stock subject to cancellation. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of warrants, options, restricted shares and convertible preferred stock. The dilutive effect of outstanding restricted shares, options and warrants is reflected in diluted earnings per share by application of the treasury stock method. Convertible preferred stock is reflected on an if-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 280, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; requires use of the &#x201c;management approach&#x201d; model for segment reporting. The management approach model is based on the way a Company&#x2019;s management organizes segments within the Company for making operating decisions and assessing performance. The Company determined it had three reportable segments, however the Recycling and Technology segments have been consolidated and presented as discontinued operations. See Note 21.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains cash balances at a bank in Nevada. The account is insured by the Federal Deposit Insurance Corporation up to $250,000. At times, balances may exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-318">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-319">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Statement Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The prior year amounts have also been modified in these financial statements to properly present amounts under continuing and discontinued operations. See Note 6.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-320">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates made in connection with the accompanying consolidated financial statements include the fair values in connection with the GeoTraq promissory note, analysis of other intangibles and long-lived assets for impairment, valuation allowance against deferred tax assets, lease terminations, and estimated useful lives for intangible assets and property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-321">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;Financial instruments consist primarily of cash equivalents, trade and other receivables, notes receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company&#x2019;s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at December&#160;30, 2023 and December&#160;31, 2022 approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with a maturity of three months or less at the time of purchase. Fair value of cash equivalents approximates carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-323">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and Other Receivables and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;The Company carries unsecured trade receivables at the original invoice amount less an estimate made for doubtful accounts based on a monthly review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions. The Company writes off trade receivables when it deems them to be uncollectible. The Company records recoveries of trade receivables previously written off when we receive them. The Company considers a trade receivable to be past due if any portion of the receivable balance is outstanding for more than ninety days. The Company does not charge interest on past due receivables.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-326">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the Company's trade and other receivables as of December&#160;30, 2023 and December&#160;31, 2022 (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-41" decimals="-3" id="f-327" unitRef="usd">266000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-42" decimals="-3" id="f-328" unitRef="usd">106000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-43" decimals="-3" id="f-329" unitRef="usd">266000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-44" decimals="-3" id="f-330" unitRef="usd">106000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-331">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for intangible assets in accordance with ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under ASC 350, intangible assets subject to amortization, shall be reviewed for impairment in accordance with the Impairment or Disposal of Long-Lived Assets in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 360, long-lived assets are tested for recoverability whenever events or changes in circumstances (&#x2018;triggering event&#x2019;) indicate that the carrying amount may not be recoverable. In making this determination, triggering events that were considered included:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant decrease in the market price of a long-lived asset (asset group);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); and,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;A current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a triggering event has occurred, for purposes of recognition and measurement of an impairment loss, a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If after identifying a triggering event it is determined that the asset group&#x2019;s carrying value may not be recoverable, a recoverability test is performed by forecasting the expected cash flows to be derived from the asset group for the remaining useful life of the asset group&#x2019;s primary asset compared to its carrying value. The recoverability test relies upon the undiscounted cash flows (excluding interest and taxes) which are derived from the Company&#x2019;s specific use of those assets (not how a market participant would use those assets); and, are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based upon the existing service potential of the current assets (excluding any improvements that would materially enhance the assets). If the expected undiscounted cash flows exceed the carrying value, the assets are considered recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consist of trade names, licenses for the use of internet domain names, Universal Resource Locators, or URL&#x2019;s, computer software, patent USPTO reference No. 10,182,402, and designs and related manufacturing procedures. In connection with the Soin merger (see Note 3), intangible assets consist of three patents pending, orphan drug status for Naltrexone, as granted by the FDA, and the formula for Naltrexone. Upon acquisition, critical estimates are made in valuing acquired intangible assets, which include but are not limited to: future expected cash flows from customer contracts, customer lists, and estimating cash flows from projects when completed; tradename and market position, as well as assumptions about the period of time that customer relationships will continue; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from the assumptions used in determining the fair values. All intangible assets are capitalized at their original cost and amortized over their estimated useful lives as follows: domain name and marketing &#x2013; 3 to 20 years; software &#x2013; 3 to 5 years, technology intangibles &#x2013; 7 years, customer relationships &#x2013; 7 to 15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <jan:NumberOfAcquiredIntangibleAssets
      contextRef="c-45"
      decimals="INF"
      id="f-332"
      unitRef="patent">3</jan:NumberOfAcquiredIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-46" id="f-333">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-47" id="f-334">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-48" id="f-335">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-49" id="f-336">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-50" id="f-337">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-51" id="f-338">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-52" id="f-339">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Biotechnology Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently generates no revenue from its Biotechnology segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recycling Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, retroactive to March 1, 2023, the Company entered into the Recycling Purchase Agreement with VM7, under which VM7 agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries. As discussed previously, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements..&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Technology Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates no revenue from its Technology segment. GeoTraq was the Company&#x2019;s Technology segment. The Company suspended all operations for GeoTraq during the year ended December&#160;31, 2022. On May 24, 2022, the Company sold substantially all of the GeoTraq assets . GeoTraq is being presented as a discontinued operation. See Note 5. As discussed previously, the accounts for the Technology segment have been presented as discontinued operations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-341">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &#x201c;Financial Instruments,&#x201d; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: Level 1 - inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Level 2 &#x2013; to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-342">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided on deferred taxes if it is determined that it is more likely than not that the asset will not be realized. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision for income taxes in its Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the amount of benefit to be recognized in relation to an uncertain tax position. The Company uses a two-step process to evaluate tax positions. The first step requires an entity to determine whether it is more likely than not (greater than 50% chance) that the tax position will be sustained. The second step requires an entity to recognize in the financial statements the benefit of a tax position that meets the more-likely-than-not recognition criterion. The amounts ultimately paid upon resolution of issues raised by taxing authorities may differ materially from the amounts accrued and may materially impact the financial statements of the Company in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-343">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share is calculated in accordance with ASC 260, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;. Under ASC 260 basic earnings per share is computed using the weighted average number of common shares outstanding during the period except that it does not include unvested restricted stock subject to cancellation. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of warrants, options, restricted shares and convertible preferred stock. The dilutive effect of outstanding restricted shares, options and warrants is reflected in diluted earnings per share by application of the treasury stock method. Convertible preferred stock is reflected on an if-converted basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 280, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; requires use of the &#x201c;management approach&#x201d; model for segment reporting. The management approach model is based on the way a Company&#x2019;s management organizes segments within the Company for making operating decisions and assessing performance. The Company determined it had three reportable segments, however the Recycling and Technology segments have been consolidated and presented as discontinued operations. See Note 21.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-346"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-347">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains cash balances at a bank in Nevada. The account is insured by the Federal Deposit Insurance Corporation up to $250,000. At times, balances may exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c-53" decimals="INF" id="f-348" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-349">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 3: Mergers and Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Soin Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#x201c;STLLC&#x201d;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In anticipation of the closing of the merger, the Company formed a merger subsidiary known as STI Merger Sub, Inc., a Delaware corporation (our &#x201c;Merger Sub&#x201d;), and designated a series of 200,000 shares of its preferred stock, stated value of $300.00 per share (the &#x201c;Series S Convertible Preferred Stock&#x201d; or the &#x201c;Series S Stock&#x201d;). See Note 15. The acquisition was memorialized by an Agreement and Plan of Merger, dated as of December&#160;28, 2022 (the &#x201c;Merger Agreement&#x201d;), by and among STLLC, Amol Soin, M.D., the sole stockholder of STLLC (&#x201c;Dr. Soin&#x201d;), the Company's Merger Sub, and us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For not less than six months after the closing and potentially up to approximately one year from the closing, Dr. Soin will remain the Company's Chief Medical Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing of the merger, (i) our Merger Sub merged with and into STLLC with STLLC as the surviving entity and (ii) the Company issued 100,000 shares of its Series S Stock to Dr. Soin. This all-stock transaction has an initial value of $13,000,000, potentially increasing by an additional $17,000,000 to up to a total value of $30,000,000, depending on revenues generated by the STLLC product. Dr. Soin agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of 4.99% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the completion of the merger, the Company performed a screen test, as defined in ASC 805 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine whether the Soin Pharmaceutical merger was considered a business combination or an asset acquisition. The results of the screen test revealed that substantially all of the fair value was concentrated in a group of similar assets, and that the assets did not possess the inputs, outputs, nor processes required to be considered a business, as defined in ASC 805. Consequently, no goodwill was recognized as part of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Series S Stock issued in connection with the merger, as valued by a third-party, independent, valuation firm was approximately $14.5 million. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. Consequently, the Company has recorded the assets as intangible assets on its consolidated balance sheets. In addition, the Company recognized a deferred tax liability of $4.8 million. The total value of the intangible assets purchased is $19.3 million. The Company will amortize the intangible assets ratably over a 10-year period. See Note 9. Because of certain conversion features of the Series S Stock that place redemption of these shares outside the control of the Company, the Series S Stock will be presented as mezzanine equity on the Company's consolidated balance sheets. As of December&#160;30, 2023, the Soin intangible had a carrying value of approximately $17.8 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-54"
      decimals="INF"
      id="f-351"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-54"
      decimals="2"
      id="f-352"
      unitRef="usdPerShare">300.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-55"
      decimals="INF"
      id="f-353"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-55" decimals="0" id="f-354" unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <jan:StockIssuedDuringPeriodAdditionalValueAcquisitions contextRef="c-55" decimals="0" id="f-355" unitRef="usd">17000000</jan:StockIssuedDuringPeriodAdditionalValueAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-55" decimals="0" id="f-356" unitRef="usd">30000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jan:CommonStockSharesOutstandingPercentage contextRef="c-56" decimals="4" id="f-357" unitRef="number">0.0499</jan:CommonStockSharesOutstandingPercentage>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c-57" decimals="0" id="f-358" unitRef="usd">3000000</us-gaap:ConversionOfStockAmountConverted1>
    <jan:ConversionOfStockCommencementPeriod contextRef="c-58" id="f-359">P1Y</jan:ConversionOfStockCommencementPeriod>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c-59" decimals="-6" id="f-360" unitRef="usd">10000000</us-gaap:ConversionOfStockAmountConverted1>
    <jan:ConversionOfStockPeriodFollowingClosing contextRef="c-60" id="f-361">P10Y</jan:ConversionOfStockPeriodFollowingClosing>
    <jan:ConversionOfStockPeriodFollowingClosing contextRef="c-60" id="f-362">P10Y</jan:ConversionOfStockPeriodFollowingClosing>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c-61" decimals="-6" id="f-363" unitRef="usd">17000000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:Goodwill contextRef="c-62" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:Goodwill>
    <jan:FairValueOfStockIssued contextRef="c-63" decimals="-5" id="f-365" unitRef="usd">14500000</jan:FairValueOfStockIssued>
    <jan:NumberOfAcquiredIntangibleAssets
      contextRef="c-45"
      decimals="INF"
      id="f-366"
      unitRef="patent">3</jan:NumberOfAcquiredIntangibleAssets>
    <us-gaap:DeferredTaxLiabilities contextRef="c-64" decimals="-5" id="f-367" unitRef="usd">4800000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-64" decimals="-5" id="f-368" unitRef="usd">19300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-65" id="f-369">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-66" decimals="-5" id="f-370" unitRef="usd">17800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-371">Sale of Recycling Subsidiaries&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#x201c;Recycling Purchase Agreement&#x201d;) with VM7 Corporation, a Delaware corporation (&#x201c;VM7&#x201d;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#x2019;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The economic aspects of the Disposition Transaction are: (i) the Company reduced the liabilities on its consolidated balance sheets by approximately $17.6&#160;million, and includes those liabilities related to the California Business Fee and Tax Division; (ii) the Company will receive not less than $24.0&#160;million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries&#x2019; future performance; and (iii) during the next five years, the Company may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1&#160;million. The Company also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&#x2019; aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&#x2019; aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 9, 2023. Additionally, upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to the Company 50% of the amount of the reduction between the current assessment and any such settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6&#160;million per year for 15 years, or $24.0&#160;million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0&#160;million, which, in addition to the $3,000 paid at close, comprises the approximately $6.0&#160;million of net consideration. Additionally, the calculation of the gain on disposition includes the book value in excess of assets disposed of, or approximately $9.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities. In connection with the shutdown of the Recycling Subsidiaries, because the Company is a guarantor on the Gulf Coast Bank and Trust credit facility (see Note 6), the Company recorded a liability for approximately $1.7&#160;million for estimated liability associated with this facility, which has been offset against the gain on the sale the Recycling Subsidiaries. Further, the Company has recorded additional liabilities, in the amount of approximately $2.0&#160;million, that were originally associated with the sale of the Recycling Subsidiaries and have reverted to the Company, which has been offset against the gain on the sale the Recycling Subsidiaries. See Note 18.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary calculation of the gain on sale was approximately $15.8 million. The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total minimum consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment from buyer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities - California state sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total disposal of liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gain on sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 5: GeoTraq&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of GeoTraq&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. The aggregate purchase price for the GeoTraq Assets was $13.5 million, payable in cash and shares of SPYR&#x2019;s common stock. As of the closing of the transaction on May&#160;24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock at $0.03 per share, and delivered a five-year Promissory Note in the principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may be prepaid at any time without penalty. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May&#160;24, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Purchase Agreement, the Company employed an independent third-party firm to assess the fair value of the 30,000,000 shares of SPYR stock and the Promissory Note. The assessment determined that the fair market value of the SPYR common stock was approximately $946,000, or approximately $0.032 per share, which was approximately $46,000 greater than the amount of the shares received at close. The Promissory Note was valued at approximately $11.3 million, which was approximately $1.4 million less than the Note issued. Consequently, the Company recorded the shares of SPYR stock at fair market value of $946,000, and recorded a discount offsetting the Promissory Note in the amount of $1.35 million. The discount will be accreted ratably over the term of the Promissory Note, and recorded as interest income. Additionally, approximately $105,000 in GeoTraq inventory was transferred as part of the sale, and was, thus, derecognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, based on declining financial trends at SPYR, the Company reviewed the original valuation of the Promissory Note to determine whether a revision of the estimate of the original 10.5% used to discount the note should occur to account for the additional risk the note would not be repaid. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took an additional $1.85 million charge against income for the 13 and 26 weeks ended July 2, 2022, and restated its Quarterly Reports on Form 10-Q for the 13 and 26 weeks ended July 2, 2022, and the 13 and 39 weeks ended October 1, 2022. Additionally, due to the declining financial trends at SPYR, the Company recorded an additional $813,000 charge against income for the year ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022. No additional charges against income have been recorded by the Company for the year ended December&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount on note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium on shares received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derecognition of GeoTraq inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, as of December&#160;30, 2023, the Company recorded a charge to fully impair the promissory note (see Note 8).&lt;/span&gt;&lt;/div&gt;Discontinued Operations&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;30, 2023, the Company discontinued operations of its Recycling and Technology segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, the Company executed a Recycling Purchase Agreement with VM7, under which, as of March 1, 2023, it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. See Note 4. The assets and liabilities for the Recycling Subsidiaries were included in discontinued operations December&#160;31, 2022, but were not included at December&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to which the Company sold to SPYR substantially all the assets and none of the liabilities of its wholly-owned subsidiary GeoTraq Inc. No GeoTraq assets or liabilities were included in discontinued operations at December&#160;30, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities - other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - California sales taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligation short-term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligation long-term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes payable - long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion related party note payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s property and equipment consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projects under construction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net, from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was approximately $60,000 and $326,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent and domains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was approximately $36,000 and $229,000 for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accrued liabilities consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued incentive and rebate checks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically the Company operated its recycling business in fourteen states in the U.S. and in various provinces in Canada. From time to time, the Company is subject to sales and use tax audits that could result in additional taxes, penalties and interest owed to various taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The California Department of Tax and Fee Administration (formerly known as the California Board of Equalization) (&#x201c;CDTFA&#x201d;) conducted a sales and use tax examination covering ARCA Recycling&#x2019;s California operations for years 2011, 2012, and 2013. The Company believed it was exempt from collecting sales taxes under service agreements with utility customers that included appliance replacement programs. During the fourth quarter of 2014, the Company received communication from the CDTFA indicating they were not in agreement with the Company&#x2019;s interpretation of the law. As a result, the Company applied for and, as of February 9, 2015, received approval to participate in the CDTFA&#x2019;s Managed Audit Program. The period covered under this program included the years 2011, 2012, and 2013 and extended through the nine-month period ended September 30, 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;13, 2017 the Company received the formal CDTFA assessment for sales tax for tax years 2011, 2012, and 2013 in the amount of approximately $4.1 million plus applicable interest of $500,000 related to the appliance replacement programs that the Company administered on behalf of its customers on which it did not assess, collect, or remit sales tax. The Company has appealed this assessment to the CDTFA Appeals Bureau. The appeal remains in process. Interest has continued to accrue until the matter is resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accrual relating to the California sales tax assessment consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - CA sales tax assessment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - interest on CA sales tax assessment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gulf Coast Bank and Trust Company&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gulf Coast Bank and Trust Company loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;6 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;KLC Financial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;KLC Financial loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party ICG Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;28, 2019, ARCA Recycling entered into and delivered to Isaac Capital Group LLC (&#x201c;ICG&#x201d;) a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#x201c;ICG Note&#x201d;). The ICG Note originally matured on August 28, 2020. On August 25, 2020, the ICG Note was amended to extend the maturity date to December 31, 2020. On March 30, 2021, ARCA Recycling entered into a Second Amendment and Waiver (the &#x201c;Second Amendment&#x201d;) to the ICG Note to further extend the maturity date to August 18, 2021 and waive certain defaults under the ICG Note. The ICG Note bears interest at 8.75% per annum and provides for the payment of interest, monthly in arrears. ARCA Recycling will pay a loan fee of 2.0% on each borrowing made under the ICG Note. In connection with entering into the ICG Note, the Borrower also entered into a security agreement in favor of the Lender, pursuant to which ARCA Recycling granted a security interest in all of its assets to the Lender.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The obligations of ARCA Recycling under the ICG Note are guaranteed by the Company. The foregoing transaction did not include the issuance of any shares of the Company&#x2019;s common stock, warrants, or other derivative securities. As of January&#160;1, 2022, the balance due on ICG Note was $1.0 million. Beginning in April 2022, the revolving credit facility was converted to a term note that amortized ratably through its maturity date of March 2026. The principal amount of the note was $1.0 million, and was to bear interest at 8.75% per annum. Monthly payments on the ICG Note were approximately $24,767.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;7 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s related party debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Isaac Capital Group LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses from discontinued operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of ARCA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of GeoTraq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating expenses from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before provision for income taxes from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of ARCA, net of cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of GeoTraq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash provided by (used in) operating activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash used in investing activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments on related party note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments on notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash used in (provided by) financing activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of changes in exchange rate on cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DECREASE IN CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CASH AND CASH EQUIVALENTS, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CASH AND CASH EQUIVALENTS, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <jan:DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities contextRef="c-67" decimals="-5" id="f-372" unitRef="usd">17600000</jan:DisposalGroupIncludingDiscontinuedOperationsReductionInLiabilities>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer contextRef="c-67" decimals="-5" id="f-373" unitRef="usd">24000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod contextRef="c-67" id="f-374">P5Y</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPeriod>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment contextRef="c-67" decimals="-6" id="f-375" unitRef="usd">1000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyerPrepayment>
    <jan:DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary contextRef="c-67" decimals="-3" id="f-376" unitRef="usd">1000</jan:DisposalGroupIncludingDiscontinuedOperationsProceedsReceivedForEquityOfEachSubsidiary>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer contextRef="c-67" decimals="-3" id="f-377" unitRef="usd">140000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer contextRef="c-68" decimals="-3" id="f-378" unitRef="usd">100000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyMinimumPaymentsFromBuyer>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod contextRef="c-67" id="f-379">P15Y</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue contextRef="c-69" decimals="2" id="f-380" unitRef="number">0.05</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark contextRef="c-69" decimals="-6" id="f-381" unitRef="usd">2000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue contextRef="c-70" decimals="2" id="f-382" unitRef="number">0.04</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark contextRef="c-71" decimals="-6" id="f-383" unitRef="usd">2000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark contextRef="c-72" decimals="-6" id="f-384" unitRef="usd">3000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue contextRef="c-73" decimals="2" id="f-385" unitRef="number">0.03</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPercentageOfGrossRevenue>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark contextRef="c-73" decimals="-6" id="f-386" unitRef="usd">3000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentSubsidiaryRevenueBenchmark>
    <jan:DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue contextRef="c-67" decimals="2" id="f-387" unitRef="number">0.50</jan:DisposalGroupIncludingDiscontinuedOperationsPaymentReceivablePercentageOfDifferenceBetweenAssessmentAndSettlementValue>
    <jan:DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction contextRef="c-67" decimals="-5" id="f-388" unitRef="usd">1600000</jan:DisposalGroupIncludingDiscontinuedOperationsConsiderationReceivedOnTransaction>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod contextRef="c-67" id="f-389">P15Y</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentPaymentPeriod>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer contextRef="c-67" decimals="-5" id="f-390" unitRef="usd">24000000</jan:DisposalGroupIncludingDiscontinuedOperationsAggregateMonthlyPaymentsFromBuyer>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure contextRef="c-67" decimals="-3" id="f-391" unitRef="usd">3000</jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure>
    <jan:DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage contextRef="c-67" decimals="2" id="f-392" unitRef="number">0.20</jan:DisposalGroupIncludingDiscontinuedOperationsDiscountRatePercentage>
    <jan:DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount contextRef="c-74" decimals="-5" id="f-393" unitRef="usd">6000000</jan:DisposalGroupIncludingDiscontinuedOperationsPresentValueOfDiscountRecordedAsOffsetToThePrincipalAmount>
    <jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure contextRef="c-67" decimals="-3" id="f-394" unitRef="usd">3000</jan:DisposalGroupIncludingDiscontinuedOperationsAssetAcquisitionConsiderationTransferredAtClosure>
    <jan:DisposalGroupIncludingDiscontinuedOperationNetConsideration contextRef="c-74" decimals="-5" id="f-395" unitRef="usd">6000000</jan:DisposalGroupIncludingDiscontinuedOperationNetConsideration>
    <jan:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag contextRef="c-1" id="f-396">disposition</jan:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag>
    <jan:DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets contextRef="c-74" decimals="-5" id="f-397" unitRef="usd">9800000</jan:DisposalGroupNotDiscontinuedOperationBookValueInExcessOfAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-75" decimals="-5" id="f-398" unitRef="usd">-5300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-76" decimals="-5" id="f-399" unitRef="usd">1700000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-77" decimals="-5" id="f-400" unitRef="usd">2000000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-67" decimals="-5" id="f-401" unitRef="usd">15800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-402">The following table details the final calculation of the gain on sale of the Recycling Subsidiaries, as shown on the income statement (in $000&#x2019;s):&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total minimum consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment from buyer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities - California state sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total disposal of liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gain on sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the calculation of the gain on sale of GeoTraq, including the charges to income referenced above, as shown on the income statement (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount on note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium on shares received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derecognition of GeoTraq inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December&#160;31, 2022, and consist of the following (in $000&#x2019;s):&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities - other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - California sales taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligation short-term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligation long-term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes payable - long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion related party note payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s property and equipment consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projects under construction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net, from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent and domains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accrued liabilities consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued incentive and rebate checks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accrual relating to the California sales tax assessment consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - CA sales tax assessment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liability - interest on CA sales tax assessment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gulf Coast Bank and Trust Company&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gulf Coast Bank and Trust Company loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;6 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;KLC Financial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;KLC Financial loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s related party debt consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Isaac Capital Group LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The results of operations for these entities for the year ended December&#160;30, 2023 and December&#160;31, 2022, respectively, have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following (in $000&#x2019;s):&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses from discontinued operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of ARCA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of GeoTraq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating expenses from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before provision for income taxes from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The cash flow activity from discontinued operations for the year ended December&#160;30, 2023 and December&#160;31, 2022 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in $000&#x2019;s):&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of ARCA, net of cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of GeoTraq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash provided by (used in) operating activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash used in investing activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DISCONTINUED FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments on related party note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments on notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net cash used in (provided by) financing activities from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of changes in exchange rate on cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DECREASE IN CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CASH AND CASH EQUIVALENTS, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CASH AND CASH EQUIVALENTS, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <jan:TotalGuaranteedConsideration contextRef="c-67" decimals="-3" id="f-403" unitRef="usd">6023000</jan:TotalGuaranteedConsideration>
    <jan:PaymentFromBuyer contextRef="c-67" decimals="-3" id="f-404" unitRef="usd">3000</jan:PaymentFromBuyer>
    <jan:NetConsideration contextRef="c-67" decimals="-3" id="f-405" unitRef="usd">6026000</jan:NetConsideration>
    <jan:DisposalOfAccountsPayable contextRef="c-67" decimals="-3" id="f-406" unitRef="usd">5323000</jan:DisposalOfAccountsPayable>
    <jan:DisposalOfAccruedLiability contextRef="c-67" decimals="-3" id="f-407" unitRef="usd">1857000</jan:DisposalOfAccruedLiability>
    <jan:DisposalOfAccruedLiabilityCaliforniaStateSalesTax contextRef="c-67" decimals="-3" id="f-408" unitRef="usd">6320000</jan:DisposalOfAccruedLiabilityCaliforniaStateSalesTax>
    <jan:DisposalOfLeaseLiability contextRef="c-67" decimals="-3" id="f-409" unitRef="usd">5285000</jan:DisposalOfLeaseLiability>
    <jan:DisposalOfDebt contextRef="c-67" decimals="-3" id="f-410" unitRef="usd">2139000</jan:DisposalOfDebt>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-67" decimals="-3" id="f-411" unitRef="usd">-604000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <jan:TotalDisposalOfLiability contextRef="c-67" decimals="-3" id="f-412" unitRef="usd">20320000</jan:TotalDisposalOfLiability>
    <jan:TotalConsiderations contextRef="c-67" decimals="-3" id="f-413" unitRef="usd">26346000</jan:TotalConsiderations>
    <jan:CashDisposal contextRef="c-67" decimals="-3" id="f-414" unitRef="usd">145000</jan:CashDisposal>
    <jan:DisposalOfAccountsReceivable contextRef="c-67" decimals="-3" id="f-415" unitRef="usd">4884000</jan:DisposalOfAccountsReceivable>
    <jan:DisposalOfInventory contextRef="c-67" decimals="-3" id="f-416" unitRef="usd">67000</jan:DisposalOfInventory>
    <jan:DisposalOfPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-417" unitRef="usd">2767000</jan:DisposalOfPropertyPlantAndEquipment>
    <jan:DisposalOfIntangibleAssets contextRef="c-67" decimals="-3" id="f-418" unitRef="usd">732000</jan:DisposalOfIntangibleAssets>
    <jan:DisposalOfRightOfUseAssets contextRef="c-67" decimals="-3" id="f-419" unitRef="usd">5075000</jan:DisposalOfRightOfUseAssets>
    <jan:DisposalOfOtherAssets contextRef="c-67" decimals="-3" id="f-420" unitRef="usd">574000</jan:DisposalOfOtherAssets>
    <jan:TotalDisposalOfAssets contextRef="c-67" decimals="-3" id="f-421" unitRef="usd">14244000</jan:TotalDisposalOfAssets>
    <jan:TotalGainOnSale contextRef="c-67" decimals="-3" id="f-422" unitRef="usd">12102000</jan:TotalGainOnSale>
    <jan:AgreedPrepaymentAmount contextRef="c-78" decimals="-5" id="f-423" unitRef="usd">13500000</jan:AgreedPrepaymentAmount>
    <us-gaap:CommonStockSharesIssued contextRef="c-78" decimals="0" id="f-424" unitRef="shares">30000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-78"
      decimals="INF"
      id="f-425"
      unitRef="usdPerShare">0.03</us-gaap:CommonStockParOrStatedValuePerShare>
    <jan:NotesReceivableTerm contextRef="c-79" id="f-426">P5Y</jan:NotesReceivableTerm>
    <jan:NoteReceivableFaceAmount contextRef="c-78" decimals="-5" id="f-427" unitRef="usd">12600000</jan:NoteReceivableFaceAmount>
    <jan:NoteReceivableStatedInterestRate contextRef="c-78" decimals="2" id="f-428" unitRef="number">0.08</jan:NoteReceivableStatedInterestRate>
    <jan:NoteReceivableMaturityDate contextRef="c-80" id="f-429">2027-05-24</jan:NoteReceivableMaturityDate>
    <us-gaap:CommonStockSharesIssued contextRef="c-81" decimals="0" id="f-430" unitRef="shares">30000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-81" decimals="0" id="f-431" unitRef="usd">946000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-81"
      decimals="3"
      id="f-432"
      unitRef="usdPerShare">0.032</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-82" decimals="0" id="f-433" unitRef="usd">46000</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c-81" decimals="-5" id="f-434" unitRef="usd">11300000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c-83" decimals="-5" id="f-435" unitRef="usd">1400000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <jan:NoteReceivableFaceAmount contextRef="c-84" decimals="0" id="f-436" unitRef="usd">946000</jan:NoteReceivableFaceAmount>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="c-84" decimals="-4" id="f-437" unitRef="usd">1350000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding contextRef="c-78" decimals="0" id="f-438" unitRef="usd">105000</us-gaap:DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding>
    <jan:NoteReceivableDiscountRate contextRef="c-85" decimals="3" id="f-439" unitRef="number">0.105</jan:NoteReceivableDiscountRate>
    <jan:NoteReceivableRevisedDiscountRate contextRef="c-85" decimals="3" id="f-440" unitRef="number">0.145</jan:NoteReceivableRevisedDiscountRate>
    <jan:ChargeAgainstIncomeForIncreaseInDiscountRate contextRef="c-85" decimals="-4" id="f-441" unitRef="usd">1850000</jan:ChargeAgainstIncomeForIncreaseInDiscountRate>
    <jan:ChargeAgainstIncomeForIncreaseInDiscountRate contextRef="c-86" decimals="0" id="f-442" unitRef="usd">813000</jan:ChargeAgainstIncomeForIncreaseInDiscountRate>
    <jan:ChargeAgainstIncomeForIncreaseInDiscountRate contextRef="c-87" decimals="INF" id="f-443" unitRef="usd">0</jan:ChargeAgainstIncomeForIncreaseInDiscountRate>
    <us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">13500000</us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtPurchasePrice>
    <us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">4013000</us-gaap:GainLossOnSaleOfAccountsReceivable>
    <us-gaap:PolicyholderAccountBalancePremiumReceived contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">46000</us-gaap:PolicyholderAccountBalancePremiumReceived>
    <us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax contextRef="c-1" decimals="-3" id="f-447" unitRef="usd">-105000</us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskAdjustmentFromAociForDerecognitionBeforeTax>
    <us-gaap:GainLossOnSaleOfProject contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">9428000</us-gaap:GainLossOnSaleOfProject>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-88" decimals="-3" id="f-449" unitRef="usd">53000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-88" decimals="-3" id="f-450" unitRef="usd">7816000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-88" decimals="-3" id="f-451" unitRef="usd">366000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c-88" decimals="-3" id="f-452" unitRef="usd">377000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-88" decimals="-3" id="f-453" unitRef="usd">8612000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent contextRef="c-88" decimals="-3" id="f-454" unitRef="usd">2705000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset contextRef="c-88" decimals="-3" id="f-455" unitRef="usd">5290000</jan:DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent contextRef="c-88" decimals="-3" id="f-456" unitRef="usd">735000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets contextRef="c-88" decimals="-3" id="f-457" unitRef="usd">249000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="c-88" decimals="-3" id="f-458" unitRef="usd">8979000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-88" decimals="-3" id="f-459" unitRef="usd">17591000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent contextRef="c-88" decimals="-3" id="f-460" unitRef="usd">4423000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="c-88" decimals="-3" id="f-461" unitRef="usd">3278000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes contextRef="c-88" decimals="-3" id="f-462" unitRef="usd">6264000</jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes>
    <jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases contextRef="c-88" decimals="-3" id="f-463" unitRef="usd">1631000</jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationShortTermOperatingLeases>
    <jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt contextRef="c-88" decimals="-3" id="f-464" unitRef="usd">4172000</jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent contextRef="c-88" decimals="-3" id="f-465" unitRef="usd">381000</jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote contextRef="c-88" decimals="-3" id="f-466" unitRef="usd">233000</jan:DisposalGroupIncludingDiscontinuedOperationRelatedPartyNote>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-88" decimals="-3" id="f-467" unitRef="usd">20382000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases contextRef="c-88" decimals="-3" id="f-468" unitRef="usd">3816000</jan:DisposalGroupIncludingDiscontinuedOperationLeaseObligationLongTermOperatingLeases>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent contextRef="c-88" decimals="-3" id="f-469" unitRef="usd">1339000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable contextRef="c-88" decimals="-3" id="f-470" unitRef="usd">605000</jan:DisposalGroupIncludingDiscontinuedOperationLongTermPortionRelatedPartyNotePayable>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-88" decimals="-3" id="f-471" unitRef="usd">5760000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-88" decimals="-3" id="f-472" unitRef="usd">26142000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-89" id="f-473">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-90" id="f-474">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross contextRef="c-91" decimals="-3" id="f-475" unitRef="usd">69000</jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-92" id="f-476">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-93" id="f-477">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross contextRef="c-94" decimals="-3" id="f-478" unitRef="usd">2556000</jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross>
    <jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross contextRef="c-95" decimals="-3" id="f-479" unitRef="usd">1447000</jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross>
    <jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross contextRef="c-88" decimals="-3" id="f-480" unitRef="usd">4072000</jan:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-481" unitRef="usd">1367000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent contextRef="c-88" decimals="-3" id="f-482" unitRef="usd">2705000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:Depreciation contextRef="c-96" decimals="-3" id="f-483" unitRef="usd">60000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-97" decimals="-3" id="f-484" unitRef="usd">326000</us-gaap:Depreciation>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-98" decimals="-3" id="f-485" unitRef="usd">19000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-99" decimals="-3" id="f-486" unitRef="usd">1682000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-88" decimals="-3" id="f-487" unitRef="usd">1701000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-88" decimals="-3" id="f-488" unitRef="usd">966000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent contextRef="c-88" decimals="-3" id="f-489" unitRef="usd">735000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:AdjustmentForAmortization contextRef="c-96" decimals="-3" id="f-490" unitRef="usd">36000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-97" decimals="-3" id="f-491" unitRef="usd">229000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-88" decimals="-3" id="f-492" unitRef="usd">685000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-88" decimals="-3" id="f-493" unitRef="usd">290000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <jan:AccruedIncentiveAndRebateChecksCurrent contextRef="c-88" decimals="-3" id="f-494" unitRef="usd">2037000</jan:AccruedIncentiveAndRebateChecksCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-88" decimals="-3" id="f-495" unitRef="usd">219000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-88" decimals="-3" id="f-496" unitRef="usd">47000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="c-88" decimals="-3" id="f-497" unitRef="usd">3278000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="c-100"
      decimals="INF"
      id="f-498"
      unitRef="state">14</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-101" decimals="-5" id="f-499" unitRef="usd">4100000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <jan:SalesTaxAssessmentAccruedInterest contextRef="c-101" decimals="-3" id="f-500" unitRef="usd">500000</jan:SalesTaxAssessmentAccruedInterest>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-88" decimals="-3" id="f-501" unitRef="usd">4132000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <jan:SalesTaxAssessmentAccruedInterest contextRef="c-88" decimals="-3" id="f-502" unitRef="usd">2132000</jan:SalesTaxAssessmentAccruedInterest>
    <jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes contextRef="c-88" decimals="-3" id="f-503" unitRef="usd">6264000</jan:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesSalesTaxes>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-102" decimals="-3" id="f-504" unitRef="usd">4206000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-102" decimals="-3" id="f-505" unitRef="usd">34000</us-gaap:DeferredFinanceCostsCurrentNet>
    <jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt contextRef="c-88" decimals="-3" id="f-506" unitRef="usd">4172000</jan:DisposalGroupIncludingDiscontinuedOperationShortTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-103" decimals="-3" id="f-507" unitRef="usd">1781000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-103" decimals="-3" id="f-508" unitRef="usd">61000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable contextRef="c-88" decimals="-3" id="f-509" unitRef="usd">1720000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent contextRef="c-103" decimals="-3" id="f-510" unitRef="usd">381000</jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent contextRef="c-103" decimals="-3" id="f-511" unitRef="usd">1339000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-104" decimals="INF" id="f-512" unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="c-105" decimals="4" id="f-513" unitRef="number">0.0875</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c-105" decimals="3" id="f-514" unitRef="number">0.020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCredit contextRef="c-106" decimals="-5" id="f-515" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-107" decimals="-5" id="f-516" unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-107" decimals="4" id="f-517" unitRef="number">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="c-108" decimals="0" id="f-518" unitRef="usd">24767</us-gaap:DebtInstrumentPeriodicPayment>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable contextRef="c-109" decimals="-3" id="f-519" unitRef="usd">838000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable contextRef="c-109" decimals="-3" id="f-520" unitRef="usd">838000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayable>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent contextRef="c-109" decimals="-3" id="f-521" unitRef="usd">233000</jan:DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent>
    <jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent contextRef="c-109" decimals="-3" id="f-522" unitRef="usd">605000</jan:DisposalGroupIncludingDiscontinuedOperationNotesPayableNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-96" decimals="-3" id="f-523" unitRef="usd">3795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-97" decimals="-3" id="f-524" unitRef="usd">39611000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-96" decimals="-3" id="f-525" unitRef="usd">3992000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-97" decimals="-3" id="f-526" unitRef="usd">31992000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c-96" decimals="-3" id="f-527" unitRef="usd">-197000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c-97" decimals="-3" id="f-528" unitRef="usd">7619000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-96" decimals="-3" id="f-529" unitRef="usd">1467000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-97" decimals="-3" id="f-530" unitRef="usd">8652000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-110" decimals="-3" id="f-531" unitRef="usd">12102000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-111" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-112" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-113" decimals="-3" id="f-534" unitRef="usd">9428000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations contextRef="c-96" decimals="-3" id="f-535" unitRef="usd">10635000</jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations>
    <jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations contextRef="c-97" decimals="-3" id="f-536" unitRef="usd">776000</jan:DisposalGroupIncludingDiscontinuedOperationTotalOperatingIncomeExpensesFromDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-96" decimals="-3" id="f-537" unitRef="usd">10438000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-97" decimals="-3" id="f-538" unitRef="usd">8395000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-96" decimals="-3" id="f-539" unitRef="usd">181000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-97" decimals="-3" id="f-540" unitRef="usd">957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense contextRef="c-96" decimals="-3" id="f-541" unitRef="usd">0</jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense>
    <jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense contextRef="c-97" decimals="-3" id="f-542" unitRef="usd">1008000</jan:DisposalGroupIncludingDiscontinuedOperationLitigationSettlementExpense>
    <jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet contextRef="c-96" decimals="-3" id="f-543" unitRef="usd">3000</jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet contextRef="c-97" decimals="-3" id="f-544" unitRef="usd">1349000</jan:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet contextRef="c-96" decimals="-3" id="f-545" unitRef="usd">-184000</jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet>
    <jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet contextRef="c-97" decimals="-3" id="f-546" unitRef="usd">-3314000</jan:DisposalGroupIncludingDiscontinuedOperationsTotalOtherIncomeLossNet>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-96" decimals="-3" id="f-547" unitRef="usd">10254000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-97" decimals="-3" id="f-548" unitRef="usd">5081000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-96" decimals="-3" id="f-549" unitRef="usd">971000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-97" decimals="-3" id="f-550" unitRef="usd">2109000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-96" decimals="-3" id="f-551" unitRef="usd">9283000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-97" decimals="-3" id="f-552" unitRef="usd">2972000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-96" decimals="-3" id="f-553" unitRef="usd">9283000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-97" decimals="-3" id="f-554" unitRef="usd">2972000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-96" decimals="-3" id="f-555" unitRef="usd">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-97" decimals="-3" id="f-556" unitRef="usd">555000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-96" decimals="-3" id="f-557" unitRef="usd">11000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-97" decimals="-3" id="f-558" unitRef="usd">31000</us-gaap:AmortizationOfFinancingCosts>
    <jan:GainLossOnLitigationSettlement contextRef="c-96" decimals="-3" id="f-559" unitRef="usd">0</jan:GainLossOnLitigationSettlement>
    <jan:GainLossOnLitigationSettlement contextRef="c-97" decimals="-3" id="f-560" unitRef="usd">-1009000</jan:GainLossOnLitigationSettlement>
    <jan:AmortizationOfRightOfUseAssets contextRef="c-96" decimals="-3" id="f-561" unitRef="usd">52000</jan:AmortizationOfRightOfUseAssets>
    <jan:AmortizationOfRightOfUseAssets contextRef="c-97" decimals="-3" id="f-562" unitRef="usd">55000</jan:AmortizationOfRightOfUseAssets>
    <jan:GainOnSaleNetOfCash contextRef="c-96" decimals="-3" id="f-563" unitRef="usd">12248000</jan:GainOnSaleNetOfCash>
    <jan:GainOnSaleNetOfCash contextRef="c-97" decimals="-3" id="f-564" unitRef="usd">0</jan:GainOnSaleNetOfCash>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-96" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-97" decimals="-3" id="f-566" unitRef="usd">9428000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-96" decimals="-3" id="f-567" unitRef="usd">-2932000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-97" decimals="-3" id="f-568" unitRef="usd">-1482000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-96" decimals="-3" id="f-569" unitRef="usd">-299000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-97" decimals="-3" id="f-570" unitRef="usd">-738000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-96" decimals="-3" id="f-571" unitRef="usd">-56000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-97" decimals="-3" id="f-572" unitRef="usd">-583000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-96" decimals="-3" id="f-573" unitRef="usd">1837000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-97" decimals="-3" id="f-574" unitRef="usd">-454000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-96" decimals="-3" id="f-575" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-97" decimals="-3" id="f-576" unitRef="usd">44000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-96" decimals="-3" id="f-577" unitRef="usd">2319000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-97" decimals="-3" id="f-578" unitRef="usd">-2501000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-96" decimals="-3" id="f-579" unitRef="usd">123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-97" decimals="-3" id="f-580" unitRef="usd">808000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-96" decimals="-3" id="f-581" unitRef="usd">32000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-97" decimals="-3" id="f-582" unitRef="usd">701000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-96" decimals="-3" id="f-583" unitRef="usd">-155000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-97" decimals="-3" id="f-584" unitRef="usd">-1509000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-96" decimals="-3" id="f-585" unitRef="usd">5162000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-97" decimals="-3" id="f-586" unitRef="usd">17545000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-96" decimals="-3" id="f-587" unitRef="usd">38000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-97" decimals="-3" id="f-588" unitRef="usd">162000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-96" decimals="-3" id="f-589" unitRef="usd">7336000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-97" decimals="-3" id="f-590" unitRef="usd">13390000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-96" decimals="-3" id="f-591" unitRef="usd">-2212000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-97" decimals="-3" id="f-592" unitRef="usd">3993000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-96" decimals="-3" id="f-593" unitRef="usd">-5000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-97" decimals="-3" id="f-594" unitRef="usd">-4000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-96" decimals="-3" id="f-595" unitRef="usd">-53000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-97" decimals="-3" id="f-596" unitRef="usd">-21000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-88" decimals="-3" id="f-597" unitRef="usd">53000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-114" decimals="-3" id="f-598" unitRef="usd">74000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-100" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-88" decimals="-3" id="f-600" unitRef="usd">53000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-601">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 7: Prepaids and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaids and other current assets consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaids and other current assets consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-603" unitRef="usd">3000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-5" decimals="-3" id="f-604" unitRef="usd">364000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-605" unitRef="usd">72000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-606" unitRef="usd">30000</us-gaap:OtherPrepaidExpenseCurrent>
    <jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent contextRef="c-4" decimals="-3" id="f-607" unitRef="usd">75000</jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent>
    <jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent contextRef="c-5" decimals="-3" id="f-608" unitRef="usd">394000</jan:PrepaidExpenseAndOtherAssetsIncludingDiscontinuedOperationsCurrent>
    <us-gaap:FinancingReceivablesTextBlock contextRef="c-1" id="f-609">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 8: Notes receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;SPYR Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc. (&#x201c;SPYR&#x201d;), pursuant to which the Company sold to SPYR substantially all of the assets and none of the specified liabilities of GeoTraq, as discussed in Note 5. In connection with the Purchase Agreement, SPYR delivered to the Company a five-year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8.0% per annum, provides quarterly interest payments due on the first day of each calendar quarter, and may be prepaid at any time without penalty. Interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. The Promissory Note matures on May 24, 2027. The Company has received restricted shares of Series G Convertible Preferred Stock of SPYR equivalent to approximately 922,442,000 shares of its common stock during the year ended December&#160;30, 2023, and 30,000,000 shares of SPYR's common stock during the year ended December&#160;31, 2022. As of December&#160;30, 2023, the Company has accrued receivables of approximately $254,000 in interest income related to the Promissory Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the asset sale, the Company engaged a third-party valuation firm to assess the fair value of the consideration received. Based on the valuation, the Promissory Note (&#x201c;Note&#x201d;) was valued at approximately $11.3 million. The amount of the discount, or approximately $1.3 million, has been recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. At December&#160;31, 2022, the Company reviewed the original valuation of the Promissory Note to determine if the original 10.5% used to discount the Note was appropriate. In connection with this review, the Company determined that the discount rate should be revised to 14.5%. Consequently, the Company took a $1.85 million charge against income, and restated the 13 and 26 weeks ended July&#160;2, 2022, as discussed previously. Further, the Company recorded an additional $813,000 charge against income for the year ended December&#160;31, 2022 due to SPYR's declining financial trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;30, 2023, the Company performed a qualitative analysis of the SPYR note receivable and concluded that, due to a number of triggering factors, it was probable that SPYR would be unable to fulfill its obligation to repay the principal amount under the promissory note on or before the maturity date. Consequently, the Company recorded an impairment charge of approximately $9.8&#160;million for the fiscal year ended December&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022, approximately $806,000 and $387,000, respectively, of the discount was recorded as interest income. As of December&#160;30, 2023 and December&#160;31, 2022, the net principal balance on the Note was approximately $0 and $9.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;VM7 Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#x201c;Recycling Purchase Agreement&#x201d;) with VM7 Corporation, a Delaware corporation (&#x201c;VM7&#x201d;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Purchase Agreement. The Company&#x2019;s Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactive to March 1, 2023. See Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum consideration to be received by the Company from the Disposition Transaction, as discussed above, is $1.6 million per year for 15 years, or $24.0 million in the aggregate, plus cash of $3,000 paid at close. In connection with the Disposition Transaction, the Company used a discount rate of 20.0% when it valued the aggregate minimum consideration. Management determined that discount rate appropriately addresses any risk that the minimum payments would not be received. The valuation, factoring in that discount rate, yielded a present value of approximately $6.0 million, which, in addition to the $3,000 paid at close, comprises the approximately 6.0 million of net consideration. The amount of the revised discount amount, or approximately $18.0 million, was recorded as an offset to the principal amount of the Note, and will be accreted ratably to interest income over the term of the Note. During the year ended December&#160;30, 2023, approximately $720,000 of the discount was recorded as interest income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understand that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3 million carrying value of the Disposition Transaction on our balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
    <jan:NotesReceivableTerm contextRef="c-115" id="f-610">P5Y</jan:NotesReceivableTerm>
    <jan:NoteReceivableFaceAmount contextRef="c-116" decimals="-5" id="f-611" unitRef="usd">12600000</jan:NoteReceivableFaceAmount>
    <jan:NoteReceivableStatedInterestRate contextRef="c-116" decimals="2" id="f-612" unitRef="number">0.080</jan:NoteReceivableStatedInterestRate>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="c-117"
      decimals="-3"
      id="f-613"
      unitRef="shares">922442000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="c-118"
      decimals="-3"
      id="f-614"
      unitRef="shares">30000000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:InterestReceivable contextRef="c-119" decimals="-3" id="f-615" unitRef="usd">254000</us-gaap:InterestReceivable>
    <us-gaap:OriginationOfNotesReceivableFromRelatedParties contextRef="c-120" decimals="-5" id="f-616" unitRef="usd">11300000</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
    <jan:DiscountRecordedAsOffsetToThePrincipalAmount contextRef="c-121" decimals="-5" id="f-617" unitRef="usd">1300000</jan:DiscountRecordedAsOffsetToThePrincipalAmount>
    <jan:DebtDiscountRate contextRef="c-120" decimals="3" id="f-618" unitRef="number">0.105</jan:DebtDiscountRate>
    <jan:DebtRevisedDiscountRate contextRef="c-120" decimals="3" id="f-619" unitRef="number">0.145</jan:DebtRevisedDiscountRate>
    <jan:DiscountCharges contextRef="c-122" decimals="-4" id="f-620" unitRef="usd">1850000</jan:DiscountCharges>
    <jan:DiscountCharges contextRef="c-123" decimals="-4" id="f-621" unitRef="usd">1850000</jan:DiscountCharges>
    <jan:AdditionalAmountChargedAgainstIncome contextRef="c-12" decimals="0" id="f-622" unitRef="usd">813000</jan:AdditionalAmountChargedAgainstIncome>
    <jan:GainLossOnWriteOffOfNotesReceivable contextRef="c-1" decimals="-5" id="f-623" unitRef="usd">-9800000</jan:GainLossOnWriteOffOfNotesReceivable>
    <us-gaap:InterestIncomeInterestEarningAsset contextRef="c-120" decimals="-3" id="f-624" unitRef="usd">806000</us-gaap:InterestIncomeInterestEarningAsset>
    <us-gaap:InterestIncomeInterestEarningAsset contextRef="c-124" decimals="-3" id="f-625" unitRef="usd">387000</us-gaap:InterestIncomeInterestEarningAsset>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-121" decimals="-5" id="f-626" unitRef="usd">0</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-125" decimals="-5" id="f-627" unitRef="usd">9000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <jan:DispositionTransactionConsiderAmount contextRef="c-126" decimals="-5" id="f-628" unitRef="usd">1600000</jan:DispositionTransactionConsiderAmount>
    <jan:DispositionTransactionTermPeriod contextRef="c-126" id="f-629">P15Y</jan:DispositionTransactionTermPeriod>
    <jan:DispositionTransactionAggregateCost contextRef="c-126" decimals="-5" id="f-630" unitRef="usd">24000000</jan:DispositionTransactionAggregateCost>
    <us-gaap:PaymentsForCommissions contextRef="c-126" decimals="-3" id="f-631" unitRef="usd">3000</us-gaap:PaymentsForCommissions>
    <jan:DispositionDiscountRate contextRef="c-126" decimals="3" id="f-632" unitRef="number">0.200</jan:DispositionDiscountRate>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="c-127" decimals="-5" id="f-633" unitRef="usd">6000000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:PaymentsForCommissions contextRef="c-126" decimals="-3" id="f-634" unitRef="usd">3000</us-gaap:PaymentsForCommissions>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="c-127" decimals="-5" id="f-635" unitRef="usd">6000000.0</us-gaap:ReceivableWithImputedInterestNetAmount>
    <jan:RevisedDiscountAmount contextRef="c-127" decimals="-5" id="f-636" unitRef="usd">18000000</jan:RevisedDiscountAmount>
    <us-gaap:InterestIncomeInterestEarningAsset contextRef="c-128" decimals="-3" id="f-637" unitRef="usd">720000</us-gaap:InterestIncomeInterestEarningAsset>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-129" decimals="-5" id="f-638" unitRef="usd">5300000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-639">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 9: Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets as of consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Soin intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents and domains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible amortization expense for continuing operations was approximately $1.5&#160;million and $0, respectively, for the fiscal years ended December&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Soin Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&#x201c;STLLC&#x201d;), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a 10-year period. See Note 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-640">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets as of consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Soin intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents and domains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-130" decimals="-3" id="f-641" unitRef="usd">19293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-131" decimals="-3" id="f-642" unitRef="usd">19293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-132" decimals="-3" id="f-643" unitRef="usd">4000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-133" decimals="-3" id="f-644" unitRef="usd">4000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-134" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-135" decimals="-3" id="f-646" unitRef="usd">3563000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-41" decimals="-3" id="f-647" unitRef="usd">19297000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-42" decimals="-3" id="f-648" unitRef="usd">22860000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-41" decimals="-3" id="f-649" unitRef="usd">1451000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-42" decimals="-3" id="f-650" unitRef="usd">3563000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-41" decimals="-3" id="f-651" unitRef="usd">17846000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-42" decimals="-3" id="f-652" unitRef="usd">19297000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-653" unitRef="usd">1500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-5" id="f-654" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <jan:NumberOfAcquiredIntangibleAssets
      contextRef="c-45"
      decimals="INF"
      id="f-655"
      unitRef="patent">3</jan:NumberOfAcquiredIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-45" id="f-656">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-657">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 10: Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of the following (in $000&#x2019;s, except shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series G Convertible Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common Shares Equivalent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amount &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mark-to-market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;922,442,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mark-to-market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance, December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;952,442,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities reflect shares of SPYR stock received by the Company in connection with the sale of GeoTraq. See Note 5. Quarterly interest payments may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash. Shares of Series G Convertible Preferred Stock are convertible into the SPYR&#x2019;s common shares at a ratio of 1:100,000. Shares held are marked to fair market value as of each balance sheet date, with the resulting change recorded as an unrealized gain or loss. For the year ended December&#160;30, 2023, the Company received 9,224 shares of Series G Convertible Preferred Stock, which are convertible into approximately 922.4 million shares of SPYR&#x2019;s common stock. For the year ended December&#160;31, 2022, the Company received 30 million shares of SPYR&#x2019;s common stock. Unrealized loss was approximately $926,000 and $631,000 for the years ended December&#160;30, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-658">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of the following (in $000&#x2019;s, except shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series G Convertible Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common Shares Equivalent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amount &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mark-to-market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;922,442,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mark-to-market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance, December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;952,442,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <jan:MarketableSecuritiesSharesOutstanding
      contextRef="c-136"
      id="f-659"
      unitRef="shares"
      xsi:nil="true"/>
    <jan:MarketableSecuritiesSharesOutstanding contextRef="c-137" decimals="0" id="f-660" unitRef="shares">0</jan:MarketableSecuritiesSharesOutstanding>
    <us-gaap:MarketableSecurities contextRef="c-18" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:MarketableSecurities>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares contextRef="c-138" decimals="0" id="f-662" unitRef="shares">0</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares contextRef="c-139" decimals="0" id="f-663" unitRef="shares">30000000</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-12" decimals="-3" id="f-664" unitRef="usd">946000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-665" unitRef="usd">-631000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <jan:MarketableSecuritiesSharesOutstanding contextRef="c-140" decimals="0" id="f-666" unitRef="shares">0</jan:MarketableSecuritiesSharesOutstanding>
    <jan:MarketableSecuritiesSharesOutstanding contextRef="c-141" decimals="0" id="f-667" unitRef="shares">30000000</jan:MarketableSecuritiesSharesOutstanding>
    <us-gaap:MarketableSecurities contextRef="c-5" decimals="-3" id="f-668" unitRef="usd">315000</us-gaap:MarketableSecurities>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares contextRef="c-142" decimals="0" id="f-669" unitRef="shares">9224</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares contextRef="c-143" decimals="0" id="f-670" unitRef="shares">922442000</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-671" unitRef="usd">897000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-672" unitRef="usd">-926000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <jan:MarketableSecuritiesSharesOutstanding contextRef="c-144" decimals="0" id="f-673" unitRef="shares">9224</jan:MarketableSecuritiesSharesOutstanding>
    <jan:MarketableSecuritiesSharesOutstanding contextRef="c-145" decimals="0" id="f-674" unitRef="shares">952442000</jan:MarketableSecuritiesSharesOutstanding>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-675" unitRef="usd">286000</us-gaap:MarketableSecurities>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares
      contextRef="c-142"
      decimals="INF"
      id="f-676"
      unitRef="shares">9224</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <jan:ConvertiblePreferredStockSharesIssuableUponConversion
      contextRef="c-145"
      decimals="-5"
      id="f-677"
      unitRef="shares">922400000</jan:ConvertiblePreferredStockSharesIssuableUponConversion>
    <jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares
      contextRef="c-118"
      decimals="INF"
      id="f-678"
      unitRef="shares">30000000</jan:NoncashOrPartNoncashDivestitureConsiderationReceivedShares>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-679" unitRef="usd">-926000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-680" unitRef="usd">-631000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-682">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 11: Deposits and other assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-43" decimals="-3" id="f-684" unitRef="usd">9000</jan:DepositsAndOtherAssetsNoncurrent>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-44" decimals="-3" id="f-685" unitRef="usd">18000</jan:DepositsAndOtherAssetsNoncurrent>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-43" decimals="-3" id="f-686" unitRef="usd">9000</jan:DepositsAndOtherAssetsNoncurrent>
    <jan:DepositsAndOtherAssetsNoncurrent contextRef="c-44" decimals="-3" id="f-687" unitRef="usd">18000</jan:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-688">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 12: Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities of continuing consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued guarantees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued litigation/legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-689">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities of continuing consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued guarantees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued litigation/legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-690" unitRef="usd">37000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-691" unitRef="usd">81000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <jan:AccruedGuaranteesCurrent contextRef="c-4" decimals="-3" id="f-692" unitRef="usd">3049000</jan:AccruedGuaranteesCurrent>
    <jan:AccruedGuaranteesCurrent contextRef="c-5" decimals="-3" id="f-693" unitRef="usd">130000</jan:AccruedGuaranteesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-3" id="f-694" unitRef="usd">102000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-695" unitRef="usd">5000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-4" decimals="-3" id="f-696" unitRef="usd">397000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-5" decimals="-3" id="f-697" unitRef="usd">510000</us-gaap:LitigationReserveCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-4" decimals="-3" id="f-698" unitRef="usd">48000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-5" decimals="-3" id="f-699" unitRef="usd">280000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-700" unitRef="usd">3633000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-701" unitRef="usd">1006000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermDebtTextBlock contextRef="c-1" id="f-702">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 13: Short-term debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt and other financing obligations consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AFCO Finance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AFCO Finance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into a financing agreement with AFCO Credit Corporation (&#x201c;AFCO&#x201d;) purchased through Marsh Insurance on an annual basis to fund the annual premiums on insurance policies due July 1 of each year. These policies relate to workers&#x2019; compensation and various liability policies including, but not limited to, General, Auto, Umbrella, Property, and Directors&#x2019; and Officers&#x2019; insurance. The total amount of the premiums financed in July 2022 was approximately $516,000 with an interest rate ranging from approximately 6.0% over the period. An initial down payment of approximately $129,000 was made on July 21, 2022 with additional monthly payments of approximately $59,000, escalating to approximately $69,000 over the term, being made beginning August&#160;1, 2022 and ending on April&#160;1, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding principal due AFCO at December&#160;31, 2022 was approximately $274,000. No such financing agreement was entered into by the Company during fiscal 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-703">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt and other financing obligations consist of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AFCO Finance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c-146" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-147" decimals="-3" id="f-705" unitRef="usd">274000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-5" decimals="-3" id="f-707" unitRef="usd">274000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-148" decimals="-3" id="f-708" unitRef="usd">516000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-148" decimals="3" id="f-709" unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-149" decimals="-3" id="f-710" unitRef="usd">129000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-150" decimals="-3" id="f-711" unitRef="usd">59000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-151" decimals="-3" id="f-712" unitRef="usd">69000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:LongTermDebt contextRef="c-152" decimals="-3" id="f-713" unitRef="usd">274000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-153" decimals="-3" id="f-714" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-154" decimals="-3" id="f-715" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PreferredStockTextBlock contextRef="c-1" id="f-716">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 14: Series A-1 Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;History&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;18, 2017, the Company acquired GeoTraq by way of merger. In connection with this transaction, the Company tendered to the owners of GeoTraq $200,000, issued to them an aggregate of 288,588 shares (number of shares specific &#x2013; not rounded) of the Company&#x2019;s Series A Convertible Preferred Stock valued at $12.3 million, including the beneficial conversion feature of $2.6 million, and entered into one-year unsecured promissory notes in the aggregate principal amount of $800,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &#x201c;Conversion Ratio&#x201d; per share of the Series A-1 Convertible Preferred Stock in connection with any conversion shall be at a ratio of 20:1, one share of Series A-1 Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into twenty shares Common Stock. Each holder shall have the right, exercisable at any time and from time to time (unless otherwise prohibited by law, rule, or regulation, or as restricted below), to convert any or all of such holder&#x2019;s shares of Series A-1 Convertible Preferred Stock into shares of Common Stock at the Conversion Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;30, 2023 and December&#160;31, 2022, 27,353 and 16,141 shares of the Company&#x2019;s Series A-1 Convertible Preferred Stock were converted into 547,069 and 322,820 shares, respectively, of the Company&#x2019;s common stock. Additionally, during the year ended December&#160;30, 2023, 1,505 shares of the Company&#x2019;s Series A-1 Convertible Preferred Stock were forfeited. As of December&#160;30, 2023 and December&#160;31, 2022, there were 193,730 and 222,588 shares, respectively, of Series A-1 Convertible Preferred Stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company cannot declare, pay or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the obtaining of any consents required by our Articles of Incorporation) the holders of the Series A Convertible Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend in the aggregate amount of one dollar, regardless of the number of then-issued and outstanding shares of Series A Convertible Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount per share to the holders of outstanding common stock and Series A-1 Convertible Preferred Stock (on an as-if-converted to common stock basis pursuant to the Conversion Ratio as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voting Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each holder of a share of Series A Convertible Preferred Stock has a number of votes as is determined by multiplying (i) the number of shares of Series A Preferred Stock held by such holder, and (ii) 17. The holders of Series A-1 Convertible Preferred Stock vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the common stockholders of the Company, except to the extent that voting as a separate class or series is required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A-1 Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preemptive Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Series A-1 Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Protective Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Without first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Convertible Preferred Stock; or (iv) alter or change the rights, preferences or privileges of the shares of Series A-1 Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series A-1 Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series A-1 Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 15: Series S Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;History&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;28, 2022 the acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Soin further agreed to certain restrictions on the maximum number of shares of Series S Stock that he may ultimately keep or that he may convert into shares of our common stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares of Series S Stock into shares of the Company's common stock in an amount such that, upon any such conversion, he beneficially own shares of the Company's common stock in excess of 4.99% of the Company's then-outstanding common stock and (ii) during the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Stock into shares of the Company's common stock, he will not dispose of any of such shares into the public markets in an amount that exceeds five percent of the daily trading volume of the Company's common stock during any trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of Series S Convertible Preferred Stock are convertible into the Company&#x2019;s common shares at a ratio of 1:1. As of December&#160;30, 2023 and December&#160;31, 2022, there were 100,000 of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#x2019;s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Series S Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Series S preferred issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of Series S Convertible Preferred Stock do not have dividend rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voting Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Holder of each share of Series S Convertible Preferred Stock shall have one vote for such share. With respect to any stockholder vote, the Holder shall have full voting rights and powers equal to the voting rights and powers of the Common Stock stockholders, and shall be entitled to notice of any stockholders' meeting in accordance with the Bylaws of the Company, and shall be entitled to vote, together with Common Stock stockholders, with respect to any question upon which the Common Stock stockholders have the right to vote. The Holders of Series S Convertible Preferred Stock shall vote together with all other classes and series of common and preferred stock of the Company as a single class on all actions to be taken by the Common Stock stockholders, except to the extent that voting as a separate class or series is required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series S Convertible Preferred Stock has no redemption rights by JanOne, or any other entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preemptive Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Series S Convertible Preferred Stock and holders of JanOne common stock are not entitled to any preemptive, subscription, or similar rights in respect of any securities of JanOne, except as set forth in the Amended and Restated Series A-1 Certificate of Designation or in any other document agreed to by JanOne.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Protective Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Without first obtaining the affirmative approval of a majority of the holders of the shares of Series S Convertible Preferred Stock, the Company may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Convertible Preferred Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Convertible Preferred Stock, but excluding a stock split or reverse stock split or combination of the common stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series S Convertible Preferred Stock; (iv) issue additional shares of Series S Convertible Preferred Stock other than in connection with the merger agreement, or (v) alter or change the rights, preferences or privileges of the shares of Series S Convertible Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in this Designation; provided, however, that we may, without any vote of the holders of shares of the Series S Convertible Preferred Stock, make technical, corrective, administrative or similar changes to the Amended and Restated Series S Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the Series S Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-155" decimals="-3" id="f-717" unitRef="usd">200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-155"
      decimals="INF"
      id="f-718"
      unitRef="shares">288588</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-156" decimals="-3" id="f-719" unitRef="usd">12300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jan:BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue contextRef="c-157" decimals="-5" id="f-720" unitRef="usd">2600000</jan:BusinessCombinationConsiderationTransferredBeneficialConversionFeatureValue>
    <jan:BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm contextRef="c-155" id="f-721">P1Y</jan:BusinessCombinationConsiderationTransferredLiabilitiesIncurredTerm>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-155" decimals="-3" id="f-722" unitRef="usd">800000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-158"
      decimals="INF"
      id="f-723"
      unitRef="number">20</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-158"
      decimals="INF"
      id="f-724"
      unitRef="shares">27353</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-159"
      decimals="INF"
      id="f-725"
      unitRef="shares">16141</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-160"
      decimals="INF"
      id="f-726"
      unitRef="shares">547069</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-161"
      decimals="INF"
      id="f-727"
      unitRef="shares">322820</us-gaap:ConversionOfStockSharesIssued1>
    <jan:ConversionOfStockSharesForfeited
      contextRef="c-160"
      decimals="INF"
      id="f-728"
      unitRef="shares">1505</jan:ConversionOfStockSharesForfeited>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-158"
      decimals="INF"
      id="f-729"
      unitRef="shares">193730</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-159"
      decimals="INF"
      id="f-730"
      unitRef="shares">222588</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-162" decimals="-6" id="f-731" unitRef="usd">30000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-162"
      decimals="INF"
      id="f-732"
      unitRef="shares">100000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <jan:ConversionOfStockAmountConvertible contextRef="c-163" decimals="-6" id="f-733" unitRef="usd">3000000</jan:ConversionOfStockAmountConvertible>
    <jan:ConversionOfStockCommencementPeriod contextRef="c-58" id="f-734">P1Y</jan:ConversionOfStockCommencementPeriod>
    <jan:ConversionOfStockAmountConvertible contextRef="c-164" decimals="-6" id="f-735" unitRef="usd">10000000</jan:ConversionOfStockAmountConvertible>
    <jan:ConversionOfStockPeriodFollowingClosing contextRef="c-60" id="f-736">P10Y</jan:ConversionOfStockPeriodFollowingClosing>
    <jan:ConversionOfStockPeriodFollowingClosing contextRef="c-60" id="f-737">P10Y</jan:ConversionOfStockPeriodFollowingClosing>
    <jan:ConversionOfStockAmountConvertible contextRef="c-165" decimals="-6" id="f-738" unitRef="usd">17000000</jan:ConversionOfStockAmountConvertible>
    <jan:PercentageOfGrossRevenue contextRef="c-166" decimals="2" id="f-739" unitRef="number">0.05</jan:PercentageOfGrossRevenue>
    <jan:CommonStockSharesOutstandingPercentage contextRef="c-167" decimals="4" id="f-740" unitRef="number">0.0499</jan:CommonStockSharesOutstandingPercentage>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-66"
      decimals="INF"
      id="f-741"
      unitRef="number">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="c-1" id="f-742">As of December&#160;30, 2023 and December&#160;31, 2022, there were 100,000 of Series S Convertible Preferred Stock outstanding, as reflected in the following (dollars in $000&#x2019;s).&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Series S Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Series S preferred issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance, December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-66" decimals="-3" id="f-743" unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-168"
      decimals="-3"
      id="f-744"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-169"
      decimals="INF"
      id="f-745"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-169" decimals="-3" id="f-746" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <jan:TemporaryEquitySharesIssuedDuringPeriodShares
      contextRef="c-170"
      decimals="INF"
      id="f-747"
      unitRef="shares">100000</jan:TemporaryEquitySharesIssuedDuringPeriodShares>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-170" decimals="-3" id="f-748" unitRef="usd">14510000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-168"
      decimals="INF"
      id="f-749"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-168" decimals="-3" id="f-750" unitRef="usd">14510000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-66"
      decimals="INF"
      id="f-751"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-66" decimals="-3" id="f-752" unitRef="usd">14510000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <jan:PreferredStockVotingRightsNumberOfVotesEntitledToEachShare contextRef="c-66" decimals="INF" id="f-753" unitRef="vote">1</jan:PreferredStockVotingRightsNumberOfVotesEntitledToEachShare>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c-1" id="f-754">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 16: Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company's Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. As of December&#160;30, 2023, and December&#160;31, 2022, there were 4,957,647 and 3,150,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares, respectively, of common stock issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Offerings:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;22, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company in a registered direct offering of 361,000 shares of the Company&#x2019;s common stock, par value $0.001 per share, at a purchase price per share of Common Stock of $1.17. The offering closed on March&#160;24, 2023. The aggregate gross proceeds for the sale of the shares of Common Stock were approximately $422,000, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;18, 2023, the Company entered into a Securities Purchase Agreement with a certain institutional investor for the sale by the Company in a registered direct offering of: (i) 418,000 shares of the Company&#x2019;s common stock, par value $0.001 per share, at an offering price of $0.8811 per share and (ii) pre-funded warrants exercisable for up to 481,348 shares of Common Stock to the Investor at an offering price equal to $0.8801 per pre-funded Warrant. The aggregate gross proceeds from the offering were approximately $790,000, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes. On August&#160;31, 2023, 481,348 of the pre-funded warrants were exercised. In a concurrent private placement, the Company also granted warrants to purchase up to 899,348 shares of Common Stock. Each warrant is exercisable immediately following issuance at an exercise price of $0.7561 per share and expires August&#160;31, 2023. As of December&#160;30, 2023, there were 899,348 of the private placement warrants outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Incentives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 annual meeting of stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the year ended December&#160;30, 2023, the Company granted $345,000 in restricted stock units, or 908,852 underlying shares of the Company's common stock, which were all immediately vested. As of December&#160;30, 2023, $345,000 in restricted stock units, or 908,852 underlying shares of the Company's common stock, were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October&#160;28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November&#160;4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of December&#160;30, 2023 and December&#160;31, 2022, 100,000 and 90,000 options were outstanding under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May&#160;12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of December&#160;30, 2023 and December&#160;31, 2022, 14,000 and 20,000 options, respectively, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022 (Aggregate Intrinsic Value in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;br/&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price for stock options outstanding and exercisable outstanding at December&#160;30, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.35 to $23.45&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.35 to $23.45&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.10 to $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.10 to $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.70 to $9.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.70 to $9.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.54 to $5.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.54 to $5.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the Company&#x2019;s non-vested shares outstanding as of December&#160;30, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-vested Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense related to equity incentive awards of approximately $14,000 and approximately $5,000 for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively. As of December&#160;30, 2023, the Company had no unrecognized share-based compensation expense associated with stock option awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-171"
      decimals="INF"
      id="f-755"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-171"
      decimals="INF"
      id="f-756"
      unitRef="shares">4957647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-172"
      decimals="INF"
      id="f-757"
      unitRef="shares">3150230</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering
      contextRef="c-173"
      decimals="INF"
      id="f-758"
      unitRef="shares">361000</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-174"
      decimals="INF"
      id="f-759"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <jan:CommonStockPurchasePricePerShare
      contextRef="c-174"
      decimals="2"
      id="f-760"
      unitRef="usdPerShare">1.17</jan:CommonStockPurchasePricePerShare>
    <us-gaap:ProceedsFromSaleOfInterestInPartnershipUnit contextRef="c-173" decimals="-3" id="f-761" unitRef="usd">422000</us-gaap:ProceedsFromSaleOfInterestInPartnershipUnit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-175"
      decimals="INF"
      id="f-762"
      unitRef="shares">418000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-176"
      decimals="INF"
      id="f-763"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-176"
      decimals="INF"
      id="f-764"
      unitRef="usdPerShare">0.8811</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-177"
      decimals="INF"
      id="f-765"
      unitRef="shares">481348</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-177"
      decimals="INF"
      id="f-766"
      unitRef="usdPerShare">0.8801</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-175" decimals="-3" id="f-767" unitRef="usd">790000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <jan:ClassOfWarrantOrRightWarrantsOrRightsExercised
      contextRef="c-178"
      decimals="INF"
      id="f-768"
      unitRef="shares">481348</jan:ClassOfWarrantOrRightWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-176"
      decimals="INF"
      id="f-769"
      unitRef="shares">899348</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-176"
      decimals="INF"
      id="f-770"
      unitRef="usdPerShare">0.7561</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-179"
      decimals="INF"
      id="f-771"
      unitRef="shares">899348</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-180"
      decimals="INF"
      id="f-772"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-181" decimals="-3" id="f-773" unitRef="usd">345000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-182" decimals="0" id="f-774" unitRef="shares">908852</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-183" decimals="-3" id="f-775" unitRef="usd">345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-180" decimals="0" id="f-776" unitRef="shares">908852</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-184"
      decimals="INF"
      id="f-777"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-185"
      decimals="INF"
      id="f-778"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-186"
      decimals="-3"
      id="f-779"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-187"
      decimals="-3"
      id="f-780"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-188"
      decimals="INF"
      id="f-781"
      unitRef="shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-189"
      decimals="INF"
      id="f-782"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <jan:AdditionalAwardsToBeGranted
      contextRef="c-190"
      decimals="INF"
      id="f-783"
      unitRef="shares">0</jan:AdditionalAwardsToBeGranted>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-784">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022 (Aggregate Intrinsic Value in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;br/&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-18"
      decimals="INF"
      id="f-785"
      unitRef="shares">117500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-18"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-18" decimals="-3" id="f-787" unitRef="usd">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-191" id="f-788">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-12"
      decimals="INF"
      id="f-789"
      unitRef="shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-790" unitRef="shares">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-791"
      unitRef="usdPerShare">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-792" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-793">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-794" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-796" unitRef="shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-797"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-798" unitRef="shares">114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-799"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-800" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-801">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-802" unitRef="shares">114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-803"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-804" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-805">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-806">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price for stock options outstanding and exercisable outstanding at December&#160;30, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.35 to $23.45&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.35 to $23.45&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.10 to $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.10 to $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.70 to $9.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.70 to $9.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.54 to $5.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.54 to $5.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-192"
      decimals="INF"
      id="f-807"
      unitRef="shares">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-193"
      decimals="2"
      id="f-808"
      unitRef="usdPerShare">17.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-193"
      decimals="2"
      id="f-809"
      unitRef="usdPerShare">23.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-192"
      decimals="INF"
      id="f-810"
      unitRef="shares">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-193"
      decimals="2"
      id="f-811"
      unitRef="usdPerShare">17.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-193"
      decimals="2"
      id="f-812"
      unitRef="usdPerShare">23.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-194"
      decimals="INF"
      id="f-813"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-195"
      decimals="2"
      id="f-814"
      unitRef="usdPerShare">11.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-195"
      decimals="2"
      id="f-815"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-194"
      decimals="INF"
      id="f-816"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-195"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">11.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-195"
      decimals="2"
      id="f-818"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-196"
      decimals="INF"
      id="f-819"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-197"
      decimals="2"
      id="f-820"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-197"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">9.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-196"
      decimals="INF"
      id="f-822"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-197"
      decimals="2"
      id="f-823"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-197"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">9.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-198"
      decimals="INF"
      id="f-825"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-199"
      decimals="2"
      id="f-826"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-199"
      decimals="2"
      id="f-827"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-198"
      decimals="INF"
      id="f-828"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-199"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-199"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c-4" decimals="INF" id="f-831" unitRef="shares">114000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c-4" decimals="INF" id="f-832" unitRef="shares">114000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-833">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the Company&#x2019;s non-vested shares outstanding as of December&#160;30, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-vested Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested at December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-18"
      decimals="INF"
      id="f-834"
      unitRef="shares">7500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c-12"
      decimals="INF"
      id="f-835"
      unitRef="shares">7500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-5" decimals="INF" id="f-836" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-837" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c-1" decimals="INF" id="f-838" unitRef="shares">10000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-4" decimals="INF" id="f-839" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-200" decimals="-3" id="f-840" unitRef="usd">14000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-201" decimals="-3" id="f-841" unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-202" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-843">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 17: Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, the Company recorded an income tax benefit from continuing operations of approximately $429,000 and an income tax benefit of $6.6&#160;million, respectively, and an income tax provision from discontinued operations of approximately $971,000 and $2.1 million, respectively, which consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax provision (benefit) - domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision (benefit) of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company's income tax benefit (provision) with the federal statutory tax rate for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively, is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal income tax for installment sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impact of sale of ARCA Recycling and Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-65.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before provision of income taxes was derived from the following sources for fiscal years December&#160;30, 2023 and December&#160;31, 2022, respectively, as shown below (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred tax assets (liabilities) as of December&#160;30, 2023 and December&#160;31, 2022, respectively, are as follows (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 174 expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Installment sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 163(j) interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;30, 2023, the Company has net operating loss carryforwards of approximately $20.9 million for federal income tax purposes, and approximately $14.8 million for state income tax purposes, which will be available to offset future taxable income. Due to recent tax legislation, the federal net operating losses are eligible for indefinite carryforward, limited by certain taxable income limitations. State net operating losses begin to expire in 2029. The Company evaluates all available evidence to determine if a valuation allowance is needed to reduce its deferred tax assets. During the fourth quarter of fiscal year 2023, management concluded that a valuation allowance is necessary for the state net operating loss carryforward and a portion of the federal net operating loss carryforward. Due to the 2023 sale of ARCA Canada (as part of the Recycling Subsidiaries transaction), the valuation allowance was released. The Company has recorded a valuation allowance of approximately $2.8 million and $904,000 as of December&#160;30, 2023, and December&#160;31, 2022, respectfully.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company annually conducts an analysis of its uncertain tax positions and has concluded that it has no uncertain tax positions as of December&#160;30, 2023. The Company&#x2019;s policy is to record uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S. and state income tax returns in jurisdictions with differing statutes of limitations. The 2020 through 2023 tax years remain subject to selection for examination as of December&#160;30, 2023. None of the Company&#x2019;s income tax returns are currently under audit.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-844">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, the Company recorded an income tax benefit from continuing operations of approximately $429,000 and an income tax benefit of $6.6&#160;million, respectively, and an income tax provision from discontinued operations of approximately $971,000 and $2.1 million, respectively, which consisted of the following (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax provision (benefit) - domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision (benefit) of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-203" decimals="-3" id="f-845" unitRef="usd">-429000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-846" unitRef="usd">-6600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-204" decimals="-3" id="f-847" unitRef="usd">971000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-205" decimals="-5" id="f-848" unitRef="usd">2100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-849" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-850" unitRef="usd">32000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-851" unitRef="usd">97000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-852" unitRef="usd">45000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-853" unitRef="usd">97000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-854" unitRef="usd">77000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-855" unitRef="usd">445000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-856" unitRef="usd">-4589000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <jan:ProvisionBenefitOfIncomeTaxes contextRef="c-1" decimals="-3" id="f-857" unitRef="usd">542000</jan:ProvisionBenefitOfIncomeTaxes>
    <jan:ProvisionBenefitOfIncomeTaxes contextRef="c-12" decimals="-3" id="f-858" unitRef="usd">-4512000</jan:ProvisionBenefitOfIncomeTaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-859">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company's income tax benefit (provision) with the federal statutory tax rate for the fiscal years ended December&#160;30, 2023, and December&#160;31, 2022, respectively, is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal income tax for installment sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impact of sale of ARCA Recycling and Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-65.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-860" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="3" id="f-861" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent contextRef="c-1" decimals="3" id="f-862" unitRef="number">0</jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent>
    <jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent contextRef="c-12" decimals="3" id="f-863" unitRef="number">0.006</jan:EffectiveIncomeTaxRateReconciliationFederalIncomeTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-864" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-865" unitRef="number">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-866" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-12" decimals="3" id="f-867" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-1" decimals="3" id="f-868" unitRef="number">0.001</jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-12" decimals="3" id="f-869" unitRef="number">-0.004</jan:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-870" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="3" id="f-871" unitRef="number">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c-1" decimals="3" id="f-872" unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c-12" decimals="3" id="f-873" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-874" unitRef="number">-0.257</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="3" id="f-875" unitRef="number">-0.964</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-876" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="3" id="f-877" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-878" unitRef="number">-0.073</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-879" unitRef="number">-0.659</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-880">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before provision of income taxes was derived from the following sources for fiscal years December&#160;30, 2023 and December&#160;31, 2022, respectively, as shown below (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-881" unitRef="usd">-6613000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-3" id="f-882" unitRef="usd">6717000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-883" unitRef="usd">-657000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-3" id="f-884" unitRef="usd">-237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes contextRef="c-1" decimals="-3" id="f-885" unitRef="usd">-7270000</jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes>
    <jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes contextRef="c-12" decimals="-3" id="f-886" unitRef="usd">6480000</jan:IncomeLossFromContinuingOperationsBeforeProvisionBenefitOfIncomeTaxes>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-887">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred tax assets (liabilities) as of December&#160;30, 2023 and December&#160;31, 2022, respectively, are as follows (in $000&#x2019;s):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 174 expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Installment sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 163(j) interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-888" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-889" unitRef="usd">1723000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-4" decimals="-3" id="f-890" unitRef="usd">3000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-891" unitRef="usd">82000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <jan:Section174Expenses contextRef="c-4" decimals="-3" id="f-892" unitRef="usd">61000</jan:Section174Expenses>
    <jan:Section174Expenses contextRef="c-5" decimals="-3" id="f-893" unitRef="usd">92000</jan:Section174Expenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-3" id="f-894" unitRef="usd">16000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-3" id="f-895" unitRef="usd">184000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-896" unitRef="usd">5360000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-897" unitRef="usd">5494000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <jan:DeferredTaxAssetsLeaseLiability contextRef="c-4" decimals="-3" id="f-898" unitRef="usd">0</jan:DeferredTaxAssetsLeaseLiability>
    <jan:DeferredTaxAssetsLeaseLiability contextRef="c-5" decimals="-3" id="f-899" unitRef="usd">39000</jan:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-900" unitRef="usd">3000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-901" unitRef="usd">3000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-902" unitRef="usd">136000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-903" unitRef="usd">171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-904" unitRef="usd">3747000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-905" unitRef="usd">4782000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-906" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-907" unitRef="usd">483000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <jan:DeferredTaxLiabilitiesInstallmentSale contextRef="c-4" decimals="-3" id="f-908" unitRef="usd">0</jan:DeferredTaxLiabilitiesInstallmentSale>
    <jan:DeferredTaxLiabilitiesInstallmentSale contextRef="c-5" decimals="-3" id="f-909" unitRef="usd">2114000</jan:DeferredTaxLiabilitiesInstallmentSale>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="c-4" decimals="-3" id="f-910" unitRef="usd">327000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="c-5" decimals="-3" id="f-911" unitRef="usd">305000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <jan:DeferredTaxAssetsInterest contextRef="c-4" decimals="-3" id="f-912" unitRef="usd">0</jan:DeferredTaxAssetsInterest>
    <jan:DeferredTaxAssetsInterest contextRef="c-5" decimals="-3" id="f-913" unitRef="usd">363000</jan:DeferredTaxAssetsInterest>
    <jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance contextRef="c-4" decimals="-3" id="f-914" unitRef="usd">2134000</jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance>
    <jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance contextRef="c-5" decimals="-3" id="f-915" unitRef="usd">709000</jan:DeferredTaxAssetsLiabilitiesGrossBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-916" unitRef="usd">2773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-917" unitRef="usd">904000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-918" unitRef="usd">639000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-919" unitRef="usd">195000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-206" decimals="-5" id="f-920" unitRef="usd">20900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-207" decimals="-5" id="f-921" unitRef="usd">14800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c-4" decimals="-5" id="f-922" unitRef="usd">2800000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c-5" decimals="-3" id="f-923" unitRef="usd">904000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-924">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 18: Related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tony Isaac, the Company&#x2019;s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures Incorporated (&#x201c;Live Ventures&#x201d;) and managing member of ICG. Tony Isaac, Chief Executive Officer and Richard Butler, Board of Directors member of the Company, are both Board of Directors members of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $203,000 and approximately $314,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively. Connexx rents approximately 9,900 square feet of office space from Live Ventures at its Las Vegas, Nevada office. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, we ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expenses for Connexx at the Las Vegas, Nevada office were approximately $103,000 and approximately $215,000 for fiscal years ending December&#160;30, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During Q4 2023, operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. See Note 4. Consequently, outstanding liabilities for shared rent and services for the Recycling Subsidiaries reverted to the Company. As such, the Company has recorded a liability in the amount of approximately $258,000, which was offset against the gain on sale of the Recycling Subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Recycling Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2023, the Company entered into a Stock Purchase Agreement (the &#x201c;Recycling Purchase Agreement&#x201d;) with VM7 Corporation, a Delaware corporation (&#x201c;VM7&#x201d;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries consisting of: (a) ARCA Recycling, Inc., (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement was consummated simultaneously with the execution of the Recycling Agreement. The Company's Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction. The Recycling Purchase Agreement is retroactively effective as of March 1, 2023. During the fourth quarter of fiscal 2023, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, the Company was advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because the Company did not receive all of the economic benefits of the Disposition Transaction and understands that it will not receive any future benefits of the Disposition Transaction, the Company determined to fully impair the $5.3&#160;million carrying value of the Disposition Transaction on its balance sheet. The Company also determined not to exercise any of its remedies under the Recycling Purchase Agreement so that the Company could maintain its focus on its clinical-stage biopharmaceutical activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ICG Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;28, 2019, ARCA Recycling entered into and delivered to ICG a secured revolving line of credit promissory note, whereby ICG agreed to provide ARCA Recycling with a $2.5 million revolving credit facility (the &#x201c;ICG Note&#x201d;). See Note 6. Jon Isaac is the manager and sole member of ICG, and the son of Tony Isaac, the Chief Executive Officer of JanOne and, previously, ARCA Recycling. ICG is a record and beneficial owner of 13.6% of the outstanding common stock of the Company. The ICG Note was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the ICG Note was guaranteed by the Company, it recorded a liability in the amount of approximately $690,000 for the principal balance due on the note, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. Additionally, effective February 2024, the ICG Note was amended to reflect the Company as co-maker on the ICG Note. See Note 22. The ICG Note matures in March 2026, and bears interest at 8.75% per annum. Monthly payments on the note are approximately $24,767. As of December&#160;30, 2023, the balance outstanding was approximately $706,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ARCA Recycling Purchasing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, ARCA Recycling entered into a Purchasing Agreement with Live Ventures. Pursuant to the Purchasing Agreement, Live Ventures agrees to purchase inventory from time to time for ARCA, as set forth in submitted purchase orders. The inventory is owned by Live Ventures until payment from ARCA Recycling is received. All purchases made by ARCA Recycling shall be paid back to Live Ventures in full plus an additional five percent surcharge or broker-type fee. The term of the Purchasing Agreement is one year, and automatically renews if not terminated by either party, as provided for in the Purchasing Agreement. The liability for the Purchasing Agreement was originally a component of the sale of the Recycling Subsidiaries in March 2023; however, because of the winding down of operations of the Recycling Subsidiaries during Q4 2023, and because the Purchasing Agreement was guaranteed by the Company, it recorded a liability in the amount of approximately $692,000 for the principal balance due under the Purchasing Agreement, which was offset against the gain on sale of the Recycling Subsidiaries. See Note 4. As of the years ended December&#160;30, 2023 and December&#160;31, 2022, the amount due to Live Ventures was approximately $692,000 and $624,000, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-208" decimals="-3" id="f-925" unitRef="usd">203000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-209" decimals="-3" id="f-926" unitRef="usd">314000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:NetRentableArea contextRef="c-210" decimals="0" id="f-927" unitRef="sqft">9900</us-gaap:NetRentableArea>
    <us-gaap:OperatingLeaseExpense contextRef="c-208" decimals="-3" id="f-928" unitRef="usd">103000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-209" decimals="-3" id="f-929" unitRef="usd">215000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccruedRentCurrentAndNoncurrent contextRef="c-6" decimals="-3" id="f-930" unitRef="usd">258000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-75" decimals="-5" id="f-931" unitRef="usd">-5300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-104" decimals="INF" id="f-932" unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-211" decimals="3" id="f-933" unitRef="number">0.136</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-212" decimals="-3" id="f-934" unitRef="usd">690000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-107" decimals="4" id="f-935" unitRef="number">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="c-108" decimals="0" id="f-936" unitRef="usd">24767</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:OtherLiabilities contextRef="c-212" decimals="-3" id="f-937" unitRef="usd">706000</us-gaap:OtherLiabilities>
    <jan:RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent contextRef="c-213" decimals="2" id="f-938" unitRef="number">0.05</jan:RelatedPartyTransactionPurchasesFromRelatedPartySurchargeOrBrokerFeePercent>
    <jan:RelatedPartyTransactionPurchaseAgreementTerm contextRef="c-213" id="f-939">P1Y</jan:RelatedPartyTransactionPurchaseAgreementTerm>
    <us-gaap:OtherLiabilities contextRef="c-214" decimals="-3" id="f-940" unitRef="usd">692000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c-215" decimals="-3" id="f-941" unitRef="usd">692000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c-216" decimals="-3" id="f-942" unitRef="usd">624000</us-gaap:OtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-943">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 19: Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SEC Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2021, the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) filed a civil complaint (the &#x201c;SEC Complaint&#x201d;) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the &#x201c;Defendants&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEC Complaint alleges financial, disclosure and reporting violations against the Company and the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC seeks permanent injunctions and civil penalties against the Defendants, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC&#x2019;s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to assert that the SEC&#x2019;s pursuit of this matter will not result in any benefit to investors and instead will only serve as a distraction from its core business. On October 1, 2021, the Company, filed a motion with the court to dismiss the complaint. The SEC filed its response opposing the motions on November 1, 2021. On September 7, 2022, the motions to dismiss were denied by the court. Pursuant to the automatic stay of proceedings under the Private Securities Litigation Reform Act, all discovery was stayed pending the motions to dismiss and the June 23, 2023 mediation to which all of the parties agreed. As of the date of these financial statements, the Company and the SEC have reached a settlement agreement in principal, the written agreement for which is pending at the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Skybridge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 29, 2016, the Company served a Minnesota state court complaint for breach of contract on Skybridge Americas, Inc. (&#x201c;SA&#x201d;), the Company&#x2019;s primary call center vendor throughout 2015 and most of 2016. The Company seeks damages in the millions of dollars as a result of alleged overcharging by SA and lost client contracts. On January&#160;25, 2017, SA served a counterclaim for unpaid invoices in the amount of approximately $460,000 plus interest and attorneys&#x2019; fees. On March 29, 2017, the Hennepin County district court (the &#x201c;District Court&#x201d;) dismissed the Company&#x2019;s breach of contract claim based on SA&#x2019;s overuse of its Canadian call center but permitted the Company&#x2019;s remaining claims to proceed. Following motion practice, on January 8, 2018 the District Court entered judgment in SA&#x2019;s favor, which was amended as of February&#160;28, 2018, for a total amount of approximately $614,000 including interest and attorneys&#x2019; fees. On March 4, 2019, the Minnesota Court of Appeals (the &#x201c;Court of Appeals&#x201d;) ruled and (i) reversed the District Court&#x2019;s judgment in favor of Skybridge on the call center location claim and remanded the issue back to the District Court for further proceedings, (ii) reversed the District Court&#x2019;s judgment in favor of Skybridge on the net payment issue and remanded the issue to the District Court for further proceedings, and (iii) affirmed the District Court&#x2019;s judgment in Skybridge&#x2019;s favor against the Company&#x2019;s claim that Skybridge breached the contract when it failed to meet the service level agreements. As a result of the decision by the Court of Appeals, the District Court&#x2019;s award of interest and attorneys&#x2019; fees, etc. was reversed. The Company and SA held a mediation session in July 2020. Trial was held in August 2020 and on February&#160;1, 2021, the District Court assessed damages against the Company in the amount of approximately $715,000, plus interest, fees, and costs and attorneys&#x2019; fees of $475,000. In subsequent proceedings, the Appeals Court affirmed the District Court judgment. Of the total amount awarded to SA, less the funds that the Company had previously deposited with the District Court, SA remains entitled to approximately $422,000 of statutory interest, which obligation has been assumed by VM7 in connection with the Recycling Subsidiaries Disposition transaction. See Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;AMTIM Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMTIM Capital, Inc. (&#x201c;AMTIM&#x201d;) acts as the Company&#x2019;s representative to market our recycling services in Canada under an arrangement that pays AMTIM for revenues generated by recycling services in Canada as set forth in the agreement between the parties. A dispute has arisen between AMTIM and the Company with respect to the calculation of amounts due to AMTIM pursuant to the agreement. In a lawsuit filed by AMTIM in the province of Ontario, AMTIM claims a discrepancy in the calculation of fees due to AMTIM by the Company of approximately $2.0 million. Trial commenced in February 2022, and, on December 12, 2022, a decree was issued by the court dismissing the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;GeoTraq&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or about April&#160;9, 2021, GeoTraq, Gregg Sullivan, Tony Isaac, and the Company, among others, resolved all of the claims that related to, among other items, the Company's acquisition of GeoTraq in August 2017, all post-acquisition activities, and Mr. Sullivan&#x2019;s post-acquisition employment relationship with GeoTraq (all of such claims, the &#x201c;GeoTraq Matters&#x201d;). The resolution was effectuated through the parties&#x2019; execution and delivery of a Settlement Agreement and Mutual Agreement of Claims (the &#x201c;GeoTraq Settlement Agreement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Settlement Agreement, the Company, on its own behalf and on behalf of GeoTraq and Mr. Isaac, agreed to tender to Mr. Sullivan an aggregate of $1.95 million (the &#x201c;GeoTraq Settlement Consideration&#x201d;) in the following manner: (i) $250,000, which was tendered in cash on or about the date of the Settlement Agreement and (ii) up to 10 quarterly installments of not less than $170,000 that commenced on June&#160;1, 2021, and continued not less frequently than every three months thereafter (the &#x201c;GeoTraq Installments&#x201d;). The Company may tender the GeoTraq Installments in cash or in the equivalent value of shares of its common stock (the value of the shares to be determined by a formula set forth in the Settlement Agreement), in either case at the Company's discretion. The Company may also prepay one or more GeoTraq Installments in full or in part at any time or from time to time either in cash or in shares of its common stock (a &#x201c;GeoTraq Prepayment&#x201d;). If the Company elected to prepay one or more GeoTraq Installments with shares of its common stock, Mr. Sullivan reserved the right not to consent to a tender thereof in excess of 50% of the value of that specific GeoTraq Prepayment; however, Mr. Sullivan was restricted in the reasons for which he can refuse to provide his written consent. The number of shares of the Company's common stock to be issued upon any GeoTraq Prepayment is determined by a different formula than the one to be utilized for a GeoTraq Installment. On March 17, 2023, the Company converted 5,185 of Mr. Sullivan&#x2019;s Series A-1 Preferred shares and issued 103,707 shares of the Company's common stock as payment for its quarterly installment. On June 1, 2023, the Company converted 7,697 of Mr. Sullivan&#x2019;s Series A-1 Preferred shares into 153,941 shares of the Company&#x2019;s common stock in payment of its June 30, 2023 quarterly installment. On September 1, 2023, the Company converted 14,471 of Mr. Sullivan&#x2019;s Series A-1 Preferred shares into 289,421 shares of the Company&#x2019;s common stock in payment of its September 30, 2023 quarterly installment. See Note 14. As of September 30, 2023, the full balance due under the Settlement Agreement had been repaid and the remaining 1,505 shares of Mr. Sullivan&#x2019;s Series A-1 Preferred shares were returned to the Company for cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The parties to the Settlement Agreement released and forever discharged one another from any and all known and unknown claims that were asserted or could have been asserted arising out of the GeoTraq Litigation Matters. The accrued liability for payments due to Mr. Sullivan is $0 and $510,000 as of December&#160;30, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alixpartners, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;19, 2022, Alixpartners, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, styled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alixpartners, LLC, plaintiff/petitioner, against JanOne Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Index No. 653877/2022. Plaintiff alleged the breach of an agreement and sought damages in the amount of approximately $345,000. The Company denied that obligation. After extensive negotiations, the parties reached a settlement, pursuant to which the Company agreed to pay to Alixpartners the sum of $125,000 in two tranches and to provide a confession of judgment in its favor in the amount of approximately $450,000, which represented the amount sought in the complaint plus interest thereon. The confession of judgment will be null and void and the complaint will be dismissed with prejudice upon the Company tendering both tranches timely. The Company tendered both settlement payments in May 2023, and the complaint was subsequently dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sieggreen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Main/270&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $90,000 therefor. Plaintiff also seeks approximately $1,420,000 against ApplianceSmart and the Company on a joint and several basis. The Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Westerville Square&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In an attempt to recover payments due under a lease, in 2021, Westerville Square, Inc., as the landlord, initiated a civil action against the Company, styled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Westerville Square, Inc. v. Appliance Recycling Centers Of America, Inc., et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Court of Common Pleas of Franklin County, Ohio, Case No. 19 CV 8627. The case was stayed during the bankruptcy proceedings of ApplianceSmart, Inc., and was reinstated on June 7, 2021. The landlord is currently seeking $120,000, which amount is disputed by the Company. Effective June 4, 2023, the parties settled the matter, pursuant to which settlement the Company tendered the sum of $110,000 to the landlord, the parties entered into a Settlement Agreement and Release, and the case was dismissed with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January&#160;2, 2021, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000 which represented amounts guaranteed or which may have been owed under certain lease agreements to three third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (&#x201c;ApplianceSmart Leases&#x201d;). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December&#160;30, 2023, the Company reversed approximately $637,000 of the accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December&#160;30, 2023, a balance of approximately $130,000 remains as an accrued liability due to an ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys&#x2019; fees expended in relation thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of December&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <jan:LossContingencyNumberOfExecutiveOfficersNamedInComplaint
      contextRef="c-217"
      decimals="INF"
      id="f-944"
      unitRef="officer">1</jan:LossContingencyNumberOfExecutiveOfficersNamedInComplaint>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-218" decimals="0" id="f-945" unitRef="usd">460000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-219" decimals="0" id="f-946" unitRef="usd">614000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-220" decimals="0" id="f-947" unitRef="usd">715000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LegalFees contextRef="c-220" decimals="0" id="f-948" unitRef="usd">475000</us-gaap:LegalFees>
    <jan:StatutoryInterestReceivable contextRef="c-221" decimals="0" id="f-949" unitRef="usd">422000</jan:StatutoryInterestReceivable>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-222" decimals="-5" id="f-950" unitRef="usd">2000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-120" decimals="-4" id="f-951" unitRef="usd">1950000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-120" decimals="0" id="f-952" unitRef="usd">250000</us-gaap:PaymentsForLegalSettlements>
    <jan:NumberOfInstallment
      contextRef="c-1"
      decimals="INF"
      id="f-953"
      unitRef="quarterly">10</jan:NumberOfInstallment>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-223" decimals="0" id="f-954" unitRef="usd">170000</us-gaap:PaymentsForLegalSettlements>
    <jan:PercentOfPrepaymentTenderRestrictions contextRef="c-224" decimals="2" id="f-955" unitRef="number">0.50</jan:PercentOfPrepaymentTenderRestrictions>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-225" decimals="0" id="f-956" unitRef="shares">5185</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c-226" decimals="0" id="f-957" unitRef="shares">103707</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-227" decimals="0" id="f-958" unitRef="shares">7697</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c-228" decimals="0" id="f-959" unitRef="shares">153941</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-229" decimals="0" id="f-960" unitRef="shares">14471</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c-230" decimals="0" id="f-961" unitRef="shares">289421</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-231"
      decimals="INF"
      id="f-962"
      unitRef="shares">1505</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-232" decimals="0" id="f-963" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-233" decimals="-3" id="f-964" unitRef="usd">510000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-234" decimals="0" id="f-965" unitRef="usd">345000</us-gaap:LossContingencyDamagesSoughtValue>
    <jan:AgreedSettlementValue contextRef="c-235" decimals="0" id="f-966" unitRef="usd">125000</jan:AgreedSettlementValue>
    <jan:NumberOfTranches
      contextRef="c-236"
      decimals="INF"
      id="f-967"
      unitRef="traches">2</jan:NumberOfTranches>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-235" decimals="0" id="f-968" unitRef="usd">450000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-237" decimals="0" id="f-969" unitRef="usd">90000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-238" decimals="0" id="f-970" unitRef="usd">1420000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-239" decimals="0" id="f-971" unitRef="usd">120000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-240" decimals="0" id="f-972" unitRef="usd">110000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-241" decimals="0" id="f-973" unitRef="usd">767000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <jan:OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor
      contextRef="c-242"
      decimals="INF"
      id="f-974"
      unitRef="landlord">3</jan:OtherCommitmentsNumberOfLandlordsOriginallyPurportedToBeLiableFor>
    <jan:OperatingLeasesFutureMinimumPaymentsDue1 contextRef="c-241" decimals="0" id="f-975" unitRef="usd">637000</jan:OperatingLeasesFutureMinimumPaymentsDue1>
    <jan:OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor
      contextRef="c-4"
      decimals="INF"
      id="f-976"
      unitRef="landlord">2</jan:OtherCommitmentsNumberOfLandlordsCompanyIsNoLongerLiableFor>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-241" decimals="0" id="f-977" unitRef="usd">130000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-978">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 20: Earnings (Loss) per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company&#x2019;s Consolidated Balance Sheet. Diluted net earnings per share is computed using the weighted average number of common shares outstanding, and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable with respect to restricted share awards, stock options and convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share (in $000&#x2019;s, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) income per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic income per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,444,361&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted income per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Potentially dilutive securities totaling approximately 3.9&#160;million and 4.6&#160;million shares, respectively, were excluded from the calculation of diluted net earnings (loss) per share for the years ended December&#160;30, 2023 and December&#160;31, 2022 because the effects were anti-dilutive based on the application of the treasury stock method.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-979">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share (in $000&#x2019;s, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) income per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic income per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,444,361&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted income per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,005,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,150,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-1" decimals="-3" id="f-980" unitRef="usd">-17095000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted contextRef="c-1" decimals="-3" id="f-981" unitRef="usd">-17095000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted contextRef="c-12" decimals="-3" id="f-982" unitRef="usd">8020000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-12" decimals="-3" id="f-983" unitRef="usd">8020000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-984" unitRef="shares">4005334</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-985" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-986" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-987"
      unitRef="usdPerShare">-4.27</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-988"
      unitRef="usdPerShare">-4.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-989"
      unitRef="usdPerShare">2.55</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-990"
      unitRef="usdPerShare">2.55</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic contextRef="c-1" decimals="-3" id="f-991" unitRef="usd">9283000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic contextRef="c-12" decimals="-3" id="f-992" unitRef="usd">2972000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-993" unitRef="shares">4005334</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-994" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-995"
      unitRef="usdPerShare">2.32</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-996"
      unitRef="usdPerShare">0.94</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted contextRef="c-1" decimals="-3" id="f-997" unitRef="usd">9283000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted contextRef="c-12" decimals="-3" id="f-998" unitRef="usd">2972000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-999" unitRef="shares">4444361</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-1000" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-1001"
      unitRef="usdPerShare">2.09</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-1002"
      unitRef="usdPerShare">0.94</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-1003" unitRef="usd">-7812000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-1004" unitRef="usd">-7812000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-12" decimals="-3" id="f-1005" unitRef="usd">10992000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-12" decimals="-3" id="f-1006" unitRef="usd">10992000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-1007" unitRef="shares">4005334</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-1008" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-1009" unitRef="shares">3150230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1010"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1011"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-1012"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-1013"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-1014" unitRef="shares">3900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-12"
      decimals="-5"
      id="f-1015"
      unitRef="shares">4600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1016">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 21: Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates within targeted markets through three reportable segments for continuing operations: biotechnology, recycling, and technology. The biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The technology segment designed wireless modules to connect devices to the Mobile Internet of Things (&#x201c;IoT&#x201d;) which contain location-based service (&#x201c;LBS&#x201d;) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in $000&#x2019;s): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income after provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Net income after provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinue operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1017"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1018">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in $000&#x2019;s): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Years Ended &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income after provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Net income after provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinue operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-243" decimals="-3" id="f-1019" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-244" decimals="-3" id="f-1020" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-204" decimals="-3" id="f-1021" unitRef="usd">3795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-205" decimals="-3" id="f-1022" unitRef="usd">39611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-245" decimals="-3" id="f-1023" unitRef="usd">3795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-246" decimals="-3" id="f-1024" unitRef="usd">39611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit contextRef="c-243" decimals="-3" id="f-1025" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-244" decimals="-3" id="f-1026" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-204" decimals="-3" id="f-1027" unitRef="usd">-197000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-205" decimals="-3" id="f-1028" unitRef="usd">7619000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-245" decimals="-3" id="f-1029" unitRef="usd">-197000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-246" decimals="-3" id="f-1030" unitRef="usd">7619000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss contextRef="c-243" decimals="-3" id="f-1031" unitRef="usd">-19846000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-244" decimals="-3" id="f-1032" unitRef="usd">-3149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-204" decimals="-3" id="f-1033" unitRef="usd">10438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-205" decimals="-3" id="f-1034" unitRef="usd">8395000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-245" decimals="-3" id="f-1035" unitRef="usd">-9408000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-246" decimals="-3" id="f-1036" unitRef="usd">5246000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-243" decimals="-3" id="f-1037" unitRef="usd">1452000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-244" decimals="-3" id="f-1038" unitRef="usd">2000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-204" decimals="-3" id="f-1039" unitRef="usd">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-205" decimals="-3" id="f-1040" unitRef="usd">555000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-245" decimals="-3" id="f-1041" unitRef="usd">1548000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-246" decimals="-3" id="f-1042" unitRef="usd">557000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-243" decimals="-3" id="f-1043" unitRef="usd">2250000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-244" decimals="-3" id="f-1044" unitRef="usd">468000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-204" decimals="-3" id="f-1045" unitRef="usd">-181000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-205" decimals="-3" id="f-1046" unitRef="usd">-957000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-245" decimals="-3" id="f-1047" unitRef="usd">2069000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-246" decimals="-3" id="f-1048" unitRef="usd">-489000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss contextRef="c-243" decimals="-3" id="f-1049" unitRef="usd">-17095000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-244" decimals="-3" id="f-1050" unitRef="usd">8020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-204" decimals="-3" id="f-1051" unitRef="usd">9283000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-205" decimals="-3" id="f-1052" unitRef="usd">2972000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-245" decimals="-3" id="f-1053" unitRef="usd">-7812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-246" decimals="-3" id="f-1054" unitRef="usd">10992000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets contextRef="c-247" decimals="-3" id="f-1055" unitRef="usd">18487000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-248" decimals="-3" id="f-1056" unitRef="usd">29165000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-249" decimals="-3" id="f-1057" unitRef="usd">0</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-250" decimals="-3" id="f-1058" unitRef="usd">17591000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-1059" unitRef="usd">18487000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-1060" unitRef="usd">46756000</us-gaap:Assets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-247" decimals="-3" id="f-1061" unitRef="usd">17846000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-248" decimals="-3" id="f-1062" unitRef="usd">19297000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-249" decimals="-3" id="f-1063" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-250" decimals="-3" id="f-1064" unitRef="usd">735000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-1065" unitRef="usd">17846000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-1066" unitRef="usd">20032000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1067">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 22: Subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the filing of this Form 10-K, and determined that there have been no events that have occurred that would require adjustments to disclosures in its consolidated financial statements other than as discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Warrant Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2024, the Company entered into a Warrant Purchase Agreement with a certain institutional investor that had purchased a Common Stock Purchase Warrant on August 22, 2023, in connection with such Investor&#x2019;s purchase of shares of the Company&#x2019;s common stock. The Warrant is exercisable from time to time for an aggregate of 899,348 shares of the Company&#x2019;s common stock with a per-share exercise price of $0.7561. Pursuant to the terms of the Warrant Purchase Agreement, the Company or assigns agreed to purchase the Warrant for an aggregate price of $250,000, of which $200,000 was paid at the closing of the transaction and the remaining $50,000 was paid on March 5, 2024. In connection with the January transaction, the Company assigned the Common Stock Purchase Warrant to an otherwise unaffiliated third party. See Note 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Soin Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 24, 2024, the Company, Amol Soin (&#x201c;Dr. Soin&#x201d;), and Soin Therapeutics LLC, a wholly-owned subsidiary of ours that we had purchased from Dr. Soin entered into an amendment (the &#x201c;Soin Amendment&#x201d;) to the parties&#x2019; Agreement and Plan of Merger that was dated as of December 28, 2022 (the &#x201c;Soin Agreement&#x201d;). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0&#160;million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the &#x201c;Soin Preferred&#x201d;) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8&#160;million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ICG Promissory Obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2024, the Company amended its outstanding related party promissory obligations in favor of ICG and in favor of Live Ventures to add convertibility provisions to each. The per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#x2019;s board of directors provided its final approvals of the amendments on February 7, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Amended Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2024, the Company entered into a promissory note with each of the holders of the amended promissory notes (see above). The initial principal amount of each note is $300,000, with an interest rate of 10% per annum. Pursuant to an amendment to each note, one hundred thousand dollars of principal, and accrued interest thereon, is due on September 7, 2024 for each note, and the balance of each note is due on December 31, 2024. At the Company&#x2019;s option, the obligation under each note is convertible after the six-month anniversary thereof at a per-share conversion price of $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company&#x2019;s board of directors approved the issuance of the notes on February 7, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Unit Purchase Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2024, the Company entered into Unit Purchase Agreements &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with two otherwise unaffiliated third-party investors, pursuant to which each Investor agreed to purchase 408,163 units of securities from the Company, at a price per Unit of $0.735, for an aggregate purchase price of $300,000 per investor for an aggregate price of $600,000. Each Unit consists of one share of the Com&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pany&#x2019;s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock and one warrant to purchase an additional share of common stock. The per-Unit price is allocated as follows: $0.61 per share of common stock and $0.125 per Warrant. The Warrant has a three-year term and will be immediately exercisable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Warrant is exercisable at $0.61 per share. The Company intends to use the proceeds from the Unit Purchases for its working capital needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Isaac Consulting Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2024, we entered into a two-year Consulting Agreement (the &#x201c;Consulting Agreement&#x201d;) with Jon Isaac, pursuant to which he will &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provide to us (the &#x201c;Services&#x201d;):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i) strategic financial advice, including growth strategies, capital &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocation, and financial restructuring; (ii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which we and he may be agree that will be memorialized in writing if, when, and as needed during the two-year term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mr. Isaac is the son of our Chief Executive Officer, but otherwise does not have a current relationship with us.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As compensation for the Services, we agreed to (i) assign to him two universal life insurance policies that relate to the life of one of the founders of our now-disposed legacy recycling business (the first policy has an accumulated value/surrender value of approximately $3,854 and the second has an accumulated value/surrender value of approximately $468); (ii) contingently tender to him funds in our Canadian counsel&#x2019;s trust account in the event that the prospective Order of the Court of Appeal for Ontario Canada in the matter styled, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amtim Capital Inc. and Appliance Recycling Centers of America&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. COA-23-CV-0156, becomes the final Order of the Court, which amount we estimated not to exceed approximately US$220,000; (iii) issue to him 200,000 restricted shares of our common stock with the per-share value being the average of the Nasdaq historical NOCP closing price during the five trading days prior to our board approving the Consulting Agreement, which shares were awarded from our 2023 Equity Incentive Plan; and (iv) a two-year, straight 10% convertible promissory note in the initial principal amount of $500,000, with a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($1.16).&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-251"
      decimals="INF"
      id="f-1068"
      unitRef="shares">899348</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-251"
      decimals="INF"
      id="f-1069"
      unitRef="usdPerShare">0.7561</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-252" decimals="-3" id="f-1070" unitRef="usd">250000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-253" decimals="-3" id="f-1071" unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-254" decimals="-3" id="f-1072" unitRef="usd">50000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-255" decimals="-5" id="f-1073" unitRef="usd">3000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-256" decimals="-3" id="f-1074" unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-257" decimals="-3" id="f-1075" unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-258" decimals="-5" id="f-1076" unitRef="usd">2800000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-259"
      decimals="INF"
      id="f-1077"
      unitRef="usdPerShare">0.61</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-259" decimals="INF" id="f-1078" unitRef="usd">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-259"
      decimals="2"
      id="f-1079"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="c-259" id="f-1080">P6M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-259"
      decimals="INF"
      id="f-1081"
      unitRef="usdPerShare">0.61</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <jan:NumberOfAgreementsToBePurchased
      contextRef="c-260"
      decimals="INF"
      id="f-1082"
      unitRef="agreements">2</jan:NumberOfAgreementsToBePurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-261"
      decimals="INF"
      id="f-1083"
      unitRef="shares">408163</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-260"
      decimals="INF"
      id="f-1084"
      unitRef="usdPerShare">0.735</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-261" decimals="-3" id="f-1085" unitRef="usd">300000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-261" decimals="-3" id="f-1086" unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <jan:SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit
      contextRef="c-261"
      decimals="INF"
      id="f-1087"
      unitRef="shares">1</jan:SaleOfStockUnitCompositionNumberOfCommonSharesInEachUnit>
    <jan:SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit
      contextRef="c-261"
      decimals="INF"
      id="f-1088"
      unitRef="shares">1</jan:SaleOfStockUnitCompositionNumberOfWarrantsIssuedInEachUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-262"
      decimals="2"
      id="f-1089"
      unitRef="usdPerShare">0.61</us-gaap:SaleOfStockPricePerShare>
    <jan:ClassOfWarrantPricePerShare
      contextRef="c-261"
      decimals="INF"
      id="f-1090"
      unitRef="usdPerShare">0.125</jan:ClassOfWarrantPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-260" id="f-1091">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-260"
      decimals="INF"
      id="f-1092"
      unitRef="usdPerShare">0.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <jan:RelatedPartyTransactionConsultingAgreementTerm contextRef="c-263" id="f-1093">P2Y</jan:RelatedPartyTransactionConsultingAgreementTerm>
    <jan:RelatedPartyTransactionConsultingAgreementTerm contextRef="c-263" id="f-1094">P2Y</jan:RelatedPartyTransactionConsultingAgreementTerm>
    <jan:RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned
      contextRef="c-264"
      decimals="INF"
      id="f-1095"
      unitRef="insurance_policy">2</jan:RelatedPartyTransactionConsultingAgreementNumberOfLifeInsurancePoliciesAssigned>
    <us-gaap:CashSurrenderValueOfLifeInsurance contextRef="c-265" decimals="0" id="f-1096" unitRef="usd">3854</us-gaap:CashSurrenderValueOfLifeInsurance>
    <us-gaap:CashSurrenderValueOfLifeInsurance contextRef="c-266" decimals="0" id="f-1097" unitRef="usd">468</us-gaap:CashSurrenderValueOfLifeInsurance>
    <jan:RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds contextRef="c-263" decimals="-3" id="f-1098" unitRef="usd">220000</jan:RelatedPartyTransactionConsultingAgreementContingentlyTenderedFunds>
    <jan:RelatedPartyTransactionConsultingAgreementSharesIssued
      contextRef="c-263"
      decimals="INF"
      id="f-1099"
      unitRef="shares">200000</jan:RelatedPartyTransactionConsultingAgreementSharesIssued>
    <jan:NumberOfTradingDaysBeforeBoardApproval contextRef="c-264" decimals="INF" id="f-1100" unitRef="d">5</jan:NumberOfTradingDaysBeforeBoardApproval>
    <jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm contextRef="c-263" id="f-1101">P2Y</jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtTerm>
    <jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate
      contextRef="c-264"
      decimals="2"
      id="f-1102"
      unitRef="number">0.10</jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtStatedRate>
    <jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount contextRef="c-264" decimals="-3" id="f-1103" unitRef="usd">500000</jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtFaceAmount>
    <jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice
      contextRef="c-264"
      decimals="2"
      id="f-1104"
      unitRef="usdPerShare">1.16</jan:RelatedPartyTransactionConsultingAgreementConvertibleDebtConversionPrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
